,entities,start_tokens,end_tokens,start_chars,end_chars,text,pmid,lf_chemicals_distsv,lf_disease_distsv,olabel,orig_index,label,prob_0,prob_1
0,secondary hyperparathyroidism,2,4,28,57,22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.,10027919_0,-1,-1,-1,0,-1,0.004582852,0.9954171
1,low bone turnover,6,9,75,92,22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.,10027919_0,-1,-1,-1,1,-1,0.017673215,0.9823268
2,renal failure,12,14,106,119,22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.,10027919_0,-1,-1,-1,2,-1,0.0032565396,0.9967435
3,Calcitriol,2,3,12,22,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,-1,-1,3,-1,0.9992538,0.000746215
4,parathyroid hormone,8,10,58,77,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,-1,-1,4,-1,0.9940209,0.0059790798
5,renal failure,16,18,101,114,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,-1,-1,5,-1,0.0036418492,0.9963581
7,suppression of bone turnover,27,31,180,208,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,-1,-1,7,-1,0.008960106,0.99103993
8,lead,34,35,220,224,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,-1,-1,8,-1,0.01458153,0.98541844
9,adynamic bone disease,36,39,228,249,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,-1,-1,-1,9,-1,0.0046856543,0.99531436
10,vitamin D,2,4,6,15,"A new vitamin D analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.",10027919_2,-1,-1,-1,10,-1,0.9971366,0.002863426
11,22-oxacalcitriol,6,7,26,42,"A new vitamin D analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.",10027919_2,-1,-1,-1,11,-1,0.99848,0.0015199779
12,OCT,8,9,44,47,"A new vitamin D analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.",10027919_2,-1,-1,-1,12,-1,0.99775046,0.0022495869
13,OCT,9,10,54,57,This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function.,10027919_3,-1,-1,-1,13,-1,0.9987097,0.0012903321
14,impaired renal function,22,25,119,142,This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function.,10027919_3,-1,-1,-1,14,-1,0.010025112,0.9899749
15,N,10,11,52,53,"METHODS: Sixty dogs were either nephrectomized (Nx, N = 38) or sham-operated (Sham, N = 22).",10027919_4,-1,-1,-1,15,-1,0.3353785,0.6646215
16,N,19,20,84,85,"METHODS: Sixty dogs were either nephrectomized (Nx, N = 38) or sham-operated (Sham, N = 22).",10027919_4,-1,-1,-1,16,-1,0.28261724,0.7173828
19,OCT,19,20,108,111,"Fourteen weeks after the start of phosphate supplementation, half of the Nx and Sham dogs received doses of OCT (three times per week); the other half were given vehicle for 60 weeks.",10027919_6,-1,-1,-1,19,-1,0.998885,0.0011149814
21,OCT,26,27,156,159,"Biochemical and hormonal indices of calcium and bone metabolism were measured throughout the study, and bone biopsies were done at baseline, 60 weeks after OCT or vehicle treatment, and at the end of the crossover period.",10027919_8,-1,-1,-1,21,-1,0.9984993,0.0015007893
22,OCT,6,7,21,24,"RESULTS: In Nx dogs, OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency.",10027919_9,-1,-1,-1,22,-1,0.99811196,0.0018880456
23,renal insufficiency,17,19,94,113,"RESULTS: In Nx dogs, OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency.",10027919_9,-1,-1,-1,23,-1,0.0026673146,0.9973327
24,secondary hyperparathyroidism,2,4,17,46,"In long-standing secondary hyperparathyroidism, OCT (0.03 microg/kg) stabilized serum PTH levels during the first months.",10027919_10,-1,-1,-1,24,-1,0.0050003384,0.99499965
25,OCT,5,6,48,51,"In long-standing secondary hyperparathyroidism, OCT (0.03 microg/kg) stabilized serum PTH levels during the first months.",10027919_10,-1,-1,-1,25,-1,0.99835074,0.0016492766
27,hyperphosphatemia,9,10,64,81,These effects were accompanied by episodes of hypercalcemia and hyperphosphatemia.,10027919_12,-1,-1,-1,27,-1,0.03340606,0.966594
28,OCT,7,8,39,42,"In animals with normal renal function, OCT induced a transient decrease in serum PTH levels at a dose of 0.1 microg/kg, which was not sustained with lowering of the doses.",10027919_13,-1,-1,-1,28,-1,0.9984877,0.0015122066
29,OCT,4,5,12,15,"In Nx dogs, OCT reversed abnormal bone formation, such as woven osteoid and fibrosis, but did not significantly alter the level of bone turnover.",10027919_14,-1,-1,-1,29,-1,0.9979857,0.002014249
31,OCT,3,4,13,16,"In addition, OCT improved mineralization lag time, (that is, the rate at which osteoid mineralizes) in both Nx and Sham dogs.",10027919_15,-1,-1,-1,31,-1,0.99751925,0.0024808133
32,OCT,8,9,53,56,"CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.",10027919_16,-1,-1,-1,32,-1,0.9986198,0.0013802068
34,renal insufficiency,21,23,143,162,"CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.",10027919_16,-1,-1,-1,34,-1,0.004886278,0.9951138
35,secondary hyperparathyroidism,33,35,202,231,"CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.",10027919_16,-1,-1,-1,35,-1,0.005391697,0.9946083
36,low bone turnover,40,43,259,276,"CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.",10027919_16,-1,-1,-1,36,-1,0.020321188,0.97967887
37,adynamic bone disease,53,56,323,344,"CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.",10027919_16,-1,-1,-1,37,-1,0.004275798,0.9957242
46,ischemic cardiac disease,5,8,23,47,There was a history of ischemic cardiac disease 9 years earlier.,10074612_2,-1,-1,-1,46,-1,0.0031188724,0.9968811
47,hemoptysis,9,10,62,72,"The patient was admitted with a pulmonary-renal syndrome with hemoptysis, rapidly progressive renal failure, and hypoxemia that required mechanical ventilation in the intensive care unit.",10074612_3,-1,-1,-1,47,-1,0.0029888037,0.9970112
48,progressive renal failure,12,15,82,107,"The patient was admitted with a pulmonary-renal syndrome with hemoptysis, rapidly progressive renal failure, and hypoxemia that required mechanical ventilation in the intensive care unit.",10074612_3,-1,-1,-1,48,-1,0.0031691683,0.9968309
49,hypoxemia,17,18,113,122,"The patient was admitted with a pulmonary-renal syndrome with hemoptysis, rapidly progressive renal failure, and hypoxemia that required mechanical ventilation in the intensive care unit.",10074612_3,-1,-1,-1,49,-1,0.0039976686,0.9960024
50,ventricular arrhythmia,7,9,43,65,The ECG showed a junctional rhythm without ventricular arrhythmia.,10074612_5,-1,-1,-1,50,-1,0.0036738426,0.99632615
51,sudden death,8,10,54,66,This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone (IVMP).,10074612_6,-1,-1,-1,51,-1,0.0025183058,0.99748176
53,IVMP,18,19,120,124,This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone (IVMP).,10074612_6,-1,-1,-1,53,-1,0.9980465,0.0019534456
54,cardiac disease,4,6,30,45,"Rapid infusion and underlying cardiac disease were important risk factors in the case reported here, and the authors discount ventricular arrhythmia as the main mechanism.",10074612_8,-1,-1,-1,54,-1,0.0029383793,0.99706155
55,ventricular arrhythmia,20,22,126,148,"Rapid infusion and underlying cardiac disease were important risk factors in the case reported here, and the authors discount ventricular arrhythmia as the main mechanism.",10074612_8,-1,-1,-1,55,-1,0.0032160734,0.996784
57,Parkinson's disease,4,7,21,40,"Ten patients who had Parkinson's disease with disabling dyskinesia were included in this study to evaluate the role of mental (mental calculation) and motor (flexion/extension of right fingers, flexion/extension of left fingers, flexion/extension of the neck, speaking aloud) tasks on the worsening of peak-dose dyskinesia following administration of an effective single dose of apomorphine.",10091616_1,-1,-1,-1,57,-1,0.004471287,0.99552876
62,p<0.05,25,26,142,148,"Compared with the score at rest (1.3+/-0.3), a significant aggravation of the dyskinesia score was observed during speaking aloud (5.2+/-1.1, p<0.05), movements of right (4.5+/-1.0, p<0.05) and left (3.7+/-0.8, p<0.05) fingers, movements of the neck (5.1+/-1.0, p<0.05), and mental calculation (3.1+/-1.0, p<0.05).",10091616_2,-1,-1,-1,62,-1,0.22576025,0.7742397
63,p<0.05,34,35,182,188,"Compared with the score at rest (1.3+/-0.3), a significant aggravation of the dyskinesia score was observed during speaking aloud (5.2+/-1.1, p<0.05), movements of right (4.5+/-1.0, p<0.05) and left (3.7+/-0.8, p<0.05) fingers, movements of the neck (5.1+/-1.0, p<0.05), and mental calculation (3.1+/-1.0, p<0.05).",10091616_2,-1,-1,-1,63,-1,0.24953909,0.7504609
64,p<0.05,41,42,211,217,"Compared with the score at rest (1.3+/-0.3), a significant aggravation of the dyskinesia score was observed during speaking aloud (5.2+/-1.1, p<0.05), movements of right (4.5+/-1.0, p<0.05) and left (3.7+/-0.8, p<0.05) fingers, movements of the neck (5.1+/-1.0, p<0.05), and mental calculation (3.1+/-1.0, p<0.05).",10091616_2,-1,-1,-1,64,-1,0.2352002,0.76479983
65,p<0.05,52,53,262,268,"Compared with the score at rest (1.3+/-0.3), a significant aggravation of the dyskinesia score was observed during speaking aloud (5.2+/-1.1, p<0.05), movements of right (4.5+/-1.0, p<0.05) and left (3.7+/-0.8, p<0.05) fingers, movements of the neck (5.1+/-1.0, p<0.05), and mental calculation (3.1+/-1.0, p<0.05).",10091616_2,-1,-1,-1,65,-1,0.23437417,0.7656258
66,p<0.05,61,62,306,312,"Compared with the score at rest (1.3+/-0.3), a significant aggravation of the dyskinesia score was observed during speaking aloud (5.2+/-1.1, p<0.05), movements of right (4.5+/-1.0, p<0.05) and left (3.7+/-0.8, p<0.05) fingers, movements of the neck (5.1+/-1.0, p<0.05), and mental calculation (3.1+/-1.0, p<0.05).",10091616_2,-1,-1,-1,66,-1,0.22181107,0.7781889
68,postural hypotension,1,3,19,39,Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal.,10091617_0,-1,-1,-1,68,-1,0.0021586665,0.99784136
69,Parkinson's disease,4,7,43,62,Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal.,10091617_0,-1,-1,-1,69,-1,0.0041905097,0.99580956
70,Parkinson's Disease,5,8,31,50,OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.,10091617_1,-1,-1,-1,70,-1,0.012334963,0.9876651
71,Parkinson's disease,21,24,127,146,OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.,10091617_1,-1,-1,-1,71,-1,0.0075254636,0.9924745
72,PD,25,26,148,150,OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.,10091617_1,-1,-1,-1,72,-1,0.0039609247,0.99603903
73,mg selegiline,31,33,177,190,OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.,10091617_1,-1,-1,-1,73,-1,0.99788874,0.0021113139
75,systolic orthostatic hypotension,14,17,89,121,"Recently, we found that therapy with selegiline and L-dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline.",10091617_2,-1,-1,-1,75,-1,0.0030615386,0.99693847
79,PD,14,15,94,96,METHODS: The cardiovascular responses to standing and head-up tilt were studied repeatedly in PD patients receiving selegiline and as the drug was withdrawn.,10091617_5,-1,-1,-1,79,-1,0.016943442,0.9830565
81,systolic orthostatic hypotension,5,8,29,61,"RESULTS: Head-up tilt caused systolic orthostatic hypotension which was marked in six of 20 PD patients on selegiline, one of whom lost consciousness with unrecordable blood pressures.",10091617_6,-1,-1,-1,81,-1,0.0060727717,0.99392724
82,PD,15,16,92,94,"RESULTS: Head-up tilt caused systolic orthostatic hypotension which was marked in six of 20 PD patients on selegiline, one of whom lost consciousness with unrecordable blood pressures.",10091617_6,-1,-1,-1,82,-1,0.010186044,0.989814
87,the supine,5,7,47,57,Stopping selegiline also significantly reduced the supine systolic and diastolic blood pressures consistent with a previously undescribed supine pressor action.,10091617_9,-1,-1,-1,87,-1,0.47973898,0.520261
88,and diastolic,8,10,67,80,Stopping selegiline also significantly reduced the supine systolic and diastolic blood pressures consistent with a previously undescribed supine pressor action.,10091617_9,-1,-1,-1,88,-1,0.07837014,0.9216299
91,monoamine oxidase,14,16,104,121,The possibilities that these cardiovascular findings might be the result of non-selective inhibition of monoamine oxidase or of amphetamine and metamphetamine are discussed.,10091617_11,-1,-1,-1,91,-1,0.9975719,0.002428138
93,metamphetamine,20,21,144,158,The possibilities that these cardiovascular findings might be the result of non-selective inhibition of monoamine oxidase or of amphetamine and metamphetamine are discussed.,10091617_11,-1,-1,-1,93,-1,0.9991122,0.0008878405
96,Picloxydine,0,1,0,11,Picloxydine irrigations appeared to have a lower incidence of erosive cystitis but further studies would have to be performed before it could be recommended for use in urological procedures.,1009330_4,-1,-1,-1,96,-1,0.99910647,0.0008935385
98,tetrandrine,2,3,11,22,Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation.,10193204_0,-1,-1,-1,98,-1,0.99917287,0.00082710286
99,fangchinoline,4,5,27,40,Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation.,10193204_0,-1,-1,-1,99,-1,0.9991605,0.00083945505
102,TET,2,3,13,16,Tetrandrine (TET) and fangchinoline (FAN) are two naturally occurring analogues with a bisbenzylisoquinoline structure.,10193204_1,-1,-1,-1,102,-1,0.9958127,0.0041872812
103,fangchinoline,5,6,22,35,Tetrandrine (TET) and fangchinoline (FAN) are two naturally occurring analogues with a bisbenzylisoquinoline structure.,10193204_1,-1,-1,-1,103,-1,0.9988299,0.0011700875
104,FAN,7,8,37,40,Tetrandrine (TET) and fangchinoline (FAN) are two naturally occurring analogues with a bisbenzylisoquinoline structure.,10193204_1,-1,-1,-1,104,-1,0.99408615,0.0059138406
105,bisbenzylisoquinoline,16,17,87,108,Tetrandrine (TET) and fangchinoline (FAN) are two naturally occurring analogues with a bisbenzylisoquinoline structure.,10193204_1,-1,-1,-1,105,-1,0.99590045,0.004099499
106,TET,10,11,63,66,"The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.",10193204_2,-1,-1,-1,106,-1,0.99791044,0.0020895805
107,FAN,12,13,71,74,"The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.",10193204_2,-1,-1,-1,107,-1,0.99843925,0.0015607815
110,EP,23,24,144,146,"The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.",10193204_2,-1,-1,-1,110,-1,0.9965648,0.003435192
113,TET,16,17,61,64,"In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.",10193204_3,-1,-1,-1,113,-1,0.9850959,0.014904096
114,FAN,18,19,69,72,"In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.",10193204_3,-1,-1,-1,114,-1,0.9918326,0.008167413
117,ASA,39,40,175,178,"In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.",10193204_3,-1,-1,-1,117,-1,0.9979006,0.0020993983
118,platelet aggregations,4,6,19,40,"In the vitro human platelet aggregations induced by the agonists used in tests, TET and FAN showed the inhibitions dose dependently.",10193204_4,-1,-1,-1,118,-1,0.0065786564,0.9934214
119,TET,14,15,80,83,"In the vitro human platelet aggregations induced by the agonists used in tests, TET and FAN showed the inhibitions dose dependently.",10193204_4,-1,-1,-1,119,-1,0.99772006,0.002279877
120,FAN,16,17,88,91,"In the vitro human platelet aggregations induced by the agonists used in tests, TET and FAN showed the inhibitions dose dependently.",10193204_4,-1,-1,-1,120,-1,0.99819285,0.0018072014
121,TET,4,5,21,24,"In addition, neither TET nor FAN showed any anticoagulation activities in the measurement of the activated partial thromboplastin time (APTT), prothrombin time (PT) and thrombin time (TT) using human-citrated plasma.",10193204_5,-1,-1,-1,121,-1,0.99683976,0.0031601815
122,FAN,6,7,29,32,"In addition, neither TET nor FAN showed any anticoagulation activities in the measurement of the activated partial thromboplastin time (APTT), prothrombin time (PT) and thrombin time (TT) using human-citrated plasma.",10193204_5,-1,-1,-1,122,-1,0.99764794,0.0023520377
123,TET,6,7,45,48,These results suggest that antithrombosis of TET and FAN in mice may be mainly related to the antiplatelet aggregation activities.,10193204_6,-1,-1,-1,123,-1,0.94806725,0.051932722
124,FAN,8,9,53,56,These results suggest that antithrombosis of TET and FAN in mice may be mainly related to the antiplatelet aggregation activities.,10193204_6,-1,-1,-1,124,-1,0.9796069,0.020393116
125,renal tubular dysfunction,13,16,103,128,"Urine N-acetyl-beta-D-glucosaminidase--a marker of tubular damage?BACKGROUND: Although an indicator of renal tubular dysfunction, an increased urinary N-acetyl-beta-D-glucosaminidase (NAG) activity might reflect increased lysosomal activity in renal tubular cells.",10193809_0,-1,-1,-1,125,-1,0.0037955334,0.99620444
126,Puromycin aminonucleoside,2,4,9,34,METHODS: Puromycin aminonucleoside (PAN) was administered to Sprague Dawley rats to induce proteinuria.,10193809_1,-1,-1,-1,126,-1,0.99826694,0.0017330619
127,PAN,5,6,36,39,METHODS: Puromycin aminonucleoside (PAN) was administered to Sprague Dawley rats to induce proteinuria.,10193809_1,-1,-1,-1,127,-1,0.9970415,0.002958516
129,PAN,4,5,31,34,"RESULTS: Following intravenous PAN urine volume and urine NAG activity increased significantly by day two, but returned to normal by day four. After day four all treated animals exhibited a marked rise in urine albumin, total protein excretion and NAG activity.",10193809_4,-1,-1,-1,129,-1,0.99696475,0.0030352718
130,protein excretion,40,42,226,243,"RESULTS: Following intravenous PAN urine volume and urine NAG activity increased significantly by day two, but returned to normal by day four. After day four all treated animals exhibited a marked rise in urine albumin, total protein excretion and NAG activity.",10193809_4,-1,-1,-1,130,-1,0.8656998,0.13430013
132,Cauda equina syndrome,0,3,0,21,Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993-1997.,10225068_0,-1,-1,-1,132,-1,0.009737461,0.9902625
134,cauda equina syndrome,18,21,103,124,Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993-1997.,10225068_0,-1,-1,-1,134,-1,0.010542752,0.9894573
135,cauda equina syndrome,32,35,197,218,Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993-1997.,10225068_0,-1,-1,-1,135,-1,0.009769012,0.990231
138,mg,13,14,72,74,The dose of hyperbaric 5% lignocaine administered ranged from 60 to 120 mg.,10225068_3,-1,-1,-1,138,-1,0.93423665,0.06576339
142,neurological deficits,4,6,30,51,All cases sustained permanent neurological deficits.,10225068_6,-1,-1,-1,142,-1,0.0025810478,0.997419
144,mg,24,25,149,151,We recommend that hyperbaric lignocaine should be administered in concentrations not greater than 2% and at a total dose preferably not exceeding 60 mg.,10225068_7,-1,-1,-1,144,-1,0.9787289,0.021271065
149,capillary leak syndrome,15,18,107,130,Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.,10328196_0,-1,-1,-1,149,-1,0.003026143,0.9969739
153,capillary leak syndrome,7,10,47,70,After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis.,10328196_2,-1,-1,-1,153,-1,0.0035451977,0.99645483
155,capillary leak syndrome,11,14,77,100,OBSERVATIONS: A keratome skin specimen from 1 patient with sirolimus-induced capillary leak syndrome had a 2.3-fold increase in percentage of apoptotic cells (to 48%) compared with an unaffected sirolimus-treated patient with psoriasis (21%).,10328196_3,-1,-1,-1,155,-1,0.003391256,0.99660873
162,capillary leak syndrome,13,16,76,99,"CONCLUSIONS: Severe adverse effects of sirolimus include fever, anemia, and capillary leak syndrome.",10328196_5,-1,-1,-1,162,-1,0.0032311266,0.99676883
164,capillary leak,7,9,51,65,"Because patients with severe psoriasis may develop capillary leak from various systemic therapies, clinical monitoring is advisable for patients with inflammatory diseases who are treated with immune modulators.",10328196_7,-1,-1,-1,164,-1,0.003502944,0.9964971
165,inflammatory diseases,21,23,150,171,"Because patients with severe psoriasis may develop capillary leak from various systemic therapies, clinical monitoring is advisable for patients with inflammatory diseases who are treated with immune modulators.",10328196_7,-1,-1,-1,165,-1,0.0029910982,0.997009
167,ACE inhibitors,3,5,18,32,Angioedema due to ACE inhibitors: common and inadequately diagnosed.,10342929_0,-1,-1,-1,167,-1,0.9977889,0.00221111
172,thyroid disease,30,32,160,175,"These were evaluated with respect to the duration of lithium therapy, age, sex, and family history (whether or not the patient had a first-degree relative with thyroid disease).",10354657_2,-1,-1,-1,172,-1,0.0051243706,0.9948756
173,Affective Disorders,2,4,9,28,"SETTING: Affective Disorders Clinic at St. Mary's Hospital, Montreal.",10354657_4,-1,-1,-1,173,-1,0.01226778,0.9877322
174,bipolar disorder,15,17,66,82,PATIENTS: One hundred and one patients (28 men and 73 women) with bipolar disorder receiving lithium maintenance therapy ranging from 1 year's to 32 years' duration.,10354657_5,-1,-1,-1,174,-1,0.0066703246,0.9933297
182,thyroid illness,7,9,55,70,All patients having first-degree relatives affected by thyroid illness had accelerated onset of hypothyroidism (3.7 years after onset of lithium therapy) compared with patients without a family history (8.6 years after onset of lithium therapy).,10354657_9,-1,-1,-1,182,-1,0.0068127527,0.9931872
193,thyroid illness,3,5,22,37,CONCLUSIONS: Familial thyroid illness is a risk factor for hypothyroidism and hypercalcemia during lithium therapy.,10354657_14,-1,-1,-1,193,-1,0.004320223,0.99567974
197,mood disorder,1,3,16,29,Cocaine-induced mood disorder: prevalence rates and psychiatric symptoms in an outpatient cocaine-dependent sample.,10365197_0,-1,-1,-1,197,-1,0.0028783728,0.99712163
198,psychiatric symptoms,7,9,52,72,Cocaine-induced mood disorder: prevalence rates and psychiatric symptoms in an outpatient cocaine-dependent sample.,10365197_0,-1,-1,-1,198,-1,0.0030205604,0.9969795
199,mood disorders,17,19,116,130,This paper attempts to examine and compare prevalence rates and symptom patterns of DSM substance-induced and other mood disorders.,10365197_1,-1,-1,-1,199,-1,0.0032986011,0.9967014
200,mood disorder,5,7,55,68,"243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.",10365197_2,-1,-1,-1,200,-1,0.0032995264,0.99670047
201,CIMD,8,9,70,74,"243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.",10365197_2,-1,-1,-1,201,-1,0.40804583,0.59195423
202,mood disorders,12,14,83,97,"243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.",10365197_2,-1,-1,-1,202,-1,0.0029398424,0.9970601
203,mood disorder,17,19,105,118,"243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.",10365197_2,-1,-1,-1,203,-1,0.0033500015,0.99665004
204,psychiatric symptoms,24,26,148,168,"243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.",10365197_2,-1,-1,-1,204,-1,0.0036225459,0.9963774
205,CIMD,4,5,24,28,The prevalence rate for CIMD was 12% at baseline.,10365197_3,-1,-1,-1,205,-1,0.71557164,0.28442836
206,CIMD,6,7,40,44,Introduction of the DSM-IV diagnosis of CIMD did not substantially affect rates of the other depressive disorders.,10365197_4,-1,-1,-1,206,-1,0.8379381,0.16206197
207,depressive disorders,15,17,93,113,Introduction of the DSM-IV diagnosis of CIMD did not substantially affect rates of the other depressive disorders.,10365197_4,-1,-1,-1,207,-1,0.004386469,0.9956136
208,CIMD,2,3,14,18,Patients with CIMD had symptom severity levels between those of patients with and without a mood disorder.,10365197_5,-1,-1,-1,208,-1,0.7160415,0.28395855
209,mood disorder,15,17,92,105,Patients with CIMD had symptom severity levels between those of patients with and without a mood disorder.,10365197_5,-1,-1,-1,209,-1,0.0041353265,0.9958646
210,CIMD,11,12,69,73,"These findings suggest some validity for the new DSM-IV diagnosis of CIMD, but also suggest that it requires further specification and replication.",10365197_6,-1,-1,-1,210,-1,0.07549837,0.92450166
211,fucoidan,2,3,10,18,Effect of fucoidan treatment on collagenase-induced intracerebral hemorrhage in rats.,10406016_0,-1,-1,-1,211,-1,0.998777,0.0012230458
212,intracerebral hemorrhage,6,8,52,76,Effect of fucoidan treatment on collagenase-induced intracerebral hemorrhage in rats.,10406016_0,-1,-1,-1,212,-1,0.0031566056,0.99684346
217,fucoidan,5,6,38,46,"We tested the sulfated polysaccharide fucoidan, which has been reported to reduce inflammatory brain damage, in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus.",10406016_3,-1,-1,-1,217,-1,0.997698,0.0023019877
219,intracerebral hemorrhage,22,24,127,151,"We tested the sulfated polysaccharide fucoidan, which has been reported to reduce inflammatory brain damage, in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus.",10406016_3,-1,-1,-1,219,-1,0.0028522534,0.99714774
220,fucoidan,9,10,57,65,Rats were treated with seven day intravenous infusion of fucoidan (30 micrograms h-1) or vehicle.,10406016_4,-1,-1,-1,220,-1,0.9989004,0.0010995751
222,impaired blood clotting,5,8,44,67,"Fucoidan-treated rats exhibited evidence of impaired blood clotting and hemodilution, had larger hematomas, and tended to have less inflammation in the vicinity of the hematoma after three days.",10406016_7,-1,-1,-1,222,-1,0.015428108,0.98457193
223,hemodilution,9,10,72,84,"Fucoidan-treated rats exhibited evidence of impaired blood clotting and hemodilution, had larger hematomas, and tended to have less inflammation in the vicinity of the hematoma after three days.",10406016_7,-1,-1,-1,223,-1,0.0034111508,0.9965888
224,hematomas,13,14,97,106,"Fucoidan-treated rats exhibited evidence of impaired blood clotting and hemodilution, had larger hematomas, and tended to have less inflammation in the vicinity of the hematoma after three days.",10406016_7,-1,-1,-1,224,-1,0.0029098406,0.9970901
228,matter edema,2,4,12,24,Acute white matter edema and eventual neuronal loss in the striatum adjacent to the hematoma did not differ between the two groups.,10406016_9,-1,-1,-1,228,-1,0.005172891,0.9948271
229,neuronal loss,6,8,38,51,Acute white matter edema and eventual neuronal loss in the striatum adjacent to the hematoma did not differ between the two groups.,10406016_9,-1,-1,-1,229,-1,0.003031381,0.9969687
231,intracerebral hemorrhage,12,14,97,121,Investigation of more specific anti-inflammatory agents and hemodiluting agents are warranted in intracerebral hemorrhage.,10406016_10,-1,-1,-1,231,-1,0.0028603561,0.9971397
233,cefotetan,9,10,67,76,Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures.,10411803_0,-1,-1,-1,233,-1,0.9991405,0.0008594901
235,cefotetan,6,7,56,65,"Second- and third-generation cephalosporins, especially cefotetan, are increasingly associated with severe, sometimes fatal immune hemolytic anemia.",10411803_1,-1,-1,-1,235,-1,0.99919635,0.0008036133
237,hemolytic anemias,10,12,56,73,We noticed that 10 of our 35 cases of cefotetan-induced hemolytic anemias were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures.,10411803_2,-1,-1,-1,237,-1,0.0024503937,0.9975496
238,cefotetan,18,19,108,117,We noticed that 10 of our 35 cases of cefotetan-induced hemolytic anemias were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures.,10411803_2,-1,-1,-1,238,-1,0.9992111,0.0007888422
240,aneurysmal subarachnoid hemorrhage,10,13,79,113,Effects of nonsteroidal anti-inflammatory drugs on hemostasis in patients with aneurysmal subarachnoid hemorrhage.,10414674_0,-1,-1,-1,240,-1,0.003651319,0.9963486
241,NSAIDs,9,10,71,77,Platelet function is impaired by nonsteroidal anti-inflammatory drugs (NSAIDs) with prominent anti-inflammatory properties.,10414674_1,-1,-1,-1,241,-1,0.9977428,0.0022571974
242,aneurysmal subarachnoid hemorrhage,2,5,14,48,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,242,-1,0.0034038252,0.99659616
243,SAH,6,7,50,53,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,243,-1,0.0026479794,0.997352
244,ketoprofen,13,14,89,99,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,244,-1,0.9994235,0.0005765397
245,mg,16,17,105,107,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,245,-1,0.9813385,0.018661555
246,ketoprofen,23,24,128,138,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,246,-1,0.9993979,0.00060212455
247,n,26,27,146,147,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,247,-1,0.16758229,0.8324177
248,NSAID,33,34,163,168,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,248,-1,0.9973098,0.0026902156
251,n,48,49,230,231,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,251,-1,0.17420751,0.8257925
252,aneurysmal SAH,58,60,281,295,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,-1,-1,-1,252,-1,0.0035749378,0.9964251
254,adenosine diphosphate,8,10,52,73,Maximal platelet aggregation induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen.,10414674_6,-1,-1,-1,254,-1,0.9990344,0.00096565846
255,ketoprofen,14,15,108,118,Maximal platelet aggregation induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen.,10414674_6,-1,-1,-1,255,-1,0.9992842,0.00071583735
256,P,4,5,23,24,Aggregation was lower (P < .05) in the ketoprofen group than in the acetaminophen group just before surgery and on the third postoperative day.,10414674_7,-1,-1,-1,256,-1,0.25794142,0.7420586
257,ketoprofen,10,11,39,49,Aggregation was lower (P < .05) in the ketoprofen group than in the acetaminophen group just before surgery and on the third postoperative day.,10414674_7,-1,-1,-1,257,-1,0.9993729,0.0006270733
259,contrast,1,2,3,11,"In contrast, maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results (P < .05).",10414674_8,-1,-1,-1,259,-1,0.17891411,0.8210859
263,P,25,26,174,175,"In contrast, maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results (P < .05).",10414674_8,-1,-1,-1,263,-1,0.3512794,0.6487206
264,ketoprofen,4,5,19,29,One patient in the ketoprofen group developed a postoperative intracranial hematoma.,10414674_9,-1,-1,-1,264,-1,0.9993224,0.00067760807
266,antithrombin III,20,22,112,128,"Coagulation (prothrombin time [PT], activated partial thromboplastin time [APPT], fibrinogen concentration, and antithrombin III [AT III]) was comparable between the two groups.",10414674_10,-1,-1,-1,266,-1,0.99528944,0.004710538
267,AT III,23,25,130,136,"Coagulation (prothrombin time [PT], activated partial thromboplastin time [APPT], fibrinogen concentration, and antithrombin III [AT III]) was comparable between the two groups.",10414674_10,-1,-1,-1,267,-1,0.9924885,0.0075115627
268,Ketoprofen,0,1,0,10,Ketoprofen but not acetaminophen impaired platelet function in patients with SAH.,10414674_11,-1,-1,-1,268,-1,0.99932265,0.0006774176
270,SAH,10,11,77,80,Ketoprofen but not acetaminophen impaired platelet function in patients with SAH.,10414674_11,-1,-1,-1,270,-1,0.0034789678,0.996521
271,ketoprofen,1,2,3,13,"If ketoprofen is used before surgery on cerebral artery aneurysms, it may pose an additional risk factor for hemorrhage.",10414674_12,-1,-1,-1,271,-1,0.99935406,0.0006459656
272,artery aneurysms,8,10,49,65,"If ketoprofen is used before surgery on cerebral artery aneurysms, it may pose an additional risk factor for hemorrhage.",10414674_12,-1,-1,-1,272,-1,0.0061646723,0.99383533
274,atracurium,2,3,16,26,Accumulation of atracurium in the intravenous line led to recurarization after flushing the line in the recovery room.,10457883_2,-1,-1,-1,274,-1,0.9992205,0.00077947305
275,flushing,11,12,79,87,Accumulation of atracurium in the intravenous line led to recurarization after flushing the line in the recovery room.,10457883_2,-1,-1,-1,275,-1,0.5244973,0.47550273
276,respiratory arrest,1,3,2,20,A respiratory arrest with severe desaturation and bradycardia occurred.,10457883_3,-1,-1,-1,276,-1,0.0035107192,0.9964893
277,desaturation,5,6,33,45,A respiratory arrest with severe desaturation and bradycardia occurred.,10457883_3,-1,-1,-1,277,-1,0.038691245,0.9613088
279,neuromuscular blockade,10,12,66,88,"Circumstances leading to this event and the mechanisms enabling a neuromuscular blockade to occur, following the administration of a small dose of relaxant, are discussed.",10457883_4,-1,-1,-1,279,-1,0.026566114,0.97343385
282,ASA,13,14,88,91,The haemodynamic effects of propofol in combination with ephedrine in elderly patients (ASA groups 3 and 4).The marked vasodilator and negative inotropic effects of propofol are disadvantages in frail elderly patients.,10520387_0,-1,-1,-1,282,-1,0.9811686,0.018831404
287,mg,10,11,48,50,"The haemodynamic effects of adding 15, 20 or 25 mg of ephedrine to 200 mg of propofol were compared to control in 40 ASA 3/4 patients over 60 years presenting for genito-urinary surgery.",10520387_2,-1,-1,-1,287,-1,0.98839694,0.011603093
289,mg,15,16,71,73,"The haemodynamic effects of adding 15, 20 or 25 mg of ephedrine to 200 mg of propofol were compared to control in 40 ASA 3/4 patients over 60 years presenting for genito-urinary surgery.",10520387_2,-1,-1,-1,289,-1,0.99094725,0.009052743
291,ASA,24,25,117,120,"The haemodynamic effects of adding 15, 20 or 25 mg of ephedrine to 200 mg of propofol were compared to control in 40 ASA 3/4 patients over 60 years presenting for genito-urinary surgery.",10520387_2,-1,-1,-1,291,-1,0.9906232,0.009376822
300,myocardial ischemia,8,10,45,64,"Due to the risk of this tachycardia inducing myocardial ischemia, we would not recommend the use in elderly patients of any of the ephedrine/propofol/mixtures studied.",10520387_5,-1,-1,-1,300,-1,0.0022168779,0.9977831
301,Nitric oxide,0,2,0,12,Nitric oxide synthase expression in the course of lead-induced hypertension.,10523326_0,-1,-1,-1,301,-1,0.99536765,0.0046323403
303,reactive oxygen species,4,7,28,51,"We recently showed elevated reactive oxygen species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-induced hypertension.",10523326_1,-1,-1,-1,303,-1,0.98930794,0.010692042
304,nitrotyrosine,26,27,144,157,"We recently showed elevated reactive oxygen species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-induced hypertension.",10523326_1,-1,-1,-1,304,-1,0.9990264,0.00097358925
309,drinking water,19,21,105,119,"Male Sprague-Dawley rats were randomly assigned to a lead-treated group (given lead acetate, 100 ppm, in drinking water and regular rat chow), a group given lead and vitamin E-fortified chow, or a normal control group given either regular food and water or vitamin E-fortified food for 12 weeks.",10523326_3,-1,-1,-1,309,-1,0.992062,0.007938035
310,lead,30,31,157,161,"Male Sprague-Dawley rats were randomly assigned to a lead-treated group (given lead acetate, 100 ppm, in drinking water and regular rat chow), a group given lead and vitamin E-fortified chow, or a normal control group given either regular food and water or vitamin E-fortified food for 12 weeks.",10523326_3,-1,-1,-1,310,-1,0.99808705,0.0019129688
312,MDA,11,12,68,71,"Tail blood pressure, urinary NOx excretion, plasma malondialdehyde (MDA), and endothelial and inducible NOS (eNOS and iNOS) isotypes in the aorta and kidney were measured.",10523326_4,-1,-1,-1,312,-1,0.9981299,0.0018701492
313,rise in,5,7,35,42,"The lead-treated group exhibited a rise in blood pressure and plasma MDA concentration, a fall in urinary NOx excretion, and a paradoxical rise in vascular and renal tissue eNOS and iNOS expression.",10523326_5,-1,-1,-1,313,-1,0.0492965,0.95070344
314,pressure,8,9,49,57,"The lead-treated group exhibited a rise in blood pressure and plasma MDA concentration, a fall in urinary NOx excretion, and a paradoxical rise in vascular and renal tissue eNOS and iNOS expression.",10523326_5,-1,-1,-1,314,-1,0.073099144,0.9269009
315,MDA,11,12,69,72,"The lead-treated group exhibited a rise in blood pressure and plasma MDA concentration, a fall in urinary NOx excretion, and a paradoxical rise in vascular and renal tissue eNOS and iNOS expression.",10523326_5,-1,-1,-1,315,-1,0.99873596,0.0012640378
316,Vitamin E,0,2,0,9,"Vitamin E supplementation ameliorated hypertension, lowered plasma MDA concentration, and raised urinary NOx excretion while significantly lowering vascular, but not renal, tissue eNOS and iNOS expression.",10523326_6,-1,-1,-1,316,-1,0.9984871,0.0015129088
318,MDA,8,9,67,70,"Vitamin E supplementation ameliorated hypertension, lowered plasma MDA concentration, and raised urinary NOx excretion while significantly lowering vascular, but not renal, tissue eNOS and iNOS expression.",10523326_6,-1,-1,-1,318,-1,0.99838877,0.0016112316
319,Vitamin E,0,2,0,9,"Vitamin E supplementation had no effect on either blood pressure, plasma MDA, or NOS expression in the control group.",10523326_7,-1,-1,-1,319,-1,0.99845517,0.0015447991
320,MDA,12,13,73,76,"Vitamin E supplementation had no effect on either blood pressure, plasma MDA, or NOS expression in the control group.",10523326_7,-1,-1,-1,320,-1,0.99592185,0.004078105
321,lead,11,12,76,80,The study also revealed significant inhibition of NOS enzymatic activity by lead in cell-free preparations.,10523326_8,-1,-1,-1,321,-1,0.99826413,0.0017359209
324,migraine without aura,5,8,39,60,Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura.,10524660_0,-1,-1,-1,324,-1,0.003526093,0.99647385
325,migraine with aura,11,14,77,95,Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura.,10524660_0,-1,-1,-1,325,-1,0.0033705153,0.9966294
326,Migraine with aura,0,3,0,18,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,-1,-1,-1,326,-1,0.014594775,0.98540527
327,migraine without aura,4,7,23,44,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,-1,-1,-1,327,-1,0.014110011,0.98589003
329,migraine with aura,16,19,92,110,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,-1,-1,-1,329,-1,0.015323527,0.98467654
330,migraine without aura,20,23,115,136,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,-1,-1,-1,330,-1,0.016530782,0.98346925
331,nitric oxide,12,14,79,91,"In recent years, increasing evidence has suggested that the messenger molecule nitric oxide (NO) is involved in pain mechanisms of migraine without aura.",10524660_2,-1,-1,-1,331,-1,0.996967,0.0030330531
333,migraine without aura,23,26,131,152,"In recent years, increasing evidence has suggested that the messenger molecule nitric oxide (NO) is involved in pain mechanisms of migraine without aura.",10524660_2,-1,-1,-1,333,-1,0.005067626,0.99493235
334,migraine with aura,10,13,49,67,"In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.",10524660_3,-1,-1,-1,334,-1,0.003429252,0.9965707
336,glyceryl trinitrate,27,29,151,170,"In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.",10524660_3,-1,-1,-1,336,-1,0.9990727,0.0009273581
337,GTN,30,31,172,175,"In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.",10524660_3,-1,-1,-1,337,-1,0.9982185,0.001781517
338,migraine with aura,43,46,227,245,"In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.",10524660_3,-1,-1,-1,338,-1,0.003199135,0.9968009
339,migraine without aura,13,16,70,91,The specific aim was to elucidate whether an aura and/or an attack of migraine without aura could be induced.,10524660_4,-1,-1,-1,339,-1,0.004562494,0.99543756
340,migraineurs,5,6,28,39,Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).,10524660_7,-1,-1,-1,340,-1,0.0037412646,0.99625874
341,GTN,14,15,90,93,Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).,10524660_7,-1,-1,-1,341,-1,0.9987269,0.001273115
342,p=0.037,17,18,104,111,Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).,10524660_7,-1,-1,-1,342,-1,0.35542512,0.6445749
343,h,26,27,148,149,Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).,10524660_7,-1,-1,-1,343,-1,0.45634937,0.5436507
344,p,28,29,151,152,Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).,10524660_7,-1,-1,-1,344,-1,0.2208214,0.7791786
346,migraineurs,12,13,76,87,"In the controls, the GTN-induced headache gradually disappeared, whereas in migraineurs peak headache intensity occurred at a mean time of 240 min post-infusion.",10524660_8,-1,-1,-1,346,-1,0.012147032,0.98785293
349,migraineurs,10,11,45,56,At this time the induced headache in 6 of 12 migraineurs fulfilled the diagnostic criteria for migraine without aura of the International Headache Society.,10524660_9,-1,-1,-1,349,-1,0.008627228,0.9913728
350,migraine without aura,16,19,95,116,At this time the induced headache in 6 of 12 migraineurs fulfilled the diagnostic criteria for migraine without aura of the International Headache Society.,10524660_9,-1,-1,-1,350,-1,0.0045925598,0.9954074
353,migraine with aura,13,16,76,94,The results therefore suggest that NO is involved in the pain mechanisms of migraine with aura.,10524660_10,-1,-1,-1,353,-1,0.004844991,0.995155
357,migraine with aura,29,32,188,206,"Since cortical spreading depression has been shown to liberate NO in animals, this finding may help our understanding of the coupling between cortical spreading depression and headache in migraine with aura.",10524660_11,-1,-1,-1,357,-1,0.004528866,0.9954711
359,cell lung carcinoma,5,8,41,60,Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin.,10526274_0,-1,-1,-1,359,-1,0.0072991457,0.9927008
361,nonsmall cell lung carcinoma,6,10,39,67,"BACKGROUND: Although the prevalence of nonsmall cell lung carcinoma (NSCLC) is high among elderly patients, few data are available regarding the efficacy and toxicity of chemotherapy in this group of patients.",10526274_2,-1,-1,-1,361,-1,0.031324286,0.96867573
362,NSCLC,11,12,69,74,"BACKGROUND: Although the prevalence of nonsmall cell lung carcinoma (NSCLC) is high among elderly patients, few data are available regarding the efficacy and toxicity of chemotherapy in this group of patients.",10526274_2,-1,-1,-1,362,-1,0.008061907,0.99193805
365,VNB,10,11,68,71,"Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable toxicity and improvement in symptoms and quality of life.",10526274_3,-1,-1,-1,365,-1,0.9978934,0.0021066857
367,GEM,15,16,89,92,"Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable toxicity and improvement in symptoms and quality of life.",10526274_3,-1,-1,-1,367,-1,0.9974795,0.0025204795
370,GEM,12,13,69,72,In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.,10526274_4,-1,-1,-1,370,-1,0.9988801,0.001119877
371,VNB,14,15,77,80,In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.,10526274_4,-1,-1,-1,371,-1,0.99861383,0.0013861993
372,NSCLC,20,21,115,120,In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.,10526274_4,-1,-1,-1,372,-1,0.0055540926,0.9944459
374,NSCLC,6,7,43,48,"METHODS: Forty-nine patients with advanced NSCLC were included, 38 of whom were age >/= 70 years and 11 were age < 70 years but who had some contraindication to receiving cisplatin.",10526274_5,-1,-1,-1,374,-1,0.004820408,0.99517965
377,VNB,4,5,27,30,"Treatment was comprised of VNB, 25 mg/m(2), plus GEM, 1000 mg/m(2), both on Days 1, 8, and 15 every 28 days.",10526274_7,-1,-1,-1,377,-1,0.9986015,0.0013985445
378,GEM,11,12,49,52,"Treatment was comprised of VNB, 25 mg/m(2), plus GEM, 1000 mg/m(2), both on Days 1, 8, and 15 every 28 days.",10526274_7,-1,-1,-1,378,-1,0.9983479,0.0016521685
386,P,28,29,151,152,The median age of those patients developing Grade 3-4 neutropenia was significantly higher than that of the remaining patients (75 years vs. 72 years; P = 0.047).,10526274_17,-1,-1,-1,386,-1,0.2951518,0.70484823
387,GEM,5,6,32,35,CONCLUSIONS: The combination of GEM and VNB is moderately active and well tolerated except in patients age >/= 75 years.,10526274_18,-1,-1,-1,387,-1,0.99857235,0.0014276734
388,VNB,7,8,40,43,CONCLUSIONS: The combination of GEM and VNB is moderately active and well tolerated except in patients age >/= 75 years.,10526274_18,-1,-1,-1,388,-1,0.99861646,0.0013835614
391,NSCLC,16,17,116,121,New chemotherapy combinations with higher activity and lower toxicity are needed for elderly patients with advanced NSCLC.,10526274_21,-1,-1,-1,391,-1,0.005402496,0.99459743
393,calcium chloride,7,9,65,81,Rapid reversal of life-threatening diltiazem-induced tetany with calcium chloride.,10533019_0,-1,-1,-1,393,-1,0.99882084,0.0011791796
395,respiratory arrest,9,11,55,73,We describe a patient who developed tetany with sudden respiratory arrest after the infusion of intravenous diltiazem.,10533019_1,-1,-1,-1,395,-1,0.0022979358,0.99770206
397,calcium chloride,3,5,22,38,"The administration of calcium chloride rapidly resolved the patient's tetany with prompt recovery of respiratory function, averting the need for more aggressive airway management and ventilatory support.",10533019_2,-1,-1,-1,397,-1,0.99896216,0.0010378864
401,calcium chloride,18,20,136,152,The emergency physician should be aware that life-threatening tetany may accompany the administration of intravenous diltiazem and that calcium chloride may be a rapid and effective remedy.,10533019_3,-1,-1,-1,401,-1,0.99890053,0.0010994095
402,decreased renal function,2,5,14,38,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,-1,-1,402,-1,0.0054644994,0.99453557
403,heart failure,8,10,56,69,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,-1,-1,403,-1,0.003085355,0.9969146
404,left ventricular dysfunction,21,24,154,182,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,-1,-1,404,-1,0.0070826225,0.9929174
405,congestive heart failure,37,40,300,324,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,-1,-1,405,-1,0.0037781387,0.9962218
406,CHF,41,42,326,329,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,-1,-1,406,-1,0.0029954836,0.99700457
407,decreased renal function,48,51,350,374,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,-1,-1,-1,407,-1,0.0054179225,0.9945821
408,reduction in renal function,8,12,55,82,OBJECTIVE: To quantify specific clinical predictors of reduction in renal function in patients with CHF who are prescribed angiotensin-converting enzyme inhibitor therapy.,10539815_2,-1,-1,-1,408,-1,0.006113813,0.9938862
409,CHF,15,16,100,103,OBJECTIVE: To quantify specific clinical predictors of reduction in renal function in patients with CHF who are prescribed angiotensin-converting enzyme inhibitor therapy.,10539815_2,-1,-1,-1,409,-1,0.0034375843,0.9965624
410,Left Ventricular Dysfunction,9,12,45,73,"METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.",10539815_3,-1,-1,-1,410,-1,0.0082236435,0.99177635
412,CHF,29,30,170,173,"METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.",10539815_3,-1,-1,-1,412,-1,0.0030284887,0.9969715
414,Decreased renal function,0,3,0,24,Decreased renal function was defined as a rise in serum creatinine >/=0.5 mg/dL (44 micromol/L) from baseline.,10539815_5,-1,-1,-1,414,-1,0.005241402,0.99475855
417,mm Hg,30,32,192,197,"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.",10539815_6,-1,-1,-1,417,-1,0.40025225,0.5997477
420,diuretic,45,46,260,268,"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.",10539815_6,-1,-1,-1,420,-1,0.99769527,0.0023046888
422,decreased renal function,14,17,81,105,RESULTS: Patients randomly assigned to enalapril had a 33% greater likelihood of decreased renal function than controls (P =.003).,10539815_7,-1,-1,-1,422,-1,0.005177151,0.99482286
423,P,20,21,121,122,RESULTS: Patients randomly assigned to enalapril had a 33% greater likelihood of decreased renal function than controls (P =.003).,10539815_7,-1,-1,-1,423,-1,0.38751277,0.61248726
425,diuretic,14,15,78,86,"By multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective.",10539815_8,-1,-1,-1,425,-1,0.9984281,0.0015718662
427,decreased renal function,22,25,130,154,"By multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective.",10539815_8,-1,-1,-1,427,-1,0.0047196597,0.9952803
428,decreased renal function,10,13,59,83,"Older age was associated with a greater risk of developing decreased renal function in both groups, but significantly more so in the enalapril group (enalapril: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with enalapril; placebo: RR 1.18, 95% CI 1.12-1.25).",10539815_9,-1,-1,-1,428,-1,0.0046130437,0.995387
432,decreased renal function,10,13,64,88,"Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group (RR 1.89, 95% CI 1.70-2.08) than in the placebo group (RR 1.35, 95% CI 1.09-1.66).",10539815_10,-1,-1,-1,432,-1,0.004119756,0.99588025
436,renal impairment,4,6,16,32,"A lower risk of renal impairment was seen in both groups with beta-blocker therapy (RR 0.70, 95% CI 0.57-0.85) and higher baseline ejection fraction (RR 0.93 per 5% increment, 95% CI 0.91-0. 96).",10539815_12,-1,-1,-1,436,-1,0.0026611974,0.99733883
438,decreased renal function,13,16,64,88,CONCLUSIONS: Enalapril use caused a 33% increase in the risk of decreased renal function in patients with CHF.,10539815_13,-1,-1,-1,438,-1,0.0045895004,0.9954105
439,CHF,19,20,106,109,CONCLUSIONS: Enalapril use caused a 33% increase in the risk of decreased renal function in patients with CHF.,10539815_13,-1,-1,-1,439,-1,0.0029177445,0.9970823
440,Diuretic,0,1,0,8,Diuretic use and advanced age increased this risk.,10539815_14,-1,-1,-1,440,-1,0.9985434,0.0014566302
441,renal impairment,8,10,50,66,"Diabetes was associated with an increased risk of renal impairment in all patients with CHF, but this risk was reduced in the enalapril group compared with the placebo group.",10539815_15,-1,-1,-1,441,-1,0.0027220775,0.9972779
442,CHF,14,15,88,91,"Diabetes was associated with an increased risk of renal impairment in all patients with CHF, but this risk was reduced in the enalapril group compared with the placebo group.",10539815_15,-1,-1,-1,442,-1,0.0024925119,0.99750745
445,psychotic disorder,13,15,73,91,We report a female patient with a diagnosis of a not otherwise specified psychotic disorder (DSM-IV) who developed hypomania shortly after the introduction of olanzapine treatment.,10565806_1,-1,-1,-1,445,-1,0.002675669,0.99732435
446,hypomania,20,21,115,124,We report a female patient with a diagnosis of a not otherwise specified psychotic disorder (DSM-IV) who developed hypomania shortly after the introduction of olanzapine treatment.,10565806_1,-1,-1,-1,446,-1,0.0038857902,0.99611413
449,NRA0160,7,8,45,52,"A selective dopamine D4 receptor antagonist, NRA0160: a preclinical neuropharmacological profile.",10579464_0,-1,-1,-1,449,-1,0.99647504,0.0035249675
451,NRA0160,0,1,0,7,"NRA0160 is over 20,000fold more potent at the dopamine D4.2 receptor compared with the human cloned dopamine D2L receptor.",10579464_2,-1,-1,-1,451,-1,0.9962578,0.0037422604
454,NRA0160,0,1,0,7,"NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM).",10579464_3,-1,-1,-1,454,-1,0.9956625,0.004337478
460,MAP,10,11,86,89,NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (MAP) in mice.,10579464_4,-1,-1,-1,460,-1,0.99485683,0.005143187
461,NRA0160,0,1,0,7,"NRA0160 and clozapine antagonized MAP-induced stereotyped behavior in mice, although their effects did not exceed 50% inhibition, even at the highest dose given.",10579464_5,-1,-1,-1,461,-1,0.996711,0.0032889706
465,NRA0160,0,1,0,7,NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine.,10579464_7,-1,-1,-1,465,-1,0.9963792,0.0036208217
469,phencyclidine,6,7,50,63,NRA0160 and clozapine significantly shortened the phencyclidine (PCP)-induced prolonged swimming latency in rats in a water maze task.,10579464_8,-1,-1,-1,469,-1,0.99925977,0.0007401676
470,NRA0160,4,5,28,35,These findings suggest that NRA0160 may have unique antipsychotic activities without the liability of motor side effects typical of classical antipsychotics.,10579464_9,-1,-1,-1,470,-1,0.99837697,0.0016230522
471,antipsychotics,20,21,142,156,These findings suggest that NRA0160 may have unique antipsychotic activities without the liability of motor side effects typical of classical antipsychotics.,10579464_9,-1,-1,-1,471,-1,0.9833176,0.016682332
473,vitamin D.The,8,10,67,80,"Warfarin-induced artery calcification is accelerated by growth and vitamin D.The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.",10669626_0,-1,-1,-1,473,-1,0.9638458,0.03615428
474,vitamin D,16,18,125,134,"Warfarin-induced artery calcification is accelerated by growth and vitamin D.The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.",10669626_0,-1,-1,-1,474,-1,0.99834824,0.0016517942
480,calcification of the artery,9,13,57,84,Treatment for 2 weeks with Warfarin caused massive focal calcification of the artery media in 20-day-old rats and less extensive focal calcification in 42-day-old rats.,10669626_2,-1,-1,-1,480,-1,0.014219652,0.9857803
482,contrast,1,2,3,11,"In contrast, no artery calcification could be detected in 10-month-old adult rats even after 4 weeks of Warfarin treatment.",10669626_3,-1,-1,-1,482,-1,0.10315193,0.896848
486,ad,27,28,161,163,"To directly examine the importance of growth to Warfarin-induced artery calcification in animals of the same age, 20-day-old rats were fed for 2 weeks either an ad libitum diet or a 6-g/d restricted diet that maintains weight but prevents growth.",10669626_4,-1,-1,-1,486,-1,0.9625185,0.03748142
488,calcification of the artery,11,15,81,108,"Concurrent treatment of both dietary groups with Warfarin produced massive focal calcification of the artery media in the ad libitum-fed rats but no detectable artery calcification in the restricted-diet, growth-inhibited group.",10669626_5,-1,-1,-1,488,-1,0.012935918,0.9870641
489,ad,18,19,122,124,"Concurrent treatment of both dietary groups with Warfarin produced massive focal calcification of the artery media in the ad libitum-fed rats but no detectable artery calcification in the restricted-diet, growth-inhibited group.",10669626_5,-1,-1,-1,489,-1,0.97650117,0.02349887
495,ad,46,47,289,291,"Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.",10669626_6,-1,-1,-1,495,-1,0.96226496,0.037735052
497,ie,63,64,405,407,"Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.",10669626_6,-1,-1,-1,497,-1,0.16572373,0.83427626
500,vitamin D,10,12,68,77,The second set of experiments examined the possible synergy between vitamin D and Warfarin in artery calcification.,10669626_8,-1,-1,-1,500,-1,0.9982445,0.0017554548
503,vitamin D,3,5,14,23,High doses of vitamin D are known to cause calcification of the artery media in as little as 3 to 4 days.,10669626_9,-1,-1,-1,503,-1,0.99768984,0.0023102215
504,calcification of the artery,9,13,43,70,High doses of vitamin D are known to cause calcification of the artery media in as little as 3 to 4 days.,10669626_9,-1,-1,-1,504,-1,0.015316305,0.9846837
505,vitamin K,4,6,18,27,"High doses of the vitamin K antagonist Warfarin are also known to cause calcification of the artery media, but at treatment times of 2 weeks or longer yet not at 1 week.",10669626_10,-1,-1,-1,505,-1,0.9983303,0.0016697032
507,calcification of the artery,13,17,72,99,"High doses of the vitamin K antagonist Warfarin are also known to cause calcification of the artery media, but at treatment times of 2 weeks or longer yet not at 1 week.",10669626_10,-1,-1,-1,507,-1,0.014495371,0.9855047
510,vitamin D,9,11,49,58,"There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.",10669626_12,-1,-1,-1,510,-1,0.99851435,0.0014856432
512,vitamin D,19,21,106,115,"There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.",10669626_12,-1,-1,-1,512,-1,0.99825567,0.0017443392
514,vitamin D,32,34,176,185,"There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.",10669626_12,-1,-1,-1,514,-1,0.9983553,0.00164465
519,vitamin D,14,16,87,96,"Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.",10669626_13,-1,-1,-1,519,-1,0.99862754,0.001372514
521,vitamin D,22,24,131,140,"Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.",10669626_13,-1,-1,-1,521,-1,0.99861085,0.0013891397
525,vitamin D,17,19,98,107,"High levels of matrix Gla protein are found at sites of artery calcification in rats treated with vitamin D plus Warfarin, and chemical analysis showed that the protein that accumulated was indeed not gamma-carboxylated.",10669626_14,-1,-1,-1,525,-1,0.99832946,0.0016704964
529,dopamine agonist,4,6,28,44,"Apomorphine, a nonselective dopamine agonist, was selected due to its biphasic behavioral effects, its ability to induce hypothermia, and to produce distinct changes to dopamine turnover in the rodent brain.",10683478_2,-1,-1,-1,529,-1,0.99377936,0.0062206206
536,contrast,1,2,3,11,"By contrast, apomorphine-induced locomotion was more prominent in the novel exploratory box.",10683478_8,-1,-1,-1,536,-1,0.23931019,0.7606898
537,DOPAC,4,5,26,31,Dopamine turnover ratios (DOPAC:DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts.,10683478_9,-1,-1,-1,537,-1,0.99878484,0.0012151755
538,DA,6,7,32,34,Dopamine turnover ratios (DOPAC:DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts.,10683478_9,-1,-1,-1,538,-1,0.99788874,0.0021112002
539,HVA,8,9,39,42,Dopamine turnover ratios (DOPAC:DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts.,10683478_9,-1,-1,-1,539,-1,0.9983375,0.001662419
540,DA,10,11,43,45,Dopamine turnover ratios (DOPAC:DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts.,10683478_9,-1,-1,-1,540,-1,0.9975025,0.0024974856
542,Gerstmann syndrome,1,3,22,40,Acetazolamide-induced Gerstmann syndrome.,10692744_0,-1,-1,-1,542,-1,0.010301886,0.9896981
544,acetazolamide,4,5,27,40,Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment.,10692744_1,-1,-1,-1,544,-1,0.9993742,0.00062577624
545,adverse drug reaction,9,12,57,78,Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment.,10692744_1,-1,-1,-1,545,-1,0.02464968,0.9753504
546,renal impairment,15,17,96,112,Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment.,10692744_1,-1,-1,-1,546,-1,0.0030114383,0.9969886
547,Gerstmann syndrome,6,8,42,60,"We report a case of acetazolamide-induced Gerstmann syndrome in a patient with normal renal function, to highlight predisposing factors that are frequently overlooked.",10692744_2,-1,-1,-1,547,-1,0.018568614,0.98143137
550,TAM,2,3,11,14,"Tamoxifen (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, induces changes in normal discoid shape of erythrocytes and hemolytic anemia.",10704919_1,-1,-1,-1,550,-1,0.9980457,0.0019543124
553,TAM,6,7,35,38,"This work evaluates the effects of TAM on isolated human erythrocytes, attempting to identify the underlying mechanisms on TAM-induced hemolytic anemia and the involvement of biomembranes in its cytostatic action mechanisms.",10704919_2,-1,-1,-1,553,-1,0.99829775,0.0017022929
555,TAM,0,1,0,3,TAM induces hemolysis of erythrocytes as a function of concentration.,10704919_3,-1,-1,-1,555,-1,0.99841297,0.0015870612
558,TAM,13,14,81,84,"The extension of hemolysis is variable with erythrocyte samples, but 12.5 microM TAM induces total hemolysis of all tested suspensions.",10704919_4,-1,-1,-1,558,-1,0.99847776,0.0015222186
560,TAM,6,7,46,49,"Despite inducing extensive erythrocyte lysis, TAM does not shift the osmotic fragility curves of erythrocytes.",10704919_5,-1,-1,-1,560,-1,0.9986089,0.0013910944
561,hemolytic,1,2,4,13,The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.,10704919_6,-1,-1,-1,561,-1,0.0022537285,0.9977463
562,TAM,4,5,24,27,The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.,10704919_6,-1,-1,-1,562,-1,0.99813074,0.0018693251
563,hydroxyl,24,25,158,166,The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.,10704919_6,-1,-1,-1,563,-1,0.9938094,0.0061905957
567,TAM,6,7,34,37,"Furthermore, it was observed that TAM inhibits the peroxidation of human erythrocytes induced by AAPH, thus ruling out TAM-induced cell oxidative stress.",10704919_8,-1,-1,-1,567,-1,0.99827754,0.0017224713
568,AAPH,15,16,97,101,"Furthermore, it was observed that TAM inhibits the peroxidation of human erythrocytes induced by AAPH, thus ruling out TAM-induced cell oxidative stress.",10704919_8,-1,-1,-1,568,-1,0.9958729,0.0041270875
570,TAM,3,4,20,23,"Hemolysis caused by TAM was not preceded by the leakage of K(+) from the cells, also excluding a colloid-osmotic type mechanism of hemolysis, according to the effects on osmotic fragility curves.",10704919_9,-1,-1,-1,570,-1,0.9982608,0.0017392427
572,TAM,2,3,9,12,"However, TAM induces release of peripheral proteins of membrane-cytoskeleton and cytosol proteins essentially bound to band 3.",10704919_10,-1,-1,-1,572,-1,0.99855083,0.0014491583
573,TAM,9,10,68,71,Either alpha-T or alpha-TAc increases membrane packing and prevents TAM partition into model membranes.,10704919_11,-1,-1,-1,573,-1,0.9947995,0.0052004424
575,tocopherols,9,10,60,71,These effects suggest that the protection from hemolysis by tocopherols is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided.,10704919_12,-1,-1,-1,575,-1,0.9990508,0.00094921485
576,TAM,15,16,98,101,These effects suggest that the protection from hemolysis by tocopherols is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided.,10704919_12,-1,-1,-1,576,-1,0.99818265,0.0018173922
578,TAM,13,14,100,103,"These defects explain the abnormal erythrocyte shape and decreased mechanical stability promoted by TAM, resulting in hemolytic anemia.",10704919_14,-1,-1,-1,578,-1,0.99811965,0.0018803612
580,cytotoxicity,10,11,57,69,"Additionally, since membrane leakage is a final stage of cytotoxicity, the disruption of the structural characteristics of biomembranes by TAM may contribute to the multiple mechanisms of its anticancer action.",10704919_15,-1,-1,-1,580,-1,0.0035487502,0.99645126
581,TAM,21,22,139,142,"Additionally, since membrane leakage is a final stage of cytotoxicity, the disruption of the structural characteristics of biomembranes by TAM may contribute to the multiple mechanisms of its anticancer action.",10704919_15,-1,-1,-1,581,-1,0.99709153,0.0029084575
583,ATP,4,5,22,25,"Changes of sodium and ATP affinities of the cardiac (Na,K)-ATPase during and after nitric oxide deficient hypertension.",10706004_0,-1,-1,-1,583,-1,0.997943,0.0020570399
584,nitric oxide,15,17,83,95,"Changes of sodium and ATP affinities of the cardiac (Na,K)-ATPase during and after nitric oxide deficient hypertension.",10706004_0,-1,-1,-1,584,-1,0.9980148,0.0019851793
590,ATP,9,10,53,56,"When activating the (Na,K)-ATPase with its substrate ATP, no changes in Km and Vmax values were observed in NO-deficient rats.",10706004_7,-1,-1,-1,590,-1,0.9975758,0.002424242
592,ATP-binding,19,20,105,116,"After recovery from hypertension, the activity of (Na,K)-ATPase increased, due to higher affinity of the ATP-binding site, as revealed from the lowered Km value for ATP.",10706004_9,-1,-1,-1,592,-1,0.873491,0.12650906
593,ATP,30,31,165,168,"After recovery from hypertension, the activity of (Na,K)-ATPase increased, due to higher affinity of the ATP-binding site, as revealed from the lowered Km value for ATP.",10706004_9,-1,-1,-1,593,-1,0.99774665,0.0022532844
611,domperidone,0,1,0,11,domperidone (0.5 mg/kg).,10721819_6,-1,-1,-1,611,-1,0.99903333,0.00096672674
622,heart failure,9,11,72,85,Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure.,10728962_0,-1,-1,-1,622,-1,0.0024763038,0.9975237
623,phosphodiesterase inhibitors,3,5,11,39,The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension.,10728962_1,-1,-1,-1,623,-1,0.9610069,0.03899313
624,milrinone,7,8,48,57,The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension.,10728962_1,-1,-1,-1,624,-1,0.9991511,0.0008488379
625,heart failure,13,15,85,98,The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension.,10728962_1,-1,-1,-1,625,-1,0.002620207,0.9973797
627,heart failure,4,6,31,44,"In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.",10728962_2,-1,-1,-1,627,-1,0.0025033301,0.99749666
629,milrinone,11,12,83,92,"In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.",10728962_2,-1,-1,-1,629,-1,0.99926394,0.000736103
631,milrinone,26,27,186,195,"In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.",10728962_2,-1,-1,-1,631,-1,0.9993055,0.0006945087
642,venous thromboembolism,10,12,59,81,Recurrent use of newer oral contraceptives and the risk of venous thromboembolism.,10739826_0,-1,-1,-1,642,-1,0.0029264996,0.99707353
643,venous thromboembolism,8,10,54,76,"The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.",10739826_1,-1,-1,-1,643,-1,0.0030945193,0.9969055
644,VTE,11,12,78,81,"The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.",10739826_1,-1,-1,-1,644,-1,0.003535295,0.9964647
646,OC,19,20,126,128,"The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.",10739826_1,-1,-1,-1,646,-1,0.99590826,0.0040917895
647,OC,27,28,170,172,"The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.",10739826_1,-1,-1,-1,647,-1,0.9962798,0.0037201883
648,VTE,13,14,77,80,"Data from a Transnational case-control study were used to assess the risk of VTE for the latter patterns of use, while accounting for duration of use.",10739826_2,-1,-1,-1,648,-1,0.004005508,0.99599445
649,VTE,10,11,40,43,"Over the period 1993-1996, 551 cases of VTE were identified in Germany and the UK along with 2066 controls.",10739826_3,-1,-1,-1,649,-1,0.010657548,0.98934245
650,VTE,5,6,27,30,"The adjusted rate ratio of VTE for repeat users of third generation OC was 0.6 (95% CI:0.3-1.2) relative to repeat users of second generation pills, whereas it was 1.3 (95% CI:0.7-2.4) for switchers from second to third generation pills relative to switchers from third to second generation pills.",10739826_5,-1,-1,-1,650,-1,0.006473176,0.9935268
651,OC,12,13,68,70,"The adjusted rate ratio of VTE for repeat users of third generation OC was 0.6 (95% CI:0.3-1.2) relative to repeat users of second generation pills, whereas it was 1.3 (95% CI:0.7-2.4) for switchers from second to third generation pills relative to switchers from third to second generation pills.",10739826_5,-1,-1,-1,651,-1,0.9961792,0.0038208377
652,VTE,14,15,92,95,We conclude that second and third generation agents are associated with equivalent risks of VTE when the same agent is used repeatedly after interruption periods or when users are switched between the two generations of pills.,10739826_6,-1,-1,-1,652,-1,0.003453776,0.9965462
653,OC,11,12,67,69,These analyses suggest that the higher risk observed for the newer OC in other studies may be the result of inadequate comparisons of pill users with different patterns of pill use.,10739826_7,-1,-1,-1,653,-1,0.99695337,0.0030466267
665,mg,6,7,32,34,"infusion of ketamine (bolus 0.1 mg kg-1 over 10 min followed by infusion of 7 micrograms kg-1 min-1), lidocaine 5 mg kg-1 or saline for 50 min.",10743446_4,-1,-1,-1,665,-1,0.98687416,0.013125878
667,mg,23,24,114,116,"infusion of ketamine (bolus 0.1 mg kg-1 over 10 min followed by infusion of 7 micrograms kg-1 min-1), lidocaine 5 mg kg-1 or saline for 50 min.",10743446_4,-1,-1,-1,667,-1,0.9869538,0.013046234
684,CyA,14,15,113,116,"When tacrolimus side effects persist despite dose reduction, conversion to cyclosporine-based immunosuppression (CyA) is necessary.",10743694_1,-1,-1,-1,684,-1,0.99629223,0.0037077882
687,CyA.,15,16,104,108,"Of 388 liver recipients who received tacrolimus as primary immunosuppression, 70 required conversion to CyA. We recorded indication for conversion, whether conversion was early or late after transplantation, tacrolimus dose and trough blood level at conversion, and incidence of rejection after conversion.",10743694_3,-1,-1,-1,687,-1,0.9895583,0.010441725
690,diabetes mellitus,13,15,78,95,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,-1,690,-1,0.0034602226,0.99653983
691,IDDM,16,17,97,101,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,-1,691,-1,0.016313082,0.983687
693,GI,29,30,146,148,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,-1,693,-1,0.011948955,0.98805106
697,IDDM,52,53,237,241,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,-1,697,-1,0.0079628015,0.9920372
699,GI toxicity,62,64,268,279,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,-1,699,-1,0.004285196,0.9957147
701,PTLD,77,78,347,351,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,-1,-1,-1,701,-1,0.016953994,0.98304605
706,CyA,12,13,79,82,"When tacrolimus side effects are unresponsive to dose reduction, conversion to CyA can be accomplished safely, with no increased risk of rejection and excellent long-term outcome.",10743694_10,-1,-1,-1,706,-1,0.998965,0.0010349231
714,juvenile rheumatoid arthritis,3,6,25,54,Ocular manifestations of juvenile rheumatoid arthritis.,1079693_0,-1,-1,-1,714,-1,0.012239141,0.9877608
715,juvenile rheumatoid arthritis,5,8,25,54,We followed 210 cases of juvenile rheumatoid arthritis closely for eleven years.,1079693_1,-1,-1,-1,715,-1,0.0044928226,0.9955071
716,iridocyclitis,10,11,49,62,Thirty-six of the 210 patients (17.2%) developed iridocyclitis.,1079693_2,-1,-1,-1,716,-1,0.8669396,0.13306041
717,Iridocyclitis,0,1,0,13,Iridocyclitis was seen most frequently in young female patients (0 to 4 years) with the monoarticular or pauciatricular form of the arthritis.,1079693_3,-1,-1,-1,717,-1,0.880445,0.11955503
719,uveitis,8,9,39,46,"However, 30% of the patients developed uveitis after 16 years of age.",1079693_4,-1,-1,-1,719,-1,0.0023955684,0.9976044
720,uveitis,17,18,87,94,"Although 61% of patients had a noncontributory ocular history on entry, 42% had active uveitis on entry.",1079693_5,-1,-1,-1,720,-1,0.0025720105,0.997428
721,uveitis,6,7,40,47,Our approach was effective in detecting uveitis in new cases and exacerbations of uveitis in established cases.,1079693_6,-1,-1,-1,721,-1,0.0024434405,0.99755657
722,uveitis,13,14,82,89,Our approach was effective in detecting uveitis in new cases and exacerbations of uveitis in established cases.,1079693_6,-1,-1,-1,722,-1,0.0023219825,0.997678
723,uveitis,5,6,36,43,"Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or photophobia, in order of decreasing frequency.",1079693_7,-1,-1,-1,723,-1,0.0030325733,0.9969675
725,decreased visual acuity,23,26,122,145,"Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or photophobia, in order of decreasing frequency.",1079693_7,-1,-1,-1,725,-1,0.019017031,0.98098296
726,photophobia,28,29,150,161,"Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or photophobia, in order of decreasing frequency.",1079693_7,-1,-1,-1,726,-1,0.0075490167,0.992451
727,uveitis,13,14,65,72,"Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.",1079693_8,-1,-1,-1,727,-1,0.0023343652,0.99766564
729,uveitis,17,18,94,101,"Despite this, there was a dramatic decrease in the 50% incidence of blinding complications of uveitis cited in earlier studies.",1079693_9,-1,-1,-1,729,-1,0.0026319094,0.99736816
731,band keratopathy,2,4,13,29,"Cataract and band keratopathy occurred in only 22 and 13% of our group, respectively.",1079693_10,-1,-1,-1,731,-1,0.009589271,0.9904108
733,hydroxychloroquine,4,5,23,41,We used chloroquine or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs.,1079693_11,-1,-1,-1,733,-1,0.9990571,0.00094293896
734,chorioretinopathy,16,17,89,106,We used chloroquine or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs.,1079693_11,-1,-1,-1,734,-1,0.008331042,0.99166894
737,keratoconjunctivitis sicca,1,3,8,34,Typical keratoconjunctivitis sicca developed in three of the uveitis cases.,1079693_13,-1,-1,-1,737,-1,0.034357328,0.96564263
738,uveitis,8,9,61,68,Typical keratoconjunctivitis sicca developed in three of the uveitis cases.,1079693_13,-1,-1,-1,738,-1,0.0026495568,0.99735045
739,uveitis,3,4,22,29,This association with uveitis and JRA was not noted previously.,1079693_14,-1,-1,-1,739,-1,0.0024730524,0.99752694
740,JRA,5,6,34,37,This association with uveitis and JRA was not noted previously.,1079693_14,-1,-1,-1,740,-1,0.021196676,0.97880334
742,band keratopathy,5,7,33,49,"Surgical treatment of cataracts, band keratopathy, and glaucoma achieved uniformly discouraging results.",1079693_15,-1,-1,-1,742,-1,0.020549392,0.97945064
744,Intracranial aneurysms,0,2,0,22,Intracranial aneurysms and cocaine abuse: analysis of prognostic indicators.,10807237_0,-1,-1,-1,744,-1,0.0042119627,0.99578804
746,subarachnoid hemorrhage,5,7,26,49,OBJECTIVE: The outcome of subarachnoid hemorrhage associated with cocaine abuse is reportedly poor.,10807237_1,-1,-1,-1,746,-1,0.0043954006,0.99560463
749,ruptured aneurysms,12,14,66,84,This group was compared with a control group of 135 patients with ruptured aneurysms and no history of cocaine abuse.,10807237_4,-1,-1,-1,749,-1,0.0045596706,0.99544036
751,subarachnoid hemorrhage,15,17,78,101,"Age at presentation, time of ictus after intoxication, Hunt and Hess grade of subarachnoid hemorrhage, size of the aneurysm, location of the aneurysm, and the Glasgow Outcome Scale score were assessed and compared.",10807237_5,-1,-1,-1,751,-1,0.0049025943,0.99509734
754,P,19,20,108,109,RESULTS: The patients in the study group were significantly younger than the patients in the control group (P < 0.002).,10807237_6,-1,-1,-1,754,-1,0.20620118,0.7937988
757,mm,18,19,89,91,The majority of these aneurysms were smaller than those of the control group (8 +/- 6.08 mm versus 11 +/- 5.4 mm; P = 0.05).,10807237_8,-1,-1,-1,757,-1,0.025203537,0.9747965
758,mm,24,25,110,112,The majority of these aneurysms were smaller than those of the control group (8 +/- 6.08 mm versus 11 +/- 5.4 mm; P = 0.05).,10807237_8,-1,-1,-1,758,-1,0.02195233,0.97804767
759,P,26,27,114,115,The majority of these aneurysms were smaller than those of the control group (8 +/- 6.08 mm versus 11 +/- 5.4 mm; P = 0.05).,10807237_8,-1,-1,-1,759,-1,0.19922033,0.8007797
760,P,5,6,21,22,Hunt and Hess grade (P < 0.005) and age (P < 0.007) were significant predictors of outcome for the patients with cocaine-related aneurysms.,10807237_10,-1,-1,-1,760,-1,0.40275377,0.5972462
761,P,12,13,41,42,Hunt and Hess grade (P < 0.005) and age (P < 0.007) were significant predictors of outcome for the patients with cocaine-related aneurysms.,10807237_10,-1,-1,-1,761,-1,0.3480346,0.6519654
764,aneurysmal rupture,5,7,36,54,CONCLUSION: Cocaine use predisposed aneurysmal rupture at a significantly earlier age and in much smaller aneurysms.,10807237_11,-1,-1,-1,764,-1,0.0042560697,0.99574393
767,acute stroke,10,12,69,81,Effect of intravenous nimodipine on blood pressure and outcome after acute stroke.,10835440_0,-1,-1,-1,767,-1,0.0053172824,0.9946827
770,reduction in blood pressure,19,23,134,161,BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.,10835440_1,-1,-1,-1,770,-1,0.06790466,0.9320953
771,acute stroke,31,33,197,209,BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.,10835440_1,-1,-1,-1,771,-1,0.0033992236,0.9966008
772,BP reduction,23,25,157,169,We sought to confirm this correlation with and without adjustment for prognostic variables and to investigate outcome in subgroups with increasing levels of BP reduction.,10835440_2,-1,-1,-1,772,-1,0.9388248,0.061175186
774,n=100,22,23,130,135,"METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).",10835440_3,-1,-1,-1,774,-1,0.32844886,0.67155117
776,n=101,32,33,168,173,"METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).",10835440_3,-1,-1,-1,776,-1,0.27281106,0.72718894
778,n=94,43,44,210,214,"METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).",10835440_3,-1,-1,-1,778,-1,0.25873443,0.74126554
779,n=92,12,13,73,77,"RESULTS: Two hundred sixty-five patients were included in this analysis (n=92, 93, and 80 for placebo, low dose, and high dose, respectively).",10835440_5,-1,-1,-1,779,-1,0.3496554,0.6503446
780,reduction in systolic,7,10,61,82,Nimodipine treatment resulted in a statistically significant reduction in systolic BP (SBP) and diastolic BP (DBP) from baseline compared with placebo during the first few days.,10835440_6,-1,-1,-1,780,-1,0.0377287,0.96227133
781,DBP reduction,8,10,60,73,"In multivariate analysis, a significant correlation between DBP reduction and worsening of the neurological score was found for the high-dose group (beta=0.49, P=0. 048).",10835440_7,-1,-1,-1,781,-1,0.93906116,0.06093888
782,P=0,25,26,160,163,"In multivariate analysis, a significant correlation between DBP reduction and worsening of the neurological score was found for the high-dose group (beta=0.49, P=0. 048).",10835440_7,-1,-1,-1,782,-1,0.43929413,0.5607059
783,DBP reduction,3,5,16,29,"Patients with a DBP reduction of > or =20% in the high-dose group had a significantly increased adjusted OR for the compound outcome variable death or dependency (Barthel Index <60) (n/N=25/26, OR 10. 16, 95% CI 1.02 to 101.74) and death alone (n/N=9/26, OR 4.336, 95% CI 1.131 16.619) compared with all placebo patients (n/N=62/92 and 14/92, respectively).",10835440_8,-1,-1,-1,783,-1,0.69579697,0.30420303
787,acute stroke,22,24,151,163,"CONCLUSIONS: DBP, but not SBP, reduction was associated with neurological worsening after the intravenous administration of high-dose nimodipine after acute stroke.",10835440_10,-1,-1,-1,787,-1,0.0037265033,0.9962735
791,visceral pain,14,16,105,118,Cyclophosphamide-induced cystitis in freely-moving conscious rats: behavioral approach to a new model of visceral pain.,10840460_0,-1,-1,-1,791,-1,0.0035863514,0.99641365
792,visceral pain,7,9,31,44,PURPOSE: To develop a model of visceral pain in rats using a behavioral approach.,10840460_1,-1,-1,-1,792,-1,0.003784064,0.9962159
794,CP,2,3,18,20,"Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce cystitis.",10840460_2,-1,-1,-1,794,-1,0.99694806,0.0030519366
795,acrolein,22,23,129,137,"Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce cystitis.",10840460_2,-1,-1,-1,795,-1,0.9989593,0.0010406983
797,CP,4,5,23,25,"MATERIALS AND METHODS: CP was administered at doses of 50, 100 and 200 mg./kg.",10840460_3,-1,-1,-1,797,-1,0.99823207,0.0017679477
800,CP,6,7,30,32,"In addition, 90 minutes after CP injection, that is, at the time of administration of morphine, the bladder was removed in some rats for histological examination.",10840460_8,-1,-1,-1,800,-1,0.9984541,0.0015459331
802,CP,19,20,118,120,"Finally, to show that the bladder is essential for the CP-induced behavioral modifications, female rats also received CP at doses of 200 mg./kg.",10840460_9,-1,-1,-1,802,-1,0.99840206,0.0015978956
803,mg,5,6,15,17,i.p. and of 20 mg.,10840460_10,-1,-1,-1,803,-1,0.90647006,0.09352998
804,acrolein,6,7,31,39,"by the intravesical route, and acrolein at doses of 0.5 mg.",10840460_11,-1,-1,-1,804,-1,0.9990128,0.0009871154
805,mg,11,12,56,58,"by the intravesical route, and acrolein at doses of 0.5 mg.",10840460_11,-1,-1,-1,805,-1,0.9367388,0.063261226
806,CP,4,5,14,16,"i.v. RESULTS: CP dose-relatedly induced marked behavioral modifications in male rats: breathing rate decrease, closing of the eyes and occurrence of specific postures.",10840460_13,-1,-1,-1,806,-1,0.9986784,0.0013216276
808,behavioral disorders,4,6,41,61,Morphine dose-dependently reversed these behavioral disorders.,10840460_14,-1,-1,-1,808,-1,0.0028839537,0.9971161
809,CP,19,20,92,94,A dose of 0.5 mg./kg. produced a reduction of almost 50% of the behavioral score induced by CP 200 mg./kg.,10840460_15,-1,-1,-1,809,-1,0.99815804,0.0018419764
813,CP,4,5,16,18,"In female rats, CP 200 mg./kg.",10840460_18,-1,-1,-1,813,-1,0.9977723,0.0022277283
814,mg,6,7,31,33,Administered at the dose of 20 mg.,10840460_20,-1,-1,-1,814,-1,0.9388717,0.061128337
815,CP,2,3,16,18,"intravesically, CP did not produce any behavioral effects, whereas acrolein at 0.5 mg.",10840460_21,-1,-1,-1,815,-1,0.9984124,0.0015875719
816,acrolein,11,12,67,75,"intravesically, CP did not produce any behavioral effects, whereas acrolein at 0.5 mg.",10840460_21,-1,-1,-1,816,-1,0.9990522,0.00094776397
817,mg,14,15,83,85,"intravesically, CP did not produce any behavioral effects, whereas acrolein at 0.5 mg.",10840460_21,-1,-1,-1,817,-1,0.9741455,0.025854524
818,CP,8,9,73,75,intravesically induced behavioral modifications identical to those under CP 200 mg./kg.,10840460_22,-1,-1,-1,818,-1,0.99869114,0.0013089192
819,acrolein,2,3,12,20,"Conversely, acrolein 5 mg./kg.",10840460_24,-1,-1,-1,819,-1,0.9989518,0.0010481637
821,visceral pain,23,25,156,169,"CONCLUSIONS: Overall, these results indicate that this experimental model of CP-induced cystitis may be an interesting new behavioral model of inflammatory visceral pain, allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them.",10840460_26,-1,-1,-1,821,-1,0.003403785,0.99659616
822,painful syndromes,32,34,212,229,"CONCLUSIONS: Overall, these results indicate that this experimental model of CP-induced cystitis may be an interesting new behavioral model of inflammatory visceral pain, allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them.",10840460_26,-1,-1,-1,822,-1,0.0027070167,0.99729294
828,clonic fits,21,23,129,140,A 17-day-old infant on isoniazid therapy 13 mg/kg daily from birth because of maternal tuberculosis was admitted after 4 days of clonic fits.,1085609_1,-1,-1,-1,828,-1,0.8205862,0.17941387
829,fits,1,2,4,8,"The fits ceased within 4 hours of administering intramuscular pyridoxine, suggesting an aetiology of pyridoxine deficiency secondary to isoniazid medication.",1085609_3,-1,-1,-1,829,-1,0.0028798976,0.99712014
835,emergency department,11,13,67,87,Ketamine sedation for the reduction of children's fractures in the emergency department.,10901305_0,-1,-1,-1,835,-1,0.011811089,0.98818886
839,emergency department,26,28,145,165,The purpose of the present study was to examine the safety and efficacy of ketamine for sedation in the treatment of children's fractures in the emergency department.,10901305_2,-1,-1,-1,839,-1,0.012305521,0.9876945
840,fracture,32,33,164,172,"METHODS: One hundred and fourteen children (average age, 5.3 years; range, twelve months to ten years and ten months) who underwent closed reduction of an isolated fracture or dislocation in the emergency department at a level-I trauma center were prospectively evaluated.",10901305_3,-1,-1,-1,840,-1,0.005477149,0.9945228
841,dislocation,34,35,176,187,"METHODS: One hundred and fourteen children (average age, 5.3 years; range, twelve months to ten years and ten months) who underwent closed reduction of an isolated fracture or dislocation in the emergency department at a level-I trauma center were prospectively evaluated.",10901305_3,-1,-1,-1,841,-1,0.004209973,0.99579006
842,emergency department,37,39,195,215,"METHODS: One hundred and fourteen children (average age, 5.3 years; range, twelve months to ten years and ten months) who underwent closed reduction of an isolated fracture or dislocation in the emergency department at a level-I trauma center were prospectively evaluated.",10901305_3,-1,-1,-1,842,-1,0.017748531,0.98225147
843,trauma,42,43,229,235,"METHODS: One hundred and fourteen children (average age, 5.3 years; range, twelve months to ten years and ten months) who underwent closed reduction of an isolated fracture or dislocation in the emergency department at a level-I trauma center were prospectively evaluated.",10901305_3,-1,-1,-1,843,-1,0.02064225,0.9793578
844,Ketamine hydrochloride,0,2,0,22,Ketamine hydrochloride was administered intravenously (at a dose of two milligrams per kilogram of body weight) in ninety-nine of the patients and intramuscularly (at a dose of four milligrams per kilogram of body weight) in the other fifteen.,10901305_4,-1,-1,-1,844,-1,0.99887687,0.0011230893
845,body weight,15,17,99,110,Ketamine hydrochloride was administered intravenously (at a dose of two milligrams per kilogram of body weight) in ninety-nine of the patients and intramuscularly (at a dose of four milligrams per kilogram of body weight) in the other fifteen.,10901305_4,-1,-1,-1,845,-1,0.542375,0.45762497
846,body weight,35,37,209,220,Ketamine hydrochloride was administered intravenously (at a dose of two milligrams per kilogram of body weight) in ninety-nine of the patients and intramuscularly (at a dose of four milligrams per kilogram of body weight) in the other fifteen.,10901305_4,-1,-1,-1,846,-1,0.44262108,0.55737895
850,fracture,14,15,93,101,"RESULTS: The average time from intravenous administration of ketamine to manipulation of the fracture or dislocation was one minute and thirty-six seconds (range, twenty seconds to five minutes), and the average time from intramuscular administration to manipulation was four minutes and forty-two seconds (range, sixty seconds to fifteen minutes).",10901305_7,-1,-1,-1,850,-1,0.0039267475,0.99607325
851,dislocation,16,17,105,116,"RESULTS: The average time from intravenous administration of ketamine to manipulation of the fracture or dislocation was one minute and thirty-six seconds (range, twenty seconds to five minutes), and the average time from intramuscular administration to manipulation was four minutes and forty-two seconds (range, sixty seconds to fifteen minutes).",10901305_7,-1,-1,-1,851,-1,0.0033321306,0.9966679
854,fracture reduction,32,34,162,180,"The average score according to the Children's Hospital of Eastern Ontario Pain Scale was 6.4 points (range, 5 to 10 points), reflecting minimal or no pain during fracture reduction.",10901305_8,-1,-1,-1,854,-1,0.021623684,0.97837627
855,fracture,1,2,9,17,Adequate fracture reduction was obtained in 111 of the children.,10901305_9,-1,-1,-1,855,-1,0.006689054,0.9933109
857,emesis,10,11,56,62,"Minor side effects included nausea (thirteen patients), emesis (eight of the thirteen patients with nausea), clumsiness (evident as ataxic movements in ten patients), and dysphoric reaction (one patient).",10901305_13,-1,-1,-1,857,-1,0.002617634,0.99738234
859,clumsiness,21,22,109,119,"Minor side effects included nausea (thirteen patients), emesis (eight of the thirteen patients with nausea), clumsiness (evident as ataxic movements in ten patients), and dysphoric reaction (one patient).",10901305_13,-1,-1,-1,859,-1,0.012372733,0.98762727
860,ataxic movements,25,27,132,148,"Minor side effects included nausea (thirteen patients), emesis (eight of the thirteen patients with nausea), clumsiness (evident as ataxic movements in ten patients), and dysphoric reaction (one patient).",10901305_13,-1,-1,-1,860,-1,0.023967318,0.97603273
861,dysphoric reaction,33,35,171,189,"Minor side effects included nausea (thirteen patients), emesis (eight of the thirteen patients with nausea), clumsiness (evident as ataxic movements in ten patients), and dysphoric reaction (one patient).",10901305_13,-1,-1,-1,861,-1,0.0035406407,0.9964593
865,emergency department,23,25,150,170,"CONCLUSIONS: Ketamine reliably, safely, and quickly provided adequate sedation to effectively facilitate the reduction of children's fractures in the emergency department at our institution.",10901305_15,-1,-1,-1,865,-1,0.010958905,0.98904103
867,emergency department,11,13,59,79,"Ketamine should only be used in an environment such as the emergency department, where proper one-on-one monitoring is used and board-certified physicians skilled in airway management are directly involved in the care of the patient.",10901305_16,-1,-1,-1,867,-1,0.018009242,0.98199075
868,muscle dysfunction,1,3,21,39,Prednisolone-induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression.,10910842_0,-1,-1,-1,868,-1,0.003025336,0.9969747
870,glucocorticoids,3,4,15,30,Large doses of glucocorticoids can alter muscle physiology and susceptibility to neuromuscular blocking drugs by mechanisms not clearly understood.,10910842_1,-1,-1,-1,870,-1,0.998857,0.0011429556
875,twitch,7,8,32,38,"On Day 8, the nerve-evoked peak twitch tensions, tetanic tensions, and fatigability, and the dose-response curves of d-tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs.",10910842_5,-1,-1,-1,875,-1,0.007928068,0.9920719
876,tetanic,10,11,49,56,"On Day 8, the nerve-evoked peak twitch tensions, tetanic tensions, and fatigability, and the dose-response curves of d-tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs.",10910842_5,-1,-1,-1,876,-1,0.020434055,0.9795659
877,body weight gain,2,5,8,24,"Rate of body weight gain was depressed in the P100, FR, and P10 groups compared with the S group.",10910842_6,-1,-1,-1,877,-1,0.010398664,0.9896013
879,twitch,3,4,16,22,"The evoked peak twitch and tetanic tensions were less in the P100 group than in the P10 or S groups, however, tension per milligram of muscle mass was greater in the P100 group than in the S group.",10910842_8,-1,-1,-1,879,-1,0.009200803,0.9907991
880,tetanic,5,6,27,34,"The evoked peak twitch and tetanic tensions were less in the P100 group than in the P10 or S groups, however, tension per milligram of muscle mass was greater in the P100 group than in the S group.",10910842_8,-1,-1,-1,880,-1,0.05400179,0.9459982
881,P,13,14,62,63,"The evoked tensions correlated with muscle mass (r(2) = 0.32, P < 0.001), however, not with expression of AChR. The 50% effective dose of d-tubocurarine did not correlate with muscle mass or AChR expression.",10910842_11,-1,-1,-1,881,-1,0.36442375,0.63557625
882,neuromuscular dysfunction,5,7,29,54,"Our results suggest that the neuromuscular dysfunction after prednisolone is dose-dependent, and derives primarily from muscle atrophy and derives less so from changes in AChR expression.",10910842_12,-1,-1,-1,882,-1,0.0026197983,0.9973802
884,muscle atrophy,16,18,120,134,"Our results suggest that the neuromuscular dysfunction after prednisolone is dose-dependent, and derives primarily from muscle atrophy and derives less so from changes in AChR expression.",10910842_12,-1,-1,-1,884,-1,0.0041185548,0.99588144
885,muscle atrophy,12,14,82,96,We suggest that the observed effects are dose-dependent and derive primarily from muscle atrophy and derive less from changes in acetylcholine receptor expression.,10910842_14,-1,-1,-1,885,-1,0.004255674,0.9957443
889,TMA,6,7,47,50,The development of thrombotic microangiopathy (TMA) associated with the use of cyclosporine has been well documented.,11007689_1,-1,-1,-1,889,-1,0.0138058,0.9861942
892,immunoglobulin G,23,25,169,185,"Treatments have included discontinuation or reduction of cyclosporine dose with or without concurrent plasma exchange, plasma infusion, anticoagulation, and intravenous immunoglobulin G infusion.",11007689_2,-1,-1,-1,892,-1,0.99840635,0.0015936459
896,TMA,21,22,128,131,"As a result, switching to tacrolimus has been reported to be a viable therapeutic option in the setting of cyclosporine-induced TMA.",11007689_5,-1,-1,-1,896,-1,0.17510803,0.8248919
898,TMA,12,13,99,102,"With the more widespread application of tacrolimus in organ transplantation, tacrolimus-associated TMA has also been recognized.",11007689_6,-1,-1,-1,898,-1,0.9000768,0.099923156
899,TMA,10,11,65,68,"However, literature regarding the incidence of the recurrence of TMA in patients exposed sequentially to cyclosporine and tacrolimus is limited.",11007689_7,-1,-1,-1,899,-1,0.6374722,0.36252776
902,TMA,14,15,97,100,We report a case of a living donor renal transplant recipient who developed cyclosporine-induced TMA that responded to the withdrawal of cyclosporine in conjunction with plasmapheresis and fresh frozen plasma replacement therapy.,11007689_8,-1,-1,-1,902,-1,0.48925236,0.5107476
905,TMA,13,14,99,102,Introduction of tacrolimus as an alternative immunosuppressive agent resulted in the recurrence of TMA and the subsequent loss of the renal allograft.,11007689_9,-1,-1,-1,905,-1,0.99621767,0.0037823026
908,signs and symptoms,17,20,108,126,Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA.,11007689_10,-1,-1,-1,908,-1,0.0060679093,0.99393207
909,TMA,22,23,140,143,Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA.,11007689_10,-1,-1,-1,909,-1,0.04178377,0.9582162
910,Parkinson's disease,6,9,42,61,Apomorphine: an underutilized therapy for Parkinson's disease.,11009181_0,-1,-1,-1,910,-1,0.0074272305,0.9925728
912,Parkinson's disease,12,15,75,94,Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease.,11009181_1,-1,-1,-1,912,-1,0.005029626,0.9949704
913,Parkinson's disease,17,20,114,133,"While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study.",11009181_2,-1,-1,-1,913,-1,0.005218645,0.9947813
919,dopamine agonists,35,37,209,226,"Continuous subcutaneous apomorphine infusions can reduce daily off-time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add-on therapy with oral dopamine agonists or COMT inhibitors.",11009181_4,-1,-1,-1,919,-1,0.99767643,0.0023235702
926,Parkinson's disease,12,15,89,108,"Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson's disease, this approach seems to deserve more widespread clinical use.",11009181_8,-1,-1,-1,926,-1,0.0042202687,0.99577975
927,Alzheimer's disease,31,34,189,208,"OBJECTIVE: The pharmacological response to drugs that act on the cholinergic system of the iris has been used to predict deficits in central cholinergic functioning due to diseases such as Alzheimer's disease, yet correlations between central and peripheral responses have not been properly studied.",11022397_1,-1,-1,-1,927,-1,0.009425821,0.9905742
928,in,15,16,87,89,"This study assessed the effect of normal aging on (1) the tropicamide-induced increase in pupil diameter, and (2) the reversal of this effect with pilocarpine.",11022397_2,-1,-1,-1,928,-1,0.047367383,0.95263267
931,tropicamide,4,5,14,25,"In 1 session, tropicamide (20 microL, 0.01%) was administered to one eye and placebo to the other.",11022397_8,-1,-1,-1,931,-1,0.99925894,0.000741093
932,tropicamide,4,5,20,31,"In another session, tropicamide (20 microL, 0.01%) was administered to both eyes, followed 23 minutes later by the application of pilocarpine (20 microL, 0.1%) to one eye and placebo to the other.",11022397_9,-1,-1,-1,932,-1,0.9992987,0.00070135156
935,mg,12,13,58,60,"In 2 separate sessions, a single dose of scopolamine (0.5 mg, intravenously) or placebo was administered, and the effects on word recall were measured using the Buschke Selective Reminding Test over 2 hours.",11022397_11,-1,-1,-1,935,-1,0.9715109,0.028489146
936,tropicamide,11,12,68,79,OUTCOME MEASURES: Pupil size at time points after administration of tropicamide and pilocarpine; scopolamine-induced impairment in word recall.,11022397_12,-1,-1,-1,936,-1,0.99930644,0.0006935351
938,impairment in word recall,16,20,117,142,OUTCOME MEASURES: Pupil size at time points after administration of tropicamide and pilocarpine; scopolamine-induced impairment in word recall.,11022397_12,-1,-1,-1,938,-1,0.020338973,0.979661
939,tropicamide,16,17,107,118,RESULTS: There was no significant difference between elderly and young volunteers in pupillary response to tropicamide at any time point (p > 0.05).,11022397_13,-1,-1,-1,939,-1,0.9993591,0.0006409076
940,p,22,23,138,139,RESULTS: There was no significant difference between elderly and young volunteers in pupillary response to tropicamide at any time point (p > 0.05).,11022397_13,-1,-1,-1,940,-1,0.24592169,0.7540783
941,p,30,31,175,176,"The elderly group had a significantly greater pilocarpine-induced net decrease in pupil size 85, 125, 165 and 215 minutes after administration, compared with the young group (p < 0.05).",11022397_14,-1,-1,-1,941,-1,0.23705898,0.762941
942,impairment in word recall 60,12,17,81,109,"Compared with the young group, the elderly group had greater scopolamine-induced impairment in word recall 60, 90 and 120 minutes after administration (p < 0.05).",11022397_15,-1,-1,-1,942,-1,0.08141377,0.91858625
943,p,25,26,152,153,"Compared with the young group, the elderly group had greater scopolamine-induced impairment in word recall 60, 90 and 120 minutes after administration (p < 0.05).",11022397_15,-1,-1,-1,943,-1,0.27445626,0.72554374
945,tropicamide,15,16,93,104,CONCLUSION: There is an age-related pupillary response to pilocarpine that is not found with tropicamide.,11022397_16,-1,-1,-1,945,-1,0.9992648,0.000735275
951,MM,21,22,141,143,This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).,11027904_2,-1,-1,-1,951,-1,0.99579704,0.004203012
952,n,25,26,156,157,This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).,11027904_2,-1,-1,-1,952,-1,0.22007999,0.77992004
953,n,37,38,220,221,This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).,11027904_2,-1,-1,-1,953,-1,0.15896632,0.8410337
954,CP,13,14,84,86,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,-1,-1,-1,954,-1,0.9273239,0.0726761
956,hydromorphone,32,33,188,201,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,-1,-1,-1,956,-1,0.999137,0.0008630402
957,mg,34,35,204,206,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,-1,-1,-1,957,-1,0.9576428,0.042357177
958,ketorolac,40,41,244,253,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,-1,-1,-1,958,-1,0.9991848,0.00081516744
959,mg,42,43,257,259,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,-1,-1,-1,959,-1,0.92925984,0.07074012
960,MM,3,4,20,22,"Results showed that MM individuals were significantly less tolerant of CP pain than control subjects, replicating previous work.",11027904_4,-1,-1,-1,960,-1,0.17672884,0.82327116
961,CP pain,10,12,71,78,"Results showed that MM individuals were significantly less tolerant of CP pain than control subjects, replicating previous work.",11027904_4,-1,-1,-1,961,-1,0.16022493,0.8397751
962,MM,4,5,25,27,These data indicate that MM opioid abusers represent a pain-intolerant subset of clinical patients.,11027904_6,-1,-1,-1,962,-1,0.9910631,0.0089369295
969,NMDA,9,10,70,74,"Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_2,-1,-1,-1,969,-1,0.99855095,0.0014489891
971,analgesia,23,24,144,153,"Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_2,-1,-1,-1,971,-1,0.045215756,0.9547842
981,drowsiness,14,15,66,76,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,-1,-1,-1,981,-1,0.00444277,0.99555725
988,mg,9,10,63,65,These episodes reversed after the administration of diazepam 1 mg intravenously.,11027905_8,-1,-1,-1,988,-1,0.98448896,0.015511023
989,drowsiness,3,4,25,35,Significant increases in drowsiness were reported in patients treated with ketamine in both groups and were more marked with ketamine 0.50 mg/kg.,11027905_9,-1,-1,-1,989,-1,0.0022383886,0.9977616
994,morphine analgesia,3,5,21,39,"Ketamine can improve morphine analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_11,-1,-1,-1,994,-1,0.91756815,0.08243183
999,spinal cord injury,7,10,50,68,High-dose methylprednisolone may do more harm for spinal cord injury.,11058428_0,-1,-1,-1,999,-1,0.00365066,0.99634933
1000,Acute Spinal Cord Injury,4,8,24,48,"Because of the National Acute Spinal Cord Injury Studies (NASCIS), high-dose methylprednisolone became the standard of care for the acute spinal cord injury.",11058428_1,-1,-1,-1,1000,-1,0.0056938976,0.99430615
1002,acute spinal cord injury,22,26,132,156,"Because of the National Acute Spinal Cord Injury Studies (NASCIS), high-dose methylprednisolone became the standard of care for the acute spinal cord injury.",11058428_1,-1,-1,-1,1002,-1,0.0040287874,0.99597114
1003,corticosteroid myopathy,13,15,71,94,"In the NASCIS, there was no mention regarding the possibility of acute corticosteroid myopathy that high-dose methylprednisolone may cause.",11058428_2,-1,-1,-1,1003,-1,0.03308666,0.9669133
1007,damage to the muscle,7,11,38,58,We hypothesize that it may cause some damage to the muscle of spinal cord injury patients.,11058428_4,-1,-1,-1,1007,-1,0.031200526,0.9687995
1008,spinal cord injury,12,15,62,80,We hypothesize that it may cause some damage to the muscle of spinal cord injury patients.,11058428_4,-1,-1,-1,1008,-1,0.0076400293,0.99235994
1009,steroid myopathy,2,4,9,25,"Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.",11058428_5,-1,-1,-1,1009,-1,0.036988918,0.96301115
1010,steroid myopathy,26,28,162,178,"Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.",11058428_5,-1,-1,-1,1010,-1,0.03592305,0.96407694
1012,spinal cord injury,38,41,244,262,"Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.",11058428_5,-1,-1,-1,1012,-1,0.005512938,0.9944871
1014,corticosteroid myopathy,21,23,141,164,"To our knowledge, this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid myopathy.",11058428_6,-1,-1,-1,1014,-1,0.022389363,0.97761065
1016,RAPA,13,14,64,68,BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.,11063349_1,-1,-1,-1,1016,-1,0.9981527,0.001847266
1018,CsA,20,21,117,120,BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.,11063349_1,-1,-1,-1,1018,-1,0.9981121,0.001887899
1020,Tac,25,26,137,140,BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.,11063349_1,-1,-1,-1,1020,-1,0.9971238,0.0028762496
1023,RAPA,13,14,83,87,METHODS: Twenty renal transplant recipients were switched to fixed dose rapamycin (RAPA) (5 mg/day) 0 to 204 months posttransplant.,11063349_2,-1,-1,-1,1023,-1,0.9972421,0.0027579463
1024,CsA,6,7,40,43,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1024,-1,0.9986791,0.0013208506
1025,Tac nephrotoxicity,8,10,47,65,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1025,-1,0.05479699,0.94520307
1026,CsA,15,16,78,81,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1026,-1,0.9984627,0.001537377
1027,Tac toxicity,17,19,85,97,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1027,-1,0.24725471,0.7527452
1028,facial dysmorphism,24,26,110,128,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1028,-1,0.0038430642,0.996157
1029,posttransplant lymphoproliferative disorder,30,33,134,177,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1029,-1,0.006238096,0.99376196
1030,PTLD,34,35,179,183,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,-1,-1,-1,1030,-1,0.004466516,0.99553347
1034,P<0.05,25,26,162,168,RESULTS: In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum creatinine [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].,11063349_6,-1,-1,-1,1034,-1,0.33765736,0.66234267
1035,dysmorphism,1,2,7,18,Facial dysmorphism improved in two patients.,11063349_7,-1,-1,-1,1035,-1,0.0025514937,0.9974485
1036,PTLD,3,4,14,18,No relapse of PTLD was observed.,11063349_8,-1,-1,-1,1036,-1,0.0052551855,0.9947448
1037,pneumonia,3,4,24,33,"Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.",11063349_9,-1,-1,-1,1037,-1,0.002801565,0.99719846
1038,Pneumocystis carinii pneumonia,6,9,39,69,"Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.",11063349_9,-1,-1,-1,1038,-1,0.25722623,0.7427738
1039,infectious mononucleosis,11,13,75,99,"Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.",11063349_9,-1,-1,-1,1039,-1,0.0103713665,0.9896287
1040,PTLD,15,16,116,120,"Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.",11063349_9,-1,-1,-1,1040,-1,0.018304583,0.9816954
1041,bronchiolitis obliterans,22,24,150,174,"Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.",11063349_9,-1,-1,-1,1041,-1,0.011928942,0.9880711
1043,RAPA,0,1,0,4,"RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral aphtous ulcers in one.",11063349_11,-1,-1,-1,1043,-1,0.99756515,0.0024348137
1044,pneumonia,9,10,51,60,"RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral aphtous ulcers in one.",11063349_11,-1,-1,-1,1044,-1,0.0032381727,0.9967618
1045,PTLD,13,14,69,73,"RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral aphtous ulcers in one.",11063349_11,-1,-1,-1,1045,-1,0.008198966,0.9918011
1046,aphtous ulcers,19,21,91,105,"RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral aphtous ulcers in one.",11063349_11,-1,-1,-1,1046,-1,0.006340183,0.9936598
1047,RAPA,0,1,0,4,RAPA levels were high (>15 ng/ml) in 7 of 13 (54%) patients.,11063349_12,-1,-1,-1,1047,-1,0.9977475,0.002252545
1048,RAPA,2,3,13,17,CONCLUSIONS: RAPA conversion provides adequate immunosuppression to enable CsA withdrawal.,11063349_13,-1,-1,-1,1048,-1,0.99785113,0.0021488327
1049,CsA,9,10,75,78,CONCLUSIONS: RAPA conversion provides adequate immunosuppression to enable CsA withdrawal.,11063349_13,-1,-1,-1,1049,-1,0.99815184,0.0018481481
1050,RAPA,6,7,37,41,"However, when converting patients to RAPA drug levels should be monitored to avoid over-immunosuppression and adequate antiviral and Pneumocystis carinii pneumonia prophylaxis should be given.",11063349_14,-1,-1,-1,1050,-1,0.9977481,0.0022518719
1051,Pneumocystis carinii pneumonia,19,22,133,163,"However, when converting patients to RAPA drug levels should be monitored to avoid over-immunosuppression and adequate antiviral and Pneumocystis carinii pneumonia prophylaxis should be given.",11063349_14,-1,-1,-1,1051,-1,0.9125962,0.08740381
1052,visual field constriction,15,18,142,167,"Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction.",11077455_0,-1,-1,-1,1052,-1,0.007142444,0.9928576
1053,visual field constriction,3,6,21,46,PURPOSE: Symptomatic visual field constriction thought to be associated with vigabatrin has been reported.,11077455_1,-1,-1,-1,1053,-1,0.005771634,0.99422836
1055,visual field loss,16,19,129,146,"The current study investigated the visual fields and visual electrophysiology of eight patients with known vigabatrin-attributed visual field loss, three of whom were reported previously.",11077455_2,-1,-1,-1,1055,-1,0.005522203,0.99447775
1057,visual field constriction,6,9,38,63,RESULTS: Seven patients showed marked visual field constriction with some sparing of the temporal visual field.,11077455_6,-1,-1,-1,1057,-1,0.005629974,0.99437004
1058,visual field constriction,3,6,19,44,CONCLUSION: Marked visual field constriction appears to be associated with vigabatrin therapy.,11077455_11,-1,-1,-1,1058,-1,0.0064697694,0.9935302
1061,coronary artery spasm,4,7,27,48,Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography.,11078231_0,-1,-1,-1,1061,-1,0.0042796126,0.99572045
1064,myocardial ischemia,14,16,83,102,Dobutamine stress echocardiography (DSE) is a useful and safe provocation test for myocardial ischemia.,11078231_1,-1,-1,-1,1064,-1,0.003114243,0.9968857
1065,coronary artery stenosis,28,31,153,177,"Until now, the test has been focused only on the organic lesion in the coronary artery, and positive DSE has indicated the presence of significant fixed coronary artery stenosis.",11078231_2,-1,-1,-1,1065,-1,0.010607022,0.989393
1066,myocardial ischemia,10,12,51,70,The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by dobutamine.,11078231_3,-1,-1,-1,1066,-1,0.0032275885,0.99677235
1069,coronary spastic angina,7,10,37,60,We performed DSE on 51 patients with coronary spastic angina but without significant fixed coronary artery stenosis.,11078231_4,-1,-1,-1,1069,-1,0.0036101476,0.9963898
1070,coronary artery stenosis,14,17,91,115,We performed DSE on 51 patients with coronary spastic angina but without significant fixed coronary artery stenosis.,11078231_4,-1,-1,-1,1070,-1,0.011577789,0.9884222
1071,anginal attacks,3,5,17,32,All patients had anginal attacks at rest with ST elevation on the electrocardiogram (variant angina).,11078231_5,-1,-1,-1,1071,-1,0.0036584383,0.9963415
1075,coronary artery stenosis,13,16,85,109,"Coronary spasm was induced by intracoronary injection of acetylcholine, and no fixed coronary artery stenosis was documented on angiograms in all patients.",11078231_6,-1,-1,-1,1075,-1,0.0060323444,0.99396765
1077,chest pain,8,10,27,37,"All 7 patients (13.7%) had chest pain during asynergy, and both chest pain and electrocardiographic changes were preceded by asynergy.",11078231_9,-1,-1,-1,1077,-1,0.0028039615,0.9971961
1078,chest pain,15,17,64,74,"All 7 patients (13.7%) had chest pain during asynergy, and both chest pain and electrocardiographic changes were preceded by asynergy.",11078231_9,-1,-1,-1,1078,-1,0.0030873737,0.9969126
1081,coronary spastic angina,13,16,89,112,These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina.,11078231_10,-1,-1,-1,1081,-1,0.0025306381,0.9974694
1082,coronary artery disease,6,9,34,57,"When DSE is performed to evaluate coronary artery disease, not only fixed coronary stenosis, but also coronary spasm should be considered as a genesis of asynergy.",11078231_11,-1,-1,-1,1082,-1,0.006671917,0.9933281
1083,coronary stenosis,13,15,74,91,"When DSE is performed to evaluate coronary artery disease, not only fixed coronary stenosis, but also coronary spasm should be considered as a genesis of asynergy.",11078231_11,-1,-1,-1,1083,-1,0.0068569644,0.99314296
1087,myocardial ischemia,11,13,95,114,Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on dobutamine-induced myocardial ischemia.,11079278_0,-1,-1,-1,1087,-1,0.003042874,0.9969572
1090,technetium-99m sestamibi,14,17,89,113,"STUDY OBJECTIVE: To determine the effect of metoprolol on dobutamine stress testing with technetium-99m sestamibi single-photon emission computed tomography imaging and ST-segment monitoring, and to assess the impact of intravenous glucagon on metoprolol's effects.",11079278_1,-1,-1,-1,1090,-1,0.9985671,0.0014328914
1095,mg,29,30,176,178,"Before dobutamine was begun, no therapy was given during the first visit, and patients were randomized on subsequent visits to receive metoprolol or metoprolol plus glucagon 1 mg.",11079278_6,-1,-1,-1,1095,-1,0.9684743,0.031525694
1096,predobutamine,7,8,42,55,Metoprolol was dosed to achieve a resting predobutamine heart rate below 65 beats/minute or a total intravenous dose of 20 mg.,11079278_7,-1,-1,-1,1096,-1,0.99936336,0.0006366632
1097,mg,20,21,123,125,Metoprolol was dosed to achieve a resting predobutamine heart rate below 65 beats/minute or a total intravenous dose of 20 mg.,11079278_7,-1,-1,-1,1097,-1,0.982808,0.017192058
1103,myocardial ischemia,13,15,94,113,"CONCLUSION: During dobutamine stress testing, metoprolol attenuates or eliminates evidence of myocardial ischemia.",11079278_12,-1,-1,-1,1103,-1,0.0030911083,0.99690896
1104,mg,2,3,11,13,"Glucagon 1 mg, although somewhat effective, does not correct this effect to the extent that it can be administered clinically.",11079278_13,-1,-1,-1,1104,-1,0.9933595,0.0066405153
1107,LID,36,37,216,219,The objective of this study was to explore the functional anatomy of the globus pallidus internus (GPi) by studying the effects of unilateral pallidotomy on parkinsonian 'off' signs and levodopa-induced dyskinesias (LID).,11099450_1,-1,-1,-1,1107,-1,0.004106115,0.99589384
1110,LID,52,53,360,363,"We found significant positive correlations between the preoperative levodopa responsiveness of motor signs and the levodopa responsiveness of scores in timed tests (Core Assessment Program for Intracerebral Transplantations) in the contralateral limbs and the improvement in these scores after surgery, whereas there was no correlation with the improvement in LID.",11099450_2,-1,-1,-1,1110,-1,0.003968565,0.99603146
1111,P,8,9,48,49,"We also found a highly significant correlation (P: < 0.0001, r = 0.8) between the volume of the ventral lesion in the GPi and the improvement in LID in the contralateral limbs, whereas there was no correlation between the ventral volume and the improvement in parkinsonian 'off' signs.",11099450_3,-1,-1,-1,1111,-1,0.55208665,0.44791332
1112,LID,31,32,145,148,"We also found a highly significant correlation (P: < 0.0001, r = 0.8) between the volume of the ventral lesion in the GPi and the improvement in LID in the contralateral limbs, whereas there was no correlation between the ventral volume and the improvement in parkinsonian 'off' signs.",11099450_3,-1,-1,-1,1112,-1,0.008276564,0.9917235
1118,LID,17,18,109,112,The differential predictive value of levodopa responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.,11099450_5,-1,-1,-1,1118,-1,0.0052789673,0.99472106
1124,LID,26,27,137,140,"Whereas cells in a wider area of the GPi may be implicated in parkinsonism, the ventral GPi seems to be crucial for the manifestation of LID.",11099450_6,-1,-1,-1,1124,-1,0.0036110468,0.99638903
1130,nonsmall cell lung carcinoma,15,19,126,154,"Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.",11135224_0,-1,-1,-1,1130,-1,0.013209259,0.9867907
1131,nonsmall cell lung carcinoma,13,17,103,131,BACKGROUND: Cisplatin-based chemotherapy combinations improve quality of life and survival in advanced nonsmall cell lung carcinoma (NSCLC).,11135224_1,-1,-1,-1,1131,-1,0.019845182,0.9801548
1132,NSCLC,18,19,133,138,BACKGROUND: Cisplatin-based chemotherapy combinations improve quality of life and survival in advanced nonsmall cell lung carcinoma (NSCLC).,11135224_1,-1,-1,-1,1132,-1,0.006138415,0.99386156
1137,NSCLC,30,31,175,180,"METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.",11135224_3,-1,-1,-1,1137,-1,0.0055131945,0.99448687
1138,NSCLC,7,8,66,71,"Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.",11135224_4,-1,-1,-1,1138,-1,0.005118516,0.9948815
1142,disease progression,17,19,149,168,"Although responding patients were scheduled to receive consolidation radiotherapy and 24 patients received preplanned second-line chemotherapy after disease progression, the response and toxicity rates reported refer only to the chemotherapy regimen given.",11135224_5,-1,-1,-1,1142,-1,0.0034910762,0.9965089
1155,NSCLC,20,21,127,132,"CONCLUSIONS: The combination of paclitaxel, cisplatin, and gemcitabine is well tolerated and shows high activity in metastatic NSCLC.",11135224_14,-1,-1,-1,1155,-1,0.00393403,0.99606603
1156,Serotonergic,0,1,0,12,Serotonergic antidepressants and urinary incontinence.,11147747_0,-1,-1,-1,1156,-1,0.99722373,0.0027763033
1158,urinary incontinence,3,5,33,53,Serotonergic antidepressants and urinary incontinence.,11147747_0,-1,-1,-1,1158,-1,0.003970476,0.9960295
1159,serotonergic antidepressants,2,4,9,37,Many new serotonergic antidepressants have been introduced over the past decade.,11147747_1,-1,-1,-1,1159,-1,0.9966139,0.0033860302
1160,urinary incontinence,1,3,9,29,Although urinary incontinence is listed as one side effect of these drugs in their package inserts there is only one report in the literature.,11147747_2,-1,-1,-1,1160,-1,0.0027559756,0.997244
1164,serotonin reuptake inhibitors paroxetine,17,21,114,154,"In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.",11147747_4,-1,-1,-1,1164,-1,0.99782467,0.0021753781
1167,lithium carbonate,11,13,50,67,"In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.",11147747_5,-1,-1,-1,1167,-1,0.99870324,0.0012967878
1170,serotonergic antidepressants,7,9,54,82,Animal studies suggest that incontinence secondary to serotonergic antidepressants could be mediated by the 5HT4 receptors found on the bladder.,11147747_6,-1,-1,-1,1170,-1,0.9985196,0.0014803613
1180,emergency department seizure,6,9,37,65,Screening for stimulant use in adult emergency department seizure patients.,11185967_0,-1,-1,-1,1180,-1,0.011581665,0.9884184
1183,emergency department seizure,23,26,141,169,OBJECTIVE: The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or amphetamine in adult emergency department seizure patients.,11185967_1,-1,-1,-1,1183,-1,0.010987487,0.9890125
1190,seizure disorder,9,11,68,84,"Patient demographics, history of underlying drug or alcohol-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.",11185967_5,-1,-1,-1,1190,-1,0.0025311436,0.9974688
1193,amphetamine abuse,26,28,171,188,"Patient demographics, history of underlying drug or alcohol-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.",11185967_5,-1,-1,-1,1193,-1,0.9050816,0.094918385
1197,amphetamine abuse,19,21,110,127,Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse (p < 0.0005).,11185967_7,-1,-1,-1,1197,-1,0.91318977,0.086810164
1198,p,22,23,129,130,Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse (p < 0.0005).,11185967_7,-1,-1,-1,1198,-1,0.43551892,0.5644811
1200,amphetamines,13,14,80,92,"CONCLUSIONS: During this study period, routine plasma screening for cocaine and amphetamines in adult seizure patients had a low yield.",11185967_8,-1,-1,-1,1200,-1,0.9987025,0.0012974289
1203,sodium valproate,2,4,16,32,Contribution of sodium valproate to the syndrome of inappropriate secretion of antidiuretic hormone.,11195262_0,-1,-1,-1,1203,-1,0.99903095,0.00096904906
1204,syndrome of inappropriate secretion of antidiuretic hormone,6,13,40,99,Contribution of sodium valproate to the syndrome of inappropriate secretion of antidiuretic hormone.,11195262_0,-1,-1,-1,1204,-1,0.40989062,0.5901094
1205,sodium valproate,11,13,61,77,We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).,11195262_1,-1,-1,-1,1205,-1,0.9990374,0.00096260407
1206,VPA,14,15,79,82,We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).,11195262_1,-1,-1,-1,1206,-1,0.99757993,0.0024200052
1207,syndrome of inappropriate secretion of antidiuretic hormone,21,28,119,178,We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).,11195262_1,-1,-1,-1,1207,-1,0.2657333,0.7342667
1208,SIADH,29,30,180,185,We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).,11195262_1,-1,-1,-1,1208,-1,0.42190194,0.57809806
1209,VPA,4,5,19,22,He had been taking VPA for treatment of idiopathic generalized tonic-clonic convulsions since he was 56 years old.,11195262_2,-1,-1,-1,1209,-1,0.9985475,0.0014524519
1211,VPA,2,3,19,22,"After substituting VPA with zonisamide, the serum sodium level returned to normal.",11195262_3,-1,-1,-1,1211,-1,0.9985624,0.00143767
1214,SIADH,5,6,28,33,We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long-term administration of VPA.,11195262_4,-1,-1,-1,1214,-1,0.08735111,0.9126489
1215,weakness of the,17,20,91,106,We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long-term administration of VPA.,11195262_4,-1,-1,-1,1215,-1,0.03568039,0.96431965
1216,nervous,21,22,115,122,We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long-term administration of VPA.,11195262_4,-1,-1,-1,1216,-1,0.005868943,0.994131
1217,VPA,28,29,166,169,We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long-term administration of VPA.,11195262_4,-1,-1,-1,1217,-1,0.9987,0.0012999603
1218,tizanidine,5,6,40,50,Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension.,11198499_0,-1,-1,-1,1218,-1,0.99925464,0.0007453806
1220,adrenergic agonists,3,5,25,44,Centrally acting alpha-2 adrenergic agonists are one of several pharmacologic agents used in the treatment of spasticity related to disorders of the central nervous system.,11198499_1,-1,-1,-1,1220,-1,0.9950664,0.004933585
1221,spasticity,16,17,110,120,Centrally acting alpha-2 adrenergic agonists are one of several pharmacologic agents used in the treatment of spasticity related to disorders of the central nervous system.,11198499_1,-1,-1,-1,1221,-1,0.0021979902,0.99780196
1222,disorders of the central nervous system,19,25,132,171,Centrally acting alpha-2 adrenergic agonists are one of several pharmacologic agents used in the treatment of spasticity related to disorders of the central nervous system.,11198499_1,-1,-1,-1,1222,-1,0.010495066,0.98950493
1223,spasticity,6,7,32,42,"In addition to their effects on spasticity, certain adverse cardiorespiratory effects have been reported.",11198499_2,-1,-1,-1,1223,-1,0.002232009,0.99776804
1224,angiotensin converting enzyme inhibitors,4,8,32,72,Adults chronically treated with angiotensin converting enzyme inhibitors may have a limited ability to respond to hypotension when the sympathetic response is simultaneously blocked.,11198499_3,-1,-1,-1,1224,-1,0.99655765,0.0034422872
1226,lisinopril,9,10,63,73,"The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.",11198499_4,-1,-1,-1,1226,-1,0.9988925,0.0011075806
1229,tizanidine,27,28,195,205,"The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.",11198499_4,-1,-1,-1,1229,-1,0.9992526,0.00074735394
1230,spasticity,37,38,248,258,"The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.",11198499_4,-1,-1,-1,1230,-1,0.0020269135,0.997973
1231,tizanidine,4,5,28,38,The possible interaction of tizanidine and other antihypertensive agents should be kept in mind when prescribing therapy to treat either hypertension or spasticity in such patients.,11198499_5,-1,-1,-1,1231,-1,0.9993248,0.0006752274
1232,antihypertensive agents,7,9,49,72,The possible interaction of tizanidine and other antihypertensive agents should be kept in mind when prescribing therapy to treat either hypertension or spasticity in such patients.,11198499_5,-1,-1,-1,1232,-1,0.93963736,0.06036263
1234,spasticity,22,23,153,163,The possible interaction of tizanidine and other antihypertensive agents should be kept in mind when prescribing therapy to treat either hypertension or spasticity in such patients.,11198499_5,-1,-1,-1,1234,-1,0.0022640552,0.997736
1236,BS,11,12,70,72,Two mouse lines were selectively bred according to their sensitivity (BS line) or resistance (BR line) to seizures induced by a single i.p.,11206082_1,-1,-1,-1,1236,-1,0.6229815,0.37701854
1240,BS,9,10,67,69,"Results presented here show that the differential sensitivities of BS and BR lines to beta-CCM can be extended to diazepam, picrotoxin, and pentylenetetrazol, suggesting a genetic selection of a general sensitivity and resistance to several ligands of the GABA(A) receptor.",11206082_5,-1,-1,-1,1240,-1,0.90544015,0.09455988
1243,pentylenetetrazol,24,25,140,157,"Results presented here show that the differential sensitivities of BS and BR lines to beta-CCM can be extended to diazepam, picrotoxin, and pentylenetetrazol, suggesting a genetic selection of a general sensitivity and resistance to several ligands of the GABA(A) receptor.",11206082_5,-1,-1,-1,1243,-1,0.9992155,0.0007844959
1244,nitric oxide,2,4,15,27,Association of nitric oxide production and apoptosis in a model of experimental nephropathy.,11208990_0,-1,-1,-1,1244,-1,0.99808013,0.0019198157
1246,nitric oxide,8,10,51,63,BACKGROUND: In recent studies increased amounts of nitric oxide (NO) and apoptosis have been implicated in various pathological conditions in the kidney.,11208990_1,-1,-1,-1,1246,-1,0.99763,0.002369971
1247,nephrotic syndrome,17,19,94,112,We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of adriamycin (ADR).,11208990_2,-1,-1,-1,1247,-1,0.0021110233,0.997889
1249,ADR,27,28,158,161,We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of adriamycin (ADR).,11208990_2,-1,-1,-1,1249,-1,0.99752444,0.0024755523
1250,nitrite,12,13,68,75,METHODS: The alteration in the NO pathway was assessed by measuring nitrite levels in serum/urine and by evaluating the changes in vascular reactivity of the isolated perfused rat kidney (IPRK) system.,11208990_3,-1,-1,-1,1250,-1,0.9984281,0.0015719712
1252,aminoguanidine,21,22,107,121,"These two groups were then divided into: group 1, animals receiving saline; and group 2, animals receiving aminoguanidine (AG) which is a specific inhibitor of inducible-NO synthase.",11208990_5,-1,-1,-1,1252,-1,0.99871385,0.0012861823
1253,AG,23,24,123,125,"These two groups were then divided into: group 1, animals receiving saline; and group 2, animals receiving aminoguanidine (AG) which is a specific inhibitor of inducible-NO synthase.",11208990_5,-1,-1,-1,1253,-1,0.9959947,0.0040053367
1254,ADR,11,12,75,78,RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild tubulointerstitial inflammation.,11208990_7,-1,-1,-1,1254,-1,0.99856156,0.0014384681
1255,mesangial proliferation,16,18,103,126,RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild tubulointerstitial inflammation.,11208990_7,-1,-1,-1,1255,-1,0.008453968,0.991546
1256,tubulointerstitial inflammation,20,22,136,167,RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild tubulointerstitial inflammation.,11208990_7,-1,-1,-1,1256,-1,0.008001703,0.99199826
1258,P,15,16,101,102,They also had significantly higher levels of proteinuria compared with control and treatment groups (P < 0.05).,11208990_8,-1,-1,-1,1258,-1,0.22594148,0.77405846
1259,nitrite,1,2,6,13,Urine nitrite levels were significantly increased in the ADR-nephropathy group (P < 0.05).,11208990_9,-1,-1,-1,1259,-1,0.99855477,0.0014452788
1260,P,11,12,80,81,Urine nitrite levels were significantly increased in the ADR-nephropathy group (P < 0.05).,11208990_9,-1,-1,-1,1260,-1,0.23859333,0.7614067
1262,AG,2,3,15,17,Treatment with AG prevented the impairment of renal vascular bed responses and reduced both urine nitrite levels and apoptosis to control levels.,11208990_14,-1,-1,-1,1262,-1,0.9987702,0.001229776
1263,nitrite,15,16,98,105,Treatment with AG prevented the impairment of renal vascular bed responses and reduced both urine nitrite levels and apoptosis to control levels.,11208990_14,-1,-1,-1,1263,-1,0.9986016,0.0013983424
1265,melatonin,3,4,16,25,Dual effects of melatonin on barbiturate-induced narcosis in rats.,11226639_0,-1,-1,-1,1265,-1,0.9987306,0.001269448
1266,narcosis,6,7,49,57,Dual effects of melatonin on barbiturate-induced narcosis in rats.,11226639_0,-1,-1,-1,1266,-1,0.028290935,0.9717091
1267,Melatonin,0,1,0,9,"Melatonin affects the circadian sleep/wake cycle, but it is not clear whether it may influence drug-induced narcosis.",11226639_1,-1,-1,-1,1267,-1,0.9984921,0.0015078916
1268,narcosis,17,18,108,116,"Melatonin affects the circadian sleep/wake cycle, but it is not clear whether it may influence drug-induced narcosis.",11226639_1,-1,-1,-1,1268,-1,0.9694514,0.030548519
1269,Sodium thiopenthal,0,2,0,18,"Sodium thiopenthal was administered intraperitoneally into male rats pre-treated with melatonin (0.05, 0.5, 5 and 50 mg/kg).",11226639_2,-1,-1,-1,1269,-1,0.99907506,0.0009249698
1270,melatonin,10,11,86,95,"Sodium thiopenthal was administered intraperitoneally into male rats pre-treated with melatonin (0.05, 0.5, 5 and 50 mg/kg).",11226639_2,-1,-1,-1,1270,-1,0.9987282,0.0012718139
1271,barbiturate narcosis,7,9,50,70,"Melatonin pre-treatment affected in a dual manner barbiturate narcosis, however, no dose-effect correlation was found.",11226639_3,-1,-1,-1,1271,-1,0.9641392,0.035860825
1272,barbiturate narcosis,14,16,78,98,"In particular, low doses reduced the latency to and prolonged the duration of barbiturate narcosis.",11226639_4,-1,-1,-1,1272,-1,0.94370556,0.056294493
1273,contrast,1,2,3,11,"In contrast, the highest dose of melatonin (50 mg/kg) caused a paradoxical increase in the latency and produced a sustained reduction of the duration of narcosis, and a reduction in mortality rate.",11226639_5,-1,-1,-1,1273,-1,0.20731173,0.7926883
1274,melatonin,7,8,33,42,"In contrast, the highest dose of melatonin (50 mg/kg) caused a paradoxical increase in the latency and produced a sustained reduction of the duration of narcosis, and a reduction in mortality rate.",11226639_5,-1,-1,-1,1274,-1,0.9987924,0.0012075849
1275,narcosis,28,29,153,161,"In contrast, the highest dose of melatonin (50 mg/kg) caused a paradoxical increase in the latency and produced a sustained reduction of the duration of narcosis, and a reduction in mortality rate.",11226639_5,-1,-1,-1,1275,-1,0.8895152,0.110484734
1276,Melatonin,0,1,0,9,Melatonin 0.5 and 5 mg/kg influenced the duration but not the latency of ketamine- or diazepam-induced narcosis.,11226639_6,-1,-1,-1,1276,-1,0.99865854,0.001341466
1277,narcosis,16,17,103,111,Melatonin 0.5 and 5 mg/kg influenced the duration but not the latency of ketamine- or diazepam-induced narcosis.,11226639_6,-1,-1,-1,1277,-1,0.018229702,0.98177034
1278,melatonin,6,7,25,34,"Thus, the dual action of melatonin on pharmacological narcosis seems to be specific for the barbiturate mechanism of action.",11226639_7,-1,-1,-1,1278,-1,0.998845,0.0011550522
1279,narcosis,9,10,54,62,"Thus, the dual action of melatonin on pharmacological narcosis seems to be specific for the barbiturate mechanism of action.",11226639_7,-1,-1,-1,1279,-1,0.94755864,0.052441362
1280,barbiturate,16,17,92,103,"Thus, the dual action of melatonin on pharmacological narcosis seems to be specific for the barbiturate mechanism of action.",11226639_7,-1,-1,-1,1280,-1,0.9992918,0.00070815877
1287,Myocet,5,6,30,36,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,-1,-1,-1,1287,-1,0.9906757,0.009324305
1290,doxorubicin cardiotoxicity,27,29,187,213,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,-1,-1,-1,1290,-1,0.043956127,0.95604384
1292,MBC,42,43,313,316,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,-1,-1,-1,1292,-1,0.010073953,0.9899261
1293,MBC,9,10,61,64,"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.",11230490_2,-1,-1,-1,1293,-1,0.040735975,0.9592641
1294,Myocet,26,27,162,168,"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.",11230490_2,-1,-1,-1,1294,-1,0.17281927,0.82718074
1297,C,46,47,259,260,"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.",11230490_2,-1,-1,-1,1297,-1,0.99235004,0.0076499814
1298,disease progression,53,55,283,302,"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.",11230490_2,-1,-1,-1,1298,-1,0.0034011754,0.9965989
1301,congestive heart failure,19,22,145,169,"Cardiotoxicity was defined by reductions in left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or congestive heart failure (CHF).",11230490_3,-1,-1,-1,1301,-1,0.00317686,0.9968232
1302,CHF,23,24,171,174,"Cardiotoxicity was defined by reductions in left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or congestive heart failure (CHF).",11230490_3,-1,-1,-1,1302,-1,0.0026426404,0.9973573
1304,MC,5,6,24,26,RESULTS: Six percent of MC patients versus 21% (including five cases of CHF) of AC patients developed cardiotoxicity (P =.0002).,11230490_5,-1,-1,-1,1304,-1,0.68509394,0.31490612
1305,CHF,15,16,72,75,RESULTS: Six percent of MC patients versus 21% (including five cases of CHF) of AC patients developed cardiotoxicity (P =.0002).,11230490_5,-1,-1,-1,1305,-1,0.002632455,0.99736756
1307,P,23,24,118,119,RESULTS: Six percent of MC patients versus 21% (including five cases of CHF) of AC patients developed cardiotoxicity (P =.0002).,11230490_5,-1,-1,-1,1307,-1,0.34408,0.65591997
1309,MC,13,14,76,78,"Median cumulative doxorubicin dose at onset was more than 2,220 mg/m(2) for MC versus 480 mg/m(2) for AC (P =.0001, hazard ratio, 5.04).",11230490_6,-1,-1,-1,1309,-1,0.98926735,0.010732651
1310,P,21,22,106,107,"Median cumulative doxorubicin dose at onset was more than 2,220 mg/m(2) for MC versus 480 mg/m(2) for AC (P =.0001, hazard ratio, 5.04).",11230490_6,-1,-1,-1,1310,-1,0.4464442,0.5535558
1311,MC,0,1,0,2,MC patients also experienced less grade 4 neutropenia.,11230490_7,-1,-1,-1,1311,-1,0.49626642,0.5037335
1313,MC,3,4,22,24,"Antitumor efficacy of MC versus AC was comparable: objective response rates, 43% versus 43%; median time to progression, 5.1% versus 5.5 months; median time to treatment failure, 4.6 versus 4.4 months; and median survival, 19 versus 16 months.",11230490_8,-1,-1,-1,1313,-1,0.9976775,0.0023225704
1314,Myocet,2,3,12,18,"CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.",11230490_9,-1,-1,-1,1314,-1,0.5891604,0.41083965
1319,MBC,33,34,247,250,"CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.",11230490_9,-1,-1,-1,1319,-1,0.015838,0.984162
1321,nitric oxide,9,11,58,70,"The effects of N-nitro-L-arginine-methyl ester (L-NAME) a nitric oxide (NO) synthase inhibitor and L-arginine, a NO precursor, were investigated on lidocaine-induced convulsions.",11243580_1,-1,-1,-1,1321,-1,0.99191755,0.008082456
1329,contrast,1,2,3,11,"In contrast, the L-arginine treatment increased the incidence of lidocaine (80 mg/kg, i.p.)-induced convulsions significantly.",11243580_6,-1,-1,-1,1329,-1,0.23439865,0.76560134
1332,lidocaine-induced,11,12,65,82,These results may suggest that NO is a proconvulsant mediator in lidocaine-induced convulsions.,11243580_7,-1,-1,-1,1332,-1,0.23043504,0.7695649
1334,cyclophosphamide cytotoxicity,6,8,56,85,Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors.,11245434_0,-1,-1,-1,1334,-1,0.8906848,0.10931524
1337,cytotoxicity,23,24,131,143,The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin (rHuEPO) treatment on the cytotoxicity of cyclophosphamide in solid experimental tumors.,11245434_1,-1,-1,-1,1337,-1,0.0038666094,0.99613345
1347,se,10,11,74,76,Neither carboplatin nor rHuEPO treatment influenced tumor growth rate per se.,11245434_6,-1,-1,-1,1347,-1,0.19262649,0.8073736
1354,cytotoxicity,7,8,63,75,"These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.",11245434_10,-1,-1,-1,1354,-1,0.004349868,0.9956501
1369,Graves' disease,6,9,34,49,"RESULTS: A 25-year-old woman with Graves' disease had a febrile illness and evidence of pericarditis, which was confirmed by biopsy.",11250767_4,-1,-1,-1,1369,-1,0.027434802,0.9725652
1370,febrile illness,11,13,56,71,"RESULTS: A 25-year-old woman with Graves' disease had a febrile illness and evidence of pericarditis, which was confirmed by biopsy.",11250767_4,-1,-1,-1,1370,-1,0.0032845938,0.9967154
1382,solitary kidney,11,13,80,95,Repeated transient anuria following losartan administration in a patient with a solitary kidney.,11256525_0,-1,-1,-1,1382,-1,0.005465813,0.99453413
1384,solitary kidney,11,13,60,75,We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration.,11256525_1,-1,-1,-1,1384,-1,0.0061204457,0.99387956
1385,chronic renal insufficiency,14,17,80,107,We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration.,11256525_1,-1,-1,-1,1385,-1,0.0030066404,0.9969933
1388,myocardial infarction,5,7,26,47,"He was hospitalized for a myocardial infarction with pulmonary edema, treated with high-dose diuretics.",11256525_2,-1,-1,-1,1388,-1,0.0023715126,0.9976285
1389,pulmonary edema,8,10,53,68,"He was hospitalized for a myocardial infarction with pulmonary edema, treated with high-dose diuretics.",11256525_2,-1,-1,-1,1389,-1,0.00215766,0.9978423
1390,systolic dysfunction losartan,3,6,14,43,Due to severe systolic dysfunction losartan was prescribed.,11256525_3,-1,-1,-1,1390,-1,0.74046904,0.259531
1391,mg,7,8,35,37,"Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and amine infusion.",11256525_4,-1,-1,-1,1391,-1,0.99347234,0.00652764
1395,amine,24,25,137,142,"Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and amine infusion.",11256525_4,-1,-1,-1,1395,-1,0.99868387,0.0013161467
1397,mg,18,19,90,92,"One week later, by mistake, losartan was prescribed again and after the second dose of 50 mg, the patient developed a second episode of transient anuria lasting 10 hours.",11256525_5,-1,-1,-1,1397,-1,0.9940767,0.0059232474
1400,renal artery stenosis,10,13,45,66,"Ultimately, an arteriography showed a 70-80% renal artery stenosis.",11256525_7,-1,-1,-1,1400,-1,0.011714233,0.9882858
1401,renal artery stenosis,4,7,17,38,"In this patient, renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS).",11256525_8,-1,-1,-1,1401,-1,0.006728146,0.9932719
1402,heart failure,9,11,53,66,"In this patient, renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS).",11256525_8,-1,-1,-1,1402,-1,0.0034422053,0.9965578
1403,diuretic,12,13,71,79,"In this patient, renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS).",11256525_8,-1,-1,-1,1403,-1,0.9984823,0.0015177515
1404,angiotensin II,4,6,23,37,"Under such conditions, angiotensin II receptor blockade by losartan probably induced a critical fall in glomerular filtration pressure.",11256525_9,-1,-1,-1,1404,-1,0.99497956,0.005020433
1406,angiotensin II,8,10,46,60,This case report highlights the fact that the angiotensin II receptor antagonist losartan can cause serious unexpected complications in patients with renovascular disease and should be used with extreme caution in this setting.,11256525_10,-1,-1,-1,1406,-1,0.99457103,0.0054289927
1408,renovascular disease,21,23,150,170,This case report highlights the fact that the angiotensin II receptor antagonist losartan can cause serious unexpected complications in patients with renovascular disease and should be used with extreme caution in this setting.,11256525_10,-1,-1,-1,1408,-1,0.0038513297,0.9961487
1409,pain syndrome,2,4,30,43,Calcineurin-inhibitor induced pain syndrome (CIPS): a severe disabling complication after organ transplantation.,11263551_0,-1,-1,-1,1409,-1,0.0026342373,0.9973658
1410,CIPS,5,6,45,49,Calcineurin-inhibitor induced pain syndrome (CIPS): a severe disabling complication after organ transplantation.,11263551_0,-1,-1,-1,1410,-1,0.012220202,0.98777974
1414,oedema,6,7,52,58,Magnetic resonance imaging demonstrated bone marrow oedema in the painful bones.,11263551_5,-1,-1,-1,1414,-1,0.0030521196,0.99694794
1415,painful,9,10,66,73,Magnetic resonance imaging demonstrated bone marrow oedema in the painful bones.,11263551_5,-1,-1,-1,1415,-1,0.003651083,0.99634886
1417,reflex sympathetic dystrophy,12,15,65,93,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1417,-1,0.11997752,0.88002247
1419,Morton's neuralgia,18,21,111,129,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1419,-1,0.054975145,0.9450249
1420,gout,22,23,131,135,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1420,-1,0.008825046,0.99117494
1422,avascular necrosis,26,28,151,169,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1422,-1,0.00693986,0.9930601
1423,intermittent claudication,29,31,171,196,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1423,-1,0.0040453332,0.99595463
1424,foot deformities,33,35,210,226,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1424,-1,0.0047832397,0.9952167
1425,stress fractures,36,38,228,244,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1425,-1,0.014588383,0.9854116
1426,hyperparathyroidism,40,41,250,269,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,-1,-1,-1,1426,-1,0.024568051,0.9754319
1428,calcium channel blockers,12,15,85,109,The reduction of cyclosporine- or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain.,11263551_7,-1,-1,-1,1428,-1,0.9962734,0.0037265774
1430,Pain Syndrome,3,5,34,47,"The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.",11263551_8,-1,-1,-1,1430,-1,0.002471485,0.9975285
1431,CIPS,6,7,49,53,"The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.",11263551_8,-1,-1,-1,1431,-1,0.0057355952,0.9942644
1434,lead,6,7,41,45,Incorrect diagnosis of the syndrome will lead to a significant reduction of life quality in patients suffering from CIPS.,11263551_9,-1,-1,-1,1434,-1,0.04679118,0.95320874
1435,CIPS,18,19,116,120,Incorrect diagnosis of the syndrome will lead to a significant reduction of life quality in patients suffering from CIPS.,11263551_9,-1,-1,-1,1435,-1,0.0051142145,0.99488574
1436,haemorrhagic myocarditis,1,3,6,30,Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy.,11271907_0,-1,-1,-1,1436,-1,0.002374631,0.9976254
1440,antineoplastic drugs,3,5,29,49,"Anthracyclines are effective antineoplastic drugs, but they frequently cause dose-related cardiotoxicity.",11279304_1,-1,-1,-1,1440,-1,0.6766674,0.32333255
1446,acute leukemia,29,31,191,205,We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.,11279304_3,-1,-1,-1,1446,-1,0.0026217902,0.99737823
1448,acute leukemia,3,5,23,37,Thirteen patients with acute leukemia were treated with a DNR-containing regimen.,11279304_4,-1,-1,-1,1448,-1,0.0026777491,0.99732226
1449,ANP,8,9,49,52,The plasma levels of atrial natriuretic peptide (ANP) and BNP were measured at the time of radionuclide angiography.,11279304_6,-1,-1,-1,1449,-1,0.99615866,0.003841365
1450,congestive heart failure,3,6,25,49,Three patients developed congestive heart failure after the completion of chemotherapy.,11279304_7,-1,-1,-1,1450,-1,0.002407559,0.9975924
1451,heart failure,7,9,51,64,Five patients were diagnosed as having subclinical heart failure after the completion of chemotherapy.,11279304_8,-1,-1,-1,1451,-1,0.0026570319,0.997343
1452,heart failure,13,15,75,88,The plasma levels of BNP in all the patients with clinical and subclinical heart failure increased above the normal limit (40 pg/ml) before the detection of clinical or subclinical heart failure by radionuclide angiography.,11279304_9,-1,-1,-1,1452,-1,0.0025819845,0.99741805
1453,heart failure,31,33,181,194,The plasma levels of BNP in all the patients with clinical and subclinical heart failure increased above the normal limit (40 pg/ml) before the detection of clinical or subclinical heart failure by radionuclide angiography.,11279304_9,-1,-1,-1,1453,-1,0.0027277325,0.9972723
1454,heart failure,13,15,64,77,"On the other hand, BNP did not increase in the patients without heart failure given DNR, even at more than 700 mg/m(2).",11279304_10,-1,-1,-1,1454,-1,0.002788656,0.9972114
1455,DNR,16,17,84,87,"On the other hand, BNP did not increase in the patients without heart failure given DNR, even at more than 700 mg/m(2).",11279304_10,-1,-1,-1,1455,-1,0.99838793,0.0016120509
1456,ANP,4,5,20,23,The plasma level of ANP did not always increase in all the patients with clinical and subclinical heart failure.,11279304_11,-1,-1,-1,1456,-1,0.99807465,0.0019253837
1457,heart failure,17,19,98,111,The plasma level of ANP did not always increase in all the patients with clinical and subclinical heart failure.,11279304_11,-1,-1,-1,1457,-1,0.0026517652,0.9973482
1460,atrial fibrillation,4,6,24,43,Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs.,11282081_0,-1,-1,-1,1460,-1,0.008012657,0.99198735
1461,atrial fibrillation,11,13,93,112,BACKGROUND: Atrial tachycardia-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.,11282081_1,-1,-1,-1,1461,-1,0.005442511,0.9945575
1462,AF,14,15,114,116,BACKGROUND: Atrial tachycardia-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.,11282081_1,-1,-1,-1,1462,-1,0.0042464295,0.9957535
1463,AF,15,16,89,91,"There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.",11282081_2,-1,-1,-1,1463,-1,0.003876917,0.996123
1464,AF,20,21,112,114,"There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.",11282081_2,-1,-1,-1,1464,-1,0.006153642,0.99384636
1465,AF,8,9,49,51,"METHODS: To evaluate the potential mechanisms of AF promotion by Ca(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs.",11282081_3,-1,-1,-1,1465,-1,0.007872047,0.992128
1469,nadolol,13,14,81,88,Diltiazem was used as a comparison drug and autonomic blockade with atropine and nadolol was applied in some experiments.,11282081_4,-1,-1,-1,1469,-1,0.99896467,0.0010352919
1470,AF,12,13,89,91,Epicardial mapping with 240 epicardial electrodes was used to evaluate activation during AF.,11282081_5,-1,-1,-1,1470,-1,0.006545314,0.99345464
1472,AF,4,5,26,28,"RESULTS: Verapamil caused AF promotion in six dogs, increasing mean duration of AF induced by burst pacing, from 8+/-4 s (mean+/-S.E.) to 95+/-39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228+/-101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg.",11282081_6,-1,-1,-1,1472,-1,0.0034624657,0.99653757
1473,AF,14,15,80,82,"RESULTS: Verapamil caused AF promotion in six dogs, increasing mean duration of AF induced by burst pacing, from 8+/-4 s (mean+/-S.E.) to 95+/-39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228+/-101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg.",11282081_6,-1,-1,-1,1473,-1,0.0033665022,0.99663347
1474,P<0.01,30,31,149,155,"RESULTS: Verapamil caused AF promotion in six dogs, increasing mean duration of AF induced by burst pacing, from 8+/-4 s (mean+/-S.E.) to 95+/-39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228+/-101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg.",11282081_6,-1,-1,-1,1474,-1,0.4706554,0.5293446
1475,P<0.0005,45,46,217,225,"RESULTS: Verapamil caused AF promotion in six dogs, increasing mean duration of AF induced by burst pacing, from 8+/-4 s (mean+/-S.E.) to 95+/-39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228+/-101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg.",11282081_6,-1,-1,-1,1475,-1,0.5451678,0.45483226
1478,ms,17,18,105,107,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,-1,-1,-1,1478,-1,0.0473053,0.95269465
1479,P<0.02,19,20,109,115,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,-1,-1,-1,1479,-1,0.57707363,0.4229264
1480,ms,27,28,142,144,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,-1,-1,-1,1480,-1,0.07664073,0.9233593
1481,P<0.05,39,40,199,205,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,-1,-1,-1,1481,-1,0.35510686,0.64489317
1482,AF,52,53,288,290,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,-1,-1,-1,1482,-1,0.006018459,0.99398154
1483,P<0.005,59,60,313,320,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,-1,-1,-1,1483,-1,0.45241976,0.54758024
1484,AF,6,7,30,32,"Diltiazem did not affect ERP, AF cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n=5).",11282081_9,-1,-1,-1,1484,-1,0.017688693,0.98231125
1485,AF,10,11,49,51,"Diltiazem did not affect ERP, AF cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n=5).",11282081_9,-1,-1,-1,1485,-1,0.009207083,0.99079293
1487,n=5,24,25,136,139,"Diltiazem did not affect ERP, AF cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n=5).",11282081_9,-1,-1,-1,1487,-1,0.3786295,0.62137043
1489,AF,11,12,67,69,"In the presence of autonomic blockade, verapamil failed to promote AF and increased, rather than decreasing, refractoriness.",11282081_10,-1,-1,-1,1489,-1,0.0042308765,0.99576914
1493,AF,6,7,53,55,Epicardial mapping suggested that verapamil promoted AF by increasing the number of simultaneous wavefronts reflected by separate zones of reactivation in each cycle.,11282081_12,-1,-1,-1,1493,-1,0.004456469,0.99554354
1495,AF,4,5,32,34,"CONCLUSIONS: Verapamil promotes AF in normal dogs by promoting multiple circuit reentry, an effect dependent on intact autonomic tone and not shared by diltiazem.",11282081_13,-1,-1,-1,1495,-1,0.004264444,0.9957355
1500,nitric oxide,5,7,26,38,It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).,11284996_1,-1,-1,-1,1500,-1,0.99768806,0.002311919
1502,primary headaches,13,15,64,81,It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).,11284996_1,-1,-1,-1,1502,-1,0.0032276101,0.99677235
1504,CGRP,25,26,149,153,It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).,11284996_1,-1,-1,-1,1504,-1,0.99508446,0.0049155015
1505,CGRP,11,12,62,66,In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.,11284996_2,-1,-1,-1,1505,-1,0.9982167,0.0017832349
1507,glyceryl trinitrate,19,21,107,126,In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.,11284996_2,-1,-1,-1,1507,-1,0.9991233,0.00087672105
1508,GTN,22,23,128,131,In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.,11284996_2,-1,-1,-1,1508,-1,0.9984883,0.0015116422
1510,GTN,9,10,66,69,The subjects were randomly allocated to receive 0.5 microg/kg/min GTN or placebo over 20 min on two headache-free days.,11284996_3,-1,-1,-1,1510,-1,0.9988165,0.0011835041
1512,GTN,11,12,86,89,Both patients and controls developed significantly stronger immediate headache on the GTN day than on the placebo day and the headache was significantly more pronounced in patients than in controls.,11284996_5,-1,-1,-1,1512,-1,0.99863297,0.0013669839
1514,CGRP,9,10,51,55,There was no difference between the area under the CGRP curve (AUCCGRP) on GTN vs. placebo day in either patients (P=0.65) or controls (P=0.48).,11284996_6,-1,-1,-1,1514,-1,0.9990079,0.0009921058
1515,GTN,15,16,75,78,There was no difference between the area under the CGRP curve (AUCCGRP) on GTN vs. placebo day in either patients (P=0.65) or controls (P=0.48).,11284996_6,-1,-1,-1,1515,-1,0.9986186,0.0013814087
1516,P=0.65,23,24,115,121,There was no difference between the area under the CGRP curve (AUCCGRP) on GTN vs. placebo day in either patients (P=0.65) or controls (P=0.48).,11284996_6,-1,-1,-1,1516,-1,0.20359185,0.7964081
1517,P=0.48,28,29,136,142,There was no difference between the area under the CGRP curve (AUCCGRP) on GTN vs. placebo day in either patients (P=0.65) or controls (P=0.48).,11284996_6,-1,-1,-1,1517,-1,0.20827264,0.79172736
1518,GTN,5,6,28,31,The AUCCGRP recorded on the GTN day did not differ between patients and controls (P=0.36).,11284996_7,-1,-1,-1,1518,-1,0.99833786,0.0016621106
1519,P=0.36,15,16,82,88,The AUCCGRP recorded on the GTN day did not differ between patients and controls (P=0.36).,11284996_7,-1,-1,-1,1519,-1,0.32042828,0.6795717
1520,CGRP,6,7,31,35,"Both in patients and controls, CGRP levels changed significantly over time, on both the GTN and placebo days (P < 0.05).",11284996_8,-1,-1,-1,1520,-1,0.99882513,0.001174816
1521,GTN,16,17,88,91,"Both in patients and controls, CGRP levels changed significantly over time, on both the GTN and placebo days (P < 0.05).",11284996_8,-1,-1,-1,1521,-1,0.9986864,0.0013136088
1522,P,21,22,110,111,"Both in patients and controls, CGRP levels changed significantly over time, on both the GTN and placebo days (P < 0.05).",11284996_8,-1,-1,-1,1522,-1,0.3218344,0.6781656
1524,CGRP,14,15,97,101,The present study indicates that NO-induced immediate headache is not associated with release of CGRP.,11284996_9,-1,-1,-1,1524,-1,0.9986016,0.0013983658
1525,torsade de pointes,1,4,20,38,Fluconazole-induced torsade de pointes.,11302406_0,-1,-1,-1,1525,-1,0.009063928,0.9909361
1526,torsade de pointes,8,11,55,73,OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.,11302406_1,-1,-1,-1,1526,-1,0.017018758,0.98298126
1527,TDP,12,13,75,78,OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.,11302406_1,-1,-1,-1,1527,-1,0.032623705,0.96737623
1528,fluconazole,16,17,92,103,OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.,11302406_1,-1,-1,-1,1528,-1,0.9993948,0.0006052618
1529,TDP,21,22,122,125,OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.,11302406_1,-1,-1,-1,1529,-1,0.044686303,0.95531374
1530,TDP,16,17,106,109,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1530,-1,0.6721621,0.3278379
1531,fluconazole,22,23,143,154,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1531,-1,0.9994603,0.00053967116
1532,TDP,31,32,197,200,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1532,-1,0.6761277,0.32387227
1533,coronary artery disease,34,37,212,235,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1533,-1,0.008152882,0.99184704
1535,congestive heart failure,40,43,253,277,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1535,-1,0.0034774805,0.99652255
1536,fluconazole,56,57,368,379,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1536,-1,0.9994547,0.00054528547
1537,TDP,58,59,384,387,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,-1,-1,-1,1537,-1,0.90692437,0.093075596
1538,TDP,1,2,4,7,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,-1,-1,1538,-1,0.011837644,0.98816234
1539,fluconazole,4,5,22,33,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,-1,-1,1539,-1,0.9994387,0.0005613064
1540,premature ventricular contractions,15,18,91,125,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,-1,-1,1540,-1,0.0029529876,0.997047
1542,NSVT,23,24,168,172,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,-1,-1,1542,-1,0.010652521,0.98934746
1543,fluconazole,47,48,312,323,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,-1,-1,1543,-1,0.9994655,0.0005345255
1544,TDP,52,53,347,350,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,-1,-1,-1,1544,-1,0.009900247,0.9900997
1547,QT prolongation,13,15,74,89,"In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.",11302406_5,-1,-1,-1,1547,-1,0.03547336,0.96452665
1548,TDP,16,17,93,96,"In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.",11302406_5,-1,-1,-1,1548,-1,0.24536878,0.7546313
1549,NSVT,21,22,127,131,"In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.",11302406_5,-1,-1,-1,1549,-1,0.0436453,0.95635474
1550,premature ventricular contractions,23,26,136,170,"In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.",11302406_5,-1,-1,-1,1550,-1,0.00442688,0.99557316
1551,fluconazole,39,40,257,268,"In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.",11302406_5,-1,-1,-1,1551,-1,0.9994831,0.0005168708
1552,fluconazole,7,8,45,56,"CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to TDP.",11302406_6,-1,-1,-1,1552,-1,0.9993907,0.00060929335
1553,prolongation of the QT interval,16,21,87,118,"CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to TDP.",11302406_6,-1,-1,-1,1553,-1,0.0179823,0.98201764
1554,TDP,24,25,131,134,"CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to TDP.",11302406_6,-1,-1,-1,1554,-1,0.21696655,0.78303343
1555,fluconazole,7,8,62,73,Serial electrocardiographic monitoring may be considered when fluconazole is administered in patients who are at risk for ventricular arrhythmias.,11302406_7,-1,-1,-1,1555,-1,0.9994149,0.0005851305
1559,renal failure,12,14,90,103,"Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.",1130930_1,-1,-1,-1,1559,-1,0.002368152,0.9976318
1560,cephalothin sodium,22,24,148,166,"Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.",1130930_1,-1,-1,-1,1560,-1,0.9987576,0.001242421
1561,gentamicin sulfate,25,27,171,189,"Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.",1130930_1,-1,-1,-1,1561,-1,0.9984275,0.0015725206
1563,renal insufficiency,2,4,14,33,Patients with renal insufficiency should not be given this regimen.,1130930_4,-1,-1,-1,1563,-1,0.0029725046,0.99702746
1567,lung toxicity,17,19,143,156,"In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.",11334364_0,-1,-1,-1,1567,-1,0.0033721752,0.99662775
1569,IH636 grape seed proanthocyanidin extract,25,30,207,248,"In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.",11334364_0,-1,-1,-1,1569,-1,0.9907906,0.009209353
1570,proanthocyanidins,8,9,43,60,"Grape seed extract, primarily a mixture of proanthocyanidins, has been shown to modulate a wide-range of biological, pharmacological and toxicological effects which are mainly cytoprotective.",11334364_1,-1,-1,-1,1570,-1,0.99423534,0.0057647107
1571,IH636 grape seed proanthocyanidin extract,6,11,35,76,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,-1,-1,-1,1571,-1,0.99108094,0.008919073
1572,GSPE,12,13,78,82,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,-1,-1,-1,1572,-1,0.9904253,0.009574689
1576,lung toxicity,22,24,164,177,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,-1,-1,-1,1576,-1,0.002733064,0.997267
1579,GSPE,13,14,71,75,"Experimental design consisted of four groups: control (vehicle alone), GSPE alone, drug alone and GSPE+drug.",11334364_3,-1,-1,-1,1579,-1,0.997696,0.0023039673
1580,GSPE+drug,19,20,98,107,"Experimental design consisted of four groups: control (vehicle alone), GSPE alone, drug alone and GSPE+drug.",11334364_3,-1,-1,-1,1580,-1,0.9908717,0.009128302
1581,GSPE,11,12,68,72,"For the cytoprotection study, animals were orally gavaged 100 mg/Kg GSPE for 7-10 days followed by i.p.",11334364_4,-1,-1,-1,1581,-1,0.9978956,0.002104324
1582,AAP,7,8,42,45,injections of organ specific three drugs (AAP: 500 mg/Kg for 24 h; AMI: 50 mg/Kg/day for four days; DOX: 20 mg/Kg for 48 h).,11334364_5,-1,-1,-1,1582,-1,0.99828476,0.0017152285
1583,h,13,14,64,65,injections of organ specific three drugs (AAP: 500 mg/Kg for 24 h; AMI: 50 mg/Kg/day for four days; DOX: 20 mg/Kg for 48 h).,11334364_5,-1,-1,-1,1583,-1,0.26956972,0.7304303
1584,AMI,15,16,67,70,injections of organ specific three drugs (AAP: 500 mg/Kg for 24 h; AMI: 50 mg/Kg/day for four days; DOX: 20 mg/Kg for 48 h).,11334364_5,-1,-1,-1,1584,-1,0.9976947,0.0023052697
1585,DOX,23,24,100,103,injections of organ specific three drugs (AAP: 500 mg/Kg for 24 h; AMI: 50 mg/Kg/day for four days; DOX: 20 mg/Kg for 48 h).,11334364_5,-1,-1,-1,1585,-1,0.99793786,0.002062139
1586,h,29,30,121,122,injections of organ specific three drugs (AAP: 500 mg/Kg for 24 h; AMI: 50 mg/Kg/day for four days; DOX: 20 mg/Kg for 48 h).,11334364_5,-1,-1,-1,1586,-1,0.23790377,0.7620962
1587,BUN,11,12,63,66,"Parameters of study included analysis of serum chemistry (ALT, BUN and CPK), and orderly fragmentation of genomic DNA (both endonuclease-dependent and independent) in addition to microscopic evaluation of damage and/or protection in corresponding PAS stained tissues.",11334364_6,-1,-1,-1,1587,-1,0.99760926,0.002390689
1588,PAS,39,40,247,250,"Parameters of study included analysis of serum chemistry (ALT, BUN and CPK), and orderly fragmentation of genomic DNA (both endonuclease-dependent and independent) in addition to microscopic evaluation of damage and/or protection in corresponding PAS stained tissues.",11334364_6,-1,-1,-1,1588,-1,0.98758686,0.012413137
1589,GSPE,3,4,22,26,"Results indicate that GSPE preexposure prior to AAP, AMI and DOX, provided near complete protection in terms of serum chemistry changes (ALT, BUN and CPK), and significantly reduced DNA fragmentation.",11334364_7,-1,-1,-1,1589,-1,0.9976331,0.0023668353
1590,AAP,7,8,48,51,"Results indicate that GSPE preexposure prior to AAP, AMI and DOX, provided near complete protection in terms of serum chemistry changes (ALT, BUN and CPK), and significantly reduced DNA fragmentation.",11334364_7,-1,-1,-1,1590,-1,0.9981693,0.0018306874
1591,AMI,9,10,53,56,"Results indicate that GSPE preexposure prior to AAP, AMI and DOX, provided near complete protection in terms of serum chemistry changes (ALT, BUN and CPK), and significantly reduced DNA fragmentation.",11334364_7,-1,-1,-1,1591,-1,0.99819994,0.0018000278
1592,DOX,11,12,61,64,"Results indicate that GSPE preexposure prior to AAP, AMI and DOX, provided near complete protection in terms of serum chemistry changes (ALT, BUN and CPK), and significantly reduced DNA fragmentation.",11334364_7,-1,-1,-1,1592,-1,0.99861836,0.0013815876
1593,BUN,26,27,142,145,"Results indicate that GSPE preexposure prior to AAP, AMI and DOX, provided near complete protection in terms of serum chemistry changes (ALT, BUN and CPK), and significantly reduced DNA fragmentation.",11334364_7,-1,-1,-1,1593,-1,0.98760134,0.012398601
1594,tissue damage,13,15,94,107,"Histopathological examination of kidney, heart and lung sections revealed moderate to massive tissue damage with a variety of morphological aberrations by all the three drugs in the absence of GSPE preexposure than in its presence.",11334364_8,-1,-1,-1,1594,-1,0.0034954883,0.99650455
1595,GSPE,30,31,193,197,"Histopathological examination of kidney, heart and lung sections revealed moderate to massive tissue damage with a variety of morphological aberrations by all the three drugs in the absence of GSPE preexposure than in its presence.",11334364_8,-1,-1,-1,1595,-1,0.9982747,0.0017253681
1596,GSPE+drug,0,1,0,9,GSPE+drug exposed tissues exhibited minor residual damage or near total recovery.,11334364_9,-1,-1,-1,1596,-1,0.9934923,0.006507669
1597,AAP,9,10,39,42,"Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.",11334364_11,-1,-1,-1,1597,-1,0.99795437,0.0020455848
1598,AMI,11,12,44,47,"Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.",11334364_11,-1,-1,-1,1598,-1,0.9977943,0.0022057614
1599,DOX,13,14,52,55,"Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.",11334364_11,-1,-1,-1,1599,-1,0.99799675,0.0020031787
1602,GSPE,31,32,167,171,"Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.",11334364_11,-1,-1,-1,1602,-1,0.9975562,0.0024437844
1603,AAP,1,2,6,9,"Since AAP, AMI and DOX undergo biotransformation and are known to produce damaging radicals in vivo, the protection by GSPE may be linked to both inhibition of metabolism and/or detoxification of cytotoxic radicals.",11334364_12,-1,-1,-1,1603,-1,0.9980452,0.001954729
1604,AMI,3,4,11,14,"Since AAP, AMI and DOX undergo biotransformation and are known to produce damaging radicals in vivo, the protection by GSPE may be linked to both inhibition of metabolism and/or detoxification of cytotoxic radicals.",11334364_12,-1,-1,-1,1604,-1,0.99815124,0.001848771
1605,DOX,5,6,19,22,"Since AAP, AMI and DOX undergo biotransformation and are known to produce damaging radicals in vivo, the protection by GSPE may be linked to both inhibition of metabolism and/or detoxification of cytotoxic radicals.",11334364_12,-1,-1,-1,1605,-1,0.9981495,0.0018505078
1606,GSPE,21,22,119,123,"Since AAP, AMI and DOX undergo biotransformation and are known to produce damaging radicals in vivo, the protection by GSPE may be linked to both inhibition of metabolism and/or detoxification of cytotoxic radicals.",11334364_12,-1,-1,-1,1606,-1,0.9969061,0.0030938424
1607,apoptotic death,11,13,65,80,"Additionally, this may have been the first report on AMI-induced apoptotic death in the lung tissue.",11334364_14,-1,-1,-1,1607,-1,0.004019644,0.9959804
1608,GSPE,7,8,51,55,"Taken together, these events undoubtedly establish GSPE's abundant bioavailability, and the power to defend multiple target organs from toxic assaults induced by structurally diverse and functionally different entities in vivo.",11334364_15,-1,-1,-1,1608,-1,0.9965694,0.0034306275
1609,oxacillin,5,6,54,63,Cutaneous leucocytoclastic vasculitis associated with oxacillin.,11337188_0,-1,-1,-1,1609,-1,0.999273,0.0007270014
1610,oxacillin,7,8,39,48,"A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.",11337188_1,-1,-1,-1,1610,-1,0.9992581,0.00074190774
1611,bacteremia,15,16,95,105,"A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.",11337188_1,-1,-1,-1,1611,-1,0.0043823654,0.9956176
1612,renal failure,18,20,117,130,"A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.",11337188_1,-1,-1,-1,1612,-1,0.002838235,0.99716175
1613,purpuric lesions,26,28,164,180,"A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.",11337188_1,-1,-1,-1,1613,-1,0.003489544,0.99651045
1615,leucocytoclastic vasculitis,6,8,44,71,Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis.,11337188_3,-1,-1,-1,1615,-1,0.0067705237,0.9932295
1616,Oxacillin,0,1,0,9,Oxacillin was discontinued and patient was treated with corticosteroids.,11337188_4,-1,-1,-1,1616,-1,0.9992465,0.0007536032
1619,purpura,5,6,49,56,"Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.",11337188_6,-1,-1,-1,1619,-1,0.0039043357,0.9960957
1620,abdominal pain,13,15,103,117,"Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.",11337188_6,-1,-1,-1,1620,-1,0.003960307,0.9960396
1621,arthralgia,16,17,119,129,"Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.",11337188_6,-1,-1,-1,1621,-1,0.005545271,0.9944548
1622,renal involvement,19,21,135,152,"Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.",11337188_6,-1,-1,-1,1622,-1,0.00516626,0.9948337
1624,collagen vascular disease,10,13,75,100,"Etiologic factors or associated disorders include infections, medications, collagen vascular disease and neoplasia.",11337188_7,-1,-1,-1,1624,-1,0.030291293,0.96970874
1625,neoplasia,14,15,105,114,"Etiologic factors or associated disorders include infections, medications, collagen vascular disease and neoplasia.",11337188_7,-1,-1,-1,1625,-1,0.0038306327,0.9961694
1626,corticosteroid,8,9,43,57,"Usually it is a self-limited disorder, but corticosteroid therapy may be needed in life-threatening cases since early treatment with corticosteroids in severe cases can prevent complications.",11337188_9,-1,-1,-1,1626,-1,0.99854386,0.0014561136
1628,Oxacillin,0,1,0,9,Oxacillin should be included among the drugs that can cause leucocytoclastic vasculitis.,11337188_10,-1,-1,-1,1628,-1,0.9992035,0.00079647487
1629,leucocytoclastic vasculitis,10,12,60,87,Oxacillin should be included among the drugs that can cause leucocytoclastic vasculitis.,11337188_10,-1,-1,-1,1629,-1,0.0022750488,0.99772495
1630,mania,1,2,23,28,Antidepressant-induced mania in bipolar patients: identification of risk factors.,11379838_0,-1,-1,-1,1630,-1,0.0028434626,0.9971565
1632,mania,9,10,58,63,BACKGROUND: Concerns about possible risks of switching to mania associated with antidepressants continue to interfere with the establishment of an optimal treatment paradigm for bipolar depression.,11379838_1,-1,-1,-1,1632,-1,0.005486183,0.99451387
1634,bipolar depression,25,27,178,196,BACKGROUND: Concerns about possible risks of switching to mania associated with antidepressants continue to interfere with the establishment of an optimal treatment paradigm for bipolar depression.,11379838_1,-1,-1,-1,1634,-1,0.010878859,0.98912114
1635,bipolar disorder,11,13,64,80,METHOD: The response of 44 patients meeting DSM-IV criteria for bipolar disorder to naturalistic treatment was assessed for at least 6 weeks using the Montgomery-Asberg Depression Rating Scale and the Bech-Rafaelson Mania Rating Scale.,11379838_2,-1,-1,-1,1635,-1,0.0059111193,0.9940889
1638,hypomanic,6,7,36,45,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,-1,-1,-1,1638,-1,0.0063412376,0.9936587
1639,bipolar I,26,28,149,158,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,-1,-1,-1,1639,-1,0.066672534,0.93332744
1640,bipolar II,29,31,163,173,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,-1,-1,-1,1640,-1,0.04976014,0.95023984
1644,serotonin reuptake inhibitors,56,59,333,362,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,-1,-1,-1,1644,-1,0.99269134,0.0073086987
1645,SSRIs,60,61,364,369,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,-1,-1,-1,1645,-1,0.99451727,0.005482721
1647,hypomania,4,5,21,30,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1647,-1,0.0032365355,0.99676347
1648,mania,6,7,34,39,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1648,-1,0.0027577928,0.9972422
1649,N,15,16,73,74,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1649,-1,0.24349701,0.75650305
1650,SSRIs,31,32,134,139,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1650,-1,0.9987595,0.0012404964
1651,N,40,41,154,155,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1651,-1,0.2445421,0.7554579
1653,N,52,53,198,199,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1653,-1,0.19985089,0.8001491
1654,hypomanic,57,58,217,226,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,-1,-1,-1,1654,-1,0.0032980398,0.9967019
1655,bipolar I,6,8,21,30,"Sex, age, diagnosis (bipolar I vs. bipolar II), and additional treatment did not affect the risk of switching.",11379838_5,-1,-1,-1,1655,-1,0.792844,0.20715597
1656,bipolar II,9,11,35,45,"Sex, age, diagnosis (bipolar I vs. bipolar II), and additional treatment did not affect the risk of switching.",11379838_5,-1,-1,-1,1656,-1,0.8768274,0.12317259
1657,contrast,1,2,3,11,"In contrast, mood switches were less frequent in patients receiving lithium (15%, 4/26) than in patients not treated with lithium (44%, 8/18; p = .04).",11379838_7,-1,-1,-1,1657,-1,0.13198128,0.8680187
1660,p,31,32,142,143,"In contrast, mood switches were less frequent in patients receiving lithium (15%, 4/26) than in patients not treated with lithium (44%, 8/18; p = .04).",11379838_7,-1,-1,-1,1660,-1,0.2692042,0.73079574
1662,p,37,38,236,237,"The number of previous manic episodes did not affect the probability of switching, whereas a high score on the hyperthymia component of the Semistructured Affective Temperament Interview was associated with a greater risk of switching (p = .008).",11379838_8,-1,-1,-1,1662,-1,0.3640724,0.63592756
1665,kidney disease,9,11,79,93,Peritubular capillary basement membrane reduplication in allografts and native kidney disease: a clinicopathologic study of 278 consecutive renal specimens.,11391224_0,-1,-1,-1,1665,-1,0.0050987103,0.9949013
1666,transplant glomerulopathy,8,10,50,75,BACKGROUND: An association has been found between transplant glomerulopathy (TG) and reduplication of peritubular capillary basement membranes (PTCR).,11391224_1,-1,-1,-1,1666,-1,0.006356877,0.99364305
1667,TG,11,12,77,79,BACKGROUND: An association has been found between transplant glomerulopathy (TG) and reduplication of peritubular capillary basement membranes (PTCR).,11391224_1,-1,-1,-1,1667,-1,0.09421216,0.9057878
1668,TG,6,7,37,39,"In addition to renal allografts with TG, we also examined grafts with acute rejection, recurrent glomerulonephritis, chronic allograft nephropathy and stable grafts (""protocol biopsies"").",11391224_4,-1,-1,-1,1668,-1,0.99449146,0.005508516
1670,chronic allograft nephropathy,19,22,117,146,"In addition to renal allografts with TG, we also examined grafts with acute rejection, recurrent glomerulonephritis, chronic allograft nephropathy and stable grafts (""protocol biopsies"").",11391224_4,-1,-1,-1,1670,-1,0.0044075744,0.9955924
1671,glomerulopathies,8,9,49,65,"Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy, malignant hypertension, acute interstitial nephritis, and acute tubular necrosis.",11391224_5,-1,-1,-1,1671,-1,0.0030737945,0.99692625
1673,malignant hypertension,17,19,114,136,"Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy, malignant hypertension, acute interstitial nephritis, and acute tubular necrosis.",11391224_5,-1,-1,-1,1673,-1,0.0047377404,0.99526227
1674,acute interstitial nephritis,20,23,138,166,"Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy, malignant hypertension, acute interstitial nephritis, and acute tubular necrosis.",11391224_5,-1,-1,-1,1674,-1,0.0036260586,0.99637395
1676,TG,11,12,44,46,"RESULTS: We found PTCR in 14 of 15 cases of TG, in 7 transplant biopsy specimens without TG, and in 13 of 143 native kidney biopsy specimens.",11391224_6,-1,-1,-1,1676,-1,0.9659321,0.034067895
1677,TG,19,20,89,91,"RESULTS: We found PTCR in 14 of 15 cases of TG, in 7 transplant biopsy specimens without TG, and in 13 of 143 native kidney biopsy specimens.",11391224_6,-1,-1,-1,1677,-1,0.97713906,0.022860957
1678,malignant hypertension,5,7,27,49,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,-1,-1,-1,1678,-1,0.003515577,0.9964844
1680,lupus nephritis,11,13,79,94,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,-1,-1,-1,1680,-1,0.0027836477,0.99721634
1681,nephritis,15,16,113,122,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,-1,-1,-1,1681,-1,0.0031731396,0.9968268
1683,acute renal failure,22,25,175,194,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,-1,-1,-1,1683,-1,0.0024839977,0.99751604
1684,TG,5,6,32,34,Mild PTCR in allografts without TG did not predict renal failure or significant proteinuria after follow-up periods of between 3 months and 1 year.,11391224_8,-1,-1,-1,1684,-1,0.99649245,0.003507566
1685,renal failure,9,11,51,64,Mild PTCR in allografts without TG did not predict renal failure or significant proteinuria after follow-up periods of between 3 months and 1 year.,11391224_8,-1,-1,-1,1685,-1,0.0024563475,0.99754363
1687,TG,17,18,108,110,"CONCLUSIONS: We conclude that in transplants, there is a strong association between well-developed PTCR and TG, while the significance of mild PTCR and its predictive value in the absence of TG is unclear.",11391224_9,-1,-1,-1,1687,-1,0.12837991,0.8716201
1688,TG,33,34,191,193,"CONCLUSIONS: We conclude that in transplants, there is a strong association between well-developed PTCR and TG, while the significance of mild PTCR and its predictive value in the absence of TG is unclear.",11391224_9,-1,-1,-1,1688,-1,0.05193688,0.9480632
1689,kidney diseases,6,8,35,50,"PTCR also occurs in certain native kidney diseases, though the association is not as strong as that for TG.",11391224_10,-1,-1,-1,1689,-1,0.0042449418,0.9957551
1690,TG,19,20,104,106,"PTCR also occurs in certain native kidney diseases, though the association is not as strong as that for TG.",11391224_10,-1,-1,-1,1690,-1,0.99554825,0.004451745
1691,endothelial injury,4,6,25,43,"We suggest that repeated endothelial injury, including immunologic injury, may be the cause of this lesion both in allografts and native kidneys.",11391224_11,-1,-1,-1,1691,-1,0.034310088,0.9656899
1692,immunologic injury,8,10,55,73,"We suggest that repeated endothelial injury, including immunologic injury, may be the cause of this lesion both in allografts and native kidneys.",11391224_11,-1,-1,-1,1692,-1,0.015597691,0.9844023
1693,diabetes insipidus,8,10,49,67,The renal pathology in a case of lithium-induced diabetes insipidus.,1141447_0,-1,-1,-1,1693,-1,0.005396095,0.99460393
1694,diabetes insipidus,4,6,26,44,A case of lithium-induced diabetes insipidus is reported.,1141447_1,-1,-1,-1,1694,-1,0.0040336633,0.9959663
1696,cardiac arrhythmia,1,3,17,35,Caffeine-induced cardiac arrhythmia: an unrecognised danger of healthfood products.,11419773_0,-1,-1,-1,1696,-1,0.0026868698,0.9973131
1697,mitral valve prolapse,7,10,50,71,"We describe a 25-year-old woman with pre-existing mitral valve prolapse who developed intractable ventricular fibrillation after consuming a ""natural energy"" guarana health drink containing a high concentration of caffeine.",11419773_1,-1,-1,-1,1697,-1,0.0063930745,0.9936069
1698,ventricular fibrillation,13,15,98,122,"We describe a 25-year-old woman with pre-existing mitral valve prolapse who developed intractable ventricular fibrillation after consuming a ""natural energy"" guarana health drink containing a high concentration of caffeine.",11419773_1,-1,-1,-1,1698,-1,0.002416757,0.99758327
1700,BD1008,4,5,39,45,Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma1 receptors produce anti-cocaine effects in mice.,11426838_0,-1,-1,-1,1700,-1,0.9987709,0.0012291431
1701,oligodeoxynucleotide,8,9,63,83,Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma1 receptors produce anti-cocaine effects in mice.,11426838_0,-1,-1,-1,1701,-1,0.9928342,0.0071657905
1703,BD1018,17,18,109,115,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1703,-1,0.9967308,0.00326925
1704,"3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane)",19,21,117,182,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1704,-1,0.96725947,0.032740522
1705,BD1063,22,23,184,190,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1705,-1,0.9866889,0.013311099
1707,LR132,28,29,249,254,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1707,-1,0.9947109,0.0052890647
1708,"1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine",30,31,256,335,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1708,-1,0.98792136,0.012078659
1709,"1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine",30,31,256,335,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1709,-1,0.98792136,0.012078659
1710,"1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine",30,31,256,335,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1710,-1,0.98792136,0.012078659
1711,"1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine",30,31,256,335,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1711,-1,0.98792136,0.012078659
1712,"1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine",30,31,256,335,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1712,-1,0.98792136,0.012078659
1713,"1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine",30,31,256,335,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1713,-1,0.98792136,0.012078659
1714,"1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine",30,31,256,335,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,-1,-1,-1,1714,-1,0.98792136,0.012078659
1716,NMDA,22,23,134,138,"The three compounds vary in their affinities for sigma2 receptors and exhibit negligible affinities for dopamine, opioid, GABA(A) and NMDA receptors.",11426838_4,-1,-1,-1,1716,-1,0.99718,0.0028200587
1717,BD1018,8,9,50,56,"In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced convulsions and lethality.",11426838_5,-1,-1,-1,1717,-1,0.99840707,0.0015930125
1718,BD1063,10,11,58,64,"In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced convulsions and lethality.",11426838_5,-1,-1,-1,1718,-1,0.9970181,0.002981927
1719,LR132,13,14,69,74,"In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced convulsions and lethality.",11426838_5,-1,-1,-1,1719,-1,0.9984894,0.0015105645
1721,LR132,4,5,30,35,"Moreover, post-treatment with LR132 prevented cocaine-induced lethality in a significant proportion of animals.",11426838_6,-1,-1,-1,1721,-1,0.99900407,0.000996012
1722,contrast,1,2,3,11,"In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.",11426838_7,-1,-1,-1,1722,-1,0.24168274,0.7583173
1723,DTG),18,20,135,139,"In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.",11426838_7,-1,-1,-1,1723,-1,0.9894671,0.010532872
1724,BD1031,26,27,177,183,"In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.",11426838_7,-1,-1,-1,1724,-1,0.99591655,0.0040834034
1725,"3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane)",28,30,185,250,"In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.",11426838_7,-1,-1,-1,1725,-1,0.9643797,0.03562031
1728,BD1018,13,14,74,80,"At doses where alone, they produced no significant effects on locomotion, BD1018, BD1063 and LR132 significantly attenuated the locomotor stimulatory effects of cocaine.",11426838_8,-1,-1,-1,1728,-1,0.9987857,0.0012143226
1729,BD1063,15,16,82,88,"At doses where alone, they produced no significant effects on locomotion, BD1018, BD1063 and LR132 significantly attenuated the locomotor stimulatory effects of cocaine.",11426838_8,-1,-1,-1,1729,-1,0.99771607,0.0022840004
1730,LR132,17,18,93,98,"At doses where alone, they produced no significant effects on locomotion, BD1018, BD1063 and LR132 significantly attenuated the locomotor stimulatory effects of cocaine.",11426838_8,-1,-1,-1,1730,-1,0.9986645,0.0013354553
1732,oligodeoxynucleotide,21,22,139,159,"To further validate the hypothesis that the anti-cocaine effects of the novel ligands involved antagonism of sigma receptors, an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the convulsive and locomotor stimulatory effects of cocaine.",11426838_9,-1,-1,-1,1732,-1,0.9964055,0.0035945072
1739,acute allograft dysfunction,19,22,130,157,We report a case of ranitidine-induced acute interstitial nephritis in a recipient of a cadaveric renal allograft presenting with acute allograft dysfunction within 48 hours of exposure to the drug.,11431197_4,-1,-1,-1,1739,-1,0.003880353,0.9961196
1740,eosinophilic,8,9,61,73,"The biopsy specimen showed pathognomonic features, including eosinophilic infiltration of the interstitial compartment.",11431197_5,-1,-1,-1,1740,-1,0.053050693,0.9469493
1741,metformin,7,8,48,57,Cholestatic jaundice associated with the use of metformin.,11467664_0,-1,-1,-1,1741,-1,0.9984478,0.0015522263
1742,cholestatic jaundice,6,8,34,54,We report a patient who developed cholestatic jaundice shortly after initiation of treatment with metformin hydrochloride.,11467664_1,-1,-1,-1,1742,-1,0.0031895693,0.9968104
1743,metformin hydrochloride,14,16,98,121,We report a patient who developed cholestatic jaundice shortly after initiation of treatment with metformin hydrochloride.,11467664_1,-1,-1,-1,1743,-1,0.9987085,0.0012914693
1746,acute inflammation,18,20,116,134,"A percutaneous liver biopsy was obtained showing marked cholestasis, with portal edema, ductular proliferation, and acute inflammation.",11467664_4,-1,-1,-1,1746,-1,0.003319025,0.9966809
1749,metformin,12,13,61,70,"Given the onset of his jaundice 2 wk after the initiation of metformin, we believe that this case represents an example of metformin-associated hepatotoxicity, the first such case reported.",11467664_6,-1,-1,-1,1749,-1,0.99861336,0.0013866125
1754,chronic liver disease,17,20,86,107,This is an addition to the list of drugs that must be considered in the evaluation of chronic liver disease.,1147734_2,-1,-1,-1,1754,-1,0.0038313442,0.9961687
1758,levobupivacaine,8,9,50,65,"We compared the systemic toxicity of bupivacaine, levobupivacaine, and ropivacaine in anesthetized rats.",11524350_1,-1,-1,-1,1758,-1,0.9991221,0.00087795587
1759,ropivacaine,11,12,71,82,"We compared the systemic toxicity of bupivacaine, levobupivacaine, and ropivacaine in anesthetized rats.",11524350_1,-1,-1,-1,1759,-1,0.9992748,0.00072522275
1760,levobupivacaine,2,3,13,28,"Bupivacaine, levobupivacaine, or ropivacaine was infused at a rate of 2 mg.",11524350_3,-1,-1,-1,1760,-1,0.9990926,0.00090744725
1761,ropivacaine,5,6,33,44,"Bupivacaine, levobupivacaine, or ropivacaine was infused at a rate of 2 mg.",11524350_3,-1,-1,-1,1761,-1,0.99926037,0.0007395782
1762,mg,13,14,72,74,"Bupivacaine, levobupivacaine, or ropivacaine was infused at a rate of 2 mg.",11524350_3,-1,-1,-1,1762,-1,0.9640589,0.035941124
1765,mm Hg,13,15,84,89,Resuscitation was considered successful when a systolic arterial pressure > or =100 mm Hg was achieved within 5 min.,11524350_8,-1,-1,-1,1765,-1,0.74045104,0.259549
1766,levobupivacaine,4,5,24,39,The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine.,11524350_9,-1,-1,-1,1766,-1,0.9991714,0.00082866405
1767,ropivacaine,6,7,44,55,The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine.,11524350_9,-1,-1,-1,1767,-1,0.99924254,0.0007575005
1770,levobupivacaine,4,5,24,39,"The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.",11524350_10,-1,-1,-1,1770,-1,0.9991885,0.00081146375
1771,dysrhythmias,7,8,54,66,"The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.",11524350_10,-1,-1,-1,1771,-1,0.0025035394,0.9974964
1773,ropivacaine,17,18,125,136,"The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.",11524350_10,-1,-1,-1,1773,-1,0.99926823,0.00073175225
1776,Ropivacaine,11,12,59,70,"However, a smaller dose of epinephrine was required in the Ropivacaine group than in the other groups.",11524350_12,-1,-1,-1,1776,-1,0.9992581,0.00074184936
1778,levobupivacaine,7,8,42,57,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,-1,-1,-1,1778,-1,0.99914396,0.00085596583
1779,ropivacaine,13,14,90,101,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,-1,-1,-1,1779,-1,0.9992824,0.0007176201
1783,levobupivacaine,40,41,277,292,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,-1,-1,-1,1783,-1,0.99894494,0.0010550765
1784,rabbit syndrome,1,3,20,35,Withdrawal-emergent rabbit syndrome during dose reduction of risperidone.,11532387_0,-1,-1,-1,1784,-1,0.00445722,0.9955428
1786,Rabbit syndrome,0,2,0,15,Rabbit syndrome (RS) is a rare extrapyramidal side effect caused by prolonged neuroleptic medication.,11532387_1,-1,-1,-1,1786,-1,0.011456187,0.9885438
1787,RS,3,4,17,19,Rabbit syndrome (RS) is a rare extrapyramidal side effect caused by prolonged neuroleptic medication.,11532387_1,-1,-1,-1,1787,-1,0.008058324,0.9919417
1788,neuroleptic,14,15,78,89,Rabbit syndrome (RS) is a rare extrapyramidal side effect caused by prolonged neuroleptic medication.,11532387_1,-1,-1,-1,1788,-1,0.99897385,0.0010261626
1789,RS,7,8,46,48,"Here we present a case of withdrawal-emergent RS, which is the first of its kind to be reported.",11532387_2,-1,-1,-1,1789,-1,0.009106771,0.99089324
1792,RS,5,6,48,50,"The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.",11532387_5,-1,-1,-1,1792,-1,0.0042806836,0.9957194
1795,RS,37,38,261,263,"The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.",11532387_5,-1,-1,-1,1795,-1,0.004498448,0.9955016
1796,E4031,6,7,61,66,"Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog.1.",11569530_0,-1,-1,-1,1796,-1,0.997948,0.0020520478
1800,TDP,4,5,21,24,Torsades de pointes (TDP) is a potentially fatal ventricular tachycardia associated with increases in QT interval and monophasic action potential duration (MAPD).,11569530_1,-1,-1,-1,1800,-1,0.98293173,0.017068181
1802,TDP,0,1,0,3,TDP is a side-effect that has led to withdrawal of several drugs from the market (e.g. terfenadine and terodiline).,11569530_2,-1,-1,-1,1802,-1,0.7462427,0.25375736
1805,TDP,6,7,36,39,The potential of compounds to cause TDP was evaluated by monitoring their effects on MAPD in dog.,11569530_4,-1,-1,-1,1805,-1,0.5078132,0.49218675
1806,TDP,9,10,55,58,"Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.",11569530_5,-1,-1,-1,1806,-1,0.0063400627,0.9936599
1810,E4031,19,20,117,122,"Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.",11569530_5,-1,-1,-1,1810,-1,0.99732745,0.0026725892
1814,E4031,28,29,117,122,"These data indicate that the free ED50 in plasma for terfenadine (1.9 nM), terodiline (76 nM), cisapride (11 nM) and E4031 (1.9 nM) closely correlate with the free concentration in man causing QT effects.",11569530_9,-1,-1,-1,1814,-1,0.9967775,0.0032224965
1815,TDP,5,6,30,33,"For compounds that have shown TDP in the clinic (terfenadine, terodiline, cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins.",11569530_10,-1,-1,-1,1815,-1,0.13622722,0.8637728
1819,TDP,13,14,80,83,These data underline the need to maximize the therapeutic ratio with respect to TDP in potential development candidates and the importance of using free drug concentrations in pharmacokinetic/pharmacodynamic studies.,11569530_11,-1,-1,-1,1819,-1,0.9985488,0.0014512134
1822,amphotericin B,24,26,152,166,Amphotericin B-induced seizures in a patient with AIDS.OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.,11573852_0,-1,-1,-1,1822,-1,0.9990048,0.0009951949
1823,grand mal seizures,9,12,71,89,"CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.",11573852_1,-1,-1,-1,1823,-1,0.0039603775,0.9960396
1824,amphotericin B,16,18,121,135,"CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.",11573852_1,-1,-1,-1,1824,-1,0.9989329,0.0010670968
1827,hydroxyzine,7,8,57,68,"The patients concurrent medications included didanosine, hydroxyzine, promethazine, hydrocortisone, and prochlorperazine.",11573852_2,-1,-1,-1,1827,-1,0.99917823,0.0008217052
1828,promethazine,9,10,70,82,"The patients concurrent medications included didanosine, hydroxyzine, promethazine, hydrocortisone, and prochlorperazine.",11573852_2,-1,-1,-1,1828,-1,0.9991228,0.0008772275
1832,lorazepam,5,6,40,49,"Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.",11573852_3,-1,-1,-1,1832,-1,0.99906844,0.00093161466
1834,amphotercin B,14,16,99,112,"Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.",11573852_3,-1,-1,-1,1834,-1,0.998936,0.0010640211
1835,AIDS,2,3,12,16,"DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures.",11573852_4,-1,-1,-1,1835,-1,0.16718689,0.8328131
1836,cryptococcal meningitis,4,6,21,44,"DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures.",11573852_4,-1,-1,-1,1836,-1,0.018176934,0.9818231
1838,alcohol abuse,6,8,29,42,The patient had a history of alcohol abuse; alcohol intake as well as withdrawal can also cause seizures.,11573852_5,-1,-1,-1,1838,-1,0.32012928,0.6798707
1844,amphotericin B,7,9,41,55,The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.,11573852_8,-1,-1,-1,1844,-1,0.99902225,0.0009777065
1846,AIDS,17,18,94,98,The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.,11573852_8,-1,-1,-1,1846,-1,0.0069732424,0.99302673
1847,Amphotericin B,2,4,13,27,CONCLUSIONS: Amphotericin B seems to be the probable cause of the seizures.,11573852_9,-1,-1,-1,1847,-1,0.9990182,0.0009817872
1850,amphotericin B,10,12,54,68,"To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.",11573852_10,-1,-1,-1,1850,-1,0.99908614,0.00091387547
1851,retention of urine,1,4,8,26,Bladder retention of urine as a result of continuous intravenous infusion of fentanyl: 2 case reports.,11581460_0,-1,-1,-1,1851,-1,0.013739827,0.9862601
1856,chest wall rigidity,8,11,65,84,"Various reported side effects of fentanyl administration include chest wall rigidity, hypotension, respiratory depression, and bradycardia.",11581460_3,-1,-1,-1,1856,-1,0.031134019,0.96886593
1858,respiratory depression,14,16,99,121,"Various reported side effects of fentanyl administration include chest wall rigidity, hypotension, respiratory depression, and bradycardia.",11581460_3,-1,-1,-1,1858,-1,0.0037931777,0.99620676
1860,urinary bladder retention,5,8,17,42,"Here, 2 cases of urinary bladder retention leading to renal pelvocalyceal dilatation mimicking hydronephrosis as a result of continuous infusion of fentanyl are reported.",11581460_4,-1,-1,-1,1860,-1,0.003770388,0.9962296
1861,hydronephrosis,14,15,95,109,"Here, 2 cases of urinary bladder retention leading to renal pelvocalyceal dilatation mimicking hydronephrosis as a result of continuous infusion of fentanyl are reported.",11581460_4,-1,-1,-1,1861,-1,0.0030089745,0.99699104
1863,mycophenolate mofetil,2,4,14,35,Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients.,11583940_0,-1,-1,-1,1863,-1,0.9987913,0.0012087962
1867,Acute nephrotoxicity,0,2,0,20,"Acute nephrotoxicity, which occurs in the early period after transplantation, leads to a higher rate of dialysis, and chronic nephrotoxicity may eventually result in graft loss.",11583940_3,-1,-1,-1,1867,-1,0.0041120984,0.99588794
1870,immunosuppressive agents,3,5,23,47,"Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (rapamycin), have no nephrotoxicity.",11583940_5,-1,-1,-1,1870,-1,0.4666359,0.5333641
1871,mycophenolate mofetil,6,8,49,70,"Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (rapamycin), have no nephrotoxicity.",11583940_5,-1,-1,-1,1871,-1,0.9989197,0.0010803085
1875,myeloencephalopathy,1,2,6,25,Fatal myeloencephalopathy due to accidental intrathecal vincristin administration: a report of two cases.,11587867_0,-1,-1,-1,1875,-1,0.0022482888,0.99775165
1876,vincristin,6,7,56,66,Fatal myeloencephalopathy due to accidental intrathecal vincristin administration: a report of two cases.,11587867_0,-1,-1,-1,1876,-1,0.99942005,0.0005799369
1878,acute lymphoblastic leucemia,18,21,116,144,We report on two fatal cases of accidental intrathecal vincristine instillation in a 5-year old girl with recurrent acute lymphoblastic leucemia and a 57-year old man with lymphoblastic lymphoma.,11587867_1,-1,-1,-1,1878,-1,0.0027117622,0.9972882
1879,lymphoblastic lymphoma,27,29,172,194,We report on two fatal cases of accidental intrathecal vincristine instillation in a 5-year old girl with recurrent acute lymphoblastic leucemia and a 57-year old man with lymphoblastic lymphoma.,11587867_1,-1,-1,-1,1879,-1,0.0026053826,0.99739456
1881,motor dysfunction,14,16,82,99,"Clinically, the onset was characterized by the signs of opistothonus, sensory and motor dysfunction and ascending paralysis.",11587867_3,-1,-1,-1,1881,-1,0.0029989237,0.9970011
1883,degeneration of myelin and axons,12,17,92,124,"Histological and immunohistochemical investigations (HE-LFB, CD-68, Neurofilament) revealed degeneration of myelin and axons as well as pseudocystic transformation in areas exposed to vincristine, accompanied by secondary changes with numerous prominent macrophages.",11587867_4,-1,-1,-1,1883,-1,0.010595674,0.9894043
1891,palpebral twitching,18,20,117,136,We report a favorable response to treatment with citalopram by a 15-year-old boy with major depression who exhibited palpebral twitching during his first 2 weeks of treatment.,11642480_2,-1,-1,-1,1891,-1,0.010364526,0.9896354
1900,necrotising,11,12,72,83,"Cervical and inguinal lymph node biopsies showed the features of severe necrotising lymphadenitis, associated with erythrophagocytosis and prominent eosinophilic infiltrates, without viral inclusion bodies, suggestive of an adverse drug reaction.",11672959_2,-1,-1,-1,1900,-1,0.0048490535,0.9951509
1901,lymphadenitis,12,13,84,97,"Cervical and inguinal lymph node biopsies showed the features of severe necrotising lymphadenitis, associated with erythrophagocytosis and prominent eosinophilic infiltrates, without viral inclusion bodies, suggestive of an adverse drug reaction.",11672959_2,-1,-1,-1,1901,-1,0.0023328508,0.9976672
1902,adverse drug reaction,30,33,224,245,"Cervical and inguinal lymph node biopsies showed the features of severe necrotising lymphadenitis, associated with erythrophagocytosis and prominent eosinophilic infiltrates, without viral inclusion bodies, suggestive of an adverse drug reaction.",11672959_2,-1,-1,-1,1902,-1,0.032561664,0.9674383
1904,autoimmunity,22,23,139,151,"A week later, fulminant drug-induced hepatitis, associated with the presence of anti-nuclear autoantibodies (but not with other markers of autoimmunity), and accompanied by multi-organ failure and sepsis, supervened.",11672959_3,-1,-1,-1,1904,-1,0.0061840573,0.993816
1906,massive hepatocellular necrosis,5,8,43,74,"Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity myocarditis, focal acute tubulo-interstitial nephritis and extensive bone marrow necrosis, with no evidence of malignancy.",11672959_5,-1,-1,-1,1906,-1,0.009423595,0.9905764
1907,hypersensitivity myocarditis,10,12,82,110,"Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity myocarditis, focal acute tubulo-interstitial nephritis and extensive bone marrow necrosis, with no evidence of malignancy.",11672959_5,-1,-1,-1,1907,-1,0.004511099,0.99548894
1908,nephritis,16,17,144,153,"Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity myocarditis, focal acute tubulo-interstitial nephritis and extensive bone marrow necrosis, with no evidence of malignancy.",11672959_5,-1,-1,-1,1908,-1,0.0034943277,0.99650574
1909,bone marrow necrosis,19,22,168,188,"Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity myocarditis, focal acute tubulo-interstitial nephritis and extensive bone marrow necrosis, with no evidence of malignancy.",11672959_5,-1,-1,-1,1909,-1,0.02490717,0.9750929
1911,sulphasalazine syndrome,20,22,125,148,"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called ""3-week sulphasalazine syndrome"", a rare, but often fatal, immunoallergic reaction to sulphasalazine.",11672959_6,-1,-1,-1,1911,-1,0.9158148,0.084185176
1914,akathisia,16,17,124,133,"Intravenous administration of prochlorperazine by 15-minute infusion versus 2-minute bolus does not affect the incidence of akathisia: a prospective, randomized, controlled trial.",11679859_0,-1,-1,-1,1914,-1,0.013990373,0.9860096
1915,akathisia,10,11,50,59,STUDY OBJECTIVE: We sought to compare the rate of akathisia after administration of intravenous prochlorperazine as a 2-minute bolus or 15-minute infusion.,11679859_1,-1,-1,-1,1915,-1,0.012924999,0.98707503
1917,emergency department,13,15,75,95,"METHODS: We conducted a prospective, randomized, double-blind study in the emergency department of a central-city teaching hospital.",11679859_2,-1,-1,-1,1917,-1,0.01077054,0.9892294
1922,mg,7,8,49,51,Study participants were randomized to receive 10 mg of prochlorperazine administered intravenously by means of 2-minute push (bolus group) or 10 mg diluted in 50 mL of normal saline solution administered by means of intravenous infusion during a 15-minute period (infusion group).,11679859_4,-1,-1,-1,1922,-1,0.98760754,0.012392454
1924,mg,23,24,145,147,Study participants were randomized to receive 10 mg of prochlorperazine administered intravenously by means of 2-minute push (bolus group) or 10 mg diluted in 50 mL of normal saline solution administered by means of intravenous infusion during a 15-minute period (infusion group).,11679859_4,-1,-1,-1,1924,-1,0.985756,0.014244063
1925,saline solution,30,32,175,190,Study participants were randomized to receive 10 mg of prochlorperazine administered intravenously by means of 2-minute push (bolus group) or 10 mg diluted in 50 mL of normal saline solution administered by means of intravenous infusion during a 15-minute period (infusion group).,11679859_4,-1,-1,-1,1925,-1,0.9932365,0.0067635044
1926,akathisia,10,11,67,76,The main outcome was the number of study participants experiencing akathisia within 60 minutes of administration.,11679859_5,-1,-1,-1,1926,-1,0.98358166,0.01641838
1927,restlessness,9,10,56,68,Akathisia was defined as either a spontaneous report of restlessness or agitation or a change of 2 or more in the patient-reported akathisia rating scale and a change of at least 1 in the investigator-observed akathisia rating scale.,11679859_6,-1,-1,-1,1927,-1,0.0040896367,0.9959104
1929,akathisia,22,23,131,140,Akathisia was defined as either a spontaneous report of restlessness or agitation or a change of 2 or more in the patient-reported akathisia rating scale and a change of at least 1 in the investigator-observed akathisia rating scale.,11679859_6,-1,-1,-1,1929,-1,0.0144316945,0.9855682
1930,akathisia,35,36,210,219,Akathisia was defined as either a spontaneous report of restlessness or agitation or a change of 2 or more in the patient-reported akathisia rating scale and a change of at least 1 in the investigator-observed akathisia rating scale.,11679859_6,-1,-1,-1,1930,-1,0.013527535,0.9864725
1935,akathisia,11,12,38,47,"In the bolus group, 26.0% (13/50) had akathisia compared with 32.7% (16/49) in the infusion group (Delta=-6.7%; 95% confidence interval [CI] -24.6% to 11.2%).",11679859_11,-1,-1,-1,1935,-1,0.00493699,0.995063
1938,akathisia,10,11,48,57,CONCLUSION: A 50% reduction in the incidence of akathisia when prochlorperazine was administered by means of 15-minute intravenous infusion versus a 2-minute intravenous push was not detected.,11679859_14,-1,-1,-1,1938,-1,0.008429423,0.9915706
1943,nimesulide,2,3,16,26,Tolerability of nimesulide and paracetamol in patients with NSAID-induced urticaria/angioedema.,11694026_0,-1,-1,-1,1943,-1,0.9990853,0.000914724
1945,nimesulide,6,7,44,54,"Previous studies evaluated the tolerance of nimesulide and paracetamol in subjects with cutaneous, respiratory and anaphylactoid reactions induced by nonsteroidal anti-inflammatory drugs (NSAIDs).",11694026_1,-1,-1,-1,1945,-1,0.9991911,0.0008088601
1947,NSAIDs,24,25,188,194,"Previous studies evaluated the tolerance of nimesulide and paracetamol in subjects with cutaneous, respiratory and anaphylactoid reactions induced by nonsteroidal anti-inflammatory drugs (NSAIDs).",11694026_1,-1,-1,-1,1947,-1,0.9968951,0.0031049307
1948,nimesulide,9,10,62,72,In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well-documented history of NSAID-induced urticaria/angioedema.,11694026_2,-1,-1,-1,1948,-1,0.99923825,0.0007617315
1951,nimesulide,19,20,118,128,"Furthermore, we evaluated whether some factors have the potential to increase the risk of reaction to paracetamol and nimesulide.",11694026_3,-1,-1,-1,1951,-1,0.99895716,0.0010427763
1952,nimesulide,6,7,58,68,A single-placebo-controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID-induced urticaria/angioedema.,11694026_4,-1,-1,-1,1952,-1,0.999138,0.0008619344
1954,nimesulide,12,13,59,69,A total of 75/829 (9.4%) patients experienced reactions to nimesulide or paracetamol.,11694026_5,-1,-1,-1,1954,-1,0.9991032,0.0008967965
1956,nimesulide,6,7,32,42,"Of the 715 patients tested with nimesulide 62 (8.6%) showed a positive test, while of 114 subjects submitted to the challenge with paracetamol, 13 (9.6%) did not tolerate this drug.",11694026_6,-1,-1,-1,1956,-1,0.999148,0.00085193565
1961,nimesulide,10,11,61,71,"Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.",11694026_8,-1,-1,-1,1961,-1,0.99917465,0.0008253669
1963,NSAIDs,20,21,147,153,"Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.",11694026_8,-1,-1,-1,1963,-1,0.9984938,0.0015062254
1975,ocular hypertension,10,12,76,95,"METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).",11704023_4,-1,-1,-1,1975,-1,0.0027583516,0.9972416
1980,P,18,19,109,110,"RESULTS: Both timolol solution and timolol gellan reduced the mean 24-hour heart rate compared with placebo (P < or = .001), and this reduction was most pronounced during the daytime (-7.5% change in mean heart rate, -5.7 beats/min).",11704023_6,-1,-1,-1,1980,-1,0.39325038,0.6067496
1985,P,34,35,216,217,"During the night, the mean 12-hour heart rate on placebo and timolol gellan were both significantly less than on timolol solution; the difference between solution and gellan treatments was statistically significant (P = .01).",11704023_8,-1,-1,-1,1985,-1,0.26912925,0.7308707
1991,hepatitis C,10,12,81,92,Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications.,11705128_0,-1,-1,-1,1991,-1,0.012441724,0.98755825
1992,interferon,15,16,127,137,OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).,11705128_1,-1,-1,-1,1992,-1,0.998123,0.0018770458
1993,chronic hepatitis C,26,29,224,243,OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).,11705128_1,-1,-1,-1,1993,-1,0.0047170483,0.99528295
1994,CHC,30,31,245,248,OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).,11705128_1,-1,-1,-1,1994,-1,0.003663298,0.9963367
1996,RIHA,15,16,114,118,Combination therapy is associated with a clinically important adverse effect: ribavirin-induced hemolytic anemia (RIHA).,11705128_2,-1,-1,-1,1996,-1,0.28075257,0.71924746
1997,RIHA,15,16,91,95,The objective of this study was to evaluate the direct health-care costs and management of RIHA during treatment of CHC in a clinical trial setting.,11705128_3,-1,-1,-1,1997,-1,0.9983553,0.0016446608
1998,CHC,19,20,116,119,The objective of this study was to evaluate the direct health-care costs and management of RIHA during treatment of CHC in a clinical trial setting.,11705128_3,-1,-1,-1,1998,-1,0.014767375,0.9852327
1999,RIHA,17,18,115,119,METHODS: A systematic literature review was conducted to synthesize information on the incidence and management of RIHA.,11705128_4,-1,-1,-1,1999,-1,0.51732695,0.48267305
2000,RIHA,10,11,72,76,Decision-analytic techniques were used to estimate the cost of treating RIHA.,11705128_5,-1,-1,-1,2000,-1,0.99652076,0.003479307
2001,RIHA,2,3,9,13,"RESULTS: RIHA, defined as a reduction in hemoglobin to less than 100 g/L, occurs in approximately 7% to 9% of patients treated with combination therapy.",11705128_7,-1,-1,-1,2001,-1,0.95616406,0.043835893
2002,RIHA,7,8,39,43,The standard of care for management of RIHA is reduction or discontinuation of the ribavirin dosage.,11705128_8,-1,-1,-1,2002,-1,0.9917378,0.008262267
2004,RIHA,9,10,64,68,We estimated the direct cost of treating clinically significant RIHA to be  170 per patient receiving combination therapy per 48-week treatment course (range  68- 692).,11705128_9,-1,-1,-1,2004,-1,0.99707294,0.0029270672
2005,RIHA,24,25,135,139,"In comparison, the cost of 48 weeks of combination therapy is  16,459. CONCLUSIONS: The direct cost of treating clinically significant RIHA is 1% ( 170/ 16,459) of drug treatment costs.",11705128_11,-1,-1,-1,2005,-1,0.9873684,0.012631567
2007,RIHA,12,13,74,78,Questions remain about the optimal dose of ribavirin and the incidence of RIHA in a real-world population.,11705128_12,-1,-1,-1,2007,-1,0.9659282,0.03407187
2008,RIHA,13,14,84,88,"Despite these uncertainties, this initial evaluation of the direct cost of treating RIHA provides an estimate of the cost and management implications of this clinically important adverse effect.",11705128_13,-1,-1,-1,2008,-1,0.99809474,0.0019052258
2010,lactate,8,9,74,81,Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice.,11706060_0,-1,-1,-1,2010,-1,0.998516,0.0014839309
2011,AIDS,11,12,96,100,Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice.,11706060_0,-1,-1,-1,2011,-1,0.041897837,0.95810217
2013,CM,12,13,78,80,Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.,11706060_1,-1,-1,-1,2013,-1,0.007192323,0.9928076
2014,lactate,18,19,105,112,Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.,11706060_1,-1,-1,-1,2014,-1,0.9984665,0.001533569
2015,LA,20,21,114,116,Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.,11706060_1,-1,-1,-1,2015,-1,0.9956864,0.0043136724
2016,AIDS,23,24,121,125,Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.,11706060_1,-1,-1,-1,2016,-1,0.008303936,0.99169606
2018,AIDS,12,13,87,91,"To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and indinavir or vehicle control for 10 days or 35 days.",11706060_2,-1,-1,-1,2018,-1,0.011727766,0.98827225
2019,TG,20,21,118,120,"To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and indinavir or vehicle control for 10 days or 35 days.",11706060_2,-1,-1,-1,2019,-1,0.1599322,0.8400678
2023,CM,17,18,118,120,"At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.",11706060_3,-1,-1,-1,2023,-1,0.54114175,0.45885825
2024,atrial natriuretic factor,22,25,148,173,"At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.",11706060_3,-1,-1,-1,2024,-1,0.99320495,0.0067950077
2025,ANF,26,27,175,178,"At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.",11706060_3,-1,-1,-1,2025,-1,0.9965084,0.0034915528
2027,LA,41,42,251,253,"At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.",11706060_3,-1,-1,-1,2027,-1,0.9956328,0.004367151
2028,TG,5,6,21,23,"After 35 days in the TG + HAART cohort, left ventricular mass increased 160% by echocardiography.",11706060_5,-1,-1,-1,2028,-1,0.99548435,0.0045156144
2029,ANF,2,3,13,16,"Molecularly, ANF mRNA increased 250% and SERCA2 mRNA decreased 57%.",11706060_6,-1,-1,-1,2029,-1,0.9970716,0.0029283115
2030,LA,2,3,15,17,"Biochemically, LA was elevated (8.5 +/- 2.0 mM).",11706060_7,-1,-1,-1,2030,-1,0.9979274,0.0020726111
2031,mM,10,11,44,46,"Biochemically, LA was elevated (8.5 +/- 2.0 mM).",11706060_7,-1,-1,-1,2031,-1,0.8091964,0.19080362
2032,ANF,5,6,20,23,"After 10 days, only ANF was elevated, and only in the TG + HAART cohort.",11706060_11,-1,-1,-1,2032,-1,0.99793977,0.002060255
2033,TG,13,14,54,56,"After 10 days, only ANF was elevated, and only in the TG + HAART cohort.",11706060_11,-1,-1,-1,2033,-1,0.9950635,0.0049365773
2034,CM,7,8,56,58,Results show that cumulative HAART caused mitochondrial CM with elevated LA in AIDS transgenic mice.,11706060_12,-1,-1,-1,2034,-1,0.014913326,0.9850867
2035,LA,10,11,73,75,Results show that cumulative HAART caused mitochondrial CM with elevated LA in AIDS transgenic mice.,11706060_12,-1,-1,-1,2035,-1,0.99714655,0.0028533982
2036,AIDS,12,13,79,83,Results show that cumulative HAART caused mitochondrial CM with elevated LA in AIDS transgenic mice.,11706060_12,-1,-1,-1,2036,-1,0.01897841,0.98102164
2038,WR-2721,7,8,35,42,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,-1,-1,-1,2038,-1,0.9971124,0.0028875319
2053,alkylating agents,13,15,86,103,Amifostine subsequently was shown to protect normal tissues from the toxic effects of alkylating agents and cisplatin without decreasing the antitumor effect of the chemotherapy.,11745184_4,-1,-1,-1,2053,-1,0.9914197,0.008580292
2068,disease progression,7,9,47,66,Treatment was administered every 3 weeks until disease progression.,11745184_10,-1,-1,-1,2068,-1,0.0035653198,0.9964347
2069,disease progression,10,12,49,68,Most patients (57%) stopped treatment because of disease progression.,11745184_14,-1,-1,-1,2069,-1,0.0031465774,0.9968534
2070,Neurologic toxicity,0,2,0,19,Neurologic toxicity was reported in 52% of patients.,11745184_15,-1,-1,-1,2070,-1,0.0026580251,0.99734193
2077,myocardial infarction,6,8,36,57,Oral contraceptives and the risk of myocardial infarction.,11752354_0,-1,-1,-1,2077,-1,0.002964086,0.997036
2079,myocardial infarction,14,16,82,103,"BACKGROUND: An association between the use of oral contraceptives and the risk of myocardial infarction has been found in some, but not all, studies.",11752354_1,-1,-1,-1,2079,-1,0.002685582,0.9973144
2080,progestagen,10,11,59,70,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,-1,-1,-1,2080,-1,0.99864537,0.0013546834
2082,gestodene,19,20,122,131,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,-1,-1,-1,2082,-1,0.9988261,0.0011738518
2083,levonorgestrel,26,27,162,176,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,-1,-1,-1,2083,-1,0.99876225,0.0012377169
2086,myocardial infarction,72,74,424,445,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,-1,-1,-1,2086,-1,0.003125321,0.9968747
2087,myocardial infarction,87,89,508,529,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,-1,-1,-1,2087,-1,0.003175808,0.99682426
2088,factor V Leiden,3,6,16,31,"An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS: The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive, as compared with nonusers, was 2.0 (95 percent confidence interval, 1.5 to 2.8).",11752354_4,-1,-1,-1,2088,-1,0.8745643,0.12543574
2089,myocardial infarction,28,30,156,177,"An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS: The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive, as compared with nonusers, was 2.0 (95 percent confidence interval, 1.5 to 2.8).",11752354_4,-1,-1,-1,2089,-1,0.0026772807,0.99732274
2094,myocardial infarction,50,52,257,278,"Among women who used oral contraceptives, the odds ratio was 2.1 (95 percent confidence interval, 1.5 to 3.0) for those without a prothrombotic mutation and 1.9 (95 percent confidence interval, 0.6 to 5.5) for those with a mutation CONCLUSIONS: The risk of myocardial infarction was increased among women who used second-generation oral contraceptives.",11752354_6,-1,-1,-1,2094,-1,0.0026192851,0.9973807
2098,myocardial infarction,3,5,12,33,The risk of myocardial infarction was similar among women who used oral contraceptives whether or not they had a prothrombotic mutation.,11752354_8,-1,-1,-1,2098,-1,0.0025403695,0.9974597
2108,mg,38,39,242,244,"METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg.",11752998_3,-1,-1,-1,2108,-1,0.973503,0.026496986
2110,mg,49,50,306,308,"METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg.",11752998_3,-1,-1,-1,2110,-1,0.9618927,0.038107198
2112,mechanical hyperalgesia,20,22,127,150,"Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.",11752998_4,-1,-1,-1,2112,-1,0.0067999493,0.9932
2113,allodynia,23,24,155,164,"Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.",11752998_4,-1,-1,-1,2113,-1,0.0033344815,0.99666554
2118,allodynia,21,22,142,151,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,-1,-1,-1,2118,-1,0.0026956059,0.99730444
2120,h.,30,31,205,207,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,-1,-1,-1,2120,-1,0.5539335,0.4460665
2121,contrast,32,33,211,219,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,-1,-1,-1,2121,-1,0.24536054,0.75463945
2123,h,46,47,287,288,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,-1,-1,-1,2123,-1,0.20532009,0.79467994
2129,renal disease,1,3,10,23,End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.,11773892_0,-1,-1,-1,2129,-1,0.0027807557,0.9972192
2130,ESRD,4,5,25,29,End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.,11773892_0,-1,-1,-1,2130,-1,0.0030968883,0.9969031
2131,calcineurin inhibitors cyclosporine,3,6,16,51,BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic.,11773892_1,-1,-1,-1,2131,-1,0.99772686,0.002273131
2134,renal disease,18,20,100,113,"Recently, however, we have had an increase of patients who are presenting after OLTX with end-stage renal disease (ESRD).",11773892_3,-1,-1,-1,2134,-1,0.0027834123,0.9972166
2135,ESRD,21,22,115,119,"Recently, however, we have had an increase of patients who are presenting after OLTX with end-stage renal disease (ESRD).",11773892_3,-1,-1,-1,2135,-1,0.0037904468,0.9962095
2136,ESRD,9,10,65,69,This retrospective study examines the incidence and treatment of ESRD and chronic renal failure (CRF) in OLTX patients.,11773892_4,-1,-1,-1,2136,-1,0.009536788,0.9904632
2138,CRF,15,16,97,100,This retrospective study examines the incidence and treatment of ESRD and chronic renal failure (CRF) in OLTX patients.,11773892_4,-1,-1,-1,2138,-1,0.016045535,0.9839544
2139,n=834,22,23,133,138,METHODS: Patients receiving an OLTX only from June 1985 through December of 1994 who survived 6 months postoperatively were studied (n=834).,11773892_5,-1,-1,-1,2139,-1,0.16209723,0.8379027
2140,CRF,10,11,54,57,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2140,-1,0.85145533,0.14854461
2141,ESRD,12,13,61,65,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2141,-1,0.009208683,0.9907913
2142,n=748,14,15,67,72,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2142,-1,0.2940064,0.70599365
2143,CRF,16,17,74,77,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2143,-1,0.8315934,0.16840655
2145,n=41,25,26,118,122,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2145,-1,0.19023207,0.80976796
2146,ESRD,28,29,128,132,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2146,-1,0.008168556,0.9918315
2147,n=45,30,31,134,138,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,-1,-1,-1,2147,-1,0.15582073,0.8441793
2148,ESRD,17,18,114,118,"Groups were compared for preoperative laboratory variables, diagnosis, postoperative variables, survival, type of ESRD therapy, and survival from onset of ESRD.",11773892_8,-1,-1,-1,2148,-1,0.98566717,0.014332826
2149,ESRD,25,26,155,159,"Groups were compared for preoperative laboratory variables, diagnosis, postoperative variables, survival, type of ESRD therapy, and survival from onset of ESRD.",11773892_8,-1,-1,-1,2149,-1,0.9497298,0.05027025
2151,CRF,18,19,86,89,"RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%).",11773892_9,-1,-1,-1,2151,-1,0.023382055,0.97661793
2152,ESRD,22,23,99,103,"RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%).",11773892_9,-1,-1,-1,2152,-1,0.007386236,0.9926138
2153,CRF,5,6,32,35,"Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.",11773892_10,-1,-1,-1,2153,-1,0.3080681,0.6919319
2154,ESRD,7,8,40,44,"Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.",11773892_10,-1,-1,-1,2154,-1,0.10582017,0.8941799
2156,hepatorenal syndrome,22,24,141,161,"Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.",11773892_10,-1,-1,-1,2156,-1,0.007817419,0.99218255
2159,CRF,39,40,270,273,"Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively.",11773892_11,-1,-1,-1,2159,-1,0.0074941274,0.99250585
2160,ESRD,41,42,277,281,"Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively.",11773892_11,-1,-1,-1,2160,-1,0.0048534367,0.9951466
2161,ESRD,26,27,138,142,"Overall survival from the time of OLTX was not significantly different among groups, but by year 13, the survival of the patients who had ESRD was only 28.2% compared with 54.6% in the control group.",11773892_12,-1,-1,-1,2161,-1,0.009134969,0.99086505
2162,ESRD,2,3,20,24,Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants.,11773892_13,-1,-1,-1,2162,-1,0.004453927,0.9955461
2163,ESRD,10,11,62,66,Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants.,11773892_13,-1,-1,-1,2163,-1,0.0046727303,0.99532723
2164,ESRD,26,27,155,159,Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants.,11773892_13,-1,-1,-1,2164,-1,0.004658284,0.9953418
2165,CRF,11,12,64,67,CONCLUSIONS: Patients who are more than 10 years post-OLTX have CRF and ESRD at a high rate.,11773892_14,-1,-1,-1,2165,-1,0.005747028,0.994253
2166,ESRD,13,14,72,76,CONCLUSIONS: Patients who are more than 10 years post-OLTX have CRF and ESRD at a high rate.,11773892_14,-1,-1,-1,2166,-1,0.00320155,0.99679846
2167,ESRD,3,4,19,23,"The development of ESRD decreases survival, particularly in those patients treated with dialysis only.",11773892_15,-1,-1,-1,2167,-1,0.012170275,0.9878298
2168,ESRD,3,4,21,25,Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome.,11773892_16,-1,-1,-1,2168,-1,0.0033151077,0.99668485
2170,hepatorenal syndrome,18,20,109,129,Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome.,11773892_16,-1,-1,-1,2170,-1,0.0042215693,0.99577844
2172,CRF,18,19,115,118,"However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD.",11773892_17,-1,-1,-1,2172,-1,0.0048598936,0.9951401
2173,ESRD,20,21,122,126,"However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD.",11773892_17,-1,-1,-1,2173,-1,0.003670615,0.99632937
2174,tranexamic acid,9,11,80,95,Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats.,11807648_0,-1,-1,-1,2174,-1,0.9991893,0.00081067433
2175,tranexamic acid,7,9,52,67,"Recently, synthetic fibrinolysis inhibitors such as tranexamic acid (tAMCA) have been considered as substitutes for aprotinin.",11807648_3,-1,-1,-1,2175,-1,0.99926823,0.00073179975
2176,tAMCA,10,11,69,74,"Recently, synthetic fibrinolysis inhibitors such as tranexamic acid (tAMCA) have been considered as substitutes for aprotinin.",11807648_3,-1,-1,-1,2176,-1,0.99840325,0.0015967847
2177,tAMCA,2,3,9,14,"However, tAMCA has been shown to cause epileptic seizures.",11807648_4,-1,-1,-1,2177,-1,0.9982285,0.0017714855
2178,epileptic seizures,8,10,39,57,"However, tAMCA has been shown to cause epileptic seizures.",11807648_4,-1,-1,-1,2178,-1,0.0023617402,0.9976382
2179,tAMCA,5,6,27,32,We wanted to study whether tAMCA retains its convulsive action if incorporated into a FS.,11807648_5,-1,-1,-1,2179,-1,0.9984896,0.0015103869
2181,tAMCA,9,10,63,68,METHOD: FS containing aprotinin or different concentrations of tAMCA (0.5-47.5 mg/ml) were applied to the pial surface of the cortex of anaesthetized rats.,11807648_6,-1,-1,-1,2181,-1,0.9987224,0.0012776508
2182,tAMCA,4,5,24,29,FINDINGS: FS containing tAMCA caused paroxysmal brain activity which was associated with distinct convulsive behaviours.,11807648_8,-1,-1,-1,2182,-1,0.9986634,0.0013365911
2185,tAMCA,10,11,72,77,The degree of these seizures increased with increasing concentration of tAMCA.,11807648_9,-1,-1,-1,2185,-1,0.9988556,0.0011444276
2186,tAMCA,6,7,31,36,"Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.",11807648_10,-1,-1,-1,2186,-1,0.9989796,0.0010203779
2187,generalized seizures,8,10,44,64,"Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.",11807648_10,-1,-1,-1,2187,-1,0.0023149622,0.9976851
2188,n=6,15,16,85,88,"Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.",11807648_10,-1,-1,-1,2188,-1,0.22712937,0.77287066
2189,tAMCA,22,23,124,129,"Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.",11807648_10,-1,-1,-1,2189,-1,0.9989723,0.0010276957
2191,contrast,1,2,3,11,"In contrast, FS containing aprotinin did not evoke any paroxysmal activity.",11807648_11,-1,-1,-1,2191,-1,0.25519937,0.7448006
2192,Tranexamic acid,2,4,16,31,INTERPRETATION: Tranexamic acid retains its convulsive action within FS.,11807648_12,-1,-1,-1,2192,-1,0.99933666,0.0006633363
2194,tAMCA,6,7,27,32,"Thus, use of FS containing tAMCA for surgery within or close to the CNS may pose a substantial risk to the patient.",11807648_13,-1,-1,-1,2194,-1,0.9988599,0.0011401806
2198,thromboemboli,19,20,126,139,"BACKGROUND: Heparin-induced thrombocytopenia presents 5 to 12 days after heparin exposure, with or without arterial or venous thromboemboli.",11827497_1,-1,-1,-1,2198,-1,0.0052903597,0.9947096
2202,thromboembolic complications,19,21,134,162,PATIENTS: 14 patients seen over a 3-year period in whom heparin-induced thrombocytopenia became apparent on delayed presentation with thromboembolic complications.,11827497_6,-1,-1,-1,2202,-1,0.0028228369,0.9971771
2203,thromboembolism,9,10,63,78,"MEASUREMENTS: Platelet counts, onset of objectively determined thromboembolism, results of heparin-induced platelet factor 4 antibody tests, and outcomes.",11827497_7,-1,-1,-1,2203,-1,0.0025592977,0.9974407
2204,factor 4,15,17,116,124,"MEASUREMENTS: Platelet counts, onset of objectively determined thromboembolism, results of heparin-induced platelet factor 4 antibody tests, and outcomes.",11827497_7,-1,-1,-1,2204,-1,0.9826561,0.017343925
2208,Thromboemboli,0,1,0,13,"Thromboemboli were venous (12 patients, 7 with pulmonary emboli) or arterial (4 patients) or both.",11827497_9,-1,-1,-1,2208,-1,0.004542751,0.9954573
2209,pulmonary emboli),9,12,47,64,"Thromboemboli were venous (12 patients, 7 with pulmonary emboli) or arterial (4 patients) or both.",11827497_9,-1,-1,-1,2209,-1,0.03280311,0.9671969
2215,thromboembolism,17,18,142,157,"To avoid disastrous outcomes, physicians must consider heparin-induced thrombocytopenia whenever a recently hospitalized patient returns with thromboembolism; therapy with alternative anticoagulants, not heparin, should be initiated.",11827497_16,-1,-1,-1,2215,-1,0.0028356696,0.9971643
2218,dopamine agonist,6,8,59,75,Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children.,11838826_0,-1,-1,-1,2218,-1,0.9965371,0.003462933
2221,prolactinomas,7,8,55,68,Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either delayed puberty or short stature.,11838826_2,-1,-1,-1,2221,-1,0.3454852,0.65451473
2222,delayed puberty,19,21,144,159,Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either delayed puberty or short stature.,11838826_2,-1,-1,-1,2222,-1,0.0041845487,0.99581546
2225,cabergoline,9,10,82,93,We report the successful treatment of risperidone-induced hyperprolactinemia with cabergoline in youth.,11838826_4,-1,-1,-1,2225,-1,0.9993923,0.0006077547
2227,cabergoline,16,17,124,135,METHODS: We undertook a retrospective case review of four children with risperidone-induced hyperprolactinemia treated with cabergoline.,11838826_5,-1,-1,-1,2227,-1,0.99928844,0.00071150315
2228,Mental Disorders,17,19,79,95,"RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).",11838826_6,-1,-1,-1,2228,-1,0.007865447,0.9921346
2229,bipolar disorder,23,25,113,129,"RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).",11838826_6,-1,-1,-1,2229,-1,0.0042858776,0.9957141
2230,psychoses,26,27,133,142,"RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).",11838826_6,-1,-1,-1,2230,-1,0.0041005914,0.9958994
2231,cabergoline,51,52,261,272,"RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).",11838826_6,-1,-1,-1,2231,-1,0.9992834,0.00071665226
2232,cabergoline,19,20,92,103,"When serum prolactin levels normalized in all four subjects (mean 11.2 +/- 10.9 ng/mL), the cabergoline dose was reduced to 1 mg/week in three of four subjects.",11838826_7,-1,-1,-1,2232,-1,0.99935323,0.0006467331
2233,cabergoline,6,7,34,45,"The mean duration of therapy with cabergoline was 523.5 +/- 129.7 days, and the mean duration of therapy with risperidone was 788.5 +/- 162.5 days.",11838826_8,-1,-1,-1,2233,-1,0.99921083,0.00078908546
2235,Cabergoline,0,1,0,11,Cabergoline was well tolerated without adverse effects.,11838826_9,-1,-1,-1,2235,-1,0.9993137,0.000686298
2236,Cabergoline,2,3,13,24,"CONCLUSIONS: Cabergoline may be useful for the treatment of risperidone-induced hyperprolactinemia in youth; however, further research is needed.",11838826_10,-1,-1,-1,2236,-1,0.99928313,0.0007168829
2238,cholestatic hepatitis,1,3,6,27,Acute cholestatic hepatitis after exposure to isoflurane.,11847945_0,-1,-1,-1,2238,-1,0.0041023735,0.99589765
2240,cholestatic hepatitis,8,10,37,58,OBJECTIVE: To report a case of acute cholestatic hepatitis following exposure to the inhalational anesthetic isoflurane.,11847945_1,-1,-1,-1,2240,-1,0.004021586,0.99597836
2242,acute cholestatic hepatitis 3,10,14,62,91,CASE SUMMARY: A 70-year-old healthy woman from Iraq developed acute cholestatic hepatitis 3 weeks following repair of the right rotator cuff under general anesthesia.,11847945_2,-1,-1,-1,2242,-1,0.009309838,0.99069023
2244,dipyrone,7,8,46,54,No other medications were involved except for dipyrone for analgesia.,11847945_4,-1,-1,-1,2244,-1,0.99936837,0.0006316184
2245,analgesia,9,10,59,68,No other medications were involved except for dipyrone for analgesia.,11847945_4,-1,-1,-1,2245,-1,0.40495676,0.59504324
2248,dipyrone,6,7,40,48,Accidental reexposure by the patient to dipyrone was uneventful.,11847945_6,-1,-1,-1,2248,-1,0.9993087,0.0006912361
2249,halothane hepatitis,11,13,71,90,"DISCUSSION: The clinical and histologic picture of this case resembles halothane hepatitis, which has a significant mortality rate.",11847945_7,-1,-1,-1,2249,-1,0.9230709,0.07692914
2251,cholestatic hepatitis,12,14,69,90,"CONCLUSIONS: Isoflurane, a common anesthetic agent, can cause severe cholestatic hepatitis.",11847945_8,-1,-1,-1,2251,-1,0.0038628457,0.9961371
2253,left bundle branch block,13,17,91,115,Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block.,11858397_0,-1,-1,-1,2253,-1,0.022221662,0.9777784
2254,acquired long QT syndrome,9,13,47,72,There is a growing list of drugs implicated in acquired long QT syndrome and torsade de pointes.,11858397_1,-1,-1,-1,2254,-1,0.0125367725,0.98746324
2255,torsade de pointes,14,17,77,95,There is a growing list of drugs implicated in acquired long QT syndrome and torsade de pointes.,11858397_1,-1,-1,-1,2255,-1,0.40481612,0.59518385
2258,left bundle branch block,9,13,59,83,We report on a 92-year-old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide.,11858397_3,-1,-1,-1,2258,-1,0.01539739,0.9846026
2259,torsade de pointes,15,18,98,116,We report on a 92-year-old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide.,11858397_3,-1,-1,-1,2259,-1,0.015446568,0.98455346
2261,torsade de pointes,4,7,28,46,This patient also developed torsade de pointes when cisapride and erythromycin were given simultaneously.,11858397_4,-1,-1,-1,2261,-1,0.005738272,0.99426174
2263,erythromycin,10,11,66,78,This patient also developed torsade de pointes when cisapride and erythromycin were given simultaneously.,11858397_4,-1,-1,-1,2263,-1,0.9988859,0.0011140673
2265,torsade de pointes,8,11,61,79,This is the first documentation that metoclopramide provokes torsade de pointes clinically.,11858397_6,-1,-1,-1,2265,-1,0.019505339,0.9804946
2267,torsade de pointes,11,14,68,86,Metoclopramide should be used cautiously in patients with a risk of torsade de pointes.,11858397_7,-1,-1,-1,2267,-1,0.01143619,0.9885638
2271,DA,2,3,10,12,"Dopamine (DA), through D1/D2 receptor-mediated signaling, plays a major role in the control of epileptic seizures arising in the limbic system.",11860278_1,-1,-1,-1,2271,-1,0.99749833,0.0025016968
2272,epileptic seizures,18,20,95,113,"Dopamine (DA), through D1/D2 receptor-mediated signaling, plays a major role in the control of epileptic seizures arising in the limbic system.",11860278_1,-1,-1,-1,2272,-1,0.002351861,0.9976482
2273,Excitotoxicity,0,1,0,14,Excitotoxicity leading to neuronal cell death in the affected areas is a major consequence of seizures at the cellular level.,11860278_2,-1,-1,-1,2273,-1,0.0029540157,0.99704605
2274,neuronal cell death,3,6,26,45,Excitotoxicity leading to neuronal cell death in the affected areas is a major consequence of seizures at the cellular level.,11860278_2,-1,-1,-1,2274,-1,0.0030906908,0.9969093
2276,DA,11,12,51,53,"In this respect, little is known about the role of DA receptors in the occurrence of epilepsy-induced neuronal cell death.",11860278_3,-1,-1,-1,2276,-1,0.99783295,0.0021670877
2277,neuronal cell death,18,21,102,121,"In this respect, little is known about the role of DA receptors in the occurrence of epilepsy-induced neuronal cell death.",11860278_3,-1,-1,-1,2277,-1,0.0028603831,0.9971397
2281,kainic acid,9,11,62,73,"We compared these results with those previously obtained with kainic acid (KA), a potent glutamate agonist.",11860278_5,-1,-1,-1,2281,-1,0.9991252,0.000874801
2282,KA,12,13,75,77,"We compared these results with those previously obtained with kainic acid (KA), a potent glutamate agonist.",11860278_5,-1,-1,-1,2282,-1,0.9978982,0.002101768
2287,neuronal death,9,11,66,80,"However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.",11860278_7,-1,-1,-1,2287,-1,0.0023396583,0.9976603
2288,KA,21,22,128,130,"However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.",11860278_7,-1,-1,-1,2288,-1,0.99620277,0.003797238
2292,neurodegeneration,7,8,55,72,"Moreover, the dopaminergic control of epilepsy-induced neurodegeneration seems to be mediated by distinct interactions of D2R signaling with these two neurotransmitters.",11860278_9,-1,-1,-1,2292,-1,0.0022495794,0.99775046
2294,pregnenolone sulphate,10,12,87,108,Steroid structure and pharmacological properties determine the anti-amnesic effects of pregnenolone sulphate in the passive avoidance task in rats.,11860495_0,-1,-1,-1,2294,-1,0.9991328,0.00086724944
2295,PREGS,3,4,23,28,"Pregnenolone sulphate (PREGS) has generated interest as one of the most potent memory-enhancing neurosteroids to be examined in rodent learning studies, with particular importance in the ageing process.",11860495_1,-1,-1,-1,2295,-1,0.9959181,0.0040818793
2297,PREGS,6,7,41,46,This hypothesis stems from findings that PREGS is a potent positive modulator of N-methyl-d-aspartate receptors (NMDARs) and a negative modulator of gamma-aminobutyric acid(A) receptors (GABA(A)Rs).,11860495_3,-1,-1,-1,2297,-1,0.99717677,0.0028232504
2298,PREGS,2,3,10,15,"Moreover, PREGS is able to reverse the amnesic-like effects of NMDAR and GABA(A)R ligands.",11860495_4,-1,-1,-1,2298,-1,0.99772674,0.0022733137
2299,PREGS,18,19,122,127,"To investigate this hypothesis, the present study in rats examined the memory-altering abilities of structural analogs of PREGS, which differ in their modulation of NMDAR and/or GABA(A)R function.",11860495_5,-1,-1,-1,2299,-1,0.99447083,0.005529133
2300,: 11-ketopregnenolone,4,6,23,44,"The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs).",11860495_6,-1,-1,-1,2300,-1,0.99664474,0.003355328
2301,11-ketopregnenolone sulphate,5,7,25,53,"The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs).",11860495_6,-1,-1,-1,2301,-1,0.997477,0.0025229885
2302,PREGS,42,43,243,248,"The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs).",11860495_6,-1,-1,-1,2302,-1,0.9879503,0.012049691
2303,PREGS,49,50,283,288,"The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs).",11860495_6,-1,-1,-1,2303,-1,0.9882974,0.011702568
2304,PREGS,4,5,32,37,The memory-enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of scopolamine-induced amnesia.,11860495_7,-1,-1,-1,2304,-1,0.9972005,0.0027995477
2306,PREGS,1,2,5,10,Both PREGS and its (-) enantiomer blocked the effects of scopolamine.,11860495_8,-1,-1,-1,2306,-1,0.99743795,0.0025619916
2308,PREGS,6,7,30,35,"The results show that, unlike PREGS, 11-ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.",11860495_9,-1,-1,-1,2308,-1,0.97614473,0.023855245
2309,11-ketopregnenolone sulphate,8,10,37,65,"The results show that, unlike PREGS, 11-ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.",11860495_9,-1,-1,-1,2309,-1,0.99817777,0.0018223035
2310,epipregnanolone sulphate,11,13,70,94,"The results show that, unlike PREGS, 11-ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.",11860495_9,-1,-1,-1,2310,-1,0.9985782,0.0014218308
2312,NMDA,27,28,181,185,"The results show that, unlike PREGS, 11-ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.",11860495_9,-1,-1,-1,2312,-1,0.9869162,0.013083845
2313,PREGS,34,35,239,244,"The results show that, unlike PREGS, 11-ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.",11860495_9,-1,-1,-1,2313,-1,0.9752424,0.024757585
2314,PREGS,10,11,72,77,"Moreover, enantioselectivity was demonstrated by the ability of natural PREGS to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine-induced amnesia.",11860495_10,-1,-1,-1,2314,-1,0.993218,0.00678199
2317,heart failure,10,12,92,105,Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure.,11861791_0,-1,-1,-1,2317,-1,0.002314897,0.9976851
2318,tissue injury,23,25,147,160,Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.,11861791_1,-1,-1,-1,2318,-1,0.004850409,0.9951497
2321,DOX,14,15,94,97,"Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.",11861791_2,-1,-1,-1,2321,-1,0.9984365,0.0015634461
2324,PJ34,19,20,136,140,"Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX.",11861791_4,-1,-1,-1,2324,-1,0.99720436,0.0027956553
2326,DOX,36,37,231,234,"Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX.",11861791_4,-1,-1,-1,2326,-1,0.9980198,0.001980219
2327,DOX,9,10,60,63,PARP-1+/+ and PARP-1-/- mice received a single injection of DOX (25 mg/kg i.p).,11861791_5,-1,-1,-1,2327,-1,0.9986022,0.0013977628
2328,DOX,3,4,16,19,"Five days after DOX administration, left ventricular performance was significantly depressed in PARP-1+/+ mice, but only to a smaller extent in PARP-1-/- ones.",11861791_6,-1,-1,-1,2328,-1,0.9987457,0.001254309
2330,PJ34,9,10,63,67,Similar experiments were conducted in BALB/c mice treated with PJ34 or vehicle.,11861791_7,-1,-1,-1,2330,-1,0.9976272,0.0023728262
2331,a PJ34,2,4,15,21,Treatment with a PJ34 significantly improved cardiac dysfunction and increased the survival of the animals.,11861791_8,-1,-1,-1,2331,-1,0.99733514,0.0026648422
2333,PJ34,2,3,12,16,In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.,11861791_9,-1,-1,-1,2333,-1,0.997174,0.0028260078
2334,lactate,11,12,77,84,In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.,11861791_9,-1,-1,-1,2334,-1,0.99782854,0.0021713832
2335,creatine kinase,14,16,103,118,In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.,11861791_9,-1,-1,-1,2335,-1,0.9954573,0.0045427335
2337,DOX,9,10,59,62,"Thus, PARP activation contributes to the cardiotoxicity of DOX.",11861791_10,-1,-1,-1,2337,-1,0.99844176,0.0015583121
2338,cardiac complications,11,13,79,100,PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment.,11861791_11,-1,-1,-1,2338,-1,0.002348651,0.9976514
2339,DOX,16,17,121,124,PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment.,11861791_11,-1,-1,-1,2339,-1,0.9979779,0.0020220503
2341,amphotericin,11,12,57,69,"Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.",11868798_0,-1,-1,-1,2341,-1,0.99874324,0.001256752
2342,hypokalemia,13,14,80,91,"Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.",11868798_0,-1,-1,-1,2342,-1,0.0037131738,0.99628687
2344,amphotericin B,25,27,168,182,"Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.",11868798_0,-1,-1,-1,2344,-1,0.99901164,0.0009883444
2345,AmB,28,29,184,187,"Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.",11868798_0,-1,-1,-1,2345,-1,0.99798006,0.0020199132
2348,AmB.,24,25,159,163,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,-1,2348,-1,0.98392844,0.01607157
2351,AmB.,33,34,225,229,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,-1,2351,-1,0.9816798,0.018320167
2354,hypokalemia,51,52,342,353,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,-1,2354,-1,0.00360951,0.9963905
2355,neutropenic,53,54,357,368,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,-1,2355,-1,0.0026121694,0.9973878
2356,AmB,56,57,381,384,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,-1,-1,-1,2356,-1,0.9983103,0.0016896758
2357,hematological disorders,9,11,48,71,METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.,11868798_2,-1,-1,-1,2357,-1,0.0031499718,0.9968501
2358,AmB,17,18,118,121,METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.,11868798_2,-1,-1,-1,2358,-1,0.9987112,0.0012888275
2359,AmB,20,21,131,134,METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.,11868798_2,-1,-1,-1,2359,-1,0.99855536,0.0014446347
2361,mg,25,26,163,165,METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.,11868798_2,-1,-1,-1,2361,-1,0.98967046,0.0103295855
2362,fungal infection,34,36,216,232,METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.,11868798_2,-1,-1,-1,2362,-1,0.0042156866,0.99578434
2363,AmB,5,6,40,43,RESULTS: Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone (P = 0.0027).,11868798_3,-1,-1,-1,2363,-1,0.99873894,0.0012611247
2366,AmB,17,18,133,136,RESULTS: Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone (P = 0.0027).,11868798_3,-1,-1,-1,2366,-1,0.9984119,0.0015881148
2367,P,20,21,144,145,RESULTS: Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone (P = 0.0027).,11868798_3,-1,-1,-1,2367,-1,0.36508247,0.63491756
2368,AmB,3,4,25,28,Those patients receiving AmB and spironolactone required significantly less potassium supplementation to maintain their plasma potassium within the normal range (P = 0.022).,11868798_4,-1,-1,-1,2368,-1,0.9988587,0.0011413727
2372,P,21,22,162,163,Those patients receiving AmB and spironolactone required significantly less potassium supplementation to maintain their plasma potassium within the normal range (P = 0.022).,11868798_4,-1,-1,-1,2372,-1,0.42398965,0.57601035
2374,AmB,11,12,81,84,"Moreover, urinary potassium losses were significantly less in patients receiving AmB and spironolactone than those receiving AmB alone (P = 0.040).",11868798_5,-1,-1,-1,2374,-1,0.9983657,0.0016343483
2376,AmB,17,18,125,128,"Moreover, urinary potassium losses were significantly less in patients receiving AmB and spironolactone than those receiving AmB alone (P = 0.040).",11868798_5,-1,-1,-1,2376,-1,0.99819994,0.0018000003
2377,P,20,21,136,137,"Moreover, urinary potassium losses were significantly less in patients receiving AmB and spironolactone than those receiving AmB alone (P = 0.040).",11868798_5,-1,-1,-1,2377,-1,0.27587074,0.72412926
2380,hypokalemia,13,14,96,107,CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.,11868798_6,-1,-1,-1,2380,-1,0.006724473,0.9932755
2382,neutropenic,20,21,146,157,CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.,11868798_6,-1,-1,-1,2382,-1,0.005140855,0.9948592
2383,AmB,23,24,170,173,CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.,11868798_6,-1,-1,-1,2383,-1,0.99852824,0.0014717705
2399,hemorrhaging,11,12,83,95,"Microscopic observation showed the configuration of exencephaly at E13.5, frequent hemorrhaging and detachment of the neural plate from surface ectoderm in the exencephalic head at E15.5, and multiple modes of reduction in the exencephalic tissue at E18.5.",11875660_8,-1,-1,-1,2399,-1,0.0034071186,0.9965928
2404,circulatory failure,20,22,148,167,"These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels, subsequent peripheral circulatory failure and/or hemorrhaging in various parts of the exencephalic head, leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly.",11875660_10,-1,-1,-1,2404,-1,0.0071668383,0.99283314
2405,hemorrhaging,23,24,175,187,"These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels, subsequent peripheral circulatory failure and/or hemorrhaging in various parts of the exencephalic head, leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly.",11875660_10,-1,-1,-1,2405,-1,0.003957846,0.99604213
2409,Erectile dysfunction,0,2,0,20,Erectile dysfunction occurs following substantia nigra lesions in the rat.,11890511_0,-1,-1,-1,2409,-1,0.0029193773,0.9970806
2412,erectile dysfunction,9,11,62,82,Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study erectile dysfunction in Parkinson's disease.,11890511_6,-1,-1,-1,2412,-1,0.002989773,0.99701023
2413,erectile dysfunction,21,23,125,145,Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study erectile dysfunction in Parkinson's disease.,11890511_6,-1,-1,-1,2413,-1,0.0035268806,0.99647313
2414,Parkinson's disease,24,27,149,168,Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study erectile dysfunction in Parkinson's disease.,11890511_6,-1,-1,-1,2414,-1,0.0070881415,0.9929119
2415,myocardial infarction,5,7,55,76,99mTc-glucarate for detection of isoproterenol-induced myocardial infarction in rats.,11897407_0,-1,-1,-1,2415,-1,0.0023622822,0.99763775
2419,glucaric acid,6,8,48,61,A new infarct-avid radiopharmaceutical based on glucaric acid was prepared in the hospital radiopharmacy of the INCMNSZ.,11897407_3,-1,-1,-1,2419,-1,0.9982267,0.0017732843
2420,h,9,10,51,52,"99mTc-glucarate was easy to prepare, stable for 96 h and was used to study its biodistribution in rats with isoproterenol-induced acute myocardial infarction.",11897407_4,-1,-1,-1,2420,-1,0.13092591,0.86907405
2422,infarct,8,9,61,68,Histological studies demonstrated that the rats developed an infarct 18 h after isoproterenol administration.,11897407_5,-1,-1,-1,2422,-1,0.0026155657,0.9973845
2423,h,10,11,72,73,Histological studies demonstrated that the rats developed an infarct 18 h after isoproterenol administration.,11897407_5,-1,-1,-1,2423,-1,0.09217429,0.9078257
2425,contrast,7,8,42,50,"The high image quality suggests that high contrast images can be obtained in humans and the 96 h stability makes it an ideal agent to detect, in patients, early cardiac infarction.",11897407_9,-1,-1,-1,2425,-1,0.5548348,0.4451652
2426,h,17,18,95,96,"The high image quality suggests that high contrast images can be obtained in humans and the 96 h stability makes it an ideal agent to detect, in patients, early cardiac infarction.",11897407_9,-1,-1,-1,2426,-1,0.8082909,0.19170906
2427,cardiac infarction,31,33,161,179,"The high image quality suggests that high contrast images can be obtained in humans and the 96 h stability makes it an ideal agent to detect, in patients, early cardiac infarction.",11897407_9,-1,-1,-1,2427,-1,0.002676761,0.9973232
2438,mecamylamine,7,8,54,66,"Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.",11900788_4,-1,-1,-1,2438,-1,0.9992949,0.00070504897
2452,morphine catalepsy,4,6,22,40,"It was concluded that morphine catalepsy can be elicited by opioid and cholinergic receptors, and the potentiation of morphine induced by nicotine may also be mediated through cholinergic receptor mechanisms.",11900788_7,-1,-1,-1,2452,-1,0.24218531,0.75781465
2456,Parkinson's disease,6,9,51,70,Force overflow and levodopa-induced dyskinesias in Parkinson's disease.,11912119_0,-1,-1,-1,2456,-1,0.0055332566,0.9944667
2457,Parkinson's disease,8,11,46,65,"We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of levodopa therapy, particularly to levodopa-induced dyskinesias (LID).",11912119_1,-1,-1,-1,2457,-1,0.005366571,0.99463344
2460,LID,26,27,177,180,"We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of levodopa therapy, particularly to levodopa-induced dyskinesias (LID).",11912119_1,-1,-1,-1,2460,-1,0.004273752,0.9957262
2461,Parkinson's disease,5,8,25,44,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2461,-1,0.0068343654,0.9931657
2462,Parkinson's disease,11,14,60,79,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2462,-1,0.007219819,0.99278015
2463,LID,15,16,82,85,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2463,-1,0.005336443,0.9946635
2464,n,17,18,87,88,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2464,-1,0.15256044,0.8474395
2466,Parkinson's disease,26,29,137,156,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2466,-1,0.007219026,0.992781
2467,LID,30,31,159,162,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2467,-1,0.0055311946,0.9944688
2468,n,32,33,164,165,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,-1,-1,-1,2468,-1,0.1091684,0.89083153
2469,Parkinson's Disease,6,9,31,50,"The motor score of the Unified Parkinson's Disease Rating Scale, a dyskinesia score and force in a grip-lift paradigm were assessed ON and OFF levodopa.",11912119_3,-1,-1,-1,2469,-1,0.0087972935,0.9912027
2472,Parkinson's disease,10,13,58,77,A pathological increase of forces was seen in ON-state in Parkinson's disease + LID only.,11912119_4,-1,-1,-1,2472,-1,0.009596078,0.9904039
2473,LID,14,15,80,83,A pathological increase of forces was seen in ON-state in Parkinson's disease + LID only.,11912119_4,-1,-1,-1,2473,-1,0.43051988,0.5694802
2474,Parkinson's disease,1,4,3,22,"In Parkinson's disease + LID, the force involved in pressing down the object before lifting was significantly increased by levodopa (by 61%, P < 0.05).",11912119_5,-1,-1,-1,2474,-1,0.007917676,0.99208236
2475,LID,5,6,25,28,"In Parkinson's disease + LID, the force involved in pressing down the object before lifting was significantly increased by levodopa (by 61%, P < 0.05).",11912119_5,-1,-1,-1,2475,-1,0.01060397,0.98939604
2477,P,27,28,141,142,"In Parkinson's disease + LID, the force involved in pressing down the object before lifting was significantly increased by levodopa (by 61%, P < 0.05).",11912119_5,-1,-1,-1,2477,-1,0.37388748,0.6261125
2478,P,10,11,43,44,An overshooting of peak grip force by 51% (P < 0.05) and of static grip force by 45% (P < 0.01) was observed in the ON- compared with the OFF-drug condition.,11912119_6,-1,-1,-1,2478,-1,0.23779078,0.76220924
2479,P,23,24,86,87,An overshooting of peak grip force by 51% (P < 0.05) and of static grip force by 45% (P < 0.01) was observed in the ON- compared with the OFF-drug condition.,11912119_6,-1,-1,-1,2479,-1,0.252637,0.74736303
2480,contrast,1,2,3,11,"In contrast, no excessive force was found in Parkinson's disease - LID.",11912119_7,-1,-1,-1,2480,-1,0.25583592,0.74416405
2481,Parkinson's disease,9,12,45,64,"In contrast, no excessive force was found in Parkinson's disease - LID.",11912119_7,-1,-1,-1,2481,-1,0.0083059855,0.99169403
2482,LID,13,14,67,70,"In contrast, no excessive force was found in Parkinson's disease - LID.",11912119_7,-1,-1,-1,2482,-1,0.0076043224,0.99239576
2483,P,9,10,38,39,"Peak grip force in ON-state was 140% (P < 0.05) higher in Parkinson's disease + LID than in Parkinson's disease - LID, while static grip force was increased by 138% (P < 0.01) between groups.",11912119_8,-1,-1,-1,2483,-1,0.33187497,0.66812503
2484,Parkinson's disease,15,18,58,77,"Peak grip force in ON-state was 140% (P < 0.05) higher in Parkinson's disease + LID than in Parkinson's disease - LID, while static grip force was increased by 138% (P < 0.01) between groups.",11912119_8,-1,-1,-1,2484,-1,0.01479581,0.9852042
2485,LID,19,20,80,83,"Peak grip force in ON-state was 140% (P < 0.05) higher in Parkinson's disease + LID than in Parkinson's disease - LID, while static grip force was increased by 138% (P < 0.01) between groups.",11912119_8,-1,-1,-1,2485,-1,0.19301455,0.80698544
2486,Parkinson's,22,24,92,103,"Peak grip force in ON-state was 140% (P < 0.05) higher in Parkinson's disease + LID than in Parkinson's disease - LID, while static grip force was increased by 138% (P < 0.01) between groups.",11912119_8,-1,-1,-1,2486,-1,0.0251469,0.9748531
2487,LID,26,27,114,117,"Peak grip force in ON-state was 140% (P < 0.05) higher in Parkinson's disease + LID than in Parkinson's disease - LID, while static grip force was increased by 138% (P < 0.01) between groups.",11912119_8,-1,-1,-1,2487,-1,0.23061314,0.7693869
2488,P,38,39,166,167,"Peak grip force in ON-state was 140% (P < 0.05) higher in Parkinson's disease + LID than in Parkinson's disease - LID, while static grip force was increased by 138% (P < 0.01) between groups.",11912119_8,-1,-1,-1,2488,-1,0.30776784,0.6922322
2490,P,20,21,113,114,"Severity of peak-dose dyskinesias was strongly correlated with grip force in ON-state (r = 0.79 with peak force, P < 0.01).",11912119_9,-1,-1,-1,2490,-1,0.42970622,0.57029384
2491,LID,8,9,48,51,Force excess was only observed in patients with LID and motor fluctuations.,11912119_11,-1,-1,-1,2491,-1,0.036372967,0.963627
2493,LID,4,5,23,26,We postulate that both LID and grip force excess share common pathophysiological mechanisms related to motor fluctuations.,11912119_13,-1,-1,-1,2493,-1,0.9963612,0.003638769
2494,Zyban,2,3,11,16,Bupropion (Zyban) toxicity.,11928786_0,-1,-1,-1,2494,-1,0.99772245,0.0022774986
2498,bupropion hydrochloride,6,8,42,65,"Zyban, a sustained-release formulation of bupropion hydrochloride, was recently released in Ireland, as a smoking cessation aid.",11928786_2,-1,-1,-1,2498,-1,0.9991748,0.0008252174
2503,drowsiness,5,6,38,48,"Common features included tachycardia, drowsiness, hallucinations and convulsions.",11928786_5,-1,-1,-1,2503,-1,0.0035472128,0.9964528
2513,cardiovascular toxicity,5,7,42,65,Zyban caused significant neurological and cardiovascular toxicity in overdose.,11928786_10,-1,-1,-1,2513,-1,0.0032984002,0.99670154
2517,PAN nephrosis,9,11,52,65,GLEPP1 receptor tyrosine phosphatase (Ptpro) in rat PAN nephrosis.,11961407_0,-1,-1,-1,2517,-1,0.0054360465,0.99456394
2519,glomerular injury,11,13,58,75,"To better understand the utility of GLEPP1 as a marker of glomerular injury, the amount and distribution of GLEPP1 protein and mRNA were examined by immunohistochemistry, Western blot and RNase protection assay in a model of podocyte injury in the rat.",11961407_4,-1,-1,-1,2519,-1,0.0031843162,0.99681574
2520,Puromycin aminonucleoside nephrosis,0,3,0,35,"Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW).",11961407_5,-1,-1,-1,2520,-1,0.62972385,0.37027612
2521,puromycin aminonucleoside,10,12,87,112,"Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW).",11961407_5,-1,-1,-1,2521,-1,0.9984761,0.0015239075
2522,PAN,13,14,114,117,"Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW).",11961407_5,-1,-1,-1,2522,-1,0.9969829,0.0030171592
2523,PAN,21,22,68,71,"Tissues were analyzed at 0, 5, 7, 11, 21, 45, 80 and 126 days after PAN injection so as to include both the acute phase of proteinuria associated with foot process effacement (days 5-11) and the chronic phase of proteinuria associated with glomerulosclerosis (days 45-126).",11961407_6,-1,-1,-1,2523,-1,0.99652416,0.0034758116
2527,p,42,43,177,178,"At day 5, GLEPP1 protein and mRNA were reduced from the normal range (265.2 +/- 79.6 x 10(6) moles/glomerulus and 100%) to 15% of normal (41.8 +/- 4.8 x 10(6) moles/glomerulus, p < 0.005).",11961407_7,-1,-1,-1,2527,-1,0.28195158,0.71804845
2528,p,23,24,111,112,This occurred in association with an increase in urinary protein content from 1.8 +/- 1 to 99.0 +/- 61 mg/day (p < 0.001).,11961407_8,-1,-1,-1,2528,-1,0.40495986,0.59504014
2529,contrast,1,2,3,11,"In contrast, podocalyxin did not change significantly at this time.",11961407_9,-1,-1,-1,2529,-1,0.38506275,0.6149373
2530,PAN,14,15,92,95,"We conclude that GLEPP1 expression, unlike podocalyxin, reflects podocyte injury induced by PAN.",11961407_12,-1,-1,-1,2530,-1,0.9931092,0.006890711
2531,MK-801,3,4,22,28,Behavioral effects of MK-801 on reserpine-treated mice.,11999899_0,-1,-1,-1,2531,-1,0.997908,0.00209197
2532,dizocilpine,3,4,15,26,"The effects of dizocilpine (MK-801), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, were studied on dopamine-related behaviors induced by reserpine treatments.",11999899_1,-1,-1,-1,2532,-1,0.99917597,0.0008239767
2533,MK-801,5,6,28,34,"The effects of dizocilpine (MK-801), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, were studied on dopamine-related behaviors induced by reserpine treatments.",11999899_1,-1,-1,-1,2533,-1,0.997943,0.0020570527
2534,NMDA,12,13,76,80,"The effects of dizocilpine (MK-801), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, were studied on dopamine-related behaviors induced by reserpine treatments.",11999899_1,-1,-1,-1,2534,-1,0.9979784,0.0020216135
2536,Parkinson's disease,12,15,71,90,"This study focuses on behavioral syndromes that may used as models for Parkinson's disease, or tardive dyskinesia, and its response after glutamatergic blockage.",11999899_2,-1,-1,-1,2536,-1,0.0048768036,0.9951232
2537,tardive dyskinesia,17,19,95,113,"This study focuses on behavioral syndromes that may used as models for Parkinson's disease, or tardive dyskinesia, and its response after glutamatergic blockage.",11999899_2,-1,-1,-1,2537,-1,0.0024180494,0.99758196
2539,orofacial dyskinesia,18,20,89,109,"Reserpine (1 mg/kg), administered once every other day for 4 days, produced increases in orofacial dyskinesia, tongue protrusion and vacuous chewing in mice, which are signs indicative of tardive dyskinesia.",11999899_3,-1,-1,-1,2539,-1,0.005262155,0.9947378
2540,tardive dyskinesia,34,36,188,206,"Reserpine (1 mg/kg), administered once every other day for 4 days, produced increases in orofacial dyskinesia, tongue protrusion and vacuous chewing in mice, which are signs indicative of tardive dyskinesia.",11999899_3,-1,-1,-1,2540,-1,0.0024150594,0.99758494
2544,Parkinson's disease,12,15,76,95,"Reserpine also produced tremor and catalepsy, which are signs suggestive of Parkinson's disease.",11999899_4,-1,-1,-1,2544,-1,0.0036940335,0.99630594
2545,MK-801,0,1,0,6,"MK-801 (0.1 mg/kg), administered 30 min before the observation test, prevented the vacuous chewing movements, tongue protrusions and catalepsy induced by reserpine.",11999899_5,-1,-1,-1,2545,-1,0.9983479,0.0016521204
2548,MK-801,2,3,9,15,"However, MK-801 injection produced a significant increase of tremor in reserpine-treated mice.",11999899_6,-1,-1,-1,2548,-1,0.9981743,0.0018256422
2551,apomophine,15,16,73,83,"Reserpine (1 mg/kg), administered 90 min before the test and followed by apomophine injection (0.1 mg/kg) 5 min before the test, did not produce oral dyskinesia in mice.",11999899_7,-1,-1,-1,2551,-1,0.99883515,0.0011648495
2552,oral dyskinesia,30,32,145,160,"Reserpine (1 mg/kg), administered 90 min before the test and followed by apomophine injection (0.1 mg/kg) 5 min before the test, did not produce oral dyskinesia in mice.",11999899_7,-1,-1,-1,2552,-1,0.0030694387,0.99693054
2556,MK-801,0,1,0,6,MK-801 (0.1 mg/kg) administration attenuated the catalepsy and tremor induced by reserpine.,11999899_9,-1,-1,-1,2556,-1,0.9982331,0.0017668598
2561,h,8,9,41,42,"Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.",11999899_10,-1,-1,-1,2561,-1,0.5024384,0.49756157
2564,MK-801,33,34,196,202,"Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.",11999899_10,-1,-1,-1,2564,-1,0.99832517,0.0016748713
2567,abnormal movements,8,10,57,75,"These results show that reserpine produces different and abnormal movements, which are related to dose and schedule employed and can be considered as parkinsonian-like and tardive dsykinesia signs.",11999899_11,-1,-1,-1,2567,-1,0.0032706156,0.9967294
2568,tardive dsykinesia,26,28,172,190,"These results show that reserpine produces different and abnormal movements, which are related to dose and schedule employed and can be considered as parkinsonian-like and tardive dsykinesia signs.",11999899_11,-1,-1,-1,2568,-1,0.012304466,0.9876956
2569,NMDA,5,6,39,43,"The glutamatergic blockage produced by NMDA can restore these signs, such as vacuous chewing movements, tongue protrusions, catalepsy and tremor according to the employed model.",11999899_12,-1,-1,-1,2569,-1,0.9987631,0.0012369049
2572,visual disturbances,4,6,41,60,"Risperidone-associated, benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse.",12013711_0,-1,-1,-1,2572,-1,0.0024904676,0.9975095
2574,LSD,14,15,110,113,"Risperidone-associated, benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse.",12013711_0,-1,-1,-1,2574,-1,0.9964309,0.0035690789
2576,LSD,10,11,55,58,"Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.",12013711_1,-1,-1,-1,2576,-1,0.99758863,0.0024113448
2577,EPS,17,18,98,101,"Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.",12013711_1,-1,-1,-1,2577,-1,0.003461564,0.9965384
2578,antipsychotics,20,21,115,129,"Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.",12013711_1,-1,-1,-1,2578,-1,0.9967439,0.003256041
2580,visual disturbances,7,9,47,66,"They both reported short episodes of transient visual disturbances, which appeared immediately after starting treatment with risperidone.",12013711_2,-1,-1,-1,2580,-1,0.0025155067,0.99748445
2582,visual disturbances,3,5,23,42,"This imagery resembled visual disturbances previously experienced as ""flashbacks"" related to prior LSD consumption.",12013711_3,-1,-1,-1,2582,-1,0.0044131833,0.99558675
2583,LSD,14,15,99,102,"This imagery resembled visual disturbances previously experienced as ""flashbacks"" related to prior LSD consumption.",12013711_3,-1,-1,-1,2583,-1,0.9984927,0.0015073058
2585,visual disturbances,6,8,49,68,Risperidone administration was continued and the visual disturbances gradually wore off.,12013711_4,-1,-1,-1,2585,-1,0.0028571005,0.99714285
2586,visual disturbances,11,13,64,83,"During a six-month follow-up period, there was no recurrence of visual disturbances.",12013711_5,-1,-1,-1,2586,-1,0.0030629304,0.99693704
2589,antithymocyte globulin,4,6,23,45,A patient who received antithymocyte globulin therapy for aplastic anemia due to D-penicillamine therapy is described.,12041669_1,-1,-1,-1,2589,-1,0.9973206,0.0026794039
2591,antithymocyte globulin,2,4,7,29,Use of antithymocyte globulin may be the optimal treatment of D-penicillamine-induced aplastic anemia.,12041669_3,-1,-1,-1,2591,-1,0.9922909,0.0077091246
2594,Topiramate,0,1,0,10,Topiramate is a recently developed antiepileptic medication that is becoming more widely prescribed because of its efficacy in treating refractory seizures.,12042105_1,-1,-1,-1,2594,-1,0.99913764,0.0008623526
2595,refractory seizures,19,21,136,155,Topiramate is a recently developed antiepileptic medication that is becoming more widely prescribed because of its efficacy in treating refractory seizures.,12042105_1,-1,-1,-1,2595,-1,0.0028265666,0.9971734
2597,lead,23,24,138,142,"In addition, a distal tubular acidification defect may result, thus impairing the normal compensatory drop in urine pH. These factors can lead to the development of calcium phosphate nephrolithiasis.",12042105_3,-1,-1,-1,2597,-1,0.038193196,0.96180683
2598,calcium phosphate nephrolithiasis,28,31,165,198,"In addition, a distal tubular acidification defect may result, thus impairing the normal compensatory drop in urine pH. These factors can lead to the development of calcium phosphate nephrolithiasis.",12042105_3,-1,-1,-1,2598,-1,0.19215481,0.8078452
2600,Metamizol,0,1,0,9,Metamizol potentiates morphine antinociception but not constipation after chronic treatment.,12063090_0,-1,-1,-1,2600,-1,0.9994628,0.0005372723
2603,constipating,6,7,44,56,This work evaluates the antinociceptive and constipating effects of the combination of 3.2 mg/kg s.c.,12063090_1,-1,-1,-1,2603,-1,0.01896382,0.9810362
2605,metamizol,0,1,0,9,metamizol in acutely and chronically treated (once a day for 12 days) rats.,12063090_3,-1,-1,-1,2605,-1,0.9993874,0.00061263115
2606,charcoal,23,24,148,156,"On the 13th day, antinociceptive effects were assessed using a model of inflammatory nociception, pain-induced functional impairment model, and the charcoal meal test was used to evaluate the intestinal transit.",12063090_4,-1,-1,-1,2606,-1,0.99638915,0.0036108303
2608,metamizol,5,6,45,54,Simultaneous administration of morphine with metamizol resulted in a markedly antinociceptive potentiation and an increasing of the duration of action after a single (298+/-7 vs. 139+/-36 units area (ua); P<0.001) and repeated administration (280+/-17 vs. 131+/-22 ua; P<0.001).,12063090_5,-1,-1,-1,2608,-1,0.9994261,0.0005738627
2609,P<0.001,33,34,205,212,Simultaneous administration of morphine with metamizol resulted in a markedly antinociceptive potentiation and an increasing of the duration of action after a single (298+/-7 vs. 139+/-36 units area (ua); P<0.001) and repeated administration (280+/-17 vs. 131+/-22 ua; P<0.001).,12063090_5,-1,-1,-1,2609,-1,0.41373906,0.5862609
2610,P<0.001,44,45,269,276,Simultaneous administration of morphine with metamizol resulted in a markedly antinociceptive potentiation and an increasing of the duration of action after a single (298+/-7 vs. 139+/-36 units area (ua); P<0.001) and repeated administration (280+/-17 vs. 131+/-22 ua; P<0.001).,12063090_5,-1,-1,-1,2610,-1,0.3634727,0.63652736
2613,P<0.05,16,17,102,108,"Acute antinociceptive effects of the combination were partially prevented by 3.2 mg/kg naloxone s.c. (P<0.05), suggesting the partial involvement of the opioidergic system in the synergism observed.",12063090_7,-1,-1,-1,2613,-1,0.44861853,0.5513815
2615,constipating,31,32,186,198,"In independent groups, morphine inhibited the intestinal transit in 48+/-4% and 38+/-4% after acute and chronic treatment, respectively, suggesting that tolerance did not develop to the constipating effects.",12063090_8,-1,-1,-1,2615,-1,0.009464675,0.9905353
2617,metamizol,20,21,135,144,"The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment, suggesting that metamizol did not potentiate morphine-induced constipation.",12063090_9,-1,-1,-1,2617,-1,0.9994906,0.00050936645
2620,metamizol,9,10,67,76,"These findings show a significant interaction between morphine and metamizol in chronically treated rats, suggesting that this combination could be useful for the treatment of chronic pain.",12063090_10,-1,-1,-1,2620,-1,0.99947745,0.0005225442
2621,chronic pain,26,28,176,188,"These findings show a significant interaction between morphine and metamizol in chronically treated rats, suggesting that this combination could be useful for the treatment of chronic pain.",12063090_10,-1,-1,-1,2621,-1,0.004427981,0.995572
2624,IFX,9,10,58,61,CNS toxic effects of the antineoplastic agent ifosfamide (IFX) are frequent and include a variety of neurological symptoms that can limit drug use.,12084448_1,-1,-1,-1,2624,-1,0.9980823,0.0019177574
2625,neurological symptoms,18,20,101,122,CNS toxic effects of the antineoplastic agent ifosfamide (IFX) are frequent and include a variety of neurological symptoms that can limit drug use.,12084448_1,-1,-1,-1,2625,-1,0.002554924,0.9974451
2628,plasmacytoma,27,28,161,173,"We report a case of a 51-year-old man who developed severe, disabling negative myoclonus of the upper and lower extremities after the infusion of ifosfamide for plasmacytoma.",12084448_2,-1,-1,-1,2628,-1,0.013344296,0.9866557
2629,structural lesions of the brain,11,16,85,116,Cranial magnetic resonance imaging and extensive laboratory studies failed to reveal structural lesions of the brain and metabolic abnormalities.,12084448_4,-1,-1,-1,2629,-1,0.016393712,0.98360634
2630,metabolic abnormalities,17,19,121,144,Cranial magnetic resonance imaging and extensive laboratory studies failed to reveal structural lesions of the brain and metabolic abnormalities.,12084448_4,-1,-1,-1,2630,-1,0.0074748024,0.9925252
2633,h,9,10,64,65,The administration of ifosfamide was discontinued and within 12 h the asterixis resolved completely.,12084448_6,-1,-1,-1,2633,-1,0.116019174,0.8839809
2638,IFX,41,42,265,268,"In the patient described, the presence of asterixis during infusion of ifosfamide, normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX.",12084448_7,-1,-1,-1,2638,-1,0.9988071,0.0011929664
2642,thymidine,6,7,37,46,There was a significant reduction of thymidine incorporation into both erythroid and endothelial cells in cultures pre-treated with IGF-IL-3 and EPO.,12090760_5,-1,-1,-1,2642,-1,0.996384,0.0036159323
2643,thymidine,18,19,150,159,Endothelial cell culture supernatants separated by ultrafiltration and ultracentrifugation from cells treated with EPO and IL-3 significantly reduced thymidine incorporation into erythroid cells as compared to identical fractions obtained from the media of cells cultured with EPO alone.,12090760_6,-1,-1,-1,2643,-1,0.99670595,0.003294014
2653,analgesia,11,12,85,94,Local anaesthetic blocks were useful in decreasing the requirement for postoperative analgesia.,12091028_5,-1,-1,-1,2653,-1,0.1675276,0.8324724
2654,h,11,12,70,71,"An antisialogue was usually unnecessary in operations lasting up to 2 h, glycopyrrolate being the best choice for its lowest psychotropic and chronotropic effects, especially in a hot climate.",12091028_6,-1,-1,-1,2654,-1,0.109144665,0.8908553
2657,adenovirus disease,5,7,43,61,Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children.,12093990_0,-1,-1,-1,2657,-1,0.037375595,0.9626244
2658,adenovirus disease,4,6,24,42,"The incidence of severe adenovirus disease in pediatrics is increasing in association with growing numbers of immunocompromised children, where case fatality rates as high as 50% to 80% have been reported.",12093990_2,-1,-1,-1,2658,-1,0.07590855,0.9240914
2659,antiviral agents,4,6,22,38,"There are no approved antiviral agents with proven efficacy for the treatment of severe adenovirus disease, nor are there any prospective randomized, controlled trials of potentially useful anti-adenovirus therapies.",12093990_3,-1,-1,-1,2659,-1,0.96898556,0.031014413
2660,adenovirus disease,14,16,88,106,"There are no approved antiviral agents with proven efficacy for the treatment of severe adenovirus disease, nor are there any prospective randomized, controlled trials of potentially useful anti-adenovirus therapies.",12093990_3,-1,-1,-1,2660,-1,0.0767147,0.92328525
2661,adenovirus disease,8,10,53,71,Apparent clinical success in the treatment of severe adenovirus disease is limited to a few case reports and small series.,12093990_4,-1,-1,-1,2661,-1,0.069597036,0.93040293
2663,cidofovir,7,8,54,63,Experience is greatest with intravenous ribavirin and cidofovir.,12093990_5,-1,-1,-1,2663,-1,0.9991416,0.0008584351
2664,guanosine,3,4,13,22,"Ribavirin, a guanosine analogue, has broad antiviral activity against both RNA and DNA viruses, including documented activity against adenovirus in vitro.",12093990_6,-1,-1,-1,2664,-1,0.9976465,0.0023534433
2666,respiratory syncytial virus infection,10,14,59,96,"Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.",12093990_7,-1,-1,-1,2666,-1,0.009230513,0.99076945
2667,interferon,20,21,129,139,"Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.",12093990_7,-1,-1,-1,2667,-1,0.997719,0.0022809966
2669,infection with hemorrhagic fever viruses,33,38,215,255,"Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.",12093990_7,-1,-1,-1,2669,-1,0.008312075,0.99168795
2672,cidofovir,3,4,11,20,"The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.",12093990_9,-1,-1,-1,2672,-1,0.99918073,0.00081924215
2673,adenovirus infection,6,8,31,51,"The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.",12093990_9,-1,-1,-1,2673,-1,0.1836487,0.8163513
2676,adenovirus disease,12,14,82,100,OBJECTIVE: We report our experience with intravenous ribavirin therapy for severe adenovirus disease in a series of immunocompromised children and review the literature.,12093990_10,-1,-1,-1,2676,-1,0.02017956,0.97982043
2678,adenovirus disease,18,20,135,153,DESIGN/METHODS: We retrospectively reviewed the medical records of 5 children treated with intravenous ribavirin for documented severe adenovirus disease.,12093990_11,-1,-1,-1,2678,-1,0.026898684,0.9731013
2679,hemorrhagic cystitis,4,6,34,54,"Two patients developed adenovirus hemorrhagic cystitis after cardiac and bone marrow transplants, respectively.",12093990_12,-1,-1,-1,2679,-1,0.0027757513,0.9972242
2680,cidofovir,8,9,61,70,The bone marrow transplant patient also received intravenous cidofovir for progressive disseminated disease.,12093990_13,-1,-1,-1,2680,-1,0.9991372,0.00086279766
2681,disseminated disease,11,13,87,107,The bone marrow transplant patient also received intravenous cidofovir for progressive disseminated disease.,12093990_13,-1,-1,-1,2681,-1,0.0028530874,0.9971469
2682,pneumonia,6,7,46,55,"An additional 3 children developed adenovirus pneumonia; 2 were neonates, 1 of whom had partial DiGeorge syndrome.",12093990_14,-1,-1,-1,2682,-1,0.0032973564,0.9967026
2683,DiGeorge syndrome,17,19,96,113,"An additional 3 children developed adenovirus pneumonia; 2 were neonates, 1 of whom had partial DiGeorge syndrome.",12093990_14,-1,-1,-1,2683,-1,0.009803289,0.9901967
2685,hemorrhagic cystitis,22,24,147,167,RESULTS: Complete clinical recovery followed later by viral clearance was observed in 2 children: the cardiac transplant recipient with adenovirus hemorrhagic cystitis and the immunocompetent neonate with adenovirus pneumonia.,12093990_17,-1,-1,-1,2685,-1,0.003612862,0.9963871
2686,pneumonia,30,31,216,225,RESULTS: Complete clinical recovery followed later by viral clearance was observed in 2 children: the cardiac transplant recipient with adenovirus hemorrhagic cystitis and the immunocompetent neonate with adenovirus pneumonia.,12093990_17,-1,-1,-1,2686,-1,0.0038944543,0.9961055
2687,adenovirus disease,6,8,33,51,The remaining 3 children died of adenovirus disease.,12093990_18,-1,-1,-1,2687,-1,0.14950909,0.8504909
2689,cidofovir,2,3,7,16,Use of cidofovir in 1 child was associated with progressive renal failure and neutropenia.,12093990_20,-1,-1,-1,2689,-1,0.999225,0.00077502837
2690,progressive renal failure,9,12,48,73,Use of cidofovir in 1 child was associated with progressive renal failure and neutropenia.,12093990_20,-1,-1,-1,2690,-1,0.0027945735,0.99720544
2692,adenovirus disease,19,21,127,145,"DISCUSSION: Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease, namely solid-organ and bone marrow transplant recipients, neonates, and children with immunodeficiency.",12093990_21,-1,-1,-1,2692,-1,0.012388235,0.9876117
2693,immunodeficiency,35,36,233,249,"DISCUSSION: Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease, namely solid-organ and bone marrow transplant recipients, neonates, and children with immunodeficiency.",12093990_21,-1,-1,-1,2693,-1,0.0034882277,0.99651176
2695,adenovirus disease,11,13,78,96,"Although intravenous ribavirin was not effective for all children with severe adenovirus disease in this series or in the literature, therapy is unlikely to be of benefit if begun late in the course of the infection.",12093990_22,-1,-1,-1,2695,-1,0.021278655,0.9787214
2697,adenovirus disease,15,17,96,114,"Early identification, eg by polymerase chain reaction of those patients at risk of disseminated adenovirus disease may permit earlier antiviral treatment and better evaluation of therapeutic response.",12093990_23,-1,-1,-1,2697,-1,0.09811197,0.90188795
2698,adenovirus disease,8,10,43,61,CONCLUSIONS: Two of 5 children with severe adenovirus disease treated with intravenous ribavirin recovered.,12093990_24,-1,-1,-1,2698,-1,0.036863234,0.96313673
2700,adenovirus infection,22,24,136,156,"The availability of newer rapid diagnostic techniques, such as polymerase chain reaction, may make earlier, more effective treatment of adenovirus infection possible.",12093990_25,-1,-1,-1,2700,-1,0.2813847,0.7186153
2701,adenovirus disease,7,9,51,69,"Given the seriousness and increasing prevalence of adenovirus disease in certain hosts, especially children, a large, multicenter clinical trial of potentially useful anti-adenoviral therapies, such as intravenous ribavirin, is clearly required to demonstrate the most effective and least toxic therapy.",12093990_26,-1,-1,-1,2701,-1,0.11212844,0.88787156
2703,asystolic cardiac arrest,1,4,8,32,Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.,12101159_0,-1,-1,-1,2703,-1,0.00830659,0.99169344
2704,diltiazem overdose,5,7,39,57,Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.,12101159_0,-1,-1,-1,2704,-1,0.8609118,0.13908826
2710,isosorbide nitrate,21,23,96,114,"A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.",12101159_1,-1,-1,-1,2710,-1,0.99882025,0.0011797482
2713,charcoal,16,17,104,112,He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.,12101159_2,-1,-1,-1,2713,-1,0.99824715,0.0017528505
2717,asystolic,15,16,108,117,"The patient remained unresponsive with junctional bradycardia, unrecordable blood pressure, and then became asystolic.",12101159_4,-1,-1,-1,2717,-1,0.55654395,0.44345608
2722,diltiazem overdose,16,18,98,116,"This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe diltiazem overdose, particularly with the onset of asystole.",12101159_7,-1,-1,-1,2722,-1,0.743382,0.25661802
2725,diltiazem overdose,11,13,63,81,It should be considered early in cases of cardiac arrest after diltiazem overdose.,12101159_8,-1,-1,-1,2725,-1,0.8635612,0.1364388
2728,Unfractionated heparin,0,2,0,22,Unfractionated heparin (UH) is currently the substitute for selected patients.,12109865_2,-1,-1,-1,2728,-1,0.9983298,0.001670216
2729,UH,3,4,24,26,Unfractionated heparin (UH) is currently the substitute for selected patients.,12109865_2,-1,-1,-1,2729,-1,0.9965918,0.003408231
2731,LMWH,3,4,30,34,"Low-molecular-weight heparin (LMWH) offers theoretical advantages over UH, but is not currently considered in clinical guidelines as an alternative to UH in patients with prosthetic valves.",12109865_3,-1,-1,-1,2731,-1,0.9974101,0.0025899494
2732,UH,9,10,71,73,"Low-molecular-weight heparin (LMWH) offers theoretical advantages over UH, but is not currently considered in clinical guidelines as an alternative to UH in patients with prosthetic valves.",12109865_3,-1,-1,-1,2732,-1,0.98588735,0.014112591
2733,UH,23,24,151,153,"Low-molecular-weight heparin (LMWH) offers theoretical advantages over UH, but is not currently considered in clinical guidelines as an alternative to UH in patients with prosthetic valves.",12109865_3,-1,-1,-1,2733,-1,0.98534226,0.014657703
2734,LMWH,20,21,97,101,HYPOTHESIS: The aim of the present study was to review the data accumulated so far on the use of LMWH in this patient population and to discuss its applicability in common practice.,12109865_4,-1,-1,-1,2734,-1,0.9987533,0.0012467337
2735,LMWH,11,12,59,63,"METHODS: For this paper, the current medical literature on LMWH in patients with mechanical heart valves was extensively reviewed.",12109865_5,-1,-1,-1,2735,-1,0.9989121,0.001087934
2737,n,21,22,123,124,"After excluding case reports, the following groups were constructed: (a) short-term administration, after valve insertion (n = 212); (b) short-term, perioperative (noncardiac)/periprocedural (n = 114); (c) long-term, due to intolerance to OAC (n = 16); (d) long-term, in pregnancy (n = 10).",12109865_9,-1,-1,-1,2737,-1,0.17129506,0.82870495
2738,n,34,35,192,193,"After excluding case reports, the following groups were constructed: (a) short-term administration, after valve insertion (n = 212); (b) short-term, perioperative (noncardiac)/periprocedural (n = 114); (c) long-term, due to intolerance to OAC (n = 16); (d) long-term, in pregnancy (n = 10).",12109865_9,-1,-1,-1,2738,-1,0.13718775,0.8628123
2739,c,40,41,203,204,"After excluding case reports, the following groups were constructed: (a) short-term administration, after valve insertion (n = 212); (b) short-term, perioperative (noncardiac)/periprocedural (n = 114); (c) long-term, due to intolerance to OAC (n = 16); (d) long-term, in pregnancy (n = 10).",12109865_9,-1,-1,-1,2739,-1,0.24513169,0.75486827
2740,n,50,51,244,245,"After excluding case reports, the following groups were constructed: (a) short-term administration, after valve insertion (n = 212); (b) short-term, perioperative (noncardiac)/periprocedural (n = 114); (c) long-term, due to intolerance to OAC (n = 16); (d) long-term, in pregnancy (n = 10).",12109865_9,-1,-1,-1,2740,-1,0.11769235,0.88230765
2741,n,63,64,282,283,"After excluding case reports, the following groups were constructed: (a) short-term administration, after valve insertion (n = 212); (b) short-term, perioperative (noncardiac)/periprocedural (n = 114); (c) long-term, due to intolerance to OAC (n = 16); (d) long-term, in pregnancy (n = 10).",12109865_9,-1,-1,-1,2741,-1,0.115260065,0.88473994
2742,thromboembolism,4,5,22,37,"The incidence rate of thromboembolism was 0.9% for all the studies and 0.5, 0, 20, and 0% in groups a, b, c, and d, respectively; for hemorrhage, the overall rate was 3.4% (3.8, 2.6, 10, and 0% for the respective groups).",12109865_10,-1,-1,-1,2742,-1,0.0031006814,0.99689937
2743,c,28,29,106,107,"The incidence rate of thromboembolism was 0.9% for all the studies and 0.5, 0, 20, and 0% in groups a, b, c, and d, respectively; for hemorrhage, the overall rate was 3.4% (3.8, 2.6, 10, and 0% for the respective groups).",12109865_10,-1,-1,-1,2743,-1,0.27045497,0.72954506
2745,LMWH,10,11,66,70,"CONCLUSIONS: In patients with mechanical heart valves, short-term LMWH therapy compares favorably with UH.",12109865_11,-1,-1,-1,2745,-1,0.99895704,0.0010429054
2746,UH,15,16,103,105,"CONCLUSIONS: In patients with mechanical heart valves, short-term LMWH therapy compares favorably with UH.",12109865_11,-1,-1,-1,2746,-1,0.9894978,0.010502164
2747,LMWH,5,6,27,31,Data on mid- and long-term LMWH administration in these patients are sparse.,12109865_12,-1,-1,-1,2747,-1,0.99887544,0.0011245367
2748,LMWH,16,17,99,103,Further randomized studies are needed to confirm the safety and precise indications for the use of LMWH in patients with mechanical heart valves.,12109865_13,-1,-1,-1,2748,-1,0.99893266,0.0010672793
2755,mg,5,6,39,41,The patient received metoclopramide 10 mg i.v.,12139551_2,-1,-1,-1,2755,-1,0.9581433,0.041856643
2756,h.,4,5,21,23,"five times during 48 h. After interviewing the attending nurses and reviewing the written documentation, it is clear that every administration of metoclopramide was immediately (within s) followed by asystole.",12139551_3,-1,-1,-1,2756,-1,0.748506,0.251494
2761,mg,7,8,36,38,"The patient received atropine 0.5-1 mg and chest compressions, before sinus rhythm again took over.",12139551_5,-1,-1,-1,2761,-1,0.99163896,0.008361079
2765,adverse drug reaction,21,24,143,164,The rapid injection via the central venous route and the concomitant tapering of dopamine infusion might have contributed in precipitating the adverse drug reaction.,12139551_7,-1,-1,-1,2765,-1,0.016379617,0.9836204
2766,nitric oxide,6,8,47,59,"Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.",12180796_0,-1,-1,-1,2766,-1,0.9953192,0.0046808473
2768,arteritis,27,28,151,160,"Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.",12180796_0,-1,-1,-1,2768,-1,0.002533566,0.99746644
2769,fenoldopam,32,33,180,190,"Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.",12180796_0,-1,-1,-1,2769,-1,0.99910563,0.0008943745
2771,vasodilators,36,37,209,221,"Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.",12180796_0,-1,-1,-1,2771,-1,0.075878896,0.92412114
2772,vasodilators,5,6,29,41,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,-1,-1,-1,2772,-1,0.7210623,0.2789377
2773,fenoldopam,7,8,43,53,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,-1,-1,-1,2773,-1,0.9992636,0.0007364072
2775,nitric oxide,20,22,144,156,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,-1,-1,-1,2775,-1,0.9887888,0.0112111885
2776,fenoldopam,3,4,23,33,Rats were administered fenoldopam for 24 hours by intravenous infusion with or without following repeated daily oral administrations of theophylline.,12180796_2,-1,-1,-1,2776,-1,0.9992926,0.0007073808
2779,arteritis,31,32,172,181,"These results suggest that the peak expression of iNOS antigen was followed by that of bFGF antigen, and bFGF may have a suppressive effect on iNOS expression in these rat arteritis models.",12180796_4,-1,-1,-1,2779,-1,0.0026688373,0.99733114
2781,cholinergic agents,19,21,140,158,"BACKGROUND: The septo-hippocampal cholinergic pathway has been implicated in epileptogenesis, and genetic factors influence the response to cholinergic agents, but limited data are available on cholinergic involvement in alcohol withdrawal severity.",12198388_1,-1,-1,-1,2781,-1,0.9967519,0.0032480964
2787,neostigmine,8,9,50,61,"Animals were administered nicotine, carbachol, or neostigmine via timed tail vein infusion, and the latencies to onset of tremor and clonus were recorded and converted to threshold dose.",12198388_4,-1,-1,-1,2787,-1,0.9990959,0.00090404693
2790,ACh,11,12,84,87,We also used microdialysis to measure basal and potassium-stimulated acetylcholine (ACh) release in the CA1 region of the hippocampus.,12198388_5,-1,-1,-1,2790,-1,0.9978721,0.0021278306
2792,ACh,1,2,12,15,Hippocampal ACh also was measured during testing for handling-induced convulsions.,12198388_7,-1,-1,-1,2792,-1,0.99802387,0.00197615
2797,neostigmine,14,15,89,100,"RESULTS: Sensitivity to several convulsion endpoints induced by nicotine, carbachol, and neostigmine were significantly greater in WSR versus WSP mice.",12198388_8,-1,-1,-1,2797,-1,0.9990339,0.0009661066
2798,ACh,13,14,75,78,"In microdialysis experiments, the lines did not differ in basal release of ACh, and 50 mM KCl increased ACh output in both lines of mice.",12198388_9,-1,-1,-1,2798,-1,0.9981055,0.0018944985
2799,mM KCl,17,19,87,93,"In microdialysis experiments, the lines did not differ in basal release of ACh, and 50 mM KCl increased ACh output in both lines of mice.",12198388_9,-1,-1,-1,2799,-1,0.9965329,0.0034670476
2800,ACh,20,21,104,107,"In microdialysis experiments, the lines did not differ in basal release of ACh, and 50 mM KCl increased ACh output in both lines of mice.",12198388_9,-1,-1,-1,2800,-1,0.99827373,0.0017262321
2801,ACh,7,8,36,39,"However, the increase in release of ACh produced by the first application of KCl was 2-fold higher in WSP versus WSR mice.",12198388_10,-1,-1,-1,2801,-1,0.9972615,0.0027385226
2802,KCl,14,15,77,80,"However, the increase in release of ACh produced by the first application of KCl was 2-fold higher in WSP versus WSR mice.",12198388_10,-1,-1,-1,2802,-1,0.9984674,0.0015326288
2803,ACh,2,3,17,20,"When hippocampal ACh was measured during testing for handling-induced convulsions, extracellular ACh was significantly elevated (192%) in WSP mice, but was nonsignificantly elevated (59%) in WSR mice.",12198388_11,-1,-1,-1,2803,-1,0.99846905,0.0015309594
2805,ACh,12,13,97,100,"When hippocampal ACh was measured during testing for handling-induced convulsions, extracellular ACh was significantly elevated (192%) in WSP mice, but was nonsignificantly elevated (59%) in WSR mice.",12198388_11,-1,-1,-1,2805,-1,0.998487,0.0015129701
2806,convulsants,15,16,120,131,CONCLUSIONS: These results suggest that differences in cholinergic activity and postsynaptic sensitivity to cholinergic convulsants may be associated with ethanol withdrawal severity and implicate cholinergic mechanisms in alcohol withdrawal.,12198388_12,-1,-1,-1,2806,-1,0.8886882,0.111311756
2809,convulsants,10,11,65,76,"Specifically, WSP mice may have lower sensitivity to cholinergic convulsants compared with WSR because of postsynaptic receptor desensitization brought on by higher activity of cholinergic neurons.",12198388_13,-1,-1,-1,2809,-1,0.8140488,0.18595119
2810,muscle pain,1,3,18,29,Capsaicin-induced muscle pain alters the excitability of the human jaw-stretch reflex.,12202650_0,-1,-1,-1,2810,-1,0.003467992,0.99653196
2811,painful temporomandibular disorders,3,6,23,58,"The pathophysiology of painful temporomandibular disorders is not fully understood, but evidence suggests that muscle pain modulates motor function in characteristic ways.",12202650_1,-1,-1,-1,2811,-1,0.009864395,0.9901356
2812,muscle pain,15,17,111,122,"The pathophysiology of painful temporomandibular disorders is not fully understood, but evidence suggests that muscle pain modulates motor function in characteristic ways.",12202650_1,-1,-1,-1,2812,-1,0.036827423,0.96317255
2813,muscle,9,10,64,70,This study tested the hypothesis that activation of nociceptive muscle afferent fibers would be linked to an increased excitability of the human jaw-stretch reflex and whether this process would be sensitive to length and velocity of the stretch.,12202650_2,-1,-1,-1,2813,-1,0.40157324,0.5984267
2818,painful,17,18,106,113,"The normalized reflex amplitude was significantly higher during pain, but only at faster stretches in the painful muscle.",12202650_6,-1,-1,-1,2818,-1,0.0045880233,0.99541193
2822,muscle rigidity,8,10,51,66,"Haloperidol (1 mg/kg ip) induced parkinsonian-like muscle rigidity, measured as an increased resistance of a rat's hind foot to passive flexion and extension at the ankle joint.",12231232_2,-1,-1,-1,2822,-1,0.0024430382,0.9975569
2823,AIDA,0,1,0,4,AIDA in doses of 7.5-15 microg/0.5 microl diminished the haloperidol-induced muscle rigidity.,12231232_4,-1,-1,-1,2823,-1,0.99837935,0.0016206725
2824,muscle rigidity,12,14,77,92,AIDA in doses of 7.5-15 microg/0.5 microl diminished the haloperidol-induced muscle rigidity.,12231232_4,-1,-1,-1,2824,-1,0.0022934647,0.99770653
2825,contrast,1,2,3,11,"In contrast, 2R,4R-APDC injections were ineffective.",12231232_5,-1,-1,-1,2825,-1,0.31269962,0.6873004
2826,parkinsonian muscle rigidity,23,26,129,157,"The present results may suggest that the blockade of striatal mGluR1, but not the stimulation of group II mGluRs, may ameliorate parkinsonian muscle rigidity.",12231232_6,-1,-1,-1,2826,-1,0.0031892022,0.99681073
2830,GR 55562,21,23,128,136,"Male Wistar rats were implanted bilaterally with cannulae into the accumbens shell or core, and then were locally injected with GR 55562 (an antagonist of 5-HT1B receptors) or CP 93129 (an agonist of 5-HT1B receptors).",12369736_2,-1,-1,-1,2830,-1,0.9978188,0.0021811174
2831,CP 93129,31,33,176,184,"Male Wistar rats were implanted bilaterally with cannulae into the accumbens shell or core, and then were locally injected with GR 55562 (an antagonist of 5-HT1B receptors) or CP 93129 (an agonist of 5-HT1B receptors).",12369736_2,-1,-1,-1,2831,-1,0.9967644,0.003235551
2832,GR 55562,7,9,39,47,"Given alone to any accumbal subregion, GR 55562 (0.1-10 microg/side) or CP 93129 (0.1-10 microg/side) did not change basal locomotor activity.",12369736_3,-1,-1,-1,2832,-1,0.99737525,0.0026248144
2833,CP 93129,16,18,72,80,"Given alone to any accumbal subregion, GR 55562 (0.1-10 microg/side) or CP 93129 (0.1-10 microg/side) did not change basal locomotor activity.",12369736_3,-1,-1,-1,2833,-1,0.99680483,0.003195196
2835,GR 55562,0,2,0,8,"GR 55562 (0.1-10 microg/side), administered intra-accumbens shell prior to cocaine, dose-dependently attenuated the psychostimulant-induced locomotor hyperactivity.",12369736_5,-1,-1,-1,2835,-1,0.99806875,0.0019313141
2838,GR 55562,12,14,71,79,Such attenuation was not found in animals which had been injected with GR 55562 into the accumbens core.,12369736_6,-1,-1,-1,2838,-1,0.99814165,0.001858365
2840,CP 93129,15,17,74,82,"When injected into the accumbens shell (but not the core) before cocaine, CP 93129 (0.1-10 microg/side) enhanced the locomotor response to cocaine; the maximum effect being observed after 10 microg/side of the agonist.",12369736_7,-1,-1,-1,2840,-1,0.9981331,0.0018668994
2842,GR 55562,10,12,80,88,The later enhancement was attenuated after intra-accumbens shell treatment with GR 55562 (1 microg/side).,12369736_8,-1,-1,-1,2842,-1,0.9973948,0.0026051619
2844,hyperlocomotion,6,7,43,58,"Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.",12369736_9,-1,-1,-1,2844,-1,0.0032616355,0.9967384
2845,GR 55562,37,39,255,263,"Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.",12369736_9,-1,-1,-1,2845,-1,0.9957408,0.00425927
2846,CP 93129,43,45,278,286,"Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.",12369736_9,-1,-1,-1,2846,-1,0.9926696,0.007330377
2848,chest pain,2,4,16,26,Cocaine related chest pain: are we seeing the tip of an iceberg?The recreational use of cocaine is on the increase.,12443032_0,-1,-1,-1,2848,-1,0.003064716,0.99693525
2852,chest pain,9,11,50,60,"In particular, the tendency of cocaine to produce chest pain ought to be in the mind of the emergency nurse when faced with a young victim of chest pain who is otherwise at low risk.",12443032_2,-1,-1,-1,2852,-1,0.0029360135,0.99706393
2853,chest pain,28,30,142,152,"In particular, the tendency of cocaine to produce chest pain ought to be in the mind of the emergency nurse when faced with a young victim of chest pain who is otherwise at low risk.",12443032_2,-1,-1,-1,2853,-1,0.0030213862,0.99697864
2854,chest pain,3,5,17,27,The mechanism of chest pain related to cocaine use is discussed and treatment dilemmas are discussed.,12443032_3,-1,-1,-1,2854,-1,0.0029169796,0.997083
2858,renal cell carcinoma,9,12,55,75,A phase II study of thalidomide in advanced metastatic renal cell carcinoma.,12448656_0,-1,-1,-1,2858,-1,0.0056480803,0.99435186
2861,renal cell cancer,15,18,102,119,"OBJECTIVES: To evaluate the toxicity and activity of thalidomide in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor, vascular endothelial growth factor (VEGF)165, with therapy.",12448656_1,-1,-1,-1,2861,-1,0.0059260866,0.9940739
2864,metastases,23,24,137,147,"RESULTS: 24 patients were evaluable for response with one partial response of 11 months duration of a patient with hepatic and pulmonary metastases (4%), one minor response, and 2 patients stable for over 6 months.",12448656_6,-1,-1,-1,2864,-1,0.0033192148,0.9966808
2868,renal cell carcinoma,15,18,88,108,CONCLUSION: These results are consistent with a low level of activity of thalidomide in renal cell carcinoma.,12448656_9,-1,-1,-1,2868,-1,0.004908014,0.99509203
2870,renal cell carcinoma,10,13,59,79,"The dose-response relationship, if any, of thalidomide for renal cell carcinoma is unclear.",12448656_11,-1,-1,-1,2870,-1,0.0051050954,0.9948949
2875,blind,17,18,99,104,"One hundred and thirty-five patients were assigned to one of three groups in a prospective, double blind, randomized manner.",12452237_1,-1,-1,-1,2875,-1,0.26284304,0.7371569
2876,PS,1,2,6,8,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,-1,-1,-1,2876,-1,0.42661792,0.57338214
2878,mg,13,14,76,78,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,-1,-1,-1,2878,-1,0.94570535,0.054294657
2880,mg,23,24,113,115,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,-1,-1,-1,2880,-1,0.95598614,0.04401394
2882,mg,30,31,149,151,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,-1,-1,-1,2882,-1,0.9343636,0.06563637
2883,rocuronium,41,42,190,200,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,-1,-1,-1,2883,-1,0.9989196,0.0010804516
2884,mg,43,44,205,207,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,-1,-1,-1,2884,-1,0.93622136,0.063778624
2886,mg,2,3,13,15,"Morphine 0.1 mg x kg(-1) iv was given for premedication and all patients were monitored with a noninvasive blood pressure monitor, ECG and pulse oximetry.",12452237_3,-1,-1,-1,2886,-1,0.9796855,0.020314476
2887,mg.kg(-1,5,6,30,38,"Anesthesia was induced with 5 mg.kg(-1) thiopental iv. followed by succinylcholine (Group PS, LS) or rocuronium (Group PR) for tracheal intubation.",12452237_4,-1,-1,-1,2887,-1,0.96315897,0.036840986
2888,thiopental,7,8,40,50,"Anesthesia was induced with 5 mg.kg(-1) thiopental iv. followed by succinylcholine (Group PS, LS) or rocuronium (Group PR) for tracheal intubation.",12452237_4,-1,-1,-1,2888,-1,0.9993487,0.00065127376
2890,PS,15,16,90,92,"Anesthesia was induced with 5 mg.kg(-1) thiopental iv. followed by succinylcholine (Group PS, LS) or rocuronium (Group PR) for tracheal intubation.",12452237_4,-1,-1,-1,2890,-1,0.9639083,0.036091708
2891,rocuronium,20,21,101,111,"Anesthesia was induced with 5 mg.kg(-1) thiopental iv. followed by succinylcholine (Group PS, LS) or rocuronium (Group PR) for tracheal intubation.",12452237_4,-1,-1,-1,2891,-1,0.9992161,0.0007838928
2893,muscle fasciculation,4,6,26,46,The results indicate that muscle fasciculation was not found in Group PR while the patients in Group LS had a lower incidence of muscle fasciculation than those in Group PS (p < 0.001).,12452237_8,-1,-1,-1,2893,-1,0.0102526415,0.9897474
2894,muscle fasciculation,23,25,129,149,The results indicate that muscle fasciculation was not found in Group PR while the patients in Group LS had a lower incidence of muscle fasciculation than those in Group PS (p < 0.001).,12452237_8,-1,-1,-1,2894,-1,0.00872335,0.9912766
2895,PS,29,30,170,172,The results indicate that muscle fasciculation was not found in Group PR while the patients in Group LS had a lower incidence of muscle fasciculation than those in Group PS (p < 0.001).,12452237_8,-1,-1,-1,2895,-1,0.8193483,0.18065171
2896,p,31,32,174,175,The results indicate that muscle fasciculation was not found in Group PR while the patients in Group LS had a lower incidence of muscle fasciculation than those in Group PS (p < 0.001).,12452237_8,-1,-1,-1,2896,-1,0.25312275,0.74687725
2897,h,2,3,6,7,"At 24 h, the incidence of myalgia was higher in Group PS than in Group LS and PR (p < 0.05).",12452237_9,-1,-1,-1,2897,-1,0.121162236,0.8788377
2898,PS,12,13,54,56,"At 24 h, the incidence of myalgia was higher in Group PS than in Group LS and PR (p < 0.05).",12452237_9,-1,-1,-1,2898,-1,0.8095935,0.19040652
2899,p,20,21,82,83,"At 24 h, the incidence of myalgia was higher in Group PS than in Group LS and PR (p < 0.05).",12452237_9,-1,-1,-1,2899,-1,0.27203363,0.72796637
2901,muscle fasciculation,14,16,83,103,A correlation was not found between the incidence of myalgia and the occurrence of muscle fasciculation.,12452237_10,-1,-1,-1,2901,-1,0.007990216,0.99200976
2906,mg,9,10,67,69,Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine.,12464714_0,-1,-1,-1,2906,-1,0.98763883,0.012361236
2911,mg,14,15,102,104,This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg/caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy.,12464714_2,-1,-1,-1,2911,-1,0.9615669,0.03843309
2912,2 ergotamine,17,19,115,127,This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg/caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy.,12464714_2,-1,-1,-1,2912,-1,0.9975521,0.002447903
2913,mg,22,23,146,148,This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg/caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy.,12464714_2,-1,-1,-1,2913,-1,0.9730461,0.026953945
2916,p,25,26,131,132,"Of patients expressing a preference (89.1%), more than twice as many preferred rizatriptan to ergotamine/caffeine (69.9 vs. 30.1%, p < or = 0.001).",12464714_3,-1,-1,-1,2916,-1,0.35848877,0.64151126
2920,h,9,10,48,49,The co-primary endpoint of being pain free at 2 h was also in favor of rizatriptan.,12464714_5,-1,-1,-1,2920,-1,0.21592107,0.78407896
2923,h,8,9,48,49,"Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.",12464714_6,-1,-1,-1,2923,-1,0.109234974,0.8907651
2925,p,20,21,123,124,"Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.",12464714_6,-1,-1,-1,2925,-1,0.35247082,0.6475291
2927,h,32,33,176,177,"Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.",12464714_6,-1,-1,-1,2927,-1,0.10341101,0.89658904
2929,h,4,5,21,22,"Headache relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine/caffeine (p < or = 0.001), with rizatriptan being superior to ergotamine/caffeine within 30 min of dosing.",12464714_7,-1,-1,-1,2929,-1,0.059615973,0.940384
2931,p,16,17,84,85,"Headache relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine/caffeine (p < or = 0.001), with rizatriptan being superior to ergotamine/caffeine within 30 min of dosing.",12464714_7,-1,-1,-1,2931,-1,0.39854443,0.60145557
2935,h,12,13,62,63,"Almost 36% of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/caffeine (p < or = 0.001).",12464714_8,-1,-1,-1,2935,-1,0.23401587,0.7659842
2936,h,24,25,130,131,"Almost 36% of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/caffeine (p < or = 0.001).",12464714_8,-1,-1,-1,2936,-1,0.1615149,0.83848506
2937,p,35,36,185,186,"Almost 36% of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/caffeine (p < or = 0.001).",12464714_8,-1,-1,-1,2937,-1,0.35224327,0.64775676
2941,phonophobia,17,18,110,121,"Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).",12464714_9,-1,-1,-1,2941,-1,0.0061450284,0.99385494
2942,photophobia,19,20,125,136,"Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).",12464714_9,-1,-1,-1,2942,-1,0.0030743524,0.99692565
2943,h,27,28,177,178,"Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).",12464714_9,-1,-1,-1,2943,-1,0.13584949,0.8641505
2944,p,32,33,198,199,"Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).",12464714_9,-1,-1,-1,2944,-1,0.41481072,0.5851893
2945,h,12,13,62,63,"More patients were (completely, very or somewhat) satisfied 2 h after treatment with rizatriptan (69.8%) than at 2 h after treatment with ergotamine/caffeine (38.6%, p < or = 0.001).",12464714_10,-1,-1,-1,2945,-1,0.35490185,0.64509815
2947,h,24,25,115,116,"More patients were (completely, very or somewhat) satisfied 2 h after treatment with rizatriptan (69.8%) than at 2 h after treatment with ergotamine/caffeine (38.6%, p < or = 0.001).",12464714_10,-1,-1,-1,2947,-1,0.28057912,0.71942085
2948,p,33,34,166,167,"More patients were (completely, very or somewhat) satisfied 2 h after treatment with rizatriptan (69.8%) than at 2 h after treatment with ergotamine/caffeine (38.6%, p < or = 0.001).",12464714_10,-1,-1,-1,2948,-1,0.32963824,0.67036176
2959,STX,4,5,33,36,Measurements of [(3)H]saxitoxin (STX) binding showed a significant reduction in the level of plasma membrane sodium channels in beta2(-/-) neurons.,12481039_3,-1,-1,-1,2959,-1,0.9976102,0.0023897442
2962,sodium channels,34,36,219,234,"The integral of the compound action potential in optic nerve was significantly reduced, and the threshold for action potential generation was increased, indicating a reduction in the level of functional plasma membrane sodium channels.",12481039_5,-1,-1,-1,2962,-1,0.96271396,0.037286043
2963,contrast,1,2,3,11,"In contrast, the conduction velocity, the number and size of axons in the optic nerve, and the specific localization of Na(v)1.6 channels in the nodes of Ranvier were unchanged.",12481039_6,-1,-1,-1,2963,-1,0.15194492,0.84805506
2969,glioblastomas,12,13,93,106,Severe ocular and orbital toxicity after intracarotid injection of carboplatin for recurrent glioblastomas.,12483326_0,-1,-1,-1,2969,-1,0.0037349907,0.996265
2971,malignant tumor,5,7,30,45,BACKGROUND: Glioblastoma is a malignant tumor that occurs in the cerebrum during adulthood.,12483326_1,-1,-1,-1,2971,-1,0.0045880065,0.99541205
2979,glioblastomas,13,14,88,101,CASE: A 58-year-old man received an intracarotid injection of carboplatin for recurrent glioblastomas in his left temporal lobe.,12483326_6,-1,-1,-1,2979,-1,0.004071089,0.99592894
2981,visual disturbance,5,7,26,44,He complained of pain and visual disturbance in the ipsilateral eye 30 h after the injection.,12483326_7,-1,-1,-1,2981,-1,0.0033674047,0.99663264
2982,h,12,13,71,72,He complained of pain and visual disturbance in the ipsilateral eye 30 h after the injection.,12483326_7,-1,-1,-1,2982,-1,0.13998477,0.8600152
2983,carboplatin toxicity,7,9,47,67,Various ocular symptoms and findings caused by carboplatin toxicity were seen.,12483326_8,-1,-1,-1,2983,-1,0.90398806,0.096011914
2985,glycerin,11,12,79,87,RESULTS: He was treated with intravenous administration of corticosteroids and glycerin for 6 days after the injection.,12483326_9,-1,-1,-1,2985,-1,0.9986078,0.0013922602
2987,ocular pain,13,15,107,118,"Although the intraocular pressure elevation caused by secondary acute angle-closure glaucoma decreased and ocular pain diminished, inexorable papilledema and exudative retinal detachment continued for 3 weeks.",12483326_10,-1,-1,-1,2987,-1,0.0032210206,0.996779
2988,papilledema,18,19,142,153,"Although the intraocular pressure elevation caused by secondary acute angle-closure glaucoma decreased and ocular pain diminished, inexorable papilledema and exudative retinal detachment continued for 3 weeks.",12483326_10,-1,-1,-1,2988,-1,0.0036248495,0.99637514
2989,retinal detachment,21,23,168,186,"Although the intraocular pressure elevation caused by secondary acute angle-closure glaucoma decreased and ocular pain diminished, inexorable papilledema and exudative retinal detachment continued for 3 weeks.",12483326_10,-1,-1,-1,2989,-1,0.0035120056,0.996488
2990,chorioretinal atrophy,7,9,32,53,"Finally, 6 weeks later, diffuse chorioretinal atrophy with optic atrophy occurred and the vision in his left eye was lost.",12483326_11,-1,-1,-1,2990,-1,0.0399348,0.9600652
2991,optic atrophy,10,12,59,72,"Finally, 6 weeks later, diffuse chorioretinal atrophy with optic atrophy occurred and the vision in his left eye was lost.",12483326_11,-1,-1,-1,2991,-1,0.0046735285,0.9953265
2993,ocular toxicity,17,19,112,127,"CONCLUSION: When performing intracarotid injection of carboplatin, we must be aware of its potentially blinding ocular toxicity.",12483326_12,-1,-1,-1,2993,-1,0.0025560863,0.9974439
3005,absence seizures,4,6,37,53,Anti-epileptic drugs-induced de novo absence seizures.,12536034_0,-1,-1,-1,3005,-1,0.0034320136,0.99656796
3006,absence epilepsy,8,10,48,64,The authors present three patients with de novo absence epilepsy after administration of carbamazepine and vigabatrin.,12536034_1,-1,-1,-1,3006,-1,0.0034294084,0.9965706
3009,absence seizure,11,13,72,87,"Despite the underlying diseases, the prognosis for drug-induced de novo absence seizure is good because it subsides rapidly after discontinuing the use of the offending drugs.",12536034_2,-1,-1,-1,3009,-1,0.004821112,0.99517894
3010,absence epilepsy,16,18,133,149,The gamma-aminobutyric acid-transmitted thalamocortical circuitry accounts for a major part of the underlying neurophysiology of the absence epilepsy.,12536034_3,-1,-1,-1,3010,-1,0.006166041,0.993834
3011,absence seizure,4,6,29,44,"Because drug-induced de novo absence seizure is rare, pro-absence drugs can only be considered a promoting factor.",12536034_4,-1,-1,-1,3011,-1,0.0040120115,0.99598795
3012,absence seizure,21,23,136,151,The underlying epileptogenecity of the patients or the synergistic effects of the accompanying drugs is required to trigger the de novo absence seizure.,12536034_5,-1,-1,-1,3012,-1,0.0052594496,0.99474055
3015,absence epilepsy,6,8,45,61,"By understanding the underlying mechanism of absence epilepsy, we can avoid the inappropriate use of anticonvulsants in children with epilepsy and prevent drug-induced absence seizures.",12536034_7,-1,-1,-1,3015,-1,0.003273908,0.99672604
3017,absence seizures,24,26,168,184,"By understanding the underlying mechanism of absence epilepsy, we can avoid the inappropriate use of anticonvulsants in children with epilepsy and prevent drug-induced absence seizures.",12536034_7,-1,-1,-1,3017,-1,0.002727608,0.99727243
3020,liver failure,8,10,37,50,OBJECTIVE: To report a case of fatal liver failure possibly associated with concurrent use of bupropion and carbimazole.,12549952_1,-1,-1,-1,3020,-1,0.002272749,0.9977272
3029,acute liver injury,7,10,57,75,Liver biopsy showed evidence of nonspecific drug-induced acute liver injury.,12549952_5,-1,-1,-1,3029,-1,0.0024795039,0.9975205
3040,acute liver insult,10,13,62,80,CONCLUSIONS: Clinicians should be aware of the possibility of acute liver insult induced by bupropion given concurrently with other hepatotoxic drugs.,12549952_10,-1,-1,-1,3040,-1,0.0025029716,0.997497
3043,pyeloureteritis cystica,3,5,16,39,The etiology of pyeloureteritis cystica has long been attributed to chronic infection and inflammation.,1255900_1,-1,-1,-1,3043,-1,0.030641621,0.9693583
3048,thrombophlebitis,13,14,90,106,The disease occurred subsequent to the initiation of heparin therapy for suspected pelvic thrombophlebitis and cleared rapidly subsequent to its discontinuation.,1255900_4,-1,-1,-1,3048,-1,0.0025090233,0.997491
3049,pyeloureteritis cystica,15,17,98,121,The rate of resolution of the radiographic findings may be helpful in distinguishing between true pyeloureteritis cystica and submucosal hemorrhage.,1255900_5,-1,-1,-1,3049,-1,0.020683669,0.9793163
3050,submucosal hemorrhage,18,20,126,147,The rate of resolution of the radiographic findings may be helpful in distinguishing between true pyeloureteritis cystica and submucosal hemorrhage.,1255900_5,-1,-1,-1,3050,-1,0.028735718,0.9712643
3052,contrast medium,6,8,33,48,BACKGROUND: The use of iodinated contrast medium can result in nephropathy.,12571256_1,-1,-1,-1,3052,-1,0.99486035,0.005139655
3054,contrast medium,2,4,20,35,Whether iso-osmolar contrast medium is less nephrotoxic than low-osmolar contrast medium in high-risk patients is uncertain.,12571256_2,-1,-1,-1,3054,-1,0.996414,0.0035860057
3056,contrast medium,9,11,73,88,Whether iso-osmolar contrast medium is less nephrotoxic than low-osmolar contrast medium in high-risk patients is uncertain.,12571256_2,-1,-1,-1,3056,-1,0.99614584,0.0038541444
3058,contrast medium,24,26,152,167,"METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.",12571256_3,-1,-1,-1,3058,-1,0.9507943,0.049205743
3060,contrast medium,38,40,229,244,"METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.",12571256_3,-1,-1,-1,3060,-1,0.9463729,0.053627104
3061,iohexol,41,42,246,253,"METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.",12571256_3,-1,-1,-1,3061,-1,0.99929583,0.00070414756
3064,mg,15,16,97,99,The study involved 129 patients with diabetes with serum creatinine concentrations of 1.5 to 3.5 mg per deciliter who underwent coronary or aortofemoral angiography.,12571256_4,-1,-1,-1,3064,-1,0.96060413,0.039395902
3067,mg,12,13,73,75,"Other end points were an increase in the creatinine concentration of 0.5 mg per deciliter or more, an increase of 1.0 mg per deciliter or more, and a change in the creatinine concentration from day 0 to day 7.",12571256_6,-1,-1,-1,3067,-1,0.9697772,0.03022282
3068,mg,22,23,118,120,"Other end points were an increase in the creatinine concentration of 0.5 mg per deciliter or more, an increase of 1.0 mg per deciliter or more, and a change in the creatinine concentration from day 0 to day 7.",12571256_6,-1,-1,-1,3068,-1,0.9650553,0.034944765
3073,mg,15,16,67,69,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,-1,3073,-1,0.8525393,0.1474607
3075,mg,24,25,116,118,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,-1,3075,-1,0.83705103,0.16294901
3076,iohexol,29,30,140,147,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,-1,3076,-1,0.9993936,0.00060636544
3077,P=0.001,32,33,155,162,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,-1,3077,-1,0.4427644,0.5572356
3079,iohexol,42,43,216,223,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,-1,3079,-1,0.99931157,0.00068846473
3080,mg,45,46,231,233,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,-1,-1,-1,3080,-1,0.8629914,0.13700862
3083,mg,22,23,113,115,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,-1,-1,-1,3083,-1,0.96468604,0.035313997
3084,iohexol,38,39,185,192,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,-1,-1,-1,3084,-1,0.99940455,0.00059549167
3085,P=0.002,45,46,213,220,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,-1,-1,-1,3085,-1,0.4085602,0.5914398
3088,mg,9,10,54,56,"No patient receiving iodixanol had an increase of 1.0 mg per deciliter or more, but 10 patients in the iohexol group (15 percent) did.",12571256_10,-1,-1,-1,3088,-1,0.9724586,0.027541367
3089,iohexol,20,21,103,110,"No patient receiving iodixanol had an increase of 1.0 mg per deciliter or more, but 10 patients in the iohexol group (15 percent) did.",12571256_10,-1,-1,-1,3089,-1,0.9994105,0.00058945845
3091,mg,15,16,77,79,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,-1,-1,-1,3091,-1,0.89072865,0.109271355
3093,mg,24,25,126,128,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,-1,-1,-1,3093,-1,0.8593107,0.14068934
3094,iohexol,29,30,150,157,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,-1,-1,-1,3094,-1,0.999428,0.0005720099
3095,P=0.003,32,33,165,172,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,-1,-1,-1,3095,-1,0.31177902,0.6882209
3097,iohexol,44,45,226,233,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,-1,-1,-1,3097,-1,0.99936813,0.0006318451
3098,mg,48,49,247,249,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,-1,-1,-1,3098,-1,0.87700474,0.12299531
3100,contrast medium,5,7,36,51,"CONCLUSIONS: Nephropathy induced by contrast medium may be less likely to develop in high-risk patients when iodixanol is used rather than a low-osmolar, nonionic contrast medium.",12571256_12,-1,-1,-1,3100,-1,0.995911,0.004089054
3102,contrast medium,26,28,163,178,"CONCLUSIONS: Nephropathy induced by contrast medium may be less likely to develop in high-risk patients when iodixanol is used rather than a low-osmolar, nonionic contrast medium.",12571256_12,-1,-1,-1,3102,-1,0.9897021,0.010297909
3108,increase in blood pressure,15,19,101,127,The purpose of the present study was to determine if prenatal dexamethasone programmed a progressive increase in blood pressure and renal injury in rats.,12574103_2,-1,-1,-1,3108,-1,0.01836779,0.98163223
3111,body weight,16,18,106,117,"Pregnant rats were given either vehicle or 2 daily intraperitoneal injections of dexamethasone (0.2 mg/kg body weight) on gestational days 11 and 12, 13 and 14, 15 and 16, 17 and 18, or 19 and 20.",12574103_3,-1,-1,-1,3111,-1,0.77966094,0.22033909
3114,P<0.05,36,37,195,201,"Offspring of rats administered dexamethasone on days 15 and 16 gestation had a 20% reduction in glomerular number compared with control at 6 to 9 months of age (22 527+/-509 versus 28 050+/-561, P<0.05), which was comparable to the percent reduction in glomeruli measured at 3 weeks of age.",12574103_4,-1,-1,-1,3114,-1,0.28760982,0.7123902
3116,P<0.05,31,32,165,171,Six- to 9-month old rats receiving prenatal dexamethasone on days 17 and 18 of gestation had a 17% reduction in glomeruli (23 380+/-587) compared with control rats (P<0.05).,12574103_5,-1,-1,-1,3116,-1,0.30873248,0.6912675
3118,blood,24,25,117,122,"Male rats that received prenatal dexamethasone on days 15 and 16, 17 and 18, and 13 and 14 of gestation had elevated blood pressures at 6 months of age; the latter group did not have a reduction in glomerular number.",12574103_6,-1,-1,-1,3118,-1,0.10841667,0.8915833
3126,reduction in glomeruli,8,11,48,70,"Hypertension was observed in animals that had a reduction in glomeruli as well as in a group that did not have a reduction in glomerular number, suggesting that a reduction in glomerular number is not the sole cause for the development of hypertension.",12574103_9,-1,-1,-1,3126,-1,0.029001731,0.9709982
3127,a reduction in glomerular number,21,26,111,143,"Hypertension was observed in animals that had a reduction in glomeruli as well as in a group that did not have a reduction in glomerular number, suggesting that a reduction in glomerular number is not the sole cause for the development of hypertension.",12574103_9,-1,-1,-1,3127,-1,0.06652641,0.9334736
3130,cyclosporine A,9,11,73,87,"Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat.",12584269_0,-1,-1,-1,3130,-1,0.9987207,0.0012793167
3134,SRL,4,5,23,26,BACKGROUND: Sirolimus (SRL) may supplement calcineurin inhibitors in clinical organ transplantation.,12584269_1,-1,-1,-1,3134,-1,0.9980404,0.0019596647
3135,calcineurin inhibitors,8,10,43,65,BACKGROUND: Sirolimus (SRL) may supplement calcineurin inhibitors in clinical organ transplantation.,12584269_1,-1,-1,-1,3135,-1,0.99576974,0.0042302697
3137,SRL,5,6,27,30,"These are nephrotoxic, but SRL seems to act differently displaying only minor nephrotoxic effects, although this question is still open.",12584269_2,-1,-1,-1,3137,-1,0.9985636,0.0014363998
3139,SRL,7,8,41,44,In a number of treatment protocols where SRL was combined with a calcineurin inhibitor indications of a synergistic nephrotoxic effect were described.,12584269_3,-1,-1,-1,3139,-1,0.9986572,0.0013426994
3141,cyclosporine A,26,28,161,175,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,-1,-1,-1,3141,-1,0.99868137,0.0013185882
3142,CsA,29,30,177,180,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,-1,-1,-1,3142,-1,0.9982936,0.0017064259
3144,FK506,34,35,195,200,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,-1,-1,-1,3144,-1,0.9989089,0.0010911823
3145,SRL,37,38,205,208,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,-1,-1,-1,3145,-1,0.9983536,0.0016464847
3146,CsA,9,10,34,37,"METHODS: For a period of 2 weeks, CsA 15 mg/kg/day (given orally), FK506 3.0 mg/kg/day (given orally) or SRL 0.4 mg/kg/day (given intraperitoneally) was administered once a day as these doses have earlier been found to achieve a significant immunosuppressive effect in Sprague-Dawley rats.",12584269_5,-1,-1,-1,3146,-1,0.9989497,0.0010503113
3147,FK506,17,18,67,72,"METHODS: For a period of 2 weeks, CsA 15 mg/kg/day (given orally), FK506 3.0 mg/kg/day (given orally) or SRL 0.4 mg/kg/day (given intraperitoneally) was administered once a day as these doses have earlier been found to achieve a significant immunosuppressive effect in Sprague-Dawley rats.",12584269_5,-1,-1,-1,3147,-1,0.999255,0.00074492994
3148,SRL,25,26,105,108,"METHODS: For a period of 2 weeks, CsA 15 mg/kg/day (given orally), FK506 3.0 mg/kg/day (given orally) or SRL 0.4 mg/kg/day (given intraperitoneally) was administered once a day as these doses have earlier been found to achieve a significant immunosuppressive effect in Sprague-Dawley rats.",12584269_5,-1,-1,-1,3148,-1,0.99864465,0.00135537
3152,CsA,2,3,9,12,"RESULTS: CsA, FK506 and SRL all significantly decreased the GFR.",12584269_8,-1,-1,-1,3152,-1,0.998607,0.001393095
3153,FK506,4,5,14,19,"RESULTS: CsA, FK506 and SRL all significantly decreased the GFR.",12584269_8,-1,-1,-1,3153,-1,0.9991406,0.0008593558
3154,SRL,6,7,24,27,"RESULTS: CsA, FK506 and SRL all significantly decreased the GFR.",12584269_8,-1,-1,-1,3154,-1,0.998262,0.0017380327
3155,CsA,6,7,38,41,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,-1,-1,-1,3155,-1,0.99894243,0.0010575469
3156,FK506,11,12,67,72,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,-1,-1,-1,3156,-1,0.9992575,0.0007424944
3157,SRL,13,14,76,79,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,-1,-1,-1,3157,-1,0.9984566,0.0015433539
3158,FK506,25,26,142,147,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,-1,-1,-1,3158,-1,0.99917346,0.0008265226
3159,SRL,27,28,153,156,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,-1,-1,-1,3159,-1,0.99836725,0.001632789
3160,CsA,11,12,80,83,The semi-quantitative scoring was significantly worst in the group treated with CsA plus SRL (P<0.001 compared with controls) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls (P<0.02).,12584269_11,-1,-1,-1,3160,-1,0.99886,0.0011400578
3161,SRL,13,14,89,92,The semi-quantitative scoring was significantly worst in the group treated with CsA plus SRL (P<0.001 compared with controls) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls (P<0.02).,12584269_11,-1,-1,-1,3161,-1,0.99822575,0.0017743146
3162,P<0.001,15,16,94,101,The semi-quantitative scoring was significantly worst in the group treated with CsA plus SRL (P<0.001 compared with controls) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls (P<0.02).,12584269_11,-1,-1,-1,3162,-1,0.37722167,0.6227783
3164,P<0.02,45,46,274,280,The semi-quantitative scoring was significantly worst in the group treated with CsA plus SRL (P<0.001 compared with controls) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls (P<0.02).,12584269_11,-1,-1,-1,3164,-1,0.43898475,0.56101525
3165,FK506,1,2,4,9,The FK506 plus SRL combination showed only a marginally higher degree of fibrosis as compared with controls (P=0.05).,12584269_12,-1,-1,-1,3165,-1,0.9991326,0.0008673931
3166,SRL,3,4,15,18,The FK506 plus SRL combination showed only a marginally higher degree of fibrosis as compared with controls (P=0.05).,12584269_12,-1,-1,-1,3166,-1,0.99841166,0.0015882811
3168,P=0.05,18,19,109,115,The FK506 plus SRL combination showed only a marginally higher degree of fibrosis as compared with controls (P=0.05).,12584269_12,-1,-1,-1,3168,-1,0.34636545,0.65363455
3170,CsA,11,12,76,79,"CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.",12584269_13,-1,-1,-1,3170,-1,0.9989956,0.0010044106
3171,SRL,13,14,85,88,"CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.",12584269_13,-1,-1,-1,3171,-1,0.9986388,0.0013611768
3172,FK506,16,17,98,103,"CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.",12584269_13,-1,-1,-1,3172,-1,0.999203,0.0007969551
3173,SRL,18,19,109,112,"CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.",12584269_13,-1,-1,-1,3173,-1,0.99849796,0.001502056
3174,troponin I,3,5,22,32,"Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings.",12589964_0,-1,-1,-1,3174,-1,0.995654,0.004346012
3177,myocardial cell injury,24,27,115,137,BACKGROUND: Cardiac troponins I (cTnI) and T (cTnT) have been shown to be highly sensitive and specific markers of myocardial cell injury.,12589964_1,-1,-1,-1,3177,-1,0.008172536,0.9918275
3181,cardiac disorders,38,40,239,256,"We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.",12589964_2,-1,-1,-1,3181,-1,0.0023756542,0.99762434
3182,DOX,9,10,54,57,"METHODS: Thirty-five Wistar rats were given 1.5 mg/kg DOX, i.v., weekly for up to 8 weeks for a total cumulative dose of 12 mg/kg BW.",12589964_3,-1,-1,-1,3182,-1,0.9988115,0.0011885676
3183,LV,11,12,80,82,"By using transthoracic echocardiography, anterior and posterior wall thickness, LV diameters and LV fractional shortening (FS) were measured in all rats before DOX or saline, and at weeks 6 and 9 after treatment in all surviving rats.",12589964_6,-1,-1,-1,3183,-1,0.15837656,0.8416234
3184,LV,14,15,97,99,"By using transthoracic echocardiography, anterior and posterior wall thickness, LV diameters and LV fractional shortening (FS) were measured in all rats before DOX or saline, and at weeks 6 and 9 after treatment in all surviving rats.",12589964_6,-1,-1,-1,3184,-1,0.24059774,0.7594023
3185,DOX,26,27,160,163,"By using transthoracic echocardiography, anterior and posterior wall thickness, LV diameters and LV fractional shortening (FS) were measured in all rats before DOX or saline, and at weeks 6 and 9 after treatment in all surviving rats.",12589964_6,-1,-1,-1,3185,-1,0.99879396,0.0012059875
3186,DOX,13,14,68,71,Histology was performed in DOX-rats at 6 and 9 weeks after the last DOX dose and in all controls.,12589964_7,-1,-1,-1,3186,-1,0.9984322,0.001567723
3187,DOX,5,6,25,28,RESULTS: Eighteen of the DOX rats died prematurely of general toxicity during the 9-week period.,12589964_8,-1,-1,-1,3187,-1,0.99784505,0.00215489
3189,DOX,24,25,131,134,"End-diastolic (ED) and end-systolic (ES) LV diameters/BW significantly increased, whereas LV FS was decreased after 9 weeks in the DOX group (p<0.001).",12589964_9,-1,-1,-1,3189,-1,0.9984628,0.0015372488
3190,p<0.001,27,28,142,149,"End-diastolic (ED) and end-systolic (ES) LV diameters/BW significantly increased, whereas LV FS was decreased after 9 weeks in the DOX group (p<0.001).",12589964_9,-1,-1,-1,3190,-1,0.3695638,0.6304362
3191,DOX,8,9,54,57,Histological evaluation of hearts from all rats given DOX revealed significant slight degrees of perivascular and interstitial fibrosis.,12589964_11,-1,-1,-1,3191,-1,0.99871254,0.0012874888
3192,interstitial fibrosis,16,18,114,135,Histological evaluation of hearts from all rats given DOX revealed significant slight degrees of perivascular and interstitial fibrosis.,12589964_11,-1,-1,-1,3192,-1,0.004412281,0.9955877
3194,DOX,8,9,40,43,A significant rise in cTnT was found in DOX rats after cumulative doses of 7.5 and 12 mg/kg in comparison with baseline (p<0.05).,12589964_14,-1,-1,-1,3194,-1,0.99855953,0.0014404819
3195,p<0.05,23,24,121,127,A significant rise in cTnT was found in DOX rats after cumulative doses of 7.5 and 12 mg/kg in comparison with baseline (p<0.05).,12589964_14,-1,-1,-1,3195,-1,0.37334907,0.626651
3196,DOX,16,17,93,96,cTnT found in rats after 12 mg/kg were significantly greater than that found after 7.5 mg/kg DOX.,12589964_15,-1,-1,-1,3196,-1,0.998803,0.0011969456
3197,DOX,12,13,69,72,"Maximal cTnI (pg/ml) and cTnT levels were significantly increased in DOX rats compared with controls (p=0.006, 0.007).",12589964_16,-1,-1,-1,3197,-1,0.9982982,0.0017018451
3198,p=0.006,18,19,102,109,"Maximal cTnI (pg/ml) and cTnT levels were significantly increased in DOX rats compared with controls (p=0.006, 0.007).",12589964_16,-1,-1,-1,3198,-1,0.49839845,0.5016015
3199,DOX,12,13,54,57,"cTnI (ng/ml), CK-MB mass and CK remained unchanged in DOX rats compared with controls.",12589964_17,-1,-1,-1,3199,-1,0.9980015,0.0019985067
3200,LV,14,15,87,89,Analysis of data revealed a significant correlation between maximal cTnT and ED and ES LV diameters/BW (r=0.81 and 0.65; p<0.0001).,12589964_19,-1,-1,-1,3200,-1,0.24545503,0.7545449
3201,p<0.0001,21,22,121,129,Analysis of data revealed a significant correlation between maximal cTnT and ED and ES LV diameters/BW (r=0.81 and 0.65; p<0.0001).,12589964_19,-1,-1,-1,3201,-1,0.519448,0.480552
3202,LV,18,19,125,127,"A significant relationship was observed between maximal cTnT and the extent of myocardial morphological changes, and between LV diameters/BW and histological findings.",12589964_20,-1,-1,-1,3202,-1,0.23036471,0.7696353
3203,ischemic injury,5,7,30,45,"CONCLUSIONS: Among markers of ischemic injury after DOX in rats, cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes.",12589964_21,-1,-1,-1,3203,-1,0.0029666654,0.99703336
3204,DOX,8,9,52,55,"CONCLUSIONS: Among markers of ischemic injury after DOX in rats, cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes.",12589964_21,-1,-1,-1,3204,-1,0.9986601,0.0013399018
3206,DOX,13,14,75,78,"Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments.",12589964_22,-1,-1,-1,3206,-1,0.99884075,0.0011592678
3207,DOX,38,39,209,212,"Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments.",12589964_22,-1,-1,-1,3207,-1,0.99871576,0.0012842225
3209,hypoxemia,1,2,19,28,Octreotide-induced hypoxemia and pulmonary hypertension in premature neonates.,12596116_0,-1,-1,-1,3209,-1,0.0023977272,0.9976023
3211,fistula,11,12,73,80,The authors report 2 cases of premature neonates who had enterocutaneous fistula complicating necrotizing enterocolitis.,12596116_1,-1,-1,-1,3211,-1,0.0028510115,0.99714905
3212,necrotizing enterocolitis,13,15,94,119,The authors report 2 cases of premature neonates who had enterocutaneous fistula complicating necrotizing enterocolitis.,12596116_1,-1,-1,-1,3212,-1,0.0031392602,0.99686074
3215,fistula,17,18,123,130,"Pulmonary hypertension developed after administration of a somatostatin analogue, octreotide, to enhance resolution of the fistula.",12596116_2,-1,-1,-1,3215,-1,0.0031463173,0.99685365
3216,edaravone,3,4,21,30,Protective effect of edaravone against streptomycin-induced vestibulotoxicity in the guinea pig.,12600698_0,-1,-1,-1,3216,-1,0.99915946,0.0008405585
3217,vestibulotoxicity,6,7,60,77,Protective effect of edaravone against streptomycin-induced vestibulotoxicity in the guinea pig.,12600698_0,-1,-1,-1,3217,-1,0.0031769022,0.9968231
3218,vestibulotoxicity,6,7,60,77,This study investigated alleviation of streptomycin-induced vestibulotoxicity by edaravone in guinea pigs.,12600698_1,-1,-1,-1,3218,-1,0.0026109717,0.997389
3219,edaravone,8,9,81,90,This study investigated alleviation of streptomycin-induced vestibulotoxicity by edaravone in guinea pigs.,12600698_1,-1,-1,-1,3219,-1,0.99913675,0.00086324656
3220,Edaravone,0,1,0,9,"Edaravone, a free radical scavenger, has potent free radical quenching action and is used in clinical practice to treat cerebral infarction.",12600698_2,-1,-1,-1,3220,-1,0.9991084,0.0008916462
3221,cerebral infarction,21,23,120,139,"Edaravone, a free radical scavenger, has potent free radical quenching action and is used in clinical practice to treat cerebral infarction.",12600698_2,-1,-1,-1,3221,-1,0.0021726305,0.99782735
3223,h,12,13,70,71,"Streptomycin was administered to the inner ear by osmotic pump for 24 h, and edaravone (n=8) or saline (n=6) was intraperitoneally injected once a day for 7 days.",12600698_3,-1,-1,-1,3223,-1,0.35838068,0.6416193
3224,edaravone,15,16,77,86,"Streptomycin was administered to the inner ear by osmotic pump for 24 h, and edaravone (n=8) or saline (n=6) was intraperitoneally injected once a day for 7 days.",12600698_3,-1,-1,-1,3224,-1,0.99881977,0.0011802275
3225,n=8,17,18,88,91,"Streptomycin was administered to the inner ear by osmotic pump for 24 h, and edaravone (n=8) or saline (n=6) was intraperitoneally injected once a day for 7 days.",12600698_3,-1,-1,-1,3225,-1,0.6781172,0.32188272
3226,n=6,22,23,104,107,"Streptomycin was administered to the inner ear by osmotic pump for 24 h, and edaravone (n=8) or saline (n=6) was intraperitoneally injected once a day for 7 days.",12600698_3,-1,-1,-1,3226,-1,0.6021177,0.3978823
3227,edaravone,12,13,89,98,Animals injected with saline showed statistically smaller gains than those injected with edaravone.,12600698_5,-1,-1,-1,3227,-1,0.9989648,0.0010352596
3228,edaravone,4,5,27,36,These results suggest that edaravone suppresses streptomycin-induced vestibulotoxicity.,12600698_6,-1,-1,-1,3228,-1,0.9991829,0.00081706385
3229,vestibulotoxicity,7,8,69,86,These results suggest that edaravone suppresses streptomycin-induced vestibulotoxicity.,12600698_6,-1,-1,-1,3229,-1,0.0028902409,0.99710983
3230,venous thromboembolism,3,5,12,34,The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.,12615818_0,-1,-1,-1,3230,-1,0.0024436906,0.9975563
3231,cyproterone acetate,8,10,55,74,The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.,12615818_0,-1,-1,-1,3231,-1,0.9990596,0.000940334
3232,ethinyl estradiol,13,15,95,112,The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.,12615818_0,-1,-1,-1,3232,-1,0.9986909,0.0013091493
3233,Cyproterone acetate,2,4,12,31,BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).,12615818_1,-1,-1,-1,3233,-1,0.9990079,0.0009921408
3234,ethinyl estradiol,6,8,46,63,BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).,12615818_1,-1,-1,-1,3234,-1,0.99897975,0.0010202257
3236,hirsutism,24,25,136,145,BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).,12615818_1,-1,-1,-1,3236,-1,0.004009379,0.9959906
3237,polycystic ovary syndrome,32,35,181,206,BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).,12615818_1,-1,-1,-1,3237,-1,0.0044095414,0.99559045
3238,PCOS,36,37,208,212,BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).,12615818_1,-1,-1,-1,3238,-1,0.0034256035,0.9965744
3239,venous thromboembolism,8,10,56,78,Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).,12615818_2,-1,-1,-1,3239,-1,0.002768088,0.9972319
3240,VTE,11,12,80,83,Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).,12615818_2,-1,-1,-1,3240,-1,0.0028003785,0.99719965
3241,combined oral contraceptives,19,22,135,163,Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).,12615818_2,-1,-1,-1,3241,-1,0.99606943,0.0039305864
3242,COCs,23,24,165,169,Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).,12615818_2,-1,-1,-1,3242,-1,0.99548244,0.0045176134
3244,hirsutism,31,32,184,193,"METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.",12615818_4,-1,-1,-1,3244,-1,0.06197507,0.93802494
3245,PCOS,33,34,197,201,"METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.",12615818_4,-1,-1,-1,3245,-1,0.015266053,0.984734
3246,VTE,39,40,226,229,"METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.",12615818_4,-1,-1,-1,3246,-1,0.0036863885,0.99631363
3247,COCs,11,12,78,82,RESULTS: The age-adjusted incidence rate ratio for CPA/EE versus conventional COCs was 2.20 [95% confidence interval (CI) 1.35-3.58].,12615818_5,-1,-1,-1,3247,-1,0.99549234,0.0045075887
3248,oral contraception,10,12,54,72,"Using as the reference group women who were not using oral contraception, had no recent pregnancy or menopausal symptoms, the case-control analysis gave an adjusted odds ratio (OR(adj)) of 7.44 (95% CI 3.67-15.08) for CPA/EE use compared with an OR(adj) of 2.58 (95% CI 1.60-4.18) for use of conventional COCs.",12615818_6,-1,-1,-1,3248,-1,0.99457175,0.00542821
3249,menopausal symptoms,18,20,101,120,"Using as the reference group women who were not using oral contraception, had no recent pregnancy or menopausal symptoms, the case-control analysis gave an adjusted odds ratio (OR(adj)) of 7.44 (95% CI 3.67-15.08) for CPA/EE use compared with an OR(adj) of 2.58 (95% CI 1.60-4.18) for use of conventional COCs.",12615818_6,-1,-1,-1,3249,-1,0.0050735003,0.99492645
3250,COCs,65,66,305,309,"Using as the reference group women who were not using oral contraception, had no recent pregnancy or menopausal symptoms, the case-control analysis gave an adjusted odds ratio (OR(adj)) of 7.44 (95% CI 3.67-15.08) for CPA/EE use compared with an OR(adj) of 2.58 (95% CI 1.60-4.18) for use of conventional COCs.",12615818_6,-1,-1,-1,3250,-1,0.9969394,0.0030606266
3251,VTE,9,10,55,58,"CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.",12615818_7,-1,-1,-1,3251,-1,0.0030190244,0.99698097
3253,hirsutism,21,22,113,122,"CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.",12615818_7,-1,-1,-1,3253,-1,0.034053024,0.965947
3254,PCOS,23,24,126,130,"CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.",12615818_7,-1,-1,-1,3254,-1,0.0070225205,0.99297744
3255,gum Arabic,5,7,29,39,The effect of treatment with gum Arabic on gentamicin nephrotoxicity in rats: a preliminary study.,12617329_0,-1,-1,-1,3255,-1,0.99770147,0.002298489
3256,gentamicin nephrotoxicity,8,10,43,68,The effect of treatment with gum Arabic on gentamicin nephrotoxicity in rats: a preliminary study.,12617329_0,-1,-1,-1,3256,-1,0.040488176,0.9595118
3257,gum Arabic,13,15,69,79,In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.,12617329_1,-1,-1,-1,3257,-1,0.99790573,0.002094233
3258,acute renal failure,16,19,83,102,In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.,12617329_1,-1,-1,-1,3258,-1,0.002318723,0.99768126
3260,GM,23,24,126,128,In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.,12617329_1,-1,-1,-1,3260,-1,0.9944271,0.005572934
3262,gum Arabic,22,24,95,105,"Rats were treated with the vehicle (2 mL/kg of distilled water and 5% w/v cellulose, 10 days), gum Arabic (2 mL/kg of a 10% w/v aqueous suspension of gum Arabic powder, orally for 10 days), or gum Arabic concomitantly with GM (80mg/kg/day intramuscularly, during the last six days of the treatment period).",12617329_2,-1,-1,-1,3262,-1,0.9978198,0.002180169
3263,gum Arabic,35,37,150,160,"Rats were treated with the vehicle (2 mL/kg of distilled water and 5% w/v cellulose, 10 days), gum Arabic (2 mL/kg of a 10% w/v aqueous suspension of gum Arabic powder, orally for 10 days), or gum Arabic concomitantly with GM (80mg/kg/day intramuscularly, during the last six days of the treatment period).",12617329_2,-1,-1,-1,3263,-1,0.99633574,0.003664224
3264,gum Arabic,46,48,193,203,"Rats were treated with the vehicle (2 mL/kg of distilled water and 5% w/v cellulose, 10 days), gum Arabic (2 mL/kg of a 10% w/v aqueous suspension of gum Arabic powder, orally for 10 days), or gum Arabic concomitantly with GM (80mg/kg/day intramuscularly, during the last six days of the treatment period).",12617329_2,-1,-1,-1,3264,-1,0.997168,0.0028320504
3265,GM,50,51,223,225,"Rats were treated with the vehicle (2 mL/kg of distilled water and 5% w/v cellulose, 10 days), gum Arabic (2 mL/kg of a 10% w/v aqueous suspension of gum Arabic powder, orally for 10 days), or gum Arabic concomitantly with GM (80mg/kg/day intramuscularly, during the last six days of the treatment period).",12617329_2,-1,-1,-1,3265,-1,0.9884675,0.0115324985
3269,reduced glutathione,15,17,101,120,"Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.",12617329_3,-1,-1,-1,3269,-1,0.99730444,0.0026955751
3270,GSH,18,19,122,125,"Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.",12617329_3,-1,-1,-1,3270,-1,0.99596256,0.004037464
3271,gum Arabic,7,9,54,64,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3271,-1,0.9978573,0.0021427148
3272,GM,10,11,69,71,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3272,-1,0.99724066,0.002759279
3275,GM,40,41,228,230,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3275,-1,0.9955448,0.004455172
3276,GSH,48,49,264,267,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3276,-1,0.98686534,0.013134715
3277,GM,61,62,314,316,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3277,-1,0.99151117,0.008488842
3279,GM,78,79,415,417,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3279,-1,0.9944964,0.0055035916
3280,gum Arabic,81,83,432,442,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3280,-1,0.9975903,0.0024097625
3281,GM,87,88,463,465,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,-1,-1,-1,3281,-1,0.99544394,0.0045560617
3282,gum Arabic,5,7,26,36,It could be inferred that gum Arabic treatment has induced a modest amelioration of some of the histological and biochemical indices of GM nephrotoxicity.,12617329_5,-1,-1,-1,3282,-1,0.9981864,0.0018135727
3283,GM nephrotoxicity,22,24,136,153,It could be inferred that gum Arabic treatment has induced a modest amelioration of some of the histological and biochemical indices of GM nephrotoxicity.,12617329_5,-1,-1,-1,3283,-1,0.021513807,0.9784862
3285,thromboembolism,4,5,30,45,Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.,12627929_0,-1,-1,-1,3285,-1,0.0025737798,0.9974262
3289,venous thromboembolism,8,10,46,68,STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.,12627929_1,-1,-1,-1,3289,-1,0.0032641818,0.99673575
3290,VTE,11,12,70,73,STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.,12627929_1,-1,-1,-1,3290,-1,0.0034598706,0.9965402
3297,mg,29,30,182,184,"INTERVENTION: Each patient received either intravenous docetaxel 30 mg/m2/week for 3 consecutive weeks, followed by 1 week off, or the combination of continuous oral thalidomide 200 mg every evening plus the same docetaxel regimen.",12627929_5,-1,-1,-1,3297,-1,0.9755452,0.02445473
3300,disease progression,13,15,81,100,This 4-week cycle was repeated until there was evidence of excessive toxicity or disease progression.,12627929_6,-1,-1,-1,3300,-1,0.0029358156,0.9970642
3302,VTE,14,15,90,93,"MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).",12627929_7,-1,-1,-1,3302,-1,0.0029267082,0.9970733
3305,VTE,31,32,176,179,"MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).",12627929_7,-1,-1,-1,3305,-1,0.0030028895,0.9969971
3306,p=0.025,33,34,181,188,"MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).",12627929_7,-1,-1,-1,3306,-1,0.38984877,0.61015123
3310,VTE,19,20,130,133,CONCLUSION: The addition of thalidomide to docetaxel in the treatment of prostate cancer significantly increases the frequency of VTE.,12627929_8,-1,-1,-1,3310,-1,0.003239272,0.9967608
3312,cholestatic hepatitis,1,3,20,41,Ticlopidine-induced cholestatic hepatitis.,12639165_0,-1,-1,-1,3312,-1,0.0038073147,0.9961927
3313,cholestatic hepatitis,8,10,52,73,"OBJECTIVE: To report 2 cases of ticlopidine-induced cholestatic hepatitis, investigate its mechanism, and compare the observed main characteristics with those of the published cases.",12639165_1,-1,-1,-1,3313,-1,0.0037299641,0.99627006
3314,cholestatic hepatitis,7,9,49,70,"CASE SUMMARIES: Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angioplasty, with complete remission during the follow-up period.",12639165_2,-1,-1,-1,3314,-1,0.008945599,0.9910545
3317,Cholestatic hepatitis,2,4,12,33,DISCUSSION: Cholestatic hepatitis is a rare complication of the antiplatelet agent ticlopidine; several cases have been reported but few in the English literature.,12639165_4,-1,-1,-1,3317,-1,0.003546657,0.9964534
3321,cholestatic hepatitis,16,18,127,148,"Our patients developed jaundice following treatment with ticlopidine and showed the clinical and laboratory characteristics of cholestatic hepatitis, which resolved after discontinuation of the drug.",12639165_5,-1,-1,-1,3321,-1,0.0040064706,0.9959935
3326,Cholestatic hepatitis,2,4,13,34,CONCLUSIONS: Cholestatic hepatitis is a rare adverse effect of ticlopidine that may be immune mediated.,12639165_10,-1,-1,-1,3326,-1,0.0040066214,0.9959934
3331,nephrotic syndrome,16,18,116,134,Epithelial sodium channel (ENaC) subunit mRNA and protein expression in rats with puromycin aminonucleoside-induced nephrotic syndrome.,12653683_0,-1,-1,-1,3331,-1,0.0021698817,0.9978301
3332,nephrotic syndrome,2,4,16,34,"In experimental nephrotic syndrome, urinary sodium excretion is decreased during the early phase of the disease.",12653683_1,-1,-1,-1,3332,-1,0.003159958,0.99684
3337,puromycin aminonucleoside,11,13,64,89,We examined the abundance of ENaC subunit mRNAs and proteins in puromycin aminonucleoside (PAN)-induced nephrotic syndrome.,12653683_4,-1,-1,-1,3337,-1,0.9983985,0.0016014598
3338,nephrotic syndrome,14,16,104,122,We examined the abundance of ENaC subunit mRNAs and proteins in puromycin aminonucleoside (PAN)-induced nephrotic syndrome.,12653683_4,-1,-1,-1,3338,-1,0.0021230248,0.997877
3342,PAN,26,27,173,176,"The time courses of urinary sodium excretion, plasma aldosterone concentration and proteinuria were studied in male Sprague-Dawley rats treated with a single dose of either PAN or vehicle.",12653683_5,-1,-1,-1,3342,-1,0.9988362,0.0011637548
3346,PAN,11,12,51,54,"Sodium retention occurred on days 2, 3 and 6 after PAN injection.",12653683_8,-1,-1,-1,3346,-1,0.99853206,0.0014679758
3351,nephrotic syndrome,23,25,137,155,"In conclusion, ENaC mRNA expression, especially alphaENaC, is increased in the very early phase of the experimental model of PAN-induced nephrotic syndrome in rats, but appears to escape from the regulation by aldosterone after day 3.",12653683_12,-1,-1,-1,3351,-1,0.0022742231,0.9977258
3353,GABA,4,5,33,37,Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine.,12684739_0,-1,-1,-1,3353,-1,0.998749,0.0012509582
3356,GABA,3,4,23,27,RATIONALE: gamma-Vinyl GABA (GVG) irreversibly inhibits GABA-transaminase.,12684739_1,-1,-1,-1,3356,-1,0.99858356,0.0014165059
3357,GVG,5,6,29,32,RATIONALE: gamma-Vinyl GABA (GVG) irreversibly inhibits GABA-transaminase.,12684739_1,-1,-1,-1,3357,-1,0.99767286,0.0023270836
3358,GABA-transaminase,9,10,56,73,RATIONALE: gamma-Vinyl GABA (GVG) irreversibly inhibits GABA-transaminase.,12684739_1,-1,-1,-1,3358,-1,0.9835466,0.016453423
3359,GABA,12,13,95,99,This non-receptor mediated inhibition requires de novo synthesis for restoration of functional GABA catabolism.,12684739_2,-1,-1,-1,3359,-1,0.99818355,0.0018164746
3360,substance abuse,8,10,55,70,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,-1,-1,-1,3360,-1,0.22985667,0.7701434
3362,VFD,19,20,119,122,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,-1,-1,-1,3362,-1,0.0041375426,0.9958625
3363,GVG,35,36,218,221,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,-1,-1,-1,3363,-1,0.99714535,0.0028546685
3365,DA,47,48,289,291,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,-1,-1,-1,3365,-1,0.99725515,0.0027449138
3366,GVG,3,4,21,24,"RESULTS: Sub-chronic GVG exposure inhibited the effect of cocaine for 3 days, which exceeded in magnitude and duration the identical acute dose.",12684739_6,-1,-1,-1,3366,-1,0.9983846,0.0016154452
3368,GVG,5,6,34,37,"CONCLUSIONS: Sub-chronic low dose GVG potentiates and extends the inhibition of cocaine-induced increases in dopamine, effectively reducing cumulative exposures and the risk for VFDS.",12684739_7,-1,-1,-1,3368,-1,0.9984528,0.0015471913
3370,VFDS,25,26,178,182,"CONCLUSIONS: Sub-chronic low dose GVG potentiates and extends the inhibition of cocaine-induced increases in dopamine, effectively reducing cumulative exposures and the risk for VFDS.",12684739_7,-1,-1,-1,3370,-1,0.0035682262,0.9964317
3371,oromandibular dystonia,1,3,17,39,Levodopa-induced oromandibular dystonia in progressive supranuclear palsy.,12691807_0,-1,-1,-1,3371,-1,0.017658638,0.9823414
3372,progressive supranuclear palsy,4,7,43,73,Levodopa-induced oromandibular dystonia in progressive supranuclear palsy.,12691807_0,-1,-1,-1,3372,-1,0.0048411693,0.99515885
3374,Parkinson's disease,6,9,51,70,Levodopa-induced dyskinesias have been reported in Parkinson's disease and multiple system atrophy.,12691807_1,-1,-1,-1,3374,-1,0.0046725078,0.9953275
3376,dystonias,1,2,8,17,Cranial dystonias are rare in patients with progressive supranuclear palsy (PSP).,12691807_2,-1,-1,-1,3376,-1,0.0029667811,0.99703324
3377,progressive supranuclear palsy,7,10,44,74,Cranial dystonias are rare in patients with progressive supranuclear palsy (PSP).,12691807_2,-1,-1,-1,3377,-1,0.006095603,0.9939044
3378,PSP,11,12,76,79,Cranial dystonias are rare in patients with progressive supranuclear palsy (PSP).,12691807_2,-1,-1,-1,3378,-1,0.0039060868,0.9960939
3379,Oromandibular dystonia,11,13,74,96,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,-1,-1,-1,3379,-1,0.0075518256,0.9924482
3380,OMD,14,15,98,101,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,-1,-1,-1,3380,-1,0.008232259,0.99176776
3381,PSP,18,19,108,111,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,-1,-1,-1,3381,-1,0.0045811124,0.9954189
3382,PSP,34,35,215,218,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,-1,-1,-1,3382,-1,0.0035821877,0.99641776
3383,MR,0,1,0,2,MR imaging with quantitative diffusion mapping of tacrolimus-induced neurotoxicity in organ transplant patients.,12695819_0,-1,-1,-1,3383,-1,0.74890256,0.25109747
3385,MR,6,7,39,41,Our objective was to investigate brain MR imaging findings and the utility of diffusion-weighted (DW) imaging in organ transplant patients who developed neurologic symptoms during tacrolimus therapy.,12695819_1,-1,-1,-1,3385,-1,0.7466729,0.2533271
3387,MR,1,2,6,8,"Brain MR studies, including DW imaging, were prospectively performed in 14 organ transplant patients receiving tacrolimus who developed neurologic complications.",12695819_2,-1,-1,-1,3387,-1,0.3446434,0.65535665
3389,neurologic complications,20,22,136,160,"Brain MR studies, including DW imaging, were prospectively performed in 14 organ transplant patients receiving tacrolimus who developed neurologic complications.",12695819_2,-1,-1,-1,3389,-1,0.0021226357,0.99787736
3390,MR,9,10,53,55,"In each patient who had abnormalities on the initial MR study, a follow-up MR study was performed 1 month later.",12695819_3,-1,-1,-1,3390,-1,0.30974445,0.6902555
3391,MR,14,15,75,77,"In each patient who had abnormalities on the initial MR study, a follow-up MR study was performed 1 month later.",12695819_3,-1,-1,-1,3391,-1,0.24034457,0.7596555
3392,MR,10,11,59,61,Apparent diffusion coefficient (ADC) values on the initial MR study were correlated with reversibility of the lesions.,12695819_4,-1,-1,-1,3392,-1,0.6360023,0.3639977
3393,white matter abnormalities,11,14,34,60,"Of the 14 patients, 5 (35.7%) had white matter abnormalities, 1 (7.1%) had putaminal hemorrhage, and 8 (57.1%) had normal findings on initial MR images.",12695819_5,-1,-1,-1,3393,-1,0.0102052,0.9897948
3394,putaminal hemorrhage,21,23,75,95,"Of the 14 patients, 5 (35.7%) had white matter abnormalities, 1 (7.1%) had putaminal hemorrhage, and 8 (57.1%) had normal findings on initial MR images.",12695819_5,-1,-1,-1,3394,-1,0.6800117,0.3199883
3395,MR,35,36,142,144,"Of the 14 patients, 5 (35.7%) had white matter abnormalities, 1 (7.1%) had putaminal hemorrhage, and 8 (57.1%) had normal findings on initial MR images.",12695819_5,-1,-1,-1,3395,-1,0.50802946,0.49197057
3396,white matter abnormalities,5,8,26,52,"Among the 5 patients with white matter abnormalities, 4 patients (80.0%) showed higher than normal ADC values on initial MR images, and all showed complete resolution on follow-up images.",12695819_6,-1,-1,-1,3396,-1,0.010036191,0.9899638
3397,MR,23,24,121,123,"Among the 5 patients with white matter abnormalities, 4 patients (80.0%) showed higher than normal ADC values on initial MR images, and all showed complete resolution on follow-up images.",12695819_6,-1,-1,-1,3397,-1,0.7011907,0.29880932
3398,cortical laminar necrosis,19,22,105,130,The remaining 1 patient (20.0%) showed lower than normal ADC value and showed incomplete resolution with cortical laminar necrosis.,12695819_7,-1,-1,-1,3398,-1,0.013014695,0.98698527
3399,tacrolimus-induced,13,14,86,104,Diffusion-weighted imaging may be useful in predicting the outcomes of the lesions of tacrolimus-induced neurotoxicity.,12695819_8,-1,-1,-1,3399,-1,0.75507665,0.24492334
3404,mg,4,5,27,29,Hydrocortisone acetate (50 mg) was given orally every 6 hours for 24 hours after a 5-day fixed-salt diet (150 mmol/d).,12707296_4,-1,-1,-1,3404,-1,0.96159846,0.038401574
3405,C.,30,31,182,184,"L-arginine uptake was assessed in mononuclear cells incubated with L-arginine (1 to 300 micromol/L), incorporating 100 nmol/L [3H]-l-arginine for a period of 5 minutes at 37 degrees C. Forearm [3H]-L-arginine extraction was calculated after infusion of [3H]-L-arginine into the brachial artery at a rate of 100 nCi/min for 80 minutes.",12707296_7,-1,-1,-1,3405,-1,0.9050909,0.09490913
3407,P<0.05,16,17,113,119,"Plasma cortisol concentrations were significantly raised during the active phase (323+/-43 to 1082+/-245 mmol/L, P<0.05).",12707296_9,-1,-1,-1,3407,-1,0.43006253,0.5699375
3408,mm Hg,10,12,56,61,Systolic blood pressure was elevated by an average of 7 mm Hg.,12707296_10,-1,-1,-1,3408,-1,0.22320013,0.77679986
3410,ie,65,66,377,379,"Neither L-arginine transport into mononuclear cells (placebo vs active, 26.3+/-3.6 vs 29.0+/-2.1 pmol/10 000 cells per 5 minutes, respectively, at an l-arginine concentration of 300 micromol/L) nor L-arginine extraction in the forearm (at 80 minutes, placebo vs active, 1 868 904+/-434 962 vs 2 013 910+/-770 619 disintegrations per minute) was affected by cortisol treatment; ie, that L-arginine uptake is not affected by short-term cortisol treatment.",12707296_11,-1,-1,-1,3410,-1,0.50450927,0.49549076
3412,increases in blood pressure,4,8,34,61,We conclude that cortisol-induced increases in blood pressure are not associated with abnormalities in the l-arginine transport system.,12707296_12,-1,-1,-1,3412,-1,0.00943712,0.9905629
3415,intracerebral hemorrhage,9,11,64,88,Amount of bleeding and hematoma size in the collagenase-induced intracerebral hemorrhage rat model.,12716030_0,-1,-1,-1,3415,-1,0.002882931,0.99711704
3416,intracerebral hemorrhage,4,6,23,47,The aggravated risk on intracerebral hemorrhage (ICH) with drugs used for stroke patients should be estimated carefully.,12716030_1,-1,-1,-1,3416,-1,0.0026405398,0.99735945
3417,ICH,7,8,49,52,The aggravated risk on intracerebral hemorrhage (ICH) with drugs used for stroke patients should be estimated carefully.,12716030_1,-1,-1,-1,3417,-1,0.0029939276,0.9970061
3419,ICH,10,11,77,80,We therefore established sensitive quantification methods and provided a rat ICH model for detection of ICH deterioration.,12716030_2,-1,-1,-1,3419,-1,0.0029103735,0.9970897
3420,ICH,15,16,104,107,We therefore established sensitive quantification methods and provided a rat ICH model for detection of ICH deterioration.,12716030_2,-1,-1,-1,3420,-1,0.0029421188,0.9970579
3421,ICH,1,2,3,6,"In ICH intrastriatally induced by 0.014-unit, 0.070-unit, and 0.350-unit collagenase, the amount of bleeding was measured using a hemoglobin assay developed in the present study and was compared with the morphologically determined hematoma volume.",12716030_3,-1,-1,-1,3421,-1,0.003443573,0.9965564
3426,ICH,21,22,144,147,"The blood amounts and hematoma volumes were significantly correlated, and the hematoma induced by 0.014-unit collagenase was adequate to detect ICH deterioration.",12716030_4,-1,-1,-1,3426,-1,0.0031120174,0.996888
3427,ICH,1,2,3,6,"In ICH induction using 0.014-unit collagenase, heparin enhanced the hematoma volume 3.4-fold over that seen in control ICH animals and the bleeding 7.6-fold.",12716030_5,-1,-1,-1,3427,-1,0.0035096616,0.9964903
3430,ICH,18,19,119,122,"In ICH induction using 0.014-unit collagenase, heparin enhanced the hematoma volume 3.4-fold over that seen in control ICH animals and the bleeding 7.6-fold.",12716030_5,-1,-1,-1,3430,-1,0.00428389,0.99571615
3432,ICH,10,11,64,67,"Data suggest that this sensitive hemoglobin assay is useful for ICH detection, and that a model with a small ICH induced with a low-dose collagenase should be used for evaluation of drugs that may affect ICH.",12716030_6,-1,-1,-1,3432,-1,0.003054908,0.9969451
3433,ICH,20,21,109,112,"Data suggest that this sensitive hemoglobin assay is useful for ICH detection, and that a model with a small ICH induced with a low-dose collagenase should be used for evaluation of drugs that may affect ICH.",12716030_6,-1,-1,-1,3433,-1,0.002539702,0.99746025
3434,ICH,36,37,204,207,"Data suggest that this sensitive hemoglobin assay is useful for ICH detection, and that a model with a small ICH induced with a low-dose collagenase should be used for evaluation of drugs that may affect ICH.",12716030_6,-1,-1,-1,3434,-1,0.0025013895,0.9974986
3435,Dexatrim,3,4,13,21,Case report: Dexatrim (Phenylpropanolamine) as a cause of myocardial infarction.,12734532_0,-1,-1,-1,3435,-1,0.999305,0.0006949721
3436,Phenylpropanolamine,5,6,23,42,Case report: Dexatrim (Phenylpropanolamine) as a cause of myocardial infarction.,12734532_0,-1,-1,-1,3436,-1,0.998722,0.001277952
3437,myocardial infarction,11,13,58,79,Case report: Dexatrim (Phenylpropanolamine) as a cause of myocardial infarction.,12734532_0,-1,-1,-1,3437,-1,0.0022894288,0.9977106
3438,Phenylpropanolamine,0,1,0,19,Phenylpropanolamine (PPA) is a sympathetic amine used in over-the-counter cold remedies and weight-control preparations worldwide.,12734532_1,-1,-1,-1,3438,-1,0.99890065,0.0010993205
3439,PPA,2,3,21,24,Phenylpropanolamine (PPA) is a sympathetic amine used in over-the-counter cold remedies and weight-control preparations worldwide.,12734532_1,-1,-1,-1,3439,-1,0.99644744,0.0035525498
3440,amine,7,8,43,48,Phenylpropanolamine (PPA) is a sympathetic amine used in over-the-counter cold remedies and weight-control preparations worldwide.,12734532_1,-1,-1,-1,3440,-1,0.994863,0.0051370133
3442,hemorrhagic strokes,9,11,59,78,Its use has been associated with hypertensive episodes and hemorrhagic strokes in younger women.,12734532_2,-1,-1,-1,3442,-1,0.0022978112,0.9977022
3443,PPA,7,8,41,44,"Several reports have linked the abuse of PPA with myocardial injury, especially when overdose is involved.",12734532_3,-1,-1,-1,3443,-1,0.99857557,0.0014243827
3446,Dexatrim,7,8,33,41,We report here the first case of Dexatrim (PPA)-induced myocardial injury in a young woman who was using it at recommended doses for weight control.,12734532_4,-1,-1,-1,3446,-1,0.99938655,0.00061342976
3448,PPA,10,11,44,47,"In addition, we review the 7 other cases of PPA related myocardial injury that have been reported so far.",12734532_5,-1,-1,-1,3448,-1,0.9966973,0.0033026668
3450,PPA,16,17,97,100,"Physicians and patients should be alert to the potential cardiac risk associated with the use of PPA, even at doses generally considered to be safe.",12734532_6,-1,-1,-1,3450,-1,0.99856734,0.0014326089
3451,creatine kinase,5,7,37,52,Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus.,12739036_0,-1,-1,-1,3451,-1,0.99826753,0.001732492
3452,systemic lupus erythematosus,9,12,63,91,Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus.,12739036_0,-1,-1,-1,3452,-1,0.0054163192,0.99458367
3454,systemic lupus erythematosus,8,11,40,68,"Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.",12739036_2,-1,-1,-1,3454,-1,0.0033192583,0.9966807
3455,SLE,12,13,70,73,"Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.",12739036_2,-1,-1,-1,3455,-1,0.0038265404,0.99617344
3456,renal involvement,15,17,80,97,"Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.",12739036_2,-1,-1,-1,3456,-1,0.0027543223,0.99724567
3460,CQ,5,6,37,39,Additional therapy with chloroquine (CQ) was started because of arthralgia.,12739036_3,-1,-1,-1,3460,-1,0.99773955,0.0022604107
3461,arthralgia,11,12,64,74,Additional therapy with chloroquine (CQ) was started because of arthralgia.,12739036_3,-1,-1,-1,3461,-1,0.0021612337,0.9978388
3462,creatine kinase,7,9,37,52,"At the same time, slightly increased creatine kinase (CK) levels were noted.",12739036_4,-1,-1,-1,3462,-1,0.99717665,0.0028233267
3463,Myositis,0,1,0,8,"Myositis was suspected, and the patient was treated with steroids.",12739036_5,-1,-1,-1,3463,-1,0.0025698892,0.99743015
3465,muscular weakness,11,13,66,83,"The CK increase persisted, however, and she developed progressive muscular weakness and muscular atrophy.",12739036_6,-1,-1,-1,3465,-1,0.002855893,0.99714404
3466,muscular atrophy,14,16,88,104,"The CK increase persisted, however, and she developed progressive muscular weakness and muscular atrophy.",12739036_6,-1,-1,-1,3466,-1,0.0028226005,0.99717736
3467,myositis,9,10,71,79,The neurological and electrophysiological findings were not typical of myositis.,12739036_8,-1,-1,-1,3467,-1,0.0026939602,0.997306
3468,polymyositis,14,15,76,88,"Thus, muscle biopsy of the deltoid muscle was performed in order to exclude polymyositis or toxic myopathy.",12739036_9,-1,-1,-1,3468,-1,0.0035518776,0.99644804
3471,affection of the musculoskeletal system,4,9,43,82,Discriminating between primary SLE-induced affection of the musculoskeletal system and drug-induced side effects is important for appropriate treatment of SLE patients.,12739036_11,-1,-1,-1,3471,-1,0.00788373,0.9921163
3472,SLE,19,20,155,158,Discriminating between primary SLE-induced affection of the musculoskeletal system and drug-induced side effects is important for appropriate treatment of SLE patients.,12739036_11,-1,-1,-1,3472,-1,0.0091342125,0.99086577
3473,sleep deprivation,3,5,24,41,Seizure associated with sleep deprivation and sustained-release bupropion.,12745515_0,-1,-1,-1,3473,-1,0.1712416,0.8287584
3477,sleep deprivation,13,15,101,118,This case report describes a generalized seizure associated with sustained-release bupropion use and sleep deprivation.,12745515_1,-1,-1,-1,3477,-1,0.23363629,0.76636374
3481,clonic seizure,13,15,76,90,"After 5 weeks of bupropion use, the subject experienced a generalized tonic clonic seizure after staying up nearly all night packing and moving to a new residence.",12745515_3,-1,-1,-1,3481,-1,0.0047773034,0.99522275
3483,sleep deprivation,3,5,16,33,We suggest that sleep deprivation may add to the risk of bupropion-associated seizures.,12745515_5,-1,-1,-1,3483,-1,0.82089895,0.17910103
3486,hippocampal injury,3,5,34,52,Estradiol reduces seizure-induced hippocampal injury in ovariectomized female but not in male rats.,12757899_0,-1,-1,-1,3486,-1,0.0032698808,0.9967301
3487,Estrogens,0,1,0,9,Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE).,12757899_1,-1,-1,-1,3487,-1,0.9962669,0.0037331155
3488,hippocampal injury,5,7,43,61,Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE).,12757899_1,-1,-1,-1,3488,-1,0.0036963425,0.9963037
3489,status epilepticus,11,13,93,111,Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE).,12757899_1,-1,-1,-1,3489,-1,0.0039116507,0.9960884
3490,SE,14,15,113,115,Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE).,12757899_1,-1,-1,-1,3490,-1,0.012642324,0.98735774
3491,SE,16,17,130,132,We compared the effects of 17beta-estradiol in adult male and ovariectomized female rats subjected to lithium-pilocarpine-induced SE.,12757899_2,-1,-1,-1,3491,-1,0.011759104,0.9882409
3492,oil,11,12,76,79,Rats received subcutaneous injections of 17beta-estradiol (2 microg/rat) or oil once daily for four consecutive days.,12757899_3,-1,-1,-1,3492,-1,0.9977235,0.0022765128
3493,SE,0,1,0,2,SE was induced 20 h following the second injection and terminated 3 h later.,12757899_4,-1,-1,-1,3493,-1,0.99751866,0.0024813772
3494,h,4,5,18,19,SE was induced 20 h following the second injection and terminated 3 h later.,12757899_4,-1,-1,-1,3494,-1,0.12207547,0.8779245
3495,h,12,13,68,69,SE was induced 20 h following the second injection and terminated 3 h later.,12757899_4,-1,-1,-1,3495,-1,0.09857477,0.9014252
3496,SE,14,15,88,90,The extent of silver-stained CA3 and CA1 hippocampal neurons was evaluated 2 days after SE.,12757899_5,-1,-1,-1,3496,-1,0.9853496,0.014650474
3503,postoperative myalgia,8,10,56,77,A common side effect associated with succinylcholine is postoperative myalgia.,12760988_1,-1,-1,-1,3503,-1,0.003016479,0.99698347
3509,n,20,21,159,160,The incidence and severity of succinylcholine-associated myalgia was determined in 64 patients pretreated with saline or dexamethasone before succinylcholine (n = 32 for each).,12760988_4,-1,-1,-1,3509,-1,0.3795946,0.6204054
3514,h,2,3,6,7,"At 48 h after surgery, 12 patients in both groups still suffered from myalgia (not significant).",12760988_6,-1,-1,-1,3514,-1,0.18018442,0.8198156
3522,postoperative myalgia,19,21,158,179,IMPLICATIONS: Administration of dexamethasone before succinylcholine was not effective in decreasing the incidence or the severity of succinylcholine-induced postoperative myalgia.,12760988_10,-1,-1,-1,3522,-1,0.0024610444,0.9975389
3526,minoxidil,7,8,49,58,Pseudoacromegaly induced by the long-term use of minoxidil.,12789195_0,-1,-1,-1,3526,-1,0.9992982,0.00070179417
3527,endocrine disorder,3,5,17,35,Acromegaly is an endocrine disorder caused by chronic excessive growth hormone secretion from the anterior pituitary gland.,12789195_1,-1,-1,-1,3527,-1,0.003319757,0.99668026
3528,growth hormone,9,11,64,78,Acromegaly is an endocrine disorder caused by chronic excessive growth hormone secretion from the anterior pituitary gland.,12789195_1,-1,-1,-1,3528,-1,0.9881124,0.011887602
3530,cutis verticis gyrata,30,33,172,193,"Significant disfiguring changes occur as a result of bone, cartilage, and soft tissue hypertrophy, including the thickening of the skin, coarsening of facial features, and cutis verticis gyrata.",12789195_2,-1,-1,-1,3530,-1,0.078278385,0.92172164
3531,Pseudoacromegaly,0,1,0,16,"Pseudoacromegaly, on the other hand, is the presence of similar acromegaloid features in the absence of elevated growth hormone or insulin-like growth factor levels.",12789195_3,-1,-1,-1,3531,-1,0.0034945318,0.9965055
3532,growth hormone,19,21,113,127,"Pseudoacromegaly, on the other hand, is the presence of similar acromegaloid features in the absence of elevated growth hormone or insulin-like growth factor levels.",12789195_3,-1,-1,-1,3532,-1,0.98894006,0.011059913
3533,pseudoacromegaly,5,6,26,42,We present a patient with pseudoacromegaly that resulted from the long-term use of minoxidil at an unusually high dose.,12789195_4,-1,-1,-1,3533,-1,0.0025835447,0.9974165
3534,minoxidil,13,14,83,92,We present a patient with pseudoacromegaly that resulted from the long-term use of minoxidil at an unusually high dose.,12789195_4,-1,-1,-1,3534,-1,0.99942505,0.00057491765
3535,pseudoacromegaly,7,8,33,49,This is the first case report of pseudoacromegaly as a side effect of minoxidil use.,12789195_5,-1,-1,-1,3535,-1,0.002927535,0.99707246
3536,minoxidil,13,14,70,79,This is the first case report of pseudoacromegaly as a side effect of minoxidil use.,12789195_5,-1,-1,-1,3536,-1,0.99936765,0.00063238695
3537,androgen,1,2,9,17,Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement.,12820454_0,-1,-1,-1,3537,-1,0.99650973,0.0034902554
3540,androgen,10,11,58,66,BACKGROUND: To determine the onset and extent of combined androgen blockade (CAB)-induced anemia in prostate cancer patients without bone involvement.,12820454_1,-1,-1,-1,3540,-1,0.9968472,0.0031527516
3543,prostatic adenocarcinoma,8,10,60,84,PATIENTS AND METHODS: Forty-two patients with biopsy-proven prostatic adenocarcinoma [26 with stage C (T3N0M0) and 16 with stage D1 (T3N1M0)] were included in this study.,12820454_2,-1,-1,-1,3543,-1,0.0065595396,0.99344045
3544,C,14,15,100,101,PATIENTS AND METHODS: Forty-two patients with biopsy-proven prostatic adenocarcinoma [26 with stage C (T3N0M0) and 16 with stage D1 (T3N1M0)] were included in this study.,12820454_2,-1,-1,-1,3544,-1,0.2173523,0.7826477
3545,leuprolide acetate,5,7,27,45,"All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).",12820454_3,-1,-1,-1,3545,-1,0.99900097,0.0009990752
3546,mg,11,12,60,62,"All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).",12820454_3,-1,-1,-1,3546,-1,0.96768326,0.032316707
3547,mg flutamide,20,22,104,116,"All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).",12820454_3,-1,-1,-1,3547,-1,0.9971716,0.0028284693
3553,SE,24,25,100,102,"At six months post-CAB, patients with severe anemia had a Hb mean value of 10.2 +/- 0.1 g/dl (X +/- SE), whereas the other patients had mild anemia with Hb mean value of 13.2 +/- 0.17 (X +/- SE).",12820454_10,-1,-1,-1,3553,-1,0.38016978,0.61983025
3555,SE,47,48,191,193,"At six months post-CAB, patients with severe anemia had a Hb mean value of 10.2 +/- 0.1 g/dl (X +/- SE), whereas the other patients had mild anemia with Hb mean value of 13.2 +/- 0.17 (X +/- SE).",12820454_10,-1,-1,-1,3555,-1,0.29382667,0.70617336
3557,p,29,30,153,154,The development of severe anemia at 6 months post-CAB was predictable by the reduction of Hb baseline value of more than 2.5 g/dl after 3 months of CAB (p = 0.01).,12820454_11,-1,-1,-1,3557,-1,0.30790257,0.6920974
3560,C,50,51,221,222,"The development of severe CAB-induced anemia in prostate cancer patients did not correlate with T baseline values (T < 3 ng/ml versus T > or = 3 ng/ml), with age (< 76 yrs versus > or = 76 yrs), and clinical stage (stage C versus stage D1).",12820454_12,-1,-1,-1,3560,-1,0.12075636,0.8792437
3568,body weight,14,16,57,68,"Oral administration of lindane (2.5, 5, 10 and 15 mg/kg, body weight) for 5 days was found to produce a dose-dependent increase in the activity of P450 dependent 7-ethoxyresorufin-O-deethylase (EROD), 7-pentoxyresorufin-O-dealkylase (PROD) and N-nitrosodimethylamine demethylase (NDMA-d) in rat brain and liver.",12842176_1,-1,-1,-1,3568,-1,0.5096539,0.49034604
3570,3-methylcholanthrene,9,10,64,84,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,-1,-1,-1,3570,-1,0.99829465,0.001705415
3571,MC,11,12,86,88,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,-1,-1,-1,3571,-1,0.9975764,0.0024236317
3572,did,19,20,118,121,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,-1,-1,-1,3572,-1,0.17328387,0.8267162
3576,PB,37,38,239,241,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,-1,-1,-1,3576,-1,0.99741036,0.002589703
3581,cobalt chloride,11,13,71,86,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,-1,-1,-1,3581,-1,0.998804,0.0011960703
3585,se,27,28,186,188,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,-1,-1,-1,3585,-1,0.9934337,0.0065663178
3586,PB,33,34,218,220,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,-1,-1,-1,3586,-1,0.998114,0.0018860687
3589,thromboembolism,6,7,41,56,Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol.,12851669_0,-1,-1,-1,3589,-1,0.0026199066,0.9973801
3590,cyproterone acetate,11,13,78,97,Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol.,12851669_0,-1,-1,-1,3590,-1,0.99892384,0.0010760982
3591,ethinylestradiol,14,15,102,118,Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol.,12851669_0,-1,-1,-1,3591,-1,0.9989963,0.001003685
3592,venous thromboembolism,8,10,49,71,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,-1,-1,-1,3592,-1,0.0030234281,0.9969766
3593,VTE,11,12,73,76,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,-1,-1,-1,3593,-1,0.0030133375,0.9969867
3594,cyproterone acetate,16,18,93,112,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,-1,-1,-1,3594,-1,0.9989058,0.0010942479
3595,ethinylestradiol,19,20,118,134,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,-1,-1,-1,3595,-1,0.99903727,0.00096272054
3596,combined oral contraceptives,28,31,164,192,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,-1,-1,-1,3596,-1,0.9861309,0.013869106
3597,COCs,32,33,194,198,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,-1,-1,-1,3597,-1,0.9862738,0.013726225
3598,VTE,36,37,168,171,"METHODS: From the Danish National Register of Patients (NRP), 1996 to 1998, the records of 1.1 million Danish women, ages 15 to 44 years, were searched for evidence of VTE.",12851669_2,-1,-1,-1,3598,-1,0.0055616456,0.9944384
3599,COC,0,1,0,3,COC use was ascertained through mailed questionnaires.,12851669_3,-1,-1,-1,3599,-1,0.9984718,0.0015281365
3600,COCs,3,4,20,24,Sales statistics of COCs and CPA/EE were provided through Danish Drug Statistics.,12851669_4,-1,-1,-1,3600,-1,0.997895,0.002104992
3601,VTE,17,18,78,81,"RESULTS: During the time frame of the study, 330 women were found to have had VTE while on COCs.",12851669_5,-1,-1,-1,3601,-1,0.0044357483,0.9955642
3602,COCs,20,21,91,95,"RESULTS: During the time frame of the study, 330 women were found to have had VTE while on COCs.",12851669_5,-1,-1,-1,3602,-1,0.99781287,0.002187064
3603,COCs,8,9,53,57,"Of these women, 67 were on levonorgestrel-containing COCs.",12851669_6,-1,-1,-1,3603,-1,0.99700636,0.0029936815
3604,VTE,5,6,35,38,"The corresponding absolute risk of VTE was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE.",12851669_8,-1,-1,-1,3604,-1,0.0032076384,0.9967924
3605,COCs,24,25,106,110,"The corresponding absolute risk of VTE was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE.",12851669_8,-1,-1,-1,3605,-1,0.9944431,0.0055568637
3606,COCs,43,44,197,201,"The corresponding absolute risk of VTE was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE.",12851669_8,-1,-1,-1,3606,-1,0.98979,0.010209922
3607,VTE,9,10,53,56,CONCLUSION: Our results suggest the absolute risk of VTE among Danish women on COCs is similar to that among women taking CPA/EE.,12851669_9,-1,-1,-1,3607,-1,0.003377235,0.9966228
3608,COCs,14,15,79,83,CONCLUSION: Our results suggest the absolute risk of VTE among Danish women on COCs is similar to that among women taking CPA/EE.,12851669_9,-1,-1,-1,3608,-1,0.99783957,0.002160368
3611,NSAIDs,11,12,81,87,BACKGROUND: Analysis of the literature for nonsteroidal anti-inflammatory drugs (NSAIDs) suggests that a low incidence of developmental anomalies occurs in rats given NSAIDs on specific days during organogenesis.,12852481_1,-1,-1,-1,3611,-1,0.9983956,0.0016043413
3612,developmental anomalies,19,21,122,145,BACKGROUND: Analysis of the literature for nonsteroidal anti-inflammatory drugs (NSAIDs) suggests that a low incidence of developmental anomalies occurs in rats given NSAIDs on specific days during organogenesis.,12852481_1,-1,-1,-1,3612,-1,0.0050792783,0.9949207
3613,NSAIDs,25,26,167,173,BACKGROUND: Analysis of the literature for nonsteroidal anti-inflammatory drugs (NSAIDs) suggests that a low incidence of developmental anomalies occurs in rats given NSAIDs on specific days during organogenesis.,12852481_1,-1,-1,-1,3613,-1,0.9986141,0.001385889
3616,ASA,5,6,31,34,"Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.",12852481_2,-1,-1,-1,3616,-1,0.9976489,0.0023510843
3617,developmental anomalies,18,20,96,119,"Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.",12852481_2,-1,-1,-1,3617,-1,0.0037551553,0.99624485
3618,CA,39,40,198,200,"Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.",12852481_2,-1,-1,-1,3618,-1,0.45797753,0.5420224
3619,ASA,4,5,23,26,There are no published ASA studies using the multiple dosing paradigm of GDs 6 to 17.,12852481_4,-1,-1,-1,3619,-1,0.9929461,0.0070538986
3620,SD,12,13,80,82,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,-1,-1,3620,-1,0.08280346,0.9171965
3621,ASA,18,19,108,111,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,-1,-1,3621,-1,0.99872357,0.0012763912
3622,SD,43,44,247,249,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,-1,-1,3622,-1,0.07482975,0.9251703
3623,gastrointestinal toxicity,53,55,297,322,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,-1,-1,3623,-1,0.0035292776,0.9964707
3624,malformations,61,62,364,377,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,-1,-1,3624,-1,0.002720671,0.99727935
3625,ASA,63,64,383,386,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,-1,-1,-1,3625,-1,0.99851376,0.0014861977
3626,ASA,2,3,9,12,"METHODS: ASA was administered as a single dose on GD 9 (0, 250, 500, or 625 mg/kg), 10 (0, 500, 625, or 750 mg/kg), or 11 (0, 500, 750, or 1000 mg/kg) and from GD 6 to GD 17 (0, 50, 125, or 250 mg/kg a day) in the multiple dose study to SD rats.",12852481_6,-1,-1,-1,3626,-1,0.99851006,0.0014898834
3627,SD,76,77,237,239,"METHODS: ASA was administered as a single dose on GD 9 (0, 250, 500, or 625 mg/kg), 10 (0, 500, 625, or 750 mg/kg), or 11 (0, 500, 750, or 1000 mg/kg) and from GD 6 to GD 17 (0, 50, 125, or 250 mg/kg a day) in the multiple dose study to SD rats.",12852481_6,-1,-1,-1,3627,-1,0.0781718,0.9218282
3628,NSAIDs,7,8,50,56,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3628,-1,0.99874616,0.0012537767
3629,ventricular septal defects,9,12,64,90,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3629,-1,0.008798599,0.9912014
3630,VSDs,13,14,92,96,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3630,-1,0.008105602,0.9918944
3631,midline defects,16,18,102,117,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3631,-1,0.004340313,0.99565965
3632,MDs,19,20,119,122,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3632,-1,0.004999518,0.9950004
3633,diaphragmatic hernia,24,26,136,156,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3633,-1,0.007206372,0.9927937
3634,DH,27,28,158,160,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3634,-1,0.026566576,0.9734334
3635,MDs,30,31,163,166,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3635,-1,0.0051274104,0.9948725
3636,VSDs,33,34,172,176,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3636,-1,0.0060451636,0.99395484
3637,malformations,53,54,254,267,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3637,-1,0.003002745,0.99699724
3638,ASA,57,58,281,284,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3638,-1,0.9985959,0.0014040478
3639,malformations,62,63,321,334,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,-1,-1,-1,3639,-1,0.0028766461,0.9971233
3640,DH,5,6,24,26,"In single dose studies, DH, MD, and VSD were induced on GDs 9 and 10.",12852481_9,-1,-1,-1,3640,-1,0.99766773,0.0023322871
3641,MD,7,8,28,30,"In single dose studies, DH, MD, and VSD were induced on GDs 9 and 10.",12852481_9,-1,-1,-1,3641,-1,0.99798846,0.0020115229
3642,VSD,10,11,36,39,"In single dose studies, DH, MD, and VSD were induced on GDs 9 and 10.",12852481_9,-1,-1,-1,3642,-1,0.9957889,0.0042111147
3643,VSD,0,1,0,3,VSD also was noted following treatment on GD 11.,12852481_10,-1,-1,-1,3643,-1,0.0096521685,0.99034786
3644,contrast,1,2,3,11,"In contrast, DH and MD were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.",12852481_11,-1,-1,-1,3644,-1,0.24838035,0.7516197
3645,DH,3,4,13,15,"In contrast, DH and MD were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.",12852481_11,-1,-1,-1,3645,-1,0.99270904,0.0072909337
3646,MD,5,6,20,22,"In contrast, DH and MD were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.",12852481_11,-1,-1,-1,3646,-1,0.9921301,0.007869924
3647,VSD,21,22,101,104,"In contrast, DH and MD were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.",12852481_11,-1,-1,-1,3647,-1,0.4216935,0.57830656
3648,developmental anomalies,6,8,39,62,CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats.,12852481_12,-1,-1,-1,3648,-1,0.0038078213,0.9961922
3649,SD,11,12,82,84,CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats.,12852481_12,-1,-1,-1,3649,-1,0.36164784,0.6383521
3650,VSD,19,20,123,126,CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats.,12852481_12,-1,-1,-1,3650,-1,0.012069495,0.98793054
3651,SD,22,23,134,136,CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats.,12852481_12,-1,-1,-1,3651,-1,0.18280575,0.8171942
3652,hydrocephalus,25,26,146,159,CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats.,12852481_12,-1,-1,-1,3652,-1,0.0025724703,0.9974275
3653,malformations,2,3,15,28,Variations and malformations were similar when ASA was administered as a single dose or during the period of organogenesis (GDs 6 to 17).,12852481_13,-1,-1,-1,3653,-1,0.0033118024,0.9966882
3654,ASA,6,7,47,50,Variations and malformations were similar when ASA was administered as a single dose or during the period of organogenesis (GDs 6 to 17).,12852481_13,-1,-1,-1,3654,-1,0.9988796,0.0011203507
3655,malformations,17,18,85,98,"It was also evident that, by titrating the dose to achieve a maximum tolerated dose, malformations that normally occur at low incidence, as reported from previous single dose studies, could also be induced with ASA given at multiple doses.",12852481_14,-1,-1,-1,3655,-1,0.0029441672,0.9970559
3656,ASA,38,39,211,214,"It was also evident that, by titrating the dose to achieve a maximum tolerated dose, malformations that normally occur at low incidence, as reported from previous single dose studies, could also be induced with ASA given at multiple doses.",12852481_14,-1,-1,-1,3656,-1,0.99879897,0.0012009763
3658,flumazenil,6,7,46,56,Reversal of central benzodiazepine effects by flumazenil after intravenous conscious sedation with diazepam and opioids: report of a double-blind multicenter study.,1286498_0,-1,-1,-1,3658,-1,0.9991868,0.0008131333
3660,Flumazenil,1,2,4,14,"The Flumazenil in Intravenous Conscious Sedation with Diazepam Multicenter Study Group II.The efficacy and safety of a new benzodiazepine antagonist, flumazenil, were assessed in a double-blind multicenter study.",1286498_1,-1,-1,-1,3660,-1,0.99928087,0.00071913336
3663,flumazenil,21,22,150,160,"The Flumazenil in Intravenous Conscious Sedation with Diazepam Multicenter Study Group II.The efficacy and safety of a new benzodiazepine antagonist, flumazenil, were assessed in a double-blind multicenter study.",1286498_1,-1,-1,-1,3663,-1,0.999236,0.0007640219
3664,mg,6,7,28,30,"Flumazenil (mean dose, 0.76 mg) or placebo (mean dose, 8.9 ml) was administered intravenously to 130 and 67 patients, respectively, who had been given diazepam in conjunction with an opioid (fentanyl, meperidine, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.",1286498_2,-1,-1,-1,3664,-1,0.9811396,0.018860456
3667,meperidine,41,42,201,211,"Flumazenil (mean dose, 0.76 mg) or placebo (mean dose, 8.9 ml) was administered intravenously to 130 and 67 patients, respectively, who had been given diazepam in conjunction with an opioid (fentanyl, meperidine, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.",1286498_2,-1,-1,-1,3667,-1,0.999243,0.00075703074
3669,flumazenil,10,11,70,80,The group assessable for efficacy comprised 122 patients treated with flumazenil and 64 patients given placebo.,1286498_3,-1,-1,-1,3669,-1,0.99919075,0.0008092661
3670,Flumazenil,0,1,0,10,"Flumazenil was well tolerated, with no serious adverse effects reported.",1286498_7,-1,-1,-1,3670,-1,0.99922204,0.00077795185
3673,flumazenil,11,12,64,74,The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection-site pain in the placebo group.,1286498_9,-1,-1,-1,3673,-1,0.9991954,0.0008046616
3676,Flumazenil,0,1,0,10,Flumazenil was found to promptly reverse sedation induced by diazepam in the presence of opioids.,1286498_10,-1,-1,-1,3676,-1,0.9992949,0.00070508296
3685,n,4,5,19,20,"RESULTS: Subjects (n = 139) were 72 women and 67 men, aged 40.8 +/- 12.1 years, hospitalized for 24.9 +/- 23.3 days, and given clozapine, gradually increased to an average daily dose of 282 +/- 203 mg (3.45 +/- 2.45 mg/kg) for 18.9 +/- 16.4 days.",12905102_3,-1,-1,-1,3685,-1,0.35620362,0.6437964
3687,mg,46,47,198,200,"RESULTS: Subjects (n = 139) were 72 women and 67 men, aged 40.8 +/- 12.1 years, hospitalized for 24.9 +/- 23.3 days, and given clozapine, gradually increased to an average daily dose of 282 +/- 203 mg (3.45 +/- 2.45 mg/kg) for 18.9 +/- 16.4 days.",12905102_3,-1,-1,-1,3687,-1,0.89475834,0.1052417
3692,MPEP,3,4,26,30,"Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.",12907309_0,-1,-1,-1,3692,-1,0.99907374,0.000926267
3699,h,25,26,143,144,"Methamphetamine (10 mg/kg sc), administered five times, reduced the levels of dopamine and its metabolites in striatal tissue when measured 72 h after the last injection.",12907309_2,-1,-1,-1,3699,-1,0.14283441,0.8571656
3701,MPEP,8,9,70,74,"A selective antagonist of mGluR5, 2-methyl-6-(phenylethynyl)pyridine (MPEP; 5 mg/kg ip), when administered five times immediately before each methamphetamine injection reversed the above-mentioned methamphetamine effects.",12907309_3,-1,-1,-1,3701,-1,0.99818546,0.0018145276
3704,MPEP,2,3,9,13,"A single MPEP (5 mg/kg ip) injection reduced the basal extracellular dopamine level in the striatum, as well as dopamine release stimulated either by methamphetamine (10 mg/kg sc) or by intrastriatally administered veratridine (100 microM).",12907309_4,-1,-1,-1,3704,-1,0.9988978,0.0011021969
3708,veratridine,37,38,215,226,"A single MPEP (5 mg/kg ip) injection reduced the basal extracellular dopamine level in the striatum, as well as dopamine release stimulated either by methamphetamine (10 mg/kg sc) or by intrastriatally administered veratridine (100 microM).",12907309_4,-1,-1,-1,3708,-1,0.9992938,0.00070620066
3711,MPEP,0,1,0,4,"MPEP administered into the striatum at high concentrations (500 microM) increased extracellular dopamine levels, while lower concentrations (50-100 microM) were devoid of any effect.",12907309_6,-1,-1,-1,3711,-1,0.99915504,0.00084500306
3713,MPEP,12,13,65,69,The results of this study suggest that the blockade of mGluR5 by MPEP may protect dopaminergic neurones against methamphetamine-induced toxicity.,12907309_7,-1,-1,-1,3713,-1,0.9991308,0.0008691794
3715,MPEP,3,4,28,32,"Neuroprotection rendered by MPEP may be associated with the reduction of the methamphetamine-induced dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5, and with a decrease in hyperthermia.",12907309_8,-1,-1,-1,3715,-1,0.99903417,0.00096583174
3719,Alzheimer's disease,8,11,65,84,An 82-year-old man with treatment-resistant depression and early Alzheimer's disease was started on methylphenidate.,12907924_1,-1,-1,-1,3719,-1,0.005039397,0.99496055
3722,fluvoxamine,14,15,120,131,Significant obsessive-compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by fluvoxamine.,12907924_2,-1,-1,-1,3722,-1,0.9992642,0.0007357568
3734,renal disease,12,14,97,110,"Unfortunately, acute interstitial nephritis was irreversible and the patient developed end-stage renal disease.",12911170_5,-1,-1,-1,3734,-1,0.0024597861,0.99754024
3737,kindled-seizures,7,8,60,76,Protective efficacy of neuroactive steroids against cocaine kindled-seizures in mice.,12921865_0,-1,-1,-1,3737,-1,0.07479643,0.92520356
3739,psychiatric disorders,14,16,108,129,Neuroactive steroids demonstrate pharmacological actions that have relevance for a host of neurological and psychiatric disorders.,12921865_1,-1,-1,-1,3739,-1,0.0028767844,0.9971232
3741,drug dependence,17,19,98,113,They offer protection against seizures in a range of models and seem to inhibit certain stages of drug dependence in preclinical assessments.,12921865_2,-1,-1,-1,3741,-1,0.09633492,0.90366507
3746,Allopregnanolone,0,1,0,16,"Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.",12921865_4,-1,-1,-1,3746,-1,0.99904054,0.00095946353
3747,pregnanolone,5,6,57,69,"Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.",12921865_4,-1,-1,-1,3747,-1,0.9990349,0.000965147
3748,ganaxolone,10,11,112,122,"Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.",12921865_4,-1,-1,-1,3748,-1,0.9991078,0.00089220144
3749,allopregnanolone,16,17,150,166,"Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.",12921865_4,-1,-1,-1,3749,-1,0.99879634,0.0012035909
3753,allopregnanolone,16,17,101,117,"All of these positive GABA(A) modulators suppressed the expression of kindled seizures, whereas only allopregnanolone and ganaxolone inhibited the development of kindling.",12921865_6,-1,-1,-1,3753,-1,0.999175,0.000824919
3754,ganaxolone,18,19,122,132,"All of these positive GABA(A) modulators suppressed the expression of kindled seizures, whereas only allopregnanolone and ganaxolone inhibited the development of kindling.",12921865_6,-1,-1,-1,3754,-1,0.99912614,0.0008738496
3755,Allopregnanolone,0,1,0,16,"Allopregnanolone and pregnanolone, but not ganaxolone, also reduced cumulative lethality associated with kindling.",12921865_7,-1,-1,-1,3755,-1,0.9991806,0.00081930956
3756,pregnanolone,2,3,21,33,"Allopregnanolone and pregnanolone, but not ganaxolone, also reduced cumulative lethality associated with kindling.",12921865_7,-1,-1,-1,3756,-1,0.99925274,0.00074722216
3757,ganaxolone,6,7,43,53,"Allopregnanolone and pregnanolone, but not ganaxolone, also reduced cumulative lethality associated with kindling.",12921865_7,-1,-1,-1,3757,-1,0.9992525,0.00074749644
3764,renal insufficiency,15,17,90,109,"18 patients, referred to a radiocontrast study, considered at risk because of preexisting renal insufficiency, were enrolled in a prospective, randomized, controlled trial, performed at the secondary care center of a 1,100-bed private university hospital.",1300436_2,-1,-1,-1,3764,-1,0.0028177986,0.99718225
3766,mg,14,15,78,80,"In addition to fluids, the treatment group received furosemide (mean dose 110 mg) intravenously 30 min prior to the injection of contrast material.",1300436_3,-1,-1,-1,3766,-1,0.97544926,0.024550753
3767,contrast material,24,26,129,146,"In addition to fluids, the treatment group received furosemide (mean dose 110 mg) intravenously 30 min prior to the injection of contrast material.",1300436_3,-1,-1,-1,3767,-1,0.9920447,0.007955252
3768,contrast material,11,13,87,104,"Radiological studies were mostly angiographies performed with both ionic and non-ionic contrast material, at an average dose of 245 ml.",1300436_5,-1,-1,-1,3768,-1,0.99376535,0.0062346198
3770,p,11,12,83,84,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,-1,-1,-1,3770,-1,0.27207485,0.7279252
3772,h,37,38,180,181,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,-1,-1,-1,3772,-1,0.1280817,0.8719184
3773,Renal failure,0,2,0,13,Renal failure was associated with weight loss in the furosemide-treated group.,1300436_7,-1,-1,-1,3773,-1,0.0024984146,0.99750155
3774,weight loss,5,7,34,45,Renal failure was associated with weight loss in the furosemide-treated group.,1300436_7,-1,-1,-1,3774,-1,0.0061728954,0.99382704
3780,blood coagulation factors,14,17,111,136,Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors: summary report of a ten-year study.,133615_2,-1,-1,-1,3780,-1,0.6059475,0.3940525
3784,myocardial infarction,6,8,34,55,"One of these patients developed a myocardial infarction before receiving any medication, shortly after the base-line values were obtained.",133615_8,-1,-1,-1,3784,-1,0.0023230235,0.997677
3785,retinopathy,3,4,22,33,"One patient developed retinopathy 19 months after she began therapy, and another developed thrombophlebitis after 27 months of therapy.",133615_9,-1,-1,-1,3785,-1,0.0025596237,0.99744034
3786,thrombophlebitis,14,15,91,107,"One patient developed retinopathy 19 months after she began therapy, and another developed thrombophlebitis after 27 months of therapy.",133615_9,-1,-1,-1,3786,-1,0.0031142698,0.9968857
3787,thrombophlebitis,4,5,29,45,The fourth patient developed thrombophlebitis 14 days after initiation of contraceptive therapy.,133615_10,-1,-1,-1,3787,-1,0.0023867663,0.9976132
3788,thromboembolic episodes,9,11,72,95,Previous studies suggested the possiblility of increased propensity for thromboembolic episodes in patients possessing the A antigen.,133615_12,-1,-1,-1,3788,-1,0.0027664828,0.99723357
3795,mg,28,29,134,136,2. Conscious SHR (male 300-350 g) were subjected to 90 degrees head-up tilts for 60 s following acute administration of prazosin (0.1 mg kg-1 i.p.) or rauwolscine (3 mg kg-1 i.v.).,1355091_2,-1,-1,-1,3795,-1,0.88455456,0.11544537
3796,rauwolscine,34,35,151,162,2. Conscious SHR (male 300-350 g) were subjected to 90 degrees head-up tilts for 60 s following acute administration of prazosin (0.1 mg kg-1 i.p.) or rauwolscine (3 mg kg-1 i.v.).,1355091_2,-1,-1,-1,3796,-1,0.99877375,0.0012262261
3797,mg,37,38,166,168,2. Conscious SHR (male 300-350 g) were subjected to 90 degrees head-up tilts for 60 s following acute administration of prazosin (0.1 mg kg-1 i.p.) or rauwolscine (3 mg kg-1 i.v.).,1355091_2,-1,-1,-1,3797,-1,0.78265387,0.21734612
3799,MAP,16,17,94,97,Orthostatic hypotension was determined by the average decrease (%) in mean arterial pressure (MAP femoral) over the 60-s tilt period.,1355091_3,-1,-1,-1,3799,-1,0.9265223,0.07347768
3800,MAP,2,3,10,13,The basal MAP of conscious SHR was reduced to a similar extent by prazosin (-23%(-)-26% MAP) and rauwolscine (-16%(-)-33% MAP).,1355091_4,-1,-1,-1,3800,-1,0.14334765,0.8566524
3802,MAP,17,18,88,91,The basal MAP of conscious SHR was reduced to a similar extent by prazosin (-23%(-)-26% MAP) and rauwolscine (-16%(-)-33% MAP).,1355091_4,-1,-1,-1,3802,-1,0.16516891,0.83483106
3803,rauwolscine,20,21,97,108,The basal MAP of conscious SHR was reduced to a similar extent by prazosin (-23%(-)-26% MAP) and rauwolscine (-16%(-)-33% MAP).,1355091_4,-1,-1,-1,3803,-1,0.9986835,0.0013165002
3804,MAP,24,25,122,125,The basal MAP of conscious SHR was reduced to a similar extent by prazosin (-23%(-)-26% MAP) and rauwolscine (-16%(-)-33% MAP).,1355091_4,-1,-1,-1,3804,-1,0.12745039,0.8725496
3807,MAP,17,18,97,100,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,-1,-1,-1,3807,-1,0.22713369,0.77286637
3808,n,19,20,102,103,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,-1,-1,-1,3808,-1,0.22996004,0.7700399
3809,rauwolscine,31,32,142,153,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,-1,-1,-1,3809,-1,0.99836165,0.0016384053
3810,MAP,38,39,169,172,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,-1,-1,-1,3810,-1,0.13054176,0.86945826
3811,n,40,41,174,175,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,-1,-1,-1,3811,-1,0.17891373,0.8210862
3813,mg,13,14,60,62,3. Conscious SHR were treated for 4 days with prazosin at 2 mg kg-1 day-1 i.p. for chronic alpha 1-adrenoceptor blockade.,1355091_6,-1,-1,-1,3813,-1,0.8909861,0.10901389
3815,n,18,19,95,96,MAP in conscious SHR after chronic prazosin treatment was 14% lower than in the untreated SHR (n = 8).,1355091_7,-1,-1,-1,3815,-1,0.32909542,0.6709046
3818,mg,23,24,138,140,Head-up tilts in these rats did not produce orthostatic hypotension when performed either prior to or after acute dosing of prazosin (0.1 mg kg-1 i.p.).,1355091_8,-1,-1,-1,3818,-1,0.9106565,0.0893435
3819,rauwolscine,4,5,30,41,"Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.",1355091_9,-1,-1,-1,3819,-1,0.9987703,0.0012297322
3820,mg,7,8,45,47,"Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.",1355091_9,-1,-1,-1,3820,-1,0.83167976,0.16832025
3822,MAP,20,21,111,114,"Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.",1355091_9,-1,-1,-1,3822,-1,0.1500139,0.8499861
3823,n,27,28,126,127,"Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.",1355091_9,-1,-1,-1,3823,-1,0.2635002,0.7364998
3824,MAP,39,40,180,183,"Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.",1355091_9,-1,-1,-1,3824,-1,0.09172522,0.90827477
3826,cirazoline,11,12,64,74,"4. The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.",1355091_10,-1,-1,-1,3826,-1,0.9991316,0.0008684543
3827,Abbott-53693,25,26,129,141,"4. The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.",1355091_10,-1,-1,-1,3827,-1,0.9893624,0.01063753
3831,cirazoline,7,8,44,54,Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4).,1355091_11,-1,-1,-1,3831,-1,0.9993216,0.0006783814
3833,n,16,17,103,104,Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4).,1355091_11,-1,-1,-1,3833,-1,0.22451875,0.7754813
3834,n,27,28,144,145,Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4).,1355091_11,-1,-1,-1,3834,-1,0.14734228,0.85265774
3835,Abbott-53693,9,10,42,54,"On the other hand, the pressor effects of Abbott-53693 were similar in both groups of SHR, but the accompanying bradycardia was greater in SHR with chronic prazosin treatment than without such treatment.",1355091_12,-1,-1,-1,3835,-1,0.9975435,0.0024565042
3840,increase in locomotor activity,6,10,49,79,Effect of humoral modulators of morphine-induced increase in locomotor activity of mice.,137340_0,-1,-1,-1,3840,-1,0.011024,0.988976
3841,increase in locomotor activity,8,12,57,87,The effect of humoral modulators on the morphine-induced increase in locomotor activity of mice was studied.,137340_1,-1,-1,-1,3841,-1,0.007257688,0.9927423
3842,increase in locomotor activity,11,15,78,108,The subcutaneous administration of 10 mg/kg of morphine-HC1 produced a marked increase in locomotor activity in mice.,137340_2,-1,-1,-1,3842,-1,0.006798349,0.9932017
3845,physostigmine,10,11,84,97,The morphine-induced hyperactivity was potentiated by scopolamine and attenuated by physostigmine.,137340_3,-1,-1,-1,3845,-1,0.9990183,0.0009816984
3846,contrast,1,2,3,11,"In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the hyperactivity produced by morphine.",137340_4,-1,-1,-1,3846,-1,0.3767611,0.62323886
3847,methscopolamine,4,5,18,33,"In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the hyperactivity produced by morphine.",137340_4,-1,-1,-1,3847,-1,0.999047,0.0009529913
3848,neostigmine,6,7,38,49,"In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the hyperactivity produced by morphine.",137340_4,-1,-1,-1,3848,-1,0.998887,0.001112965
3863,renal failure,35,37,208,221,"Rats with lithium-induced nephropathy were subjected to high protein (HP) feeding, uninephrectomy (NX) or a combination of these, in an attempt to induce glomerular hyperfiltration and further progression of renal failure.",1378968_1,-1,-1,-1,3863,-1,0.0024759374,0.9975241
3868,Li,15,16,102,104,"Consequently, lithium pretreatment caused a fall in filtration fraction and an increase in fractional Li excretion.",1378968_5,-1,-1,-1,3868,-1,0.998128,0.0018720333
3872,renal failure,6,8,40,53,HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma creatinine levels in lithium pretreated rats.,1378968_7,-1,-1,-1,3872,-1,0.0022337588,0.99776626
3878,renal failure,5,7,25,38,"In this model of chronic renal failure the decline in GFR is not accompanied by a corresponding fall in effective renal plasma flow, which may be the functional expression of the formation of nonfiltrating atubular glomeruli.",1378968_11,-1,-1,-1,3878,-1,0.0030570829,0.99694294
3886,Crohn's disease,2,5,13,28,Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin.,1420741_0,-1,-1,-1,3886,-1,0.004882931,0.99511707
3887,fusidic acid,6,8,34,46,Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin.,1420741_0,-1,-1,-1,3887,-1,0.9990754,0.0009246226
3888,cyclosporin,16,17,107,118,Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin.,1420741_0,-1,-1,-1,3888,-1,0.99830365,0.0016962826
3889,Fusidic acid,0,2,0,12,Fusidic acid is an antibiotic with T-cell specific immunosuppressive effects similar to those of cyclosporin.,1420741_1,-1,-1,-1,3889,-1,0.9991804,0.000819579
3890,cyclosporin,14,15,97,108,Fusidic acid is an antibiotic with T-cell specific immunosuppressive effects similar to those of cyclosporin.,1420741_1,-1,-1,-1,3890,-1,0.9989178,0.0010822049
3891,Crohn's disease,11,14,62,77,"Because of the need for the development of new treatments for Crohn's disease, a pilot study was undertaken to estimate the pharmacodynamics and tolerability of fusidic acid treatment in chronic active, therapy-resistant patients.",1420741_2,-1,-1,-1,3891,-1,0.010608339,0.9893917
3892,fusidic acid,27,29,161,173,"Because of the need for the development of new treatments for Crohn's disease, a pilot study was undertaken to estimate the pharmacodynamics and tolerability of fusidic acid treatment in chronic active, therapy-resistant patients.",1420741_2,-1,-1,-1,3892,-1,0.99924207,0.00075800135
3893,Crohn's disease,1,4,6,21,Eight Crohn's disease patients were included.,1420741_3,-1,-1,-1,3893,-1,0.014940852,0.98505914
3894,Fusidic acid,0,2,0,12,Fusidic acid was administered orally in a dose of 500 mg t.d.s. and the treatment was planned to last 8 weeks.,1420741_4,-1,-1,-1,3894,-1,0.99910164,0.00089843106
3895,mg,10,11,54,56,Fusidic acid was administered orally in a dose of 500 mg t.d.s. and the treatment was planned to last 8 weeks.,1420741_4,-1,-1,-1,3895,-1,0.96569365,0.034306344
3896,fusidic acid,10,12,41,53,Five of 8 patients (63%) improved during fusidic acid treatment: 3 at two weeks and 2 after four weeks.,1420741_6,-1,-1,-1,3896,-1,0.99907684,0.00092314015
3898,alkaline,5,6,30,38,"Biochemically, an increase in alkaline phosphatases was noted in 5 of 8 cases (63%), and the greatest increases were seen in those who had elevated levels prior to treatment.",1420741_8,-1,-1,-1,3898,-1,0.9855929,0.014407035
3899,fusidic acid,8,10,45,57,The results of this pilot study suggest that fusidic acid may be of benefit in selected chronic active Crohn's disease patients in whom conventional treatment is ineffective.,1420741_10,-1,-1,-1,3899,-1,0.9991504,0.0008495726
3900,Crohn's disease,18,21,103,118,The results of this pilot study suggest that fusidic acid may be of benefit in selected chronic active Crohn's disease patients in whom conventional treatment is ineffective.,1420741_10,-1,-1,-1,3900,-1,0.0096925255,0.99030745
3901,fusidic acid,12,14,67,79,"Because there seems to exist a scientific rationale for the use of fusidic acid at the cytokine level in inflammatory bowel disease, we suggest that the role of this treatment should be further investigated.",1420741_11,-1,-1,-1,3901,-1,0.99917537,0.0008246554
3902,inflammatory bowel disease,19,22,105,131,"Because there seems to exist a scientific rationale for the use of fusidic acid at the cytokine level in inflammatory bowel disease, we suggest that the role of this treatment should be further investigated.",1420741_11,-1,-1,-1,3902,-1,0.0031460032,0.996854
3903,Amnestic syndrome,0,2,0,17,Amnestic syndrome associated with propranolol toxicity: a case report.,1423339_0,-1,-1,-1,3903,-1,0.0026501743,0.99734986
3904,propranolol toxicity,4,6,34,54,Amnestic syndrome associated with propranolol toxicity: a case report.,1423339_0,-1,-1,-1,3904,-1,0.88286567,0.11713435
3906,propranolol toxicity,12,14,78,98,An elderly woman developed an Alzheimer-like subacute dementia as a result of propranolol toxicity.,1423339_1,-1,-1,-1,3906,-1,0.88227296,0.11772707
3907,drug toxicity,7,9,45,58,There is evidence that cerebral reactions to drug toxicity can exhibit patterns that suggest highly selective involvement of functional subdivisions of the brain.,1423339_3,-1,-1,-1,3907,-1,0.25723106,0.74276894
3912,betaxolol,24,25,147,156,We performed a preliminary study in order to determine any difference between a non selective beta-blocker (timolol) and a selective beta-blocker (betaxolol) regarding CNS side effects.,1428568_2,-1,-1,-1,3912,-1,0.9989256,0.0010743999
3913,glaucomatous,1,2,6,18,"Eight glaucomatous patients chronically treated with timolol 0.5%/12h, suffering from depression diagnosed through DMS-III-R criteria, were included in the study.",1428568_3,-1,-1,-1,3913,-1,0.004306682,0.9956934
3917,blind,3,4,12,17,"In a double blind cross-over study with control group, the patients under timolol treatment presented higher depression values measured through the Beck and the Zung-Conde scales (p < 0.001 vs control).",1428568_5,-1,-1,-1,3917,-1,0.14740586,0.85259414
3920,p,28,29,180,181,"In a double blind cross-over study with control group, the patients under timolol treatment presented higher depression values measured through the Beck and the Zung-Conde scales (p < 0.001 vs control).",1428568_5,-1,-1,-1,3920,-1,0.21672168,0.7832783
3924,LY274614,11,12,100,108,"Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.",1436384_0,-1,-1,-1,3924,-1,0.9985946,0.0014053843
3926,NMDA,18,19,161,165,"LY274614, 3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr oisoquinoline-3- carboxylic acid, has been described as a potent antagonist of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor.",1436384_1,-1,-1,-1,3926,-1,0.9912095,0.008790531
3929,iprindole,18,19,96,105,"A single 18.4 mg/kg (i.p.) dose of (+/-)-amphetamine hemisulfate, given to rats pretreated with iprindole, resulted in persistent depletion of dopamine in the striatum 1 week later.",1436384_3,-1,-1,-1,3929,-1,0.9988299,0.0011701433
3932,dizocilpine,11,12,72,83,"This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors).",1436384_4,-1,-1,-1,3932,-1,0.9990496,0.00095036137
3933,MK-801,13,14,85,91,"This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors).",1436384_4,-1,-1,-1,3933,-1,0.99765164,0.0023483636
3934,NMDA,19,20,125,129,"This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors).",1436384_4,-1,-1,-1,3934,-1,0.99805605,0.0019439629
3935,LY274614,24,25,147,155,"This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors).",1436384_4,-1,-1,-1,3935,-1,0.99811494,0.0018850385
3936,NMDA,30,31,185,189,"This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors).",1436384_4,-1,-1,-1,3936,-1,0.99710196,0.0028980179
3937,LY274614,4,5,25,33,"The protective effect of LY274614 was dose-dependent, being maximum at 10-40 mgkg (i.p.).",1436384_5,-1,-1,-1,3937,-1,0.9987852,0.0012148416
3938,LY274614,5,6,19,27,"A 10 mg/kg dose of LY274614 was effective in antagonizing the depletion of dopamine in the striatum, when given as long as 8 hr prior to amphetamine but not when given 24 hr prior to amphetamine.",1436384_6,-1,-1,-1,3938,-1,0.9990175,0.0009824702
3943,LY274614,10,11,64,72,Depletion of dopamine in the striatum was also antagonized when LY274614 was given after the injection of amphetamine; LY274614 protected when given up to 4 hr after but not when given 8 or 24 hr after amphetamine.,1436384_7,-1,-1,-1,3943,-1,0.9989818,0.0010182327
3945,LY274614,19,20,119,127,Depletion of dopamine in the striatum was also antagonized when LY274614 was given after the injection of amphetamine; LY274614 protected when given up to 4 hr after but not when given 8 or 24 hr after amphetamine.,1436384_7,-1,-1,-1,3945,-1,0.99888855,0.0011115125
3949,LY274614,24,25,163,171,"The prolonged depletion of dopamine in the striatum in mice, given multiple injections of methamphetamine, was also antagonized dose-dependently and completely by LY274614.",1436384_8,-1,-1,-1,3949,-1,0.99837554,0.001624486
3953,NMDA,19,20,144,148,The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.,1436384_9,-1,-1,-1,3953,-1,0.9958404,0.004159555
3954,LY274614,23,24,168,176,The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.,1436384_9,-1,-1,-1,3954,-1,0.9989147,0.0010853207
3955,NMDA,26,27,183,187,The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.,1436384_9,-1,-1,-1,3955,-1,0.9950283,0.0049717054
3958,penicillins,15,16,110,121,Immune hemolytic anemia due to a drug-adsorption mechanism has been described primarily in patients receiving penicillins and first-generation cephalosporins.,1445986_1,-1,-1,-1,3958,-1,0.9980692,0.0019308408
3961,cefotetan,10,11,71,80,We describe a patient who developed anemia while receiving intravenous cefotetan.,1445986_2,-1,-1,-1,3961,-1,0.999175,0.0008249501
3962,cefotetan,13,14,70,79,"The eluate also reacted weakly with red blood cells in the absence of cefotetan, suggesting the concomitant formation of warm-reactive autoantibodies.",1445986_4,-1,-1,-1,3962,-1,0.9990232,0.0009768077
3965,hemolytic,9,10,57,66,This case emphasizes the need for increased awareness of hemolytic reactions to all cephalosporins.,1445986_6,-1,-1,-1,3965,-1,0.0026040424,0.997396
3967,neurologic sequelae,1,3,21,40,Ketoconazole-induced neurologic sequelae.,14513889_0,-1,-1,-1,3967,-1,0.0023100113,0.99768996
3968,weakness of extremities,4,7,29,52,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,-1,-1,-1,3968,-1,0.0053984546,0.9946016
3969,legs paralysis,8,10,54,68,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,-1,-1,-1,3969,-1,0.0037208283,0.9962792
3970,dysarthria,11,12,70,80,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,-1,-1,-1,3970,-1,0.0028457171,0.99715424
3972,h,15,16,94,95,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,-1,-1,-1,3972,-1,0.30491534,0.69508463
3973,mg ketoconazole,20,22,119,134,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,-1,-1,-1,3973,-1,0.9984742,0.0015257935
3974,h.,6,7,36,38,"All complaints faded away within 24 h. Few days later, the patient used another 200 mg ketoconazole tablet, and within an hour experienced a similar clinical picture, which resolved again spontaneously within hours.",14513889_2,-1,-1,-1,3974,-1,0.38117436,0.6188257
3975,mg ketoconazole,16,18,84,99,"All complaints faded away within 24 h. Few days later, the patient used another 200 mg ketoconazole tablet, and within an hour experienced a similar clinical picture, which resolved again spontaneously within hours.",14513889_2,-1,-1,-1,3975,-1,0.99764,0.0023599635
3976,drug,10,11,62,66,"This case illustrates the need for close vigilance in adverse drug reactions, particularly in the elderly.",14513889_4,-1,-1,-1,3976,-1,0.88516456,0.114835404
3980,LIDs,3,4,30,34,Levodopa-induced dyskinesias (LIDs) present a major problem for the long-term management of Parkinson's disease (PD) patients.,14568327_1,-1,-1,-1,3980,-1,0.006128654,0.99387133
3981,Parkinson's disease,14,17,92,111,Levodopa-induced dyskinesias (LIDs) present a major problem for the long-term management of Parkinson's disease (PD) patients.,14568327_1,-1,-1,-1,3981,-1,0.0065041436,0.9934958
3982,PD,18,19,113,115,Levodopa-induced dyskinesias (LIDs) present a major problem for the long-term management of Parkinson's disease (PD) patients.,14568327_1,-1,-1,-1,3982,-1,0.0041802805,0.9958197
3983,LIDs,24,25,155,159,"Due to the interdependence of risk factors in clinical populations, it is difficult to independently examine factors that may influence the development of LIDs.",14568327_2,-1,-1,-1,3983,-1,0.0045297844,0.9954703
3986,LIDs,41,42,255,259,"Using macaque monkeys with different types of MPTP-induced parkinsonism, the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of levodopa therapy may be involved in the development of LIDs.",14568327_3,-1,-1,-1,3986,-1,0.002941604,0.9970584
3987,MPTP,6,7,32,36,"Monkeys with acute (short-term) MPTP exposure, rapid symptom onset and short symptom duration prior to initiation of levodopa therapy developed dyskinesia between 11 and 24 days of daily levodopa administration.",14568327_4,-1,-1,-1,3987,-1,0.99901116,0.0009888221
3991,contrast,1,2,3,11,"In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).",14568327_5,-1,-1,-1,3991,-1,0.14380065,0.8561993
3992,MPTP,6,7,36,40,"In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).",14568327_5,-1,-1,-1,3992,-1,0.9989297,0.0010703165
3994,LIDs,27,28,179,183,"In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).",14568327_5,-1,-1,-1,3994,-1,0.0033510479,0.99664897
3998,LIDs,10,11,69,73,These data suggest distinct differences in the propensity to develop LIDs in monkeys with different rates of symptom progression or symptom durations prior to levodopa and demonstrate the value of these models for further studying the pathophysiology of LIDs.,14568327_7,-1,-1,-1,3998,-1,0.0032742878,0.9967257
4000,LIDs,38,39,254,258,These data suggest distinct differences in the propensity to develop LIDs in monkeys with different rates of symptom progression or symptom durations prior to levodopa and demonstrate the value of these models for further studying the pathophysiology of LIDs.,14568327_7,-1,-1,-1,4000,-1,0.003057292,0.9969427
4001,sugar dependency,3,5,17,33,A diet promoting sugar dependency causes behavioral cross-sensitization to a low dose of amphetamine.,14596845_0,-1,-1,-1,4001,-1,0.29118842,0.7088116
4003,drug dependency,24,26,170,185,Previous research in this laboratory has shown that a diet of intermittent excessive sugar consumption produces a state with neurochemical and behavioral similarities to drug dependency.,14596845_1,-1,-1,-1,4003,-1,0.120927356,0.87907267
4005,sucrose,30,31,155,162,"After a 30-min baseline measure of locomotor activity (day 0), animals were maintained on a cyclic diet of 12-h deprivation followed by 12-h access to 10% sucrose solution and chow pellets (12 h access starting 4 h after onset of the dark period) for 21 days.",14596845_3,-1,-1,-1,4005,-1,0.9983581,0.0016419345
4006,h,37,38,193,194,"After a 30-min baseline measure of locomotor activity (day 0), animals were maintained on a cyclic diet of 12-h deprivation followed by 12-h access to 10% sucrose solution and chow pellets (12 h access starting 4 h after onset of the dark period) for 21 days.",14596845_3,-1,-1,-1,4006,-1,0.49817538,0.5018246
4007,h,41,42,213,214,"After a 30-min baseline measure of locomotor activity (day 0), animals were maintained on a cyclic diet of 12-h deprivation followed by 12-h access to 10% sucrose solution and chow pellets (12 h access starting 4 h after onset of the dark period) for 21 days.",14596845_3,-1,-1,-1,4007,-1,0.28484535,0.71515465
4008,ad,10,11,49,51,"Beginning on day 22, all rats were maintained on ad libitum chow.",14596845_5,-1,-1,-1,4008,-1,0.9670975,0.032902416
4010,sucrose,6,7,40,47,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,-1,-1,-1,4010,-1,0.99782664,0.002173367
4011,hyperactive,10,11,62,73,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,-1,-1,-1,4011,-1,0.004964664,0.9950354
4013,ad,21,22,136,138,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,-1,-1,-1,4013,-1,0.9452856,0.054714434
4014,sucrose,25,26,151,158,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,-1,-1,-1,4014,-1,0.9982553,0.0017446629
4017,ad,40,41,250,252,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,-1,-1,-1,4017,-1,0.9458056,0.054194402
4019,sucrose,50,51,298,305,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,-1,-1,-1,4019,-1,0.99799097,0.0020090635
4024,hemorrhagic cystitis,10,12,73,93,Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis.,14633084_0,-1,-1,-1,4024,-1,0.002084325,0.9979157
4025,Hemorrhagic cystitis,2,4,5,25,AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS).,14633084_1,-1,-1,-1,4025,-1,0.0024543412,0.99754566
4026,HC,5,6,27,29,AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS).,14633084_1,-1,-1,-1,4026,-1,0.0064284895,0.9935715
4028,IFS,16,17,90,93,AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS).,14633084_1,-1,-1,-1,4028,-1,0.99478865,0.005211343
4031,HC,21,22,130,132,"In the study presented here, we investigated the use of dexamethasone in combination with mesna for the prevention of IFS-induced HC.",14633084_2,-1,-1,-1,4031,-1,0.00966956,0.99033046
4033,h,33,34,122,123,METHODS: Male Wistar rats (150-200 g; 6 rats per group) were treated with saline or mesna 5 min (i.p.) before and 2 and 6 h after (v.o.) administration of IFS.,14633084_3,-1,-1,-1,4033,-1,0.42423615,0.5757639
4034,IFS,41,42,155,158,METHODS: Male Wistar rats (150-200 g; 6 rats per group) were treated with saline or mesna 5 min (i.p.) before and 2 and 6 h after (v.o.) administration of IFS.,14633084_3,-1,-1,-1,4034,-1,0.9972717,0.0027282853
4040,h,4,5,26,27,Cystitis was evaluated 24 h after its induction by the changes in bladder wet weight and by macroscopic and microscopic analysis.,14633084_5,-1,-1,-1,4040,-1,0.07707886,0.9229211
4043,IFS,26,27,146,149,"RESULTS: The replacement of the last dose or the last two doses of mesna with dexamethasone reduced the increase in bladder wet weight induced by IFS by 84.79% and 89.13%, respectively.",14633084_6,-1,-1,-1,4043,-1,0.9566731,0.043326885
4044,IFS,13,14,88,91,"In addition, it almost abolished the macroscopic and microscopic alterations induced by IFS.",14633084_7,-1,-1,-1,4044,-1,0.9943445,0.005655579
4050,HC,12,13,90,92,CONCLUSION: Dexamethasone in combination with mesna was efficient in blocking IFS-induced HC.,14633084_9,-1,-1,-1,4050,-1,0.00947606,0.990524
4054,HC,23,24,125,127,"However, the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent HC.",14633084_10,-1,-1,-1,4054,-1,0.49465474,0.5053453
4055,erythema nodosum,3,5,33,49,All- trans-retinoic acid-induced erythema nodosum in patients with acute promyelocytic leukemia.,14648024_0,-1,-1,-1,4055,-1,0.0031727098,0.9968273
4056,acute promyelocytic leukemia,8,11,67,95,All- trans-retinoic acid-induced erythema nodosum in patients with acute promyelocytic leukemia.,14648024_0,-1,-1,-1,4056,-1,0.005613709,0.9943863
4057,Erythema nodosum,0,2,0,16,Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.,14648024_1,-1,-1,-1,4057,-1,0.0029475328,0.99705243
4058,ATRA,8,9,59,63,Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.,14648024_1,-1,-1,-1,4058,-1,0.9952579,0.0047421358
4059,acute promyelocytic leukemia,11,14,69,97,Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.,14648024_1,-1,-1,-1,4059,-1,0.0051431824,0.99485683
4060,APL,15,16,99,102,Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.,14648024_1,-1,-1,-1,4060,-1,0.0043153805,0.9956846
4061,APL,6,7,39,42,We describe four patients with classic APL who developed erythema nodosum during ATRA therapy.,14648024_2,-1,-1,-1,4061,-1,0.008426275,0.99157375
4062,erythema nodosum,9,11,57,73,We describe four patients with classic APL who developed erythema nodosum during ATRA therapy.,14648024_2,-1,-1,-1,4062,-1,0.003812527,0.9961875
4063,ATRA,12,13,81,85,We describe four patients with classic APL who developed erythema nodosum during ATRA therapy.,14648024_2,-1,-1,-1,4063,-1,0.9980405,0.0019595034
4065,painful erythematous nodules,4,7,30,58,"Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.",14648024_3,-1,-1,-1,4065,-1,0.0030799783,0.99692
4066,ATRA,23,24,133,137,"Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.",14648024_3,-1,-1,-1,4066,-1,0.9984926,0.0015073875
4067,erythema nodosum,10,12,60,76,The skin biopsy taken from each patient was consistent with erythema nodosum.,14648024_4,-1,-1,-1,4067,-1,0.004552726,0.9954472
4070,ATRA,8,9,63,67,All patients achieved complete remission without withdrawal of ATRA.,14648024_7,-1,-1,-1,4070,-1,0.9986401,0.0013599285
4071,erythema nodosum,9,11,48,64,ATRA seemed to be the most possible etiology of erythema nodosum in our patients.,14648024_8,-1,-1,-1,4071,-1,0.0054140897,0.9945859
4073,erythema nodosum,9,11,60,76,Short-term use of steroid is very effective in ATRA-induced erythema nodosum.,14648024_9,-1,-1,-1,4073,-1,0.0026239308,0.9973761
4075,amphotericin B,5,7,45,59,Reversible dilated cardiomyopathy related to amphotericin B therapy.,14657095_0,-1,-1,-1,4075,-1,0.9988544,0.0011455547
4077,congestive heart failure,10,13,72,96,We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.,14657095_1,-1,-1,-1,4077,-1,0.0025161433,0.99748385
4078,amphotericin B,19,21,128,142,We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.,14657095_1,-1,-1,-1,4078,-1,0.99890053,0.0010994956
4079,AmB,22,23,144,147,We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.,14657095_1,-1,-1,-1,4079,-1,0.99772435,0.0022755836
4080,coccidioidomycosis,26,27,166,184,We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.,14657095_1,-1,-1,-1,4080,-1,0.257255,0.742745
4081,heart failure,4,6,40,53,His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.,14657095_2,-1,-1,-1,4081,-1,0.002325219,0.99767476
4082,posaconazole,8,9,69,81,His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.,14657095_2,-1,-1,-1,4082,-1,0.9993524,0.00064761547
4086,CGRP,12,13,87,91,NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release.,14659530_0,-1,-1,-1,4086,-1,0.9970862,0.0029137458
4089,CGRP,17,18,103,107,"The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.",14659530_1,-1,-1,-1,4089,-1,0.99757224,0.0024277791
4090,serotonin (5-hydroxytriptamine,22,25,136,166,"The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.",14659530_1,-1,-1,-1,4090,-1,0.9980421,0.0019578366
4091,5-HT,26,27,168,172,"The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.",14659530_1,-1,-1,-1,4091,-1,0.9925113,0.0074887318
4095,migraineurs (without aura),2,7,15,41,Fifteen female migraineurs (without aura) and eight controls participated in the study.,14659530_2,-1,-1,-1,4095,-1,0.04401078,0.9559892
4097,mg,4,5,30,32,Sublingual nitroglycerin (0.5 mg) was administered.,14659530_3,-1,-1,-1,4097,-1,0.96634597,0.033654053
4101,CGRP,1,2,7,11,Plasma CGRP concentration increased significantly (P<0.01) during the migraine attack and returned to baseline after the cessation of the migraine.,14659530_6,-1,-1,-1,4101,-1,0.9988418,0.0011582552
4102,P<0.01,6,7,51,57,Plasma CGRP concentration increased significantly (P<0.01) during the migraine attack and returned to baseline after the cessation of the migraine.,14659530_6,-1,-1,-1,4102,-1,0.6119891,0.38801086
4105,migraine headache,13,15,81,98,"In addition, both change and peak, showed significant positive correlations with migraine headache intensity (P<0.001).",14659530_7,-1,-1,-1,4105,-1,0.003259255,0.99674076
4106,P<0.001,17,18,110,117,"In addition, both change and peak, showed significant positive correlations with migraine headache intensity (P<0.001).",14659530_7,-1,-1,-1,4106,-1,0.3966297,0.6033703
4107,CGRP,3,4,16,20,"However, plasma CGRP concentrations failed to change during immediate headache and in the subjects with no migraine attack.",14659530_8,-1,-1,-1,4107,-1,0.9989127,0.0010873647
4110,CGRP,1,2,6,10,Basal CGRP concentration was significantly higher and platelet 5-HT content tended to be lower in subjects who experienced a migraine attack.,14659530_9,-1,-1,-1,4110,-1,0.999079,0.00092099304
4113,P<0.01,6,7,52,58,Platelet serotonin content decreased significantly (P<0.01) after nitroglycerin in subjects with no migraine attack but no consistent change was observed in patients with migraine attack.,14659530_10,-1,-1,-1,4113,-1,0.4997067,0.5002933
4117,CGRP,7,8,36,40,"In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine.",14659530_11,-1,-1,-1,4117,-1,0.99892944,0.0010705553
4118,migraine headache,17,19,100,117,"In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine.",14659530_11,-1,-1,-1,4118,-1,0.0026617113,0.99733824
4119,CGRP,24,25,157,161,"In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine.",14659530_11,-1,-1,-1,4119,-1,0.99886596,0.001134121
4121,contrast,1,2,3,11,"In contrast, serotonin release from platelets does not provoke migraine, it may even counteract the headache and the concomitant CGRP release in this model.",14659530_12,-1,-1,-1,4121,-1,0.36288768,0.6371123
4125,CGRP,21,22,129,133,"In contrast, serotonin release from platelets does not provoke migraine, it may even counteract the headache and the concomitant CGRP release in this model.",14659530_12,-1,-1,-1,4125,-1,0.9986241,0.001375952
4127,hemorrhagic cystitis,8,10,78,98,Hyperbaric oxygen therapy for control of intractable cyclophosphamide-induced hemorrhagic cystitis.,1468485_0,-1,-1,-1,4127,-1,0.002212781,0.99778724
4128,hemorrhagic cystitis,6,8,32,52,We report a case of intractable hemorrhagic cystitis due to cyclophosphamide therapy for Wegener's granulomatosis.,1468485_1,-1,-1,-1,4128,-1,0.0022768085,0.99772316
4130,Wegener's granulomatosis,13,16,89,113,We report a case of intractable hemorrhagic cystitis due to cyclophosphamide therapy for Wegener's granulomatosis.,1468485_1,-1,-1,-1,4130,-1,0.054818843,0.94518113
4131,prostaglandin F2 alpha,12,15,99,121,"Conservative treatment, including bladder irrigation with physiological saline and instillation of prostaglandin F2 alpha, failed to totally control hemorrhage.",1468485_2,-1,-1,-1,4131,-1,0.9974502,0.0025498306
4136,hemorrhagic cystitis,17,19,106,126,"In future, this form of therapy can offer a safe alternative in the treatment of cyclophosphamide-induced hemorrhagic cystitis.",1468485_6,-1,-1,-1,4136,-1,0.002134974,0.997865
4137,psychosis,1,2,6,15,Acute psychosis due to treatment with phenytoin in a nonepileptic patient.,14698717_0,-1,-1,-1,4137,-1,0.0021530534,0.99784696
4139,psychosis,3,4,19,28,The development of psychosis related to antiepileptic drug treatment is usually attributed to the interaction between the epileptic brain substratum and the antiepileptic drugs.,14698717_1,-1,-1,-1,4139,-1,0.0021933247,0.9978067
4141,psychosis,8,9,49,58,The case of a nonepileptic patient who developed psychosis following phenytoin treatment for trigeminal neuralgia is described.,14698717_2,-1,-1,-1,4141,-1,0.0021086691,0.99789137
4143,trigeminal neuralgia,13,15,93,113,The case of a nonepileptic patient who developed psychosis following phenytoin treatment for trigeminal neuralgia is described.,14698717_2,-1,-1,-1,4143,-1,0.0025858176,0.9974141
4148,convulsants,3,4,15,26,Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala-kindled rats.,14704468_0,-1,-1,-1,4148,-1,0.026651394,0.97334856
4149,loreclezole,9,10,57,68,Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala-kindled rats.,14704468_0,-1,-1,-1,4149,-1,0.9994147,0.0005852905
4150,valproate,14,15,95,104,Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala-kindled rats.,14704468_0,-1,-1,-1,4150,-1,0.9991259,0.0008741578
4151,clonazepam,16,17,108,118,Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala-kindled rats.,14704468_0,-1,-1,-1,4151,-1,0.99880326,0.0011967928
4152,Loreclezole,0,1,0,11,"Loreclezole (5 mg/kg) exerted a significant protective action in amygdala-kindled rats, reducing both seizure and afterdischarge durations.",14704468_1,-1,-1,-1,4152,-1,0.99930406,0.00069593976
4154,loreclezole,3,4,20,31,"The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test.",14704468_2,-1,-1,-1,4154,-1,0.9994191,0.00058094744
4155,valproate,9,10,49,58,"The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test.",14704468_2,-1,-1,-1,4155,-1,0.9992434,0.00075662317
4156,clonazepam,11,12,60,70,"The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test.",14704468_2,-1,-1,-1,4156,-1,0.99890053,0.0010994304
4159,BAY k-8644,9,11,74,84,"Among several chemoconvulsants, bicuculline, N-methyl-D-aspartic acid and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.",14704468_4,-1,-1,-1,4159,-1,0.99701786,0.0029821922
4160,calcium channels,16,18,107,123,"Among several chemoconvulsants, bicuculline, N-methyl-D-aspartic acid and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.",14704468_4,-1,-1,-1,4160,-1,0.80786693,0.1921331
4161,loreclezole,24,25,161,172,"Among several chemoconvulsants, bicuculline, N-methyl-D-aspartic acid and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.",14704468_4,-1,-1,-1,4161,-1,0.99934024,0.000659757
4162,valproate,30,31,204,213,"Among several chemoconvulsants, bicuculline, N-methyl-D-aspartic acid and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.",14704468_4,-1,-1,-1,4162,-1,0.9987923,0.0012076274
4165,BAY k-8644,9,11,50,60,"On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.",14704468_5,-1,-1,-1,4165,-1,0.9959751,0.0040249275
4166,loreclezole,16,17,100,111,"On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.",14704468_5,-1,-1,-1,4166,-1,0.9993839,0.00061608554
4167,clonazepam,19,20,126,136,"On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.",14704468_5,-1,-1,-1,4167,-1,0.99887663,0.0011234039
4168,loreclezole,10,11,67,78,The results support the hypothesis that the protective activity of loreclezole and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L-type of calcium channels.,14704468_6,-1,-1,-1,4168,-1,0.99935776,0.00064229826
4169,calcium channels,28,30,208,224,The results support the hypothesis that the protective activity of loreclezole and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L-type of calcium channels.,14704468_6,-1,-1,-1,4169,-1,0.94591045,0.054089546
4170,doxorubicin nephrosis,10,12,70,91,Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis.,14736955_0,-1,-1,-1,4170,-1,0.052248564,0.94775146
4173,tubular lesions,13,15,113,128,BACKGROUND: Doxorubicin induces a self-perpetuating nephropathy characterized by early glomerular and late-onset tubular lesions in rats.,14736955_1,-1,-1,-1,4173,-1,0.0027809558,0.9972191
4174,mitochondrial injury,6,8,38,58,We investigated the potential role of mitochondrial injury in the onset of these lesions.,14736955_2,-1,-1,-1,4174,-1,0.08666759,0.91333246
4176,mg,10,11,59,61,METHODS: Rats were treated with intravenous doxorubicin (1 mg kg(-1) week(-1)) for 7 weeks and were sacrificed either 1 week ('short-term') or 30 weeks ('long-term') following the last dose.,14736955_3,-1,-1,-1,4176,-1,0.92223763,0.07776239
4177,h,11,12,58,59,Additional rats received a single dose either 6 days or 2 h prior to euthanasia.,14736955_4,-1,-1,-1,4177,-1,0.87373143,0.1262686
4178,tubular injury,2,4,15,29,Glomerular and tubular injury was monitored and correlated to the activity or expression of respiratory chain components.,14736955_6,-1,-1,-1,4178,-1,0.003943449,0.99605656
4180,glomerular and tubular lesions,9,13,47,77,"RESULTS: The 'long-term' group had significant glomerular and tubular lesions, depressed activities of mtDNA-encoded NADH dehydrogenase and cytochrome-c oxidase (COX) and increased citrate synthase activity.",14736955_8,-1,-1,-1,4180,-1,0.0034475422,0.99655247
4182,tubular lesions,9,11,39,54,"In 'short-term' rats, there were fewer tubular lesions, but similar numbers of glomerular lesions activity.",14736955_10,-1,-1,-1,4182,-1,0.0038222352,0.9961778
4183,glomerular lesions,16,18,79,97,"In 'short-term' rats, there were fewer tubular lesions, but similar numbers of glomerular lesions activity.",14736955_10,-1,-1,-1,4183,-1,0.0040357155,0.9959643
4184,tubular injury,6,8,34,48,"Among all animals, glomerular and tubular injury were inversely correlated with mtDNA levels, mtDNA-encoded respiratory chain activities and with the expression of the mtDNA-encoded respiratory chain subunit COX-I. Injury was positively correlated with superoxide production and the activities of nucleus-encoded mitochondrial or cytoplasmic enzymes.",14736955_11,-1,-1,-1,4184,-1,0.0038600583,0.99613994
4187,renal lesions,28,30,221,234,CONCLUSIONS: These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA-encoded respiratory chain function and induction of superoxide in doxorubicin-induced renal lesions.,14736955_13,-1,-1,-1,4187,-1,0.0029479994,0.99705195
4192,sexually dysfunctional,1,3,9,31,"Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.",14742097_2,-1,-1,-1,4192,-1,0.0030417398,0.99695826
4197,mg,30,31,207,209,"Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.",14742097_2,-1,-1,-1,4197,-1,0.976856,0.023144063
4198,mg ephedrine,16,18,119,131,"Although there were significant improvements relative to baseline in sexual desire and orgasm intensity/pleasure on 50 mg ephedrine 1-hr prior to sexual activity, significant improvements in these measures, as well as in sexual arousal and orgasmic ability also were noted with placebo.",14742097_3,-1,-1,-1,4198,-1,0.99822193,0.001778042
4201,anastrozole,7,8,48,59,"Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.",14745746_3,-1,-1,-1,4201,-1,0.9994215,0.00057855505
4203,n=94,17,18,97,101,"Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.",14745746_3,-1,-1,-1,4203,-1,0.20786786,0.79213214
4205,n=35,28,29,147,151,"Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.",14745746_3,-1,-1,-1,4205,-1,0.15395878,0.84604126
4206,p=0.032,16,17,88,95,"Compared with the control group, the patients were impaired on a processing speed task (p=0.032) and on a measure of immediate verbal memory (p=0.026) after controlling for the use of hormone replacement therapy in both groups.",14745746_4,-1,-1,-1,4206,-1,0.32568812,0.6743119
4207,p=0.026,27,28,142,149,"Compared with the control group, the patients were impaired on a processing speed task (p=0.032) and on a measure of immediate verbal memory (p=0.026) after controlling for the use of hormone replacement therapy in both groups.",14745746_4,-1,-1,-1,4207,-1,0.33157003,0.66843
4209,oestrogen,9,10,56,65,"Verbal memory may be especially sensitive to changes in oestrogen levels, a finding commonly reported in studies of hormone replacement therapy in healthy women.",14745746_7,-1,-1,-1,4209,-1,0.99903667,0.0009633698
4211,nocturnal leg cramps,12,15,75,95,"Although the United States Food and Drug Administration banned its use for nocturnal leg cramps due to lack of safety and efficacy, quinine is widely available in beverages including tonic water and bitter lemon.",14765563_1,-1,-1,-1,4211,-1,0.0041574277,0.9958425
4214,neurological complications,10,12,80,106,"Numerous anecdotal reports suggest that products containing quinine may produce neurological complications, including confusion, altered mental status, seizures, and coma, particularly in older women.",14765563_2,-1,-1,-1,4214,-1,0.002234822,0.9977652
4222,heart failure,19,21,148,161,These findings demonstrate that overexpression of p300 protects cardiac myocytes from doxorubicin-induced apoptosis and reduces the extent of acute heart failure in adult mice in vivo.,14975762_8,-1,-1,-1,4222,-1,0.0025459575,0.997454
4223,propafenone overdose,5,7,57,77,Transient platypnea-orthodeoxia-like syndrome induced by propafenone overdose in a young woman with Ebstein's anomaly.,14976857_0,-1,-1,-1,4223,-1,0.90218925,0.09781071
4224,Ebstein's anomaly,12,15,100,117,Transient platypnea-orthodeoxia-like syndrome induced by propafenone overdose in a young woman with Ebstein's anomaly.,14976857_0,-1,-1,-1,4224,-1,0.053908132,0.9460919
4225,Ebstein's anomaly,13,16,70,87,"In this report we describe the case of a 37-year-old white woman with Ebstein's anomaly, who developed a rare syndrome called platypnea-orthodeoxia, characterized by massive right-to-left interatrial shunting with transient profound hypoxia and cyanosis.",14976857_1,-1,-1,-1,4225,-1,0.089139566,0.9108604
4227,cyanosis,36,37,245,253,"In this report we describe the case of a 37-year-old white woman with Ebstein's anomaly, who developed a rare syndrome called platypnea-orthodeoxia, characterized by massive right-to-left interatrial shunting with transient profound hypoxia and cyanosis.",14976857_1,-1,-1,-1,4227,-1,0.0026227806,0.9973773
4228,propafenone overdose,26,28,146,166,"This shunt of blood via a patent foramen ovale occurred in the presence of a normal pulmonary artery pressure, and was probably precipitated by a propafenone overdose.",14976857_2,-1,-1,-1,4228,-1,0.8758674,0.12413257
4229,biventricular dysfunction,3,5,17,42,"This drug caused biventricular dysfunction, due to its negative inotropic effect, and hypotension, due to its peripheral vasodilatory effect.",14976857_3,-1,-1,-1,4229,-1,0.012826949,0.9871731
4231,contrast,12,13,74,82,In our case this interatrial shunt was very accurately detected at bubble contrast echocardiography.,14976857_5,-1,-1,-1,4231,-1,0.99621165,0.0037883138
4232,cholestatic jaundice,1,3,20,40,Methimazole-induced cholestatic jaundice.,14982270_0,-1,-1,-1,4232,-1,0.0030105708,0.9969894
4233,Methimazole,0,1,0,11,Methimazole is a widely used and generally well-tolerated antithyroid agent.,14982270_1,-1,-1,-1,4233,-1,0.99923706,0.00076290616
4235,itching,7,8,44,51,A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.,14982270_2,-1,-1,-1,4235,-1,0.0025663525,0.9974336
4236,methimazole,12,13,76,87,A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.,14982270_2,-1,-1,-1,4236,-1,0.99921453,0.000785456
4237,mg,15,16,92,94,A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.,14982270_2,-1,-1,-1,4237,-1,0.95435613,0.04564388
4239,mg,22,23,120,122,A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.,14982270_2,-1,-1,-1,4239,-1,0.9252488,0.07475124
4242,emergency department,4,6,17,37,"When seen at the emergency department 2 weeks later, she still had severe icterus, pruritus, and hyperbilirubinemia, formed mainly of the conjugated fraction.",14982270_4,-1,-1,-1,4242,-1,0.018036695,0.9819633
4243,icterus,14,15,74,81,"When seen at the emergency department 2 weeks later, she still had severe icterus, pruritus, and hyperbilirubinemia, formed mainly of the conjugated fraction.",14982270_4,-1,-1,-1,4243,-1,0.0055617574,0.9944383
4245,hyperbilirubinemia,19,20,97,115,"When seen at the emergency department 2 weeks later, she still had severe icterus, pruritus, and hyperbilirubinemia, formed mainly of the conjugated fraction.",14982270_4,-1,-1,-1,4245,-1,0.050843704,0.9491563
4249,methimazole,19,20,112,123,"Over the following 9 days, the symptoms improved and plasma bilirubin levels were normal after 12 weeks without methimazole.",14982270_6,-1,-1,-1,4249,-1,0.9992655,0.00073453155
4250,cholestatic jaundice,18,20,95,115,"In rare cases within the first few weeks of therapy, this drug can cause severe and reversible cholestatic jaundice.",14982270_7,-1,-1,-1,4250,-1,0.003075516,0.99692446
4251,methimazole,19,20,110,121,"Physicians and patients should be aware of this adverse effect so that, upon occurrence, they can discontinue methimazole therapy and avoid unnecessary invasive procedures.",14982270_8,-1,-1,-1,4251,-1,0.99918,0.00082000013
4252,vascular dysfunctions,20,22,154,175,Noxious chemical stimulation of rat facial mucosa increases intracranial blood flow through a trigemino-parasympathetic reflex--an experimental model for vascular dysfunctions in cluster headache.,15009014_0,-1,-1,-1,4252,-1,0.005025497,0.9949745
4253,cluster headache,23,25,179,195,Noxious chemical stimulation of rat facial mucosa increases intracranial blood flow through a trigemino-parasympathetic reflex--an experimental model for vascular dysfunctions in cluster headache.,15009014_0,-1,-1,-1,4253,-1,0.0036325282,0.99636745
4254,Cluster headache,0,2,0,16,Cluster headache is characterized by typical autonomic dysfunctions including facial and intracranial vascular disturbances.,15009014_1,-1,-1,-1,4254,-1,0.003219975,0.9967801
4255,intracranial vascular disturbances,11,14,89,123,Cluster headache is characterized by typical autonomic dysfunctions including facial and intracranial vascular disturbances.,15009014_1,-1,-1,-1,4255,-1,0.004514368,0.9954856
4257,mm,5,6,18,20,Capsaicin (0.01-1 mm) applied to oral or nasal mucosa induced increases in dural and cortical blood flow and provoked lacrimation.,15009014_5,-1,-1,-1,4257,-1,0.95967805,0.040321983
4258,increases in dural and cortical blood flow,14,21,62,104,Capsaicin (0.01-1 mm) applied to oral or nasal mucosa induced increases in dural and cortical blood flow and provoked lacrimation.,15009014_5,-1,-1,-1,4258,-1,0.0492087,0.9507913
4259,hexamethonium chloride,8,10,63,85,These responses were blocked by systemic pre-administration of hexamethonium chloride (20 mg/kg).,15009014_6,-1,-1,-1,4259,-1,0.9992483,0.0007516587
4260,increases in dural blood flow,2,7,11,40,"The evoked increases in dural blood flow were also abolished by topical pre-administration of atropine (1 mm) and [Lys1, Pro2,5, Arg3,4, Tyr6]-VIP (0.1 mm), a vasoactive intestinal polypeptide (VIP) antagonist, onto the exposed dura mater.",15009014_7,-1,-1,-1,4260,-1,0.020302834,0.97969717
4262,mm,17,18,106,108,"The evoked increases in dural blood flow were also abolished by topical pre-administration of atropine (1 mm) and [Lys1, Pro2,5, Arg3,4, Tyr6]-VIP (0.1 mm), a vasoactive intestinal polypeptide (VIP) antagonist, onto the exposed dura mater.",15009014_7,-1,-1,-1,4262,-1,0.91775006,0.082250014
4263,mm,30,31,152,154,"The evoked increases in dural blood flow were also abolished by topical pre-administration of atropine (1 mm) and [Lys1, Pro2,5, Arg3,4, Tyr6]-VIP (0.1 mm), a vasoactive intestinal polypeptide (VIP) antagonist, onto the exposed dura mater.",15009014_7,-1,-1,-1,4263,-1,0.8962904,0.10370957
4265,cluster headache,9,11,58,74,Similar mechanisms may be involved in the pathogenesis of cluster headache.,15009014_10,-1,-1,-1,4265,-1,0.0035615035,0.9964385
4267,neuropathological damages,5,7,54,79,Organophosphate-induced convulsions and prevention of neuropathological damages.,15036754_0,-1,-1,-1,4267,-1,0.0024923733,0.9975076
4268,organophosphorus (OP) compounds,1,6,5,36,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,-1,-1,-1,4268,-1,0.9683192,0.03168088
4269,diisopropylfluorophosphate,7,8,40,66,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,-1,-1,-1,4269,-1,0.9978655,0.0021345112
4270,DFP,9,10,68,71,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,-1,-1,-1,4270,-1,0.9974356,0.002564425
4271,sarin,12,13,74,79,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,-1,-1,-1,4271,-1,0.99792886,0.0020710868
4272,soman,14,15,84,89,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,-1,-1,-1,4272,-1,0.9981115,0.0018884994
4274,OPs,4,5,22,25,"The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels.",15036754_2,-1,-1,-1,4274,-1,0.98867923,0.011320797
4276,ACh,27,28,148,151,"The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels.",15036754_2,-1,-1,-1,4276,-1,0.9973636,0.0026363893
4277,SC,6,7,41,43,The protective action of subcutaneously (SC) administered antidotes or their combinations in DFP (2.0 mg/kg BW) intoxication was studied in 9-10-weeks-old Han-Wistar male rats.,15036754_3,-1,-1,-1,4277,-1,0.97344697,0.026553096
4278,DFP,14,15,93,96,The protective action of subcutaneously (SC) administered antidotes or their combinations in DFP (2.0 mg/kg BW) intoxication was studied in 9-10-weeks-old Han-Wistar male rats.,15036754_3,-1,-1,-1,4278,-1,0.9986754,0.0013246187
4279,pralidoxime-2-chloride,5,6,35,57,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4279,-1,0.9987987,0.0012012252
4280,2PAM,7,8,59,63,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4280,-1,0.99747556,0.0025244385
4282,N(6)-cyclopentyl adenosine,26,28,154,180,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4282,-1,0.996225,0.0037749954
4283,CPA,29,30,182,185,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4283,-1,0.99632555,0.0036744252
4284,dizocilpine maleate,39,41,228,247,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4284,-1,0.99840075,0.0015993007
4285,hydrogen maleate,44,46,257,273,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4285,-1,0.99514717,0.0048528328
4286,atropine sulfate,58,60,335,351,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4286,-1,0.99851125,0.0014887374
4287,DFP,75,76,423,426,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,-1,-1,-1,4287,-1,0.998126,0.0018739697
4288,atropine sulfate,4,6,26,42,"The control rats received atropine sulfate, but also saline and olive oil instead of other antidotes and DFP, respectively.",15036754_5,-1,-1,-1,4288,-1,0.9989839,0.0010160552
4289,olive oil,11,13,64,73,"The control rats received atropine sulfate, but also saline and olive oil instead of other antidotes and DFP, respectively.",15036754_5,-1,-1,-1,4289,-1,0.9959488,0.00405116
4290,DFP,18,19,105,108,"The control rats received atropine sulfate, but also saline and olive oil instead of other antidotes and DFP, respectively.",15036754_5,-1,-1,-1,4290,-1,0.9972287,0.0027713068
4291,h,6,7,35,36,All rats were terminated either 24 h or 3 weeks after the DFP injection.,15036754_6,-1,-1,-1,4291,-1,0.5493178,0.45068216
4292,DFP,12,13,58,61,All rats were terminated either 24 h or 3 weeks after the DFP injection.,15036754_6,-1,-1,-1,4292,-1,0.9989785,0.001021512
4294,CPA,1,2,5,8,"When CPA, diazepam or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of poisoning.",15036754_8,-1,-1,-1,4294,-1,0.9984139,0.0015860483
4296,2PAM,5,6,22,26,"When CPA, diazepam or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of poisoning.",15036754_8,-1,-1,-1,4296,-1,0.99874914,0.001250792
4298,DFP toxicity,8,10,63,75,Atropine-MK801 did not offer any additional protection against DFP toxicity.,15036754_9,-1,-1,-1,4298,-1,0.8292546,0.17074533
4299,CPA,3,4,15,18,"In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.",15036754_10,-1,-1,-1,4299,-1,0.99800354,0.0019964639
4301,2PAM,7,8,33,37,"In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.",15036754_10,-1,-1,-1,4301,-1,0.99882513,0.0011748911
4305,DFP,26,27,155,158,"In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.",15036754_10,-1,-1,-1,4305,-1,0.99833703,0.0016628909
4306,Atrial fibrillation,0,2,0,19,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4306,-1,0.003781805,0.99621814
4307,gastric lymphoma,10,12,79,95,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4307,-1,0.00710597,0.992894
4308,myotonic dystrophy,16,18,114,132,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4308,-1,0.003657719,0.99634224
4309,gastric lymphoma,30,32,222,238,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4309,-1,0.007112664,0.9928873
4310,myotonic dystrophy,33,35,243,261,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4310,-1,0.0036352319,0.9963648
4311,muscular dystrophy,42,44,293,311,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4311,-1,0.0033536318,0.99664634
4312,atrial fibrillation,47,49,324,343,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,-1,-1,-1,4312,-1,0.0035651743,0.9964348
4313,Atrial fibrillation,0,2,0,19,Atrial fibrillation or other cardiac arrhythmias are unusual complications in patients treated with chemotherapy.,15042318_1,-1,-1,-1,4313,-1,0.0047995904,0.9952004
4319,dilevalol,7,8,46,55,OBJECTIVE: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol-induced liver injury.,1504402_1,-1,-1,-1,4319,-1,0.99916077,0.00083926116
4320,dilevalol,15,16,97,106,OBJECTIVE: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol-induced liver injury.,1504402_1,-1,-1,-1,4320,-1,0.9990251,0.0009749027
4323,dilevalol,19,20,118,127,METHODS: Peripheral blood mononuclear cells collected from the patient were cultured in the presence of a solution of dilevalol and also with sera collected from a volunteer before and after dilevalol intake.,1504402_3,-1,-1,-1,4323,-1,0.99915826,0.0008417933
4324,dilevalol,31,32,191,200,METHODS: Peripheral blood mononuclear cells collected from the patient were cultured in the presence of a solution of dilevalol and also with sera collected from a volunteer before and after dilevalol intake.,1504402_3,-1,-1,-1,4324,-1,0.99907994,0.00092008134
4325,dilevalol,20,21,119,128,RESULTS: No lymphocyte proliferation was observed either in the patient or in the healthy volunteer in the presence of dilevalol solutions.,1504402_5,-1,-1,-1,4325,-1,0.99903274,0.00096726796
4326,dilevalol,8,9,62,71,A significant proliferative response to serum collected after dilevalol intake was observed in the case of the patient compared with the proliferative response to the serum collected before the drug intake.,1504402_6,-1,-1,-1,4326,-1,0.99894506,0.001054975
4327,dilevalol,16,17,120,129,"CONCLUSIONS: The methodology used allowed the detection of lymphocyte sensitization to sera containing ex vivo-prepared dilevalol antigens, suggesting the involvement of an immunologic mechanism in dilevalol-induced liver injury.",1504402_8,-1,-1,-1,4327,-1,0.9991479,0.00085208425
4329,nephrotic syndrome,12,14,102,120,Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside-induced nephrotic syndrome in rats.,15075188_0,-1,-1,-1,4329,-1,0.0020434356,0.9979565
4333,Na,4,5,32,34,We hypothesized that epithelial Na channel (ENaC) subunit dysregulation may be responsible for the increased sodium retention.,15075188_3,-1,-1,-1,4333,-1,0.9967662,0.003233743
4335,puromycin aminonucleoside,8,10,47,72,"An experimental group of rats was treated with puromycin aminonucleoside (PAN; 180 mg/kg iv), whereas the control group received only vehicle.",15075188_4,-1,-1,-1,4335,-1,0.99845016,0.0015498004
4336,PAN,11,12,74,77,"An experimental group of rats was treated with puromycin aminonucleoside (PAN; 180 mg/kg iv), whereas the control group received only vehicle.",15075188_4,-1,-1,-1,4336,-1,0.9975994,0.002400576
4337,PAN,4,5,14,17,"After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.",15075188_5,-1,-1,-1,4337,-1,0.9985152,0.0014848058
4339,hypoalbuminemia,10,11,61,76,"After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.",15075188_5,-1,-1,-1,4339,-1,0.0077882996,0.9922117
4342,contrast,1,2,3,11,"In contrast, the protein abundances of Na(+)/H(+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased.",15075188_10,-1,-1,-1,4342,-1,0.16379087,0.8362091
4344,nephrotic syndrome,39,41,241,259,"In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with PAN-induced nephrotic syndrome.",15075188_12,-1,-1,-1,4344,-1,0.002245233,0.99775475
4346,behavioral disorder,2,4,23,42,A pyridoxine-dependent behavioral disorder unmasked by isoniazid.,150790_0,-1,-1,-1,4346,-1,0.0024173786,0.99758255
4348,behavioral deterioration,4,6,22,46,"A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of isoniazid.",150790_1,-1,-1,-1,4348,-1,0.0025924093,0.9974076
4349,hyperkinesis,8,9,53,65,"A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of isoniazid.",150790_1,-1,-1,-1,4349,-1,0.0030997896,0.9969002
4351,sleeping difficulties,13,15,85,106,"A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of isoniazid.",150790_1,-1,-1,-1,4351,-1,0.003863369,0.9961366
4353,pyridoxine hydrochloride,6,8,45,69,The administration of pharmacologic doses of pyridoxine hydrochloride led to a disappearance of symptoms.,150790_2,-1,-1,-1,4353,-1,0.99888426,0.0011157687
4356,niacinamide,7,8,29,40,"A placebo had no effect, but niacinamide was as effective as pyridoxine.",150790_4,-1,-1,-1,4356,-1,0.99927455,0.00072544976
4359,hyperkinesis,10,11,68,80,Periodic withdrawal of pyridoxine was associated with return of the hyperkinesis.,150790_5,-1,-1,-1,4359,-1,0.0022409717,0.997759
4360,pyridoxal,3,4,13,22,The level of pyridoxal in the blood was normal during the periods of relapse.,150790_6,-1,-1,-1,4360,-1,0.9992822,0.000717882
4361,kynurenine,7,8,43,53,Metabolic studies suggested a block in the kynurenine pathway of tryptophan metabolism.,150790_7,-1,-1,-1,4361,-1,0.9991092,0.00089077395
4362,tryptophan,10,11,65,75,Metabolic studies suggested a block in the kynurenine pathway of tryptophan metabolism.,150790_7,-1,-1,-1,4362,-1,0.9976525,0.002347553
4364,Parkinson's disease,15,18,106,125,Pallidal stimulation: an alternative to pallidotomy?A resurgence of interest in the surgical treatment of Parkinson's disease (PD) came with the rediscovery of posteroventral pallidotomy by Laitinen in 1985.,15096016_0,-1,-1,-1,4364,-1,0.0069895065,0.99301046
4365,PD,19,20,127,129,Pallidal stimulation: an alternative to pallidotomy?A resurgence of interest in the surgical treatment of Parkinson's disease (PD) came with the rediscovery of posteroventral pallidotomy by Laitinen in 1985.,15096016_0,-1,-1,-1,4365,-1,0.0047950465,0.9952049
4366,PD,8,9,62,64,"Laitinen's procedure improved most symptoms in drug-resistant PD, which engendered wide interest in the neurosurgical community.",15096016_1,-1,-1,-1,4366,-1,0.0056456844,0.99435437
4367,PD,12,13,70,72,"According to the literature pallidotomy improves the ""on"" symptoms of PD, such as dyskinesias, as well as the ""off"" symptoms, such as rigidity, bradykinesia, and on-off fluctuations.",15096016_4,-1,-1,-1,4367,-1,0.0053278143,0.99467224
4370,bradykinesia,31,32,144,156,"According to the literature pallidotomy improves the ""on"" symptoms of PD, such as dyskinesias, as well as the ""off"" symptoms, such as rigidity, bradykinesia, and on-off fluctuations.",15096016_4,-1,-1,-1,4370,-1,0.0024227407,0.99757725
4371,bradykinesia,3,4,30,42,"Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.",15096016_5,-1,-1,-1,4371,-1,0.0018731012,0.9981269
4374,hyper- or dyskinetic,7,10,49,69,"Stimulation often produces an improvement in the hyper- or dyskinetic upper limbs, but increases the ""freezing"" phenomenon in the lower limbs at the same time.",15096016_6,-1,-1,-1,4374,-1,0.0044707865,0.99552923
4377,status epilepticus,8,10,55,73,"Similar to rats, systemic pilocarpine injection causes status epilepticus (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice.",15120741_1,-1,-1,-1,4377,-1,0.0031271088,0.99687296
4378,SE,11,12,75,77,"Similar to rats, systemic pilocarpine injection causes status epilepticus (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice.",15120741_1,-1,-1,-1,4378,-1,0.0038706337,0.9961294
4381,SE,40,41,276,278,"In Mg(2+)-free bathing medium containing bicuculline, conditions designed to increase excitability in the slices, electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine-treated mice that did not experience SE.",15120741_3,-1,-1,-1,4381,-1,0.005333505,0.99466646
4382,SE,1,2,3,5,"In SE survivors, similar stimulation resulted in a population spike followed, at a variable latency, by negative DC shifts and repetitive afterdischarges of 3-60 s duration, which were blocked by ionotropic glutamate receptor antagonists.",15120741_4,-1,-1,-1,4382,-1,0.121218964,0.878781
4385,SE,28,29,170,172,Focal glutamate photostimulation of the granule cell layer at sites distant from the recording pipette resulted in population responses of 1-30 s duration in slices from SE survivors but not other groups.,15120741_5,-1,-1,-1,4385,-1,0.95181715,0.048182927
4389,Wegener's granulomatosis,4,7,26,50,Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.,15130900_0,-1,-1,-1,4389,-1,0.029175878,0.9708241
4393,Wegener's granulomatosis,21,24,121,145,"OBJECTIVE: To assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with Wegener's granulomatosis.",15130900_1,-1,-1,-1,4393,-1,0.062043514,0.93795645
4394,Wegener's granulomatosis,17,20,103,127,"METHODS: In the population based, nationwide Swedish Inpatient Register a cohort of 1065 patients with Wegener's granulomatosis, 1969-95, was identified.",15130900_2,-1,-1,-1,4394,-1,0.14748542,0.85251456
4400,Wegener's granulomatosis,10,13,58,82,"In the cohort the cumulative risk of bladder cancer after Wegener's granulomatosis, and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener's granulomatosis, were also estimated.",15130900_5,-1,-1,-1,4400,-1,0.29326174,0.70673823
4402,Wegener's granulomatosis,30,33,171,195,"In the cohort the cumulative risk of bladder cancer after Wegener's granulomatosis, and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener's granulomatosis, were also estimated.",15130900_5,-1,-1,-1,4402,-1,0.25117496,0.7488251
4404,n,11,12,70,71,"RESULTS: The median cumulative doses of cyclophosphamide among cases (n = 11) and controls (n = 25) were 113 g and 25 g, respectively.",15130900_6,-1,-1,-1,4404,-1,0.26879334,0.7312067
4405,n,18,19,92,93,"RESULTS: The median cumulative doses of cyclophosphamide among cases (n = 11) and controls (n = 25) were 113 g and 25 g, respectively.",15130900_6,-1,-1,-1,4405,-1,0.25895926,0.74104077
4409,Wegener's granulomatosis,17,20,91,115,"The absolute risk for bladder cancer in the cohort reached 10% 16 years after diagnosis of Wegener's granulomatosis, and a history of bladder cancer was (non-significantly) twice as common as expected at the time of diagnosis of Wegener's granulomatosis.",15130900_9,-1,-1,-1,4409,-1,0.17748785,0.82251215
4411,Wegener's granulomatosis,42,45,229,253,"The absolute risk for bladder cancer in the cohort reached 10% 16 years after diagnosis of Wegener's granulomatosis, and a history of bladder cancer was (non-significantly) twice as common as expected at the time of diagnosis of Wegener's granulomatosis.",15130900_9,-1,-1,-1,4411,-1,0.17027709,0.8297229
4414,Wegener's granulomatosis,35,38,226,250,"CONCLUSION: The results indicate a dose-response relationship between cyclophosphamide and the risk of bladder cancer, high cumulative risks in the entire cohort, and also the possibility of risk factors operating even before Wegener's granulomatosis.",15130900_10,-1,-1,-1,4414,-1,0.035110652,0.96488935
4421,rilmenidine,8,9,56,67,"Changes evoked by a single intraperitoneal injection of rilmenidine (600 microg/kg) or alpha-methyldopa (100 mg/kg), selective I1- and alpha2-receptor agonists, respectively, in blood pressure, hemodynamic variability, and locomotor activity were assessed in radiotelemetered sham-operated and ovariectomized (Ovx) Sprague-Dawley female rats with or without 12-wk estrogen replacement.",15145918_3,-1,-1,-1,4421,-1,0.99929655,0.00070342317
4423,rilmenidine,4,5,23,34,"In sham-operated rats, rilmenidine or alpha-methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.",15145918_5,-1,-1,-1,4423,-1,0.99926656,0.00073346763
4425,h,15,16,107,108,"In sham-operated rats, rilmenidine or alpha-methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.",15145918_5,-1,-1,-1,4425,-1,0.06745812,0.9325419
4427,contrast,10,11,76,84,"Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.",15145918_7,-1,-1,-1,4427,-1,0.29089078,0.7091092
4428,rilmenidine hypotension,15,17,101,124,"Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.",15145918_7,-1,-1,-1,4428,-1,0.8984199,0.10158004
4430,a reduced locomotor activity,15,19,104,132,The enhanced alpha-methyldopa hypotension in Ovx rats was paralleled with further reduction in SDRR and a reduced locomotor activity.,15145918_8,-1,-1,-1,4430,-1,0.020798596,0.97920144
4434,left ventricular systolic and diastolic dysfunction,2,8,18,69,Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic epinephrine overdose.,15188772_0,-1,-1,-1,4434,-1,0.0073927334,0.99260724
4435,iatrogenic epinephrine overdose,11,14,88,119,Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic epinephrine overdose.,15188772_0,-1,-1,-1,4435,-1,0.036466647,0.96353334
4438,contrast,1,2,3,11,"In contrast, reports of myocardial dysfunction due to acute iatrogenic overdose are rare.",15188772_2,-1,-1,-1,4438,-1,0.27257565,0.7274243
4439,myocardial dysfunction,5,7,24,46,"In contrast, reports of myocardial dysfunction due to acute iatrogenic overdose are rare.",15188772_2,-1,-1,-1,4439,-1,0.0025220935,0.99747795
4441,mg,11,12,73,75,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.",15188772_3,-1,-1,-1,4441,-1,0.9905657,0.009434257
4443,myocardial stunning,15,17,101,120,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.",15188772_3,-1,-1,-1,4443,-1,0.0030531671,0.9969469
4444,left ventricular systolic and diastolic dysfunction,30,36,206,257,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.",15188772_3,-1,-1,-1,4444,-1,0.009999579,0.9900004
4445,myocardial necrosis,44,46,309,328,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.",15188772_3,-1,-1,-1,4445,-1,0.0031846703,0.9968154
4446,tincture of Crataegus,3,6,27,48,Cardioprotective effect of tincture of Crataegus on isoproterenol-induced myocardial infarction in rats.,15233872_0,-1,-1,-1,4446,-1,0.9920993,0.007900704
4447,myocardial infarction,8,10,74,95,Cardioprotective effect of tincture of Crataegus on isoproterenol-induced myocardial infarction in rats.,15233872_0,-1,-1,-1,4447,-1,0.0025496753,0.9974503
4448,Tincture of Crataegus,0,3,0,21,"Tincture of Crataegus (TCR), an alcoholic extract of the berries of hawthorn (Crataegus oxycantha), is used in herbal and homeopathic medicine.",15233872_1,-1,-1,-1,4448,-1,0.49050665,0.50949335
4449,TCR,4,5,23,26,"Tincture of Crataegus (TCR), an alcoholic extract of the berries of hawthorn (Crataegus oxycantha), is used in herbal and homeopathic medicine.",15233872_1,-1,-1,-1,4449,-1,0.973644,0.026355978
4450,alcoholic extract of the berries,8,13,32,64,"Tincture of Crataegus (TCR), an alcoholic extract of the berries of hawthorn (Crataegus oxycantha), is used in herbal and homeopathic medicine.",15233872_1,-1,-1,-1,4450,-1,0.9081966,0.09180341
4451,hawthorn (Crataegus oxycantha,14,18,68,97,"Tincture of Crataegus (TCR), an alcoholic extract of the berries of hawthorn (Crataegus oxycantha), is used in herbal and homeopathic medicine.",15233872_1,-1,-1,-1,4451,-1,0.9809703,0.019029638
4452,TCR,11,12,67,70,The present study was done to investigate the protective effect of TCR on experimentally induced myocardial infarction in rats.,15233872_2,-1,-1,-1,4452,-1,0.9970394,0.002960624
4453,myocardial infarction,15,17,97,118,The present study was done to investigate the protective effect of TCR on experimentally induced myocardial infarction in rats.,15233872_2,-1,-1,-1,4453,-1,0.0023764092,0.9976236
4454,TCR,2,3,16,19,"Pretreatment of TCR, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in lipid peroxidation and activity of marker enzymes observed in isoproterenol-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).",15233872_3,-1,-1,-1,4454,-1,0.9982223,0.0017777417
4455,mg,37,38,206,208,"Pretreatment of TCR, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in lipid peroxidation and activity of marker enzymes observed in isoproterenol-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).",15233872_3,-1,-1,-1,4455,-1,0.9422968,0.057703216
4456,h,50,51,254,255,"Pretreatment of TCR, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in lipid peroxidation and activity of marker enzymes observed in isoproterenol-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).",15233872_3,-1,-1,-1,4456,-1,0.123697996,0.876302
4457,TCR,0,1,0,3,TCR prevented the isoproterenol-induced decrease in antioxidant enzymes in the heart and increased the rate of ADP-stimulated oxygen uptake and respiratory coupling ratio.,15233872_4,-1,-1,-1,4457,-1,0.99813205,0.0018680213
4460,TCR,6,7,40,43,The results show that pretreatment with TCR may be useful in preventing the damage induced by isoproterenol in rat heart.,15233872_6,-1,-1,-1,4460,-1,0.99789965,0.0021003687
4462,valdecoxib,6,7,51,61,Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.,15266215_0,-1,-1,-1,4462,-1,0.9992168,0.0007831279
4466,NSAIDs,24,25,192,198,There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase (COX)-2-specific inhibitors than nonselective nonsteroidal antiinflammatory drugs (NSAIDs).,15266215_1,-1,-1,-1,4466,-1,0.99570894,0.0042910185
4467,valdecoxib,6,7,43,53,"We evaluated cardiovascular event data for valdecoxib, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials.",15266215_2,-1,-1,-1,4467,-1,0.9993414,0.0006585245
4468,osteoarthritis,17,18,122,136,"We evaluated cardiovascular event data for valdecoxib, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials.",15266215_2,-1,-1,-1,4468,-1,0.004320912,0.9956791
4472,valdecoxib,23,24,160,170,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4472,-1,0.9993728,0.0006271946
4473,mg,28,29,178,180,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4473,-1,0.9478262,0.052173786
4474,NSAID,33,34,202,207,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4474,-1,0.9979912,0.0020088274
4476,mg,37,38,223,225,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4476,-1,0.927075,0.07292495
4478,mg,42,43,245,247,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4478,-1,0.9147218,0.08527819
4479,naproxen,46,47,256,264,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4479,-1,0.9990741,0.00092587434
4480,mg,48,49,269,271,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4480,-1,0.8840547,0.11594525
4481,osteoarthritis,57,58,313,327,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,-1,-1,-1,4481,-1,0.014264289,0.9857357
4483,n,11,12,63,64,The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).,15266215_4,-1,-1,-1,4483,-1,0.2033155,0.7966845
4484,mg,25,26,109,111,The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).,15266215_4,-1,-1,-1,4484,-1,0.9929583,0.0070416853
4486,n,30,31,128,129,The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).,15266215_4,-1,-1,-1,4486,-1,0.21830602,0.78169394
4488,n,39,40,163,164,The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).,15266215_4,-1,-1,-1,4488,-1,0.17574657,0.8242534
4490,valdecoxib,10,11,77,87,"Crude and exposure-adjusted incidences of thrombotic events were similar for valdecoxib, NSAIDs, and placebo.",15266215_5,-1,-1,-1,4490,-1,0.9993026,0.00069738616
4491,NSAIDs,12,13,89,95,"Crude and exposure-adjusted incidences of thrombotic events were similar for valdecoxib, NSAIDs, and placebo.",15266215_5,-1,-1,-1,4491,-1,0.9985109,0.0014891047
4493,valdecoxib,11,12,64,74,The risk of serious thrombotic events was also similar for each valdecoxib dose.,15266215_6,-1,-1,-1,4493,-1,0.9992662,0.0007337886
4497,valdecoxib,23,24,115,125,"Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1.4% vs. 0%; valdecoxib, 1.7% vs. 0.2%; NSAIDs, 1.9% vs. 0.5%).",15266215_7,-1,-1,-1,4497,-1,0.9992508,0.0007491037
4498,NSAIDs,31,32,142,148,"Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1.4% vs. 0%; valdecoxib, 1.7% vs. 0.2%; NSAIDs, 1.9% vs. 0.5%).",15266215_7,-1,-1,-1,4498,-1,0.9978309,0.0021691148
4500,valdecoxib,17,18,91,101,The rates of events in users of aspirin were similar for all 3 treatment groups and across valdecoxib doses.,15266215_8,-1,-1,-1,4500,-1,0.99934167,0.00065834064
4501,mg,10,11,66,68,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,-1,-1,4501,-1,0.98471916,0.015280862
4502,mg,19,20,107,109,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,-1,-1,4502,-1,0.970924,0.029075997
4503,valdecoxib,22,23,117,127,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,-1,-1,4503,-1,0.9993451,0.00065483013
4505,NSAIDs,37,38,227,233,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,-1,-1,4505,-1,0.99870086,0.001299118
4506,osteoarthritis,41,42,248,262,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,-1,-1,-1,4506,-1,0.003392739,0.9966073
4508,Hypersensitivity myocarditis,0,2,0,28,Hypersensitivity myocarditis complicating hypertrophic cardiomyopathy heart.,15266362_0,-1,-1,-1,4508,-1,0.006728576,0.9932714
4509,hypertrophic cardiomyopathy,3,5,42,69,Hypersensitivity myocarditis complicating hypertrophic cardiomyopathy heart.,15266362_0,-1,-1,-1,4509,-1,0.0039323377,0.99606764
4510,eosinophilic myocarditis,7,9,39,63,The present report describes a case of eosinophilic myocarditis complicating hypertrophic cardiomyopathy.,15266362_1,-1,-1,-1,4510,-1,0.0066575534,0.99334246
4511,hypertrophic cardiomyopathy,10,12,77,104,The present report describes a case of eosinophilic myocarditis complicating hypertrophic cardiomyopathy.,15266362_1,-1,-1,-1,4511,-1,0.0028994237,0.99710053
4512,hypertrophic cardiomyopathy,8,10,46,73,"The 47-year-old female patient, known to have hypertrophic cardiomyopathy, was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.",15266362_2,-1,-1,-1,4512,-1,0.0029633658,0.9970367
4513,biventricular failure,14,16,93,114,"The 47-year-old female patient, known to have hypertrophic cardiomyopathy, was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.",15266362_2,-1,-1,-1,4513,-1,0.09504983,0.90495014
4515,left ventricular dysfunction,7,10,50,78,"On transthoracic echocardiogram, she had moderate left ventricular dysfunction with regional variability and moderate mitral regurgitation.",15266362_3,-1,-1,-1,4515,-1,0.0125583485,0.98744166
4517,hypertrophic cardiomyopathy,9,11,52,79,The recipient's heart showed the features of apical hypertrophic cardiomyopathy and myocarditis with abundant eosinophils.,15266362_4,-1,-1,-1,4517,-1,0.0031993722,0.99680066
4520,eosinophilic myocarditis,4,6,24,48,Myocarditis is rare and eosinophilic myocarditis is rarer.,15266362_5,-1,-1,-1,4520,-1,0.005202412,0.9947976
4522,eosinophilic,7,8,40,52,It is likely that the hypersensitivity (eosinophilic) myocarditis was related to dobutamine infusion therapy.,15266362_6,-1,-1,-1,4522,-1,0.0038804708,0.9961195
4525,Eosinophilic myocarditis,0,2,0,24,Eosinophilic myocarditis has been reported with an incidence of 2.4% to 7.2% in explanted hearts and may be related to multidrug therapy.,15266362_7,-1,-1,-1,4525,-1,0.0029270477,0.99707294
4529,Idiopathic subjective tinnitus,0,3,0,30,Idiopathic subjective tinnitus (IST) is one of the most obscure otological pathologies.,1527456_1,-1,-1,-1,4529,-1,0.005105086,0.9948949
4530,IST,4,5,32,35,Idiopathic subjective tinnitus (IST) is one of the most obscure otological pathologies.,1527456_1,-1,-1,-1,4530,-1,0.06908912,0.9309108
4531,IST,7,8,44,47,"This paper presents the results of treating IST by intratympanic instillation of lignocaine (lidocaine) 2 per cent through a grommet, for five weekly courses.",1527456_2,-1,-1,-1,4531,-1,0.12388214,0.8761179
4537,vertigo,9,10,52,59,"Patients should be warned about the side effects of vertigo and vomiting, which subsides gradually with every new instillation, and that the tinnitus may not disappear but will be alleviated, enabling them to cope more easily with the disease and lead a more normal life.",1527456_6,-1,-1,-1,4537,-1,0.032382067,0.9676179
4540,lead,43,44,247,251,"Patients should be warned about the side effects of vertigo and vomiting, which subsides gradually with every new instillation, and that the tinnitus may not disappear but will be alleviated, enabling them to cope more easily with the disease and lead a more normal life.",1527456_6,-1,-1,-1,4540,-1,0.06942168,0.9305783
4543,hypolocomotion,14,15,111,125,The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice.,15275829_0,-1,-1,-1,4543,-1,0.004250476,0.9957495
4549,ion channels,3,5,22,34,nAChRs are pentameric ion channels usually composed of alpha and beta subunits.,15275829_2,-1,-1,-1,4549,-1,0.38882878,0.6111712
4551,hypolocomotion,12,13,76,90,We examined the role of the beta4 subunits in nicotine-induced seizures and hypolocomotion in beta4 homozygous null (beta4 -/-) and alpha3 heterozygous (+/-) mice.,15275829_4,-1,-1,-1,4551,-1,0.0037942934,0.9962057
4556,hypolocomotion,18,19,118,132,"Together, these results suggest that the beta4 and the alpha3 subunits are mediators of nicotine-induced seizures and hypolocomotion.",15275829_9,-1,-1,-1,4556,-1,0.0061348844,0.9938651
4559,intracranial bleeding,7,9,42,63,"The proportion of patients with major and intracranial bleeding increased from 20.2% and 1.9%, respectively, in the first time period, to 33.3% and 7.8%, respectively, in the second.",15276120_2,-1,-1,-1,4559,-1,0.0034228698,0.9965771
4565,SD,7,8,35,37,"The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.",15278670_2,-1,-1,-1,4565,-1,0.101670854,0.89832914
4566,mg,14,15,56,58,"The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.",15278670_2,-1,-1,-1,4566,-1,0.59337634,0.40662366
4568,mg.kg(-1).min(-1,23,24,93,109,"The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.",15278670_2,-1,-1,-1,4568,-1,0.7874501,0.2125499
4569,mg,34,35,155,157,"The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.",15278670_2,-1,-1,-1,4569,-1,0.524917,0.47508305
4571,mg,9,10,37,39,"However, the threshold (61.6 +/- 8.7 mg. l(-1)) during 1.6% sevoflurane was not significant from that during 0.8% sevoflurane, indicating a celling effect.",15278670_3,-1,-1,-1,4571,-1,0.8375397,0.16246031
4583,Apamin,0,1,0,6,"Apamin, a selective blocker of calcium-dependent potassium channels, was administered intracerebroventricularly in rats anesthetized with 0.8% sevoflurane to investigate the mechanism of the anticonvulsive effects.",15278670_7,-1,-1,-1,4583,-1,0.9990865,0.00091352157
4586,Apamin,0,1,0,6,Apamin (10 ng) had a tendency to decrease the convulsive threshold (21.6 +/- 2.2 to 19.9 +/- 2.5 mg. l(-1)) but this was not statistically significant.,15278670_8,-1,-1,-1,4586,-1,0.9989955,0.001004543
4587,ng,3,4,11,13,Apamin (10 ng) had a tendency to decrease the convulsive threshold (21.6 +/- 2.2 to 19.9 +/- 2.5 mg. l(-1)) but this was not statistically significant.,15278670_8,-1,-1,-1,4587,-1,0.9797789,0.020221155
4589,mg,23,24,97,99,Apamin (10 ng) had a tendency to decrease the convulsive threshold (21.6 +/- 2.2 to 19.9 +/- 2.5 mg. l(-1)) but this was not statistically significant.,15278670_8,-1,-1,-1,4589,-1,0.7246331,0.27536687
4592,lidocaine toxicity,10,12,66,84,It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.,15278670_9,-1,-1,-1,4592,-1,0.34426484,0.65573514
4602,thiotepa,12,13,80,88,"STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.",15325671_3,-1,-1,-1,4602,-1,0.99905866,0.00094130257
4607,congestive heart failure,30,33,238,262,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,-1,-1,-1,4607,-1,0.0029672384,0.99703276
4608,CHF,34,35,264,267,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,-1,-1,-1,4608,-1,0.0028130207,0.99718696
4611,diabetes mellitus,60,62,419,436,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,-1,-1,-1,4611,-1,0.080284275,0.91971576
4612,anthracyclines,66,67,451,465,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,-1,-1,-1,4612,-1,0.99737203,0.0026279043
4613,CHF,15,16,71,74,RESULTS: Six of 61 women (10%) developed clinically reversible grade 3 CHF following infusional cyclophosphamide with a median percent decline in ejection fraction of 31%.,15325671_5,-1,-1,-1,4613,-1,0.0022530328,0.997747
4616,CHF,7,8,48,51,"Older age was significantly correlated with the CHF development; with median ages for the entire group and for patients developing CHF of 45 and 59, respectively.",15325671_7,-1,-1,-1,4616,-1,0.0034539634,0.9965461
4617,CHF,21,22,131,134,"Older age was significantly correlated with the CHF development; with median ages for the entire group and for patients developing CHF of 45 and 59, respectively.",15325671_7,-1,-1,-1,4617,-1,0.0029553124,0.99704474
4619,CHF,9,10,74,77,Routine EKG monitoring during infusional cyclophosphamide did not predict CHF development.,15325671_10,-1,-1,-1,4619,-1,0.002531244,0.9974688
4625,obstructive lung disease,10,13,64,88,To determine sensitivity we assessed tremor in 44 patients with obstructive lung disease after administration of cumulative doses of salbutamol.,15338796_5,-1,-1,-1,4625,-1,0.0034184388,0.9965816
4634,P,14,15,75,76,Within healthy adults no age-dependency could be found (b = 0.262 mm/year; P = 0.72).,15338796_13,-1,-1,-1,4634,-1,0.4576815,0.54231846
4636,P,15,16,81,82,There was no agreement between the questionnaire and tremor severity (r = 0.093; P = 0.53).,15338796_14,-1,-1,-1,4636,-1,0.40538165,0.5946183
4638,P,13,14,86,87,Postural tremor showed no significant difference between the first and third session (P = 0.07).,15338796_15,-1,-1,-1,4638,-1,0.25664708,0.7433529
4642,sexual side effects,3,6,23,42,Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers.,1535072_0,-1,-1,-1,4642,-1,0.0025459817,0.997454
4643,serotonin reuptake blockers,8,11,54,81,Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers.,1535072_0,-1,-1,-1,4643,-1,0.9962359,0.003764103
4645,impotence,21,22,140,149,BACKGROUND: Preclinical and clinical studies suggest that yohimbine facilitates sexual behavior and may be helpful in the treatment of male impotence.,1535072_1,-1,-1,-1,4645,-1,0.0072014,0.99279857
4647,sexual side,13,15,70,81,A single case report suggests that yohimbine may be used to treat the sexual side effects of clomipramine.,1535072_2,-1,-1,-1,4647,-1,0.0031669093,0.99683315
4650,sexual side effects,9,12,54,73,This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers.,1535072_3,-1,-1,-1,4650,-1,0.0027214587,0.9972785
4651,serotonin reuptake blockers,14,17,84,111,This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers.,1535072_3,-1,-1,-1,4651,-1,0.995278,0.004722003
4652,obsessive compulsive disorder,6,9,33,62,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,-1,-1,-1,4652,-1,0.0056493953,0.9943506
4653,trichotillomania,10,11,64,80,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,-1,-1,-1,4653,-1,0.014200881,0.9857991
4654,anxiety,12,13,82,89,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,-1,-1,-1,4654,-1,0.003646688,0.99635327
4655,affective disorders,15,17,94,113,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,-1,-1,-1,4655,-1,0.0030440933,0.9969559
4656,sexual side effects,19,22,127,146,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,-1,-1,-1,4656,-1,0.0035743502,0.9964257
4657,serotonin reuptake blockers,25,28,168,195,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,-1,-1,-1,4657,-1,0.9963899,0.0036100138
4663,sweating,6,7,45,53,"Side effects of yohimbine included excessive sweating, increased anxiety, and a wound-up feeling in some patients.",1535072_9,-1,-1,-1,4663,-1,0.0037949928,0.99620503
4664,anxiety,9,10,65,72,"Side effects of yohimbine included excessive sweating, increased anxiety, and a wound-up feeling in some patients.",1535072_9,-1,-1,-1,4664,-1,0.0042816414,0.9957184
4666,sexual side effects,17,20,100,119,CONCLUSION: The results of this study indicate that yohimbine may be an effective treatment for the sexual side effects caused by serotonin reuptake blockers.,1535072_10,-1,-1,-1,4666,-1,0.0027268336,0.99727315
4667,serotonin reuptake blockers,22,25,130,157,CONCLUSION: The results of this study indicate that yohimbine may be an effective treatment for the sexual side effects caused by serotonin reuptake blockers.,1535072_10,-1,-1,-1,4667,-1,0.99617106,0.0038289626
4669,Hemorrhagic cystitis,0,2,0,20,Hemorrhagic cystitis complicating bone marrow transplantation.,1545575_0,-1,-1,-1,4669,-1,0.0030871124,0.99691284
4673,hemorrhagic cystitis,30,32,202,222,"In an attempt to obviate the inconvenience of bladder irrigation, we conducted a feasibility trial of uroprophylaxis with mesna, which neutralizes the hepatic metabolite of cyclophosphamide that causes hemorrhagic cystitis.",1545575_3,-1,-1,-1,4673,-1,0.002205841,0.99779415
4674,hemorrhagic cystitis,11,13,68,88,"Of 97 patients who received standard prophylaxis, 4 had symptomatic hemorrhagic cystitis.",1545575_4,-1,-1,-1,4674,-1,0.0022886286,0.9977114
4675,contrast,1,2,3,11,"In contrast, two of four consecutive patients who received mesna uroprophylaxis before allogeneic bone marrow transplantation had severe hemorrhagic cystitis for at least 2 weeks.",1545575_5,-1,-1,-1,4675,-1,0.14009367,0.8599063
4677,hemorrhagic cystitis,19,21,137,157,"In contrast, two of four consecutive patients who received mesna uroprophylaxis before allogeneic bone marrow transplantation had severe hemorrhagic cystitis for at least 2 weeks.",1545575_5,-1,-1,-1,4677,-1,0.002216741,0.99778324
4678,hemorrhagic cystitis,21,23,121,141,"Because of this suboptimal result, we resumed the use of bladder irrigation and forced hydration to minimize the risk of hemorrhagic cystitis.",1545575_6,-1,-1,-1,4678,-1,0.0022470034,0.99775296
4679,raloxifene,6,7,43,53,Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation.,15458908_0,-1,-1,-1,4679,-1,0.9991492,0.0008508097
4680,raloxifene,11,12,76,86,Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation.,15458908_0,-1,-1,-1,4680,-1,0.99895823,0.0010417138
4681,raloxifene,7,8,36,46,OBJECTIVE: To examine the effect of raloxifene on major adverse events that occur with postmenopausal estrogen therapy or tamoxifen.,15458908_1,-1,-1,-1,4681,-1,0.9993463,0.00065372523
4684,Raloxifene,6,7,34,44,"METHODS: The Multiple Outcomes of Raloxifene Evaluation, a multicenter, randomized, double-blind trial, enrolled 7,705 postmenopausal women with osteoporosis.",15458908_2,-1,-1,-1,4684,-1,0.9992847,0.000715317
4686,raloxifene,5,6,32,42,Women were randomly assigned to raloxifene 60 mg/d or 120 mg/d or placebo.,15458908_3,-1,-1,-1,4686,-1,0.999288,0.0007119641
4687,thromboembolism,3,4,25,40,"Outcomes included venous thromboembolism, cataracts, gallbladder disease, and endometrial hyperplasia or cancer.",15458908_4,-1,-1,-1,4687,-1,0.011451635,0.9885484
4690,endometrial hyperplasia,11,13,78,101,"Outcomes included venous thromboembolism, cataracts, gallbladder disease, and endometrial hyperplasia or cancer.",15458908_4,-1,-1,-1,4690,-1,0.007904479,0.99209553
4692,raloxifene,10,11,47,57,"RESULTS: During a mean follow-up of 3.3 years, raloxifene was associated with an increased risk for venous thromboembolism (relative risk [RR] 2.1; 95% confidence interval [CI] 1.2-3.8).",15458908_5,-1,-1,-1,4692,-1,0.99934155,0.00065843883
4693,venous thromboembolism,18,20,100,122,"RESULTS: During a mean follow-up of 3.3 years, raloxifene was associated with an increased risk for venous thromboembolism (relative risk [RR] 2.1; 95% confidence interval [CI] 1.2-3.8).",15458908_5,-1,-1,-1,4693,-1,0.0028310716,0.99716896
4694,raloxifene,3,4,12,22,"Risk in the raloxifene group was higher than in the placebo group for the first 2 years, but decreased to about the same rate as in the placebo group thereafter.",15458908_7,-1,-1,-1,4694,-1,0.9993197,0.00068033225
4697,endometrial hyperplasia,33,35,119,142,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,-1,-1,-1,4697,-1,0.004535432,0.9954646
4699,Raloxifene,2,3,12,22,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,-1,-1,-1,4699,-1,0.9993451,0.00065483386
4700,venous thromboembolism,10,12,65,87,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,-1,-1,-1,4700,-1,0.0042375345,0.9957625
4703,endometrial hyperplasia,25,27,157,180,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,-1,-1,-1,4703,-1,0.0062995595,0.9937004
4707,lead,45,46,264,268,"While there is no single correct starting dose for levodopa therapy, many individuals can be started on either the 25/100 or controlled-release formula, following the general rule not to attempt to titrate carbidopa-levodopa to the point of ""normality,"" which can lead to toxicity.",1549199_1,-1,-1,-1,4707,-1,0.019497389,0.98050267
4709,dopamine agonist,24,26,160,176,"Following the initial period of therapy, emerging difficulties require a reassessment of therapeutic approaches, such as dosage adjustment or introduction of a dopamine agonist.",1549199_3,-1,-1,-1,4709,-1,0.9976261,0.0023739166
4710,gastrointestinal disorders,7,9,40,66,"Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.",1549199_4,-1,-1,-1,4710,-1,0.0036820516,0.996318
4712,psychosis,14,15,110,119,"Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.",1549199_4,-1,-1,-1,4712,-1,0.0025234206,0.9974765
4713,sleep disturbances,16,18,121,139,"Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.",1549199_4,-1,-1,-1,4713,-1,0.0038123871,0.9961876
4714,parasomnias,19,20,143,154,"Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.",1549199_4,-1,-1,-1,4714,-1,0.00554042,0.9944596
4715,Parkinson's disease,5,8,39,58,"Nonpharmacologic concerns can help the Parkinson's disease patient achieve and maintain optimal functioning, including daily exercise, physical therapy, and involvement with support groups.",1549199_5,-1,-1,-1,4715,-1,0.008391921,0.99160814
4716,hearing loss,18,20,103,115,OBJECTIVE: The objective of this study was to identify the incidence and to monitor the progression of hearing loss in children and young adults with beta-thalassemia major.,15515654_1,-1,-1,-1,4716,-1,0.003097237,0.99690276
4718,DFO,5,6,41,44,"Subjects were receiving desferrioxamine (DFO) chelation treatment with a mean daily dose of 50-60 mg/kg, 5-6 days a week during the first six years of the study, which was then reduced to 40-50 mg/kg for the following eight years.",15515654_4,-1,-1,-1,4718,-1,0.9979219,0.002078189
4720,SNHL,21,22,107,111,"RESULTS: Overall, 21 out of 104 patients (20.2%) presented with high frequency sensorineural hearing loss (SNHL), either unilateral or bilateral.",15515654_6,-1,-1,-1,4720,-1,0.016531356,0.98346865
4721,ototoxic,1,2,3,11,"No ototoxic factor, other than DFO, was present in any of the patients.",15515654_7,-1,-1,-1,4721,-1,0.0048999204,0.9951001
4722,DFO,6,7,31,34,"No ototoxic factor, other than DFO, was present in any of the patients.",15515654_7,-1,-1,-1,4722,-1,0.99838996,0.0016100416
4723,SNHL,2,3,14,18,"Patients with SNHL presented with relatively lower serum ferritin levels than those with normal hearing, however, no statistically significant difference was observed.",15515654_8,-1,-1,-1,4723,-1,0.007983666,0.9920163
4724,SNHL,2,3,14,18,Subjects with SNHL were submitted to DFO reduction or temporary withdrawal.,15515654_9,-1,-1,-1,4724,-1,0.021929756,0.9780702
4725,DFO,6,7,37,40,Subjects with SNHL were submitted to DFO reduction or temporary withdrawal.,15515654_9,-1,-1,-1,4725,-1,0.99875987,0.0012401309
4726,DFO,7,8,43,46,CONCLUSION: The findings are indicative of DFO's contributing role in the development of hearing impairment.,15515654_11,-1,-1,-1,4726,-1,0.9970018,0.0029981479
4727,hearing impairment,15,17,89,107,CONCLUSION: The findings are indicative of DFO's contributing role in the development of hearing impairment.,15515654_11,-1,-1,-1,4727,-1,0.0028517868,0.9971482
4728,thalassemic,7,8,51,62,Regular audiologic evaluation is imperative in all thalassemic patients so that early changes may be recognized and treatment may be judiciously adjusted in order to prevent or reverse hearing impairment.,15515654_12,-1,-1,-1,4728,-1,0.037796285,0.9622037
4729,hearing impairment,28,30,185,203,Regular audiologic evaluation is imperative in all thalassemic patients so that early changes may be recognized and treatment may be judiciously adjusted in order to prevent or reverse hearing impairment.,15515654_12,-1,-1,-1,4729,-1,0.0027330974,0.9972669
4731,autoimmune diseases,14,16,124,143,"Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis.",15517007_0,-1,-1,-1,4731,-1,0.0026087563,0.9973912
4732,systemic sclerosis,21,23,171,189,"Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis.",15517007_0,-1,-1,-1,4732,-1,0.0056984834,0.99430156
4733,multiple sclerosis,24,26,194,212,"Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis.",15517007_0,-1,-1,-1,4733,-1,0.004524845,0.9954751
4734,autoimmune diseases,17,19,128,147,Autologous haematopoietic stem cell transplantation is now a feasible and effective treatment for selected patients with severe autoimmune diseases.,15517007_1,-1,-1,-1,4734,-1,0.0025527219,0.99744725
4739,anthracyclines,8,9,54,68,"However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.",15517007_7,-1,-1,-1,4739,-1,0.99618965,0.0038103831
4741,heart damage,20,22,138,150,"However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.",15517007_7,-1,-1,-1,4741,-1,0.0032368032,0.9967632
4742,systemic sclerosis,26,28,165,183,"However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.",15517007_7,-1,-1,-1,4742,-1,0.0039934404,0.99600655
4743,autoimmune disease,25,27,144,162,"The object of the meeting was to analyse existing data, both published or available, in the European Group for Blood and Marrow Transplantation autoimmune disease database, and to propose a safe approach to such patients.",15517007_9,-1,-1,-1,4743,-1,0.005067559,0.9949325
4744,vitamin C,2,4,18,27,"Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?BACKGROUND: Vitamin C acts as a potent antioxidant; however, it can also be a prooxidant and glycate protein under certain circumstances in vitro.",15531665_0,-1,-1,-1,4744,-1,0.9984402,0.0015597765
4745,cardiovascular disease,5,7,37,59,"Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?BACKGROUND: Vitamin C acts as a potent antioxidant; however, it can also be a prooxidant and glycate protein under certain circumstances in vitro.",15531665_0,-1,-1,-1,4745,-1,0.00349555,0.9965044
4746,Vitamin C,13,15,100,109,"Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?BACKGROUND: Vitamin C acts as a potent antioxidant; however, it can also be a prooxidant and glycate protein under certain circumstances in vitro.",15531665_0,-1,-1,-1,4746,-1,0.99836904,0.0016310365
4747,vitamin C,11,13,63,72,These observations led us to hypothesize that a high intake of vitamin C in diabetic persons might promote atherosclerosis.,15531665_1,-1,-1,-1,4747,-1,0.99801195,0.0019879767
4750,vitamin C,10,12,61,70,OBJECTIVE: The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease.,15531665_2,-1,-1,-1,4750,-1,0.9981627,0.0018373295
4751,cardiovascular disease,16,18,97,119,OBJECTIVE: The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease.,15531665_2,-1,-1,-1,4751,-1,0.0037921672,0.99620783
4752,vitamin C,7,9,40,49,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,-1,-1,4752,-1,0.9979923,0.0020077166
4753,cardiovascular disease,14,16,82,104,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,-1,-1,4753,-1,0.0040764282,0.9959235
4754,n,17,18,106,107,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,-1,-1,4754,-1,0.17423096,0.82576907
4755,coronary artery disease,22,25,116,139,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,-1,-1,4755,-1,0.0059632785,0.9940367
4756,n,26,27,141,142,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,-1,-1,4756,-1,0.15522592,0.84477407
4758,n,34,35,163,164,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,-1,-1,4758,-1,0.12256569,0.8774343
4760,coronary artery disease,15,18,98,121,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4760,-1,0.004272482,0.99572754
4761,cardiovascular disease,29,31,190,212,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4761,-1,0.005271763,0.99472827
4764,folate,47,48,298,304,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4764,-1,0.99781275,0.0021872139
4765,vitamin E,49,51,306,315,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4765,-1,0.9971455,0.0028545095
4766,cardiovascular disease,61,63,373,395,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4766,-1,0.0052929423,0.99470705
4767,P,76,77,444,445,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4767,-1,0.5052324,0.49476758
4768,vitamin C,86,88,490,499,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,-1,-1,-1,4768,-1,0.99718213,0.0028179302
4769,coronary artery disease,4,7,27,50,"Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of stroke were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).",15531665_5,-1,-1,-1,4769,-1,0.0075271847,0.9924729
4770,P,19,20,89,90,"Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of stroke were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).",15531665_5,-1,-1,-1,4770,-1,0.46231636,0.53768367
4772,P,40,41,161,162,"Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of stroke were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).",15531665_5,-1,-1,-1,4772,-1,0.37076926,0.62923074
4773,vitamin C,4,6,30,39,"When dietary and supplemental vitamin C were analyzed separately, only supplemental vitamin C showed a positive association with mortality endpoints.",15531665_6,-1,-1,-1,4773,-1,0.99821585,0.0017841026
4774,vitamin C,12,14,84,93,"When dietary and supplemental vitamin C were analyzed separately, only supplemental vitamin C showed a positive association with mortality endpoints.",15531665_6,-1,-1,-1,4774,-1,0.99812216,0.0018778624
4775,cardiovascular disease,8,10,49,71,Vitamin C intake was unrelated to mortality from cardiovascular disease in the nondiabetic subjects at baseline.,15531665_7,-1,-1,-1,4775,-1,0.0031052066,0.9968947
4776,vitamin C,4,6,19,28,CONCLUSION: A high vitamin C intake from supplements is associated with an increased risk of cardiovascular disease mortality in postmenopausal women with diabetes.,15531665_8,-1,-1,-1,4776,-1,0.9982843,0.0017157496
4777,cardiovascular disease,16,18,93,115,CONCLUSION: A high vitamin C intake from supplements is associated with an increased risk of cardiovascular disease mortality in postmenopausal women with diabetes.,15531665_8,-1,-1,-1,4777,-1,0.0044413023,0.9955586
4779,optic neuropathy,11,13,89,105,Optical coherence tomography can measure axonal loss in patients with ethambutol-induced optic neuropathy.,15565293_0,-1,-1,-1,4779,-1,0.0025256276,0.9974744
4780,map,3,4,12,15,"PURPOSE: To map and identify the pattern, in vivo, of axonal degeneration in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).",15565293_1,-1,-1,-1,4780,-1,0.111370355,0.8886297
4781,axonal degeneration,13,15,54,73,"PURPOSE: To map and identify the pattern, in vivo, of axonal degeneration in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).",15565293_1,-1,-1,-1,4781,-1,0.0027575686,0.99724245
4782,optic neuropathy,17,19,96,112,"PURPOSE: To map and identify the pattern, in vivo, of axonal degeneration in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).",15565293_1,-1,-1,-1,4782,-1,0.002731971,0.9972681
4783,OCT,24,25,149,152,"PURPOSE: To map and identify the pattern, in vivo, of axonal degeneration in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).",15565293_1,-1,-1,-1,4783,-1,0.8847172,0.115282774
4784,Ethambutol,0,1,0,10,Ethambutol is an antimycobacterial agent often used to treat tuberculosis.,15565293_2,-1,-1,-1,4784,-1,0.99902296,0.0009770376
4786,ethambutol,4,5,26,36,"A serious complication of ethambutol is an optic neuropathy that impairs visual acuity, contrast sensitivity, and color vision.",15565293_3,-1,-1,-1,4786,-1,0.9990139,0.0009861069
4787,optic neuropathy,7,9,43,59,"A serious complication of ethambutol is an optic neuropathy that impairs visual acuity, contrast sensitivity, and color vision.",15565293_3,-1,-1,-1,4787,-1,0.0026092078,0.9973908
4788,contrast,14,15,88,96,"A serious complication of ethambutol is an optic neuropathy that impairs visual acuity, contrast sensitivity, and color vision.",15565293_3,-1,-1,-1,4788,-1,0.98890543,0.011094571
4789,toxic optic neuropathy,7,10,28,50,"However, early on, when the toxic optic neuropathy is mild and partly reversible, the funduscopic findings are often subtle and easy to miss.",15565293_4,-1,-1,-1,4789,-1,0.0028411844,0.9971589
4790,ethambutol,8,9,42,52,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,-1,-1,-1,4790,-1,0.9989962,0.0010037869
4791,optic neuropathy,10,12,67,83,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,-1,-1,-1,4791,-1,0.0024940644,0.99750596
4792,visual deficits,19,21,124,139,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,-1,-1,-1,4792,-1,0.0035835532,0.99641645
4793,contrast,34,35,237,245,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,-1,-1,-1,4793,-1,0.98909795,0.010902066
4794,OCT,3,4,13,16,"In addition, OCT (OCT 3000, Humphrey-Zeiss, Dublin, CA) was performed on both eyes of each subject using the retinal nerve fiber layer (RNFL) analysis protocol.",15565293_6,-1,-1,-1,4794,-1,0.87704146,0.122958474
4795,OCT,5,6,18,21,"In addition, OCT (OCT 3000, Humphrey-Zeiss, Dublin, CA) was performed on both eyes of each subject using the retinal nerve fiber layer (RNFL) analysis protocol.",15565293_6,-1,-1,-1,4795,-1,0.9616474,0.038352598
4796,CA,12,13,52,54,"In addition, OCT (OCT 3000, Humphrey-Zeiss, Dublin, CA) was performed on both eyes of each subject using the retinal nerve fiber layer (RNFL) analysis protocol.",15565293_6,-1,-1,-1,4796,-1,0.7156039,0.28439608
4797,OCT,0,1,0,3,OCT interpolates data from 100 points around the optic nerve to effectively map out the RNFL.,15565293_7,-1,-1,-1,4797,-1,0.9154594,0.08454057
4798,map,12,13,76,79,OCT interpolates data from 100 points around the optic nerve to effectively map out the RNFL.,15565293_7,-1,-1,-1,4798,-1,0.0682845,0.9317155
4799,OCT,20,21,123,126,"RESULTS: The results were compared to the calculated average RNFL of normal eyes accumulated from four prior studies using OCT, n=661.",15565293_8,-1,-1,-1,4799,-1,0.98394024,0.01605977
4800,n=661,22,23,128,133,"RESULTS: The results were compared to the calculated average RNFL of normal eyes accumulated from four prior studies using OCT, n=661.",15565293_8,-1,-1,-1,4800,-1,0.25805405,0.741946
4801,optic neuropathy,7,9,44,60,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,-1,-1,-1,4801,-1,0.0028296583,0.9971704
4802,visual deficits,48,50,247,262,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,-1,-1,-1,4802,-1,0.0044112164,0.9955888
4803,C,56,57,282,283,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,-1,-1,-1,4803,-1,0.14670715,0.8532929
4804,visual deficits,60,62,298,313,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,-1,-1,-1,4804,-1,0.0038787904,0.9961212
4805,loss,65,66,319,323,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,-1,-1,-1,4805,-1,0.0045731002,0.9954269
4806,visual deficits,13,15,60,75,"In both sets (four) of eyes of the subjects with persistent visual deficits (patients B and C), there was an average loss of 79% of nerve fiber thickness in the temporal quadrant.",15565293_11,-1,-1,-1,4806,-1,0.0029118226,0.99708825
4807,C,19,20,92,93,"In both sets (four) of eyes of the subjects with persistent visual deficits (patients B and C), there was an average loss of 79% of nerve fiber thickness in the temporal quadrant.",15565293_11,-1,-1,-1,4807,-1,0.10943752,0.8905625
4808,OCT,3,4,17,20,CONCLUSIONS: The OCT results in these patients with EMB-induced optic neuropathy show considerable loss especially of the temporal fibers.,15565293_12,-1,-1,-1,4808,-1,0.9535502,0.046449773
4809,optic neuropathy,10,12,64,80,CONCLUSIONS: The OCT results in these patients with EMB-induced optic neuropathy show considerable loss especially of the temporal fibers.,15565293_12,-1,-1,-1,4809,-1,0.002601361,0.9973986
4810,optic neuropathies,27,29,189,207,This is consistent with prior histopathological studies that show predominant loss of parvo-cellular axons (or small-caliber axons) within the papillo-macular bundle in toxic or hereditary optic neuropathies.,15565293_13,-1,-1,-1,4810,-1,0.002810252,0.9971897
4811,optic neuropathies,11,13,59,77,OCT can be a valuable tool in the quantitative analysis of optic neuropathies.,15565293_14,-1,-1,-1,4811,-1,0.0031857453,0.9968143
4812,optic neuropathy,8,10,52,68,"Additionally, in terms of management of EMB-induced optic neuropathy, it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.",15565293_15,-1,-1,-1,4812,-1,0.0020205432,0.99797946
4813,ethambutol,17,18,105,115,"Additionally, in terms of management of EMB-induced optic neuropathy, it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.",15565293_15,-1,-1,-1,4813,-1,0.999106,0.0008940222
4814,renal impairment,22,24,140,156,"Additionally, in terms of management of EMB-induced optic neuropathy, it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.",15565293_15,-1,-1,-1,4814,-1,0.0043783044,0.99562174
4820,n,19,20,96,97,"After 1 week of recovery, proteinuria was induced by adriamycin [1.5 mg/kg intravenously (i.v.) n = 18; controls, saline i.v.",15572383_5,-1,-1,-1,4820,-1,0.47189355,0.5281064
4821,n,0,1,0,1,n = 9].,15572383_6,-1,-1,-1,4821,-1,0.26908657,0.7309134
4826,interstitial damage,12,14,80,99,"RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.",15572383_9,-1,-1,-1,4826,-1,0.0026839196,0.99731606
4827,focal glomerulosclerosis,16,18,109,133,"RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.",15572383_9,-1,-1,-1,4827,-1,0.0035133427,0.99648666
4830,P<0.01,18,19,107,113,"Baseline renal ACE positively correlated with the relative rise in proteinuria after adriamycin (r = 0.62, P<0.01), renal interstitial alpha-smooth muscle actin (r = 0.49, P<0.05), interstitial macrophage influx (r = 0.56, P<0.05), interstitial collagen III (r = 0.53, P<0.05), glomerular alpha-smooth muscle actin (r = 0.74, P<0.01) and glomerular desmin (r = 0.48, P<0.05).",15572383_10,-1,-1,-1,4830,-1,0.41934928,0.5806507
4831,P<0.05,31,32,172,178,"Baseline renal ACE positively correlated with the relative rise in proteinuria after adriamycin (r = 0.62, P<0.01), renal interstitial alpha-smooth muscle actin (r = 0.49, P<0.05), interstitial macrophage influx (r = 0.56, P<0.05), interstitial collagen III (r = 0.53, P<0.05), glomerular alpha-smooth muscle actin (r = 0.74, P<0.01) and glomerular desmin (r = 0.48, P<0.05).",15572383_10,-1,-1,-1,4831,-1,0.38708535,0.6129146
4832,P<0.05,42,43,223,229,"Baseline renal ACE positively correlated with the relative rise in proteinuria after adriamycin (r = 0.62, P<0.01), renal interstitial alpha-smooth muscle actin (r = 0.49, P<0.05), interstitial macrophage influx (r = 0.56, P<0.05), interstitial collagen III (r = 0.53, P<0.05), glomerular alpha-smooth muscle actin (r = 0.74, P<0.01) and glomerular desmin (r = 0.48, P<0.05).",15572383_10,-1,-1,-1,4832,-1,0.3719968,0.6280032
4833,P<0.05,53,54,269,275,"Baseline renal ACE positively correlated with the relative rise in proteinuria after adriamycin (r = 0.62, P<0.01), renal interstitial alpha-smooth muscle actin (r = 0.49, P<0.05), interstitial macrophage influx (r = 0.56, P<0.05), interstitial collagen III (r = 0.53, P<0.05), glomerular alpha-smooth muscle actin (r = 0.74, P<0.01) and glomerular desmin (r = 0.48, P<0.05).",15572383_10,-1,-1,-1,4833,-1,0.37451634,0.6254837
4834,P<0.01,65,66,326,332,"Baseline renal ACE positively correlated with the relative rise in proteinuria after adriamycin (r = 0.62, P<0.01), renal interstitial alpha-smooth muscle actin (r = 0.49, P<0.05), interstitial macrophage influx (r = 0.56, P<0.05), interstitial collagen III (r = 0.53, P<0.05), glomerular alpha-smooth muscle actin (r = 0.74, P<0.01) and glomerular desmin (r = 0.48, P<0.05).",15572383_10,-1,-1,-1,4834,-1,0.44026333,0.55973667
4835,P<0.05,75,76,367,373,"Baseline renal ACE positively correlated with the relative rise in proteinuria after adriamycin (r = 0.62, P<0.01), renal interstitial alpha-smooth muscle actin (r = 0.49, P<0.05), interstitial macrophage influx (r = 0.56, P<0.05), interstitial collagen III (r = 0.53, P<0.05), glomerular alpha-smooth muscle actin (r = 0.74, P<0.01) and glomerular desmin (r = 0.48, P<0.05).",15572383_10,-1,-1,-1,4835,-1,0.37539166,0.6246084
4836,focal glomerulosclerosis,7,9,42,66,"Baseline renal ACE did not correlate with focal glomerulosclerosis (r = 0.22, NS).",15572383_11,-1,-1,-1,4836,-1,0.0030808968,0.99691916
4837,NS,14,15,78,80,"Baseline renal ACE did not correlate with focal glomerulosclerosis (r = 0.22, NS).",15572383_11,-1,-1,-1,4837,-1,0.12214004,0.87786
4841,renal disease,2,4,11,24,Hypoxia in renal disease with proteinuria and/or glomerular hypertension.,15579441_0,-1,-1,-1,4841,-1,0.0033660477,0.99663395
4845,diseased kidney,14,16,88,103,We then applied this animal model to the detection of tubulointerstitial hypoxia in the diseased kidney.,15579441_3,-1,-1,-1,4845,-1,0.006125042,0.99387497
4847,nephrotic syndrome,16,18,108,126,"With this model, we were able to identify diffuse cortical hypoxia in the puromycin aminonucleoside-induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model.",15579441_4,-1,-1,-1,4847,-1,0.0023571486,0.9976428
4849,puromycin aminonucleoside,18,20,128,153,"Expression of the hypoxia-responsive transgene increased throughout the observation period, reaching 2.2-fold at 2 weeks in the puromycin aminonucleoside model and 2.6-fold at 4 weeks in the remnant kidney model, whereas that of vascular endothelial growth factor showed a mild decrease, reflecting distinct behaviors of the two genes.",15579441_5,-1,-1,-1,4849,-1,0.99846053,0.0015395187
4851,tubulointerstitial injury,10,12,69,94,The degree of hypoxia showed a positive correlation with microscopic tubulointerstitial injury in both models.,15579441_6,-1,-1,-1,4851,-1,0.0048374836,0.99516255
4852,dUTP,16,17,116,120,"Finally, we identified the localization of proliferating cell nuclear antigen-positive, ED-1-positive, and terminal dUTP nick-end labeled-positive cells in the hypoxic cortical area in the remnant kidney model.",15579441_7,-1,-1,-1,4852,-1,0.99336493,0.0066350624
4853,hypoxic,22,23,160,167,"Finally, we identified the localization of proliferating cell nuclear antigen-positive, ED-1-positive, and terminal dUTP nick-end labeled-positive cells in the hypoxic cortical area in the remnant kidney model.",15579441_7,-1,-1,-1,4853,-1,0.012838414,0.9871616
4855,glomerular diseases,13,15,103,122,We propose here a possible pathological tie between chronic tubulointerstitial hypoxia and progressive glomerular diseases.,15579441_8,-1,-1,-1,4855,-1,0.0031013195,0.99689865
4856,ribavirin reduction,3,5,19,38,Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.,15580403_0,-1,-1,-1,4856,-1,0.9945116,0.0054883817
4858,interferon,13,14,96,106,Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.,15580403_0,-1,-1,-1,4858,-1,0.99832743,0.0016725144
4861,interferon,35,36,239,249,Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.,15580403_0,-1,-1,-1,4861,-1,0.9983278,0.0016722088
4864,ribavirin reduction,13,15,84,103,In this clinical retrospective cohort study we have examined the suitable timing of ribavirin reduction in patients with hemolysis during combination therapy.,15580403_2,-1,-1,-1,4864,-1,0.99483573,0.0051642237
4868,mg,14,15,72,74,"After that, these 37 patients were reduced one tablet of ribavirin (200 mg) per day.",15580403_4,-1,-1,-1,4868,-1,0.9588163,0.04118368
4872,P,26,27,96,97,"A 34.4% (12/27) of SVR + biological response in group A was higher than 10% (1/10) in group B ( P = 0.051), with slight significance.",15580403_8,-1,-1,-1,4872,-1,0.221663,0.778337
4874,P,38,39,194,195,"With respect to hemoglobin level at the time of ribavirin reduction, a rate of continuation of therapy in patients with > or =10 g/dl hemoglobin was higher than that in patients with <10 g/dl ( P = 0.036).",15580403_9,-1,-1,-1,4874,-1,0.31919652,0.6808035
4879,corticosteroid,17,18,97,111,"The second episode was more severe than the first; and although both were treated with intensive corticosteroid therapy, renal function remained impaired.",15602202_2,-1,-1,-1,4879,-1,0.99856216,0.0014378814
4882,renal insufficiency,1,3,23,42,Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.,15632880_0,-1,-1,-1,4882,-1,0.0025771835,0.9974228
4884,heart failure,8,10,77,90,Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.,15632880_0,-1,-1,-1,4884,-1,0.0027279218,0.9972721
4886,heart failure,13,15,91,104,BACKGROUND: A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%).,15632880_1,-1,-1,-1,4886,-1,0.0034542454,0.99654573
4888,renal insufficiency,27,29,159,178,BACKGROUND: A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%).,15632880_1,-1,-1,-1,4888,-1,0.0032691502,0.9967308
4889,heart failure,3,5,23,36,"Because treatments for heart failure have changed since the benefits of spironolactone were reported, the prevalence of these complications may differ in current clinical practice.",15632880_2,-1,-1,-1,4889,-1,0.0027825255,0.9972174
4892,renal insufficiency,13,15,94,113,We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in heart failure patients treated with spironolactone.,15632880_3,-1,-1,-1,4892,-1,0.0025701213,0.9974299
4893,heart failure,16,18,117,130,We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in heart failure patients treated with spironolactone.,15632880_3,-1,-1,-1,4893,-1,0.0031632297,0.9968368
4895,heart failure,9,11,46,59,METHODS: We performed a case control study of heart failure patients treated with spironolactone in our clinical practice.,15632880_4,-1,-1,-1,4895,-1,0.003689744,0.9963103
4898,renal insufficiency,14,16,68,87,"Cases were patients who developed hyperkalemia (K(+) >5.0 mEq/L) or renal insufficiency (Cr >or=2.5 mg/dL), and they were compared to 2 randomly selected controls per case.",15632880_5,-1,-1,-1,4898,-1,0.0028174983,0.9971825
4899,Cr,17,18,89,91,"Cases were patients who developed hyperkalemia (K(+) >5.0 mEq/L) or renal insufficiency (Cr >or=2.5 mg/dL), and they were compared to 2 randomly selected controls per case.",15632880_5,-1,-1,-1,4899,-1,0.6599763,0.34002373
4902,n,18,19,108,109,RESULTS: Sixty-seven of 926 patients (7.2%) required discontinuation of spironolactone due to hyperkalemia (n = 33) or renal failure (n = 34).,15632880_7,-1,-1,-1,4902,-1,0.15647241,0.8435276
4903,renal failure,23,25,119,132,RESULTS: Sixty-seven of 926 patients (7.2%) required discontinuation of spironolactone due to hyperkalemia (n = 33) or renal failure (n = 34).,15632880_7,-1,-1,-1,4903,-1,0.0026838228,0.9973162
4904,n,26,27,134,135,RESULTS: Sixty-seven of 926 patients (7.2%) required discontinuation of spironolactone due to hyperkalemia (n = 33) or renal failure (n = 34).,15632880_7,-1,-1,-1,4904,-1,0.1041888,0.8958112
4909,n,38,39,240,241,"Patients who developed hyperkalemia were older and more likely to have diabetes, had higher baseline serum potassium levels and lower baseline potassium supplement doses, and were more likely to be treated with beta-blockers than controls (n = 134).",15632880_8,-1,-1,-1,4909,-1,0.31916386,0.68083614
4910,renal insufficiency,3,5,23,42,"Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.",15632880_9,-1,-1,-1,4910,-1,0.002365396,0.99763465
4911,body weight,8,10,62,73,"Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.",15632880_9,-1,-1,-1,4911,-1,0.39987314,0.60012686
4913,thiazide,31,32,193,201,"Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.",15632880_9,-1,-1,-1,4913,-1,0.9993036,0.00069642346
4915,renal insufficiency,5,7,53,72,CONCLUSIONS: Spironolactone-induced hyperkalemia and renal insufficiency are more common in our clinical experience than reported previously.,15632880_10,-1,-1,-1,4915,-1,0.0022418185,0.9977582
4920,HAL,17,18,97,100,"The aim of the study was to examine the influence of hyperprolactinemia, induced by haloperidol (HAL) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe.",15638391_1,-1,-1,-1,4920,-1,0.99824333,0.001756661
4921,PRL,5,6,35,38,Serum concentrations of prolactin (PRL) and testosterone (T) were measured.,15638391_3,-1,-1,-1,4921,-1,0.99367553,0.006324404
4923,PCNA,8,9,75,79,Immunohistochemical reactions for Anti-Proliferating Cell Nuclear Antigen (PCNA) were performed.,15638391_5,-1,-1,-1,4923,-1,0.97772217,0.022277793
4924,PRL,12,13,62,65,"In rats of the experimental group, the mean concentration of: PRL was more than twice higher, whereas T concentration was almost twice lower than that in the control group.",15638391_6,-1,-1,-1,4924,-1,0.9978516,0.0021483868
4926,hyperplasia,9,10,70,81,"Light microscopy visualized the following: hypertrophy and epithelium hyperplasia of the glandular ducts, associated with increased PCNA expression.",15638391_7,-1,-1,-1,4926,-1,0.004943243,0.99505675
4927,PCNA,18,19,132,136,"Light microscopy visualized the following: hypertrophy and epithelium hyperplasia of the glandular ducts, associated with increased PCNA expression.",15638391_7,-1,-1,-1,4927,-1,0.99272984,0.0072701667
4928,contrast,7,8,55,63,Relation of perfusion defects observed with myocardial contrast echocardiography to the severity of coronary stenosis: correlation with thallium-201 single-photon emission tomography.,1564236_0,-1,-1,-1,4928,-1,0.99516004,0.004839989
4929,coronary stenosis,13,15,100,117,Relation of perfusion defects observed with myocardial contrast echocardiography to the severity of coronary stenosis: correlation with thallium-201 single-photon emission tomography.,1564236_0,-1,-1,-1,4929,-1,0.00431391,0.9956862
4930,contrast,7,8,45,53,It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to coronary occlusion and to critical coronary stenoses in the presence of hyperemic stimulation.,1564236_1,-1,-1,-1,4930,-1,0.9962548,0.003745202
4931,coronary occlusion,21,23,161,179,It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to coronary occlusion and to critical coronary stenoses in the presence of hyperemic stimulation.,1564236_1,-1,-1,-1,4931,-1,0.010181712,0.9898183
4932,coronary stenoses,26,28,196,213,It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to coronary occlusion and to critical coronary stenoses in the presence of hyperemic stimulation.,1564236_1,-1,-1,-1,4932,-1,0.007336299,0.99266374
4933,hyperemic,32,33,233,242,It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to coronary occlusion and to critical coronary stenoses in the presence of hyperemic stimulation.,1564236_1,-1,-1,-1,4933,-1,0.23254046,0.7674596
4934,contrast,10,11,58,66,The aim of this study was to determine whether myocardial contrast echocardiography performed with a stable solution of sonicated albumin could detect regions of myocardial underperfusion resulting from various degrees of coronary stenosis.,1564236_2,-1,-1,-1,4934,-1,0.9357958,0.06420418
4935,coronary stenosis,31,33,222,239,The aim of this study was to determine whether myocardial contrast echocardiography performed with a stable solution of sonicated albumin could detect regions of myocardial underperfusion resulting from various degrees of coronary stenosis.,1564236_2,-1,-1,-1,4935,-1,0.004608034,0.99539196
4936,coronary occlusion,6,8,26,44,"During a transient (20-s) coronary occlusion, a perfusion defect was observed with contrast echocardiography in 14 of the 15 dogs in which the occlusion was produced.",1564236_4,-1,-1,-1,4936,-1,0.019959765,0.9800402
4937,contrast,15,16,83,91,"During a transient (20-s) coronary occlusion, a perfusion defect was observed with contrast echocardiography in 14 of the 15 dogs in which the occlusion was produced.",1564236_4,-1,-1,-1,4937,-1,0.9927176,0.0072824014
4938,p,16,17,88,89,The perfusion defect correlated significantly with the anatomic area at risk (r = 0.74; p less than 0.002).,1564236_5,-1,-1,-1,4938,-1,0.34292492,0.65707505
4940,coronary stenosis,12,14,72,89,"During dipyridamole-induced hyperemia, 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography.",1564236_6,-1,-1,-1,4940,-1,0.005054202,0.9949458
4941,contrast,21,22,129,137,"During dipyridamole-induced hyperemia, 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography.",1564236_6,-1,-1,-1,4941,-1,0.9904151,0.009584832
4942,stenosis,9,10,47,55,The four dogs without a perfusion defect had a stenosis that resulted in a mild (0% to 50%) reduction in dipyridamole-induced hyperemia.,1564236_7,-1,-1,-1,4942,-1,0.0033124257,0.9966876
4944,stenosis,7,8,40,48,The size of the perfusion defect during stenosis correlated significantly with the anatomic area at risk (r = 0.61; p = 0.02).,1564236_8,-1,-1,-1,4944,-1,0.0080312835,0.9919687
4945,p,21,22,116,117,The size of the perfusion defect during stenosis correlated significantly with the anatomic area at risk (r = 0.61; p = 0.02).,1564236_8,-1,-1,-1,4945,-1,0.42403716,0.57596284
4947,p,33,34,200,201,Thallium-201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole-induced hyperemia; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).,1564236_9,-1,-1,-1,4947,-1,0.3611325,0.63886756
4948,contrast,44,45,251,259,Thallium-201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole-induced hyperemia; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).,1564236_9,-1,-1,-1,4948,-1,0.94993746,0.050062485
4949,p,51,52,288,289,Thallium-201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole-induced hyperemia; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).,1564236_9,-1,-1,-1,4949,-1,0.25447476,0.74552524
4950,contrast,3,4,17,25,"Thus, myocardial contrast echocardiography can be used to visualize and quantitate the amount of jeopardized myocardium during moderate to severe degrees of coronary stenosis.",1564236_10,-1,-1,-1,4950,-1,0.99113727,0.008862756
4951,coronary stenosis,23,25,157,174,"Thus, myocardial contrast echocardiography can be used to visualize and quantitate the amount of jeopardized myocardium during moderate to severe degrees of coronary stenosis.",1564236_10,-1,-1,-1,4951,-1,0.007051922,0.99294806
4955,orofacial dyskinesia,13,15,108,128,Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.,15649445_0,-1,-1,-1,4955,-1,0.0041131196,0.99588686
4956,orofacial dyskinesia,3,5,35,55,Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.,15649445_1,-1,-1,-1,4956,-1,0.0033306582,0.99666935
4957,tardive dyskinesia,10,12,86,104,Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.,15649445_1,-1,-1,-1,4957,-1,0.00255365,0.9974464
4958,TD,13,14,106,108,Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.,15649445_1,-1,-1,-1,4958,-1,0.0048720897,0.9951279
4959,orofacial dyskinesia,8,10,42,62,"In the present study, the authors induced orofacial dyskinesia by acute reserpine and subchronic haloperidol administration to rats.",15649445_2,-1,-1,-1,4959,-1,0.0033891099,0.9966108
4969,orofacial,16,17,103,112,"Importantly, a decrease in glutamate uptake correlates negatively with an increase in the incidence of orofacial diskinesia.",15649445_7,-1,-1,-1,4969,-1,0.030029088,0.9699709
4970,diskinesia,17,18,113,123,"Importantly, a decrease in glutamate uptake correlates negatively with an increase in the incidence of orofacial diskinesia.",15649445_7,-1,-1,-1,4970,-1,0.056245063,0.9437549
4973,spinal cord ischemia,23,26,174,194,The activation of spinal N-methyl-D-aspartate receptors may contribute to degeneration of spinal motor neurons induced by neuraxial morphine after a noninjurious interval of spinal cord ischemia.,15673851_0,-1,-1,-1,4973,-1,0.008724003,0.991276
4974,NMDA,16,17,122,126,We investigated the relationship between the degeneration of spinal motor neurons and activation of N-methyl-d-aspartate (NMDA) receptors after neuraxial morphine following a noninjurious interval of aortic occlusion in rats.,15673851_1,-1,-1,-1,4974,-1,0.99808156,0.0019184538
4976,aortic occlusion,27,29,200,216,We investigated the relationship between the degeneration of spinal motor neurons and activation of N-methyl-d-aspartate (NMDA) receptors after neuraxial morphine following a noninjurious interval of aortic occlusion in rats.,15673851_1,-1,-1,-1,4976,-1,0.060306646,0.9396934
4977,Spinal cord ischemia,0,3,0,20,Spinal cord ischemia was induced by aortic occlusion for 6 min with a balloon catheter.,15673851_2,-1,-1,-1,4977,-1,0.008091518,0.9919085
4978,aortic occlusion,6,8,36,52,Spinal cord ischemia was induced by aortic occlusion for 6 min with a balloon catheter.,15673851_2,-1,-1,-1,4978,-1,0.7144923,0.28550768
4979,C,11,12,50,51,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,4979,-1,0.874312,0.12568802
4980,n,13,14,53,54,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,4980,-1,0.27589962,0.72410035
4982,n,25,26,92,93,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,4982,-1,0.29840022,0.70159984
4983,h,35,36,135,136,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,4983,-1,0.13556583,0.86443424
4985,SM,46,47,181,183,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,4985,-1,0.9794516,0.02054838
4986,n,48,49,185,186,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,4986,-1,0.25379,0.74621004
4987,n,60,61,223,224,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,4987,-1,0.28315002,0.71685
4988,h,67,68,250,251,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,-1,-1,-1,4988,-1,0.12958549,0.87041456
4989,h,22,23,98,99,"Microdialysis samples were collected preischemia, before IT injection, and at 2, 4, 8, 24, and 48 h of reperfusion (after IT injection).",15673851_4,-1,-1,-1,4989,-1,0.14074108,0.8592589
4990,MK-801,8,9,41,47,"Second, we investigated the effect of IT MK-801 (30 mug) on the histopathologic changes in the spinal cord after morphine-induced spastic paraparesis.",15673851_5,-1,-1,-1,4990,-1,0.9978434,0.0021565864
4991,spastic paraparesis,23,25,130,149,"Second, we investigated the effect of IT MK-801 (30 mug) on the histopathologic changes in the spinal cord after morphine-induced spastic paraparesis.",15673851_5,-1,-1,-1,4991,-1,0.0021799267,0.99782014
4994,C,23,24,134,135,"After IT morphine, the cerebrospinal fluid (CSF) glutamate concentration was increased in group M relative to both baseline and group C (P < 0.05).",15673851_6,-1,-1,-1,4994,-1,0.81929255,0.1807074
4995,P,25,26,137,138,"After IT morphine, the cerebrospinal fluid (CSF) glutamate concentration was increased in group M relative to both baseline and group C (P < 0.05).",15673851_6,-1,-1,-1,4995,-1,0.33449957,0.66550046
4996,MK-801,1,2,3,9,IT MK-801 significantly reduced the number of dark-stained alpha-motoneurons after morphine-induced spastic paraparesis compared with the saline group.,15673851_8,-1,-1,-1,4996,-1,0.99756634,0.0024336223
4997,spastic paraparesis,11,13,100,119,IT MK-801 significantly reduced the number of dark-stained alpha-motoneurons after morphine-induced spastic paraparesis compared with the saline group.,15673851_8,-1,-1,-1,4997,-1,0.0023531457,0.99764687
4999,spastic paraparesis,7,9,45,64,"These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.",15673851_9,-1,-1,-1,4999,-1,0.002114079,0.9978859
5001,NMDA,21,22,132,136,"These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.",15673851_9,-1,-1,-1,5001,-1,0.9981002,0.0018997813
5003,spinal cord ischemia,11,14,60,80,We suggest that opioids may be neurotoxic in the setting of spinal cord ischemia via NMDA receptor activation.,15673851_10,-1,-1,-1,5003,-1,0.006186707,0.9938133
5004,NMDA,15,16,85,89,We suggest that opioids may be neurotoxic in the setting of spinal cord ischemia via NMDA receptor activation.,15673851_10,-1,-1,-1,5004,-1,0.9979576,0.0020423634
5005,low back pain,1,4,6,19,Acute low back pain during intravenous administration of amiodarone: a report of two cases.,15686794_0,-1,-1,-1,5005,-1,0.004295664,0.99570435
5008,atrial fibrillation,10,12,89,108,Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent-onset atrial fibrillation (AF) and maintenance of sinus rhythm.,15686794_1,-1,-1,-1,5008,-1,0.0087733595,0.9912266
5009,AF,13,14,110,112,Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent-onset atrial fibrillation (AF) and maintenance of sinus rhythm.,15686794_1,-1,-1,-1,5009,-1,0.0044812276,0.9955188
5010,atrial fibrillation,8,10,61,80,"We briefly describe two patients suffering from recent-onset atrial fibrillation, who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading.",15686794_2,-1,-1,-1,5010,-1,0.037020616,0.96297944
5011,low back pain,16,19,119,132,"We briefly describe two patients suffering from recent-onset atrial fibrillation, who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading.",15686794_2,-1,-1,-1,5011,-1,0.00434206,0.9956579
5013,biliary pseudolithiasis,1,3,23,46,Ceftriaxone-associated biliary pseudolithiasis in paediatric surgical patients.,15737522_0,-1,-1,-1,5013,-1,0.004845727,0.99515426
5016,gallbladder dysfunction,9,11,71,94,"Clinical and experimental studies also suggest that situations causing gallbladder dysfunction, such as fasting, may have a role for the development of pseudolithiasis.",15737522_2,-1,-1,-1,5016,-1,0.0044508427,0.9955492
5024,psychosis,5,6,38,47,"Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia.",15764424_0,-1,-1,-1,5024,-1,0.003006872,0.99699306
5026,hyperkinesia,14,15,102,114,"Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia.",15764424_0,-1,-1,-1,5026,-1,0.0022376156,0.9977623
5030,psychosis,30,31,217,226,"To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.",15764424_1,-1,-1,-1,5030,-1,0.0022528458,0.9977471
5034,hyperkinesia,13,14,100,112,Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating.,15764424_2,-1,-1,-1,5034,-1,0.0021931378,0.99780685
5035,hyperkinesia,6,7,34,46,HVA levels were related to global hyperkinesia but not to psychopathology ratings.,15764424_3,-1,-1,-1,5035,-1,0.002279275,0.99772066
5037,stereotypies,18,19,121,133,"Although many other factors such as sensitization may play a role, intensity of stimulant-induced psychotic symptoms and stereotypies appears to be at least in part dose-related.",15764424_4,-1,-1,-1,5037,-1,0.002546902,0.99745303
5038,Coronary aneurysm,0,2,0,17,Coronary aneurysm after implantation of a paclitaxel-eluting stent.,15804801_0,-1,-1,-1,5038,-1,0.00452038,0.9954796
5039,coronary aneurysm,2,4,13,30,"Formation of coronary aneurysm is a rare complication of stenting with bare metal stents, but based on experimental studies drug-eluting stents may induce toxic effects on the vessel wall with incomplete stent apposition, aneurysm formation and with the potential of stent thrombosis or vessel rupture.",15804801_1,-1,-1,-1,5039,-1,0.004022937,0.9959771
5042,vessel rupture,45,47,287,301,"Formation of coronary aneurysm is a rare complication of stenting with bare metal stents, but based on experimental studies drug-eluting stents may induce toxic effects on the vessel wall with incomplete stent apposition, aneurysm formation and with the potential of stent thrombosis or vessel rupture.",15804801_1,-1,-1,-1,5042,-1,0.004251837,0.9957482
5043,coronary aneurysm,8,10,45,62,We present a 43-year-old man who developed a coronary aneurysm in the right coronary artery 6 months after receiving a paclitaxel-eluting stent.,15804801_2,-1,-1,-1,5043,-1,0.0037377686,0.99626225
5046,mm,24,25,162,164,Angiography and intracoronary ultrasound demonstrated lack of contact between stent and vessel wall in a 15-mm long segment with maximal aneurysm diameter of 6.0 mm.,15804801_4,-1,-1,-1,5046,-1,0.048095997,0.95190394
5047,amisulpride,3,4,29,40,Pheochromocytoma unmasked by amisulpride and tiapride.,15811908_0,-1,-1,-1,5047,-1,0.9987864,0.0012136474
5048,tiapride,5,6,45,53,Pheochromocytoma unmasked by amisulpride and tiapride.,15811908_0,-1,-1,-1,5048,-1,0.99907815,0.00092178484
5049,pheochromocytoma,7,8,40,56,OBJECTIVE: To describe the unmasking of pheochromocytoma in a patient treated with amisulpride and tiapride.,15811908_1,-1,-1,-1,5049,-1,0.0059264577,0.99407357
5050,amisulpride,13,14,83,94,OBJECTIVE: To describe the unmasking of pheochromocytoma in a patient treated with amisulpride and tiapride.,15811908_1,-1,-1,-1,5050,-1,0.9988801,0.0011198742
5051,tiapride,15,16,99,107,OBJECTIVE: To describe the unmasking of pheochromocytoma in a patient treated with amisulpride and tiapride.,15811908_1,-1,-1,-1,5051,-1,0.99924266,0.0007573489
5055,amisulpride,22,23,134,145,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.,15811908_2,-1,-1,-1,5055,-1,0.99891984,0.001080165
5056,mg,24,25,150,152,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.,15811908_2,-1,-1,-1,5056,-1,0.9850397,0.014960247
5057,tiapride,26,27,157,165,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.,15811908_2,-1,-1,-1,5057,-1,0.9990976,0.00090248114
5058,mg,28,29,170,172,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.,15811908_2,-1,-1,-1,5058,-1,0.9722953,0.027704732
5059,nicardipine,12,13,85,96,"Both drugs were immediately discontinued, and the patient recovered after subsequent nicardipine and verapamil treatment.",15811908_3,-1,-1,-1,5059,-1,0.9993351,0.0006648879
5061,pheochromocytoma,15,16,113,129,"Abdominal ultrasound showed an adrenal mass, and postoperative histologic examination confirmed the diagnosis of pheochromocytoma.",15811908_4,-1,-1,-1,5061,-1,0.03016493,0.9698351
5062,pheochromocytoma,5,6,37,53,"DISCUSSION: Drug-induced symptoms of pheochromocytoma are often associated with the use of substituted benzamide drugs, but the underlying mechanism is unknown.",15811908_5,-1,-1,-1,5062,-1,0.0053348895,0.99466515
5063,benzamide,14,15,103,112,"DISCUSSION: Drug-induced symptoms of pheochromocytoma are often associated with the use of substituted benzamide drugs, but the underlying mechanism is unknown.",15811908_5,-1,-1,-1,5063,-1,0.9989152,0.001084866
5065,amisulpride,19,20,120,131,"In our case, use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy.",15811908_6,-1,-1,-1,5065,-1,0.99897015,0.001029913
5066,tiapride,21,22,136,144,"In our case, use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy.",15811908_6,-1,-1,-1,5066,-1,0.999215,0.0007849434
5068,pheochromocytoma,25,26,142,158,"CONCLUSIONS: As of March 24, 2005, this is the first reported case of amisulpride- and tiapride-induced hypertensive crisis in a patient with pheochromocytoma.",15811908_7,-1,-1,-1,5068,-1,0.0042160926,0.99578387
5069,tiapride,14,15,98,106,Physicians and other healthcare professionals should be aware of this potential adverse effect of tiapride and amisulpride.,15811908_8,-1,-1,-1,5069,-1,0.99930716,0.0006927912
5070,amisulpride,16,17,111,122,Physicians and other healthcare professionals should be aware of this potential adverse effect of tiapride and amisulpride.,15811908_8,-1,-1,-1,5070,-1,0.99887556,0.0011244237
5071,neurological dysfunction,1,3,6,30,"Minor neurological dysfunction, cognitive development, and somatic development at the age of 3 to 7 years after dexamethasone treatment in very-low birth-weight infants.",15814210_0,-1,-1,-1,5071,-1,0.0023870799,0.99761295
5073,neurological dysfunction,9,11,48,72,"The objective of this study was to assess minor neurological dysfunction, cognitive development, and somatic development after dexamethasone therapy in very-low-birthweight infants.",15814210_1,-1,-1,-1,5073,-1,0.0023371188,0.9976629
5078,asphyxia,3,4,24,32,"Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.",15814210_5,-1,-1,-1,5078,-1,0.014242703,0.9857573
5079,malformations,5,6,34,47,"Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.",15814210_5,-1,-1,-1,5079,-1,0.0047169137,0.99528307
5080,haemorrhage grades III,17,20,123,145,"Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.",15814210_5,-1,-1,-1,5080,-1,0.019183593,0.9808164
5081,periventricular leukomalacia,23,25,154,182,"Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.",15814210_5,-1,-1,-1,5081,-1,0.0082989335,0.99170107
5082,psychomotor retardation,28,30,195,218,"Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.",15814210_5,-1,-1,-1,5082,-1,0.0029390797,0.99706095
5083,neurological dysfunctions,9,11,57,82,Each child was examined by a neuropediatrician for minor neurological dysfunctions and tested by a psychologist for cognitive development with a Kaufman Assessment Battery for Children and a Draw-a-Man Test.,15814210_6,-1,-1,-1,5083,-1,0.0037587439,0.9962412
5084,p<0.01,15,16,91,97,Fine motor skills and gross motor function were significantly better in the control group (p<0.01).,15814210_8,-1,-1,-1,5084,-1,0.4150046,0.5849954
5085,p<0.001,12,13,65,72,"In the Draw-a-Man Test, the control group showed better results (p<0.001).",15814210_9,-1,-1,-1,5085,-1,0.35065106,0.649349
5087,neurological dysfunctions,11,13,70,95,"After dexamethasone treatment, children showed a higher rate of minor neurological dysfunctions.",15814210_11,-1,-1,-1,5087,-1,0.0025174888,0.9974825
5089,Valproic acid,0,2,0,13,"Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.",15858223_0,-1,-1,-1,5089,-1,0.9990409,0.0009591052
5090,liver toxicity,11,13,63,77,"Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.",15858223_0,-1,-1,-1,5090,-1,0.0030897064,0.9969103
5091,valproic acid,15,17,83,96,"Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.",15858223_0,-1,-1,-1,5091,-1,0.9988412,0.0011588081
5092,valproic acid,4,6,17,30,"A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).",15858223_1,-1,-1,-1,5092,-1,0.99900526,0.0009947949
5093,VPA,7,8,32,35,"A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).",15858223_1,-1,-1,-1,5093,-1,0.99817145,0.0018284929
5094,15-F(2t)-isoprostane,33,34,173,193,"A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).",15858223_1,-1,-1,-1,5094,-1,0.9936196,0.006380299
5095,15-F(2t)-IsoP,35,36,195,208,"A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).",15858223_1,-1,-1,-1,5095,-1,0.99105495,0.00894504
5097,VPA,23,24,167,170,"To determine whether there was a temporal relationship between VPA-associated oxidative stress and hepatotoxicity, adult male Sprague-Dawley rats were treated ip with VPA (500 mg/kg) or 0.9% saline (vehicle) once daily for 2, 4, 7, 10, or 14 days.",15858223_2,-1,-1,-1,5097,-1,0.998917,0.0010830786
5098,"15-F(2t)-IsoP, lipid hydroperoxides",11,15,72,107,"Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).",15858223_3,-1,-1,-1,5098,-1,0.9906446,0.009355448
5099,LPO),16,18,109,113,"Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).",15858223_3,-1,-1,-1,5099,-1,0.98666,0.013339951
5100,thiobarbituric acid reactive substances,20,24,119,158,"Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).",15858223_3,-1,-1,-1,5100,-1,0.9920746,0.007925346
5101,TBARs,25,26,160,165,"Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).",15858223_3,-1,-1,-1,5101,-1,0.99670476,0.0032952793
5102,15-F(2t)-IsoP,3,4,17,30,Plasma and liver 15-F(2t)-IsoP were elevated and reached a plateau after day 2 of VPA treatment compared to control.,15858223_4,-1,-1,-1,5102,-1,0.9957769,0.0042230785
5103,VPA,14,15,82,85,Plasma and liver 15-F(2t)-IsoP were elevated and reached a plateau after day 2 of VPA treatment compared to control.,15858223_4,-1,-1,-1,5103,-1,0.9987679,0.0012320206
5104,LPO,1,2,6,9,"Liver LPO levels were not elevated until day 7 of treatment (1.8-fold versus control, p < 0.05).",15858223_5,-1,-1,-1,5104,-1,0.99681526,0.0031847944
5105,p,16,17,86,87,"Liver LPO levels were not elevated until day 7 of treatment (1.8-fold versus control, p < 0.05).",15858223_5,-1,-1,-1,5105,-1,0.24604395,0.7539561
5106,TBARs,3,4,17,22,"Liver and plasma TBARs were not increased until 14 days (2-fold vs. control, p < 0.05).",15858223_6,-1,-1,-1,5106,-1,0.9981529,0.0018470602
5107,p,15,16,77,78,"Liver and plasma TBARs were not increased until 14 days (2-fold vs. control, p < 0.05).",15858223_6,-1,-1,-1,5107,-1,0.26723537,0.7327646
5112,steatosis,30,31,187,196,"Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.",15858223_8,-1,-1,-1,5112,-1,0.0031532885,0.99684674
5113,VPA,7,8,50,53,"The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of 4-ene-VPA and (E)-2,4-diene-VPA were not elevated throughout the study.",15858223_9,-1,-1,-1,5113,-1,0.99821305,0.0017870195
5114,VPA,6,7,38,41,"Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.",15858223_10,-1,-1,-1,5114,-1,0.9987754,0.00122453
5115,15-F(2t)-IsoP,18,19,106,119,"Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.",15858223_10,-1,-1,-1,5115,-1,0.9949568,0.005043254
5117,steatosis,27,28,159,168,"Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.",15858223_10,-1,-1,-1,5117,-1,0.0029553543,0.9970446
5124,n=25,45,46,252,256,"MATERIALS AND METHODS: We investigated the causes of thrombotic microangiopathy during a 1-year period, from June 2003 to June 2004, at the King Fahad National Guard Hospital in Riyadh, Saudi Arabia, by reviewing the slides of all transplant biopsies (n=25) performed during this interval.",15859940_4,-1,-1,-1,5124,-1,0.21778409,0.78221595
5130,antiphospholipid syndrome,11,13,72,97,The fifth case had features of thrombotic microangiopathy related to an antiphospholipid syndrome in a patient with systemic lupus erythematosus.,15859940_9,-1,-1,-1,5130,-1,0.50983596,0.4901641
5131,systemic lupus erythematosus,17,20,116,144,The fifth case had features of thrombotic microangiopathy related to an antiphospholipid syndrome in a patient with systemic lupus erythematosus.,15859940_9,-1,-1,-1,5131,-1,0.0033668862,0.9966331
5141,DFU,15,16,125,128,Comparison of developmental toxicity of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI)WUBR Wistar rats--DFU and piroxicam study.,15863244_0,-1,-1,-1,5141,-1,0.9978496,0.0021503945
5146,DFU,20,21,117,120,"The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.",15863244_3,-1,-1,-1,5146,-1,0.9977787,0.0022212532
5147,"5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl",22,23,122,174,"The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.",15863244_3,-1,-1,-1,5147,-1,0.9809488,0.019051211
5148,"5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon",22,25,122,196,"The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.",15863244_3,-1,-1,-1,5148,-1,0.9904075,0.009592445
5149,phenyl-2(5H)-furanon,24,25,176,196,"The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.",15863244_3,-1,-1,-1,5149,-1,0.9872262,0.012773866
5150,COX-2 inhibitors,26,28,198,214,"The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.",15863244_3,-1,-1,-1,5150,-1,0.6171012,0.38289878
5152,DFU,18,19,86,89,"Doses were set at 0.3, 3.0 and 30.0mg/kg for piroxicam and 0.2, 2.0 and 20.0mg/kg for DFU.",15863244_5,-1,-1,-1,5152,-1,0.9983053,0.0016946064
5153,VSD,8,9,56,59,"The pooled statistical analysis for ventricular septal (VSD) and midline (MD) defects was performed for rat fetuses exposed to piroxicam, selective and non-selective COX-2 inhibitor based on present and historic data.",15863244_8,-1,-1,-1,5153,-1,0.03103686,0.9689631
5154,MD,13,14,74,76,"The pooled statistical analysis for ventricular septal (VSD) and midline (MD) defects was performed for rat fetuses exposed to piroxicam, selective and non-selective COX-2 inhibitor based on present and historic data.",15863244_8,-1,-1,-1,5154,-1,0.014640393,0.9853596
5157,intrauterine growth retardation,5,8,28,59,"RESULTS: Maternal toxicity, intrauterine growth retardation, and increase of external and skeletal variations were found in rats treated with the highest dose of piroxicam.",15863244_9,-1,-1,-1,5157,-1,0.004413328,0.99558663
5158,increase of external and skeletal variations,10,16,65,109,"RESULTS: Maternal toxicity, intrauterine growth retardation, and increase of external and skeletal variations were found in rats treated with the highest dose of piroxicam.",15863244_9,-1,-1,-1,5158,-1,0.009083509,0.99091655
5160,DFU,10,11,51,54,Decrease of fetal length was the only signs of the DFU developmental toxicity observed in pups exposed to the highest compound dose.,15863244_10,-1,-1,-1,5160,-1,0.99834204,0.001657897
5163,VSD,10,11,72,75,Prenatal exposure to non-selective COX inhibitors increases the risk of VSD and MD when compared to historic control but not with selective COX-2 inhibitors.,15863244_12,-1,-1,-1,5163,-1,0.022179656,0.97782034
5164,MD,12,13,80,82,Prenatal exposure to non-selective COX inhibitors increases the risk of VSD and MD when compared to historic control but not with selective COX-2 inhibitors.,15863244_12,-1,-1,-1,5164,-1,0.022356968,0.977643
5165,COX-2 inhibitors,22,24,140,156,Prenatal exposure to non-selective COX inhibitors increases the risk of VSD and MD when compared to historic control but not with selective COX-2 inhibitors.,15863244_12,-1,-1,-1,5165,-1,0.9912006,0.008799449
5166,DFU,1,2,7,10,"Unlike DFU, piroxicam was also highly toxic to the dams.",15863244_14,-1,-1,-1,5166,-1,0.99779093,0.0022090825
5168,hepatitis B,3,5,24,35,Assessment of perinatal hepatitis B and rubella prevention in New Hampshire delivery hospitals.,15867025_0,-1,-1,-1,5168,-1,0.13358599,0.86641395
5169,rubella,6,7,40,47,Assessment of perinatal hepatitis B and rubella prevention in New Hampshire delivery hospitals.,15867025_0,-1,-1,-1,5169,-1,0.9947573,0.0052426923
5170,hepatitis B,9,11,68,79,OBJECTIVE: To evaluate current performance on recommended perinatal hepatitis B and rubella prevention practices in New Hampshire.,15867025_1,-1,-1,-1,5170,-1,0.3647137,0.6352863
5171,rubella,12,13,84,91,OBJECTIVE: To evaluate current performance on recommended perinatal hepatitis B and rubella prevention practices in New Hampshire.,15867025_1,-1,-1,-1,5171,-1,0.9947119,0.0052881725
5172,hepatitis B,10,12,61,72,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5172,-1,0.77389026,0.22610976
5173,rubella,13,14,77,84,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5173,-1,0.96432865,0.03567133
5174,hepatitis B vaccine,18,21,108,127,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5174,-1,0.98333573,0.016664298
5175,hepatitis B,29,31,173,184,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5175,-1,0.97736424,0.022635728
5176,hepatitis B,39,41,229,240,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5176,-1,0.8858109,0.11418911
5177,rubella,45,46,275,282,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5177,-1,0.9762308,0.023769224
5178,rubella vaccine,53,55,338,353,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5178,-1,0.97309804,0.026902005
5179,rubella,56,57,357,364,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,-1,-1,-1,5179,-1,0.9616065,0.038393464
5180,hepatitis B,6,8,38,49,RESULTS: Prenatal screening rates for hepatitis B (98.8%) and rubella (99.4%) were high.,15867025_4,-1,-1,-1,5180,-1,0.12636347,0.8736365
5181,rubella,13,14,62,69,RESULTS: Prenatal screening rates for hepatitis B (98.8%) and rubella (99.4%) were high.,15867025_4,-1,-1,-1,5181,-1,0.76955783,0.23044215
5182,Hepatitis B vaccine,0,3,0,19,Hepatitis B vaccine birth dose was administered to 76.2% of all infants.,15867025_5,-1,-1,-1,5182,-1,0.99400806,0.0059918887
5183,hepatitis B,6,8,29,40,All infants who were born to hepatitis B surface antigen-positive mothers also received hepatitis B immune globulin.,15867025_6,-1,-1,-1,5183,-1,0.613072,0.38692802
5184,hepatitis B,13,15,88,99,All infants who were born to hepatitis B surface antigen-positive mothers also received hepatitis B immune globulin.,15867025_6,-1,-1,-1,5184,-1,0.7302916,0.26970837
5185,birth weight,11,13,78,90,Multivariate logistic regression showed that the month of delivery and infant birth weight were independent predictors of hepatitis B vaccination.,15867025_7,-1,-1,-1,5185,-1,0.051717788,0.94828224
5186,hepatitis B,17,19,122,133,Multivariate logistic regression showed that the month of delivery and infant birth weight were independent predictors of hepatitis B vaccination.,15867025_7,-1,-1,-1,5186,-1,0.9872721,0.012727909
5187,rubella,13,14,66,73,Women who were born between 1971 and 1975 had the highest rate of rubella nonimmunity (9.5%).,15867025_9,-1,-1,-1,5187,-1,0.99441,0.0055900365
5188,rubella vaccine,2,4,23,38,In-hospital postpartum rubella vaccine administration was documented for 75.6% of nonimmune women.,15867025_10,-1,-1,-1,5188,-1,0.9975606,0.0024393338
5189,hepatitis B,18,20,126,137,CONCLUSION: This study documents good compliance in New Hampshire's birthing hospitals with national guidelines for perinatal hepatitis B and rubella prevention and highlights potential areas for improvement.,15867025_11,-1,-1,-1,5189,-1,0.30785084,0.6921491
5190,rubella,21,22,142,149,CONCLUSION: This study documents good compliance in New Hampshire's birthing hospitals with national guidelines for perinatal hepatitis B and rubella prevention and highlights potential areas for improvement.,15867025_11,-1,-1,-1,5190,-1,0.99694246,0.0030575667
5191,masseter muscle rigidity,1,4,24,48,Succinylcholine-induced masseter muscle rigidity during bronchoscopic removal of a tracheal foreign body.,15893386_0,-1,-1,-1,5191,-1,0.017462919,0.9825371
5192,Masseter muscle rigidity,0,3,0,24,Masseter muscle rigidity during general anesthesia is considered an early warning sign of a possible episode of malignant hyperthermia.,15893386_1,-1,-1,-1,5192,-1,0.09030644,0.90969354
5193,malignant hyperthermia,17,19,112,134,Masseter muscle rigidity during general anesthesia is considered an early warning sign of a possible episode of malignant hyperthermia.,15893386_1,-1,-1,-1,5193,-1,0.0031402837,0.99685967
5194,masseter muscle rigidity,19,22,116,140,The decision whether to continue or discontinue the procedure depends on the urgency of the surgery and severity of masseter muscle rigidity.,15893386_2,-1,-1,-1,5194,-1,0.12883487,0.87116516
5195,masseter muscle rigidity,8,11,35,59,"Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.",15893386_3,-1,-1,-1,5195,-1,0.022333197,0.9776668
5196,jaw of steel,12,15,61,73,"Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.",15893386_3,-1,-1,-1,5196,-1,0.061011963,0.93898803
5198,Sch,19,20,98,101,"Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.",15893386_3,-1,-1,-1,5198,-1,0.99726653,0.002733537
5200,malignant hyperthermia,16,18,117,139,Anesthesia was continued uneventfully with propofol infusion while all facilities were available to detect and treat malignant hyperthermia.,15893386_4,-1,-1,-1,5200,-1,0.0028435802,0.9971564
5205,anthracyclines daunorubicin,3,5,13,40,"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.",15897593_1,-1,-1,-1,5205,-1,0.9982503,0.0017496169
5207,epipodophyllotoxin etoposide,9,11,65,93,"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.",15897593_1,-1,-1,-1,5207,-1,0.99813545,0.0018644929
5210,Dexrazoxane,0,1,0,11,Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.,15897593_2,-1,-1,-1,5210,-1,0.9992674,0.0007326141
5211,ICRF-187,2,3,13,21,Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.,15897593_2,-1,-1,-1,5211,-1,0.9978834,0.0021166278
5213,hematologic toxicity,10,12,58,78,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,-1,-1,-1,5213,-1,0.0031013535,0.99689865
5214,dexrazoxane,15,16,109,120,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,-1,-1,-1,5214,-1,0.99915266,0.0008473591
5221,dexrazoxane,20,21,107,118,"Likewise, in vivo, B6D2F1 mice were treated with etoposide, daunorubicin, and doxorubicin, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done.",15897593_4,-1,-1,-1,5221,-1,0.99893636,0.0010636172
5222,dexrazoxane,5,6,27,38,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,-1,-1,-1,5222,-1,0.9991986,0.0008014465
5224,weight loss,9,11,68,79,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,-1,-1,-1,5224,-1,0.0034996832,0.99650025
5227,dexrazoxane,29,30,198,209,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,-1,-1,-1,5227,-1,0.999213,0.0007870347
5229,weight loss,34,36,244,255,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,-1,-1,-1,5229,-1,0.0032405434,0.9967595
5230,cytotoxicity,41,42,274,286,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,-1,-1,-1,5230,-1,0.003460696,0.99653935
5232,dexrazoxane,9,10,63,74,"CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.",15897593_6,-1,-1,-1,5232,-1,0.9991597,0.0008402966
5236,dexrazoxane,16,17,99,110,Our data also suggest that significant etoposide dose escalation is perhaps possible by the use of dexrazoxane.,15897593_7,-1,-1,-1,5236,-1,0.99908316,0.00091686525
5237,metastases,6,7,39,49,Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.,15897593_8,-1,-1,-1,5237,-1,0.0028073206,0.9971927
5238,dexrazoxane,8,9,60,71,Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.,15897593_8,-1,-1,-1,5238,-1,0.9992138,0.00078622025
5240,hematologic toxicity,24,26,166,186,Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.,15897593_8,-1,-1,-1,5240,-1,0.0032690973,0.9967309
5241,atrial fibrillation,1,3,5,24,Lone atrial fibrillation associated with creatine monohydrate supplementation.,15899738_0,-1,-1,-1,5241,-1,0.0038976874,0.99610233
5243,Atrial fibrillation,0,2,0,19,Atrial fibrillation in young patients without structural heart disease is rare.,15899738_1,-1,-1,-1,5243,-1,0.014554827,0.9854452
5244,heart disease,7,9,57,70,Atrial fibrillation in young patients without structural heart disease is rare.,15899738_1,-1,-1,-1,5244,-1,0.004912279,0.9950877
5246,Thyroid disorders,0,2,0,17,"Thyroid disorders, illicit drug or stimulant use, and acute alcohol intoxication are among these causes.",15899738_3,-1,-1,-1,5246,-1,0.0046963035,0.99530375
5248,intoxication,12,13,68,80,"Thyroid disorders, illicit drug or stimulant use, and acute alcohol intoxication are among these causes.",15899738_3,-1,-1,-1,5248,-1,0.0033740618,0.9966259
5249,emergency department,13,15,66,86,We report the case of a 30-year-old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response.,15899738_4,-1,-1,-1,5249,-1,0.013996017,0.98600394
5250,atrial fibrillation,16,18,90,109,We report the case of a 30-year-old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response.,15899738_4,-1,-1,-1,5250,-1,0.011381056,0.98861897
5256,unfractionated heparin,10,12,62,84,"The patient was admitted to the hospital, anticoagulated with unfractionated heparin, and given intravenous diltiazem for rate control and intravenous amiodarone for rate and rhythm control.",15899738_8,-1,-1,-1,5256,-1,0.9979253,0.0020747387
5293,inability to repeat words,8,12,48,73,The mean highest BIS score corresponding to the inability to repeat words was 81.5 (95% CI = 78.1 to 84.8).,15930398_13,-1,-1,-1,5293,-1,0.3244341,0.6755659
5294,retrograde amnesia,25,27,161,179,"Furthermore, patients had no recall of words repeated prior to procedural sedation in BIS ranges associated with recall after procedural sedation, suggestive of retrograde amnesia.",15930398_19,-1,-1,-1,5294,-1,0.014741004,0.98525894
5295,Ro4368554,5,6,40,49,The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat.,15957009_0,-1,-1,-1,5295,-1,0.99833244,0.0016675504
5296,memory deficiency,15,17,120,137,The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat.,15957009_0,-1,-1,-1,5296,-1,0.0033851357,0.9966149
5298,ACh,19,20,118,121,"Although the underlying mechanism(s) are not well understood, these effects may involve an increase in acetylcholine (ACh) levels.",15957009_2,-1,-1,-1,5298,-1,0.9977912,0.002208849
5299,Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole,14,17,99,164,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,-1,-1,-1,5299,-1,0.99704605,0.0029539845
5301,tryptophan,35,36,271,281,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,-1,-1,-1,5301,-1,0.9956695,0.0043304963
5302,TRP,37,38,283,286,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,-1,-1,-1,5302,-1,0.9948068,0.0051932223
5303,metrifonate,56,57,399,410,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,-1,-1,-1,5303,-1,0.99881786,0.0011820755
5304,metrifonate,17,18,116,127,"Initial testing in a time-dependent forgetting task employing a 24-h delay between training and testing showed that metrifonate improved object recognition (at 10 and 30 mg/kg, p.o.), whereas Ro4368554 was inactive.",15957009_4,-1,-1,-1,5304,-1,0.9990928,0.00090722425
5305,Ro4368554,33,34,192,201,"Initial testing in a time-dependent forgetting task employing a 24-h delay between training and testing showed that metrifonate improved object recognition (at 10 and 30 mg/kg, p.o.), whereas Ro4368554 was inactive.",15957009_4,-1,-1,-1,5305,-1,0.9974511,0.002548909
5306,Ro4368554,2,3,6,15,"Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).",15957009_5,-1,-1,-1,5306,-1,0.99724704,0.002752958
5307,metrifonate,16,17,63,74,"Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).",15957009_5,-1,-1,-1,5307,-1,0.9990464,0.00095365266
5308,memory deficits,27,29,115,130,"Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).",15957009_5,-1,-1,-1,5308,-1,0.0028922544,0.9971078
5310,TRP,33,34,158,161,"Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).",15957009_5,-1,-1,-1,5310,-1,0.9963993,0.0036007538
5311,Ro4368554,4,5,24,33,"In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.",15957009_6,-1,-1,-1,5311,-1,0.9985031,0.0014969698
5312,retention deficit,10,12,65,82,"In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.",15957009_6,-1,-1,-1,5312,-1,0.005367648,0.99463236
5313,memory deficit,20,22,129,143,"In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.",15957009_6,-1,-1,-1,5313,-1,0.003953469,0.9960465
5314,Ro4368554,37,38,233,242,"In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.",15957009_6,-1,-1,-1,5314,-1,0.9984169,0.0015830533
5316,pneumonitis,18,19,122,133,"Amiodarone is an effective antiarrhythmic agent whose utility is limited by many side-effects, the most problematic being pneumonitis.",1595783_1,-1,-1,-1,5316,-1,0.0023704197,0.9976295
5317,pulmonary toxicity,1,3,4,22,The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated hypersensitivity pneumonitis.,1595783_2,-1,-1,-1,5317,-1,0.002797142,0.9972029
5319,hypersensitivity pneumonitis,22,24,155,183,The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated hypersensitivity pneumonitis.,1595783_2,-1,-1,-1,5319,-1,0.0028422328,0.9971578
5320,pulmonary toxicity,7,9,61,79,The clinical and radiographic features of amiodarone-induced pulmonary toxicity are characteristic but nonspecific.,1595783_3,-1,-1,-1,5320,-1,0.002420818,0.99757916
5321,heart failure,11,13,62,75,"The diagnosis depends on exclusion of other entities, such as heart failure, infection, and malignancy.",1595783_4,-1,-1,-1,5321,-1,0.0046958085,0.9953042
5326,kainate,7,8,43,50,Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain.,15974569_0,-1,-1,-1,5326,-1,0.998264,0.00173604
5328,Amino acids 5,0,3,0,13,"Amino acids 5 and 7, two potent and selective competitive GluR5 KA receptor antagonists, exhibited high GluR5 receptor affinity over other glutamate receptors.",15974569_1,-1,-1,-1,5328,-1,0.973769,0.026231024
5329,7,4,5,18,19,"Amino acids 5 and 7, two potent and selective competitive GluR5 KA receptor antagonists, exhibited high GluR5 receptor affinity over other glutamate receptors.",15974569_1,-1,-1,-1,5329,-1,0.97997916,0.020020792
5332,thermal hyperalgesia,22,24,135,155,"Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.",15974569_2,-1,-1,-1,5332,-1,0.0033968284,0.99660313
5333,mechanical hyperalgesia,27,29,179,202,"Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.",15974569_2,-1,-1,-1,5333,-1,0.0036781977,0.9963218
5339,pharyngitis,17,18,116,127,CASE SUMMARY: A 76-year-old man presented with persistent hiccups after beginning azithromycin for the treatment of pharyngitis.,15985056_2,-1,-1,-1,5339,-1,0.013710502,0.9862895
5342,baclofen,6,7,49,57,Discontinuation of azithromycin and therapy with baclofen finally resolved hiccups.,15985056_4,-1,-1,-1,5342,-1,0.9991423,0.0008576567
5352,macrolide,10,11,64,73,Few cases of drug-induced hiccups have been reported related to macrolide antimicrobials.,15985056_8,-1,-1,-1,5352,-1,0.99899584,0.0010041092
5353,macrolides,36,37,213,223,"Using the Naranjo adverse effect reaction probability scale this event could be classified as possible (score 5 points), mostly because of the close temporal sequence, previous reports on this reaction with other macrolides and the absence of any alternative explanation for hiccups.",15985056_9,-1,-1,-1,5353,-1,0.99807644,0.0019235095
5358,macrolide,2,3,9,18,"However, macrolide antimicrobials have been reported to be associated with hiccups and vagal mechanism could explain the development of this side-effect.",15985056_12,-1,-1,-1,5358,-1,0.9985329,0.0014671128
5360,GNC92H2,6,7,50,57,Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose.,16005948_0,-1,-1,-1,5360,-1,0.9936871,0.006312965
5361,cocaine overdose,11,13,82,98,Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose.,16005948_0,-1,-1,-1,5361,-1,0.06431968,0.9356803
5363,cocaine overdose,12,14,79,95,The illicit use of cocaine continues in epidemic proportions and treatment for cocaine overdose remains elusive.,16005948_1,-1,-1,-1,5363,-1,0.09517089,0.9048291
5364,GNC92H2,7,8,54,61,The therapeutic potential of the anticocaine antibody GNC92H2 was examined using a model of cocaine overdose.,16005948_3,-1,-1,-1,5364,-1,0.99348116,0.0065188636
5365,cocaine overdose,14,16,92,108,The therapeutic potential of the anticocaine antibody GNC92H2 was examined using a model of cocaine overdose.,16005948_3,-1,-1,-1,5365,-1,0.07030276,0.9296972
5367,GNC92H2,23,24,141,148,Swiss albino mice prepared with intrajugular catheters were tested in photocell cages after administration of 93 mg/kg (LD50) of cocaine and GNC92H2 infusions ranging from 30 to 190 mg/kg.,16005948_4,-1,-1,-1,5367,-1,0.9979298,0.0020701499
5369,cocaine toxicity,3,5,24,40,"Significant blockade of cocaine toxicity was observed with the higher dose of GNC92H2 (190 mg/kg), where premorbid behaviors were reduced up to 40%, seizures up to 77% and death by 72%.",16005948_6,-1,-1,-1,5369,-1,0.40177596,0.5982241
5370,GNC92H2,12,13,78,85,"Significant blockade of cocaine toxicity was observed with the higher dose of GNC92H2 (190 mg/kg), where premorbid behaviors were reduced up to 40%, seizures up to 77% and death by 72%.",16005948_6,-1,-1,-1,5370,-1,0.9983808,0.0016192449
5373,GNC92H2,2,3,13,20,"Importantly, GNC92H2 prevented death even post-cocaine injection.",16005948_7,-1,-1,-1,5373,-1,0.9974166,0.0025833186
5375,GNC92H2,7,8,47,54,The results support the important potential of GNC92H2 as a therapeutic tool against cocaine overdose.,16005948_8,-1,-1,-1,5375,-1,0.99672914,0.003270824
5376,cocaine overdose,13,15,85,101,The results support the important potential of GNC92H2 as a therapeutic tool against cocaine overdose.,16005948_8,-1,-1,-1,5376,-1,0.07001775,0.92998224
5377,Calcium carbonate toxicity,0,3,0,26,Calcium carbonate toxicity: the updated milk-alkali syndrome; report of 3 cases and review of the literature.,16006300_0,-1,-1,-1,5377,-1,0.8400643,0.1599357
5382,acute renal insufficiency,6,9,28,53,"RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.",16006300_3,-1,-1,-1,5382,-1,0.0030334021,0.99696666
5383,metabolic alkalosis,11,13,64,83,"RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.",16006300_3,-1,-1,-1,5383,-1,0.005819882,0.9941801
5384,parathyroid hormone,16,18,93,112,"RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.",16006300_3,-1,-1,-1,5384,-1,0.9907023,0.009297693
5385,"1,25-dihydroxyvitamin D",26,28,145,168,"RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.",16006300_3,-1,-1,-1,5385,-1,0.9967721,0.0032278204
5388,pamidronate,10,11,69,80,"The 2 patients with the higher serum calcium concentrations received pamidronate intravenously (60 and 30 mg, respectively), which caused severe hypocalcemia.",16006300_6,-1,-1,-1,5388,-1,0.9991948,0.0008052446
5389,mg,16,17,106,108,"The 2 patients with the higher serum calcium concentrations received pamidronate intravenously (60 and 30 mg, respectively), which caused severe hypocalcemia.",16006300_6,-1,-1,-1,5389,-1,0.9771663,0.02283367
5392,calcium carbonate,27,29,123,140,"Of the 3 patients, 2 were ingesting acceptable doses of elemental calcium (1 g and 2 g daily, respectively) in the form of calcium carbonate.",16006300_7,-1,-1,-1,5392,-1,0.99803704,0.0019629945
5394,calcium carbonate,22,24,144,161,CONCLUSION: Milk-alkali syndrome may be a common cause of unexplained hypercalcemia and can be precipitated by small amounts of orally ingested calcium carbonate in susceptible persons.,16006300_9,-1,-1,-1,5394,-1,0.9985493,0.0014507199
5397,vitamin D,12,14,77,86,"Treatment with hydration, furosemide, and discontinuation of the calcium and vitamin D source is adequate.",16006300_10,-1,-1,-1,5397,-1,0.9975497,0.0024502464
5405,myocardial infarction,19,21,116,137,"Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ischemia, and bundle branch block.",1601297_2,-1,-1,-1,5405,-1,0.0029946833,0.9970053
5407,bundle branch block,25,28,153,172,"Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ischemia, and bundle branch block.",1601297_2,-1,-1,-1,5407,-1,0.071430124,0.92856985
5408,leukocytoclastic vasculitis,1,3,17,44,Warfarin-induced leukocytoclastic vasculitis.,16047871_0,-1,-1,-1,5408,-1,0.0028157118,0.9971842
5409,LV,3,4,29,31,"Leukocytoclastic vasculitis (LV) is primarily a cutaneous small vessel vasculitis, though systemic involvement may be encountered.",16047871_2,-1,-1,-1,5409,-1,0.031781923,0.96821815
5410,cutaneous small vessel vasculitis,8,12,48,81,"Leukocytoclastic vasculitis (LV) is primarily a cutaneous small vessel vasculitis, though systemic involvement may be encountered.",16047871_2,-1,-1,-1,5410,-1,0.00555317,0.99444675
5411,LV,6,7,37,39,We report 4 patients with late-onset LV probably due to warfarin.,16047871_3,-1,-1,-1,5411,-1,0.0046286723,0.9953713
5413,skin eruptions,5,7,30,44,All 4 patients presented with skin eruptions that developed after receiving warfarin for several years.,16047871_4,-1,-1,-1,5413,-1,0.0026658955,0.9973341
5415,lesion,4,5,20,26,"The results of skin lesion biopsies were available in 3 patients, confirming LV Cutaneous lesions resolved in all patients after warfarin was discontinued.",16047871_5,-1,-1,-1,5415,-1,0.0047841733,0.9952159
5416,LV Cutaneous lesions,13,16,77,97,"The results of skin lesion biopsies were available in 3 patients, confirming LV Cutaneous lesions resolved in all patients after warfarin was discontinued.",16047871_5,-1,-1,-1,5416,-1,0.010611612,0.9893884
5419,LV,0,1,0,2,LV may be a late-onset adverse reaction associated with warfarin therapy.,16047871_7,-1,-1,-1,5419,-1,0.44293156,0.55706847
5430,Parkinson disease,9,11,74,91,rTMS of supplementary motor area modulates therapy-induced dyskinesias in Parkinson disease.,16116131_0,-1,-1,-1,5430,-1,0.003113688,0.9968863
5432,advanced Parkinson disease,22,25,126,152,"Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion.",16116131_2,-1,-1,-1,5432,-1,0.0046051634,0.99539477
5433,dyskinetic,41,42,252,262,"Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion.",16116131_2,-1,-1,-1,5433,-1,0.0026578407,0.99734217
5437,brain tumors,2,4,16,28,Human malignant brain tumors have a poor prognosis in spite of surgery and radiation therapy.,16132524_1,-1,-1,-1,5437,-1,0.0032928868,0.99670714
5438,lipid bilayers,6,8,45,59,"Cubic phases consist of curved biocontinuous lipid bilayers, separating two congruent networks of water channels.",16132524_2,-1,-1,-1,5438,-1,0.14654082,0.85345924
5442,glioblastoma multiforme,10,12,46,69,A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re-resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages.,16132524_5,-1,-1,-1,5442,-1,0.004344066,0.9956559
5445,mg paclitaxel,8,10,42,55,"Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.",16132524_6,-1,-1,-1,5445,-1,0.9977964,0.0022035805
5446,brain edema,16,18,93,104,"Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.",16132524_6,-1,-1,-1,5446,-1,0.0020771883,0.99792284
5447,mg paclitaxel,29,31,163,176,"Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.",16132524_6,-1,-1,-1,5447,-1,0.99754804,0.0024520003
5448,brain edema,5,7,21,32,"In the latter group, brain edema was markedly reduced and dealt medically.",16132524_7,-1,-1,-1,5448,-1,0.0023543236,0.9976457
5451,epilepsies,11,12,88,98,Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies.,16157917_0,-1,-1,-1,5451,-1,0.0021279855,0.997872
5452,idiopathic generalized epilepsies,3,6,19,52,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,-1,-1,-1,5452,-1,0.0030192337,0.9969807
5453,IGE,7,8,54,57,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,-1,-1,-1,5453,-1,0.030602988,0.969397
5454,lamotrigine,11,12,72,83,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,-1,-1,-1,5454,-1,0.9992473,0.00075273716
5455,LTG,13,14,85,88,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,-1,-1,-1,5455,-1,0.99743736,0.002562591
5457,MJ,25,26,157,159,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,-1,-1,-1,5457,-1,0.012695515,0.9873045
5458,LTG,4,5,19,22,"In three patients, LTG exacerbated MJ in a dose-dependent manner with early aggravation during titration.",16157917_2,-1,-1,-1,5458,-1,0.9983552,0.0016447987
5459,MJ,6,7,35,37,"In three patients, LTG exacerbated MJ in a dose-dependent manner with early aggravation during titration.",16157917_2,-1,-1,-1,5459,-1,0.66382533,0.33617464
5460,MJ,0,1,0,2,MJ disappeared when LTG dose was decreased by 25 to 50%.,16157917_3,-1,-1,-1,5460,-1,0.99590766,0.004092314
5461,LTG,3,4,20,23,MJ disappeared when LTG dose was decreased by 25 to 50%.,16157917_3,-1,-1,-1,5461,-1,0.9983051,0.0016949583
5462,LTG,4,5,17,20,"In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.",16157917_4,-1,-1,-1,5462,-1,0.99835545,0.0016445278
5463,MJ,6,7,33,35,"In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.",16157917_4,-1,-1,-1,5463,-1,0.041621994,0.958378
5464,myoclonic status,16,18,78,94,"In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.",16157917_4,-1,-1,-1,5464,-1,0.0031697073,0.9968303
5465,LTG,22,23,118,121,"In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.",16157917_4,-1,-1,-1,5465,-1,0.99817693,0.0018230599
5468,thyrotropin,16,17,116,127,Intracerebroventricular (i.c.v.) injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion.,16160878_2,-1,-1,-1,5468,-1,0.9979786,0.0020213404
5469,penile erection,20,22,126,141,"Whatever was the dose, the central administration of U-II had no effect on body temperature, nociception, apomorphine-induced penile erection and climbing behavior, and stress-induced plasma corticosterone level.",16160878_8,-1,-1,-1,5469,-1,0.0037035951,0.99629647
5471,psychiatric disorders,12,14,64,85,These data suggest that U-II may be involved in some aspects of psychiatric disorders.,16160878_10,-1,-1,-1,5471,-1,0.0024399676,0.99756
5477,memory dissociation,4,6,18,37,It was shown that memory dissociation occurred in both groups.,1616457_5,-1,-1,-1,5477,-1,0.0048644524,0.9951356
5480,raloxifene,4,5,26,36,"The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.",16167916_0,-1,-1,-1,5480,-1,0.9992473,0.0007527225
5481,raloxifene,52,53,331,341,"The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.",16167916_0,-1,-1,-1,5481,-1,0.9992079,0.00079206424
5482,osteopenia,6,7,47,57,"METHODS: Thirty-nine postmenopausal women with osteopenia or osteoporosis were included in this prospective, controlled clinical study.",16167916_1,-1,-1,-1,5482,-1,0.0029129009,0.99708706
5484,raloxifene hydrochloride,4,6,29,53,Twenty-five women were given raloxifene hydrochloride (60 mg/day) plus calcium (500 mg/day).,16167916_2,-1,-1,-1,5484,-1,0.998979,0.0010210809
5486,n,3,4,22,23,Age-matched controls (n = 14) were given only calcium.,16167916_3,-1,-1,-1,5486,-1,0.27777258,0.72222745
5488,raloxifene,5,6,25,35,"RESULTS: Three months of raloxifene treatment was associated with a significant decrease in the plasma TAFI antigen concentrations (16% change, P < 0.01), and a significant increase in tPA antigen concentrations (25% change, P < 0.05).",16167916_7,-1,-1,-1,5488,-1,0.9993518,0.0006481845
5489,P,24,25,144,145,"RESULTS: Three months of raloxifene treatment was associated with a significant decrease in the plasma TAFI antigen concentrations (16% change, P < 0.01), and a significant increase in tPA antigen concentrations (25% change, P < 0.05).",16167916_7,-1,-1,-1,5489,-1,0.2931148,0.7068852
5490,P,42,43,225,226,"RESULTS: Three months of raloxifene treatment was associated with a significant decrease in the plasma TAFI antigen concentrations (16% change, P < 0.01), and a significant increase in tPA antigen concentrations (25% change, P < 0.05).",16167916_7,-1,-1,-1,5490,-1,0.2252441,0.7747559
5491,amenorrhea,14,15,101,111,A significant correlation was found between baseline TAFI antigen concentrations and the duration of amenorrhea (P < 0.05; r = 0.33).,16167916_8,-1,-1,-1,5491,-1,0.0020964902,0.99790347
5492,P,16,17,113,114,A significant correlation was found between baseline TAFI antigen concentrations and the duration of amenorrhea (P < 0.05; r = 0.33).,16167916_8,-1,-1,-1,5492,-1,0.38125724,0.61874276
5493,thromboembolism,10,11,57,72,"CONCLUSION: We suggest that the increased risk of venous thromboembolism due to raloxifene treatment may be related to increased tPA levels, but not TAFI levels.",16167916_9,-1,-1,-1,5493,-1,0.002514496,0.9974855
5494,raloxifene,13,14,80,90,"CONCLUSION: We suggest that the increased risk of venous thromboembolism due to raloxifene treatment may be related to increased tPA levels, but not TAFI levels.",16167916_9,-1,-1,-1,5494,-1,0.99931693,0.00068306935
5495,subarachnoid hemorrhage,7,9,68,91,Absence of acute cerebral vasoconstriction after cocaine-associated subarachnoid hemorrhage.,16174948_0,-1,-1,-1,5495,-1,0.005252664,0.99474734
5497,neurovascular complications,8,10,51,78,"INTRODUCTION: Cocaine use has been associated with neurovascular complications, including arterial vasoconstriction and vasculitis.",16174948_1,-1,-1,-1,5497,-1,0.003081765,0.9969182
5500,subarachnoid hemorrhage,13,15,99,122,Information on these effects could be obtained from angiograms of patients with cocaine-associated subarachnoid hemorrhage (SAH) who underwent angiography shortly after cocaine use.,16174948_3,-1,-1,-1,5500,-1,0.0029195992,0.9970804
5501,SAH,16,17,124,127,Information on these effects could be obtained from angiograms of patients with cocaine-associated subarachnoid hemorrhage (SAH) who underwent angiography shortly after cocaine use.,16174948_3,-1,-1,-1,5501,-1,0.0022692767,0.9977308
5503,SAH,6,7,35,38,METHODS: We screened patients with SAH retrospectively and identified those with positive urine toxicology for cocaine or its metabolites.,16174948_4,-1,-1,-1,5503,-1,0.0031630248,0.9968369
5505,SAH,17,18,135,138,Quantitative arterial diameter measurements from angiograms of these patients were compared to measurements from control patients with SAH who were matched for factors known to influence arterial diameter.,16174948_5,-1,-1,-1,5505,-1,0.0040117446,0.9959882
5507,p,35,36,226,227,"There were no significant differences between groups in the mean diameters of the intradural internal carotid, sphenoidal segment of the middle cerebral, precommunicating segment of the anterior cerebral, or basilar arteries (p greater than 0.05 for all comparisons, unpaired t-tests).",16174948_8,-1,-1,-1,5507,-1,0.29196388,0.7080361
5508,p,48,49,316,317,"There also were no significant differences between groups when expressing diameters as the sum of the precommunicating segment of the anterior cerebral + sphenoidal segment of the middle cerebral + supraclinoid internal carotid artery + basilar artery divided by the diameter of the petrous internal carotid artery (p greater than 0.05, unpaired t-tests).",16174948_9,-1,-1,-1,5508,-1,0.21887721,0.7811228
5510,aneurysmal SAH,29,31,209,223,CONCLUSION: No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal SAH associated with cocaine use.,16174948_11,-1,-1,-1,5510,-1,0.005467763,0.9945322
5518,MAP,5,6,42,45,Methamphetamine causes alterations in the MAP kinase-related pathways in the brains of mice that display increased aggressiveness.,16192988_0,-1,-1,-1,5518,-1,0.9503289,0.04967111
5520,Aggressive behaviors,0,2,0,20,"Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders, and are common in methamphetamine (METH) abusers.",16192988_1,-1,-1,-1,5520,-1,0.00370967,0.9962903
5521,psychiatric disorders,11,13,73,94,"Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders, and are common in methamphetamine (METH) abusers.",16192988_1,-1,-1,-1,5521,-1,0.002509707,0.9974903
5523,METH,20,21,131,135,"Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders, and are common in methamphetamine (METH) abusers.",16192988_1,-1,-1,-1,5523,-1,0.9950565,0.004943492
5524,METH,13,14,63,67,"Herein, we report that multiple (but not single) injections of METH significantly increased aggressiveness in male CD-1 mice.",16192988_2,-1,-1,-1,5524,-1,0.9987074,0.0012925583
5528,MAP,14,15,112,115,Analysis of protein expression using antibody microarrays and Western blotting revealed differential changes in MAP kinase-related pathways after multiple and single METH injections.,16192988_4,-1,-1,-1,5528,-1,0.93187714,0.06812286
5529,METH,21,22,166,170,Analysis of protein expression using antibody microarrays and Western blotting revealed differential changes in MAP kinase-related pathways after multiple and single METH injections.,16192988_4,-1,-1,-1,5529,-1,0.998353,0.00164698
5530,p<0.05,5,6,38,44,"There were statistically significant (p<0.05) decreases in MEK1, Erk2p, GSK3alpha, 14-3-3e, and MEK7 in the striata of mice after multiple injections of METH.",16192988_5,-1,-1,-1,5530,-1,0.3530915,0.6469085
5531,METH,32,33,153,157,"There were statistically significant (p<0.05) decreases in MEK1, Erk2p, GSK3alpha, 14-3-3e, and MEK7 in the striata of mice after multiple injections of METH.",16192988_5,-1,-1,-1,5531,-1,0.9982722,0.0017278007
5532,METH,10,11,66,70,"MEK1 was significantly decreased also after a single injection of METH, but to a much lesser degree than after multiple injections of METH.",16192988_6,-1,-1,-1,5532,-1,0.998681,0.0013190078
5533,METH,23,24,134,138,"MEK1 was significantly decreased also after a single injection of METH, but to a much lesser degree than after multiple injections of METH.",16192988_6,-1,-1,-1,5533,-1,0.9986596,0.001340429
5534,METH,22,23,129,133,"In the frontal cortex, there was a statistically significant decrease in GSK3alpha after multiple (but not single) injections of METH.",16192988_7,-1,-1,-1,5534,-1,0.99870753,0.0012924857
5535,MAP,6,7,43,46,These findings suggest that alterations in MAP kinase-related pathways in the prefronto-striatal circuitries might be involved in the manifestation of aggressive behaviors in mice.,16192988_8,-1,-1,-1,5535,-1,0.97756726,0.022432823
5536,aggressive behaviors,20,22,151,171,These findings suggest that alterations in MAP kinase-related pathways in the prefronto-striatal circuitries might be involved in the manifestation of aggressive behaviors in mice.,16192988_8,-1,-1,-1,5536,-1,0.003240636,0.99675936
5537,Amisulpride,0,1,0,11,Amisulpride related tic-like symptoms in an adolescent schizophrenic.,16225977_0,-1,-1,-1,5537,-1,0.99887484,0.0011251862
5539,Tic disorders,0,2,0,13,"Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.",16225977_1,-1,-1,-1,5539,-1,0.0026667705,0.9973333
5540,antipsychotics,8,9,53,67,"Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.",16225977_1,-1,-1,-1,5540,-1,0.9928266,0.0071734926
5543,ziprasidone,15,16,104,115,"Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.",16225977_1,-1,-1,-1,5543,-1,0.9991202,0.0008797747
5544,quetiapine,22,23,134,144,"However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.",16225977_2,-1,-1,-1,5544,-1,0.99933726,0.000662674
5547,amisulpride,16,17,120,131,We present a 15-year-old girl schizophrenic who developed frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day).,16225977_3,-1,-1,-1,5547,-1,0.99902,0.0009800415
5548,amisulpride,11,12,71,82,The tic-like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day.,16225977_4,-1,-1,-1,5548,-1,0.99894494,0.001055096
5549,mg,15,16,95,97,The tic-like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day.,16225977_4,-1,-1,-1,5549,-1,0.9656682,0.034331772
5550,psychosis,3,4,13,22,"However, her psychosis recurred after the dose reduction.",16225977_5,-1,-1,-1,5550,-1,0.0020536731,0.9979463
5551,mg,8,9,40,42,We then placed her on an additional 100 mg per day of quetiapine.,16225977_6,-1,-1,-1,5551,-1,0.9606677,0.039332293
5552,quetiapine,12,13,54,64,We then placed her on an additional 100 mg per day of quetiapine.,16225977_6,-1,-1,-1,5552,-1,0.99940825,0.0005917695
5553,antipsychotics,22,23,162,176,"Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.",16225977_9,-1,-1,-1,5553,-1,0.9937822,0.0062177526
5554,quetiapine,25,26,185,195,"Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.",16225977_9,-1,-1,-1,5554,-1,0.999343,0.0006570469
5556,amisulpride,30,31,211,222,"Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.",16225977_9,-1,-1,-1,5556,-1,0.9986228,0.0013772051
5557,dysphonia,1,2,10,19,Recurrent dysphonia and acitretin.,16274958_0,-1,-1,-1,5557,-1,0.0021703907,0.9978296
5558,acitretin,3,4,24,33,Recurrent dysphonia and acitretin.,16274958_0,-1,-1,-1,5558,-1,0.9987783,0.0012217143
5559,dysphonia,9,10,45,54,We report the case of a woman complaining of dysphonia while she was treated by acitretin.,16274958_1,-1,-1,-1,5559,-1,0.0020174636,0.9979825
5560,acitretin,15,16,80,89,We report the case of a woman complaining of dysphonia while she was treated by acitretin.,16274958_1,-1,-1,-1,5560,-1,0.99915147,0.00084851764
5561,acitretin,10,11,73,82,Her symptoms totally regressed after drug withdrawal and reappeared when acitretin was reintroduced.,16274958_2,-1,-1,-1,5561,-1,0.99914217,0.0008578275
5562,dysphonia,11,12,62,71,"To our knowledge, this is the first case of acitretin-induced dysphonia.",16274958_3,-1,-1,-1,5562,-1,0.0020262771,0.99797374
5563,heart block,3,5,29,40,Chloroquine related complete heart block with blindness: case report.,1628552_0,-1,-1,-1,5563,-1,0.004057127,0.9959429
5564,blindness,6,7,46,55,Chloroquine related complete heart block with blindness: case report.,1628552_0,-1,-1,-1,5564,-1,0.002582036,0.9974179
5566,deterioration of vision,14,17,101,124,"A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.",1628552_1,-1,-1,-1,5566,-1,0.010054361,0.9899456
5567,dyspnoea,21,22,146,154,"A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.",1628552_1,-1,-1,-1,5567,-1,0.0037373654,0.9962626
5569,syncopal attacks,26,28,181,197,"A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.",1628552_1,-1,-1,-1,5569,-1,0.0029721234,0.99702793
5570,chloroquine retinopathy,5,7,49,72,"Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.",1628552_2,-1,-1,-1,5570,-1,0.9030832,0.096916854
5571,heart failure,13,15,114,127,"Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.",1628552_2,-1,-1,-1,5571,-1,0.0032025077,0.9967975
5572,heart block,18,20,143,154,"Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.",1628552_2,-1,-1,-1,5572,-1,0.0055790306,0.99442095
5573,right bundle branch block pattern,21,26,160,193,"Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.",1628552_2,-1,-1,-1,5573,-1,0.033571992,0.96642804
5574,heart block,1,3,4,15,The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following chloroquine discontinuation.,1628552_3,-1,-1,-1,5574,-1,0.0035856208,0.9964143
5575,heart failure,10,12,59,72,The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following chloroquine discontinuation.,1628552_3,-1,-1,-1,5575,-1,0.0028827472,0.9971173
5577,gentamicin ototoxicity,8,10,61,83,Nitro-L-arginine methyl ester: a potential protector against gentamicin ototoxicity.,16298782_0,-1,-1,-1,5577,-1,0.046302155,0.95369786
5578,nitric oxide,1,3,4,16,"The nitric oxide (NO) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against high-frequency hearing loss caused by gentamicin, but further studies are needed to confirm this.",16298782_1,-1,-1,-1,5578,-1,0.99340075,0.006599265
5579,hearing loss,20,22,122,134,"The nitric oxide (NO) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against high-frequency hearing loss caused by gentamicin, but further studies are needed to confirm this.",16298782_1,-1,-1,-1,5579,-1,0.002955402,0.9970446
5583,ototoxic,11,12,60,68,"Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.",16298782_3,-1,-1,-1,5583,-1,0.003084412,0.9969156
5586,hearing loss,9,11,53,65,"Its effect was determined in terms of attenuation of hearing loss, measured by shifts in the auditory brainstem response threshold.",16298782_6,-1,-1,-1,5586,-1,0.0034397494,0.9965603
5587,hearing loss,3,5,34,46,"L-NAME reduced gentamicin-induced hearing loss in the high-frequency range, but gave no protection in the middle or low frequencies.",16298782_7,-1,-1,-1,5587,-1,0.0026931223,0.9973068
5596,heart disease,15,17,84,97,"METHODS: This was a multicenter, randomized, open-label study in adult smokers with heart disease, hypertension not controlled by medication, and/or diabetes mellitus.",16330293_4,-1,-1,-1,5596,-1,0.005976176,0.99402386
5598,diabetes mellitus,25,27,149,166,"METHODS: This was a multicenter, randomized, open-label study in adult smokers with heart disease, hypertension not controlled by medication, and/or diabetes mellitus.",16330293_4,-1,-1,-1,5598,-1,0.0043358966,0.99566406
5608,Cl,51,52,162,164,"The most common adverse events were nausea (17.2% and 16.1%; 95% CI, -3.7 to 6.0), hiccups (10.7% and 6.6%; 95% CI, 0.5 to 7.8), and headache (8.7% and 9.9%; 95% Cl, -5.0 to 2.6).",16330293_14,-1,-1,-1,5608,-1,0.55554867,0.44445133
5611,nervous,8,9,59,66,Abnormal processing of somatosensory inputs in the central nervous system (central sensitization) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding tissue injury (secondary hyperalgesia).,16330766_1,-1,-1,-1,5611,-1,0.07768091,0.92231905
5613,tissue injury,27,29,184,197,Abnormal processing of somatosensory inputs in the central nervous system (central sensitization) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding tissue injury (secondary hyperalgesia).,16330766_1,-1,-1,-1,5613,-1,0.011702116,0.9882979
5615,neurogenic hyperalgesia,6,8,60,83,Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain.,16330766_2,-1,-1,-1,5615,-1,0.0035521782,0.9964478
5622,mg,6,7,33,35,"The dose of gabapentin was 1,800 mg per os, in a single administration.",16330766_6,-1,-1,-1,5622,-1,0.9776098,0.022390189
5630,Mitochondrial abnormalities,0,2,0,27,"Mitochondrial abnormalities have been associated with several aspects of epileptogenesis, such as energy generation, control of cell death, neurotransmitter synthesis, and free radical (FR) production.",16337777_1,-1,-1,-1,5630,-1,0.02145029,0.9785498
5632,status epilepticus,12,14,73,91,"In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.",16337777_3,-1,-1,-1,5632,-1,0.004560783,0.99543923
5633,c,30,31,195,196,"In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.",16337777_3,-1,-1,-1,5633,-1,0.9828332,0.017166851
5636,mitochondrial abnormalities,3,5,22,49,"Although evidences of mitochondrial abnormalities were found in previously published studies, our results do not suggest that the FRs, generated during the acute phase, determined important abnormalities in mtDNA, in expression of CCO-I, and in CCO activity.",16337777_7,-1,-1,-1,5636,-1,0.02836895,0.97163105
5637,suprofen,2,3,11,19,Effects of suprofen on the isolated perfused rat kidney.,1636026_0,-1,-1,-1,5637,-1,0.9991874,0.00081262604
5638,suprofen,1,2,9,17,"Although suprofen has been associated with the development of acute renal failure in greater than 100 subjects, the mechanism of damage remains unclear.",1636026_1,-1,-1,-1,5638,-1,0.99920386,0.00079619227
5639,acute renal failure,9,12,62,81,"Although suprofen has been associated with the development of acute renal failure in greater than 100 subjects, the mechanism of damage remains unclear.",1636026_1,-1,-1,-1,5639,-1,0.0021945063,0.99780554
5641,mg,10,11,54,56,The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.,1636026_2,-1,-1,-1,5641,-1,0.9899379,0.01006215
5642,suprofen,12,13,60,68,The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.,1636026_2,-1,-1,-1,5642,-1,0.9993285,0.0006715876
5643,uric acid,34,36,198,207,The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.,1636026_2,-1,-1,-1,5643,-1,0.99831116,0.0016888614
5646,suprofen,21,22,132,140,"There were no significant differences in renal sodium excretion, oxygen consumption, or urinary flow rates in kidneys perfused with suprofen compared with the drug-free control groups.",1636026_3,-1,-1,-1,5646,-1,0.9992611,0.00073886174
5647,contrast,1,2,3,11,"In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.",1636026_4,-1,-1,-1,5647,-1,0.12809907,0.871901
5648,suprofen,16,17,101,109,"In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.",1636026_4,-1,-1,-1,5648,-1,0.99922466,0.0007753319
5649,uric acid,22,24,138,147,"In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.",1636026_4,-1,-1,-1,5649,-1,0.99818546,0.0018145648
5650,suprofen,30,31,176,184,"In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.",1636026_4,-1,-1,-1,5650,-1,0.99914813,0.00085184234
5651,uric acid,35,37,203,212,"In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.",1636026_4,-1,-1,-1,5651,-1,0.9976011,0.0023989219
5652,uric acid,9,11,57,66,"A significant decrease in the baseline excretion rate of uric acid was found in rats given suprofen, compared with drug-free controls.",1636026_5,-1,-1,-1,5652,-1,0.99826556,0.0017344771
5653,suprofen,16,17,91,99,"A significant decrease in the baseline excretion rate of uric acid was found in rats given suprofen, compared with drug-free controls.",1636026_5,-1,-1,-1,5653,-1,0.9992768,0.0007232395
5654,uric acid,6,8,37,46,"However, the fractional excretion of uric acid was unchanged between the groups over the experimental period.",1636026_6,-1,-1,-1,5654,-1,0.9983687,0.0016313656
5655,suprofen,3,4,12,20,"In summary, suprofen causes acute declines in renal function, most likely by directly altering the intrarenal distribution of uric acid.",1636026_7,-1,-1,-1,5655,-1,0.99921334,0.000786674
5656,acute declines in renal function,5,10,28,60,"In summary, suprofen causes acute declines in renal function, most likely by directly altering the intrarenal distribution of uric acid.",1636026_7,-1,-1,-1,5656,-1,0.0053706933,0.9946293
5657,uric acid,20,22,126,135,"In summary, suprofen causes acute declines in renal function, most likely by directly altering the intrarenal distribution of uric acid.",1636026_7,-1,-1,-1,5657,-1,0.9986413,0.0013587207
5658,ritanserin,2,3,18,28,Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine-induced amnesia in adult male rats.,16364460_0,-1,-1,-1,5658,-1,0.9994081,0.0005919222
5660,ritanserin,3,4,14,24,The effect of ritanserin (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced amnesia in Morris water maze (MWM) was investigated.,16364460_1,-1,-1,-1,5660,-1,0.999483,0.0005169392
5663,DMSO,11,12,59,63,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,-1,-1,-1,5663,-1,0.99735945,0.002640482
5664,saline+DMSO,13,14,65,76,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,-1,-1,-1,5664,-1,0.9883306,0.011669388
5666,ritanserin,29,30,150,160,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,-1,-1,-1,5666,-1,0.999418,0.0005819971
5668,DMSO,61,62,332,336,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,-1,-1,-1,5668,-1,0.9948315,0.0051685255
5670,ritanserin,4,5,25,35,"However, scopolamine and ritanserin co-administration resulted in a significant decrease in escape latencies and traveled distances as compared to the scopolamine-treated rats.",16364460_8,-1,-1,-1,5670,-1,0.9993631,0.00063683663
5671,ritanserin,6,7,41,51,Our findings show that microinjection of ritanserin into the CA1 region of the hippocampus improves the scopolamine-induced amnesia.,16364460_9,-1,-1,-1,5671,-1,0.99941504,0.0005849974
5675,nephrosclerosis,9,10,62,77,Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.,1639466_0,-1,-1,-1,5675,-1,0.002554788,0.9974452
5676,renovascular hypertension,13,15,91,116,Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.,1639466_0,-1,-1,-1,5676,-1,0.004685152,0.99531484
5681,renovascular hypertension,43,45,274,299,"The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.",1639466_1,-1,-1,-1,5681,-1,0.0033518374,0.99664813
5683,mm Hg,16,18,75,80,"Six weeks after clipping of one renal artery, hypertensive rats (178 +/- 4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), enalapril-treated (n = 8), or nitrendipine-treated (n = 10).",1639466_2,-1,-1,-1,5683,-1,0.15034322,0.8496568
5685,n,30,31,155,156,"Six weeks after clipping of one renal artery, hypertensive rats (178 +/- 4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), enalapril-treated (n = 8), or nitrendipine-treated (n = 10).",1639466_2,-1,-1,-1,5685,-1,0.21093355,0.78906643
5686,n,36,37,182,183,"Six weeks after clipping of one renal artery, hypertensive rats (178 +/- 4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), enalapril-treated (n = 8), or nitrendipine-treated (n = 10).",1639466_2,-1,-1,-1,5686,-1,0.21234925,0.78765076
5687,n,43,44,215,216,"Six weeks after clipping of one renal artery, hypertensive rats (178 +/- 4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), enalapril-treated (n = 8), or nitrendipine-treated (n = 10).",1639466_2,-1,-1,-1,5687,-1,0.17704968,0.8229503
5688,mm Hg,11,13,62,67,"Sham-operated rats served as normotensive controls (128 +/- 3 mm Hg, n = 8).",1639466_3,-1,-1,-1,5688,-1,0.39558902,0.604411
5689,n,14,15,69,70,"Sham-operated rats served as normotensive controls (128 +/- 3 mm Hg, n = 8).",1639466_3,-1,-1,-1,5689,-1,0.24791133,0.7520887
5690,sclerosis,10,11,67,76,Renal tissue was obtained for determination of glomerular size and sclerosis.,1639466_5,-1,-1,-1,5690,-1,0.0030945926,0.9969054
5695,contrast,1,2,3,11,"In contrast, in the nitrendipine-treated group albuminuria increased from 12.8 +/- 2 progressively to 163 +/- 55 compared with 19.2 +/- 9 mg/24 hr in the hypertensive controls.",1639466_9,-1,-1,-1,5695,-1,0.1419767,0.8580233
5702,torsades de pointes,2,5,21,40,Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug.,16403073_0,-1,-1,-1,5702,-1,0.008024357,0.9919756
5704,coronary artery disease,5,8,23,46,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,-1,-1,-1,5704,-1,0.0049292375,0.9950708
5705,prolonged QT interval,12,15,72,93,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,-1,-1,-1,5705,-1,0.098405235,0.90159476
5706,torsades de pointes,16,19,98,117,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,-1,-1,-1,5706,-1,0.05990321,0.9400968
5707,TdP,20,21,119,122,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,-1,-1,-1,5707,-1,0.9885748,0.011425161
5709,fungal infection,28,30,167,183,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,-1,-1,-1,5709,-1,0.008495463,0.9915045
5713,acquired long QT syndrome,36,40,218,243,"We postulate that by virtue of its direct blocking action on IKr, ketoconazole alone may prolong QT interval and induce TdP. This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome.",16403073_5,-1,-1,-1,5713,-1,0.00518815,0.9948119
5715,Turner Syndrome,6,8,41,56,PTU-associated vasculitis in a girl with Turner Syndrome and Graves' disease.,16418614_0,-1,-1,-1,5715,-1,0.011074955,0.98892504
5716,Graves' disease,9,12,61,76,PTU-associated vasculitis in a girl with Turner Syndrome and Graves' disease.,16418614_0,-1,-1,-1,5716,-1,0.011649238,0.98835075
5717,purpura,1,2,9,16,"Palpable purpura is a concerning clinical finding in pediatric patients and can have many causes, including infectious and autoimmune processes.",16418614_1,-1,-1,-1,5717,-1,0.0034089067,0.9965911
5719,Turner syndrome,5,7,22,37,We report a girl with Turner syndrome and Graves' disease who presented with palpable purpuric lesions.,16418614_3,-1,-1,-1,5719,-1,0.011743449,0.9882565
5720,Graves' disease,8,11,42,57,We report a girl with Turner syndrome and Graves' disease who presented with palpable purpuric lesions.,16418614_3,-1,-1,-1,5720,-1,0.017941685,0.98205835
5721,purpuric lesions,15,17,86,102,We report a girl with Turner syndrome and Graves' disease who presented with palpable purpuric lesions.,16418614_3,-1,-1,-1,5721,-1,0.0035278928,0.9964721
5724,PTU,36,37,245,248,"The diagnosis of propylthiouracil (PTU)-associated vasculitis was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of PTU.",16418614_4,-1,-1,-1,5724,-1,0.9943862,0.005613863
5727,Cerebral vasculitis,0,2,0,19,Cerebral vasculitis following oral methylphenidate intake in an adult: a case report.,16428221_0,-1,-1,-1,5727,-1,0.0023864212,0.99761355
5730,amphetamine abuse,4,6,36,53,"Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.",16428221_2,-1,-1,-1,5730,-1,0.9402122,0.05978779
5731,ischaemic stroke,14,16,92,108,"Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.",16428221_2,-1,-1,-1,5731,-1,0.002763895,0.9972362
5735,ischaemic strokes,20,22,128,145,We report the case of a 63-year-old female who was treated with methylphenidate due to hyperactivity and suffered from multiple ischaemic strokes.,16428221_3,-1,-1,-1,5735,-1,0.0029945925,0.9970054
5736,cerebral vasculitis,3,5,25,44,We consider drug-induced cerebral vasculitis as the most likely cause of recurrent ischaemic strokes in the absence of any pathological findings during the diagnostic work-up.,16428221_4,-1,-1,-1,5736,-1,0.0021800676,0.9978199
5737,ischaemic strokes,12,14,83,100,We consider drug-induced cerebral vasculitis as the most likely cause of recurrent ischaemic strokes in the absence of any pathological findings during the diagnostic work-up.,16428221_4,-1,-1,-1,5737,-1,0.0024557856,0.9975442
5740,neurological symptoms,12,14,91,112,We conclude that methylphenidate mediated vasculitis should be considered in patients with neurological symptoms and a history of methylphenidate therapy.,16428221_5,-1,-1,-1,5740,-1,0.0023132346,0.99768674
5743,Daidzein,0,1,0,8,Daidzein activates choline acetyltransferase from MC-IXC cells and improves drug-induced amnesia.,16428827_0,-1,-1,-1,5743,-1,0.9993298,0.0006702208
5748,ACh,22,23,154,157,"The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).",16428827_1,-1,-1,-1,5748,-1,0.9973037,0.0026962804
5749,Alzheimer's disease,33,36,203,222,"The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).",16428827_1,-1,-1,-1,5749,-1,0.00585963,0.9941403
5750,AD,37,38,224,226,"The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).",16428827_1,-1,-1,-1,5750,-1,0.0034126542,0.9965874
5751,daidzein,15,16,105,113,"Via the sequential isolation of Pueraria thunbergiana, the active component was ultimately identified as daidzein (4',7-dihydroxy-isoflavone).",16428827_3,-1,-1,-1,5751,-1,0.9992124,0.0007876225
5752,daidzein,7,8,39,47,"In order to investigate the effects of daidzein from Pueraria thunbergiana on scopolamine-induced impairments of learning and memory, we conducted a series of in vivo tests.",16428827_4,-1,-1,-1,5752,-1,0.9993895,0.00061049376
5753,daidzein,2,3,18,26,"Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced amnesia, according to the results of a Y-maze test.",16428827_5,-1,-1,-1,5753,-1,0.9993216,0.00067845715
5754,body weight,6,8,38,49,"Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced amnesia, according to the results of a Y-maze test.",16428827_5,-1,-1,-1,5754,-1,0.7738167,0.22618325
5757,contrast,3,4,10,18,"By way of contrast, mice treated with daidzein prior to the scopolamine injections were noticeably protected from this performance impairment (an approximately 12%-21% decrease in alternation behavior).",16428827_7,-1,-1,-1,5757,-1,0.8008347,0.19916534
5758,daidzein,8,9,38,46,"By way of contrast, mice treated with daidzein prior to the scopolamine injections were noticeably protected from this performance impairment (an approximately 12%-21% decrease in alternation behavior).",16428827_7,-1,-1,-1,5758,-1,0.99930644,0.00069353473
5760,daidzein,4,5,28,36,"These results indicate that daidzein might play a role in acetylcholine biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced amnesia.",16428827_8,-1,-1,-1,5760,-1,0.99941134,0.0005886528
5763,overactive bladder,11,13,64,82,Urinary symptoms and quality of life changes in Thai women with overactive bladder after tolterodine treatment.,16471092_0,-1,-1,-1,5763,-1,0.003918358,0.99608165
5764,tolterodine,14,15,89,100,Urinary symptoms and quality of life changes in Thai women with overactive bladder after tolterodine treatment.,16471092_0,-1,-1,-1,5764,-1,0.99915135,0.0008486681
5765,overactive bladder,16,18,89,107,OBJECTIVES: To study the urinary symptoms and quality of life changes in Thai women with overactive bladder (OAB) after tolterodine treatment.,16471092_1,-1,-1,-1,5765,-1,0.0038101408,0.99618983
5766,OAB,19,20,109,112,OBJECTIVES: To study the urinary symptoms and quality of life changes in Thai women with overactive bladder (OAB) after tolterodine treatment.,16471092_1,-1,-1,-1,5766,-1,0.07656091,0.923439
5767,tolterodine,22,23,120,131,OBJECTIVES: To study the urinary symptoms and quality of life changes in Thai women with overactive bladder (OAB) after tolterodine treatment.,16471092_1,-1,-1,-1,5767,-1,0.99915576,0.00084430043
5768,OAB,16,17,73,76,"MATERIAL AND METHOD: Thirty women (aged 30-77 years) diagnosed as having OAB at the Gynecology Clinic, King Chulalongkorn Memorial Hospital from January to April 2004 were included in the present study.",16471092_2,-1,-1,-1,5768,-1,0.08583454,0.91416544
5769,Tolterodine,0,1,0,11,"Tolterodine 2 mg, twice daily was given.",16471092_3,-1,-1,-1,5769,-1,0.99914145,0.00085856474
5770,mg,2,3,14,16,"Tolterodine 2 mg, twice daily was given.",16471092_3,-1,-1,-1,5770,-1,0.9712313,0.028768769
5771,nocturia,3,4,14,22,The number of nocturia episodes decreased from 5.4 +/- 4.2 to 1.1 +/- 1.0 times per night.,16471092_8,-1,-1,-1,5771,-1,0.0049194098,0.9950806
5772,dry month,6,8,32,41,The most common side effect was dry month in 5 cases (16.7%) with 2 cases reporting a moderate degree and 1 case with severe degree.,16471092_9,-1,-1,-1,5772,-1,0.01186844,0.98813164
5774,Tolterodine,2,3,12,23,CONCLUSION: Tolterodine was well tolerated and its effects improved the quality of life in Thai women with OAB.,16471092_12,-1,-1,-1,5774,-1,0.99927086,0.0007291266
5775,OAB,18,19,107,110,CONCLUSION: Tolterodine was well tolerated and its effects improved the quality of life in Thai women with OAB.,16471092_12,-1,-1,-1,5775,-1,0.9337642,0.06623577
5777,etomidate,5,6,50,59,Remifentanil pretreatment reduces myoclonus after etomidate.,16563323_0,-1,-1,-1,5777,-1,0.99927825,0.0007218218
5778,remifentanil,16,17,85,97,STUDY OBJECTIVE: The aim of the study was to compare the effect of pretreatment with remifentanil 1 microg/kg and the effect of gender on the incidence of myoclonus after anesthesia induction with etomidate.,16563323_1,-1,-1,-1,5778,-1,0.99928975,0.00071019365
5780,etomidate,33,34,197,206,STUDY OBJECTIVE: The aim of the study was to compare the effect of pretreatment with remifentanil 1 microg/kg and the effect of gender on the incidence of myoclonus after anesthesia induction with etomidate.,16563323_1,-1,-1,-1,5780,-1,0.9993001,0.0006998652
5781,remifentanil,12,13,85,97,PATIENTS: Sixty patients were pretreated in a randomized double-blinded fashion with remifentanil 1 microg/kg or placebo.,16563323_4,-1,-1,-1,5781,-1,0.99926025,0.000739795
5782,remifentanil,3,4,18,30,"Two minutes after remifentanil or placebo injection, etomidate 0.3 mg/kg was given.",16563323_5,-1,-1,-1,5782,-1,0.99932265,0.00067737815
5783,etomidate,8,9,53,62,"Two minutes after remifentanil or placebo injection, etomidate 0.3 mg/kg was given.",16563323_5,-1,-1,-1,5783,-1,0.9993575,0.00064249476
5789,remifentanil,12,13,72,84,MAIN RESULTS: The incidence of myoclonus was significantly lower in the remifentanil group (6.7%) than in the placebo group (70%) (P < 0.001).,16563323_8,-1,-1,-1,5789,-1,0.9993261,0.00067394995
5790,P,28,29,131,132,MAIN RESULTS: The incidence of myoclonus was significantly lower in the remifentanil group (6.7%) than in the placebo group (70%) (P < 0.001).,16563323_8,-1,-1,-1,5790,-1,0.19487977,0.8051202
5795,etomidate,16,17,110,119,"In the placebo group, male patients were associated with significantly increased incidence of myoclonus after etomidate administration.",16563323_10,-1,-1,-1,5795,-1,0.9992969,0.0007030915
5796,remifentanil,4,5,30,42,"CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.",16563323_11,-1,-1,-1,5796,-1,0.99923897,0.00076100737
5798,etomidate,10,11,79,88,"CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.",16563323_11,-1,-1,-1,5798,-1,0.9992586,0.0007414073
5803,etomidate,9,10,65,74,Men experience increased incidence of myoclonus than women after etomidate administration.,16563323_12,-1,-1,-1,5803,-1,0.99931693,0.00068311294
5804,impaired social and emotional judgement processes,10,16,85,134,MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes.,16574712_0,-1,-1,-1,5804,-1,0.023047581,0.97695243
5805,memory deficits,4,6,24,39,"In recent years working memory deficits have been reported in users of MDMA (3,4-methylenedioxymethamphetamine, ecstasy).",16574712_1,-1,-1,-1,5805,-1,0.0069775125,0.9930225
5806,MDMA,12,13,71,75,"In recent years working memory deficits have been reported in users of MDMA (3,4-methylenedioxymethamphetamine, ecstasy).",16574712_1,-1,-1,-1,5806,-1,0.99877626,0.0012237565
5809,MDMA,9,10,48,52,"The current study aimed to assess the impact of MDMA use on three separate central executive processes (set shifting, inhibition and memory updating) and also on ""prefrontal"" mediated social and emotional judgement processes.",16574712_2,-1,-1,-1,5809,-1,0.9990446,0.00095534866
5812,MDMA,6,7,43,47,"Compared with MDMA-free polydrug controls, MDMA polydrug users showed impairments in set shifting and memory updating, and also in social and emotional judgement processes.",16574712_4,-1,-1,-1,5812,-1,0.99890184,0.001098188
5816,MDMA,11,12,81,85,Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users.,16574713_0,-1,-1,-1,5816,-1,0.9982487,0.0017513853
5818,MDMA,3,4,44,48,"Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.",16574713_1,-1,-1,-1,5818,-1,0.9984053,0.0015947175
5821,5-HT,15,16,103,107,"Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.",16574713_1,-1,-1,-1,5821,-1,0.99278027,0.007219699
5822,5-HT neurotoxic lesions,33,36,214,237,"Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.",16574713_1,-1,-1,-1,5822,-1,0.21606654,0.7839334
5823,5-HT,40,41,260,264,"Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.",16574713_1,-1,-1,-1,5823,-1,0.98967326,0.010326758
5824,5-HT,1,2,8,12,Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.,16574713_2,-1,-1,-1,5824,-1,0.99478453,0.00521547
5825,5-HT,12,13,75,79,Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.,16574713_2,-1,-1,-1,5825,-1,0.9954887,0.004511313
5826,MDMA,43,44,263,267,Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.,16574713_2,-1,-1,-1,5826,-1,0.99882156,0.0011783656
5827,MDMA,14,15,74,78,"The aim of the study was to investigate the effects of moderate and heavy MDMA use on cognitive function, as well as the effects of long-term abstention from MDMA, in subjects genotyped for 5-HTTLPR.",16574713_3,-1,-1,-1,5827,-1,0.9988682,0.0011317757
5828,MDMA,29,30,158,162,"The aim of the study was to investigate the effects of moderate and heavy MDMA use on cognitive function, as well as the effects of long-term abstention from MDMA, in subjects genotyped for 5-HTTLPR.",16574713_3,-1,-1,-1,5828,-1,0.99885917,0.0011408448
5829,MDMA,2,3,17,21,"Fifteen moderate MDMA users (<55 lifetime tablets), 22 heavy MDMA+ users (>55 lifetime tablets), 16 ex-MDMA+ users (last tablet > 1 year ago) and 13 controls were compared on a battery of neuropsychological tests.",16574713_5,-1,-1,-1,5829,-1,0.9983531,0.0016469008
5830,p,12,13,71,72,A significant group effect was observed only on memory function tasks (p = 0.04) but not on reaction times (p = 0.61) or attention/executive functioning (p = 0.59).,16574713_7,-1,-1,-1,5830,-1,0.27846488,0.7215351
5831,p,22,23,108,109,A significant group effect was observed only on memory function tasks (p = 0.04) but not on reaction times (p = 0.61) or attention/executive functioning (p = 0.59).,16574713_7,-1,-1,-1,5831,-1,0.16308488,0.83691514
5832,p,30,31,154,155,A significant group effect was observed only on memory function tasks (p = 0.04) but not on reaction times (p = 0.61) or attention/executive functioning (p = 0.59).,16574713_7,-1,-1,-1,5832,-1,0.15244299,0.847557
5833,contrast,1,2,3,11,"In contrast, no evidence of memory impairment was observed in moderate MDMA users.",16574713_9,-1,-1,-1,5833,-1,0.17157172,0.8284283
5835,MDMA,12,13,71,75,"In contrast, no evidence of memory impairment was observed in moderate MDMA users.",16574713_9,-1,-1,-1,5835,-1,0.99878126,0.0012187585
5836,MDMA,4,5,17,21,"While the use of MDMA in quantities that may be considered ""moderate"" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.",16574713_11,-1,-1,-1,5836,-1,0.9988489,0.0011511013
5837,impaired memory functioning,18,21,93,120,"While the use of MDMA in quantities that may be considered ""moderate"" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.",16574713_11,-1,-1,-1,5837,-1,0.003613161,0.9963869
5838,MDMA,25,26,135,139,"While the use of MDMA in quantities that may be considered ""moderate"" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.",16574713_11,-1,-1,-1,5838,-1,0.9987845,0.0012155112
5839,lead,28,29,148,152,"While the use of MDMA in quantities that may be considered ""moderate"" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.",16574713_11,-1,-1,-1,5839,-1,0.021567164,0.9784329
5840,memory impairments,32,34,169,187,"While the use of MDMA in quantities that may be considered ""moderate"" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.",16574713_11,-1,-1,-1,5840,-1,0.0033253059,0.99667466
5841,MDMA,10,11,54,58,No effect of 5-HTTLPR or gender on memory function or MDMA use was observed.,16574713_12,-1,-1,-1,5841,-1,0.99849224,0.0015077408
5842,mangiferin,2,3,8,18,Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol-induced myocardial infarction in rats.,16584858_0,-1,-1,-1,5842,-1,0.9992118,0.000788201
5843,myocardial infarction,11,13,94,115,Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol-induced myocardial infarction in rats.,16584858_0,-1,-1,-1,5843,-1,0.0023865278,0.99761343
5844,mangiferin,9,10,52,62,"The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.",16584858_1,-1,-1,-1,5844,-1,0.998458,0.0015420268
5845,polyphenol,12,13,66,76,"The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.",16584858_1,-1,-1,-1,5845,-1,0.9737569,0.026243065
5847,myocardial infarction,25,27,154,175,"The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.",16584858_1,-1,-1,-1,5847,-1,0.0025545596,0.99744546
5848,MI,28,29,177,179,"The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.",16584858_1,-1,-1,-1,5848,-1,0.0028176648,0.99718237
5849,ISPH,3,4,26,30,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,-1,-1,-1,5849,-1,0.9979152,0.0020848212
5850,body weight,7,9,42,53,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,-1,-1,-1,5850,-1,0.7322686,0.2677314
5852,lactate,36,37,196,203,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,-1,-1,-1,5852,-1,0.9942544,0.005745562
5853,uric acid,50,52,281,290,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,-1,-1,-1,5853,-1,0.9975011,0.0024989638
5855,mangiferin,4,5,23,33,The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.,16584858_3,-1,-1,-1,5855,-1,0.99901974,0.0009802338
5856,triphenyl tetrazolium chloride,8,11,50,80,The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.,16584858_3,-1,-1,-1,5856,-1,0.99860793,0.0013920837
5857,TTC,12,13,82,85,The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.,16584858_3,-1,-1,-1,5857,-1,0.994518,0.005482071
5858,ischemic myocardium,23,25,141,160,The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.,16584858_3,-1,-1,-1,5858,-1,0.003675352,0.9963246
5859,superoxide dismutase,7,9,45,65,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5859,-1,0.9977526,0.002247423
5860,glutathione peroxidase,12,14,77,99,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5860,-1,0.99361706,0.0063829417
5861,glutathione transferase,15,17,101,124,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5861,-1,0.9886335,0.011366477
5862,glutathione reductase,18,20,129,150,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5862,-1,0.9890548,0.01094525
5863,Vitamin C,28,30,212,221,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5863,-1,0.99698704,0.0030129233
5864,Vitamin E,31,33,223,232,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5864,-1,0.9965305,0.0034695512
5866,MI,39,40,272,274,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,-1,-1,-1,5866,-1,0.0074779512,0.99252206
5867,mangiferin,3,4,23,33,Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.,16584858_5,-1,-1,-1,5867,-1,0.99917954,0.00082041667
5868,body weight suspended,7,10,45,66,Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.,16584858_5,-1,-1,-1,5868,-1,0.91430724,0.085692786
5869,dimethyl sulphoxide,14,16,78,97,Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.,16584858_5,-1,-1,-1,5869,-1,0.9984908,0.0015091915
5870,MI,23,24,138,140,Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.,16584858_5,-1,-1,-1,5870,-1,0.036209486,0.9637905
5871,mangiferin,14,15,114,124,Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats.,16584858_6,-1,-1,-1,5871,-1,0.99912375,0.0008761999
5872,MI,20,21,168,170,Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats.,16584858_6,-1,-1,-1,5872,-1,0.0041172532,0.99588275
5873,mangiferin,8,9,44,54,"From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.",16584858_7,-1,-1,-1,5873,-1,0.99904174,0.00095822744
5874,MI,15,16,103,105,"From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.",16584858_7,-1,-1,-1,5874,-1,0.0027394055,0.9972606
5875,cardiac damage,29,31,191,205,"From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.",16584858_7,-1,-1,-1,5875,-1,0.0028912742,0.99710876
5876,cyclooxygenase inhibitors,3,5,25,50,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,-1,-1,-1,5876,-1,0.9970157,0.0029842458
5877,myocardial infarction,23,25,189,210,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,-1,-1,-1,5877,-1,0.0033953195,0.9966047
5880,heart failure,30,32,237,250,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,-1,-1,-1,5880,-1,0.0030924063,0.99690765
5881,cyclooxygenase inhibitors,35,37,273,298,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,-1,-1,-1,5881,-1,0.9965835,0.003416498
5882,Cyclooxygenase inhibitors,0,2,0,25,"Cyclooxygenase inhibitors cause complex changes in renal, vascular and cardiac prostanoid profiles thereby increasing vascular resistance and fluid retention.",16586083_2,-1,-1,-1,5882,-1,0.99490744,0.005092507
5883,cyclooxygenase inhibitors,7,9,53,78,"A comparison of individual selective and unselective cyclooxygenase inhibitors suggests substance-specific differences, which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by prostaglandin-independent effects.",16586083_4,-1,-1,-1,5883,-1,0.9903148,0.009685193
5884,cardiovascular toxicity,33,35,217,240,"Diagnostic markers such as N-terminal pro brain natriuretic peptide (NT-proBNP) or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious cardiovascular toxicity.",16586083_5,-1,-1,-1,5884,-1,0.0027519555,0.997248
5885,impairment in auditory location discrimination,4,9,41,87,Pilocarpine seizures cause age-dependent impairment in auditory location discrimination.,16596970_0,-1,-1,-1,5885,-1,0.03137301,0.968627
5886,status epilepticus,3,5,18,36,Children who have status epilepticus have continuous or rapidly repeating seizures that may be life-threatening and may cause life-long changes in brain and behavior.,16596970_1,-1,-1,-1,5886,-1,0.011138241,0.98886174
5888,status epilepticus,4,6,20,38,The extent to which status epilepticus causes deficits in auditory discrimination is unknown.,16596970_2,-1,-1,-1,5888,-1,0.062050235,0.9379498
5889,deficits in auditory discrimination,7,11,46,81,The extent to which status epilepticus causes deficits in auditory discrimination is unknown.,16596970_2,-1,-1,-1,5889,-1,0.042332746,0.9576673
5890,status epilepticus,17,19,115,133,A naturalistic auditory location discrimination method was used to evaluate this question using an animal model of status epilepticus.,16596970_3,-1,-1,-1,5890,-1,0.003545777,0.99645424
5891,P,11,12,69,70,"Male Sprague-Dawley rats were injected with saline on postnatal day (P) 20, or a convulsant dose of pilocarpine on P20 or P45.",16596970_4,-1,-1,-1,5891,-1,0.5235363,0.47646365
5893,status epilepticus,5,7,34,52,"Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.",16596970_5,-1,-1,-1,5893,-1,0.0031030437,0.996897
5894,status epilepticus,8,10,54,72,"Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.",16596970_5,-1,-1,-1,5894,-1,0.003472751,0.99652725
5897,status epilepticus,1,3,3,21,"In status epilepticus (P20) rats, acquisition of the sound-source location discrimination was moderately impaired.",16596970_8,-1,-1,-1,5897,-1,0.0057470035,0.994253
5898,Status epilepticus,0,2,0,18,Status epilepticus (P45) rats failed to acquire either sound-source location or sound-silence discriminations.,16596970_9,-1,-1,-1,5898,-1,0.005844694,0.9941553
5899,Status epilepticus,0,2,0,18,"Status epilepticus in rat causes an age-dependent, long-term impairment in auditory discrimination.",16596970_10,-1,-1,-1,5899,-1,0.008246161,0.9917538
5900,impairment in auditory discrimination,9,13,61,98,"Status epilepticus in rat causes an age-dependent, long-term impairment in auditory discrimination.",16596970_10,-1,-1,-1,5900,-1,0.02387608,0.9761239
5901,impaired auditory location discrimination,7,11,41,82,This impairment may explain one cause of impaired auditory location discrimination in humans.,16596970_11,-1,-1,-1,5901,-1,0.06453104,0.9354689
5902,Nerve growth factor,0,3,0,19,Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder.,16600756_0,-1,-1,-1,5902,-1,0.9733483,0.026651667
5904,overactive bladder,12,14,76,94,Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder.,16600756_0,-1,-1,-1,5904,-1,0.003789061,0.99621093
5905,NGF,2,3,9,12,PURPOSE: NGF and PGs in the bladder can be affected by pathological changes in the bladder and these changes can be detected in urine.,16600756_1,-1,-1,-1,5905,-1,0.99717367,0.0028262818
5906,PGs,4,5,17,20,PURPOSE: NGF and PGs in the bladder can be affected by pathological changes in the bladder and these changes can be detected in urine.,16600756_1,-1,-1,-1,5906,-1,0.9938053,0.0061947573
5907,NGF,5,6,35,38,We investigated changes in urinary NGF and PGs in women with OAB.,16600756_2,-1,-1,-1,5907,-1,0.9975827,0.0024173663
5908,PGs,7,8,43,46,We investigated changes in urinary NGF and PGs in women with OAB.,16600756_2,-1,-1,-1,5908,-1,0.99461347,0.005386496
5909,OAB,11,12,61,64,We investigated changes in urinary NGF and PGs in women with OAB.,16600756_2,-1,-1,-1,5909,-1,0.9962482,0.0037517527
5910,OAB,11,12,63,66,MATERIALS AND METHODS: The study groups included 65 women with OAB and 20 without bladder symptoms who served as controls.,16600756_3,-1,-1,-1,5910,-1,0.9973242,0.002675794
5911,PGE2,2,3,5,9,"NGF, PGE2, PGF2alpha and PGI2 were measured using enzyme-linked immunosorbent assay and compared between the groups.",16600756_6,-1,-1,-1,5911,-1,0.99772745,0.002272598
5912,PGF2alpha,4,5,11,20,"NGF, PGE2, PGF2alpha and PGI2 were measured using enzyme-linked immunosorbent assay and compared between the groups.",16600756_6,-1,-1,-1,5912,-1,0.99784386,0.0021561782
5913,PGI2,6,7,25,29,"NGF, PGE2, PGF2alpha and PGI2 were measured using enzyme-linked immunosorbent assay and compared between the groups.",16600756_6,-1,-1,-1,5913,-1,0.9977556,0.0022444606
5914,NGF,6,7,42,45,"In addition, correlations between urinary NGF and PG, and urodynamic parameters in patients with OAB were examined.",16600756_7,-1,-1,-1,5914,-1,0.9974827,0.002517302
5915,PG,8,9,50,52,"In addition, correlations between urinary NGF and PG, and urodynamic parameters in patients with OAB were examined.",16600756_7,-1,-1,-1,5915,-1,0.9969693,0.003030793
5916,OAB,16,17,97,100,"In addition, correlations between urinary NGF and PG, and urodynamic parameters in patients with OAB were examined.",16600756_7,-1,-1,-1,5916,-1,0.46395212,0.5360479
5917,NGF,3,4,17,20,"RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).",16600756_8,-1,-1,-1,5917,-1,0.9981281,0.0018719247
5918,PGE2,5,6,22,26,"RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).",16600756_8,-1,-1,-1,5918,-1,0.9974922,0.002507842
5919,PGF2alpha,7,8,31,40,"RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).",16600756_8,-1,-1,-1,5919,-1,0.9977701,0.0022299804
5920,OAB,14,15,87,90,"RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).",16600756_8,-1,-1,-1,5920,-1,0.14493935,0.8550607
5921,p,19,20,115,116,"RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).",16600756_8,-1,-1,-1,5921,-1,0.35490632,0.6450937
5922,PGI2,3,4,17,21,"However, urinary PGI2 was not different between controls and patients with OAB.",16600756_9,-1,-1,-1,5922,-1,0.99826884,0.0017310986
5923,OAB,12,13,75,78,"However, urinary PGI2 was not different between controls and patients with OAB.",16600756_9,-1,-1,-1,5923,-1,0.8821295,0.11787047
5924,OAB,3,4,17,20,In patients with OAB urinary PGE2 positively correlated with volume at first desire to void and maximum cystometric capacity (p <0.05).,16600756_10,-1,-1,-1,5924,-1,0.6096786,0.39032137
5925,PGE2,5,6,29,33,In patients with OAB urinary PGE2 positively correlated with volume at first desire to void and maximum cystometric capacity (p <0.05).,16600756_10,-1,-1,-1,5925,-1,0.9983876,0.0016124133
5926,p,20,21,126,127,In patients with OAB urinary PGE2 positively correlated with volume at first desire to void and maximum cystometric capacity (p <0.05).,16600756_10,-1,-1,-1,5926,-1,0.45291337,0.5470866
5927,NGF,1,2,8,11,"Urinary NGF, PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB.",16600756_11,-1,-1,-1,5927,-1,0.9979055,0.002094581
5928,PGF2alpha,3,4,13,22,"Urinary NGF, PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB.",16600756_11,-1,-1,-1,5928,-1,0.9980406,0.0019594682
5929,PGI2,5,6,27,31,"Urinary NGF, PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB.",16600756_11,-1,-1,-1,5929,-1,0.99797326,0.0020267225
5930,OAB,15,16,94,97,"Urinary NGF, PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB.",16600756_11,-1,-1,-1,5930,-1,0.43758726,0.56241274
5931,NGF,2,3,13,16,CONCLUSIONS: NGF and PGs have important roles in the development of OAB symptoms in female patients.,16600756_12,-1,-1,-1,5931,-1,0.99764025,0.0023597945
5932,PGs,4,5,21,24,CONCLUSIONS: NGF and PGs have important roles in the development of OAB symptoms in female patients.,16600756_12,-1,-1,-1,5932,-1,0.99511284,0.0048872004
5933,OAB,12,13,68,71,CONCLUSIONS: NGF and PGs have important roles in the development of OAB symptoms in female patients.,16600756_12,-1,-1,-1,5933,-1,0.20966384,0.79033613
5934,OAB,12,13,67,70,Urinary levels of these factors may be used as markers to evaluate OAB symptoms.,16600756_13,-1,-1,-1,5934,-1,0.9938425,0.006157505
5936,infected with hepatitis C virus,7,12,48,79,Definition and management of anemia in patients infected with hepatitis C virus.,16629641_0,-1,-1,-1,5936,-1,0.24487956,0.75512046
5937,Chronic infection with hepatitis C virus,0,6,0,40,"Chronic infection with hepatitis C virus (HCV) can progress to cirrhosis, hepatocellular carcinoma, and end-stage liver disease.",16629641_1,-1,-1,-1,5937,-1,0.37996736,0.6200326
5941,HCV infection,5,7,31,44,The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.,16629641_2,-1,-1,-1,5941,-1,0.033955507,0.96604455
5942,pegylated interferon,11,13,73,93,The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.,16629641_2,-1,-1,-1,5942,-1,0.99864334,0.0013567016
5947,HCV infection,20,22,138,151,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.",16629641_4,-1,-1,-1,5947,-1,0.2811135,0.71888655
5951,Viramidine,0,1,0,10,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",16629641_8,-1,-1,-1,5951,-1,0.9990785,0.0009215171
5955,hepatitis C.,29,31,189,201,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",16629641_8,-1,-1,-1,5955,-1,0.062015407,0.9379846
5959,fetal growth impairment,10,13,74,97,This study examined the utility of biometry for detecting alcohol-related fetal growth impairment.,16634859_3,-1,-1,-1,5959,-1,0.004917351,0.9950826
5965,reduced cerebellar growth,11,14,87,112,Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers.,16634859_11,-1,-1,-1,5965,-1,0.013660478,0.98633957
5966,decreased cranial to body growth,17,22,124,156,Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers.,16634859_11,-1,-1,-1,5966,-1,0.027839947,0.9721601
5967,Amphetamine abuse,0,2,0,17,Amphetamine abuse was predictive of larger cranial to body growth ratios.,16634859_12,-1,-1,-1,5967,-1,0.95776975,0.042230316
5969,amsacrine,5,6,22,31,Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.,1664218_0,-1,-1,-1,5969,-1,0.99836093,0.0016390692
5970,CI-921,7,8,41,47,Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.,1664218_0,-1,-1,-1,5970,-1,0.9968539,0.0031461588
5971,NSC 343499,9,11,49,59,Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.,1664218_0,-1,-1,-1,5971,-1,0.9886447,0.0113553265
5972,lung cancer,15,17,79,90,Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.,1664218_0,-1,-1,-1,5972,-1,0.0039608306,0.99603915
5973,"NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide",2,9,8,110,"CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity.",1664218_1,-1,-1,-1,5973,-1,0.9838657,0.016134333
5974,lung cancer,14,16,84,95,"It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial.",1664218_2,-1,-1,-1,5974,-1,0.00347121,0.9965288
5975,NSCLC,17,18,97,102,"It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial.",1664218_2,-1,-1,-1,5975,-1,0.003506373,0.99649364
5976,squamous carcinoma,3,5,24,42,"The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1).",1664218_4,-1,-1,-1,5976,-1,0.012996503,0.9870035
5977,adenocarcinoma,9,10,49,63,"The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1).",1664218_4,-1,-1,-1,5977,-1,0.0077080303,0.992292
5979,undifferentiated carcinoma,28,30,137,163,"The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1).",1664218_4,-1,-1,-1,5979,-1,0.01598912,0.9840109
5982,grand mal seizures,21,24,105,123,"Neutropenia grade greater than or equal to 3 was seen in 15 patients, infections with recovery in 3, and grand mal seizures in 1 patient.",1664218_5,-1,-1,-1,5982,-1,0.004743991,0.995256
5985,phlebitis,16,17,78,87,Grade less than or equal to 2 nausea and vomiting occurred in 66% courses and phlebitis in the infusion arm in 37%.,1664218_6,-1,-1,-1,5985,-1,0.0033907176,0.99660933
5986,squamous cell carcinoma,3,6,15,38,1 patient with squamous cell carcinoma achieved a partial response lasting 5 months.,1664218_7,-1,-1,-1,5986,-1,0.010285699,0.9897143
5987,tumour,6,7,34,40,Further testing in this and other tumour types using multiple daily schedules is warranted.,1664218_8,-1,-1,-1,5987,-1,0.006052629,0.9939474
5988,desipramine HCl,2,4,20,35,Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl.,16680561_0,-1,-1,-1,5988,-1,0.9992576,0.0007423034
5989,cinacalcet HCl,7,9,59,73,Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl.,16680561_0,-1,-1,-1,5989,-1,0.998936,0.0010640349
5994,mg,31,32,191,193,"METHODS: Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized, open-label, crossover study to receive a single oral dose of desipramine (50 mg) on two separate occasions, once alone and once after multiple doses of cinacalcet (90 mg for 7 days).",16680561_3,-1,-1,-1,5994,-1,0.9179288,0.0820712
5996,mg,49,50,281,283,"METHODS: Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized, open-label, crossover study to receive a single oral dose of desipramine (50 mg) on two separate occasions, once alone and once after multiple doses of cinacalcet (90 mg for 7 days).",16680561_3,-1,-1,-1,5996,-1,0.8556236,0.14437644
5997,h,9,10,49,50,Blood samples were obtained predose and up to 72 h postdose.,16680561_4,-1,-1,-1,5997,-1,0.22248885,0.7775111
5999,C(max,8,9,44,49,"Relative to desipramine alone, mean AUC and C(max) of desipramine increased 3.6- and 1.8-fold when coadministered with cinacalcet.",16680561_6,-1,-1,-1,5999,-1,0.5990953,0.4009047
6014,optic neuropathy,1,3,22,38,Ethambutol-associated optic neuropathy.,16710500_0,-1,-1,-1,6014,-1,0.0025070952,0.9974929
6015,Ethambutol,2,3,14,24,"INTRODUCTION: Ethambutol is used in the treatment of tuberculosis, which is still prevalent in Southeast Asia, and can be associated with permanent visual loss.",16710500_1,-1,-1,-1,6015,-1,0.99898714,0.0010128552
6018,bitemporal hemianopia,7,9,39,60,We report 3 cases which presented with bitemporal hemianopia.,16710500_2,-1,-1,-1,6018,-1,0.006848624,0.9931513
6019,toxic optic neuropathy,7,10,60,82,CLINICAL PICTURE: Three patients with ethambutol-associated toxic optic neuropathy are described.,16710500_3,-1,-1,-1,6019,-1,0.0022090855,0.99779093
6020,"loss of central visual acuity, colour vision (Ishihara) and visual field",4,18,19,91,"All 3 patients had loss of central visual acuity, colour vision (Ishihara) and visual field.",16710500_4,-1,-1,-1,6020,-1,0.019977635,0.9800223
6021,visual field loss,1,4,4,21,"The visual field loss had a bitemporal flavour, suggesting involvement of the optic chiasm.",16710500_5,-1,-1,-1,6021,-1,0.006291923,0.993708
6022,ethambutol,4,5,28,38,"TREATMENT: Despite stopping ethambutol on diagnosis, visual function continued to deteriorate for a few months.",16710500_6,-1,-1,-1,6022,-1,0.9990939,0.00090616074
6023,loss of visual function,8,12,43,66,OUTCOME: All 3 patients had some permanent loss of visual function.,16710500_9,-1,-1,-1,6023,-1,0.0068496624,0.9931504
6024,Ethambutol,2,3,13,23,CONCLUSIONS: Ethambutol usage is associated with permanent visual loss and should be avoided if possible or used with caution and proper ophthalmological follow-up.,16710500_10,-1,-1,-1,6024,-1,0.9989562,0.0010437623
6026,ethambutol,7,8,39,49,"The author postulates that in cases of ethambutol associated chiasmopathy, ethambutol may initially affect the optic nerves and subsequently progress to involve the optic chiasm.",16710500_11,-1,-1,-1,6026,-1,0.9991135,0.000886529
6027,ethambutol,11,12,75,85,"The author postulates that in cases of ethambutol associated chiasmopathy, ethambutol may initially affect the optic nerves and subsequently progress to involve the optic chiasm.",16710500_11,-1,-1,-1,6027,-1,0.9990306,0.0009694342
6028,neuroleptic malignant syndrome,1,4,9,39,Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam.,16720068_0,-1,-1,-1,6028,-1,0.057395246,0.9426047
6031,depressive symptoms,4,6,23,42,"A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation.",16720068_1,-1,-1,-1,6031,-1,0.0041702804,0.99582976
6033,insomnia,14,15,89,97,"A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation.",16720068_1,-1,-1,-1,6033,-1,0.0034640585,0.9965359
6034,loss of appetite,16,19,99,115,"A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation.",16720068_1,-1,-1,-1,6034,-1,0.022676993,0.97732306
6036,mg paroxetine,10,12,54,67,Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.,16720068_2,-1,-1,-1,6036,-1,0.99799407,0.0020059615
6037,mg alprazolam,14,16,76,89,Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.,16720068_2,-1,-1,-1,6037,-1,0.99685967,0.0031403557
6040,psychomotor retardation,14,16,85,108,"On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.",16720068_3,-1,-1,-1,6040,-1,0.0027707035,0.9972293
6041,disorientation,17,18,110,124,"On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.",16720068_3,-1,-1,-1,6041,-1,0.0028824783,0.9971175
6042,muscle rigidity,21,23,137,152,"On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.",16720068_3,-1,-1,-1,6042,-1,0.0034903313,0.9965096
6045,C,8,9,38,39,"The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.",16720068_4,-1,-1,-1,6045,-1,0.47197413,0.52802587
6046,mg mm Hg,19,22,96,104,"The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.",16720068_4,-1,-1,-1,6046,-1,0.8654912,0.13450883
6051,BUN,28,29,155,158,"Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.",16720068_5,-1,-1,-1,6051,-1,0.9830888,0.016911259
6055,neuroleptic malignant syndrome,6,9,40,70,"This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.",16720068_8,-1,-1,-1,6055,-1,0.3940538,0.60594624
6056,NMS,10,11,72,75,"This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.",16720068_8,-1,-1,-1,6056,-1,0.005408847,0.9945912
6059,adverse drug reaction,1,4,4,25,"The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case.",16720068_9,-1,-1,-1,6059,-1,0.016049594,0.9839504
6060,NMS,4,5,25,28,"Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration, agitation, malnutrition, and exhaustion.",16720068_11,-1,-1,-1,6060,-1,0.02404214,0.97595793
6064,malnutrition,20,21,129,141,"Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration, agitation, malnutrition, and exhaustion.",16720068_11,-1,-1,-1,6064,-1,0.004877299,0.99512273
6075,tricaine,6,7,47,55,"Co-administration of lidocaine, bupivacaine or tricaine with desipramine reversed this effect.",16725121_3,-1,-1,-1,6075,-1,0.99902785,0.0009721312
6088,lidocaine convulsions,21,23,167,188,These results suggest that down-regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine-induced sensitization of lidocaine convulsions.,16725121_7,-1,-1,-1,6088,-1,0.0389009,0.961099
6090,lidocaine seizures,3,5,37,55,Desipramine-induced sensitization of lidocaine seizures may have a mechanism distinct from kindling resulting from repeated administration of cocaine.,16725121_10,-1,-1,-1,6090,-1,0.3161156,0.6838844
6095,plant extracts,16,18,100,114,METHODS: The son of an 84-year-old male discovered a newspaper report stating clinical success with plant extracts in Alzheimer's disease.,16740173_3,-1,-1,-1,6095,-1,0.98620516,0.013794833
6096,Alzheimer's disease,19,22,118,137,METHODS: The son of an 84-year-old male discovered a newspaper report stating clinical success with plant extracts in Alzheimer's disease.,16740173_3,-1,-1,-1,6096,-1,0.008176754,0.99182326
6097,carbamylcholin,16,17,80,94,"The mode of action was said to be comparable to that of the synthetic compound 'carbamylcholin'; that is, carbachol.",16740173_4,-1,-1,-1,6097,-1,0.9991461,0.0008538479
6100,mg,21,22,104,106,"He bought 25 g of carbachol as pure substance in a pharmacy, and the father was administered 400 to 500 mg.",16740173_5,-1,-1,-1,6100,-1,0.98420346,0.015796559
6103,sweating,12,13,74,82,"RESULTS: Minutes after oral administration, the patient developed nausea, sweating and hypotension, and finally collapsed.",16740173_7,-1,-1,-1,6103,-1,0.003080847,0.99691916
6111,hyperhidrosis,3,4,19,32,"Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation.",16740173_11,-1,-1,-1,6111,-1,0.008436029,0.9915639
6112,hypersalivation,5,6,34,49,"Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation.",16740173_11,-1,-1,-1,6112,-1,0.3524685,0.6475315
6113,bronchorrhoea,7,8,51,64,"Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation.",16740173_11,-1,-1,-1,6113,-1,0.008514361,0.99148566
6114,miosis,11,12,77,83,"Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation.",16740173_11,-1,-1,-1,6114,-1,0.004672273,0.9953277
6116,mg,8,9,33,35,"High doses of atropine (up to 50 mg per 24 hours), adrenaline and dopamine were necessary.",16740173_12,-1,-1,-1,6116,-1,0.9655722,0.034427833
6119,dyspnoea,3,4,19,27,"However, increased dyspnoea and bronchospasm necessitated reintubation.",16740173_14,-1,-1,-1,6119,-1,0.0026111086,0.9973889
6120,bronchospasm,5,6,32,44,"However, increased dyspnoea and bronchospasm necessitated reintubation.",16740173_14,-1,-1,-1,6120,-1,0.0024258418,0.99757415
6121,Proteus mirabilis infection,6,9,50,77,Respiratory insufficiency was further worsened by Proteus mirabilis infection and severe bronchoconstriction.,16740173_15,-1,-1,-1,6121,-1,0.65730715,0.34269282
6122,heart failure,12,14,49,62,"On the next day he died, probably as a result of heart failure.",16740173_17,-1,-1,-1,6122,-1,0.003089338,0.99691063
6126,cholinergics,11,12,77,89,"Especially in old patients, intensivists should consider intoxications (with cholinergics) as a cause of acute cardiovascular failure.",16740173_23,-1,-1,-1,6126,-1,0.996718,0.0032819938
6127,acute cardiovascular failure,17,20,105,133,"Especially in old patients, intensivists should consider intoxications (with cholinergics) as a cause of acute cardiovascular failure.",16740173_23,-1,-1,-1,6127,-1,0.0025687856,0.9974312
6128,cognitive dysfunctions,12,14,81,103,Pharmacological evidence for the potential of Daucus carota in the management of cognitive dysfunctions.,16755009_0,-1,-1,-1,6128,-1,0.002684042,0.99731594
6130,extract of Daucus carota seeds (DCE),2,10,14,50,"The ethanolic extract of Daucus carota seeds (DCE) was administered orally in three doses (100, 200, 400 mg/kg) for seven successive days to different groups of young and aged mice.",16755009_2,-1,-1,-1,6130,-1,0.95045745,0.049542617
6132,DCE,0,1,0,3,"DCE (200, 400 mg/kg, p.o.) showed significant improvement in memory scores of young and aged mice.",16755009_5,-1,-1,-1,6132,-1,0.99870956,0.0012904654
6133,DCE,7,8,43,46,The extent of memory improvement evoked by DCE was 23% at the dose of 200 mg/kg and 35% at the dose of 400 mg/kg in young mice using elevated plus maze.,16755009_6,-1,-1,-1,6133,-1,0.9988558,0.0011442231
6134,DCE,2,3,13,16,"Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.).",16755009_8,-1,-1,-1,6134,-1,0.99813473,0.0018652101
6139,DCE,10,11,68,71,The extent of inhibition of brain cholinesterase activity evoked by DCE at the dose of 400 mg/kg was 22% in young and 19% in aged mice.,16755009_10,-1,-1,-1,6139,-1,0.99895823,0.0010417873
6141,DCE,30,31,141,144,"There was a remarkable reduction in total cholesterol level as well, to the extent of 23% in young and 21% in aged animals with this dose of DCE.",16755009_11,-1,-1,-1,6141,-1,0.99866545,0.0013344942
6142,DCE,2,3,11,14,"Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.",16755009_12,-1,-1,-1,6142,-1,0.9986216,0.0013783717
6143,cognitive dysfunctions,14,16,69,91,"Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.",16755009_12,-1,-1,-1,6143,-1,0.002735693,0.99726427
6145,Valproic acid,0,2,0,13,Valproic acid induced encephalopathy--19 new cases in Germany from 1994 to 2003--a side effect associated to VPA-therapy not only in young children.,16787750_0,-1,-1,-1,6145,-1,0.99908745,0.0009125655
6146,Valproic acid,0,2,0,13,Valproic acid (VPA) is a broad-spectrum antiepileptic drug and is usually well-tolerated.,16787750_1,-1,-1,-1,6146,-1,0.99906427,0.00093576557
6147,VPA,3,4,15,18,Valproic acid (VPA) is a broad-spectrum antiepileptic drug and is usually well-tolerated.,16787750_1,-1,-1,-1,6147,-1,0.9981834,0.0018165811
6148,haemorrhagic pancreatitis,10,12,65,90,"Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy.",16787750_2,-1,-1,-1,6148,-1,0.0026835904,0.9973164
6153,impaired consciousness,7,9,52,74,"The typical signs of VPA-induced encephalopathy are impaired consciousness, sometimes marked EEG background slowing, increased seizure frequency, with or without hyperammonemia.",16787750_3,-1,-1,-1,6153,-1,0.0060702795,0.99392974
6156,VPA,9,10,47,50,"There is still no proof of causative effect of VPA in patients with encephalopathy, but only of an association with an assumed causal relation.",16787750_4,-1,-1,-1,6156,-1,0.9986432,0.0013567519
6159,Atorvastatin,0,1,0,12,Atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat.,16820346_0,-1,-1,-1,6159,-1,0.9989355,0.001064458
6161,atorvastatin,6,7,37,49,"To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.",16820346_1,-1,-1,-1,6161,-1,0.9990652,0.0009347452
6162,atorva,8,9,51,57,"To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.",16820346_1,-1,-1,-1,6162,-1,0.99882704,0.0011729622
6165,atorva,22,23,150,156,"To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.",16820346_1,-1,-1,-1,6165,-1,0.9989955,0.0010044881
6169,P,36,37,152,153,"Dex increased systolic blood pressure (SBP) from 109 +/- 1.8 to 135 +/- 0.6 mmHg and plasma superoxide (5711 +/- 284.9 saline, 7931 +/- 392.8 U/ml dex, P < 0.001).",16820346_2,-1,-1,-1,6169,-1,0.28157765,0.7184224
6170,atorva,8,9,37,43,"In this prevention study, SBP in the atorva + dex group was increased from 115 +/- 0.4 to 124 +/- 1.5 mmHg, but this was significantly lower than in the dex-only group (P' < 0.05).",16820346_3,-1,-1,-1,6170,-1,0.9980447,0.001955251
6172,P,37,38,169,170,"In this prevention study, SBP in the atorva + dex group was increased from 115 +/- 0.4 to 124 +/- 1.5 mmHg, but this was significantly lower than in the dex-only group (P' < 0.05).",16820346_3,-1,-1,-1,6172,-1,0.36365727,0.6363427
6173,Atorva,0,1,0,6,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,-1,-1,-1,6173,-1,0.9971552,0.002844841
6175,P,17,18,81,82,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,-1,-1,-1,6175,-1,0.47626483,0.52373517
6178,atorva,37,38,160,166,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,-1,-1,-1,6178,-1,0.9940446,0.005955375
6180,P,41,42,174,175,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,-1,-1,-1,6180,-1,0.2876188,0.71238124
6181,P,29,30,154,155,"Plasma nitrate/nitrite (NOx) was decreased in dex-treated rats compared to saline-treated rats (11.2 +/- 1.08 microm, 15.3 +/- 1.17 microm, respectively, P < 0.05).",16820346_5,-1,-1,-1,6181,-1,0.24700095,0.752999
6182,Atorva,0,1,0,6,Atorva affected neither plasma NOx nor thymus weight.,16820346_6,-1,-1,-1,6182,-1,0.99837863,0.0016213469
6183,atorvastatin,2,3,6,18,"Thus, atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat.",16820346_7,-1,-1,-1,6183,-1,0.998961,0.0010390438
6185,cytosine arabinoside,5,7,42,62,Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia.,16826348_0,-1,-1,-1,6185,-1,0.99881136,0.001188606
6186,acute myeloid leukemia,12,15,91,113,Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia.,16826348_0,-1,-1,-1,6186,-1,0.0046949866,0.99530506
6188,cytosine arabinoside,7,9,49,69,"The central nervous system toxicity of high-dose cytosine arabinoside is well recognized, but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported.",16826348_1,-1,-1,-1,6188,-1,0.99905795,0.0009421029
6190,cytosine arabinoside,17,19,110,130,"The central nervous system toxicity of high-dose cytosine arabinoside is well recognized, but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported.",16826348_1,-1,-1,-1,6190,-1,0.99896324,0.0010367137
6191,acute myeloid leukemia,7,10,46,68,A 49-year-old Japanese man was diagnosed with acute myeloid leukemia.,16826348_2,-1,-1,-1,6191,-1,0.0057427734,0.9942572
6192,cytosine arabinoside,9,11,60,80,"After he achieved complete remission, he received high-dose cytosine arabinoside treatment (2 g/m2 twice a day for 5 days; total, 20 g/m2) as consolidation therapy.",16826348_3,-1,-1,-1,6192,-1,0.99888617,0.0011138327
6193,cytosine arabinoside,5,7,30,50,"The first course of high-dose cytosine arabinoside resulted in no unusual symptoms, but on day 21 of the second course of treatment, the patient complained of numbness in his right foot.",16826348_4,-1,-1,-1,6193,-1,0.99886924,0.0011306884
6194,numbness,28,29,159,167,"The first course of high-dose cytosine arabinoside resulted in no unusual symptoms, but on day 21 of the second course of treatment, the patient complained of numbness in his right foot.",16826348_4,-1,-1,-1,6194,-1,0.0025666603,0.99743336
6199,cytosine arabinoside,11,13,78,98,"Although the mechanisms of peripheral neuropathy are still unclear, high-dose cytosine arabinoside is a therapy that is potentially toxic to the peripheral nervous system, and auto/alloimmunity may play an important role in these mechanisms.",16826348_7,-1,-1,-1,6199,-1,0.999038,0.00096199714
6204,free radicals,14,16,117,130,Methamphetamine (MA)-induced dopaminergic neurotoxicity is believed to be associated with the increased formation of free radicals.,16844102_1,-1,-1,-1,6204,-1,0.8457103,0.15428971
6205,reactive oxygen species,14,17,78,101,"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.",16844102_2,-1,-1,-1,6205,-1,0.8831339,0.11686615
6207,DFO,21,22,121,124,"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.",16844102_2,-1,-1,-1,6207,-1,0.99761176,0.0023882086
6210,h,12,13,50,51,"Male rats were treated with MA (10 mg/kg, every 2 h for four injections).",16844102_3,-1,-1,-1,6210,-1,0.5224174,0.47758257
6211,DFO,21,22,114,117,The rat received either alpha-TC (20 mg/kg) intraperitoneally for 3 days and 30 min prior to MA administration or DFO (50 mg/kg) subcutaneously 30 min before MA administration.,16844102_4,-1,-1,-1,6211,-1,0.998885,0.0011150707
6213,DA,5,6,32,34,"The concentrations of dopamine (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment.",16844102_5,-1,-1,-1,6213,-1,0.9971795,0.0028205253
6215,DFO,25,26,158,161,"The concentrations of dopamine (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment.",16844102_5,-1,-1,-1,6215,-1,0.9984357,0.0015643555
6216,DFO,2,3,13,16,alpha-TC and DFO attenuated the MA-induced hyperthermia as well as the alterations in the locomotor activity.,16844102_6,-1,-1,-1,6216,-1,0.9983847,0.001615279
6218,reduced glutathione,9,11,51,70,The level of lipid peroxidation was higher and the reduced glutathione concentration was lower in the MA-treated rats.,16844102_7,-1,-1,-1,6218,-1,0.9972403,0.0027596871
6219,DFO,8,9,60,63,These changes were significantly attenuated by alpha-TC and DFO.,16844102_8,-1,-1,-1,6219,-1,0.9983625,0.0016375359
6220,DFO,5,6,32,35,This suggests that alpha-TC and DFO ameliorate the MA-induced neuronal damage by decreasing the level of oxidative stress.,16844102_9,-1,-1,-1,6220,-1,0.99836034,0.0016396968
6224,warfarin-induced,11,12,67,83,"PURPOSE: To evaluate the frequency, severity and preventability of warfarin-induced cerebral haemorrhages due to warfarin and warfarin-drug interactions in patients living in the county of Osterg  tland, Sweden. METHODS: All patients with a diagnosed cerebral haemorrhage at three hospitals during the period 2000-2002 were identified.",16858720_1,-1,-1,-1,6224,-1,0.19441262,0.8055874
6225,cerebral haemorrhages,12,14,84,105,"PURPOSE: To evaluate the frequency, severity and preventability of warfarin-induced cerebral haemorrhages due to warfarin and warfarin-drug interactions in patients living in the county of Osterg  tland, Sweden. METHODS: All patients with a diagnosed cerebral haemorrhage at three hospitals during the period 2000-2002 were identified.",16858720_1,-1,-1,-1,6225,-1,0.002478473,0.99752146
6227,warfarin-drug,18,19,126,139,"PURPOSE: To evaluate the frequency, severity and preventability of warfarin-induced cerebral haemorrhages due to warfarin and warfarin-drug interactions in patients living in the county of Osterg  tland, Sweden. METHODS: All patients with a diagnosed cerebral haemorrhage at three hospitals during the period 2000-2002 were identified.",16858720_1,-1,-1,-1,6227,-1,0.98194385,0.018056087
6230,warfarin-drug,10,11,78,91,Medical records were studied retrospectively to evaluate whether warfarin and warfarin-drug interactions could have caused the cerebral haemorrhage.,16858720_2,-1,-1,-1,6230,-1,0.98019147,0.019808551
6234,p,27,28,102,103,"Of the 59 cases, 26 (44%) had a fatal outcome, compared to 136 (25%) among the non-warfarin patients (p < 0.01).",16858720_6,-1,-1,-1,6234,-1,0.3496549,0.65034515
6235,warfarin-drug,1,2,2,15,A warfarin-drug interaction could have contributed to the haemorrhage in 24 (41%) of the warfarin patients and in 7 of these (12%) the bleeding complication was considered being possible to avoid.,16858720_7,-1,-1,-1,6235,-1,0.96208185,0.037918217
6236,haemorrhage,8,9,58,69,A warfarin-drug interaction could have contributed to the haemorrhage in 24 (41%) of the warfarin patients and in 7 of these (12%) the bleeding complication was considered being possible to avoid.,16858720_7,-1,-1,-1,6236,-1,0.0026736846,0.99732625
6239,Warfarin-induced,2,3,13,29,CONCLUSIONS: Warfarin-induced cerebral haemorrhages are a major clinical problem with a high fatality rate.,16858720_8,-1,-1,-1,6239,-1,0.21694368,0.7830563
6240,cerebral haemorrhages,3,5,30,51,CONCLUSIONS: Warfarin-induced cerebral haemorrhages are a major clinical problem with a high fatality rate.,16858720_8,-1,-1,-1,6240,-1,0.0026942834,0.99730575
6241,warfarin-drug,9,10,42,55,Almost half of the cases was related to a warfarin-drug interaction.,16858720_9,-1,-1,-1,6241,-1,0.9700918,0.02990817
6242,cerebral haemorrhages,5,7,45,66,A significant proportion of warfarin-related cerebral haemorrhages might have been prevented if greater caution had been taken when prescribing drugs known to interact with warfarin.,16858720_10,-1,-1,-1,6242,-1,0.002457412,0.9975426
6244,thioperamide,3,4,30,42,"Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice.",16867021_0,-1,-1,-1,6244,-1,0.99922824,0.00077176857
6252,RAMH,2,3,27,31,"(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.",16867021_4,-1,-1,-1,6252,-1,0.997672,0.0023279996
6253,thioperamide,11,12,55,67,"(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.",16867021_4,-1,-1,-1,6253,-1,0.9989405,0.0010595083
6254,THP,13,14,69,72,"(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.",16867021_4,-1,-1,-1,6254,-1,0.99765056,0.0023494265
6255,se,23,24,95,97,"(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.",16867021_4,-1,-1,-1,6255,-1,0.8648789,0.13512112
6257,THP,2,3,18,21,"Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P < 0.05).",16867021_5,-1,-1,-1,6257,-1,0.9986827,0.0013173575
6258,h,14,15,54,55,"Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P < 0.05).",16867021_5,-1,-1,-1,6258,-1,0.52026623,0.4797338
6261,P,28,29,139,140,"Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P < 0.05).",16867021_5,-1,-1,-1,6261,-1,0.26365975,0.7363402
6262,RAMH,4,5,27,31,"However, pretreatment with RAMH significantly reversed such an effect of THP (15 mg/kg i.p.).",16867021_6,-1,-1,-1,6262,-1,0.9987313,0.0012686936
6263,THP,11,12,73,76,"However, pretreatment with RAMH significantly reversed such an effect of THP (15 mg/kg i.p.).",16867021_6,-1,-1,-1,6263,-1,0.9987214,0.0012786083
6264,RAMH,0,1,0,4,"RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters.",16867021_7,-1,-1,-1,6264,-1,0.99777055,0.002229512
6265,se,2,3,9,11,"RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters.",16867021_7,-1,-1,-1,6265,-1,0.9969849,0.003015153
6266,THP,16,17,100,103,"RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters.",16867021_7,-1,-1,-1,6266,-1,0.99865866,0.0013413407
6267,se,24,25,124,126,"RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters.",16867021_7,-1,-1,-1,6267,-1,0.9957938,0.004206215
6269,THP,4,5,38,41,"On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P < 0.05).",16867021_8,-1,-1,-1,6269,-1,0.99865,0.0013499677
6270,P,23,24,129,130,"On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P < 0.05).",16867021_8,-1,-1,-1,6270,-1,0.2918723,0.70812774
6271,RAMH,2,3,18,22,Pretreatment with RAMH (5 microg i.c.v.) could partially reverse such effects of THP (3.75 mg/kg i.p.).,16867021_9,-1,-1,-1,6271,-1,0.9986777,0.0013223076
6272,THP,15,16,81,84,Pretreatment with RAMH (5 microg i.c.v.) could partially reverse such effects of THP (3.75 mg/kg i.p.).,16867021_9,-1,-1,-1,6272,-1,0.9984862,0.0015138406
6274,THP,11,12,77,80,Climbing behavior induced by apomorphine was reduced in animals treated with THP.,16867021_10,-1,-1,-1,6274,-1,0.99854726,0.0014527176
6275,RAMH,11,12,53,57,"Such an effect was, however, reversed in presence of RAMH.",16867021_11,-1,-1,-1,6275,-1,0.9982186,0.00178136
6276,THP,0,1,0,3,"THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.",16867021_12,-1,-1,-1,6276,-1,0.99862945,0.0013705498
6279,THP,3,4,16,19,Such effects of THP were reversed by RAMH indicating the involvement of histamine H(3)-receptors.,16867021_13,-1,-1,-1,6279,-1,0.9985384,0.0014616303
6280,RAMH,7,8,37,41,Such effects of THP were reversed by RAMH indicating the involvement of histamine H(3)-receptors.,16867021_13,-1,-1,-1,6280,-1,0.9986828,0.0013172164
6286,dopamine antagonists,4,6,25,45,The catalepsy induced by dopamine antagonists has been tested and the possible dopamine subtypes involved in catalepsy was determined.,1687392_1,-1,-1,-1,6286,-1,0.9975562,0.002443796
6290,fluphenazine,4,5,23,35,"2. Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced catalepsy.",1687392_2,-1,-1,-1,6290,-1,0.99928194,0.00071808725
6291,SCH 23390,8,10,52,61,"2. Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced catalepsy.",1687392_2,-1,-1,-1,6291,-1,0.9985536,0.0014464449
6294,fluphenazine,3,4,14,26,The effect of fluphenazine and sulpiride was dose-dependent.,1687392_3,-1,-1,-1,6294,-1,0.9993761,0.0006238626
6296,SCH 23390,2,4,15,24,Combination of SCH 23390 with sulpiride did not induce catalepsy potentiation.,1687392_4,-1,-1,-1,6296,-1,0.99887365,0.0011263195
6299,SKF 38393,4,6,15,24,"3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_5,-1,-1,-1,6299,-1,0.9972608,0.0027391296
6300,quinpirole,9,10,40,50,"3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_5,-1,-1,-1,6300,-1,0.9993241,0.0006758789
6302,fluphenazine,15,16,86,98,"3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_5,-1,-1,-1,6302,-1,0.9992562,0.00074382697
6303,SCH 23390,17,19,100,109,"3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_5,-1,-1,-1,6303,-1,0.99818075,0.0018192823
6305,SKF 38393,2,4,15,24,Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists.,1687392_7,-1,-1,-1,6305,-1,0.9981893,0.0018107643
6306,quinpirole,5,6,30,40,Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists.,1687392_7,-1,-1,-1,6306,-1,0.9993507,0.0006493173
6308,dopamine antagonists,16,18,109,129,Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists.,1687392_7,-1,-1,-1,6308,-1,0.9976526,0.0023474311
6310,Cauda equina syndrome,0,3,0,21,Cauda equina syndrome after epidural steroid injection: a case report.,16904497_0,-1,-1,-1,6310,-1,0.037134416,0.96286553
6312,radiculopathy,7,8,57,70,"OBJECTIVE: Conventional treatment methods of lumbusacral radiculopathy are physical therapy, epidural steroid injections, oral medications, and spinal manipulative therapy.",16904497_1,-1,-1,-1,6312,-1,0.004729909,0.9952701
6314,Cauda equina syndrome,0,3,0,21,Cauda equina syndrome is a rare complication of epidural anesthesia.,16904497_2,-1,-1,-1,6314,-1,0.07003158,0.9299684
6315,cauda equina syndrome,7,10,34,55,The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine.,16904497_3,-1,-1,-1,6315,-1,0.027269235,0.97273076
6316,triamcinolone,16,17,97,110,The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine.,16904497_3,-1,-1,-1,6316,-1,0.99909985,0.0009001215
6318,low,7,8,44,47,CLINICAL FEATURES: A 50-year-old woman with low back and right leg pain was scheduled for epidural steroid injection.,16904497_4,-1,-1,-1,6318,-1,0.009721542,0.9902784
6321,contrast medium,3,5,14,29,Spread of the contrast medium within the epidural space was determined by radiographic imaging.,16904497_6,-1,-1,-1,6321,-1,0.9946479,0.005352103
6324,numbness,8,9,46,54,"Three hours later, she complained of perineal numbness and lower extremity weakness.",16904497_9,-1,-1,-1,6324,-1,0.0031879933,0.99681205
6325,lower extremity weakness,10,13,59,83,"Three hours later, she complained of perineal numbness and lower extremity weakness.",16904497_9,-1,-1,-1,6325,-1,0.007226179,0.9927738
6326,loss of sensation,4,7,35,52,The neurologic evaluation revealed loss of sensation in the saddle area and medial aspect of her right leg.,16904497_10,-1,-1,-1,6326,-1,0.007791141,0.99220884
6328,neurologic deterioration,6,8,49,73,Clinical examination and continued vigilance for neurologic deterioration after epidural steroid injections is important.,16904497_18,-1,-1,-1,6328,-1,0.0023645982,0.99763536
6333,estradiol- and testosterone esters,29,33,212,246,"METHODS: In a population-based study in 513 naturally postmenopausal women aged 54-67 years, we studied the association between self-reported intramuscularly administered high-dose estrogen-testosterone therapy (estradiol- and testosterone esters) and aortic atherosclerosis.",16938416_2,-1,-1,-1,6333,-1,0.9968304,0.0031695536
6338,n=11,14,15,79,83,"In almost half of these women severe atherosclerosis of the aorta was present (n=11), while in women without hormone use severe atherosclerosis of the aorta was present in less than 20% (OR 3.1; 95% CI, 1.1-8.5, adjusted for age, years since menopause, smoking, and body mass index).",16938416_6,-1,-1,-1,6338,-1,0.2782754,0.7217246
6346,androgen,19,20,147,155,CONCLUSION: Our results suggest that high-dose testosterone therapy may adversely affect atherosclerosis in postmenopausal women and indicate that androgen replacement in these women may not be harmless.,16938416_9,-1,-1,-1,6346,-1,0.9985032,0.001496783
6347,hepatitis B,8,10,63,74,Sustained clinical improvement of a patient with decompensated hepatitis B virus-related cirrhosis after treatment with lamivudine monotherapy.,16960342_0,-1,-1,-1,6347,-1,0.11508307,0.8849169
6350,Hepatitis B virus,0,3,0,17,"Hepatitis B virus (HBV) infection, which causes liver cirrhosis and hepatocellular carcinoma, remains a major health problem in Asian countries.",16960342_1,-1,-1,-1,6350,-1,0.8957911,0.104208946
6351,HBV) infection,4,7,19,33,"Hepatitis B virus (HBV) infection, which causes liver cirrhosis and hepatocellular carcinoma, remains a major health problem in Asian countries.",16960342_1,-1,-1,-1,6351,-1,0.25688502,0.74311495
6352,liver cirrhosis,10,12,48,63,"Hepatitis B virus (HBV) infection, which causes liver cirrhosis and hepatocellular carcinoma, remains a major health problem in Asian countries.",16960342_1,-1,-1,-1,6352,-1,0.003841456,0.99615854
6356,hepatitis B surface antigen,3,7,15,42,"Moreover, both hepatitis B surface antigen and e antigen were observed to have disappeared in this patient.",16960342_9,-1,-1,-1,6356,-1,0.43038476,0.5696152
6357,e,8,9,47,48,"Moreover, both hepatitis B surface antigen and e antigen were observed to have disappeared in this patient.",16960342_9,-1,-1,-1,6357,-1,0.97094834,0.029051643
6360,cibenzoline,6,7,45,56,Antiarrhythmic effects of optical isomers of cibenzoline on canine ventricular arrhythmias.,1700207_0,-1,-1,-1,6360,-1,0.99920076,0.0007992271
6362,ventricular arrhythmia,11,13,93,115,Antiarrhythmic effects of (+)-cibenzoline and (-)-cibenzoline were examined using two canine ventricular arrhythmia models.,1700207_1,-1,-1,-1,6362,-1,0.0029773985,0.99702257
6363,Digitalis arrhythmia,0,2,0,20,"Digitalis arrhythmia, which is suppressed by Na channel blockers, was induced by intermittent intravenous (i.v.) injection of ouabain in pentobarbital-anesthetized dogs.",1700207_2,-1,-1,-1,6363,-1,0.6567662,0.34323376
6365,Adrenaline arrhythmia,0,2,0,21,"Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.",1700207_3,-1,-1,-1,6365,-1,0.87576675,0.124233276
6369,SD,29,30,184,186,"The minimum effective plasma concentrations of (+)-cibenzoline for digitalis- and adrenaline-induced arrhythmias were 1.4 +/- 0.4 and 2.0 +/- 0.6 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_6,-1,-1,-1,6369,-1,0.14807212,0.8519278
6370,n,31,32,188,189,"The minimum effective plasma concentrations of (+)-cibenzoline for digitalis- and adrenaline-induced arrhythmias were 1.4 +/- 0.4 and 2.0 +/- 0.6 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_6,-1,-1,-1,6370,-1,0.2802465,0.71975356
6374,SD,29,30,185,187,"The minimum effective plasma concentrations of (-)-cibenzoline for digitalis- and adrenaline-induced arrhythmia were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_8,-1,-1,-1,6374,-1,0.14785203,0.852148
6375,n,31,32,189,190,"The minimum effective plasma concentrations of (-)-cibenzoline for digitalis- and adrenaline-induced arrhythmia were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_8,-1,-1,-1,6375,-1,0.28940433,0.7105957
6376,Ca,30,31,183,185,"The stronger antiarrhythmic effect of (-)-cibenzoline indicates that (-)-isomer may have an effect nearly 5-20 times stronger in suppressing Na channels, but effects of both drugs on Ca channels may be almost equipotent.",1700207_9,-1,-1,-1,6376,-1,0.9940323,0.0059677185
6378,gliomas,7,8,42,49,Passage of mannitol into the brain around gliomas: a potential cause of rebound phenomenon.,17019386_0,-1,-1,-1,6378,-1,0.003288239,0.99671173
6381,elevated ICP,12,14,64,76,AIM: Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.,17019386_2,-1,-1,-1,6381,-1,0.0096878875,0.9903121
6382,brain tumor,15,17,80,91,AIM: Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.,17019386_2,-1,-1,-1,6382,-1,0.0031028471,0.9968971
6385,brain tumor,22,24,130,141,As a contribution to this issue we decided to research the possible passage of mannitol into the brain after administration to 21 brain tumor patients.,17019386_5,-1,-1,-1,6385,-1,0.0034843928,0.99651563
6387,malignant glioma,21,23,90,106,"METHODS: Mannitol (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain metastases and four meningioma) about 30 minutes before craniotomy.",17019386_6,-1,-1,-1,6387,-1,0.005261376,0.99473864
6388,metastases,26,27,120,130,"METHODS: Mannitol (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain metastases and four meningioma) about 30 minutes before craniotomy.",17019386_6,-1,-1,-1,6388,-1,0.00371223,0.9962878
6389,meningioma,29,30,140,150,"METHODS: Mannitol (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain metastases and four meningioma) about 30 minutes before craniotomy.",17019386_6,-1,-1,-1,6389,-1,0.0038494857,0.9961505
6390,edematous,8,9,46,55,"During resection, a sample of the surrounding edematous white matter was taken at the same time as a 10 ml venous blood sample.",17019386_7,-1,-1,-1,6390,-1,0.00851851,0.99148154
6392,glioma,25,26,144,150,"Mannitol concentrations were measured in plasma and white matter by a modified version of the enzyme assay of Blonquist et al. RESULTS: In most glioma patients, mannitol concentrations in white matter were 2 to 6 times higher than in plasma (mean 3.5 times).",17019386_8,-1,-1,-1,6392,-1,0.0039937836,0.9960062
6394,meningioma,1,2,3,13,In meningioma and metastases patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells.,17019386_9,-1,-1,-1,6394,-1,0.0031166421,0.99688333
6395,metastases,3,4,18,28,In meningioma and metastases patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells.,17019386_9,-1,-1,-1,6395,-1,0.0039445134,0.9960555
6398,gliomas,23,24,122,129,"CONCLUSIONS: The results of our study show that even after a single bolus, mannitol may leak through the altered BBB near gliomas, reversing the initial plasma-to-blood osmotic gradient, aggravating peritumoral edema and promoting rebound of ICP.",17019386_10,-1,-1,-1,6398,-1,0.00433063,0.99566936
6401,atrial fibrillation,5,7,45,64,Optimising stroke prevention in non-valvular atrial fibrillation.,17020434_0,-1,-1,-1,6401,-1,0.16271743,0.8372826
6402,Atrial fibrillation,0,2,0,19,Atrial fibrillation is associated with substantial morbidity and mortality.,17020434_1,-1,-1,-1,6402,-1,0.9319406,0.06805941
6409,Ximelagatran,0,1,0,12,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,-1,-1,-1,6409,-1,0.99918276,0.000817186
6410,direct thrombin inhibitor,4,7,22,47,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,-1,-1,-1,6410,-1,0.9944807,0.0055192257
6411,vitamin K,15,17,81,90,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,-1,-1,-1,6411,-1,0.99840325,0.0015967977
6412,embolic events,23,25,129,143,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,-1,-1,-1,6412,-1,0.0027096095,0.9972904
6413,abnormal liver function,33,36,188,211,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,-1,-1,-1,6413,-1,0.009147074,0.9908529
6414,Atrial Fibrillation Clopidogrel,3,6,14,45,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,-1,-1,-1,6414,-1,0.38606817,0.6139319
6415,Irbesartan,8,9,57,67,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,-1,-1,-1,6415,-1,0.9992487,0.0007513046
6419,af embolic events,33,36,217,234,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,-1,-1,-1,6419,-1,0.0051655495,0.9948344
6420,Factor Xa,3,5,15,24,"Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation.",17020434_6,-1,-1,-1,6420,-1,0.9835829,0.016417054
6421,atrial fibrillation,13,15,72,91,"Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation.",17020434_6,-1,-1,-1,6421,-1,0.005579359,0.9944206
6422,angiotensin II,4,6,45,59,Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.,17020434_7,-1,-1,-1,6422,-1,0.99475765,0.0052423645
6423,atrial fibrillation,11,13,100,119,Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.,17020434_7,-1,-1,-1,6423,-1,0.025781682,0.9742183
6424,cardiac remodelling,14,16,128,147,Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.,17020434_7,-1,-1,-1,6424,-1,0.0039992924,0.9960007
6427,EPS,6,7,52,55,Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.,17042884_0,-1,-1,-1,6427,-1,0.0032686158,0.9967314
6428,quetiapine,9,10,62,72,Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.,17042884_0,-1,-1,-1,6428,-1,0.9993975,0.00060249766
6429,bipolar mania,16,18,112,125,Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.,17042884_0,-1,-1,-1,6429,-1,0.0035006115,0.9964994
6431,EPS,7,8,49,52,"OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.",17042884_1,-1,-1,-1,6431,-1,0.003686017,0.996314
6432,akathisia,11,12,65,74,"OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.",17042884_1,-1,-1,-1,6432,-1,0.0109687615,0.98903126
6433,quetiapine,14,15,81,91,"OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.",17042884_1,-1,-1,-1,6433,-1,0.99943787,0.00056214543
6434,bipolar mania,18,20,109,122,"OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.",17042884_1,-1,-1,-1,6434,-1,0.0040546195,0.9959454
6435,quetiapine,3,4,22,32,"Two studies evaluated quetiapine monotherapy (up to 800 mg/day) (n = 209) versus placebo (n = 198), with lithium or haloperidol monotherapy as respective active controls.",17042884_3,-1,-1,-1,6435,-1,0.9994311,0.00056892744
6436,n,12,13,65,66,"Two studies evaluated quetiapine monotherapy (up to 800 mg/day) (n = 209) versus placebo (n = 198), with lithium or haloperidol monotherapy as respective active controls.",17042884_3,-1,-1,-1,6436,-1,0.2941097,0.70589036
6437,n,19,20,90,91,"Two studies evaluated quetiapine monotherapy (up to 800 mg/day) (n = 209) versus placebo (n = 198), with lithium or haloperidol monotherapy as respective active controls.",17042884_3,-1,-1,-1,6437,-1,0.2628766,0.73712337
6440,quetiapine,3,4,22,32,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,-1,-1,-1,6440,-1,0.99938107,0.00061895204
6442,divalproex,19,20,102,112,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,-1,-1,-1,6442,-1,0.9989241,0.0010758773
6443,QTP,21,22,114,117,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,-1,-1,-1,6443,-1,0.9968156,0.0031843823
6444,n,26,27,129,130,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,-1,-1,-1,6444,-1,0.2327251,0.7672749
6445,n,42,43,194,195,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,-1,-1,-1,6445,-1,0.18374863,0.8162514
6447,Akathisia,14,15,87,96,"Extrapyramidal symptoms were evaluated using the Simpson-Angus Scale (SAS), the Barnes Akathisia Rating Scale (BARS), adverse event reports and anticholinergic drug usage.",17042884_5,-1,-1,-1,6447,-1,0.023861693,0.97613835
6448,akathisia,10,11,64,73,"RESULTS: The incidence of EPS-related adverse events, including akathisia, was no different with quetiapine monotherapy (12.9%) than with placebo (13.1%).",17042884_6,-1,-1,-1,6448,-1,0.01284331,0.9871567
6449,quetiapine,16,17,97,107,"RESULTS: The incidence of EPS-related adverse events, including akathisia, was no different with quetiapine monotherapy (12.9%) than with placebo (13.1%).",17042884_6,-1,-1,-1,6449,-1,0.99945575,0.0005442431
6450,QTP,6,7,43,46,"Similarly, EPS-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + Li/DVP (19.2%).",17042884_7,-1,-1,-1,6450,-1,0.97105306,0.028946957
6451,EPS,4,5,26,29,"Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.",17042884_8,-1,-1,-1,6451,-1,0.0034039435,0.99659604
6453,n,15,16,86,87,"Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.",17042884_8,-1,-1,-1,6453,-1,0.5996599,0.40034008
6455,n,30,31,155,156,"Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.",17042884_8,-1,-1,-1,6455,-1,0.5329369,0.4670631
6456,EPS,40,41,213,216,"Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.",17042884_8,-1,-1,-1,6456,-1,0.0029125814,0.9970874
6457,akathisia,3,4,17,26,"The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).",17042884_9,-1,-1,-1,6457,-1,0.00308697,0.99691296
6458,quetiapine,9,10,52,62,"The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).",17042884_9,-1,-1,-1,6458,-1,0.99944085,0.00055913
6459,QTP,24,25,111,114,"The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).",17042884_9,-1,-1,-1,6459,-1,0.99280965,0.0071903663
6461,p,9,10,62,63,"Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.",17042884_10,-1,-1,-1,6461,-1,0.26760262,0.7323973
6463,quetiapine,20,21,95,105,"Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.",17042884_10,-1,-1,-1,6463,-1,0.9992773,0.0007226635
6468,p,7,8,54,55,"Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.",17042884_11,-1,-1,-1,6468,-1,0.2106772,0.7893228
6469,akathisia,12,13,68,77,"Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.",17042884_11,-1,-1,-1,6469,-1,0.002661982,0.997338
6471,extrapyramidal syndrome,31,33,131,154,"Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.",17042884_11,-1,-1,-1,6471,-1,0.002728385,0.9972716
6472,quetiapine,41,42,180,190,"Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.",17042884_11,-1,-1,-1,6472,-1,0.99927264,0.0007273365
6473,quetiapine,6,7,49,59,No significant differences were observed between quetiapine and placebo on SAS and BARS scores.,17042884_12,-1,-1,-1,6473,-1,0.9994289,0.0005710761
6474,quetiapine,7,8,45,55,Anticholinergic use was low and similar with quetiapine or placebo.,17042884_13,-1,-1,-1,6474,-1,0.9993949,0.0006051398
6476,mania,4,5,24,29,"CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with quetiapine therapy is similar to that with placebo.",17042884_14,-1,-1,-1,6476,-1,0.0031822855,0.9968177
6477,EPS,9,10,48,51,"CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with quetiapine therapy is similar to that with placebo.",17042884_14,-1,-1,-1,6477,-1,0.0028960234,0.997104
6478,akathisia,12,13,63,72,"CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with quetiapine therapy is similar to that with placebo.",17042884_14,-1,-1,-1,6478,-1,0.04258584,0.95741415
6479,quetiapine,15,16,79,89,"CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with quetiapine therapy is similar to that with placebo.",17042884_14,-1,-1,-1,6479,-1,0.99941385,0.00058612396
6480,atorvastatin,3,4,24,36,Anti-oxidant effects of atorvastatin in dexamethasone-induced hypertension in the rat.1.,17042910_0,-1,-1,-1,6480,-1,0.99905807,0.0009419786
6484,nitric oxide,10,12,101,113,Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.,17042910_1,-1,-1,-1,6484,-1,0.99560875,0.004391221
6486,O2-,20,21,156,159,Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.,17042910_1,-1,-1,-1,6486,-1,0.98481303,0.015186959
6487,Atorvastatin,0,1,0,12,Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of hypertension.,17042910_2,-1,-1,-1,6487,-1,0.9990226,0.000977361
6488,Ato,2,3,14,17,Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of hypertension.,17042910_2,-1,-1,-1,6488,-1,0.99772424,0.0022757829
6489,O2-,22,23,157,160,Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of hypertension.,17042910_2,-1,-1,-1,6489,-1,0.9869805,0.0130194845
6491,Ato,16,17,70,73,"In the present study, we investigated whether 50 mg/kg per day, p.o., Ato could prevent endothelial NO synthase (eNOS) downregulation and the increase in O2- in Sprague-Dawley (SD) rats, thereby reducing blood pressure.",17042910_3,-1,-1,-1,6491,-1,0.99803835,0.0019616587
6492,O2-,30,31,154,157,"In the present study, we investigated whether 50 mg/kg per day, p.o., Ato could prevent endothelial NO synthase (eNOS) downregulation and the increase in O2- in Sprague-Dawley (SD) rats, thereby reducing blood pressure.",17042910_3,-1,-1,-1,6492,-1,0.9880371,0.011962874
6493,SD,34,35,177,179,"In the present study, we investigated whether 50 mg/kg per day, p.o., Ato could prevent endothelial NO synthase (eNOS) downregulation and the increase in O2- in Sprague-Dawley (SD) rats, thereby reducing blood pressure.",17042910_3,-1,-1,-1,6493,-1,0.108935975,0.89106405
6494,SD,3,4,8,10,2. Male SD rats (n = 30) were treated with Ato (50 mg/kg per day in drinking water) or tap water for 15 days.,17042910_4,-1,-1,-1,6494,-1,0.02344725,0.9765528
6495,n,6,7,17,18,2. Male SD rats (n = 30) were treated with Ato (50 mg/kg per day in drinking water) or tap water for 15 days.,17042910_4,-1,-1,-1,6495,-1,0.176187,0.823813
6496,Ato,13,14,43,46,2. Male SD rats (n = 30) were treated with Ato (50 mg/kg per day in drinking water) or tap water for 15 days.,17042910_4,-1,-1,-1,6496,-1,0.9984554,0.0015445447
6497,drinking water,20,22,68,82,2. Male SD rats (n = 30) were treated with Ato (50 mg/kg per day in drinking water) or tap water for 15 days.,17042910_4,-1,-1,-1,6497,-1,0.98575926,0.014240802
6500,P,30,31,119,120,"In rats treated with Dex alone, SBP was increased from 109 +/- 2 to 133 +/- 2 mmHg on Days 4 and Day 14, respectively (P < 0.001).",17042910_10,-1,-1,-1,6500,-1,0.23437202,0.765628
6501,Ato,2,3,7,10,"In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).",17042910_11,-1,-1,-1,6501,-1,0.9887299,0.011270111
6503,P,29,30,106,107,"In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).",17042910_11,-1,-1,-1,6503,-1,0.24526508,0.75473493
6505,P,48,49,192,193,"In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).",17042910_11,-1,-1,-1,6505,-1,0.18694596,0.8130541
6507,Ato,12,13,84,87,"Endothelial-dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group (P < 0.05 and P < 0.0001, respectively).",17042910_12,-1,-1,-1,6507,-1,0.9974994,0.002500526
6509,P,21,22,122,123,"Endothelial-dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group (P < 0.05 and P < 0.0001, respectively).",17042910_12,-1,-1,-1,6509,-1,0.34007335,0.65992665
6510,P,25,26,135,136,"Endothelial-dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group (P < 0.05 and P < 0.0001, respectively).",17042910_12,-1,-1,-1,6510,-1,0.3418279,0.6581721
6513,Ato,9,10,52,55,Aortic superoxide production was lower in the Dex + Ato group compared with the group treated with Dex alone (P < 0.0001).,17042910_13,-1,-1,-1,6513,-1,0.997884,0.002116064
6515,P,20,21,110,111,Aortic superoxide production was lower in the Dex + Ato group compared with the group treated with Dex alone (P < 0.0001).,17042910_13,-1,-1,-1,6515,-1,0.28356254,0.7164374
6516,Ato,2,3,15,18,"Treatment with Ato improved endothelial function, reduced superoxide production and reduced SBP in Dex-treated SD rats.",17042910_15,-1,-1,-1,6516,-1,0.99864537,0.0013546972
6518,SD,15,16,111,113,"Treatment with Ato improved endothelial function, reduced superoxide production and reduced SBP in Dex-treated SD rats.",17042910_15,-1,-1,-1,6518,-1,0.13693382,0.8630662
6520,Chiari malformation,12,14,78,97,Is phenytoin administration safe in a hypothermic child?A male neonate with a Chiari malformation and a leaking myelomeningocoele underwent ventriculoperitoneal shunt insertion followed by repair of myelomeningocoele.,17049862_0,-1,-1,-1,6520,-1,0.0051026884,0.9948973
6521,hypothermic,9,10,67,78,"During anaesthesia and surgery, he inadvertently became moderately hypothermic.",17049862_1,-1,-1,-1,6521,-1,0.525203,0.474797
6532,lead,9,10,63,67,Administration of phenytoin in the presence of hypothermia may lead to an adverse cardiac event in children.,17049862_5,-1,-1,-1,6532,-1,0.014439016,0.98556095
6534,chorea,1,2,18,24,Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia.,17074608_0,-1,-1,-1,6534,-1,0.0024258997,0.99757415
6536,nonketotic hyperglycinemia,6,8,56,82,Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia.,17074608_0,-1,-1,-1,6536,-1,0.013750828,0.98624915
6537,hyperglycinemia,1,2,11,26,Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.,17074608_1,-1,-1,-1,6537,-1,0.14666976,0.8533302
6538,disorder of amino acid,4,8,32,54,Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.,17074608_1,-1,-1,-1,6538,-1,0.6627211,0.3372789
6543,hypotonia,14,15,79,88,"In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.",17074608_2,-1,-1,-1,6543,-1,0.0023771285,0.9976229
6544,psychomotor retardation,19,21,114,137,"In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.",17074608_2,-1,-1,-1,6544,-1,0.0026919064,0.99730814
6545,nonketotic hyperglycinemia,6,8,37,63,An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.,17074608_3,-1,-1,-1,6545,-1,0.08606212,0.91393787
6546,language delay,7,9,42,56,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,-1,-1,-1,6546,-1,0.0056670937,0.9943329
6547,mental retardation,10,12,61,79,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,-1,-1,-1,6547,-1,0.0026241527,0.99737585
6548,nonketotic hyperglycinemia,18,20,103,129,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,-1,-1,-1,6548,-1,0.05841546,0.9415846
6549,acute encephalopathy,24,26,162,182,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,-1,-1,-1,6549,-1,0.0033844921,0.99661547
6550,chorea,27,28,187,193,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,-1,-1,-1,6550,-1,0.002569839,0.99743015
6551,valproate,32,33,222,231,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,-1,-1,-1,6551,-1,0.9993125,0.0006875179
6552,citrate toxicity,1,3,7,23,Severe citrate toxicity complicating volunteer apheresis platelet donation.,17111419_0,-1,-1,-1,6552,-1,0.30516255,0.6948374
6553,citrate toxicity,6,8,27,43,We report a case of severe citrate toxicity during volunteer donor apheresis platelet collection.,17111419_1,-1,-1,-1,6553,-1,0.310635,0.689365
6555,hyperlipidemia,8,9,54,68,"Past medical history was remarkable for hypertension, hyperlipidemia, and depression.",17111419_3,-1,-1,-1,6555,-1,0.0073249387,0.9926751
6557,bumetanide,3,4,30,40,"Reported medications included bumetanide, pravastatin, and paroxetine.",17111419_4,-1,-1,-1,6557,-1,0.99930024,0.0006997799
6561,calcium gluconate,4,6,37,54,"Empirical treatment with intravenous calcium gluconate was initiated, and muscle contractions slowly subsided over approximately 10 to 15 minutes.",17111419_7,-1,-1,-1,6561,-1,0.9992848,0.0007152209
6565,bumetanide,9,10,58,68,"Upon additional retrospective analysis, it was noted that bumetanide is a loop diuretic that may cause significant hypocalcemia.",17111419_9,-1,-1,-1,6565,-1,0.9992204,0.0007796565
6566,loop diuretic,12,14,74,87,"Upon additional retrospective analysis, it was noted that bumetanide is a loop diuretic that may cause significant hypocalcemia.",17111419_9,-1,-1,-1,6566,-1,0.9856983,0.014301643
6569,citrate toxicity,22,24,161,177,We conclude that careful screening for medications and underlying conditions predisposing to hypocalcemia is recommended to help prevent severe reactions due to citrate toxicity.,17111419_10,-1,-1,-1,6569,-1,0.3314631,0.6685369
6572,cerebral ischemia,6,8,49,66,Delayed institution of hypertension during focal cerebral ischemia: effect on brain edema.,1711760_0,-1,-1,-1,6572,-1,0.00299665,0.9970034
6573,brain edema,11,13,78,89,Delayed institution of hypertension during focal cerebral ischemia: effect on brain edema.,1711760_0,-1,-1,-1,6573,-1,0.002614568,0.99738544
6575,middle cerebral artery occlusion,11,15,74,106,The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.,1711760_1,-1,-1,-1,6575,-1,0.09460596,0.905394
6576,MCAO,16,17,108,112,The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.,1711760_1,-1,-1,-1,6576,-1,0.22462724,0.7753728
6580,n,5,6,22,23,"In the control group (n = 7), the mean arterial pressure (MAP) was not manipulated.",1711760_3,-1,-1,-1,6580,-1,0.26148632,0.7385137
6581,MAP,15,16,58,61,"In the control group (n = 7), the mean arterial pressure (MAP) was not manipulated.",1711760_3,-1,-1,-1,6581,-1,0.87442213,0.12557787
6583,n,5,6,27,28,"In the hypertensive group (n = 7), the MAP was elevated by 25-30 mm Hg beginning 2 h after MCAO.",1711760_4,-1,-1,-1,6583,-1,0.17939733,0.8206027
6584,MAP,11,12,39,42,"In the hypertensive group (n = 7), the MAP was elevated by 25-30 mm Hg beginning 2 h after MCAO.",1711760_4,-1,-1,-1,6584,-1,0.9589314,0.04106862
6585,mm Hg,18,20,65,70,"In the hypertensive group (n = 7), the MAP was elevated by 25-30 mm Hg beginning 2 h after MCAO.",1711760_4,-1,-1,-1,6585,-1,0.8230264,0.17697352
6586,h,22,23,83,84,"In the hypertensive group (n = 7), the MAP was elevated by 25-30 mm Hg beginning 2 h after MCAO.",1711760_4,-1,-1,-1,6586,-1,0.21386,0.78613997
6587,MCAO,24,25,91,95,"In the hypertensive group (n = 7), the MAP was elevated by 25-30 mm Hg beginning 2 h after MCAO.",1711760_4,-1,-1,-1,6587,-1,0.96692914,0.033070907
6588,MCAO,3,4,17,21,"Four hours after MCAO, the rats were killed and the brains harvested.",1711760_5,-1,-1,-1,6588,-1,0.12253522,0.8774648
6590,MCAO,14,15,97,101,The brains were sectioned along coronal planes spanning the distribution of ischemia produced by MCAO.,1711760_6,-1,-1,-1,6590,-1,0.92666364,0.073336296
6591,ischemic,23,24,112,120,Specific gravity (SG) was determined in the subcortex and in two sites in the cortex (core and periphery of the ischemic territory).,1711760_7,-1,-1,-1,6591,-1,0.0051594567,0.99484056
6592,neuronal injury,3,5,14,29,"The extent of neuronal injury was determined by 2,3,5-triphenyltetrazolium staining.",1711760_8,-1,-1,-1,6592,-1,0.002787762,0.99721223
6593,"2,3,5-triphenyltetrazolium",8,9,48,74,"The extent of neuronal injury was determined by 2,3,5-triphenyltetrazolium staining.",1711760_8,-1,-1,-1,6593,-1,0.9955225,0.0044774506
6594,ischemic,2,3,7,15,"In the ischemic core, there was no difference in SG in the subcortex and cortex in the two groups.",1711760_9,-1,-1,-1,6594,-1,0.0041812947,0.9958187
6595,ischemic,5,6,24,32,"In the periphery of the ischemic territory, SG in the cortex was greater (less edema accumulation) in the hypertensive group (1.041 +/- 0.001 vs 1.039 +/- 0.001, P less than 0.05).",1711760_10,-1,-1,-1,6595,-1,0.004155871,0.9958442
6598,P,34,35,162,163,"In the periphery of the ischemic territory, SG in the cortex was greater (less edema accumulation) in the hypertensive group (1.041 +/- 0.001 vs 1.039 +/- 0.001, P less than 0.05).",1711760_10,-1,-1,-1,6598,-1,0.27005997,0.72994
6600,P,36,37,154,155,"The area of histochemical injury (as a percent of the cross-sectional area of the hemisphere) was less in the hypertensive group (33 +/- 3% vs 21 +/- 2%, P less than 0.05).",1711760_11,-1,-1,-1,6600,-1,0.25864422,0.7413558
6602,h,8,9,71,72,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",1711760_12,-1,-1,-1,6602,-1,0.32963789,0.6703621
6603,MCAO,10,11,79,83,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",1711760_12,-1,-1,-1,6603,-1,0.39902422,0.60097575
6605,ischemic,17,18,116,124,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",1711760_12,-1,-1,-1,6605,-1,0.0042772642,0.9957228
6607,ischemic,29,30,178,186,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",1711760_12,-1,-1,-1,6607,-1,0.003962044,0.99603796
6608,neuronal dysfunction,40,42,244,264,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",1711760_12,-1,-1,-1,6608,-1,0.0032102575,0.99678975
6614,chronic allograft nephropathy,15,18,106,135,Sirolimus represents a major therapeutic advance in the prevention of acute renal allograft rejection and chronic allograft nephropathy.,17147461_2,-1,-1,-1,6614,-1,0.00444831,0.99555165
6616,autoimmunity,8,9,47,59,"Its role in the therapy of glomerulonephritis, autoimmunity, cystic renal diseases and renal cancer is under investigation.",17147461_3,-1,-1,-1,6616,-1,0.0030273632,0.9969727
6617,cystic renal diseases,10,13,61,82,"Its role in the therapy of glomerulonephritis, autoimmunity, cystic renal diseases and renal cancer is under investigation.",17147461_3,-1,-1,-1,6617,-1,0.003758421,0.99624157
6618,renal cancer,14,16,87,99,"Its role in the therapy of glomerulonephritis, autoimmunity, cystic renal diseases and renal cancer is under investigation.",17147461_3,-1,-1,-1,6618,-1,0.0029480334,0.99705195
6620,calcineurin inhibitors,12,14,82,104,"Because sirolimus does not share the vasomotor renal adverse effects exhibited by calcineurin inhibitors, it has been designated a 'non-nephrotoxic drug'.",17147461_4,-1,-1,-1,6620,-1,0.9927731,0.00722687
6623,acute renal dysfunction,17,20,111,134,"However, clinical reports suggest that, under some circumstances, sirolimus is associated with proteinuria and acute renal dysfunction.",17147461_5,-1,-1,-1,6623,-1,0.0023324161,0.9976676
6624,chronic renal damage,10,13,60,80,A common risk factor appears to be presence of pre-existing chronic renal damage.,17147461_6,-1,-1,-1,6624,-1,0.0033287369,0.99667126
6627,acute renal dysfunction,1,4,4,27,The acute renal dysfunction associated with sirolimus (such as in delayed graft function) may be due to suppression of compensatory renal cell proliferation and survival/repair processes.,17147461_9,-1,-1,-1,6627,-1,0.002805187,0.99719477
6629,delayed graft function,11,14,66,88,The acute renal dysfunction associated with sirolimus (such as in delayed graft function) may be due to suppression of compensatory renal cell proliferation and survival/repair processes.,17147461_9,-1,-1,-1,6629,-1,0.004879688,0.9951202
6638,SRL,2,3,11,14,"Sirolimus (SRL) is a new, potent immunosuppressive agent.",17175308_1,-1,-1,-1,6638,-1,0.9980362,0.0019638296
6642,SRL,18,19,128,131,"We retrospectively examined the records of 25 renal transplant patients, who developed or displayed increased proteinuria after SRL conversion.",17175308_3,-1,-1,-1,6642,-1,0.99841607,0.0015839112
6643,SRL,13,14,55,58,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6643,-1,0.9986582,0.0013417534
6644,chronic allograft nephropathy,20,23,89,118,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6644,-1,0.0064684674,0.9935315
6645,n,27,28,126,127,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6645,-1,0.17015709,0.8298429
6646,neoplasia,31,32,134,143,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6646,-1,0.0040433374,0.9959566
6647,n,33,34,145,146,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6647,-1,0.11506398,0.88493603
6648,Kaposi,37,38,153,159,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6648,-1,0.060103968,0.93989605
6649,'s sarcoma,38,40,159,169,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6649,-1,0.02565939,0.9743406
6650,skin cancers,42,44,176,188,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6650,-1,0.0061780177,0.993822
6651,intestinal tumors,46,48,194,211,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6651,-1,0.006966335,0.99303365
6652,renal cell carsinom,50,53,217,236,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6652,-1,0.023867274,0.9761327
6654,n,59,60,263,264,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,-1,-1,-1,6654,-1,0.101199955,0.8988001
6655,SRL,0,1,0,3,SRL was started at a mean of 78 +/- 42 (15 to 163) months after transplantation.,17175308_5,-1,-1,-1,6655,-1,0.9984785,0.0015215302
6656,SRL,3,4,18,21,Mean follow-up on SRL therapy was 20 +/- 12 (6 to 43) months.,17175308_6,-1,-1,-1,6656,-1,0.99858594,0.001414131
6658,P,23,24,108,109,Proteinuria increased from 0.445 (0 to 1.5) g/d before conversion to 3.2 g/dL (0.2 to 12) after conversion (P = 0.001).,17175308_7,-1,-1,-1,6658,-1,0.23866123,0.7613388
6664,membranoproliferative glomerulopathy,11,13,75,111,Biopsies performed in five patients revealed new pathological changes: One membranoproliferative glomerulopathy and interstitial nephritis.,17175308_12,-1,-1,-1,6664,-1,0.008203841,0.99179614
6667,SRL,3,4,17,20,0.8 mg/dL before SRL therapy and 2.53 +/- 1.9 mg/dL at last follow-up (P = .14).,17175308_15,-1,-1,-1,6667,-1,0.99871194,0.0012880629
6668,P,15,16,71,72,0.8 mg/dL before SRL therapy and 2.53 +/- 1.9 mg/dL at last follow-up (P = .14).,17175308_15,-1,-1,-1,6668,-1,0.41122714,0.5887729
6669,Kaposi's sarcoma,5,8,32,48,Five patients displayed CAN and Kaposi's sarcoma.,17175308_17,-1,-1,-1,6669,-1,0.0248254,0.9751746
6670,P,29,30,131,132,Mean urinary protein of patients who returned to dialysis was 1.26 (0.5 to 3.5) g/d before and 4.7 (3 to 12) g/d after conversion (P = .01).,17175308_18,-1,-1,-1,6670,-1,0.32178944,0.6782106
6672,P,15,16,89,90,"Mean serum creatinine level before conversion was 2.21 mg/dL and thereafter, 4.93 mg/dL (P = .02).",17175308_19,-1,-1,-1,6672,-1,0.45504192,0.5449581
6674,SRL,8,9,46,49,Heavy proteinuria was common after the use of SRL as rescue therapy for renal transplantation.,17175308_20,-1,-1,-1,6674,-1,0.99894387,0.0010561133
6676,SRL,8,9,54,57,The possibility of de novo glomerular pathology under SRL treatment requires further investigation by renal biopsy.,17175308_22,-1,-1,-1,6676,-1,0.9984609,0.0015391156
6681,"5-hydroxytryptamine, 5-HT",24,27,136,161,"The goal of this study was to assess the interactive effects of chronic anabolic androgenic steroid (AAS) exposure and brain serotonin (5-hydroxytryptamine, 5-HT) depletion on behavior of pubertal male rats.",17194457_1,-1,-1,-1,6681,-1,0.9956904,0.0043096473
6682,parachlorophenylalanine,9,10,58,81,"Serotonin was depleted beginning on postnatal day 26 with parachlorophenylalanine (PCPA 100 mg/kg, every other day); controls received saline.",17194457_2,-1,-1,-1,6682,-1,0.9990989,0.00090118404
6683,PCPA,11,12,83,87,"Serotonin was depleted beginning on postnatal day 26 with parachlorophenylalanine (PCPA 100 mg/kg, every other day); controls received saline.",17194457_2,-1,-1,-1,6683,-1,0.9982224,0.0017775384
6688,5-HT,3,4,16,20,"Brain levels of 5-HT and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA), were determined using HPLC.",17194457_6,-1,-1,-1,6688,-1,0.9967528,0.0032471656
6689,5-hydroxyindoleacetic acid,8,10,41,67,"Brain levels of 5-HT and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA), were determined using HPLC.",17194457_6,-1,-1,-1,6689,-1,0.9975999,0.0024000965
6690,5-HIAA,11,12,69,75,"Brain levels of 5-HT and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA), were determined using HPLC.",17194457_6,-1,-1,-1,6690,-1,0.9972403,0.0027597307
6691,5-HT,5,6,46,50,PCPA significantly and substantially depleted 5-HT and 5-HIAA in all brain regions examined.,17194457_7,-1,-1,-1,6691,-1,0.99690264,0.0030972827
6692,5-HIAA,7,8,55,61,PCPA significantly and substantially depleted 5-HT and 5-HIAA in all brain regions examined.,17194457_7,-1,-1,-1,6692,-1,0.99770504,0.0022950124
6693,T,1,2,8,9,"Chronic T treatment significantly decreased 5-HT and 5-HIAA in certain brain areas, but to a much lesser extent than PCPA.",17194457_8,-1,-1,-1,6693,-1,0.9981949,0.0018051742
6694,5-HT,5,6,44,48,"Chronic T treatment significantly decreased 5-HT and 5-HIAA in certain brain areas, but to a much lesser extent than PCPA.",17194457_8,-1,-1,-1,6694,-1,0.9973653,0.0026347395
6695,5-HIAA,7,8,53,59,"Chronic T treatment significantly decreased 5-HT and 5-HIAA in certain brain areas, but to a much lesser extent than PCPA.",17194457_8,-1,-1,-1,6695,-1,0.99792886,0.0020711105
6696,PCPA,20,21,117,121,"Chronic T treatment significantly decreased 5-HT and 5-HIAA in certain brain areas, but to a much lesser extent than PCPA.",17194457_8,-1,-1,-1,6696,-1,0.9987759,0.0012241489
6697,PCPA,3,4,20,24,"Chronic exposure to PCPA alone significantly decreased locomotor activity and increased irritability but had no effect on sexual behavior, partner preference, or aggression.",17194457_9,-1,-1,-1,6697,-1,0.99888414,0.001115907
6702,5-HT,16,17,83,87,"Based on these data, it can be speculated that pubertal AAS users with low central 5-HT may be especially prone to exhibit aggressive behavior.",17194457_12,-1,-1,-1,6702,-1,0.99795073,0.0020492666
6704,ifosfamide renal toxicity,3,6,23,48,Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.,1720453_0,-1,-1,-1,6704,-1,0.7281973,0.27180278
6705,malignant mesenchymal tumors,10,13,73,101,Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.,1720453_0,-1,-1,-1,6705,-1,0.009249319,0.99075073
6706,mesenchymal tumors,8,10,49,67,The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol (International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [SIOP MMT 84]) were studied 1 year after the completion of treatment.,1720453_1,-1,-1,-1,6706,-1,0.008242792,0.9917572
6708,Malignant Mesenchymal Tumor,28,31,199,226,The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol (International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [SIOP MMT 84]) were studied 1 year after the completion of treatment.,1720453_1,-1,-1,-1,6708,-1,0.012552773,0.9874472
6712,dactinomycin,21,22,106,118,"Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]).",1720453_2,-1,-1,-1,6712,-1,0.99927527,0.0007247581
6713,IVA,23,24,120,123,"Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]).",1720453_2,-1,-1,-1,6713,-1,0.9957178,0.0042821816
6716,glucosuria,11,12,78,88,"Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.",1720453_6,-1,-1,-1,6716,-1,0.82071865,0.1792814
6718,aminoaciduria,15,16,103,116,"Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.",1720453_6,-1,-1,-1,6718,-1,0.80585915,0.19414087
6721,renal abnormalities,19,21,81,100,"Fifty-eight patients (78%) had normal renal tests, whereas 16 patients (22%) had renal abnormalities.",1720453_7,-1,-1,-1,6721,-1,0.0039956016,0.9960044
6723,Fanconi's syndrome,30,33,168,186,Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption.,1720453_8,-1,-1,-1,6723,-1,0.046970803,0.9530292
6724,TDFS,34,35,188,192,Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption.,1720453_8,-1,-1,-1,6724,-1,0.017196152,0.9828038
6728,tumor involvement,32,34,170,187,"Severe toxicity was correlated with the higher cumulative dose of 60 g/m2 of ifosfamide, a younger age (less than 2 1/2 years old), and a predominance of vesicoprostatic tumor involvement.",1720453_10,-1,-1,-1,6728,-1,0.0029272316,0.9970728
6729,TDFS,8,9,28,32,This low percentage (5%) of TDFS must be evaluated with respect to the efficacy of ifosfamide in the treatment of mesenchymal tumors in children.,1720453_11,-1,-1,-1,6729,-1,0.96975255,0.030247398
6731,mesenchymal tumors,23,25,114,132,This low percentage (5%) of TDFS must be evaluated with respect to the efficacy of ifosfamide in the treatment of mesenchymal tumors in children.,1720453_11,-1,-1,-1,6731,-1,0.0067674015,0.9932326
6732,UMB24,2,3,11,16,"Effects of UMB24 and (+/-)-SM 21, putative sigma2-preferring antagonists, on behavioral toxic and stimulant effects of cocaine in mice.",17241657_0,-1,-1,-1,6732,-1,0.998553,0.0014470139
6736,contrast,1,2,3,11,"In contrast, the contribution of sigma2 receptors is unclear because experimental tools to selectively target this subtype are unavailable.",17241657_2,-1,-1,-1,6736,-1,0.18257794,0.81742203
6737,UMB24,8,9,48,53,"To begin addressing this need, we characterized UMB24 (1-(2-phenethyl)-4-(2-pyridyl)-piperazine) and (+/-)-SM 21 (3alpha-tropanyl-2-(4-chorophenoxy)butyrate) in receptor binding and behavioral studies.",17241657_3,-1,-1,-1,6737,-1,0.99678755,0.0032124782
6738,1-(2-phenethyl)-4-(2-pyridyl)-piperazine),10,12,55,96,"To begin addressing this need, we characterized UMB24 (1-(2-phenethyl)-4-(2-pyridyl)-piperazine) and (+/-)-SM 21 (3alpha-tropanyl-2-(4-chorophenoxy)butyrate) in receptor binding and behavioral studies.",17241657_3,-1,-1,-1,6738,-1,0.9849021,0.015097965
6739,UMB24,5,6,40,45,Receptor binding studies confirmed that UMB24 and (+/-)-SM 21 display preferential affinity for sigma2 over sigma1 receptors.,17241657_4,-1,-1,-1,6739,-1,0.9982816,0.0017184108
6740,UMB24,10,11,63,68,"In behavioral studies, pretreatment of Swiss Webster mice with UMB24 or (+/-)-SM 21 significantly attenuated cocaine-induced convulsions and locomotor activity, but not lethality.",17241657_5,-1,-1,-1,6740,-1,0.9988011,0.0011989275
6742,UMB24,18,19,115,120,"When administered alone, (+/-)-SM 21 produced no significant effects compared to control injections of saline, but UMB24 had locomotor depressant actions.",17241657_6,-1,-1,-1,6742,-1,0.99884605,0.0011538831
6747,hyperCKaemia,7,8,45,57,Statins can cause a necrotizing myopathy and hyperCKaemia which is reversible on cessation of the drug.,17241784_1,-1,-1,-1,6747,-1,0.013520123,0.98647994
6772,contrast,8,9,49,57,"Generally, atropine reduced contractions, but in contrast to controls, it also reduced responses to low electrical field stimulation intensity (1-5 Hz) in inflamed preparations.",17244258_4,-1,-1,-1,6772,-1,0.18670982,0.8132901
6773,-,24,25,145,146,"Generally, atropine reduced contractions, but in contrast to controls, it also reduced responses to low electrical field stimulation intensity (1-5 Hz) in inflamed preparations.",17244258_4,-1,-1,-1,6773,-1,0.46215856,0.53784144
6774,Hz,26,27,148,150,"Generally, atropine reduced contractions, but in contrast to controls, it also reduced responses to low electrical field stimulation intensity (1-5 Hz) in inflamed preparations.",17244258_4,-1,-1,-1,6774,-1,0.9251289,0.074871115
6775,adenosine-5'-triphosphate,10,11,70,95,"In both types, purinoceptor desensitization with alpha,beta-methylene adenosine-5'-triphosphate (alpha,beta-meATP) caused further reductions at low frequencies (<10 Hz).",17244258_5,-1,-1,-1,6775,-1,0.9970317,0.002968302
6777,4-diphenylacetoxy-N-methylpiperidine,6,7,46,82,"The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.",17244258_6,-1,-1,-1,6777,-1,0.9977049,0.0022950748
6778,4-DAMP,8,9,84,90,"The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.",17244258_6,-1,-1,-1,6778,-1,0.99443746,0.005562516
6779,methoctramine,16,17,122,135,"The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.",17244258_6,-1,-1,-1,6779,-1,0.99907756,0.0009224113
6780,pirenzepine,23,24,159,170,"The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.",17244258_6,-1,-1,-1,6780,-1,0.9990435,0.00095640414
6781,4-DAMP,0,1,0,6,4-DAMP inhibited the tonic contractions in controls more potently than methoctramine and pirenzepine.,17244258_7,-1,-1,-1,6781,-1,0.9979911,0.0020089736
6782,methoctramine,10,11,71,84,4-DAMP inhibited the tonic contractions in controls more potently than methoctramine and pirenzepine.,17244258_7,-1,-1,-1,6782,-1,0.99926037,0.0007395803
6783,pirenzepine,12,13,89,100,4-DAMP inhibited the tonic contractions in controls more potently than methoctramine and pirenzepine.,17244258_7,-1,-1,-1,6783,-1,0.9991586,0.0008413875
6784,pirenzepine,22,23,162,173,"In inflamed preparations, the muscarinic receptor antagonism on the phasic component of the electrical field stimulation-evoked contraction was decreased and the pirenzepine and 4-DAMP antagonism on the tonic component was much less efficient than in controls.",17244258_8,-1,-1,-1,6784,-1,0.9991296,0.0008704583
6785,4-DAMP,24,25,178,184,"In inflamed preparations, the muscarinic receptor antagonism on the phasic component of the electrical field stimulation-evoked contraction was decreased and the pirenzepine and 4-DAMP antagonism on the tonic component was much less efficient than in controls.",17244258_8,-1,-1,-1,6785,-1,0.996869,0.0031309652
6786,contrast,1,2,3,11,"In contrast to controls, methoctramine increased -- instead of decreased -- the tonic responses at high frequencies.",17244258_9,-1,-1,-1,6786,-1,0.21678771,0.7832123
6787,methoctramine,5,6,25,38,"In contrast to controls, methoctramine increased -- instead of decreased -- the tonic responses at high frequencies.",17244258_9,-1,-1,-1,6787,-1,0.99927133,0.00072866614
6789,ATP,5,6,36,39,"While contractions to carbachol and ATP were the same in inflamed and in control strips when related to a reference potassium response, isoprenaline-induced relaxations were smaller in inflamed strips.",17244258_10,-1,-1,-1,6789,-1,0.998811,0.0011889617
6793,cardiovascular disease,14,16,101,123,"BACKGROUND: Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease, including arrhythmia, coronary heart disease, and chronic heart failure.",17261653_1,-1,-1,-1,6793,-1,0.0034983363,0.9965017
6795,coronary heart disease,20,23,147,169,"BACKGROUND: Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease, including arrhythmia, coronary heart disease, and chronic heart failure.",17261653_1,-1,-1,-1,6795,-1,0.004503666,0.9954964
6796,chronic heart failure,25,28,175,196,"BACKGROUND: Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease, including arrhythmia, coronary heart disease, and chronic heart failure.",17261653_1,-1,-1,-1,6796,-1,0.0062768315,0.9937232
6803,bradycardic,2,3,10,21,A similar bradycardic effect of clonidine was observed in isolated spontaneously beating right atria from alpha2ABC-knockout and wild-type mice.,17261653_6,-1,-1,-1,6803,-1,0.0024700651,0.9975299
6807,bradycardic,12,13,84,95,"CONCLUSIONS: Direct inhibition of cardiac HCN pacemaker channels contributes to the bradycardic effects of clonidine gene-targeted mice in vivo, and thus, clonidine-like drugs represent novel structures for future HCN channel inhibitors.",17261653_9,-1,-1,-1,6807,-1,0.0025981981,0.99740183
6809,cerebral palsy,6,8,31,45,Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine.,17263743_0,-1,-1,-1,6809,-1,0.0024500333,0.99754995
6813,cerebral palsy,9,11,45,59,"We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.",17263743_2,-1,-1,-1,6813,-1,0.0021814862,0.99781847
6814,seizure disorder,12,14,64,80,"We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.",17263743_2,-1,-1,-1,6814,-1,0.0019110063,0.998089
6816,restlessness,18,19,106,118,"We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.",17263743_2,-1,-1,-1,6816,-1,0.008983884,0.99101615
6817,baclofen,26,27,153,161,"We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.",17263743_2,-1,-1,-1,6817,-1,0.9992118,0.0007881811
6819,anxiety,27,28,166,173,"Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety.",17263743_3,-1,-1,-1,6819,-1,0.0036710128,0.996329
6825,mg,26,27,166,168,"This is a case report on a 45-year old African-American female with newly diagnosed hypertension, who was started on a combination pill of amlodipine/benazapril 10/5 mg.",17285209_1,-1,-1,-1,6825,-1,0.9775963,0.022403756
6826,abdominal pain,15,17,65,79,"The very next day, she presented at the emergency room (ER) with abdominal pain, nausea and vomiting.",17285209_2,-1,-1,-1,6826,-1,0.0030720748,0.9969279
6831,ARB,13,14,89,92,"The recognition of angiotensin-converting enzyme (ACE) and angiotensin receptor blocker (ARB) intestinal angioedema constitutes a challenge to primary care physicians, internists, emergency room personal and surgeons.",17285209_10,-1,-1,-1,6831,-1,0.99535334,0.004646647
6834,combination of amoxicillin,4,7,31,57,Granulomatous hepatitis due to combination of amoxicillin and clavulanic acid.,1728522_0,-1,-1,-1,6834,-1,0.99450994,0.0054900604
6835,clavulanic acid,8,10,62,77,Granulomatous hepatitis due to combination of amoxicillin and clavulanic acid.,1728522_0,-1,-1,-1,6835,-1,0.9987752,0.0012248632
6837,granulomas,14,15,108,118,We report the case of a patient with amoxicillin-clavulanic acid-induced hepatitis with histologic multiple granulomas.,1728522_1,-1,-1,-1,6837,-1,0.0023925798,0.99760735
6839,cholestatic syndrome,21,23,119,139,"This type of lesion broadens the spectrum of liver injury due to this drug combination, mainly represented by a benign cholestatic syndrome.",1728522_2,-1,-1,-1,6839,-1,0.0039121415,0.9960879
6840,granulomas,3,4,19,29,The association of granulomas and eosinophilia favor an immunoallergic mechanism.,1728522_3,-1,-1,-1,6840,-1,0.002556378,0.9974437
6845,clavulanic acid,26,28,159,174,"As penicillin derivatives and amoxicillin alone are known to induce such types of lesions, the amoxicillin component, with or without a potentiating effect of clavulanic acid, might have a major role.",1728522_4,-1,-1,-1,6845,-1,0.99904984,0.0009501074
6848,atrioventricular block,6,8,37,59,"A patient with sinus bradycardia and atrioventricular block, induced by carbamazepine, prompted an extensive literature review of all previously reported cases.",1728915_2,-1,-1,-1,6848,-1,0.05454835,0.9454517
6851,sinus tachycardias,4,6,28,46,One patient group developed sinus tachycardias in the setting of a massive carbamazepine overdose.,1728915_4,-1,-1,-1,6851,-1,0.003124596,0.9968754
6852,carbamazepine overdose,12,14,75,97,One patient group developed sinus tachycardias in the setting of a massive carbamazepine overdose.,1728915_4,-1,-1,-1,6852,-1,0.88531226,0.11468775
6853,bradyarrhythmias,13,14,106,122,"The second group consisted almost exclusively of elderly women who developed potentially life-threatening bradyarrhythmias or atrioventricular conduction delay, associated with either therapeutic or modestly elevated carbamazepine serum levels.",1728915_5,-1,-1,-1,6853,-1,0.0021693767,0.99783057
6854,atrioventricular conduction delay,15,18,126,159,"The second group consisted almost exclusively of elderly women who developed potentially life-threatening bradyarrhythmias or atrioventricular conduction delay, associated with either therapeutic or modestly elevated carbamazepine serum levels.",1728915_5,-1,-1,-1,6854,-1,0.09411302,0.905887
6862,cardiac damage,9,11,65,79,"To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.",1732369_2,-1,-1,-1,6862,-1,0.00325942,0.99674064
6871,mm,17,18,116,118,End-systolic left ventricular posterior wall dimension at baseline for the doxorubicin-treated group was 11 +/- 1.9 mm versus 13.1 +/- 1.5 mm for control subjects (p less than 0.01).,1732369_8,-1,-1,-1,6871,-1,0.05380464,0.9461953
6872,mm,23,24,139,141,End-systolic left ventricular posterior wall dimension at baseline for the doxorubicin-treated group was 11 +/- 1.9 mm versus 13.1 +/- 1.5 mm for control subjects (p less than 0.01).,1732369_8,-1,-1,-1,6872,-1,0.04375209,0.95624787
6873,p,28,29,164,165,End-systolic left ventricular posterior wall dimension at baseline for the doxorubicin-treated group was 11 +/- 1.9 mm versus 13.1 +/- 1.5 mm for control subjects (p less than 0.01).,1732369_8,-1,-1,-1,6873,-1,0.26875055,0.7312494
6875,mm,22,23,157,159,End-systolic left ventricular posterior wall dimension at the 5-micrograms/kg per min dobutamine infusion for the doxorubicin-treated group was 14.1 +/- 2.4 mm versus 19.3 +/- 2.6 mm for control subjects (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS),1732369_9,-1,-1,-1,6875,-1,0.030655788,0.9693442
6876,mm,28,29,180,182,End-systolic left ventricular posterior wall dimension at the 5-micrograms/kg per min dobutamine infusion for the doxorubicin-treated group was 14.1 +/- 2.4 mm versus 19.3 +/- 2.6 mm for control subjects (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS),1732369_9,-1,-1,-1,6876,-1,0.028628629,0.9713714
6877,p,33,34,205,206,End-systolic left ventricular posterior wall dimension at the 5-micrograms/kg per min dobutamine infusion for the doxorubicin-treated group was 14.1 +/- 2.4 mm versus 19.3 +/- 2.6 mm for control subjects (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS),1732369_9,-1,-1,-1,6877,-1,0.23946178,0.7605382
6879,iodine-125-metaiodobenzylguanidine,11,12,99,133,Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced cardiomyopathy with iodine-125-metaiodobenzylguanidine.,1732442_0,-1,-1,-1,6879,-1,0.99833506,0.0016650122
6880,metaiodobenzylguanidine,1,2,13,36,"Radiolabeled metaiodobenzylguanidine (MIBG), an analog of norepinephrine (NE), serves as an index of adrenergic neuron integrity and function.",1732442_1,-1,-1,-1,6880,-1,0.998372,0.0016280265
6881,MIBG,3,4,38,42,"Radiolabeled metaiodobenzylguanidine (MIBG), an analog of norepinephrine (NE), serves as an index of adrenergic neuron integrity and function.",1732442_1,-1,-1,-1,6881,-1,0.99806756,0.0019325074
6883,NE,11,12,74,76,"Radiolabeled metaiodobenzylguanidine (MIBG), an analog of norepinephrine (NE), serves as an index of adrenergic neuron integrity and function.",1732442_1,-1,-1,-1,6883,-1,0.99767286,0.0023271446
6885,adriamycin cardiomyopathy,25,27,180,205,"Using a rat model of adriamycin-induced cardiomyopathy, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in adriamycin cardiomyopathy.",1732442_2,-1,-1,-1,6885,-1,0.8636919,0.13630807
6886,vacuolar degeneration of myocardial cells,3,8,14,55,"The degree of vacuolar degeneration of myocardial cells was analyzed in relation to the duration of adriamycin treatment (2 mg/kg, once a week).",1732442_3,-1,-1,-1,6886,-1,0.0062365592,0.9937635
6888,p,39,40,202,203,"However, the 4-wk group had a slightly lower accumulation in the right ventricular wall (82% of the control) and significantly lower accumulation in the left ventricular wall (about 66% of the control: p less than 0.05).",1732442_6,-1,-1,-1,6888,-1,0.2011861,0.7988139
6889,MIBG,5,6,19,23,"In the 5-wk group, MIBG accumulation in the right and left ventricular wall was 35% and 27% of that in controls, respectively (p less than 0.001).",1732442_7,-1,-1,-1,6889,-1,0.9987226,0.0012774045
6890,p,27,28,127,128,"In the 5-wk group, MIBG accumulation in the right and left ventricular wall was 35% and 27% of that in controls, respectively (p less than 0.001).",1732442_7,-1,-1,-1,6890,-1,0.31261396,0.68738604
6891,MIBG,5,6,19,23,"In the 8-wk group, MIBG accumulation in the right and left ventricular wall was 18% and 14% of that in controls, respectively (p less than 0.001).",1732442_8,-1,-1,-1,6891,-1,0.9987262,0.0012737997
6892,p,27,28,127,128,"In the 8-wk group, MIBG accumulation in the right and left ventricular wall was 18% and 14% of that in controls, respectively (p less than 0.001).",1732442_8,-1,-1,-1,6892,-1,0.30807093,0.6919291
6893,MIBG,2,3,6,10,"Thus, MIBG accumulation in the myocardium decreased in an adriamycin dose-dependent manner.",1732442_9,-1,-1,-1,6893,-1,0.99778855,0.0022113854
6895,myocardial impairment,13,15,88,109,The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.,1732442_10,-1,-1,-1,6895,-1,0.00323291,0.99676704
6896,degeneration,20,21,139,151,The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.,1732442_10,-1,-1,-1,6896,-1,0.0029790206,0.9970209
6897,MIBG,24,25,168,172,The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.,1732442_10,-1,-1,-1,6897,-1,0.9984518,0.0015481419
6904,hearing loss,22,24,145,157,"The influence of smoking during pregnancy on the developing cochlea has not been estimated, although smoking has been positively associated with hearing loss in adults.",17343925_1,-1,-1,-1,6904,-1,0.0038177096,0.99618226
6906,hearing impairment,12,14,69,87,METHODS: This study was undertaken as part of neonatal screening for hearing impairment and involved both ears of 200 newborns.,17343925_3,-1,-1,-1,6906,-1,0.0037574307,0.99624264
6908,n=200,8,9,58,63,"Newborns whose mothers reported smoking during pregnancy (n=200 ears) were compared to a control group of newborns (n=200 ears), whose mothers were non-smokers.",17343925_4,-1,-1,-1,6908,-1,0.30145356,0.6985464
6909,n=200,20,21,116,121,"Newborns whose mothers reported smoking during pregnancy (n=200 ears) were compared to a control group of newborns (n=200 ears), whose mothers were non-smokers.",17343925_4,-1,-1,-1,6909,-1,0.24464357,0.75535643
6910,n=88,14,15,69,73,"Exposure to tobacco was characterized as low (<5 cigarettes per day, n=88 ears), moderate (5< or =cigarettes per day<10, n=76) or high (> or =10 cigarettes per day, n=36).",17343925_5,-1,-1,-1,6910,-1,0.32597956,0.67402047
6911,n=76,28,29,121,125,"Exposure to tobacco was characterized as low (<5 cigarettes per day, n=88 ears), moderate (5< or =cigarettes per day<10, n=76) or high (> or =10 cigarettes per day, n=36).",17343925_5,-1,-1,-1,6911,-1,0.29511374,0.7048863
6912,n=36,41,42,165,169,"Exposure to tobacco was characterized as low (<5 cigarettes per day, n=88 ears), moderate (5< or =cigarettes per day<10, n=76) or high (> or =10 cigarettes per day, n=36).",17343925_5,-1,-1,-1,6912,-1,0.26362714,0.7363729
6913,decreases of TEOAEs amplitudes,14,18,89,119,"However, by comparing each subgroup to control group, we found statistically significant decreases of TEOAEs amplitudes at 4000Hz for all three groups.",17343925_8,-1,-1,-1,6913,-1,0.14935087,0.8506491
6916,QT prolongation,2,4,12,27,Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.,17344330_0,-1,-1,-1,6916,-1,0.006860856,0.9931391
6918,heroin dependence,10,12,70,87,Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.,17344330_0,-1,-1,-1,6918,-1,0.84536546,0.1546345
6920,heroin,6,7,39,45,BACKGROUND: Methadone is prescribed to heroin addicts to decrease illicit opioid use.,17344330_1,-1,-1,-1,6920,-1,0.9987085,0.0012914581
6921,Prolongation of the QT interval,0,5,0,31,Prolongation of the QT interval in the ECG of patients with torsade de pointes (TdP) has been reported in methadone users.,17344330_2,-1,-1,-1,6921,-1,0.027167737,0.97283226
6922,torsade de pointes,11,14,60,78,Prolongation of the QT interval in the ECG of patients with torsade de pointes (TdP) has been reported in methadone users.,17344330_2,-1,-1,-1,6922,-1,0.2325069,0.76749307
6923,TdP,15,16,80,83,Prolongation of the QT interval in the ECG of patients with torsade de pointes (TdP) has been reported in methadone users.,17344330_2,-1,-1,-1,6923,-1,0.22363472,0.7763653
6925,heroin,1,2,3,9,"As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.",17344330_3,-1,-1,-1,6925,-1,0.9988136,0.0011863434
6927,TdP,28,29,177,180,"As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.",17344330_3,-1,-1,-1,6927,-1,0.7414285,0.25857148
6929,heroin,19,20,113,119,"METHODS: In this cross-sectional study interview, ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or buprenorphine on a daily basis.",17344330_4,-1,-1,-1,6929,-1,0.998353,0.0016470429
6931,buprenorphine,25,26,154,167,"METHODS: In this cross-sectional study interview, ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or buprenorphine on a daily basis.",17344330_4,-1,-1,-1,6931,-1,0.9988757,0.0011242754
6932,lead,7,8,38,42,The QT interval was estimated from 12 lead ECGs.,17344330_6,-1,-1,-1,6932,-1,0.38152584,0.6184742
6937,p,14,15,79,80,RESULTS: Methadone dose was associated with longer QT interval of 0.140 ms/mg (p = 0.002).,17344330_9,-1,-1,-1,6937,-1,0.31283897,0.6871611
6938,buprenorphine,3,4,23,36,No association between buprenorphine and QTc was found.,17344330_10,-1,-1,-1,6938,-1,0.99917644,0.00082353246
6940,prolonged QTc interval,15,18,69,91,"Among the subjects treated with methadone, 28% men and 32% women had prolonged QTc interval.",17344330_11,-1,-1,-1,6940,-1,0.030857636,0.9691423
6941,buprenorphine,6,7,34,47,None of the subjects treated with buprenorphine had QTc interval >0.440 s((1/2)).,17344330_12,-1,-1,-1,6941,-1,0.9990747,0.00092524645
6942,mg,2,3,5,7,A 50 mg higher methadone dose was associated with a 1.2 (95% CI 1.1 to 1.4) times higher odds for syncope.,17344330_13,-1,-1,-1,6942,-1,0.9730354,0.02696458
6946,QT prolongation,6,8,42,57,CONCLUSIONS: Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts.,17344330_14,-1,-1,-1,6946,-1,0.024914952,0.9750851
6948,heroin,17,18,109,115,CONCLUSIONS: Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts.,17344330_14,-1,-1,-1,6948,-1,0.99848264,0.0015173563
6949,compartment syndrome,3,5,34,54,Simvastatin-induced bilateral leg compartment syndrome and myonecrosis associated with hypothyroidism.,17344566_0,-1,-1,-1,6949,-1,0.002430772,0.99756926
6950,myonecrosis,6,7,59,70,Simvastatin-induced bilateral leg compartment syndrome and myonecrosis associated with hypothyroidism.,17344566_0,-1,-1,-1,6950,-1,0.0024477355,0.99755234
6955,compartment syndrome,12,14,93,113,A 54-year-old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis.,17344566_1,-1,-1,-1,6955,-1,0.0024607484,0.9975393
6956,myonecrosis,15,16,118,129,A 54-year-old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis.,17344566_1,-1,-1,-1,6956,-1,0.002263762,0.9977362
6958,arteriopathic,24,25,131,144,It is likely that this complication will be seen more often with the increased worldwide use of this drug and its approval for all arteriopathic patients.,17344566_3,-1,-1,-1,6958,-1,0.0030047526,0.9969952
6959,ziprasidone,5,6,42,53,Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment.,17366349_0,-1,-1,-1,6959,-1,0.9992518,0.00074821553
6960,NMS,4,5,32,35,Neuroleptic malignant syndrome (NMS) is the rarest and most serious of the neuroleptic-induced movement disorders.,17366349_1,-1,-1,-1,6960,-1,0.006206387,0.9937936
6961,movement disorders,15,17,95,113,Neuroleptic malignant syndrome (NMS) is the rarest and most serious of the neuroleptic-induced movement disorders.,17366349_1,-1,-1,-1,6961,-1,0.0024700137,0.99753004
6962,neuroleptic malignant syndrome,5,8,22,52,We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone.,17366349_2,-1,-1,-1,6962,-1,0.3012617,0.6987383
6963,NMS,9,10,54,57,We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone.,17366349_2,-1,-1,-1,6963,-1,0.004378851,0.99562114
6964,ziprasidone,16,17,86,97,We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone.,17366349_2,-1,-1,-1,6964,-1,0.99935836,0.0006416656
6965,neuroleptics,2,3,22,34,"Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ziprasidone may also be a cause.",17366349_3,-1,-1,-1,6965,-1,0.9981772,0.0018228934
6966,NMS,8,9,71,74,"Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ziprasidone may also be a cause.",17366349_3,-1,-1,-1,6966,-1,0.015566275,0.98443377
6967,antipsychotic drugs,11,13,85,104,"Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ziprasidone may also be a cause.",17366349_3,-1,-1,-1,6967,-1,0.9918852,0.008114878
6968,ziprasidone,14,15,110,121,"Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ziprasidone may also be a cause.",17366349_3,-1,-1,-1,6968,-1,0.99927574,0.000724281
6970,signs and symptoms,13,16,80,98,The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone.,17366349_4,-1,-1,-1,6970,-1,0.0045644473,0.99543554
6971,NMS,17,18,102,105,The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone.,17366349_4,-1,-1,-1,6971,-1,0.012204626,0.98779535
6972,ziprasidone,30,31,179,190,The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone.,17366349_4,-1,-1,-1,6972,-1,0.99925584,0.0007441999
6973,NMS,11,12,52,55,This case is the earliest (second day of treatment) NMS due to ziprasidone reported in the literature.,17366349_5,-1,-1,-1,6973,-1,0.046432562,0.95356745
6974,ziprasidone,14,15,63,74,This case is the earliest (second day of treatment) NMS due to ziprasidone reported in the literature.,17366349_5,-1,-1,-1,6974,-1,0.99923253,0.00076749653
6975,behavioral abnormalities,2,4,22,46,Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism.,17400887_0,-1,-1,-1,6975,-1,0.0031963033,0.99680364
6977,autism,13,14,110,116,Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism.,17400887_0,-1,-1,-1,6977,-1,0.006335456,0.9936645
6978,Autism,0,1,0,6,Autism is a neurodevelopmental disorder presenting before 3 years of age with deficits in communication and social skills and repetitive behaviors.,17400887_1,-1,-1,-1,6978,-1,0.008671107,0.99132884
6979,neurodevelopmental disorder,3,5,12,39,Autism is a neurodevelopmental disorder presenting before 3 years of age with deficits in communication and social skills and repetitive behaviors.,17400887_1,-1,-1,-1,6979,-1,0.0040273047,0.9959727
6980,deficits in communication and social skills,12,18,78,121,Autism is a neurodevelopmental disorder presenting before 3 years of age with deficits in communication and social skills and repetitive behaviors.,17400887_1,-1,-1,-1,6980,-1,0.013795691,0.9862044
6981,repetitive behaviors,19,21,126,146,Autism is a neurodevelopmental disorder presenting before 3 years of age with deficits in communication and social skills and repetitive behaviors.,17400887_1,-1,-1,-1,6981,-1,0.008778656,0.9912213
6982,autism,19,20,120,126,"In addition to genetic influences, recent studies suggest that prenatal drug or chemical exposures are risk factors for autism.",17400887_2,-1,-1,-1,6982,-1,0.0035762836,0.99642366
6984,preterm labor,8,10,57,70,"Terbutaline, a beta2-adrenoceptor agonist used to arrest preterm labor, has been associated with increased concordance for autism in dizygotic twins.",17400887_3,-1,-1,-1,6984,-1,0.004778473,0.99522156
6985,autism,18,19,123,129,"Terbutaline, a beta2-adrenoceptor agonist used to arrest preterm labor, has been associated with increased concordance for autism in dizygotic twins.",17400887_3,-1,-1,-1,6985,-1,0.004075522,0.9959245
6988,h,27,28,114,115,Newborn rats were given terbutaline (10 mg/kg) daily on postnatal days (PN) 2 to 5 or PN 11 to 14 and examined 24 h after the last dose and at PN 30.,17400887_5,-1,-1,-1,6988,-1,0.19601178,0.8039882
6992,startle,37,38,210,217,"In behavioral tests, animals treated with terbutaline on PN 2 to 5 showed consistent patterns of hyper-reactivity to novelty and aversive stimuli when assessed in a novel open field, as well as in the acoustic startle response test.",17400887_8,-1,-1,-1,6992,-1,0.026681395,0.97331864
6993,behavioral abnormalities,21,23,181,205,"Our findings indicate that beta2-adrenoceptor overstimulation during an early critical period results in microglial activation associated with innate neuroinflammatory pathways and behavioral abnormalities, similar to those described in autism.",17400887_9,-1,-1,-1,6993,-1,0.0042562457,0.9957437
6994,autism,29,30,237,243,"Our findings indicate that beta2-adrenoceptor overstimulation during an early critical period results in microglial activation associated with innate neuroinflammatory pathways and behavioral abnormalities, similar to those described in autism.",17400887_9,-1,-1,-1,6994,-1,0.0051323436,0.9948677
6995,autism spectrum disorders,13,16,103,128,This study provides a useful animal model for understanding the neuropathological processes underlying autism spectrum disorders.,17400887_10,-1,-1,-1,6995,-1,0.0038569386,0.99614304
6998,Pgp,6,7,48,51,Experiments with systemic administration of the Pgp substrate phenobarbital and the selective Pgp inhibitor tariquidar in TR(-) rats substantiated that Pgp is functional and compensates for the lack of MRP2 in the BBB.,17437408_11,-1,-1,-1,6998,-1,0.9933542,0.006645846
7000,tariquidar,14,15,108,118,Experiments with systemic administration of the Pgp substrate phenobarbital and the selective Pgp inhibitor tariquidar in TR(-) rats substantiated that Pgp is functional and compensates for the lack of MRP2 in the BBB.,17437408_11,-1,-1,-1,7000,-1,0.9994265,0.00057357125
7001,injury to the brain,10,14,67,86,"Because such a compensatory mechanism most likely occurs to reduce injury to the brain from cytotoxic compounds, the present data substantiate the concept that MRP2 performs a protective role in the BBB.",17437408_13,-1,-1,-1,7001,-1,0.014438546,0.98556143
7003,xanthine oxidase,2,4,8,24,Role of xanthine oxidase in dexamethasone-induced hypertension in rats.1.,17439425_0,-1,-1,-1,7003,-1,0.9988065,0.0011934902
7006,nitric oxide-redox,11,13,74,92,Glucocorticoid-induced hypertension (GC-HT) in the rat is associated with nitric oxide-redox imbalance.,17439425_1,-1,-1,-1,7006,-1,0.9923267,0.007673329
7007,xanthine,7,8,26,34,"2. We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT).",17439425_2,-1,-1,-1,7007,-1,0.9982917,0.0017083611
7008,reactive oxygen species,20,23,90,113,"2. We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT).",17439425_2,-1,-1,-1,7008,-1,0.926653,0.07334694
7012,allopurinol,21,22,114,125,"3. Thirty male Sprague-Dawley rats were divided randomly into four treatment groups: saline, dexamethasone (dex), allopurinol plus saline, and allopurinol plus dex.",17439425_3,-1,-1,-1,7012,-1,0.9991279,0.000872122
7013,allopurinol,26,27,143,154,"3. Thirty male Sprague-Dawley rats were divided randomly into four treatment groups: saline, dexamethasone (dex), allopurinol plus saline, and allopurinol plus dex.",17439425_3,-1,-1,-1,7013,-1,0.999086,0.000913932
7015,urate,13,14,73,78,"Thymus weight was used as a marker of glucocorticoid activity, and serum urate to assess XO inhibition.",17439425_5,-1,-1,-1,7015,-1,0.9984138,0.0015861441
7016,Dex increased SBP,0,3,0,17,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,-1,-1,-1,7016,-1,0.7027575,0.29724252
7017,P,15,16,45,46,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,-1,-1,-1,7017,-1,0.33903787,0.66096216
7018,decreased thymus (P < 0.001) and bodyweights,20,29,60,104,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,-1,-1,-1,7018,-1,0.10963742,0.89036256
7019,P,30,31,106,107,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,-1,-1,-1,7019,-1,0.3765703,0.62342966
7020,Allopurinol,0,1,0,11,Allopurinol decreased serum urate from 76 +/- 5 to 30 +/- 3 micromol/L (P < 0.001) in saline and from 84 +/- 13 to 28 +/- 2 micromol/L in dex-treated (P < 0.01) groups.,17439425_8,-1,-1,-1,7020,-1,0.9992768,0.0007232092
7021,urate,3,4,28,33,Allopurinol decreased serum urate from 76 +/- 5 to 30 +/- 3 micromol/L (P < 0.001) in saline and from 84 +/- 13 to 28 +/- 2 micromol/L in dex-treated (P < 0.01) groups.,17439425_8,-1,-1,-1,7021,-1,0.9972445,0.0027555525
7022,P,16,17,72,73,Allopurinol decreased serum urate from 76 +/- 5 to 30 +/- 3 micromol/L (P < 0.001) in saline and from 84 +/- 13 to 28 +/- 2 micromol/L in dex-treated (P < 0.01) groups.,17439425_8,-1,-1,-1,7022,-1,0.34234953,0.6576505
7023,P,37,38,151,152,Allopurinol decreased serum urate from 76 +/- 5 to 30 +/- 3 micromol/L (P < 0.001) in saline and from 84 +/- 13 to 28 +/- 2 micromol/L in dex-treated (P < 0.01) groups.,17439425_8,-1,-1,-1,7023,-1,0.26135746,0.7386425
7024,Allopurinol,2,3,3,14,6. Allopurinol did not prevent dex-HT.,17439425_9,-1,-1,-1,7024,-1,0.9991035,0.00089648477
7025,allopurinol,8,9,47,58,"This, together with our previous findings that allopurinol failed to prevent adrenocorticotrophic hormone induced hypertension, suggests that XO activity is not a major determinant of GC-HT in the rat.",17439425_10,-1,-1,-1,7025,-1,0.99921834,0.00078169425
7032,n,10,11,38,39,"At the end of the procedure, Group A (n = 20) had 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub-Tenon's space and Group B (n = 20) had the same combination injected into the anterior sub-Tenon's space.",17466854_4,-1,-1,-1,7032,-1,0.19736762,0.8026324
7035,n,37,38,175,176,"At the end of the procedure, Group A (n = 20) had 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub-Tenon's space and Group B (n = 20) had the same combination injected into the anterior sub-Tenon's space.",17466854_4,-1,-1,-1,7035,-1,0.19976357,0.8002364
7036,"nausea, vomiting",9,12,60,76,"Postoperatively, all patients were assessed for symptoms of nausea, vomiting, and headache.",17466854_5,-1,-1,-1,7036,-1,0.00679042,0.99320954
7038,postoperative emetic symptoms,8,11,44,73,"RESULTS: Sixty percent in Group A developed postoperative emetic symptoms, headache, or both; 1 patient in Group B developed symptoms.",17466854_7,-1,-1,-1,7038,-1,0.01677543,0.98322463
7045,iron dextran,1,3,11,23,Peripheral iron dextran induced degeneration of dopaminergic neurons in rat substantia nigra.,17490790_0,-1,-1,-1,7045,-1,0.9981079,0.0018921178
7046,degeneration of dopaminergic neurons,4,8,32,68,Peripheral iron dextran induced degeneration of dopaminergic neurons in rat substantia nigra.,17490790_0,-1,-1,-1,7046,-1,0.0052934014,0.9947066
7048,Parkinson's disease,11,14,70,89,Iron accumulation is considered to be involved in the pathogenesis of Parkinson's disease.,17490790_1,-1,-1,-1,7048,-1,0.0050471597,0.9949529
7049,iron overload,6,8,51,64,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,-1,7049,-1,0.52413666,0.47586337
7050,SN,17,18,119,121,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,-1,7050,-1,0.05014264,0.94985735
7053,degeneration of dopaminergic neurons,51,55,330,366,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,-1,7053,-1,0.007796838,0.9922031
7055,SN,61,62,401,403,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,-1,7055,-1,0.071659975,0.9283401
7056,iron dextran,63,65,407,419,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,-1,-1,-1,7056,-1,0.9912485,0.008751541
7057,iron dextran,5,7,36,48,The findings showed that peripheral iron dextran overload increased the iron staining positive cells and reduced the number of TH-immunoreactive neurons in the SN.,17490790_3,-1,-1,-1,7057,-1,0.9978694,0.0021306635
7059,SN,23,24,160,162,The findings showed that peripheral iron dextran overload increased the iron staining positive cells and reduced the number of TH-immunoreactive neurons in the SN.,17490790_3,-1,-1,-1,7059,-1,0.06585731,0.9341427
7061,iron dextran,5,7,38,50,"These results suggest that peripheral iron dextran can increase the iron level in the SN, where excessive iron causes the degeneration of dopaminergic neurons.",17490790_6,-1,-1,-1,7061,-1,0.9974974,0.0025025653
7063,SN,14,15,86,88,"These results suggest that peripheral iron dextran can increase the iron level in the SN, where excessive iron causes the degeneration of dopaminergic neurons.",17490790_6,-1,-1,-1,7063,-1,0.13091245,0.8690875
7065,degeneration of dopaminergic neurons,21,25,122,158,"These results suggest that peripheral iron dextran can increase the iron level in the SN, where excessive iron causes the degeneration of dopaminergic neurons.",17490790_6,-1,-1,-1,7065,-1,0.007846372,0.9921536
7066,iron overload,2,4,12,25,The chronic iron overload may be more destructive to dopaminergic neurons than the acute iron overload.,17490790_7,-1,-1,-1,7066,-1,0.69966894,0.30033103
7067,iron overload,14,16,89,102,The chronic iron overload may be more destructive to dopaminergic neurons than the acute iron overload.,17490790_7,-1,-1,-1,7067,-1,0.6049734,0.39502662
7079,myocardial ischemia,13,15,98,117,Assessment of a new non-invasive index of cardiac performance for detection of dobutamine-induced myocardial ischemia.,17491223_0,-1,-1,-1,7079,-1,0.0028569903,0.997143
7080,myocardial ischemia,11,13,91,110,BACKGROUND: Electrocardiography has a very low sensitivity in detecting dobutamine-induced myocardial ischemia.,17491223_1,-1,-1,-1,7080,-1,0.0029306083,0.9970694
7081,myocardial ischemia,36,38,217,236,"OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting dobutamine-induced myocardial ischemia, using Tc99m-Sestamibi single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia.",17491223_2,-1,-1,-1,7081,-1,0.00292448,0.99707556
7086,myocardial ischemia,34,36,208,227,"CONCLUSIONS: If ECG alone is used for specificity, the combination with dP/dtejc improved the sensitivity of the test and could be a cost-savings alternative to cardiac imaging or perfusion studies to detect myocardial ischemia, especially in patients unable to exercise.",17491223_9,-1,-1,-1,7086,-1,0.0033402515,0.99665976
7087,myocardial infarction,1,3,16,37,Cocaine-induced myocardial infarction: clinical observations and pathogenetic considerations.,1749407_0,-1,-1,-1,7087,-1,0.00247832,0.9975217
7092,atherosclerotic obstruction,6,8,40,67,"In other individuals with no underlying atherosclerotic obstruction, coronary occlusion may be due to spasm, thrombus, or both.",1749407_3,-1,-1,-1,7092,-1,0.0053219544,0.994678
7093,coronary occlusion,9,11,69,87,"In other individuals with no underlying atherosclerotic obstruction, coronary occlusion may be due to spasm, thrombus, or both.",1749407_3,-1,-1,-1,7093,-1,0.0074071917,0.99259275
7095,thrombus,17,18,109,117,"In other individuals with no underlying atherosclerotic obstruction, coronary occlusion may be due to spasm, thrombus, or both.",1749407_3,-1,-1,-1,7095,-1,0.0064984397,0.9935016
7101,delusional parasitosis,5,7,26,48,An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.,17511042_0,-1,-1,-1,7101,-1,0.002997119,0.9970029
7102,chronic hepatitis C,9,12,54,73,An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.,17511042_0,-1,-1,-1,7102,-1,0.005093957,0.99490607
7103,pegylated interferon alpha-2b,14,17,89,118,An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.,17511042_0,-1,-1,-1,7103,-1,0.9981311,0.0018689604
7105,chronic hepatitis C,3,6,20,39,"During treatment of chronic hepatitis C patients with interferon and ribavirin, a lot of side effects are described.",17511042_1,-1,-1,-1,7105,-1,0.0052883,0.99471176
7106,interferon,8,9,54,64,"During treatment of chronic hepatitis C patients with interferon and ribavirin, a lot of side effects are described.",17511042_1,-1,-1,-1,7106,-1,0.9980615,0.0019384853
7109,psychosis,6,7,33,42,A minority of patients evolve to psychosis.,17511042_3,-1,-1,-1,7109,-1,0.0026970974,0.9973029
7110,psychogenic parasitosis,10,12,42,65,"To the best of our knowledge, no cases of psychogenic parasitosis occurring during interferon therapy have been described in the literature.",17511042_4,-1,-1,-1,7110,-1,0.0024476768,0.99755234
7111,interferon,14,15,83,93,"To the best of our knowledge, no cases of psychogenic parasitosis occurring during interferon therapy have been described in the literature.",17511042_4,-1,-1,-1,7111,-1,0.99811244,0.001887545
7112,delusional parasitosis,8,10,47,69,We present a 49-year-old woman who developed a delusional parasitosis during treatment with pegylated interferon alpha-2b weekly and ribavirin.,17511042_5,-1,-1,-1,7112,-1,0.0030095407,0.99699044
7113,pegylated interferon alpha-2b,13,16,92,121,We present a 49-year-old woman who developed a delusional parasitosis during treatment with pegylated interferon alpha-2b weekly and ribavirin.,17511042_5,-1,-1,-1,7113,-1,0.9980731,0.0019268604
7115,pegylated interferon alpha-2b,6,9,46,75,All the complaints disappeared after stopping pegylated interferon alpha-2b and reappeared after restarting it.,17511042_8,-1,-1,-1,7115,-1,0.99816763,0.0018323822
7118,LID,3,4,27,30,L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.,17532790_1,-1,-1,-1,7118,-1,0.0040135933,0.9959864
7119,Parkinson's disease,13,16,79,98,L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.,17532790_1,-1,-1,-1,7119,-1,0.004895302,0.9951047
7120,PD,17,18,100,102,L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.,17532790_1,-1,-1,-1,7120,-1,0.003294017,0.99670595
7121,LID,14,15,73,76,"To this day, transcriptome analysis has been performed in a rat model of LID [Neurobiol. Dis., 17 (2004), 219] but information regarding the proteome is still lacking.",17532790_2,-1,-1,-1,7121,-1,0.02282887,0.9771712
7122,PD,25,26,170,172,"In the present study, we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6-hydroxydopamine-lesion rat model of PD treated with saline, L-DOPA or bromocriptine using two-dimensional difference gel electrophoresis and mass spectrometry (MS).",17532790_3,-1,-1,-1,7122,-1,0.0039337217,0.9960663
7124,MS,42,43,294,296,"In the present study, we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6-hydroxydopamine-lesion rat model of PD treated with saline, L-DOPA or bromocriptine using two-dimensional difference gel electrophoresis and mass spectrometry (MS).",17532790_3,-1,-1,-1,7124,-1,0.60897636,0.39102367
7125,LID,16,17,90,93,Rats treated with L-DOPA were allocated to two groups based on the presence or absence of LID.,17532790_4,-1,-1,-1,7125,-1,0.9888939,0.011106077
7126,MS,23,24,187,189,"Among the 2000 spots compared for statistical difference, 67 spots were significantly changed in abundance and identified using matrix-assisted laser desorption/ionization time-of-flight MS, atmospheric pressure matrix-assisted laser desorption/ionization and HPLC coupled tandem MS (LC/MS/MS).",17532790_5,-1,-1,-1,7126,-1,0.89116496,0.10883501
7127,LID,6,7,26,29,"Out of these 67 proteins, LID significantly changed the expression level of five proteins: alphabeta-crystalin, gamma-enolase, guanidoacetate methyltransferase, vinculin, and proteasome alpha-2 subunit.",17532790_6,-1,-1,-1,7127,-1,0.9701248,0.029875208
7128,LID,14,15,86,89,"In conclusion, this study provides new insights into the protein changes occurring in LID.",17532790_8,-1,-1,-1,7128,-1,0.08254125,0.9174588
7130,chronic kidney disease,21,24,144,166,Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease.,17562951_0,-1,-1,-1,7130,-1,0.0049998574,0.9950001
7131,contrast medium iopamidol,13,16,88,113,BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium iopamidol with that of the iso-osmolality contrast medium iodixanol in high-risk patients.,17562951_1,-1,-1,-1,7131,-1,0.9974131,0.0025868951
7132,contrast medium iodixanol,21,24,146,171,BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium iopamidol with that of the iso-osmolality contrast medium iodixanol in high-risk patients.,17562951_1,-1,-1,-1,7132,-1,0.99671894,0.003281016
7135,chronic kidney disease,22,25,137,159,"METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.",17562951_2,-1,-1,-1,7135,-1,0.004471474,0.9955285
7137,contrast volume,4,6,17,32,"In 414 patients, contrast volume, presence of diabetes mellitus, use of N-acetylcysteine, mean baseline SCr, and estimated glomerular filtration rate were comparable in the 2 groups.",17562951_6,-1,-1,-1,7137,-1,0.9885765,0.011423545
7138,diabetes mellitus,9,11,46,63,"In 414 patients, contrast volume, presence of diabetes mellitus, use of N-acetylcysteine, mean baseline SCr, and estimated glomerular filtration rate were comparable in the 2 groups.",17562951_6,-1,-1,-1,7138,-1,0.0051899003,0.9948101
7141,P=0.39,31,32,131,137,"SCr increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).",17562951_7,-1,-1,-1,7141,-1,0.276654,0.723346
7142,P=0.44,53,54,217,223,"SCr increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).",17562951_7,-1,-1,-1,7142,-1,0.25092813,0.7490719
7146,P=0.11,35,36,148,154,"In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).",17562951_8,-1,-1,-1,7146,-1,0.30967343,0.69032663
7147,P=0.37,55,56,226,232,"In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).",17562951_8,-1,-1,-1,7147,-1,0.27052113,0.7294789
7149,P=0.03,22,23,130,136,"Mean post-SCr increases were significantly less with iopamidol (all patients: 0.07 versus 0.12 mg/dL, 6.2 versus 10.6 micromol/L, P=0.03; patients with diabetes: 0.07 versus 0.16 mg/dL, 6.2 versus 14.1 micromol/L, P=0.01).",17562951_9,-1,-1,-1,7149,-1,0.27029303,0.729707
7151,P=0.01,38,39,214,220,"Mean post-SCr increases were significantly less with iopamidol (all patients: 0.07 versus 0.12 mg/dL, 6.2 versus 10.6 micromol/L, P=0.03; patients with diabetes: 0.07 versus 0.16 mg/dL, 6.2 versus 14.1 micromol/L, P=0.01).",17562951_9,-1,-1,-1,7151,-1,0.30586955,0.6941304
7155,diabetes mellitus,33,35,222,239,"CONCLUSIONS: The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.",17562951_10,-1,-1,-1,7155,-1,0.0025766948,0.9974233
7156,Hepatonecrosis,0,1,0,14,Hepatonecrosis and cholangitis related to long-term phenobarbital therapy: an autopsy report of two patients.,17574447_0,-1,-1,-1,7156,-1,0.00335932,0.9966407
7157,cholangitis,2,3,19,30,Hepatonecrosis and cholangitis related to long-term phenobarbital therapy: an autopsy report of two patients.,17574447_0,-1,-1,-1,7157,-1,0.0023127287,0.9976872
7160,PB,2,3,15,17,"Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.",17574447_1,-1,-1,-1,7160,-1,0.99779737,0.0022026678
7161,chronic liver disease,31,34,193,214,"Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.",17574447_1,-1,-1,-1,7161,-1,0.0024377957,0.99756217
7163,PB,15,16,82,84,"Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia.",17574447_2,-1,-1,-1,7163,-1,0.9977475,0.0022525094
7165,bronchopneumonia,31,32,161,177,"Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia.",17574447_2,-1,-1,-1,7165,-1,0.016899189,0.9831009
7167,PB,4,5,29,31,"Our findings illustrate that PB may be associated with chronic liver damage, which may lead to more serious and deleterious consequences.",17574447_5,-1,-1,-1,7167,-1,0.9969983,0.0030017074
7169,lead,15,16,87,91,"Our findings illustrate that PB may be associated with chronic liver damage, which may lead to more serious and deleterious consequences.",17574447_5,-1,-1,-1,7169,-1,0.022612216,0.97738785
7170,chronic hepatic enzyme dysfunction,17,21,118,152,"For this reason, each clinician should recognize this entity in the differential diagnosis of PB-related asymptomatic chronic hepatic enzyme dysfunction.",17574447_6,-1,-1,-1,7170,-1,0.013395597,0.9866044
7173,maltol,24,25,164,170,"To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid.",17600377_1,-1,-1,-1,7173,-1,0.99735534,0.0026447352
7174,cognitive decline,12,14,81,98,"In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats.",17600377_2,-1,-1,-1,7174,-1,0.0025370352,0.997463
7177,amyloid beta peptide(1-42),10,16,67,93,"Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2.",17600377_5,-1,-1,-1,7177,-1,0.9002702,0.09972973
7179,H2O2,19,20,108,112,"Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2.",17600377_5,-1,-1,-1,7179,-1,0.9924576,0.007542425
7181,reactive oxygen species,12,15,92,115,"We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation.",17600377_6,-1,-1,-1,7181,-1,0.9785574,0.021442562
7182,c,17,18,128,129,"We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation.",17600377_6,-1,-1,-1,7182,-1,0.99108446,0.008915571
7183,caspase 3,21,23,143,152,"We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation.",17600377_6,-1,-1,-1,7183,-1,0.91510236,0.084897675
7184,Alzheimer's disease,22,25,142,161,"Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.",17600377_7,-1,-1,-1,7184,-1,0.005475508,0.9945245
7185,neuronal death,31,33,199,213,"Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.",17600377_7,-1,-1,-1,7185,-1,0.002876884,0.99712306
7186,decline of cognitive function,35,39,230,259,"Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.",17600377_7,-1,-1,-1,7186,-1,0.0046641645,0.9953359
7189,dopaminergic terminal damage,11,14,85,113,Immunological activation has been proposed to play a role in methamphetamine-induced dopaminergic terminal damage.,17608141_1,-1,-1,-1,7189,-1,0.33504072,0.6649593
7191,dopamine neurotoxicity,23,25,170,192,"In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.",17608141_2,-1,-1,-1,7191,-1,0.26972258,0.7302775
7196,"3,4-dihydroxyphenylacetic acid",9,11,99,129,"Such systemic lipopolysaccharide treatment mitigated methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions in a dose-dependent manner.",17608141_4,-1,-1,-1,7196,-1,0.9970385,0.0029614992
7200,"3,4-dihydroxyphenylacetic acid",30,32,190,220,"As the most potent dose (1 mg/kg) of lipopolysaccharide was administered two weeks, one day before or after the methamphetamine dosing regimen, methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions remained unaltered.",17608141_5,-1,-1,-1,7200,-1,0.99672604,0.0032739206
7203,"dopamine and 3,4-dihydroxyphenylacetic acid",13,17,112,155,"Moreover, systemic lipopolysaccharide pretreatment (1 mg/kg) attenuated local methamphetamine infusion-produced dopamine and 3,4-dihydroxyphenylacetic acid depletions in the striatum, indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine.",17608141_6,-1,-1,-1,7203,-1,0.9972262,0.0027738253
7207,dopamine neurotoxicity,17,19,160,182,We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine-induced nigrostriatal dopamine neurotoxicity.,17608141_7,-1,-1,-1,7207,-1,0.2799936,0.7200064
7221,gold,5,6,39,43,"Considering that clozapine remains the gold standard in treatment of resistant psychosis, there is an urgent need to raise awareness among medical and paramedical staff involved in the care of these patients.",17612891_9,-1,-1,-1,7221,-1,0.5130603,0.48693976
7222,psychosis,11,12,79,88,"Considering that clozapine remains the gold standard in treatment of resistant psychosis, there is an urgent need to raise awareness among medical and paramedical staff involved in the care of these patients.",17612891_9,-1,-1,-1,7222,-1,0.0025955476,0.9974044
7225,acute renal failure,3,6,26,45,"Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.",17615423_0,-1,-1,-1,7225,-1,0.0025087919,0.99749124
7228,atazanavir,16,17,107,117,"Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.",17615423_0,-1,-1,-1,7228,-1,0.998877,0.0011230428
7231,atazanavir,16,17,89,99,"OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.",17615423_1,-1,-1,-1,7231,-1,0.99903655,0.00096348085
7233,acute renal failure,21,24,132,151,"OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.",17615423_1,-1,-1,-1,7233,-1,0.0023961563,0.99760383
7234,human immunodeficiency virus,8,11,52,80,"BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.",17615423_2,-1,-1,-1,7234,-1,0.8463748,0.15362519
7235,atrial fibrillation,12,14,82,101,"BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.",17615423_2,-1,-1,-1,7235,-1,0.035737183,0.9642628
7236,coronary artery disease,15,18,103,126,"BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.",17615423_2,-1,-1,-1,7236,-1,0.008042681,0.9919573
7237,hyperlipidemia,20,21,132,146,"BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.",17615423_2,-1,-1,-1,7237,-1,0.0049206517,0.9950793
7240,mg simvastatin,5,7,26,40,"The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously).",17615423_3,-1,-1,-1,7240,-1,0.9974612,0.0025387881
7242,mg,22,23,109,111,"The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously).",17615423_3,-1,-1,-1,7242,-1,0.97070676,0.029293256
7243,mg,30,31,139,141,"The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously).",17615423_3,-1,-1,-1,7243,-1,0.9691488,0.03085124
7244,mg atazanavir,41,43,185,198,"The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously).",17615423_3,-1,-1,-1,7244,-1,0.9958617,0.004138269
7245,creatine kinase,5,7,42,57,"Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase.",17615423_4,-1,-1,-1,7245,-1,0.9981488,0.001851269
7249,human immunodeficiency virus,8,11,43,71,"Simvastatin, amiodarone, and the patient's human immunodeficiency virus medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis.",17615423_5,-1,-1,-1,7249,-1,0.22449192,0.77550805
7250,creatine kinase,6,8,30,45,Nine days later the patient's creatine kinase had dropped to 1695 U/L and creatinine was 3.3 mg/dL. The patient was discharged and continued outpatient dialysis for 1 month until his renal function recovered.,17615423_6,-1,-1,-1,7250,-1,0.9979898,0.002010264
7256,atazanavir,2,3,15,25,Amiodarone and atazanavir are recognized CYP3A4 inhibitors.,17615423_9,-1,-1,-1,7256,-1,0.99904484,0.00095514295
7260,fluvastatin,14,15,88,99,"In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.",17615423_11,-1,-1,-1,7260,-1,0.99867827,0.0013216868
7261,rosuvastatin,17,18,105,117,"In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.",17615423_11,-1,-1,-1,7261,-1,0.9989998,0.0010002895
7262,atorvastatin,26,27,162,174,"In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.",17615423_11,-1,-1,-1,7262,-1,0.99888414,0.0011158468
7269,fluoroquinolone,3,4,16,31,"Levofloxacin, a fluoroquinolone, is one of the most commonly prescribed antibiotics in clinical practice and is effective against Gram-positive, Gram-negative, and atypical bacteria.",17639754_2,-1,-1,-1,7269,-1,0.99901485,0.0009850693
7281,cerebrovascular accident,6,8,54,78,"BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal methotrexate for childhood leukaemia.",17682013_1,-1,-1,-1,7281,-1,0.0022533208,0.99774665
7283,leukaemia,26,27,203,212,"BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal methotrexate for childhood leukaemia.",17682013_1,-1,-1,-1,7283,-1,0.0031427152,0.9968573
7284,cerebrovascular accidents,2,4,14,39,Patients with cerebrovascular accidents were excluded.,17682013_5,-1,-1,-1,7284,-1,0.0036347844,0.9963652
7288,carmofur,24,25,160,168,"RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.",17682013_6,-1,-1,-1,7288,-1,0.999196,0.0008040573
7290,lesions within the subcortical white matter of the,13,21,87,137,"Diffusion weighted imaging (DWI) of all patients revealed well demarcated hyperintense lesions within the subcortical white matter of the cerebral hemispheres and the corpus callosum, corresponding to areas of decreased proton diffusion on apparent diffusion coefficient (ADC) maps (available in 21/27 patients).",17682013_7,-1,-1,-1,7290,-1,0.051324215,0.9486758
7291,white matter abnormalities,13,16,94,120,"However, fluid attenuated inversion recovery (FLAIR) sequences frequently revealed persistent white matter abnormalities.",17682013_10,-1,-1,-1,7291,-1,0.00574791,0.9942521
7293,oedema,9,10,56,62,DWI findings in this cohort are indicative of cytotoxic oedema within cerebral white matter and lend support to an at least partially reversible metabolic derangement as the basis for this syndrome.,17682013_12,-1,-1,-1,7293,-1,0.003088265,0.9969118
7297,selective serotonin reuptake inhibitor antidepressant,5,10,27,80,RATIONALE: Fluoxetine is a selective serotonin reuptake inhibitor antidepressant widely used by pregnant women.,17702969_1,-1,-1,-1,7297,-1,0.99505275,0.004947251
7299,pulmonary hypertension syndrome,12,15,104,135,Epidemiological data suggest that fluoxetine exposure prenatally increases the prevalence of persistent pulmonary hypertension syndrome of the newborn.,17702969_2,-1,-1,-1,7299,-1,0.0027783713,0.9972216
7306,P,32,33,194,195,"As compared with controls, fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01).",17702969_7,-1,-1,-1,7306,-1,0.26222223,0.7377777
7307,P,46,47,263,264,"As compared with controls, fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01).",17702969_7,-1,-1,-1,7307,-1,0.22304407,0.7769559
7309,P,26,27,161,162,"Postnatal mortality was increased among experimental animals, and arterial oxygen saturation was 96 +/- 1% in 1-day-old control animals and significantly lower (P < 0.01) in fluoxetine-exposed pups (79 +/- 2%).",17702969_8,-1,-1,-1,7309,-1,0.30719492,0.69280505
7311,P,18,19,101,102,"In vitro, fluoxetine induced pulmonary arterial muscle contraction in fetal, but not adult, animals (P < 0.01) and reduced serotonin-induced contraction at both ages (P < 0.01).",17702969_9,-1,-1,-1,7311,-1,0.3099164,0.6900836
7312,P,30,31,167,168,"In vitro, fluoxetine induced pulmonary arterial muscle contraction in fetal, but not adult, animals (P < 0.01) and reduced serotonin-induced contraction at both ages (P < 0.01).",17702969_9,-1,-1,-1,7312,-1,0.24689831,0.75310165
7314,P,29,30,179,180,"After in utero exposure to a low fluoxetine concentration the pulmonary arterial smooth muscle cell proliferation rate was significantly increased in fetal, but not adult, cells (P < 0.01).",17702969_10,-1,-1,-1,7314,-1,0.367186,0.63281405
7315,contrast,3,4,16,24,"CONCLUSIONS: In contrast to the adult, fluoxetine exposure in utero induces pulmonary hypertension in the fetal rat as a result of a developmentally regulated increase in pulmonary vascular smooth muscle proliferation.",17702969_11,-1,-1,-1,7315,-1,0.11781459,0.88218546
7321,alcohol dependence,17,19,93,111,AIM: To report a case of optic and peripheral neuropathy after chronic use of disulfiram for alcohol dependence management.,17786501_1,-1,-1,-1,7321,-1,0.32756174,0.67243826
7322,loss of vision,8,11,51,65,RESULTS: A 57-year-old male presented with gradual loss of vision in both eyes with intermittent headaches for 2 months.,17786501_3,-1,-1,-1,7322,-1,0.007809266,0.9921908
7323,headaches,16,17,97,106,RESULTS: A 57-year-old male presented with gradual loss of vision in both eyes with intermittent headaches for 2 months.,17786501_3,-1,-1,-1,7323,-1,0.0031111906,0.9968888
7324,paraesthesia,4,5,22,34,He also complained of paraesthesia with numbness in both feet.,17786501_4,-1,-1,-1,7324,-1,0.003256629,0.9967434
7325,numbness,6,7,40,48,He also complained of paraesthesia with numbness in both feet.,17786501_4,-1,-1,-1,7325,-1,0.0030513913,0.99694866
7326,scotomata,6,7,56,65,Visual field testing confirmed bilateral central-caecal scotomata.,17786501_7,-1,-1,-1,7326,-1,0.0037237993,0.99627626
7328,alcohol dependence,6,8,34,52,He had been taking disulfiram for alcohol dependence for the preceding 3 years.,17786501_8,-1,-1,-1,7328,-1,0.32964745,0.6703525
7330,lead,2,3,27,31,Disulfiram discontinuation lead to an immediate symptomatic improvement.,17786501_9,-1,-1,-1,7330,-1,0.09628198,0.903718
7332,hepatitis B virus (HBV) infected,8,15,66,98,Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.,17854040_0,-1,-1,-1,7332,-1,0.032542404,0.9674576
7333,hepatitis B virus,8,11,66,83,This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.,17854040_1,-1,-1,-1,7333,-1,0.042528696,0.9574713
7334,human immunodeficiency virus,25,28,158,186,This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.,17854040_1,-1,-1,-1,7334,-1,0.2551651,0.7448349
7335,HBV infected,4,6,30,42,Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.,17854040_2,-1,-1,-1,7335,-1,0.063395135,0.93660486
7336,HBsAg,0,1,0,5,"HBsAg, anti-HBs, anti-HBc, and anti-HIV 1/2 were determined as part of routine diagnosis using Axsym assays (Abbott Laboratories, North Chicago, IL).",17854040_4,-1,-1,-1,7336,-1,0.9943011,0.005698975
7337,C,32,33,209,210,"Serum samples were PCR amplified with HBV reverse transcriptase (RT) primers, followed by direct sequencing across the tyrosine-methionine-aspartate-aspartate (YMDD) motif of the major catalytic region in the C domain of the HBV RT enzyme.",17854040_5,-1,-1,-1,7337,-1,0.79660535,0.2033946
7338,chronic hepatitis B,10,13,72,91,HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 HBV-HIV co-infected patients.,17854040_7,-1,-1,-1,7338,-1,0.007978773,0.99202126
7339,Rabbit syndrome,0,2,0,15,"Rabbit syndrome, antidepressant use, and cerebral perfusion SPECT scan findings.",1786266_0,-1,-1,-1,7339,-1,0.026007762,0.97399217
7341,rabbit syndrome,1,3,4,19,The rabbit syndrome is an extrapyramidal side effect associated with chronic neuroleptic therapy.,1786266_1,-1,-1,-1,7341,-1,0.010250068,0.98974997
7342,neuroleptic,11,12,77,88,The rabbit syndrome is an extrapyramidal side effect associated with chronic neuroleptic therapy.,1786266_1,-1,-1,-1,7342,-1,0.99901676,0.0009831932
7343,imipramine,8,9,47,57,"Its occurrence in a patient being treated with imipramine is described, representing the first reported case of this syndrome in conjunction with antidepressants.",1786266_2,-1,-1,-1,7343,-1,0.99950206,0.0004979722
7345,decreased basal ganglia perfusion,6,10,49,82,"Repeated cerebral perfusion SPECT scans revealed decreased basal ganglia perfusion while the movement disorder was present, and a return to normal perfusion when the rabbit syndrome resolved.",1786266_3,-1,-1,-1,7345,-1,0.1395842,0.86041576
7346,movement disorder,12,14,93,110,"Repeated cerebral perfusion SPECT scans revealed decreased basal ganglia perfusion while the movement disorder was present, and a return to normal perfusion when the rabbit syndrome resolved.",1786266_3,-1,-1,-1,7346,-1,0.00394281,0.99605715
7347,rabbit syndrome,25,27,166,181,"Repeated cerebral perfusion SPECT scans revealed decreased basal ganglia perfusion while the movement disorder was present, and a return to normal perfusion when the rabbit syndrome resolved.",1786266_3,-1,-1,-1,7347,-1,0.017968211,0.9820318
7349,cholesteryl ester,2,4,18,35,Estrogen prevents cholesteryl ester accumulation in macrophages induced by the HIV protease inhibitor ritonavir.,17879945_0,-1,-1,-1,7349,-1,0.99756026,0.0024397215
7350,HIV protease inhibitor ritonavir,10,14,79,111,Estrogen prevents cholesteryl ester accumulation in macrophages induced by the HIV protease inhibitor ritonavir.,17879945_0,-1,-1,-1,7350,-1,0.99424297,0.0057570194
7351,protease inhibitors,14,16,83,102,Individuals with HIV can now live long lives with drug therapy that often includes protease inhibitors such as ritonavir.,17879945_1,-1,-1,-1,7351,-1,0.9922397,0.00776022
7353,premature atherosclerosis,12,14,72,97,"Many patients, however, develop negative long-term side effects such as premature atherosclerosis.",17879945_2,-1,-1,-1,7353,-1,0.0032920828,0.9967079
7355,atherosclerotic lesion,8,10,67,89,We have previously demonstrated that ritonavir treatment increases atherosclerotic lesion formation in male mice to a greater extent than in female mice.,17879945_3,-1,-1,-1,7355,-1,0.003675047,0.99632496
7356,cholesteryl ester,11,13,89,106,"Furthermore, peripheral blood monocytes isolated from ritonavir-treated females had less cholesteryl ester accumulation.",17879945_4,-1,-1,-1,7356,-1,0.99785405,0.002145886
7358,HIV protease inhibitor ritonavir,24,28,160,192,"In the present study, we have investigated the molecular mechanisms by which female hormones influence cholesterol metabolism in macrophages in response to the HIV protease inhibitor ritonavir.",17879945_5,-1,-1,-1,7358,-1,0.9950552,0.0049447916
7359,h,7,8,42,43,"Briefly, cells were differentiated for 72 h with 100 nM PMA to obtain a macrophage-like phenotype in the presence or absence of 1 nM 17beta-estradiol (E2), 100 nM progesterone or vehicle (0.01% ethanol).",17879945_7,-1,-1,-1,7359,-1,0.06578436,0.9342156
7360,E2,27,28,151,153,"Briefly, cells were differentiated for 72 h with 100 nM PMA to obtain a macrophage-like phenotype in the presence or absence of 1 nM 17beta-estradiol (E2), 100 nM progesterone or vehicle (0.01% ethanol).",17879945_7,-1,-1,-1,7360,-1,0.99749255,0.0025074242
7364,h.,18,19,100,102,"Cells were then treated with 30 ng/ml ritonavir or vehicle in the presence of aggregated LDL for 24 h. Cell extracts were harvested, and lipid or total RNA was isolated.",17879945_8,-1,-1,-1,7364,-1,0.7678737,0.23212631
7365,Cell extracts,19,21,103,116,"Cells were then treated with 30 ng/ml ritonavir or vehicle in the presence of aggregated LDL for 24 h. Cell extracts were harvested, and lipid or total RNA was isolated.",17879945_8,-1,-1,-1,7365,-1,0.33466712,0.6653329
7366,E2,0,1,0,2,E2 decreased the accumulation of cholesteryl esters in macrophages following ritonavir treatment.,17879945_9,-1,-1,-1,7366,-1,0.99837446,0.0016255622
7367,cholesteryl esters,5,7,33,51,E2 decreased the accumulation of cholesteryl esters in macrophages following ritonavir treatment.,17879945_9,-1,-1,-1,7367,-1,0.9970099,0.0029901555
7371,E2,2,3,15,17,"Treatment with E2, however, failed to prevent these increases at the mRNA level.",17879945_12,-1,-1,-1,7371,-1,0.99778783,0.0022121451
7372,E2,0,1,0,2,"E2 did, however, significantly suppress CD36 protein levels as measured by fluorescent immunocytochemistry.",17879945_13,-1,-1,-1,7372,-1,0.9972535,0.0027465168
7373,E2,4,5,24,26,This data suggests that E2 modifies the expression of CD36 at the level of protein expression in monocyte-derived macrophages resulting in reduced cholesteryl ester accumulation following ritonavir treatment.,17879945_14,-1,-1,-1,7373,-1,0.9969428,0.003057151
7374,cholesteryl ester,22,24,147,164,This data suggests that E2 modifies the expression of CD36 at the level of protein expression in monocyte-derived macrophages resulting in reduced cholesteryl ester accumulation following ritonavir treatment.,17879945_14,-1,-1,-1,7374,-1,0.9984524,0.0015475227
7379,adverse drug reactions,16,19,98,120,"With widespread use of antimicrobial agents, however, hepatic injury occurs frequently, and among adverse drug reactions, idiosyncratic reactions are the most serious.",17919553_2,-1,-1,-1,7379,-1,0.02343011,0.97656983
7380,cm,13,14,63,65,"CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of jaundice, malaise, nausea, and vomiting.",17919553_3,-1,-1,-1,7380,-1,0.15132792,0.84867203
7381,Emergency Department,24,26,127,147,"CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of jaundice, malaise, nausea, and vomiting.",17919553_3,-1,-1,-1,7381,-1,0.026785472,0.9732145
7383,malaise,39,40,201,208,"CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of jaundice, malaise, nausea, and vomiting.",17919553_3,-1,-1,-1,7383,-1,0.003704626,0.9962954
7386,telithromycin 400,4,6,23,40,He had been prescribed telithromycin 400 mg/d PO to treat an upper respiratory tract infection 7 days prior.,17919553_4,-1,-1,-1,7386,-1,0.9981135,0.0018865105
7387,respiratory tract infection,12,15,67,94,He had been prescribed telithromycin 400 mg/d PO to treat an upper respiratory tract infection 7 days prior.,17919553_4,-1,-1,-1,7387,-1,0.004750252,0.99524975
7390,alkaline phosphatase,34,36,155,175,"Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20.1 mg/dL (0.2-1.0 mg/dL); direct bilirubin, 14.8 mg/dL (0-0.3 mg/dL); and albumin, 4.7 mg/dL (3.5-5.4 mg/dL).",17919553_5,-1,-1,-1,7390,-1,0.99327636,0.00672369
7394,acute hepatitis,9,11,48,63,"The patient had suffered a previous episode of ""acute hepatitis of unknown origin,"" that occurred after telithromycin usage.",17919553_7,-1,-1,-1,7394,-1,0.002691561,0.9973085
7397,hepatic dysfunction,10,12,69,88,It has been associated with infrequent and usually reversible severe hepatic dysfunction.,17919553_10,-1,-1,-1,7397,-1,0.0026298296,0.9973701
7398,adverse drug reaction,9,12,37,58,"Based on a score of 8 on the Naranjo adverse drug reaction probability scale, telithromycin was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis.",17919553_11,-1,-1,-1,7398,-1,0.0629059,0.93709415
7400,acute hepatitis,21,23,118,133,"Based on a score of 8 on the Naranjo adverse drug reaction probability scale, telithromycin was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis.",17919553_11,-1,-1,-1,7400,-1,0.002519868,0.9974801
7401,toxic hepatitis,32,34,200,215,"Based on a score of 8 on the Naranjo adverse drug reaction probability scale, telithromycin was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis.",17919553_11,-1,-1,-1,7401,-1,0.002506783,0.99749327
7404,acute hepatitis,8,10,37,52,CONCLUSION: Here we report a case of acute hepatitis probably associated with the administration of telithromycin.,17919553_13,-1,-1,-1,7404,-1,0.002361599,0.99763846
7406,uveitis,5,6,38,45,Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants.,17923537_0,-1,-1,-1,7406,-1,0.0027142148,0.99728584
7407,fluocinolone acetonide,8,10,59,81,Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants.,17923537_0,-1,-1,-1,7407,-1,0.9992194,0.00078059733
7408,elevated intraocular pressure,9,12,53,82,OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.,17923537_1,-1,-1,-1,7408,-1,0.101615645,0.89838433
7409,IOP,13,14,84,87,OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.,17923537_1,-1,-1,-1,7409,-1,0.43669167,0.56330836
7410,uveitis,18,19,106,113,OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.,17923537_1,-1,-1,-1,7410,-1,0.0025344626,0.9974655
7411,fluocinolone acetonide,22,24,131,153,OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.,17923537_1,-1,-1,-1,7411,-1,0.9992086,0.000791346
7412,FA,25,26,155,157,OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.,17923537_1,-1,-1,-1,7412,-1,0.99660563,0.0033944065
7413,FA,28,29,166,168,"DESIGN: Pooled data from 3 multicenter, double-masked, randomized, controlled, phase 2b/3 clinical trials evaluating the safety and efficacy of the 0.59-mg or 2.1-mg FA intravitreal implant or standard therapy were analyzed.",17923537_2,-1,-1,-1,7413,-1,0.99774504,0.0022549347
7414,mm Hg,18,20,88,93,"RESULTS: During the 3-year follow-up, 71.0% of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55.1%, 24.7%, and 6.2% of eyes reached an IOP of 30 mm Hg or more, 40 mm Hg or more, and 50 mm Hg or more, respectively.",17923537_3,-1,-1,-1,7414,-1,0.15997423,0.8400257
7415,mm Hg,41,43,172,177,"RESULTS: During the 3-year follow-up, 71.0% of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55.1%, 24.7%, and 6.2% of eyes reached an IOP of 30 mm Hg or more, 40 mm Hg or more, and 50 mm Hg or more, respectively.",17923537_3,-1,-1,-1,7415,-1,0.14062768,0.8593723
7416,mm Hg,47,49,190,195,"RESULTS: During the 3-year follow-up, 71.0% of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55.1%, 24.7%, and 6.2% of eyes reached an IOP of 30 mm Hg or more, 40 mm Hg or more, and 50 mm Hg or more, respectively.",17923537_3,-1,-1,-1,7416,-1,0.13172185,0.86827815
7417,mm Hg,54,56,212,217,"RESULTS: During the 3-year follow-up, 71.0% of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55.1%, 24.7%, and 6.2% of eyes reached an IOP of 30 mm Hg or more, 40 mm Hg or more, and 50 mm Hg or more, respectively.",17923537_3,-1,-1,-1,7417,-1,0.1069757,0.8930243
7418,mm Hg,14,16,93,98,Intraocular pressure-lowering surgeries were considered a success (postoperative IOP of 6-21 mm Hg with or without additional IOP-lowering medication) in 85.1% of eyes at 1 year.,17923537_5,-1,-1,-1,7418,-1,0.42666227,0.57333773
7419,hypotony,3,4,12,20,The rate of hypotony (IOP </= 5 mm Hg) following IOP-lowering surgery (42.5%) was not different from that of implanted eyes not subjected to surgery (35.4%) (P = .09).,17923537_6,-1,-1,-1,7419,-1,0.0021575913,0.99784243
7420,mm Hg,9,11,32,37,The rate of hypotony (IOP </= 5 mm Hg) following IOP-lowering surgery (42.5%) was not different from that of implanted eyes not subjected to surgery (35.4%) (P = .09).,17923537_6,-1,-1,-1,7420,-1,0.62304413,0.3769558
7421,P,36,37,158,159,The rate of hypotony (IOP </= 5 mm Hg) following IOP-lowering surgery (42.5%) was not different from that of implanted eyes not subjected to surgery (35.4%) (P = .09).,17923537_6,-1,-1,-1,7421,-1,0.2851531,0.7148469
7422,FA,10,11,64,66,CONCLUSION: Elevated IOP is a significant complication with the FA intravitreal implant but may be controlled with medication and surgery.,17923537_7,-1,-1,-1,7422,-1,0.99810684,0.0018931257
7451,DCM,5,6,36,39,"BACKGROUND: Dilated cardiomyopathy (DCM) and myocarditis occur in many HIV-infected individuals, resulting in symptomatic heart failure in up to 5% of patients.",17943461_1,-1,-1,-1,7451,-1,0.0031021421,0.9968978
7453,heart failure,18,20,122,135,"BACKGROUND: Dilated cardiomyopathy (DCM) and myocarditis occur in many HIV-infected individuals, resulting in symptomatic heart failure in up to 5% of patients.",17943461_1,-1,-1,-1,7453,-1,0.0028267778,0.9971732
7454,acquired immunodeficiency syndrome,14,17,98,132,"Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in cardiac and skeletal myopathies.",17943461_2,-1,-1,-1,7454,-1,0.005676635,0.9943234
7455,AIDS,18,19,134,138,"Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in cardiac and skeletal myopathies.",17943461_2,-1,-1,-1,7455,-1,0.0069265733,0.9930734
7456,cardiac and skeletal myopathies,28,32,176,207,"Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in cardiac and skeletal myopathies.",17943461_2,-1,-1,-1,7456,-1,0.0037351775,0.9962649
7458,"3'-azido-2',3'-deoxythymidine",14,15,85,114,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,-1,7458,-1,0.9956827,0.004317241
7459,AZT,16,17,116,119,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,-1,7459,-1,0.99794525,0.0020547211
7460,DCM,32,33,222,225,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,-1,7460,-1,0.0027011777,0.9972989
7461,Tg,45,46,296,298,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,-1,7461,-1,0.1221838,0.8778162
7462,NTg,50,51,320,323,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,-1,7462,-1,0.24708349,0.7529165
7463,ad,55,56,345,347,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,-1,7463,-1,0.7266241,0.27337593
7464,AZT,61,62,395,398,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,-1,-1,-1,7464,-1,0.9981792,0.0018208269
7465,NTg,0,1,0,3,NTg and untreated FasL Tg mice showed little or no change in cardiac structure or function.,17943461_5,-1,-1,-1,7465,-1,0.9979802,0.002019875
7466,Tg,4,5,23,25,NTg and untreated FasL Tg mice showed little or no change in cardiac structure or function.,17943461_5,-1,-1,-1,7466,-1,0.09006457,0.9099354
7467,contrast,1,2,3,11,"In contrast, AZT-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.",17943461_6,-1,-1,-1,7467,-1,0.08330121,0.9166988
7468,Tg,5,6,30,32,"In contrast, AZT-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.",17943461_6,-1,-1,-1,7468,-1,0.04674499,0.953255
7469,cardiac dilation,8,10,48,64,"In contrast, AZT-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.",17943461_6,-1,-1,-1,7469,-1,0.0030131652,0.9969868
7471,caspase 3,20,22,123,132,"These changes were associated with an increased sarcolemmal expression of Fas and FasL, as well as increased activation of caspase 3, translocation of calpain 1 to the sarcolemma and sarcomere, and increased numbers of cells undergoing apoptosis.",17943461_7,-1,-1,-1,7471,-1,0.95143753,0.048562415
7472,troponin I,9,11,61,71,"These were associated with changes in dystrophin and cardiac troponin I localization, as well as loss of sarcolemmal integrity.",17943461_8,-1,-1,-1,7472,-1,0.9946457,0.0053543397
7474,cardiac dilation,33,35,221,237,"CONCLUSIONS: The expression of Fas ligand in the myocardium, as identified in HIV-positive patients, might increase the susceptibility to HAART-induced cardiomyopathy due to activation of apoptotic pathways, resulting in cardiac dilation and dysfunction.",17943461_9,-1,-1,-1,7474,-1,0.0031296262,0.99687034
7475,dysfunction,36,37,242,253,"CONCLUSIONS: The expression of Fas ligand in the myocardium, as identified in HIV-positive patients, might increase the susceptibility to HAART-induced cardiomyopathy due to activation of apoptotic pathways, resulting in cardiac dilation and dysfunction.",17943461_9,-1,-1,-1,7475,-1,0.0026890812,0.997311
7476,etoricoxib,3,4,33,43,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,-1,-1,7476,-1,0.99908173,0.00091830746
7478,etoricoxib,12,13,93,103,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,-1,-1,7478,-1,0.99897027,0.0010297082
7479,diclofenac sodium,14,16,107,124,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,-1,-1,7479,-1,0.9989153,0.0010846633
7480,etoricoxib,41,42,307,317,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,-1,-1,7480,-1,0.99907994,0.0009200998
7483,RA,50,51,372,374,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,-1,-1,-1,7483,-1,0.0048171193,0.9951828
7484,RA,17,18,84,86,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,-1,-1,-1,7484,-1,0.0063330736,0.99366695
7485,etoricoxib,22,23,114,124,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,-1,-1,-1,7485,-1,0.99935025,0.00064977
7486,mg,24,25,128,130,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,-1,-1,-1,7486,-1,0.9779432,0.022056837
7487,n,27,28,138,139,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,-1,-1,-1,7487,-1,0.50376505,0.49623498
7489,mg,34,35,165,167,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,-1,-1,-1,7489,-1,0.95335776,0.046642277
7490,n,38,39,181,182,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,-1,-1,-1,7490,-1,0.43710065,0.56289935
7493,SD,4,5,15,17,"RESULTS: Mean (SD; maximum) duration of treatment was 19.3 (10.3; 32.9) and 19.1 (10.4; 33.1) months in the etoricoxib and diclofenac groups, respectively.",17965424_6,-1,-1,-1,7493,-1,0.20053081,0.7994692
7494,etoricoxib,28,29,108,118,"RESULTS: Mean (SD; maximum) duration of treatment was 19.3 (10.3; 32.9) and 19.1 (10.4; 33.1) months in the etoricoxib and diclofenac groups, respectively.",17965424_6,-1,-1,-1,7494,-1,0.99910647,0.00089350267
7496,GI AEs,6,8,43,49,"The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).",17965424_7,-1,-1,-1,7496,-1,0.003745397,0.99625456
7497,etoricoxib,12,13,79,89,"The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).",17965424_7,-1,-1,-1,7497,-1,0.9993311,0.0006688686
7499,p,38,39,201,202,"The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).",17965424_7,-1,-1,-1,7499,-1,0.30684966,0.69315034
7500,etoricoxib,13,14,113,123,The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).,17965424_8,-1,-1,-1,7500,-1,0.99930763,0.0006923318
7502,p<0.001,33,34,207,214,The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).,17965424_8,-1,-1,-1,7502,-1,0.42396146,0.5760386
7504,p<0.01,37,38,236,242,The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).,17965424_8,-1,-1,-1,7504,-1,0.35222033,0.64777964
7505,oedema,39,40,247,253,The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).,17965424_8,-1,-1,-1,7505,-1,0.0028217728,0.9971782
7507,PGADS,9,10,66,71,"Etoricoxib and diclofenac treatment resulted in similar efficacy (PGADS mean changes from baseline -0.62 vs -0.58, respectively).",17965424_9,-1,-1,-1,7507,-1,0.9444439,0.055556186
7508,Etoricoxib,2,3,13,23,CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.,17965424_10,-1,-1,-1,7508,-1,0.9992811,0.0007188541
7509,mg,4,5,27,29,CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.,17965424_10,-1,-1,-1,7509,-1,0.97506624,0.024933785
7510,GI AEs,15,17,105,111,CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.,17965424_10,-1,-1,-1,7510,-1,0.0033389213,0.99666107
7512,mg,21,22,141,143,CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.,17965424_10,-1,-1,-1,7512,-1,0.97949845,0.020501496
7513,GI AEs,11,13,88,94,"Discontinuations from renovascular AEs, although less common than discontinuations from GI AEs, were significantly higher with etoricoxib.",17965424_11,-1,-1,-1,7513,-1,0.0034858317,0.99651414
7514,etoricoxib,18,19,127,137,"Discontinuations from renovascular AEs, although less common than discontinuations from GI AEs, were significantly higher with etoricoxib.",17965424_11,-1,-1,-1,7514,-1,0.9991021,0.00089788757
7516,norfloxacin,5,6,42,53,Anxiogenic potential of ciprofloxacin and norfloxacin in rats.,17975693_0,-1,-1,-1,7516,-1,0.99911565,0.0008843468
7517,fluoroquinolones,7,8,49,65,"INTRODUCTION: The possible anxiogenic effects of fluoroquinolones, namely ciprofloxacin and norfloxacin, were investigated in adult Charles Foster albino rats of either sex, weighing 150-200 g. METHODS: The drugs were given orally, in doses of 50 mg/kg for five consecutive days and the experiments were performed on the fifth day.",17975693_1,-1,-1,-1,7517,-1,0.9991198,0.000880144
7519,norfloxacin,12,13,92,103,"INTRODUCTION: The possible anxiogenic effects of fluoroquinolones, namely ciprofloxacin and norfloxacin, were investigated in adult Charles Foster albino rats of either sex, weighing 150-200 g. METHODS: The drugs were given orally, in doses of 50 mg/kg for five consecutive days and the experiments were performed on the fifth day.",17975693_1,-1,-1,-1,7519,-1,0.99921966,0.00078028307
7520,anxious behaviour,11,13,86,103,RESULTS: The results indicate that ciprofloxacin- and norfloxacin-treated rats showed anxious behaviour in comparison to control rats in all the parameters studied.,17975693_3,-1,-1,-1,7520,-1,0.003002778,0.99699724
7522,norfloxacin,15,16,125,136,CONCLUSION: The present experimental findings substantiate the clinically observed anxiogenic potential of ciprofloxacin and norfloxacin.,17975693_5,-1,-1,-1,7522,-1,0.99917394,0.0008260392
7531,liver failure,16,18,92,105,CASE REPORT: We describe 2 patients who were regular consumers of alcohol and who developed liver failure within 3-5 days after hospitalization and stopping alcohol consumption while being treated with 4 g paracetamol/day.,18004067_2,-1,-1,-1,7531,-1,0.0022824144,0.9977176
7537,liver failure,14,16,80,93,"CONCLUSION: In patients with risk factors, e.g. regular consumption of alcohol, liver failure is possible when therapeutic doses are ingested.",18004067_5,-1,-1,-1,7537,-1,0.0026130218,0.997387
7542,remifentanil,9,10,71,83,Reduction of pain during induction with target-controlled propofol and remifentanil.,18006530_0,-1,-1,-1,7542,-1,0.99916196,0.0008381108
7547,remifentanil,11,12,75,87,We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used.,18006530_2,-1,-1,-1,7547,-1,0.9993113,0.0006886579
7549,Ce,17,18,124,126,"A prospective, randomized, double-blind, placebo-controlled trial was performed to determine the effect-site concentration (Ce) of remifentanil to prevent the pain without producing complications.",18006530_3,-1,-1,-1,7549,-1,0.98533535,0.014664612
7550,remifentanil,20,21,131,143,"A prospective, randomized, double-blind, placebo-controlled trial was performed to determine the effect-site concentration (Ce) of remifentanil to prevent the pain without producing complications.",18006530_3,-1,-1,-1,7550,-1,0.999308,0.00069205684
7552,remifentanil,21,22,122,134,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,-1,-1,-1,7552,-1,0.9992847,0.0007153313
7553,Ce,25,26,147,149,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,-1,-1,-1,7553,-1,0.9903189,0.009681109
7554,ng,28,29,155,157,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,-1,-1,-1,7554,-1,0.8658464,0.13415362
7555,ng,36,37,173,175,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,-1,-1,-1,7555,-1,0.7991933,0.20080672
7556,ng,45,46,194,196,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,-1,-1,-1,7556,-1,0.79608417,0.20391585
7557,Ce,3,4,17,19,"After the target Ce was achieved, the infusion of propofol was started.",18006530_5,-1,-1,-1,7557,-1,0.21174176,0.78825825
7559,remifentanil,6,7,60,72,"Remifentanil-related complications were assessed during the remifentanil infusion, and pain caused by propofol was evaluated using a four-point scale during the propofol infusion.",18006530_6,-1,-1,-1,7559,-1,0.9993043,0.00069565064
7564,P<0.001,32,33,159,166,"RESULTS: The incidence of pain was significantly lower in Groups R4 and R6 than in the control and R2 groups (12/32 and 6/31 vs 26/31 and 25/32, respectively, P<0.001).",18006530_7,-1,-1,-1,7564,-1,0.33426574,0.66573423
7566,P<0.001,17,18,76,83,Pain was less severe in Groups R4 and R6 than in the control and R2 groups (P<0.001).,18006530_8,-1,-1,-1,7566,-1,0.41109863,0.5889014
7569,remifentanil,11,12,70,82,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,-1,-1,-1,7569,-1,0.99926084,0.0007391146
7572,remifentanil,29,30,208,220,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,-1,-1,-1,7572,-1,0.9993082,0.00069177983
7573,Ce,33,34,233,235,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,-1,-1,-1,7573,-1,0.9928605,0.0071395435
7574,ng,36,37,241,243,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,-1,-1,-1,7574,-1,0.9348153,0.065184765
7577,SD,10,11,47,49,164 patients (mean age +/- standard deviation [SD] 81.6 +/- 6.8 years) were admitted.,18020536_3,-1,-1,-1,7577,-1,0.23450175,0.7654983
7578,n,6,7,23,24,"Of these, nearly half (n = 78)",18020536_4,-1,-1,-1,7578,-1,0.47598806,0.5240119
7579,n,10,11,55,56,"had used BZDs/RDs before admission, and the remainder (n = 86) were non-users.",18020536_5,-1,-1,-1,7579,-1,0.3410326,0.65896744
7580,n,12,13,60,61,Patients scoring > or =20 MMSE sum points were interviewed (n = 79) and questioned regarding symptoms and functional abilities during the week prior to admission.,18020536_7,-1,-1,-1,7580,-1,0.33845064,0.6615494
7581,oxazepam,5,6,37,45,"The residual serum concentrations of oxazepam, temazepam and zopiclone were analysed.",18020536_10,-1,-1,-1,7581,-1,0.9989458,0.0010542048
7582,temazepam,7,8,47,56,"The residual serum concentrations of oxazepam, temazepam and zopiclone were analysed.",18020536_10,-1,-1,-1,7582,-1,0.9989718,0.0010282192
7583,zopiclone,9,10,61,70,"The residual serum concentrations of oxazepam, temazepam and zopiclone were analysed.",18020536_10,-1,-1,-1,7583,-1,0.99900645,0.0009935247
7584,SD,6,7,22,24,RESULTS: The mean +/- SD duration of BZD/RD use was 7 +/- 7 years (range 1-31).,18020536_11,-1,-1,-1,7584,-1,0.27888927,0.72111076
7585,n,13,14,64,65,Two or three BZDs/RDs were concomitantly taken by 26% of users (n = 20).,18020536_12,-1,-1,-1,7585,-1,0.30189577,0.6981042
7588,inability to sleep,10,13,56,74,"However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay.",18020536_15,-1,-1,-1,7588,-1,0.014839302,0.9851607
7589,tiredness,18,19,102,111,"However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay.",18020536_15,-1,-1,-1,7589,-1,0.0048570256,0.99514294
7590,depressive symptoms,31,33,181,200,"However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay.",18020536_15,-1,-1,-1,7590,-1,0.0027912452,0.9972088
7591,temazepam,6,7,41,50,A higher residual serum concentration of temazepam correlated with a lower MMSE sum score after adjustment for confounding variables.,18020536_17,-1,-1,-1,7591,-1,0.9990742,0.0009258003
7592,acute illnesses,20,22,127,142,CONCLUSIONS: Long-term use and concomitant use of more than one BZD/RD were common in elderly patients hospitalised because of acute illnesses.,18020536_18,-1,-1,-1,7592,-1,0.0035664414,0.9964335
7593,vocal fold palsy,1,4,6,22,Acute vocal fold palsy after acute disulfiram intoxication.,18023325_0,-1,-1,-1,7593,-1,0.006950042,0.99305
7596,disulfiram overdose,6,8,40,59,Acute peripheral neuropathy caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy.,18023325_1,-1,-1,-1,7596,-1,0.83906233,0.16093767
7597,vocal fold palsy,20,23,113,129,Acute peripheral neuropathy caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy.,18023325_1,-1,-1,-1,7597,-1,0.015940141,0.9840598
7598,quadriparesis,10,11,65,78,"A 49-year-old woman was transferred to our department because of quadriparesis, lancinating pain, sensory loss, and paresthesia of the distal limbs.",18023325_2,-1,-1,-1,7598,-1,0.008735316,0.99126464
7600,sensory loss,15,17,98,110,"A 49-year-old woman was transferred to our department because of quadriparesis, lancinating pain, sensory loss, and paresthesia of the distal limbs.",18023325_2,-1,-1,-1,7600,-1,0.0033681314,0.9966319
7601,paresthesia,19,20,116,127,"A 49-year-old woman was transferred to our department because of quadriparesis, lancinating pain, sensory loss, and paresthesia of the distal limbs.",18023325_2,-1,-1,-1,7601,-1,0.0028339392,0.9971661
7605,giddiness,21,22,104,113,"For the first few days after ingestion, she was in a confused state and had mild to moderate ataxia and giddiness.",18023325_6,-1,-1,-1,7605,-1,0.0048231715,0.9951768
7609,palsy,6,7,25,30,This was a case of acute palsy of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal polyneuropathy caused by high-dose disulfiram intoxication.,18023325_12,-1,-1,-1,7609,-1,0.0027446707,0.9972554
7613,valproate,6,7,49,58,Encephalopathy induced by levetiracetam added to valproate.,18081909_0,-1,-1,-1,7613,-1,0.9989747,0.0010252841
7617,generalized seizures,10,12,68,88,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,-1,-1,7617,-1,0.002465811,0.99753416
7618,LEV,15,16,106,109,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,-1,-1,7618,-1,0.9987896,0.001210371
7619,mg,18,19,116,118,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,-1,-1,7619,-1,0.9707818,0.029218178
7620,valproate,22,23,129,138,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,-1,-1,7620,-1,0.99923,0.000769949
7621,VPA,24,25,140,143,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,-1,-1,7621,-1,0.9978288,0.0021712377
7622,mg,28,29,151,153,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,-1,-1,7622,-1,0.95940727,0.04059272
7624,"impaired word fluency, psychomotor speed and working memory",3,12,34,93,"Neuropsychological testing showed impaired word fluency, psychomotor speed and working memory.",18081909_4,-1,-1,-1,7624,-1,0.03182442,0.96817553
7625,LEV,5,6,38,41,"OUTCOME: Following discontinuation of LEV, EEG and neuropsychological findings improved and seizure frequency decreased.",18081909_6,-1,-1,-1,7625,-1,0.9984761,0.0015238726
7628,anxiety,11,12,105,112,Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaine-induced anxiety.,18083142_0,-1,-1,-1,7628,-1,0.0027556377,0.99724436
7632,anxiety,29,30,184,191,"While the mechanisms underlying cocaine's rewarding effects have been studied extensively, less attention has been paid to the unpleasant behavioral states induced by cocaine, such as anxiety.",18083142_2,-1,-1,-1,7632,-1,0.003791151,0.9962088
7635,NE,24,25,134,136,"METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety.",18083142_3,-1,-1,-1,7635,-1,0.99801266,0.001987341
7636,anxiety,44,45,245,252,"METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety.",18083142_3,-1,-1,-1,7636,-1,0.0029173472,0.99708265
7639,anxiety,1,2,16,23,"Cocaine-induced anxiety was also attenuated in Dbh +/- mice following administration of disulfiram, a dopamine beta-hydroxylase (DBH) inhibitor.",18083142_6,-1,-1,-1,7639,-1,0.0023149312,0.9976851
7642,adrenergic antagonists,4,6,30,52,"In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.",18083142_7,-1,-1,-1,7642,-1,0.98833793,0.011662103
7646,anxiety,15,16,127,134,CONCLUSIONS: These results indicate that noradrenergic signaling via beta-adrenergic receptors is required for cocaine-induced anxiety in mice.,18083142_8,-1,-1,-1,7646,-1,0.0025957772,0.99740416
7647,Dexmedetomidine,0,1,0,15,Dexmedetomidine and cardiac protection for non-cardiac surgery: a meta-analysis of randomised controlled trials.,18086064_0,-1,-1,-1,7647,-1,0.9991949,0.00080508494
7648,dexmedetomidine,9,10,51,66,We conducted a systematic review of the effects of dexmedetomidine on cardiac outcomes following non-cardiac surgery.,18086064_1,-1,-1,-1,7648,-1,0.99925405,0.0007459906
7649,dexmedetomidine,8,9,62,77,"We included prospective, randomised peri-operative studies of dexmedetomidine that reported mortality, cardiac morbidity or adverse drug events.",18086064_2,-1,-1,-1,7649,-1,0.99923646,0.0007634901
7650,Dexmedetomidine,0,1,0,15,"Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).",18086064_6,-1,-1,-1,7650,-1,0.99915564,0.000844401
7651,p,24,25,127,128,"Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).",18086064_6,-1,-1,-1,7651,-1,0.2525861,0.7474139
7652,myocardial infarction,30,32,148,169,"Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).",18086064_6,-1,-1,-1,7652,-1,0.002838729,0.99716127
7653,p,43,44,198,199,"Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).",18086064_6,-1,-1,-1,7653,-1,0.22759032,0.7724097
7654,myocardial ischaemia,49,51,213,233,"Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).",18086064_6,-1,-1,-1,7654,-1,0.00279477,0.9972052
7655,p,62,63,262,263,"Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).",18086064_6,-1,-1,-1,7655,-1,0.24423954,0.7557605
7657,p,16,17,60,61,"Peri-operative hypotension (26%, OR 3.80, 95% CI 1.91-7.54, p = 0.0001) and bradycardia (17%, OR 5.45, 95% CI 2.98-9.95, p < 0.00001) were significantly increased.",18086064_7,-1,-1,-1,7657,-1,0.25833428,0.7416657
7659,p,36,37,121,122,"Peri-operative hypotension (26%, OR 3.80, 95% CI 1.91-7.54, p = 0.0001) and bradycardia (17%, OR 5.45, 95% CI 2.98-9.95, p < 0.00001) were significantly increased.",18086064_7,-1,-1,-1,7659,-1,0.21434063,0.7856594
7661,p,10,11,64,65,An anticholinergic did not reduce the incidence of bradycardia (p = 0.43).,18086064_8,-1,-1,-1,7661,-1,0.40378165,0.5962183
7662,dexmedetomidine,5,6,41,56,A randomised placebo-controlled trial of dexmedetomidine is warranted.,18086064_9,-1,-1,-1,7662,-1,0.99922264,0.0007773631
7663,clomiphene citrate,6,8,51,69,Myocardial infarction in pregnancy associated with clomiphene citrate for ovulation induction: a case report.,18161408_0,-1,-1,-1,7663,-1,0.9991246,0.0008754348
7664,Clomiphene citrate,2,4,12,30,BACKGROUND: Clomiphene citrate (CC) is commonly prescribed for ovulation induction.,18161408_1,-1,-1,-1,7664,-1,0.99907124,0.0009286728
7665,CC,5,6,32,34,BACKGROUND: Clomiphene citrate (CC) is commonly prescribed for ovulation induction.,18161408_1,-1,-1,-1,7665,-1,0.9968599,0.0031401168
7666,Thromboembolism,0,1,0,15,Thromboembolism is a rare but life-threatening complication that has been reported after ovulation induction with CC.,18161408_3,-1,-1,-1,7666,-1,0.0026877644,0.9973123
7667,CC,15,16,114,116,Thromboembolism is a rare but life-threatening complication that has been reported after ovulation induction with CC.,18161408_3,-1,-1,-1,7667,-1,0.9975847,0.002415341
7669,thromboembolism,4,5,35,50,"Spontaneous coronary thrombosis or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction (MI) during pregnancy, with a subsequently normal coronary angiogram.",18161408_4,-1,-1,-1,7669,-1,0.0034247898,0.9965752
7670,myocardial infarction,20,22,133,154,"Spontaneous coronary thrombosis or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction (MI) during pregnancy, with a subsequently normal coronary angiogram.",18161408_4,-1,-1,-1,7670,-1,0.0028039974,0.99719596
7671,MI,23,24,156,158,"Spontaneous coronary thrombosis or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction (MI) during pregnancy, with a subsequently normal coronary angiogram.",18161408_4,-1,-1,-1,7671,-1,0.0037316617,0.99626833
7672,CC,12,13,72,74,CASE: A 33-year-old woman with a 5-week gestation had recently received CC for ovulation induction and presented with chest pain.,18161408_5,-1,-1,-1,7672,-1,0.9979311,0.0020688393
7673,chest pain,19,21,118,128,CASE: A 33-year-old woman with a 5-week gestation had recently received CC for ovulation induction and presented with chest pain.,18161408_5,-1,-1,-1,7673,-1,0.003514047,0.99648595
7674,myocardial infarction,8,10,56,77,An electrocardiogram showed a lateral and anterior wall myocardial infarction.,18161408_6,-1,-1,-1,7674,-1,0.0030155946,0.9969844
7675,troponin I,7,9,38,48,Cardiac enzymes showed a peak rise in troponin I to 9.10 ng/mL. An initial exercise stress test was normal.,18161408_7,-1,-1,-1,7675,-1,0.99369365,0.0063063423
7676,radiation injury,13,15,58,74,"At the time of admission, the patient was at high risk of radiation injury to the fetus, so a coronary angiogram was postponed until the second trimester.",18161408_8,-1,-1,-1,7676,-1,0.082248986,0.9177511
7677,CC,15,16,98,100,CONCLUSION: This appears to be the first reported case documenting a possible association between CC and myocardial infarction.,18161408_10,-1,-1,-1,7677,-1,0.98590523,0.014094784
7678,myocardial infarction,17,19,105,126,CONCLUSION: This appears to be the first reported case documenting a possible association between CC and myocardial infarction.,18161408_10,-1,-1,-1,7678,-1,0.0025917287,0.99740833
7679,CC,9,10,57,59,Thrombosis might be a rare but hazardous complication of CC.,18161408_11,-1,-1,-1,7679,-1,0.9075641,0.09243585
7680,ribonucleic acid,4,6,42,58,"Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol.",18162529_0,-1,-1,-1,7680,-1,0.98447937,0.015520622
7681,hyperprolactinemic,12,13,92,110,"Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol.",18162529_0,-1,-1,-1,7681,-1,0.32874358,0.6712565
7682,luteinizing hormone,16,18,135,154,"Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol.",18162529_0,-1,-1,-1,7682,-1,0.9976545,0.0023455021
7700,left ventricular apical ballooning syndrome,3,8,20,63,Reverse or inverted left ventricular apical ballooning syndrome (reverse Takotsubo cardiomyopathy) in a young woman in the setting of amphetamine use.,18177388_0,-1,-1,-1,7700,-1,0.019013982,0.98098606
7701,Takotsubo cardiomyopathy,10,12,73,97,Reverse or inverted left ventricular apical ballooning syndrome (reverse Takotsubo cardiomyopathy) in a young woman in the setting of amphetamine use.,18177388_0,-1,-1,-1,7701,-1,0.037329372,0.9626706
7703,Takotsubo cardiomyopathy,13,15,87,111,"Transient left ventricular apical ballooning syndrome was first described in Japan as ""Takotsubo cardiomyopathy."" This syndrome has been identified in many other countries.",18177388_1,-1,-1,-1,7703,-1,0.342369,0.657631
7704,akinesia,17,18,92,100,"One of the rarest is the reverse type of this syndrome, with hyperdynamic apex and complete akinesia of the base (as opposed to the classic apical ballooning).",18177388_3,-1,-1,-1,7704,-1,0.005029397,0.9949706
7705,apical ballooning,27,29,140,157,"One of the rarest is the reverse type of this syndrome, with hyperdynamic apex and complete akinesia of the base (as opposed to the classic apical ballooning).",18177388_3,-1,-1,-1,7705,-1,0.85617775,0.14382224
7706,apical ballooning syndrome,21,24,109,135,"In this article, we report an interesting case of a young woman who presented with this rare type of reverse apical ballooning syndrome occurring after amphetamine use.",18177388_4,-1,-1,-1,7706,-1,0.07727693,0.92272305
7711,ADHD,21,22,157,161,OBJECTIVE: To examine the safety and tolerability of clonidine used alone or with methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD).,18182964_2,-1,-1,-1,7711,-1,0.004021263,0.9959787
7712,ADHD,13,14,72,76,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,-1,-1,-1,7712,-1,0.004982383,0.9950176
7714,n,20,21,114,115,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,-1,-1,-1,7714,-1,0.30275616,0.69724387
7716,n,27,28,140,141,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,-1,-1,-1,7716,-1,0.2745311,0.7254689
7719,n,36,37,180,181,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,-1,-1,-1,7719,-1,0.29464194,0.7053581
7720,n,44,45,201,202,"METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).",18182964_3,-1,-1,-1,7720,-1,0.24939346,0.75060654
7726,p,27,28,152,153,"RESULTS: There were more incidents of bradycardia in subjects treated with clonidine compared with those not treated with clonidine (17.5% versus 3.4%; p =.02), but no other significant group differences regarding electrocardiogram and other cardiovascular outcomes.",18182964_6,-1,-1,-1,7726,-1,0.2260552,0.7739448
7730,p,19,20,97,98,Moderate or severe adverse events were more common in subjects on clonidine (79.4% versus 49.2%; p =.0006) but not associated with higher rates of early study withdrawal.,18182964_8,-1,-1,-1,7730,-1,0.3593815,0.6406185
7731,Drowsiness,0,1,0,10,"Drowsiness was common on clonidine, but generally resolved by 6 to 8 weeks.",18182964_9,-1,-1,-1,7731,-1,0.0024806052,0.9975193
7735,ADHD,17,18,105,109,"CONCLUSIONS: Clonidine, used alone or with methylphenidate, appears safe and well tolerated in childhood ADHD.",18182964_10,-1,-1,-1,7735,-1,0.0036778746,0.99632215
7738,drowsiness,16,17,121,131,Physicians prescribing clonidine should monitor for bradycardia and advise patients about the high likelihood of initial drowsiness.,18182964_11,-1,-1,-1,7738,-1,0.0024152626,0.9975847
7739,Fanconi syndrome,1,3,6,22,Renal Fanconi syndrome and myopathy after liver transplantation: drug-related mitochondrial cytopathy?Advances in the field of transplantation provide a better quality of life and allow more favorable conditions for growth and development in children.,18186898_0,-1,-1,-1,7739,-1,0.01883883,0.9811612
7741,Wilson's disease,12,15,81,97,We describe a 15-yr-old girl who had orthotopic liver transplantation because of Wilson's disease.,18186898_2,-1,-1,-1,7741,-1,0.008673197,0.99132675
7743,MMF,2,3,12,15,"Tacrolimus, MMF, and steroids were given as immunosuppressant.",18186898_3,-1,-1,-1,7743,-1,0.9984847,0.0015154018
7745,hepatitis B infection,7,10,40,61,Lamivudine was added because of de nova hepatitis B infection during her follow-up.,18186898_4,-1,-1,-1,7745,-1,0.011301263,0.98869866
7746,renal Fanconi syndrome,6,9,45,67,"Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and aminoaciduria.",18186898_5,-1,-1,-1,7746,-1,0.017034527,0.9829655
7748,hypophosphatemia,14,15,100,116,"Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and aminoaciduria.",18186898_5,-1,-1,-1,7748,-1,0.05268941,0.9473106
7750,aminoaciduria,19,20,134,147,"Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and aminoaciduria.",18186898_5,-1,-1,-1,7750,-1,0.71793765,0.28206238
7755,muscle weakness,1,3,9,24,Proximal muscle weakness has developed during her follow-up.,18186898_7,-1,-1,-1,7755,-1,0.0036729765,0.996327
7757,mitochondrial disorders,14,16,75,98,"Fanconi syndrome, as well as myopathy, is well recognized in patients with mitochondrial disorders and caused by depletion of mtDNA.",18186898_8,-1,-1,-1,7757,-1,0.0096125435,0.9903875
7758,tubular dysfunction,6,8,30,49,We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.,18186898_9,-1,-1,-1,7758,-1,0.0049723354,0.9950277
7763,telmisartan,28,29,172,183,"Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.",18201582_0,-1,-1,-1,7763,-1,0.999172,0.0008280989
7764,amlodipine,30,31,188,198,"Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.",18201582_0,-1,-1,-1,7764,-1,0.99903643,0.0009635354
7765,amlodipine,32,33,206,216,"Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.",18201582_0,-1,-1,-1,7765,-1,0.99898463,0.0010153082
7767,telmisartan,23,24,120,131,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,-1,-1,-1,7767,-1,0.99929476,0.0007052577
7768,mg,25,26,135,137,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,-1,-1,-1,7768,-1,0.98592025,0.014079777
7769,amlodipine,27,28,140,150,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,-1,-1,-1,7769,-1,0.9990928,0.00090723886
7770,mg,29,30,153,155,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,-1,-1,-1,7770,-1,0.9758159,0.024184138
7771,amlodipine,35,36,176,186,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,-1,-1,-1,7771,-1,0.99900275,0.0009972536
7774,FDC,5,6,32,35,Patients were treated with oral FDC of T+A or A QD before breakfast for 12 weeks; blood pressure (BP) and heart rate were measured in the sitting position.,18201582_3,-1,-1,-1,7774,-1,0.99855715,0.0014428633
7775,ie,26,27,146,148,"Primary efficacy end points were reduction in clinical systolic BP (SBP)/ diastolic BP (DBP) from baseline to study end and number of responders (ie, patients who achieved target SBP/ DBP <130/<80 mm Hg) at end of study.",18201582_4,-1,-1,-1,7775,-1,0.18963018,0.8103698
7776,mm Hg,36,38,197,202,"Primary efficacy end points were reduction in clinical systolic BP (SBP)/ diastolic BP (DBP) from baseline to study end and number of responders (ie, patients who achieved target SBP/ DBP <130/<80 mm Hg) at end of study.",18201582_4,-1,-1,-1,7776,-1,0.49942473,0.5005753
7777,P,50,51,198,199,"At study end, statistically significant percentage reductions from baseline within groups and between groups were observed in SBP (T+A [-27.4%]; A [-16.6%]) and DBP (T+A [-20.1%]; A [-13.3%]) (all, P < 0.05).",18201582_7,-1,-1,-1,7777,-1,0.1947846,0.8052154
7778,P,23,24,87,88,Response rates were 87.3% (89/102) in the T+A group and 69.3% (70/101) in the A group (P < 0.05).,18201582_8,-1,-1,-1,7778,-1,0.2009675,0.79903245
7780,cough,28,29,121,126,"Peripheral edema was reported in 8.5% patients (9/106) in the T+A group compared with 13.5% (14/104) in the A group, and cough was reported in 3.8% patients (4/106) in the T+A group and 1.0% (1/104) patients in the A group; these differences did not reach statistical significance.",18201582_10,-1,-1,-1,7780,-1,0.0029671155,0.9970329
7788,HIT,15,16,112,115,OBJECTIVES: To correlate optical density and percent inhibition of a two-step heparin-induced thrombocytopenia (HIT) antigen assay with thrombosis; the assay utilizes reaction inhibition characteristics of a high heparin concentration.,18208574_1,-1,-1,-1,7788,-1,0.022794312,0.97720563
7794,HIT,5,6,21,24,RESULTS: Forty of 94 HIT patients had thrombosis at diagnosis; 54/94 had isolated-HIT without thrombosis.,18208574_3,-1,-1,-1,7794,-1,0.008826907,0.9911731
7799,HIT,10,11,63,66,At diagnosis there was no significant difference in OD between HIT patients with thrombosis and those with isolated-HIT.,18208574_5,-1,-1,-1,7799,-1,0.022309355,0.97769064
7802,n,12,13,70,71,"However, OD was significantly higher in all patients with thrombosis (n = 48, 1.34 +/- 0.89), including isolated-HIT patients who later developed thrombosis within 30 d (n = 8, 1.84 +/- 0.64) as compared to isolated-HIT patients who did not develop thrombosis (0.96 +/- 0.75; P = 0.011 and P = 0.008).",18208574_6,-1,-1,-1,7802,-1,0.21764289,0.7823571
7804,n,33,34,170,171,"However, OD was significantly higher in all patients with thrombosis (n = 48, 1.34 +/- 0.89), including isolated-HIT patients who later developed thrombosis within 30 d (n = 8, 1.84 +/- 0.64) as compared to isolated-HIT patients who did not develop thrombosis (0.96 +/- 0.75; P = 0.011 and P = 0.008).",18208574_6,-1,-1,-1,7804,-1,0.17771335,0.8222866
7806,P,58,59,276,277,"However, OD was significantly higher in all patients with thrombosis (n = 48, 1.34 +/- 0.89), including isolated-HIT patients who later developed thrombosis within 30 d (n = 8, 1.84 +/- 0.64) as compared to isolated-HIT patients who did not develop thrombosis (0.96 +/- 0.75; P = 0.011 and P = 0.008).",18208574_6,-1,-1,-1,7806,-1,0.34524617,0.65475386
7807,P,62,63,290,291,"However, OD was significantly higher in all patients with thrombosis (n = 48, 1.34 +/- 0.89), including isolated-HIT patients who later developed thrombosis within 30 d (n = 8, 1.84 +/- 0.64) as compared to isolated-HIT patients who did not develop thrombosis (0.96 +/- 0.75; P = 0.011 and P = 0.008).",18208574_6,-1,-1,-1,7807,-1,0.30944252,0.6905575
7813,lymphomas,11,12,93,102,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,-1,-1,7813,-1,0.0030639323,0.9969361
7815,Leukemia,21,22,139,147,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,-1,-1,7815,-1,0.012351542,0.9876485
7816,multiple myeloma,32,34,227,243,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,-1,-1,7816,-1,0.004735551,0.9952644
7817,mantle cell lymphoma,35,38,245,265,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,-1,-1,7817,-1,0.0065403027,0.9934597
7818,lymphoplasmacytic lymphoma,39,41,270,296,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,-1,-1,7818,-1,0.004885081,0.9951149
7819,tumour,10,11,53,59,"Its activity is believed to be due modulation of the tumour milieu, including downregulation of angiogenesis and inflammatory cytokines.",18217897_1,-1,-1,-1,7819,-1,0.012011086,0.98798895
7820,lymphomas,12,13,80,89,"Between July 2001 and April 2004, 24 patients with relapsed/refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg daily every 1-2 weeks as tolerated, up to a maximum of 800 mg daily.",18217897_2,-1,-1,-1,7820,-1,0.0033402515,0.99665976
7822,mg,16,17,115,117,"Between July 2001 and April 2004, 24 patients with relapsed/refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg daily every 1-2 weeks as tolerated, up to a maximum of 800 mg daily.",18217897_2,-1,-1,-1,7822,-1,0.98814976,0.011850269
7823,mg,22,23,147,149,"Between July 2001 and April 2004, 24 patients with relapsed/refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg daily every 1-2 weeks as tolerated, up to a maximum of 800 mg daily.",18217897_2,-1,-1,-1,7823,-1,0.98349977,0.016500156
7824,mg,38,39,209,211,"Between July 2001 and April 2004, 24 patients with relapsed/refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg daily every 1-2 weeks as tolerated, up to a maximum of 800 mg daily.",18217897_2,-1,-1,-1,7824,-1,0.9744803,0.025519734
7828,dyspnea,16,17,104,111,"Grade 3-4 adverse effects included myelosuppression, fatigue, somnolence/depressed mood, neuropathy and dyspnea.",18217897_6,-1,-1,-1,7828,-1,0.003512156,0.99648786
7831,lymphomas,15,16,101,110,"Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide.",18217897_8,-1,-1,-1,7831,-1,0.0031452156,0.9968548
7832,contrast,17,18,115,123,"Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide.",18217897_8,-1,-1,-1,7832,-1,0.20368372,0.7963163
7833,lenalidomide,31,32,215,227,"Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide.",18217897_8,-1,-1,-1,7833,-1,0.99928576,0.00071422977
7834,NMDA,3,4,19,23,Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain.,18221780_0,-1,-1,-1,7834,-1,0.99848527,0.0015147836
7838,acute pain,22,24,146,156,Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain.,18221780_0,-1,-1,-1,7838,-1,0.005161489,0.99483854
7839,acute pain,1,3,3,13,"In acute pain models, N-methyl-D-aspartate (NMDA) antagonists enhance the antinociceptive effects of morphine to a greater extent in males than females.",18221780_1,-1,-1,-1,7839,-1,0.003725864,0.9962741
7840,NMDA,7,8,44,48,"In acute pain models, N-methyl-D-aspartate (NMDA) antagonists enhance the antinociceptive effects of morphine to a greater extent in males than females.",18221780_1,-1,-1,-1,7840,-1,0.9985851,0.0014149164
7843,acute pain,20,22,124,134,"The purpose of this investigation was to extend these findings to a persistent pain model which could be distinguished from acute pain models on the basis of the nociceptive fibers activated, neurochemical substrates, and duration of the nociceptive stimulus.",18221780_2,-1,-1,-1,7843,-1,0.004946387,0.9950536
7846,acute pain,8,10,44,54,"For comparison, tests were conducted in two acute pain models, the hotplate and warm water tail-withdrawal procedures.",18221780_4,-1,-1,-1,7846,-1,0.0048568896,0.9951432
7847,NMDA,5,6,30,34,"In males, the non-competitive NMDA antagonist dextromethorphan enhanced the antihyperalgesic effect of low to moderate doses of morphine in a dose-and time-dependent manner.",18221780_5,-1,-1,-1,7847,-1,0.9985728,0.0014271375
7848,dextromethorphan,7,8,46,62,"In males, the non-competitive NMDA antagonist dextromethorphan enhanced the antihyperalgesic effect of low to moderate doses of morphine in a dose-and time-dependent manner.",18221780_5,-1,-1,-1,7848,-1,0.99929917,0.0007008608
7851,dextromethorphan,5,6,43,59,"Enhancement of morphine antinociception by dextromethorphan was seen in both males and females in the acute pain models, with the magnitude of this effect being greater in males.",18221780_7,-1,-1,-1,7851,-1,0.99924845,0.00075150613
7852,acute pain,15,17,102,112,"Enhancement of morphine antinociception by dextromethorphan was seen in both males and females in the acute pain models, with the magnitude of this effect being greater in males.",18221780_7,-1,-1,-1,7852,-1,0.006069566,0.99393046
7853,NMDA,7,8,68,72,These findings demonstrate a sexually-dimorphic interaction between NMDA antagonists and morphine in a persistent pain model that can be distinguished from those observed in acute pain models.,18221780_8,-1,-1,-1,7853,-1,0.99882394,0.0011760386
7856,acute pain,24,26,174,184,These findings demonstrate a sexually-dimorphic interaction between NMDA antagonists and morphine in a persistent pain model that can be distinguished from those observed in acute pain models.,18221780_8,-1,-1,-1,7856,-1,0.0064670215,0.993533
7857,mental slowing,1,3,10,24,Increased mental slowing associated with the APOE epsilon4 allele after trihexyphenidyl oral anticholinergic challenge in healthy elderly.,18239197_0,-1,-1,-1,7857,-1,0.0029966417,0.9970034
7861,trihexyphenidyl-induced,32,33,228,251,OBJECTIVES: The objectives of this study were to examine the relationship between APOE epsilon4 and subjective effects of trihexyphenidyl on measures reflecting sedation and confusion and to investigate the relationship between trihexyphenidyl-induced subjective effects and objective memory performance.,18239197_1,-1,-1,-1,7861,-1,0.94634134,0.053658694
7862,blind,6,7,30,35,"This was a randomized, double blind, placebo-controlled, three-way, crossover experimental design.",18239197_3,-1,-1,-1,7862,-1,0.24858329,0.7514167
7863,mg,4,5,30,32,All participants received 1.0 mg or 2.0 mg trihexyphenidyl or placebo administered in counterbalanced sequences over a period of three consecutive weeks.,18239197_4,-1,-1,-1,7863,-1,0.9856026,0.014397302
7864,mg trihexyphenidyl,7,9,40,58,All participants received 1.0 mg or 2.0 mg trihexyphenidyl or placebo administered in counterbalanced sequences over a period of three consecutive weeks.,18239197_4,-1,-1,-1,7864,-1,0.99772424,0.0022757787
7866,mental slowness,14,16,91,106,RESULTS: A 2.0-mg oral dose of trihexyphenidyl resulted in increased subjective ratings of mental slowness in carriers of the APOE epsilon4 allele only.,18239197_6,-1,-1,-1,7866,-1,0.0037224514,0.9962775
7867,mg trihexyphenidyl,9,11,60,78,Drug effects as determined by difference scores between 2.0 mg trihexyphenidyl and placebo on ratings of mental slowness significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only.,18239197_7,-1,-1,-1,7867,-1,0.99773824,0.002261788
7868,mental slowness,16,18,105,120,Drug effects as determined by difference scores between 2.0 mg trihexyphenidyl and placebo on ratings of mental slowness significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only.,18239197_7,-1,-1,-1,7868,-1,0.00526358,0.9947364
7869,mental slowing,13,15,92,106,CONCLUSION: The epsilon4 allele in healthy elderly was associated with increased subjective mental slowing after trihexyphenidyl anticholinergic challenge.,18239197_9,-1,-1,-1,7869,-1,0.0036127332,0.99638724
7872,lead,3,4,34,38,Calcineurin-inhibitor therapy can lead to renal dysfunction in heart transplantation patients.,18261172_1,-1,-1,-1,7872,-1,0.015160345,0.9848396
7874,sirolmus,7,8,38,46,"The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.",18261172_2,-1,-1,-1,7874,-1,0.9992493,0.00075068016
7875,Srl,9,10,48,51,"The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.",18261172_2,-1,-1,-1,7875,-1,0.9979347,0.0020652607
7878,Srl,20,21,117,120,"The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.",18261172_2,-1,-1,-1,7878,-1,0.9977551,0.002244878
7880,Srl,10,11,73,76,"In cardiac transplantation, the incidence of proteinuria associated with Srl is unknown.",18261172_3,-1,-1,-1,7880,-1,0.9981673,0.0018326995
7882,mycophenolate mofetil,4,6,28,49,Concomitant IS consisted of mycophenolate mofetil +/- steroids.,18261172_5,-1,-1,-1,7882,-1,0.9989518,0.0010482316
7885,p,29,30,136,137,Proteinuria increased significantly from a median of 0.13 g/day (range 0-5.7) preswitch to 0.23 g/day (0-9.88) at 24 months postswitch (p = 0.0024).,18261172_6,-1,-1,-1,7885,-1,0.27781332,0.7221867
7887,p,24,25,114,115,"Before the switch, 11.5% of patients had high-grade proteinuria (>1.0 g/day); this increased to 22.9% postswitch (p = 0.006).",18261172_7,-1,-1,-1,7887,-1,0.23355427,0.76644576
7888,ACE inhibitor,0,2,0,13,ACE inhibitor and angiotensin-releasing blocker (ARB) therapy reduced proteinuria development.,18261172_8,-1,-1,-1,7888,-1,0.99750865,0.0024913729
7889,ARB,6,7,49,52,ACE inhibitor and angiotensin-releasing blocker (ARB) therapy reduced proteinuria development.,18261172_8,-1,-1,-1,7889,-1,0.9961242,0.0038758365
7892,p,13,14,81,82,"Patients without proteinuria had increased renal function (median 42.5 vs. 64.1, p = 0.25), whereas patients who developed high-grade proteinuria showed decreased renal function at the end of follow-up (median 39.6 vs. 29.2, p = 0.125).",18261172_9,-1,-1,-1,7892,-1,0.26887438,0.73112565
7894,decreased renal function,25,28,153,177,"Patients without proteinuria had increased renal function (median 42.5 vs. 64.1, p = 0.25), whereas patients who developed high-grade proteinuria showed decreased renal function at the end of follow-up (median 39.6 vs. 29.2, p = 0.125).",18261172_9,-1,-1,-1,7894,-1,0.005707644,0.9942924
7895,p,39,40,225,226,"Patients without proteinuria had increased renal function (median 42.5 vs. 64.1, p = 0.25), whereas patients who developed high-grade proteinuria showed decreased renal function at the end of follow-up (median 39.6 vs. 29.2, p = 0.125).",18261172_9,-1,-1,-1,7895,-1,0.21779795,0.782202
7897,Srl,12,13,77,80,"Thus, proteinuria may develop in cardiac transplant patients after switch to Srl, which may have an adverse effect on renal function in these patients.",18261172_10,-1,-1,-1,7897,-1,0.9985917,0.0014082004
7898,Srl,0,1,0,3,Srl should be used with ACEi/ARB therapy and patients monitored for proteinuria and increased renal dysfunction.,18261172_11,-1,-1,-1,7898,-1,0.99863535,0.0013646777
7900,impairment of learning,4,7,29,51,Ginsenoside Rg1 restores the impairment of learning induced by chronic morphine administration in rats.,18308784_0,-1,-1,-1,7900,-1,0.007557674,0.99244237
7902,ginsenoside,4,5,10,21,"Rg1, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial learning impairment.",18308784_1,-1,-1,-1,7902,-1,0.9976495,0.0023505567
7903,Panax ginseng,7,9,37,50,"Rg1, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial learning impairment.",18308784_1,-1,-1,-1,7903,-1,0.97931916,0.020680824
7904,learning impairment,13,15,77,96,"Rg1, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial learning impairment.",18308784_1,-1,-1,-1,7904,-1,0.0041533634,0.9958467
7905,Rg1,5,6,40,43,Previous studies have demonstrated that Rg1 might be a useful agent for the prevention and treatment of the adverse effects of morphine.,18308784_2,-1,-1,-1,7905,-1,0.99796677,0.002033279
7907,Rg1,11,12,55,58,The aim of this study was to investigate the effect of Rg1 on learning impairment by chronic morphine administration and the mechanism responsible for this effect.,18308784_3,-1,-1,-1,7907,-1,0.9964276,0.0035724316
7908,learning impairment,13,15,62,81,The aim of this study was to investigate the effect of Rg1 on learning impairment by chronic morphine administration and the mechanism responsible for this effect.,18308784_3,-1,-1,-1,7908,-1,0.003688743,0.99631125
7911,Rg1,23,24,114,117,"Male rats were subcutaneously injected with morphine (10 mg/kg) twice a day at 12 hour intervals for 10 days, and Rg1 (30 mg/kg) was intraperitoneally injected 2 hours after the second injection of morphine once a day for 10 days.",18308784_4,-1,-1,-1,7911,-1,0.99754035,0.002459641
7913,Rg1,14,15,98,101,"By implantation of electrodes and electrophysiological recording in vivo, the results showed that Rg1 restored the long-term potentiation (LTP) impaired by morphine in both freely moving and anaesthetised rats.",18308784_7,-1,-1,-1,7913,-1,0.9973007,0.002699317
7915,Rg1,7,8,56,59,"The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist MK801.",18308784_8,-1,-1,-1,7915,-1,0.99773407,0.0022659593
7917,NMDA,42,43,269,273,"The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist MK801.",18308784_8,-1,-1,-1,7917,-1,0.9973896,0.0026103882
7918,MK801,46,47,295,300,"The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist MK801.",18308784_8,-1,-1,-1,7918,-1,0.9975672,0.0024328912
7919,Rg1,3,4,17,20,We conclude that Rg1 may significantly improve the spatial learning capacity impaired by chonic morphine administration and restore the morphine-inhibited LTP.,18308784_9,-1,-1,-1,7919,-1,0.98715276,0.012847192
7921,NMDA,3,4,15,19,This effect is NMDA receptor dependent.,18308784_10,-1,-1,-1,7921,-1,0.99693596,0.0030640415
7925,Parkinson's disease,41,44,187,206,"SAR studies led to compound 14 with excellent potency (K(i) = 0.4 nM), selectivity (A(1)/A(2A) > 100), and efficacy (MED 10 mg/kg p.o.) in the rat haloperidol-induced catalepsy model for Parkinson's disease.",18329269_2,-1,-1,-1,7925,-1,0.0040663183,0.9959337
7931,antagonists,26,27,179,190,"In addition, the role of dopamine receptors in mediating nicotine-induced locomotor stimulation was investigated by examining the effects of selective D1 and D2 dopamine receptor antagonists on activity induced by nicotine.",1833784_3,-1,-1,-1,7931,-1,0.99368954,0.0063104467
7934,increase in locomotor activity,8,12,42,72,"Nicotine (1.0 mg/kg) caused a significant increase in locomotor activity in rats that were habituated to the test environment, but had only a weak and delayed stimulant action in rats that were unfamiliar with the test environment.",1833784_5,-1,-1,-1,7934,-1,0.008455465,0.9915446
7936,mecamylamine,12,13,81,93,"The stimulant action of nicotine was blocked by the central nicotinic antagonist mecamylamine but not by the peripheral nicotinic blocker hexamethonium, indicating that the response is probably mediated by central nicotinic receptors.",1833784_6,-1,-1,-1,7936,-1,0.99939847,0.0006014964
7939,SCH 23390,9,11,74,83,"Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.",1833784_7,-1,-1,-1,7939,-1,0.99874085,0.0012591418
7940,raclopride,16,17,113,123,"Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.",1833784_7,-1,-1,-1,7940,-1,0.99914455,0.0008554628
7941,fluphenazine,21,22,149,161,"Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.",1833784_7,-1,-1,-1,7941,-1,0.99928916,0.00071079703
7942,PHNO,5,6,33,37,"Pretreatment with the D2 agonist PHNO enhanced nicotine-induced hyperactivity, whereas the D1 agonist SKF 38393 had no effect.",1833784_8,-1,-1,-1,7942,-1,0.9985461,0.0014538773
7944,SKF 38393,14,16,102,111,"Pretreatment with the D2 agonist PHNO enhanced nicotine-induced hyperactivity, whereas the D1 agonist SKF 38393 had no effect.",1833784_8,-1,-1,-1,7944,-1,0.99714965,0.0028503228
7949,retinal vein occlusion,1,4,8,30,Central retinal vein occlusion associated with clomiphene-induced ovulation.,18343374_0,-1,-1,-1,7949,-1,0.0056033744,0.9943967
7950,retinal vein occlusion,8,11,39,61,OBJECTIVE: To report a case of central retinal vein occlusion associated with clomiphene citrate (CC).,18343374_1,-1,-1,-1,7950,-1,0.00332956,0.9966704
7951,clomiphene citrate,13,15,78,96,OBJECTIVE: To report a case of central retinal vein occlusion associated with clomiphene citrate (CC).,18343374_1,-1,-1,-1,7951,-1,0.9991973,0.0008027355
7952,CC,16,17,98,100,OBJECTIVE: To report a case of central retinal vein occlusion associated with clomiphene citrate (CC).,18343374_1,-1,-1,-1,7952,-1,0.9959716,0.0040283487
7953,infertility,8,9,50,61,PATIENT(S): A 36-year-old woman referred from the infertility clinic for blurred vision.,18343374_4,-1,-1,-1,7953,-1,0.015114918,0.9848851
7954,blurred vision,11,13,73,87,PATIENT(S): A 36-year-old woman referred from the infertility clinic for blurred vision.,18343374_4,-1,-1,-1,7954,-1,0.004614379,0.9953856
7955,CC,5,6,46,48,INTERVENTION(S): Ophthalmic examination after CC therapy.,18343374_5,-1,-1,-1,7955,-1,0.99696344,0.003036521
7956,retinal vein occlusion,5,8,33,55,MAIN OUTCOME MEASURE(S): Central retinal vein occlusion after ovulation induction with CC.,18343374_6,-1,-1,-1,7956,-1,0.017896239,0.98210377
7957,CC,12,13,87,89,MAIN OUTCOME MEASURE(S): Central retinal vein occlusion after ovulation induction with CC.,18343374_6,-1,-1,-1,7957,-1,0.9970239,0.0029761004
7958,retinal vein occlusion,8,11,57,79,RESULT(S): A 36-year-old Chinese woman developed central retinal vein occlusion after eight courses of CC.,18343374_7,-1,-1,-1,7958,-1,0.0038043205,0.9961957
7959,CC,15,16,103,105,RESULT(S): A 36-year-old Chinese woman developed central retinal vein occlusion after eight courses of CC.,18343374_7,-1,-1,-1,7959,-1,0.9964923,0.0035076176
7961,CC,10,11,66,68,"A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication, although mild visual disturbance after CC intake is not uncommon.",18343374_8,-1,-1,-1,7961,-1,0.99686533,0.0031346586
7962,visual disturbance,21,23,137,155,"A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication, although mild visual disturbance after CC intake is not uncommon.",18343374_8,-1,-1,-1,7962,-1,0.0027531702,0.99724686
7963,CC,24,25,162,164,"A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication, although mild visual disturbance after CC intake is not uncommon.",18343374_8,-1,-1,-1,7963,-1,0.9974942,0.0025057443
7964,retinal vein occlusion,10,13,58,80,CONCLUSION(S): This is the first reported case of central retinal vein occlusion after treatment with CC.,18343374_9,-1,-1,-1,7964,-1,0.005279891,0.9947201
7965,CC,16,17,102,104,CONCLUSION(S): This is the first reported case of central retinal vein occlusion after treatment with CC.,18343374_9,-1,-1,-1,7965,-1,0.99612564,0.0038743822
7966,infertility,6,7,39,50,"Extra caution is warranted in treating infertility patients with CC, and patients should be well informed of this side effect before commencement of therapy.",18343374_10,-1,-1,-1,7966,-1,0.0027366504,0.9972633
7967,CC,9,10,65,67,"Extra caution is warranted in treating infertility patients with CC, and patients should be well informed of this side effect before commencement of therapy.",18343374_10,-1,-1,-1,7967,-1,0.9871322,0.012867768
7968,ipratropium bromide,4,6,33,52,Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease.,1835291_0,-1,-1,-1,7968,-1,0.99897087,0.0010291704
7970,chronic obstructive pulmonary disease,9,13,73,110,Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease.,1835291_0,-1,-1,-1,7970,-1,0.003250192,0.9967499
7971,ipratropium bromide,8,10,47,66,"The bronchodilator effects of a single dose of ipratropium bromide aerosol (36 micrograms) and short-acting theophylline tablets (dose titrated to produce serum levels of 10-20 micrograms/mL) were compared in a double-blind, placebo-controlled crossover study in 21 patients with stable, chronic obstructive pulmonary disease.",1835291_1,-1,-1,-1,7971,-1,0.999148,0.000851973
7973,chronic obstructive pulmonary disease,47,51,288,325,"The bronchodilator effects of a single dose of ipratropium bromide aerosol (36 micrograms) and short-acting theophylline tablets (dose titrated to produce serum levels of 10-20 micrograms/mL) were compared in a double-blind, placebo-controlled crossover study in 21 patients with stable, chronic obstructive pulmonary disease.",1835291_1,-1,-1,-1,7973,-1,0.0031517465,0.9968483
7974,ipratropium,42,43,204,215,"Mean peak forced expiratory volume in 1 second (FEV1) increases over baseline and the proportion of patients attaining at least a 15% increase in the FEV1 (responders) were 31% and 90%, respectively, for ipratropium and 17% and 50%, respectively, for theophylline.",1835291_2,-1,-1,-1,7974,-1,0.999175,0.00082499534
7976,ipratropium,13,14,77,88,The average FEV1 increases during the 6-hour observation period were 18% for ipratropium and 8% for theophylline.,1835291_3,-1,-1,-1,7976,-1,0.99917537,0.0008246605
7978,ipratropium,9,10,47,58,The mean duration of action was 3.8 hours with ipratropium and 2.4 hours with theophylline.,1835291_4,-1,-1,-1,7978,-1,0.9992384,0.0007616143
7981,ipratropium,4,5,24,35,These results show that ipratropium is a more potent bronchodilator than oral theophylline in patients with chronic airflow obstruction.,1835291_6,-1,-1,-1,7981,-1,0.9993352,0.0006646898
7983,chronic airflow obstruction,16,19,108,135,These results show that ipratropium is a more potent bronchodilator than oral theophylline in patients with chronic airflow obstruction.,1835291_6,-1,-1,-1,7983,-1,0.006303776,0.9936963
7984,amikacin nephrotoxicity,3,5,17,40,An evaluation of amikacin nephrotoxicity in the hematology/oncology population.,18356633_0,-1,-1,-1,7984,-1,0.43453524,0.56546474
7987,febrile neutropenia,13,15,100,119,Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.,18356633_1,-1,-1,-1,7987,-1,0.0024458682,0.9975541
7996,P,22,23,129,130,"The occurrence of nephrotoxicity was similar between the conventional and extended-interval groups, at 10% and 5%, respectively (P = 1.00).",18356633_6,-1,-1,-1,7996,-1,0.2974223,0.7025777
7997,P,19,20,114,115,"Six patients in the conventional group had a positive culture, compared with none in the extended-interval group (P = 0.002).",18356633_7,-1,-1,-1,7997,-1,0.23289543,0.76710457
7999,dexmedetomidine,2,3,10,25,High dose dexmedetomidine as the sole sedative for pediatric MRI.OBJECTIVE: This large-scale retrospective review evaluates the sedation profile of dexmedetomidine.,18363626_0,-1,-1,-1,7999,-1,0.99924266,0.0007573467
8000,dexmedetomidine,20,21,148,163,High dose dexmedetomidine as the sole sedative for pediatric MRI.OBJECTIVE: This large-scale retrospective review evaluates the sedation profile of dexmedetomidine.,18363626_0,-1,-1,-1,8000,-1,0.9992562,0.00074377516
8001,dexmedetomidine,19,20,110,125,"AIM: To determine the hemodynamic responses, efficacy and adverse events associated with the use of high dose dexmedetomidine as the sole sedative for magnetic resonance imaging (MRI) studies.",18363626_1,-1,-1,-1,8001,-1,0.99926215,0.00073786196
8002,Dexmedetomidine,2,3,12,27,BACKGROUND: Dexmedetomidine has been used at our institution since 2005 to provide sedation for pediatric radiological imaging studies.,18363626_2,-1,-1,-1,8002,-1,0.999213,0.00078701664
8003,dexmedetomidine,9,10,53,68,"Over time, an effective protocol utilizing high dose dexmedetomidine as the sole sedative agent has evolved.",18363626_3,-1,-1,-1,8003,-1,0.99922144,0.0007785823
8004,dexmedetomidine,10,11,66,81,Data were analyzed from all 747 consecutive patients who received dexmedetomidine for MRI sedation from April 2005 to April 2007.,18363626_5,-1,-1,-1,8004,-1,0.9992254,0.0007746363
8005,dexmedetomidine,11,12,52,67,"RESULTS: Since 2005, the 10-min loading dose of our dexmedetomidine protocol increased from 2 to 3 microg.kg(-1), and the infusion rate increased from 1 to 1.5 to 2 microg.kg(-1).h(-1).",18363626_6,-1,-1,-1,8005,-1,0.9992506,0.00074933295
8006,dexmedetomidine,21,22,134,149,"The current sedation protocol progressively increased the rate of successful sedation (able to complete the imaging study) when using dexmedetomidine alone from 91.8% to 97.6% (P = 0.009), reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min (P < 0.001).",18363626_7,-1,-1,-1,8006,-1,0.99916804,0.00083201326
8007,P,30,31,177,178,"The current sedation protocol progressively increased the rate of successful sedation (able to complete the imaging study) when using dexmedetomidine alone from 91.8% to 97.6% (P = 0.009), reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min (P < 0.001).",18363626_7,-1,-1,-1,8007,-1,0.31793958,0.6820604
8009,dexmedetomidine,48,49,279,294,"The current sedation protocol progressively increased the rate of successful sedation (able to complete the imaging study) when using dexmedetomidine alone from 91.8% to 97.6% (P = 0.009), reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min (P < 0.001).",18363626_7,-1,-1,-1,8009,-1,0.9991535,0.0008464955
8010,P,60,61,349,350,"The current sedation protocol progressively increased the rate of successful sedation (able to complete the imaging study) when using dexmedetomidine alone from 91.8% to 97.6% (P = 0.009), reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min (P < 0.001).",18363626_7,-1,-1,-1,8010,-1,0.30255356,0.6974464
8011,dexmedetomidine,1,2,9,24,"Although dexmedetomidine sedation was associated with a 16% incidence of bradycardia, all concomitant mean arterial blood pressures were within 20% of age-adjusted normal range and oxygen saturations were 95% or higher.",18363626_8,-1,-1,-1,8011,-1,0.9991503,0.0008497573
8014,Dexmedetomidine,2,3,12,27,CONCLUSION: Dexmedetomidine in high doses provides adequate sedation for pediatric MRI studies.,18363626_9,-1,-1,-1,8014,-1,0.9992945,0.0007054365
8015,dexmedetomidine,5,6,23,38,"While use of high dose dexmedetomidine is associated with decreases in heart rate and blood pressure outside the established 'awake' norms, this deviation is generally within 20% of norms, and is not associated with adverse sequelae.",18363626_10,-1,-1,-1,8015,-1,0.999243,0.00075704296
8016,decreases,9,10,58,67,"While use of high dose dexmedetomidine is associated with decreases in heart rate and blood pressure outside the established 'awake' norms, this deviation is generally within 20% of norms, and is not associated with adverse sequelae.",18363626_10,-1,-1,-1,8016,-1,0.012393337,0.9876067
8017,Dexmedetomidine,0,1,0,15,Dexmedetomidine is useful as the sole sedative for pediatric MRI.,18363626_11,-1,-1,-1,8017,-1,0.9991892,0.000810835
8021,adverse drug reactions,6,9,46,68,BACKGROUND: Spontaneous reporting systems for adverse drug reactions (ADRs) are handicapped by under-reporting and limited detail on individual cases.,18405372_1,-1,-1,-1,8021,-1,0.012838721,0.9871612
8022,adverse drug reactions,10,13,65,87,We report an investigation from a local surveillance for serious adverse drug reactions associated with disease modifying anti-rheumatic drugs that was triggered by the occurrence of liver failure in two of our patients.,18405372_2,-1,-1,-1,8022,-1,0.02602173,0.9739783
8023,liver failure,26,28,183,196,We report an investigation from a local surveillance for serious adverse drug reactions associated with disease modifying anti-rheumatic drugs that was triggered by the occurrence of liver failure in two of our patients.,18405372_2,-1,-1,-1,8023,-1,0.0026609774,0.99733907
8024,ADR,3,4,17,20,METHODS: Serious ADR reports have been solicited from local clinicians by regular postcards over the past seven years.,18405372_3,-1,-1,-1,8024,-1,0.016894855,0.9831051
8027,ADR,15,16,85,88,"Patients', who had hepatotoxicity on sulfasalazine and met a definition of a serious ADR, were identified.",18405372_4,-1,-1,-1,8027,-1,0.0040601203,0.99593985
8030,hepatic failure,7,9,41,56,"Eight patients were hospitalised, two in hepatic failure - one died after a liver transplant.",18405372_8,-1,-1,-1,8030,-1,0.003552281,0.9964477
8031,skin rash,4,6,21,30,"Seven patients had a skin rash, three eosinophilia and one interstitial nephritis.",18405372_10,-1,-1,-1,8031,-1,0.0037363907,0.99626356
8041,METH,2,3,17,21,Methamphetamine (METH) damages dopamine (DA) nerve endings by a process that has been linked to microglial activation but the signaling pathways that mediate this response have not yet been delineated.,18410508_1,-1,-1,-1,8041,-1,0.9980165,0.001983524
8043,DA,7,8,41,43,Methamphetamine (METH) damages dopamine (DA) nerve endings by a process that has been linked to microglial activation but the signaling pathways that mediate this response have not yet been delineated.,18410508_1,-1,-1,-1,8043,-1,0.99703574,0.002964218
8044,neurodegeneration,22,23,130,147,"9 (2006), 917] recently identified the microglial-specific fractalkine receptor (CX3CR1) as an important mediator of MPTP-induced neurodegeneration of DA neurons.",18410508_3,-1,-1,-1,8044,-1,0.0025961762,0.9974038
8045,DA,24,25,151,153,"9 (2006), 917] recently identified the microglial-specific fractalkine receptor (CX3CR1) as an important mediator of MPTP-induced neurodegeneration of DA neurons.",18410508_3,-1,-1,-1,8045,-1,0.7122709,0.28772914
8046,CNS damage,2,4,12,22,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,-1,-1,-1,8046,-1,0.0027833963,0.9972166
8047,METH,6,7,33,37,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,-1,-1,-1,8047,-1,0.9986878,0.0013121726
8048,MPTP,8,9,42,46,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,-1,-1,-1,8048,-1,0.99878055,0.001219503
8049,DA,14,15,75,77,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,-1,-1,-1,8049,-1,0.9963651,0.0036349315
8052,METH,25,26,141,145,Mice in which the CX3CR1 gene has been deleted and replaced with a cDNA encoding enhanced green fluorescent protein (eGFP) were treated with METH and examined for striatal neurotoxicity.,18410508_5,-1,-1,-1,8052,-1,0.998312,0.00168799
8054,METH,0,1,0,4,"METH depleted DA, caused microglial activation, and increased body temperature in CX3CR1 knockout mice to the same extent and over the same time course seen in wild-type controls.",18410508_6,-1,-1,-1,8054,-1,0.9984274,0.0015726779
8055,DA,2,3,14,16,"METH depleted DA, caused microglial activation, and increased body temperature in CX3CR1 knockout mice to the same extent and over the same time course seen in wild-type controls.",18410508_6,-1,-1,-1,8055,-1,0.9981766,0.0018233862
8056,METH,3,4,15,19,The effects of METH in CX3CR1 knockout mice were not gender-dependent and did not extend beyond the striatum.,18410508_7,-1,-1,-1,8056,-1,0.9985428,0.001457265
8057,METH,9,10,83,87,Striatal microglia expressing eGFP constitutively show morphological changes after METH that are characteristic of activation.,18410508_8,-1,-1,-1,8057,-1,0.9977939,0.0022061362
8058,METH,22,23,152,156,This response was restricted to the striatum and contrasted sharply with unresponsive eGFP-microglia in surrounding brain areas that are not damaged by METH.,18410508_9,-1,-1,-1,8058,-1,0.9981958,0.0018042044
8059,METH neurotoxicity,11,13,71,89,We conclude from these studies that CX3CR1 signaling does not modulate METH neurotoxicity or microglial activation.,18410508_10,-1,-1,-1,8059,-1,0.28502297,0.714977
8060,METH,9,10,68,72,"Furthermore, it appears that striatal-resident microglia respond to METH with an activation cascade and then return to a surveying state without undergoing apoptosis or migration.",18410508_11,-1,-1,-1,8060,-1,0.998259,0.0017409596
8061,nystagmus,1,2,17,26,Nicotine-induced nystagmus correlates with midpontine activation.,18417364_0,-1,-1,-1,8061,-1,0.0023988043,0.9976012
8062,nystagmus,4,5,39,48,The pathomechanism of nicotine-induced nystagmus (NIN) is unknown.,18417364_1,-1,-1,-1,8062,-1,0.0029127628,0.9970873
8063,NIN,6,7,50,53,The pathomechanism of nicotine-induced nystagmus (NIN) is unknown.,18417364_1,-1,-1,-1,8063,-1,0.21262673,0.7873733
8064,NIN,14,15,77,80,The aim of this study was to delineate brain structures that are involved in NIN generation.,18417364_2,-1,-1,-1,8064,-1,0.97939223,0.020607816
8066,NIN,0,1,0,3,NIN correlated with blood oxygen level-dependent (BOLD) activity levels in a midpontine site in the posterior basis pontis.,18417364_4,-1,-1,-1,8066,-1,0.9461949,0.05380517
8068,pontis,19,20,116,122,NIN correlated with blood oxygen level-dependent (BOLD) activity levels in a midpontine site in the posterior basis pontis.,18417364_4,-1,-1,-1,8068,-1,0.026329782,0.9736702
8069,N-(2-propylpentanoyl)urea,3,4,17,42,Acute effects of N-(2-propylpentanoyl)urea on hippocampal amino acid neurotransmitters in pilocarpine-induced seizure in rats.,18439803_0,-1,-1,-1,8069,-1,0.9972343,0.0027657896
8076,GABA,29,30,182,186,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,-1,-1,-1,8076,-1,0.9975387,0.0024613228
8077,N-(2-propylpentanoyl)urea,32,33,191,216,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,-1,-1,-1,8077,-1,0.99688137,0.0031186221
8078,VPU,34,35,218,221,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,-1,-1,-1,8078,-1,0.9978288,0.0021711641
8079,valproic acid,43,45,261,274,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,-1,-1,-1,8079,-1,0.9979086,0.0020914944
8080,VPA,46,47,276,279,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,-1,-1,-1,8080,-1,0.9954423,0.0045576645
8081,VPU,0,1,0,3,"VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced seizure whereas the corresponding value for VPA was 322 mg/kg.",18439803_2,-1,-1,-1,8081,-1,0.9987729,0.0012270428
8082,VPA,5,6,25,28,"VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced seizure whereas the corresponding value for VPA was 322 mg/kg.",18439803_2,-1,-1,-1,8082,-1,0.99870205,0.0012979136
8084,VPA,30,31,179,182,"VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced seizure whereas the corresponding value for VPA was 322 mg/kg.",18439803_2,-1,-1,-1,8084,-1,0.99840504,0.001595006
8089,GABA,31,32,230,234,In vivo microdialysis demonstrated that an intraperitoneal administration of pilocarpine induced a pronounced increment of hippocampal glutamate and aspartate whereas no significant change was observed on the level of glycine and GABA.,18439803_3,-1,-1,-1,8089,-1,0.99859565,0.0014042779
8090,VPU,3,4,25,28,Pretreatment with either VPU (50 and 100 mg/kg) or VPA (300 and 600 mg/kg) completely abolished pilocarpine-evoked increases in extracellular glutamate and aspartate.,18439803_4,-1,-1,-1,8090,-1,0.9988642,0.001135885
8091,VPA,11,12,51,54,Pretreatment with either VPU (50 and 100 mg/kg) or VPA (300 and 600 mg/kg) completely abolished pilocarpine-evoked increases in extracellular glutamate and aspartate.,18439803_4,-1,-1,-1,8091,-1,0.998645,0.0013550331
8094,GABA,14,15,85,89,"In addition, a statistically significant reduction was also observed on the level of GABA and glycine but less than a drastic reduction of glutamate and aspartate level.",18439803_5,-1,-1,-1,8094,-1,0.9986254,0.0013746369
8098,VPU,5,6,26,29,Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.,18439803_6,-1,-1,-1,8098,-1,0.9986394,0.0013605476
8099,VPA,7,8,34,37,Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.,18439803_6,-1,-1,-1,8099,-1,0.9984205,0.0015794925
8104,VPA,3,4,16,19,"Therefore, like VPA, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced seizure in experimental animals.",18439803_7,-1,-1,-1,8104,-1,0.9979475,0.0020525265
8105,VPU,8,9,38,41,"Therefore, like VPA, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced seizure in experimental animals.",18439803_7,-1,-1,-1,8105,-1,0.9983845,0.0016155737
8109,atrioventricular block,1,3,9,31,Complete atrioventricular block secondary to lithium therapy.,18441470_0,-1,-1,-1,8109,-1,0.03005426,0.9699458
8111,Sinus node dysfunction,0,3,0,22,Sinus node dysfunction has been reported most frequently among the adverse cardiovascular effects of lithium.,18441470_1,-1,-1,-1,8111,-1,0.009969639,0.9900303
8113,atrioventricular,6,7,30,46,"In the present case, complete atrioventricular (AV) block with syncopal attacks developed secondary to lithium therapy, necessitating permanent pacemaker implantation.",18441470_2,-1,-1,-1,8113,-1,0.7680002,0.23199986
8114,atrioventricular (AV) block,6,11,30,57,"In the present case, complete atrioventricular (AV) block with syncopal attacks developed secondary to lithium therapy, necessitating permanent pacemaker implantation.",18441470_2,-1,-1,-1,8114,-1,0.096152514,0.9038475
8115,syncopal attacks,12,14,63,79,"In the present case, complete atrioventricular (AV) block with syncopal attacks developed secondary to lithium therapy, necessitating permanent pacemaker implantation.",18441470_2,-1,-1,-1,8115,-1,0.0023931037,0.9976069
8118,syncopal attacks,12,14,79,95,Serum lithium levels remained under or within the therapeutic range during the syncopal attacks.,18441470_3,-1,-1,-1,8118,-1,0.0029403768,0.99705964
8121,hemorrhagic ulcers,6,8,42,60,Protective effect of verapamil on gastric hemorrhagic ulcers in severe atherosclerotic rats.,18442015_0,-1,-1,-1,8121,-1,0.0026152036,0.99738485
8123,gastric hemorrhage,5,7,40,58,Studies concerning with pathogenesis of gastric hemorrhage and mucosal ulceration produced in atherosclerotic rats are lacking.,18442015_1,-1,-1,-1,8123,-1,0.0028921403,0.9971079
8126,peroxide,21,22,112,120,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,-1,-1,-1,8126,-1,0.996938,0.0030620047
8127,LPO,23,24,122,125,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,-1,-1,-1,8127,-1,0.99630666,0.0036933247
8128,gastric hemorrhage,32,34,191,209,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,-1,-1,-1,8128,-1,0.003326991,0.996673
8131,vitamin D2,44,46,280,290,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,-1,-1,-1,8131,-1,0.99747014,0.002529898
8135,corn oil,15,17,90,98,Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis.,18442015_4,-1,-1,-1,8135,-1,0.9965828,0.0034172628
8136,vitamin D2,18,20,110,120,Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis.,18442015_4,-1,-1,-1,8136,-1,0.9979309,0.0020691704
8139,corn oil,3,5,22,30,Control rats received corn oil only.,18442015_5,-1,-1,-1,8139,-1,0.9958865,0.004113509
8140,h,10,11,57,58,"After gastric surgery, rat stomachs were irrigated for 3 h with either simulated gastric juice or normal saline.",18442015_6,-1,-1,-1,8140,-1,0.21853425,0.7814657
8141,LPO,5,6,37,40,"Gastric acid back-diffusion, mucosal LPO generation, histamine concentration, microvascular permeability, luminal hemoglobin content and ulcer areas were determined.",18442015_7,-1,-1,-1,8141,-1,0.9876902,0.012309757
8148,gastric ulcers,1,3,7,21,"Severe gastric ulcers accompanied with increased ulcerogenic factors, including gastric acid back-diffusion, histamine release, LPO generation and luminal hemoglobin content were also observed in these rats.",18442015_9,-1,-1,-1,8148,-1,0.0024108838,0.9975891
8150,LPO,17,18,128,131,"Severe gastric ulcers accompanied with increased ulcerogenic factors, including gastric acid back-diffusion, histamine release, LPO generation and luminal hemoglobin content were also observed in these rats.",18442015_9,-1,-1,-1,8150,-1,0.99710566,0.0028943412
8152,gastric hemorrhage,8,10,49,67,"Moreover, a positive correlation of histamine to gastric hemorrhage and to ulcer was found in those atherosclerotic rats.",18442015_10,-1,-1,-1,8152,-1,0.0031920597,0.9968079
8155,hemorrhagic ulcer,1,3,5,22,This hemorrhagic ulcer and various ulcerogenic parameters were dose-dependently ameliorated by daily intragastric verapamil.,18442015_11,-1,-1,-1,8155,-1,0.0022209773,0.9977791
8158,gastric hemorrhagic ulcer,3,6,30,55,"Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.",18442015_12,-1,-1,-1,8158,-1,0.0031494533,0.99685055
8159,LPO,13,14,104,107,"Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.",18442015_12,-1,-1,-1,8159,-1,0.99575233,0.0042476878
8163,hepatitis B virus,5,8,33,50,Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.,18464113_0,-1,-1,-1,8163,-1,0.18071355,0.81928647
8164,HBSAG,14,15,96,101,Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.,18464113_0,-1,-1,-1,8164,-1,0.94430107,0.055698954
8166,Hepatitis B,0,2,0,11,Hepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.,18464113_1,-1,-1,-1,8166,-1,0.7050196,0.29498044
8167,chronic liver disease,13,16,54,75,Hepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.,18464113_1,-1,-1,-1,8167,-1,0.0032684337,0.9967315
8169,hepatic complication,11,13,62,82,Cancer patients who are chronic carriers of HBV have a higher hepatic complication rate while receiving cytotoxic chemotherapy (CT) and this has mainly been attributed to HBV reactivation.,18464113_2,-1,-1,-1,8169,-1,0.0030989628,0.99690104
8171,hematological malignancies,10,12,50,76,"In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.",18464113_3,-1,-1,-1,8171,-1,0.0035779083,0.9964222
8172,HBV infection,14,16,90,103,"In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.",18464113_3,-1,-1,-1,8172,-1,0.14870064,0.8512994
8176,lamivudin,2,3,17,26,The prophylactic lamivudin group consisted of 37 patients who received prophylactic lamivudine treatment.,18464113_6,-1,-1,-1,8176,-1,0.99920124,0.00079876464
8179,n=,5,6,22,24,"Of our control group (n= 50), 21 patients (42%) were established hepatitis.",18464113_10,-1,-1,-1,8179,-1,0.18524255,0.8147575
8184,p,21,22,109,110,In the prophylactic lamivudine group severe hepatitis were observed only in 1 patient (2.7%) of 37 patients (p < 0.006).,18464113_12,-1,-1,-1,8184,-1,0.37989652,0.6201034
8187,p,28,29,176,177,Comparison of the mean ALT values revealed significantly higher mean alanine aminotransferase (ALT) values in the control group than the prophylactic lamivudine group; 154:64 (p < 0.32).,18464113_13,-1,-1,-1,8187,-1,0.43744576,0.56255424
8190,nucleoside,9,10,61,71,Further studies are needed to determine the most appropriate nucleoside or nucleotide analogue for antiviral prophylaxis during CT and the optimal duration of administration after completion of CT.,18464113_15,-1,-1,-1,8190,-1,0.9979569,0.0020431275
8191,nucleotide,11,12,75,85,Further studies are needed to determine the most appropriate nucleoside or nucleotide analogue for antiviral prophylaxis during CT and the optimal duration of administration after completion of CT.,18464113_15,-1,-1,-1,8191,-1,0.9979115,0.0020884392
8198,h,42,43,223,224,A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type (WT) and VIP(-/-) mice with or without CYP-induced cystitis (150 mg/kg; i.p.; 48 h).,18483878_4,-1,-1,-1,8198,-1,0.0788823,0.9211177
8199,CYP,9,10,53,56,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8199,-1,0.99639976,0.0036002076
8200,h,13,14,71,72,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8200,-1,0.34128883,0.6587112
8201,CYP,20,21,99,102,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8201,-1,0.993507,0.0064929216
8202,h,24,25,117,118,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8202,-1,0.35779035,0.64220965
8203,CYP,37,38,169,172,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8203,-1,0.99473685,0.005263106
8204,h,41,42,187,188,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8204,-1,0.3011472,0.69885284
8205,CYP,47,48,211,214,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8205,-1,0.9922111,0.007788949
8206,h,51,52,229,230,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,-1,-1,-1,8206,-1,0.21324608,0.78675395
8207,p,19,20,95,96,The genes presented represent (1) greater than 1.5-fold change in either direction and (2) the p value is less than 0.05 for the comparison being made.,18483878_6,-1,-1,-1,8207,-1,0.38629282,0.6137072
8208,CYP,0,1,0,3,"CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",18483878_8,-1,-1,-1,8208,-1,0.99843365,0.0015663191
8209,p,4,5,29,30,"CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",18483878_8,-1,-1,-1,8209,-1,0.36877185,0.63122815
8210,CYP,34,35,173,176,"CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",18483878_8,-1,-1,-1,8210,-1,0.9984523,0.0015476422
8211,p,39,40,206,207,"CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",18483878_8,-1,-1,-1,8211,-1,0.2795216,0.72047836
8212,bladder inflammation,9,11,44,64,"The data suggest that in VIP(-/-) mice with bladder inflammation, inflammatory mediators are increased above that observed in WT with CYP.",18483878_9,-1,-1,-1,8212,-1,0.00389898,0.996101
8213,CYP,22,23,134,137,"The data suggest that in VIP(-/-) mice with bladder inflammation, inflammatory mediators are increased above that observed in WT with CYP.",18483878_9,-1,-1,-1,8213,-1,0.9980088,0.0019911977
8214,bladder dysfunction,8,10,50,69,This shift in balance may contribute to increased bladder dysfunction in VIP(-/-) mice with bladder inflammation and altered neurochemical expression in micturition pathways.,18483878_10,-1,-1,-1,8214,-1,0.0028951587,0.9971048
8215,bladder inflammation,15,17,92,112,This shift in balance may contribute to increased bladder dysfunction in VIP(-/-) mice with bladder inflammation and altered neurochemical expression in micturition pathways.,18483878_10,-1,-1,-1,8215,-1,0.0033830917,0.9966169
8216,Debrisoquine,0,1,0,12,Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers.,1848636_0,-1,-1,-1,8216,-1,0.99927753,0.0007224679
8222,hypokalemia,11,12,80,91,The drug effect studied was the antagonism by metoprolol of terbutaline-induced hypokalemia.,1848636_4,-1,-1,-1,8222,-1,0.002812125,0.9971879
8225,mg,4,5,21,23,Six EMs received 0.5 mg of terbutaline s.c. on two different occasions: 1) 1 hr after administration of a placebo and 2) 1 hr after 150 mg of metoprolol p.o.,1848636_6,-1,-1,-1,8225,-1,0.9740582,0.025941774
8227,mg,30,31,136,138,Six EMs received 0.5 mg of terbutaline s.c. on two different occasions: 1) 1 hr after administration of a placebo and 2) 1 hr after 150 mg of metoprolol p.o.,1848636_6,-1,-1,-1,8227,-1,0.975529,0.024471015
8230,mg,18,19,97,99,"Five PMs were studied according to the same protocol, except for a higher terbutaline dose (0.75 mg) on day 2.",1848636_7,-1,-1,-1,8230,-1,0.9776824,0.022317605
8239,ng.ml-1,20,21,105,112,"There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs (72 +/- 7 ng.ml-1) than EMs (42 +/- 8 ng.ml-1, P less than .001).(ABSTRACT TRUNCATED AT 250 WORDS)",1848636_11,-1,-1,-1,8239,-1,0.84566385,0.15433615
8240,ng.ml-1,29,30,133,140,"There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs (72 +/- 7 ng.ml-1) than EMs (42 +/- 8 ng.ml-1, P less than .001).(ABSTRACT TRUNCATED AT 250 WORDS)",1848636_11,-1,-1,-1,8240,-1,0.8206538,0.1793462
8241,P,31,32,142,143,"There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs (72 +/- 7 ng.ml-1) than EMs (42 +/- 8 ng.ml-1, P less than .001).(ABSTRACT TRUNCATED AT 250 WORDS)",1848636_11,-1,-1,-1,8241,-1,0.3177558,0.6822442
8242,brachial neuritis,3,5,34,51,Recovery of tacrolimus-associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient--case report and review of the literature.,18503483_0,-1,-1,-1,8242,-1,0.0026508346,0.99734914
8244,TAC,0,1,0,3,TAC has been shown to be a potent immunosuppressive agent for solid organ transplantation in pediatrics.,18503483_1,-1,-1,-1,8244,-1,0.9983531,0.0016469
8247,headaches,6,7,39,48,"It is characterized by encephalopathy, headaches, seizures, or neurological deficits.",18503483_3,-1,-1,-1,8247,-1,0.0035396465,0.9964604
8249,neurological deficits,11,13,63,84,"It is characterized by encephalopathy, headaches, seizures, or neurological deficits.",18503483_3,-1,-1,-1,8249,-1,0.0027224075,0.99727756
8250,myelitis,17,18,113,121,MRI demonstrated hyperintense T2 signals in the cervical cord and right brachial plexus roots indicative of both myelitis and right brachial plexitis.,18503483_5,-1,-1,-1,8250,-1,0.0022761358,0.9977239
8251,brachial plexitis,20,22,132,149,MRI demonstrated hyperintense T2 signals in the cervical cord and right brachial plexus roots indicative of both myelitis and right brachial plexitis.,18503483_5,-1,-1,-1,8251,-1,0.0057494314,0.99425054
8252,TAC,6,7,44,47,"Symptoms persisted for three months despite TAC dose reduction, administration of IVIG and four doses of methylprednisolone pulse therapy.",18503483_6,-1,-1,-1,8252,-1,0.997962,0.0020379645
8254,TAC,8,9,61,64,Improvement and eventually full recovery only occurred after TAC was completely discontinued and successfully replaced by everolimus.,18503483_7,-1,-1,-1,8254,-1,0.99845195,0.0015480313
8263,blood loss,10,12,83,93,Oxytocin-induced hypotension at cesarean delivery may be incorrectly attributed to blood loss.,18513945_4,-1,-1,-1,8263,-1,0.005357282,0.99464273
8268,puromycin aminonucleoside nephrosis,5,8,38,73,Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats.,18541230_0,-1,-1,-1,8268,-1,0.61175066,0.38824937
8269,coagulation factors,11,13,67,86,"We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.",18541230_1,-1,-1,-1,8269,-1,0.7636331,0.23636688
8271,nephrotic syndrome,28,30,186,204,"We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.",18541230_1,-1,-1,-1,8271,-1,0.0021072116,0.9978928
8272,puromycin aminonucleoside,23,25,119,144,Antithrombin (50 or 500 IU/kg/i.v.) was administered to rats once a day for 10 days immediately after the injection of puromycin aminonucleoside (50 mg/kg/i.v.).,18541230_2,-1,-1,-1,8272,-1,0.99873227,0.0012676783
8273,hematological abnormalities,7,9,77,104,Treatment with antithrombin attenuated the puromycin aminonucleoside-induced hematological abnormalities.,18541230_3,-1,-1,-1,8273,-1,0.0025545887,0.99744546
8275,hyperlipidemia,5,6,56,70,Puromycin aminonucleoside-induced renal dysfunction and hyperlipidemia were also suppressed.,18541230_4,-1,-1,-1,8275,-1,0.0024931203,0.9975069
8277,nephrotic syndrome,15,17,118,136,These findings suggest that thrombin plays an important role in the pathogenesis of puromycin aminonucleoside-induced nephrotic syndrome.,18541230_8,-1,-1,-1,8277,-1,0.0019393455,0.99806064
8278,nephrotic syndrome,10,12,73,91,Treatment with antithrombin may be clinically effective in patients with nephrotic syndrome.,18541230_9,-1,-1,-1,8278,-1,0.0025360011,0.99746394
8288,analgesia,17,18,97,106,"Fentanyl is a commonly used supplement that may contribute to this, although it may also improve analgesia.",18544179_2,-1,-1,-1,8288,-1,0.009209528,0.9907905
8289,postoperative nausea and vomiting,11,15,72,105,METHODS: This double-blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients.,18544179_3,-1,-1,-1,8289,-1,0.005814047,0.9941859
8291,h,21,22,131,132,METHODS: This double-blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients.,18544179_3,-1,-1,-1,8291,-1,0.27422836,0.72577167
8297,postoperative nausea and vomiting,12,16,70,103,"RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).",18544179_5,-1,-1,-1,8297,-1,0.004002751,0.9959973
8300,P,49,50,278,279,"RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).",18544179_5,-1,-1,-1,8300,-1,0.26121846,0.7387815
8301,P,14,15,61,62,Antiemetic requirements were reduced from 24% and 31% to 7% (P = 0.0012).,18544179_6,-1,-1,-1,8301,-1,0.29490885,0.7050911
8303,postoperative nausea and vomiting,11,15,72,105,Dexamethasone had no significant effect on the incidence or severity of postoperative nausea and vomiting.,18544179_7,-1,-1,-1,8303,-1,0.0046041757,0.99539584
8308,P,38,39,209,210,"Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).",18544179_8,-1,-1,-1,8308,-1,0.33228558,0.6677144
8309,P,42,43,223,224,"Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).",18544179_8,-1,-1,-1,8309,-1,0.3252906,0.6747094
8311,h,55,56,278,279,"Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).",18544179_8,-1,-1,-1,8311,-1,0.057606827,0.9423931
8312,P,65,66,311,312,"Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).",18544179_8,-1,-1,-1,8312,-1,0.2139583,0.7860417
8315,respiratory depression,13,15,102,124,"Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.",18544179_10,-1,-1,-1,8315,-1,0.004345719,0.9956542
8323,Parkinson's disease,6,9,40,59,Valvular heart disease in patients with Parkinson's disease treated with pergolide.,18560792_0,-1,-1,-1,8323,-1,0.006454368,0.9935456
8325,Parkinson's disease,9,12,65,84,Valvular heart abnormalities have been reported in patients with Parkinson's disease (PD) treated with pergolide.,18560792_2,-1,-1,-1,8325,-1,0.0050095054,0.9949905
8326,PD,13,14,86,88,Valvular heart abnormalities have been reported in patients with Parkinson's disease (PD) treated with pergolide.,18560792_2,-1,-1,-1,8326,-1,0.003594805,0.99640524
8328,valvular heart abnormality,9,12,54,80,OBJECTIVES: To estimate the frequency and severity of valvular heart abnormality and its possible reversibility after drug withdrawal in a case-control study.,18560792_4,-1,-1,-1,8328,-1,0.005755608,0.9942444
8329,PD,3,4,13,15,METHODS: All PD patients in the Amiens area treated with pergolide were invited to attend a cardiologic assessment including transthoracic echocardiography.,18560792_5,-1,-1,-1,8329,-1,0.0066309213,0.99336904
8331,PD,1,2,7,9,Thirty PD patients participated in the study.,18560792_6,-1,-1,-1,8331,-1,0.008530205,0.9914698
8333,n=10,16,17,97,101,A second echocardiography was performed (median interval: 13 months) after pergolide withdrawal (n=10 patients).,18560792_7,-1,-1,-1,8333,-1,0.31233278,0.6876672
8334,aortic regurgitation,6,8,31,51,"RESULTS: Compared to controls, aortic regurgitation (OR: 3.1; 95% IC: 1.1-8.8) and mitral regurgitation (OR: 10.7; 95% IC: 2.1-53) were more frequent in PD patients (tricuspid: NS).",18560792_9,-1,-1,-1,8334,-1,0.016552253,0.9834478
8336,PD,41,42,153,155,"RESULTS: Compared to controls, aortic regurgitation (OR: 3.1; 95% IC: 1.1-8.8) and mitral regurgitation (OR: 10.7; 95% IC: 2.1-53) were more frequent in PD patients (tricuspid: NS).",18560792_9,-1,-1,-1,8336,-1,0.015458046,0.984542
8337,NS,46,47,177,179,"RESULTS: Compared to controls, aortic regurgitation (OR: 3.1; 95% IC: 1.1-8.8) and mitral regurgitation (OR: 10.7; 95% IC: 2.1-53) were more frequent in PD patients (tricuspid: NS).",18560792_9,-1,-1,-1,8337,-1,0.18171094,0.81828904
8338,n=2.4+/-0.7,6,7,31,42,"The number of affected valves (n=2.4+/-0.7) and the sum of regurgitation grades (n=2.8+/-1.09) were higher (p=0.008 and p=0.006, respectively) in the pergolide group.",18560792_10,-1,-1,-1,8338,-1,0.22159457,0.7784054
8339,n=2.8+/-1.09,15,16,81,93,"The number of affected valves (n=2.4+/-0.7) and the sum of regurgitation grades (n=2.8+/-1.09) were higher (p=0.008 and p=0.006, respectively) in the pergolide group.",18560792_10,-1,-1,-1,8339,-1,0.36303538,0.6369647
8340,p=0.008,20,21,108,115,"The number of affected valves (n=2.4+/-0.7) and the sum of regurgitation grades (n=2.8+/-1.09) were higher (p=0.008 and p=0.006, respectively) in the pergolide group.",18560792_10,-1,-1,-1,8340,-1,0.4818473,0.5181528
8341,p=0.006,22,23,120,127,"The number of affected valves (n=2.4+/-0.7) and the sum of regurgitation grades (n=2.8+/-1.09) were higher (p=0.008 and p=0.006, respectively) in the pergolide group.",18560792_10,-1,-1,-1,8341,-1,0.3445861,0.65541387
8344,valvular regurgitation,4,6,25,47,"A restrictive pattern of valvular regurgitation, suggestive of the role of pergolide, was observed in 12/30 (40%) patients including two with heart failure.",18560792_12,-1,-1,-1,8344,-1,0.0039032567,0.9960968
8346,heart failure,26,28,142,155,"A restrictive pattern of valvular regurgitation, suggestive of the role of pergolide, was observed in 12/30 (40%) patients including two with heart failure.",18560792_12,-1,-1,-1,8346,-1,0.0025971308,0.99740285
8348,p=0.01,18,19,113,119,"Pergolide was discontinued in 10 patients with valvular heart disease, resulting in a lower regurgitation grade (p=0.01) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination.",18560792_13,-1,-1,-1,8348,-1,0.46045277,0.53954726
8349,heart failure,30,32,192,205,"Pergolide was discontinued in 10 patients with valvular heart disease, resulting in a lower regurgitation grade (p=0.01) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination.",18560792_13,-1,-1,-1,8349,-1,0.0026353374,0.9973647
8350,valve regurgitation,8,10,54,73,This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.,18560792_14,-1,-1,-1,8350,-1,0.004452246,0.9955478
8351,PD,11,12,77,79,This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.,18560792_14,-1,-1,-1,8351,-1,0.009822738,0.9901772
8353,dopamine agonists,31,33,209,226,This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.,18560792_14,-1,-1,-1,8353,-1,0.997623,0.0023769406
8355,Unfractionated heparin sodium,2,5,12,41,BACKGROUND: Unfractionated heparin sodium (UFH) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.,18589141_1,-1,-1,-1,8355,-1,0.9981133,0.0018867278
8356,UFH,6,7,43,46,BACKGROUND: Unfractionated heparin sodium (UFH) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.,18589141_1,-1,-1,-1,8356,-1,0.9981481,0.0018518866
8358,LMWH,13,14,81,85,BACKGROUND: Unfractionated heparin sodium (UFH) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.,18589141_1,-1,-1,-1,8358,-1,0.9973736,0.0026264377
8361,HIT,3,4,34,37,"Heparin-induced thrombocytopenia (HIT) is an adverse immune-mediated reaction to heparin, resulting in platelet count decreases of more than 50%.",18589141_2,-1,-1,-1,8361,-1,0.0034138444,0.9965861
8363,HIT,3,4,19,22,"The frequencies of HIT after liver transplantation and platelet factor 4/heparin-reactive antibody (HIT antibody) positivity in liver transplantation patients, however, are unknown.",18589141_3,-1,-1,-1,8363,-1,0.19567268,0.8043273
8364,HIT,13,14,100,103,"The frequencies of HIT after liver transplantation and platelet factor 4/heparin-reactive antibody (HIT antibody) positivity in liver transplantation patients, however, are unknown.",18589141_3,-1,-1,-1,8364,-1,0.6457196,0.35428044
8365,LMWH,2,3,11,15,"We started LMWH (25 IU/kg/h) on postoperative day (POD) 1, switching to UFH (5000 U/d) on POD 2 or 3.",18589141_5,-1,-1,-1,8365,-1,0.99888605,0.0011139484
8366,UFH,17,18,72,75,"We started LMWH (25 IU/kg/h) on postoperative day (POD) 1, switching to UFH (5000 U/d) on POD 2 or 3.",18589141_5,-1,-1,-1,8366,-1,0.9987563,0.0012436855
8367,UFH,3,4,12,15,The dose of UFH was changed according to the activated clotting time level.,18589141_6,-1,-1,-1,8367,-1,0.99864954,0.0013504416
8368,HIT,0,1,0,3,HIT antibody levels were measured the day before surgery and on POD 7 and 14.,18589141_7,-1,-1,-1,8368,-1,0.97755504,0.022444965
8370,HIT,17,18,100,103,"Two patients developed hepatic artery thrombosis on POD 11 and 19, respectively, although they were HIT antibody-negative and their platelet counts were stable.",18589141_10,-1,-1,-1,8370,-1,0.96204,0.037959985
8372,HIT,3,4,18,21,"The percentage of HIT antibody-positive patients was 0.5% preoperatively, 5.6% on POD 7, and 5.6% on POD 14.",18589141_13,-1,-1,-1,8372,-1,0.9780888,0.021911217
8373,HIT,6,7,52,55,None of the subjects/patients developed UFH-related HIT.,18589141_14,-1,-1,-1,8373,-1,0.0037151675,0.99628484
8374,HIT,9,10,46,49,"CONCLUSIONS: In our series, the occurrence of HIT after liver transplantation was uncommon.",18589141_15,-1,-1,-1,8374,-1,0.018981056,0.98101896
8376,heart failure,13,15,92,105,Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure.,18619688_0,-1,-1,-1,8376,-1,0.0024979382,0.997502
8377,heart failure,5,7,38,51,BACKGROUND: The mechanisms underlying heart failure induced by adriamycin are very complicated and still unclear.,18619688_1,-1,-1,-1,8377,-1,0.0026327558,0.9973673
8379,heart failure,16,18,94,107,"The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by adriamycin, so that we can develop a novel treatment strategy for heart failure.",18619688_2,-1,-1,-1,8379,-1,0.002527038,0.99747294
8381,heart failure,32,34,185,198,"The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by adriamycin, so that we can develop a novel treatment strategy for heart failure.",18619688_2,-1,-1,-1,8381,-1,0.002669618,0.9973304
8383,3MA,4,5,26,29,"METHODS: 3-methyladenine (3MA), a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin.",18619688_3,-1,-1,-1,8383,-1,0.996833,0.0031669664
8384,heart failure,16,18,80,93,"METHODS: 3-methyladenine (3MA), a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin.",18619688_3,-1,-1,-1,8384,-1,0.002825266,0.99717474
8386,3MA,20,21,140,143,"Neonatal cardiomyocytes were isolated from Sprague-Dawley rat hearts and randomly divided into controls, an adriamycin-treated group, and a 3MA plus adriamycin-treated group.",18619688_4,-1,-1,-1,8386,-1,0.99665916,0.0033408836
8387,3MA,2,3,9,12,RESULTS: 3MA significantly improved cardiac function and reduced mitochondrial injury.,18619688_8,-1,-1,-1,8387,-1,0.99619895,0.0038009896
8388,mitochondrial injury,9,11,65,85,RESULTS: 3MA significantly improved cardiac function and reduced mitochondrial injury.,18619688_8,-1,-1,-1,8388,-1,0.019506555,0.9804935
8390,3MA,11,12,74,77,"Furthermore, adriamycin induced the formation of autophagic vacuoles, and 3MA strongly downregulated the expression of beclin 1 in adriamycin-induced failing heart and inhibited the formation of autophagic vacuoles.",18619688_9,-1,-1,-1,8390,-1,0.99444205,0.005557923
8392,heart failure,13,15,90,103,CONCLUSION: Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by adriamycin.,18619688_10,-1,-1,-1,8392,-1,0.0024604474,0.9975395
8394,heart failure,9,11,59,72,Mitochondrial injury may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway.,18619688_11,-1,-1,-1,8394,-1,0.0027752828,0.9972247
8398,anthracycline doxorubicin,4,6,20,45,"Clinical use of the anthracycline doxorubicin (DOX) is limited by its cardiotoxic effects, which are attributed to the induction of apoptosis.",18627295_1,-1,-1,-1,8398,-1,0.997678,0.0023220466
8399,DOX,7,8,47,50,"Clinical use of the anthracycline doxorubicin (DOX) is limited by its cardiotoxic effects, which are attributed to the induction of apoptosis.",18627295_1,-1,-1,-1,8399,-1,0.9983209,0.0016790815
8401,DOX cardiomyopathy,17,19,88,106,"To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.",18627295_2,-1,-1,-1,8401,-1,0.23703611,0.7629639
8404,DOX,0,1,0,3,DOX control mice showed cardiac dysfunction measured by pressure-volume loops in vivo.,18627295_3,-1,-1,-1,8404,-1,0.9978223,0.0021777207
8406,cardiac apoptosis,23,25,128,145,"This was associated with a reduced activation state of AKT, as well as an increased bax/bcl2 ratio in Western blots, indicating cardiac apoptosis.",18627295_4,-1,-1,-1,8406,-1,0.0047879745,0.99521196
8407,DOX,1,2,3,6,"In DOX B1R(-/-) mice, cardiac dysfunction was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state.",18627295_6,-1,-1,-1,8407,-1,0.9978198,0.0021801963
8409,DOX,12,13,67,70,"In DOX B1R(-/-) mice, cardiac dysfunction was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state.",18627295_6,-1,-1,-1,8409,-1,0.9976708,0.0023291914
8410,DOX cardiomyopathy,8,10,50,68,These findings suggest that B1R is detrimental in DOX cardiomyopathy in that it mediates the inflammatory response and apoptosis.,18627295_7,-1,-1,-1,8410,-1,0.28664276,0.7133572
8411,DOX cardiomyopathy,16,18,114,132,These insights might have useful implications for future studies utilizing B1R antagonists for treatment of human DOX cardiomyopathy.,18627295_8,-1,-1,-1,8411,-1,0.26970434,0.73029566
8413,protein excretion,2,4,16,33,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.",18631865_1,-1,-1,-1,8413,-1,0.15328152,0.84671843
8414,calcineurin inhibitors,10,12,74,96,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.",18631865_1,-1,-1,-1,8414,-1,0.9973188,0.00268121
8417,chronic allograft nephropathy,30,33,207,236,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.",18631865_1,-1,-1,-1,8417,-1,0.004936636,0.99506336
8421,calcineurin inhibitors,11,13,66,88,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.,18631865_3,-1,-1,-1,8421,-1,0.9967135,0.0032865112
8425,focal segmental glomerulosclerosis,3,6,20,54,"Podocyte injury and focal segmental glomerulosclerosis have been related to mToR inhibition in some patients, but the pathways underlying these lesions remain hypothetic.",18631865_4,-1,-1,-1,8425,-1,0.0040103616,0.9959896
8427,epileptiform activity,6,8,57,78,Detailed spectral profile analysis of penicillin-induced epileptiform activity in anesthetized rats.,18657397_0,-1,-1,-1,8427,-1,0.0028568031,0.9971432
8430,epileptiform activity,14,16,92,113,In the present study we aimed to portray a detailed spectral analysis of penicillin-induced epileptiform activity in comparison with basal brain activity in anesthetized Wistar rats.,18657397_2,-1,-1,-1,8430,-1,0.003044086,0.9969559
8431,urethane,8,9,45,53,Male Wistar rats were anesthetized with i.p. urethane and connected to an electrocorticogram setup.,18657397_3,-1,-1,-1,8431,-1,0.99853873,0.0014613292
8433,epileptiform activity,8,10,57,78,"Basal activity, latent period and the penicillin-induced epileptiform activity periods were then analyzed using both conventional methods and spectral analysis.",18657397_5,-1,-1,-1,8433,-1,0.0040917033,0.99590826
8434,epileptiform activity,20,22,111,132,"Our results show that the most affected frequency bands were delta, theta, beta-2 and gamma-2 bands during the epileptiform activity and there were marked differences in terms of spectral densities between three investigated episodes (basal activity, latent period and epileptiform activity).",18657397_7,-1,-1,-1,8434,-1,0.004849684,0.9951504
8435,epileptiform activity,43,45,269,290,"Our results show that the most affected frequency bands were delta, theta, beta-2 and gamma-2 bands during the epileptiform activity and there were marked differences in terms of spectral densities between three investigated episodes (basal activity, latent period and epileptiform activity).",18657397_7,-1,-1,-1,8435,-1,0.004822238,0.99517775
8436,epilepsies,39,40,246,256,Our results may help to analyze novel data obtained using similar experimental models and the simple analysis method described here can be used in similar studies to investigate the basic neuronal mechanism of this or other types of experimental epilepsies.,18657397_8,-1,-1,-1,8436,-1,0.0025883312,0.99741167
8440,psychoses,7,8,46,55,"Reactions consisted mainly of seizures, acute psychoses, anxiety neurosis, and major disturbances of sleep-wake rhythm.",1867351_2,-1,-1,-1,8440,-1,0.0064336294,0.99356633
8441,anxiety neurosis,9,11,57,73,"Reactions consisted mainly of seizures, acute psychoses, anxiety neurosis, and major disturbances of sleep-wake rhythm.",1867351_2,-1,-1,-1,8441,-1,0.0097817555,0.9902182
8443,neuropsychiatric reactions,27,29,157,183,"The incidence calculation revealed that one of 215 therapeutic users had reactions, compared with one of 13,000 in the prophylaxis group, making the risk of neuropsychiatric reactions after mefloquine treatment 60 times higher than after prophylaxis.",1867351_5,-1,-1,-1,8443,-1,0.0023310406,0.9976689
8445,malaria,5,6,35,42,"Therefore, certain limitations for malaria prophylaxis and treatment with mefloquine are recommended.",1867351_6,-1,-1,-1,8445,-1,0.0250842,0.97491574
8447,fat,1,2,5,8,High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity.,18674790_0,-1,-1,-1,8447,-1,0.96002716,0.03997281
8448,obese,3,4,18,23,High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity.,18674790_0,-1,-1,-1,8448,-1,0.020369044,0.97963095
8454,triglycerides,10,11,79,92,"This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway.",18674790_3,-1,-1,-1,8454,-1,0.99450463,0.0054953825
8455,ATP,17,18,137,140,"This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway.",18674790_3,-1,-1,-1,8455,-1,0.9955272,0.0044727772
8456,fat,16,17,95,98,"In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.",18674790_4,-1,-1,-1,8456,-1,0.9530014,0.046998598
8457,obesity,24,25,125,132,"In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.",18674790_4,-1,-1,-1,8457,-1,0.0032583014,0.9967417
8461,obese,37,38,186,191,"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",18674790_5,-1,-1,-1,8461,-1,0.013323456,0.9866766
8462,OB,39,40,193,195,"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",18674790_5,-1,-1,-1,8462,-1,0.030843878,0.9691561
8466,doxorubicinol,11,12,89,102,Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.,18674790_6,-1,-1,-1,8466,-1,0.9981901,0.0018098844
8467,ND,21,22,146,148,Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.,18674790_6,-1,-1,-1,8467,-1,0.60975283,0.39024717
8468,OB,24,25,154,156,Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.,18674790_6,-1,-1,-1,8468,-1,0.5887066,0.41129336
8469,OB,4,5,34,36,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,-1,-1,-1,8469,-1,0.30850422,0.6914958
8470,peroxisome proliferators,33,35,180,204,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,-1,-1,-1,8470,-1,0.93758523,0.062414784
8471,OB,64,65,392,394,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,-1,-1,-1,8471,-1,0.47763425,0.52236575
8472,ATP,85,86,480,483,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,-1,-1,-1,8472,-1,0.99673504,0.0032649375
8474,obese,4,5,27,32,"In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.",18674790_9,-1,-1,-1,8474,-1,0.0060397913,0.99396026
8476,ATP,17,18,152,155,"In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.",18674790_9,-1,-1,-1,8476,-1,0.99739134,0.0026086757
8479,PD,7,8,44,46,We report that prenatally protein deprived (PD) female rats showed an increased stereotypic response to apomorphine and an increased locomotor response to amphetamine in adulthood.,18703024_3,-1,-1,-1,8479,-1,0.12295597,0.8770441
8483,PD,11,12,93,95,No changes in haloperidol-induced catalepsy or MK-801-induced locomotion were seen following PD.,18703024_5,-1,-1,-1,8483,-1,0.021647153,0.9783529
8484,PD,3,4,13,15,"In addition, PD female rats showed increased (3)H-MK-801 binding in the striatum and hippocampus, but not in the cortex.",18703024_6,-1,-1,-1,8484,-1,0.054983113,0.9450169
8485,PD,0,1,0,2,PD female rats also showed increased (3)H-haloperidol binding and decreased dopamine transporter binding in striatum.,18703024_7,-1,-1,-1,8485,-1,0.0125061255,0.9874938
8487,PD,12,13,83,85,No statistically significant changes in behavior or receptor binding were found in PD males with the exception of increased (3)H-MK-801 binding in cortex.,18703024_8,-1,-1,-1,8487,-1,0.0881048,0.9118952
8488,nutritional deficiency,13,15,76,98,This animal model may be useful to explore the mechanisms by which prenatal nutritional deficiency enhances risk for schizophrenia in humans and may also have implications for developmental processes leading to differential sensitivity to drugs of abuse.,18703024_9,-1,-1,-1,8488,-1,0.91440225,0.08559777
8491,Papaverine hydrochloride,2,4,12,36,BACKGROUND: Papaverine hydrochloride is a direct-acting vasodilator used to manage vasospasm during various neurosurgical operations.,18726058_1,-1,-1,-1,8491,-1,0.99902105,0.0009789505
8493,Transient cranial nerve dysfunction,0,4,0,35,Transient cranial nerve dysfunction has been described in a few cases with topical papaverine.,18726058_2,-1,-1,-1,8493,-1,0.002637789,0.9973622
8506,adverse effect on the proximal eighth nerve,14,21,98,141,The complete disappearance of BAEP waveforms with a consistent temporal delay suggests a possible adverse effect on the proximal eighth nerve.,18726058_15,-1,-1,-1,8506,-1,0.023598129,0.97640187
8507,cranial nerve deficits,4,7,35,57,Recommendations to avoid potential cranial nerve deficits from papaverine are provided.,18726058_16,-1,-1,-1,8507,-1,0.0031551323,0.9968449
8509,hepatic failure,1,3,30,45,Simvastatin-ezetimibe-induced hepatic failure necessitating liver transplantation.,18752389_0,-1,-1,-1,8509,-1,0.0024705061,0.99752957
8510,coenzyme A reductase,12,15,109,129,Abstract Serum aminotransferase elevations are a commonly known adverse effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy.,18752389_1,-1,-1,-1,8510,-1,0.9963653,0.0036346898
8513,ezetimibe,10,11,64,73,"However, hepatotoxic events have not been widely published with ezetimibe or the combination agent simvastatin-ezetimibe.",18752389_2,-1,-1,-1,8513,-1,0.99902487,0.00097518647
8519,escitalopram,2,3,25,37,"Simvastatinezetimibe and escitalopram (which she was taking for depression) were discontinued, and other potential causes of hepatotoxicity were excluded.",18752389_6,-1,-1,-1,8519,-1,0.9991579,0.0008421029
8522,drug toxicity,17,19,130,143,"A repeat work-up revealed further elevations in aminotransferase levels, and liver biopsy revealed evidence of moderate-to-severe drug toxicity.",18752389_7,-1,-1,-1,8522,-1,0.15296201,0.8470379
8523,uridine diphosphate,5,7,49,68,"Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.",18752389_10,-1,-1,-1,8523,-1,0.99790335,0.002096648
8524,simvastatin hydroxy acid,23,26,173,197,"Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.",18752389_10,-1,-1,-1,8524,-1,0.9981468,0.001853257
8527,liver failure,12,14,81,94,"To our knowledge, this is the first case report of simvastatin-ezetimibe-induced liver failure that resulted in liver transplantation.",18752389_11,-1,-1,-1,8527,-1,0.0025653767,0.9974347
8530,ezetimibe,15,16,124,133,We postulate that the mechanism of the simvastatinezetimibe-induced hepatotoxicity is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes.,18752389_12,-1,-1,-1,8530,-1,0.99901223,0.0009877562
8533,acute renal failure,3,6,24,43,Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.,18754075_0,-1,-1,-1,8533,-1,0.0025515638,0.99744844
8534,bisphosphonate,8,9,55,69,Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.,18754075_0,-1,-1,-1,8534,-1,0.9992742,0.00072580867
8535,alendronate,10,11,71,82,Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.,18754075_0,-1,-1,-1,8535,-1,0.9989862,0.0010138009
8536,focal segmental glomerulosclerosis,17,20,117,151,Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.,18754075_0,-1,-1,-1,8536,-1,0.004495724,0.9955043
8537,nephrotic syndrome,5,7,32,50,A 61-year-old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy.,18754075_1,-1,-1,-1,8537,-1,0.0024007442,0.9975993
8538,focal segmental glomerulosclerosis,9,12,58,92,A 61-year-old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy.,18754075_1,-1,-1,-1,8538,-1,0.0038091687,0.9961908
8540,bisphosphonate,18,19,93,107,"The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure.",18754075_2,-1,-1,-1,8540,-1,0.9991879,0.0008120644
8541,alendronate sodium,20,22,109,127,"The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure.",18754075_2,-1,-1,-1,8541,-1,0.99848926,0.001510707
8542,acute renal failure,38,41,217,236,"The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure.",18754075_2,-1,-1,-1,8542,-1,0.0025296356,0.9974704
8543,alendronate,4,5,29,40,"After discontinuing the oral alendronate, the patient underwent six cycles of hemodialysis and four cycles of LDL apheresis.",18754075_3,-1,-1,-1,8543,-1,0.99917525,0.00082468917
8545,bisphosphonates,11,12,66,81,"This report demonstrates that not only intravenous, but also oral bisphosphonates can aggravate proteinuria and acute renal failure.",18754075_5,-1,-1,-1,8545,-1,0.9989256,0.0010743196
8547,acute renal failure,16,19,112,131,"This report demonstrates that not only intravenous, but also oral bisphosphonates can aggravate proteinuria and acute renal failure.",18754075_5,-1,-1,-1,8547,-1,0.002199459,0.9978005
8548,nephrotic syndrome,7,9,68,86,Serum- and glucocorticoid-inducible kinase 1 in doxorubicin-induced nephrotic syndrome.,18768591_0,-1,-1,-1,8548,-1,0.002166934,0.9978331
8551,volume retention,8,10,84,100,Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis.,18768591_1,-1,-1,-1,8551,-1,0.13745949,0.8625405
8555,volume retention,13,15,69,85,The present study was performed to elucidate the role of SGK1 in the volume retention and fibrosis during nephrotic syndrome.,18768591_3,-1,-1,-1,8555,-1,0.17270353,0.8272965
8557,nephrotic syndrome,18,20,106,124,The present study was performed to elucidate the role of SGK1 in the volume retention and fibrosis during nephrotic syndrome.,18768591_3,-1,-1,-1,8557,-1,0.0027014357,0.99729854
8561,mg,9,10,58,60,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.",18768591_5,-1,-1,-1,8561,-1,0.89216566,0.10783433
8562,nephrotic syndrome,27,29,146,164,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.",18768591_5,-1,-1,-1,8562,-1,0.0023991251,0.99760085
8564,lipidemia,32,33,179,188,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.",18768591_5,-1,-1,-1,8564,-1,0.011130686,0.9888693
8565,hypoalbuminemia,35,36,194,209,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.",18768591_5,-1,-1,-1,8565,-1,0.00367402,0.9963259
8569,body weight gain,39,42,197,213,Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g).,18768591_7,-1,-1,-1,8569,-1,0.008399289,0.99160075
8570,nephrotic syndrome,4,6,21,39,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).",18768591_8,-1,-1,-1,8570,-1,0.0023427466,0.9976572
8572,uremia,24,25,150,156,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).",18768591_8,-1,-1,-1,8572,-1,0.003818004,0.996182
8573,volume retention,9,11,62,78,"In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.",18768591_9,-1,-1,-1,8573,-1,0.24738762,0.7526124
8575,nephrotic syndrome,21,23,146,164,"In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.",18768591_9,-1,-1,-1,8575,-1,0.0025751023,0.99742496
8577,haemolytic anaemia,3,5,28,46,Severe thrombocytopenia and haemolytic anaemia associated with ciprofloxacin: a case report with fatal outcome.,18791946_0,-1,-1,-1,8577,-1,0.0030545522,0.99694544
8583,urinary tract infection,21,24,136,159,A 30-year old Caucasian man reported with abdominal pain and jaundice after 3-day administration of oral ciprofloxacin for a suspect of urinary tract infection.,18791946_2,-1,-1,-1,8583,-1,0.008053603,0.9919464
8585,haemolysis,10,11,83,93,Clinical evaluations suggested an initial diagnosis of severe thrombocytopenia and haemolysis.,18791946_3,-1,-1,-1,8585,-1,0.0025465412,0.9974535
8586,petechiae,4,5,36,45,The patient progressively developed petechiae and purpura on thorax and lower limbs.,18791946_4,-1,-1,-1,8586,-1,0.0046478156,0.99535215
8587,purpura,6,7,50,57,The patient progressively developed petechiae and purpura on thorax and lower limbs.,18791946_4,-1,-1,-1,8587,-1,0.005666468,0.9943335
8588,haemorrhages,9,10,64,76,An accurate autopsy revealed most organs with diffuse petechial haemorrhages.,18791946_6,-1,-1,-1,8588,-1,0.003136605,0.99686337
8589,bone marrow depression,3,6,12,34,No signs of bone marrow depression were found.,18791946_7,-1,-1,-1,8589,-1,0.009080594,0.99091935
8591,microangiopathies,5,6,23,40,No thrombi or signs of microangiopathies were observed in arterial vessels.,18791946_8,-1,-1,-1,8591,-1,0.0034587036,0.9965413
8594,haemolytic anaemia,11,13,96,114,"This case report shows that ciprofloxacin may precipitate life-threatening thrombocytopenia and haemolytic anaemia, even in the early phases of treatment and without apparent previous exposures.",18791946_10,-1,-1,-1,8594,-1,0.0022189822,0.997781
8599,vs.,15,16,101,104,"The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.",18808529_1,-1,-1,-1,8599,-1,0.7989292,0.2010708
8601,myocardial hyperactivity,21,23,147,171,"The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.",18808529_1,-1,-1,-1,8601,-1,0.0035069478,0.99649304
8606,ischaemic injury,5,7,26,42,"These changes, related to ischaemic injury, explain the severe alterations in the structural integrity of the sarcolemma of cardiomyocytes and hence severe and irreversible injury induced by isoproterenol.",18808529_9,-1,-1,-1,8606,-1,0.0070424667,0.9929576
8608,mitochondrial damage,3,5,27,47,Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy.,18809400_0,-1,-1,-1,8608,-1,0.007046141,0.99295384
8612,mitochondrial damage,14,16,110,130,"The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.",18809400_1,-1,-1,-1,8612,-1,0.02925217,0.9707479
8616,axonal damage,11,13,84,97,This approach allowed investigating the efficacy of alpha-lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha-lipoic acid.,18809400_3,-1,-1,-1,8616,-1,0.0034203464,0.9965797
8617,toxic agents,26,28,194,206,This approach allowed investigating the efficacy of alpha-lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha-lipoic acid.,18809400_3,-1,-1,-1,8617,-1,0.8048451,0.19515494
8620,mitochondrial impairment,10,12,71,95,Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons.,18809400_4,-1,-1,-1,8620,-1,0.0144825205,0.98551744
8621,loss of membrane potential,13,17,101,127,Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons.,18809400_4,-1,-1,-1,8621,-1,0.05363981,0.94636023
8623,mitochondrial toxicity,16,18,127,149,"Alpha-lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.",18809400_5,-1,-1,-1,8623,-1,0.014052406,0.9859476
8628,peripheral nerve toxicity,12,15,82,107,These findings suggest that alpha-lipoic acid might reduce the risk of developing peripheral nerve toxicity in patients undergoing chemotherapy and encourage further confirmatory clinical trials.,18809400_8,-1,-1,-1,8628,-1,0.0025820043,0.99741805
8633,8-aminoquinoline WR242511,5,7,26,51,"Using this rationale, the 8-aminoquinoline WR242511, a potent long-lasting MHb former in rodents and beagle dogs, was studied in the rhesus monkey for advanced development as a potential CN pretreatment.",18821488_2,-1,-1,-1,8633,-1,0.9965676,0.0034323593
8634,WR242511,6,7,24,32,"METHODS: In this study, WR242511 was administered intravenously (IV) in 2 female and 4 male rhesus monkeys in doses of 3.5 and/or 7.0 mg/kg; a single male also received WR242511 orally (PO) at 7.0 mg/kg.",18821488_3,-1,-1,-1,8634,-1,0.99797004,0.0020299098
8635,WR242511,34,35,169,177,"METHODS: In this study, WR242511 was administered intravenously (IV) in 2 female and 4 male rhesus monkeys in doses of 3.5 and/or 7.0 mg/kg; a single male also received WR242511 orally (PO) at 7.0 mg/kg.",18821488_3,-1,-1,-1,8635,-1,0.99799275,0.0020072495
8636,WR242511,6,7,31,39,"RESULTS: The selected doses of WR242511, which produced significant methemoglobinemia in beagle dogs in earlier studies conducted elsewhere, produced very little MHb (mean < 2.0%) in the rhesus monkey.",18821488_5,-1,-1,-1,8636,-1,0.9972995,0.002700583
8637,methemoglobinemia,11,12,68,85,"RESULTS: The selected doses of WR242511, which produced significant methemoglobinemia in beagle dogs in earlier studies conducted elsewhere, produced very little MHb (mean < 2.0%) in the rhesus monkey.",18821488_5,-1,-1,-1,8637,-1,0.085715726,0.91428435
8638,hemoglobinuria,3,4,23,37,"Furthermore, transient hemoglobinuria was noted approximately 60 minutes postinjection of WR242511 (3.5 or 7.0 mg/kg), and 2 lethalities occurred (one IV and one PO) following the 7.0 mg/kg dose.",18821488_6,-1,-1,-1,8638,-1,0.0029029478,0.997097
8639,WR242511,11,12,90,98,"Furthermore, transient hemoglobinuria was noted approximately 60 minutes postinjection of WR242511 (3.5 or 7.0 mg/kg), and 2 lethalities occurred (one IV and one PO) following the 7.0 mg/kg dose.",18821488_6,-1,-1,-1,8639,-1,0.99729013,0.0027098747
8640,Myoglobinuria,0,1,0,13,Myoglobinuria was also observed following the 7.0 mg/kg dose.,18821488_7,-1,-1,-1,8640,-1,0.008422649,0.9915774
8643,WR242511,4,5,21,29,It is concluded that WR242511 should not be pursued as a pretreatment for CN poisoning unless the anti-CN characteristics of this compound can be successfully dissociated from those producing undesirable toxicity.,18821488_10,-1,-1,-1,8643,-1,0.9967483,0.0032517295
8646,liver tumors,6,8,41,53,Etiologic factors in the pathogenesis of liver tumors associated with oral contraceptives.,188339_0,-1,-1,-1,8646,-1,0.0029614402,0.9970386
8648,liver tumors,8,10,47,59,"Within the last several years, previously rare liver tumors have been seen in young women using oral contraceptive steroids.",188339_1,-1,-1,-1,8648,-1,0.0031658858,0.9968341
8649,oral contraceptive steroids,17,20,96,123,"Within the last several years, previously rare liver tumors have been seen in young women using oral contraceptive steroids.",188339_1,-1,-1,-1,8649,-1,0.9980896,0.0019103596
8650,Liver Tumors,3,5,17,29,"The Registry for Liver Tumors Associated with Oral Contraceptives at the University of California, Irvine, has clearly identified 27 cases.",188339_2,-1,-1,-1,8650,-1,0.0036437067,0.99635637
8652,focal nodular hyperplasia,11,14,65,90,"Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia, adenoma, hamartoma, and hepatoma.",188339_4,-1,-1,-1,8652,-1,0.006459345,0.9935407
8653,adenoma,15,16,92,99,"Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia, adenoma, hamartoma, and hepatoma.",188339_4,-1,-1,-1,8653,-1,0.0054801637,0.9945199
8654,hamartoma,17,18,101,110,"Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia, adenoma, hamartoma, and hepatoma.",188339_4,-1,-1,-1,8654,-1,0.02713963,0.97286034
8655,hepatoma,20,21,116,124,"Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia, adenoma, hamartoma, and hepatoma.",188339_4,-1,-1,-1,8655,-1,0.0038725461,0.9961274
8656,oral contraceptive steroids,9,12,83,110,Significant statistical etiologic factors include prolonged uninterrupted usage of oral contraceptive steroids.,188339_5,-1,-1,-1,8656,-1,0.99798906,0.0020108863
8658,liver rupture,3,5,17,30,Eight deaths and liver rupture in 18 patients attest to the seriousness of this new potentially lethal adverse phenomenon.,188339_6,-1,-1,-1,8658,-1,0.002935083,0.9970649
8660,Parkinson's disease,8,11,81,100,Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson's disease.,18951540_0,-1,-1,-1,8660,-1,0.0053363824,0.9946636
8662,Parkinson's disease,39,42,214,233,"In a placebo-controlled, single-blinded, crossover study, we assessed the effect of ""real"" repetitive transcranial magnetic stimulation (rTMS) versus ""sham"" rTMS (placebo) on peak dose dyskinesias in patients with Parkinson's disease (PD).",18951540_1,-1,-1,-1,8662,-1,0.00535657,0.99464345
8663,PD,43,44,235,237,"In a placebo-controlled, single-blinded, crossover study, we assessed the effect of ""real"" repetitive transcranial magnetic stimulation (rTMS) versus ""sham"" rTMS (placebo) on peak dose dyskinesias in patients with Parkinson's disease (PD).",18951540_1,-1,-1,-1,8663,-1,0.003069738,0.9969303
8664,PD,3,4,18,20,"Ten patients with PD and prominent dyskinesias had rTMS (1,800 pulses; 1 Hz rate) delivered over the motor cortex for 4 consecutive days twice, once real stimuli and once sham stimulation were used; evaluations were done at the baseline and 1 day after the end of each of the treatment series.",18951540_2,-1,-1,-1,8664,-1,0.0032938637,0.9967062
8670,PD,14,15,77,79,"Following rTMS, no side effects and no adverse effects on motor function and PD symptoms were noted.",18951540_7,-1,-1,-1,8670,-1,0.0036286854,0.9963714
8672,PD,20,21,153,155,The results suggest the existence of residual beneficial clinical aftereffects of consecutive daily applications of low-frequency rTMS on dyskinesias in PD.,18951540_8,-1,-1,-1,8672,-1,0.0035831921,0.9964168
8690,priapism,8,9,63,71,Intracavernous epinephrine: a minimally invasive treatment for priapism in the emergency department.,18996674_0,-1,-1,-1,8690,-1,0.7368675,0.2631325
8691,emergency department,11,13,79,99,Intracavernous epinephrine: a minimally invasive treatment for priapism in the emergency department.,18996674_0,-1,-1,-1,8691,-1,0.0071855853,0.9928145
8692,erection of the penis,4,8,26,47,Priapism is the prolonged erection of the penis in the absence of sexual arousal.,18996674_1,-1,-1,-1,8692,-1,0.024442786,0.97555727
8694,Emergency Department,13,15,71,91,"A 45-year-old man, an admitted frequent cocaine user, presented to the Emergency Department (ED) on two separate occasions with a history of priapism after cocaine use.",18996674_2,-1,-1,-1,8694,-1,0.016945522,0.98305446
8695,priapism,26,27,141,149,"A 45-year-old man, an admitted frequent cocaine user, presented to the Emergency Department (ED) on two separate occasions with a history of priapism after cocaine use.",18996674_2,-1,-1,-1,8695,-1,0.014916771,0.9850832
8704,ventricular ectopy,26,28,178,196,Intravenous caffeine is commonly used to improve seizure duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign ventricular ectopy.,18997632_2,-1,-1,-1,8704,-1,0.0036725926,0.99632734
8705,cardiac disease,9,11,50,65,We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.,18997632_3,-1,-1,-1,8705,-1,0.0028583927,0.99714154
8707,bigeminy,16,17,104,112,We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.,18997632_3,-1,-1,-1,8707,-1,0.99850273,0.0014973348
8713,rheumatologic disorders,9,11,74,97,Prophylactic use of lamivudine with chronic immunosuppressive therapy for rheumatologic disorders.,19037603_0,-1,-1,-1,8713,-1,0.0035024132,0.9964976
8715,hepatitis B virus surface antigen,20,25,138,171,The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen (HBs Ag) positive patients with rheumatologic disease.,19037603_1,-1,-1,-1,8715,-1,0.691161,0.30883902
8716,HBs Ag,26,28,173,179,The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen (HBs Ag) positive patients with rheumatologic disease.,19037603_1,-1,-1,-1,8716,-1,0.9590565,0.040943563
8717,rheumatologic disease,32,34,204,225,The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen (HBs Ag) positive patients with rheumatologic disease.,19037603_1,-1,-1,-1,8717,-1,0.0030014333,0.99699855
8718,HBs Ag,8,10,35,41,"From June 2004 to October 2006, 11 HBs Ag positive patients with rheumatologic diseases, who were on both immunosuppressive and prophylactic lamivudine therapies, were retrospectively assessed.",19037603_2,-1,-1,-1,8718,-1,0.9634,0.03659996
8719,rheumatologic diseases,13,15,65,87,"From June 2004 to October 2006, 11 HBs Ag positive patients with rheumatologic diseases, who were on both immunosuppressive and prophylactic lamivudine therapies, were retrospectively assessed.",19037603_2,-1,-1,-1,8719,-1,0.0034274987,0.9965725
8721,hepatitis B,4,6,22,33,"Liver function tests, hepatitis B virus (HBV) serologic markers, and HBV DNA levels of the patients during follow-up were obtained from hospital file records.",19037603_3,-1,-1,-1,8721,-1,0.7318126,0.26818743
8723,abnormal liver function,15,18,100,123,Shortly after treatment their tests normalized and during follow-up period none of the patients had abnormal liver function tests.,19037603_7,-1,-1,-1,8723,-1,0.009704682,0.9902953
8727,vitamin E,5,7,24,33,Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.,19058010_0,-1,-1,-1,8727,-1,0.9983342,0.0016657796
8729,myocardial infarction,11,13,71,92,Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.,19058010_0,-1,-1,-1,8729,-1,0.0024284765,0.9975715
8731,vitamin E,14,16,81,90,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,-1,-1,-1,8731,-1,0.9985216,0.0014783693
8732,body weight,20,22,108,119,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,-1,-1,-1,8732,-1,0.012749425,0.98725057
8734,myocardial infarction,39,41,245,266,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,-1,-1,-1,8734,-1,0.0024603,0.99753976
8735,ISO,7,8,37,40,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,-1,-1,-1,8735,-1,0.9987664,0.0012335917
8736,h,23,24,91,92,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,-1,-1,-1,8736,-1,0.4670804,0.5329196
8737,P<0.05,28,29,115,121,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,-1,-1,-1,8737,-1,0.33873945,0.6612605
8738,P<0.05,51,52,246,252,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,-1,-1,-1,8738,-1,0.3044345,0.69556546
8739,body weight,55,57,266,277,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,-1,-1,-1,8739,-1,0.010966955,0.989033
8741,vitamin E,12,14,54,63,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,-1,-1,-1,8741,-1,0.9978257,0.002174255
8742,ISO,29,30,139,142,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,-1,-1,-1,8742,-1,0.9977792,0.0022208444
8743,P<0.05,41,42,191,197,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,-1,-1,-1,8743,-1,0.317384,0.682616
8744,body weight,63,65,313,324,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,-1,-1,-1,8744,-1,0.013091907,0.9869081
8745,ISO,77,78,400,403,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,-1,-1,-1,8745,-1,0.9976398,0.0023602152
8747,vitamin E,84,86,435,444,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,-1,-1,-1,8747,-1,0.9978066,0.0021933643
8749,vitamin E,11,13,75,84,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,19058010_4,-1,-1,-1,8749,-1,0.9986185,0.0013814705
8750,ISO,14,15,92,95,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,19058010_4,-1,-1,-1,8750,-1,0.9978131,0.002186814
8751,myocardial infarction,16,18,104,125,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,19058010_4,-1,-1,-1,8751,-1,0.0024238534,0.9975762
8752,haemorrhage,4,5,44,55,Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.,19058474_0,-1,-1,-1,8752,-1,0.0024935496,0.99750644
8754,haemorrhage,7,8,35,46,We report a case of fatal internal haemorrhage in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of warfarin.,19058474_1,-1,-1,-1,8754,-1,0.0024034646,0.99759656
8756,flavonoids,8,9,54,64,"We propose that naturally occurring compounds such as flavonoids, which are present in fruit juices, may increase the potency of warfarin by competing for the enzymes that normally inactivate warfarin.",19058474_2,-1,-1,-1,8756,-1,0.99734396,0.0026561199
8759,adverse drug reactions,16,19,115,137,"While traditionally regarded as foodstuffs, consumption of fruit juices should be considered when patients develop adverse drug reactions.",19058474_3,-1,-1,-1,8759,-1,0.006673557,0.9933264
8764,bupropion HCl,13,15,85,98,"METHODS: We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg/kg, a known convulsive dose 50 (CD50), on the incidence and severity of bupropion-induced convulsions in the Swiss albino mice.",19105845_3,-1,-1,-1,8764,-1,0.9991775,0.000822502
8767,bupropion HCl,22,24,104,117,"A total of 69 mice, approximately 7 weeks of age, and weighing 21.0 to 29.1 g were randomly assigned to bupropion HCl 120 mg/kg treatment by intraperitoneal (IP) administration in 7 groups (9 to 10 animals per group).",19105845_4,-1,-1,-1,8767,-1,0.9992125,0.00078743446
8768,Bupropion HCl,0,2,0,13,"Bupropion HCl was infused through a surgically implanted IP dosing catheter with infusions in each group of 0 min, 15 min, 30 min, 60 min, 90 min, 120 min, and 240 min.",19105845_5,-1,-1,-1,8768,-1,0.9992848,0.00071526796
8771,bupropion HCl,9,11,54,67,RESULTS: The results showed that IP administration of bupropion HCl 120 mg/kg by bolus injection induced convulsions in 6 out of 10 mice (60% of convulsing mice) in group 1.,19105845_7,-1,-1,-1,8771,-1,0.99924785,0.00075209147
8773,p,10,11,74,75,Logistic regression analysis revealed that infusion time was significant (p = 0.0004; odds ratio = 0.974) and increasing the IP infusion time of bupropion HCl 120 mg/kg was associated with a 91% reduced odds of convulsions at infusion times of 15 to 90 min compared to bolus injection.,19105845_8,-1,-1,-1,8773,-1,0.5327344,0.4672656
8774,bupropion HCl,26,28,145,158,Logistic regression analysis revealed that infusion time was significant (p = 0.0004; odds ratio = 0.974) and increasing the IP infusion time of bupropion HCl 120 mg/kg was associated with a 91% reduced odds of convulsions at infusion times of 15 to 90 min compared to bolus injection.,19105845_8,-1,-1,-1,8774,-1,0.99924767,0.00075238466
8782,sinusoidal obstruction syndrome,14,17,108,139,Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.,19135948_0,-1,-1,-1,8782,-1,0.0041757748,0.9958242
8783,microangiopathy,18,19,144,159,Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.,19135948_0,-1,-1,-1,8783,-1,0.0034381642,0.9965618
8785,GVHD,14,15,110,114,A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).,19135948_1,-1,-1,-1,8785,-1,0.0027743925,0.9972256
8790,myelodysplastic syndrome,21,23,106,130,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8790,-1,0.0038710362,0.9961289
8791,MDS,24,25,132,135,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8791,-1,0.0030490279,0.996951
8792,n,26,27,137,138,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8792,-1,0.08448733,0.9155126
8793,acute myeloid leukemia,31,34,148,170,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8793,-1,0.0036867037,0.9963133
8794,AML,35,36,172,175,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8794,-1,0.0036204157,0.99637955
8795,n,37,38,177,178,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8795,-1,0.062478457,0.9375215
8796,n,50,51,249,250,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8796,-1,0.076345965,0.9236541
8797,n,57,58,270,271,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,-1,-1,-1,8797,-1,0.069430694,0.93056935
8799,GVHD,10,11,48,52,"Nine patients (37%) developed acute grade II-IV GVHD, and 11 of 17 evaluable patients (64%) developed chronic extensive GVHD.",19135948_5,-1,-1,-1,8799,-1,0.0027039726,0.99729604
8800,GVHD,25,26,120,124,"Nine patients (37%) developed acute grade II-IV GVHD, and 11 of 17 evaluable patients (64%) developed chronic extensive GVHD.",19135948_5,-1,-1,-1,8800,-1,0.002763753,0.9972363
8801,microangiopathy,1,2,27,42,"Transplantation-associated microangiopathy (TMA) occurred in 7 patients (29%), with 2 cases of acute renal failure.",19135948_6,-1,-1,-1,8801,-1,0.0034907511,0.99650925
8802,TMA,3,4,44,47,"Transplantation-associated microangiopathy (TMA) occurred in 7 patients (29%), with 2 cases of acute renal failure.",19135948_6,-1,-1,-1,8802,-1,0.14707059,0.8529295
8803,acute renal failure,18,21,95,114,"Transplantation-associated microangiopathy (TMA) occurred in 7 patients (29%), with 2 cases of acute renal failure.",19135948_6,-1,-1,-1,8803,-1,0.0025574637,0.9974425
8804,sinusoidal obstruction syndrome,15,18,86,117,"The study was terminated prematurely because an additional 6 patients (25%) developed sinusoidal obstruction syndrome (SOS), which was fatal in 2 cases.",19135948_7,-1,-1,-1,8804,-1,0.0048241927,0.99517584
8805,SOS,19,20,119,122,"The study was terminated prematurely because an additional 6 patients (25%) developed sinusoidal obstruction syndrome (SOS), which was fatal in 2 cases.",19135948_7,-1,-1,-1,8805,-1,0.005858511,0.9941415
8806,GVHD,14,15,90,94,"Although this new combination appears to be effective as a prophylactic regimen for acute GVHD, the incidence of TMA and SOS is considerably higher than seen with other regimens.",19135948_9,-1,-1,-1,8806,-1,0.0025465267,0.9974535
8807,TMA,19,20,113,116,"Although this new combination appears to be effective as a prophylactic regimen for acute GVHD, the incidence of TMA and SOS is considerably higher than seen with other regimens.",19135948_9,-1,-1,-1,8807,-1,0.9982279,0.0017720938
8808,SOS,21,22,121,124,"Although this new combination appears to be effective as a prophylactic regimen for acute GVHD, the incidence of TMA and SOS is considerably higher than seen with other regimens.",19135948_9,-1,-1,-1,8808,-1,0.99691784,0.0030821506
8809,difluoromethylornithine,13,14,86,109,Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.,19139001_0,-1,-1,-1,8809,-1,0.9990388,0.0009612615
8811,colorectal adenomas,20,22,150,169,Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.,19139001_0,-1,-1,-1,8811,-1,0.0043437257,0.99565625
8812,adenomatous polyps,9,11,54,72,A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.,19139001_1,-1,-1,-1,8812,-1,0.004866482,0.99513346
8813,difluoromethylornithine,17,18,108,131,A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.,19139001_1,-1,-1,-1,8813,-1,0.9990952,0.0009047942
8814,DFMO,19,20,133,137,A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.,19139001_1,-1,-1,-1,8814,-1,0.998623,0.0013770171
8816,hearing loss,1,3,10,22,"Temporary hearing loss is a known toxicity of treatment with DFMO, thus a comprehensive approach was developed to analyze serial air conduction audiograms.",19139001_2,-1,-1,-1,8816,-1,0.0025265045,0.9974734
8818,DFMO,10,11,61,65,"Temporary hearing loss is a known toxicity of treatment with DFMO, thus a comprehensive approach was developed to analyze serial air conduction audiograms.",19139001_2,-1,-1,-1,8818,-1,0.99893194,0.0010680534
8819,DFMO,17,18,96,100,"Based on 290 subjects, there was an average difference of 0.50 dB between subjects treated with DFMO plus sulindac compared with those treated with placebo (95% confidence interval, -0.64 to 1.63 dB; P = 0.39), adjusted for baseline values, age, and frequencies.",19139001_4,-1,-1,-1,8819,-1,0.9989864,0.0010135763
8821,P,37,38,200,201,"Based on 290 subjects, there was an average difference of 0.50 dB between subjects treated with DFMO plus sulindac compared with those treated with placebo (95% confidence interval, -0.64 to 1.63 dB; P = 0.39), adjusted for baseline values, age, and frequencies.",19139001_4,-1,-1,-1,8821,-1,0.37330723,0.6266927
8822,P,23,24,101,102,"In the normal speech range of 500 to 3,000 Hz, an estimated difference of 0.99 dB (-0.17 to 2.14 dB; P = 0.09) was detected.",19139001_5,-1,-1,-1,8822,-1,0.37844232,0.62155765
8823,DFMO,11,12,35,39,There were 14 of 151 (9.3%) in the DFMO plus sulindac group and 4 of 139 (2.9%) in the placebo group who experienced at least 15 dB hearing reduction from baseline in 2 or more consecutive frequencies across the entire range tested (P = 0.02).,19139001_7,-1,-1,-1,8823,-1,0.9990252,0.0009747819
8825,hearing reduction,33,35,132,149,There were 14 of 151 (9.3%) in the DFMO plus sulindac group and 4 of 139 (2.9%) in the placebo group who experienced at least 15 dB hearing reduction from baseline in 2 or more consecutive frequencies across the entire range tested (P = 0.02).,19139001_7,-1,-1,-1,8825,-1,0.0059840046,0.99401593
8826,P,49,50,233,234,There were 14 of 151 (9.3%) in the DFMO plus sulindac group and 4 of 139 (2.9%) in the placebo group who experienced at least 15 dB hearing reduction from baseline in 2 or more consecutive frequencies across the entire range tested (P = 0.02).,19139001_7,-1,-1,-1,8826,-1,0.26930845,0.73069155
8827,P,29,30,158,159,Follow-up air conduction done at least 6 months after end of treatment showed an adjusted mean difference in hearing thresholds of 1.08 dB (-0.81 to 2.96 dB; P = 0.26) between treatment arms.,19139001_8,-1,-1,-1,8827,-1,0.36253378,0.63746625
8828,DFMO,12,13,73,77,There was no significant difference in the proportion of subjects in the DFMO plus sulindac group who experienced clinically significant hearing loss compared with the placebo group.,19139001_9,-1,-1,-1,8828,-1,0.99907196,0.00092803466
8830,hearing loss,20,22,137,149,There was no significant difference in the proportion of subjects in the DFMO plus sulindac group who experienced clinically significant hearing loss compared with the placebo group.,19139001_9,-1,-1,-1,8830,-1,0.003245982,0.996754
8832,P,26,27,123,124,"The estimated attributable risk of ototoxicity from exposure to the drug is 8.4% (95% confidence interval, -2.0% to 18.8%; P = 0.12).",19139001_10,-1,-1,-1,8832,-1,0.33500016,0.6649998
8833,DFMO,14,15,72,76,There is a <2 dB difference in mean threshold for patients treated with DFMO plus sulindac compared with those treated with placebo.,19139001_11,-1,-1,-1,8833,-1,0.9990783,0.0009216944
8836,RPN,4,5,26,29,Renal papillary necrosis (RPN) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and paracetamol in female Fischer 344 rats.,1919871_1,-1,-1,-1,8836,-1,0.008187539,0.99181247
8839,RPN,27,28,183,186,This study shows that prolonged analgesic treatment in Fischer 344 rats causes progressive and irreversible damage to the interstitial matrix and type 1 interstitial cells leading to RPN.,1919871_6,-1,-1,-1,8839,-1,0.15940638,0.8405936
8842,ulcerative colitis,4,6,25,43,"A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.",19203554_1,-1,-1,-1,8842,-1,0.003903093,0.9960969
8843,red eyes,7,9,54,62,"A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.",19203554_1,-1,-1,-1,8843,-1,0.00694545,0.99305457
8844,pleural effusion,10,12,64,80,"A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.",19203554_1,-1,-1,-1,8844,-1,0.0035289107,0.99647117
8846,urinary abnormalities,15,17,99,120,"A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.",19203554_1,-1,-1,-1,8846,-1,0.019701919,0.9802981
8848,segmental necrotizing glomerulonephritis,7,10,45,85,Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement.,19203554_2,-1,-1,-1,8848,-1,0.003496309,0.9965037
8849,pleural effusions,8,10,39,56,"PR3-ANCA titer was 250 and 1,070 EU in pleural effusions on right and left side, respectively.",19203554_4,-1,-1,-1,8849,-1,0.0042998632,0.9957001
8852,red eyes,11,13,82,90,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,-1,-1,-1,8852,-1,0.008382296,0.99161774
8853,chest pain,14,16,92,102,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,-1,-1,-1,8853,-1,0.0037560489,0.99624395
8854,pleural effusions,25,27,150,167,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,-1,-1,-1,8854,-1,0.005000953,0.99499905
8856,pleural effusion,50,52,296,312,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,-1,-1,-1,8856,-1,0.004044031,0.9959559
8858,pleural effusion,7,9,37,53,"One month after steroid therapy, the pleural effusion disappeared, and PR3-ANCA titer normalized 3 months later.",19203554_6,-1,-1,-1,8858,-1,0.0034612648,0.99653876
8861,Testosterone-dependent,0,1,0,22,Testosterone-dependent hypertension and upregulation of intrarenal angiotensinogen in Dahl salt-sensitive rats.,19211690_0,-1,-1,-1,8861,-1,0.3686721,0.6313279
8864,contrast,1,2,3,11,"In contrast to the systemic renin-angiotensin system, which is suppressed in response to HS in male DS, intrarenal angiotensinogen expression is increased, and intrarenal levels of ANG II are not suppressed.",19211690_3,-1,-1,-1,8864,-1,0.2533266,0.74667346
8872,idiopathic Parkinson's disease,9,13,77,107,Comparison of unilateral pallidotomy and subthalamotomy findings in advanced idiopathic Parkinson's disease.,19234905_0,-1,-1,-1,8872,-1,0.00592902,0.99407095
8873,idiopathic Parkinson's disease,20,24,145,175,"A prospective, randomized, double-blind pilot study to compare the results of stereotactic unilateral pallidotomy and subthalamotomy in advanced idiopathic Parkinson's disease (PD) refractory to medical treatment was designed.",19234905_1,-1,-1,-1,8873,-1,0.0066405837,0.9933594
8874,PD,25,26,177,179,"A prospective, randomized, double-blind pilot study to compare the results of stereotactic unilateral pallidotomy and subthalamotomy in advanced idiopathic Parkinson's disease (PD) refractory to medical treatment was designed.",19234905_1,-1,-1,-1,8874,-1,0.0044957567,0.9955043
8877,Parkinson's Disease,8,11,52,71,"Clinical evaluation included the use of the Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn_Yahr score and Schwab England activities of daily living (ADL) score in 'on'- and 'off'-drug conditions before surgery and 6 months after surgery.",19234905_5,-1,-1,-1,8877,-1,0.017146403,0.9828536
8879,homonymous hemianopsia,11,13,60,82,Complications were observed in two patients: one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg/day.,19234905_10,-1,-1,-1,8879,-1,0.0076149264,0.992385
8880,pallidotomy,14,15,89,100,Complications were observed in two patients: one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg/day.,19234905_10,-1,-1,-1,8880,-1,0.45210588,0.5478942
8881,Valproate,33,34,226,235,Complications were observed in two patients: one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg/day.,19234905_10,-1,-1,-1,8881,-1,0.9991326,0.0008674055
8882,PD,22,23,137,139,The findings of this study suggest that lesions of the unilateral STN and GPi are equally effective treatment for patients with advanced PD refractory to medical treatment.,19234905_11,-1,-1,-1,8882,-1,0.01034755,0.98965245
8891,pains,4,5,29,34,Subjects also recalled their pains one week later.,19269743_5,-1,-1,-1,8891,-1,0.0051774257,0.9948226
8893,p<0.001,8,9,61,68,Capsaicin injection reliably induced a dose-dependent flare (p<0.001) without any difference within or across sessions.,19269743_6,-1,-1,-1,8893,-1,0.4744432,0.5255568
8897,p<0.001,15,16,101,108,"Subjects were able to reliably discriminate pain magnitude and duration across capsaicin doses (both p<0.001), regardless of whether first-time ratings were requested immediately, after one hour or after one day.",19269743_8,-1,-1,-1,8897,-1,0.39054745,0.6094525
8899,p<0.01,11,12,61,67,"Pain recall after one week was similarly precise (magnitude: p<0.01, duration: p<0.05).",19269743_9,-1,-1,-1,8899,-1,0.44755694,0.552443
8900,p<0.05,15,16,79,85,"Pain recall after one week was similarly precise (magnitude: p<0.01, duration: p<0.05).",19269743_9,-1,-1,-1,8900,-1,0.34830835,0.6516917
8903,myeloma,21,22,166,173,DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.,19274460_0,-1,-1,-1,8903,-1,0.0032669199,0.99673307
8905,bortezomib,15,16,104,114,A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).,19274460_1,-1,-1,-1,8905,-1,0.99903405,0.0009659257
8907,multiple myeloma,31,33,231,247,A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).,19274460_1,-1,-1,-1,8907,-1,0.0037644228,0.99623555
8908,MM,34,35,249,251,A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).,19274460_1,-1,-1,-1,8908,-1,0.0042374106,0.99576265
8909,bortezomib,9,10,57,67,"Thirty patients were treated with three 21-day cycles of bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900, 1,200, or 1,500 mg/m(2) on day 1.",19274460_2,-1,-1,-1,8909,-1,0.9991148,0.0008852329
8911,mg,26,27,126,128,"Thirty patients were treated with three 21-day cycles of bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900, 1,200, or 1,500 mg/m(2) on day 1.",19274460_2,-1,-1,-1,8911,-1,0.98886526,0.011134722
8912,bortezomib,31,32,143,153,"Thirty patients were treated with three 21-day cycles of bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900, 1,200, or 1,500 mg/m(2) on day 1.",19274460_2,-1,-1,-1,8912,-1,0.9990089,0.0009910865
8915,CR,8,9,46,48,"The overall response rate [complete response (CR) plus partial response (PR)] across all dose levels was 77%, with a 10% CR rate.",19274460_5,-1,-1,-1,8915,-1,0.011917089,0.98808295
8916,CR,29,30,121,123,"The overall response rate [complete response (CR) plus partial response (PR)] across all dose levels was 77%, with a 10% CR rate.",19274460_5,-1,-1,-1,8916,-1,0.008436603,0.9915633
8919,bortezomib,4,5,25,35,The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.,19274460_8,-1,-1,-1,8919,-1,0.9990171,0.0009829
8922,MM,25,26,176,178,The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.,19274460_8,-1,-1,-1,8922,-1,0.0053425236,0.99465746
8924,captopril overdose,6,8,40,58,Naloxone reversal of hypotension due to captopril overdose.,1928887_0,-1,-1,-1,8924,-1,0.768693,0.23130706
8929,captopril overdose,7,9,35,53,"We report a case of an intentional captopril overdose, manifested by marked hypotension, that resolved promptly with the administration of naloxone.",1928887_3,-1,-1,-1,8929,-1,0.7500266,0.24997337
8937,chondroitin sulfate,13,15,93,112,Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products.,19289093_0,-1,-1,-1,8937,-1,0.9986939,0.0013061004
8940,critically ill,9,11,62,76,Heparin is a commonly implemented anticoagulant used to treat critically ill patients.,19289093_1,-1,-1,-1,8940,-1,0.006496562,0.9935035
8942,chondroitin sulfate,18,20,109,128,"Recently, a number of commercial lots of heparin products were found to be contaminated with an oversulfated chondroitin sulfate (OSCS) derivative that could elicit a hypotensive response in pigs following a single high-dose infusion.",19289093_2,-1,-1,-1,8942,-1,0.9981238,0.0018761811
8950,Pneumocystis pneumonia,10,12,81,103,Severe and long lasting cholestasis after high-dose co-trimoxazole treatment for Pneumocystis pneumonia in HIV-infected patients--a report of two cases.,19299179_0,-1,-1,-1,8950,-1,0.043444358,0.9565556
8951,PCP,3,4,24,27,"Pneumocystis pneumonia (PCP), a common opportunistic infection in HIV-infected individuals, is generally treated with high doses of co-trimoxazole.",19299179_1,-1,-1,-1,8951,-1,0.008500051,0.99149996
8952,opportunistic infection,8,10,39,62,"Pneumocystis pneumonia (PCP), a common opportunistic infection in HIV-infected individuals, is generally treated with high doses of co-trimoxazole.",19299179_1,-1,-1,-1,8952,-1,0.0035190636,0.99648094
8953,intrahepatic cholestasis,14,16,99,123,"Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during co-trimoxazole treatment for PCP.",19299179_3,-1,-1,-1,8953,-1,0.004649166,0.99535084
8954,liver abscess,23,25,162,175,"Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during co-trimoxazole treatment for PCP.",19299179_3,-1,-1,-1,8954,-1,0.0036254213,0.99637455
8955,PCP,34,35,243,246,"Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during co-trimoxazole treatment for PCP.",19299179_3,-1,-1,-1,8955,-1,0.04759969,0.9524003
8956,cm,9,10,44,46,"Whereas patient 1 showed lesions of up to 1 cm readily detectable on magnetic resonance imaging under prolonged co-trimoxazole treatment, therapy of patient 2 was switched early.",19299179_4,-1,-1,-1,8956,-1,0.03186312,0.9681369
8957,apical ballooning syndrome,2,5,23,49,5 flourouracil-induced apical ballooning syndrome: a case report.,19300240_0,-1,-1,-1,8957,-1,0.01265605,0.9873439
8958,apical ballooning syndrome,1,4,4,30,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,-1,-1,-1,8958,-1,0.07399043,0.9260096
8959,ABS,5,6,32,35,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,-1,-1,-1,8959,-1,0.15888335,0.84111667
8960,acute cardiac syndrome,12,15,77,99,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,-1,-1,-1,8960,-1,0.00311693,0.9968831
8961,hyperkinesis,26,27,194,206,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,-1,-1,-1,8961,-1,0.0042508636,0.9957491
8962,LV,33,34,238,240,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,-1,-1,-1,8962,-1,0.1732171,0.8267829
8963,epicardial coronary disease,38,41,271,298,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,-1,-1,-1,8963,-1,0.007975298,0.9920248
8965,ABS,7,8,33,36,"However, there are no reports of ABS secondary to chemotherapeutic agents.",19300240_3,-1,-1,-1,8965,-1,0.13790673,0.86209327
8967,ischemic chest pain,6,9,43,62,"A 79-year-old woman presented with typical ischemic chest pain, elevated cardiac enzymes with significant ST-segment abnormalities on her electrocardiogram.",19300240_5,-1,-1,-1,8967,-1,0.003486753,0.9965133
8968,fluorouracil,5,6,39,51,She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer.,19300240_6,-1,-1,-1,8968,-1,0.99874395,0.0012560862
8971,akinesis,12,13,82,90,Echocardiogram revealed a normal ejection fraction and a resolution of the apical akinesis.,19300240_11,-1,-1,-1,8971,-1,0.0030079358,0.996992
8972,cardiac complications,3,5,27,48,"Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm, endothelial damage and consequent thrombus formation.",19300240_12,-1,-1,-1,8972,-1,0.0028889491,0.9971111
8974,coronary vasospasm,11,13,100,118,"Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm, endothelial damage and consequent thrombus formation.",19300240_12,-1,-1,-1,8974,-1,0.005439113,0.9945609
8975,thrombus,18,19,154,162,"Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm, endothelial damage and consequent thrombus formation.",19300240_12,-1,-1,-1,8975,-1,0.007139976,0.99286
8978,ABS,28,29,194,197,"In our patient, both supraphysiologic levels of plasma catecholamines and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of ABS.",19300240_13,-1,-1,-1,8978,-1,0.032814864,0.9671852
8979,nitric oxide,4,6,37,49,Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.,19300402_0,-1,-1,-1,8979,-1,0.99316156,0.006838383
8983,diabetic neuropathy,17,19,145,164,Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.,19300402_0,-1,-1,-1,8983,-1,0.0024655317,0.9975344
8985,HOE 140,68,70,385,392,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,-1,-1,-1,8985,-1,0.99765295,0.0023471105
8986,des Arg10 HOE 140,76,80,412,429,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,-1,-1,-1,8986,-1,0.9977143,0.002285673
8991,diabetic hyperalgesia,24,26,155,176,RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia.,19300402_3,-1,-1,-1,8991,-1,0.0031026155,0.99689734
8992,HOE 140,14,16,105,112,"Pretreatment with L-NOArg and L-NIL but not 7-NI, significantly increases antihyperalgesic activity both HOE 140 and des Arg10 HOE 140.",19300402_4,-1,-1,-1,8992,-1,0.9974915,0.002508565
8993,des Arg10 HOE 140,17,21,117,134,"Pretreatment with L-NOArg and L-NIL but not 7-NI, significantly increases antihyperalgesic activity both HOE 140 and des Arg10 HOE 140.",19300402_4,-1,-1,-1,8993,-1,0.99787843,0.0021215666
8997,HOE 140,12,14,80,87,"Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in toxic neuropathy.",19300402_6,-1,-1,-1,8997,-1,0.9981645,0.0018355175
8998,des-Arg10HOE 140,15,17,91,107,"Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in toxic neuropathy.",19300402_6,-1,-1,-1,8998,-1,0.9978974,0.0021025485
8999,toxic neuropathy,18,20,111,127,"Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in toxic neuropathy.",19300402_6,-1,-1,-1,8999,-1,0.0020018846,0.99799806
9001,toxic neuropathy,23,25,143,159,CONCLUSIONS: Results of these studies suggest that B1 and B2 receptors are engaged in transmission of nociceptive stimuli in both diabetic and toxic neuropathy.,19300402_7,-1,-1,-1,9001,-1,0.0029406506,0.99705935
9004,hyperalgesia bradykinin,17,19,148,171,"In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.",19300402_8,-1,-1,-1,9004,-1,0.28831038,0.71168965
9005,bradykinin receptor antagonists,8,11,56,87,"Therefore, concomitant administration of small doses of bradykinin receptor antagonists and NO synthase inhibitors can be effective in alleviation of neuropathic pain, even in hospital care.",19300402_9,-1,-1,-1,9005,-1,0.9964715,0.0035285132
9007,adverse drug reaction,5,8,28,49,"Confusion, a rather serious adverse drug reaction with valproic acid: a review of the French Pharmacovigilance database.",19308880_0,-1,-1,-1,9007,-1,0.0060008364,0.9939991
9008,valproic acid,9,11,55,68,"Confusion, a rather serious adverse drug reaction with valproic acid: a review of the French Pharmacovigilance database.",19308880_0,-1,-1,-1,9008,-1,0.9990626,0.00093741826
9010,adverse drug reaction,5,8,30,51,INTRODUCTION: Confusion is an adverse drug reaction frequently observed with valproic acid.,19308880_1,-1,-1,-1,9010,-1,0.009844342,0.9901557
9011,valproic acid,11,13,77,90,INTRODUCTION: Confusion is an adverse drug reaction frequently observed with valproic acid.,19308880_1,-1,-1,-1,9011,-1,0.9991425,0.00085742783
9012,adverse drug reaction,13,16,78,99,We performed this study in order to describe the main characteristics of this adverse drug reaction.,19308880_3,-1,-1,-1,9012,-1,0.018108994,0.981891
9014,valproic acid,18,20,114,127,"METHODS: Using the French Pharmacovigilance database, we selected the cases of confusion reported since 1985 with valproic acid.",19308880_4,-1,-1,-1,9014,-1,0.9991067,0.00089330436
9016,valproic acid,9,11,51,64,RESULTS: 272 cases of confusion were reported with valproic acid: 153 women and 119 men.,19308880_5,-1,-1,-1,9016,-1,0.9991289,0.0008710847
9017,valproic acid,9,11,63,76,Confusion mostly occurred during the two first weeks following valproic acid exposure (39.7%).,19308880_6,-1,-1,-1,9017,-1,0.9990976,0.00090243417
9018,ADR,4,5,23,26,The occurrence of this ADR was more frequent in patients aged between 61 and 80 years.,19308880_8,-1,-1,-1,9018,-1,0.06959317,0.93040687
9020,valproic acid,8,10,48,61,"CONCLUSION: This work shows that confusion with valproic acid is a serious, rather frequent but reversible adverse drug reaction.",19308880_9,-1,-1,-1,9020,-1,0.99921966,0.00078035187
9021,adverse drug reaction,18,21,107,128,"CONCLUSION: This work shows that confusion with valproic acid is a serious, rather frequent but reversible adverse drug reaction.",19308880_9,-1,-1,-1,9021,-1,0.012896546,0.9871034
9023,intracerebral hemorrhage,13,15,100,124,Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage.,19319147_0,-1,-1,-1,9023,-1,0.0023288988,0.99767107
9024,intracerebral hemorrhage,1,3,20,44,Warfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke.,19319147_1,-1,-1,-1,9024,-1,0.0029220115,0.99707806
9026,prothrombin complex concentrate,15,18,89,120,"Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume.",19319147_3,-1,-1,-1,9026,-1,0.9958553,0.004144649
9027,PCC,19,20,122,125,"Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume.",19319147_3,-1,-1,-1,9027,-1,0.9958593,0.0041407226
9030,h,12,13,59,60,"Male CD-1 mice were treated with warfarin (2 mg/kg over 24 h), resulting in a mean (+/-s.d.) International Normalized Ratio of 3.5+/-0.9.",19319147_4,-1,-1,-1,9030,-1,0.25645646,0.74354357
9031,PCC,10,11,61,64,"First, we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice.",19319147_5,-1,-1,-1,9031,-1,0.9983145,0.0016855733
9033,PCC,10,11,65,68,"Forty-five minutes later, the animals were randomly treated with PCC (100 U/kg) or saline i.v. (n=12 per group).",19319147_7,-1,-1,-1,9033,-1,0.9986203,0.001379785
9034,n=12,20,21,96,100,"Forty-five minutes later, the animals were randomly treated with PCC (100 U/kg) or saline i.v. (n=12 per group).",19319147_7,-1,-1,-1,9034,-1,0.3979955,0.60200447
9038,P=0.015,22,23,139,146,"The mean hemorrhagic blood volume was reduced in PCC-treated animals (6.5+/-3.1 microL) compared with saline controls (15.3+/-11.2 microL, P=0.015).",19319147_9,-1,-1,-1,9038,-1,0.3356976,0.66430247
9039,hematomas,12,13,53,62,"In the saline group, 45% of the mice developed large hematomas (i.e., >15 microL).",19319147_10,-1,-1,-1,9039,-1,0.0026841417,0.9973158
9040,contrast,1,2,3,11,"In contrast, such extensive lesions were never found in the PCC group.",19319147_11,-1,-1,-1,9040,-1,0.15654163,0.8434584
9041,PCC,11,12,60,63,"In contrast, such extensive lesions were never found in the PCC group.",19319147_11,-1,-1,-1,9041,-1,0.9607778,0.03922215
9042,PCC,5,6,40,43,We provide experimental data suggesting PCC to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume.,19319147_12,-1,-1,-1,9042,-1,0.9980259,0.0019741838
9044,inferior colliculus lesion,1,4,11,37,Reversible inferior colliculus lesion in metronidazole-induced encephalopathy: magnetic resonance findings on diffusion-weighted and fluid attenuated inversion recovery imaging.,19346865_0,-1,-1,-1,9044,-1,0.026769947,0.9732301
9046,inferior colliculus lesions,7,10,41,68,"OBJECTIVE: This is to present reversible inferior colliculus lesions in metronidazole-induced encephalopathy, to focus on the diffusion-weighted imaging (DWI) and fluid attenuated inversion recovery (FLAIR) imaging.",19346865_1,-1,-1,-1,9046,-1,0.020578079,0.979422
9051,map,26,27,146,149,"Initial brain magnetic resonance imaging (MRI) were obtained after the hospitalization, including DWI (8/8), apparent diffusion coefficient (ADC) map (4/8), FLAIR (7/8), and T2-weighted image (8/8).",19346865_4,-1,-1,-1,9051,-1,0.8457661,0.15423384
9053,map,13,14,80,83,"High-signal intensity lesions on DWI tended to show low signal intensity on ADC map (3/4), but in one patient, high signal intensity was shown at bilateral dentate nuclei on not only DWI but also ADC map.",19346865_8,-1,-1,-1,9053,-1,0.15552004,0.84448
9054,map,39,40,200,203,"High-signal intensity lesions on DWI tended to show low signal intensity on ADC map (3/4), but in one patient, high signal intensity was shown at bilateral dentate nuclei on not only DWI but also ADC map.",19346865_8,-1,-1,-1,9054,-1,0.15047868,0.84952134
9055,callosal lesion,32,34,163,178,"All the lesions in dentate, inferior colliculus, pons, and medullas had been resolved completely on follow-up MRIs in 5 patients, but in 1 patient of them, corpus callosal lesion persisted.",19346865_9,-1,-1,-1,9055,-1,0.09158186,0.9084181
9056,inferior colliculus lesions,3,6,24,51,"CONCLUSIONS: Reversible inferior colliculus lesions could be considered as the characteristic for metronidazole-induced encephalopathy, next to the dentate nucleus involvement.",19346865_10,-1,-1,-1,9056,-1,0.044017628,0.9559824
9062,calcineurin,19,20,125,136,"BACKGROUND: Sirolimus is the latest immunosuppressive agent used to prevent rejection, and may have less nephrotoxicity than calcineurin inhibitor (CNI)-based regimens.",19356053_1,-1,-1,-1,9062,-1,0.99841714,0.0015828167
9089,PA,16,17,111,113,The anti-dementia effects of s-limonene and s-perillyl alcohol were observed using the passive avoidance test (PA) and the open field habituation test (OFH).,19356307_1,-1,-1,-1,9089,-1,0.77646756,0.22353244
9090,memory impaired,9,11,60,75,"These lemon essential oils showed strong ability to improve memory impaired by scopolamine; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH.",19356307_2,-1,-1,-1,9090,-1,0.0046799346,0.99532
9093,deficit of associative memory,20,24,133,162,"These lemon essential oils showed strong ability to improve memory impaired by scopolamine; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH.",19356307_2,-1,-1,-1,9093,-1,0.006880834,0.9931191
9094,PA,25,26,166,168,"These lemon essential oils showed strong ability to improve memory impaired by scopolamine; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH.",19356307_2,-1,-1,-1,9094,-1,0.9929469,0.0070530637
9098,HT,5,6,29,31,"BACKGROUND: Hormone therapy (HT) is widely used for controlling menopausal symptoms and has also been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women.",19370593_1,-1,-1,-1,9098,-1,0.9937795,0.0062205615
9099,menopausal symptoms,12,14,64,83,"BACKGROUND: Hormone therapy (HT) is widely used for controlling menopausal symptoms and has also been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women.",19370593_1,-1,-1,-1,9099,-1,0.025825428,0.9741745
9100,cardiovascular disease,25,27,144,166,"BACKGROUND: Hormone therapy (HT) is widely used for controlling menopausal symptoms and has also been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women.",19370593_1,-1,-1,-1,9100,-1,0.00422686,0.99577314
9103,HT,8,9,46,48,"OBJECTIVES: To assess the effect of long-term HT on mortality, cardiovascular outcomes, cancer, gallbladder disease, cognition, fractures and quality of life.",19370593_3,-1,-1,-1,9103,-1,0.99654937,0.0034506381
9107,Menstrual Disorders,17,19,103,122,"SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.",19370593_4,-1,-1,-1,9107,-1,0.032513984,0.967486
9108,Subfertility,20,21,127,139,"SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.",19370593_4,-1,-1,-1,9108,-1,0.028187444,0.97181255
9109,HT,7,8,54,56,"SELECTION CRITERIA: Randomised double-blind trials of HT versus placebo, taken for at least one year by perimenopausal or postmenopausal women.",19370593_6,-1,-1,-1,9109,-1,0.99810517,0.0018948285
9110,oestrogens,2,3,12,22,"HT included oestrogens, with or without progestogens, via oral, transdermal, subcutaneous or transnasal routes.",19370593_7,-1,-1,-1,9110,-1,0.99860483,0.0013951941
9111,progestogens,7,8,40,52,"HT included oestrogens, with or without progestogens, via oral, transdermal, subcutaneous or transnasal routes.",19370593_7,-1,-1,-1,9111,-1,0.99833244,0.0016676006
9112,HT,7,8,49,51,"In relatively healthy women, combined continuous HT significantly increased the risk of venous thrombo-embolism or coronary event (after one year's use), stroke (after three years), breast cancer and gallbladder disease.",19370593_10,-1,-1,-1,9112,-1,0.99809223,0.0019077484
9116,HT,2,3,25,27,"Long-term oestrogen-only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.",19370593_11,-1,-1,-1,9116,-1,0.9973024,0.0026976038
9120,HT,6,7,47,49,"The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.",19370593_12,-1,-1,-1,9120,-1,0.9971022,0.0028977671
9122,HT,17,18,108,110,"The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.",19370593_12,-1,-1,-1,9122,-1,0.99547464,0.0045254133
9123,colon cancer,19,21,112,124,"The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.",19370593_12,-1,-1,-1,9123,-1,0.004628576,0.9953714
9124,HT,22,23,128,130,"Among women aged over 65 who were relatively healthy (i.e. generally fit, without overt disease) and taking continuous combined HT, there was a statistically significant increase in the incidence of dementia.",19370593_13,-1,-1,-1,9124,-1,0.9981153,0.0018847443
9126,cardiovascular disease,3,5,17,39,"Among women with cardiovascular disease, long-term use of combined continuous HT significantly increased the risk of venous thrombo-embolism.",19370593_14,-1,-1,-1,9126,-1,0.003033079,0.9969669
9127,HT,11,12,78,80,"Among women with cardiovascular disease, long-term use of combined continuous HT significantly increased the risk of venous thrombo-embolism.",19370593_14,-1,-1,-1,9127,-1,0.9981415,0.0018584295
9128,HT,17,18,107,109,"One trial analysed subgroups of 2839 relatively healthy 50 to 59 year old women taking combined continuous HT and 1637 taking oestrogen-only HT, versus similar-sized placebo groups.",19370593_15,-1,-1,-1,9128,-1,0.9982014,0.0017985778
9129,HT,22,23,141,143,"One trial analysed subgroups of 2839 relatively healthy 50 to 59 year old women taking combined continuous HT and 1637 taking oestrogen-only HT, versus similar-sized placebo groups.",19370593_15,-1,-1,-1,9129,-1,0.9973851,0.0026148676
9130,HT,15,16,115,117,"The only significantly increased risk reported was for venous thrombo-embolism in women taking combined continuous HT: their absolute risk remained low, at less than 1/500.",19370593_16,-1,-1,-1,9130,-1,0.9974693,0.002530714
9131,HT,4,5,22,24,AUTHORS' CONCLUSIONS: HT is not indicated for the routine management of chronic disease.,19370593_18,-1,-1,-1,9131,-1,0.99539137,0.0046086847
9132,chronic disease,13,15,72,87,AUTHORS' CONCLUSIONS: HT is not indicated for the routine management of chronic disease.,19370593_18,-1,-1,-1,9132,-1,0.0049517956,0.9950482
9133,HT,8,9,39,41,"We need more evidence on the safety of HT for menopausal symptom control, though short-term use appears to be relatively safe for healthy younger women.",19370593_19,-1,-1,-1,9133,-1,0.99693763,0.003062386
9141,painful,19,20,125,132,Here we show that perceived pain intensity in secondary hyperalgesia is decreased when attention is distracted away from the painful pinprick stimulus with a visual task.,19387625_3,-1,-1,-1,9141,-1,0.022339007,0.977661
9146,salvianolic acid A,3,6,27,45,Cardioprotective effect of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.,19445921_0,-1,-1,-1,9146,-1,0.9970305,0.0029695316
9147,myocardial infarction,8,10,71,92,Cardioprotective effect of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.,19445921_0,-1,-1,-1,9147,-1,0.0025386505,0.9974613
9148,salvianolic acid A,11,14,77,95,The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.,19445921_1,-1,-1,-1,9148,-1,0.9969072,0.0030928736
9149,myocardial infarction,16,18,121,142,The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.,19445921_1,-1,-1,-1,9149,-1,0.0024363238,0.9975637
9150,lead,3,4,27,31,Hemodynamic parameters and lead II electrocardiograph were monitored and recorded continuously.,19445921_2,-1,-1,-1,9150,-1,0.92824,0.07175999
9151,lactate,9,10,73,80,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,-1,-1,-1,9151,-1,0.9980596,0.0019403904
9153,creatine kinase,15,17,120,135,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,-1,-1,-1,9153,-1,0.9971409,0.0028591594
9155,superoxide dismutase,26,28,203,223,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,-1,-1,-1,9155,-1,0.99806684,0.0019331512
9156,glutathione peroxidase,31,33,238,260,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,-1,-1,-1,9156,-1,0.9917352,0.00826483
9157,respiratory dysfunction,4,6,27,50,"In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats.",19445921_7,-1,-1,-1,9157,-1,0.00893586,0.9910642
9158,salvianolic acid A,2,5,18,36,Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function.,19445921_8,-1,-1,-1,9158,-1,0.9977157,0.0022842817
9161,salvianolic acid A,4,7,23,41,The protective role of salvianolic acid A against isoproterenol-induced myocardial damage was further confirmed by histopathological examination.,19445921_9,-1,-1,-1,9161,-1,0.9970113,0.0029886758
9163,salvianolic acid A,7,10,38,56,The results of our study suggest that salvianolic acid A possessing antioxidant activity has a significant protective effect against isoproterenol-induced myocardial infarction.,19445921_10,-1,-1,-1,9163,-1,0.99619895,0.0038009915
9164,myocardial infarction,20,22,155,176,The results of our study suggest that salvianolic acid A possessing antioxidant activity has a significant protective effect against isoproterenol-induced myocardial infarction.,19445921_10,-1,-1,-1,9164,-1,0.0024673808,0.9975326
9170,PAC,14,15,101,104,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,-1,-1,-1,9170,-1,0.99824643,0.0017536159
9172,amino acid glutamine,23,26,150,170,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,-1,-1,-1,9172,-1,0.9851109,0.014889184
9173,PAC neurotoxicity,30,32,198,215,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,-1,-1,-1,9173,-1,0.24716295,0.75283706
9178,mg,37,38,226,228,"Forty-three ovarian cancer patients were available for analysis following six cycles of the same PAC-containing regimen: 23 had been supplemented by glutamate all along the treatment period, at a daily dose of three times 500 mg (group G), and 20 had received a placebo (group P).",19473225_3,-1,-1,-1,9178,-1,0.97315854,0.026841428
9179,P,51,52,277,278,"Forty-three ovarian cancer patients were available for analysis following six cycles of the same PAC-containing regimen: 23 had been supplemented by glutamate all along the treatment period, at a daily dose of three times 500 mg (group G), and 20 had received a placebo (group P).",19473225_3,-1,-1,-1,9179,-1,0.84190226,0.15809771
9182,P,44,45,291,292,"There was no significant difference in the frequency of signs or symptoms between the two groups although neurotoxicity symptoms presented mostly with lower scores of severity in group G. However, this difference reached statistical significance only with regard to reported pain sensation (P = 0.011).",19473225_5,-1,-1,-1,9182,-1,0.2871363,0.7128637
9183,P,21,22,118,119,Also the frequency of abnormal electro-diagnostic findings showed similarity between the two groups (G: 7/23 = 30.4%; P: 6/20 = 30%).,19473225_6,-1,-1,-1,9183,-1,0.36903456,0.6309654
9186,PAC,21,22,147,150,This pilot study leads to the conclusion that glutamate supplementation at the chosen regimen fails to protect against peripheral neurotoxicity of PAC.,19473225_7,-1,-1,-1,9186,-1,0.993697,0.006303017
9187,ocular myasthenia,2,4,15,32,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9187,-1,0.0024845316,0.99751544
9188,pegylated interferon,5,7,40,60,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9188,-1,0.99872774,0.0012722682
9190,chronic hepatitis C.A,11,14,89,110,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9190,-1,0.036709342,0.9632907
9191,sudden diplopia,17,19,140,155,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9191,-1,0.0023484936,0.9976515
9192,pegylated interferon (IFN) alpha-2b,25,31,191,226,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9192,-1,0.9973431,0.002656856
9194,chronic hepatitis C,34,37,245,264,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9194,-1,0.005874766,0.99412525
9195,CHC,38,39,266,269,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,-1,-1,-1,9195,-1,0.0034274757,0.9965725
9196,ptosis on the right upper lid,3,9,35,64,Ophthalmologic examinations showed ptosis on the right upper lid and restricted right eye movement without any other neurological signs.,19581773_1,-1,-1,-1,9196,-1,0.023816274,0.97618365
9197,restricted right eye movement,10,14,69,98,Ophthalmologic examinations showed ptosis on the right upper lid and restricted right eye movement without any other neurological signs.,19581773_1,-1,-1,-1,9197,-1,0.009473614,0.9905263
9199,acetylcholinesterase inhibitors,8,10,58,89,"The acetylcholine receptor antibody titer and response to acetylcholinesterase inhibitors were negative, and the results of thyroid function tests were normal.",19581773_3,-1,-1,-1,9199,-1,0.9970445,0.0029555329
9200,pegylated IFN alpha-2b,12,15,90,112,The patient's ophthalmological symptoms improved rapidly 3 weeks after discontinuation of pegylated IFN alpha-2b and ribavirin.,19581773_4,-1,-1,-1,9200,-1,0.99819356,0.0018063928
9202,ocular myasthenia,1,3,4,21,"The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.",19581773_5,-1,-1,-1,9202,-1,0.002403705,0.9975963
9203,pegylated IFN alpha-2b,8,11,61,83,"The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.",19581773_5,-1,-1,-1,9203,-1,0.99803835,0.0019616943
9205,CHC,14,15,102,105,"The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.",19581773_5,-1,-1,-1,9205,-1,0.0044306996,0.9955693
9206,IFN,35,36,213,216,"The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.",19581773_5,-1,-1,-1,9206,-1,0.99806565,0.0019343753
9207,memory deficits,2,4,13,28,Learning and memory deficits in ecstasy users and their neural correlates during a face-learning task.,19631624_0,-1,-1,-1,9207,-1,0.004395459,0.9956045
9216,hypoactivity,10,11,82,94,Deficits in learning and memory: parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users.,19631624_5,-1,-1,-1,9216,-1,0.007220144,0.9927799
9221,hypoactivity,1,2,17,29,Ecstasy-specific hypoactivity was evident in the right dorsal anterior cingulated cortex (ACC) and left posterior cingulated cortex.,19631624_9,-1,-1,-1,9221,-1,0.0046223714,0.99537766
9227,AIDS,6,7,37,41,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.,19642243_0,-1,-1,-1,9227,-1,0.008184059,0.991816
9228,tenofovir,8,9,45,54,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.,19642243_0,-1,-1,-1,9228,-1,0.9992244,0.00077559584
9230,osteomyelitis,15,16,103,116,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.,19642243_0,-1,-1,-1,9230,-1,0.0024534538,0.9975465
9232,tenofovir disoproxil fumarate,16,19,104,133,Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.,19642243_1,-1,-1,-1,9232,-1,0.9988298,0.0011702089
9233,Fanconi syndrome,8,10,52,68,Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule.,19642243_2,-1,-1,-1,9233,-1,0.046129547,0.9538705
9234,renal insufficiency,11,13,73,92,Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule.,19642243_2,-1,-1,-1,9234,-1,0.0026403943,0.9973596
9235,Vancomycin nephrotoxicity,0,2,0,25,Vancomycin nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent.,19642243_3,-1,-1,-1,9235,-1,0.05395949,0.94604045
9237,tenofovir,5,6,32,41,Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin.,19642243_4,-1,-1,-1,9237,-1,0.99923944,0.00076054386
9238,renal failure,11,13,64,77,Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin.,19642243_4,-1,-1,-1,9238,-1,0.002300108,0.9976999
9240,hydrogen cyanamide,3,5,31,49,Disulfiram-like syndrome after hydrogen cyanamide professional skin exposure: two case reports in France.,19657887_0,-1,-1,-1,9240,-1,0.99920636,0.0007936702
9241,Hydrogen cyanamide,0,2,0,18,Hydrogen cyanamide is a plant growth regulator used in agriculture to induce bud break in fruit trees.,19657887_1,-1,-1,-1,9241,-1,0.9990626,0.00093745627
9242,aldehyde dehydrogenase,14,16,91,113,Contact with the skin can result in percutaneous absorption of the substance that inhibits aldehyde dehydrogenase and can induce acetaldehyde syndrome in case of alcohol use.,19657887_2,-1,-1,-1,9242,-1,0.9897305,0.010269498
9243,acetaldehyde,19,20,129,141,Contact with the skin can result in percutaneous absorption of the substance that inhibits aldehyde dehydrogenase and can induce acetaldehyde syndrome in case of alcohol use.,19657887_2,-1,-1,-1,9243,-1,0.998965,0.0010349266
9245,hydrogen cyanamide,18,20,117,135,The purpose of this report is to describe two cases of a disulfiram-like syndrome following occupational exposure to hydrogen cyanamide.,19657887_3,-1,-1,-1,9245,-1,0.9992902,0.00070979213
9246,Dormex,9,10,51,57,"The first case involved a 59-year-old man who used Dormex, which contains hydrogen cyanamide, without protection after consuming a large amount of alcohol during a meal.",19657887_4,-1,-1,-1,9246,-1,0.9983333,0.0016666861
9247,hydrogen cyanamide,13,15,74,92,"The first case involved a 59-year-old man who used Dormex, which contains hydrogen cyanamide, without protection after consuming a large amount of alcohol during a meal.",19657887_4,-1,-1,-1,9247,-1,0.99899954,0.0010004591
9250,malaise,13,14,65,72,"In less than 1 hour after the ingestion of alcohol, he developed malaise with flushing of the face, tachycardia, and dyspnea.",19657887_5,-1,-1,-1,9250,-1,0.0030848326,0.9969151
9251,flushing of the face,15,19,78,98,"In less than 1 hour after the ingestion of alcohol, he developed malaise with flushing of the face, tachycardia, and dyspnea.",19657887_5,-1,-1,-1,9251,-1,0.008648616,0.99135137
9253,dyspnea,23,24,117,124,"In less than 1 hour after the ingestion of alcohol, he developed malaise with flushing of the face, tachycardia, and dyspnea.",19657887_5,-1,-1,-1,9253,-1,0.00323748,0.9967625
9254,Dormex,12,13,82,88,The second case occurred in a 55-year-old farmer following cutaneous contact with Dormex.,19657887_7,-1,-1,-1,9254,-1,0.9982539,0.0017460603
9255,flushing,10,11,70,78,"Five hours after exposure, he developed disulfiram-like syndrome with flushing, tachycardia, and arterial hypotension after consuming three glasses of wine.",19657887_8,-1,-1,-1,9255,-1,0.008961601,0.99103844
9257,arterial hypotension,15,17,97,117,"Five hours after exposure, he developed disulfiram-like syndrome with flushing, tachycardia, and arterial hypotension after consuming three glasses of wine.",19657887_8,-1,-1,-1,9257,-1,0.0028077038,0.9971923
9259,Dormex,17,18,112,118,These cases confirm the necessity of avoiding alcohol consumption as recommended in the instructions for use of Dormex and of preventing cutaneous contact during use.,19657887_10,-1,-1,-1,9259,-1,0.99855286,0.001447189
9260,dysosmia,1,2,10,18,Recurrent dysosmia induced by pyrazinamide.,19674115_0,-1,-1,-1,9260,-1,0.002139512,0.9978605
9261,pyrazinamide,4,5,30,42,Recurrent dysosmia induced by pyrazinamide.,19674115_0,-1,-1,-1,9261,-1,0.9991621,0.00083797344
9263,hyperuricemia,10,11,64,77,"Pyrazinamide can have adverse effects such as hepatic toxicity, hyperuricemia or digestive disorders.",19674115_1,-1,-1,-1,9263,-1,0.005997811,0.99400216
9264,pyrazinamide,14,15,78,90,"In rare cases, alterations in taste and smell function have been reported for pyrazinamide when combined with other drugs.",19674115_2,-1,-1,-1,9264,-1,0.9993542,0.0006457624
9265,olfactory disorder,6,8,31,49,"We report a case of reversible olfactory disorder related to pyrazinamide in a woman, with a positive rechallenge.",19674115_3,-1,-1,-1,9265,-1,0.0031038325,0.99689615
9266,pyrazinamide,10,11,61,73,"We report a case of reversible olfactory disorder related to pyrazinamide in a woman, with a positive rechallenge.",19674115_3,-1,-1,-1,9266,-1,0.9993437,0.00065624836
9267,pyrazinamide,4,5,38,50,Dysosmia disappeared completely after pyrazinamide withdrawal and recurred after its rechallenge.,19674115_5,-1,-1,-1,9267,-1,0.99929965,0.00070033496
9268,tardive dystonia,1,3,18,34,Sulpiride-induced tardive dystonia.,1967484_0,-1,-1,-1,9268,-1,0.0023358427,0.9976642
9270,antipsychotic,7,8,53,66,Sulpiride is a selective D2-receptor antagonist with antipsychotic and antidepressant properties.,1967484_1,-1,-1,-1,9270,-1,0.9967674,0.0032325767
9272,tardive dyskinesia,12,14,88,106,"Although initially thought to be free of extrapyramidal side effects, sulpiride-induced tardive dyskinesia and parkinsonism have been reported occasionally.",1967484_2,-1,-1,-1,9272,-1,0.0021535985,0.99784636
9276,tardive dystonia,9,11,60,76,We could not find any previous reports of sulpiride-induced tardive dystonia.,1967484_4,-1,-1,-1,9276,-1,0.0020525944,0.9979474
9279,prostaglandin,9,10,49,62,"However, the involvement of a specific, terminal prostaglandin (PG) isomerase has not been evaluated.",19692487_2,-1,-1,-1,9279,-1,0.9954027,0.004597306
9280,PG,11,12,64,66,"However, the involvement of a specific, terminal prostaglandin (PG) isomerase has not been evaluated.",19692487_2,-1,-1,-1,9280,-1,0.9938095,0.006190425
9282,prostaglandin,14,15,100,113,The present study was undertaken to assess lithium-induced polyuria in mice deficient in microsomal prostaglandin E synthase-1 (mPGES-1).,19692487_3,-1,-1,-1,9282,-1,0.97881615,0.021183843
9283,LiCl,4,5,25,29,A 2-wk administration of LiCl (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked polyuria with hyposmotic urine.,19692487_4,-1,-1,-1,9283,-1,0.99889416,0.0011058588
9285,PGE(2,12,13,87,92,This was associated with elevated renal mPGES-1 protein expression and increased urine PGE(2) excretion.,19692487_5,-1,-1,-1,9285,-1,0.99359494,0.0064050923
9286,),13,14,92,93,This was associated with elevated renal mPGES-1 protein expression and increased urine PGE(2) excretion.,19692487_5,-1,-1,-1,9286,-1,0.98012114,0.01987879
9287,contrast,1,2,3,11,"In contrast, mPGES-1 -/- mice were largely resistant to lithium-induced polyuria and a urine concentrating defect, accompanied by nearly complete blockade of high urine PGE(2) and cAMP output.",19692487_6,-1,-1,-1,9287,-1,0.095027484,0.9049725
9289,PGE(2),26,28,169,175,"In contrast, mPGES-1 -/- mice were largely resistant to lithium-induced polyuria and a urine concentrating defect, accompanied by nearly complete blockade of high urine PGE(2) and cAMP output.",19692487_6,-1,-1,-1,9289,-1,0.98961467,0.010385324
9290,cAMP,29,30,180,184,"In contrast, mPGES-1 -/- mice were largely resistant to lithium-induced polyuria and a urine concentrating defect, accompanied by nearly complete blockade of high urine PGE(2) and cAMP output.",19692487_6,-1,-1,-1,9290,-1,0.99729127,0.0027087026
9292,contrast,1,2,3,11,"In contrast, the dowregulation of renal medullary NKCC2 expression was significantly attenuated in the -/- mice.",19692487_11,-1,-1,-1,9292,-1,0.1790423,0.82095766
9293,PGE(2),4,6,33,39,We conclude that mPGES-1-derived PGE(2) mediates lithium-induced polyuria likely via inhibition of AQP2 and NKCC2 expression.,19692487_12,-1,-1,-1,9293,-1,0.9936121,0.006387937
9296,fenoldopam,9,10,65,75,Preservation of renal blood flow during hypotension induced with fenoldopam in dogs.,1969772_0,-1,-1,-1,9296,-1,0.9992161,0.00078391866
9298,Fenoldopam mesylate,0,2,0,19,Fenoldopam mesylate is a specific DA1 receptor agonist that lowers blood pressure by vasodilatation.,1969772_3,-1,-1,-1,9298,-1,0.99915206,0.00084792083
9299,fenoldopam,3,4,20,30,The hypothesis that fenoldopam could be used to induce hypotension and preserve blood flow to the kidney was tested.,1969772_4,-1,-1,-1,9299,-1,0.99929297,0.0007070647
9301,fenoldopam,34,35,229,239,"Systemic aortic blood pressure and renal blood flow were measured continuously with a carotid arterial catheter and an electromagnetic flow probe respectively, in order to compare the cardiovascular and renal vascular effects of fenoldopam and sodium nitroprusside in ten dogs under halothane general anaesthesia.",1969772_5,-1,-1,-1,9301,-1,0.9993136,0.00068637053
9304,fenoldopam,16,17,85,95,Mean arterial pressure was decreased 30 +/- 8 per cent from control with infusion of fenoldopam (3.4 +/- 2.0 micrograms.kg-1.min-1) and 34 +/- 4 per cent with infusion of sodium nitroprusside (5.9 micrograms.kg-1.min-1) (NS).,1969772_6,-1,-1,-1,9304,-1,0.99922884,0.0007711812
9306,NS,41,42,221,223,Mean arterial pressure was decreased 30 +/- 8 per cent from control with infusion of fenoldopam (3.4 +/- 2.0 micrograms.kg-1.min-1) and 34 +/- 4 per cent with infusion of sodium nitroprusside (5.9 micrograms.kg-1.min-1) (NS).,1969772_6,-1,-1,-1,9306,-1,0.11798108,0.882019
9310,P,29,30,170,171,Renal blood flow (RBF) increased during fenoldopam-induced hypotension 11 +/- 7 per cent and decreased 21 +/- 8 per cent during sodium nitroprusside-induced hypotension (P less than 0.01).,1969772_7,-1,-1,-1,9310,-1,0.36479023,0.63520974
9313,Fenoldopam,0,1,0,10,Fenoldopam is a selective dopamine-1 (DA1) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced hypotension.,1969772_9,-1,-1,-1,9313,-1,0.9992392,0.0007607667
9324,Etodolac,0,1,0,8,"Etodolac (E), is a non-narcotic analgesic and antiinflammatory drug.",19719056_1,-1,-1,-1,9324,-1,0.9991327,0.00086729776
9325,E,2,3,10,11,"Etodolac (E), is a non-narcotic analgesic and antiinflammatory drug.",19719056_1,-1,-1,-1,9325,-1,0.99598384,0.0040161307
9327,etodolac,8,9,56,64,"An activated moiety, i.e. N-acylimidazole derivative of etodolac (EAI), was condensed with the polysaccharide polymer dextran of different molecular weights (40000, 60000, 110000 and 200000).",19719056_3,-1,-1,-1,9327,-1,0.99862456,0.0013754449
9328,EAI,10,11,66,69,"An activated moiety, i.e. N-acylimidazole derivative of etodolac (EAI), was condensed with the polysaccharide polymer dextran of different molecular weights (40000, 60000, 110000 and 200000).",19719056_3,-1,-1,-1,9328,-1,0.99237704,0.00762293
9330,Etodolac,0,1,0,8,Etodolac contents were evaluated by UV-spectrophotometric analysis.,19719056_5,-1,-1,-1,9330,-1,0.9986349,0.001365108
9331,etodolac,8,9,26,34,"At pH 9, a higher rate of etodolac release from ED was observed as compared to aqueous buffer of pH 7.4 and 80% human plasma (pH 7.4), following first-order kinetics.",19719056_8,-1,-1,-1,9331,-1,0.9991211,0.0008788145
9332,acetic acid,8,10,71,82,"Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively.",19719056_10,-1,-1,-1,9332,-1,0.9982231,0.0017769159
9333,writhing,11,12,91,99,"Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively.",19719056_10,-1,-1,-1,9333,-1,0.004351244,0.9956488
9335,E,5,6,26,27,"In comparison to control, E and ED1-ED4 showed highly significant analgesic and antiinflammatory activities (p <0.001).",19719056_11,-1,-1,-1,9335,-1,0.9969457,0.0030543373
9336,p,16,17,109,110,"In comparison to control, E and ED1-ED4 showed highly significant analgesic and antiinflammatory activities (p <0.001).",19719056_11,-1,-1,-1,9336,-1,0.34264317,0.6573568
9337,etodolac,25,26,193,201,Biological evaluation suggested that conjugates (ED1-ED4) retained comparable analgesic and antiinflammatory activities with remarkably reduced ulcerogenicity as compared to their parent drug--etodolac.,19719056_12,-1,-1,-1,9337,-1,0.9989404,0.0010596259
9344,fibrillation,20,21,142,154,"The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.",19721134_3,-1,-1,-1,9344,-1,0.0030763056,0.9969236
9346,arrhythmic,32,33,217,227,"The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.",19721134_3,-1,-1,-1,9346,-1,0.00277027,0.99722975
9347,aconitine,5,6,32,41,[Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.,19721134_4,-1,-1,-1,9347,-1,0.9987085,0.0012915308
9351,4-DAMP,9,10,68,74,"Moreover, M(3)-muscarinic acetylcholine receptor (mAChR) antagonist 4-DAMP (4-diphenylacetoxy-N-methylpiperidine-methiodide) partially abolished the beneficial effects of pilocarpine.",19721134_5,-1,-1,-1,9351,-1,0.9957688,0.0042312904
9354,arrhythmic,9,10,71,81,These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR. The mechanism may be related to the improvement of Ca(2+) handling.,19721134_6,-1,-1,-1,9354,-1,0.0024517623,0.9975483
9355,aconitine,17,18,119,128,These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR. The mechanism may be related to the improvement of Ca(2+) handling.,19721134_6,-1,-1,-1,9355,-1,0.9988225,0.0011774366
9360,blind,9,10,66,71,"Seventy-one participants completed 2 separate study days and were blind to medication condition (placebo, 10-mg oxycodone).",19729346_2,-1,-1,-1,9360,-1,0.23378673,0.7662133
9363,P,11,12,74,75,"Plasma oxycodone concentration peaked between 60 and 90 minutes postdose (P < .01) and pupil size, an indication of physiological effects of the medication, peaked at approximately 90 to 120 minutes postdose (P < .01).",19729346_3,-1,-1,-1,9363,-1,0.33021933,0.6697806
9364,P,37,38,209,210,"Plasma oxycodone concentration peaked between 60 and 90 minutes postdose (P < .01) and pupil size, an indication of physiological effects of the medication, peaked at approximately 90 to 120 minutes postdose (P < .01).",19729346_3,-1,-1,-1,9364,-1,0.30709308,0.6929069
9365,chronic pain,13,15,77,89,"This study suggests that for healthy older adults who are not suffering from chronic pain, neurocognitive and pharmacodynamic changes in response to a 10-mg dose of immediate-release oxycodone are similar to those observed for middle-aged adults.",19729346_6,-1,-1,-1,9365,-1,0.0034878696,0.9965121
9369,SSR103800,4,5,36,45,The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice.,19759529_0,-1,-1,-1,9369,-1,0.99884856,0.0011513765
9372,NMDA,11,12,81,85,"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor.",19759529_2,-1,-1,-1,9372,-1,0.9969574,0.0030426409
9373,NMDA,33,34,218,222,"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor.",19759529_2,-1,-1,-1,9373,-1,0.99574727,0.0042527243
9374,NMDA,32,33,204,208,"As a result, there is a growing interest in the development of pharmacological agents with potential antipsychotic properties that enhance the activity of the glutamatergic system via a modulation of the NMDA receptor.",19759529_3,-1,-1,-1,9374,-1,0.99702066,0.002979364
9376,SSR103800,11,12,64,73,"Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.",19759529_4,-1,-1,-1,9376,-1,0.9986498,0.0013502449
9377,NMDA,16,17,100,104,"Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.",19759529_4,-1,-1,-1,9377,-1,0.9958039,0.00419609
9379,NMDA,28,29,171,175,"Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.",19759529_4,-1,-1,-1,9379,-1,0.9953034,0.004696676
9380,SSR103800,10,11,81,90,"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).",19759529_5,-1,-1,-1,9380,-1,0.99905866,0.0009412864
9382,ie,26,27,177,179,"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).",19759529_5,-1,-1,-1,9382,-1,0.6342027,0.36579725
9384,MK-801,30,31,197,203,"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).",19759529_5,-1,-1,-1,9384,-1,0.9967565,0.0032434524
9385,ie,36,37,225,227,"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).",19759529_5,-1,-1,-1,9385,-1,0.3569056,0.64309436
9386,SSR103800,3,4,20,29,"Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.",19759529_6,-1,-1,-1,9386,-1,0.998787,0.0012130771
9388,NMDA,18,19,102,106,"Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.",19759529_6,-1,-1,-1,9388,-1,0.99718326,0.002816727
9389,MK-801,22,23,128,134,"Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.",19759529_6,-1,-1,-1,9389,-1,0.99788505,0.002114884
9391,NMDA,29,30,187,191,"Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.",19759529_6,-1,-1,-1,9391,-1,0.99689037,0.0031096898
9392,contrast,1,2,3,11,"In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).",19759529_7,-1,-1,-1,9392,-1,0.29604274,0.70395726
9393,SSR103800,3,4,13,22,"In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).",19759529_7,-1,-1,-1,9393,-1,0.99887913,0.001120863
9400,aripiprazole,14,15,82,94,"Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.",19759529_8,-1,-1,-1,9400,-1,0.9988575,0.00114253
9401,antipsychotics,16,17,96,110,"Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.",19759529_8,-1,-1,-1,9401,-1,0.9926233,0.0073766513
9403,SSR103800,6,7,30,39,"However, unlike these latter, SSR103800 did not produce catalepsy (retention on the bar test) up to 30 mg/kg p.o.",19759529_9,-1,-1,-1,9403,-1,0.9986482,0.0013518042
9405,SSR103800,9,10,55,64,"Together these findings show that the GlyT1 inhibitor, SSR103800, produces antipsychotic-like effects, which differ from those observed with compounds primarily targeting the dopaminergic system, and has a reduced side-effect potential as compared with these latter drugs.",19759529_10,-1,-1,-1,9405,-1,0.9988336,0.0011664085
9406,Hibiscus rosa sinensis,2,5,10,32,Effect of Hibiscus rosa sinensis on reserpine-induced neurobehavioral and biochemical alterations in rats.,19761039_0,-1,-1,-1,9406,-1,0.9651207,0.034879338
9407,Hibiscus rosa sinensis,5,8,32,54,Effect of methanolic extract of Hibiscus rosa sinensis (100-300 mg/kg) was studied on reserpine-induced orofacial dyskinesia and neurochemical alterations.,19761039_1,-1,-1,-1,9407,-1,0.9682426,0.031757407
9408,orofacial dyskinesia,18,20,104,124,Effect of methanolic extract of Hibiscus rosa sinensis (100-300 mg/kg) was studied on reserpine-induced orofacial dyskinesia and neurochemical alterations.,19761039_1,-1,-1,-1,9408,-1,0.0035939508,0.996406
9411,Hibiscus rosa sinensis,15,18,125,147,"Reserpine treated rats significantly developed vacuous chewing movements and tongue protrusions however, coadministration of Hibiscus rosa sinensis roots extract (100, 200 and 300 mg/kg, per orally) attenuated the effects.",19761039_4,-1,-1,-1,9411,-1,0.95400536,0.0459947
9413,superoxide dismutase,17,19,135,155,"Biochemical analysis of brain revealed that the reserpine treatment significantly increased lipid peroxidation and decreased levels of superoxide dismutase (SOD), catalase (CAT) and glutathione reductase (GSH), an index of oxidative stress process.",19761039_5,-1,-1,-1,9413,-1,0.9971541,0.002845881
9414,glutathione reductase,28,30,182,203,"Biochemical analysis of brain revealed that the reserpine treatment significantly increased lipid peroxidation and decreased levels of superoxide dismutase (SOD), catalase (CAT) and glutathione reductase (GSH), an index of oxidative stress process.",19761039_5,-1,-1,-1,9414,-1,0.9942912,0.0057087974
9415,GSH,31,32,205,208,"Biochemical analysis of brain revealed that the reserpine treatment significantly increased lipid peroxidation and decreased levels of superoxide dismutase (SOD), catalase (CAT) and glutathione reductase (GSH), an index of oxidative stress process.",19761039_5,-1,-1,-1,9415,-1,0.9932774,0.006722556
9416,GSH,18,19,121,124,"Coadministration of extract significantly reduced the lipid peroxidation and reversed the decrease in brain SOD, CAT and GSH levels.",19761039_6,-1,-1,-1,9416,-1,0.9972249,0.002775045
9417,Hibiscus rosa sinensis,8,11,48,70,The results of the present study suggested that Hibiscus rosa sinensis had a protective role against reserpine-induced orofacial dyskinesia and oxidative stress.,19761039_7,-1,-1,-1,9417,-1,0.95890933,0.041090645
9418,orofacial dyskinesia,17,19,119,139,The results of the present study suggested that Hibiscus rosa sinensis had a protective role against reserpine-induced orofacial dyskinesia and oxidative stress.,19761039_7,-1,-1,-1,9418,-1,0.003980187,0.9960198
9419,Pyrrolidine dithiocarbamate,0,2,0,27,Pyrrolidine dithiocarbamate protects the piriform cortex in the pilocarpine status epilepticus model.,19767176_0,-1,-1,-1,9419,-1,0.99843425,0.0015657854
9420,pilocarpine status epilepticus,8,11,64,94,Pyrrolidine dithiocarbamate protects the piriform cortex in the pilocarpine status epilepticus model.,19767176_0,-1,-1,-1,9420,-1,0.47663552,0.52336454
9421,PDTC,3,4,29,33,Pyrrolidine dithiocarbamate (PDTC) has a dual mechanism of action as an antioxidant and an inhibitor of the transcription factor kappa-beta.,19767176_1,-1,-1,-1,9421,-1,0.9976279,0.0023721538
9422,reactive oxygen species,4,7,20,43,"Both, production of reactive oxygen species as well as activation of NF-kappaB have been implicated in severe neuronal damage in different sub-regions of the hippocampus as well as in the surrounding cortices.",19767176_2,-1,-1,-1,9422,-1,0.98290145,0.017098578
9424,PDTC,3,4,14,18,The effect of PDTC on status epilepticus-associated cell loss in the hippocampus and piriform cortex was evaluated in the rat fractionated pilocarpine model.,19767176_3,-1,-1,-1,9424,-1,0.99835545,0.0016445842
9426,PDTC,4,5,25,29,Treatment with 150 mg/kg PDTC before and following status epilepticus significantly increased the mortality rate to 100%.,19767176_4,-1,-1,-1,9426,-1,0.9986639,0.0013360864
9427,status epilepticus,8,10,51,69,Treatment with 150 mg/kg PDTC before and following status epilepticus significantly increased the mortality rate to 100%.,19767176_4,-1,-1,-1,9427,-1,0.0037497946,0.9962502
9428,PDTC,4,5,27,31,Administration of 50 mg/kg PDTC (low-dose) did not exert major effects on the development of a status epilepticus or the mortality rate.,19767176_5,-1,-1,-1,9428,-1,0.9986533,0.0013466444
9429,status epilepticus,18,20,95,113,Administration of 50 mg/kg PDTC (low-dose) did not exert major effects on the development of a status epilepticus or the mortality rate.,19767176_5,-1,-1,-1,9429,-1,0.0024236895,0.9975763
9430,status epilepticus,4,6,25,43,"In vehicle-treated rats, status epilepticus caused pronounced neuronal damage in the piriform cortex comprising both pyramidal cells and interneurons.",19767176_6,-1,-1,-1,9430,-1,0.014065837,0.9859342
9432,PDTC,1,2,9,13,Low-dose PDTC treatment almost completely protected from lesions in the piriform cortex.,19767176_7,-1,-1,-1,9432,-1,0.9985329,0.0014671526
9433,status epilepticus,19,21,137,155,A significant decrease in neuronal density of the hippocampal hilar formation was identified in vehicle- and PDTC-treated rats following status epilepticus.,19767176_8,-1,-1,-1,9433,-1,0.006102176,0.99389786
9434,PDTC,8,9,55,59,"In conclusion, the NF-kappaB inhibitor and antioxidant PDTC protected the piriform cortex, whereas it did not affect hilar neuronal loss.",19767176_9,-1,-1,-1,9434,-1,0.99871016,0.0012898037
9435,neuronal loss,20,22,123,136,"In conclusion, the NF-kappaB inhibitor and antioxidant PDTC protected the piriform cortex, whereas it did not affect hilar neuronal loss.",19767176_9,-1,-1,-1,9435,-1,0.0029284065,0.9970716
9436,reactive oxygen species,8,11,49,72,These data might indicate that the generation of reactive oxygen species and activation of NF-kappaB plays a more central role in seizure-associated neuronal damage in the temporal cortex as compared to the hippocampal hilus.,19767176_10,-1,-1,-1,9436,-1,0.98269457,0.017305396
9438,PDTC,14,15,100,104,"However, future investigations are necessary to exactly analyze the biochemical mechanisms by which PDTC exerted its beneficial effects in the piriform cortex.",19767176_11,-1,-1,-1,9438,-1,0.99880576,0.0011942522
9439,masseter spasm,4,6,26,40,Anaesthetists' nightmare: masseter spasm after induction in an undiagnosed case of myotonia congenita.,19803309_0,-1,-1,-1,9439,-1,0.29501668,0.70498335
9440,myotonia congenita,13,15,83,101,Anaesthetists' nightmare: masseter spasm after induction in an undiagnosed case of myotonia congenita.,19803309_0,-1,-1,-1,9440,-1,0.0060094376,0.99399054
9441,myotonia congenita,6,8,33,51,"We report an undiagnosed case of myotonia congenita in a 24-year-old previously healthy primigravida, who developed life threatening masseter spasm following a standard dose of intravenous suxamethonium for induction of anaesthesia.",19803309_1,-1,-1,-1,9441,-1,0.0043541323,0.9956458
9442,masseter spasm,19,21,133,147,"We report an undiagnosed case of myotonia congenita in a 24-year-old previously healthy primigravida, who developed life threatening masseter spasm following a standard dose of intravenous suxamethonium for induction of anaesthesia.",19803309_1,-1,-1,-1,9442,-1,0.020684054,0.97931594
9445,human immunodeficiency virus infection,17,21,92,130,We report twin neonates who were born prematurely at 32 weeks of gestation to a mother with human immunodeficiency virus infection.,19820426_1,-1,-1,-1,9445,-1,0.40923008,0.59076995
9446,heart block,6,8,36,47,"One of the twins developed complete heart block and dilated cardiomyopathy related to lopinavir/ritonavir therapy, a boosted protease-inhibitor agent, while the other twin developed mild bradycardia.",19820426_2,-1,-1,-1,9446,-1,0.0026206132,0.9973794
9449,right heart failure,8,11,71,90,"Twenty-three hours after heart transplantation, life-threatening acute right heart failure was diagnosed in a patient requiring continuous venovenous hemodiafiltration (CVVHDF).",19843802_1,-1,-1,-1,9449,-1,0.008401727,0.99159825
9465,birth defects,8,10,58,71,Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study.,19884587_0,-1,-1,-1,9465,-1,0.0052468595,0.9947531
9466,Birth Defects,12,14,82,95,Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study.,19884587_0,-1,-1,-1,9466,-1,0.01258726,0.9874127
9467,birth defects,11,13,86,99,OBJECTIVE: To estimate the association between antibacterial medications and selected birth defects.,19884587_1,-1,-1,-1,9467,-1,0.0039499104,0.99605006
9468,birth defects,27,29,157,170,"DESIGN, SETTING, AND PARTICIPANTS: Population-based, multisite, case-control study of women who had pregnancies affected by 1 of more than 30 eligible major birth defects identified via birth defect surveillance programs in 10 states (n = 13 155) and control women randomly selected from the same geographical regions (n = 4941).",19884587_2,-1,-1,-1,9468,-1,0.011427683,0.98857236
9469,birth defect,31,33,186,198,"DESIGN, SETTING, AND PARTICIPANTS: Population-based, multisite, case-control study of women who had pregnancies affected by 1 of more than 30 eligible major birth defects identified via birth defect surveillance programs in 10 states (n = 13 155) and control women randomly selected from the same geographical regions (n = 4941).",19884587_2,-1,-1,-1,9469,-1,0.013166399,0.98683363
9470,n,39,40,235,236,"DESIGN, SETTING, AND PARTICIPANTS: Population-based, multisite, case-control study of women who had pregnancies affected by 1 of more than 30 eligible major birth defects identified via birth defect surveillance programs in 10 states (n = 13 155) and control women randomly selected from the same geographical regions (n = 4941).",19884587_2,-1,-1,-1,9470,-1,0.283941,0.71605897
9471,n,55,56,319,320,"DESIGN, SETTING, AND PARTICIPANTS: Population-based, multisite, case-control study of women who had pregnancies affected by 1 of more than 30 eligible major birth defects identified via birth defect surveillance programs in 10 states (n = 13 155) and control women randomly selected from the same geographical regions (n = 4941).",19884587_2,-1,-1,-1,9471,-1,0.2927022,0.7072978
9472,birth defects,17,19,105,118,MAIN OUTCOME MEASURE: Odds ratios (ORs) measuring the association between antibacterial use and selected birth defects adjusted for potential confounders.,19884587_4,-1,-1,-1,9472,-1,0.0041290517,0.9958709
9474,hypoplastic left heart syndrome,27,31,112,143,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,-1,9474,-1,0.005475062,0.99452496
9475,coarctation of the aorta,45,49,174,198,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,-1,9475,-1,0.01559051,0.9844095
9476,choanal atresia,63,65,229,244,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,-1,9476,-1,0.014597826,0.9854021
9477,transverse limb deficiency,79,82,276,302,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,-1,9477,-1,0.016144222,0.9838558
9478,diaphragmatic hernia,97,99,337,357,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,-1,-1,-1,9478,-1,0.00642869,0.9935713
9479,anophthalmia,4,5,37,49,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9479,-1,0.0036082421,0.9963917
9480,microphthalmos,6,7,53,67,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9480,-1,0.008244936,0.991755
9481,hypoplastic left heart syndrome,21,25,99,130,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9481,-1,0.006066264,0.99393374
9482,atrial septal defects,39,42,161,182,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9482,-1,0.010477209,0.98952276
9483,cleft lip,57,59,217,226,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9483,-1,0.004798984,0.995201
9484,cleft palate,60,62,232,244,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,-1,-1,-1,9484,-1,0.004774751,0.9952252
9485,erythromycins,7,8,61,74,"Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect).",19884587_8,-1,-1,-1,9485,-1,0.9984238,0.0015761738
9486,penicillins,13,14,88,99,"Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect).",19884587_8,-1,-1,-1,9486,-1,0.9967127,0.0032872858
9488,quinolones,26,27,143,153,"Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect).",19884587_8,-1,-1,-1,9488,-1,0.998126,0.0018740052
9489,penicillins,4,5,27,38,"CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many birth defects.",19884587_9,-1,-1,-1,9489,-1,0.99769455,0.002305483
9490,erythromycins,6,7,40,53,"CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many birth defects.",19884587_9,-1,-1,-1,9490,-1,0.99833125,0.0016687209
9492,birth defects,23,25,147,160,"CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many birth defects.",19884587_9,-1,-1,-1,9492,-1,0.0034571292,0.9965429
9493,Sulfonamides,0,1,0,12,"Sulfonamides and nitrofurantoins were associated with several birth defects, indicating a need for additional scrutiny.",19884587_10,-1,-1,-1,9493,-1,0.9987184,0.0012817016
9494,nitrofurantoins,2,3,17,32,"Sulfonamides and nitrofurantoins were associated with several birth defects, indicating a need for additional scrutiny.",19884587_10,-1,-1,-1,9494,-1,0.9987367,0.0012633554
9495,birth defects,7,9,62,75,"Sulfonamides and nitrofurantoins were associated with several birth defects, indicating a need for additional scrutiny.",19884587_10,-1,-1,-1,9495,-1,0.0028397513,0.9971603
9496,hepatitis B,15,17,106,117,Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains.,19889778_0,-1,-1,-1,9496,-1,0.09107782,0.90892214
9497,e,18,19,124,125,Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains.,19889778_0,-1,-1,-1,9497,-1,0.9140468,0.08595313
9498,hepatitis B,5,7,30,41,"Immune escape variants of the hepatitis B virus (HBV) represent an emerging clinical challenge, because they can be associated with vaccine escape, HBV reactivation, and failure of diagnostic tests.",19889778_1,-1,-1,-1,9498,-1,0.45524314,0.5447569
9500,LAM,40,41,274,277,"We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the sG145R and sP120T mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to lamivudine (LAM) and/or HBeAg negativity.",19889778_3,-1,-1,-1,9500,-1,0.994987,0.005013062
9501,HBeAg,43,44,286,291,"We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the sG145R and sP120T mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to lamivudine (LAM) and/or HBeAg negativity.",19889778_3,-1,-1,-1,9501,-1,0.94195217,0.05804776
9502,LAM,9,10,60,63,Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants.,19889778_4,-1,-1,-1,9502,-1,0.99412435,0.0058757016
9503,rtM204I,12,13,76,83,Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants.,19889778_4,-1,-1,-1,9503,-1,0.9936991,0.0063009453
9504,HBsAg,5,6,37,42,"The sG145R mutation strongly reduced HBsAg levels and was able to fully restore the impaired replication of LAM-resistant HBV mutants to the levels of wild-type HBV, and PC or BCP mutations further enhanced viral replication.",19889778_5,-1,-1,-1,9504,-1,0.99601704,0.0039829756
9505,PC,28,29,170,172,"The sG145R mutation strongly reduced HBsAg levels and was able to fully restore the impaired replication of LAM-resistant HBV mutants to the levels of wild-type HBV, and PC or BCP mutations further enhanced viral replication.",19889778_5,-1,-1,-1,9505,-1,0.99406177,0.005938237
9506,HBsAg,7,8,47,52,"Although the sP120T substitution also impaired HBsAg secretion, it did not enhance the replication of LAM-resistant clones.",19889778_6,-1,-1,-1,9506,-1,0.99552405,0.004476006
9507,HBeAg,6,7,39,44,"However, the concomitant occurrence of HBeAg negativity (PC/BCP), sP120T, and LAM resistance resulted in the restoration of replication to levels of wild-type HBV.",19889778_7,-1,-1,-1,9507,-1,0.9949066,0.0050933287
9508,LAM,8,9,46,49,"In all clones with combined immune escape and LAM resistance mutations, the nucleotide analogues adefovir and tenofovir remained effective in suppressing viral replication in vitro.",19889778_8,-1,-1,-1,9508,-1,0.9749624,0.025037602
9509,nucleotide,13,14,76,86,"In all clones with combined immune escape and LAM resistance mutations, the nucleotide analogues adefovir and tenofovir remained effective in suppressing viral replication in vitro.",19889778_8,-1,-1,-1,9509,-1,0.9966557,0.0033443007
9510,adefovir,15,16,97,105,"In all clones with combined immune escape and LAM resistance mutations, the nucleotide analogues adefovir and tenofovir remained effective in suppressing viral replication in vitro.",19889778_8,-1,-1,-1,9510,-1,0.9991084,0.00089165976
9511,tenofovir,17,18,110,119,"In all clones with combined immune escape and LAM resistance mutations, the nucleotide analogues adefovir and tenofovir remained effective in suppressing viral replication in vitro.",19889778_8,-1,-1,-1,9511,-1,0.9990988,0.00090126216
9512,acute renal failure,6,9,36,55,Dynamic response of blood vessel in acute renal failure.,19893084_0,-1,-1,-1,9512,-1,0.0036861326,0.99631387
9513,acute renal failure,7,10,40,59,"In this study we postulated that during acute renal failure induced by gentamicin the transient or dynamic response of blood vessels could be affected, and that antioxidants can prevent the changes in dynamic responses of blood vessels.",19893084_1,-1,-1,-1,9513,-1,0.0031928837,0.9968071
9515,vitamin C,4,6,26,35,The beneficial effects of vitamin C administration to gentamicin-treated animals are also confirmed through: lower level of blood urea and creatinine and higher level of potassium.,19893084_4,-1,-1,-1,9515,-1,0.99868757,0.0013124583
9519,Vitamin C,0,2,0,9,Vitamin C administration induced slowdown of pressure change back to the control values.,19893084_6,-1,-1,-1,9519,-1,0.99847645,0.0015235352
9520,vitamin C,37,39,262,271,"The pressure dynamic properties, quantitatively defined by comparative pressure dynamic and total pressure dynamic, confirm the alteration in dynamic response of blood vessels during the change of pressure in gentamicin-treated animals and beneficial effects of vitamin C administration.",19893084_7,-1,-1,-1,9520,-1,0.9984668,0.0015331769
9521,myocardial hypertrophy,1,3,11,33,Reversible myocardial hypertrophy induced by tacrolimus in a pediatric heart transplant recipient: case report.,19917396_0,-1,-1,-1,9521,-1,0.0026755799,0.99732435
9525,myocardial hypertrophy,4,6,29,51,Herein we describe transient myocardial hypertrophy induced by tacrolimus after heart transplantation.,19917396_3,-1,-1,-1,9525,-1,0.0028310486,0.99716896
9529,myocardial hypertrophy,18,20,120,142,"Initially, allograft rejection was feared; however, myocardial biopsy samples revealed only interstitial edema and mild myocardial hypertrophy; neither cellular nor humoral rejection was detected.",19917396_5,-1,-1,-1,9529,-1,0.0041074553,0.9958925
9540,cognitive dysfunction,18,20,115,136,BACKGROUND: Hypotension and a resultant decrease in cerebral blood flow have been implicated in the development of cognitive dysfunction.,19923525_1,-1,-1,-1,9540,-1,0.0022715705,0.9977284
9542,NIMO,7,8,42,46,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory.,19923525_2,-1,-1,-1,9542,-1,0.9983734,0.0016265677
9545,PA,6,7,32,34,METHODS: The passive avoidance (PA) paradigm was used to assess memory retention.,19923525_3,-1,-1,-1,9545,-1,0.9157424,0.08425758
9546,PA,1,2,4,6,"For PA training, latencies (seconds) were recorded for entry from a suspended platform into a Plexiglas tube where a shock was automatically delivered.",19923525_4,-1,-1,-1,9546,-1,0.9950793,0.004920748
9548,h,4,5,27,28,Latencies were recorded 48 h later for a testing trial.,19923525_5,-1,-1,-1,9548,-1,0.11244278,0.88755727
9549,NTG,29,30,103,106,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,-1,-1,-1,9549,-1,0.9977806,0.0022193505
9550,NTG,36,37,138,141,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,-1,-1,-1,9550,-1,0.9966941,0.0033059462
9551,h,38,39,144,145,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,-1,-1,-1,9551,-1,0.5020754,0.49792463
9552,NTG,44,45,165,168,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,-1,-1,-1,9552,-1,0.99797815,0.0020218792
9553,NIMO,46,47,173,177,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,-1,-1,-1,9553,-1,0.9979479,0.0020521786
9554,NIMO,55,56,198,202,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,-1,-1,-1,9554,-1,0.997954,0.0020459362
9557,NTG,26,27,143,146,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).",19923525_9,-1,-1,-1,9557,-1,0.99814546,0.001854531
9558,NIMO,28,29,149,153,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).",19923525_9,-1,-1,-1,9558,-1,0.99811375,0.0018862033
9559,NTG,32,33,166,169,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).",19923525_9,-1,-1,-1,9559,-1,0.9979881,0.0020119129
9560,H,16,17,109,110,A Kruskal-Wallis 1-way analysis of variance indicated a significant difference among the 4 treatment groups (H = 15.34; P < 0.001).,19923525_10,-1,-1,-1,9560,-1,0.6227157,0.37728435
9561,P,20,21,120,121,A Kruskal-Wallis 1-way analysis of variance indicated a significant difference among the 4 treatment groups (H = 15.34; P < 0.001).,19923525_10,-1,-1,-1,9561,-1,0.31382236,0.6861776
9562,NTG,16,17,82,85,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9562,-1,0.99844545,0.001554578
9563,n,18,19,87,88,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9563,-1,0.40027338,0.5997266
9564,NTG,23,24,98,101,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9564,-1,0.99848264,0.0015173872
9565,NIMO,25,26,104,108,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9565,-1,0.9981515,0.0018484875
9566,n,27,28,110,111,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9566,-1,0.40961415,0.59038585
9567,mm Hg,43,45,183,188,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9567,-1,0.11050471,0.8894953
9568,mm Hg,51,53,209,214,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9568,-1,0.10511662,0.89488333
9569,mm Hg,60,62,241,246,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9569,-1,0.10137038,0.89862967
9570,mm Hg,68,70,267,272,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,-1,-1,-1,9570,-1,0.11244867,0.8875513
9571,NIMO,8,9,50,54,Mean arterial blood pressure in mice treated with NIMO alone decreased from 88.1 +/- 3.8 mm Hg to 80.0 +/- 2.9 mm Hg.,19923525_12,-1,-1,-1,9571,-1,0.99889106,0.0011090075
9572,mm Hg,16,18,89,94,Mean arterial blood pressure in mice treated with NIMO alone decreased from 88.1 +/- 3.8 mm Hg to 80.0 +/- 2.9 mm Hg.,19923525_12,-1,-1,-1,9572,-1,0.08527678,0.91472316
9573,mm Hg,23,25,111,116,Mean arterial blood pressure in mice treated with NIMO alone decreased from 88.1 +/- 3.8 mm Hg to 80.0 +/- 2.9 mm Hg.,19923525_12,-1,-1,-1,9573,-1,0.072455786,0.92754424
9574,P,7,8,57,58,The intergroup difference was statistically significant (P < 0.05).,19923525_13,-1,-1,-1,9574,-1,0.2420312,0.7579688
9575,mm Hg,8,10,36,41,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9575,-1,0.663252,0.33674803
9576,mm Hg,16,18,62,67,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9576,-1,0.6183508,0.38164923
9577,NTG,21,22,79,82,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9577,-1,0.99518245,0.0048175585
9578,mm Hg,29,31,111,116,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9578,-1,0.53571755,0.4642825
9579,mm Hg,37,39,137,142,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9579,-1,0.50873804,0.491262
9580,NTG,42,43,154,157,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9580,-1,0.99517137,0.0048286566
9581,NIMO,44,45,160,164,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,-1,-1,-1,9581,-1,0.99739814,0.0026018757
9582,PA,4,5,17,19,"CONCLUSION: In a PA retention paradigm, the injection of NTG immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced hypotension had no effect.",19923525_16,-1,-1,-1,9582,-1,0.9965731,0.0034269125
9583,NTG,11,12,57,60,"CONCLUSION: In a PA retention paradigm, the injection of NTG immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced hypotension had no effect.",19923525_16,-1,-1,-1,9583,-1,0.9986084,0.0013915626
9585,NIMO,0,1,0,4,NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension.,19923525_17,-1,-1,-1,9585,-1,0.99872214,0.0012778692
9586,NTG,11,12,78,81,NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension.,19923525_17,-1,-1,-1,9586,-1,0.9980394,0.001960578
9588,NIMO,4,5,23,27,"The observed effect of NIMO may have been attributable to the preservation of calcium homeostasis during hypotension, because there were no differences in the PbtO(2) indices among groups.",19923525_18,-1,-1,-1,9588,-1,0.9988152,0.0011848556
9593,peptic ulcer disease,12,15,64,84,"It has been shown to be extremely effective in the treatment of peptic ulcer disease, reflux esophagitis, and the Zollinger-Ellison syndrome.",1992636_2,-1,-1,-1,9593,-1,0.0031486093,0.9968514
9594,reflux esophagitis,16,18,86,104,"It has been shown to be extremely effective in the treatment of peptic ulcer disease, reflux esophagitis, and the Zollinger-Ellison syndrome.",1992636_2,-1,-1,-1,9594,-1,0.0028792978,0.9971207
9599,lethargy,5,6,32,40,"The patient developed weakness, lethargy, and shortness of breath 2 days after starting therapy with omeprazole.",1992636_5,-1,-1,-1,9599,-1,0.002977911,0.9970221
9600,shortness of breath 2,8,12,46,67,"The patient developed weakness, lethargy, and shortness of breath 2 days after starting therapy with omeprazole.",1992636_5,-1,-1,-1,9600,-1,0.019896341,0.9801036
9607,Parkinson's disease,12,15,87,106,Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease.,19940105_0,-1,-1,-1,9607,-1,0.005398772,0.99460125
9609,Parkinson's disease,23,26,174,193,Metabotropic glutamate (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD).,19940105_1,-1,-1,-1,9609,-1,0.0068210536,0.99317896
9610,PD,27,28,195,197,Metabotropic glutamate (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD).,19940105_1,-1,-1,-1,9610,-1,0.0043498287,0.99565023
9611,PD,28,29,163,165,"Among the eight mGlu receptor subtypes, mGlu7 receptor is prominently expressed in the basal ganglia, but its role in restoring motor function in animal models of PD is not known.",19940105_2,-1,-1,-1,9611,-1,0.0035262841,0.9964737
9612,"N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride",3,7,15,66,"The effects of N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), the first selective allosteric activator of mGlu7 receptors, were thus tested in different rodent models of PD.",19940105_3,-1,-1,-1,9612,-1,0.99633825,0.0036618118
9613,AMN082,8,9,68,74,"The effects of N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), the first selective allosteric activator of mGlu7 receptors, were thus tested in different rodent models of PD.",19940105_3,-1,-1,-1,9613,-1,0.9962058,0.0037941672
9614,PD,28,29,185,187,"The effects of N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), the first selective allosteric activator of mGlu7 receptors, were thus tested in different rodent models of PD.",19940105_3,-1,-1,-1,9614,-1,0.0032142592,0.99678576
9615,AMN082,20,21,88,94,"Here, we show that oral (5 mg/kg) or intrastriatal administration (0.1 and 0.5 nmol) of AMN082 reverses haloperidol-induced catalepsy in rats.",19940105_4,-1,-1,-1,9615,-1,0.9983734,0.0016265893
9617,AMN082,0,1,0,6,AMN082 (2.5 and 5 mg/kg) reduces apomorphine-induced rotations in unilateral 6-hydroxydopamine (6-OHDA)-lesioned rats.,19940105_5,-1,-1,-1,9617,-1,0.9981735,0.0018265097
9620,PD,13,14,76,78,"In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.",19940105_6,-1,-1,-1,9620,-1,0.003548892,0.99645114
9621,AMN082,18,19,97,103,"In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.",19940105_6,-1,-1,-1,9621,-1,0.9983985,0.0016014857
9622,AMN082,3,4,13,19,"In addition, AMN082 reduces the duration of haloperidol-induced catalepsy in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice.",19940105_7,-1,-1,-1,9622,-1,0.998616,0.0013840505
9624,AMN082,3,4,16,22,Higher doses of AMN082 (10 and 20 mg/kg p.o.) have no effect on the same models of PD.,19940105_8,-1,-1,-1,9624,-1,0.998716,0.0012839803
9625,PD,20,21,83,85,Higher doses of AMN082 (10 and 20 mg/kg p.o.) have no effect on the same models of PD.,19940105_8,-1,-1,-1,9625,-1,0.0046590175,0.99534094
9628,coronary artery spasm,6,9,53,74,Sorafenib-induced acute myocardial infarction due to coronary artery spasm.,19944333_0,-1,-1,-1,9628,-1,0.0036667697,0.99633324
9629,renal cell carcinoma,5,8,32,52,A 65-year-old man with advanced renal cell carcinoma was admitted due to continuing chest pain at rest.,19944333_1,-1,-1,-1,9629,-1,0.014758259,0.9852417
9630,chest pain,13,15,84,94,A 65-year-old man with advanced renal cell carcinoma was admitted due to continuing chest pain at rest.,19944333_1,-1,-1,-1,9630,-1,0.004219986,0.99578
9632,myocardial infarction,5,7,39,60,He was diagnosed with non-ST-elevation myocardial infarction by laboratory data and electrocardiogram.,19944333_3,-1,-1,-1,9632,-1,0.002548133,0.99745184
9634,stenosis,5,6,22,30,"However, there was no stenosis in coronary arteries on angiography.",19944333_5,-1,-1,-1,9634,-1,0.0041820053,0.99581796
9637,nitrates,9,10,68,76,"Cessation of sorafenib and administration of Ca-channel blocker and nitrates ameliorated his symptoms, but relapse occurred after resumption of sorafenib.",19944333_7,-1,-1,-1,9637,-1,0.99807954,0.0019204672
9639,nicorandil,3,4,17,27,Addition of oral nicorandil reduced his symptoms and maintained stable angina status.,19944333_8,-1,-1,-1,9639,-1,0.99918205,0.0008179835
9640,stable angina,9,11,64,77,Addition of oral nicorandil reduced his symptoms and maintained stable angina status.,19944333_8,-1,-1,-1,9640,-1,0.0045770872,0.9954229
9641,coronary artery spasm,7,10,46,67,We report the first case of sorafenib-induced coronary artery spasm.,19944333_9,-1,-1,-1,9641,-1,0.003654827,0.9963452
9643,coronary artery spasm,16,19,85,106,"On the other hand, the Rho/ROCK pathway has an important role in the pathogenesis of coronary artery spasm.",19944333_11,-1,-1,-1,9643,-1,0.0036132487,0.99638677
9645,Tacrine,0,1,0,7,"Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed hippocampal damage.",19944736_2,-1,-1,-1,9645,-1,0.9991677,0.0008323729
9646,LiCl,4,5,25,29,"Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed hippocampal damage.",19944736_2,-1,-1,-1,9646,-1,0.9989484,0.0010516836
9648,hippocampal damage,13,15,99,117,"Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed hippocampal damage.",19944736_2,-1,-1,-1,9648,-1,0.0038485532,0.9961514
9649,tacrine,16,17,100,107,"The toxic effects of tacrine-loaded poly-L-lactid acid nanoparticles (5mg/kg), a saline solution of tacrine (5mg/kg) and an empty colloidal nanoparticle suspension were compared following i.p.",19944736_3,-1,-1,-1,9649,-1,0.9989644,0.0010355545
9651,tacrine,27,28,175,182,"In addition, tacrine-loaded nanoparticles administration induced damage of neuronal cells in CA1 field of the hippocampus in all treated animals, while the saline solution of tacrine only in 60% of animals.",19944736_6,-1,-1,-1,9651,-1,0.9990994,0.00090066117
9653,ephedrine reduces frontal lobe oxygenation,3,8,22,64,Phenylephrine but not ephedrine reduces frontal lobe oxygenation following anesthesia-induced hypotension.,19957053_0,-1,-1,-1,9653,-1,0.922951,0.07704909
9655,Vasopressor,2,3,12,23,BACKGROUND: Vasopressor agents are used to correct anesthesia-induced hypotension.,19957053_1,-1,-1,-1,9655,-1,0.9983601,0.0016399467
9661,mg,10,11,61,63,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,-1,-1,-1,9661,-1,0.9510654,0.048934616
9663,mg,18,19,90,92,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,-1,-1,-1,9663,-1,0.93225837,0.067741655
9665,mg,29,30,142,144,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,-1,-1,-1,9665,-1,0.9318556,0.06814442
9667,mg,39,40,188,190,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,-1,-1,-1,9667,-1,0.86399376,0.13600622
9668,MAP,48,49,230,233,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,-1,-1,-1,9668,-1,0.08549005,0.91450995
9669,MAP,6,7,17,20,"Heart rate (HR), MAP, stroke volume (SV), cardiac output (CO), and frontal lobe oxygenation (S(c)O(2)) were registered.",19957053_4,-1,-1,-1,9669,-1,0.945754,0.05424605
9671,CO,17,18,58,60,"Heart rate (HR), MAP, stroke volume (SV), cardiac output (CO), and frontal lobe oxygenation (S(c)O(2)) were registered.",19957053_4,-1,-1,-1,9671,-1,0.98290056,0.0170994
9672,MAP,11,12,63,66,"RESULTS: Induction of anesthesia was followed by a decrease in MAP, HR, SV, and CO concomitant with an elevation in S(c)O(2).",19957053_5,-1,-1,-1,9672,-1,0.99404645,0.005953498
9673,CO,18,19,80,82,"RESULTS: Induction of anesthesia was followed by a decrease in MAP, HR, SV, and CO concomitant with an elevation in S(c)O(2).",19957053_5,-1,-1,-1,9673,-1,0.99580526,0.004194708
9675,MAP,5,6,39,42,"After administration of phenylephrine, MAP increased (51 +/- 12 to 81 +/- 13 mmHg; P < 0.001; mean +/- SD).",19957053_6,-1,-1,-1,9675,-1,0.9467208,0.053279206
9676,P,19,20,83,84,"After administration of phenylephrine, MAP increased (51 +/- 12 to 81 +/- 13 mmHg; P < 0.001; mean +/- SD).",19957053_6,-1,-1,-1,9676,-1,0.43125772,0.5687423
9677,SD,26,27,103,105,"After administration of phenylephrine, MAP increased (51 +/- 12 to 81 +/- 13 mmHg; P < 0.001; mean +/- SD).",19957053_6,-1,-1,-1,9677,-1,0.17658655,0.8234135
9678,S(c)O(2,21,22,58,65,"However, a 14% (from 70 +/- 8% to 60 +/- 7%) reduction in S(c)O(2) (P < 0.05) followed with no change in CO (3.7 +/- 1.1 to 3.4 +/- 0.9 l min(-1)).",19957053_7,-1,-1,-1,9678,-1,0.98767686,0.012323109
9679,P,24,25,68,69,"However, a 14% (from 70 +/- 8% to 60 +/- 7%) reduction in S(c)O(2) (P < 0.05) followed with no change in CO (3.7 +/- 1.1 to 3.4 +/- 0.9 l min(-1)).",19957053_7,-1,-1,-1,9679,-1,0.35114244,0.64885753
9681,increase in MAP,8,11,49,64,"The administration of ephedrine led to a similar increase in MAP (53 +/- 9 to 79 +/- 8 mmHg; P < 0.001), restored CO (3.2 +/- 1.2 to 5.0 +/- 1.3 l min(-1)), and preserved S(c)O(2).",19957053_8,-1,-1,-1,9681,-1,0.15649,0.84351
9682,P,23,24,93,94,"The administration of ephedrine led to a similar increase in MAP (53 +/- 9 to 79 +/- 8 mmHg; P < 0.001), restored CO (3.2 +/- 1.2 to 5.0 +/- 1.3 l min(-1)), and preserved S(c)O(2).",19957053_8,-1,-1,-1,9682,-1,0.30340692,0.6965931
9683,CO,29,30,114,116,"The administration of ephedrine led to a similar increase in MAP (53 +/- 9 to 79 +/- 8 mmHg; P < 0.001), restored CO (3.2 +/- 1.2 to 5.0 +/- 1.3 l min(-1)), and preserved S(c)O(2).",19957053_8,-1,-1,-1,9683,-1,0.99428624,0.005713785
9687,CO,31,32,214,216,CONCLUSIONS: The utilization of phenylephrine to correct hypotension induced by anesthesia has a negative impact on S(c)O(2) while ephedrine maintains frontal lobe oxygenation potentially related to an increase in CO.,19957053_9,-1,-1,-1,9687,-1,0.9932944,0.006705556
9688,tranexamic Acid,1,3,10,25,High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.,19996135_0,-1,-1,-1,9688,-1,0.99937326,0.000626733
9690,convulsive seizures,17,19,100,119,"BACKGROUND: In 2 separate centers, we observed a notable increase in the incidence of postoperative convulsive seizures from 1.3% to 3.8% in patients having undergone major cardiac surgical procedures.",19996135_1,-1,-1,-1,9690,-1,0.0023504416,0.9976496
9691,tranexamic acid,11,13,74,89,These events were temporally coincident with the initial use of high-dose tranexamic acid (TXA) therapy after withdrawal of aprotinin from general clinical usage.,19996135_2,-1,-1,-1,9691,-1,0.9993543,0.0006457065
9692,TXA,14,15,91,94,These events were temporally coincident with the initial use of high-dose tranexamic acid (TXA) therapy after withdrawal of aprotinin from general clinical usage.,19996135_2,-1,-1,-1,9692,-1,0.9978124,0.002187527
9693,TXA,19,20,115,118,The purpose of this review was to perform a retrospective analysis to examine whether there was a relation between TXA usage and seizures after cardiac surgery.,19996135_3,-1,-1,-1,9693,-1,0.99867153,0.0013284796
9696,cerebral ischemic injury,13,16,68,92,"RESULTS: Twenty-one of the 24 patients did not have evidence of new cerebral ischemic injury, but seizures were likely due to ischemic brain injury in 3 patients.",19996135_6,-1,-1,-1,9696,-1,0.0030077428,0.99699223
9698,ischemic brain injury,23,26,126,147,"RESULTS: Twenty-one of the 24 patients did not have evidence of new cerebral ischemic injury, but seizures were likely due to ischemic brain injury in 3 patients.",19996135_6,-1,-1,-1,9698,-1,0.00371074,0.99628925
9700,neurological abnormalities,8,10,50,76,All patients with seizures did not have permanent neurological abnormalities.,19996135_7,-1,-1,-1,9700,-1,0.0024619014,0.9975381
9702,TXA,9,10,53,56,"All 24 patients with seizures received high doses of TXA intraoperatively ranging from 61 to 259 mg/kg, had a mean age of 69.9 years, and 21 of 24 had undergone open chamber rather than coronary bypass procedures.",19996135_8,-1,-1,-1,9702,-1,0.9989064,0.001093634
9703,ischemic,4,5,21,29,"No evidence of brain ischemic, metabolic, or hyperthermia-induced causes for their seizures was apparent.",19996135_10,-1,-1,-1,9703,-1,0.004994544,0.9950054
9705,TXA,9,10,54,57,CONCLUSION: Our results suggest that use of high-dose TXA in older patients in conjunction with cardiopulmonary bypass and open-chamber cardiac surgery is associated with clinical seizures in susceptible patients.,19996135_11,-1,-1,-1,9705,-1,0.9989021,0.0010978464
9710,thrombin inhibitors,3,5,19,38,BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).,20003049_1,-1,-1,-1,9710,-1,0.9916705,0.0083295535
9712,HIT,23,24,160,163,BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).,20003049_1,-1,-1,-1,9712,-1,0.00552076,0.9944792
9713,HIT,26,27,168,171,BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).,20003049_1,-1,-1,-1,9713,-1,0.004257863,0.99574214
9715,HITT,30,31,189,193,BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).,20003049_1,-1,-1,-1,9715,-1,0.0105282515,0.98947173
9716,critically ill,7,9,39,53,"In the following report, a 65-year-old critically ill patient with a suspected history of HITT was administered argatroban for anticoagulation on bypass during heart transplantation.",20003049_2,-1,-1,-1,9716,-1,0.0084412275,0.9915588
9717,HITT,15,16,90,94,"In the following report, a 65-year-old critically ill patient with a suspected history of HITT was administered argatroban for anticoagulation on bypass during heart transplantation.",20003049_2,-1,-1,-1,9717,-1,0.14473057,0.8552695
9719,recombinant Factor VIIa,34,37,183,206,"The patient required massive transfusion support (55 units of red blood cells, 42 units of fresh-frozen plasma, 40 units of cryoprecipitate, 40 units of platelets, and three doses of recombinant Factor VIIa) for severe intraoperative and postoperative bleeding.",20003049_3,-1,-1,-1,9719,-1,0.9952004,0.0047995998
9724,hepatic impairment,54,56,265,283,"RESULTS: Unexpectedly high concentrations of argatroban were measured in these samples (range, 0-32 microg/mL), and a prolonged plasma argatroban half life (t(1/2)) of 514 minutes was observed (published elimination t(1/2) is 39-51 minutes [< or = 181 minutes with hepatic impairment]).",20003049_5,-1,-1,-1,9724,-1,0.004085999,0.99591404
9731,psychotropic drugs,8,10,75,93,Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs.,2004_0,-1,-1,-1,9731,-1,0.99764806,0.002351946
9732,psychotropic drugs,12,14,90,108,"Eight patients had cardiac manifestations that were life-threatening in five while taking psychotropic drugs, either phenothiazines or tricyclic antidepressants.",2004_1,-1,-1,-1,9732,-1,0.9942578,0.0057422235
9733,phenothiazines,16,17,117,131,"Eight patients had cardiac manifestations that were life-threatening in five while taking psychotropic drugs, either phenothiazines or tricyclic antidepressants.",2004_1,-1,-1,-1,9733,-1,0.99901485,0.000985134
9735,Mellaril,8,9,53,61,"Although most patients were receiving several drugs, Mellaril (thioridazine) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman.",2004_2,-1,-1,-1,9735,-1,0.9983858,0.0016141981
9736,thioridazine,10,11,63,75,"Although most patients were receiving several drugs, Mellaril (thioridazine) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman.",2004_2,-1,-1,-1,9736,-1,0.99934274,0.0006572771
9738,Thorazine,7,8,64,73,Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).,2004_3,-1,-1,-1,9738,-1,0.9986822,0.0013178407
9740,nortriptyline,2,3,9,22,Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.,2004_4,-1,-1,-1,9740,-1,0.9993957,0.0006042663
9741,Elavil,5,6,28,34,Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.,2004_4,-1,-1,-1,9741,-1,0.9990694,0.0009306676
9743,left bundle branch block,11,15,65,89,Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.,2004_4,-1,-1,-1,9743,-1,0.011313109,0.9886869
9748,tachyarrhythmias,1,2,4,20,The tachyarrhythmias generally subsided within 48 hours after administration of the drugs was stopped.,2004_7,-1,-1,-1,9748,-1,0.002172968,0.997827
9749,heart disease,18,20,92,105,Five of the eight patients were 50 years of age or younger; only one clearly had antecedent heart disease.,2004_8,-1,-1,-1,9749,-1,0.0039041298,0.99609584
9751,heart disease,10,12,69,82,Major cardiac arrhythmias are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs.,2004_9,-1,-1,-1,9751,-1,0.002751937,0.997248
9752,psychotropic drugs,19,21,132,150,Major cardiac arrhythmias are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs.,2004_9,-1,-1,-1,9752,-1,0.99714893,0.0028510792
9753,cardiac complications,11,13,66,87,A prospective clinical trial is suggested to quantify the risk of cardiac complications to patients receiving phenothiazines or tricyclic antidepressant drugs.,2004_10,-1,-1,-1,9753,-1,0.0025636859,0.99743634
9754,phenothiazines,16,17,110,124,A prospective clinical trial is suggested to quantify the risk of cardiac complications to patients receiving phenothiazines or tricyclic antidepressant drugs.,2004_10,-1,-1,-1,9754,-1,0.9991304,0.0008696393
9755,antidepressant drugs,19,21,138,158,A prospective clinical trial is suggested to quantify the risk of cardiac complications to patients receiving phenothiazines or tricyclic antidepressant drugs.,2004_10,-1,-1,-1,9755,-1,0.9957015,0.004298514
9757,immunodeficient,10,11,89,104,Sensitivity of erythroid progenitor colonies to erythropoietin in azidothymidine treated immunodeficient mice.,2004015_0,-1,-1,-1,9757,-1,0.01427735,0.9857226
9758,anaemia,1,2,4,11,The anaemia induced by 3'-azido-3'dideoxythymidine (AZT) is poorly understood.,2004015_1,-1,-1,-1,9758,-1,0.002647025,0.99735296
9759,3'-azido-3'dideoxythymidine,4,5,23,50,The anaemia induced by 3'-azido-3'dideoxythymidine (AZT) is poorly understood.,2004015_1,-1,-1,-1,9759,-1,0.9965575,0.0034424982
9760,AZT,6,7,52,55,The anaemia induced by 3'-azido-3'dideoxythymidine (AZT) is poorly understood.,2004015_1,-1,-1,-1,9760,-1,0.9962459,0.0037540437
9761,AIDS,7,8,31,35,"We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).",2004015_2,-1,-1,-1,9761,-1,0.0033933725,0.9966066
9763,leukaemia,17,18,89,98,"We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).",2004015_2,-1,-1,-1,9763,-1,0.007768942,0.9922311
9764,anaemia,27,28,141,148,"We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).",2004015_2,-1,-1,-1,9764,-1,0.0026638906,0.9973361
9765,AZT,11,12,58,61,Mice in the early stage of LP-BM5 MuLV disease were given AZT in their drinking water at 1.0 and 2.5 mg/ml.,2004015_3,-1,-1,-1,9765,-1,0.9986083,0.0013917942
9766,drinking water,14,16,71,85,Mice in the early stage of LP-BM5 MuLV disease were given AZT in their drinking water at 1.0 and 2.5 mg/ml.,2004015_3,-1,-1,-1,9766,-1,0.96566087,0.034339093
9767,AZT,0,1,0,3,"AZT produced anaemia in both groups, in a dose-dependent fashion.",2004015_4,-1,-1,-1,9767,-1,0.99855393,0.0014461165
9768,anaemia,2,3,13,20,"AZT produced anaemia in both groups, in a dose-dependent fashion.",2004015_4,-1,-1,-1,9768,-1,0.00253987,0.9974602
9769,anaemia,2,3,12,19,"Despite the anaemia, the number of splenic and bone marrow BFU-e in AZT treated mice increased up to five-fold over levels observed in infected untreated animals after 15 d of treatment.",2004015_5,-1,-1,-1,9769,-1,0.0032228094,0.99677724
9770,AZT,13,14,68,71,"Despite the anaemia, the number of splenic and bone marrow BFU-e in AZT treated mice increased up to five-fold over levels observed in infected untreated animals after 15 d of treatment.",2004015_5,-1,-1,-1,9770,-1,0.99818003,0.0018200082
9771,AZT,18,19,113,116,"Colony formation by splenic and bone marrow BFUe was stimulated at lower concentrations of EPO in mice receiving AZT for 15 d than for infected, untreated mice.",2004015_6,-1,-1,-1,9771,-1,0.99873084,0.0012691766
9772,AZT,8,9,42,45,The mean plasma levels of EPO observed in AZT treated mice,2004015_8,-1,-1,-1,9772,-1,0.9971324,0.0028675185
9773,anaemia,6,7,35,42,were appropriate for the degree of anaemia observed when compared with phenylhydrazine (PHZ) treated mice.,2004015_9,-1,-1,-1,9773,-1,0.00239872,0.99760133
9774,phenylhydrazine,11,12,71,86,were appropriate for the degree of anaemia observed when compared with phenylhydrazine (PHZ) treated mice.,2004015_9,-1,-1,-1,9774,-1,0.9988538,0.0011462125
9775,PHZ,13,14,88,91,were appropriate for the degree of anaemia observed when compared with phenylhydrazine (PHZ) treated mice.,2004015_9,-1,-1,-1,9775,-1,0.99706954,0.0029305024
9776,AZT,15,16,97,100,The numbers of BFU-e and the percentage of bone marrow erythroblasts observed were comparable in AZT and PHZ treated mice with similar degrees of anaemia.,2004015_10,-1,-1,-1,9776,-1,0.99812716,0.0018728425
9777,PHZ,17,18,105,108,The numbers of BFU-e and the percentage of bone marrow erythroblasts observed were comparable in AZT and PHZ treated mice with similar degrees of anaemia.,2004015_10,-1,-1,-1,9777,-1,0.9981325,0.0018675305
9778,anaemia,24,25,146,153,The numbers of BFU-e and the percentage of bone marrow erythroblasts observed were comparable in AZT and PHZ treated mice with similar degrees of anaemia.,2004015_10,-1,-1,-1,9778,-1,0.0028696544,0.99713033
9779,reticulocytosis,2,3,9,24,"However, reticulocytosis was inappropriate for the degree of anaemia observed in AZT treated infected mice.",2004015_11,-1,-1,-1,9779,-1,0.012172842,0.9878271
9780,anaemia,9,10,61,68,"However, reticulocytosis was inappropriate for the degree of anaemia observed in AZT treated infected mice.",2004015_11,-1,-1,-1,9780,-1,0.0025345085,0.9974655
9781,AZT,12,13,81,84,"However, reticulocytosis was inappropriate for the degree of anaemia observed in AZT treated infected mice.",2004015_11,-1,-1,-1,9781,-1,0.99844825,0.0015517592
9782,anaemia,2,3,23,30,AZT-induced peripheral anaemia in the face of increased numbers of BFU-e and increased levels of plasma EPO suggest a lesion in terminal differentiation.,2004015_12,-1,-1,-1,9782,-1,0.0025235573,0.9974764
9784,hip fracture,15,17,117,129,Sedation depth during spinal anesthesia and the development of postoperative delirium in elderly patients undergoing hip fracture repair.,20042557_0,-1,-1,-1,9784,-1,0.00853588,0.9914641
9785,hip fracture,13,15,100,112,OBJECTIVE: To determine whether limiting intraoperative sedation depth during spinal anesthesia for hip fracture repair in elderly patients can decrease the prevalence of postoperative delirium.,20042557_1,-1,-1,-1,9785,-1,0.010344697,0.98965526
9786,postoperative delirium,24,26,171,193,OBJECTIVE: To determine whether limiting intraoperative sedation depth during spinal anesthesia for hip fracture repair in elderly patients can decrease the prevalence of postoperative delirium.,20042557_1,-1,-1,-1,9786,-1,0.0063034836,0.9936965
9789,hip fracture,33,35,207,219,"PATIENTS AND METHODS: We performed a double-blind, randomized controlled trial at an academic medical center of elderly patients (>or=65 years) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with propofol sedation.",20042557_2,-1,-1,-1,9789,-1,0.008012715,0.99198735
9792,Mental Disorders,12,14,87,103,Postoperative delirium was assessed as defined by Diagnostic and Statistical Manual of Mental Disorders (Third Edition Revised) criteria using the Confusion Assessment Method beginning at any time from the second day after surgery.,20042557_4,-1,-1,-1,9792,-1,0.07686865,0.92313135
9794,postoperative delirium,3,5,18,40,"The prevalence of postoperative delirium was significantly lower in the light sedation group (11/57 [19%] vs 23/57 [40%] in the deep sedation group; P=.02), indicating that 1 incident of delirium will be prevented for every 4.7 patients treated with light sedation.",20042557_6,-1,-1,-1,9794,-1,0.0030942305,0.99690574
9795,P=.02,31,32,149,154,"The prevalence of postoperative delirium was significantly lower in the light sedation group (11/57 [19%] vs 23/57 [40%] in the deep sedation group; P=.02), indicating that 1 incident of delirium will be prevented for every 4.7 patients treated with light sedation.",20042557_6,-1,-1,-1,9795,-1,0.46232897,0.537671
9797,SD,4,5,13,15,The mean +/- SD number of days of delirium during hospitalization was lower in the light sedation group than in the deep sedation group (0.5+/-1.5 days vs 1.4+/-4.0 days; P=.01).,20042557_7,-1,-1,-1,9797,-1,0.2162393,0.7837607
9799,P=.01,32,33,171,176,The mean +/- SD number of days of delirium during hospitalization was lower in the light sedation group than in the deep sedation group (0.5+/-1.5 days vs 1.4+/-4.0 days; P=.01).,20042557_7,-1,-1,-1,9799,-1,0.39481238,0.60518765
9801,postoperative delirium,12,14,75,97,CONCLUSION: The use of light propofol sedation decreased the prevalence of postoperative delirium by 50% compared with deep sedation.,20042557_8,-1,-1,-1,9801,-1,0.003677728,0.9963223
9802,postoperative delirium,18,20,118,140,"Limiting depth of sedation during spinal anesthesia is a simple, safe, and cost-effective intervention for preventing postoperative delirium in elderly patients that could be widely and readily adopted.",20042557_9,-1,-1,-1,9802,-1,0.003532949,0.996467
9805,serotonin reuptake inhibitor,14,17,90,118,The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.,20067456_0,-1,-1,-1,9805,-1,0.99343216,0.006567826
9808,SD,20,21,123,125,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,-1,-1,-1,9808,-1,0.0056410013,0.99435896
9809,selective serotonin reuptake inhibitor,25,29,140,178,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,-1,-1,-1,9809,-1,0.9934307,0.006569382
9810,SSRI,30,31,180,184,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,-1,-1,-1,9810,-1,0.99447787,0.0055221007
9811,SD,34,35,190,192,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,-1,-1,-1,9811,-1,0.004589805,0.99541014
9812,SSRIs,40,41,220,225,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,-1,-1,-1,9812,-1,0.9949568,0.005043254
9813,SSRI,18,19,106,110,PATIENTS AND METHODS: The randomized sample consisted of 234 euthymic men who were receiving some type of SSRI.,20067456_2,-1,-1,-1,9813,-1,0.9982065,0.0017935504
9815,mg,10,11,52,54,"The men were randomly assigned to bupropion SR (150 mg twice daily, 117) or placebo (twice daily, 117) for 12 weeks.",20067456_3,-1,-1,-1,9815,-1,0.98112744,0.018872546
9816,Erectile Dysfunction,37,39,212,232,"Efficacy was evaluated using the Clinical Global Impression-Sexual Function (CGI-SF; the primary outcome measure), the International Index of Erectile Function (IIEF), Arizona Sexual Experience Scale (ASEX), and Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) (secondary outcome measures).",20067456_4,-1,-1,-1,9816,-1,0.012742404,0.98725754
9817,sd,11,12,48,50,"RESULTS: After 12 weeks of treatment, the mean (sd) scores for CGI-SF were significantly lower, i.e. better, in patients on bupropion SR, at 2.4 (1.2), than in the placebo group, at 3.9 (1.1) (P= 0.01).",20067456_6,-1,-1,-1,9817,-1,0.23615189,0.7638482
9819,P=,47,48,193,195,"RESULTS: After 12 weeks of treatment, the mean (sd) scores for CGI-SF were significantly lower, i.e. better, in patients on bupropion SR, at 2.4 (1.2), than in the placebo group, at 3.9 (1.1) (P= 0.01).",20067456_6,-1,-1,-1,9819,-1,0.30823457,0.6917654
9821,P=,20,21,94,96,"Men who received bupropion had a significant increase in the total IIEF score (54.4% vs 1.2%; P= 0.003), and in the five different domains of the IIEF.",20067456_7,-1,-1,-1,9821,-1,0.32539493,0.6746051
9823,P=,29,30,133,135,"Total ASEX scores were significantly lower, i.e. better, among men who received bupropion than placebo, at 15.5 (4.3) vs 21.5 (4.7) (P= 0.002).",20067456_8,-1,-1,-1,9823,-1,0.3063305,0.69366944
9825,P=,21,22,91,93,The EDITS scores were 67.4 (10.2) for the bupropion and 36.3 (11.7) for the placebo group (P= 0.001).,20067456_9,-1,-1,-1,9825,-1,0.30651104,0.693489
9826,P=,9,10,49,51,The ASEX score and CGI-SF score were correlated (P= 0.003).,20067456_10,-1,-1,-1,9826,-1,0.37760186,0.6223981
9827,SD,15,16,97,99,"In linear regression analyses the CGI-SF score was not affected significantly by the duration of SD, type of SSRI used and age.",20067456_11,-1,-1,-1,9827,-1,0.017699238,0.98230076
9828,SSRI,19,20,109,113,"In linear regression analyses the CGI-SF score was not affected significantly by the duration of SD, type of SSRI used and age.",20067456_11,-1,-1,-1,9828,-1,0.997494,0.0025060913
9830,SD,9,10,58,60,CONCLUSIONS: Bupropion is an effective treatment for male SD induced by SSRIs.,20067456_12,-1,-1,-1,9830,-1,0.004254569,0.9957455
9831,SSRIs,12,13,72,77,CONCLUSIONS: Bupropion is an effective treatment for male SD induced by SSRIs.,20067456_12,-1,-1,-1,9831,-1,0.9979602,0.0020397806
9837,status epilepticus,19,21,126,144,BMCs obtained from green fluorescent protein (GFP) transgenic mice or rats were transplanted intravenously after induction of status epilepticus (SE).,20080419_2,-1,-1,-1,9837,-1,0.0032737262,0.9967263
9838,SE,22,23,146,148,BMCs obtained from green fluorescent protein (GFP) transgenic mice or rats were transplanted intravenously after induction of status epilepticus (SE).,20080419_2,-1,-1,-1,9838,-1,0.01206625,0.98793375
9839,Spontaneous recurrent seizures,0,3,0,30,Spontaneous recurrent seizures (SRS) were monitored using Racine's seizure severity scale.,20080419_3,-1,-1,-1,9839,-1,0.0037773168,0.9962226
9840,SRS,4,5,32,35,Spontaneous recurrent seizures (SRS) were monitored using Racine's seizure severity scale.,20080419_3,-1,-1,-1,9840,-1,0.006884922,0.9931151
9843,SRS,11,12,72,75,"All of the rats in the saline-treated epileptic control group developed SRS, whereas none of the BMC-treated epileptic animals had seizures in the short term (15 days after transplantation), regardless of the BMC source.",20080419_4,-1,-1,-1,9843,-1,0.7924852,0.20751482
9852,neuronal loss,15,17,91,104,"In conclusion, treatment with BMCs can prevent the development of chronic seizures, reduce neuronal loss, and influence the reorganization of the hippocampal neuronal network.",20080419_9,-1,-1,-1,9852,-1,0.002952252,0.9970477
9856,daytime sleepiness,19,21,112,130,OBJECTIVE: The purpose of the present study was to determine the effect of morning-dosed modafinil on sleep and daytime sleepiness in chronic cocaine users.,20080983_1,-1,-1,-1,9856,-1,0.004083458,0.99591655
9859,mg,13,14,95,97,"METHOD: Twenty cocaine-dependent participants were randomly assigned to receive modafinil, 400 mg (N=10), or placebo (N=10) every morning at 7:30 a.m. for 16 days in an inpatient, double-blind randomized trial.",20080983_2,-1,-1,-1,9859,-1,0.97559017,0.024409806
9860,N=10,15,16,99,103,"METHOD: Twenty cocaine-dependent participants were randomly assigned to receive modafinil, 400 mg (N=10), or placebo (N=10) every morning at 7:30 a.m. for 16 days in an inpatient, double-blind randomized trial.",20080983_2,-1,-1,-1,9860,-1,0.52610576,0.4738942
9861,N=10,21,22,118,122,"METHOD: Twenty cocaine-dependent participants were randomly assigned to receive modafinil, 400 mg (N=10), or placebo (N=10) every morning at 7:30 a.m. for 16 days in an inpatient, double-blind randomized trial.",20080983_2,-1,-1,-1,9861,-1,0.5534793,0.44652072
9867,daytime sleepiness,25,27,159,177,"Modafinil was associated with increased daytime sleep latency, as measured by the Multiple Sleep Latency Test, and a nearly significant decrease in subjective daytime sleepiness.",20080983_10,-1,-1,-1,9867,-1,0.0057531227,0.9942469
9869,daytime sleepiness,14,16,108,126,"CONCLUSIONS: Morning-dosed modafinil promotes nocturnal sleep, normalizes sleep architecture, and decreases daytime sleepiness in abstinent cocaine users.",20080983_11,-1,-1,-1,9869,-1,0.00435145,0.99564856
9871,cocaine dependence,9,11,50,68,These effects may be relevant in the treatment of cocaine dependence.,20080983_12,-1,-1,-1,9871,-1,0.40182665,0.5981734
9872,Midazolan,13,14,69,78,OBJECTIVE: to analyze aspects of TEE safety associated to the use of Midazolan (MZ) and Flumazenil (FL) and the influence of the clinical variables on the event rate.,20084309_2,-1,-1,-1,9872,-1,0.99949956,0.00050048734
9873,MZ,15,16,80,82,OBJECTIVE: to analyze aspects of TEE safety associated to the use of Midazolan (MZ) and Flumazenil (FL) and the influence of the clinical variables on the event rate.,20084309_2,-1,-1,-1,9873,-1,0.9980919,0.0019080752
9874,Flumazenil,18,19,88,98,OBJECTIVE: to analyze aspects of TEE safety associated to the use of Midazolan (MZ) and Flumazenil (FL) and the influence of the clinical variables on the event rate.,20084309_2,-1,-1,-1,9874,-1,0.9990194,0.0009806392
9875,FL,20,21,100,102,OBJECTIVE: to analyze aspects of TEE safety associated to the use of Midazolan (MZ) and Flumazenil (FL) and the influence of the clinical variables on the event rate.,20084309_2,-1,-1,-1,9875,-1,0.9962528,0.0037471717
9876,MZ,11,12,68,70,METHOD: prospective study with 137 patients that underwent TEE with MZ associated to moderate sedation.,20084309_3,-1,-1,-1,9876,-1,0.99846137,0.0015386855
9877,MZ,14,15,90,92,"We analyzed the following events: complications related with the topical anesthesia, with MZ use and with the procedure.",20084309_4,-1,-1,-1,9877,-1,0.99853647,0.0014635789
9879,myocardiopathy,21,22,108,122,"Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.",20084309_5,-1,-1,-1,9879,-1,0.023914594,0.9760854
9880,MP,23,24,124,126,"Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.",20084309_5,-1,-1,-1,9880,-1,0.96095943,0.039040554
9882,MR,34,35,173,175,"Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.",20084309_5,-1,-1,-1,9882,-1,0.009528252,0.9904717
9883,MZ,38,39,185,187,"Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.",20084309_5,-1,-1,-1,9883,-1,0.9954886,0.0045114565
9884,MZ,4,5,18,20,"The mean doses of MZ and FL were 4.3+/-1.9 mg and 0.28+/-0.2 mg, respectively.",20084309_7,-1,-1,-1,9884,-1,0.99853003,0.0014699608
9885,FL,6,7,25,27,"The mean doses of MZ and FL were 4.3+/-1.9 mg and 0.28+/-0.2 mg, respectively.",20084309_7,-1,-1,-1,9885,-1,0.9974221,0.0025778618
9886,mg,9,10,43,45,"The mean doses of MZ and FL were 4.3+/-1.9 mg and 0.28+/-0.2 mg, respectively.",20084309_7,-1,-1,-1,9886,-1,0.9540689,0.045931105
9887,mg,12,13,61,63,"The mean doses of MZ and FL were 4.3+/-1.9 mg and 0.28+/-0.2 mg, respectively.",20084309_7,-1,-1,-1,9887,-1,0.93626094,0.06373909
9890,airway obstruction,28,30,121,139,Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.,20084309_9,-1,-1,-1,9890,-1,0.005545989,0.99445397
9892,MZ,44,45,200,202,Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.,20084309_9,-1,-1,-1,9892,-1,0.9965004,0.003499563
9894,MR,6,7,45,47,"The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).",20084309_11,-1,-1,-1,9894,-1,0.0039024334,0.99609756
9895,MP,8,9,49,51,"The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).",20084309_11,-1,-1,-1,9895,-1,0.010584782,0.9894153
9896,MZ,17,18,79,81,"The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).",20084309_11,-1,-1,-1,9896,-1,0.9984365,0.0015635103
9897,mg,21,22,85,87,"The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).",20084309_11,-1,-1,-1,9897,-1,0.9830655,0.01693451
9898,p<0.001,28,29,118,125,"The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).",20084309_11,-1,-1,-1,9898,-1,0.3903568,0.6096432
9899,MP,10,11,34,36,"The EF was 40%, in the group with MP and 44% in the group with severe MR and it can be a factor associated with clinical events in the last group.",20084309_12,-1,-1,-1,9899,-1,0.9944306,0.0055694073
9900,MR,19,20,70,72,"The EF was 40%, in the group with MP and 44% in the group with severe MR and it can be a factor associated with clinical events in the last group.",20084309_12,-1,-1,-1,9900,-1,0.0034199466,0.99658006
9901,methylergonovine,6,7,49,65,Effect of direct intracoronary administration of methylergonovine in patients with and without variant angina.,2008831_0,-1,-1,-1,9901,-1,0.99924916,0.00075085444
9903,methylergonovine,6,7,47,63,The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).,2008831_1,-1,-1,-1,9903,-1,0.99927264,0.0007273757
9905,chest pain,20,22,142,152,The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).,2008831_1,-1,-1,-1,9905,-1,0.0029275825,0.99707246
9906,angina pectoris,26,28,175,190,The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).,2008831_1,-1,-1,-1,9906,-1,0.0030974862,0.9969025
9907,Methylergonovine,0,1,0,16,Methylergonovine was administered continuously at a rate of 10 micrograms/min up to 50 micrograms.,2008831_2,-1,-1,-1,9907,-1,0.99928063,0.00071933377
9910,SD,25,26,114,116,"In all patients with variant angina, coronary spasm was provoked at a mean dose of 28 +/- 13 micrograms (mean +/- SD).",2008831_3,-1,-1,-1,9910,-1,0.18949133,0.8105087
9911,ischemic,5,6,29,37,In the control group neither ischemic ST change nor localized spasm occurred.,2008831_4,-1,-1,-1,9911,-1,0.026369128,0.9736309
9914,methylergonovine,19,20,117,133,"These results suggest that spasm provocation tests, which use an intracoronary injection of a relatively low dose of methylergonovine, have a high sensitivity in variant angina and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries.",2008831_7,-1,-1,-1,9914,-1,0.99915135,0.0008486382
9916,manifestations,1,2,5,19,"Oral manifestations of ""meth mouth"": a case report.",20098969_0,-1,-1,-1,9916,-1,0.0039219745,0.9960781
9920,cardiac dysrhythmias,23,25,155,175,"BACKGROUND: Methamphetamine is a very addictive, powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias, hypertension, hallucinations, and violent behavior.",20098969_2,-1,-1,-1,9920,-1,0.00463465,0.9953654
9923,violent behavior,31,33,211,227,"BACKGROUND: Methamphetamine is a very addictive, powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias, hypertension, hallucinations, and violent behavior.",20098969_2,-1,-1,-1,9923,-1,0.003431609,0.9965683
9925,xerostomia,11,12,76,86,"Dental patients abusing methamphetamine can present with poor oral hygiene, xerostomia, rampant caries (""meth mouth""), and excessive tooth wear.",20098969_3,-1,-1,-1,9925,-1,0.0057698344,0.99423015
9926,caries,14,15,96,102,"Dental patients abusing methamphetamine can present with poor oral hygiene, xerostomia, rampant caries (""meth mouth""), and excessive tooth wear.",20098969_3,-1,-1,-1,9926,-1,0.0033433994,0.99665654
9928,tooth wear,24,26,133,143,"Dental patients abusing methamphetamine can present with poor oral hygiene, xerostomia, rampant caries (""meth mouth""), and excessive tooth wear.",20098969_3,-1,-1,-1,9928,-1,0.005870117,0.9941299
9931,bad breath,12,14,76,86,"CASE DESCRIPTION: A 30-year-old Caucasian woman presented with dental pain, bad breath, and self-reported poor esthetics.",20098969_5,-1,-1,-1,9931,-1,0.014760313,0.98523974
9932,carious lesions,16,18,119,134,"A comprehensive examination including her medical history, panoramic radiograph, and intraoral examination revealed 19 carious lesions, which is not very common for a healthy adult.",20098969_6,-1,-1,-1,9932,-1,0.011236072,0.9887639
9934,carious episodes,15,17,89,105,She reported her use of methamphetamine for five years and had not experienced any major carious episodes before she started using the drug.,20098969_7,-1,-1,-1,9934,-1,0.0045110905,0.99548894
9935,lead,15,16,98,102,"SUMMARY: The patient's medical and dental histories along with radiographic and clinical findings lead to a diagnosis of ""meth mouth."" Although three different dental treatment modalities (either conventional or implant-supported) have been offered to the patient since August 2007, the patient has yet to initiate any treatment.",20098969_8,-1,-1,-1,9935,-1,0.038672354,0.9613276
9937,oral manifestations,7,9,50,69,CLINICAL SIGNIFICANCE: This clinical case showing oral manifestations of meth mouth was presented to help dental practitioners recognize and manage patients who may be abusing methamphetamines.,20098969_9,-1,-1,-1,9937,-1,0.0039226296,0.99607736
9939,methamphetamines,26,27,176,192,CLINICAL SIGNIFICANCE: This clinical case showing oral manifestations of meth mouth was presented to help dental practitioners recognize and manage patients who may be abusing methamphetamines.,20098969_9,-1,-1,-1,9939,-1,0.998204,0.0017959609
9942,renal failure,11,13,62,75,"OBJECTIVE: Diabetic nephropathy is one of the major causes of renal failure, which is accompanied by the production of reactive oxygen species (ROS).",20103708_1,-1,-1,-1,9942,-1,0.0027664774,0.99723357
9943,reactive oxygen species,21,24,119,142,"OBJECTIVE: Diabetic nephropathy is one of the major causes of renal failure, which is accompanied by the production of reactive oxygen species (ROS).",20103708_1,-1,-1,-1,9943,-1,0.9636283,0.036371745
9955,Metformin,0,1,0,9,Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway.,20164825_0,-1,-1,-1,9955,-1,0.99861205,0.0013879124
9957,metformin,3,4,22,31,The antidiabetic drug metformin can diminish apoptosis induced by oxidative stress in endothelial cells and prevent vascular dysfunction even in nondiabetic patients.,20164825_1,-1,-1,-1,9957,-1,0.99816847,0.0018314787
9958,vascular dysfunction,16,18,116,136,The antidiabetic drug metformin can diminish apoptosis induced by oxidative stress in endothelial cells and prevent vascular dysfunction even in nondiabetic patients.,20164825_1,-1,-1,-1,9958,-1,0.002989146,0.9970108
9959,gentamicin toxicity,14,16,68,87,Here we tested whether it has a beneficial effect in a rat model of gentamicin toxicity.,20164825_2,-1,-1,-1,9959,-1,0.3246684,0.67533153
9960,reactive oxygen species,8,11,57,80,"Mitochondrial analysis, respiration intensity, levels of reactive oxygen species, permeability transition, and cytochrome c release were assessed 3 and 6 days after gentamicin administration.",20164825_3,-1,-1,-1,9960,-1,0.9814895,0.018510478
9961,c,17,18,122,123,"Mitochondrial analysis, respiration intensity, levels of reactive oxygen species, permeability transition, and cytochrome c release were assessed 3 and 6 days after gentamicin administration.",20164825_3,-1,-1,-1,9961,-1,0.9888049,0.011195131
9963,Metformin,0,1,0,9,Metformin treatment fully blocked gentamicin-mediated acute renal failure.,20164825_4,-1,-1,-1,9963,-1,0.9984053,0.0015947616
9964,acute renal failure,5,8,54,73,Metformin treatment fully blocked gentamicin-mediated acute renal failure.,20164825_4,-1,-1,-1,9964,-1,0.0023232563,0.9976768
9965,Metformin,0,1,0,9,Metformin also protected the kidney from histological damage 6 days after gentamicin administration.,20164825_6,-1,-1,-1,9965,-1,0.99872154,0.0012784109
9967,kidney dysfunction,5,7,25,43,These in vivo markers of kidney dysfunction and their correction by metformin were complemented by in vitro studies of mitochondrial function.,20164825_7,-1,-1,-1,9967,-1,0.0028942942,0.99710566
9968,metformin,11,12,68,77,These in vivo markers of kidney dysfunction and their correction by metformin were complemented by in vitro studies of mitochondrial function.,20164825_7,-1,-1,-1,9968,-1,0.9986972,0.0013028292
9970,c,10,11,79,80,"We found that gentamicin treatment depleted respiratory components (cytochrome c, NADH), probably due to the opening of mitochondrial transition pores.",20164825_8,-1,-1,-1,9970,-1,0.992176,0.007823947
9971,reactive oxygen species,9,12,45,68,"These injuries, partly mediated by a rise in reactive oxygen species from the electron transfer chain, were significantly decreased by metformin.",20164825_9,-1,-1,-1,9971,-1,0.9716466,0.028353365
9972,metformin,22,23,135,144,"These injuries, partly mediated by a rise in reactive oxygen species from the electron transfer chain, were significantly decreased by metformin.",20164825_9,-1,-1,-1,9972,-1,0.9987476,0.0012523362
9973,metformin,9,10,53,62,"Thus, our study suggests that pleiotropic effects of metformin can lessen gentamicin nephrotoxicity and improve mitochondrial homeostasis.",20164825_10,-1,-1,-1,9973,-1,0.99887675,0.0011232123
9974,gentamicin nephrotoxicity,12,14,74,99,"Thus, our study suggests that pleiotropic effects of metformin can lessen gentamicin nephrotoxicity and improve mitochondrial homeostasis.",20164825_10,-1,-1,-1,9974,-1,0.048317935,0.95168203
9976,contrast media,7,9,50,64,Risk of nephropathy after consumption of nonionic contrast media by children undergoing cardiac angiography: a prospective study.,20195852_0,-1,-1,-1,9976,-1,0.99718374,0.0028162852
9977,contrast,5,6,39,47,"Despite increasing reports on nonionic contrast media-induced nephropathy (CIN) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography.",20195852_1,-1,-1,-1,9977,-1,0.99767584,0.0023241397
9979,CIN,9,10,75,78,"Despite increasing reports on nonionic contrast media-induced nephropathy (CIN) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography.",20195852_1,-1,-1,-1,9979,-1,0.0180086,0.98199135
9980,CIN,7,8,51,54,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,-1,9980,-1,0.01261264,0.98738736
9981,contrast media,11,13,72,86,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,-1,9981,-1,0.9922868,0.0077132476
9982,CM,14,15,88,90,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,-1,9982,-1,0.98156446,0.018435543
9983,iopromide,17,18,93,102,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,-1,9983,-1,0.99940777,0.00059220847
9984,iohexol,19,20,107,114,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,-1,9984,-1,0.99941564,0.0005843449
9985,CM,43,44,239,241,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,-1,9985,-1,0.9754959,0.024504121
9986,cyanosis,48,49,262,270,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,-1,-1,-1,9986,-1,0.0024849158,0.9975151
9987,iopromide,9,10,59,68,"The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40).",20195852_3,-1,-1,-1,9987,-1,0.99945253,0.00054752105
9988,n,14,15,79,80,"The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40).",20195852_3,-1,-1,-1,9988,-1,0.29648116,0.7035188
9989,iohexol,19,20,90,97,"The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40).",20195852_3,-1,-1,-1,9989,-1,0.99946326,0.0005367246
9990,n,24,25,108,109,"The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40).",20195852_3,-1,-1,-1,9990,-1,0.27559564,0.72440434
9992,Na,3,4,14,16,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,-1,-1,-1,9992,-1,0.99788386,0.002116088
9994,K,8,9,30,31,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,-1,-1,-1,9994,-1,0.99728537,0.0027146032
9996,Cr,14,15,50,52,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,-1,-1,-1,9996,-1,0.99693453,0.0030654254
9997,h,19,20,71,72,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,-1,-1,-1,9997,-1,0.25169873,0.7483013
9998,CM,38,39,170,172,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,-1,-1,-1,9998,-1,0.99706763,0.0029324219
9999,Na,3,4,18,20,Urine samples for Na and Cr also were checked at the same intervals.,20195852_5,-1,-1,-1,9999,-1,0.9975042,0.0024958625
10000,Cr,5,6,25,27,Urine samples for Na and Cr also were checked at the same intervals.,20195852_5,-1,-1,-1,10000,-1,0.99658465,0.0034152982
10001,renal failure,2,4,8,21,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,-1,-1,-1,10001,-1,0.0030871988,0.9969127
10002,Injury to the kidney,5,9,23,43,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,-1,-1,-1,10002,-1,0.012599249,0.9874007
10003,Failure of kidney function,10,14,45,71,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,-1,-1,-1,10003,-1,0.008130014,0.99187005
10004,Loss of kidney function,15,19,73,96,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,-1,-1,-1,10004,-1,0.009217927,0.9907821
10006,CIN,32,33,162,165,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,-1,-1,-1,10006,-1,0.036753576,0.96324646
10007,CIN,5,6,26,29,"Accordingly, among the 15 CIN patients (18.75%), 7.5% of the patients in group A had increased risk and 3.75% had renal injury, whereas 5% of group B had increased risk and 2.5% had renal injury.",20195852_7,-1,-1,-1,10007,-1,0.0073792087,0.9926208
10010,CIN,7,8,35,38,"Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).",20195852_8,-1,-1,-1,10010,-1,0.003574476,0.99642557
10011,CM,17,18,90,92,"Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).",20195852_8,-1,-1,-1,10011,-1,0.9970367,0.0029633644
10012,CIN,40,41,217,220,"Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).",20195852_8,-1,-1,-1,10012,-1,0.0033088732,0.9966911
10013,CM,47,48,257,259,"Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).",20195852_8,-1,-1,-1,10013,-1,0.996705,0.0032950176
10014,p,49,50,261,262,"Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).",20195852_8,-1,-1,-1,10014,-1,0.23503739,0.7649626
10015,CIN,5,6,27,30,"Among the 15 patients with CIN, 6 had cyanotic congenital heart diseases, but the incidence did not differ significantly from that for the noncyanotic patients (p = 0.243).",20195852_9,-1,-1,-1,10015,-1,0.09903153,0.90096843
10016,congenital heart diseases,10,13,47,72,"Among the 15 patients with CIN, 6 had cyanotic congenital heart diseases, but the incidence did not differ significantly from that for the noncyanotic patients (p = 0.243).",20195852_9,-1,-1,-1,10016,-1,0.0038902059,0.9961098
10017,p,28,29,161,162,"Among the 15 patients with CIN, 6 had cyanotic congenital heart diseases, but the incidence did not differ significantly from that for the noncyanotic patients (p = 0.243).",20195852_9,-1,-1,-1,10017,-1,0.3120592,0.6879408
10018,CIN,4,5,28,31,"Although clinically silent, CIN is not rare in pediatrics.",20195852_10,-1,-1,-1,10018,-1,0.014912933,0.98508704
10019,CM,13,14,73,75,"The incidence depends on dosage but not on the type of consumed nonionic CM, nor on the presence of cyanosis, and although CIN usually is reversible, more concern is needed for the prevention of such a complication in children.",20195852_11,-1,-1,-1,10019,-1,0.9963677,0.003632316
10020,cyanosis,20,21,100,108,"The incidence depends on dosage but not on the type of consumed nonionic CM, nor on the presence of cyanosis, and although CIN usually is reversible, more concern is needed for the prevention of such a complication in children.",20195852_11,-1,-1,-1,10020,-1,0.0026125247,0.99738747
10021,CIN,24,25,123,126,"The incidence depends on dosage but not on the type of consumed nonionic CM, nor on the presence of cyanosis, and although CIN usually is reversible, more concern is needed for the prevention of such a complication in children.",20195852_11,-1,-1,-1,10021,-1,0.99335325,0.0066467584
10023,Antituberculosis,0,1,0,16,Antituberculosis therapy (ATT)-associated acute liver failure (ATT-ALF) is the commonest drug-induced ALF in South Asia.,20196116_1,-1,-1,-1,10023,-1,0.99743456,0.0025655194
10025,ALF,13,14,102,105,Antituberculosis therapy (ATT)-associated acute liver failure (ATT-ALF) is the commonest drug-induced ALF in South Asia.,20196116_1,-1,-1,-1,10025,-1,0.0051356433,0.9948644
10026,ALF,9,10,52,55,"From January 1986 to January 2009, 1223 consecutive ALF patients were evaluated: ATT alone was the cause in 70 (5.7%) patients.",20196116_4,-1,-1,-1,10026,-1,0.04456932,0.9554307
10027,hepatitis virus infection,10,13,43,68,Another 15 (1.2%) had ATT and simultaneous hepatitis virus infection.,20196116_5,-1,-1,-1,10027,-1,0.018475888,0.98152417
10029,icterus encephalopathy,7,9,45,67,Most had hyperacute presentation; the median icterus encephalopathy interval was 4.5 (0-30) days.,20196116_8,-1,-1,-1,10029,-1,0.015334452,0.9846656
10030,ALF,6,7,34,37,The median duration of ATT before ALF was 30 (7-350) days.,20196116_9,-1,-1,-1,10030,-1,0.9928987,0.007101275
10032,cerebral edema,6,8,45,59,"At presentation, advanced encephalopathy and cerebral edema were present in 51 (76%) and 29 (41.4%) patients, respectively.",20196116_10,-1,-1,-1,10032,-1,0.0022025083,0.9977975
10033,bleed,1,2,17,22,"Gastrointestinal bleed, seizures, infection, and acute renal failure were documented in seven (10%), five (7.1%), 26 (37.1%), and seven (10%) patients, respectively.",20196116_11,-1,-1,-1,10033,-1,0.0035374623,0.9964625
10036,acute renal failure,8,11,49,68,"Gastrointestinal bleed, seizures, infection, and acute renal failure were documented in seven (10%), five (7.1%), 26 (37.1%), and seven (10%) patients, respectively.",20196116_11,-1,-1,-1,10036,-1,0.0034574908,0.9965425
10037,hepatitis E,2,4,14,25,"Compared with hepatitis E virus (HEV) and non-A non-E-induced ALF, ATT-ALF patients had nearly similar presentations except for older age and less elevation of liver enzymes.",20196116_12,-1,-1,-1,10037,-1,0.80414885,0.19585116
10038,ALF,11,12,62,65,"Compared with hepatitis E virus (HEV) and non-A non-E-induced ALF, ATT-ALF patients had nearly similar presentations except for older age and less elevation of liver enzymes.",20196116_12,-1,-1,-1,10038,-1,0.0037991612,0.99620086
10039,n,13,14,64,65,"The mortality rate among patients with ATT-ALF was high (67.1%, n = 47), and only 23 (32.9%) patients recovered with medical treatment.",20196116_13,-1,-1,-1,10039,-1,0.23821881,0.7617812
10042,ALF,7,8,40,43,CONCLUSION: ATT-ALF constituted 5.7% of ALF at our center and had a high mortality rate.,20196116_15,-1,-1,-1,10042,-1,0.024675293,0.97532475
10045,PAH,21,22,121,124,"Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured by inulin and para-aminohippurate (PAH) clearance, respectively.",2021202_2,-1,-1,-1,10045,-1,0.9949745,0.0050255307
10047,nitrous oxide,6,8,41,54,"Anesthesia was maintained with fentanyl, nitrous oxide, oxygen, and isoflurane.",2021202_3,-1,-1,-1,10047,-1,0.99876475,0.0012352325
10057,congestive heart failure,20,23,122,146,Design and analysis of the HYPREN-trial: safety of enalapril and prazosin in the initial treatment phase of patients with congestive heart failure.,2024540_0,-1,-1,-1,10057,-1,0.0033113584,0.99668866
10058,angiotensin converting enzyme (ACE) inhibitors,4,11,26,72,"Since the introduction of angiotensin converting enzyme (ACE) inhibitors into the adjunctive treatment of patients with congestive heart failure, cases of severe hypotension, especially on the first day of treatment, have occasionally been reported.",2024540_1,-1,-1,-1,10058,-1,0.9965256,0.0034743585
10059,congestive heart failure,18,21,120,144,"Since the introduction of angiotensin converting enzyme (ACE) inhibitors into the adjunctive treatment of patients with congestive heart failure, cases of severe hypotension, especially on the first day of treatment, have occasionally been reported.",2024540_1,-1,-1,-1,10059,-1,0.0025558528,0.99744415
10061,ACE inhibitor enalapril,6,9,28,51,"To assess the safety of the ACE inhibitor enalapril a multicenter, randomized, prazosin-controlled trial was designed that compared the incidence and severity of symptomatic hypotension on the first day of treatment.",2024540_2,-1,-1,-1,10061,-1,0.9981116,0.001888361
10063,mg enalapril,4,6,25,37,Trial medication was 2.5 mg enalapril or 0.5 prazosin.,2024540_3,-1,-1,-1,10063,-1,0.9977368,0.0022632217
10072,fetal anomalies,15,17,89,104,Vasoconstriction appears to be the common mechanism of action leading to a wide range of fetal anomalies.,20304337_2,-1,-1,-1,10072,-1,0.0055209543,0.99447906
10073,brainstem dysgenesis,11,13,79,99,"We report on an infant with multiple cranial-nerve involvement attributable to brainstem dysgenesis, born to a cocaine-addicted mother.",20304337_3,-1,-1,-1,10073,-1,0.003589638,0.9964103
10075,serotonin reuptake inhibitors,10,13,72,101,A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys.,20331935_0,-1,-1,-1,10075,-1,0.9953666,0.0046334905
10079,n,12,13,59,60,RESULTS: Hyperprolactinemia was present in 49% of 83 boys (n = 41) treated with risperidone for a mean of 2.9 years.,20331935_6,-1,-1,-1,10079,-1,0.30009717,0.6999028
10083,P,29,30,181,182,"After adjusting for the stage of sexual development and height and BMI z scores, serum prolactin was negatively associated with trabecular volumetric BMD at the ultradistal radius (P < .03).",20331935_9,-1,-1,-1,10083,-1,0.48473135,0.5152686
10084,serotonin reuptake inhibitors,11,14,76,105,"Controlling for relevant covariates, we also found treatment with selective serotonin reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05).",20331935_10,-1,-1,-1,10084,-1,0.99576664,0.0042334083
10085,SSRIs,15,16,107,112,"Controlling for relevant covariates, we also found treatment with selective serotonin reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05).",20331935_10,-1,-1,-1,10085,-1,0.9967348,0.0032652265
10086,P,28,29,172,173,"Controlling for relevant covariates, we also found treatment with selective serotonin reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05).",20331935_10,-1,-1,-1,10086,-1,0.329294,0.67070603
10087,P,41,42,218,219,"Controlling for relevant covariates, we also found treatment with selective serotonin reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05).",20331935_10,-1,-1,-1,10087,-1,0.2864574,0.7135426
10090,SSRIs,10,11,61,66,"Of 13 documented fractures, 3 occurred after risperidone and SSRIs were started, and none occurred in patients with hyperprolactinemia.",20331935_12,-1,-1,-1,10090,-1,0.9984269,0.0015730746
10093,SSRI,12,13,88,92,CONCLUSIONS: This is the first study to link risperidone-induced hyperprolactinemia and SSRI treatment to lower BMD in children and adolescents.,20331935_13,-1,-1,-1,10093,-1,0.9981446,0.0018553431
10094,fracture,20,21,135,143,Future research should evaluate the longitudinal course of this adverse event to determine its temporal stability and whether a higher fracture rate ensues.,20331935_14,-1,-1,-1,10094,-1,0.003152368,0.99684757
10095,startle,1,2,17,24,"Fear-potentiated startle, but not light-enhanced startle, is enhanced by anxiogenic drugs.",20394767_0,-1,-1,-1,10095,-1,0.022523893,0.9774761
10096,startle,6,7,49,56,"Fear-potentiated startle, but not light-enhanced startle, is enhanced by anxiogenic drugs.",20394767_0,-1,-1,-1,10096,-1,0.01817243,0.98182756
10097,startle,6,7,45,52,"RATIONALE AND OBJECTIVES: The light-enhanced startle paradigm (LES) is suggested to model anxiety, because of the non-specific cue and the long-term effect.",20394767_1,-1,-1,-1,10097,-1,0.99299663,0.007003337
10098,anxiety,15,16,90,97,"RATIONALE AND OBJECTIVES: The light-enhanced startle paradigm (LES) is suggested to model anxiety, because of the non-specific cue and the long-term effect.",20394767_1,-1,-1,-1,10098,-1,0.0035601635,0.99643975
10099,contrast,1,2,3,11,"In contrast, the fear-potentiated startle (FPS) is suggested to model conditioned fear.",20394767_2,-1,-1,-1,10099,-1,0.19784455,0.80215544
10100,startle,5,6,34,41,"In contrast, the fear-potentiated startle (FPS) is suggested to model conditioned fear.",20394767_2,-1,-1,-1,10100,-1,0.12164505,0.87835497
10102,0.25,14,15,96,100,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,-1,-1,-1,10102,-1,0.96194637,0.038053676
10103,m-chlorophenylpiperazine,24,25,142,166,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,-1,-1,-1,10103,-1,0.9982653,0.0017346942
10104,mCPP,26,27,168,172,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,-1,-1,-1,10104,-1,0.99774086,0.0022591355
10105,pentylenetetrazole,39,40,228,246,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,-1,-1,-1,10105,-1,0.99913055,0.000869519
10106,PTZ,41,42,248,251,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,-1,-1,-1,10106,-1,0.99724895,0.0027509923
10107,mCPP,10,11,49,53,"RESULTS: None of the drugs enhanced LES, whereas mCPP increased percentage FPS and yohimbine increased absolute FPS values.",20394767_6,-1,-1,-1,10107,-1,0.99812955,0.0018704454
10110,startle,5,6,42,49,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,-1,-1,-1,10110,-1,0.028153256,0.97184676
10111,mCPP,12,13,78,82,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,-1,-1,-1,10111,-1,0.9985228,0.0014771592
10112,startle,15,16,103,110,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,-1,-1,-1,10112,-1,0.015686154,0.98431385
10113,PTZ,23,24,139,142,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,-1,-1,-1,10113,-1,0.9977696,0.0022304603
10114,startle,26,27,163,170,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,-1,-1,-1,10114,-1,0.016748117,0.9832519
10115,contrast,3,4,16,24,"CONCLUSIONS: In contrast to findings in the FPS paradigm, none of the drugs were able to exacerbate the LES response.",20394767_8,-1,-1,-1,10115,-1,0.17891438,0.82108563
10118,dermatitis eruptions,8,10,57,77,We describe herein 3 patients who developed rosacea-like dermatitis eruptions while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis.,20466178_1,-1,-1,-1,10118,-1,0.0025341723,0.99746585
10120,facial dermatitis,20,22,128,145,We describe herein 3 patients who developed rosacea-like dermatitis eruptions while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis.,20466178_1,-1,-1,-1,10120,-1,0.0028675841,0.9971324
10121,telangiectasia,4,5,29,43,Skin biopsy specimens showed telangiectasia and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis.,20466178_2,-1,-1,-1,10121,-1,0.0066549745,0.993345
10123,pimecrolimus,9,10,65,77,"Continuous topical use of immunomodulators such as tacrolimus or pimecrolimus should be regarded as a potential cause of rosaceiform dermatitis, although many cases have not been reported.",20466178_3,-1,-1,-1,10123,-1,0.9990891,0.00091082463
10126,CNS) complications,4,7,24,42,Central nervous system (CNS) complications during treatment of childhood acute lymphoblastic leukemia (ALL) remain a challenging clinical problem.,20470218_1,-1,-1,-1,10126,-1,0.006663636,0.9933363
10128,neurological complications,6,8,37,63,"This study analyzed the incidence of neurological complications during ALL treatment in a single pediatric institution, focusing on clinical, radiological, and electrophysiological findings.",20470218_3,-1,-1,-1,10128,-1,0.0022183722,0.9977817
10129,leukemic infiltration,4,6,32,53,"Exclusion criteria included CNS leukemic infiltration at diagnosis, therapy-related peripheral neuropathy, late-onset encephalopathy, or long-term neurocognitive defects.",20470218_4,-1,-1,-1,10129,-1,0.0033930696,0.99660695
10132,neurocognitive defects,18,20,147,169,"Exclusion criteria included CNS leukemic infiltration at diagnosis, therapy-related peripheral neuropathy, late-onset encephalopathy, or long-term neurocognitive defects.",20470218_4,-1,-1,-1,10132,-1,0.0026887679,0.99731123
10134,n,8,9,78,79,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10134,-1,0.1199891,0.8800109
10136,n,15,16,95,96,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10136,-1,0.08313477,0.9168652
10138,n,24,25,127,128,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10138,-1,0.085525125,0.9144749
10139,methotrexate toxicity,30,32,145,166,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10139,-1,0.29745612,0.70254385
10140,n,33,34,168,169,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10140,-1,0.08205854,0.91794145
10141,syndrome of inappropriate antidiuretic hormone secretion,38,44,176,232,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10141,-1,0.13526559,0.8647344
10142,n,45,46,234,235,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10142,-1,0.11130768,0.88869226
10143,n,55,56,273,274,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,-1,-1,-1,10143,-1,0.10560532,0.89439464
10145,topiramate,22,23,134,144,"Cocaine causes memory and learning impairments in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate.",20477932_0,-1,-1,-1,10145,-1,0.9986395,0.0013604972
10146,cocaine toxicity,6,8,45,61,Different mechanisms have been suggested for cocaine toxicity including an increase in oxidative stress but the association between oxidative status in the brain and cocaine induced-behaviour is poorly understood.,20477932_1,-1,-1,-1,10146,-1,0.42785442,0.5721455
10147,drug toxicity,23,25,129,142,Nuclear factor kappa B (NFkappaB) is a sensor of oxidative stress and participates in memory formation that could be involved in drug toxicity and addiction mechanisms.,20477932_2,-1,-1,-1,10147,-1,0.11472312,0.88527685
10148,nitric oxide,8,10,56,68,"Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.",20477932_3,-1,-1,-1,10148,-1,0.99027854,0.009721395
10149,topiramate,26,27,148,158,"Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.",20477932_3,-1,-1,-1,10149,-1,0.99896634,0.0010337151
10150,cocaine addiction,33,35,194,211,"Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.",20477932_3,-1,-1,-1,10150,-1,0.3666752,0.6333248
10153,GSH,16,17,90,93,"NFkappaB activity was decreased in the frontal cortex of cocaine treated rats, as well as GSH concentration and glutathione peroxidase activity in the hippocampus, whereas nNOS activity in the hippocampus was increased.",20477932_4,-1,-1,-1,10153,-1,0.9976115,0.0023884976
10154,glutathione peroxidase,19,21,112,134,"NFkappaB activity was decreased in the frontal cortex of cocaine treated rats, as well as GSH concentration and glutathione peroxidase activity in the hippocampus, whereas nNOS activity in the hippocampus was increased.",20477932_4,-1,-1,-1,10154,-1,0.9929852,0.007014844
10156,contrast,1,2,3,11,"In contrast, learning of new tasks was enhanced and correlated with the increase of nNOS activity and the decrease of glutathione peroxidase.",20477932_6,-1,-1,-1,10156,-1,0.19866592,0.8013341
10157,glutathione peroxidase,21,23,118,140,"In contrast, learning of new tasks was enhanced and correlated with the increase of nNOS activity and the decrease of glutathione peroxidase.",20477932_6,-1,-1,-1,10157,-1,0.9942498,0.005750145
10159,Topiramate,0,1,0,10,"Topiramate prevented all the alterations observed, showing novel neuroprotective properties.",20477932_8,-1,-1,-1,10159,-1,0.99910116,0.00089882145
10160,cisplatin nephrotoxicity,5,7,41,65,Coenzyme Q10 treatment ameliorates acute cisplatin nephrotoxicity in mice.,20510337_0,-1,-1,-1,10160,-1,0.048641257,0.9513588
10161,coenzyme Q10,4,6,31,43,The nephroprotective effect of coenzyme Q10 was investigated in mice with acute renal injury induced by a single i.p.,20510337_1,-1,-1,-1,10161,-1,0.9989202,0.0010798177
10162,acute renal injury,11,14,74,92,The nephroprotective effect of coenzyme Q10 was investigated in mice with acute renal injury induced by a single i.p.,20510337_1,-1,-1,-1,10162,-1,0.0025695506,0.9974305
10164,Coenzyme Q10,0,2,0,12,"Coenzyme Q10 treatment (10 mg/kg/day, i.p.) was applied for 6 consecutive days, starting 1 day before cisplatin administration.",20510337_3,-1,-1,-1,10164,-1,0.9987992,0.0012008364
10169,Coenzyme Q10,0,2,0,12,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10169,-1,0.998725,0.0012749576
10170,reduced glutathione,11,13,87,106,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10170,-1,0.97884345,0.021156522
10171,superoxide dismutase,15,17,117,137,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10171,-1,0.99647766,0.0035223034
10172,nitric oxide,32,34,237,249,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10172,-1,0.99673754,0.0032624602
10173,platinum,35,36,254,262,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10173,-1,0.9981834,0.0018165411
10174,selenium,44,45,315,323,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10174,-1,0.99831545,0.0016845544
10175,zinc,46,47,328,332,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,-1,-1,-1,10175,-1,0.99806553,0.0019345032
10177,renal tissue damage,3,6,24,43,"Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.",20510337_6,-1,-1,-1,10177,-1,0.003511255,0.9964888
10179,coenzyme Q10,12,14,85,97,"Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.",20510337_6,-1,-1,-1,10179,-1,0.9986374,0.0013625699
10180,coenzyme Q10,4,6,43,55,"Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the cisplatin-induced overexpression of inducible nitric oxide synthase, nuclear factor-kappaB, caspase-3 and p53 in renal tissue.",20510337_7,-1,-1,-1,10180,-1,0.99883586,0.0011641335
10181,nitric oxide,13,15,130,142,"Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the cisplatin-induced overexpression of inducible nitric oxide synthase, nuclear factor-kappaB, caspase-3 and p53 in renal tissue.",20510337_7,-1,-1,-1,10181,-1,0.99286556,0.0071344785
10182,coenzyme Q10,4,6,22,34,It was concluded that coenzyme Q10 represents a potential therapeutic option to protect against acute cisplatin nephrotoxicity commonly encountered in clinical practice.,20510337_8,-1,-1,-1,10182,-1,0.998777,0.0012229832
10183,cisplatin nephrotoxicity,15,17,102,126,It was concluded that coenzyme Q10 represents a potential therapeutic option to protect against acute cisplatin nephrotoxicity commonly encountered in clinical practice.,20510337_8,-1,-1,-1,10183,-1,0.04720253,0.9527975
10185,bile duct injury,3,6,28,44,Reversible cholestasis with bile duct injury following azathioprine therapy.,2051906_0,-1,-1,-1,10185,-1,0.008791225,0.9912088
10187,polymyositis,6,7,36,48,"A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy.",2051906_2,-1,-1,-1,10187,-1,0.003955877,0.99604416
10194,bile duct injury,19,22,140,156,It is believed that this is the first reported case of reversible azathioprine-induced cholestasis associated with histological evidence of bile duct injury.,2051906_5,-1,-1,-1,10194,-1,0.016958779,0.98304117
10200,bipolar I disorder,24,27,152,170,Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features.,20520283_1,-1,-1,-1,10200,-1,0.012853506,0.9871465
10201,psychotic,30,31,187,196,Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features.,20520283_1,-1,-1,-1,10201,-1,0.0030710571,0.996929
10204,mg,21,22,137,139,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).",20520283_2,-1,-1,-1,10204,-1,0.9546414,0.045358535
10206,mg,31,32,175,177,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).",20520283_2,-1,-1,-1,10206,-1,0.9389014,0.061098598
10208,mg,40,41,212,214,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).",20520283_2,-1,-1,-1,10208,-1,0.91389775,0.08610229
10210,mg,29,30,185,187,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).",20520283_3,-1,-1,-1,10210,-1,0.97505593,0.02494402
10212,P,45,46,250,251,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).",20520283_3,-1,-1,-1,10212,-1,0.2339959,0.76600415
10214,mg,73,74,381,383,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).",20520283_3,-1,-1,-1,10214,-1,0.9739212,0.026078884
10216,P,93,94,469,470,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).",20520283_3,-1,-1,-1,10216,-1,0.22865668,0.7713433
10218,mg,24,25,138,140,"On the Positive and Negative Syndrome Scale positive subscale, all treatments were superior to placebo with LOCF and MMRM; asenapine at 5 mg BID was superior to placebo on the negative subscale with MMRM and on the general psychopathology subscale with LOCF and MMRM.",20520283_4,-1,-1,-1,10218,-1,0.96812403,0.031875923
10220,mg,27,28,106,108,"Treatment-related adverse events (AEs) occurred in 44% and 52%, 57%, and 41% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.",20520283_5,-1,-1,-1,10220,-1,0.9830891,0.016910879
10224,mg,26,27,107,109,"Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.",20520283_6,-1,-1,-1,10224,-1,0.9817438,0.01825618
10232,leukaemia,14,15,120,129,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.",20528871_0,-1,-1,-1,10232,-1,0.0030664592,0.9969336
10233,lymphoma,16,17,134,142,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.",20528871_0,-1,-1,-1,10233,-1,0.0029633292,0.9970367
10235,AraG,8,9,36,40,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,-1,-1,-1,10235,-1,0.99787974,0.0021203253
10237,VP,16,17,65,67,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,-1,-1,-1,10237,-1,0.9978072,0.0021927727
10239,CPM,21,22,91,94,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,-1,-1,-1,10239,-1,0.99693453,0.0030654182
10240,leukaemia,40,41,219,228,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,-1,-1,-1,10240,-1,0.0026144465,0.99738556
10241,lymphoma,42,43,232,240,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,-1,-1,-1,10241,-1,0.0025562902,0.9974437
10242,AraG,8,9,49,53,The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.,20528871_2,-1,-1,-1,10242,-1,0.99800247,0.0019975787
10243,motor neuropathy,16,18,89,105,The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.,20528871_2,-1,-1,-1,10243,-1,0.0034124206,0.99658763
10244,musculoskeletal pain,19,21,110,130,The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.,20528871_2,-1,-1,-1,10244,-1,0.0028868169,0.9971132
10246,AraG,8,9,61,65,"Haematological toxicity was greater for the combination than AraG alone, although median time to neutrophil and platelet recovery was consistent with other salvage therapies.",20528871_3,-1,-1,-1,10246,-1,0.998767,0.0012329968
10247,AraG,7,8,45,49,"Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.",20528871_5,-1,-1,-1,10247,-1,0.9987697,0.0012302833
10250,neurological toxicity,19,21,128,149,"Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.",20528871_5,-1,-1,-1,10250,-1,0.0026542738,0.99734575
10254,DA,7,8,37,39,"It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.",20533999_1,-1,-1,-1,10254,-1,0.9974353,0.0025647983
10257,DA,23,24,155,157,"It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.",20533999_1,-1,-1,-1,10257,-1,0.9971501,0.002849903
10259,DA,32,33,223,225,"It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.",20533999_1,-1,-1,-1,10259,-1,0.9967231,0.0032768531
10261,DA,13,14,78,80,"However, temperature effects of drugs that have been used to manipulate brain DA neurotransmission confound interpretation of the data.",20533999_2,-1,-1,-1,10261,-1,0.9965276,0.00347234
10262,DA neurotoxicity,19,21,155,171,Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.,20533999_3,-1,-1,-1,10262,-1,0.21761954,0.78238046
10263,DA,13,14,75,77,"Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.",20533999_4,-1,-1,-1,10263,-1,0.9920433,0.007956724
10264,METH neurotoxicity,15,17,86,104,"Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.",20533999_4,-1,-1,-1,10264,-1,0.21523942,0.7847606
10265,METH,25,26,140,144,"Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.",20533999_4,-1,-1,-1,10265,-1,0.9983234,0.00167662
10266,DA deficits,13,15,86,97,"In addition, we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop METH-induced dopaminergic deficits that are of comparable magnitude on both sides of the brain.",20533999_5,-1,-1,-1,10266,-1,0.28910285,0.71089715
10267,dopaminergic deficits,17,19,119,140,"In addition, we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop METH-induced dopaminergic deficits that are of comparable magnitude on both sides of the brain.",20533999_5,-1,-1,-1,10267,-1,0.16714993,0.83285004
10268,DA,7,8,48,50,"Taken together, these findings demonstrate that DA is not essential for the development of METH-induced dopaminergic neurotoxicity and suggest that mechanisms independent of DA warrant more intense investigation.",20533999_6,-1,-1,-1,10268,-1,0.99846447,0.0015355949
10270,DA,24,25,174,176,"Taken together, these findings demonstrate that DA is not essential for the development of METH-induced dopaminergic neurotoxicity and suggest that mechanisms independent of DA warrant more intense investigation.",20533999_6,-1,-1,-1,10270,-1,0.9983997,0.0016003478
10281,and kidney injury,20,23,123,140,"Acute normal tissue toxicities (i.e., leukopenia and thrombocytopenia) and late normal tissue toxicities (i.e., myocardial and kidney injury) were evaluated by functional/physiological assays and by morphological techniques.",2054792_3,-1,-1,-1,10281,-1,0.0071121687,0.9928878
10283,C,9,10,49,50,Whole body hyperthermia (120 min at 41.5 degrees C) enhanced both Adriamycin-mediated antitumor activity and toxic side effects.,2054792_4,-1,-1,-1,10283,-1,0.9436697,0.05633036
10284,renal lesions,27,29,159,172,"Thermal enhancement ratios estimated for ""acute"" hematological changes were 1.3, whereas those estimated for ""late"" damage (based on morphological cardiac and renal lesions) varied between 2.4 and 4.3.",2054792_6,-1,-1,-1,10284,-1,0.005263238,0.99473673
10287,atrial tachyarrhythmia,1,3,19,41,Swallowing-induced atrial tachyarrhythmia triggered by salbutamol: case report and review of the literature.,20552622_0,-1,-1,-1,10287,-1,0.003219081,0.9967809
10289,atrial tachyarrhythmia,5,7,34,56,"On electrocardiogram, episodes of atrial tachyarrhythmia were recorded immediately after swallowing; 24-hour Holter monitoring recorded several events.",20552622_2,-1,-1,-1,10289,-1,0.009467604,0.9905324
10291,atenolol,6,7,43,51,"The arrhythmia resolved after therapy with atenolol, but recurred a year later.",20552622_3,-1,-1,-1,10291,-1,0.99874854,0.0012514497
10293,atenolol,11,12,59,67,"After stopping the beta-agonist, and after a week with the atenolol, the arrhythmia disappeared.",20552622_5,-1,-1,-1,10293,-1,0.9989095,0.0010905119
10295,atrial tachyarrhythmia,3,5,31,53,DISCUSSION: Swallowing-induced atrial tachyarrhythmia (SIAT) is a rare phenomenon.,20552622_6,-1,-1,-1,10295,-1,0.004163325,0.9958366
10296,SIAT,6,7,55,59,DISCUSSION: Swallowing-induced atrial tachyarrhythmia (SIAT) is a rare phenomenon.,20552622_6,-1,-1,-1,10296,-1,0.9414037,0.058596328
10297,SIAT,5,6,23,27,Fewer than 50 cases of SIAT have been described in the literature.,20552622_7,-1,-1,-1,10297,-1,0.9408772,0.059122853
10298,SIAT,19,20,122,126,"This article summarizes all the cases published, creating a comprehensive review of the current knowledge and approach to SIAT.",20552622_8,-1,-1,-1,10298,-1,0.35930514,0.6406949
10300,SIAT,14,15,102,106,"It discusses demographics, clinical characteristics and types of arrhythmia, postulated mechanisms of SIAT, and different treatment possibilities such as medications, surgery, and radiofrequency catheter ablation (RFCA).",20552622_9,-1,-1,-1,10300,-1,0.99425983,0.005740163
10302,SIAT,11,12,67,71,CONCLUSION: Salbutamol is presented here as a possible trigger for SIAT.,20552622_10,-1,-1,-1,10302,-1,0.789566,0.21043397
10305,atenolol,47,48,272,280,"Although it is difficult to define causality in a case report, it is logical to think that a beta-agonist like salbutamol (known to induce tachycardia) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta-blocker such as atenolol (that blocks the adrenergic activity) may relieve it.",20552622_11,-1,-1,-1,10305,-1,0.99687034,0.0031296338
10306,diabetes mellitus.1,18,20,128,147,The ability of insulin treatment to reverse or prevent the changes in urinary bladder function caused by streptozotocin-induced diabetes mellitus.1.,2055425_0,-1,-1,-1,10306,-1,0.057563417,0.9424366
10308,body weight,11,13,58,69,"2. Diabetes of 2 months duration resulted in decreases in body weight and increases in fluid consumption, urine volume, frequency of micturition, and average volume per micturition; effects which were prevented by insulin treatment.",2055425_2,-1,-1,-1,10308,-1,0.064502865,0.9354971
10310,ATP,22,23,139,142,"3. Insulin treatment also prevented the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.",2055425_3,-1,-1,-1,10310,-1,0.9978877,0.002112361
10311,bethanechol,25,26,148,159,"3. Insulin treatment also prevented the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.",2055425_3,-1,-1,-1,10311,-1,0.9985241,0.001475891
10313,body weight,10,12,60,71,"Diabetes of 4 months duration also resulted in decreases in body weight, and increases in fluid consumption, urine volume, frequency of micturition, and average volume per micturition, effects which were reversed by insulin treatment for the final 2 months of the study.",2055425_5,-1,-1,-1,10313,-1,0.07686009,0.92313987
10315,ATP,19,20,130,133,"Insulin treatment reversed the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.",2055425_7,-1,-1,-1,10315,-1,0.9979674,0.0020325263
10316,bethanechol,22,23,139,150,"Insulin treatment reversed the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.",2055425_7,-1,-1,-1,10316,-1,0.9985707,0.0014293521
10318,NMDA,4,5,44,48,Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol-induced catalepsy.,20558148_0,-1,-1,-1,10318,-1,0.99769455,0.0023054038
10325,glutamate NMDA,9,11,91,105,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,-1,-1,-1,10325,-1,0.9944013,0.0055986997
10326,MK-801,14,15,128,134,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,-1,-1,-1,10326,-1,0.9983917,0.0016083333
10327,AP7,23,24,166,169,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,-1,-1,-1,10327,-1,0.99822587,0.0017741887
10328,NMDA,35,36,208,212,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,-1,-1,-1,10328,-1,0.98922545,0.010774515
10329,NMDA,40,41,252,256,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,-1,-1,-1,10329,-1,0.99607617,0.0039238003
10330,MK-801,7,8,58,64,"The results showed that intracollicular microinjection of MK-801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.",20558148_6,-1,-1,-1,10330,-1,0.9979943,0.0020057717
10331,AP7,9,10,69,72,"The results showed that intracollicular microinjection of MK-801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.",20558148_6,-1,-1,-1,10331,-1,0.99832684,0.0016732186
10334,NMDA,5,6,47,51,"Accordingly, intracollicular microinjection of NMDA increased the latency to step down the bar.",20558148_7,-1,-1,-1,10334,-1,0.9984913,0.0015087065
10336,puromycin aminonucleoside nephrosis,16,19,109,144,"Permeability, ultrastructural changes, and distribution of novel proteins in the glomerular barrier in early puromycin aminonucleoside nephrosis.",20588063_0,-1,-1,-1,10336,-1,0.6524082,0.3475918
10338,puromycin aminonucleoside nephrosis,1,4,6,41,"Using puromycin aminonucleoside nephrosis (PAN) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes.",20588063_2,-1,-1,-1,10338,-1,0.62930036,0.37069958
10339,PAN,5,6,43,46,"Using puromycin aminonucleoside nephrosis (PAN) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes.",20588063_2,-1,-1,-1,10339,-1,0.041042857,0.95895714
10342,PAN,2,3,13,16,"CONCLUSIONS: PAN glomeruli already showed significant pathology by day 4, despite relatively mild proteinuria.",20588063_12,-1,-1,-1,10342,-1,0.6174934,0.3825066
10344,PAN,13,14,78,81,"The novel proteins dendrin and plekhh2 were both reduced, suggesting roles in PAN, whereas a-actinin was unchanged.",20588063_14,-1,-1,-1,10344,-1,0.60214365,0.39785635
10345,OCD,9,10,68,71,"BACKGROUND: Current animal models of obsessive-compulsive disorder (OCD) typically involve acute, drug-induced symptom provocation or a genetic association with stereotypies or anxiety.",20619828_1,-1,-1,-1,10345,-1,0.011075383,0.98892456
10346,stereotypies,23,24,161,173,"BACKGROUND: Current animal models of obsessive-compulsive disorder (OCD) typically involve acute, drug-induced symptom provocation or a genetic association with stereotypies or anxiety.",20619828_1,-1,-1,-1,10346,-1,0.008805606,0.99119437
10347,anxiety,25,26,177,184,"BACKGROUND: Current animal models of obsessive-compulsive disorder (OCD) typically involve acute, drug-induced symptom provocation or a genetic association with stereotypies or anxiety.",20619828_1,-1,-1,-1,10347,-1,0.0038343535,0.99616563
10348,antidepressant clomipramine,9,11,55,82,METHODS: Neonatal rats were treated with the tricyclic antidepressant clomipramine or vehicle between days 9 and 16 twice daily and behaviorally tested in adulthood.,20619828_3,-1,-1,-1,10348,-1,0.9989631,0.0010369361
10350,anxiety,16,17,126,133,"RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.",20619828_4,-1,-1,-1,10350,-1,0.003981973,0.996018
10351,marble,22,23,158,164,"RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.",20619828_4,-1,-1,-1,10351,-1,0.95123696,0.048763026
10352,behavioral inflexibility,26,28,175,199,"RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.",20619828_4,-1,-1,-1,10352,-1,0.0075763837,0.99242353
10354,hoarding,51,52,338,346,"RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.",20619828_4,-1,-1,-1,10354,-1,0.0644369,0.93556315
10355,corticostriatal dysfunction,54,56,352,379,"RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.",20619828_4,-1,-1,-1,10355,-1,0.048256952,0.95174307
10358,OCD,17,18,119,122,"Moreover, these behaviors are accompanied by biochemical changes in brain regions previously identified as relevant to OCD.",20619828_7,-1,-1,-1,10358,-1,0.010712288,0.98928773
10359,OCD,4,5,20,23,"This novel model of OCD demonstrates that drug exposure during a sensitive period can program disease-like systems permanently, which could have implications for current and future therapeutic strategies for this and other psychiatric disorders.",20619828_8,-1,-1,-1,10359,-1,0.0048669414,0.995133
10360,psychiatric disorders,33,35,223,244,"This novel model of OCD demonstrates that drug exposure during a sensitive period can program disease-like systems permanently, which could have implications for current and future therapeutic strategies for this and other psychiatric disorders.",20619828_8,-1,-1,-1,10360,-1,0.0030747864,0.9969252
10361,aortic aneurysm,16,18,112,127,"Elevation of ADAM10, ADAM17, MMP-2 and MMP-9 expression with media degeneration features CaCl2-induced thoracic aortic aneurysm in a rat model.",20621845_0,-1,-1,-1,10361,-1,0.005427098,0.99457294
10362,thoracic aortic aneurysm,12,15,61,85,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,-1,-1,-1,10362,-1,0.005918586,0.99408144
10363,TAA,16,17,87,90,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,-1,-1,-1,10363,-1,0.005684017,0.9943159
10364,calcium chloride,19,21,95,111,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,-1,-1,-1,10364,-1,0.99808973,0.0019102616
10365,arterial injury,23,25,130,145,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,-1,-1,-1,10365,-1,0.0045312443,0.99546874
10366,TAA,53,54,303,306,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,-1,-1,-1,10366,-1,0.0073019657,0.992698
10367,CaCl(2),13,15,72,79,METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).,20621845_2,-1,-1,-1,10367,-1,0.9942761,0.005723931
10368,NaCl,19,20,98,102,METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).,20621845_2,-1,-1,-1,10368,-1,0.99651885,0.0034811806
10369,n=12,12,13,80,84,"After 12weeks, animals were euthanized, and CaCl(2)-treated, CaCl(2)-untreated (n=12) and NaCl-treated aortic segments (n=12) were collected for histological and molecular assessments.",20621845_3,-1,-1,-1,10369,-1,0.25499982,0.7450002
10370,n=12,19,20,120,124,"After 12weeks, animals were euthanized, and CaCl(2)-treated, CaCl(2)-untreated (n=12) and NaCl-treated aortic segments (n=12) were collected for histological and molecular assessments.",20621845_3,-1,-1,-1,10370,-1,0.23633589,0.76366407
10371,n=6,17,18,136,139,"RESULTS: Despite similar external diameters among CaCl(2)-treated, non-CaCl(2)-treated and NaCl-treated segments, aneurymal alteration (n=6, 50%), media degeneration with regional disruption, fragmentation of elastic fiber, and increased collagen deposition (n=12, 100%) were demonstrated in CaCl(2)-treated segments.",20621845_5,-1,-1,-1,10371,-1,0.243753,0.75624704
10372,n=12,39,40,259,263,"RESULTS: Despite similar external diameters among CaCl(2)-treated, non-CaCl(2)-treated and NaCl-treated segments, aneurymal alteration (n=6, 50%), media degeneration with regional disruption, fragmentation of elastic fiber, and increased collagen deposition (n=12, 100%) were demonstrated in CaCl(2)-treated segments.",20621845_5,-1,-1,-1,10372,-1,0.25975487,0.7402451
10373,p<0.01,16,17,94,100,"MMP-2, MMP-9, ADAM-10 and ADAM-17 mRNA levels were increased in CaCl(2)-treated segments (all p<0.01), with trends of elevation in CaCl(2)-untreated segments, as compared with NaCl-treated segments.",20621845_6,-1,-1,-1,10373,-1,0.5029662,0.49703377
10374,p<0.01,15,16,109,115,"Immunohistochemistry displayed significantly increased expressions of MMP-2, MMP-9, ADAM-10 and ADAM-17 (all p<0.01) in intima and media for CaCl(2)-treated segments.",20621845_7,-1,-1,-1,10374,-1,0.5398959,0.4601041
10375,TAA,6,7,37,40,"CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.",20621845_9,-1,-1,-1,10375,-1,0.039156288,0.96084374
10376,CaCl(2,10,11,63,69,"CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.",20621845_9,-1,-1,-1,10376,-1,0.9943184,0.0056815757
10377,),11,12,69,70,"CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.",20621845_9,-1,-1,-1,10377,-1,0.9851113,0.01488873
10378,vascular remodeling,35,37,202,221,"CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.",20621845_9,-1,-1,-1,10378,-1,0.004132318,0.9958677
10383,organophosphorus (OP) poisons,13,18,105,134,Suxamethonium causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus (OP) poisons.,20633755_1,-1,-1,-1,10383,-1,0.8902711,0.10972884
10386,OP compound,13,15,85,96,Prolonged apnea in our case ensued because the information about suicidal attempt by OP compound was concealed from the treating team.,20633755_3,-1,-1,-1,10386,-1,0.9960685,0.003931512
10387,congestive heart failure,1,4,7,31,Severe congestive heart failure patient on amiodarone presenting with myxedemic coma: a case report.,20635749_0,-1,-1,-1,10387,-1,0.00320636,0.9967937
10392,congestive heart failure,17,20,111,135,This is a case report of myxedema coma secondary to amiodarone-induced hypothyroidism in a patient with severe congestive heart failure (CHF).,20635749_1,-1,-1,-1,10392,-1,0.0029997844,0.99700016
10393,CHF,21,22,137,140,This is a case report of myxedema coma secondary to amiodarone-induced hypothyroidism in a patient with severe congestive heart failure (CHF).,20635749_1,-1,-1,-1,10393,-1,0.0028070095,0.99719304
10398,T4,8,9,53,55,The condition is treated with intravenous thyroxine (T4) or intravenous tri-iodo-thyronine (T3).,20635749_4,-1,-1,-1,10398,-1,0.99666435,0.003335645
10399,T3,14,15,92,94,The condition is treated with intravenous thyroxine (T4) or intravenous tri-iodo-thyronine (T3).,20635749_4,-1,-1,-1,10399,-1,0.9935201,0.0064798584
10400,CHF,2,3,14,17,"Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.",20635749_5,-1,-1,-1,10400,-1,0.0036106037,0.9963894
10404,CHF,15,16,104,107,This case report carries an important clinical application given the frequent usage of amiodarone among CHF patients.,20635749_6,-1,-1,-1,10404,-1,0.0037692364,0.9962308
10406,CHF,22,23,148,151,"The myriad clinical presentation of myxedema coma and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with hypotension, weakness or other unexplained symptoms.",20635749_7,-1,-1,-1,10406,-1,0.028082727,0.9719173
10409,cognitive dysfunction,2,4,21,42,Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats.,20667451_0,-1,-1,-1,10409,-1,0.0024715508,0.9975285
10414,cognitive impairment,12,14,82,102,"The antiepileptic drugs, phenobarbitone and carbamazepine are well known to cause cognitive impairment on chronic use.",20667451_1,-1,-1,-1,10414,-1,0.0023043456,0.9976956
10415,cognitive impairment,16,18,98,118,The increase in free radical generation has been implicated as one of the important mechanisms of cognitive impairment by antiepileptic drugs.,20667451_2,-1,-1,-1,10415,-1,0.0024763623,0.9975236
10418,cognitive impairment,20,22,151,171,"Therefore, the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone- and carbamazepine-induced cognitive impairment and oxidative stress in rats.",20667451_4,-1,-1,-1,10418,-1,0.002707954,0.997292
10424,malondialdehyde and reduced glutathione,14,18,80,119,"At the end of study period, serum phenobarbitone and carbamazepine, whole brain malondialdehyde and reduced glutathione levels were estimated.",20667451_8,-1,-1,-1,10424,-1,0.9967874,0.0032126205
10427,impairment of learning and memory,11,16,87,120,The administration of phenobarbitone and carbamazepine for 21days caused a significant impairment of learning and memory as well as an increased oxidative stress.,20667451_9,-1,-1,-1,10427,-1,0.0067071756,0.9932928
10429,cognitive impairment,5,7,50,70,Concomitant curcumin administration prevented the cognitive impairment and decreased the increased oxidative stress induced by these antiepileptic drugs.,20667451_10,-1,-1,-1,10429,-1,0.0021900963,0.99780995
10434,deterioration of cognitive functions,11,15,73,109,These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.,20667451_12,-1,-1,-1,10434,-1,0.003712519,0.99628747
10440,cognitive impairment,22,24,154,174,The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing cognitive impairment associated with these drugs.,20667451_13,-1,-1,-1,10440,-1,0.0023789837,0.997621
10441,crocin,9,10,53,59,"Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats.",20683499_0,-1,-1,-1,10441,-1,0.9987068,0.0012931246
10442,Alzheimer's disease,15,18,102,121,"Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats.",20683499_0,-1,-1,-1,10442,-1,0.005203895,0.9947961
10443,carotenoids,6,7,45,56,"BACKGROUND: The involvement of water-soluble carotenoids, crocins, as the main and active components of Crocus sativus L. extract in learning and memory processes has been proposed.",20683499_1,-1,-1,-1,10443,-1,0.9956656,0.004334431
10444,crocins,8,9,58,65,"BACKGROUND: The involvement of water-soluble carotenoids, crocins, as the main and active components of Crocus sativus L. extract in learning and memory processes has been proposed.",20683499_1,-1,-1,-1,10444,-1,0.9975795,0.0024205002
10445,crocins,8,9,36,43,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.",20683499_2,-1,-1,-1,10445,-1,0.9988342,0.0011657976
10446,Alzheimer's disease,11,14,56,75,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.",20683499_2,-1,-1,-1,10446,-1,0.0044111162,0.9955889
10447,streptozocin,20,21,117,129,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.",20683499_2,-1,-1,-1,10447,-1,0.9991478,0.00085221743
10448,STZ,22,23,131,134,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.",20683499_2,-1,-1,-1,10448,-1,0.99796605,0.0020340118
10449,n,7,8,33,34,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups.",20683499_3,-1,-1,-1,10449,-1,0.26448822,0.73551184
10450,crocins,27,28,94,101,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups.",20683499_3,-1,-1,-1,10450,-1,0.9988381,0.0011619213
10451,STZ,37,38,124,127,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups.",20683499_3,-1,-1,-1,10451,-1,0.99570185,0.004298094
10452,STZ,43,44,138,141,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups.",20683499_3,-1,-1,-1,10452,-1,0.9949496,0.005050398
10453,crocins,45,46,144,151,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups.",20683499_3,-1,-1,-1,10453,-1,0.9986314,0.0013685427
10454,Alzheimer's disease,1,4,3,22,"In Alzheimer's disease groups, rats were injected with STZ-icv bilaterally (3 mg/kg) in first day and 3 days later, a similar STZ-icv application was repeated.",20683499_4,-1,-1,-1,10454,-1,0.0062490157,0.993751
10455,STZ,1,2,3,6,"In STZ + crocin animal groups, crocin was applied in doses of 15 and 30 mg/kg, i.p., one day pre-surgery and continued for three weeks.",20683499_5,-1,-1,-1,10455,-1,0.99865097,0.0013490005
10456,crocin,3,4,9,15,"In STZ + crocin animal groups, crocin was applied in doses of 15 and 30 mg/kg, i.p., one day pre-surgery and continued for three weeks.",20683499_5,-1,-1,-1,10456,-1,0.99902225,0.0009777751
10457,crocin,7,8,31,37,"In STZ + crocin animal groups, crocin was applied in doses of 15 and 30 mg/kg, i.p., one day pre-surgery and continued for three weeks.",20683499_5,-1,-1,-1,10457,-1,0.99903667,0.00096336287
10458,crocin,2,3,16,22,Prescription of crocin in each dose was repeated once for two days.,20683499_6,-1,-1,-1,10458,-1,0.9990308,0.00096916355
10459,crocin,7,8,31,37,RESULTS: It was found out that crocin (30 mg/kg)-treated STZ-injected rats show higher correct choices and lower errors in Y-maze than vehicle-treated STZ-injected rats.,20683499_8,-1,-1,-1,10459,-1,0.9990602,0.000939768
10460,crocin,3,4,13,19,"In addition, crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ-injected group in passive avoidance test.",20683499_9,-1,-1,-1,10460,-1,0.9990343,0.0009657472
10462,crocin,10,11,70,76,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",20683499_10,-1,-1,-1,10462,-1,0.9990398,0.00096015394
10464,neurodegenerative diseases,32,34,191,217,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",20683499_10,-1,-1,-1,10464,-1,0.0024719825,0.997528
10465,Alzheimer's disease,36,39,226,245,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",20683499_10,-1,-1,-1,10465,-1,0.004943196,0.99505675
10467,hemolytic anemia?BACKGROUND/AIMS,10,12,67,99,Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.,20698227_0,-1,-1,-1,10467,-1,0.020218406,0.9797816
10469,angiogenesis inhibitors,25,27,175,198,Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.,20698227_0,-1,-1,-1,10469,-1,0.42932695,0.5706731
10470,sunitinib,29,30,207,216,Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.,20698227_0,-1,-1,-1,10470,-1,0.9985734,0.0014265486
10474,chronically infected with hepatitis C virus,4,10,27,70,METHODS: Fourteen patients chronically infected with hepatitis C virus were treated by pegylated interferon alpha 2a and ribavirin.,20698227_2,-1,-1,-1,10474,-1,0.016503284,0.98349667
10475,pegylated interferon alpha 2a,13,17,87,116,METHODS: Fourteen patients chronically infected with hepatitis C virus were treated by pegylated interferon alpha 2a and ribavirin.,20698227_2,-1,-1,-1,10475,-1,0.9980019,0.0019981787
10477,contrast,1,2,3,11,"In contrast with the literature, serum levels of angiogenesis factors did not change significantly by pegylated interferon and ribavirin therapy.",20698227_6,-1,-1,-1,10477,-1,0.16627228,0.8337277
10478,pegylated interferon,16,18,102,122,"In contrast with the literature, serum levels of angiogenesis factors did not change significantly by pegylated interferon and ribavirin therapy.",20698227_6,-1,-1,-1,10478,-1,0.99861825,0.0013817389
10482,hepatitis C,24,26,158,169,CONCLUSION: This is the first study in the literature investigating a link between angiogenesis soluble markers and ribavirin induced anemia in patients with hepatitis C and we could not find any relation.,20698227_8,-1,-1,-1,10482,-1,0.040657338,0.9593426
10496,P,28,29,140,141,"The mean pain score for buffered lidocaine was significantly lower than the mean score for standard lidocaine (2.7 +/- 1.9 vs. 3.8 +/- 2.2, P = 0.03).",2070391_4,-1,-1,-1,10496,-1,0.23349826,0.7665017
10500,psychosis,8,9,69,78,Serotonin 6 receptor gene is associated with methamphetamine-induced psychosis in a Japanese population.,20705401_0,-1,-1,-1,10500,-1,0.002263903,0.9977361
10501,psychotic disorders,14,16,103,122,BACKGROUND: Altered serotonergic neural transmission is hypothesized to be a susceptibility factor for psychotic disorders such as schizophrenia.,20705401_1,-1,-1,-1,10501,-1,0.0029142837,0.99708575
10504,antipsychotics,14,15,90,104,"The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.",20705401_2,-1,-1,-1,10504,-1,0.9581048,0.041895237
10508,phencyclidine,11,12,75,88,"In addition, the disrupted prepulse inhibition induced by d-amphetamine or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats.",20705401_3,-1,-1,-1,10508,-1,0.99933136,0.0006686188
10510,psychotic disorders,28,30,187,206,"These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders.",20705401_4,-1,-1,-1,10510,-1,0.0027328557,0.9972671
10512,psychosis,5,6,47,56,The symptoms of methamphetamine (METH)-induced psychosis are similar to those of paranoid type schizophrenia.,20705401_5,-1,-1,-1,10512,-1,0.002188105,0.9978119
10513,paranoid type schizophrenia,11,14,81,108,The symptoms of methamphetamine (METH)-induced psychosis are similar to those of paranoid type schizophrenia.,20705401_5,-1,-1,-1,10513,-1,0.0035454903,0.9964545
10514,psychosis,18,19,98,107,"Therefore, we conducted an analysis of the association of the 5-HT6 gene (HTR6) with METH-induced psychosis.",20705401_6,-1,-1,-1,10514,-1,0.0021940335,0.997806
10515,psychosis,30,31,178,187,"METHOD: Using five tagging SNPs (rs6693503, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced psychosis patients and 337 controls) in the Japanese population.",20705401_7,-1,-1,-1,10515,-1,0.0028844883,0.9971155
10517,psychosis,7,8,52,61,RESULTS: rs6693503 was associated with METH-induced psychosis patients in the allele/genotype-wise analysis.,20705401_9,-1,-1,-1,10517,-1,0.0023396395,0.9976604
10518,psychosis,31,32,185,194,"In the haplotype-wise analysis, we detected an association between two markers (rs6693503 and rs1805054) and three markers (rs6693503, rs1805054 and rs4912138) in HTR6 and METH-induced psychosis patients, respectively.",20705401_11,-1,-1,-1,10518,-1,0.0023496351,0.9976503
10519,psychosis,13,14,83,92,CONCLUSION: HTR6 may play an important role in the pathophysiology of METH-induced psychosis in the Japanese population.,20705401_12,-1,-1,-1,10519,-1,0.0021210306,0.997879
10525,h,12,13,31,32,"Before and 0.5, 1, 2, 3, and 6 h after injection the subjects were given attention and mnemonic tests.",2071257_4,-1,-1,-1,10525,-1,0.40548158,0.59451836
10526,impairment of attention and memory,13,18,72,106,The findings of this study indicate that the drug is able to antagonize impairment of attention and memory induced by scopolamine.,2071257_5,-1,-1,-1,10526,-1,0.007998324,0.99200165
10529,Fluoropyrimidines,5,6,25,42,"IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.",20722491_1,-1,-1,-1,10529,-1,0.99819165,0.0018083405
10531,5-FU,11,12,74,78,"IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.",20722491_1,-1,-1,-1,10531,-1,0.99770314,0.0022968592
10533,head and neck cancers,30,34,176,197,"IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.",20722491_1,-1,-1,-1,10533,-1,0.009590647,0.9904094
10536,renal and kidney disease,27,31,154,178,"WHAT THE READER WILL GAIN: The reader will gain better insight into the safety of capecitabine in special populations such as patients with advanced age, renal and kidney disease.",20722491_3,-1,-1,-1,10536,-1,0.0058143665,0.9941856
10539,5-FU,10,11,54,58,TAKE HOME MESSAGE: Capecitabine is an oral prodrug of 5-FU and was developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile.,20722491_5,-1,-1,-1,10539,-1,0.9981743,0.0018257353
10540,and,26,27,162,165,"It has shown promising results alone or in combination with other chemotherapeutic agents in colorectal, breast, pancreaticobiliary, gastric, renal cell and head and neck cancers.",20722491_6,-1,-1,-1,10540,-1,0.078337945,0.9216621
10548,S-ketamine,3,4,21,31,Neural correlates of S-ketamine induced psychosis during overt continuous verbal fluency.,20727411_0,-1,-1,-1,10548,-1,0.99811625,0.0018837802
10549,psychosis,5,6,40,49,Neural correlates of S-ketamine induced psychosis during overt continuous verbal fluency.,20727411_0,-1,-1,-1,10549,-1,0.002472075,0.9975279
10550,NMDA,4,5,40,44,The glutamatergic N-methyl-D-aspartate (NMDA) receptor has been implicated in the pathophysiology of schizophrenia.,20727411_1,-1,-1,-1,10550,-1,0.9971396,0.0028604022
10552,NMDA,11,12,80,84,"Administered to healthy volunteers, a subanesthetic dose of the non-competitive NMDA receptor antagonist ketamine leads to psychopathological symptoms similar to those observed in schizophrenia.",20727411_2,-1,-1,-1,10552,-1,0.99816626,0.0018337343
10557,glutamatergic dysfunction,18,20,114,139,"In patients with schizophrenia, ketamine exacerbates the core symptoms of illness, supporting the hypothesis of a glutamatergic dysfunction.",20727411_3,-1,-1,-1,10557,-1,0.35351458,0.6464854
10559,psychosis,2,3,18,27,Ketamine elicited psychosis like psychopathology.,20727411_7,-1,-1,-1,10559,-1,0.002202959,0.997797
10564,NMDA,10,11,61,65,Our results provide further support for the hypothesis of an NMDA receptor dysfunction in the pathophysiology of schizophrenia.,20727411_11,-1,-1,-1,10564,-1,0.9974528,0.0025471759
10569,acute liver injury,10,13,77,95,"METHODS: We followed up all transplant-free survivors of paracetamol-induced acute liver injury, hospitalized in a Danish national referral centre during 1984-2004.",20735774_3,-1,-1,-1,10569,-1,0.0026776781,0.9973224
10577,substance abuse,17,19,113,128,"More likely, the elevated mortality rate ratio resulted from incomplete adjustment for the greater prevalence of substance abuse among survivors of acute liver failure.",20735774_8,-1,-1,-1,10577,-1,0.6491596,0.35084042
10580,liver failure,10,12,56,69,"Clinical follow-up may be justified by the cause of the liver failure, but not by the liver failure itself.",20735774_10,-1,-1,-1,10580,-1,0.0031187867,0.99688125
10581,liver failure,17,19,86,99,"Clinical follow-up may be justified by the cause of the liver failure, but not by the liver failure itself.",20735774_10,-1,-1,-1,10581,-1,0.003004456,0.99699557
10583,Parkinson's disease,5,8,46,65,Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap.,20880751_0,-1,-1,-1,10583,-1,0.0060300604,0.9939699
10585,Parkinson's disease,10,13,57,76,Levodopa is the most effective drug for the treatment of Parkinson's disease.,20880751_1,-1,-1,-1,10585,-1,0.005695504,0.9943045
10589,Parkinson's disease,9,12,48,67,"In recent years, evidence from animal models of Parkinson's disease has provided important information to understand the effect of specific receptor and post-receptor molecular mechanisms underlying the development of dyskinetic movements.",20880751_4,-1,-1,-1,10589,-1,0.0053372937,0.99466264
10590,dyskinetic movements,31,33,218,238,"In recent years, evidence from animal models of Parkinson's disease has provided important information to understand the effect of specific receptor and post-receptor molecular mechanisms underlying the development of dyskinetic movements.",20880751_4,-1,-1,-1,10590,-1,0.0025150594,0.9974849
10595,parkinsonian catalepsy,6,8,55,77,Effects of pallidal neurotensin on haloperidol-induced parkinsonian catalepsy: behavioral and electrophysiological studies.,20882060_0,-1,-1,-1,10595,-1,0.0036525354,0.9963475
10598,parkinsonian symptoms,13,15,98,119,The present study aimed to investigate the effects of pallidal neurotensin on haloperidol-induced parkinsonian symptoms.,20882060_3,-1,-1,-1,10598,-1,0.0024284488,0.9975715
10600,parkinsonian catalepsy,12,14,98,120,RESULTS: Bilateral infusions of neurotensin into the globus pallidus reversed haloperidol-induced parkinsonian catalepsy in rats.,20882060_5,-1,-1,-1,10600,-1,0.0029059458,0.99709404
10603,SR48692,5,6,43,50,The neurotensin type-1 receptor antagonist SR48692 blocked both the behavioral and the electrophysiological effects induced by neurotensin.,20882060_7,-1,-1,-1,10603,-1,0.99888474,0.0011152555
10606,organic mental disorders,1,4,17,41,Carmofur-induced organic mental disorders.,2096243_0,-1,-1,-1,10606,-1,0.00283547,0.99716455
10607,Organic mental disorder,0,3,0,23,Organic mental disorder was observed in a 29-year-old female in the prognostic period after the onset of carmofur-induced leukoencephalopathy.,2096243_1,-1,-1,-1,10607,-1,0.0027307277,0.9972692
10609,organic personality syndrome,17,20,106,134,"Symptoms such as euphoria, emotional lability and puerile attitude noted in the patient were diagnosed as organic personality syndrome according to the criteria defined in the DSM-III-R. It is referred to as a frontal lobe syndrome.",2096243_2,-1,-1,-1,10609,-1,0.0050208024,0.9949792
10610,frontal lobe syndrome,34,37,210,231,"Symptoms such as euphoria, emotional lability and puerile attitude noted in the patient were diagnosed as organic personality syndrome according to the criteria defined in the DSM-III-R. It is referred to as a frontal lobe syndrome.",2096243_2,-1,-1,-1,10610,-1,0.0065761697,0.9934238
10612,organic personality syndrome,8,11,76,104,"Consequently, carmofur-induced leukoencephalopathy may uncommonly result in organic personality syndrome in the residual state.",2096243_4,-1,-1,-1,10612,-1,0.0030333067,0.99696666
10613,structural damage to the frontal lobe,6,12,28,65,It may be attributed to the structural damage to the frontal lobe.,2096243_5,-1,-1,-1,10613,-1,0.017631155,0.9823689
10615,Parkinson's disease,14,17,92,111,In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.,20973483_0,-1,-1,-1,10615,-1,0.0048661656,0.9951338
10617,Parkinson's disease,17,20,108,127,The in vivo characterization of a dual adenosine A(2A)/A(1) receptor antagonist in several animal models of Parkinson's disease is described.,20973483_1,-1,-1,-1,10617,-1,0.004764624,0.9952354
10618,Parkinson's disease,44,47,198,217,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,-1,-1,-1,10618,-1,0.004038722,0.99596125
10620,akinesia,60,61,316,324,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,-1,-1,-1,10620,-1,0.0031347207,0.9968652
10622,6-OHDA,65,66,349,355,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,-1,-1,-1,10622,-1,0.99389184,0.006108145
10623,rotation,71,72,386,394,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,-1,-1,-1,10623,-1,0.0035813062,0.9964187
10638,n=10,3,4,12,16,"In group-1 (n=10) hippocampal DBS was off and in the group-2 (n=10) hippocampal DBS was on (185 Hz, 0.5V, 1V, 2V, and 5V for 60 sec) following penicillin G injection intracortically.",21294084_4,-1,-1,-1,10638,-1,0.16804619,0.83195376
10639,n=10,14,15,62,66,"In group-1 (n=10) hippocampal DBS was off and in the group-2 (n=10) hippocampal DBS was on (185 Hz, 0.5V, 1V, 2V, and 5V for 60 sec) following penicillin G injection intracortically.",21294084_4,-1,-1,-1,10639,-1,0.15547904,0.8445209
10640,penicillin G,37,39,143,155,"In group-1 (n=10) hippocampal DBS was off and in the group-2 (n=10) hippocampal DBS was on (185 Hz, 0.5V, 1V, 2V, and 5V for 60 sec) following penicillin G injection intracortically.",21294084_4,-1,-1,-1,10640,-1,0.99829334,0.0017066094
10642,lead,8,9,52,56,"In the control group, hippocampal stimulation alone lead only to diffuse slowing of cerebral bioelectrical activity at 5V stimulation.",21294084_8,-1,-1,-1,10642,-1,0.29955694,0.700443
10646,lomustine) toxicity,2,5,6,25,"CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).",21418164_0,-1,-1,-1,10646,-1,0.77075726,0.22924274
10648,1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea,32,33,203,247,"CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).",21418164_0,-1,-1,-1,10648,-1,0.99501306,0.0049868766
10649,CCNU,34,35,249,253,"CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).",21418164_0,-1,-1,-1,10649,-1,0.9978104,0.0021896076
10650,CCNU,12,13,63,67,DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.,21418164_1,-1,-1,-1,10650,-1,0.998857,0.0011429621
10651,CCNU,8,9,38,42,"RESULTS: Of the 206 dogs treated with CCNU, 185 met the inclusion criteria for at least one class of toxicity.",21418164_2,-1,-1,-1,10651,-1,0.999057,0.00094305485
10653,CCNU,0,1,0,4,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,-1,-1,-1,10653,-1,0.99891484,0.0010852142
10654,lymphoma,9,10,48,56,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,-1,-1,-1,10654,-1,0.0035299384,0.9964701
10655,mast cell tumour,11,14,58,74,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,-1,-1,-1,10655,-1,0.008737216,0.9912628
10656,brain tumour,15,17,76,88,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,-1,-1,-1,10656,-1,0.0038582615,0.99614173
10657,histiocytic tumours,18,20,90,109,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,-1,-1,-1,10657,-1,0.010732965,0.9892671
10658,epitheliotropic lymphoma,21,23,114,138,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,-1,-1,-1,10658,-1,0.065149195,0.9348508
10660,anaemia,13,14,79,86,"Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.",21418164_4,-1,-1,-1,10660,-1,0.0033039667,0.996696
10662,toxicosis,1,2,17,26,"Gastrointestinal toxicosis was detected in 37.8% of dogs, the most common sign of which was vomiting (24.3%).",21418164_5,-1,-1,-1,10662,-1,0.0028653108,0.9971347
10666,hepatic failure,3,5,17,32,The incidence of hepatic failure was 1.2%.,21418164_7,-1,-1,-1,10666,-1,0.002676798,0.9973232
10670,angina pectoris,35,37,201,216,"Peripheral neuropathy has been noted as a complication of therapy with perhexiline maleate, a drug widely used in France (and in clinical trials in the United States) for the prophylactic treatment of angina pectoris.",220563_1,-1,-1,-1,10670,-1,0.002632191,0.9973678
10671,demyelinating disorder,22,24,142,164,"In 24 patients with this complication, the marked slowing of motor nerve conduction velocity and the electromyographic changes imply mainly a demyelinating disorder.",220563_2,-1,-1,-1,10671,-1,0.0028150694,0.99718493
10673,vein thrombosis,1,3,8,23,Central vein thrombosis and topical dipivalyl epinephrine.,2220369_0,-1,-1,-1,10673,-1,0.0032746394,0.9967253
10674,dipivalyl epinephrine,5,7,36,57,Central vein thrombosis and topical dipivalyl epinephrine.,2220369_0,-1,-1,-1,10674,-1,0.9990559,0.0009440725
10675,vein thrombosis,11,13,64,79,A report is given on an 83-year-old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced glaucoma discovered in the other eye.,2220369_1,-1,-1,-1,10675,-1,0.0050522,0.9949478
10676,dipivalyl epinephrine,25,27,151,172,A report is given on an 83-year-old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced glaucoma discovered in the other eye.,2220369_1,-1,-1,-1,10676,-1,0.99904627,0.0009537244
10681,Pirarubicin,12,13,76,87,A Phase I study of intravenous (IV) bolus 4'-0-tetrahydropyranyladriamycin (Pirarubicin) was done in 55 patients in good performance status with refractory tumors.,2224762_2,-1,-1,-1,10681,-1,0.99923706,0.0007629469
10683,and/or,24,25,112,118,"Twenty-six had minimal prior therapy (good risk), 23 had extensive prior therapy (poor risk), and six had renal and/or hepatic dysfunction.",2224762_3,-1,-1,-1,10683,-1,0.111057624,0.8889424
10684,hepatic dysfunction,25,27,119,138,"Twenty-six had minimal prior therapy (good risk), 23 had extensive prior therapy (poor risk), and six had renal and/or hepatic dysfunction.",2224762_3,-1,-1,-1,10684,-1,0.0035079045,0.9964921
10685,granulocytopenia,7,8,59,75,The dose-limiting toxic effect was transient noncumulative granulocytopenia.,2224762_6,-1,-1,-1,10685,-1,0.0023838002,0.9976162
10689,alopecia,12,13,76,84,"Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and mucositis.",2224762_8,-1,-1,-1,10689,-1,0.0054469416,0.994553
10690,phlebitis,14,15,86,95,"Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and mucositis.",2224762_8,-1,-1,-1,10690,-1,0.0056532915,0.9943467
10692,hepatic dysfunction,6,8,43,62,Myelosuppression was more in patients with hepatic dysfunction.,2224762_9,-1,-1,-1,10692,-1,0.0030919958,0.996908
10693,Pirarubicin,6,7,49,60,"Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours.",2224762_10,-1,-1,-1,10693,-1,0.9992902,0.00070974283
10694,SE,14,15,85,87,"Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours.",2224762_10,-1,-1,-1,10694,-1,0.75290185,0.24709818
10696,adriamycinone,4,5,27,40,"Adriamycinol, doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites.",2224762_12,-1,-1,-1,10696,-1,0.99901617,0.0009837843
10697,tetrahydropyranyladriamycinol,7,8,46,75,"Adriamycinol, doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites.",2224762_12,-1,-1,-1,10697,-1,0.9989724,0.0010275734
10699,Pirarubicin,3,4,21,32,Urinary excretion of Pirarubicin in the first 24 hours was less than or equal to 10%.,2224762_13,-1,-1,-1,10699,-1,0.99932504,0.0006750318
10700,mesothelioma,4,5,22,34,"Activity was noted in mesothelioma, leiomyosarcoma, and basal cell carcinoma.",2224762_14,-1,-1,-1,10700,-1,0.018866844,0.98113316
10701,leiomyosarcoma,6,7,36,50,"Activity was noted in mesothelioma, leiomyosarcoma, and basal cell carcinoma.",2224762_14,-1,-1,-1,10701,-1,0.028851736,0.9711483
10702,basal cell carcinoma,9,12,56,76,"Activity was noted in mesothelioma, leiomyosarcoma, and basal cell carcinoma.",2224762_14,-1,-1,-1,10702,-1,0.013825136,0.98617494
10703,auditory toxicity,2,4,11,28,Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine.,2234245_0,-1,-1,-1,10703,-1,0.004205569,0.9957944
10706,audiovisual toxicity,29,31,169,189,During an 18-month period of study 41 hemodialyzed patients receiving desferrioxamine (10-40 mg/kg BW/3 times weekly) for the first time were monitored for detection of audiovisual toxicity.,2234245_1,-1,-1,-1,10706,-1,0.0072952053,0.9927048
10707,auditory toxicity,8,10,52,69,6 patients presented clinical symptoms of visual or auditory toxicity.,2234245_2,-1,-1,-1,10707,-1,0.007363141,0.9926368
10708,Visual toxicity,0,2,0,15,"Visual toxicity was of retinal origin and was characterized by a tritan-type dyschromatopsy, sometimes associated with a loss of visual acuity and pigmentary retinal deposits.",2234245_4,-1,-1,-1,10708,-1,0.0032877172,0.9967123
10709,dyschromatopsy,12,13,77,91,"Visual toxicity was of retinal origin and was characterized by a tritan-type dyschromatopsy, sometimes associated with a loss of visual acuity and pigmentary retinal deposits.",2234245_4,-1,-1,-1,10709,-1,0.004308835,0.9956911
10710,a loss of visual acuity,17,22,119,142,"Visual toxicity was of retinal origin and was characterized by a tritan-type dyschromatopsy, sometimes associated with a loss of visual acuity and pigmentary retinal deposits.",2234245_4,-1,-1,-1,10710,-1,0.011416439,0.98858356
10711,pigmentary retinal deposits,23,26,147,174,"Visual toxicity was of retinal origin and was characterized by a tritan-type dyschromatopsy, sometimes associated with a loss of visual acuity and pigmentary retinal deposits.",2234245_4,-1,-1,-1,10711,-1,0.007931021,0.992069
10713,neurosensorial hearing loss,9,12,64,91,Auditory toxicity was characterized by a mid- to high-frequency neurosensorial hearing loss and the lesion was of the cochlear type.,2234245_5,-1,-1,-1,10713,-1,0.005713888,0.9942861
10715,hearing loss,24,26,145,157,"Desferrioxamine withdrawal resulted in a complete recovery of visual function in 1 patient and partial recovery in 3, and a complete reversal of hearing loss in 3 patients and partial recovery in 3.",2234245_6,-1,-1,-1,10715,-1,0.004404905,0.99559504
10718,aluminium,19,20,132,141,This toxicity appeared in patients receiving the higher doses of desferrioxamine or coincided with the normalization of ferritin or aluminium serum levels.,2234245_7,-1,-1,-1,10718,-1,0.9976324,0.0023675752
10719,audiovisual toxicity,4,6,23,43,The data indicate that audiovisual toxicity is not an infrequent complication in hemodialyzed patients receiving desferrioxamine.,2234245_8,-1,-1,-1,10719,-1,0.008938893,0.99106115
10721,Benzylacyclouridine,0,1,0,19,Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity.,2257294_0,-1,-1,-1,10721,-1,0.99893147,0.0010685787
10722,marrow suppression,3,5,52,70,Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity.,2257294_0,-1,-1,-1,10722,-1,0.009349603,0.9906504
10723,immunodeficiency virus,9,11,104,126,Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity.,2257294_0,-1,-1,-1,10723,-1,0.0943238,0.90567625
10724,uridine,4,5,42,49,"Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.",2257294_1,-1,-1,-1,10724,-1,0.9984168,0.0015832087
10725,Urd,6,7,51,54,"Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.",2257294_1,-1,-1,-1,10725,-1,0.9976246,0.002375426
10728,Urd,8,9,59,62,"Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.",2257294_2,-1,-1,-1,10728,-1,0.9982224,0.0017775351
10729,benzylacyclouridine,14,15,94,113,"Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.",2257294_2,-1,-1,-1,10729,-1,0.99880433,0.0011956728
10730,BAU,16,17,115,118,"Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.",2257294_2,-1,-1,-1,10730,-1,0.99707687,0.002923105
10733,Urd,3,4,20,23,"This agent inhibits Urd catabolism and, in vivo, increases the plasma concentration of Urd in a dose-dependent manner, without Urd-related toxicity.",2257294_3,-1,-1,-1,10733,-1,0.9980253,0.0019747324
10734,Urd,15,16,87,90,"This agent inhibits Urd catabolism and, in vivo, increases the plasma concentration of Urd in a dose-dependent manner, without Urd-related toxicity.",2257294_3,-1,-1,-1,10734,-1,0.99795425,0.0020456712
10736,anemic,3,4,17,23,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10736,-1,0.0030724942,0.99692756
10737,leukopenic,5,6,28,38,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10737,-1,0.0028146987,0.9971853
10738,AZT,10,11,64,67,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10738,-1,0.9987134,0.001286605
10739,drinking water,15,17,83,97,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10739,-1,0.9946063,0.0053936588
10740,AZT,26,27,143,146,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10740,-1,0.99880683,0.0011931424
10741,BAU,29,30,158,161,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10741,-1,0.99860364,0.0013963191
10744,P,43,44,236,237,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10744,-1,0.18330288,0.8166971
10745,P,57,58,299,300,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10745,-1,0.16975711,0.8302429
10746,megaloblastosis,71,72,367,382,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,-1,-1,-1,10746,-1,0.004946568,0.99505347
10747,AZT,3,4,25,28,"When coadministered with AZT from the onset of drug administration, BAU reduced AZT-induced marrow toxicity.",2257294_5,-1,-1,-1,10747,-1,0.9984218,0.0015781936
10748,BAU,11,12,68,71,"When coadministered with AZT from the onset of drug administration, BAU reduced AZT-induced marrow toxicity.",2257294_5,-1,-1,-1,10748,-1,0.99862623,0.0013737929
10749,marrow toxicity,14,16,92,107,"When coadministered with AZT from the onset of drug administration, BAU reduced AZT-induced marrow toxicity.",2257294_5,-1,-1,-1,10749,-1,0.0027457986,0.9972542
10750,BAU,10,11,45,48,"In vitro, at a concentration of 100 mumol/L, BAU possesses minimal anti-HIV activity and has no effect on the ability of AZT to reverse the HIV-induced cytopathic effect in MT4 cells.",2257294_6,-1,-1,-1,10750,-1,0.99867743,0.0013225173
10751,AZT,23,24,121,124,"In vitro, at a concentration of 100 mumol/L, BAU possesses minimal anti-HIV activity and has no effect on the ability of AZT to reverse the HIV-induced cytopathic effect in MT4 cells.",2257294_6,-1,-1,-1,10751,-1,0.99846065,0.0015393794
10754,hallucinosis,43,44,259,271,"Two patients with similar clinical features are presented: both patients had chronic renal failure, on hemodialysis for many years but recently begun on a high-flux dialyzer; both had been receiving a carbidopa/levodopa preparation; and both had the onset of hallucinosis and recurrent seizures, which were refractory to anticonvulsants.",2265898_1,-1,-1,-1,10754,-1,0.0035894215,0.99641055
10756,vitamin B6,19,21,119,129,The first patient died without a diagnosis; the second patient had a dramatic recovery following the administration of vitamin B6.,2265898_2,-1,-1,-1,10756,-1,0.9977456,0.002254373
10758,Duchenne dystrophy,7,9,46,64,"Randomized, double-blind trial of mazindol in Duchenne dystrophy.",2266990_0,-1,-1,-1,10758,-1,0.038064905,0.9619351
10759,growth hormone,4,6,23,37,There is evidence that growth hormone may be related to the progression of weakness in Duchenne dystrophy.,2266990_1,-1,-1,-1,10759,-1,0.9955309,0.0044691735
10761,Duchenne dystrophy,15,17,87,105,There is evidence that growth hormone may be related to the progression of weakness in Duchenne dystrophy.,2266990_1,-1,-1,-1,10761,-1,0.024648068,0.9753519
10763,growth hormone,11,13,65,79,"We conducted a 12-month controlled trial of mazindol, a putative growth hormone secretion inhibitor, in 83 boys with Duchenne dystrophy.",2266990_2,-1,-1,-1,10763,-1,0.9717658,0.028234206
10764,Duchenne dystrophy,20,22,117,135,"We conducted a 12-month controlled trial of mazindol, a putative growth hormone secretion inhibitor, in 83 boys with Duchenne dystrophy.",2266990_2,-1,-1,-1,10764,-1,0.050777897,0.9492221
10765,contractures,3,4,17,29,"Muscle strength, contractures, functional ability and pulmonary function were tested at baseline, and 6 and 12 months after treatment with mazindol (3 mg/d) or placebo.",2266990_3,-1,-1,-1,10765,-1,0.0036470364,0.9963529
10768,P,28,29,138,139,The study was designed to have a power of greater than 0.90 to detect a slowing to 25% of the expected rate of progression of weakness at P less than 0.05.,2266990_4,-1,-1,-1,10768,-1,0.574869,0.42513102
10771,decreased appetite,6,8,47,65,"Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.",2266990_6,-1,-1,-1,10771,-1,0.007795209,0.9922047
10773,gastrointestinal symptoms,28,30,119,144,"Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.",2266990_6,-1,-1,-1,10773,-1,0.0030119398,0.9969881
10778,Duchenne dystrophy,9,11,55,73,Mazindol doses not slow the progression of weakness in Duchenne dystrophy.,2266990_9,-1,-1,-1,10778,-1,0.015743425,0.98425657
10794,nalozone,29,30,184,192,"In unanesthetized, spontaneously hypertensive rats the decrease in blood pressure and heart rate produced by intravenous clonidine, 5 to 20 micrograms/kg, was inhibited or reversed by nalozone, 0.2 to 2 mg/kg.",227508_1,-1,-1,-1,10794,-1,0.999243,0.0007570257
10800,10(-8,9,10,67,72,"In brain membranes from spontaneously hypertensive rats clonidine, 10(-8) to 10(-5) M, did not influence stereoselective binding of [3H]-naloxone (8 nM), and naloxone, 10(-8) to 10(-4) M, did not influence clonidine-suppressible binding of [3H]-dihydroergocryptine (1 nM).",227508_4,-1,-1,-1,10800,-1,0.96955305,0.030446941
10801,10(-8,9,10,67,72,"In brain membranes from spontaneously hypertensive rats clonidine, 10(-8) to 10(-5) M, did not influence stereoselective binding of [3H]-naloxone (8 nM), and naloxone, 10(-8) to 10(-4) M, did not influence clonidine-suppressible binding of [3H]-dihydroergocryptine (1 nM).",227508_4,-1,-1,-1,10801,-1,0.96955305,0.030446941
10803,10(-8,31,32,168,173,"In brain membranes from spontaneously hypertensive rats clonidine, 10(-8) to 10(-5) M, did not influence stereoselective binding of [3H]-naloxone (8 nM), and naloxone, 10(-8) to 10(-4) M, did not influence clonidine-suppressible binding of [3H]-dihydroergocryptine (1 nM).",227508_4,-1,-1,-1,10803,-1,0.96501,0.034990005
10804,10(-8,31,32,168,173,"In brain membranes from spontaneously hypertensive rats clonidine, 10(-8) to 10(-5) M, did not influence stereoselective binding of [3H]-naloxone (8 nM), and naloxone, 10(-8) to 10(-4) M, did not influence clonidine-suppressible binding of [3H]-dihydroergocryptine (1 nM).",227508_4,-1,-1,-1,10804,-1,0.96501,0.034990005
10809,halogenated hydroxyquinolines,2,4,17,46,Neurotoxicity of halogenated hydroxyquinolines: clinical analysis of cases reported outside Japan.,230316_0,-1,-1,-1,10809,-1,0.9959656,0.0040344046
10811,halogenated hydroxyquinolines,12,14,74,103,An analysis is presented of 220 cases of possible neurotoxic reactions to halogenated hydroxyquinolines reported from outside Japan.,230316_1,-1,-1,-1,10811,-1,0.99600714,0.0039928355
10812,clioquinol,19,20,122,132,In 80 cases insufficient information was available for adequate comment and in 29 a relationship to the administration of clioquinol could be excluded.,230316_2,-1,-1,-1,10812,-1,0.99925965,0.0007403561
10813,clioquinol,7,8,36,46,"Of the remainder, a relationship to clioquinol was considered probable in 42 and possible in 69 cases.",230316_3,-1,-1,-1,10813,-1,0.99929285,0.0007071334
10814,neurological disturbance,7,9,33,57,In six of the probable cases the neurological disturbance consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of clioquinol over a short period.,230316_4,-1,-1,-1,10814,-1,0.002164704,0.99783534
10816,clioquinol,25,26,157,167,In six of the probable cases the neurological disturbance consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of clioquinol over a short period.,230316_4,-1,-1,-1,10816,-1,0.99926823,0.0007317369
10817,optic atrophy,13,15,74,87,"The most common manifestation, observed in 15 further cases, was isolated optic atrophy.",230316_5,-1,-1,-1,10817,-1,0.0031783096,0.99682164
10818,clioquinol,13,14,70,80,"This was most frequently found in children, many of whom had received clioquinol as treatment for acrodermatitis enteropathica.",230316_6,-1,-1,-1,10818,-1,0.9992268,0.00077320734
10819,acrodermatitis enteropathica,17,19,98,126,"This was most frequently found in children, many of whom had received clioquinol as treatment for acrodermatitis enteropathica.",230316_6,-1,-1,-1,10819,-1,0.0065685483,0.9934315
10820,myelopathy,8,9,41,51,"In the remaining cases, a combination of myelopathy, visual disturbance, and peripheral neuropathy was the most common manifestation.",230316_7,-1,-1,-1,10820,-1,0.002347345,0.9976527
10821,visual disturbance,10,12,53,71,"In the remaining cases, a combination of myelopathy, visual disturbance, and peripheral neuropathy was the most common manifestation.",230316_7,-1,-1,-1,10821,-1,0.0028073112,0.9971927
10823,myelopathy,1,2,9,19,"Isolated myelopathy or peripheral neuropathy, or these manifestations occurring together, were infrequent.",230316_8,-1,-1,-1,10823,-1,0.0024295442,0.99757046
10837,isosorbide dinitrate,6,8,61,81,Myocardial infarction following sublingual administration of isosorbide dinitrate.,2312209_0,-1,-1,-1,10837,-1,0.9991435,0.0008564603
10839,myocardial infarction,9,11,63,84,A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.,2312209_1,-1,-1,-1,10839,-1,0.0026675556,0.99733245
10840,isosorbide dinitrate,19,21,138,158,A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.,2312209_1,-1,-1,-1,10840,-1,0.9991504,0.0008495475
10841,mg,22,23,161,163,A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.,2312209_1,-1,-1,-1,10841,-1,0.9857943,0.014205622
10843,myocardial ischemia,17,19,113,132,"After detailing the course of events, we discuss the role of paradoxical coronary spasm and hypotension-mediated myocardial ischemia occurring downstream to significant coronary arterial stenosis in the pathophysiology of acute coronary insufficiency.",2312209_2,-1,-1,-1,10843,-1,0.003604252,0.99639577
10844,coronary arterial stenosis,23,26,169,195,"After detailing the course of events, we discuss the role of paradoxical coronary spasm and hypotension-mediated myocardial ischemia occurring downstream to significant coronary arterial stenosis in the pathophysiology of acute coronary insufficiency.",2312209_2,-1,-1,-1,10844,-1,0.057703886,0.9422961
10845,acute coronary insufficiency,30,33,222,250,"After detailing the course of events, we discuss the role of paradoxical coronary spasm and hypotension-mediated myocardial ischemia occurring downstream to significant coronary arterial stenosis in the pathophysiology of acute coronary insufficiency.",2312209_2,-1,-1,-1,10845,-1,0.0043320945,0.99566793
10849,impaired renal function,14,17,96,119,Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function.,2320800_0,-1,-1,-1,10849,-1,0.0051615867,0.9948384
10852,renal failure,17,19,120,133,"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.",2320800_1,-1,-1,-1,10852,-1,0.0025838788,0.99741614
10855,renal failure,7,9,47,60,"A prerenal component could have contributed to renal failure because of a transient hypotension, due to an increasing ascitis, occurring just before anuria.",2320800_3,-1,-1,-1,10855,-1,0.002702046,0.99729794
10860,tubulopathies,8,9,57,70,Ifosfamide is a known nephrotoxic drug with demonstrated tubulopathies.,2320800_5,-1,-1,-1,10860,-1,0.0025118552,0.99748814
10867,prostaglandin D2,7,9,61,77,"Nociceptive effects induced by intrathecal administration of prostaglandin D2, E2, or F2 alpha to conscious mice.",2322844_0,-1,-1,-1,10867,-1,0.9984236,0.001576441
10868,E2,10,11,79,81,"Nociceptive effects induced by intrathecal administration of prostaglandin D2, E2, or F2 alpha to conscious mice.",2322844_0,-1,-1,-1,10868,-1,0.9969606,0.0030394474
10871,acetic acid writhing,20,23,134,154,The effects of intrathecal administration of prostaglandins on pain responses in conscious mice were evaluated by using hot plate and acetic acid writhing tests.,2322844_1,-1,-1,-1,10871,-1,0.6793844,0.32061562
10872,Prostaglandin D2,0,2,0,16,Prostaglandin D2 (0.5-3 ng/mouse) had a hyperalgesic action on the response to a hot plate during a 3-60 min period after injection.,2322844_2,-1,-1,-1,10872,-1,0.9984296,0.0015703645
10873,hyperalgesic,10,11,40,52,Prostaglandin D2 (0.5-3 ng/mouse) had a hyperalgesic action on the response to a hot plate during a 3-60 min period after injection.,2322844_2,-1,-1,-1,10873,-1,0.002951782,0.9970482
10874,Prostaglandin E2,0,2,0,16,"Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.",2322844_3,-1,-1,-1,10874,-1,0.99833775,0.0016622214
10875,hyperalgesic,4,5,26,38,"Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.",2322844_3,-1,-1,-1,10875,-1,0.0027189364,0.9972811
10876,pg,10,11,60,62,"Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.",2322844_3,-1,-1,-1,10876,-1,0.99009234,0.009907695
10877,prostaglandin D2,29,31,133,149,"Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.",2322844_3,-1,-1,-1,10877,-1,0.9982157,0.00178432
10878,acetic acid writhing,5,8,33,53,Similar results were obtained by acetic acid writhing tests.,2322844_4,-1,-1,-1,10878,-1,0.79924756,0.20075248
10879,hyperalgesic,1,2,4,16,"The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.",2322844_5,-1,-1,-1,10879,-1,0.0023721526,0.9976279
10880,prostaglandin D2,4,6,27,43,"The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.",2322844_5,-1,-1,-1,10880,-1,0.99826556,0.0017345061
10881,substance P,13,15,87,98,"The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.",2322844_5,-1,-1,-1,10881,-1,0.9981912,0.001808802
10882,ng,23,24,140,142,"The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.",2322844_5,-1,-1,-1,10882,-1,0.9876658,0.0123342015
10883,AH6809,28,29,155,161,"The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.",2322844_5,-1,-1,-1,10883,-1,0.99826777,0.0017322223
10885,AH6809,8,9,65,71,"Conversely, prostaglandin E2-induced hyperalgesia was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.",2322844_6,-1,-1,-1,10885,-1,0.9986744,0.0013256758
10886,ng,16,17,102,104,"Conversely, prostaglandin E2-induced hyperalgesia was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.",2322844_6,-1,-1,-1,10886,-1,0.98955345,0.010446545
10887,substance P,22,24,121,132,"Conversely, prostaglandin E2-induced hyperalgesia was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.",2322844_6,-1,-1,-1,10887,-1,0.998014,0.001986005
10888,Prostaglandin F2,0,2,0,16,Prostaglandin F2 alpha had little effect on pain responses.,2322844_7,-1,-1,-1,10888,-1,0.99789834,0.0021016651
10890,prostaglandin D2,5,7,36,52,"These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord, but in different ways.",2322844_8,-1,-1,-1,10890,-1,0.998292,0.0017079976
10891,prostaglandin E2,8,10,57,73,"These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord, but in different ways.",2322844_8,-1,-1,-1,10891,-1,0.9978452,0.0021548716
10893,localized scleroderma,5,7,36,57,D-penicillamine in the treatment of localized scleroderma.,2334179_0,-1,-1,-1,10893,-1,0.003589978,0.9964101
10894,Localized scleroderma,0,2,0,21,Localized scleroderma has no recognized internal organ involvement but may be disfiguring and disabling when the cutaneous lesions are extensive or affect children.,2334179_1,-1,-1,-1,10894,-1,0.005266532,0.99473345
10895,localized scleroderma,8,10,45,66,There is no accepted or proven treatment for localized scleroderma.,2334179_2,-1,-1,-1,10895,-1,0.0051739914,0.994826
10896,localized scleroderma,9,11,51,72,"Case reports of 11 patients with severe, extensive localized scleroderma who were treated with D-penicillamine are summarized in this article.",2334179_3,-1,-1,-1,10896,-1,0.0026628051,0.99733716
10897,contractures,3,4,20,32,Joint stiffness and contractures also improved.,2334179_6,-1,-1,-1,10897,-1,0.0029617446,0.99703825
10898,nephrotic syndrome,2,4,23,41,D-Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency.,2334179_8,-1,-1,-1,10898,-1,0.0022362536,0.99776375
10900,renal insufficiency,18,20,125,144,D-Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency.,2334179_8,-1,-1,-1,10900,-1,0.002344688,0.9976553
10901,localized scleroderma,12,14,76,97,These data suggest that D-penicillamine may be effective in severe cases of localized scleroderma.,2334179_9,-1,-1,-1,10901,-1,0.0026506153,0.9973494
10903,analgesia,5,6,35,44,infusions of morphine and regional analgesia by extradural block.,2334618_1,-1,-1,-1,10903,-1,0.068621345,0.93137866
10906,mg,6,7,32,34,infusion of morphine (mean 73.6 mg) and five patients receiving a continuous extradural infusion of 0.25% bupivacaine (mean 192 mg) in the 24-h period following upper abdominal surgery.,2334618_3,-1,-1,-1,10906,-1,0.9434043,0.05659561
10908,mg,23,24,128,130,infusion of morphine (mean 73.6 mg) and five patients receiving a continuous extradural infusion of 0.25% bupivacaine (mean 192 mg) in the 24-h period following upper abdominal surgery.,2334618_3,-1,-1,-1,10908,-1,0.94318485,0.056815077
10909,carbon dioxide,7,9,47,61,"Monitoring consisted of airflow detection by a carbon dioxide analyser, chest wall movement detected by pneumatic capsules, and continuous electrocardiograph recorded with a Holter ambulatory monitor.",2334618_4,-1,-1,-1,10909,-1,0.99751353,0.0024864718
10910,P,3,4,18,19,Both obstructive (P less than 0.05) and central apnoea (P less than 0.05) occurred more frequently in patients who had a morphine infusion.,2334618_5,-1,-1,-1,10910,-1,0.18269262,0.81730735
10912,P,12,13,56,57,Both obstructive (P less than 0.05) and central apnoea (P less than 0.05) occurred more frequently in patients who had a morphine infusion.,2334618_5,-1,-1,-1,10912,-1,0.14037871,0.8596212
10914,tachyarrhythmias,7,8,37,53,There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.,2334618_6,-1,-1,-1,10914,-1,0.002432412,0.99756765
10915,P,9,10,55,56,There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.,2334618_6,-1,-1,-1,10915,-1,0.25006855,0.74993145
10916,ventricular ectopic beats,15,18,77,102,There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.,2334618_6,-1,-1,-1,10916,-1,0.0035035866,0.9964964
10917,P,19,20,104,105,There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.,2334618_6,-1,-1,-1,10917,-1,0.19736204,0.802638
10919,sinus thrombosis,1,3,9,25,Cerebral sinus thrombosis as a potential hazard of antifibrinolytic treatment in menorrhagia.,2339463_0,-1,-1,-1,10919,-1,0.0023640697,0.99763596
10920,menorrhagia,11,12,81,92,Cerebral sinus thrombosis as a potential hazard of antifibrinolytic treatment in menorrhagia.,2339463_0,-1,-1,-1,10920,-1,0.009884941,0.99011505
10922,menorrhagia,21,22,165,176,We describe a 42-year-old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged epsilon-aminocaproic acid therapy for menorrhagia.,2339463_1,-1,-1,-1,10922,-1,0.007920942,0.9920791
10923,menorrhagia,9,10,56,67,This antifibrinolytic agent has been used in women with menorrhagia to promote clotting and reduce blood loss.,2339463_2,-1,-1,-1,10923,-1,0.008085061,0.991915
10924,blood loss,15,17,99,109,This antifibrinolytic agent has been used in women with menorrhagia to promote clotting and reduce blood loss.,2339463_2,-1,-1,-1,10924,-1,0.0040184455,0.9959816
10925,thromboembolic disease,4,6,27,49,"Although increased risk of thromboembolic disease has been reported during treatment with epsilon-aminocaproic acid, cerebral sinus thrombosis has not been previously described.",2339463_3,-1,-1,-1,10925,-1,0.002342245,0.9976578
10928,imipenem,3,4,22,30,Seizure activity with imipenem therapy: incidence and risk factors.,2343592_0,-1,-1,-1,10928,-1,0.99921095,0.0007890299
10929,cerebral vascular accident,8,11,46,72,Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.,2343592_1,-1,-1,-1,10929,-1,0.0029654782,0.99703455
10930,CVA,12,13,74,77,Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.,2343592_1,-1,-1,-1,10930,-1,0.009434401,0.99056566
10931,head trauma,15,17,82,93,Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.,2343592_1,-1,-1,-1,10931,-1,0.0030858743,0.99691415
10932,renal disease,21,23,113,126,Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.,2343592_1,-1,-1,-1,10932,-1,0.0043599205,0.99564004
10939,ventricular fibrillation,8,10,57,81,Effects of aminophylline on the threshold for initiating ventricular fibrillation during respiratory failure.,234669_0,-1,-1,-1,10939,-1,0.0069088615,0.9930911
10940,respiratory failure,11,13,89,108,Effects of aminophylline on the threshold for initiating ventricular fibrillation during respiratory failure.,234669_0,-1,-1,-1,10940,-1,0.0044654007,0.99553454
10941,respiratory failure,9,11,70,89,Cardiac arrhythmias have frequently been reported in association with respiratory failure.,234669_1,-1,-1,-1,10941,-1,0.0038921412,0.9961079
10942,cardiac disturbances,9,11,68,88,The possible additive role of pharmacologic agents in precipitating cardiac disturbances in patients with respiratory failure has only recently been emphasized.,234669_2,-1,-1,-1,10942,-1,0.0026177634,0.9973822
10943,respiratory failure,14,16,106,125,The possible additive role of pharmacologic agents in precipitating cardiac disturbances in patients with respiratory failure has only recently been emphasized.,234669_2,-1,-1,-1,10943,-1,0.0029628542,0.9970372
10945,ventricular fibrillation,6,8,36,60,The effects of aminophylline on the ventricular fibrillation threshold during normal acid-base conditions and during respiratory failure were studied in anesthetized open chest dogs.,234669_3,-1,-1,-1,10945,-1,0.0046998016,0.9953002
10946,respiratory failure,15,17,117,136,The effects of aminophylline on the ventricular fibrillation threshold during normal acid-base conditions and during respiratory failure were studied in anesthetized open chest dogs.,234669_3,-1,-1,-1,10946,-1,0.0032197714,0.99678016
10947,ventricular fibrillation,1,3,4,28,The ventricular fibrillation threshold was measured by passing a gated train of 12 constant current pulses through the ventricular myocardium during the vulnerable period of the cardiac cycle.,234669_4,-1,-1,-1,10947,-1,0.005071438,0.9949286
10949,ventricular fibrillation,7,9,42,66,"During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.",234669_5,-1,-1,-1,10949,-1,0.003391814,0.99660826
10951,PO2,28,29,165,168,"During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.",234669_5,-1,-1,-1,10951,-1,0.99620986,0.0037901085
10952,carbon dioxide,31,33,174,188,"During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.",234669_5,-1,-1,-1,10952,-1,0.9962418,0.00375818
10953,CO2,34,35,190,193,"During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.",234669_5,-1,-1,-1,10953,-1,0.99323785,0.0067621763
10954,respiratory failure,1,3,5,24,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,-1,-1,-1,10954,-1,0.0030463499,0.9969536
10955,hypoventilation,6,7,41,56,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,-1,-1,-1,10955,-1,0.029769747,0.9702303
10956,mm Hg,17,19,90,95,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,-1,-1,-1,10956,-1,0.96440834,0.035591654
10957,mm Hg,24,26,110,115,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,-1,-1,-1,10957,-1,0.95641285,0.0435872
10959,ventricular fibrillation,38,40,184,208,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,-1,-1,-1,10959,-1,0.004230776,0.99576926
10961,respiratory failure,17,19,125,144,"These experiments suggest that although many factors may contribute to the increased incidence of ventricular arrhythmias in respiratory failure, pharmacologic agents, particularly aminophylline, may play a significant role.",234669_7,-1,-1,-1,10961,-1,0.0038921058,0.9961079
10963,Trental,2,3,16,23,Pentoxifylline (Trental) does not inhibit dipyridamole-induced coronary hyperemia: implications for dipyridamole-thallium-201 myocardial imaging.,2348231_0,-1,-1,-1,10963,-1,0.99876815,0.0012318481
10965,peripheral vascular disease,12,15,95,122,Dipyridamole-thallium-201 imaging is often performed in patients unable to exercise because of peripheral vascular disease.,2348231_1,-1,-1,-1,10965,-1,0.003976923,0.99602306
10967,Trental),8,10,50,58,"Many of these patients are taking pentoxifylline (Trental), a methylxanthine derivative which may improve intermittent claudication.",2348231_2,-1,-1,-1,10967,-1,0.9970921,0.0029078561
10968,methylxanthine,12,13,62,76,"Many of these patients are taking pentoxifylline (Trental), a methylxanthine derivative which may improve intermittent claudication.",2348231_2,-1,-1,-1,10968,-1,0.9986634,0.0013365669
10969,intermittent claudication,17,19,106,131,"Many of these patients are taking pentoxifylline (Trental), a methylxanthine derivative which may improve intermittent claudication.",2348231_2,-1,-1,-1,10969,-1,0.0029464483,0.9970535
10972,methylxanthines,8,9,83,98,Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.,2348231_3,-1,-1,-1,10972,-1,0.99848014,0.0015198403
10974,hyperemic,5,6,26,35,"Therefore, we studied the hyperemic response to dipyridamole in seven open-chest anesthetized dogs after pretreatment with either pentoxifylline (0, 7.5, or 15 mg/kg i.v.) or theophylline (3 mg/kg i.v.).",2348231_4,-1,-1,-1,10974,-1,0.0024090663,0.9975909
10980,p,2,3,16,17,pentoxifylline (p less than 0.002).,2348231_7,-1,-1,-1,10980,-1,0.46126533,0.5387346
10984,p,21,22,166,167,"Neither dose of pentoxifylline significantly decreased the dipyridamole-induced hyperemia, while peak coronary blood flow was significantly lower after theophylline (p less than 0.01).",2348231_8,-1,-1,-1,10984,-1,0.34259328,0.6574067
10985,pentoxyifylline,3,4,17,32,We conclude that pentoxyifylline does not inhibit dipyridamole-induced coronary hyperemia even at high doses.,2348231_9,-1,-1,-1,10985,-1,0.9993262,0.00067382597
10988,Parkinson's disease,6,9,35,54,Cause of death among patients with Parkinson's disease: a rare mortality due to cerebral haemorrhage.,2355241_0,-1,-1,-1,10988,-1,0.015385323,0.9846147
10992,Parkinson's disease,17,20,113,132,"Causes of death, with special reference to cerebral haemorrhage, among 240 patients with pathologically verified Parkinson's disease were investigated using the Annuals of the Pathological Autopsy Cases in Japan from 1981 to 1985.",2355241_1,-1,-1,-1,10992,-1,0.009727034,0.99027294
10994,pneumonia,6,7,33,42,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,-1,-1,10994,-1,0.004445652,0.9955544
10995,bronchitis,8,9,47,57,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,-1,-1,10995,-1,0.0075386344,0.9924614
10996,neoplasms,15,16,77,86,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,-1,-1,10996,-1,0.005371753,0.99462825
10997,heart diseases,21,23,96,110,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,-1,-1,10997,-1,0.006365123,0.9936348
10998,cerebral infarction,28,30,119,138,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,-1,-1,10998,-1,0.0034704711,0.9965295
10999,septicaemia,35,36,150,161,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,-1,-1,-1,10999,-1,0.004013369,0.99598664
11005,Parkinson's disease,14,17,79,98,The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.,2355241_4,-1,-1,-1,11005,-1,0.0051366324,0.99486333
11011,cardiorespiratory arrest,3,5,44,68,Possible intramuscular midazolam-associated cardiorespiratory arrest and death.,2375138_0,-1,-1,-1,11011,-1,0.0037424255,0.99625754
11013,Midazolam hydrochloride,0,2,0,23,Midazolam hydrochloride is commonly used for dental or endoscopic procedures.,2375138_1,-1,-1,-1,11013,-1,0.99922454,0.0007755012
11015,cardiorespiratory arrest,8,10,50,74,This report describes the first published case of cardiorespiratory arrest and death associated with intramuscular administration of midazolam.,2375138_3,-1,-1,-1,11015,-1,0.0030188449,0.9969811
11021,neuromuscular disease,9,11,46,67,We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for preeclampsia.,2385256_1,-1,-1,-1,11021,-1,0.0027159306,0.99728405
11022,quadriplegic,14,15,89,101,We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for preeclampsia.,2385256_1,-1,-1,-1,11022,-1,0.115991935,0.88400805
11024,preeclampsia,20,21,148,160,We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for preeclampsia.,2385256_1,-1,-1,-1,11024,-1,0.004060766,0.99593925
11027,postsynaptic neuromuscular blockade,22,25,147,182,"While she was weak, 2-Hz repetitive stimulation revealed a decrement without significant facilitation at rapid rates or after exercise, suggesting postsynaptic neuromuscular blockade.",2385256_4,-1,-1,-1,11027,-1,0.6807589,0.3192411
11031,myasthenia gravis,12,14,92,109,"Although paralysis after magnesium administration has been described in patients with known myasthenia gravis, it has not previously been reported to be the initial or only manifestation of the disease.",2385256_7,-1,-1,-1,11031,-1,0.0054834494,0.99451655
11033,disorder of neuromuscular transmission,18,22,123,161,Patients who are unusually sensitive to the neuromuscular effects of magnesium should be suspected of having an underlying disorder of neuromuscular transmission.,2385256_8,-1,-1,-1,11033,-1,0.008386502,0.9916135
11037,hepatocellular carcinomas,5,7,36,61,"No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain choline-supplemented diet, while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing phenobarbital.",2396046_3,-1,-1,-1,11037,-1,0.003354719,0.9966453
11040,hepatocellular carcinomas,7,9,46,71,"The incidence of preneoplastic nodules and of hepatocellular carcinomas was 10% and 37%, respectively, in rats fed the plain choline-devoid diet, and 17% and 30%, in rats fed the phenobarbital-containing choline-devoid diet.",2396046_4,-1,-1,-1,11040,-1,0.0034921481,0.9965078
11053,mm Hg,32,34,192,197,"In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",2422478_3,-1,-1,-1,11053,-1,0.1388682,0.86113185
11054,h,41,42,221,222,"In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",2422478_3,-1,-1,-1,11054,-1,0.130552,0.869448
11055,"serotonin neurotoxin 5,7-dihydroxytryptamine",49,52,269,313,"In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",2422478_3,-1,-1,-1,11055,-1,0.9963301,0.003669893
11056,"5,7-DHT",53,54,315,322,"In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",2422478_3,-1,-1,-1,11056,-1,0.9935382,0.006461741
11057,"5,7-DHT",5,6,34,41,"However, intraspinal injection of 5,7-DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension.",2422478_4,-1,-1,-1,11057,-1,0.9979639,0.00203608
11060,"5,7-DHT",2,3,9,16,"Further, 5,7-DHT lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.",2422478_5,-1,-1,-1,11060,-1,0.99703455,0.0029654612
11063,serotonin methyldopa,39,41,222,242,"Further, 5,7-DHT lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.",2422478_5,-1,-1,-1,11063,-1,0.99840647,0.0015936035
11069,Liver enlargement,0,2,0,17,Liver enlargement and muscle wastage occurred in Wistar rats following the subcutaneous administration of prednisolone.,2425813_1,-1,-1,-1,11069,-1,0.0040957923,0.99590427
11070,muscle wastage,3,5,22,36,Liver enlargement and muscle wastage occurred in Wistar rats following the subcutaneous administration of prednisolone.,2425813_1,-1,-1,-1,11070,-1,0.0036046272,0.9963954
11073,cibenzoline,4,5,40,51,Antiarrhythmic plasma concentrations of cibenzoline on canine ventricular arrhythmias.,2435991_0,-1,-1,-1,11073,-1,0.9992613,0.0007386862
11076,cibenzoline,16,17,129,140,"Using two-stage coronary ligation-, digitalis-, and adrenaline-induced canine ventricular arrhythmias, antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined.",2435991_1,-1,-1,-1,11076,-1,0.999355,0.0006450029
11078,Cibenzoline,0,1,0,11,"Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).",2435991_2,-1,-1,-1,11078,-1,0.99925727,0.00074277684
11081,digitalis,24,25,167,176,"Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).",2435991_2,-1,-1,-1,11081,-1,0.99867356,0.0013265219
11083,n,86,87,368,369,"Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).",2435991_2,-1,-1,-1,11083,-1,0.25168985,0.7483101
11087,tocainide,10,11,67,76,"This pharmacological profile is similar to those of mexiletine and tocainide, and all three drugs have central nervous system (CNS) stimulant action.",2435991_4,-1,-1,-1,11087,-1,0.9992206,0.0007793334
11088,cibenzoline,1,2,8,19,"Because cibenzoline had only weak hypotensive and sinus node depressive effects and was found to be orally active when given to coronary ligation arrhythmia dogs, its clinical usefulness is expected.",2435991_5,-1,-1,-1,11088,-1,0.99929893,0.0007010067
11092,gamma-hexachlorocyclohexane,3,4,24,51,Differential effects of gamma-hexachlorocyclohexane (lindane) on pharmacologically-induced seizures.,2440413_0,-1,-1,-1,11092,-1,0.9986853,0.0013146651
11097,pentylenetrazol,21,22,139,154,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,-1,-1,-1,11097,-1,0.9993142,0.0006858161
11098,PTZ,23,24,156,159,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,-1,-1,-1,11098,-1,0.99656844,0.003431583
11099,h,26,27,163,164,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,-1,-1,-1,11099,-1,0.19046304,0.80953693
11101,h,39,40,254,255,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,-1,-1,-1,11101,-1,0.10611719,0.89388275
11102,h,19,20,101,102,"In this study, the severity of response to other seizure-inducing agents was tested in mice 1 and 24 h after intraperitoneal administration of 80 mg/kg gamma-HCH.",2440413_2,-1,-1,-1,11102,-1,0.110308886,0.88969105
11103,h,23,24,143,144,"One hour after the administration of gamma-HCH, the activity of seizure-inducing agents was increased, regardless of their mechanism, while 24 h after gamma-HCH a differential response was observed.",2440413_3,-1,-1,-1,11103,-1,0.3109533,0.68904674
11105,PTZ,4,5,24,27,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11105,-1,0.99807006,0.00193
11107,PTX,8,9,44,47,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11107,-1,0.99789363,0.0021064137
11109,3-mercaptopropionic acid,20,22,111,135,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11109,-1,0.99798346,0.0020165106
11110,MPA,23,24,137,140,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11110,-1,0.99839836,0.0016016718
11112,BCC,28,29,156,159,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11112,-1,0.9977307,0.0022693865
11113,DMCM,34,35,218,222,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11113,-1,0.9961295,0.0038705235
11114,strychnine,38,39,228,238,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11114,-1,0.9984763,0.0015236774
11115,STR,40,41,240,243,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,-1,-1,-1,11115,-1,0.995417,0.0045830505
11116,pentylenetetrazol,5,6,21,38,"In vitro, gamma-HCH, pentylenetetrazol and picrotoxin were shown to inhibit 3H-TBOB binding in mouse whole brain, with IC50 values of 4.6, 404 and 9.4 microM, respectively.",2440413_5,-1,-1,-1,11116,-1,0.9992618,0.00073823263
11118,BCC,2,3,5,8,"MPA, BCC, DMCM, and STR showed no inhibition of 3H-TBOB (t-butyl bicyclo-orthobenzoate) binding at concentrations of 100 micron.",2440413_6,-1,-1,-1,11118,-1,0.9979367,0.0020633414
11119,DMCM,4,5,10,14,"MPA, BCC, DMCM, and STR showed no inhibition of 3H-TBOB (t-butyl bicyclo-orthobenzoate) binding at concentrations of 100 micron.",2440413_6,-1,-1,-1,11119,-1,0.9980849,0.0019151297
11120,STR,7,8,20,23,"MPA, BCC, DMCM, and STR showed no inhibition of 3H-TBOB (t-butyl bicyclo-orthobenzoate) binding at concentrations of 100 micron.",2440413_6,-1,-1,-1,11120,-1,0.99766004,0.002339911
11122,PTZ,14,15,99,102,"The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.",2440413_7,-1,-1,-1,11122,-1,0.9989279,0.001072127
11123,PTX,16,17,107,110,"The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.",2440413_7,-1,-1,-1,11123,-1,0.9983992,0.0016008371
11124,h,18,19,114,115,"The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.",2440413_7,-1,-1,-1,11124,-1,0.22371192,0.7762881
11126,h,16,17,92,93,The in vitro data suggest that the site responsible for the decrease in seizure activity 24 h after gamma-HCH may be the GABA-A receptor-linked chloride channel.,2440413_8,-1,-1,-1,11126,-1,0.09205532,0.9079447
11127,chloride,24,25,144,152,The in vitro data suggest that the site responsible for the decrease in seizure activity 24 h after gamma-HCH may be the GABA-A receptor-linked chloride channel.,2440413_8,-1,-1,-1,11127,-1,0.9912081,0.008791848
11129,Argentine hemorrhagic fever,9,12,61,88,Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever.,2445283_0,-1,-1,-1,11129,-1,0.24743257,0.7525674
11131,Argentine hemorrhagic fever,12,15,75,102,Tolerance and antiviral effect of ribavirin was studied in 6 patients with Argentine hemorrhagic fever (AHF) of more than 8 days of evolution.,2445283_1,-1,-1,-1,11131,-1,0.2173975,0.7826025
11132,AHF,16,17,104,107,Tolerance and antiviral effect of ribavirin was studied in 6 patients with Argentine hemorrhagic fever (AHF) of more than 8 days of evolution.,2445283_1,-1,-1,-1,11132,-1,0.006422011,0.99357796
11134,viremia,8,9,60,67,Administration of ribavirin resulted in a neutralization of viremia and a drop of endogenous interferon titers.,2445283_2,-1,-1,-1,11134,-1,0.0034308948,0.99656904
11135,interferon,14,15,93,103,Administration of ribavirin resulted in a neutralization of viremia and a drop of endogenous interferon titers.,2445283_2,-1,-1,-1,11135,-1,0.9967344,0.0032656065
11139,AHF,16,17,92,95,"From these results, we conclude that ribavirin has an antiviral effect in advanced cases of AHF, and that anemia, the only secondary reaction observed, can be easily managed.",2445283_5,-1,-1,-1,11139,-1,0.004210241,0.9957898
11142,AHF,11,12,71,74,The possible beneficial effect of ribavirin during the initial days of AHF is discussed.,2445283_6,-1,-1,-1,11142,-1,0.038847573,0.96115243
11143,fluorouracil,5,6,44,56,Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study.,2466960_0,-1,-1,-1,11143,-1,0.9989875,0.0010125325
11145,fluorouracil,11,12,79,91,"Although there have been anecdotal reports of cardiac toxicity associated with fluorouracil (5-FU) therapy, this phenomenon has not been studied in a systematic fashion.",2466960_1,-1,-1,-1,11145,-1,0.9989856,0.0010144275
11146,5-FU,13,14,93,97,"Although there have been anecdotal reports of cardiac toxicity associated with fluorouracil (5-FU) therapy, this phenomenon has not been studied in a systematic fashion.",2466960_1,-1,-1,-1,11146,-1,0.99835,0.0016499573
11147,5-FU,11,12,90,94,We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5-FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes.,2466960_2,-1,-1,-1,11147,-1,0.9989743,0.0010256623
11149,ischemic,25,26,170,178,We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5-FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes.,2466960_2,-1,-1,-1,11149,-1,0.0065915952,0.99340844
11150,5-FU,10,11,50,54,"Patients were monitored for 23 +/- 4 hours before 5-FU infusion, and 98 +/- 9 hours during 5-FU infusion.",2466960_3,-1,-1,-1,11150,-1,0.9987047,0.0012952768
11151,5-FU,20,21,91,95,"Patients were monitored for 23 +/- 4 hours before 5-FU infusion, and 98 +/- 9 hours during 5-FU infusion.",2466960_3,-1,-1,-1,11151,-1,0.9985397,0.0014603045
11152,angina,9,10,49,55,Anginal episodes were rare: only one patient had angina (during 5-FU infusion).,2466960_4,-1,-1,-1,11152,-1,0.002441291,0.9975587
11153,5-FU,12,13,64,68,Anginal episodes were rare: only one patient had angina (during 5-FU infusion).,2466960_4,-1,-1,-1,11153,-1,0.99866784,0.0013321736
11154,mm,12,13,61,63,"However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during 5-FU infusion (P less than .002).",2466960_5,-1,-1,-1,11154,-1,0.08598604,0.9140139
11155,5-FU,31,32,138,142,"However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during 5-FU infusion (P less than .002).",2466960_5,-1,-1,-1,11155,-1,0.99879175,0.0012082183
11156,5-FU,40,41,170,174,"However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during 5-FU infusion (P less than .002).",2466960_5,-1,-1,-1,11156,-1,0.9984907,0.0015093265
11157,P,43,44,185,186,"However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during 5-FU infusion (P less than .002).",2466960_5,-1,-1,-1,11157,-1,0.31826735,0.68173265
11158,ischemic,3,4,17,25,The incidence of ischemic episodes per patient per hour was 0.05 +/-,2466960_6,-1,-1,-1,11158,-1,0.004566094,0.99543387
11159,5-FU,3,4,14,18,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,-1,-1,-1,11159,-1,0.99875844,0.0012415573
11160,5-FU,11,12,51,55,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,-1,-1,-1,11160,-1,0.99857306,0.0014269447
11161,P,14,15,66,67,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,-1,-1,-1,11161,-1,0.4059492,0.5940508
11162,5-FU,36,37,165,169,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,-1,-1,-1,11162,-1,0.9986267,0.0013733638
11163,5-FU,48,49,220,224,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,-1,-1,-1,11163,-1,0.9985045,0.0014955122
11164,P,50,51,226,227,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,-1,-1,-1,11164,-1,0.32768458,0.67231536
11165,coronary artery disease,9,12,55,78,ECG changes were more common among patients with known coronary artery disease.,2466960_8,-1,-1,-1,11165,-1,0.0065978174,0.9934022
11166,sudden death,5,7,24,36,"There were two cases of sudden death, both of which occurred at the end of the chemotherapy course.",2466960_9,-1,-1,-1,11166,-1,0.0027134859,0.99728656
11167,5-FU,3,4,17,21,"We conclude that 5-FU infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia, particularly among patients with coronary artery disease.",2466960_10,-1,-1,-1,11167,-1,0.99887806,0.0011219281
11169,coronary artery disease,24,27,161,184,"We conclude that 5-FU infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia, particularly among patients with coronary artery disease.",2466960_10,-1,-1,-1,11169,-1,0.005860697,0.9941393
11170,scabies,4,5,20,27,Is the treatment of scabies hazardous?Treatment for scabies is usually initiated by general practitioners; most consider lindane (gamma benzene hexachloride) the treatment of choice.,2476560_0,-1,-1,-1,11170,-1,0.0036864653,0.9963135
11171,scabies,7,8,52,59,Is the treatment of scabies hazardous?Treatment for scabies is usually initiated by general practitioners; most consider lindane (gamma benzene hexachloride) the treatment of choice.,2476560_0,-1,-1,-1,11171,-1,0.0035361198,0.99646395
11173,gamma benzene hexachloride,19,22,130,156,Is the treatment of scabies hazardous?Treatment for scabies is usually initiated by general practitioners; most consider lindane (gamma benzene hexachloride) the treatment of choice.,2476560_0,-1,-1,-1,11173,-1,0.998334,0.0016659857
11176,toxic to the central nervous system,7,13,45,80,Evidence is accumulating that lindane can be toxic to the central nervous system and may be associated with aplastic anaemia.,2476560_2,-1,-1,-1,11176,-1,0.00932197,0.9906781
11177,aplastic anaemia,18,20,108,124,Evidence is accumulating that lindane can be toxic to the central nervous system and may be associated with aplastic anaemia.,2476560_2,-1,-1,-1,11177,-1,0.0023474514,0.9976526
11181,biogenic amines,9,11,66,81,Mouse strain-dependent effect of amantadine on motility and brain biogenic amines.,2484011_0,-1,-1,-1,11181,-1,0.9958734,0.004126629
11182,amantadine hydrochloride,3,5,14,38,"The effect of amantadine hydrochloride, injected i.p. in 6 increments of 100 mg/kg each over 30 hr, on mouse motility and whole brain content of selected biogenic amines and major metabolites was studied in 4 strains of mice.",2484011_1,-1,-1,-1,11182,-1,0.99911815,0.0008818843
11183,biogenic amines,29,31,154,169,"The effect of amantadine hydrochloride, injected i.p. in 6 increments of 100 mg/kg each over 30 hr, on mouse motility and whole brain content of selected biogenic amines and major metabolites was studied in 4 strains of mice.",2484011_1,-1,-1,-1,11183,-1,0.9902228,0.0097772265
11185,amantadine depressed,4,6,20,40,The initial dose of amantadine depressed locomotor activity in all mouse strains studied with the BALB/C mice being the most sensitive.,2484011_4,-1,-1,-1,11185,-1,0.9791494,0.02085059
11189,suppression of motility,26,29,173,196,"Readministration of amantadine, after a drug-free overnight period, increased motility from respective saline control in all strains with exception of the BALB/C mice where suppression of motility occurred.",2484011_7,-1,-1,-1,11189,-1,0.0057546836,0.99424535
11192,"3,4-dihydroxyphenylacetic acid",15,17,97,127,"Treatment with amantadine did not alter whole brain dopamine levels but decreased the amounts of 3,4-dihydroxyphenylacetic acid in the BALB/C mice compared to saline control.",2484011_8,-1,-1,-1,11192,-1,0.99782914,0.0021707912
11193,normetanephrine,3,4,18,33,"Conversely, brain normetanephrine concentration was increased from saline control by amantadine in the BALB/C mice.",2484011_9,-1,-1,-1,11193,-1,0.99831676,0.0016832559
11197,biogenic amines,5,7,33,48,The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.,2484011_12,-1,-1,-1,11197,-1,0.9969842,0.0030157866
11199,monoamine oxidase,22,24,152,169,The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.,2484011_12,-1,-1,-1,11199,-1,0.9980354,0.0019646783
11201,behavioral depression,37,39,254,275,The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.,2484011_12,-1,-1,-1,11201,-1,0.0024989748,0.9975011
11203,Chloroacetaldehyde,0,1,0,18,Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide.,2505783_0,-1,-1,-1,11203,-1,0.99903214,0.00096785324
11206,chloroacetaldehyde,7,8,40,58,"Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.",2505783_2,-1,-1,-1,11206,-1,0.9989297,0.00107029
11207,CAA,9,10,60,63,"Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.",2505783_2,-1,-1,-1,11207,-1,0.9966934,0.0033066203
11208,CAA,32,33,197,200,"Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.",2505783_2,-1,-1,-1,11208,-1,0.9962805,0.0037194905
11209,hemorrhagic cystitis,37,39,223,243,"Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.",2505783_2,-1,-1,-1,11209,-1,0.0021261408,0.9978739
11210,CAA,4,5,26,29,The data demonstrate that CAA after i.v. administration does not contribute to bladder damage.,2505783_3,-1,-1,-1,11210,-1,0.99831784,0.0016822106
11211,bladder damage,13,15,79,93,The data demonstrate that CAA after i.v. administration does not contribute to bladder damage.,2505783_3,-1,-1,-1,11211,-1,0.0031049158,0.9968951
11212,CAA,7,8,42,45,"When instilled directly into the bladder, CAA exerts urotoxic effects, it is, however, susceptible to detoxification with mesna.",2505783_4,-1,-1,-1,11212,-1,0.99846244,0.0015375225
11218,blind,37,38,229,234,Source of pain and primitive dysfunction in migraine: an identical site?Twenty common migraine patients received a one sided frontotemporal application of nitroglycerin (10 patients) or placebo ointment (10 patients) in a double blind study.,2515254_0,-1,-1,-1,11218,-1,0.15447961,0.8455204
11229,leukemoid reaction,6,8,52,70,"Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.",2522601_0,-1,-1,-1,11229,-1,0.010422775,0.9895773
11231,erythroderma,11,12,86,98,"Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.",2522601_0,-1,-1,-1,11231,-1,0.006089938,0.9939101
11232,renal failure,14,16,104,117,"Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.",2522601_0,-1,-1,-1,11232,-1,0.0031901787,0.9968098
11235,erythroderma,12,13,89,101,"We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.",2522601_1,-1,-1,-1,11235,-1,0.004990368,0.99500966
11236,leukemoid reaction,16,18,112,130,"We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.",2522601_1,-1,-1,-1,11236,-1,0.009858459,0.9901416
11239,renal failure,24,26,164,177,"We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.",2522601_1,-1,-1,-1,11239,-1,0.0032254343,0.9967746
11242,HIV disease,30,32,161,172,"Our study group consisted of 74 HIV-positive homosexual men belonging to groups II B, III and IV C2 from the Centers for Disease Control (CDC) classification of HIV disease.",2528969_1,-1,-1,-1,11242,-1,0.043043002,0.9569569
11247,megaloblastosis,8,9,56,71,Bone marrow changes occurred rapidly as demonstrated by megaloblastosis in 95% of 65 specimens at week 18.(ABSTRACT TRUNCATED AT 250 WORDS),2528969_11,-1,-1,-1,11247,-1,0.019751519,0.9802485
11249,hepatitis B virus,9,12,68,85,"National project on the prevention of mother-to-infant infection by hepatitis B virus in Japan.In Japan, a nationwide prevention program against mother-to-infant infection by hepatitis B virus (HBV) started in 1985.",2533791_0,-1,-1,-1,11249,-1,0.6586828,0.34131715
11250,infection by hepatitis B,24,28,162,186,"National project on the prevention of mother-to-infant infection by hepatitis B virus in Japan.In Japan, a nationwide prevention program against mother-to-infant infection by hepatitis B virus (HBV) started in 1985.",2533791_0,-1,-1,-1,11250,-1,0.2062343,0.7937657
11251,hepatitis B surface antigen,18,22,116,143,This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.,2533791_1,-1,-1,-1,11251,-1,0.9104696,0.08953036
11252,HBsAg,23,24,145,150,This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.,2533791_1,-1,-1,-1,11252,-1,0.9912412,0.008758758
11253,hepatitis B e antigen,26,30,156,177,This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.,2533791_1,-1,-1,-1,11253,-1,0.92322534,0.076774724
11254,HBeAg,31,32,179,184,This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.,2533791_1,-1,-1,-1,11254,-1,0.99211043,0.007889643
11255,hepatitis B,8,10,49,60,These infants are treated with two injections of hepatitis B immune globulin (HBIG) and at least three injections of plasma derived hepatitis B vaccine.,2533791_2,-1,-1,-1,11255,-1,0.89067805,0.10932192
11256,hepatitis B vaccine,23,26,132,151,These infants are treated with two injections of hepatitis B immune globulin (HBIG) and at least three injections of plasma derived hepatitis B vaccine.,2533791_2,-1,-1,-1,11256,-1,0.9000279,0.09997217
11257,HBsAg,11,12,55,60,"93.4% pregnant women had the chance to be examined for HBsAg, and the positive rate was 1.4 to 1.5%.",2533791_4,-1,-1,-1,11257,-1,0.9948944,0.005105687
11258,HBeAg,1,2,4,9,The HBeAg positive rate in HBsAg positive was 23 to 26%.,2533791_5,-1,-1,-1,11258,-1,0.9951953,0.0048047183
11259,HBsAg,5,6,27,32,The HBeAg positive rate in HBsAg positive was 23 to 26%.,2533791_5,-1,-1,-1,11259,-1,0.99154073,0.008459239
11260,HBsAg,1,2,4,9,The HBsAg positive rate in neonates and in infants before two months were 3% and 2% respectively.,2533791_6,-1,-1,-1,11260,-1,0.9936267,0.006373253
11261,akathisia,1,2,19,28,Fluoxetine-induced akathisia: clinical and theoretical implications.,2549018_0,-1,-1,-1,11261,-1,0.009731021,0.99026895
11263,obsessive compulsive disorder,8,11,56,85,Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.,2549018_1,-1,-1,-1,11263,-1,0.008870039,0.99113
11265,akathisia,15,16,116,125,Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.,2549018_1,-1,-1,-1,11265,-1,0.011645934,0.9883541
11266,restlessness,5,6,43,55,"The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia.",2549018_2,-1,-1,-1,11266,-1,0.004292816,0.9957072
11267,anxiety,20,21,129,136,"The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia.",2549018_2,-1,-1,-1,11267,-1,0.0033186462,0.9966813
11268,akathisia,27,28,194,203,"The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia.",2549018_2,-1,-1,-1,11268,-1,0.003591761,0.9964083
11269,akathisia,6,7,55,64,"Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.",2549018_3,-1,-1,-1,11269,-1,0.018949693,0.9810503
11270,akathisia,16,17,126,135,"Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.",2549018_3,-1,-1,-1,11270,-1,0.022802627,0.97719735
11271,Akathisia,0,1,0,9,"Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.",2549018_4,-1,-1,-1,11271,-1,0.0036932619,0.9963068
11273,akathisia,5,6,44,53,"The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced ""jitteriness"" may be identical.",2549018_5,-1,-1,-1,11273,-1,0.012892304,0.9871077
11274,akathisia,22,23,193,202,"The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced ""jitteriness"" may be identical.",2549018_5,-1,-1,-1,11274,-1,0.014019179,0.98598075
11275,analgesia,7,8,52,61,Involvement of the mu-opiate receptor in peripheral analgesia.,2557556_0,-1,-1,-1,11275,-1,0.0063908095,0.9936092
11277,"trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl",15,16,98,145,"The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.",2557556_1,-1,-1,-1,11277,-1,0.9883284,0.011671576
11278,"trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl",15,16,98,145,"The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.",2557556_1,-1,-1,-1,11278,-1,0.9883284,0.011671576
11279,"trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl",15,16,98,145,"The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.",2557556_1,-1,-1,-1,11279,-1,0.9883284,0.011671576
11280,cyclohexyl]benzeneactemide,17,18,147,173,"The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.",2557556_1,-1,-1,-1,11280,-1,0.99702924,0.002970787
11281,[D-Pen2.5]-enkephalin,22,23,186,207,"The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.",2557556_1,-1,-1,-1,11281,-1,0.9942591,0.005740863
11285,pertussis toxin,17,19,126,141,The analgesic effect of the mu-agonist morphine was dose-dependently antagonized by naloxone and prevented by co-injection of pertussis toxin.,2557556_3,-1,-1,-1,11285,-1,0.99764204,0.0023580112
11287,8-bromo cyclic adenosine monophosphate,11,15,61,99,"Morphine did not, however, alter the hyperalgesia induced by 8-bromo cyclic adenosine monophosphate.",2557556_4,-1,-1,-1,11287,-1,0.9977836,0.002216452
11288,cyclic adenosine monophosphate,36,39,221,251,We conclude that the analgesic action of opioids on the peripheral terminals of primary afferents is via a binding site with characteristics of the mu-opioid receptor and that this action is mediated by inhibition of the cyclic adenosine monophosphate second messenger system.,2557556_5,-1,-1,-1,11288,-1,0.99716187,0.0028381082
11291,adriamycin nephrosis,18,20,114,134,The effect of the converting enzyme inhibitor (CEI) enalapril was assessed in Munich-Wistar rats with established adriamycin nephrosis.,2559236_1,-1,-1,-1,11291,-1,0.63825923,0.36174077
11296,mm Hg,20,22,104,109,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,-1,-1,11296,-1,0.073801056,0.92619896
11297,P,28,29,126,127,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,-1,-1,11297,-1,0.24788912,0.75211084
11298,mm Hg,47,49,201,206,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,-1,-1,11298,-1,0.050544426,0.94945556
11299,P,50,51,208,209,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,-1,-1,11299,-1,0.20130904,0.798691
11301,617,59,60,256,259,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,-1,-1,-1,11301,-1,0.5237861,0.4762138
11304,adriamycin nephrosis,24,26,122,142,Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in adriamycin nephrosis.,2559236_6,-1,-1,-1,11304,-1,0.63548374,0.3645163
11308,P,33,34,150,151,"Enalapril treatment blunted but did not prevent reduction in GFR in group 4 (0.86 +/- 0.15 ml/min at 4 months, 0.69 +/- 0.13 ml/min at 6 months, both P less than 0.05 vs. group 3).",2559236_9,-1,-1,-1,11308,-1,0.33571643,0.66428363
11310,muscular rigidity,9,11,87,104,Involvement of locus coeruleus and noradrenergic neurotransmission in fentanyl-induced muscular rigidity in the rat.,2564649_0,-1,-1,-1,11310,-1,0.0022275546,0.9977724
11311,muscular rigidity,1,3,8,25,"Whereas muscular rigidity is a well-known side effect that is associated with high-dose fentanyl anesthesia, a paucity of information exists with regard to its underlying mechanism(s).",2564649_1,-1,-1,-1,11311,-1,0.002947331,0.99705267
11314,CO2,10,11,68,71,"Under proper control of respiration, body temperature and end-tidal CO2, intravenous administration of fentanyl (50 or 100 micrograms/kg) consistently promoted an increase in electromyographic activity recorded from the gastrocnemius and abdominal rectus muscles.",2564649_3,-1,-1,-1,11314,-1,0.992289,0.0077110073
11316,muscular rigidity,3,5,16,33,"Such an induced muscular rigidity by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha-adrenoceptor blocker, prazosin.",2564649_4,-1,-1,-1,11316,-1,0.0020799283,0.9979201
11319,muscular rigidity,7,9,39,56,It is speculated that the induction of muscular rigidity by fentanyl may involve the coerulospinal noradrenergic fibers to the spinal motoneurons.,2564649_6,-1,-1,-1,11319,-1,0.0026499939,0.99735
11321,Dexmedetomidine,0,1,0,15,"Dexmedetomidine, acting through central alpha-2 adrenoceptors, prevents opiate-induced muscle rigidity in the rat.",2569282_0,-1,-1,-1,11321,-1,0.9992274,0.00077253894
11322,muscle rigidity,10,12,87,102,"Dexmedetomidine, acting through central alpha-2 adrenoceptors, prevents opiate-induced muscle rigidity in the rat.",2569282_0,-1,-1,-1,11322,-1,0.0022051635,0.99779487
11323,adrenergic agonist dexmedetomidine,3,6,29,63,The highly-selective alpha-2 adrenergic agonist dexmedetomidine (D-MED) is capable of inducing muscle flaccidity and anesthesia in rats and dogs.,2569282_1,-1,-1,-1,11323,-1,0.99598455,0.004015515
11324,muscle flaccidity,13,15,95,112,The highly-selective alpha-2 adrenergic agonist dexmedetomidine (D-MED) is capable of inducing muscle flaccidity and anesthesia in rats and dogs.,2569282_1,-1,-1,-1,11324,-1,0.0051670643,0.9948329
11325,muscle rigidity,2,4,20,35,Intense generalized muscle rigidity is an undesirable side effect of potent opiate agonists.,2569282_2,-1,-1,-1,11325,-1,0.002491911,0.99750805
11327,muscle rigidity,14,16,82,97,"In the present study, the authors determined if treatment with D-MED prevents the muscle rigidity caused by high-dose alfentanil anesthesia in the rat.",2569282_4,-1,-1,-1,11327,-1,0.0024365764,0.9975635
11329,n,2,3,9,10,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,-1,-1,-1,11329,-1,0.32125506,0.678745
11330,medetomidine,25,26,123,135,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,-1,-1,-1,11330,-1,0.9989594,0.0010405416
11331,idazoxan,58,59,283,291,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,-1,-1,-1,11331,-1,0.9990489,0.00095114636
11332,DG-5128,76,77,377,384,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,-1,-1,-1,11332,-1,0.9975811,0.0024188338
11334,ALF,8,9,44,47,"Each rat was then injected with alfentanil (ALF, 0.5 mg/kg sc).",2569282_7,-1,-1,-1,11334,-1,0.99644715,0.0035529179
11335,ALF,0,1,0,3,ALF injection resulted in a marked increase in hindlimb EMG activity in the L-MED treatment group which was indistinguishable from that seen in animals treated with saline.,2569282_8,-1,-1,-1,11335,-1,0.99868613,0.0013138903
11336,contrast,1,2,3,11,"In contrast, D-MED prevented alfentanil-induced muscle rigidity in a dose-dependent fashion.",2569282_9,-1,-1,-1,11336,-1,0.26672512,0.73327494
11337,muscle rigidity,6,8,48,63,"In contrast, D-MED prevented alfentanil-induced muscle rigidity in a dose-dependent fashion.",2569282_9,-1,-1,-1,11337,-1,0.002112627,0.9978873
11339,startle,12,13,65,72,"The high-dose D-MED animals were flaccid, akinetic, and lacked a startle response during the entire experimental period.(ABSTRACT TRUNCATED AT 250 WORDS)",2569282_11,-1,-1,-1,11339,-1,0.00990171,0.9900983
11340,acute hepatitis,1,3,20,35,Clotiazepam-induced acute hepatitis.,2572625_0,-1,-1,-1,11340,-1,0.0023665042,0.99763346
11341,acute hepatitis,9,11,46,61,"We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.",2572625_1,-1,-1,-1,11341,-1,0.0025353744,0.99746466
11342,extensive hepatocellular necrosis,12,15,67,100,"We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.",2572625_1,-1,-1,-1,11342,-1,0.0030385556,0.9969614
11343,clotiazepam,24,25,148,159,"We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.",2572625_1,-1,-1,-1,11343,-1,0.9992205,0.00077945634
11344,thienodiazepine,27,28,163,178,"We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.",2572625_1,-1,-1,-1,11344,-1,0.99894696,0.001053072
11346,clotiazepam,9,10,69,80,"The administration of several benzodiazepines, chemically related to clotiazepam, did not interfere with recovery and did not induce any relapse of hepatitis.",2572625_3,-1,-1,-1,11346,-1,0.9992576,0.0007423186
11348,clotiazepam,4,5,28,39,This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.,2572625_4,-1,-1,-1,11348,-1,0.9994455,0.00055453385
11349,acute hepatitis,7,9,51,66,This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.,2572625_4,-1,-1,-1,11349,-1,0.0022983733,0.9977016
11351,clotiazepam,18,19,126,137,This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.,2572625_4,-1,-1,-1,11351,-1,0.9993906,0.00060933165
11353,fluvoxamine,7,8,48,59,Some central effects of repeated treatment with fluvoxamine.,2576810_0,-1,-1,-1,11353,-1,0.9992804,0.0007195703
11354,fluvoxamine,8,9,54,65,"We investigated the effect of repeated treatment with fluvoxamine, a selective serotonin uptake inhibitor, on behavioral effects of dopaminomimetics and methoxamine and on the animal behavior in the ""behavioral despair"" test.",2576810_1,-1,-1,-1,11354,-1,0.9993493,0.0006506881
11356,methoxamine,22,23,153,164,"We investigated the effect of repeated treatment with fluvoxamine, a selective serotonin uptake inhibitor, on behavioral effects of dopaminomimetics and methoxamine and on the animal behavior in the ""behavioral despair"" test.",2576810_1,-1,-1,-1,11356,-1,0.9994578,0.0005422713
11357,fluvoxamine,4,5,26,37,A repeated treatment with fluvoxamine (twice daily for 14 days) potentiated in mice and in rats (weaker) the amphetamine-induced hyperactivity.,2576810_2,-1,-1,-1,11357,-1,0.99934775,0.0006522441
11360,nomifensine,4,5,29,40,The hyperactivity induced by nomifensine in mice remained unaffected by fluvoxamine.,2576810_3,-1,-1,-1,11360,-1,0.9991691,0.00083092623
11361,fluvoxamine,10,11,72,83,The hyperactivity induced by nomifensine in mice remained unaffected by fluvoxamine.,2576810_3,-1,-1,-1,11361,-1,0.99929976,0.0007002746
11362,methoxamine,8,9,80,91,The stimulation of locomotor activity by intracerebroventricularly administered methoxamine was not affected by repeated treatment with fluvoxamine.,2576810_4,-1,-1,-1,11362,-1,0.9994691,0.00053092156
11363,fluvoxamine,16,17,136,147,The stimulation of locomotor activity by intracerebroventricularly administered methoxamine was not affected by repeated treatment with fluvoxamine.,2576810_4,-1,-1,-1,11363,-1,0.9993331,0.00066685
11364,fluvoxamine,3,4,18,29,"Given three times fluvoxamine had no effect on the immobilization time in the ""behavioral despair"" test in rats.",2576810_5,-1,-1,-1,11364,-1,0.9993094,0.0006906215
11365,fluvoxamine,4,5,26,37,"The results indicate that fluvoxamine given repeatedly acts differently than citalopram, another selective serotonin uptake inhibitor, and differs also from other antidepressant drugs.",2576810_6,-1,-1,-1,11365,-1,0.99934465,0.00065529114
11368,antidepressant drugs,23,25,163,183,"The results indicate that fluvoxamine given repeatedly acts differently than citalopram, another selective serotonin uptake inhibitor, and differs also from other antidepressant drugs.",2576810_6,-1,-1,-1,11368,-1,0.9939592,0.006040813
11369,initiation induced by carcinogens,2,6,26,59,5-azacytidine potentiates initiation induced by carcinogens in rat liver.,2578334_0,-1,-1,-1,11369,-1,0.11678063,0.88321936
11370,carcinogenic,19,20,112,124,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,-1,-1,-1,11370,-1,0.004651543,0.9953485
11372,5-AzC,24,25,149,154,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,-1,-1,-1,11372,-1,0.9977055,0.0022944629
11373,benzo[a]-pyrene,53,54,290,305,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,-1,-1,-1,11373,-1,0.99669385,0.003306125
11375,"1,2-DMH",67,68,380,387,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,-1,-1,-1,11375,-1,0.9838299,0.01617006
11376,0.02,25,26,176,180,The initiated hepatocytes in the liver were assayed as the gamma-glutamyltransferase (gamma-GT) positive foci formed following a 2-week selection regimen consisting of dietary 0.02% 2-acetylaminofluorene coupled with a necrogenic dose of CCl4.,2578334_2,-1,-1,-1,11376,-1,0.9717361,0.028263884
11378,CCl4,34,35,238,242,The initiated hepatocytes in the liver were assayed as the gamma-glutamyltransferase (gamma-GT) positive foci formed following a 2-week selection regimen consisting of dietary 0.02% 2-acetylaminofluorene coupled with a necrogenic dose of CCl4.,2578334_2,-1,-1,-1,11378,-1,0.99724895,0.002751083
11379,5-AzC,12,13,81,86,"The results obtained indicate that with all three carcinogens, administration of 5-AzC during repair synthesis increased the incidence of initiated hepatocytes, for example 10-20 foci/cm2 in 5-AzC and carcinogen-treated rats compared with 3-5 foci/cm2 in rats treated with carcinogen only.",2578334_3,-1,-1,-1,11379,-1,0.99898916,0.0010108082
11380,5-AzC,30,31,191,196,"The results obtained indicate that with all three carcinogens, administration of 5-AzC during repair synthesis increased the incidence of initiated hepatocytes, for example 10-20 foci/cm2 in 5-AzC and carcinogen-treated rats compared with 3-5 foci/cm2 in rats treated with carcinogen only.",2578334_3,-1,-1,-1,11380,-1,0.9987062,0.0012937603
11381,"1,2-DMH",9,10,81,88,"Administration of [3H]-5-azadeoxycytidine during the repair synthesis induced by 1,2-DMH further showed that 0.019 mol % of cytosine residues in DNA were substituted by the analogue, indicating that incorporation of 5-AzC occurs during repair synthesis.",2578334_4,-1,-1,-1,11381,-1,0.9955538,0.004446158
11382,cytosine,17,18,124,132,"Administration of [3H]-5-azadeoxycytidine during the repair synthesis induced by 1,2-DMH further showed that 0.019 mol % of cytosine residues in DNA were substituted by the analogue, indicating that incorporation of 5-AzC occurs during repair synthesis.",2578334_4,-1,-1,-1,11382,-1,0.9941802,0.0058198497
11383,5-AzC,31,32,216,221,"Administration of [3H]-5-azadeoxycytidine during the repair synthesis induced by 1,2-DMH further showed that 0.019 mol % of cytosine residues in DNA were substituted by the analogue, indicating that incorporation of 5-AzC occurs during repair synthesis.",2578334_4,-1,-1,-1,11383,-1,0.9977114,0.002288525
11384,5-AzC,7,8,34,39,"In the absence of the carcinogen, 5-AzC given after a two thirds partial hepatectomy, when its incorporation should be maximum, failed to induce any gamma-GT positive foci.",2578334_5,-1,-1,-1,11384,-1,0.9987484,0.0012515916
11385,se,8,9,52,54,The results suggest that hypomethylation of DNA per se may not be sufficient for initiation.,2578334_6,-1,-1,-1,11385,-1,0.9480834,0.051916547
11386,BN 52021,9,11,71,79,"Protective effect of a specific platelet-activating factor antagonist, BN 52021, on bupivacaine-induced cardiovascular impairments in rats.",2594614_0,-1,-1,-1,11386,-1,0.998464,0.001536071
11387,cardiovascular impairments,14,16,104,130,"Protective effect of a specific platelet-activating factor antagonist, BN 52021, on bupivacaine-induced cardiovascular impairments in rats.",2594614_0,-1,-1,-1,11387,-1,0.003002772,0.99699724
11390,BN 52021,11,13,82,90,"Intravenous injection of the specific platelet-activating factor (PAF) antagonist BN 52021 (10 mg/kg), 30 min before bupivacaine administration (2 mg/kg i.v.) suppressed both the decrease of MBP and HR.",2594614_2,-1,-1,-1,11390,-1,0.99850297,0.0014970038
11392,contrast,1,2,3,11,"In contrast, doses of 1 mg/kg BN 52021 given 30 min before or 10 mg/kg administered 5 min before i.v.",2594614_3,-1,-1,-1,11392,-1,0.5631436,0.4368564
11393,BN 52021,7,9,30,38,"In contrast, doses of 1 mg/kg BN 52021 given 30 min before or 10 mg/kg administered 5 min before i.v.",2594614_3,-1,-1,-1,11393,-1,0.998847,0.0011530174
11395,BN 52021,1,3,5,13,"When BN 52021 (20 mg/kg i.v.) was injected immediately after bupivacaine (2 mg/kg), a partial reversion of the decrease of MBP and HR was observed, whereas the dose of 10 mg/kg was ineffective.",2594614_5,-1,-1,-1,11395,-1,0.9984133,0.0015866683
11397,BN 52021,15,17,107,115,A partial recovery of bupivacaine-induced ECG alterations was observed after pretreatment of the rats with BN 52021.,2594614_6,-1,-1,-1,11397,-1,0.9980945,0.001905478
11398,BN 52021,4,6,28,36,"Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.",2594614_7,-1,-1,-1,11398,-1,0.9986702,0.0013298508
11399,BN 52021,34,36,173,181,"Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.",2594614_7,-1,-1,-1,11399,-1,0.9985667,0.0014333705
11400,cardiovascular toxicity,45,47,241,264,"Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.",2594614_7,-1,-1,-1,11400,-1,0.0026353085,0.9973647
11401,cardiovascular alterations,17,19,102,128,"Thus, consistent with its direct effect on heart, PAF appears to be implicated in bupivacaine-induced cardiovascular alterations.",2594614_8,-1,-1,-1,11401,-1,0.0031072486,0.9968927
11402,flank pain syndrome,5,8,30,49,The epidemiology of the acute flank pain syndrome from suprofen.,2598570_0,-1,-1,-1,11402,-1,0.002877445,0.9971226
11403,suprofen,9,10,55,63,The epidemiology of the acute flank pain syndrome from suprofen.,2598570_0,-1,-1,-1,11403,-1,0.99867624,0.001323763
11404,Suprofen,0,1,0,8,"Suprofen, a new nonsteroidal anti-inflammatory drug, was marketed in early 1986 as an analgesic agent.",2598570_1,-1,-1,-1,11404,-1,0.99925774,0.0007422429
11405,flank pain syndrome,7,10,50,69,"Until physicians began reporting an unusual acute flank pain syndrome to the spontaneous reporting system, 700,000 persons used the drug in the United States. Through August 1986, a total of 163 cases of this syndrome were reported.",2598570_2,-1,-1,-1,11405,-1,0.0030386844,0.9969613
11406,hay fever,26,28,107,116,"Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).",2598570_4,-1,-1,-1,11406,-1,0.00886728,0.9911327
11407,asthma,29,30,121,127,"Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).",2598570_4,-1,-1,-1,11407,-1,0.0052098525,0.9947902
11408,p,75,76,316,317,"Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).",2598570_4,-1,-1,-1,11408,-1,0.40988126,0.59011877
11411,renal disease,19,21,119,132,"Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.",2598570_5,-1,-1,-1,11411,-1,0.0030701784,0.9969298
11412,kidney stones,25,27,147,160,"Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.",2598570_5,-1,-1,-1,11412,-1,0.0036218266,0.9963781
11413,gout,31,32,175,179,"Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.",2598570_5,-1,-1,-1,11413,-1,0.0032490876,0.99675095
11414,uric acid,17,19,120,129,These findings are consistent with the postulated mechanism for this unusual syndrome: acute diffuse crystallization of uric acid in renal tubules.,2598570_7,-1,-1,-1,11414,-1,0.9984458,0.001554205
11415,Antihypertensive drugs,0,2,0,22,Antihypertensive drugs and depression: a reappraisal.,26094_0,-1,-1,-1,11415,-1,0.9848439,0.01515603
11423,depressions,9,10,50,61,This was accounted for by a significant number of depressions occurring in methyl dopa treated patients with psychiatric histories.,26094_4,-1,-1,-1,11423,-1,0.0031984595,0.9968015
11426,diclofenac sodium,5,7,41,58,Chronic active hepatitis associated with diclofenac sodium therapy.,2611118_0,-1,-1,-1,11426,-1,0.9991622,0.000837825
11427,Diclofenac sodium,0,2,0,17,"Diclofenac sodium (Voltarol, Geigy Pharmaceuticals) is a non-steroidal anti-inflammatory derivative of phenylacetic acid.",2611118_1,-1,-1,-1,11427,-1,0.99925405,0.00074587855
11428,Voltarol,3,4,19,27,"Diclofenac sodium (Voltarol, Geigy Pharmaceuticals) is a non-steroidal anti-inflammatory derivative of phenylacetic acid.",2611118_1,-1,-1,-1,11428,-1,0.999097,0.00090300443
11430,abnormalities of liver function,5,9,48,79,"Although generally well-tolerated, asymptomatic abnormalities of liver function have been recorded and, less commonly, severe hepatitis induced by diclofenac.",2611118_2,-1,-1,-1,11430,-1,0.004036417,0.9959636
11433,chronic active hepatitis,4,7,32,56,"The patient described developed chronic active hepatitis after six months therapy with diclofenac sodium which progressed despite the withdrawal of the drug, a finding not previously reported.",2611118_3,-1,-1,-1,11433,-1,0.00303026,0.99696976
11434,diclofenac sodium,12,14,87,104,"The patient described developed chronic active hepatitis after six months therapy with diclofenac sodium which progressed despite the withdrawal of the drug, a finding not previously reported.",2611118_3,-1,-1,-1,11434,-1,0.9992855,0.0007145519
11437,Cushing's syndrome,5,8,24,42,Two of 14 patients with Cushing's syndrome treated on a long-term basis with ketoconazole developed sustained hypertension.,2632720_1,-1,-1,-1,11437,-1,0.0061137294,0.9938863
11443,deoxycorticosterone,7,8,31,50,"In patient 1, plasma levels of deoxycorticosterone and 11-deoxycortisol were elevated.",2632720_3,-1,-1,-1,11443,-1,0.99882644,0.0011735153
11445,deoxycorticosterone,11,12,49,68,"In patient 2, in addition to an increase in both deoxycorticosterone and 11-deoxycortisol levels, plasma aldosterone values were raised, with a concomitant suppression of renin levels.",2632720_4,-1,-1,-1,11445,-1,0.9988305,0.0011694662
11451,renal insufficiency,14,16,86,105,Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.,2670794_0,-1,-1,-1,11451,-1,0.002979678,0.9970203
11452,intravascular coagulation,18,20,113,138,Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.,2670794_0,-1,-1,-1,11452,-1,0.0032531144,0.9967469
11453,intravascular coagulation,2,4,13,38,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,-1,-1,-1,11453,-1,0.0050651073,0.99493486
11454,tranexamic acid,13,15,99,114,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,-1,-1,-1,11454,-1,0.9991959,0.00080408284
11455,AMCA,16,17,116,120,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,-1,-1,-1,11455,-1,0.9979335,0.0020665093
11456,and renal insufficiency,25,28,157,180,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,-1,-1,-1,11456,-1,0.006779685,0.9932203
11457,trauma,32,33,213,219,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,-1,-1,-1,11457,-1,0.015599119,0.9844009
11460,renal insufficiency,22,24,114,133,"Injection of Captopril (1 mg/kg), an inhibitor of angiotensin converting enzyme (ACE), reduced both pulmonary and renal insufficiency in this rat model.",2670794_2,-1,-1,-1,11460,-1,0.0030753727,0.9969246
11465,AMCA,18,19,108,112,The amount of fibrin in the kidneys was also considerably lower than in animals which received thrombin and AMCA alone.,2670794_6,-1,-1,-1,11465,-1,0.99848133,0.0015186245
11467,Angiotension II,27,29,151,166,It is suggested that the effects of Captopril on the lungs may be attributable to a vasodilatory effect due to a reduction in the circulating level of Angiotension II and an increase in prostacyclin (secondary to an increase in bradykinin).,2670794_7,-1,-1,-1,11467,-1,0.9957632,0.004236766
11468,prostacyclin,33,34,186,198,It is suggested that the effects of Captopril on the lungs may be attributable to a vasodilatory effect due to a reduction in the circulating level of Angiotension II and an increase in prostacyclin (secondary to an increase in bradykinin).,2670794_7,-1,-1,-1,11468,-1,0.9989812,0.0010187645
11471,kidney damage,48,50,276,289,"Captopril may, by the same mechanism, reduce the increase in glomerular filtration that is known to occur after an injection of thrombin, thereby diminishing the aggregation of fibrin monomers in the glomeruli, with the result that less fibrin will be deposited and thus less kidney damage will be produced.",2670794_8,-1,-1,-1,11471,-1,0.0035313007,0.99646866
11476,SD,9,10,38,40,Among these 47 patients the mean (+/- SD) age was 32.5 +/- 12.1 years; 76% (34/45) were men.,2673163_2,-1,-1,-1,11476,-1,0.2791797,0.7208203
11479,Intracranial aneurysms,0,2,0,22,Intracranial aneurysms or arteriovenous malformations were present in 17 of 32 patients studied angiographically or at autopsy; cerebral vasculitis was present in two patients.,2673163_4,-1,-1,-1,11479,-1,0.003896221,0.99610376
11480,arteriovenous malformations,3,5,26,53,Intracranial aneurysms or arteriovenous malformations were present in 17 of 32 patients studied angiographically or at autopsy; cerebral vasculitis was present in two patients.,2673163_4,-1,-1,-1,11480,-1,0.00954613,0.99045384
11482,Cerebral infarction,0,2,0,19,"Cerebral infarction occurred in 10 patients (22%), intracerebral hemorrhage in 22 (49%), and subarachnoid hemorrhage in 13 (29%).",2673163_5,-1,-1,-1,11482,-1,0.0028433192,0.9971566
11483,intracerebral hemorrhage,11,13,51,75,"Cerebral infarction occurred in 10 patients (22%), intracerebral hemorrhage in 22 (49%), and subarachnoid hemorrhage in 13 (29%).",2673163_5,-1,-1,-1,11483,-1,0.003360607,0.9966394
11484,subarachnoid hemorrhage,21,23,93,116,"Cerebral infarction occurred in 10 patients (22%), intracerebral hemorrhage in 22 (49%), and subarachnoid hemorrhage in 13 (29%).",2673163_5,-1,-1,-1,11484,-1,0.004612763,0.99538726
11492,intracranial aneurysms,53,55,282,304,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,-1,-1,-1,11492,-1,0.0033890652,0.99661094
11493,arteriovenous malformations,56,58,309,336,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,-1,-1,-1,11493,-1,0.009083118,0.9909169
11495,intracranial hemorrhage,70,72,393,416,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,-1,-1,-1,11495,-1,0.0032128647,0.9967872
11496,cerebral infarction,75,77,433,452,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,-1,-1,-1,11496,-1,0.0026904137,0.99730957
11502,reductions in mean arterial blood pressure,12,18,88,130,Each patient was subjected to an identical anesthetic protocol and similar drug-induced reductions in mean arterial blood pressure (BP) (50 to 55 mmHg).,2696505_2,-1,-1,-1,11502,-1,0.055045974,0.944954
11504,p,8,9,58,59,Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside.,2696505_3,-1,-1,-1,11504,-1,0.29365498,0.706345
11505,increase in heart rate and cardiac output,13,20,76,117,Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside.,2696505_3,-1,-1,-1,11505,-1,0.02950408,0.97049594
11509,PO2,1,2,9,12,Arterial PO2 decreased in both groups.,2696505_5,-1,-1,-1,11509,-1,0.9934227,0.0065773157
11513,gentamicin nephrotoxicity,5,7,46,71,Phlorizin-induced glycosuria does not prevent gentamicin nephrotoxicity in rats.,2709684_0,-1,-1,-1,11513,-1,0.04399084,0.9560092
11514,diabetes mellitus,4,6,41,58,"Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).",2709684_1,-1,-1,-1,11514,-1,0.002819089,0.99718094
11515,DM,7,8,60,62,"Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).",2709684_1,-1,-1,-1,11515,-1,0.003400503,0.9965995
11517,acute renal failure,38,41,222,241,"Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).",2709684_1,-1,-1,-1,11517,-1,0.0023369384,0.997663
11518,ARF,42,43,243,246,"Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).",2709684_1,-1,-1,-1,11518,-1,0.00264256,0.9973574
11519,gentamicin nephrotoxicity,3,5,20,45,The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).,2709684_2,-1,-1,-1,11519,-1,0.057743594,0.9422564
11521,phlorizin,22,23,165,174,The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).,2709684_2,-1,-1,-1,11521,-1,0.99921703,0.00078298093
11522,P,24,25,176,177,The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).,2709684_2,-1,-1,-1,11522,-1,0.9969477,0.0030522847
11523,DM,0,1,0,2,DM rats with mild glycosuria (similar in degree to that of the P treated animals) were also studied.,2709684_3,-1,-1,-1,11523,-1,0.012018422,0.9879816
11525,P,13,14,63,64,DM rats with mild glycosuria (similar in degree to that of the P treated animals) were also studied.,2709684_3,-1,-1,-1,11525,-1,0.99427515,0.0057248697
11526,P,3,4,9,10,"Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).",2709684_5,-1,-1,-1,11526,-1,0.99216616,0.007833858
11527,P,7,8,27,28,"Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).",2709684_5,-1,-1,-1,11527,-1,0.9971898,0.0028101732
11528,P,19,20,65,66,"Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).",2709684_5,-1,-1,-1,11528,-1,0.98946816,0.010531888
11531,DM,35,36,130,132,"Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).",2709684_5,-1,-1,-1,11531,-1,0.005189998,0.99481
11535,P,4,5,12,13,"In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).",2709684_7,-1,-1,-1,11535,-1,0.9971219,0.002878162
11537,SE,18,19,75,77,"In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).",2709684_7,-1,-1,-1,11537,-1,0.9876951,0.012304965
11540,P,4,5,13,14,"In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).",2709684_8,-1,-1,-1,11540,-1,0.99628985,0.0037101724
11541,P,19,20,85,86,"In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).",2709684_8,-1,-1,-1,11541,-1,0.51338834,0.48661172
11543,P,18,19,86,87,"These values were not different from those of Group III: maximal decrease in CCr 73% (P less than 0.001); lysozymuria, 2147 +/- 701 micrograms/day; tubular necrosis score, 3.8 +/- 0.1.(ABSTRACT TRUNCATED AT 250 WORDS)",2709684_9,-1,-1,-1,11543,-1,0.24747382,0.75252616
11550,analgesia,9,10,70,79,Previous studies demonstrated that both ketamine and morphine induced analgesia and catalepsy in the rat.,2716967_1,-1,-1,-1,11550,-1,0.0038932916,0.9961067
11556,cataleptic,22,23,169,179,"Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the cataleptic response; this augmentation was attributed to residual morphine in the brain.",2716967_2,-1,-1,-1,11556,-1,0.014460862,0.9855392
11567,cataleptic,4,5,31,41,Naloxone inhibited the induced cataleptic effects.,2716967_6,-1,-1,-1,11567,-1,0.014576083,0.98542386
11579,mm Hg,15,17,104,109,"Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01).",2722224_3,-1,-1,-1,11579,-1,0.33899048,0.6610095
11580,p,23,24,124,125,"Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01).",2722224_3,-1,-1,-1,11580,-1,0.29606578,0.7039342
11581,p,46,47,219,220,"Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01).",2722224_3,-1,-1,-1,11581,-1,0.25754207,0.7424579
11582,p,17,18,87,88,"Total peripheral vascular resistance fell from 15.1 to 12.2 mm Hg/l/min (SED +/- 1.03, p less than 0.05).",2722224_4,-1,-1,-1,11582,-1,0.42128965,0.5787104
11583,p,47,48,259,260,"Resting forearm vascular resistance remained unchanged, but the reflex response to the cold pressor test was accentuated, the rise in resistance increasing from 10.5 mm Hg/ml/100 ml/min (R units) before treatment to 32.6 R units after treatment (SED +/- 6.4, p less than 0.025).",2722224_5,-1,-1,-1,11583,-1,0.31095564,0.68904436
11587,p,53,54,288,289,"The rise in forearm vascular resistance accompanying intra-arterial norepinephrine (25, 50, and 100 ng/min) was also significantly greater after hydrocortisone, increasing from an average of 14.9 +/- 2.4 R units before treatment to 35.1 +/- 5.5 R units after hydrocortisone (SED +/- 6.0, p less than 0.05).",2722224_6,-1,-1,-1,11587,-1,0.26995674,0.73004323
11592,increased cardiac output,12,15,77,101,The rise in resting blood pressure with hydrocortisone is associated with an increased cardiac output (presumably due to increased blood volume).(ABSTRACT TRUNCATED AT 250 WORDS),2722224_9,-1,-1,-1,11592,-1,0.022346996,0.977653
11593,magnesium sulfate,3,5,28,45,Neuromuscular blockade with magnesium sulfate and nifedipine.,2750819_0,-1,-1,-1,11593,-1,0.99855834,0.0014416758
11596,neuromuscular blockade,8,10,59,81,A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered.,2750819_1,-1,-1,-1,11596,-1,0.0043495456,0.9956505
11597,mg,12,13,92,94,A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered.,2750819_1,-1,-1,-1,11597,-1,0.9902802,0.00971976
11598,magnesium sulfate,14,16,98,115,A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered.,2750819_1,-1,-1,-1,11598,-1,0.99886596,0.0011340366
11607,CBZ,5,6,30,33,The effects of carbamazepine (CBZ) treatment on local anesthetic-kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration.,2790457_1,-1,-1,-1,11607,-1,0.99895585,0.0010441586
11609,CBZ,28,29,186,189,The effects of carbamazepine (CBZ) treatment on local anesthetic-kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration.,2790457_1,-1,-1,-1,11609,-1,0.99898595,0.0010140903
11610,CBZ,2,3,13,16,"Chronic oral CBZ inhibited the development of both lidocaine- and cocaine-induced seizures, but had little effect on the fully developed local anesthetic seizures.",2790457_2,-1,-1,-1,11610,-1,0.9991955,0.00080443843
11613,CBZ,1,2,8,11,Chronic CBZ also decreased the incidence of seizure-related mortality in the cocaine-injected rats.,2790457_3,-1,-1,-1,11613,-1,0.9990957,0.000904317
11614,CBZ,1,2,6,9,Acute CBZ over a range of doses (15-50 mg/kg) had no effect on completed lidocaine-kindled or acute cocaine-induced seizures.,2790457_4,-1,-1,-1,11614,-1,0.99914503,0.0008549886
11616,CBZ,2,3,13,16,injection of CBZ (15 mg/kg) also was without effect on the development of lidocaine- or cocaine-kindled seizures.,2790457_6,-1,-1,-1,11616,-1,0.99907386,0.0009260693
11618,CBZ,4,5,28,31,The differential effects of CBZ depending upon stage of seizure development suggest that distinct mechanisms underlie the development versus maintenance of local anesthetic-kindled seizures.,2790457_7,-1,-1,-1,11618,-1,0.9991775,0.00082243263
11621,CBZ,11,12,74,77,"The effectiveness of chronic but not repeated, intermittent injections of CBZ suggests that different biochemical consequences result from the different treatment regimens.",2790457_8,-1,-1,-1,11621,-1,0.9990953,0.00090468983
11622,CBZ,5,6,32,35,"The possible utility of chronic CBZ in preventing the development of toxic side effects in human cocaine users is suggested by these data, but remains to be directly evaluated.",2790457_9,-1,-1,-1,11622,-1,0.9991986,0.0008013513
11624,amphotericin B nephrotoxicity,4,7,33,62,Sodium status influences chronic amphotericin B nephrotoxicity in rats.,2802551_0,-1,-1,-1,11624,-1,0.44806796,0.551932
11626,amphotericin B,4,6,29,43,"The nephrotoxic potential of amphotericin B (5 mg/kg per day intraperitoneally for 3 weeks) has been investigated in salt-depleted, normal-salt, and salt-loaded rats.",2802551_1,-1,-1,-1,11626,-1,0.99899846,0.0010015974
11627,amphotericin B,4,6,23,37,"In salt-depleted rats, amphotericin B decreased creatinine clearance linearly with time, with an 85% reduction by week 3.",2802551_2,-1,-1,-1,11627,-1,0.99893755,0.0010624197
11629,contrast,1,2,3,11,"In contrast, in normal-salt rats creatinine clearance was decreased but to a lesser extent at week 2 and 3, and in salt-loaded rats creatinine clearance did not change for 2 weeks and was decreased by 43% at week 3.",2802551_3,-1,-1,-1,11629,-1,0.20270644,0.7972936
11632,amphotericin B,2,4,18,32,Concentrations of amphotericin B in plasma were not significantly different among the three groups at any time during the study.,2802551_5,-1,-1,-1,11632,-1,0.99907696,0.0009230672
11633,amphotericin B,9,11,32,46,"However, at the end of 3 weeks, amphotericin B levels in the kidneys and liver were significantly higher in salt-depleted and normal-salt rats than those in salt-loaded rats, with plasma/kidney ratios of 21, 14, and 8 in salt-depleted, normal-salt, and salt-loaded rats, respectively.",2802551_6,-1,-1,-1,11633,-1,0.9988273,0.0011727711
11635,amphotericin B,9,11,60,74,"In conclusion, reductions in creatinine clearance and renal amphotericin B accumulation after chronic amphotericin B administration were enhanced by salt depletion and attenuated by sodium loading in rats.",2802551_7,-1,-1,-1,11635,-1,0.9991768,0.0008231692
11636,amphotericin B,14,16,102,116,"In conclusion, reductions in creatinine clearance and renal amphotericin B accumulation after chronic amphotericin B administration were enhanced by salt depletion and attenuated by sodium loading in rats.",2802551_7,-1,-1,-1,11636,-1,0.9990582,0.00094184803
11639,venous thrombosis,5,7,39,56,"Magnetic resonance imaging of cerebral venous thrombosis secondary to ""low-dose"" birth control pills.",2819587_0,-1,-1,-1,11639,-1,0.0030976362,0.9969023
11640,deep venous thrombosis,7,10,51,73,The clinical and radiographic features of cerebral deep venous thrombosis in a 21-year-old white woman are presented.,2819587_1,-1,-1,-1,11640,-1,0.012233495,0.9877665
11641,oral contraceptive pills,9,12,42,66,"The only known risk factor was ""low-dose"" oral contraceptive pills.",2819587_3,-1,-1,-1,11641,-1,0.9943152,0.0056847697
11642,hypokalemia,1,2,29,40,Beta-2-adrenoceptor-mediated hypokalemia and its abolishment by oxprenolol.,2826064_0,-1,-1,-1,11642,-1,0.0027210033,0.997279
11643,oxprenolol,6,7,64,74,Beta-2-adrenoceptor-mediated hypokalemia and its abolishment by oxprenolol.,2826064_0,-1,-1,-1,11643,-1,0.998415,0.0015850458
11644,hypokalemia,8,9,77,88,"The time course and concentration-effect relationship of terbutaline-induced hypokalemia was studied, using computer-aided pharmacokinetic-dynamic modeling.",2826064_1,-1,-1,-1,11644,-1,0.0025642933,0.99743575
11645,oxprenolol,6,7,45,55,"Subsequently we investigated the efficacy of oxprenolol in antagonizing such hypokalemia, together with the pharmacokinetic interaction between both drugs.",2826064_2,-1,-1,-1,11645,-1,0.998923,0.0010770162
11646,hypokalemia,10,11,77,88,"Subsequently we investigated the efficacy of oxprenolol in antagonizing such hypokalemia, together with the pharmacokinetic interaction between both drugs.",2826064_2,-1,-1,-1,11646,-1,0.0034490954,0.9965509
11647,mg,7,8,38,40,Six healthy subjects were given a 0.5 mg subcutaneous dose of terbutaline on two occasions: 1 hour after oral administration of a placebo and 1 hour after 80 mg oxprenolol orally.,2826064_3,-1,-1,-1,11647,-1,0.96984684,0.030153114
11649,mg oxprenolol,29,31,158,171,Six healthy subjects were given a 0.5 mg subcutaneous dose of terbutaline on two occasions: 1 hour after oral administration of a placebo and 1 hour after 80 mg oxprenolol orally.,2826064_3,-1,-1,-1,11649,-1,0.99616456,0.00383543
11654,Oxprenolol,0,1,0,10,"Oxprenolol caused decreases of 65% and 56% of terbutaline volume of distribution and clearance, respectively, and an increase of 130% of its AUC.",2826064_6,-1,-1,-1,11654,-1,0.99862874,0.0013712895
11657,oxprenolol,7,8,52,62,"In spite of higher terbutaline concentrations after oxprenolol pretreatment, the hypokalemia was almost completely antagonized by the beta 2-blocking action.",2826064_7,-1,-1,-1,11657,-1,0.9986376,0.001362357
11658,hypokalemia,11,12,81,92,"In spite of higher terbutaline concentrations after oxprenolol pretreatment, the hypokalemia was almost completely antagonized by the beta 2-blocking action.",2826064_7,-1,-1,-1,11658,-1,0.0025448655,0.9974552
11659,movement disorder,1,3,4,21,"The movement disorder investigated in these studies has some features in common with human idiopathic dystonia, and information obtained in these studies may be of potential clinical benefit.",2840807_1,-1,-1,-1,11659,-1,0.002467517,0.9975325
11661,ACTH,20,21,90,94,"However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.",2840807_3,-1,-1,-1,11661,-1,0.9965192,0.0034808298
11662,NE,36,37,170,172,"However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.",2840807_3,-1,-1,-1,11662,-1,0.9979006,0.0020993403
11664,movement disorder,75,77,410,427,"However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.",2840807_3,-1,-1,-1,11664,-1,0.0028678675,0.99713206
11665,c,79,80,430,431,"However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.",2840807_3,-1,-1,-1,11665,-1,0.2193016,0.7806985
11667,ACC-9089,2,3,11,19,"Flestolol (ACC-9089) is a nonselective, competitive, ultra-short-acting beta-adrenergic blocking agent, without any intrinsic sympathomimetic activity.",2870085_1,-1,-1,-1,11667,-1,0.9967417,0.0032583647
11675,contrast,1,2,3,11,"In contrast with other beta blockers, flestolol-induced effects reverse rapidly (within 30 minutes) following discontinuation because of its short half-life.",2870085_8,-1,-1,-1,11675,-1,0.30666074,0.6933393
11676,supraventricular tachyarrhythmia,8,10,58,90,Flestolol effectively reduced heart rate in patients with supraventricular tachyarrhythmia.,2870085_9,-1,-1,-1,11676,-1,0.0045709643,0.99542904
11677,unstable angina,3,5,17,32,"In patients with unstable angina, flestolol infusion was found to be safe and effective in controlling chest pain.",2870085_10,-1,-1,-1,11677,-1,0.0026524263,0.9973476
11679,chest pain,17,19,103,113,"In patients with unstable angina, flestolol infusion was found to be safe and effective in controlling chest pain.",2870085_10,-1,-1,-1,11679,-1,0.0022954557,0.99770457
11684,h,14,15,92,93,"The present study examines the effect of 6-day epinephrine treatment (100 micrograms/kg per h, s.c.) on stimulus-induced (1 Hz) endogenous neurotransmitter overflow from the isolated perfused kidney of vehicle- and epinephrine-treated rats.",2886572_1,-1,-1,-1,11684,-1,0.96626276,0.0337373
11697,Phentolamine,0,1,0,12,Phentolamine increased stimulus-induced overflow in both groups although the increment in overflow was greater in the epinephrine-treated group.,2886572_8,-1,-1,-1,11697,-1,0.9993574,0.00064265955
11699,phentolamine,5,6,32,44,"Furthermore, data obtained with phentolamine alone do not suggest alpha-adrenoceptor desensitization as the cause of the enhanced neurotransmitter overflow after epinephrine treatment.",2886572_11,-1,-1,-1,11699,-1,0.9993351,0.0006648111
11701,prolactinomas,10,11,91,104,"Immunohistochemical, electron microscopic and morphometric studies of estrogen-induced rat prolactinomas after bromocriptine treatment.",2887062_0,-1,-1,-1,11701,-1,0.010393139,0.9896068
11706,h,26,27,194,195,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,-1,-1,-1,11706,-1,0.20863147,0.79136854
11707,h,29,30,202,203,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,-1,-1,-1,11707,-1,0.13213181,0.8678682
11709,body weight,38,40,249,260,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,-1,-1,-1,11709,-1,0.39953968,0.60046035
11710,h,1,2,4,5,"One h after treatment, serum prolactin levels decreased markedly.",2887062_2,-1,-1,-1,11710,-1,0.29216322,0.7078368
11713,h,2,3,5,6,"At 6 h after injection, serum prolactin levels were still considerably lower than in controls.",2887062_6,-1,-1,-1,11713,-1,0.2580828,0.74191713
11716,h,13,14,87,88,"However, only secretory granules showed the positive reaction products for prolactin 6 h after bromocriptine treatment of the adenoma cells.",2887062_9,-1,-1,-1,11716,-1,0.3591403,0.6408597
11718,adenoma,19,20,126,133,"However, only secretory granules showed the positive reaction products for prolactin 6 h after bromocriptine treatment of the adenoma cells.",2887062_9,-1,-1,-1,11718,-1,0.0071297856,0.9928703
11721,respiratory paralysis,7,9,49,70,GABA involvement in naloxone induced reversal of respiratory paralysis produced by thiopental.,2893236_0,-1,-1,-1,11721,-1,0.002824299,0.9971757
11722,thiopental,11,12,83,93,GABA involvement in naloxone induced reversal of respiratory paralysis produced by thiopental.,2893236_0,-1,-1,-1,11722,-1,0.99928856,0.00071136525
11723,respiratory paralysis,7,9,37,58,"No agent is yet available to reverse respiratory paralysis produced by CNS depressants, such as general anesthetics.",2893236_1,-1,-1,-1,11723,-1,0.0035100335,0.99648994
11724,CNS depressants,11,13,71,86,"No agent is yet available to reverse respiratory paralysis produced by CNS depressants, such as general anesthetics.",2893236_1,-1,-1,-1,11724,-1,0.8935278,0.10647222
11726,respiratory paralysis,5,7,32,53,In this study naloxone reversed respiratory paralysis induced by thiopental in rats.,2893236_2,-1,-1,-1,11726,-1,0.0029358156,0.9970642
11727,thiopental,9,10,65,75,In this study naloxone reversed respiratory paralysis induced by thiopental in rats.,2893236_2,-1,-1,-1,11727,-1,0.99936277,0.0006372723
11728,thiopental,5,6,15,25,"25 mg/kg, i.v. thiopental produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem.",2893236_3,-1,-1,-1,11728,-1,0.9993662,0.00063377596
11729,GABA,14,15,91,95,"25 mg/kg, i.v. thiopental produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem.",2893236_3,-1,-1,-1,11729,-1,0.99901974,0.0009801917
11733,thiosemicarbazide,4,5,26,43,Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.,2893236_4,-1,-1,-1,11733,-1,0.9991328,0.0008671853
11734,thiopental,20,21,139,149,Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.,2893236_4,-1,-1,-1,11734,-1,0.9993426,0.0006573513
11735,thiopental,5,6,15,25,"50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.",2893236_5,-1,-1,-1,11735,-1,0.9993718,0.0006282138
11736,respiratory arrest,7,9,35,53,"50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.",2893236_5,-1,-1,-1,11736,-1,0.0033117647,0.9966883
11737,GABA,13,14,79,83,"50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.",2893236_5,-1,-1,-1,11737,-1,0.998979,0.0010210392
11739,amino acids,29,31,170,181,"50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.",2893236_5,-1,-1,-1,11739,-1,0.9860476,0.013952324
11741,respiratory paralysis,9,11,36,57,"Naloxone (2.5 mg/kg, i.v.) reversed respiratory paralysis, glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum.",2893236_6,-1,-1,-1,11741,-1,0.003860335,0.9961397
11743,GABA,14,15,73,77,"Naloxone (2.5 mg/kg, i.v.) reversed respiratory paralysis, glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum.",2893236_6,-1,-1,-1,11743,-1,0.9986339,0.0013660468
11745,respiratory paralysis,5,7,37,58,These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action.,2893236_7,-1,-1,-1,11745,-1,0.0031252736,0.9968747
11746,thiopental,9,10,71,81,These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action.,2893236_7,-1,-1,-1,11746,-1,0.9993926,0.00060731976
11747,GABA,12,13,95,99,These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action.,2893236_7,-1,-1,-1,11747,-1,0.9985837,0.0014162953
11752,mg,8,9,45,47,Intravenous administration of diazepam (1-30 mg kg-1) produced a dose-dependent decrease in both the mean arterial pressure and the heart rate.,2894433_2,-1,-1,-1,11752,-1,0.8969384,0.103061624
11760,chloride channels,25,27,171,188,"However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).",2894433_5,-1,-1,-1,11760,-1,0.92017645,0.079823576
11763,lupus erythematosus,1,3,22,41,Sulfasalazine-induced lupus erythematosus.,2894766_0,-1,-1,-1,11763,-1,0.0027884275,0.99721164
11764,Pneumonitis,0,1,0,11,"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.",2894766_1,-1,-1,-1,11764,-1,0.0026960135,0.99730396
11765,pleural effusions,3,5,23,40,"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.",2894766_1,-1,-1,-1,11765,-1,0.003623513,0.99637645
11766,tamponade,10,11,80,89,"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.",2894766_1,-1,-1,-1,11766,-1,0.019806901,0.9801931
11768,ulcerative colitis,29,31,213,231,"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.",2894766_1,-1,-1,-1,11768,-1,0.004366566,0.9956334
11771,lupus,8,9,59,64,"It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.",2894766_3,-1,-1,-1,11771,-1,0.0026626408,0.9973374
11772,serositis,13,14,88,97,"It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.",2894766_3,-1,-1,-1,11772,-1,0.003658793,0.99634117
11773,pulmonary parenchymal involvement,15,18,102,135,"It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.",2894766_3,-1,-1,-1,11773,-1,0.0035004583,0.99649954
11774,joint symptoms,22,24,154,168,"It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.",2894766_3,-1,-1,-1,11774,-1,0.0032094794,0.99679047
11776,inflammatory bowel disease,8,11,56,82,Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced lupus syndrome.,2894766_4,-1,-1,-1,11776,-1,0.0027468605,0.9972531
11777,lupus syndrome,19,21,137,151,Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced lupus syndrome.,2894766_4,-1,-1,-1,11777,-1,0.0024965473,0.99750346
11779,hypokalaemia,4,5,27,39,Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.,28952_0,-1,-1,-1,11779,-1,0.0049687284,0.99503124
11780,chlorthalidone,6,7,47,61,Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.,28952_0,-1,-1,-1,11780,-1,0.99932003,0.00067995297
11781,essential hypertension,11,13,94,116,Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.,28952_0,-1,-1,-1,11781,-1,0.0060381256,0.9939619
11784,hypokalaemia,9,10,61,73,"To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.",28952_1,-1,-1,-1,11784,-1,0.010144594,0.9898554
11785,diuretic,16,17,111,119,"To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.",28952_1,-1,-1,-1,11785,-1,0.99880266,0.0011973024
11786,essential hypertension,27,29,183,205,"To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.",28952_1,-1,-1,-1,11786,-1,0.0056999233,0.9943
11787,hypokalaemia,32,33,220,232,"To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.",28952_1,-1,-1,-1,11787,-1,0.008193984,0.99180603
11788,diuretic,36,37,250,258,"To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.",28952_1,-1,-1,-1,11788,-1,0.9986318,0.001368237
11789,Chlorthalidone,0,1,0,14,Chlorthalidone (50 mg daily) was given for 14 days.,28952_2,-1,-1,-1,11789,-1,0.9992465,0.000753532
11790,mg,3,4,19,21,Chlorthalidone (50 mg daily) was given for 14 days.,28952_2,-1,-1,-1,11790,-1,0.9547714,0.045228582
11792,K,11,12,58,59,All patients had a normal initial total body potassium (40K).,28952_4,-1,-1,-1,11792,-1,0.99229443,0.0077055725
11793,bromide,6,7,34,41,"The electrolyte balances, weight, bromide space, plasma renin activity, and aldosterone secretion rate were measured.",28952_5,-1,-1,-1,11793,-1,0.99418056,0.005819457
11805,buspirone,5,6,27,36,"The novel anxiolytic drug, buspirone, reverses catalepsy induced by haloperidol.",2907585_1,-1,-1,-1,11805,-1,0.99919075,0.00080921216
11808,buspirone,6,7,41,50,A series of aryl-piperazine analogues of buspirone and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy.,2907585_2,-1,-1,-1,11808,-1,0.99918324,0.0008167743
11809,5-hydroxytryptaminergic agonists,9,11,61,93,A series of aryl-piperazine analogues of buspirone and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy.,2907585_2,-1,-1,-1,11809,-1,0.98747396,0.012526057
11813,5-HT,5,6,30,34,Drugs with affinity for other 5-HT receptors or weak affinity were ineffective.,2907585_4,-1,-1,-1,11813,-1,0.9953277,0.004672237
11814,5-HT,5,6,36,40,"However, inhibition of postsynaptic 5-HT receptors neither inhibited nor potentiated reversal of catalepsy and leaves open the question as to the site or mechanism for this effect.",2907585_5,-1,-1,-1,11814,-1,0.9973514,0.0026485792
11816,Glycopyrronium,0,1,0,14,Glycopyrronium requirements for antagonism of the muscarinic side effects of edrophonium.,2917114_0,-1,-1,-1,11816,-1,0.9991385,0.0008615457
11817,edrophonium,10,11,77,88,Glycopyrronium requirements for antagonism of the muscarinic side effects of edrophonium.,2917114_0,-1,-1,-1,11817,-1,0.99922955,0.0007704136
11818,glycopyrronium,13,14,70,84,"We have compared, in 60 adult patients, the cardiovascular effects of glycopyrronium 5 micrograms kg-1 and 10 micrograms kg-1 given either simultaneously or 1 min before edrophonium 1 mg kg-1.",2917114_1,-1,-1,-1,11818,-1,0.9993136,0.00068635587
11819,edrophonium,28,29,170,181,"We have compared, in 60 adult patients, the cardiovascular effects of glycopyrronium 5 micrograms kg-1 and 10 micrograms kg-1 given either simultaneously or 1 min before edrophonium 1 mg kg-1.",2917114_1,-1,-1,-1,11819,-1,0.99934953,0.0006504023
11820,mg,30,31,184,186,"We have compared, in 60 adult patients, the cardiovascular effects of glycopyrronium 5 micrograms kg-1 and 10 micrograms kg-1 given either simultaneously or 1 min before edrophonium 1 mg kg-1.",2917114_1,-1,-1,-1,11820,-1,0.97569025,0.024309767
11821,P,9,10,63,64,Significant differences between the four groups were detected (P less than 0.001).,2917114_2,-1,-1,-1,11821,-1,0.20008442,0.79991555
11822,glycopyrronium,2,3,7,21,"Use of glycopyrronium 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-induced bradycardias.",2917114_4,-1,-1,-1,11822,-1,0.9992563,0.0007436164
11823,edrophonium,17,18,110,121,"Use of glycopyrronium 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-induced bradycardias.",2917114_4,-1,-1,-1,11823,-1,0.99934214,0.00065789756
11824,bradycardias,26,27,177,189,"Use of glycopyrronium 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-induced bradycardias.",2917114_4,-1,-1,-1,11824,-1,0.0021841219,0.99781585
11825,glycopyrronium,4,5,17,31,This low dose of glycopyrronium provided good control of oropharyngeal secretions.,2917114_5,-1,-1,-1,11825,-1,0.9992874,0.00071262394
11828,folate,17,18,96,102,"Chronic carbamazepine treatment in the rat: efficacy, toxicity, and effect on plasma and tissue folate concentrations.",2924746_0,-1,-1,-1,11828,-1,0.9975922,0.002407796
11829,Folate,0,1,0,6,Folate depletion has often been a problem in chronic antiepileptic drug (AED) therapy.,2924746_1,-1,-1,-1,11829,-1,0.9977029,0.002297103
11831,CBZ,2,3,15,18,"Carbamazepine (CBZ), a commonly used AED, has been implicated in some clinical studies.",2924746_2,-1,-1,-1,11831,-1,0.99856037,0.0014396735
11832,CBZ,11,12,60,63,A rat model was developed to examine the effects of chronic CBZ treatment on folate concentrations in the rat.,2924746_3,-1,-1,-1,11832,-1,0.99907994,0.0009199914
11833,folate,14,15,77,83,A rat model was developed to examine the effects of chronic CBZ treatment on folate concentrations in the rat.,2924746_3,-1,-1,-1,11833,-1,0.9981805,0.0018195066
11834,propylene glycol,12,14,58,74,"In the course of developing this model, a common vehicle, propylene glycol, by itself in high doses, was found to exhibit protective properties against induced seizures and inhibited weight gain.",2924746_4,-1,-1,-1,11834,-1,0.99920315,0.00079692324
11836,weight gain,32,34,183,194,"In the course of developing this model, a common vehicle, propylene glycol, by itself in high doses, was found to exhibit protective properties against induced seizures and inhibited weight gain.",2924746_4,-1,-1,-1,11836,-1,0.0055838716,0.9944161
11837,hexafluorodiethyl ether,3,5,20,43,Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).,2924746_5,-1,-1,-1,11837,-1,0.9974131,0.002586916
11838,HFDE,6,7,45,49,Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).,2924746_5,-1,-1,-1,11838,-1,0.99633104,0.0036690268
11839,CBZ,20,21,115,118,Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).,2924746_5,-1,-1,-1,11839,-1,0.99895716,0.001042839
11841,CBZ,3,4,23,26,Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment.,2924746_6,-1,-1,-1,11841,-1,0.9990822,0.0009177593
11842,h,10,11,60,61,Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment.,2924746_6,-1,-1,-1,11842,-1,0.77771837,0.22228165
11844,weight gain,30,32,182,193,Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment.,2924746_6,-1,-1,-1,11844,-1,0.008635053,0.99136496
11845,CBZ,1,2,4,7,"The CBZ levels measured in plasma and brain of these animals, however, were below those normally considered protective.",2924746_7,-1,-1,-1,11845,-1,0.9989617,0.001038261
11846,CBZ,3,4,20,23,"This treatment with CBZ had no apparent adverse effect on folate concentrations in the rat, and, indeed, the folate concentration increased in liver after 6 weeks of treatment and in plasma at 8 weeks of treatment.",2924746_8,-1,-1,-1,11846,-1,0.9990501,0.00094986113
11847,folate,10,11,58,64,"This treatment with CBZ had no apparent adverse effect on folate concentrations in the rat, and, indeed, the folate concentration increased in liver after 6 weeks of treatment and in plasma at 8 weeks of treatment.",2924746_8,-1,-1,-1,11847,-1,0.998412,0.0015880234
11848,folate,21,22,109,115,"This treatment with CBZ had no apparent adverse effect on folate concentrations in the rat, and, indeed, the folate concentration increased in liver after 6 weeks of treatment and in plasma at 8 weeks of treatment.",2924746_8,-1,-1,-1,11848,-1,0.99822897,0.0017710337
11849,myocardial ischemia,1,3,21,40,Dipyridamole-induced myocardial ischemia.,2950248_0,-1,-1,-1,11849,-1,0.0033072727,0.9966928
11850,ischemic,2,3,11,19,Angina and ischemic electrocardiographic changes occurred after administration of oral dipyridamole in four patients awaiting urgent myocardial revascularization procedures.,2950248_1,-1,-1,-1,11850,-1,0.0028313904,0.9971686
11853,myocardial ischemia,21,23,141,160,"To our knowledge, this has not previously been reported as a side effect of preoperative dipyridamole therapy, although dipyridamole-induced myocardial ischemia has been demonstrated to occur in animals and humans with coronary artery disease.",2950248_2,-1,-1,-1,11853,-1,0.0028779674,0.997122
11854,coronary artery disease,33,36,219,242,"To our knowledge, this has not previously been reported as a side effect of preoperative dipyridamole therapy, although dipyridamole-induced myocardial ischemia has been demonstrated to occur in animals and humans with coronary artery disease.",2950248_2,-1,-1,-1,11854,-1,0.003225537,0.9967745
11856,atrial natriuretic factor,5,8,42,67,Inhibition of sympathoadrenal activity by atrial natriuretic factor in dogs.,2951327_0,-1,-1,-1,11856,-1,0.99715483,0.0028451248
11860,p,37,38,155,156,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,-1,-1,-1,11860,-1,0.3055563,0.69444364
11861,p,48,49,184,185,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,-1,-1,-1,11861,-1,0.2593086,0.74069136
11862,p,61,62,217,218,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,-1,-1,-1,11862,-1,0.21916154,0.78083843
11865,contrast,92,93,381,389,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,-1,-1,-1,11865,-1,0.053257108,0.9467429
11867,hydralazine,98,99,427,438,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,-1,-1,-1,11867,-1,0.9989312,0.0010687098
11870,atrial natriuretic factor,19,22,106,131,"The release rate of epinephrine (control, 6.7 +/- 0.6 ng/kg/min) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 +/- 5% of control (p less than 0.001) during 0.1 microgram/kg/min and to 63 +/- 5% (0.1 greater than p greater than 0.05) or 95 +/- 13% (not significant) during 0.3 or 1.0 microgram/kg/min.",2951327_4,-1,-1,-1,11870,-1,0.9971942,0.0028057522
11871,p,34,35,170,171,"The release rate of epinephrine (control, 6.7 +/- 0.6 ng/kg/min) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 +/- 5% of control (p less than 0.001) during 0.1 microgram/kg/min and to 63 +/- 5% (0.1 greater than p greater than 0.05) or 95 +/- 13% (not significant) during 0.3 or 1.0 microgram/kg/min.",2951327_4,-1,-1,-1,11871,-1,0.34203288,0.6579671
11872,p,53,54,252,253,"The release rate of epinephrine (control, 6.7 +/- 0.6 ng/kg/min) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 +/- 5% of control (p less than 0.001) during 0.1 microgram/kg/min and to 63 +/- 5% (0.1 greater than p greater than 0.05) or 95 +/- 13% (not significant) during 0.3 or 1.0 microgram/kg/min.",2951327_4,-1,-1,-1,11872,-1,0.60090816,0.3990918
11873,atrial natriuretic factor,6,9,47,72,Steady state arterial plasma concentrations of atrial natriuretic factor were 39 +/- 10 pg/ml (n = 6) during infusions of saline and 284 +/- 24 pg/ml (n = 6) and 1520 +/- 300 pg/ml (n = 9) during 0.03 and 0.1 microgram/kg/min infusions of the factor.(ABSTRACT TRUNCATED AT 250 WORDS),2951327_5,-1,-1,-1,11873,-1,0.9969741,0.0030258622
11874,n,16,17,95,96,Steady state arterial plasma concentrations of atrial natriuretic factor were 39 +/- 10 pg/ml (n = 6) during infusions of saline and 284 +/- 24 pg/ml (n = 6) and 1520 +/- 300 pg/ml (n = 9) during 0.03 and 0.1 microgram/kg/min infusions of the factor.(ABSTRACT TRUNCATED AT 250 WORDS),2951327_5,-1,-1,-1,11874,-1,0.3209501,0.6790499
11875,n,31,32,151,152,Steady state arterial plasma concentrations of atrial natriuretic factor were 39 +/- 10 pg/ml (n = 6) during infusions of saline and 284 +/- 24 pg/ml (n = 6) and 1520 +/- 300 pg/ml (n = 9) during 0.03 and 0.1 microgram/kg/min infusions of the factor.(ABSTRACT TRUNCATED AT 250 WORDS),2951327_5,-1,-1,-1,11875,-1,0.30423227,0.69576776
11876,n,42,43,182,183,Steady state arterial plasma concentrations of atrial natriuretic factor were 39 +/- 10 pg/ml (n = 6) during infusions of saline and 284 +/- 24 pg/ml (n = 6) and 1520 +/- 300 pg/ml (n = 9) during 0.03 and 0.1 microgram/kg/min infusions of the factor.(ABSTRACT TRUNCATED AT 250 WORDS),2951327_5,-1,-1,-1,11876,-1,0.27889192,0.7211081
11877,iopentol,3,4,23,31,"Selective injection of iopentol, iohexol and metrizoate into the left coronary artery of the dog.",2980315_0,-1,-1,-1,11877,-1,0.9991781,0.0008218587
11878,iohexol,5,6,33,40,"Selective injection of iopentol, iohexol and metrizoate into the left coronary artery of the dog.",2980315_0,-1,-1,-1,11878,-1,0.9993481,0.0006518824
11879,metrizoate,7,8,45,55,"Selective injection of iopentol, iohexol and metrizoate into the left coronary artery of the dog.",2980315_0,-1,-1,-1,11879,-1,0.99914527,0.0008547687
11880,ventricular fibrillation,2,4,13,37,Induction of ventricular fibrillation and decrease of aortic pressure.,2980315_1,-1,-1,-1,11880,-1,0.0049402374,0.9950598
11881,iopentol,14,15,88,96,"In twenty beagle dogs selective injections were made into the left coronary artery with iopentol, iohexol and metrizoate in doses of 4 ml, 8 ml and 16 ml.",2980315_2,-1,-1,-1,11881,-1,0.9992399,0.0007600899
11882,iohexol,16,17,98,105,"In twenty beagle dogs selective injections were made into the left coronary artery with iopentol, iohexol and metrizoate in doses of 4 ml, 8 ml and 16 ml.",2980315_2,-1,-1,-1,11882,-1,0.9993955,0.00060445524
11883,metrizoate,18,19,110,120,"In twenty beagle dogs selective injections were made into the left coronary artery with iopentol, iohexol and metrizoate in doses of 4 ml, 8 ml and 16 ml.",2980315_2,-1,-1,-1,11883,-1,0.9991841,0.00081592216
11884,iopentol,1,2,11,19,"Thirty-six iopentol injections, 35 iohexol injections and 37 metrizoate injections were made.",2980315_3,-1,-1,-1,11884,-1,0.9992453,0.0007547624
11885,iohexol,5,6,35,42,"Thirty-six iopentol injections, 35 iohexol injections and 37 metrizoate injections were made.",2980315_3,-1,-1,-1,11885,-1,0.9994332,0.000566789
11886,metrizoate,9,10,61,71,"Thirty-six iopentol injections, 35 iohexol injections and 37 metrizoate injections were made.",2980315_3,-1,-1,-1,11886,-1,0.9992118,0.00078819797
11887,ventricular fibrillation,2,4,15,39,Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).,2980315_4,-1,-1,-1,11887,-1,0.002683135,0.9973169
11888,p,8,9,66,67,Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).,2980315_4,-1,-1,-1,11888,-1,0.26849914,0.73150086
11889,iopentol,14,15,90,98,Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).,2980315_4,-1,-1,-1,11889,-1,0.99922264,0.00077734014
11890,iohexol,20,21,108,115,Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).,2980315_4,-1,-1,-1,11890,-1,0.99942625,0.00057380635
11891,metrizoate,27,28,132,142,Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).,2980315_4,-1,-1,-1,11891,-1,0.9992015,0.00079857133
11892,Iopentol,0,1,0,8,Iopentol and iohexol also produced significantly less decrease in aortic blood pressure than metrizoate at the different doses.,2980315_5,-1,-1,-1,11892,-1,0.9991991,0.00080094906
11893,iohexol,2,3,13,20,Iopentol and iohexol also produced significantly less decrease in aortic blood pressure than metrizoate at the different doses.,2980315_5,-1,-1,-1,11893,-1,0.9993819,0.00061803265
11894,metrizoate,13,14,93,103,Iopentol and iohexol also produced significantly less decrease in aortic blood pressure than metrizoate at the different doses.,2980315_5,-1,-1,-1,11894,-1,0.99925166,0.0007482957
11896,nephrogenic diabetes insipidus,16,19,100,130,It has been suggested that adenylate cyclase inhibition may be important in the development of both nephrogenic diabetes insipidus and hypothyroidism during lithium treatment.,3001299_1,-1,-1,-1,11896,-1,0.0041193455,0.9958806
11900,DDAVP,15,16,96,101,We measured serum thyroxine and urine-concentrating ability (Umax) in response to desmopressin (DDAVP) in 85 patients receiving lithium.,3001299_2,-1,-1,-1,11900,-1,0.9989139,0.0010861491
11904,euthyroid,6,7,32,41,Impaired Umax was found in both euthyroid and hypothyroid patients while some hypothyroid patients concentrated their urine well.,3001299_4,-1,-1,-1,11904,-1,0.03439367,0.9656063
11908,isoniazid neuropathy,6,8,47,67,Remodelling of nerve structure in experimental isoniazid neuropathy in the rat.,3015327_0,-1,-1,-1,11908,-1,0.87629986,0.12370014
11912,ACTH,3,4,41,45,Nitroprusside-induced hypotension evokes ACTH secretion which is primarily mediated by enhanced secretion of immunoreactive corticotropin-releasing factor (irCRF) into the hypophysial-portal circulation.,3015567_1,-1,-1,-1,11912,-1,0.99585116,0.004148889
11913,arginine vasopressin,5,7,40,60,Portal plasma concentrations of neither arginine vasopressin nor oxytocin are significantly altered in this paradigm.,3015567_2,-1,-1,-1,11913,-1,0.9989604,0.0010396567
11916,arginine vasopressin,34,36,231,251,"Application of a delayed feedback signal, in the form of a 2-h systemic corticosterone infusion in urethane-anesthetized rats with pharmacological blockade of glucocorticoid synthesis, is without effect on the resting secretion of arginine vasopressin and oxytocin at any corticosterone feedback dose tested.",3015567_3,-1,-1,-1,11916,-1,0.99892503,0.0010749323
11924,delta 9-tetrahydrocannabinol,6,8,50,78,Noradrenergic involvement in catalepsy induced by delta 9-tetrahydrocannabinol.,3031535_0,-1,-1,-1,11924,-1,0.9986658,0.0013342135
11925,delta 9-tetrahydrocannabinol,15,17,95,123,"In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats.",3031535_1,-1,-1,-1,11925,-1,0.9989355,0.001064523
11926,THC,18,19,125,128,"In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats.",3031535_1,-1,-1,-1,11926,-1,0.9985671,0.0014328628
11928,6-OHDA,28,29,182,188,"In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats.",3031535_1,-1,-1,-1,11928,-1,0.9967824,0.003217533
11930,6-OHDA,34,35,214,220,"In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats.",3031535_1,-1,-1,-1,11930,-1,0.9966546,0.003345351
11931,THC,4,5,29,32,"The cataleptogenic effect of THC was significantly reduced in rats treated with 6-OHDA and in rats with lesions of the locus coeruleus but not in rats treated with desipramine and 6-OHDA, as compared with control rats.",3031535_2,-1,-1,-1,11931,-1,0.9989588,0.0010411176
11932,6-OHDA,12,13,80,86,"The cataleptogenic effect of THC was significantly reduced in rats treated with 6-OHDA and in rats with lesions of the locus coeruleus but not in rats treated with desipramine and 6-OHDA, as compared with control rats.",3031535_2,-1,-1,-1,11932,-1,0.9985911,0.0014088476
11934,6-OHDA,30,31,180,186,"The cataleptogenic effect of THC was significantly reduced in rats treated with 6-OHDA and in rats with lesions of the locus coeruleus but not in rats treated with desipramine and 6-OHDA, as compared with control rats.",3031535_2,-1,-1,-1,11934,-1,0.9982305,0.0017694581
11937,6-OHDA,18,19,121,127,"On the contrary, the cataleptogenic effect of haloperidol was significantly reduced in rats treated with desipramine and 6-OHDA but not in rats treated with 6-OHDA or in rats with lesions of the locus coeruleus.",3031535_3,-1,-1,-1,11937,-1,0.9984114,0.001588564
11938,6-OHDA,25,26,157,163,"On the contrary, the cataleptogenic effect of haloperidol was significantly reduced in rats treated with desipramine and 6-OHDA but not in rats treated with 6-OHDA or in rats with lesions of the locus coeruleus.",3031535_3,-1,-1,-1,11938,-1,0.99803406,0.001965942
11940,THC,17,18,118,121,"These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by THC, whereas dopaminergic neurons are important in catalepsy induced by haloperidol.",3031535_4,-1,-1,-1,11940,-1,0.9988901,0.0011099402
11943,azelastine,12,13,87,97,"Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis.",3057041_0,-1,-1,-1,11943,-1,0.99906486,0.0009351528
11944,chlorpheniramine,14,15,99,115,"Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis.",3057041_0,-1,-1,-1,11944,-1,0.99931455,0.00068540184
11945,spring allergic rhinitis,22,25,149,173,"Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis.",3057041_0,-1,-1,-1,11945,-1,0.007331185,0.99266875
11946,Azelastine,0,1,0,10,"Azelastine, a novel antiallergic medication, was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter, double-blind, multiple-dose, parallel-groups study.",3057041_1,-1,-1,-1,11946,-1,0.99899656,0.0010034532
11947,chlorpheniramine maleate,10,12,63,87,"Azelastine, a novel antiallergic medication, was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter, double-blind, multiple-dose, parallel-groups study.",3057041_1,-1,-1,-1,11947,-1,0.9990194,0.0009806084
11948,spring allergic rhinitis,22,25,144,168,"Azelastine, a novel antiallergic medication, was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter, double-blind, multiple-dose, parallel-groups study.",3057041_1,-1,-1,-1,11948,-1,0.008624986,0.991375
11949,spring allergic rhinitis,19,22,87,111,"Subjects ranged in age from 18 to 60 years of age and had at least a 2-year history of spring allergic rhinitis, confirmed by positive skin test to spring aeroallergens.",3057041_3,-1,-1,-1,11949,-1,0.010066652,0.9899333
11950,azelastine,8,9,45,55,"Medications were given four times daily; the azelastine groups received 0.5, 1.0, or 2.0 mg in the morning and evening with placebo in the early and late afternoon; the chlorpheniramine group received 4.0 mg four times daily.",3057041_4,-1,-1,-1,11950,-1,0.9991672,0.00083287555
11951,mg,17,18,89,91,"Medications were given four times daily; the azelastine groups received 0.5, 1.0, or 2.0 mg in the morning and evening with placebo in the early and late afternoon; the chlorpheniramine group received 4.0 mg four times daily.",3057041_4,-1,-1,-1,11951,-1,0.9895857,0.010414299
11952,chlorpheniramine,33,34,169,185,"Medications were given four times daily; the azelastine groups received 0.5, 1.0, or 2.0 mg in the morning and evening with placebo in the early and late afternoon; the chlorpheniramine group received 4.0 mg four times daily.",3057041_4,-1,-1,-1,11952,-1,0.9992499,0.0007500842
11953,mg,37,38,205,207,"Medications were given four times daily; the azelastine groups received 0.5, 1.0, or 2.0 mg in the morning and evening with placebo in the early and late afternoon; the chlorpheniramine group received 4.0 mg four times daily.",3057041_4,-1,-1,-1,11953,-1,0.98647887,0.013521142
11954,body weights,3,5,13,25,"Vital signs, body weights, serum chemistry values, complete blood cell counts, urine studies, and electrocardiograms were obtained for each subject and compared among groups.",3057041_8,-1,-1,-1,11954,-1,0.117879204,0.8821208
11955,azelastine,10,11,68,78,Symptoms relief in the group receiving the highest concentration of azelastine (2.0 mg twice daily) was statistically greater than in the placebo group during all weeks of the study.,3057041_9,-1,-1,-1,11955,-1,0.9992545,0.00074543233
11956,mg,13,14,84,86,Symptoms relief in the group receiving the highest concentration of azelastine (2.0 mg twice daily) was statistically greater than in the placebo group during all weeks of the study.,3057041_9,-1,-1,-1,11956,-1,0.9473919,0.052608073
11957,azelastine,3,4,15,25,Lower doses of azelastine were statistically more effective than placebo only during portions of the first 3 weeks of the study.,3057041_10,-1,-1,-1,11957,-1,0.9992255,0.0007745049
11958,contrast,1,2,3,11,"In contrast, although the chlorpheniramine group did have fewer symptoms than the placebo group during the study, the difference never reached statistical significance during any week of the study.",3057041_11,-1,-1,-1,11958,-1,0.2647553,0.7352447
11959,chlorpheniramine,5,6,26,42,"In contrast, although the chlorpheniramine group did have fewer symptoms than the placebo group during the study, the difference never reached statistical significance during any week of the study.",3057041_11,-1,-1,-1,11959,-1,0.99929965,0.000700381
11960,Drowsiness,0,1,0,10,Drowsiness and altered taste perception were increased significantly over placebo only in the high-dose azelastine group.,3057041_13,-1,-1,-1,11960,-1,0.00242253,0.9975775
11961,altered taste perception,2,5,15,39,Drowsiness and altered taste perception were increased significantly over placebo only in the high-dose azelastine group.,3057041_13,-1,-1,-1,11961,-1,0.006503916,0.99349606
11962,azelastine,14,15,104,114,Drowsiness and altered taste perception were increased significantly over placebo only in the high-dose azelastine group.,3057041_13,-1,-1,-1,11962,-1,0.9992055,0.0007944673
11963,Azelastine,0,1,0,10,"Azelastine appears to be a safe, efficacious medication for seasonal allergic rhinitis.",3057041_14,-1,-1,-1,11963,-1,0.9991818,0.0008182182
11964,seasonal allergic rhinitis,10,13,60,86,"Azelastine appears to be a safe, efficacious medication for seasonal allergic rhinitis.",3057041_14,-1,-1,-1,11964,-1,0.0067964243,0.9932035
11965,renal insufficiency,3,5,35,54,Reversibility of captopril-induced renal insufficiency after prolonged use in an unusual case of renovascular hypertension.,3070035_0,-1,-1,-1,11965,-1,0.0023786067,0.99762136
11966,renovascular hypertension,13,15,97,122,Reversibility of captopril-induced renal insufficiency after prolonged use in an unusual case of renovascular hypertension.,3070035_0,-1,-1,-1,11966,-1,0.0030177643,0.9969823
11968,solitary kidney,14,16,75,90,"We report a case of severe hypertension with an occluded renal artery to a solitary kidney, who developed sudden deterioration of renal function following treatment with captopril.",3070035_1,-1,-1,-1,11968,-1,0.0075086514,0.9924913
11969,sudden deterioration of renal function,19,24,106,144,"We report a case of severe hypertension with an occluded renal artery to a solitary kidney, who developed sudden deterioration of renal function following treatment with captopril.",3070035_1,-1,-1,-1,11969,-1,0.0045603327,0.9954397
11972,renal failure,5,7,50,63,This indicates reversibility in captopril-induced renal failure even after its prolonged use and suggests that no organic damage occurs to glomerular arterioles following chronic ACE inhibition.,3070035_3,-1,-1,-1,11972,-1,0.0022142977,0.9977857
11973,CoA,1,2,4,7,HMG CoA reductase inhibitors.,3076126_0,-1,-1,-1,11973,-1,0.9962333,0.003766666
11976,CoA reductase inhibitors,17,20,107,131,Lovastatin and simvastatin are the 2 best-known members of the class of hypolipidaemic agents known as HMG CoA reductase inhibitors.,3076126_2,-1,-1,-1,11976,-1,0.9632346,0.036765344
11981,creatine kinase,3,5,20,35,Minor elevations of creatine kinase levels are reported in about 5% of patients.,3076126_11,-1,-1,-1,11981,-1,0.9979247,0.002075348
11982,myoglobinuria,7,8,40,53,"Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.",3076126_12,-1,-1,-1,11982,-1,0.0042916806,0.99570835
11983,renal failure,15,17,85,98,"Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.",3076126_12,-1,-1,-1,11983,-1,0.0024491304,0.9975509
11985,cyclosporin,31,32,192,203,"Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.",3076126_12,-1,-1,-1,11985,-1,0.99887294,0.0011271032
11986,gemfibrozil,33,34,205,216,"Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.",3076126_12,-1,-1,-1,11986,-1,0.9991284,0.00087161857
11987,niacin,35,36,220,226,"Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.",3076126_12,-1,-1,-1,11987,-1,0.99876785,0.0012322343
11991,hypercholesterolaemia,18,19,112,133,"As wider use confirms their safety profile, they will gain increasing importance in the therapeutic approach to hypercholesterolaemia and its consequences.",3076126_14,-1,-1,-1,11991,-1,0.65337855,0.34662148
11994,RA,6,7,48,50,Twenty-five patients with rheumatoid arthritis (RA) who developed toxicity while taking remission inducing drugs and 30 without toxicity were studied for possible associations with class I and II HLA antigens.,3084782_2,-1,-1,-1,11994,-1,0.0038460682,0.9961539
11997,nephritis,7,8,44,53,"A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.",3084782_3,-1,-1,-1,11997,-1,0.0024485656,0.9975515
11999,Tiopronin,12,13,76,85,"A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.",3084782_3,-1,-1,-1,11999,-1,0.99897206,0.0010279749
12001,gold thiosulphate,30,32,180,197,"A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.",3084782_3,-1,-1,-1,12001,-1,0.99758506,0.002414888
12002,RA,13,14,81,83,Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group.,3084782_4,-1,-1,-1,12002,-1,0.008893017,0.99110705
12003,Tiopronin,17,18,99,108,Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group.,3084782_4,-1,-1,-1,12003,-1,0.9987765,0.0012235414
12004,nephritis,19,20,117,126,Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group.,3084782_4,-1,-1,-1,12004,-1,0.0024708055,0.9975292
12005,contralateral rotation,1,3,10,32,Transient contralateral rotation following unilateral substantia nigra lesion reflects susceptibility of the nigrostriatal system to exhaustion by amphetamine.,3088349_0,-1,-1,-1,12005,-1,0.0144231375,0.9855768
12006,substantia nigra lesion,5,8,54,77,Transient contralateral rotation following unilateral substantia nigra lesion reflects susceptibility of the nigrostriatal system to exhaustion by amphetamine.,3088349_0,-1,-1,-1,12006,-1,0.47130617,0.52869385
12008,6-OHDA,2,3,21,27,"Following unilateral 6-OHDA induced SN lesion, a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling.",3088349_1,-1,-1,-1,12008,-1,0.9982338,0.0017661991
12009,SN lesion,4,6,36,45,"Following unilateral 6-OHDA induced SN lesion, a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling.",3088349_1,-1,-1,-1,12009,-1,0.06329165,0.93670833
12010,contralateral rotation,11,13,69,91,"Following unilateral 6-OHDA induced SN lesion, a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling.",3088349_1,-1,-1,-1,12010,-1,0.06434732,0.9356527
12011,ipsilateral circling,20,22,137,157,"Following unilateral 6-OHDA induced SN lesion, a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling.",3088349_1,-1,-1,-1,12011,-1,0.18237945,0.8176206
12012,contralateral rotation,9,11,47,69,"In order to clarify the nature of this initial contralateral rotation we examined the effect of the duration of recovery period after the lesion, on amphetamine-induced rotational behavior.",3088349_2,-1,-1,-1,12012,-1,0.042289905,0.95771015
12013,rotational behavior,27,29,169,188,"In order to clarify the nature of this initial contralateral rotation we examined the effect of the duration of recovery period after the lesion, on amphetamine-induced rotational behavior.",3088349_2,-1,-1,-1,12013,-1,0.0038353188,0.9961647
12014,contralateral rotation,1,3,5,27,"Such contralateral rotation may result from either degeneration-induced breakdown of the DA pool, or lesion-induced increase of DA turnover in the spared neurons.",3088349_4,-1,-1,-1,12014,-1,0.5663335,0.4336666
12015,DA,11,12,89,91,"Such contralateral rotation may result from either degeneration-induced breakdown of the DA pool, or lesion-induced increase of DA turnover in the spared neurons.",3088349_4,-1,-1,-1,12015,-1,0.99560416,0.0043958845
12016,DA,18,19,128,130,"Such contralateral rotation may result from either degeneration-induced breakdown of the DA pool, or lesion-induced increase of DA turnover in the spared neurons.",3088349_4,-1,-1,-1,12016,-1,0.9953602,0.0046397885
12018,contralateral rotation,29,31,191,213,"A substantial degree of contralateral preference was still evident when amphetamine was administered for the first time 24 days after lesioning, indicating involvement of spared cells in the contralateral rotation.",3088349_5,-1,-1,-1,12018,-1,0.05756397,0.94243604
12020,rotation,26,27,161,169,"However, regardless of the duration of recovery (and irrespective of either lesion volume, amphetamine dose, or post-lesion motor exercise), amphetamine-induced rotation tended to become gradually more ipsilateral as the observation session progressed, and all rats circled ipsilaterally to the lesion in response to further amphetamine injections.",3088349_6,-1,-1,-1,12020,-1,0.008208389,0.9917916
12023,DA,12,13,86,88,These findings suggest that amphetamine has an irreversible effect on the post-lesion DA pool contributing to contralateral rotation.,3088349_7,-1,-1,-1,12023,-1,0.9970156,0.0029844518
12024,contralateral rotation,16,18,110,132,These findings suggest that amphetamine has an irreversible effect on the post-lesion DA pool contributing to contralateral rotation.,3088349_7,-1,-1,-1,12024,-1,0.045529507,0.95447046
12032,hepatocellular injury,8,10,52,73,The results of serum liver function tests suggested hepatocellular injury in 10 (63%); the rest showed a mixed pattern.,3101906_8,-1,-1,-1,12032,-1,0.0037066801,0.99629325
12033,contrast,1,2,3,11,"In contrast, the results of histological examination of the liver often showed evidence of cholestasis.",3101906_9,-1,-1,-1,12033,-1,0.1622876,0.8377124
12035,Allergic,0,1,0,8,Allergic manifestations such as rash and eosinophilia were rare.,3101906_11,-1,-1,-1,12035,-1,0.003974255,0.9960258
12048,sulfonylureas,12,13,87,100,"Drug-induced hepatotoxicity, although common, has been reported only infrequently with sulfonylureas.",3107448_1,-1,-1,-1,12048,-1,0.99818003,0.0018200332
12049,glyburide,1,2,4,13,"For glyburide, a second-generation sulfonylurea, only two brief reports of hepatotoxicity exist.",3107448_2,-1,-1,-1,12049,-1,0.99939454,0.0006054568
12050,sulfonylurea,5,6,35,47,"For glyburide, a second-generation sulfonylurea, only two brief reports of hepatotoxicity exist.",3107448_2,-1,-1,-1,12050,-1,0.9992487,0.00075130997
12052,type II diabetes mellitus,3,7,18,43,Two patients with type II diabetes mellitus developed an acute hepatitis-like syndrome soon after initiation of glyburide therapy.,3107448_3,-1,-1,-1,12052,-1,0.0038268932,0.9961731
12053,glyburide,16,17,112,121,Two patients with type II diabetes mellitus developed an acute hepatitis-like syndrome soon after initiation of glyburide therapy.,3107448_3,-1,-1,-1,12053,-1,0.99941707,0.0005830062
12054,viral infection,6,8,35,50,"There was no serologic evidence of viral infection, and a liver biopsy sample showed a histologic pattern consistent with drug-induced hepatitis.",3107448_4,-1,-1,-1,12054,-1,0.041932505,0.9580675
12056,glyburide,6,7,47,56,Both patients recovered quickly after stopping glyburide therapy and have remained well for a follow-up period of 1 year.,3107448_5,-1,-1,-1,12056,-1,0.99937916,0.0006207869
12057,Glyburide,0,1,0,9,Glyburide can produce an acute hepatitis-like illness in some persons.,3107448_6,-1,-1,-1,12057,-1,0.99942017,0.00057982083
12060,HUS,7,8,50,53,Mitomycin C associated Hemolytic Uremic Syndrome (HUS) is a potentially fatal but uncommon condition that is not yet widely recognised.,3108839_1,-1,-1,-1,12060,-1,0.0029455225,0.99705446
12061,microangiopathic hemolytic anemia,3,6,15,48,"It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.",3108839_2,-1,-1,-1,12061,-1,0.0029249806,0.9970751
12063,progressive renal failure,9,12,71,96,"It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.",3108839_2,-1,-1,-1,12063,-1,0.0026988906,0.99730116
12064,mitomycin C,14,16,113,124,"It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.",3108839_2,-1,-1,-1,12064,-1,0.99918944,0.0008105743
12065,renal failure,1,3,4,17,The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.,3108839_3,-1,-1,-1,12065,-1,0.0026311297,0.9973688
12066,mitomycin C,13,15,65,76,The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.,3108839_3,-1,-1,-1,12066,-1,0.999185,0.0008150045
12067,renal failure,24,26,131,144,The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.,3108839_3,-1,-1,-1,12067,-1,0.0025544844,0.9974456
12068,pulmonary edema,27,29,148,163,The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.,3108839_3,-1,-1,-1,12068,-1,0.0023650427,0.997635
12069,HUS,9,10,54,57,"Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin thrombi, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.",3108839_4,-1,-1,-1,12069,-1,0.004304711,0.99569523
12071,ischemic,24,25,158,166,"Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin thrombi, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.",3108839_4,-1,-1,-1,12071,-1,0.01645187,0.9835481
12072,gastric adenocarcinoma,14,16,82,104,We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.,3108839_6,-1,-1,-1,12072,-1,0.004522327,0.99547774
12073,renal failure,18,20,119,132,We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.,3108839_6,-1,-1,-1,12073,-1,0.0029344552,0.9970656
12075,mitomycin C,26,28,178,189,We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.,3108839_6,-1,-1,-1,12075,-1,0.9990336,0.0009664675
12076,pulmonary edema,31,33,202,217,We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.,3108839_6,-1,-1,-1,12076,-1,0.0026573744,0.99734265
12077,Ketanserin,0,1,0,10,Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.,3115150_0,-1,-1,-1,12077,-1,0.9993747,0.0006252826
12078,muscle rigidity,4,6,52,67,Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.,3115150_0,-1,-1,-1,12078,-1,0.0023431636,0.9976568
12079,ketanserin,3,4,27,37,"Systemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.",3115150_1,-1,-1,-1,12079,-1,0.999419,0.00058104075
12081,muscle rigidity,16,18,128,143,"Systemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.",3115150_1,-1,-1,-1,12081,-1,0.0023710309,0.997629
12084,ketanserin,1,2,16,26,Intraperitoneal ketanserin administration at doses of 0.63 and 2.5 mg/kg prevented the alfentanil-induced increase in electromyographic activity compared with animals pretreated with saline.,3115150_3,-1,-1,-1,12084,-1,0.9994343,0.0005657304
12085,Chlordiazepoxide,0,1,0,16,Chlordiazepoxide at doses up to 10 mg/kg failed to significantly influence the rigidity produced by alfentanil.,3115150_4,-1,-1,-1,12085,-1,0.99907136,0.0009286587
12089,ketanserin,9,10,55,65,"Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone.",3115150_5,-1,-1,-1,12089,-1,0.999416,0.0005840735
12092,ketanserin,3,4,19,29,Rats that received ketanserin and alfentanil exhibited less rearing and exploratory behavior at the end of the 60-min recording period than did animals that received ketanserin alone.,3115150_6,-1,-1,-1,12092,-1,0.9994087,0.00059132447
12094,ketanserin,25,26,166,176,Rats that received ketanserin and alfentanil exhibited less rearing and exploratory behavior at the end of the 60-min recording period than did animals that received ketanserin alone.,3115150_6,-1,-1,-1,12094,-1,0.99937564,0.0006244063
12095,muscle rigidity,11,13,63,78,"These results, in combination with previous work, suggest that muscle rigidity, a clinically relevant side-effect of parenteral narcotic administration, may be partly mediated via serotonergic pathways.",3115150_7,-1,-1,-1,12095,-1,0.0028796087,0.9971204
12096,serotonin antagonists,3,5,25,46,"Pretreatment with type-2 serotonin antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, cardiovascular, and respiratory depression.",3115150_8,-1,-1,-1,12096,-1,0.99797994,0.0020200768
12098,respiratory depression,32,34,227,249,"Pretreatment with type-2 serotonin antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, cardiovascular, and respiratory depression.",3115150_8,-1,-1,-1,12098,-1,0.0049894094,0.9950106
12099,Ro15-1788,6,9,51,60,Antagonism of diazepam-induced sedative effects by Ro15-1788 in patients after surgery under lumbar epidural block.,3120485_0,-1,-1,-1,12099,-1,0.99868387,0.0013161417
12100,Ro15-1788,11,14,52,61,"The aim of this study was to assess the efficacy of Ro15-1788 and a placebo in reversing diazepam-induced effects after surgery under epidural block, and to evaluate the local tolerance and general safety of Ro15-1788.",3120485_2,-1,-1,-1,12100,-1,0.999022,0.0009780286
12101,Ro15-1788,37,40,208,217,"The aim of this study was to assess the efficacy of Ro15-1788 and a placebo in reversing diazepam-induced effects after surgery under epidural block, and to evaluate the local tolerance and general safety of Ro15-1788.",3120485_2,-1,-1,-1,12101,-1,0.999062,0.0009379659
12103,Ro15-1788,5,8,42,51,Antagonism of diazepam-induced effects by Ro15-1788 was investigated postoperatively in a double-blind placebo-controlled trial.,3120485_4,-1,-1,-1,12103,-1,0.9986951,0.0013048893
12106,Ro15-1788,1,4,4,13,The Ro15-1788 group showed a significant improvement in the performance test up to 120 min after administration of the drug.,3120485_7,-1,-1,-1,12106,-1,0.9982158,0.001784196
12107,oral contraception,3,5,23,41,Chorea associated with oral contraception.,3123611_0,-1,-1,-1,12107,-1,0.9925107,0.007489342
12108,chorea,3,4,25,31,Three patients developed chorea while receiving oral contraceptives.,3123611_1,-1,-1,-1,12108,-1,0.0023544692,0.99764556
12110,chorea,5,6,30,36,Two were young patients whose chorea developed long after treatment had been started and disappeared soon after it had been discontinued.,3123611_2,-1,-1,-1,12110,-1,0.0023108567,0.9976891
12111,chorea,6,7,48,54,The third patient had acute amphetamine-induced chorea after prolonged oral contraception.,3123611_3,-1,-1,-1,12111,-1,0.007352345,0.99264765
12112,oral contraception,9,11,71,89,The third patient had acute amphetamine-induced chorea after prolonged oral contraception.,3123611_3,-1,-1,-1,12112,-1,0.9954236,0.00457634
12113,chorea,11,12,71,77,Prolonged administration of female sex hormones is a possible cause of chorea in women who have not previously had chorea or rheumatic fever.,3123611_4,-1,-1,-1,12113,-1,0.0031774004,0.9968226
12114,chorea,19,20,115,121,Prolonged administration of female sex hormones is a possible cause of chorea in women who have not previously had chorea or rheumatic fever.,3123611_4,-1,-1,-1,12114,-1,0.0031093557,0.9968906
12115,rheumatic fever,21,23,125,140,Prolonged administration of female sex hormones is a possible cause of chorea in women who have not previously had chorea or rheumatic fever.,3123611_4,-1,-1,-1,12115,-1,0.0023472805,0.9976527
12118,normocarbia,7,8,52,63,"The animals were mechanically ventilated to achieve normocarbia (PCO2 = 42 +/- 1 mmHg, mean +/- SE).",3125768_3,-1,-1,-1,12118,-1,0.8568291,0.14317085
12119,SE,20,21,96,98,"The animals were mechanically ventilated to achieve normocarbia (PCO2 = 42 +/- 1 mmHg, mean +/- SE).",3125768_3,-1,-1,-1,12119,-1,0.19262587,0.8073742
12123,somatic rigidity,6,8,32,48,"In the five rats that developed somatic rigidity, ICP and CVP increased significantly above baseline (delta ICP 7.5 +/- 1.0 mmHg, delta CVP 5.9 +/- 1.3 mmHg).",3125768_5,-1,-1,-1,12123,-1,0.003109864,0.9968901
12125,metocurine,10,11,70,80,These variables returned to baseline when rigidity was abolished with metocurine.,3125768_6,-1,-1,-1,12125,-1,0.9993698,0.000630202
12129,retinyl acetate,3,5,26,41,Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.,3131282_0,-1,-1,-1,12129,-1,0.99888855,0.0011114394
12130,forestomach carcinogenesis,6,8,45,71,Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.,3131282_0,-1,-1,-1,12130,-1,0.022802457,0.9771976
12131,butylated hydroxyanisole,14,16,103,127,Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.,3131282_0,-1,-1,-1,12131,-1,0.9985946,0.0014053924
12132,retinyl acetate,5,7,34,49,The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.,3131282_1,-1,-1,-1,12132,-1,0.9986356,0.0013643736
12133,RA,8,9,51,53,The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.,3131282_1,-1,-1,-1,12133,-1,0.99752027,0.002479761
12134,butylated hydroxyanisole,11,13,58,82,The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.,3131282_1,-1,-1,-1,12134,-1,0.998629,0.001371093
12135,forestomach tumorigenesis,15,17,101,126,The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.,3131282_1,-1,-1,-1,12135,-1,0.017457815,0.98254216
12136,BHA,19,20,76,79,"Male F344 rats, 5 weeks of age, were maintained on diet containing 1% or 2% BHA by weight and simultaneously on drinking water supplemented with RA at various concentrations (w/v) for 52 weeks.",3131282_2,-1,-1,-1,12136,-1,0.9977806,0.0022194225
12137,drinking water,25,27,112,126,"Male F344 rats, 5 weeks of age, were maintained on diet containing 1% or 2% BHA by weight and simultaneously on drinking water supplemented with RA at various concentrations (w/v) for 52 weeks.",3131282_2,-1,-1,-1,12137,-1,0.9919727,0.008027326
12138,RA,29,30,145,147,"Male F344 rats, 5 weeks of age, were maintained on diet containing 1% or 2% BHA by weight and simultaneously on drinking water supplemented with RA at various concentrations (w/v) for 52 weeks.",3131282_2,-1,-1,-1,12138,-1,0.9981248,0.0018752232
12139,BHA,5,6,19,22,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,-1,-1,-1,12139,-1,0.9974611,0.0025389015
12140,RA,25,26,148,150,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,-1,-1,-1,12140,-1,0.9984743,0.0015256373
12141,P,28,29,166,167,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,-1,-1,-1,12141,-1,0.32583717,0.6741628
12142,forestomach tumors,37,39,211,229,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,-1,-1,-1,12142,-1,0.008857664,0.9911423
12143,squamous cell papilloma,40,43,231,254,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,-1,-1,-1,12143,-1,0.0063117137,0.9936883
12147,BHA,5,6,17,20,"In rats given 1% BHA, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced epithelial hyperplasia.",3131282_4,-1,-1,-1,12147,-1,0.99752396,0.0024760468
12148,RA,7,8,22,24,"In rats given 1% BHA, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced epithelial hyperplasia.",3131282_4,-1,-1,-1,12148,-1,0.9984249,0.0015751177
12149,epithelial hyperplasia,32,34,157,179,"In rats given 1% BHA, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced epithelial hyperplasia.",3131282_4,-1,-1,-1,12149,-1,0.004964765,0.9950353
12151,papillomas,3,4,12,22,"Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.",3131282_5,-1,-1,-1,12151,-1,0.002887367,0.99711263
12152,RA,17,18,64,66,"Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.",3131282_5,-1,-1,-1,12152,-1,0.99840397,0.0015960603
12153,RA,29,30,99,101,"Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.",3131282_5,-1,-1,-1,12153,-1,0.99824834,0.0017516277
12154,RA,0,1,0,2,RA alone did not induce hyperplastic changes in the forestomach.,3131282_6,-1,-1,-1,12154,-1,0.9980301,0.0019698106
12155,RA,4,5,29,31,These findings indicate that RA acted as a co-carcinogen in the BHA forestomach carcinogenesis of the rat.,3131282_7,-1,-1,-1,12155,-1,0.99773645,0.0022635423
12156,BHA forestomach carcinogenesis,11,14,64,94,These findings indicate that RA acted as a co-carcinogen in the BHA forestomach carcinogenesis of the rat.,3131282_7,-1,-1,-1,12156,-1,0.13696925,0.86303073
12158,mitomycin C,14,16,95,106,"A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following doxorubicin.",3137399_0,-1,-1,-1,12158,-1,0.99915457,0.00084538554
12159,MMC,17,18,108,111,"A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following doxorubicin.",3137399_0,-1,-1,-1,12159,-1,0.9979115,0.002088461
12162,cardiac failure,5,7,30,45,One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.,3137399_6,-1,-1,-1,12162,-1,0.0021790306,0.997821
12163,mg,9,10,55,57,One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.,3137399_6,-1,-1,-1,12163,-1,0.9892268,0.0107731065
12164,MMC,11,12,62,65,One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.,3137399_6,-1,-1,-1,12164,-1,0.99839324,0.0016067713
12165,mg,15,16,79,81,One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.,3137399_6,-1,-1,-1,12165,-1,0.9789507,0.021049267
12167,cardiac failure,1,3,4,19,The cardiac failure was predicted by a drop in EF determined during a cold pressor test.,3137399_7,-1,-1,-1,12167,-1,0.0025789875,0.997421
12170,mg,29,30,174,176,"Based on the combined data from the present study and the literature, we suggest that MMC-related cardiotoxicity is dose dependent, occurring at cumulative dose levels of 30 mg m-2 or more, mainly in patients also (previously or simultaneously) treated with doxorubicin.",3137399_10,-1,-1,-1,12170,-1,0.97807294,0.021927044
12172,myocardial infarction,7,9,44,65,Verapamil withdrawal as a possible cause of myocardial infarction in a hypertensive woman with a normal coronary angiogram.,3173179_0,-1,-1,-1,12172,-1,0.0023137743,0.99768627
12176,myocardial infarction,6,8,26,47,We report a case in which myocardial infarction coincided with the introduction of captopril and the withdrawal of verapamil in a previously asymptomatic woman with severe hypertension.,3173179_3,-1,-1,-1,12176,-1,0.0022671337,0.9977329
12185,cerebral lesions,1,3,11,27,Reversible cerebral lesions associated with tiazofurin usage: MR demonstration.,3183120_0,-1,-1,-1,12185,-1,0.0024131497,0.99758685
12186,tiazofurin,5,6,44,54,Reversible cerebral lesions associated with tiazofurin usage: MR demonstration.,3183120_0,-1,-1,-1,12186,-1,0.99914455,0.0008554008
12187,MR,8,9,62,64,Reversible cerebral lesions associated with tiazofurin usage: MR demonstration.,3183120_0,-1,-1,-1,12187,-1,0.2373812,0.76261884
12188,Tiazofurin,0,1,0,10,Tiazofurin is an experimental chemotherapeutic agent currently undergoing clinical evaluation.,3183120_1,-1,-1,-1,12188,-1,0.9992556,0.0007443438
12189,MR,8,9,47,49,We report our results with magnetic resonance (MR) in demonstrating reversible cerebral abnormalities concurrent with the use of this drug.,3183120_2,-1,-1,-1,12189,-1,0.8349317,0.16506831
12190,cerebral abnormalities,13,15,79,101,We report our results with magnetic resonance (MR) in demonstrating reversible cerebral abnormalities concurrent with the use of this drug.,3183120_2,-1,-1,-1,12190,-1,0.0024779153,0.99752206
12191,MR,3,4,21,23,The abnormalities on MR were correlated with findings on CT as well as with cerebral angiography.,3183120_3,-1,-1,-1,12191,-1,0.8328103,0.16718973
12192,MR,3,4,15,17,The utility of MR in the evaluation of patients receiving this new agent is illustrated.,3183120_4,-1,-1,-1,12192,-1,0.97351515,0.02648487
12194,head and neck carcinoma,5,9,36,59,Survival for patients with advanced head and neck carcinoma and esophageal carcinoma is poor with radiotherapy and/or surgery.,3187073_1,-1,-1,-1,12194,-1,0.008927608,0.99107236
12195,esophageal carcinoma,10,12,64,84,Survival for patients with advanced head and neck carcinoma and esophageal carcinoma is poor with radiotherapy and/or surgery.,3187073_1,-1,-1,-1,12195,-1,0.006780529,0.99321944
12196,5-FU,13,14,55,59,"In the present study, cis-platin (80-120 mg/m2BSA) and 5-FU (1000 mg/m2BSA daily as a continuous infusion during 5 days) were given to 76 patients before radiotherapy and surgery.",3187073_3,-1,-1,-1,12196,-1,0.99818665,0.0018133898
12197,cardiovascular disease,7,9,42,64,"In the pre-treatment evaluation, signs of cardiovascular disease were found in 33 patients (43%).",3187073_6,-1,-1,-1,12197,-1,0.0031495641,0.99685043
12199,cardiovascular disease,12,14,73,95,The incidence of cardiotoxicity was not higher in patients with signs of cardiovascular disease than in those without in the pre-treatment evaluation.,3187073_9,-1,-1,-1,12199,-1,0.0024624777,0.9975375
12201,chest pain,7,9,45,55,"The most common signs of cardiotoxicity were chest pain, ST-T wave changes and atrial fibrillation.",3187073_10,-1,-1,-1,12201,-1,0.004865577,0.9951344
12202,atrial fibrillation,14,16,79,98,"The most common signs of cardiotoxicity were chest pain, ST-T wave changes and atrial fibrillation.",3187073_10,-1,-1,-1,12202,-1,0.01463868,0.9853614
12203,ventricular fibrillation,4,6,21,45,This was followed by ventricular fibrillation in one patient and sudden death in another.,3187073_11,-1,-1,-1,12203,-1,0.007681113,0.99231887
12204,sudden death,10,12,65,77,This was followed by ventricular fibrillation in one patient and sudden death in another.,3187073_11,-1,-1,-1,12204,-1,0.0028683448,0.9971316
12205,5-FU,6,7,33,37,It is concluded that patients on 5-FU treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed.,3187073_12,-1,-1,-1,12205,-1,0.9986443,0.0013557005
12206,chest pain,21,23,131,141,It is concluded that patients on 5-FU treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed.,3187073_12,-1,-1,-1,12206,-1,0.0027420176,0.99725795
12207,tachyarrhythmia,24,25,145,160,It is concluded that patients on 5-FU treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed.,3187073_12,-1,-1,-1,12207,-1,0.0024879812,0.997512
12208,gestational trophoblastic disease,4,7,27,60,Death from chemotherapy in gestational trophoblastic disease.,3192036_0,-1,-1,-1,12208,-1,0.007516038,0.9924839
12209,choriocarcinoma,16,17,113,128,Multiple cytotoxic drug administration is the generally accepted treatment of patients with a high-risk stage of choriocarcinoma.,3192036_1,-1,-1,-1,12209,-1,0.028879305,0.9711207
12217,pulmonary obstruction,16,18,103,124,"Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs, probably originating from the uterus.",3192036_5,-1,-1,-1,12217,-1,0.002755499,0.9972445
12218,tumor necrosis,9,11,55,69,"Formation of these plugs was probably due to extensive tumor necrosis at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli.",3192036_6,-1,-1,-1,12218,-1,0.0031867689,0.99681324
12222,embolism,18,19,103,111,"In view of the close time association between the start of chemotherapy and the acute onset of massive embolism other explanations, such as spontaneous necrosis, must be considered less likely.",3192036_7,-1,-1,-1,12222,-1,0.0033907162,0.99660933
12224,pelvic tumor,3,5,20,32,"Patients with large pelvic tumor loads are, according to existing classifications, at high risk to die and to develop drug resistance.",3192036_8,-1,-1,-1,12224,-1,0.009317753,0.99068224
12229,L-[3H]nicotine,38,39,184,198,"At the end of each pretreatment period, animals were used for (i) determining their locomotor response to acutely injected nicotine (0.2 mg/kg, s.c.) and (ii) measuring the density of L-[3H]nicotine and [3H]spiperone binding sites in the striatum.",3220106_2,-1,-1,-1,12229,-1,0.99650335,0.003496638
12233,DA,41,42,255,257,"In rats which were pretreated with nicotine for 5 days, there was a significant increase in the nicotine-stimulated locomotor response which was associated with an increase in the number of L-[3H]nicotine binding sites and also with an elevated dopamine (DA) level in the striatum.",3220106_4,-1,-1,-1,12233,-1,0.99589974,0.0041002193
12235,DA,27,28,180,182,"However, this response was correlated with an elevated number of striatal [3H]spiperone binding sites, whereas the number of striatal L-[3H]nicotine binding sites and the striatal DA level were normal.",3220106_7,-1,-1,-1,12235,-1,0.9972084,0.0027915346
12238,DA,26,27,187,189,"These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.",3220106_8,-1,-1,-1,12238,-1,0.9987344,0.0012655895
12239,DA,32,33,226,228,"These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.",3220106_8,-1,-1,-1,12239,-1,0.9983254,0.0016745867
12243,cm H2O,5,7,33,39,"Before nitroprusside infusion, 5 cm H2O CPAP significantly, P less than .05, decreased arterial blood pressure, but did not significantly alter heart rate, cardiac output, systemic vascular resistance, or QS/QT.",322550_2,-1,-1,-1,12243,-1,0.9924799,0.0075201173
12244,P,10,11,60,61,"Before nitroprusside infusion, 5 cm H2O CPAP significantly, P less than .05, decreased arterial blood pressure, but did not significantly alter heart rate, cardiac output, systemic vascular resistance, or QS/QT.",322550_2,-1,-1,-1,12244,-1,0.5744509,0.42554912
12245,cm H2O,1,3,4,10,Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.,322550_3,-1,-1,-1,12245,-1,0.9922382,0.0077617625
12247,decrease in arterial blood pressure,10,15,65,100,Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.,322550_3,-1,-1,-1,12247,-1,0.02533376,0.97466624
12248,decreased cardiac output,21,24,144,168,Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.,322550_3,-1,-1,-1,12248,-1,0.07459909,0.925401
12250,decreases in arterial blood pressure,3,8,33,69,"Nitroprusside caused significant decreases in arterial blood pressure and systemic vascular resistance and increases in heart rate, but did not change cardiac output or QS/QT.",322550_4,-1,-1,-1,12250,-1,0.04964002,0.95036
12251,cm H2O,1,3,5,11,Five cm H2O CPAP during nitroprusside did not further alter any of the above-mentioned variables.,322550_5,-1,-1,-1,12251,-1,0.9887658,0.0112341745
12253,cm H2O,3,5,12,18,"However, 10 cm H2O CPAP decreased arterial blood pressure, cardiac output, and QS/QT.",322550_6,-1,-1,-1,12253,-1,0.9920208,0.007979252
12256,cm H2O,21,23,124,130,"During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics, but high levels of CPAP (10 cm H2O), while decreasing QS/QT, produce marked decreases in arterial blood pressure and cardiac output.",322550_8,-1,-1,-1,12256,-1,0.9916854,0.008314598
12257,decreases in arterial blood pressure and cardiac output,31,39,172,227,"During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics, but high levels of CPAP (10 cm H2O), while decreasing QS/QT, produce marked decreases in arterial blood pressure and cardiac output.",322550_8,-1,-1,-1,12257,-1,0.0149283735,0.98507166
12258,hypokalemia,3,4,39,50,Amelioration of bendrofluazide-induced hypokalemia by timolol.,326460_0,-1,-1,-1,12258,-1,0.002627457,0.9973725
12261,hypokalemia,12,13,66,77,"The beta adrenergic blocking drug, timolol, tended to correct the hypokalemia of short-term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant.",326460_1,-1,-1,-1,12261,-1,0.0027315202,0.99726856
12262,bendrofluazide,15,16,92,106,"The beta adrenergic blocking drug, timolol, tended to correct the hypokalemia of short-term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant.",326460_1,-1,-1,-1,12262,-1,0.9992105,0.00078954926
12266,bendrofluazide,13,14,92,106,Timolol also reduced the rise in plasma aldosterone and urine potassium excretion following bendrofluazide and increased the urine sodium/potassium ratio.,326460_2,-1,-1,-1,12266,-1,0.999169,0.00083101646
12269,methysergide,20,21,122,134,"A rare case of morbid vasospasm, together with striking angiographic findings, is described secondary to the ingestion of methysergide by a 48-year-old woman.",3300918_1,-1,-1,-1,12269,-1,0.9992472,0.000752839
12270,ergot,6,7,31,36,"A discussion of the history of ergot includes its original discovery, the epidemics of gangrene that it has caused through the ages and its past and present role in the management of migraine headache.",3300918_3,-1,-1,-1,12270,-1,0.9989524,0.0010476316
12271,gangrene,15,16,87,95,"A discussion of the history of ergot includes its original discovery, the epidemics of gangrene that it has caused through the ages and its past and present role in the management of migraine headache.",3300918_3,-1,-1,-1,12271,-1,0.0024325415,0.99756753
12272,migraine headache,33,35,183,200,"A discussion of the history of ergot includes its original discovery, the epidemics of gangrene that it has caused through the ages and its past and present role in the management of migraine headache.",3300918_3,-1,-1,-1,12272,-1,0.0027978988,0.99720216
12274,blockers,6,7,38,46,"Despite the advent of calcium channel blockers and beta-adrenergic antagonists, ergot preparations continue to play a major role in migraine therapy, so that the danger of St. Anthony's fire persists.",3300918_4,-1,-1,-1,12274,-1,0.9818571,0.018142855
12290,mm Hg,7,9,43,48,"Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).",3341566_2,-1,-1,-1,12290,-1,0.3430457,0.6569542
12292,HEM,16,17,86,89,"Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).",3341566_2,-1,-1,-1,12292,-1,0.0057310667,0.9942689
12293,n,18,19,91,92,"Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).",3341566_2,-1,-1,-1,12293,-1,0.20107915,0.7989208
12295,SNP,30,31,149,152,"Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).",3341566_2,-1,-1,-1,12295,-1,0.9985927,0.0014073242
12296,n,32,33,154,155,"Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).",3341566_2,-1,-1,-1,12296,-1,0.23712815,0.7628719
12298,SNP,19,20,140,143,During HEM-induced hypotension the cardiac output was significantly lower and systemic vascular resistance higher compared with that in the SNP group.,3341566_3,-1,-1,-1,12298,-1,0.9981527,0.0018473532
12300,mm Hg,9,11,44,49,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,-1,-1,-1,12300,-1,0.092057005,0.907943
12301,HEM,13,14,57,60,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,-1,-1,-1,12301,-1,0.5326538,0.46734616
12302,mm Hg,22,24,94,99,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,-1,-1,-1,12302,-1,0.0972963,0.9027037
12303,SNP,26,27,107,110,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,-1,-1,-1,12303,-1,0.99632394,0.0036760562
12304,P,29,30,118,119,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,-1,-1,-1,12304,-1,0.27110705,0.7288929
12305,mm Hg,27,29,117,122,"The delta down, which is the measure of decrease of SBP after a mechanical breath, was 20.3 +/- 8.4 and 10.1 +/- 3.8 mm Hg in the HEM and SNP groups, respectively, during hypotension (P less than 0.02).",3341566_7,-1,-1,-1,12305,-1,0.10049651,0.8995035
12306,SNP,33,34,138,141,"The delta down, which is the measure of decrease of SBP after a mechanical breath, was 20.3 +/- 8.4 and 10.1 +/- 3.8 mm Hg in the HEM and SNP groups, respectively, during hypotension (P less than 0.02).",3341566_7,-1,-1,-1,12306,-1,0.9966389,0.003361131
12308,P,41,42,184,185,"The delta down, which is the measure of decrease of SBP after a mechanical breath, was 20.3 +/- 8.4 and 10.1 +/- 3.8 mm Hg in the HEM and SNP groups, respectively, during hypotension (P less than 0.02).",3341566_7,-1,-1,-1,12308,-1,0.29688504,0.7031149
12310,hypovolemia,7,8,45,56,They are thus more important during absolute hypovolemia than during deliberate hypotension.,3341566_9,-1,-1,-1,12310,-1,0.018112896,0.9818871
12312,ritodrine,6,7,59,68,Ventricular tachyarrhythmias during cesarean section after ritodrine therapy: interaction with anesthetics.,3358181_0,-1,-1,-1,12312,-1,0.99935347,0.0006465254
12313,ritodrine,6,7,46,55,This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section.,3358181_1,-1,-1,-1,12313,-1,0.9994821,0.00051794003
12314,preterm labor,8,10,60,73,This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section.,3358181_1,-1,-1,-1,12314,-1,0.00681907,0.99318093
12315,ritodrine,19,20,140,149,This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section.,3358181_1,-1,-1,-1,12315,-1,0.9994617,0.000538248
12316,cardiovascular complications,6,8,40,68,Such interactions may result in serious cardiovascular complications even after cessation of an infusion of ritodrine.,3358181_2,-1,-1,-1,12316,-1,0.002830108,0.9971699
12317,ritodrine,15,16,108,117,Such interactions may result in serious cardiovascular complications even after cessation of an infusion of ritodrine.,3358181_2,-1,-1,-1,12317,-1,0.9994342,0.0005658638
12320,vasopressor,17,18,100,111,"After delivery of the infant, there should be no contraindication to the use of an alpha-adrenergic vasopressor such as phenylephrine to treat hypotensive patients with tachycardia.",3358181_6,-1,-1,-1,12320,-1,0.9978454,0.0021546194
12324,carbamazepine neurotoxicity,1,3,18,45,Verapamil-induced carbamazepine neurotoxicity.,3371379_0,-1,-1,-1,12324,-1,0.87383026,0.12616976
12325,carbamazepine neurotoxicity,5,7,27,54,Two patients with signs of carbamazepine neurotoxicity after combined treatment with verapamil showed complete recovery after discontinuation of the calcium entry blocker.,3371379_2,-1,-1,-1,12325,-1,0.8882671,0.11173287
12332,Ethopropazine,0,1,0,13,Ethopropazine and benztropine in neuroleptic-induced parkinsonism.,33969_0,-1,-1,-1,12332,-1,0.9992613,0.00073869573
12333,benztropine,2,3,18,29,Ethopropazine and benztropine in neuroleptic-induced parkinsonism.,33969_0,-1,-1,-1,12333,-1,0.99906,0.00094007107
12335,ethopropazine,5,6,30,43,In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.,33969_1,-1,-1,-1,12335,-1,0.9994331,0.0005669144
12336,benztropine,9,10,60,71,In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.,33969_1,-1,-1,-1,12336,-1,0.9992342,0.00076586247
12340,Ethopropazine,0,1,0,13,"Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.",33969_2,-1,-1,-1,12340,-1,0.99935645,0.00064353715
12341,benztropine,2,3,18,29,"Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.",33969_2,-1,-1,-1,12341,-1,0.99917954,0.00082049414
12342,parkinsonian symptoms,11,13,80,101,"Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.",33969_2,-1,-1,-1,12342,-1,0.0026751386,0.9973248
12343,procyclidine,18,19,129,141,"Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.",33969_2,-1,-1,-1,12343,-1,0.9993759,0.00062412757
12344,benztropine,2,3,9,20,"However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.",33969_3,-1,-1,-1,12344,-1,0.99924964,0.00075036014
12345,tardive dyskinesia,10,12,68,86,"However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.",33969_3,-1,-1,-1,12345,-1,0.0020930842,0.9979069
12346,procyclindine,17,18,122,135,"However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.",33969_3,-1,-1,-1,12346,-1,0.99927205,0.0007279234
12347,anxiety,23,24,170,177,"However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.",33969_3,-1,-1,-1,12347,-1,0.0038419198,0.99615806
12349,ethopropazine,27,28,198,211,"However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.",33969_3,-1,-1,-1,12349,-1,0.9992987,0.00070131617
12350,benztropine,3,4,19,30,"This suggests that benztropine is not the anticholinergic drug of choice in the treatment of neuroleptic-induced parkinsonian symptoms, because of its more toxic central and peripheral atropinic effect.",33969_4,-1,-1,-1,12350,-1,0.9993518,0.00064823084
12351,parkinsonian symptoms,16,18,113,134,"This suggests that benztropine is not the anticholinergic drug of choice in the treatment of neuroleptic-induced parkinsonian symptoms, because of its more toxic central and peripheral atropinic effect.",33969_4,-1,-1,-1,12351,-1,0.0026851948,0.99731475
12354,hepatic failure,8,10,59,74,"Paracetamol-associated coma, metabolic acidosis, renal and hepatic failure.",3403780_0,-1,-1,-1,12354,-1,0.0027205998,0.99727947
12356,acute renal failure,6,9,30,49,"A case of metabolic acidosis, acute renal failure and hepatic failure following paracetamol ingestion is presented.",3403780_1,-1,-1,-1,12356,-1,0.002803272,0.9971967
12357,hepatic failure,10,12,54,69,"A case of metabolic acidosis, acute renal failure and hepatic failure following paracetamol ingestion is presented.",3403780_1,-1,-1,-1,12357,-1,0.002438784,0.9975612
12363,osteoarthritis,16,17,116,130,"The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis, osteoarthritis and spondyloarthropathy, 130 of whom were pair-matched to controls.",3409645_1,-1,-1,-1,12363,-1,0.003982098,0.9960179
12364,spondyloarthropathy,18,19,135,154,"The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis, osteoarthritis and spondyloarthropathy, 130 of whom were pair-matched to controls.",3409645_1,-1,-1,-1,12364,-1,0.006269816,0.9937302
12365,depressed mood,5,7,37,51,Assessments of marital happiness and depressed mood were also made using the CES-D and the Azrin Marital Happiness Scale (AMHS).,3409645_2,-1,-1,-1,12365,-1,0.005480709,0.9945193
12366,Azrin,15,16,91,96,Assessments of marital happiness and depressed mood were also made using the CES-D and the Azrin Marital Happiness Scale (AMHS).,3409645_2,-1,-1,-1,12366,-1,0.99822336,0.001776635
12367,Sexual dysfunctions,0,2,0,19,"Sexual dysfunctions were found to be common among patients and controls, the majority in both groups reporting one or more dysfunctions.",3409645_3,-1,-1,-1,12367,-1,0.0034566727,0.99654335
12368,Impotence,0,1,0,9,Impotence was more common among male patients than controls and was found to be associated with co-morbidity and the taking of methotrexate.,3409645_4,-1,-1,-1,12368,-1,0.0079045715,0.9920954
12371,impotence,18,19,112,121,"Depressed mood was more common among patients and was associated with certain sexual difficulties, but not with impotence.",3409645_5,-1,-1,-1,12371,-1,0.024262851,0.9757371
12374,Quinidine,0,1,0,9,Quinidine phenylethylbarbiturate-induced fulminant hepatitis in a pregnant woman.,3411101_0,-1,-1,-1,12374,-1,0.9987962,0.0012037227
12375,fulminant hepatitis,2,4,41,60,Quinidine phenylethylbarbiturate-induced fulminant hepatitis in a pregnant woman.,3411101_0,-1,-1,-1,12375,-1,0.008098605,0.99190134
12376,a,5,6,64,65,Quinidine phenylethylbarbiturate-induced fulminant hepatitis in a pregnant woman.,3411101_0,-1,-1,-1,12376,-1,0.016090337,0.98390967
12377,Laotian,7,8,36,43,We report the case of a 19-year-old Laotian patient affected by fulminant hepatitis during the third trimester of her pregnancy after a 1-month administration of quinidine phenylethylbarbiturate.,3411101_2,-1,-1,-1,12377,-1,0.96044344,0.039556596
12378,fulminant hepatitis,11,13,64,83,We report the case of a 19-year-old Laotian patient affected by fulminant hepatitis during the third trimester of her pregnancy after a 1-month administration of quinidine phenylethylbarbiturate.,3411101_2,-1,-1,-1,12378,-1,0.005409121,0.9945909
12379,quinidine phenylethylbarbiturate,25,27,162,194,We report the case of a 19-year-old Laotian patient affected by fulminant hepatitis during the third trimester of her pregnancy after a 1-month administration of quinidine phenylethylbarbiturate.,3411101_2,-1,-1,-1,12379,-1,0.99880064,0.0011993982
12380,phenylethylbarbiturate,3,4,20,42,Quinidine itself or phenylethylbarbiturate may be responsible for fulminant hepatitis in this patient.,3411101_5,-1,-1,-1,12380,-1,0.998944,0.0010560096
12381,fulminant hepatitis,8,10,66,85,Quinidine itself or phenylethylbarbiturate may be responsible for fulminant hepatitis in this patient.,3411101_5,-1,-1,-1,12381,-1,0.0044159563,0.9955841
12383,urothelial cancer,3,5,23,40,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,-1,-1,-1,12383,-1,0.0072818696,0.9927181
12384,renal,12,13,92,97,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,-1,-1,-1,12384,-1,0.013076482,0.9869235
12392,ureteric cancer,31,33,181,196,"The risk of renal papillary necrosis was increased nearly 20-fold by consumption of phenacetin, which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer.",3412544_1,-1,-1,-1,12392,-1,0.010247432,0.98975253
12393,contrast,1,2,3,11,"By contrast, we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter.",3412544_2,-1,-1,-1,12393,-1,0.25897577,0.74102426
12397,cancer of the ureter,32,36,199,219,"By contrast, we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter.",3412544_2,-1,-1,-1,12397,-1,0.010048677,0.9899513
12398,myocardial ischemia,2,4,14,33,Mechanisms of myocardial ischemia induced by epinephrine: comparison with exercise-induced ischemia.,3413271_0,-1,-1,-1,12398,-1,0.0036827931,0.99631715
12402,myocardial ischemia,6,8,37,56,The role of epinephrine in eliciting myocardial ischemia was examined in patients with coronary artery disease.,3413271_1,-1,-1,-1,12402,-1,0.0031746288,0.99682534
12403,coronary artery disease,13,16,87,110,The role of epinephrine in eliciting myocardial ischemia was examined in patients with coronary artery disease.,3413271_1,-1,-1,-1,12403,-1,0.003695194,0.99630475
12408,myocardial ischemia,5,7,39,58,Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina.,3413271_3,-1,-1,-1,12408,-1,0.0029378138,0.99706215
12410,angina,14,15,101,107,Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina.,3413271_3,-1,-1,-1,12410,-1,0.0023797704,0.99762017
12411,myocardial ischemia,5,7,27,46,"However, the mechanisms of myocardial ischemia induced by epinephrine were significantly different from those of exercise.",3413271_4,-1,-1,-1,12411,-1,0.003080523,0.9969195
12413,myocardial ischemia,1,3,17,36,"Exercise-induced myocardial ischemia was marked predominantly by increased heart rate and rate-pressure product with a minor contribution of end-diastolic volume, while epinephrine-induced ischemia was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate-pressure product.",3413271_5,-1,-1,-1,12413,-1,0.0035757502,0.99642426
12418,hemoglobin E trait,10,13,73,91,Dapsone-associated Heinz body hemolytic anemia in a Cambodian woman with hemoglobin E trait.,3425586_0,-1,-1,-1,12418,-1,0.28910458,0.71089536
12419,E,5,6,34,35,A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.,3425586_1,-1,-1,-1,12419,-1,0.8183479,0.18165216
12420,leprosy,11,12,51,58,A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.,3425586_1,-1,-1,-1,12420,-1,0.00939903,0.99060094
12424,reduced glutathione,15,17,83,102,"Her red blood cells (RBCs) had increased incubated Heinz body formation, decreased reduced glutathione (GSH), and decreased GSH stability.",3425586_2,-1,-1,-1,12424,-1,0.9964893,0.0035107057
12425,GSH,18,19,104,107,"Her red blood cells (RBCs) had increased incubated Heinz body formation, decreased reduced glutathione (GSH), and decreased GSH stability.",3425586_2,-1,-1,-1,12425,-1,0.9965289,0.0034711014
12426,GSH,23,24,124,127,"Her red blood cells (RBCs) had increased incubated Heinz body formation, decreased reduced glutathione (GSH), and decreased GSH stability.",3425586_2,-1,-1,-1,12426,-1,0.99637383,0.003626143
12427,pentose phosphate,1,3,4,21,The pentose phosphate shunt activity of the dapsone-exposed AE RBCs was increased compared to normal RBCs.,3425586_3,-1,-1,-1,12427,-1,0.9966516,0.0033484432
12429,GSH,18,19,109,112,"Although the AE RBCs from an individual not taking dapsone had increased incubated Heinz body formation, the GSH content and GSH stability were normal.",3425586_4,-1,-1,-1,12429,-1,0.99681216,0.0031878308
12430,GSH,21,22,125,128,"Although the AE RBCs from an individual not taking dapsone had increased incubated Heinz body formation, the GSH content and GSH stability were normal.",3425586_4,-1,-1,-1,12430,-1,0.9960699,0.003930037
12431,pentose phosphate,1,3,4,21,The pentose phosphate shunt activity of the non-dapsone-exposed AE RBCs was decreased compared to normal RBCs.,3425586_5,-1,-1,-1,12431,-1,0.99617285,0.0038271346
12434,oxidant,11,12,61,68,"Given the influx of Southeast Asians into the United States, oxidant medications should be used with caution, especially if an infection is present, in individuals of ethnic backgrounds that have an increased prevalence of hemoglobin E.",3425586_7,-1,-1,-1,12434,-1,0.9907515,0.0092484625
12436,E.,38,39,234,236,"Given the influx of Southeast Asians into the United States, oxidant medications should be used with caution, especially if an infection is present, in individuals of ethnic backgrounds that have an increased prevalence of hemoglobin E.",3425586_7,-1,-1,-1,12436,-1,0.8923533,0.10764671
12437,thymidylate synthase,7,9,49,69,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,-1,12437,-1,0.98272425,0.017275743
12438,"N10-propargyl-5,8-dideazafolic acid",10,12,80,115,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,-1,12438,-1,0.99483645,0.0051635676
12439,CB,13,14,117,119,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,-1,12439,-1,0.99394184,0.0060580703
12440,3717).CB 3717,14,16,120,133,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,-1,12440,-1,0.9839669,0.016033158
12441,"N10-propargyl-5,8-dideazafolic acid",17,19,135,170,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,-1,12441,-1,0.9938275,0.0061724423
12442,thymidylate synthase,25,27,204,224,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,-1,12442,-1,0.97687715,0.023122823
12443,TS,28,29,226,228,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,-1,12443,-1,0.9372297,0.062770315
12444,cytotoxicity,31,32,236,248,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,-1,-1,-1,12444,-1,0.0046514613,0.9953485
12445,CB 3717,10,12,74,81,Recent preclinical studies have focused on the intracellular formation of CB 3717 polyglutamates.,3431591_1,-1,-1,-1,12445,-1,0.9985267,0.0014732932
12446,CB 3717,24,26,133,140,"Following a 12-hour exposure of L1210 cells to 50 microM [3H]CB 3717, 30% of the extractable radioactivity could be accounted for as CB 3717 tetra- and pentaglutamate, as determined by high-pressure liquid chromatography (HPLC) analyses.",3431591_2,-1,-1,-1,12446,-1,0.9984414,0.0015585916
12447,TS,5,6,32,34,"As inhibitors of isolated L1210 TS, CB 3717 di-, tri-, tetra- and pentaglutamate are 26-, 87-, 119- and 114-fold more potent than CB 3717, respectively, and their formation may, therefore, be an important determinant of CB 3717 cytotoxicity.",3431591_3,-1,-1,-1,12447,-1,0.25240803,0.7475919
12448,CB 3717,7,9,36,43,"As inhibitors of isolated L1210 TS, CB 3717 di-, tri-, tetra- and pentaglutamate are 26-, 87-, 119- and 114-fold more potent than CB 3717, respectively, and their formation may, therefore, be an important determinant of CB 3717 cytotoxicity.",3431591_3,-1,-1,-1,12448,-1,0.9968188,0.0031811541
12449,CB 3717,27,29,130,137,"As inhibitors of isolated L1210 TS, CB 3717 di-, tri-, tetra- and pentaglutamate are 26-, 87-, 119- and 114-fold more potent than CB 3717, respectively, and their formation may, therefore, be an important determinant of CB 3717 cytotoxicity.",3431591_3,-1,-1,-1,12449,-1,0.997182,0.0028180317
12450,CB 3717 cytotoxicity,44,47,220,240,"As inhibitors of isolated L1210 TS, CB 3717 di-, tri-, tetra- and pentaglutamate are 26-, 87-, 119- and 114-fold more potent than CB 3717, respectively, and their formation may, therefore, be an important determinant of CB 3717 cytotoxicity.",3431591_3,-1,-1,-1,12450,-1,0.7489481,0.2510519
12451,CB 3717,5,7,31,38,"In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.",3431591_4,-1,-1,-1,12451,-1,0.9984694,0.0015305922
12454,hepatoma,19,20,97,105,"In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.",3431591_4,-1,-1,-1,12454,-1,0.0035905817,0.99640936
12455,mesothelioma,22,23,111,123,"In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.",3431591_4,-1,-1,-1,12455,-1,0.0060419897,0.993958
12457,malaise,4,5,36,43,"Toxicities included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.",3431591_5,-1,-1,-1,12457,-1,0.0040884134,0.9959116
12459,CB 3717,23,25,124,131,This latter effect is thought to be due to drug precipitation within the renal tubule as a result of the poor solubility of CB 3717 under acidic conditions.,3431591_6,-1,-1,-1,12459,-1,0.9986237,0.0013763295
12460,CB 3717,12,14,60,67,"In an attempt to overcome this problem, a clinical trial of CB 3717 administered with alkaline diuresis is under way.",3431591_7,-1,-1,-1,12460,-1,0.99864537,0.0013546125
12464,malaise,2,3,19,26,Hepatotoxicity and malaise are again the most frequent side effects.,3431591_9,-1,-1,-1,12464,-1,0.0040980936,0.9959019
12465,CB 3717,10,12,80,87,Pharmacokinetic investigations have shown that alkaline diuresis does not alter CB 3717 plasma levels or urinary excretion and that satisfactory urinary alkalinization can be readily achieved.,3431591_11,-1,-1,-1,12465,-1,0.9987929,0.0012071226
12466,hepatitis B,9,11,62,73,Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin.,343678_0,-1,-1,-1,12466,-1,0.12253007,0.8774699
12467,Hepatitis B,0,2,0,11,"Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.",343678_2,-1,-1,-1,12467,-1,0.037680835,0.96231914
12468,type B hepatitis,29,32,167,183,"Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.",343678_2,-1,-1,-1,12468,-1,0.01072469,0.9892753
12469,hepatitis B surface antigen,36,40,215,242,"Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.",343678_2,-1,-1,-1,12469,-1,0.6059087,0.39409137
12471,P,16,17,76,77,"Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001).",343678_3,-1,-1,-1,12471,-1,0.2621745,0.7378255
12472,P,37,38,167,168,"Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001).",343678_3,-1,-1,-1,12472,-1,0.18838184,0.8116182
12473,e,12,13,65,66,Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE).,343678_5,-1,-1,-1,12473,-1,0.9901016,0.009898362
12474,HBeAg,17,18,89,94,Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE).,343678_5,-1,-1,-1,12474,-1,0.99532276,0.004677283
12475,HBeAg,3,4,14,19,Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors.,343678_6,-1,-1,-1,12475,-1,0.995693,0.004307031
12476,Hepatitis B,0,2,0,11,Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups.,343678_7,-1,-1,-1,12476,-1,0.022270525,0.9777295
12477,type B hepatitis,11,14,81,97,Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups.,343678_7,-1,-1,-1,12477,-1,0.008769711,0.99123025
12478,type B hepatitis,6,9,34,50,The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included.,343678_8,-1,-1,-1,12478,-1,0.0085177515,0.99148226
12480,propafenone,17,18,110,121,"Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and sparteine.",3437726_0,-1,-1,-1,12480,-1,0.99944645,0.0005535611
12483,coronary artery disease,5,8,37,60,A 47-year-old patient suffering from coronary artery disease was admitted to the CCU in shock with III.,3437726_1,-1,-1,-1,12483,-1,0.006250701,0.9937494
12485,III,16,17,99,102,A 47-year-old patient suffering from coronary artery disease was admitted to the CCU in shock with III.,3437726_1,-1,-1,-1,12485,-1,0.92917454,0.07082543
12487,impairment of ventricular function,7,11,34,68,"AV block, severe hypotension, and impairment of ventricular function.",3437726_2,-1,-1,-1,12487,-1,0.005947313,0.9940527
12489,mg,14,15,77,79,One week prior to admission a therapy with standard doses of metoprolol (100 mg t.i.d. and then 100 mg b.i.d.) had been initiated.,3437726_3,-1,-1,-1,12489,-1,0.93591666,0.064083345
12490,mg,20,21,100,102,One week prior to admission a therapy with standard doses of metoprolol (100 mg t.i.d. and then 100 mg b.i.d.) had been initiated.,3437726_3,-1,-1,-1,12490,-1,0.94809544,0.051904567
12492,mg,7,8,40,42,Two days before admission diltiazem (60 mg b.i.d.) was prescribed in addition.,3437726_4,-1,-1,-1,12492,-1,0.9251029,0.07489709
12497,propafenone,16,17,86,97,"Three months later the patient was exposed to a single dose of metoprolol, diltiazem, propafenone (since he had received this drug in the past), and sparteine (as a probe for the debrisoquine/sparteine type polymorphism of oxidative drug metabolism).",3437726_7,-1,-1,-1,12497,-1,0.9994437,0.00055630575
12499,adverse drug reactions,26,29,187,209,"Therefore, patients belonging to the poor-metabolizer phenotype of sparteine/debrisoquine polymorphism in drug metabolism, which constitutes 6.4% of the German population, may experience adverse drug reactions when treated with standard doses of one of these drugs alone.",3437726_9,-1,-1,-1,12499,-1,0.015147422,0.9848526
12502,prostate adenocarcinomas,15,17,75,99,"More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.",3461217_1,-1,-1,-1,12502,-1,0.0042242156,0.99577576
12503,PAs,18,19,101,104,"More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.",3461217_1,-1,-1,-1,12503,-1,0.08717992,0.91282004
12504,testosterone propionate,34,36,175,198,"More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.",3461217_1,-1,-1,-1,12504,-1,0.99831426,0.0016858092
12505,TP,38,39,201,203,"More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.",3461217_1,-1,-1,-1,12505,-1,0.9943581,0.005641882
12506,PA,12,13,67,69,"Within the same timeframe, no L-W rat developed a similar palpable PA when treated only with TP.",3461217_3,-1,-1,-1,12506,-1,0.21453534,0.7854647
12507,TP,17,18,93,95,"Within the same timeframe, no L-W rat developed a similar palpable PA when treated only with TP.",3461217_3,-1,-1,-1,12507,-1,0.99838734,0.0016126898
12508,TP,4,5,13,15,"In L-W rats, TP acted as a tumor enhancement agent, with primary emphasis on the development of prostate cancer.",3461217_4,-1,-1,-1,12508,-1,0.99842215,0.001577809
12511,bromperidol,8,9,43,54,"A total of sixty patients were trated with bromperidol first in open conditions (20 patients), then on a double blind basis (40 patients) with haloperidol as the reference substance.",347884_1,-1,-1,-1,12511,-1,0.99928707,0.0007129605
12512,blind,22,23,112,117,"A total of sixty patients were trated with bromperidol first in open conditions (20 patients), then on a double blind basis (40 patients) with haloperidol as the reference substance.",347884_1,-1,-1,-1,12512,-1,0.19794048,0.80205953
12514,mg,17,18,82,84,The open study lasted for four weeks; the drug was administrated in the form of 1 mg tablets.,347884_2,-1,-1,-1,12514,-1,0.9753504,0.024649655
12515,mg,8,9,32,34,The daily dose (initial dose: 1 mg; mean dose at the end of the trial: 4.47 mg) was always administered in one single dose.,347884_3,-1,-1,-1,12515,-1,0.9466191,0.053380866
12516,mg,20,21,76,78,The daily dose (initial dose: 1 mg; mean dose at the end of the trial: 4.47 mg) was always administered in one single dose.,347884_3,-1,-1,-1,12516,-1,0.92979234,0.070207596
12517,extrapyramidal concomitant symptoms,6,9,41,76,Nine patients exhibited mild to moderate extrapyramidal concomitant symptoms; no other side effects were observed.,347884_6,-1,-1,-1,12517,-1,0.005600449,0.9943995
12518,blind,3,4,14,19,"In the double blind study with haloperidol, both substances were found to be highly effective in the treatment of psychotic syndromes belonging predominantly to the schizophrenia group.",347884_8,-1,-1,-1,12518,-1,0.1187704,0.88122964
12520,psychotic syndromes belonging predominantly to the schizophrenia group,20,28,114,184,"In the double blind study with haloperidol, both substances were found to be highly effective in the treatment of psychotic syndromes belonging predominantly to the schizophrenia group.",347884_8,-1,-1,-1,12520,-1,0.009141241,0.99085873
12521,bromperidol,17,18,90,101,"Certain clues, including the onset of action, seem to be indicative of the superiority of bromperidol.",347884_9,-1,-1,-1,12521,-1,0.99920577,0.0007942588
12523,acute hepatitis,4,6,51,66,Prolonged cholestasis after troleandomycin-induced acute hepatitis.,3496378_0,-1,-1,-1,12523,-1,0.0024218608,0.9975782
12526,troleandomycin,5,6,42,56,Jaundice occurred after administration of troleandomycin for 7 days and was associated with hypereosinophilia.,3496378_2,-1,-1,-1,12526,-1,0.9990024,0.0009976585
12527,hypereosinophilia,13,14,92,109,Jaundice occurred after administration of troleandomycin for 7 days and was associated with hypereosinophilia.,3496378_2,-1,-1,-1,12527,-1,0.009970505,0.9900295
12531,alkaline phosphatase,19,21,127,147,Jaundice disappeared within 3 months but was followed by prolonged anicteric cholestasis marked by pruritus and high levels of alkaline phosphatase and gammaglutamyltransferase activities.,3496378_3,-1,-1,-1,12531,-1,0.99512535,0.0048746616
12535,acute hepatitis,9,11,91,106,This observation demonstrates that prolonged cholestasis can follow troleandomycin-induced acute hepatitis.,3496378_5,-1,-1,-1,12535,-1,0.0022728073,0.9977272
12536,auditory neurotoxicity,3,5,18,40,Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy.,3503576_0,-1,-1,-1,12536,-1,0.010676485,0.98932356
12542,"abnormal audiograms with deficits mostly in the high frequency range of 4,000 to 8,000 Hz",7,22,46,135,"Twenty-two patients in the affected group had abnormal audiograms with deficits mostly in the high frequency range of 4,000 to 8,000 Hz and in the hearing threshold levels of 30 to 100 decibels.",3503576_2,-1,-1,-1,12542,-1,0.18398598,0.81601405
12544,permanent disability,14,16,97,117,Audiograms from 15 patients remained abnormal and four patients required hearing aids because of permanent disability.,3503576_4,-1,-1,-1,12544,-1,0.003481475,0.9965185
12546,auditory abnormality,41,43,230,250,"Since 18 of the 22 patients were initially receiving deferoxamine doses in excess of the commonly recommended 50 mg/kg per dose, therapy was restarted with lower doses, usually 50 mg/kg per dose or less depending on the degree of auditory abnormality, and with the exception of two cases no further toxicity was demonstrated.",3503576_5,-1,-1,-1,12546,-1,0.004306784,0.99569327
12554,hearing loss,5,7,26,38,"In those with symptoms of hearing loss, the drug should be stopped for four weeks, and when the audiogram is stable or improved, therapy should be restarted at 10 to 25 mg/kg per dose.",3503576_11,-1,-1,-1,12554,-1,0.0028955776,0.99710447
12555,auditory dysfunction,27,29,171,191,Serial audiograms should be performed every six months in those without problems and more frequently in young patients with normal serum ferritin values and in those with auditory dysfunction.,3503576_12,-1,-1,-1,12555,-1,0.004089175,0.9959109
12557,netilmicin,5,6,34,44,Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients.,3535719_0,-1,-1,-1,12557,-1,0.99894315,0.0010568857
12559,netilmicin sulfate,8,10,53,71,We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.,3535719_1,-1,-1,-1,12559,-1,0.9988979,0.0011020214
12560,tobramycin sulfate,11,13,75,93,We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.,3535719_1,-1,-1,-1,12560,-1,0.9989411,0.0010588418
12561,piperacillin sodium,16,18,114,133,We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.,3535719_1,-1,-1,-1,12561,-1,0.9988649,0.0011350769
12564,netilmicin,10,11,73,83,Nephrotoxicity occurred in a similar proportion in patients treated with netilmicin and tobramycin (17% vs 11%).,3535719_3,-1,-1,-1,12564,-1,0.9989747,0.0010253869
12567,netilmicin,10,11,42,52,Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.,3535719_4,-1,-1,-1,12567,-1,0.9989505,0.0010494996
12568,piperacillin,12,13,57,69,Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.,3535719_4,-1,-1,-1,12568,-1,0.9989034,0.0010966235
12570,netilmicin,10,11,62,72,"Of those evaluated with posttherapy audiograms, three of four netilmicin and piperacillin-treated patients had auditory thresholds return to baseline compared with one of nine tobramycin and piperacillin-treated patients.",3535719_5,-1,-1,-1,12570,-1,0.99901426,0.000985766
12572,netilmicin,34,35,194,204,The number of greater than or equal to 15-dB increases in auditory threshold as a proportion of total greater than or equal to 15-dB changes (increases and decreases) was significantly lower in netilmicin and piperacillin- vs tobramycin and piperacillin-treated patients (18 of 78 vs 67 of 115).,3535719_6,-1,-1,-1,12572,-1,0.99884963,0.0011503256
12575,netilmicin,13,14,102,112,We conclude that aminoglycoside-associated ototoxicity was less severe and more often reversible with netilmicin than with tobramycin.,3535719_7,-1,-1,-1,12575,-1,0.99906284,0.00093722
12577,cardiac asystole,1,3,18,34,Lidocaine-induced cardiac asystole.,354896_0,-1,-1,-1,12577,-1,0.004052124,0.9959479
12580,bradyarrhythmias,16,17,105,121,"The patient had no apparent associated conditions which might have predisposed him to the development of bradyarrhythmias; and, thus, this probably represented a true idiosyncrasy to lidocaine.",354896_2,-1,-1,-1,12580,-1,0.002177644,0.9978224
12582,juvenile rheumatoid arthritis,5,8,33,62,Flurbiprofen in the treatment of juvenile rheumatoid arthritis.,3560095_0,-1,-1,-1,12582,-1,0.006509756,0.9934902
12583,juvenile rheumatoid arthritis,3,6,26,55,"Thirty-four patients with juvenile rheumatoid arthritis, who were treated with flurbiprofen at a maximum dose of 4 mg/kg/day, had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment.",3560095_1,-1,-1,-1,12583,-1,0.003800744,0.9961992
12584,flurbiprofen,11,12,79,91,"Thirty-four patients with juvenile rheumatoid arthritis, who were treated with flurbiprofen at a maximum dose of 4 mg/kg/day, had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment.",3560095_1,-1,-1,-1,12584,-1,0.99930966,0.0006903579
12586,tender joints,7,9,40,53,"Improvements were seen in the number of tender joints, the severity of swelling and tenderness, the time of walk 50 feet, the duration of morning stiffness and the circumference of the left knee.",3560095_2,-1,-1,-1,12586,-1,0.0034514954,0.9965485
12587,swelling,13,14,71,79,"Improvements were seen in the number of tender joints, the severity of swelling and tenderness, the time of walk 50 feet, the duration of morning stiffness and the circumference of the left knee.",3560095_2,-1,-1,-1,12587,-1,0.0027027603,0.9972972
12588,tenderness,15,16,84,94,"Improvements were seen in the number of tender joints, the severity of swelling and tenderness, the time of walk 50 feet, the duration of morning stiffness and the circumference of the left knee.",3560095_2,-1,-1,-1,12588,-1,0.0030733135,0.9969267
12589,morning stiffness,27,29,138,155,"Improvements were seen in the number of tender joints, the severity of swelling and tenderness, the time of walk 50 feet, the duration of morning stiffness and the circumference of the left knee.",3560095_2,-1,-1,-1,12589,-1,0.0077741006,0.9922259
12590,gastrointestinal (GI) bleeding,25,30,123,153,"The most frequently observed side effect was fecal occult blood (25% of patients); however, there was no other evidence of gastrointestinal (GI) bleeding in these patients.",3560095_3,-1,-1,-1,12590,-1,0.0049002455,0.9950997
12592,abdominal pain,12,14,80,94,One patient was prematurely discontinued from the study for severe headache and abdominal pain.,3560095_4,-1,-1,-1,12592,-1,0.002351268,0.9976488
12595,NSAID,13,14,101,106,Hyperkalemia has recently been recognized as a complication of nonsteroidal antiinflammatory agents (NSAID) such as indomethacin.,3560096_1,-1,-1,-1,12595,-1,0.9981888,0.0018112549
12598,prostacyclin,20,21,122,134,"Several recent studies have stressed the renal sparing features of sulindac, owing to its lack of interference with renal prostacyclin synthesis.",3560096_2,-1,-1,-1,12598,-1,0.99906665,0.0009333392
12607,NSAID,19,20,123,128,These observations indicate that initial hopes that sulindac may not be associated with the adverse renal effects of other NSAID are probably not justified.,3560096_6,-1,-1,-1,12607,-1,0.99787533,0.002124692
12610,sodium pentothal,9,11,59,75,"Following major intracranial surgery in a 35-year-old man, sodium pentothal was intravenously infused to minimize cerebral ischaemia.",3564823_2,-1,-1,-1,12610,-1,0.9992329,0.00076708186
12611,ischaemia,17,18,123,132,"Following major intracranial surgery in a 35-year-old man, sodium pentothal was intravenously infused to minimize cerebral ischaemia.",3564823_2,-1,-1,-1,12611,-1,0.0031005663,0.9968995
12613,gangrene,4,5,34,42,Intense vasospasm with threatened gangrene arose in the arm used for the infusion.,3564823_3,-1,-1,-1,12613,-1,0.0022193086,0.99778074
12617,intracerebral,9,10,80,93,Regional localization of the antagonism of amphetamine-induced hyperactivity by intracerebral calcitonin injections.,3615541_0,-1,-1,-1,12617,-1,0.7073504,0.29264963
12627,cephalosporin hematotoxicity,15,17,85,113,The hematologic effects of cefonicid and cefazedone in the dog: a potential model of cephalosporin hematotoxicity in man.,3629586_0,-1,-1,-1,12627,-1,0.5167682,0.48323178
12628,hematologic disturbances,6,8,45,69,"Cephalosporin antibiotics cause a variety of hematologic disturbances in man, the pathogeneses and hematopathology of which remain poorly characterized.",3629586_1,-1,-1,-1,12628,-1,0.0028949715,0.99710506
12629,blood dyscrasias,12,14,63,79,There is a need for a well-defined animal model in which these blood dyscrasias can be studied.,3629586_2,-1,-1,-1,12629,-1,0.011568924,0.9884311
12637,cytopenias,9,10,58,68,A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50% of dogs receiving 400-500 mg/kg cefonicid or 540-840 mg/kg cefazedone.,3629586_4,-1,-1,-1,12637,-1,0.002348221,0.99765176
12640,cytopenias,2,3,10,20,All three cytopenias were completely reversible following cessation of treatment; the time required for recovery of the erythron (approximately 1 month) was considerably longer than that of the granulocytes and platelets (hours to a few days).,3629586_5,-1,-1,-1,12640,-1,0.0022282752,0.9977717
12641,cephalosporin,4,5,29,42,"Upon rechallenge with either cephalosporin, the hematologic syndrome was reproduced in most dogs tested; cefonicid (but not cefazedone)-treated dogs showed a substantially reduced induction period (15 +/- 5 days) compared to that of the first exposure to the drug (61 +/- 24 days).",3629586_6,-1,-1,-1,12641,-1,0.99921405,0.000785967
12642,hematologic syndrome,7,9,48,68,"Upon rechallenge with either cephalosporin, the hematologic syndrome was reproduced in most dogs tested; cefonicid (but not cefazedone)-treated dogs showed a substantially reduced induction period (15 +/- 5 days) compared to that of the first exposure to the drug (61 +/- 24 days).",3629586_6,-1,-1,-1,12642,-1,0.0024665713,0.99753344
12644,hemolytic,22,23,117,126,"This observation, along with the rapid rate of decline in red cell mass parameters of affected dogs, suggests that a hemolytic component complicated the red cell production problem and that multiple toxicologic mechanisms contributed to the cytopenia.",3629586_7,-1,-1,-1,12644,-1,0.0037461235,0.99625385
12645,cytopenia,38,39,241,250,"This observation, along with the rapid rate of decline in red cell mass parameters of affected dogs, suggests that a hemolytic component complicated the red cell production problem and that multiple toxicologic mechanisms contributed to the cytopenia.",3629586_7,-1,-1,-1,12645,-1,0.0023002808,0.9976997
12648,hematotoxicity,16,17,96,110,We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.,3629586_8,-1,-1,-1,12648,-1,0.002136651,0.99786335
12649,blood dyscrasias,21,23,148,164,We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.,3629586_8,-1,-1,-1,12649,-1,0.0038612206,0.99613875
12650,to,9,10,61,63,Urinary enzymes and protein patterns as indicators of injury to different regions of the kidney.,3653576_0,-1,-1,-1,12650,-1,0.058042318,0.9419577
12652,hexachloro-1:3-butadiene,24,25,147,171,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,-1,-1,12652,-1,0.99726295,0.0027369875
12653,HCBD,26,27,173,177,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,-1,-1,12653,-1,0.9973788,0.0026211992
12654,puromycin aminonucleoside,29,31,180,205,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,-1,-1,12654,-1,0.9970169,0.002983134
12655,PAN,32,33,207,210,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,-1,-1,12655,-1,0.9946721,0.0053279027
12656,2-bromoethylamine,36,37,217,234,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,-1,-1,12656,-1,0.9962515,0.0037485287
12657,BEA,38,39,236,239,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,-1,-1,-1,12657,-1,0.99090976,0.0090901945
12659,alkaline phosphatase,8,10,58,78,"Several routine indicators of nephrotoxicity, the enzymes alkaline phosphatase and N-acetyl-beta-glucosaminidase, and the molecular weight of protein excretion were determined on urine samples.",3653576_2,-1,-1,-1,12659,-1,0.9939215,0.006078464
12660,protein excretion,18,20,142,159,"Several routine indicators of nephrotoxicity, the enzymes alkaline phosphatase and N-acetyl-beta-glucosaminidase, and the molecular weight of protein excretion were determined on urine samples.",3653576_2,-1,-1,-1,12660,-1,0.4333232,0.5666768
12661,HCBD,4,5,27,31,Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN.,3653576_3,-1,-1,-1,12661,-1,0.9985448,0.0014552259
12662,BEA,6,7,35,38,Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN.,3653576_3,-1,-1,-1,12662,-1,0.99797124,0.0020288012
12663,glomerular damage,14,16,100,117,Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN.,3653576_3,-1,-1,-1,12663,-1,0.0031382039,0.9968618
12664,PAN,18,19,130,133,Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN.,3653576_3,-1,-1,-1,12664,-1,0.96644974,0.03355023
12665,protein excretion,9,11,57,74,"The latter was characterized by a pronounced increase in protein excretion, especially proteins with molecular weight greater than 40,000 Da.",3653576_4,-1,-1,-1,12665,-1,0.51241916,0.48758087
12666,Da,20,21,138,140,"The latter was characterized by a pronounced increase in protein excretion, especially proteins with molecular weight greater than 40,000 Da.",3653576_4,-1,-1,-1,12666,-1,0.86980236,0.13019766
12667,contrast,1,2,3,11,"In contrast, protein excretion in tubular damage was raised only slightly and characterized by excretion of proteins of a wide range of molecular weights.",3653576_5,-1,-1,-1,12667,-1,0.16932675,0.8306733
12668,protein excretion,3,5,13,30,"In contrast, protein excretion in tubular damage was raised only slightly and characterized by excretion of proteins of a wide range of molecular weights.",3653576_5,-1,-1,-1,12668,-1,0.42571816,0.5742818
12669,tubular damage,6,8,34,48,"In contrast, protein excretion in tubular damage was raised only slightly and characterized by excretion of proteins of a wide range of molecular weights.",3653576_5,-1,-1,-1,12669,-1,0.00440855,0.9955915
12670,excretion of proteins,15,18,95,116,"In contrast, protein excretion in tubular damage was raised only slightly and characterized by excretion of proteins of a wide range of molecular weights.",3653576_5,-1,-1,-1,12670,-1,0.2675931,0.7324069
12671,HCBD,5,6,34,38,Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.,3653576_6,-1,-1,-1,12671,-1,0.9953186,0.0046813693
12672,BEA,11,12,70,73,Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.,3653576_6,-1,-1,-1,12672,-1,0.9955812,0.004418766
12673,Alkaline phosphatase,0,2,0,20,Alkaline phosphatase and glucose were markedly and transiently elevated in proximal tubular damage and N-acetyl-beta-glucosaminidase showed a sustained elevation in papillary damage.,3653576_7,-1,-1,-1,12673,-1,0.9965758,0.00342422
12675,proximal tubular damage,10,13,75,98,Alkaline phosphatase and glucose were markedly and transiently elevated in proximal tubular damage and N-acetyl-beta-glucosaminidase showed a sustained elevation in papillary damage.,3653576_7,-1,-1,-1,12675,-1,0.009115511,0.9908845
12677,Reye,4,5,15,19,A catch in the Reye.,3670965_0,-1,-1,-1,12677,-1,0.61072296,0.38927704
12678,Reye syndrome,3,5,20,33,"Twenty-six cases of Reye syndrome from The Children's Hospital, Camperdown, Australia, occurring between 1973 and 1982 were reviewed.",3670965_1,-1,-1,-1,12678,-1,0.021177772,0.9788222
12679,Reye syndrome,20,22,110,123,"Of these, 20 cases met the US Public Health Service Centers for Disease Control criteria for the diagnosis of Reye syndrome.",3670965_2,-1,-1,-1,12679,-1,0.044720046,0.9552799
12681,salicylate,2,3,11,21,"Aspirin or salicylate ingestion had occurred in only one of the 20 cases (5%), and paracetamol (acetaminophen) had been administered in only six of the cases (30%).",3670965_3,-1,-1,-1,12681,-1,0.9987206,0.0012793451
12684,Reye syndrome,6,8,44,57,Pathologic confirmation of the diagnosis of Reye syndrome was accomplished in 90% of the cases.,3670965_4,-1,-1,-1,12684,-1,0.045230724,0.9547693
12685,Reye syndrome,3,5,17,30,"The incidence of Reye syndrome in New South Wales, Australia, is estimated from this study to be approximately nine cases per 1 million children compared with recent US data of ten to 20 cases per 1 million children and three to seven cases per 1 million children in Great Britain.",3670965_5,-1,-1,-1,12685,-1,0.018957151,0.98104286
12686,Reye syndrome,4,6,24,37,The mortality for these Reye syndrome cases in Australia was 45% as compared with a 32% case-fatality rate in the United States.,3670965_6,-1,-1,-1,12686,-1,0.01726515,0.98273486
12690,Reye syndrome,0,2,0,13,"Reye syndrome may be disappearing from Australia despite a total lack of association with salicylates or aspirin ingestion, since there were no cases found at The Children's Hospital in 1983, 1984, or 1985.",3670965_8,-1,-1,-1,12690,-1,0.008917606,0.99108243
12691,salicylates,14,15,90,101,"Reye syndrome may be disappearing from Australia despite a total lack of association with salicylates or aspirin ingestion, since there were no cases found at The Children's Hospital in 1983, 1984, or 1985.",3670965_8,-1,-1,-1,12691,-1,0.9986878,0.0013121456
12694,cerebral aneurysms,14,16,110,128,Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.,3676049_0,-1,-1,-1,12694,-1,0.002864412,0.99713564
12697,cerebral aneurysm,24,26,168,185,Cerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.,3676049_1,-1,-1,-1,12697,-1,0.004269445,0.9957306
12698,subarachnoid haemorrhage,11,13,54,78,Flow and metabolism were measured 5-13 days after the subarachnoid haemorrhage by a modification of the classical Kety-Schmidt technique using xenon-133 i.v.,3676049_2,-1,-1,-1,12698,-1,0.006870516,0.99312943
12700,nitrous oxide,15,17,88,101,"Anaesthesia was maintained with an inspired isoflurane concentration of 0.75% (plus 67% nitrous oxide in oxygen), during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa (mean +/- SEM).",3676049_3,-1,-1,-1,12700,-1,0.9987179,0.0012820647
12703,MAP,5,6,37,40,"Controlled hypotension to an average MAP of 50-55 mm Hg was induced by increasing the dose of isoflurane, and maintained at an inspired concentration of 2.2 +/- 0.2%.",3676049_4,-1,-1,-1,12703,-1,0.017124835,0.9828752
12704,mm Hg,10,12,50,55,"Controlled hypotension to an average MAP of 50-55 mm Hg was induced by increasing the dose of isoflurane, and maintained at an inspired concentration of 2.2 +/- 0.2%.",3676049_4,-1,-1,-1,12704,-1,0.09183643,0.9081636
12709,psychosis,1,2,11,20,Postpartum psychosis induced by bromocriptine.,3686155_0,-1,-1,-1,12709,-1,0.0021814746,0.99781847
12712,psychosis,12,13,86,95,"Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis, having received bromocriptine for inhibition of lactation.",3686155_1,-1,-1,-1,12712,-1,0.002114699,0.9978853
12714,inhibition of lactation,18,21,131,154,"Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis, having received bromocriptine for inhibition of lactation.",3686155_1,-1,-1,-1,12714,-1,0.73640376,0.26359627
12715,psychosis,9,10,59,68,Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson's disease.,3686155_2,-1,-1,-1,12715,-1,0.0022169878,0.997783
12716,Parkinson's disease,16,19,104,123,Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson's disease.,3686155_2,-1,-1,-1,12716,-1,0.0052233213,0.9947767
12718,psychosis,7,8,53,62,These cases demonstrate that bromocriptine may cause psychosis even when given in low doses.,3686155_3,-1,-1,-1,12718,-1,0.0020836233,0.9979164
12719,mania,5,6,46,51,Triazolam-induced brief episodes of secondary mania in a depressed patient.,3693336_0,-1,-1,-1,12719,-1,0.0021989828,0.997801
12721,triazolam,3,4,15,24,Large doses of triazolam repeatedly induced brief episodes of mania in a depressed elderly woman.,3693336_1,-1,-1,-1,12721,-1,0.99936265,0.00063741964
12722,mania,9,10,62,67,Large doses of triazolam repeatedly induced brief episodes of mania in a depressed elderly woman.,3693336_1,-1,-1,-1,12722,-1,0.0023310126,0.9976689
12724,organic mental disorder,2,5,12,35,Features of organic mental disorder (delirium) were not present.,3693336_2,-1,-1,-1,12724,-1,0.0049434826,0.9950565
12726,triazolam,10,11,63,72,Manic excitement was coincident with the duration of action of triazolam.,3693336_3,-1,-1,-1,12726,-1,0.9994252,0.00057482946
12727,triazolo,5,6,33,41,The possible contribution of the triazolo group to changes in affective status is discussed.,3693336_4,-1,-1,-1,12727,-1,0.9988751,0.0011248817
12731,lethargy,10,11,65,73,"Following short exposure to oral prednisone, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.",3703509_2,-1,-1,-1,12731,-1,0.002827645,0.9971724
12734,polyphagia,17,18,110,120,"Following short exposure to oral prednisone, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.",3703509_2,-1,-1,-1,12734,-1,0.0059116767,0.9940883
12738,hyperglycemia,13,14,77,90,"Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.",3703509_3,-1,-1,-1,12738,-1,0.0032010044,0.996799
12740,lactic acidosis,1,3,11,26,Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.,3703509_4,-1,-1,-1,12740,-1,0.011779081,0.98822093
12741,ketosis,8,9,50,57,Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.,3703509_4,-1,-1,-1,12741,-1,0.0074640024,0.99253607
12742,lactate,13,14,80,87,Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.,3703509_4,-1,-1,-1,12742,-1,0.99787927,0.0021207165
12743,Respiratory failure,0,2,0,19,Respiratory failure rapidly ensued and both patients expired in spite of efforts at resuscitation.,3703509_5,-1,-1,-1,12743,-1,0.0030546915,0.9969453
12744,cyclosporine nephrotoxicity,1,3,13,40,Experimental cyclosporine nephrotoxicity: risk of concomitant chemotherapy.,3708922_0,-1,-1,-1,12744,-1,0.21205144,0.7879486
12746,CSA,5,6,26,29,The role of cyclosporine (CSA) alone or in combination with various chemotherapeutics in the development of renal toxicity was evaluated in rats.,3708922_1,-1,-1,-1,12746,-1,0.9981566,0.001843391
12748,CSA,4,5,31,34,Administration of 20 mg/kg/day CSA for 4 weeks caused renal functional and structural changes similar to those reported in man.,3708922_2,-1,-1,-1,12748,-1,0.9990736,0.0009263782
12749,CSA,4,5,31,34,"The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.",3708922_3,-1,-1,-1,12749,-1,0.99874926,0.0012507245
12752,amphothericin B,23,25,143,158,"The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.",3708922_3,-1,-1,-1,12752,-1,0.9981712,0.0018288273
12754,CSA,40,41,255,258,"The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.",3708922_3,-1,-1,-1,12754,-1,0.9980738,0.0019261736
12757,CSA nephrotoxicity,8,10,46,64,"Gentamicin at toxic doses, however, increased CSA nephrotoxicity.",3708922_4,-1,-1,-1,12757,-1,0.050680194,0.94931984
12759,CSA,6,7,36,39,"Thus, the nephrotoxicity induced by CSA has a different pathogenetic mechanism.",3708922_5,-1,-1,-1,12759,-1,0.9987575,0.0012425358
12761,neuropathic damage,8,10,75,93,The correlation between neurotoxic esterase inhibition and mipafox-induced neuropathic damage in rats.,3714122_0,-1,-1,-1,12761,-1,0.0021787195,0.99782133
12762,neuropathic damage,3,5,24,42,"The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.",3714122_1,-1,-1,-1,12762,-1,0.002302994,0.99769694
12765,Mipafox,24,25,155,162,"The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.",3714122_1,-1,-1,-1,12765,-1,0.99929535,0.0007046464
12766,"N, N'-diisopropylphosphorodiamidofluoridate",26,29,164,207,"The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.",3714122_1,-1,-1,-1,12766,-1,0.9964359,0.003564158
12767,neurotoxic organophosphate,32,34,212,238,"The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.",3714122_1,-1,-1,-1,12767,-1,0.30131355,0.6986865
12768,Mipafox,19,20,116,123,"Brain and spinal cord NTE activities were measured in Long-Evans male rats 1 hr post-exposure to various dosages of Mipafox (ip, 1-15 mg/kg).",3714122_2,-1,-1,-1,12768,-1,0.99945647,0.0005435373
12769,cord damage,8,10,63,74,These data were correlated with histologically scored cervical cord damage in a separate group of similarly dosed rats sampled 14-21 days post-exposure.,3714122_3,-1,-1,-1,12769,-1,0.0030084276,0.9969915
12770,contrast,1,2,3,11,"In contrast, dosages of Mipafox (less than or equal to 5 mg/kg) which inhibited mean NTE activity in spinal cord less than or equal to 61% and brain less than or equal to 60% produced this degree of cord damage in only 9% of the animals.",3714122_5,-1,-1,-1,12770,-1,0.19958867,0.8004113
12771,Mipafox,5,6,24,31,"In contrast, dosages of Mipafox (less than or equal to 5 mg/kg) which inhibited mean NTE activity in spinal cord less than or equal to 61% and brain less than or equal to 60% produced this degree of cord damage in only 9% of the animals.",3714122_5,-1,-1,-1,12771,-1,0.9994499,0.00055011065
12772,cord damage,43,45,199,210,"In contrast, dosages of Mipafox (less than or equal to 5 mg/kg) which inhibited mean NTE activity in spinal cord less than or equal to 61% and brain less than or equal to 60% produced this degree of cord damage in only 9% of the animals.",3714122_5,-1,-1,-1,12772,-1,0.0038010366,0.99619895
12773,Mipafox,18,19,112,119,These data indicate that a critical percentage of NTE inhibition in brain and spinal cord sampled shortly after Mipafox exposure can predict neuropathic damage in rats several weeks later.,3714122_6,-1,-1,-1,12773,-1,0.9994056,0.00059441256
12774,neuropathic damage,22,24,141,159,These data indicate that a critical percentage of NTE inhibition in brain and spinal cord sampled shortly after Mipafox exposure can predict neuropathic damage in rats several weeks later.,3714122_6,-1,-1,-1,12774,-1,0.0025039397,0.99749607
12777,angioneurotic edema,5,7,35,54,"An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.",3719553_1,-1,-1,-1,12777,-1,0.002719517,0.9972805
12779,carcinoma of the oral cavity,18,23,140,168,"An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.",3719553_1,-1,-1,-1,12779,-1,0.021109294,0.9788907
12781,impaired renal function,28,31,203,226,"An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.",3719553_1,-1,-1,-1,12781,-1,0.005445026,0.994555
12782,diphenhydramine,1,2,5,20,Oral diphenhydramine and prednisone were ineffective in preventing the recurrence of the allergic reaction.,3719553_3,-1,-1,-1,12782,-1,0.9992306,0.0007693619
12785,disease progression,13,15,100,119,Discontinuance of effective chemotherapy in this patient during partial remission resulted in fatal disease progression.,3719553_4,-1,-1,-1,12785,-1,0.0029324188,0.99706763
12788,hypertensive coronary disease,6,9,40,69,"Diuretics, potassium and arrhythmias in hypertensive coronary disease.",3732088_0,-1,-1,-1,12788,-1,0.004219461,0.9957806
12791,coronary artery disease,7,10,31,54,"If this were so, patients with coronary artery disease might be especially susceptible.",3732088_2,-1,-1,-1,12791,-1,0.007669572,0.99233043
12792,essential hypertension,11,13,76,98,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,-1,-1,-1,12792,-1,0.005564492,0.9944354
12793,coronary artery disease,15,18,109,132,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,-1,-1,-1,12793,-1,0.0036683835,0.99633163
12794,diuretic,26,27,188,196,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,-1,-1,-1,12794,-1,0.99681205,0.0031879642
12796,chlorthalidone,39,40,262,276,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,-1,-1,-1,12796,-1,0.9992493,0.00075073744
12798,chlorthalidone,11,12,74,88,Plasma potassium concentrations were on average 1 mmol/L lower during the chlorthalidone phase compared to amiloride therapy.,3732088_4,-1,-1,-1,12798,-1,0.99933785,0.0006621842
12803,chlorthalidone,6,7,37,51,"Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.",3732088_6,-1,-1,-1,12803,-1,0.9992569,0.00074302603
12804,ventricular ectopic beats,15,18,104,129,"Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.",3732088_6,-1,-1,-1,12804,-1,0.004540294,0.99545974
12805,ischaemic heart disease,17,20,139,162,"The above results indicate that because potassium-losing diuretic therapy can increase myocardial electrical excitability in patients with ischaemic heart disease, even minor falls in plasma potassium concentrations are probably best avoided in such patients.",3732088_7,-1,-1,-1,12805,-1,0.0032083078,0.99679166
12810,myasthenia gravis,11,13,71,88,We have described a unique patient who had reversible and dose-related myasthenia gravis after penicillamine and chloroquine therapy for rheumatoid arthritis.,3750012_1,-1,-1,-1,12810,-1,0.0031789504,0.99682105
12815,Wernicke's encephalopathy,4,7,48,73,Transketolase abnormality in tolazamide-induced Wernicke's encephalopathy.,3762968_0,-1,-1,-1,12815,-1,0.022054592,0.9779454
12817,Wernicke's encephalopathy,16,19,108,133,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,-1,-1,-1,12817,-1,0.016671207,0.9833288
12818,tolazamide,22,23,152,162,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,-1,-1,-1,12818,-1,0.999146,0.0008539472
12819,thiamine pyrophosphate,39,41,250,272,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,-1,-1,-1,12819,-1,0.9975822,0.002417741
12820,TPP,42,43,274,277,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,-1,-1,-1,12820,-1,0.99027306,0.009726932
12822,Wernicke's encephalopathy,19,22,109,134,"In addition to this patient, we also studied this enzyme from three diabetic kindreds without any history of Wernicke's encephalopathy and from four normal controls.",3762968_2,-1,-1,-1,12822,-1,0.11974927,0.8802507
12824,Wernicke's encephalopathy,16,19,94,119,We found that the above-mentioned patient and one of the diabetic kindreds with no history of Wernicke's encephalopathy had abnormal transketolase as determined by its Km for TPP.,3762968_3,-1,-1,-1,12824,-1,0.13973686,0.8602631
12825,TPP,28,29,175,178,We found that the above-mentioned patient and one of the diabetic kindreds with no history of Wernicke's encephalopathy had abnormal transketolase as determined by its Km for TPP.,3762968_3,-1,-1,-1,12825,-1,0.9976307,0.0023692383
12826,Wernicke's encephalopathy,14,17,122,147,These data suggest a similarity between postalcoholic Wernicke-Korsakoff syndrome and the patient with tolazamide-induced Wernicke's encephalopathy from the standpoint of transketolase abnormality.,3762968_4,-1,-1,-1,12826,-1,0.021419493,0.9785805
12827,trihexyphenidyl hydrochloride,3,5,19,48,Bradycardia due to trihexyphenidyl hydrochloride.,3769769_0,-1,-1,-1,12827,-1,0.9987047,0.0012953201
12829,trihexyphenidyl hydrochloride,11,13,74,103,"A chronic schizophrenic patient was treated with an anticholinergic drug, trihexyphenidyl hydrochloride.",3769769_1,-1,-1,-1,12829,-1,0.9987986,0.0012013705
12836,respiratory failure,7,9,48,67,A case of thoraco-abdominal rigidity leading to respiratory failure is described in the post-operative period in an elderly patient who received a moderate dose of fentanyl.,3780697_1,-1,-1,-1,12836,-1,0.0027903987,0.9972096
12840,diethylnitrosamine,7,8,68,86,Anti-carcinogenic action of phenobarbital given simultaneously with diethylnitrosamine in the rat.,3780814_0,-1,-1,-1,12840,-1,0.99875414,0.0012458949
12842,PB,15,16,85,87,The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).,3780814_1,-1,-1,-1,12842,-1,0.9982741,0.0017258509
12843,mg,18,19,92,94,The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).,3780814_1,-1,-1,-1,12843,-1,0.88780993,0.11219004
12845,diethylnitrosamine,33,34,183,201,The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).,3780814_1,-1,-1,-1,12845,-1,0.9986298,0.0013702178
12846,DEN,35,36,203,206,The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).,3780814_1,-1,-1,-1,12846,-1,0.9976701,0.0023298818
12847,DEN,9,10,36,39,"Wistar rats (180 g) were treated by DEN alone or by DEN + PB during 2, 4 and 6 weeks according to our schedule for hepatocarcinogenesis.",3780814_2,-1,-1,-1,12847,-1,0.9983164,0.0016836019
12848,DEN,13,14,52,55,"Wistar rats (180 g) were treated by DEN alone or by DEN + PB during 2, 4 and 6 weeks according to our schedule for hepatocarcinogenesis.",3780814_2,-1,-1,-1,12848,-1,0.9980557,0.0019443377
12849,PB,15,16,58,60,"Wistar rats (180 g) were treated by DEN alone or by DEN + PB during 2, 4 and 6 weeks according to our schedule for hepatocarcinogenesis.",3780814_2,-1,-1,-1,12849,-1,0.9981699,0.001830116
12850,hepatocarcinogenesis,28,29,115,135,"Wistar rats (180 g) were treated by DEN alone or by DEN + PB during 2, 4 and 6 weeks according to our schedule for hepatocarcinogenesis.",3780814_2,-1,-1,-1,12850,-1,0.0026853138,0.99731463
12851,PAS,14,15,67,70,"After the end of the treatment, the number and the size of induced PAS positive preneoplastic foci was significantly reduced when PB was given simultaneously with DEN for 4 and 6 weeks.",3780814_3,-1,-1,-1,12851,-1,0.9919152,0.0080847815
12852,preneoplastic foci,16,18,80,98,"After the end of the treatment, the number and the size of induced PAS positive preneoplastic foci was significantly reduced when PB was given simultaneously with DEN for 4 and 6 weeks.",3780814_3,-1,-1,-1,12852,-1,0.005471376,0.9945286
12853,PB,22,23,130,132,"After the end of the treatment, the number and the size of induced PAS positive preneoplastic foci was significantly reduced when PB was given simultaneously with DEN for 4 and 6 weeks.",3780814_3,-1,-1,-1,12853,-1,0.99762493,0.0023750213
12854,DEN,27,28,163,166,"After the end of the treatment, the number and the size of induced PAS positive preneoplastic foci was significantly reduced when PB was given simultaneously with DEN for 4 and 6 weeks.",3780814_3,-1,-1,-1,12854,-1,0.9979169,0.002083177
12855,DEN,14,15,104,107,The mitotic inhibition and the production of micronuclei normally observed after partial hepatectomy in DEN treated rats were also significantly decreased in DEN + PB treated rats.,3780814_4,-1,-1,-1,12855,-1,0.9960955,0.003904562
12856,DEN,22,23,158,161,The mitotic inhibition and the production of micronuclei normally observed after partial hepatectomy in DEN treated rats were also significantly decreased in DEN + PB treated rats.,3780814_4,-1,-1,-1,12856,-1,0.9964065,0.0035934865
12857,PB,24,25,164,166,The mitotic inhibition and the production of micronuclei normally observed after partial hepatectomy in DEN treated rats were also significantly decreased in DEN + PB treated rats.,3780814_4,-1,-1,-1,12857,-1,0.9980348,0.0019651775
12858,PB,11,12,54,56,"When the treatment last only 2 weeks, the presence of PB did not change significantly the last parameters.",3780814_5,-1,-1,-1,12858,-1,0.9969626,0.0030373295
12859,DEN,1,2,3,6,"In DEN + PB treated rats, the survival was prolonged and the tumor incidence decreased as compared with the results obtained by DEN alone.",3780814_6,-1,-1,-1,12859,-1,0.9978126,0.0021873822
12860,PB,3,4,9,11,"In DEN + PB treated rats, the survival was prolonged and the tumor incidence decreased as compared with the results obtained by DEN alone.",3780814_6,-1,-1,-1,12860,-1,0.9981445,0.0018555076
12862,DEN,23,24,128,131,"In DEN + PB treated rats, the survival was prolonged and the tumor incidence decreased as compared with the results obtained by DEN alone.",3780814_6,-1,-1,-1,12862,-1,0.99825567,0.0017442919
12863,PB,4,5,21,23,"It is concluded that PB, which promotes carcinogenesis when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with DEN.",3780814_7,-1,-1,-1,12863,-1,0.9981896,0.001810354
12865,DEN,13,14,83,86,"It is concluded that PB, which promotes carcinogenesis when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with DEN.",3780814_7,-1,-1,-1,12865,-1,0.9979254,0.0020745352
12866,DEN,24,25,159,162,"It is concluded that PB, which promotes carcinogenesis when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with DEN.",3780814_7,-1,-1,-1,12866,-1,0.99811804,0.001881935
12867,precancerous lesions,17,19,88,108,This 'anti-carcinogen' effect acts on the initiation as well as on the promotion of the precancerous lesions.,3780814_8,-1,-1,-1,12867,-1,0.0065600085,0.99344
12868,PB,14,15,95,97,Biochemical investigations are in progress to obtain more information about this 'paradoxical' PB effect.,3780814_9,-1,-1,-1,12868,-1,0.99636686,0.0036331082
12869,muscular rigidity,10,12,57,74,On the mechanisms of the development of tolerance to the muscular rigidity produced by morphine in rats.,3780846_0,-1,-1,-1,12869,-1,0.0034998194,0.99650013
12871,muscular rigidity,6,8,36,53,The development of tolerance to the muscular rigidity produced by morphine was studied in rats.,3780846_1,-1,-1,-1,12871,-1,0.002679065,0.99732095
12876,h,13,14,63,64,Rats treated for 11 days with morphine and withdrawn for 36-40 h showed differences in the development of tolerance: about half of the animals showed a rigidity after the test dose of morphine that was not significantly less than in the controls and were akinetic (A group).,3780846_3,-1,-1,-1,12876,-1,0.44850007,0.55149996
12882,hyperkinetic,26,27,144,156,"The other rats showed a strong decrease in the rigidity and the occurrence of stereotyped (S) licking and/or gnawing in presence of akinetic or hyperkinetic (K) behaviour (AS/KS group), suggesting signs of dopaminergic activation.",3780846_4,-1,-1,-1,12882,-1,0.0043996717,0.99560034
12892,molindone,6,7,43,52,A case of massive rhabdomyolysis following molindone administration.,3782049_0,-1,-1,-1,12892,-1,0.9991381,0.00086179934
12895,signs and symptoms,2,5,13,31,"The clinical signs and symptoms, typical laboratory features, and complications of rhabdomyolysis are presented.",3782049_2,-1,-1,-1,12895,-1,0.01053326,0.9894667
12899,acute renal failure,14,17,100,119,The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following molindone administration.,3782049_3,-1,-1,-1,12899,-1,0.0024938341,0.9975062
12900,molindone,18,19,130,139,The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following molindone administration.,3782049_3,-1,-1,-1,12900,-1,0.99924266,0.0007574165
12901,molindone,3,4,25,34,Physicians who prescribe molindone should be aware of this reaction.,3782049_4,-1,-1,-1,12901,-1,0.9991709,0.00082907866
12902,Compression neuropathy,0,2,0,22,Compression neuropathy of the radial nerve due to pentazocine-induced fibrous myopathy.,3800626_0,-1,-1,-1,12902,-1,0.003433335,0.99656665
12903,fibrous myopathy,9,11,70,86,Compression neuropathy of the radial nerve due to pentazocine-induced fibrous myopathy.,3800626_0,-1,-1,-1,12903,-1,0.0031206075,0.99687934
12904,Fibrous myopathy,0,2,0,16,"Fibrous myopathy is a common, well-known side effect of repeated pentazocine injection.",3800626_1,-1,-1,-1,12904,-1,0.0026867506,0.9973132
12906,compression neuropathy,2,4,9,31,"However, compression neuropathy due to fibrotic muscle affected by pentazocine-induced myopathy has not previously been reported.",3800626_2,-1,-1,-1,12906,-1,0.0032408177,0.99675924
12908,fibrous myopathy,7,9,59,75,"In a 37-year-old woman with documented pentazocine-induced fibrous myopathy of triceps and deltoid muscles bilaterally and a three-week history of right wrist drop, electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps, in addition to the fibrous myopathy.",3800626_3,-1,-1,-1,12908,-1,0.0031675056,0.99683255
12909,fibrous myopathy,49,51,314,330,"In a 37-year-old woman with documented pentazocine-induced fibrous myopathy of triceps and deltoid muscles bilaterally and a three-week history of right wrist drop, electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps, in addition to the fibrous myopathy.",3800626_3,-1,-1,-1,12909,-1,0.0030456842,0.9969543
12910,acute renal failure,2,5,21,40,Recurrent reversible acute renal failure from amphotericin.,3827439_0,-1,-1,-1,12910,-1,0.0025084978,0.9974915
12911,amphotericin,6,7,46,58,Recurrent reversible acute renal failure from amphotericin.,3827439_0,-1,-1,-1,12911,-1,0.99923813,0.00076187484
12913,sporotrichosis,7,8,54,68,A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions.,3827439_1,-1,-1,-1,12913,-1,0.01890262,0.98109734
12914,acute renal failure,9,12,79,98,A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions.,3827439_1,-1,-1,-1,12914,-1,0.0025525265,0.9974475
12915,amphotericin B,17,19,143,157,A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions.,3827439_1,-1,-1,-1,12915,-1,0.99889153,0.0011084386
12916,renal failure,4,6,22,35,The abruptness of the renal failure and its reversibility within days suggests that there was a functional component to the renal dysfunction.,3827439_2,-1,-1,-1,12916,-1,0.002799111,0.99720085
12918,amphotericin,3,4,16,28,"We propose that amphotericin, in the setting of reduced effective arterial volume, may activate tubuloglomerular feedback, thereby contributing to acute renal failure.",3827439_3,-1,-1,-1,12918,-1,0.9993337,0.0006662453
12919,acute renal failure,22,25,147,166,"We propose that amphotericin, in the setting of reduced effective arterial volume, may activate tubuloglomerular feedback, thereby contributing to acute renal failure.",3827439_3,-1,-1,-1,12919,-1,0.002635968,0.997364
12920,phenylpropanolamine,8,9,47,66,Cerebral infarction with a single oral dose of phenylpropanolamine.,3828020_0,-1,-1,-1,12920,-1,0.9991085,0.00089143886
12921,Phenylpropanolamine,0,1,0,19,"Phenylpropanolamine (PPA), a synthetic sympathomimetic that is structurally similar to amphetamine, is available over the counter in anorectics, nasal congestants, and cold preparations.",3828020_1,-1,-1,-1,12921,-1,0.99908113,0.00091886753
12922,PPA,2,3,21,24,"Phenylpropanolamine (PPA), a synthetic sympathomimetic that is structurally similar to amphetamine, is available over the counter in anorectics, nasal congestants, and cold preparations.",3828020_1,-1,-1,-1,12922,-1,0.9968251,0.003174876
12925,intracerebral hemorrhage,11,13,64,88,"Its prolonged use or overuse has been associated with seizures, intracerebral hemorrhage, neuropsychiatric symptoms, and nonhemorrhagic cerebral infarction.",3828020_2,-1,-1,-1,12925,-1,0.0026093482,0.9973907
12926,neuropsychiatric symptoms,14,16,90,115,"Its prolonged use or overuse has been associated with seizures, intracerebral hemorrhage, neuropsychiatric symptoms, and nonhemorrhagic cerebral infarction.",3828020_2,-1,-1,-1,12926,-1,0.0025485717,0.99745136
12928,cerebral infarction,11,13,51,70,We report the case of a young woman who suffered a cerebral infarction after taking a single oral dose of PPA.,3828020_3,-1,-1,-1,12928,-1,0.0021231107,0.9978769
12929,PPA,20,21,106,109,We report the case of a young woman who suffered a cerebral infarction after taking a single oral dose of PPA.,3828020_3,-1,-1,-1,12929,-1,0.99864525,0.0013547976
12930,Bilateral optic neuropathy,0,3,0,26,Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment.,384871_0,-1,-1,-1,12930,-1,0.003039356,0.9969606
12931,ethambutol,6,7,43,53,Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment.,384871_0,-1,-1,-1,12931,-1,0.99900144,0.000998555
12933,ethambutol,17,18,116,126,The case of a 40-year-old patient who underwent an unsuccessful cadaver kidney transplantation and was treated with ethambutol and isoniazid is reported.,384871_1,-1,-1,-1,12933,-1,0.99876875,0.0012312557
12935,bilateral retrobulbar neuropathy,1,4,2,34,A bilateral retrobulbar neuropathy with an unusual central bitemporal hemianopic scotoma was found.,384871_2,-1,-1,-1,12935,-1,0.010489051,0.98951095
12936,scotoma,10,11,81,88,A bilateral retrobulbar neuropathy with an unusual central bitemporal hemianopic scotoma was found.,384871_2,-1,-1,-1,12936,-1,0.002807976,0.9971921
12937,Ethambutol,0,1,0,10,Ethambutol was stopped and only small improvement of the visual acuity followed.,384871_3,-1,-1,-1,12937,-1,0.99891925,0.0010808124
12939,optic nerve toxicity,3,6,15,35,The hazards of optic nerve toxicity due to ethambutol are known.,384871_5,-1,-1,-1,12939,-1,0.0031582776,0.9968418
12940,ethambutol,8,9,43,53,The hazards of optic nerve toxicity due to ethambutol are known.,384871_5,-1,-1,-1,12940,-1,0.99915767,0.00084232807
12941,ethambutol,9,10,48,58,We emphasize the potential danger in the use of ethambutol and isoniazid.,384871_6,-1,-1,-1,12941,-1,0.9989568,0.0010431345
12943,meningeal leukemia,3,5,23,41,Remission induction of meningeal leukemia with high-dose intravenous methotrexate.,3856631_0,-1,-1,-1,12943,-1,0.0035871915,0.9964128
12946,meningeal disease,8,10,64,81,Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing.,3856631_1,-1,-1,-1,12946,-1,0.00294926,0.99705076
12947,methotrexate regimen,16,18,124,144,Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing.,3856631_1,-1,-1,-1,12947,-1,0.9895148,0.010485223
12950,Leucovorin,0,1,0,10,"Leucovorin rescue was initiated 12 hours after the end of the infusion with a loading dose of 200 mg/m2 followed by 12 mg/m2 every three hours for six doses and then every six hours until the plasma methotrexate level decreased to less than 1 X 10(-7) mol/L. The mean steady-state plasma and CSF methotrexate concentrations achieved were 1.1 X 10(-3) mol/L and 3.6 X 10(-5) mol/L, respectively.",3856631_3,-1,-1,-1,12950,-1,0.9993585,0.00064158184
12958,transient hemiparesis,6,8,35,56,One patient had focal seizures and transient hemiparesis but recovered completely.,3856631_6,-1,-1,-1,12958,-1,0.0027231183,0.99727684
12961,cyclosporin A,2,4,15,28,Interaction of cyclosporin A with antineoplastic agents.,3865016_0,-1,-1,-1,12961,-1,0.99868494,0.0013150866
12962,antineoplastic agents,5,7,34,55,Interaction of cyclosporin A with antineoplastic agents.,3865016_0,-1,-1,-1,12962,-1,0.88899046,0.111009516
12964,cyclosporin A,6,8,38,51,A synergistic effect of etoposide and cyclosporin A was observed in a patient with acute T-lymphocytic leukemia in relapse.,3865016_1,-1,-1,-1,12964,-1,0.9983051,0.0016948485
12966,cyclosporin A,6,8,48,61,The concomitant administration of etoposide and cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow.,3865016_2,-1,-1,-1,12966,-1,0.99841154,0.0015884974
12967,leukemic infiltration,14,16,109,130,The concomitant administration of etoposide and cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow.,3865016_2,-1,-1,-1,12967,-1,0.002714411,0.9972856
12969,hyperbilirubinemia,10,11,65,83,"Severe side effects in terms of mental confusion and progressive hyperbilirubinemia, however, point to an enhancement not only of antineoplastic effects but also of toxicity in normal tissues.",3865016_3,-1,-1,-1,12969,-1,0.04747374,0.9525262
12971,cyclosporin A,12,14,83,96,This report demonstrates for the first time that the pharmacodynamic properties of cyclosporin A may not be confined strictly to suppression of normal T-cell functions.,3865016_4,-1,-1,-1,12971,-1,0.9991128,0.0008871855
12977,thrombophlebitis,2,3,19,35,"Reactions included thrombophlebitis (20 of 54 patients), rash (4 of 54), nephrotoxicity (4 of 50), proteinuria (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry).",3934126_4,-1,-1,-1,12977,-1,0.003621828,0.9963781
12982,Thrombophlebitis,0,1,0,16,Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.,3934126_5,-1,-1,-1,12982,-1,0.0024305452,0.9975694
12995,P,16,17,108,109,"When the parameters were examined individually, duration of therapy and total AUC correlated significantly (P less than .05) with nephrotoxicity.",3950060_5,-1,-1,-1,12995,-1,0.34321645,0.6567836
12997,contrast,1,2,3,11,"In contrast, a stepwise discriminant function analysis identified only duration of therapy (P less than .001) as an important factor.",3950060_6,-1,-1,-1,12997,-1,0.2815331,0.71846694
12998,P,14,15,92,93,"In contrast, a stepwise discriminant function analysis identified only duration of therapy (P less than .001) as an important factor.",3950060_6,-1,-1,-1,12998,-1,0.4739159,0.5260841
13000,P,25,26,120,121,"When examined individually, mean IF, MIC, total dose, mean daily dose, and ln (mean Cmax/MIC) correlated significantly (P less than .05) with cure.",3950060_8,-1,-1,-1,13000,-1,0.37226763,0.62773234
13001,contrast,1,2,3,11,"In contrast, a simultaneous multivariable analysis identified IF, MIC, and total dose according to one model and ln (mean Cmax/MIC) according to a second statistical model of parameters selected to have the greatest prospective value.",3950060_9,-1,-1,-1,13001,-1,0.23205346,0.76794654
13003,angina,6,7,32,38,Report of a case of spontaneous angina.,3952818_1,-1,-1,-1,13003,-1,0.002786609,0.9972134
13005,metastasis,12,13,61,71,We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.,3952818_2,-1,-1,-1,13005,-1,0.0027421126,0.9972579
13006,chest pain,15,17,86,96,We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.,3952818_2,-1,-1,-1,13006,-1,0.0028596027,0.9971404
13008,5-FU,20,21,119,123,We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.,3952818_2,-1,-1,-1,13008,-1,0.997997,0.0020029652
13009,Prinzmetal's angina,9,12,72,91,"Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with nifedipine.",3952818_3,-1,-1,-1,13009,-1,0.4515731,0.5484269
13010,chest pain,14,16,97,107,"Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with nifedipine.",3952818_3,-1,-1,-1,13010,-1,0.0030881707,0.9969118
13014,5-FU,14,15,81,85,"These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.",3952818_4,-1,-1,-1,13014,-1,0.9982193,0.0017806912
13016,5-FU cardiotoxicity,30,32,171,190,"These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.",3952818_4,-1,-1,-1,13016,-1,0.30597308,0.69402695
13020,TOTP),3,5,27,32,"Tri-ortho-tolyl phosphate (TOTP), 360 mg/kg, po, and 0,0'-diisopropyl phosphorofluoridate (DFP), 1 mg/kg sc, were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone.",3961813_1,-1,-1,-1,13020,-1,0.9945117,0.005488314
13021,"0,0'-diisopropyl phosphorofluoridate",12,14,53,89,"Tri-ortho-tolyl phosphate (TOTP), 360 mg/kg, po, and 0,0'-diisopropyl phosphorofluoridate (DFP), 1 mg/kg sc, were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone.",3961813_1,-1,-1,-1,13021,-1,0.9960056,0.0039943736
13022,DFP,15,16,91,94,"Tri-ortho-tolyl phosphate (TOTP), 360 mg/kg, po, and 0,0'-diisopropyl phosphorofluoridate (DFP), 1 mg/kg sc, were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone.",3961813_1,-1,-1,-1,13022,-1,0.9970252,0.0029748247
13027,TOTP,35,36,213,217,"Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on TOTP-induced neuropathy, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.",3961813_3,-1,-1,-1,13027,-1,0.99811137,0.0018886197
13028,DFP,37,38,221,224,"Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on TOTP-induced neuropathy, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.",3961813_3,-1,-1,-1,13028,-1,0.998437,0.0015630564
13029,TOTP,6,7,43,47,Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.,3961813_4,-1,-1,-1,13029,-1,0.9983182,0.0016818359
13030,DFP,8,9,51,54,Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.,3961813_4,-1,-1,-1,13030,-1,0.9985025,0.0014975016
13031,organophosphorous compounds,21,23,115,142,Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.,3961813_4,-1,-1,-1,13031,-1,0.9963019,0.0036980743
13033,TOTP,6,7,46,50,Chickens given 200 ppm corticosterone without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase.,3961813_5,-1,-1,-1,13033,-1,0.9984261,0.0015739828
13034,DFP,8,9,54,57,Chickens given 200 ppm corticosterone without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase.,3961813_5,-1,-1,-1,13034,-1,0.9984969,0.0015031599
13035,Degenerating myelinated fibers,0,3,0,30,Degenerating myelinated fibers were also evident in distal levels of the peripheral nerves of chickens given TOTP or DFP.,3961813_6,-1,-1,-1,13035,-1,0.005783423,0.99421656
13036,TOTP,16,17,109,113,Degenerating myelinated fibers were also evident in distal levels of the peripheral nerves of chickens given TOTP or DFP.,3961813_6,-1,-1,-1,13036,-1,0.99813443,0.0018655956
13037,DFP,18,19,117,120,Degenerating myelinated fibers were also evident in distal levels of the peripheral nerves of chickens given TOTP or DFP.,3961813_6,-1,-1,-1,13037,-1,0.9982455,0.0017544874
13040,tachyarrhythmias,12,13,85,101,Amiodarone has proved very effective in the treatment of otherwise resistant cardiac tachyarrhythmias.,3962737_1,-1,-1,-1,13040,-1,0.0022211983,0.99777883
13042,cholestatic hepatitis,3,5,15,36,A patient with cholestatic hepatitis due to amiodarone treatment is presented below and a review of the hepatotoxicity of amiodarone is given.,3962737_3,-1,-1,-1,13042,-1,0.0034219036,0.99657804
13048,steatosis,16,17,100,109,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,-1,-1,-1,13048,-1,0.0031572268,0.99684274
13049,alcoholic hepatitis,20,22,134,153,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,-1,-1,-1,13049,-1,0.0038534338,0.99614656
13050,cholestatic hepatitis,23,25,155,176,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,-1,-1,-1,13050,-1,0.0082726935,0.99172735
13051,cirrhosis of the liver,27,31,194,216,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,-1,-1,-1,13051,-1,0.012473296,0.9875267
13053,cholestatic injury,8,10,51,69,Therapy should be discontinued on the suspicion of cholestatic injury or hepatomegaly.,3962737_6,-1,-1,-1,13053,-1,0.028658392,0.9713416
13056,fat,6,7,48,51,Promotional effects of testosterone and dietary fat on prostate carcinogenesis in genetically susceptible rats.,3969369_0,-1,-1,-1,13056,-1,0.99326444,0.0067355465
13058,prostate adenocarcinomas,19,21,87,111,"Germfree (GF) Lobund strain Wistar (LW) rats, fed vegetable diet L-485, have developed prostate adenocarcinomas spontaneously (10% incidence) at average age 34 months.",3969369_1,-1,-1,-1,13058,-1,0.0048197126,0.99518037
13063,corn oil,18,20,120,128,"Preliminary results indicate that testosterone-treated LW rats that were fed the same diet, which was supplemented with corn oil up to 20% fat, developed prostate cancer after intervals of 6-12 months.",3969369_3,-1,-1,-1,13063,-1,0.9931953,0.0068046753
13064,fat,24,25,139,142,"Preliminary results indicate that testosterone-treated LW rats that were fed the same diet, which was supplemented with corn oil up to 20% fat, developed prostate cancer after intervals of 6-12 months.",3969369_3,-1,-1,-1,13064,-1,0.982825,0.017174985
13066,SD,4,5,24,26,Aged GF Sprague-Dawley (SD) rats have not developed prostate cancer spontaneously.,3969369_4,-1,-1,-1,13066,-1,0.51301545,0.48698455
13068,SD,1,2,13,15,Conventional SD rats fed diet L-485 and treated with testosterone developed only prostatitis.,3969369_5,-1,-1,-1,13068,-1,0.059964854,0.94003516
13070,prostatitis,12,13,81,92,Conventional SD rats fed diet L-485 and treated with testosterone developed only prostatitis.,3969369_5,-1,-1,-1,13070,-1,0.0021804606,0.99781954
13072,neoplasms,2,3,13,22,Incidence of neoplasms in patients with rheumatoid arthritis exposed to different treatment regimens.,3970039_0,-1,-1,-1,13072,-1,0.0032227878,0.99677724
13076,chlorambucil,7,8,49,61,"The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue).",3970039_2,-1,-1,-1,13076,-1,0.99928457,0.00071541034
13077,alkylating agents,9,11,63,80,"The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue).",3970039_2,-1,-1,-1,13077,-1,0.89390916,0.10609088
13079,purine,15,16,97,103,"The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue).",3970039_2,-1,-1,-1,13079,-1,0.9982899,0.0017100915
13081,folic acid,22,24,133,143,"The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue).",3970039_2,-1,-1,-1,13081,-1,0.99842876,0.0015712186
13082,synovitis,10,11,67,76,"There is evidence that all four immunosuppressive drugs can reduce synovitis, but disease activity almost always recurs after therapy is stopped.",3970039_3,-1,-1,-1,13082,-1,0.002641163,0.99735886
13083,alkylating agents,3,5,22,39,"Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.",3970039_6,-1,-1,-1,13083,-1,0.99583673,0.0041632857
13084,acute nonlymphocytic leukemia,12,15,81,110,"Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.",3970039_6,-1,-1,-1,13084,-1,0.0034065326,0.9965934
13085,alkylating agents,18,20,121,138,"Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.",3970039_6,-1,-1,-1,13085,-1,0.9954364,0.004563687
13087,lymphoma,30,31,209,217,"Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.",3970039_6,-1,-1,-1,13087,-1,0.002656956,0.997343
13096,alkylating agents,30,32,194,211,"Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications.",3970039_9,-1,-1,-1,13096,-1,0.99565095,0.004349083
13098,hypaque 76.Sequential,8,10,47,68,"Time course alterations of QTC interval due to hypaque 76.Sequential measurement of QT interval during left ventricular angiography was made 30 seconds and one, three, five and ten minutes after injection of hypaque 76.",3973521_0,-1,-1,-1,13098,-1,0.9732212,0.026778826
13099,hypaque 76,34,36,208,218,"Time course alterations of QTC interval due to hypaque 76.Sequential measurement of QT interval during left ventricular angiography was made 30 seconds and one, three, five and ten minutes after injection of hypaque 76.",3973521_0,-1,-1,-1,13099,-1,0.9986274,0.0013726066
13100,QTC prolongation,1,3,12,28,Significant QTC prolongation occurred in 30 seconds to one minute in association with marked hypotension and elevation of cardiac output.,3973521_2,-1,-1,-1,13100,-1,0.06664268,0.93335736
13103,femoral nerve palsy,5,8,54,73,Warfarin-induced iliopsoas hemorrhage with subsequent femoral nerve palsy.,3985451_0,-1,-1,-1,13103,-1,0.009637783,0.9903623
13105,muscle tear,16,18,91,102,We present the case of a 28-year-old man on chronic warfarin therapy who sustained a minor muscle tear and developed increasing pain and a flexure contracture of the right hip.,3985451_1,-1,-1,-1,13105,-1,0.006033217,0.9939668
13107,contracture,25,26,147,158,We present the case of a 28-year-old man on chronic warfarin therapy who sustained a minor muscle tear and developed increasing pain and a flexure contracture of the right hip.,3985451_1,-1,-1,-1,13107,-1,0.0037988382,0.9962012
13109,entrapment,9,10,70,80,"Surgical exploration revealed an iliopsoas hematoma and femoral nerve entrapment, resulting in a femoral nerve palsy and partial loss of quadriceps functions.",3985451_2,-1,-1,-1,13109,-1,0.011500823,0.9884992
13110,femoral nerve palsy,14,17,97,116,"Surgical exploration revealed an iliopsoas hematoma and femoral nerve entrapment, resulting in a femoral nerve palsy and partial loss of quadriceps functions.",3985451_2,-1,-1,-1,13110,-1,0.018632766,0.9813672
13111,partial loss of quadriceps functions,18,23,121,157,"Surgical exploration revealed an iliopsoas hematoma and femoral nerve entrapment, resulting in a femoral nerve palsy and partial loss of quadriceps functions.",3985451_2,-1,-1,-1,13111,-1,0.023645991,0.976354
13112,femoral nerve palsy,1,4,22,41,"Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.",3985451_3,-1,-1,-1,13112,-1,0.006153736,0.99384624
13115,motor and sensory impairment,28,32,195,223,"Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.",3985451_3,-1,-1,-1,13115,-1,0.0059137484,0.99408627
13116,contracture,35,36,237,248,"Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.",3985451_3,-1,-1,-1,13116,-1,0.0036253075,0.99637467
13117,pericardial effusion,4,6,29,49,Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy.,3997294_0,-1,-1,-1,13117,-1,0.0080076745,0.99199235
13120,sinuatrial disease,3,5,15,33,"A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias.",3997294_1,-1,-1,-1,13120,-1,0.049576867,0.9504232
13122,mg,16,17,105,107,"A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias.",3997294_1,-1,-1,-1,13122,-1,0.97987604,0.020123938
13123,mg,21,22,130,132,"A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias.",3997294_1,-1,-1,-1,13123,-1,0.97655505,0.02344491
13124,supraventricular tachyarrhythmias,31,33,170,203,"A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias.",3997294_1,-1,-1,-1,13124,-1,0.0039067175,0.99609333
13125,pneumonitis,2,3,13,24,"He developed pneumonitis, pleural and pericardial effusions, and a predominantly proximal motor neuropathy.",3997294_2,-1,-1,-1,13125,-1,0.0035848953,0.99641514
13126,pericardial effusions,6,8,38,59,"He developed pneumonitis, pleural and pericardial effusions, and a predominantly proximal motor neuropathy.",3997294_2,-1,-1,-1,13126,-1,0.02569069,0.97430927
13127,proximal motor neuropathy,12,15,81,106,"He developed pneumonitis, pleural and pericardial effusions, and a predominantly proximal motor neuropathy.",3997294_2,-1,-1,-1,13127,-1,0.0064815846,0.9935184
13130,amiodarone pneumonitis,14,16,87,109,"Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis, immediate withdrawal of amiodarone, and prompt but continued steroid therapy to ensure full recovery.",3997294_4,-1,-1,-1,13130,-1,0.53024197,0.46975806
13133,sinoatrial block,1,3,19,35,Amiodarone-induced sinoatrial block.,4008111_0,-1,-1,-1,13133,-1,0.7915103,0.20848972
13134,sinoatrial block,2,4,12,28,"We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.",4008111_1,-1,-1,-1,13134,-1,0.083554946,0.916445
13136,primary cardiomyopathy,14,16,95,117,"We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.",4008111_1,-1,-1,-1,13136,-1,0.0047933147,0.99520665
13137,supraventricular tachycardia,20,22,154,182,"We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.",4008111_1,-1,-1,-1,13137,-1,0.0052203187,0.9947797
13139,sinoatrial block,12,14,75,91,Reduction in the dosage of amiodarone resulted in the disappearance of the sinoatrial block and the persistence of asymptomatic sinus bradycardia.,4008111_2,-1,-1,-1,13139,-1,0.08899295,0.911007
13146,bupivacaine hydrochloride,12,14,70,95,"Local anesthetics that are commonly used in ophthalmic surgery (0.75% bupivacaine hydrochloride, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.",4038130_2,-1,-1,-1,13146,-1,0.99899656,0.0010035011
13147,mepivacaine hydrochloride,17,19,102,127,"Local anesthetics that are commonly used in ophthalmic surgery (0.75% bupivacaine hydrochloride, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.",4038130_2,-1,-1,-1,13147,-1,0.99889,0.0011100067
13148,lidocaine hydrochloride,23,25,138,161,"Local anesthetics that are commonly used in ophthalmic surgery (0.75% bupivacaine hydrochloride, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.",4038130_2,-1,-1,-1,13148,-1,0.997832,0.0021680044
13150,Muscle degeneration,0,2,0,19,Muscle degeneration is followed by regeneration of the damaged muscle fibers.,4038130_5,-1,-1,-1,13150,-1,0.0040876176,0.9959124
13151,muscle damage,3,5,15,28,"In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus epinephrine.",4038130_6,-1,-1,-1,13151,-1,0.0032522813,0.99674773
13152,mepivacaine,19,20,108,119,"In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus epinephrine.",4038130_6,-1,-1,-1,13152,-1,0.9992124,0.0007876303
13155,diplopia,12,13,67,75,"With these findings in rats, it is hypothesized that the temporary diplopia sometimes seen in patients after ophthalmic surgery might be due to anesthetic-induced damage to the extraocular muscles.",4038130_7,-1,-1,-1,13155,-1,0.0021009794,0.99789906
13156,Gentamicin nephropathy,0,2,0,22,Gentamicin nephropathy in a neonate.,4069770_0,-1,-1,-1,13156,-1,0.2686611,0.7313389
13157,acute renal failure,12,15,66,85,The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin (5 mg/kg/day) and penicillin are presented.,4069770_1,-1,-1,-1,13157,-1,0.002224026,0.997776
13162,periodic acid,1,3,9,22,"Numerous periodic acid Schiff (PAS) positive, diastase resistant cytoplasmic inclusion bodies which appeared as myelin figures in cytosegresomes under the electron microscope were identified in the proximal convoluted tubules.",4069770_3,-1,-1,-1,13162,-1,0.9944022,0.005597835
13163,PAS,5,6,31,34,"Numerous periodic acid Schiff (PAS) positive, diastase resistant cytoplasmic inclusion bodies which appeared as myelin figures in cytosegresomes under the electron microscope were identified in the proximal convoluted tubules.",4069770_3,-1,-1,-1,13163,-1,0.99551207,0.004487942
13165,renal insufficiency,1,3,21,40,Indomethacin-induced renal insufficiency: recurrence on rechallenge.,4071154_0,-1,-1,-1,13165,-1,0.0023695594,0.99763036
13166,renal failure,8,10,42,55,"We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.",4071154_1,-1,-1,-1,13166,-1,0.0026593807,0.9973406
13170,cor pulmonale,21,23,116,129,"We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.",4071154_1,-1,-1,-1,13170,-1,0.9920982,0.00790181
13173,oliguria,22,23,152,160,"Prompt restoration of renal function followed drug withdrawal, while re-exposure to a single dose of indomethacin caused recurrence of acute reversible oliguria.",4071154_2,-1,-1,-1,13173,-1,0.0023476055,0.9976525
13175,a,10,11,75,76,Our case supports the hypothesis that endogenous renal prostaglandins play a role in the maintenance of renal blood flow when circulating plasma volume is diminished.,4071154_3,-1,-1,-1,13175,-1,0.24420759,0.75579244
13176,acute renal failure,12,15,101,120,"Since nonsteroidal anti-inflammatory agents interfere with this compensatory mechanism and may cause acute renal failure, they should be used with caution in such patients.",4071154_4,-1,-1,-1,13176,-1,0.0021978042,0.9978022
13178,tumours,7,8,46,53,Induction by paracetamol of bladder and liver tumours in the rat.,4090988_0,-1,-1,-1,13178,-1,0.0032761528,0.99672383
13180,Papillomas,0,1,0,10,"Papillomas of the transitional epithelium of the bladder developed in all paracetamol-treated groups, and three rats bore bladder carcinomas.",4090988_5,-1,-1,-1,13180,-1,0.0033928128,0.9966072
13181,bladder carcinomas,18,20,122,140,"Papillomas of the transitional epithelium of the bladder developed in all paracetamol-treated groups, and three rats bore bladder carcinomas.",4090988_5,-1,-1,-1,13181,-1,0.004318455,0.9956815
13182,bladder tumours,5,7,31,46,"However, significant yields of bladder tumours were only obtained from low dosage females and high dosage males.",4090988_6,-1,-1,-1,13182,-1,0.0032644146,0.9967355
13183,hyperplasia,10,11,62,73,"Additionally, 20 to 25% of paracetamol-treated rats developed hyperplasia of the bladder epithelium, which was not coincident with the presence of bladder calculi.",4090988_7,-1,-1,-1,13183,-1,0.0035550823,0.9964449
13184,bladder calculi,24,26,147,162,"Additionally, 20 to 25% of paracetamol-treated rats developed hyperplasia of the bladder epithelium, which was not coincident with the presence of bladder calculi.",4090988_7,-1,-1,-1,13184,-1,0.0051884428,0.99481153
13185,tumours,4,5,15,22,A low yield of tumours at various other sites also arose following paracetamol feeding.,4090988_8,-1,-1,-1,13185,-1,0.0033500558,0.9966499
13187,hepatocarcinogens,28,29,191,208,An electron microscope study of the livers of paracetamol-treated rats revealed ultrastructural changes in the hepatocytes that resemble those that result from exposure to a variety of known hepatocarcinogens.,4090988_9,-1,-1,-1,13187,-1,0.011448688,0.9885513
13192,tender hepatomegaly,2,4,14,33,"Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients.",424937_3,-1,-1,-1,13192,-1,0.003872388,0.99612767
13193,malaise,10,11,67,74,"Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients.",424937_3,-1,-1,-1,13193,-1,0.0041485205,0.9958515
13194,anorexia,12,13,76,84,"Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients.",424937_3,-1,-1,-1,13194,-1,0.0030312974,0.9969687
13197,upper abdominal pain,21,24,127,147,"Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients.",424937_3,-1,-1,-1,13197,-1,0.0054657063,0.99453425
13198,hepatocellular necrosis,5,7,43,66,"Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.",424937_4,-1,-1,-1,13198,-1,0.0034300927,0.9965699
13200,fatty change,22,24,167,179,"Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.",424937_4,-1,-1,-1,13200,-1,0.014738445,0.9852616
13201,hepatocellular necrosis,26,28,190,213,"Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.",424937_4,-1,-1,-1,13201,-1,0.0038153583,0.99618465
13202,massive hepatic necrosis,29,32,217,241,"Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.",424937_4,-1,-1,-1,13202,-1,0.004011374,0.99598867
13203,acute hepatitis,6,8,40,55,Most patients showed moderate to severe acute hepatitis or chronic active hepatitis with associated cholestasis.,424937_5,-1,-1,-1,13203,-1,0.0032398258,0.9967602
13204,chronic active hepatitis,9,12,59,83,Most patients showed moderate to severe acute hepatitis or chronic active hepatitis with associated cholestasis.,424937_5,-1,-1,-1,13204,-1,0.0047232755,0.9952767
13206,hepatic failure,7,9,38,53,"One patient died, having presented in hepatic failure, and another, who had been taking methyldopa for 7 years, showed slower clinical and biochemical resolution over a period of several months.",424937_7,-1,-1,-1,13206,-1,0.0025283173,0.9974717
13208,fulminant hepatitis,7,9,46,65,The remaining patient in the series developed fulminant hepatitis when the drug was accidentally recommenced 1 year after a prior episode of methyldopa-induced hepatitis.,424937_8,-1,-1,-1,13208,-1,0.005472014,0.994528
13211,hepatic dysfunction,16,18,88,107,"In this latter patient, and in 2 others, the causal relationship between methyldopa and hepatic dysfunction was proved with the recurrence of hepatitis within 2 weeks of re-exposure to the drug.",424937_9,-1,-1,-1,13211,-1,0.0023726998,0.9976273
13213,diphenylhydantoin toxicity,7,9,47,73,Transient hemiparesis: a rare manifestation of diphenylhydantoin toxicity.,430165_0,-1,-1,-1,13213,-1,0.85131687,0.14868313
13214,diphenylhydantoin,6,7,33,50,"Among the common side effects of diphenylhydantoin (DPH) overdose, the most frequently encountered neurological signs are those of cerebellar dysfunction.",430165_2,-1,-1,-1,13214,-1,0.99908006,0.0009199687
13215,DPH,8,9,52,55,"Among the common side effects of diphenylhydantoin (DPH) overdose, the most frequently encountered neurological signs are those of cerebellar dysfunction.",430165_2,-1,-1,-1,13215,-1,0.9978236,0.002176382
13217,cerebellar dysfunction,21,23,131,153,"Among the common side effects of diphenylhydantoin (DPH) overdose, the most frequently encountered neurological signs are those of cerebellar dysfunction.",430165_2,-1,-1,-1,13217,-1,0.0030185836,0.99698144
13218,hemiparesis,7,8,52,63,Two patients are presented who suffered progressive hemiparesis due to DPH overdose.,430165_4,-1,-1,-1,13218,-1,0.0021446408,0.99785537
13219,DPH overdose,10,12,71,83,Two patients are presented who suffered progressive hemiparesis due to DPH overdose.,430165_4,-1,-1,-1,13219,-1,0.5615773,0.43842274
13220,DPH,5,6,30,33,Both had brain surgery before DPH treatment.,430165_5,-1,-1,-1,13220,-1,0.99851495,0.0014850661
13221,cerebral damage,7,9,38,53,It is assumed that patients with some cerebral damage are liable to manifest DPH toxicity as focal neurological signs.,430165_6,-1,-1,-1,13221,-1,0.0027065547,0.9972934
13222,DPH toxicity,13,15,77,89,It is assumed that patients with some cerebral damage are liable to manifest DPH toxicity as focal neurological signs.,430165_6,-1,-1,-1,13222,-1,0.7368502,0.26314983
13223,fasciculations,5,6,41,55,Suxamethonium infusion rate and observed fasciculations.,435349_0,-1,-1,-1,13223,-1,0.0034697785,0.99653023
13224,Sch,3,4,24,27,Suxamethonium chloride (Sch) was administered i.v. to 36 adult males at six rates: 0.25 mg s-1 to 20 mg s-1.,435349_2,-1,-1,-1,13224,-1,0.99749666,0.00250327
13225,mg,18,19,88,90,Suxamethonium chloride (Sch) was administered i.v. to 36 adult males at six rates: 0.25 mg s-1 to 20 mg s-1.,435349_2,-1,-1,-1,13225,-1,0.97353756,0.026462484
13226,mg,22,23,101,103,Suxamethonium chloride (Sch) was administered i.v. to 36 adult males at six rates: 0.25 mg s-1 to 20 mg s-1.,435349_2,-1,-1,-1,13226,-1,0.95187515,0.04812482
13227,tetanic,12,13,76,83,The infusion was discontinued either when there was no muscular response to tetanic stimulation of the ulnar nerve or when Sch 120 mg was exceeded.,435349_3,-1,-1,-1,13227,-1,0.1286585,0.87134147
13228,Sch,20,21,123,126,The infusion was discontinued either when there was no muscular response to tetanic stimulation of the ulnar nerve or when Sch 120 mg was exceeded.,435349_3,-1,-1,-1,13228,-1,0.99873966,0.0012603453
13229,mg,22,23,131,133,The infusion was discontinued either when there was no muscular response to tetanic stimulation of the ulnar nerve or when Sch 120 mg was exceeded.,435349_3,-1,-1,-1,13229,-1,0.99758303,0.0024170028
13230,Fasciculations,0,1,0,14,Fasciculations in six areas of the body were scored from 0 to 3 and summated as a total fasciculation score.,435349_6,-1,-1,-1,13230,-1,0.0058339867,0.994166
13233,twitch,6,7,34,40,"The times to first fasciculation, twitch suppression and tetanus suppression were inversely related to the infusion rates.",435349_7,-1,-1,-1,13233,-1,0.015798895,0.98420113
13234,tetanus,9,10,57,64,"The times to first fasciculation, twitch suppression and tetanus suppression were inversely related to the infusion rates.",435349_7,-1,-1,-1,13234,-1,0.9959545,0.0040455526
13237,involuntary movements,3,5,29,50,Tiapride in levodopa-induced involuntary movements.,458486_0,-1,-1,-1,13237,-1,0.0028205826,0.9971794
13238,Tiapride,0,1,0,8,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,-1,-1,-1,13238,-1,0.99916756,0.0008324771
13239,benzamide,4,5,24,33,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,-1,-1,-1,13239,-1,0.9988035,0.0011964587
13241,involuntary movements,15,17,115,136,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,-1,-1,-1,13241,-1,0.0034367791,0.99656326
13242,idiopathic Parkinson's disease,21,25,157,187,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,-1,-1,-1,13242,-1,0.0051095686,0.99489045
13244,akinesia,13,14,98,106,"However, an unacceptable increase in disability from Parkinsonism with aggravation of end-of-dose akinesia led to its cessation in 14 patients.",458486_2,-1,-1,-1,13244,-1,0.9968406,0.003159452
13245,Tiapride,0,1,0,8,"Tiapride had no effect on levodopa-induced early morning of ""off-period"" segmental dystonia.",458486_3,-1,-1,-1,13245,-1,0.9993007,0.0006992909
13257,quinidine,3,4,28,37,"Long-term administration of quinidine was associated with persistent elevation of serum concentrations of SGOT, lactic acid dehydrogenase, and alkaline phosphatase.",48362_1,-1,-1,-1,13257,-1,0.9993025,0.00069745624
13258,lactic acid,15,17,112,123,"Long-term administration of quinidine was associated with persistent elevation of serum concentrations of SGOT, lactic acid dehydrogenase, and alkaline phosphatase.",48362_1,-1,-1,-1,13258,-1,0.9962811,0.00371887
13259,alkaline phosphatase,20,22,143,163,"Long-term administration of quinidine was associated with persistent elevation of serum concentrations of SGOT, lactic acid dehydrogenase, and alkaline phosphatase.",48362_1,-1,-1,-1,13259,-1,0.99077725,0.009222715
13261,quinidine,2,3,18,27,Discontinuance of quinidine therapy led to normalization of liver function tests.,48362_3,-1,-1,-1,13261,-1,0.9990816,0.00091837434
13262,quinidine,4,5,20,29,"A challenge dose of quinidine caused clinical symptoms and abrupt elevation of SGOT, alkaline phosphatase, and lactic acid dehydrogenase values.",48362_4,-1,-1,-1,13262,-1,0.99921465,0.000785322
13263,SGOT,12,13,79,83,"A challenge dose of quinidine caused clinical symptoms and abrupt elevation of SGOT, alkaline phosphatase, and lactic acid dehydrogenase values.",48362_4,-1,-1,-1,13263,-1,0.9977126,0.0022873844
13264,alkaline phosphatase,14,16,85,105,"A challenge dose of quinidine caused clinical symptoms and abrupt elevation of SGOT, alkaline phosphatase, and lactic acid dehydrogenase values.",48362_4,-1,-1,-1,13264,-1,0.99112743,0.008872622
13265,lactic acid,18,20,111,122,"A challenge dose of quinidine caused clinical symptoms and abrupt elevation of SGOT, alkaline phosphatase, and lactic acid dehydrogenase values.",48362_4,-1,-1,-1,13265,-1,0.99514943,0.00485059
13266,quinidine hepatotoxicity,6,8,35,59,We concluded that this patient had quinidine hepatotoxicity and believe that this is the first case reported with liver biopsy documentation.,48362_5,-1,-1,-1,13266,-1,0.379735,0.620265
13269,Angiosarcoma,0,1,0,12,Angiosarcoma of the liver occurred in a 76-year-old man who had been treated for a well-differentiated adenocarcinoma of the liver with diethylstilbestrol for 13 years.,567256_1,-1,-1,-1,13269,-1,0.002940603,0.9970594
13270,adenocarcinoma,16,17,103,117,Angiosarcoma of the liver occurred in a 76-year-old man who had been treated for a well-differentiated adenocarcinoma of the liver with diethylstilbestrol for 13 years.,567256_1,-1,-1,-1,13270,-1,0.0037644801,0.99623555
13272,Angiosarcoma,0,1,0,12,Angiosarcoma was also present within pulmonary and renal arteries.,567256_2,-1,-1,-1,13272,-1,0.0040104054,0.9959896
13273,intraarterial lesions,4,6,25,46,The possibility that the intraarterial lesions might represent independent primary tumors is considered.,567256_3,-1,-1,-1,13273,-1,0.114781804,0.88521814
13275,thromboembolism,1,2,9,24,Arterial thromboembolism in patients receiving systemic heparin therapy: a complication associated with heparin-induced thrombocytopenia.,591536_0,-1,-1,-1,13275,-1,0.0028096416,0.9971904
13278,thromboembolism,1,2,9,24,Arterial thromboembolism is a recognized complication of systemic heparin therapy.,591536_1,-1,-1,-1,13278,-1,0.002725077,0.99727494
13280,arterial occlusion,5,7,32,50,"Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.",591536_2,-1,-1,-1,13280,-1,0.0051737456,0.99482626
13285,ischemic,16,17,117,125,"The clinically apparent occlusion may be preceded by gastrointestinal and musculoskeletal symptoms that appear to be ischemic in origin, and might serve to warn the clinician of these complications.",591536_3,-1,-1,-1,13285,-1,0.0042322585,0.9957677
13287,thromboembolism,4,5,27,42,The common factor relating thromboembolism and thrombocytopenia is heparin-induced platelet aggregation.,591536_5,-1,-1,-1,13287,-1,0.0023517623,0.9976482
13291,sodium warfarin,11,13,87,102,"Appropriate treatment consists of discontinuation of heparin, and anticoagulation with sodium warfarin if necessary.",591536_6,-1,-1,-1,13291,-1,0.9983493,0.0016507133
13292,Galanthamine hydrobromide,0,2,0,25,"Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine).Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.",603022_0,-1,-1,-1,13292,-1,0.9986154,0.00138462
13294,(Hyoscine).Galanthamine hydrobromide,18,20,123,159,"Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine).Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.",603022_0,-1,-1,-1,13294,-1,0.99556535,0.0044345814
13296,) overdosage,43,45,312,324,"Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine).Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.",603022_0,-1,-1,-1,13296,-1,0.043813694,0.9561863
13297,physostigmine,5,6,25,38,It is longer acting than physostigmine and is used in anaesthesia to reverse the non-depolarizing neuromuscular block.,603022_1,-1,-1,-1,13297,-1,0.9990741,0.00092591316
13298,block,16,17,112,117,It is longer acting than physostigmine and is used in anaesthesia to reverse the non-depolarizing neuromuscular block.,603022_1,-1,-1,-1,13298,-1,0.005038319,0.9949616
13300,flunitrazepam,2,3,18,31,administration of flunitrazepam in volunteers.,6103707_1,-1,-1,-1,13300,-1,0.9990445,0.00095547386
13301,Flunitrazepam,0,1,0,13,"Flunitrazepam 0.5, 1.0 or 2.0 mg was given by the oral or i.m.",6103707_2,-1,-1,-1,13301,-1,0.9989722,0.0010278235
13302,mg,6,7,30,32,"Flunitrazepam 0.5, 1.0 or 2.0 mg was given by the oral or i.m.",6103707_2,-1,-1,-1,13302,-1,0.9483533,0.051646747
13303,mg,13,14,71,73,"The most striking effect was sedation which increased with the dose, 2 mg producing deep sleep although the subjects could still be aroused.",6103707_5,-1,-1,-1,13303,-1,0.9925678,0.0074322377
13306,flunitrazepam,2,3,13,26,injection of flunitrazepam significantly more often than with isotonic saline.,6103707_9,-1,-1,-1,13306,-1,0.9991398,0.0008601315
13307,h,10,11,61,62,The drug was still present in measurable quantities after 24 h even with the smallest dose.,6103707_11,-1,-1,-1,13307,-1,0.16651967,0.83348036
13308,GYKI-41 099,2,4,16,27,"Pharmacology of GYKI-41 099 (chlorpropanol, Tobanum) a new potent beta-adrenergic antagonist.",6111982_0,-1,-1,-1,13308,-1,0.99421257,0.005787378
13309,chlorpropanol,5,6,29,42,"Pharmacology of GYKI-41 099 (chlorpropanol, Tobanum) a new potent beta-adrenergic antagonist.",6111982_0,-1,-1,-1,13309,-1,0.99921,0.0007899386
13310,Tobanum,7,8,44,51,"Pharmacology of GYKI-41 099 (chlorpropanol, Tobanum) a new potent beta-adrenergic antagonist.",6111982_0,-1,-1,-1,13310,-1,0.99905545,0.0009445728
13311,GYKI-41 099,2,4,13,24,"The compound GYKI-41 099, as a beta-adrenergic antagonist, is 3-8 times more potent than propranolol in vitro and in vivo.",6111982_1,-1,-1,-1,13311,-1,0.99590045,0.004099491
13314,pindolol,8,9,67,75,Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats.,6111982_2,-1,-1,-1,13314,-1,0.99889284,0.0011072219
13315,ouabain arrhythmia,11,13,91,109,Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats.,6111982_2,-1,-1,-1,13315,-1,0.90132964,0.09867033
13316,GYKI-41 900,0,2,0,11,GYKI-41 900 has a negligible cardiodepressant activity; it is not cardioselective.,6111982_3,-1,-1,-1,13316,-1,0.995165,0.004834952
13317,14C-41 099,12,14,78,88,There was a prolonged elimination of the radioactivity after the injection of 14C-41 099 to rats and dogs.,6111982_5,-1,-1,-1,13317,-1,0.9967116,0.0032883452
13318,bendrofluazide,3,4,21,35,Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension.,6115999_0,-1,-1,-1,13318,-1,0.99911374,0.0008862574
13323,bendrofluazide,21,22,139,153,"Participants in the Medical Research Council treatment trial for mild hypertension are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs.",6115999_2,-1,-1,-1,13323,-1,0.9992312,0.00076876284
13325,bendrofluazide,6,7,40,54,"The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.",6115999_5,-1,-1,-1,13325,-1,0.9992004,0.00079961756
13326,impotence,9,10,69,78,"The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.",6115999_5,-1,-1,-1,13326,-1,0.00486238,0.99513763
13327,impotence,12,13,84,93,"The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.",6115999_5,-1,-1,-1,13327,-1,0.0044238083,0.99557626
13329,glucose tolerance,10,12,80,97,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,-1,-1,-1,13329,-1,0.095339715,0.9046603
13330,gout,17,18,119,123,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,-1,-1,-1,13330,-1,0.0026408813,0.9973591
13331,bendrofluazide,23,24,148,162,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,-1,-1,-1,13331,-1,0.99905795,0.0009420971
13332,Raynaud's phenomenon,27,30,178,198,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,-1,-1,-1,13332,-1,0.018521616,0.98147833
13333,dyspnoea,31,32,203,211,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,-1,-1,-1,13333,-1,0.0024230736,0.9975769
13335,corneal disease,1,3,3,18,No corneal disease is known to have occurred in the propranolol group.,6115999_7,-1,-1,-1,13335,-1,0.003080927,0.99691904
13339,uric acid,9,11,46,55,"Mean serum potassium level fell, and urea and uric acid levels rose, in men and women taking bendrofluazide.",6115999_8,-1,-1,-1,13339,-1,0.9985429,0.0014571332
13340,bendrofluazide,19,20,93,107,"Mean serum potassium level fell, and urea and uric acid levels rose, in men and women taking bendrofluazide.",6115999_8,-1,-1,-1,13340,-1,0.9991373,0.0008627414
13343,uric acid,8,10,46,55,"In the propranolol group, serum potassium and uric acid levels rose in both sexes, but the urea level rose significantly in women only.",6115999_9,-1,-1,-1,13343,-1,0.9987631,0.0012369693
13346,baclofen,5,6,40,48,"Serotonergic drugs, benzodiazepines and baclofen block muscimol-induced myoclonic jerks in a strain of mice.",6118280_0,-1,-1,-1,13346,-1,0.9991047,0.0008952522
13348,muscimol,5,6,20,28,"In male Swiss mice, muscimol produced myoclonic jerks.",6118280_1,-1,-1,-1,13348,-1,0.9990571,0.0009429012
13352,muscimol,29,30,188,196,Increasing the brain serotonin levels by the administration of 5-hydroxytryptophan (80-160 mg/kg) in combination with a peripheral decarboxylase inhibitor resulted in an inhibition of the muscimol effect.,6118280_3,-1,-1,-1,13352,-1,0.9988741,0.0011258551
13354,MK-212,12,13,55,61,"In doses of 3-10 mg/kg, the serotonin receptor agonist MK-212 caused a dose-dependent blockade of the response of muscimol.",6118280_5,-1,-1,-1,13354,-1,0.99859995,0.0014000336
13355,muscimol,21,22,114,122,"In doses of 3-10 mg/kg, the serotonin receptor agonist MK-212 caused a dose-dependent blockade of the response of muscimol.",6118280_5,-1,-1,-1,13355,-1,0.99922156,0.0007784788
13357,clonazepam,4,5,24,34,"Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.",6118280_6,-1,-1,-1,13357,-1,0.99905497,0.0009449922
13360,muscimol,15,16,71,79,"While (-)-baclofen (1-3 mg/kg) proved to be an effective antagonist of muscimol, its (+)-isomer (5-20 mg/kg) lacked this property.",6118280_7,-1,-1,-1,13360,-1,0.9991848,0.00081526005
13361,5-HTP,4,5,26,31,"Considering the fact that 5-HTP and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus, the muscimol-induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.",6118280_8,-1,-1,-1,13361,-1,0.99805236,0.0019476264
13365,MK-212,8,9,50,56,Our present study indicated the possible value of MK-212 and (-)-baclofen in the management of clinical myoclonus.,6118280_9,-1,-1,-1,13365,-1,0.99863154,0.0013684905
13367,ischaemic heart disease,3,6,20,43,"Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.",6127992_1,-1,-1,-1,13367,-1,0.003089422,0.99691063
13368,cardiac failure,8,10,63,78,"Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.",6127992_1,-1,-1,-1,13368,-1,0.002412438,0.99758756
13374,inflammatory bowel disease,8,11,40,66,"Three infants, born of two mothers with inflammatory bowel disease who received treatment with sulphasalazine throughout pregnancy, were found to have major congenital anomalies.",6133211_1,-1,-1,-1,13374,-1,0.0041077035,0.9958923
13376,congenital anomalies,24,26,157,177,"Three infants, born of two mothers with inflammatory bowel disease who received treatment with sulphasalazine throughout pregnancy, were found to have major congenital anomalies.",6133211_1,-1,-1,-1,13376,-1,0.003504509,0.99649554
13377,ulcerative colitis,8,10,43,61,"In the singleton pregnancy, the mother had ulcerative colitis, and the infant, a male, had coarctation of the aorta and a ventricular septal defect.",6133211_2,-1,-1,-1,13377,-1,0.0054573356,0.9945426
13378,coarctation of the aorta,19,23,91,115,"In the singleton pregnancy, the mother had ulcerative colitis, and the infant, a male, had coarctation of the aorta and a ventricular septal defect.",6133211_2,-1,-1,-1,13378,-1,0.051468913,0.9485311
13379,ventricular septal defect,25,28,122,147,"In the singleton pregnancy, the mother had ulcerative colitis, and the infant, a male, had coarctation of the aorta and a ventricular septal defect.",6133211_2,-1,-1,-1,13379,-1,0.13853037,0.8614696
13380,Crohn's disease,8,11,38,53,"In the twin pregnancy, the mother had Crohn's disease.",6133211_3,-1,-1,-1,13380,-1,0.02140045,0.97859955
13381,rudimentary left uterine cornu,16,20,77,107,"The first twin, a female, had a left Potter-type IIa polycystic kidney and a rudimentary left uterine cornu.",6133211_4,-1,-1,-1,13381,-1,0.08352889,0.9164711
13382,Potter's facies,11,14,46,61,"The second twin, a male, had some features of Potter's facies, hypoplastic lungs, absent kidneys and ureters, and talipes equinovarus.",6133211_5,-1,-1,-1,13382,-1,0.051639,0.94836104
13383,hypoplastic lungs,15,17,63,80,"The second twin, a male, had some features of Potter's facies, hypoplastic lungs, absent kidneys and ureters, and talipes equinovarus.",6133211_5,-1,-1,-1,13383,-1,0.006700698,0.99329925
13384,absent kidneys and ureters,18,22,82,108,"The second twin, a male, had some features of Potter's facies, hypoplastic lungs, absent kidneys and ureters, and talipes equinovarus.",6133211_5,-1,-1,-1,13384,-1,0.023401858,0.97659814
13385,talipes equinovarus,24,26,114,133,"The second twin, a male, had some features of Potter's facies, hypoplastic lungs, absent kidneys and ureters, and talipes equinovarus.",6133211_5,-1,-1,-1,13385,-1,0.49962106,0.5003789
13387,teratogenic,13,14,76,87,"Despite reports to the contrary, it is suggested that sulphasalazine may be teratogenic.",6133211_6,-1,-1,-1,13387,-1,0.0038476284,0.99615234
13392,systemic mastocytosis,9,11,66,87,"Nineteen patients had Zollinger-Ellison syndrome, one patient had systemic mastocytosis, and two patients had idiopathic hypersecretion.",6150641_2,-1,-1,-1,13392,-1,0.006926433,0.9930736
13399,impotence,9,10,55,64,Sixty percent of the males developed breast changes or impotence while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine.,6150641_6,-1,-1,-1,13399,-1,0.006121659,0.9938784
13416,generalized seizures,9,11,54,74,"Two other patients suffered from partial, complex and generalized seizures uncontrolled by medication.",6153967_4,-1,-1,-1,13416,-1,0.0027977084,0.9972023
13421,epileptic foci,16,18,77,91,"On the other hand, enflurane may prove to be a safe fast acting activator of epileptic foci during corticography or depth electrode intraoperative recordings.",6153967_7,-1,-1,-1,13421,-1,0.0026591986,0.99734086
13423,renal failure,3,5,31,44,Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy.,6203452_0,-1,-1,-1,13423,-1,0.0023642606,0.9976357
13426,renal insufficiency,10,12,84,103,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,-1,-1,-1,13426,-1,0.002722419,0.99727756
13427,microangiopathic hemolytic anemia,13,16,105,138,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,-1,-1,-1,13427,-1,0.002735209,0.99726474
13430,bleomycin,26,27,202,211,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,-1,-1,-1,13430,-1,0.99865353,0.0013464502
13431,vinca alkaloid,30,32,219,233,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,-1,-1,-1,13431,-1,0.99724895,0.0027510817
13432,thrombotic thrombocytopenic purpura,3,6,16,51,"One patient had thrombotic thrombocytopenic purpura, three the hemolytic-uremic syndrome, and one an apparent forme fruste of one of these disorders.",6203452_2,-1,-1,-1,13432,-1,0.0035396365,0.9964604
13433,intravascular coagulation,9,11,62,87,"Histologic examination of the renal tissue showed evidence of intravascular coagulation, primarily affecting the small arteries, arterioles, and glomeruli.",6203452_3,-1,-1,-1,13433,-1,0.008603469,0.9913966
13436,renal failure,24,26,145,158,"Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.",6203452_5,-1,-1,-1,13436,-1,0.0028796059,0.9971204
13437,cisplatin nephrotoxicity,30,32,178,202,"Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.",6203452_5,-1,-1,-1,13437,-1,0.079340145,0.92065984
13444,ISO,19,20,137,140,The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight).,6203632_1,-1,-1,-1,13444,-1,0.99835986,0.0016401729
13445,body weight,24,26,153,164,The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight).,6203632_1,-1,-1,-1,13445,-1,0.7439337,0.25606638
13446,hydroxyproline,20,21,93,107,"A time course was established for the change in tissue mass, RNA and DNA content, as well as hydroxyproline content.",6203632_2,-1,-1,-1,13446,-1,0.9991283,0.00087174226
13447,h,9,10,50,51,Ventricular RNA content was elevated 26% after 24 h of a single injection and reached a maximal level following 8 days of therapy.,6203632_4,-1,-1,-1,13447,-1,0.5269584,0.4730416
13448,hydroxyproline,4,5,21,35,The total content of hydroxyproline remained stable during the first 2 days of treatment but increased 46% after 4 days of therapy.,6203632_6,-1,-1,-1,13448,-1,0.99926895,0.0007310626
13449,hypertrophic,16,17,75,87,Ventricular DNA content was unchanged during the early stage (1-4 days) of hypertrophic growth but increased to a new steady-state level 19% above the controls after 8 days of treatment.,6203632_7,-1,-1,-1,13449,-1,0.004699851,0.9953002
13451,P,12,13,73,74,"However, dP/dt in the ISO-treated hearts was slightly but significantly (P less than 0.05) elevated.",6203632_9,-1,-1,-1,13451,-1,0.29588768,0.7041123
13452,ISO,8,9,50,53,These data indicate that the adaptive response to ISO shows an early hypertrophic phase (1-4 days) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA.,6203632_10,-1,-1,-1,13452,-1,0.9983398,0.0016601967
13453,hypertrophic,12,13,69,81,These data indicate that the adaptive response to ISO shows an early hypertrophic phase (1-4 days) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA.,6203632_10,-1,-1,-1,13453,-1,0.0035555423,0.9964445
13455,hyperplasia,21,22,119,130,"However, prolonged stimulation (8-12 days) appears to represent a complex integration of both cellular hypertrophy and hyperplasia within the heart.",6203632_11,-1,-1,-1,13455,-1,0.004199812,0.9958002
13459,myocardial infarction,26,28,178,199,The antiarrhythmic effects of the sustained release form of mexiletine (Mexitil-Perlongets) were evaluated in a double-blind placebo trial in 630 patients with recent documented myocardial infarction.,6209318_2,-1,-1,-1,13459,-1,0.0022690692,0.9977309
13465,gastrointestinal problems,8,10,60,85,"Previously recognized side effects, particularly tremor and gastrointestinal problems, were more frequent in the mexiletine group than in the placebo group.",6209318_8,-1,-1,-1,13465,-1,0.0025265599,0.9974734
13470,systemic lupus erythematosus,5,8,26,54,"Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.",6216862_1,-1,-1,-1,13470,-1,0.0034236622,0.99657637
13471,polymyositis,9,10,56,68,"Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.",6216862_1,-1,-1,-1,13471,-1,0.0047035953,0.9952964
13472,myasthenia gravis,11,13,73,90,"Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.",6216862_1,-1,-1,-1,13472,-1,0.0050991024,0.9949008
13475,skin lesion,1,3,4,15,"The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.",6216862_3,-1,-1,-1,13475,-1,0.003745038,0.9962549
13476,elastosis perforans serpiginosa,4,7,26,57,"The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.",6216862_3,-1,-1,-1,13476,-1,0.02410068,0.97589934
13477,Wilson's disease,20,23,122,138,"The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.",6216862_3,-1,-1,-1,13477,-1,0.00929084,0.9907092
13481,myocardial infarction,9,11,63,84,Changes in heart size during long-term timolol treatment after myocardial infarction.,6229975_0,-1,-1,-1,13481,-1,0.0038756635,0.9961243
13483,myocardial infarction,10,12,62,83,"The effect of long-term timolol treatment on heart size after myocardial infarction was evaluated by X-ray in a double-blind study including 241 patients (placebo 126, timolol 115).",6229975_1,-1,-1,-1,13483,-1,0.0025196234,0.99748033
13485,contrast,15,16,100,108,The timolol-treated patients showed a small but significant increase in heart size from baseline in contrast to a decrease in the placebo group.,6229975_3,-1,-1,-1,13485,-1,0.14063767,0.85936236
13487,cardiomegaly,3,4,17,29,"In patients with cardiomegaly, the increase in heart size was similar in both groups.",6229975_6,-1,-1,-1,13487,-1,0.0029430059,0.99705696
13489,hypercalcaemia,4,5,18,32,One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-sodium bicarbonate powders for more than 20 years.,625456_1,-1,-1,-1,13489,-1,0.005255774,0.9947442
13492,bicarbonate,23,24,165,176,One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-sodium bicarbonate powders for more than 20 years.,625456_1,-1,-1,-1,13492,-1,0.998041,0.0019591083
13493,vitamin D3,4,6,26,36,"Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.",6286738_1,-1,-1,-1,13493,-1,0.99822766,0.001772351
13494,vitamin D3,14,16,60,70,"Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.",6286738_1,-1,-1,-1,13494,-1,0.9979709,0.002029055
13496,hyperphosphatemia,23,24,118,135,"Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.",6286738_1,-1,-1,-1,13496,-1,0.00868576,0.99131423
13497,vitamin D3,29,31,160,170,"Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.",6286738_1,-1,-1,-1,13497,-1,0.9982692,0.0017307872
13499,vitamin D3,11,13,73,83,Calcium concentrations 1 day postpartum were higher in cows treated with vitamin D3 about 32 days prepartum (8.8 mg/100 ml) than in control cows (5.5 mg/100 ml).,6286738_2,-1,-1,-1,13499,-1,0.9980108,0.0019892477
13500,vitamin D3,6,8,30,40,"None of the cows treated with vitamin D3 showed signs of milk fever during the peripartal period; however, 22% of the control cows developed clinical signs of milk fever during this period.",6286738_3,-1,-1,-1,13500,-1,0.9980432,0.0019567541
13503,vitamin D3 toxicity,2,5,9,28,"Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows; however, pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died.",6286738_4,-1,-1,-1,13503,-1,0.879456,0.12054409
13504,vitamin D3 toxicity,22,25,139,158,"Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows; however, pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died.",6286738_4,-1,-1,-1,13504,-1,0.86654824,0.13345174
13507,vitamin D3,6,8,35,45,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,-1,-1,-1,13507,-1,0.99880636,0.0011936533
13508,vitamin D3,21,23,116,126,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,-1,-1,-1,13508,-1,0.99873275,0.0012672372
13511,vitamin D3,37,39,203,213,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,-1,-1,-1,13511,-1,0.9987362,0.0012637682
13513,Diseases of peripheral nerves,0,4,0,29,Diseases of peripheral nerves as seen in the Nigerian African.,6287825_0,-1,-1,-1,13513,-1,0.008345069,0.9916549
13514,peripheral nerve disease,6,9,45,69,"The anatomical and aetiological diagnoses of peripheral nerve disease excluding its primary benign and malignant disorders, as seen in 358 Nigerians are presented.",6287825_1,-1,-1,-1,13514,-1,0.0070535173,0.99294645
13516,motor neuropathy,20,22,109,125,"Guillain-Barr   syndrome was the commonest identifiable cause (15.6%), accounting for half of the cases with motor neuropathy.",6287825_4,-1,-1,-1,13516,-1,0.0027037247,0.9972963
13517,nutritional deficiency,4,6,29,51,Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.,6287825_5,-1,-1,-1,13517,-1,0.084249504,0.9157505
13518,thiamine,7,8,55,63,Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.,6287825_5,-1,-1,-1,13518,-1,0.99889225,0.0011078255
13519,riboflavin,9,10,68,78,Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.,6287825_5,-1,-1,-1,13519,-1,0.9990633,0.0009366995
13521,Diabetes mellitus,0,2,0,17,Diabetes mellitus was the major cause of autonomic neuropathy.,6287825_6,-1,-1,-1,13521,-1,0.004671258,0.9953288
13526,cranial neuropathy,11,13,44,62,Migraine (20%) was not an uncommon cause of cranial neuropathy although malignancies arising from the reticuloendothelial system or related structures of the head and neck were more frequent (26%).,6287825_8,-1,-1,-1,13526,-1,0.0026036236,0.99739635
13529,connective tissue disorders,2,5,19,46,Heredofamilial and connective tissue disorders were rare.,6287825_10,-1,-1,-1,13529,-1,0.0066365683,0.9933634
13530,neuropathies,13,14,81,93,Some of the factors related to the clinical presentation and pathogenesis of the neuropathies are briefly discussed.,6287825_11,-1,-1,-1,13530,-1,0.0027572552,0.9972428
13531,Wilms tumor,6,8,55,66,Doxorubicin cardiomyopathy in children with left-sided Wilms tumor.,6292680_0,-1,-1,-1,13531,-1,0.0058255275,0.99417454
13532,Wilms tumor,3,5,18,29,Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.,6292680_1,-1,-1,-1,13532,-1,0.0029455395,0.99705446
13533,anthracycline cardiomyopathy,11,13,68,96,Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.,6292680_1,-1,-1,-1,13533,-1,0.87997204,0.12002795
13537,Wilms tumor,14,16,79,90,The cardiomyopathy is attributed 1) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2) to the interaction of doxorubicin and irradiation on cardiac muscle.,6292680_2,-1,-1,-1,13537,-1,0.009253882,0.99074614
13540,Wilms tumor,12,14,81,92,It is recommended that doxorubicin dosage be sharply restricted in children with Wilms tumor of the left kidney who receive postoperative irradiation.,6292680_3,-1,-1,-1,13540,-1,0.0048314244,0.99516857
13547,DA,15,16,100,102,Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and DOPAC concentration or GAD activity.,6293644_4,-1,-1,-1,13547,-1,0.9982835,0.001716478
13548,DOPAC,17,18,107,112,Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and DOPAC concentration or GAD activity.,6293644_4,-1,-1,-1,13548,-1,0.9985991,0.0014008773
13550,caffeine toxicity,2,4,13,30,Reduction in caffeine toxicity by acetaminophen.,6308277_0,-1,-1,-1,13550,-1,0.2988121,0.7011879
13552,sodium acetylsalicylate,12,14,89,112,"A patient who allegedly consumed 100 tablets of an over-the-counter analgesic containing sodium acetylsalicylate, caffeine, and acetaminophen displayed no significant CNS stimulation despite the presence of 175 micrograms of caffeine per mL of serum.",6308277_1,-1,-1,-1,13552,-1,0.9990337,0.000966286
13556,salicylates,1,2,8,19,"Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS, attention was focused on the possibility that the presence of acetaminophen (52 micrograms/mL) reduced the CNS toxicity of caffeine.",6308277_2,-1,-1,-1,13556,-1,0.9982526,0.0017473547
13573,pentylenetetrezol,30,31,161,178,"In the absence of caffeine, acetaminophen (up to 300 mg/kg) did not modify the seizures induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice (tests performed by the Anticonvulsant Screening Project of NINCDS).",6308277_5,-1,-1,-1,13573,-1,0.99932885,0.0006711848
13576,ATP,16,17,103,106,Acetaminophen (up to 150 micrograms/mL) did not retard the incorporation of radioactive adenosine into ATP in slices of rat cerebral cortex.,6308277_6,-1,-1,-1,13576,-1,0.9981357,0.0018643067
13579,Naloxazone,0,1,0,10,"Naloxazone pretreatment modifies cardiorespiratory, temperature, and behavioral effects of morphine.",6308526_0,-1,-1,-1,13579,-1,0.99942553,0.0005745326
13582,naloxazone,18,19,121,131,"Behavioral and cardiorespiratory responses to a lethal dose of morphine were evaluated in rats pretreated with saline or naloxazone, an antagonist of high-affinity mu 1 opioid receptors.",6308526_1,-1,-1,-1,13582,-1,0.99934727,0.00065273535
13583,naloxazone,2,3,18,28,"Pretreatment with naloxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.",6308526_2,-1,-1,-1,13583,-1,0.9993605,0.00063952745
13584,morphine analgesia,5,7,51,69,"Pretreatment with naloxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.",6308526_2,-1,-1,-1,13584,-1,0.75265884,0.24734114
13587,naloxazone,2,3,10,20,"Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.",6308526_3,-1,-1,-1,13587,-1,0.99930644,0.0006935529
13589,respiratory depression,9,11,83,105,"Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.",6308526_3,-1,-1,-1,13589,-1,0.0026586193,0.99734133
13594,NH4Ac,5,6,36,41,"Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.",6323692_1,-1,-1,-1,13594,-1,0.99841154,0.0015884663
13595,incoordination,28,29,172,186,"Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.",6323692_1,-1,-1,-1,13595,-1,0.0026551448,0.9973449
13597,NH4Ac,33,34,204,209,"Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.",6323692_1,-1,-1,-1,13597,-1,0.99839693,0.001603051
13602,mM NH4Ac,21,23,140,148,Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.,6323692_3,-1,-1,-1,13602,-1,0.99688894,0.0031111066
13603,mM NH4Ac,35,37,222,230,Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.,6323692_3,-1,-1,-1,13603,-1,0.9960691,0.003930888
13607,acetaldehyde,16,17,117,129,"Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.",6323692_4,-1,-1,-1,13607,-1,0.99911684,0.00088312663
13608,NH4Ac,21,22,149,154,"Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.",6323692_4,-1,-1,-1,13608,-1,0.9982217,0.0017783128
13609,ammonia,4,5,29,36,These results suggested that ammonia blocks calcium channels.,6323692_5,-1,-1,-1,13609,-1,0.9986387,0.0013612482
13610,calcium channels,6,8,44,60,These results suggested that ammonia blocks calcium channels.,6323692_5,-1,-1,-1,13610,-1,0.86044073,0.13955925
13611,NH4Ac,5,6,28,33,Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept.,6323692_6,-1,-1,-1,13611,-1,0.99818856,0.0018114798
13615,NH4Ac,9,10,35,40,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,-1,-1,-1,13615,-1,0.99871004,0.0012899707
13617,incoordination,17,18,113,127,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,-1,-1,-1,13617,-1,0.0033751605,0.9966248
13619,NH4Ac,28,29,206,211,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,-1,-1,-1,13619,-1,0.998911,0.0010889382
13620,metrazol,34,35,246,254,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,-1,-1,-1,13620,-1,0.9993476,0.0006524054
13623,central nervous system depressants,16,20,108,142,The data suggest that hyperammonemia exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics.,6323692_8,-1,-1,-1,13623,-1,0.31574255,0.68425745
13628,thalamic lesions,5,7,43,59,Control of levodopa-induced dyskinesias by thalamic lesions in the course of routine treatment of Parkinsonism is discussed.,6381653_2,-1,-1,-1,13628,-1,0.017436503,0.98256344
13630,dothiepin hydrochloride,9,11,51,74,A double-blind study of the efficacy and safety of dothiepin hydrochloride in the treatment of major depressive disorder.,6386793_0,-1,-1,-1,13630,-1,0.9988287,0.0011712349
13631,major depressive disorder,15,18,95,120,A double-blind study of the efficacy and safety of dothiepin hydrochloride in the treatment of major depressive disorder.,6386793_0,-1,-1,-1,13631,-1,0.0040597753,0.9959402
13632,dothiepin,8,9,51,60,"In a 6-week double-blind parallel treatment study, dothiepin and amitriptyline were compared to placebo in the treatment of 33 depressed outpatients.",6386793_1,-1,-1,-1,13632,-1,0.9991366,0.00086340995
13635,Dothiepin,0,1,0,9,"Dothiepin and amitriptyline were equally effective in alleviating the symptoms of depressive illness, and both were significantly superior to placebo.",6386793_2,-1,-1,-1,13635,-1,0.9992167,0.0007833549
13637,depressive illness,11,13,82,100,"Dothiepin and amitriptyline were equally effective in alleviating the symptoms of depressive illness, and both were significantly superior to placebo.",6386793_2,-1,-1,-1,13637,-1,0.002591306,0.9974087
13638,blurred vision,12,14,72,86,"The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.",6386793_3,-1,-1,-1,13638,-1,0.0050202166,0.9949798
13640,drowsiness,19,20,103,113,"The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.",6386793_3,-1,-1,-1,13640,-1,0.0028560017,0.99714404
13641,dothiepin,24,25,143,152,"The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.",6386793_3,-1,-1,-1,13641,-1,0.9991302,0.0008698688
13643,Dothiepin,0,1,0,9,Dothiepin also produced fewer CNS and cardiovascular effects.,6386793_4,-1,-1,-1,13643,-1,0.9990952,0.00090481393
13644,Dothiepin,0,1,0,9,Dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients.,6386793_6,-1,-1,-1,13644,-1,0.99925023,0.0007497458
13650,panic disorder,9,11,64,78,Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia.,6387529_0,-1,-1,-1,13650,-1,0.0025642174,0.99743575
13653,mg,12,13,57,59,"The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design.",6387529_1,-1,-1,-1,13653,-1,0.98550385,0.014496181
13655,panic disorders,49,51,233,248,"The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design.",6387529_1,-1,-1,-1,13655,-1,0.0027704583,0.9972295
13657,impaired immediate free recall,2,6,11,41,Both drugs impaired immediate free recall but the decrease was greater for diazepam than propranolol.,6387529_2,-1,-1,-1,13657,-1,0.028224241,0.9717757
13660,Delayed free recall was also impaired,0,6,0,37,Delayed free recall was also impaired but the two drugs did not differ.,6387529_3,-1,-1,-1,13660,-1,0.019260243,0.9807397
13665,h,11,12,48,49,"After 2 weeks of treatment, patients tested 5-8 h after the last dose of medication did not show any decrement of performance.",6387529_5,-1,-1,-1,13665,-1,0.85107386,0.14892608
13666,behavioral impairment,8,10,53,74,Accumulation of drugs was not reflected in prolonged behavioral impairment.,6387529_7,-1,-1,-1,13666,-1,0.0034549413,0.996545
13667,urothelial toxicity,3,5,32,51,Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.,6402369_0,-1,-1,-1,13667,-1,0.003639025,0.99636096
13668,sodium 2-mercaptoethane sulphonate,9,12,78,112,Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.,6402369_0,-1,-1,-1,13668,-1,0.9985582,0.001441776
13670,lung cancer,19,21,149,160,Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.,6402369_0,-1,-1,-1,13670,-1,0.0031436174,0.99685633
13671,thiol,8,9,52,57,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,-1,-1,-1,13671,-1,0.99503005,0.004969974
13672,sodium 2-mercaptoethane sulphonate,10,13,67,101,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,-1,-1,-1,13672,-1,0.99871397,0.0012860768
13674,urothelial toxicity,17,19,118,137,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,-1,-1,-1,13674,-1,0.0045437273,0.9954562
13676,lung cancer,35,37,218,229,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,-1,-1,-1,13676,-1,0.0031486424,0.9968514
13678,IF,10,11,53,55,"MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg/m2, each administered at 0 hr (= injection of IF), 4 hr and 8 hr p.i.",6402369_2,-1,-1,-1,13678,-1,0.99848014,0.0015198166
13679,haematuria,17,18,99,109,Out of a total of 88 courses of this treatment we observed 10 episodes of asymptomatic microscopic haematuria and no episodes of gross haematuria.,6402369_3,-1,-1,-1,13679,-1,0.0023343964,0.99766564
13680,haematuria,23,24,135,145,Out of a total of 88 courses of this treatment we observed 10 episodes of asymptomatic microscopic haematuria and no episodes of gross haematuria.,6402369_3,-1,-1,-1,13680,-1,0.0023088271,0.99769115
13682,haematuria,24,25,121,131,"In this group there were 1 complete and 5 partial remissions (total 24%), but nearly all patients developed either gross haematuria and/or symptoms of bladder irritation (cystitis and pollakisuria).",6402369_6,-1,-1,-1,13682,-1,0.0027674772,0.9972325
13683,bladder irritation,28,30,151,169,"In this group there were 1 complete and 5 partial remissions (total 24%), but nearly all patients developed either gross haematuria and/or symptoms of bladder irritation (cystitis and pollakisuria).",6402369_6,-1,-1,-1,13683,-1,0.0038512347,0.9961488
13685,pollakisuria,33,34,184,196,"In this group there were 1 complete and 5 partial remissions (total 24%), but nearly all patients developed either gross haematuria and/or symptoms of bladder irritation (cystitis and pollakisuria).",6402369_6,-1,-1,-1,13685,-1,0.11529223,0.88470775
13690,absence seizures,5,7,23,39,"Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children.",6415512_0,-1,-1,-1,13690,-1,0.0050456007,0.9949544
13699,ceroid lipofuscinosis,12,14,65,86,The child in whom the seizures persisted was later found to have ceroid lipofuscinosis.,6415512_3,-1,-1,-1,13699,-1,0.412332,0.587668
13700,prostaglandin,2,3,10,23,Effect of prostaglandin synthetase inhibitors on experimentally induced convulsions in rats.,6433367_0,-1,-1,-1,13700,-1,0.9935003,0.006499677
13702,prostaglandins (PGs),5,9,35,55,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,-1,-1,-1,13702,-1,0.96229815,0.037701823
13704,PG,17,18,97,99,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,-1,-1,-1,13704,-1,0.9816528,0.018347193
13706,flurothyl,24,25,148,157,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,-1,-1,-1,13706,-1,0.99945873,0.000541309
13708,pentetrazol,28,29,171,182,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,-1,-1,-1,13708,-1,0.99934405,0.0006558879
13709,PTZ,30,31,184,187,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,-1,-1,-1,13709,-1,0.9964011,0.003598913
13712,mefenamic acid,4,6,21,35,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,-1,-1,-1,13712,-1,0.9990972,0.00090275804
13713,meclofenamic acid,10,12,50,67,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,-1,-1,-1,13713,-1,0.99921036,0.0007895654
13714,flurothyl,17,18,106,115,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,-1,-1,-1,13714,-1,0.99946874,0.0005312577
13715,PTZ,19,20,123,126,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,-1,-1,-1,13715,-1,0.9954282,0.004571765
13718,PGs,4,5,27,30,"These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.",6433367_3,-1,-1,-1,13718,-1,0.95514125,0.044858806
13721,ammonia,4,5,23,30,Acute changes of blood ammonia may predict short-term adverse effects of valproic acid.,6436733_0,-1,-1,-1,13721,-1,0.9947233,0.0052766716
13722,valproic acid,11,13,73,86,Acute changes of blood ammonia may predict short-term adverse effects of valproic acid.,6436733_0,-1,-1,-1,13722,-1,0.9991793,0.000820699
13723,VPA,3,4,15,18,Valproic acid (VPA) was given to 24 epileptic patients who were already being treated with other antiepileptic drugs.,6436733_1,-1,-1,-1,13723,-1,0.9983303,0.0016696625
13725,VPA,5,6,31,34,"A standardized loading dose of VPA was administered, and venous blood was sampled at 0, 1, 2, 3, and 4 hours.",6436733_2,-1,-1,-1,13725,-1,0.9988543,0.0011456677
13726,Ammonia,0,1,0,7,"Ammonia (NH3) was higher in patients who, during continuous therapy, complained of drowsiness (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.",6436733_3,-1,-1,-1,13726,-1,0.9987043,0.0012957206
13727,NH3,2,3,9,12,"Ammonia (NH3) was higher in patients who, during continuous therapy, complained of drowsiness (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.",6436733_3,-1,-1,-1,13727,-1,0.99710494,0.0028950544
13728,drowsiness,16,17,83,93,"Ammonia (NH3) was higher in patients who, during continuous therapy, complained of drowsiness (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.",6436733_3,-1,-1,-1,13728,-1,0.0024170394,0.9975829
13729,VPA,33,34,167,170,"Ammonia (NH3) was higher in patients who, during continuous therapy, complained of drowsiness (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.",6436733_3,-1,-1,-1,13729,-1,0.9986431,0.0013569264
13730,NH3,6,7,42,45,"By measuring VPA-induced changes of blood NH3 content, it may be possible to identify patients at higher risk of obtundation when VPA is given chronically.",6436733_4,-1,-1,-1,13730,-1,0.99704856,0.0029515224
13731,VPA,22,23,130,133,"By measuring VPA-induced changes of blood NH3 content, it may be possible to identify patients at higher risk of obtundation when VPA is given chronically.",6436733_4,-1,-1,-1,13731,-1,0.99895763,0.001042314
13738,renal abnormality,6,8,40,57,The possibility of reproducing the same renal abnormality with captopril was examined in SHR.,6454943_2,-1,-1,-1,13738,-1,0.0036632805,0.9963367
13744,puromycin aminonucleoside,15,17,107,132,"Also, captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR.",6454943_4,-1,-1,-1,13744,-1,0.9987669,0.0012331319
13749,body weight,24,26,160,171,"Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and potassium, endogenous creatinine clearance, body weight, and food and water consumption.",6454943_5,-1,-1,-1,13749,-1,0.4347007,0.5652993
13750,ketone bodies,2,4,9,22,"However, ketone bodies were consistently present in urine and several lethalities occurred during multiple dosing of captopril in SHR.",6454943_6,-1,-1,-1,13750,-1,0.993568,0.0064320234
13768,heart block,1,3,9,20,Complete heart block following a single dose of trazodone.,6496797_0,-1,-1,-1,13768,-1,0.0034020871,0.99659795
13769,trazodone,8,9,48,57,Complete heart block following a single dose of trazodone.,6496797_0,-1,-1,-1,13769,-1,0.9990544,0.0009456353
13770,trazodone,9,10,56,65,"Forty minutes after receiving a single starting dose of trazodone, a patient developed complete heart block.",6496797_1,-1,-1,-1,13770,-1,0.9992205,0.0007795541
13771,heart block,15,17,96,107,"Forty minutes after receiving a single starting dose of trazodone, a patient developed complete heart block.",6496797_1,-1,-1,-1,13771,-1,0.0028707818,0.99712926
13772,trazodone,12,13,67,76,"The case illustrates that, despite the results of earlier studies, trazodone's effect on cardiac conduction may be severe in individuals at risk for conduction delay.",6496797_2,-1,-1,-1,13772,-1,0.9989773,0.0010227107
13773,conduction delay,26,28,149,165,"The case illustrates that, despite the results of earlier studies, trazodone's effect on cardiac conduction may be severe in individuals at risk for conduction delay.",6496797_2,-1,-1,-1,13773,-1,0.0037635828,0.9962365
13775,dacarbazine,4,5,35,46,Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.,6503301_0,-1,-1,-1,13775,-1,0.9991769,0.0008230123
13776,DTIC,7,8,56,60,Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.,6503301_0,-1,-1,-1,13776,-1,0.99463344,0.00536654
13777,melanoma,10,11,66,74,Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.,6503301_0,-1,-1,-1,13777,-1,0.007727092,0.992273
13778,dacarbazine,12,13,71,82,A case of veno-occlusive disease of the liver with fatal outcome after dacarbazine (DTIC) therapy for melanoma is reported.,6503301_1,-1,-1,-1,13778,-1,0.9992913,0.0007086614
13779,DTIC,14,15,84,88,A case of veno-occlusive disease of the liver with fatal outcome after dacarbazine (DTIC) therapy for melanoma is reported.,6503301_1,-1,-1,-1,13779,-1,0.9976082,0.002391765
13780,melanoma,18,19,102,110,A case of veno-occlusive disease of the liver with fatal outcome after dacarbazine (DTIC) therapy for melanoma is reported.,6503301_1,-1,-1,-1,13780,-1,0.006327555,0.9936725
13782,venous congestion,11,13,57,74,At autopsy the liver was enlarged and firm with signs of venous congestion.,6503301_3,-1,-1,-1,13782,-1,0.0063725496,0.9936274
13784,Eosinophilic,0,1,0,12,Eosinophilic infiltrations were found around the vessels.,6503301_5,-1,-1,-1,13784,-1,0.05749281,0.9425072
13786,neurologic impairment,5,7,30,51,A 2-year-old child with known neurologic impairment developed a dyskinesia soon after starting phenobarbital therapy for seizures.,6504332_1,-1,-1,-1,13786,-1,0.002342466,0.99765754
13790,movement disorders,3,5,16,34,Known causes of movement disorders were eliminated after evaluation.,6504332_2,-1,-1,-1,13790,-1,0.0026552128,0.9973448
13794,movement disorders,13,15,81,99,Phenobarbital should be added to the list of anticonvulsant drugs that can cause movement disorders.,6504332_4,-1,-1,-1,13794,-1,0.002513354,0.9974866
13796,Ebstein's anomaly,4,7,30,47,Maternal lithium and neonatal Ebstein's anomaly: evaluation with cross-sectional echocardiography.,6518066_0,-1,-1,-1,13796,-1,0.048973978,0.951026
13798,Ebstein's anomaly of the tricuspid,4,10,15,49,"In one infant, Ebstein's anomaly of the tricuspid valve was identified.",6518066_2,-1,-1,-1,13798,-1,0.39568466,0.60431534
13799,Ebstein's anomaly,14,17,103,120,In the other infant cross-sectional echocardiography provided reassurance that the infant did not have Ebstein's anomaly.,6518066_3,-1,-1,-1,13799,-1,0.10727605,0.8927239
13801,cardiac malformations,24,26,190,211,"Cross-sectional echocardiographic screening of newborns exposed to lithium during gestation can provide highly accurate, noninvasive assessment of the presence or absence of lithium-induced cardiac malformations.",6518066_4,-1,-1,-1,13801,-1,0.0030745512,0.9969254
13802,myocardial infarction,8,10,50,71,Effects of training on the extent of experimental myocardial infarction in aging rats.,6534871_0,-1,-1,-1,13802,-1,0.0029393756,0.9970606
13803,myocardial infarction,9,11,65,86,"The effects of exercise on the severity of isoproterenol-induced myocardial infarction were studied in female albino rats of 20,40,60 and 80 weeks of age.",6534871_1,-1,-1,-1,13803,-1,0.0023479704,0.997652
13804,infarcts,3,4,18,26,The occurrence of infarcts were confirmed by histological methods.,6534871_3,-1,-1,-1,13804,-1,0.0028792147,0.9971208
13805,myocardial infarction,3,5,21,42,Studies dealing with myocardial infarction are more informative when dealt with age.,6534871_7,-1,-1,-1,13805,-1,0.0032287429,0.9967713
13807,adriamycin toxicity,6,8,37,56,Effect of polyethylene glycol 400 on adriamycin toxicity in mice.,6538499_0,-1,-1,-1,13807,-1,0.85670406,0.14329591
13809,PEG 400,13,15,70,77,"The effect of a widely used organic solvent, polyethylene glycol 400 (PEG 400), on the toxic action of an acute or chronic treatment with adriamycin (ADR) was evaluated in mice.",6538499_1,-1,-1,-1,13809,-1,0.9945439,0.0054560862
13811,ADR,30,31,150,153,"The effect of a widely used organic solvent, polyethylene glycol 400 (PEG 400), on the toxic action of an acute or chronic treatment with adriamycin (ADR) was evaluated in mice.",6538499_1,-1,-1,-1,13811,-1,0.99645644,0.0035435285
13812,PEG 400,0,2,0,7,PEG 400 impressively decreased both acute high-dose and chronic low-dose-ADR-associated lethality.,6538499_2,-1,-1,-1,13812,-1,0.99859077,0.0014091972
13813,cardiac morphological alterations,9,12,79,112,Light microscopic analysis showed a significant protection against ADR-induced cardiac morphological alterations.,6538499_3,-1,-1,-1,13813,-1,0.0033295788,0.9966704
13814,ADR,6,7,36,39,Such treatment did not diminish the ADR antitumor activity in L1210 leukemia and in Ehrlich ascites tumor.,6538499_4,-1,-1,-1,13814,-1,0.9980782,0.001921728
13815,L1210 leukemia,10,12,62,76,Such treatment did not diminish the ADR antitumor activity in L1210 leukemia and in Ehrlich ascites tumor.,6538499_4,-1,-1,-1,13815,-1,0.7399671,0.26003292
13816,Ehrlich ascites tumor,14,17,84,105,Such treatment did not diminish the ADR antitumor activity in L1210 leukemia and in Ehrlich ascites tumor.,6538499_4,-1,-1,-1,13816,-1,0.020929448,0.97907054
13817,amine,2,3,11,16,Effects of amine pretreatment on ketamine catatonia in pinealectomized or hypophysectomized animals.,6540303_0,-1,-1,-1,13817,-1,0.9987704,0.0012295652
13818,ketamine catatonia,5,7,33,51,Effects of amine pretreatment on ketamine catatonia in pinealectomized or hypophysectomized animals.,6540303_0,-1,-1,-1,13818,-1,0.1792927,0.8207073
13820,catatonia,16,17,114,123,"The present studies were designed to clarify the role of catecholamines and pineal idolamines on ketamine-induced catatonia in the intact, pinealectomized or hypophysectomized chick and rat.",6540303_1,-1,-1,-1,13820,-1,0.0037020925,0.9962979
13822,catatonia,12,13,83,92,"In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with norepinephrine did not.",6540303_2,-1,-1,-1,13822,-1,0.023479942,0.97652006
13828,melatonin,22,23,121,130,"Serotonin and N-acetyl serotonin which augmented ketamine DOC, did not do so in the absence of the pineal gland, whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick.",6540303_4,-1,-1,-1,13828,-1,0.9980118,0.0019881602
13831,melatonin,22,23,132,141,"Ketamine was more potent in the hypophysectomized chick and the circadian rhythm noted in the intact chick was absent; furthermore, melatonin did not augment the ketamine DOC whereas dopamine continued to do so.",6540303_5,-1,-1,-1,13831,-1,0.9981098,0.0018901655
13834,amines,13,14,78,84,This study did not demonstrate a species difference regarding the role of the amines on the pineal in spite of the immature blood-brain barrier in the young chick and the intact barrier in the rat.,6540303_6,-1,-1,-1,13834,-1,0.99760133,0.002398736
13836,melatonin,20,21,111,120,"In addition, these data indicate a direct role of the pituitary in the augmentation of ketamine DOC induced by melatonin.",6540303_7,-1,-1,-1,13836,-1,0.9986848,0.0013152106
13838,ketamine catatonia,15,17,93,111,"Furthermore, dopamine appeared to act on systems more closely involved with the induction of ketamine catatonia rather than directly on the pituitary.",6540303_8,-1,-1,-1,13838,-1,0.15740834,0.84259164
13846,a falling platelet count,4,8,32,56,"Laboratory testing has revealed a falling platelet count, increased resistance to heparin, and aggregation of platelets by the patient's plasma when heparin is added.",6615052_3,-1,-1,-1,13846,-1,0.019163309,0.9808367
13856,diatrizoate,3,4,30,41,Ventricular fibrillation from diatrizoate with and without chelating agents.,663266_0,-1,-1,-1,13856,-1,0.99913377,0.0008662703
13857,chelating agents,7,9,59,75,Ventricular fibrillation from diatrizoate with and without chelating agents.,663266_0,-1,-1,-1,13857,-1,0.9920105,0.007989529
13859,Renografin 76%,3,6,16,30,The toxicity of Renografin 76% was compared with that of Hypaque 76% by selective injection of each into the right coronary artery of dogs.,663266_1,-1,-1,-1,13859,-1,0.99488467,0.0051153307
13860,Hypaque 76%,11,14,57,68,The toxicity of Renografin 76% was compared with that of Hypaque 76% by selective injection of each into the right coronary artery of dogs.,663266_1,-1,-1,-1,13860,-1,0.9934855,0.006514461
13861,chelating agents sodium citrate,3,7,24,55,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,-1,-1,-1,13861,-1,0.99264246,0.007357518
13862,disodium edetate,8,10,60,76,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,-1,-1,-1,13862,-1,0.9987907,0.001209289
13863,Hypaque,12,13,84,91,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,-1,-1,-1,13863,-1,0.9966562,0.0033438348
13864,calcium disodium edetate,14,17,101,125,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,-1,-1,-1,13864,-1,0.9984314,0.0015685442
13866,Renografin,7,8,64,74,"Ventricular fibrillation occurred significantly more often with Renografin, suggesting that chelating agents contribute to toxicity in coronary angiography.",663266_3,-1,-1,-1,13866,-1,0.99925035,0.00074966793
13867,chelating agents,11,13,92,108,"Ventricular fibrillation occurred significantly more often with Renografin, suggesting that chelating agents contribute to toxicity in coronary angiography.",663266_3,-1,-1,-1,13867,-1,0.9932944,0.0067056133
13869,quaternary ammonium,4,6,29,48,"Sublingual absorption of the quaternary ammonium antiarrhythmic agent, UM-272.UM-272 (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced ventricular tachycardias.",6634932_0,-1,-1,-1,13869,-1,0.99833494,0.0016650294
13870,N,11,12,86,87,"Sublingual absorption of the quaternary ammonium antiarrhythmic agent, UM-272.UM-272 (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced ventricular tachycardias.",6634932_0,-1,-1,-1,13870,-1,0.98512566,0.014874386
13871,ventricular tachycardias,28,30,206,230,"Sublingual absorption of the quaternary ammonium antiarrhythmic agent, UM-272.UM-272 (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced ventricular tachycardias.",6634932_0,-1,-1,-1,13871,-1,0.0025200525,0.99748
13872,UM-272,1,2,11,17,Sublingual UM-272 converted ventricular tachycardia to sinus rhythm in all 5 dogs.,6634932_2,-1,-1,-1,13872,-1,0.9974287,0.0025712543
13877,ventricular fibrillation,12,14,95,119,Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation.,6637851_0,-1,-1,-1,13877,-1,0.0032961783,0.9967038
13880,VT,14,15,100,102,"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.",6637851_1,-1,-1,-1,13880,-1,0.003567343,0.99643266
13881,n,17,18,105,106,"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.",6637851_1,-1,-1,-1,13881,-1,0.27511364,0.72488636
13883,n,26,27,135,136,"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.",6637851_1,-1,-1,-1,13883,-1,0.18254194,0.81745803
13885,VT,14,15,104,106,Sixty-nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/- standard deviation 14.2 +/- 8.2).,6637851_3,-1,-1,-1,13885,-1,0.0031008155,0.99689925
13886,ventricular fibrillation,16,18,110,134,Sixty-nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/- standard deviation 14.2 +/- 8.2).,6637851_3,-1,-1,-1,13886,-1,0.0033230959,0.9966769
13887,VF,19,20,136,138,Sixty-nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/- standard deviation 14.2 +/- 8.2).,6637851_3,-1,-1,-1,13887,-1,0.0031486838,0.99685127
13888,VT,10,11,57,59,Six percent of the patients had a nonfatal recurrence of VT and were successfully managed by continuing amiodarone at a higher dose or by the addition of a conventional antiarrhythmic drug.,6637851_4,-1,-1,-1,13888,-1,0.0027507779,0.9972492
13890,adverse drug reactions,3,6,12,34,One or more adverse drug reactions occurred in 51% of patients.,6637851_5,-1,-1,-1,13890,-1,0.009961392,0.99003863
13896,anorexia,17,18,86,94,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,-1,-1,-1,13896,-1,0.0030247506,0.9969753
13897,visual halos,23,25,101,113,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,-1,-1,-1,13897,-1,0.01346412,0.98653585
13898,blurring,26,27,117,125,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,-1,-1,-1,13898,-1,0.0064932937,0.99350667
13899,thyroid function abnormalities,32,35,132,162,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,-1,-1,-1,13899,-1,0.02481845,0.9751815
13900,pulmonary interstitial infiltrates,40,43,172,206,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,-1,-1,-1,13900,-1,0.006455077,0.99354494
13902,VT,11,12,81,83,"Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.",6637851_8,-1,-1,-1,13902,-1,0.0027031873,0.99729687
13903,VF,13,14,87,89,"Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.",6637851_8,-1,-1,-1,13903,-1,0.0025336188,0.9974663
13905,VT,23,24,122,124,"However, when the dose is adjusted based on clinical response or the development of adverse effects, 75% of patients with VT or VF can be successfully managed with amiodarone.",6637851_9,-1,-1,-1,13905,-1,0.0030915327,0.9969085
13906,VF,25,26,128,130,"However, when the dose is adjusted based on clinical response or the development of adverse effects, 75% of patients with VT or VF can be successfully managed with amiodarone.",6637851_9,-1,-1,-1,13906,-1,0.002774842,0.99722517
13912,h,11,12,67,68,Adriamycin (50 mg/50 ml) was administered intravesically within 24 h after transurethral resection of TA-T1 (O-A) bladder tumors.,6640832_2,-1,-1,-1,13912,-1,0.10057343,0.8994266
13913,bladder tumors,20,22,114,128,Adriamycin (50 mg/50 ml) was administered intravesically within 24 h after transurethral resection of TA-T1 (O-A) bladder tumors.,6640832_2,-1,-1,-1,13913,-1,0.0054553617,0.9945446
13917,angiopathy,1,2,24,34,D-penicillamine-induced angiopathy in rats.,6666578_0,-1,-1,-1,13917,-1,0.002318199,0.99768174
13918,hyaluronate,43,44,264,275,"The aorta/serum-ratio and the radioactive build-up 24 and 48 hours after injection of 131I-HSA was reduced in animals treated with D-pen for 42 days, indicating an impeded transmural transport of tracer which may be caused by a steric exclusion effect of abundant hyaluronate.",6666578_8,-1,-1,-1,13918,-1,0.99732375,0.002676215
13919,EACA,5,6,35,39,Why may epsilon-aminocaproic acid (EACA) induce myopathy in man? Report of a case and literature review.,6674249_0,-1,-1,-1,13919,-1,0.996452,0.0035480408
13921,necrotizing,3,4,10,21,A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.,6674249_1,-1,-1,-1,13921,-1,0.0026208677,0.9973792
13923,EACA,12,13,73,77,A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.,6674249_1,-1,-1,-1,13923,-1,0.99762875,0.002371252
13924,subarachnoid haemorrhage,21,23,119,143,A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.,6674249_1,-1,-1,-1,13924,-1,0.003130861,0.99686915
13925,SAH,24,25,145,148,A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.,6674249_1,-1,-1,-1,13925,-1,0.002425761,0.99757427
13928,N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide,5,6,38,83,The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.,6692345_1,-1,-1,-1,13928,-1,0.9965378,0.0034622587
13929,FANFT,7,8,85,90,The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.,6692345_1,-1,-1,-1,13929,-1,0.99745935,0.0025406613
13930,bladder carcinomas,18,20,149,167,The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.,6692345_1,-1,-1,-1,13930,-1,0.0041514686,0.99584854
13931,forestomach tumors,25,27,199,217,The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.,6692345_1,-1,-1,-1,13931,-1,0.0113742165,0.98862576
13932,FANFT,12,13,79,84,An autoradiographic study was performed on male F-344 rats fed diet containing FANFT at a level of 0.2% and/or aspirin at a level of 0.5% to evaluate the effect of aspirin on the increased cell proliferation induced by FANFT in the forestomach and bladder.,6692345_2,-1,-1,-1,13932,-1,0.9974438,0.0025562346
13935,FANFT,40,41,219,224,An autoradiographic study was performed on male F-344 rats fed diet containing FANFT at a level of 0.2% and/or aspirin at a level of 0.5% to evaluate the effect of aspirin on the increased cell proliferation induced by FANFT in the forestomach and bladder.,6692345_2,-1,-1,-1,13935,-1,0.99710995,0.002890045
13938,FANFT carcinogenesis,16,18,124,144,"The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach, and that aspirin's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation.",6692345_5,-1,-1,-1,13938,-1,0.621912,0.37808794
13940,FANFT,30,31,206,211,"The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach, and that aspirin's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation.",6692345_5,-1,-1,-1,13940,-1,0.9908097,0.009190299
13942,phenylpropanolamine,4,5,36,55,Cerebral hemorrhage associated with phenylpropanolamine in combination with caffeine.,6695415_0,-1,-1,-1,13942,-1,0.9992317,0.0007683098
13944,Phenylpropanolamine,0,1,0,19,Phenylpropanolamine (PPA) is a drug that has been associated with serious side effects including stroke.,6695415_1,-1,-1,-1,13944,-1,0.99902713,0.00097284274
13945,PPA,2,3,21,24,Phenylpropanolamine (PPA) is a drug that has been associated with serious side effects including stroke.,6695415_1,-1,-1,-1,13945,-1,0.9964844,0.0035155986
13948,lead,7,8,42,46,"In order to determine if PPA/caffeine can lead to stroke in normotensive and/or hypertensive rats, we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days.",6695415_3,-1,-1,-1,13948,-1,0.012871634,0.9871284
13951,cerebral hemorrhage,2,4,17,36,Subarachnoid and cerebral hemorrhage was noted in 18% of the hypertensive rats.,6695415_4,-1,-1,-1,13951,-1,0.0026912023,0.99730885
13953,lead,8,9,49,53,A single PPA/caffeine administration (same dose) lead to acute hypertension in both the normotensive and hypertensive animals.,6695415_5,-1,-1,-1,13953,-1,0.06373568,0.93626434
13956,lead,6,7,44,48,These results suggest that PPA/caffeine can lead to cerebral hemorrhage in previously hypertensive animals when administered in greater than the allowed dosage.,6695415_6,-1,-1,-1,13956,-1,0.0093200235,0.9906799
13957,cerebral hemorrhage,8,10,52,71,These results suggest that PPA/caffeine can lead to cerebral hemorrhage in previously hypertensive animals when administered in greater than the allowed dosage.,6695415_6,-1,-1,-1,13957,-1,0.001980726,0.9980192
13959,naproxen,5,6,32,40,Renal papillary necrosis due to naproxen.,6699841_0,-1,-1,-1,13959,-1,0.99917847,0.0008215178
13962,fenoprofen calcium,15,17,92,110,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,-1,-1,-1,13962,-1,0.9992106,0.0007893833
13963,salicylates,20,21,122,133,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,-1,-1,-1,13963,-1,0.9984841,0.0015159061
13964,gold salts,22,24,138,148,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,-1,-1,-1,13964,-1,0.9979109,0.0020890953
13966,RPN,30,31,186,189,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,-1,-1,-1,13966,-1,0.005082901,0.99491715
13967,naproxen,37,38,221,229,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,-1,-1,-1,13967,-1,0.99933064,0.000669382
13968,RPN,5,6,32,35,No other factor predisposing to RPN could be discovered.,6699841_2,-1,-1,-1,13968,-1,0.058633745,0.94136626
13970,naproxen,4,5,29,37,Sulindac was substituted for naproxen and no further adverse renal effects occurred over the next 12 months.,6699841_3,-1,-1,-1,13970,-1,0.9992754,0.0007246462
13971,RPN,5,6,35,38,We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced renal toxicity from other antiinflammatory agents.,6699841_4,-1,-1,-1,13971,-1,0.8224256,0.17757444
13974,tardive dyskinesia,3,5,10,28,A case of tardive dyskinesia caused by metoclopramide.,6727060_0,-1,-1,-1,13974,-1,0.0022733589,0.9977266
13976,Abnormal involuntary movements,0,3,0,30,"Abnormal involuntary movements appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days.",6727060_1,-1,-1,-1,13976,-1,0.0042202263,0.99577975
13978,gastrointestinal disorder,23,25,142,167,"Abnormal involuntary movements appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days.",6727060_1,-1,-1,-1,13978,-1,0.0025020537,0.997498
13979,mg,30,31,187,189,"Abnormal involuntary movements appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days.",6727060_1,-1,-1,-1,13979,-1,0.9749428,0.025057163
13981,tardive dyskinesia,7,9,48,66,Attention to the possible induction of specific tardive dyskinesia is called for in the use of this drug.,6727060_4,-1,-1,-1,13981,-1,0.002207165,0.99779284
13986,netilmicin,9,10,53,63,"To quantify the effects of gentamicin, kanamycin and netilmicin on renal protein reabsorption and accumulation, these drugs were administered to rats intraperitoneally (30 mg/kg/day) for 7, 14 or 21 days.",6728084_1,-1,-1,-1,13986,-1,0.9988574,0.0011426116
13991,netilmicin,2,3,14,24,Kanamycin and netilmicin appeared to have no effect at the dose used.,6728084_5,-1,-1,-1,13991,-1,0.99868363,0.0013163253
13997,netilmicin,4,5,37,47,administration of egg-white lysozyme netilmicin had no effect.,6728084_8,-1,-1,-1,13997,-1,0.9989617,0.001038257
14001,nephrotoxicants,6,7,33,48,"Thus, aminoglycosides may act as nephrotoxicants at glomerular and/or tubular level inducing impairment of renal reabsorption and accumulation of proteins.",6728084_10,-1,-1,-1,14001,-1,0.048748318,0.9512517
14002,obstructive sleep apnea syndrome,3,7,17,49,Induction of the obstructive sleep apnea syndrome in a woman by exogenous androgen administration.,6732043_0,-1,-1,-1,14002,-1,0.0031083745,0.9968917
14003,androgen,12,13,74,82,Induction of the obstructive sleep apnea syndrome in a woman by exogenous androgen administration.,6732043_0,-1,-1,-1,14003,-1,0.99807763,0.0019223748
14004,syndrome of obstructive sleep apnea,25,30,167,202,We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54-yr-old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous androgens.,6732043_1,-1,-1,-1,14004,-1,0.0032167733,0.99678326
14005,androgens,34,35,238,247,We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54-yr-old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous androgens.,6732043_1,-1,-1,-1,14005,-1,0.9973321,0.0026679186
14006,androgens,2,3,9,18,"When the androgens were withdrawn, the patient's physical changes, symptoms, sleep study, and supraglottic resistance all returned to normal.",6732043_2,-1,-1,-1,14006,-1,0.99755895,0.002440994
14007,androgen,3,4,19,27,A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone.,6732043_3,-1,-1,-1,14007,-1,0.9984291,0.001570813
14008,obstructive sleep apnea,7,10,49,72,A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone.,6732043_3,-1,-1,-1,14008,-1,0.002777572,0.9972224
14009,androgens,7,8,40,49,Previous reports have favored a role of androgens in the pathogenesis of sleep apnea.,6732043_4,-1,-1,-1,14009,-1,0.99727637,0.002723682
14010,sleep apnea,12,14,73,84,Previous reports have favored a role of androgens in the pathogenesis of sleep apnea.,6732043_4,-1,-1,-1,14010,-1,0.0035142277,0.9964858
14011,androgens,6,7,53,62,Structural and functional measurements indicate that androgens exert a permissive or necessary action on the structural configuration of the oropharynx that predisposes to obstruction during sleep.,6732043_6,-1,-1,-1,14011,-1,0.99716514,0.0028349026
14012,obstructive sleep apnea syndrome,3,7,19,51,Development of the obstructive sleep apnea syndrome must be considered a possible side effect of androgen therapy.,6732043_7,-1,-1,-1,14012,-1,0.0030195424,0.9969805
14013,androgen,15,16,97,105,Development of the obstructive sleep apnea syndrome must be considered a possible side effect of androgen therapy.,6732043_7,-1,-1,-1,14013,-1,0.99807334,0.0019266485
14014,BCNU,1,2,15,19,Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system.,6747681_0,-1,-1,-1,14014,-1,0.9984818,0.0015182552
14015,malignant gliomas,6,8,50,67,Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system.,6747681_0,-1,-1,-1,14015,-1,0.004178984,0.995821
14016,BCNU,7,8,43,47,"Because of the rapid systemic clearance of BCNU (1,3-bis-(2-chloroethyl)-1-nitrosourea), intra-arterial administration should provide a substantial advantage over intravenous administration for the treatment of malignant gliomas.",6747681_1,-1,-1,-1,14016,-1,0.99859935,0.0014006664
14018,malignant gliomas,26,28,211,228,"Because of the rapid systemic clearance of BCNU (1,3-bis-(2-chloroethyl)-1-nitrosourea), intra-arterial administration should provide a substantial advantage over intravenous administration for the treatment of malignant gliomas.",6747681_1,-1,-1,-1,14018,-1,0.0035257663,0.9964742
14019,BCNU,5,6,38,42,"Thirty-six patients were treated with BCNU every 6 to 8 weeks, either by transfemoral catheterization of the internal carotid or vertebral artery or through a fully implantable intracarotid drug delivery system, beginning with a dose of 200 mg/sq m body surface area.",6747681_2,-1,-1,-1,14019,-1,0.99879223,0.0012078524
14023,BCNU,25,26,164,168,"Twenty-four patients with recurrent Grade I to IV astrocytomas, whose resection and irradiation therapy had failed, received two to eight courses of intra-arterial BCNU therapy.",6747681_7,-1,-1,-1,14023,-1,0.9987244,0.001275537
14024,BCNU,14,15,90,94,"The catheterization procedure is safe, with no immediate complication in 111 infusions of BCNU.",6747681_9,-1,-1,-1,14024,-1,0.9987135,0.0012865314
14025,loss of vision,9,12,60,74,A delayed complication in nine patients has been unilateral loss of vision secondary to a retinal vasculitis.,6747681_10,-1,-1,-1,14025,-1,0.0063303313,0.9936697
14026,retinal vasculitis,15,17,90,108,A delayed complication in nine patients has been unilateral loss of vision secondary to a retinal vasculitis.,6747681_10,-1,-1,-1,14026,-1,0.002994222,0.99700576
14031,congestive heart failure,6,9,30,54,8 of the 10 monkeys developed congestive heart failure at an average cumulative adriamycin dose (310 mg/m2) well below that considered the safe upper limit (550 mg/m2) in man.,6769133_1,-1,-1,-1,14031,-1,0.0022429216,0.99775714
14033,myocardial lesions,3,5,20,38,"Histologically, the myocardial lesions resembled those found in human anthracycline-induced cardiomyopathy.",6769133_2,-1,-1,-1,14033,-1,0.003198545,0.9968015
14035,acute myeloblastic leukemia,6,9,30,57,1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug.,6769133_3,-1,-1,-1,14035,-1,0.0023550664,0.99764496
14038,leukemia,18,19,98,106,"Our results suggest that adriamycin is a more potent cardiotoxin in monkeys than in man, and that leukemia may be a consequence of prolonged treatment with this drug.",6769133_4,-1,-1,-1,14038,-1,0.0027464349,0.9972536
14039,postural hypotension,2,4,15,35,"Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.",6773726_0,-1,-1,-1,14039,-1,0.0028223414,0.9971776
14052,vasodilator drugs,11,13,76,93,"It is therefore suggested that caution should be exercised when prescribing vasodilator drugs in diabetic patients, particularly those with autonomic neuropathy.",6773726_2,-1,-1,-1,14052,-1,0.99582666,0.004173297
14055,Tricuspid valve regurgitation,0,3,0,29,Tricuspid valve regurgitation and lithium carbonate toxicity in a newborn infant.,6794356_0,-1,-1,-1,14055,-1,0.015012598,0.98498744
14056,lithium carbonate toxicity,4,7,34,60,Tricuspid valve regurgitation and lithium carbonate toxicity in a newborn infant.,6794356_0,-1,-1,-1,14056,-1,0.86934155,0.13065845
14057,tricuspid regurgitation,4,6,23,46,"A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.",6794356_1,-1,-1,-1,14057,-1,0.012130496,0.98786944
14058,atrial flutter,7,9,48,62,"A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.",6794356_1,-1,-1,-1,14058,-1,0.071782164,0.9282178
14059,congestive heart failure,10,13,64,88,"A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.",6794356_1,-1,-1,-1,14059,-1,0.0029945269,0.9970055
14061,tricuspid regurgitation,8,10,48,71,"This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.",6794356_2,-1,-1,-1,14061,-1,0.025648545,0.97435147
14062,atrial flutter,11,13,76,90,"This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.",6794356_2,-1,-1,-1,14062,-1,0.018697241,0.9813028
14063,cardiac disease,20,22,128,143,"This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.",6794356_2,-1,-1,-1,14063,-1,0.0025325562,0.9974674
14064,lithium compounds,26,28,169,186,"This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.",6794356_2,-1,-1,-1,14064,-1,0.9978783,0.0021216858
14065,Lithium carbonate,0,2,0,17,Lithium carbonate may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy.,6794356_4,-1,-1,-1,14065,-1,0.99881834,0.0011816014
14066,congenital heart disease,11,14,65,89,Lithium carbonate may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy.,6794356_4,-1,-1,-1,14066,-1,0.0027276364,0.9972723
14068,cyanosis,6,7,38,46,"It also causes neurologic depression, cyanosis, and cardiac arrhythmia when consumed prior to delivery.",6794356_5,-1,-1,-1,14068,-1,0.0026923763,0.99730766
14069,cardiac arrhythmia,9,11,52,70,"It also causes neurologic depression, cyanosis, and cardiac arrhythmia when consumed prior to delivery.",6794356_5,-1,-1,-1,14069,-1,0.0026772004,0.99732286
14070,aniracetam,5,6,30,40,Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents.,6817363_0,-1,-1,-1,14070,-1,0.99881893,0.0011810231
14071,Ro 13-5057,7,11,42,52,Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents.,6817363_0,-1,-1,-1,14071,-1,0.9967031,0.003296946
14072,aniracetam,3,4,14,24,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14072,-1,0.99877053,0.0012293919
14073,"Ro 13-5057, 1-anisoyl-2-pyrrolidinone",5,11,26,63,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14073,-1,0.9976544,0.002345614
14074,impaired cognitive functions,19,22,112,140,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14074,-1,0.0037520113,0.99624795
14075,hypercapnia,55,56,324,335,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14075,-1,0.030995052,0.9690049
14079,chloramphenicol,130,131,781,796,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14079,-1,0.99879706,0.0012029697
14081,h,149,150,903,904,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14081,-1,0.31101546,0.6889846
14083,hypercapnia,197,198,1178,1189,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14083,-1,0.12055231,0.87944764
14084,h,205,206,1239,1240,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,-1,-1,-1,14084,-1,0.17929304,0.8207069
14085,impaired cognitive functions,5,8,40,68,These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg.,6817363_2,-1,-1,-1,14085,-1,0.0035265773,0.9964734
14086,aniracetam,12,13,87,97,These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg.,6817363_2,-1,-1,-1,14086,-1,0.9990269,0.00097306987
14087,aniracetam,6,7,42,52,The mechanisms underlying the activity of aniracetam and its 'therapeutic window' are unknown.,6817363_4,-1,-1,-1,14087,-1,0.9990361,0.00096398086
14088,Piracetam,0,1,0,9,"Piracetam, another pyrrolidinone derivative was used for comparison.",6817363_5,-1,-1,-1,14088,-1,0.99934787,0.000652135
14089,pyrrolidinone,3,4,19,32,"Piracetam, another pyrrolidinone derivative was used for comparison.",6817363_5,-1,-1,-1,14089,-1,0.99797064,0.0020293545
14090,aniracetam,16,17,79,89,It was active only in six of nine tests and had about one-tenth the potency of aniracetam.,6817363_6,-1,-1,-1,14090,-1,0.9987954,0.0012045916
14091,aniracetam,4,5,26,36,The results indicate that aniracetam improves cognitive functions which are impaired by different procedure and in different phases of the learning and memory process.,6817363_7,-1,-1,-1,14091,-1,0.99908614,0.00091380696
14093,Sodium chloride,0,2,0,15,"Sodium chloride solution (0.9%) or noradrenaline in doses of 4, 12 and 36 micrograms h-1 kg-1 was infused for five consecutive days, either intrarenally (by a new technique) or intravenously into rats with one kidney removed.",6861444_1,-1,-1,-1,14093,-1,0.9986003,0.0013997391
14104,adenohypophyseal tumors,3,5,37,60,Characterization of estrogen-induced adenohypophyseal tumors in the Fischer 344 rat.,6888657_0,-1,-1,-1,14104,-1,0.036297936,0.963702
14105,Pituitary tumors,0,2,0,16,"Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol (DES, 8-10 mg) implanted subcutaneously in silastic capsules.",6888657_1,-1,-1,-1,14105,-1,0.0034552668,0.9965448
14107,DES,14,15,96,99,"Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol (DES, 8-10 mg) implanted subcutaneously in silastic capsules.",6888657_1,-1,-1,-1,14107,-1,0.99742967,0.0025703767
14108,mg,19,20,106,108,"Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol (DES, 8-10 mg) implanted subcutaneously in silastic capsules.",6888657_1,-1,-1,-1,14108,-1,0.9517301,0.04826989
14109,DES,9,10,30,33,"Over a range of 1-150 days of DES treatment, pairs of control and DES-treated rats were sacrificed, and their pituitaries dissociated enzymatically into single-cell preparations.",6888657_2,-1,-1,-1,14109,-1,0.9978282,0.0021717655
14110,PRL,17,18,120,123,"The cell populations were examined regarding total cell recovery correlated with gland weight, intracellular prolactin (PRL) content and subsequent release in primary culture, immunocytochemical PRL staining, density and/or size alterations via separation on Ficoll-Hypaque and by unit gravity sedimentation, and cell cycle analysis, after acriflavine DNA staining, by laser flow cytometry.",6888657_3,-1,-1,-1,14110,-1,0.99604815,0.0039518657
14111,PRL,28,29,195,198,"The cell populations were examined regarding total cell recovery correlated with gland weight, intracellular prolactin (PRL) content and subsequent release in primary culture, immunocytochemical PRL staining, density and/or size alterations via separation on Ficoll-Hypaque and by unit gravity sedimentation, and cell cycle analysis, after acriflavine DNA staining, by laser flow cytometry.",6888657_3,-1,-1,-1,14111,-1,0.996534,0.0034659822
14112,acriflavine,51,52,340,351,"The cell populations were examined regarding total cell recovery correlated with gland weight, intracellular prolactin (PRL) content and subsequent release in primary culture, immunocytochemical PRL staining, density and/or size alterations via separation on Ficoll-Hypaque and by unit gravity sedimentation, and cell cycle analysis, after acriflavine DNA staining, by laser flow cytometry.",6888657_3,-1,-1,-1,14112,-1,0.99829,0.0017099507
14113,PRL,1,2,14,17,"Intracellular PRL content ranged from 1.9 to 9.4 times control levels, and PRL release in vitro was significantly and consistently higher than controls, after at least 8 days of DES exposure.",6888657_5,-1,-1,-1,14113,-1,0.9971933,0.0028067387
14114,PRL,13,14,75,78,"Intracellular PRL content ranged from 1.9 to 9.4 times control levels, and PRL release in vitro was significantly and consistently higher than controls, after at least 8 days of DES exposure.",6888657_5,-1,-1,-1,14114,-1,0.99699116,0.0030087708
14115,DES,31,32,178,181,"Intracellular PRL content ranged from 1.9 to 9.4 times control levels, and PRL release in vitro was significantly and consistently higher than controls, after at least 8 days of DES exposure.",6888657_5,-1,-1,-1,14115,-1,0.9982449,0.0017551709
14116,DES,4,5,17,20,"Beyond 8 days of DES exposure, the immunochemically PRL-positive proportion of cells increased to over 50% of the total population.",6888657_6,-1,-1,-1,14116,-1,0.9978822,0.002117754
14117,PRL,5,6,34,37,Increased density and/or size and PRL content were indicated for the majority of the PRL cell population in both types of separation protocols.,6888657_7,-1,-1,-1,14117,-1,0.9942994,0.005700567
14118,PRL,14,15,85,88,Increased density and/or size and PRL content were indicated for the majority of the PRL cell population in both types of separation protocols.,6888657_7,-1,-1,-1,14118,-1,0.98817307,0.01182695
14119,DES,4,5,21,24,All these effects of DES were more pronounced among previously ovariectomized animals.,6888657_8,-1,-1,-1,14119,-1,0.9983012,0.0016988112
14121,PRL,20,21,120,123,"The data extend the findings of other investigators, further establishing the DES-induced tumor as a model for study of PRL cellular control mechanisms.",6888657_9,-1,-1,-1,14121,-1,0.9542736,0.045726415
14122,calcium chloride,2,4,10,26,Effect of calcium chloride on gross behavioural changes produced by carbachol and eserine in cats.,6892185_0,-1,-1,-1,14122,-1,0.99886143,0.0011386382
14124,eserine,12,13,82,89,Effect of calcium chloride on gross behavioural changes produced by carbachol and eserine in cats.,6892185_0,-1,-1,-1,14124,-1,0.9989159,0.0010841086
14125,calcium chloride,3,5,14,30,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,-1,-1,-1,14125,-1,0.9988733,0.0011266448
14126,mydriasis,41,42,233,242,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,-1,-1,-1,14126,-1,0.004924721,0.9950753
14130,eserine,51,52,306,313,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,-1,-1,-1,14130,-1,0.99898833,0.0010117008
14131,Calcium chloride depressed,0,3,0,26,Calcium chloride depressed or almost completely abolished the vocalization and fighting due to carbachol and eserine.,6892185_2,-1,-1,-1,14131,-1,0.9571585,0.042841487
14133,eserine,15,16,109,116,Calcium chloride depressed or almost completely abolished the vocalization and fighting due to carbachol and eserine.,6892185_2,-1,-1,-1,14133,-1,0.99889153,0.0011084714
14134,mydriasis,5,6,19,28,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,-1,-1,-1,14134,-1,0.0057101483,0.9942899
14138,eserine,15,16,90,97,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,-1,-1,-1,14138,-1,0.9989741,0.0010258983
14139,calcium chloride,21,23,132,148,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,-1,-1,-1,14139,-1,0.9986197,0.0013803634
14140,calcium chloride,4,6,20,36,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,-1,-1,-1,14140,-1,0.99858093,0.001419051
14141,mydriasis,20,21,123,132,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,-1,-1,-1,14141,-1,0.013930151,0.9860699
14145,eserine,30,31,194,201,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,-1,-1,-1,14145,-1,0.9988047,0.0011953596
14147,eserine,11,12,83,90,Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites.,6892185_5,-1,-1,-1,14147,-1,0.9990225,0.0009774807
14149,Thiazide,0,1,0,8,"Thiazide diuretics, hypokalemia and cardiac arrhythmias.",6942642_0,-1,-1,-1,14149,-1,0.9991062,0.00089370186
14150,hypokalemia,3,4,20,31,"Thiazide diuretics, hypokalemia and cardiac arrhythmias.",6942642_0,-1,-1,-1,14150,-1,0.0093629435,0.9906371
14152,Thiazide,0,1,0,8,Thiazide diuretics are widely accepted as the cornerstone of antihypertensive treatment programs.,6942642_1,-1,-1,-1,14152,-1,0.99919206,0.00080794544
14153,thiazide,9,10,71,79,Hypokalemia is a commonly encountered metabolic consequence of chronic thiazide therapy.,6942642_2,-1,-1,-1,14153,-1,0.9993876,0.0006124139
14154,diastolic hypertension,15,17,69,91,"We treated 38 patients (22 low renin, 16 normal renin) with moderate diastolic hypertension with hydrochlorothiazide (HCTC) administered on a twice daily schedule.",6942642_3,-1,-1,-1,14154,-1,0.0032100773,0.9967899
14155,hydrochlorothiazide,18,19,97,116,"We treated 38 patients (22 low renin, 16 normal renin) with moderate diastolic hypertension with hydrochlorothiazide (HCTC) administered on a twice daily schedule.",6942642_3,-1,-1,-1,14155,-1,0.99927634,0.0007236931
14156,HCTC,20,21,118,122,"We treated 38 patients (22 low renin, 16 normal renin) with moderate diastolic hypertension with hydrochlorothiazide (HCTC) administered on a twice daily schedule.",6942642_3,-1,-1,-1,14156,-1,0.9981158,0.0018842275
14157,mg,4,5,20,22,"Initial dose was 50 mg and the dose was increased at monthly intervals to 100 mg, 150 mg and 200 mg daily until blood pressure normalized.",6942642_4,-1,-1,-1,14157,-1,0.9814626,0.018537393
14158,mg,15,16,78,80,"Initial dose was 50 mg and the dose was increased at monthly intervals to 100 mg, 150 mg and 200 mg daily until blood pressure normalized.",6942642_4,-1,-1,-1,14158,-1,0.97528696,0.024713028
14159,mg,18,19,86,88,"Initial dose was 50 mg and the dose was increased at monthly intervals to 100 mg, 150 mg and 200 mg daily until blood pressure normalized.",6942642_4,-1,-1,-1,14159,-1,0.9743745,0.025625594
14160,mg,21,22,97,99,"Initial dose was 50 mg and the dose was increased at monthly intervals to 100 mg, 150 mg and 200 mg daily until blood pressure normalized.",6942642_4,-1,-1,-1,14160,-1,0.97302026,0.026979728
14161,K,2,3,10,11,"The serum K during the control period was 4.5 +/- 0.2 mEq/l an on 50, 100, 150 and 200 mg HCTZ daily 3.9 +/- 0.3, 3.4 +/- 0.2, 2.9 +/- 0.2, and 2.4 +/- 0.3 mEq/l, respectively.",6942642_5,-1,-1,-1,14161,-1,0.9965173,0.0034826398
14162,mg HCTZ,22,24,87,94,"The serum K during the control period was 4.5 +/- 0.2 mEq/l an on 50, 100, 150 and 200 mg HCTZ daily 3.9 +/- 0.3, 3.4 +/- 0.2, 2.9 +/- 0.2, and 2.4 +/- 0.3 mEq/l, respectively.",6942642_5,-1,-1,-1,14162,-1,0.9975337,0.00246636
14163,K,5,6,37,38,"Corresponding figures for whole body K were 4107 +/- 208, 3722 +/- 319, 3628 +/- 257, 3551 +/- 336, and 3269 +/- 380 mEq, respectively.",6942642_6,-1,-1,-1,14163,-1,0.994783,0.0052170167
14164,HCTZ,8,9,42,46,In 13 patients we observed the effects of HCTZ therapy (100 mg daily) on the occurrence of PVC's during rest as well as during static and dynamic exercise.,6942642_7,-1,-1,-1,14164,-1,0.9991032,0.0008967965
14165,mg,12,13,60,62,In 13 patients we observed the effects of HCTZ therapy (100 mg daily) on the occurrence of PVC's during rest as well as during static and dynamic exercise.,6942642_7,-1,-1,-1,14165,-1,0.9752273,0.024772724
14166,PVC,19,20,91,94,In 13 patients we observed the effects of HCTZ therapy (100 mg daily) on the occurrence of PVC's during rest as well as during static and dynamic exercise.,6942642_7,-1,-1,-1,14166,-1,0.013318692,0.98668134
14167,PVC,8,9,37,40,"During rest we observed 0.6 +/- 0.08 PVC beats/min +/- SEM and during static and dynamic exercise 0.6 +/- 0.06 and 0.8 +/- 0.15, respectively.",6942642_8,-1,-1,-1,14167,-1,0.812428,0.187572
14168,HCTZ,3,4,29,33,"Corresponding figures during HCTZ therapy 100 mg daily were 1.4 +/- 0.1, 3.6 +/- 0.7 and 5.7 4/- 0.8, respectively.",6942642_9,-1,-1,-1,14168,-1,0.9985911,0.0014088697
14169,mg,6,7,46,48,"Corresponding figures during HCTZ therapy 100 mg daily were 1.4 +/- 0.1, 3.6 +/- 0.7 and 5.7 4/- 0.8, respectively.",6942642_9,-1,-1,-1,14169,-1,0.972252,0.027748026
14170,PVC,3,4,18,21,"The occurrence of PVC's correlated significantly with the fall in serum K+ observed r = 0.72, p less than 0.001.",6942642_10,-1,-1,-1,14170,-1,0.36757863,0.6324214
14171,p,18,19,94,95,"The occurrence of PVC's correlated significantly with the fall in serum K+ observed r = 0.72, p less than 0.001.",6942642_10,-1,-1,-1,14171,-1,0.35173428,0.6482657
14172,thiazide,5,6,28,36,In conclusion we found that thiazide diuretics cause hypokalemia and depletion of body potassium.,6942642_11,-1,-1,-1,14172,-1,0.9991922,0.0008078673
14173,hypokalemia,8,9,53,64,In conclusion we found that thiazide diuretics cause hypokalemia and depletion of body potassium.,6942642_11,-1,-1,-1,14173,-1,0.005008483,0.9949915
14175,hypokalemia,3,4,18,29,"The more profound hypokalemia, the greater the propensity for the occurrence of PVC's.",6942642_12,-1,-1,-1,14175,-1,0.0072531784,0.9927468
14176,PVC,13,14,80,83,"The more profound hypokalemia, the greater the propensity for the occurrence of PVC's.",6942642_12,-1,-1,-1,14176,-1,0.97743124,0.02256878
14177,acute hepatic necrosis,4,7,34,56,Circulating lysosomal enzymes and acute hepatic necrosis.,7007443_0,-1,-1,-1,14177,-1,0.0025030773,0.9974969
14178,acid phosphatase,14,16,96,112,"The activities of the lysosomal enzymes acid and neutral protease, N-acetylglucosaminidase, and acid phosphatase were measured in the serum of patients with fulminant hepatic failure.",7007443_1,-1,-1,-1,14178,-1,0.9778733,0.022126667
14180,cathepsin D,3,5,15,26,"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.",7007443_2,-1,-1,-1,14180,-1,0.968475,0.031524986
14182,paracetamol overdose,26,28,160,180,"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.",7007443_2,-1,-1,-1,14182,-1,0.9043901,0.09560994
14184,viral hepatitis,42,44,274,289,"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.",7007443_2,-1,-1,-1,14184,-1,0.006927561,0.99307245
14185,cathepsin D,17,19,103,114,"A correlation was found between serum acid protease activity and prothrombin time, and the increase in cathepsin D activity was sustained over several days compared with aspartate aminotransferase, which showed a sharp early peak and then a fall.",7007443_3,-1,-1,-1,14185,-1,0.99379855,0.0062014125
14201,kidney disease,34,36,164,178,There was only one case of dementia possibly due to cimetidine (with a drug level of 1.9 microgram/ml 6 hr after a dose) in a group of 13 patients without liver or kidney disease who had cimetidine levels above 1.25 microgram/ml.,7053303_6,-1,-1,-1,14201,-1,0.0035283775,0.99647164
14205,6-thioguanine,5,6,41,54,Hepatic veno-occlusive disease caused by 6-thioguanine.,7053705_0,-1,-1,-1,14205,-1,0.99836534,0.001634721
14206,acute lymphocytic leukemia,13,16,94,120,Clinically reversible veno-occlusive disease of the liver developed in a 23-year-old man with acute lymphocytic leukemia after 10 months of maintenance therapy with 6-thioguanine.,7053705_1,-1,-1,-1,14206,-1,0.0040547424,0.9959453
14207,6-thioguanine,23,24,165,178,Clinically reversible veno-occlusive disease of the liver developed in a 23-year-old man with acute lymphocytic leukemia after 10 months of maintenance therapy with 6-thioguanine.,7053705_1,-1,-1,-1,14207,-1,0.9983987,0.001601225
14209,6-thioguanine,31,32,205,218,"This case presented a unique opportunity to observe the histologic features of clinically reversible hepatic veno-occlusive disease over time, and may be the first case of veno-occlusive related solely to 6-thioguanine.",7053705_4,-1,-1,-1,14209,-1,0.9982951,0.0017049133
14210,optic neuropathy,1,3,23,39,Chlorpropamide-induced optic neuropathy.,7059267_0,-1,-1,-1,14210,-1,0.0025525168,0.9974475
14212,chlorpropamide,8,9,59,73,A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.,7059267_1,-1,-1,-1,14212,-1,0.99942625,0.0005737284
14213,Diabenese,10,11,75,84,A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.,7059267_1,-1,-1,-1,14213,-1,0.8100586,0.18994136
14214,toxic optic neuropathy,14,17,92,114,A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.,7059267_1,-1,-1,-1,14214,-1,0.0026355581,0.99736446
14215,chlorpropamide,22,23,153,167,A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.,7059267_1,-1,-1,-1,14215,-1,0.99938524,0.0006147074
14217,diabetics,4,5,22,31,"Visual loss occurs in diabetics for a variety of reasons, and accurate diagnosis is necessary to institute appropriate therapy.",7059267_2,-1,-1,-1,14217,-1,0.0045933276,0.99540675
14218,optic neuropathy,5,7,34,50,The possibility of a drug-induced optic neuropathy should be considered in the differential diagnosis of visual loss in diabetics.,7059267_3,-1,-1,-1,14218,-1,0.002213038,0.997787
14220,diabetics,18,19,120,129,The possibility of a drug-induced optic neuropathy should be considered in the differential diagnosis of visual loss in diabetics.,7059267_3,-1,-1,-1,14220,-1,0.0036176338,0.99638236
14221,nephrotic syndrome,10,12,69,87,Plasma and urinary lipids and lipoproteins during the development of nephrotic syndrome induced in the rat by puromycin aminonucleoside.,7066357_0,-1,-1,-1,14221,-1,0.0021329112,0.9978671
14222,puromycin aminonucleoside,17,19,110,135,Plasma and urinary lipids and lipoproteins during the development of nephrotic syndrome induced in the rat by puromycin aminonucleoside.,7066357_0,-1,-1,-1,14222,-1,0.9985831,0.0014169565
14223,nephrotic syndrome,14,16,95,113,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,-1,-1,-1,14223,-1,0.002335159,0.9976648
14224,puromycin aminonucleoside,18,20,125,150,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,-1,-1,-1,14224,-1,0.99872917,0.001270838
14225,nephrotic syndrome,23,25,163,181,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,-1,-1,-1,14225,-1,0.0023649356,0.997635
14226,se,26,27,186,188,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,-1,-1,-1,14226,-1,0.436068,0.563932
14227,aminonucleoside,37,38,219,234,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,-1,-1,-1,14227,-1,0.99815196,0.0018480708
14228,puromycin aminonucleoside,20,22,128,153,The purpose of the present study was to investigate the changes in plasma and urinary lipoproteins during the administration of puromycin aminonucleoside (20 mg/kg for 7 days) and the subsequent development of nephrotic syndrome.,7066357_2,-1,-1,-1,14228,-1,0.9986822,0.0013178055
14229,nephrotic syndrome,34,36,210,228,The purpose of the present study was to investigate the changes in plasma and urinary lipoproteins during the administration of puromycin aminonucleoside (20 mg/kg for 7 days) and the subsequent development of nephrotic syndrome.,7066357_2,-1,-1,-1,14229,-1,0.0019999917,0.99799997
14232,fatty acids,7,9,43,54,"In pre-nephrotic stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.",7066357_4,-1,-1,-1,14232,-1,0.99534446,0.0046554855
14233,triacylglycerol,10,11,56,71,"In pre-nephrotic stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.",7066357_4,-1,-1,-1,14233,-1,0.99782,0.0021800222
14234,cholesteryl esters,19,21,119,137,"In pre-nephrotic stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.",7066357_4,-1,-1,-1,14234,-1,0.9973346,0.002665443
14237,puromycin aminonucleoside,4,6,33,58,These observations indicate that puromycin aminonucleoside alters plasma lipoproteins by lowering VLDL and increasing HDL.,7066357_11,-1,-1,-1,14237,-1,0.9986278,0.0013721817
14240,chloramphenicol,8,9,69,84,Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol.,7072798_0,-1,-1,-1,14240,-1,0.9992224,0.0007775605
14243,chloramphenicol,20,21,137,152,A 73-year-old woman died of aplastic anemia less than two months after undergoing cataract extraction and beginning topical therapy with chloramphenicol.,7072798_1,-1,-1,-1,14243,-1,0.99918216,0.00081780035
14244,pancytopenia,4,5,19,31,The first signs of pancytopenia began within one month of the surgery.,7072798_2,-1,-1,-1,14244,-1,0.006431027,0.9935689
14246,chloramphenicol,13,14,84,99,The pattern of the aplastic anemia was associated with an idiosyncratic response to chloramphenicol.,7072798_3,-1,-1,-1,14246,-1,0.9991974,0.00080263225
14248,chloramphenicol,13,14,81,96,"This was the second report of fatal aplastic anemia after topical treatment with chloramphenicol for ocular conditions, although two cases of reversible bone marrow hypoplasia have also been reported.",7072798_4,-1,-1,-1,14248,-1,0.99916875,0.00083130633
14249,bone marrow hypoplasia,23,26,153,175,"This was the second report of fatal aplastic anemia after topical treatment with chloramphenicol for ocular conditions, although two cases of reversible bone marrow hypoplasia have also been reported.",7072798_4,-1,-1,-1,14249,-1,0.0060458146,0.99395424
14250,ocular toxicity,5,7,29,44,"Any other suspected cases of ocular toxicity associated with topically applied chloramphenicol should be reported to the National Registry of Drug-Induced Ocular Side Effects, Oregon Health Sciences University, Portland, OR 97201.",7072798_5,-1,-1,-1,14250,-1,0.0021913322,0.99780864
14251,chloramphenicol,11,12,79,94,"Any other suspected cases of ocular toxicity associated with topically applied chloramphenicol should be reported to the National Registry of Drug-Induced Ocular Side Effects, Oregon Health Sciences University, Portland, OR 97201.",7072798_5,-1,-1,-1,14251,-1,0.99926406,0.0007358778
14254,atrial tachycardia,14,16,96,114,A case is presented of a reversible intra-Hisian block occurring under amiodarone treatment for atrial tachycardia in a patient without clear intraventricular conduction abnormalities.,7083920_1,-1,-1,-1,14254,-1,0.00945924,0.99054074
14255,intraventricular conduction abnormalities,21,24,142,183,A case is presented of a reversible intra-Hisian block occurring under amiodarone treatment for atrial tachycardia in a patient without clear intraventricular conduction abnormalities.,7083920_1,-1,-1,-1,14255,-1,0.012711442,0.9872886
14256,atrial tachycardia,5,7,32,50,"His bundle recordings showed an atrial tachycardia with intermittent exit block and greatly prolonged BH and HV intervals (40 and 100 msec, respectively).",7083920_2,-1,-1,-1,14256,-1,0.009911232,0.99008876
14258,atrial flutter,10,12,77,91,"Thirty days after amiodarone discontinuation, His bundle electrograms showed atrial flutter without intra-Hisian or infra-Hisian delay.",7083920_3,-1,-1,-1,14258,-1,0.02332699,0.97667295
14260,intraventricular conduction defects,16,19,103,138,Amiodarone should be used with caution during long-term oral therapy in patients with or without clear intraventricular conduction defects.,7083920_4,-1,-1,-1,14260,-1,0.0061416044,0.9938584
14261,clear cell adenocarcinoma,2,5,15,40,Development of clear cell adenocarcinoma in DES-exposed offspring under observation.,7088431_0,-1,-1,-1,14261,-1,0.006151502,0.9938485
14262,clear cell adenocarcinoma,3,6,13,38,Two cases of clear cell adenocarcinoma of the vagina detected at follow-up in young women exposed in utero to diethylstilbestrol are reported.,7088431_1,-1,-1,-1,14262,-1,0.006256597,0.99374336
14270,mg nitrazepam,10,12,57,70,"In patients premedicated with scopolamine + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v.",7102237_1,-1,-1,-1,14270,-1,0.99713945,0.0028605969
14280,EPS,7,8,46,49,The incidence of extrapyramidal side effects (EPS) was evaluated in 98 patients treated with haloperidol.,7161250_1,-1,-1,-1,14280,-1,0.011490003,0.9885101
14285,Akathisia,0,1,0,9,"Akathisia was controlled by the benzodiazepine lorazepam in 14 out of 16 patients, while prophylactic antiparkinsonians were ineffective.",7161250_5,-1,-1,-1,14285,-1,0.0045981132,0.99540186
14286,benzodiazepine lorazepam,5,7,32,56,"Akathisia was controlled by the benzodiazepine lorazepam in 14 out of 16 patients, while prophylactic antiparkinsonians were ineffective.",7161250_5,-1,-1,-1,14286,-1,0.9986052,0.001394862
14287,EPS,16,17,102,105,The present study points to patient characteristics that may be of significance in the development of EPS due to haloperidol.,7161250_6,-1,-1,-1,14287,-1,0.0032216297,0.9967784
14293,chloroprocaine,28,29,142,156,"The CD50 and LD50, respectively, were 57.7 and 58.7 mg/kg for bupivacaine, 111.0 and 133.1 mg/kg for lidocaine, and 243.4 and 266.5 mg/kg for chloroprocaine.",7189975_2,-1,-1,-1,14293,-1,0.9991561,0.00084394333
14296,chloroprocaine,20,21,117,131,"When given intraperitoneally, bupivacaine thus was only about twice as toxic as lidocaine and four times as toxic as chloroprocaine.",7189975_3,-1,-1,-1,14296,-1,0.9991297,0.00087030814
14298,cardiopulmonary arrest,8,10,60,82,"Convulsions always preceded death, except after precipitous cardiopulmonary arrest from extreme doses.",7189975_4,-1,-1,-1,14298,-1,0.0037643837,0.99623567
14301,chloroprocaine,29,30,133,147,"A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the chloroprocaine group, and in 6% of the lidocaine group.",7189975_5,-1,-1,-1,14301,-1,0.9991929,0.00080714596
14303,convulsant,4,5,23,33,The narrow gap between convulsant and lethal doses of local anesthetics indicates that untreated convulsions present much more of a threat to life than heretofore appreciated.,7189975_6,-1,-1,-1,14303,-1,0.032691345,0.96730864
14305,sleep deprivation,1,3,4,21,REM sleep deprivation changes behavioral response to catecholaminergic and serotonergic receptor activation in rats.,7197363_0,-1,-1,-1,14305,-1,0.7799831,0.2200169
14306,REM sleep deprivation,3,6,15,36,The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.,7197363_1,-1,-1,-1,14306,-1,0.59301317,0.40698686
14307,REMD,7,8,38,42,The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.,7197363_1,-1,-1,-1,14307,-1,0.655078,0.34492195
14309,head twitches,14,16,104,117,The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.,7197363_1,-1,-1,-1,14309,-1,0.0045902496,0.9954098
14310,REMD,3,4,18,22,"Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.",7197363_2,-1,-1,-1,14310,-1,0.9573155,0.042684577
14312,REMD,15,16,114,118,"Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.",7197363_2,-1,-1,-1,14312,-1,0.87531173,0.12468823
14313,REMD,25,26,160,164,"Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.",7197363_2,-1,-1,-1,14313,-1,0.87800235,0.12199763
14314,head twitches,28,30,184,197,"Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.",7197363_2,-1,-1,-1,14314,-1,0.004187796,0.9958121
14318,N,22,23,109,110,"The 65 dogs in the study received injections in the subarachnoid space as follows: 6 to 8 ml of bupivacaine (N = 15), 2-chloroprocaine-CE (N = 20), low pH normal saline (pH 3.0) (N = 20), or normal saline (N = 10).",7199841_3,-1,-1,-1,14318,-1,0.41672707,0.58327293
14319,N,29,30,139,140,"The 65 dogs in the study received injections in the subarachnoid space as follows: 6 to 8 ml of bupivacaine (N = 15), 2-chloroprocaine-CE (N = 20), low pH normal saline (pH 3.0) (N = 20), or normal saline (N = 10).",7199841_3,-1,-1,-1,14319,-1,0.32584906,0.6741509
14320,N,43,44,179,180,"The 65 dogs in the study received injections in the subarachnoid space as follows: 6 to 8 ml of bupivacaine (N = 15), 2-chloroprocaine-CE (N = 20), low pH normal saline (pH 3.0) (N = 20), or normal saline (N = 10).",7199841_3,-1,-1,-1,14320,-1,0.23656912,0.76343095
14321,N,52,53,206,207,"The 65 dogs in the study received injections in the subarachnoid space as follows: 6 to 8 ml of bupivacaine (N = 15), 2-chloroprocaine-CE (N = 20), low pH normal saline (pH 3.0) (N = 20), or normal saline (N = 10).",7199841_3,-1,-1,-1,14321,-1,0.2683051,0.7316949
14330,mg,15,16,111,113,"In four patients, polymorphous ventricular tachycardia appeared after intravenous administration of 200 to 400 mg of procainamide for the treatment of sustained ventricular tachycardia.",7234705_2,-1,-1,-1,14330,-1,0.98770636,0.012293604
14334,premature ventricular contractions,14,17,95,129,"In the remaining three patients, procainamide was administered orally for treatment of chronic premature ventricular contractions or atrial flutter.",7234705_3,-1,-1,-1,14334,-1,0.004283139,0.99571687
14335,atrial flutter,18,20,133,147,"In the remaining three patients, procainamide was administered orally for treatment of chronic premature ventricular contractions or atrial flutter.",7234705_3,-1,-1,-1,14335,-1,0.6639902,0.33600983
14341,ventricular fibrillation,9,11,62,86,"In two patients, the arrhythmia degenerated into irreversible ventricular fibrillation and both patients died.",7234705_6,-1,-1,-1,14341,-1,0.0034494298,0.99655056
14346,enlargement of the liver,1,5,23,47,Phenobarbitone-induced enlargement of the liver in the rat: its relationship to carbon tetrachloride-induced cirrhosis.,7248170_0,-1,-1,-1,14346,-1,0.011039076,0.9889609
14347,carbon,12,13,80,86,Phenobarbitone-induced enlargement of the liver in the rat: its relationship to carbon tetrachloride-induced cirrhosis.,7248170_0,-1,-1,-1,14347,-1,0.99785966,0.0021403397
14349,cirrhosis of the liver,4,8,20,42,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,-1,-1,-1,14349,-1,0.009973334,0.9900267
14351,splenomegaly,33,34,179,191,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,-1,-1,-1,14351,-1,0.0034731554,0.9965269
14353,carbon tetrachloride,52,54,285,305,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,-1,-1,-1,14353,-1,0.999132,0.0008680514
14354,carbon tetrachloride,77,79,436,456,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,-1,-1,-1,14354,-1,0.99919647,0.0008035203
14355,enlargement of the liver,85,89,499,523,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,-1,-1,-1,14355,-1,0.008626845,0.9913731
14357,carbon tetrachloride,8,10,41,61,The optimal time for the initial dose of carbon tetrachloride was after 14 days on phenobarbitone.,7248170_4,-1,-1,-1,14357,-1,0.999204,0.00079608074
14364,allopurinol,14,15,74,85,A case of fatal aplastic anemia is described in which no drugs other than allopurinol and indomethacin were given.,7263204_2,-1,-1,-1,14364,-1,0.9991365,0.0008635709
14369,dyazide,3,4,41,48,Triamterene nephrolithiasis complicating dyazide therapy.,7265370_0,-1,-1,-1,14369,-1,0.99928075,0.00071927183
14370,triamterene nephrolithiasis,3,5,10,37,A case of triamterene nephrolithiasis is reported in a man after 4 years of hydrochlorothiazide-triamterene therapy for hypertension.,7265370_1,-1,-1,-1,14370,-1,0.50713027,0.49286976
14372,triamterene,10,11,58,69,The stone passed spontaneously and was found to contain a triamterene metabolite admixed with uric acid salts.,7265370_2,-1,-1,-1,14372,-1,0.9991954,0.0008045664
14373,uric acid salts,14,17,94,109,The stone passed spontaneously and was found to contain a triamterene metabolite admixed with uric acid salts.,7265370_2,-1,-1,-1,14373,-1,0.99692255,0.0030774025
14374,triamterene nephrolithiasis,2,4,18,45,Factors affecting triamterene nephrolithiasis are discussed and 2 previously reported cases are reviewed.,7265370_3,-1,-1,-1,14374,-1,0.52173114,0.47826883
14375,hemorrhagic cystitis,1,3,17,37,Busulfan-induced hemorrhagic cystitis.,7269015_0,-1,-1,-1,14375,-1,0.0024327291,0.9975673
14376,hemorrhage cystitis,5,7,29,48,A case of a busulfan-induced hemorrhage cystitis is reported.,7269015_1,-1,-1,-1,14376,-1,0.0024710395,0.997529
14377,busulfan cystitis,7,9,53,70,The similarity between the histologic appearances of busulfan cystitis and both radiation and cyclophosphamide-induced cystitis is discussed and the world literature reviewed.,7269015_3,-1,-1,-1,14377,-1,0.57865536,0.4213446
14381,doxorubicin cardiomyopathy,5,7,52,78,Dose-effect and structure-function relationships in doxorubicin cardiomyopathy.,7282516_0,-1,-1,-1,14381,-1,0.32544786,0.67455214
14383,CM,3,4,20,22,The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.,7282516_1,-1,-1,-1,14383,-1,0.0054985518,0.9945015
14385,DXR,12,13,69,72,The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.,7282516_1,-1,-1,-1,14385,-1,0.99863607,0.001363898
14387,myocardial disease,30,32,199,217,The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.,7282516_1,-1,-1,-1,14387,-1,0.0025850933,0.9974148
14388,DXR,26,27,195,198,We measured the degree of morphologic damage by ultrastructural examination of endomyocardial biopsy and the degree of performance abnormally by right heart catheterization in patients receiving DXR.,7282516_2,-1,-1,-1,14388,-1,0.9989555,0.0010445283
14389,DXR,11,12,77,80,Morphologic damage was variable but was proportional to the total cumulative DXR dose between 100 and 600 mg/m2.,7282516_3,-1,-1,-1,14389,-1,0.9990097,0.0009902257
14391,DXR,13,14,79,82,"In DXR-CM myocardial damage is proportional to the degree of cytotoxic insult (DXR dose) while myocardial function is preserved until a critical dose or degree of damage is reached, after which myocardial performance deteriorates rapidly.",7282516_6,-1,-1,-1,14391,-1,0.9986632,0.001336754
14393,desipramine toxicity,4,6,35,55,Variant ventricular tachycardia in desipramine toxicity.,7292072_0,-1,-1,-1,14393,-1,0.9132981,0.08670189
14395,desipramine toxicity,10,12,63,83,We report a case of variant ventricular tachycardia induced by desipramine toxicity.,7292072_1,-1,-1,-1,14395,-1,0.9191609,0.080839075
14399,cerebral edema,1,3,8,22,Massive cerebral edema associated with fulminant hepatic failure in acetaminophen overdose: possible role of cranial decompression.,7337133_0,-1,-1,-1,14399,-1,0.0021910353,0.997809
14401,acetaminophen overdose,9,11,68,90,Massive cerebral edema associated with fulminant hepatic failure in acetaminophen overdose: possible role of cranial decompression.,7337133_0,-1,-1,-1,14401,-1,0.80245733,0.19754273
14404,signs and,12,14,86,95,"We present a patient with fatal acetaminophen-induced fulminant hepatic failure, with signs and symptoms of cerebral edema, unresponsive to conventional medical therapy.",7337133_3,-1,-1,-1,14404,-1,0.010681188,0.9893188
14405,cerebral edema,16,18,108,122,"We present a patient with fatal acetaminophen-induced fulminant hepatic failure, with signs and symptoms of cerebral edema, unresponsive to conventional medical therapy.",7337133_3,-1,-1,-1,14405,-1,0.0019677125,0.9980323
14413,SNP,15,16,77,80,"Control rats received halothane anesthesia (1 MAC) for one hour, followed by SNP infusion, 40 microgram/kg/min, for 30 min, followed by a 30-min recovery period.",7352670_2,-1,-1,-1,14413,-1,0.9988207,0.0011792819
14415,angiotensin II,23,25,127,141,"A second group of rats was treated identically and, in addition, received an infusion of saralasin (a competitive inhibitor of angiotensin II) throughout the experimental period.",7352670_3,-1,-1,-1,14415,-1,0.99578875,0.004211265
14416,SNP,4,5,15,18,"In each group, SNP infusion resulted in an initial decrease in blood pressure from 86 torr and 83 torr, respectively, to 48 torr.",7352670_4,-1,-1,-1,14416,-1,0.9988795,0.0011204659
14417,SNP,2,3,11,14,"During the SNP infusion the control animals demonstrated a progressive increase in blood pressure to 61 torr, whereas the saralasin-treated animals showed no change.",7352670_5,-1,-1,-1,14417,-1,0.99876547,0.0012345327
14418,increase in blood pressure,10,14,71,97,"During the SNP infusion the control animals demonstrated a progressive increase in blood pressure to 61 torr, whereas the saralasin-treated animals showed no change.",7352670_5,-1,-1,-1,14418,-1,0.011517755,0.98848224
14419,SNP,3,4,29,32,"Following discontinuation of SNP, blood pressure in the control animals rebounded to 94 torr, as compared with 78 torr in the saralasin-treated rats.",7352670_6,-1,-1,-1,14419,-1,0.99882966,0.0011703935
14421,SNP,16,17,106,109,"This study indicates that with stable halothane anesthesia, the partial recovery of blood pressure during SNP infusion and the post-SNP rebound of blood pressure can be completely blocked by saralasin.",7352670_7,-1,-1,-1,14421,-1,0.9987676,0.0012323862
14425,SNP,19,20,135,138,This demonstrates the participation of the renin--angiotensin system in antagonizing the combined hypotensive effects of halothane and SNP.,7352670_8,-1,-1,-1,14425,-1,0.99870825,0.0012917011
14427,digoxin,11,12,87,94,Subjective assessment of sexual dysfunction of patients on long-term administration of digoxin.,7416947_0,-1,-1,-1,14427,-1,0.9991541,0.00084596546
14428,digoxin,9,10,58,65,Various data suggest that male patients who have received digoxin on a longterm basis have increased levels of serum estrogen and decreased levels of plasma testosterone and luteinizing hormone (LH).,7416947_1,-1,-1,-1,14428,-1,0.9993013,0.0006987197
14431,luteinizing hormone,27,29,174,193,Various data suggest that male patients who have received digoxin on a longterm basis have increased levels of serum estrogen and decreased levels of plasma testosterone and luteinizing hormone (LH).,7416947_1,-1,-1,-1,14431,-1,0.9961612,0.0038387438
14432,digoxin,13,14,91,98,"This study was undertaken to investigate the links between the long-term administration of digoxin therapy and sexual behavior, and the effect of digoxin on plasma levels of estradiol, testosterone, and LH.",7416947_2,-1,-1,-1,14432,-1,0.99922633,0.0007737141
14433,digoxin,23,24,146,153,"This study was undertaken to investigate the links between the long-term administration of digoxin therapy and sexual behavior, and the effect of digoxin on plasma levels of estradiol, testosterone, and LH.",7416947_2,-1,-1,-1,14433,-1,0.9992513,0.000748612
14436,digoxin,10,11,53,60,The patients of the study and control group (without digoxin) were of similar cardiac functional capacity and age (25-40 years) and were randomly selected from the rheumatic heart disease patients.,7416947_3,-1,-1,-1,14436,-1,0.99928755,0.00071242626
14437,rheumatic heart disease,32,35,164,187,The patients of the study and control group (without digoxin) were of similar cardiac functional capacity and age (25-40 years) and were randomly selected from the rheumatic heart disease patients.,7416947_3,-1,-1,-1,14437,-1,0.004412195,0.9955878
14438,digoxin,6,7,44,51,"The findings support the reports concerning digoxin effect on plasma estradiol, testosterone, and LH.",7416947_6,-1,-1,-1,14438,-1,0.99922276,0.00077728345
14441,erection,21,22,127,135,"Tests used to evaluate the changes in sexual behavior showed a significant decrease in sexual desire, sexual excitement phase (erection), and frequency of sexual relations in the study group.",7416947_8,-1,-1,-1,14441,-1,0.0098791085,0.9901209
14446,tobramycin sulfate,3,5,23,41,Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.,7420681_3,-1,-1,-1,14446,-1,0.9989538,0.0010461975
14449,gentamicin sulfate,20,22,109,127,"In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.",7420681_4,-1,-1,-1,14449,-1,0.99872774,0.0012722707
14450,tobramycin sulfate,23,25,131,149,"In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.",7420681_4,-1,-1,-1,14450,-1,0.9988404,0.0011596197
14451,renal failure,40,42,255,268,"In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.",7420681_4,-1,-1,-1,14451,-1,0.0023091403,0.9976909
14452,reduction in,49,51,302,314,"In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.",7420681_4,-1,-1,-1,14452,-1,0.0122385025,0.9877615
14453,renal failure,9,11,42,55,"In these 62 patients, no other causes for renal failure could be identified.",7420681_5,-1,-1,-1,14453,-1,0.0027651438,0.9972349
14454,renal failure,24,26,112,125,Five of 33 (15%) of the tobramycin-treated patients and 16 of 29 (55.2%) of the gentamicin-treated patients had renal failure.,7420681_6,-1,-1,-1,14454,-1,0.0024073503,0.9975926
14456,renal failure,6,8,37,50,"Thus, gentamicin was associated with renal failure more than three times as often as was tobramycin.",7420681_7,-1,-1,-1,14456,-1,0.0023366362,0.9976634
14458,Hodgkin disease,3,5,28,43,Endometrial carcinoma after Hodgkin disease in childhood.,7421734_0,-1,-1,-1,14458,-1,0.10471364,0.8952863
14459,endometrial carcinoma,5,7,41,62,A 34-year-old patient developed metastic endometrial carcinoma after Hodgkin disease in childhood.,7421734_1,-1,-1,-1,14459,-1,0.007162486,0.9928375
14460,Hodgkin disease,8,10,69,84,A 34-year-old patient developed metastic endometrial carcinoma after Hodgkin disease in childhood.,7421734_1,-1,-1,-1,14460,-1,0.13534705,0.864653
14461,ovarian failure,2,4,8,23,"She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.",7421734_2,-1,-1,-1,14461,-1,0.0028029054,0.99719703
14462,Hodgkin disease,10,12,73,88,"She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.",7421734_2,-1,-1,-1,14462,-1,0.02037735,0.97962266
14463,estrogens,16,17,113,122,"She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.",7421734_2,-1,-1,-1,14463,-1,0.99771833,0.0022817303
14465,estrogens,4,5,27,36,Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.,7421734_3,-1,-1,-1,14465,-1,0.9964108,0.003589193
14466,ovarian failure,6,8,41,56,Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.,7421734_3,-1,-1,-1,14466,-1,0.0037450092,0.9962549
14468,endometrial carcinoma,17,19,110,131,Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.,7421734_3,-1,-1,-1,14468,-1,0.0038712919,0.9961287
14469,adriamycin cardiotoxicity,3,5,25,50,Metabolic involvement in adriamycin cardiotoxicity.,7423039_0,-1,-1,-1,14469,-1,0.51961905,0.48038095
14473,phosphorylcreatine,19,20,120,138,"A possible involvement of energy metabolism was suggested previously, and in this study the adenylate energy charge and phosphorylcreatine mole fraction were determined in the adriamycin-treated cells.",7423039_3,-1,-1,-1,14473,-1,0.99869365,0.0013063368
14474,phophorylcreatine,13,14,79,96,"The adenylate energy charge was found to be significantly decreased, while the phophorylcreatine mole fraction was unchanged.",7423039_4,-1,-1,-1,14474,-1,0.9978933,0.0021067606
14476,mM adenosine,4,6,18,30,The addition of 1 mM adenosine to the myocardial cell cultures markedly increases the ATP concentration through a pathway reportedly leading to a compartmentalized ATP pool.,7423039_6,-1,-1,-1,14476,-1,0.9967926,0.0032073257
14477,ATP,14,15,86,89,The addition of 1 mM adenosine to the myocardial cell cultures markedly increases the ATP concentration through a pathway reportedly leading to a compartmentalized ATP pool.,7423039_6,-1,-1,-1,14477,-1,0.9979857,0.0020142712
14478,ATP,24,25,164,167,The addition of 1 mM adenosine to the myocardial cell cultures markedly increases the ATP concentration through a pathway reportedly leading to a compartmentalized ATP pool.,7423039_6,-1,-1,-1,14478,-1,0.9971306,0.0028694402
14489,Streptomycin sulfate,0,2,0,20,Streptomycin sulfate (300 mg/kg s.c.) was injected for various periods into preweanling rats and for 3 weeks into weanling rats.,7444978_1,-1,-1,-1,14489,-1,0.9987435,0.0012565678
14490,Abnormal movements,0,2,0,18,"Abnormal movements and deafness occurred only in rats treated during the preweaning period; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11-17 and 5 to 11 days of age, respectively, indicating that the cochlea is more sensitive to streptomycin than the site (vestibular or central) responsible for the dyskinesias.",7444978_3,-1,-1,-1,14490,-1,0.003020085,0.9969799
14491,deafness,3,4,23,31,"Abnormal movements and deafness occurred only in rats treated during the preweaning period; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11-17 and 5 to 11 days of age, respectively, indicating that the cochlea is more sensitive to streptomycin than the site (vestibular or central) responsible for the dyskinesias.",7444978_3,-1,-1,-1,14491,-1,0.0023671272,0.99763286
14494,doxorubicin cardiotoxicity,3,5,11,37,"Late, late doxorubicin cardiotoxicity.",7449470_0,-1,-1,-1,14494,-1,0.058307603,0.9416924
14504,LiCl,35,36,209,213,"The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.",7453952_1,-1,-1,-1,14504,-1,0.9990207,0.0009792387
14506,h,16,17,77,78,Amiloride reduced the drinking and urine volume of rats in an acute (6 or 12 h) and a subacute (3 days) experiment.,7453952_2,-1,-1,-1,14506,-1,0.69095635,0.30904368
14507,h,1,2,2,3,"6 h after the administration of amiloride, a reduction was observed in the lithium content of the renal medulla but not in the other organs studied.",7453952_3,-1,-1,-1,14507,-1,0.22330959,0.77669036
14510,h,2,3,6,7,"At 12 h, all the tissues showed a slight increase in lithium levels.",7453952_4,-1,-1,-1,14510,-1,0.24185476,0.7581453
14522,preterm labor,7,9,71,84,Cardiovascular complications associated with terbutaline treatment for preterm labor.,7468724_0,-1,-1,-1,14522,-1,0.008606087,0.99139386
14523,cardiovascular complications,1,3,7,35,Severe cardiovascular complications occurred in eight of 160 patients treated with terbutaline for preterm labor.,7468724_1,-1,-1,-1,14523,-1,0.0028454587,0.9971545
14525,preterm labor,13,15,99,112,Severe cardiovascular complications occurred in eight of 160 patients treated with terbutaline for preterm labor.,7468724_1,-1,-1,-1,14525,-1,0.0062422887,0.9937577
14526,corticosteroid,1,2,11,25,Associated corticosteroid therapy and twin gestations appear to be predisposing factors.,7468724_2,-1,-1,-1,14526,-1,0.99854714,0.0014528179
14527,antithyroid drugs,4,6,27,44,Toxic hepatitis induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and benzylthiouracil.,7504976_0,-1,-1,-1,14527,-1,0.98823315,0.011766915
14529,benzylthiouracil,16,17,117,133,Toxic hepatitis induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and benzylthiouracil.,7504976_0,-1,-1,-1,14529,-1,0.9989512,0.0010487596
14530,hepatic adverse,11,13,64,79,OBJECTIVE: This study was conducted to assess the occurrence of hepatic adverse effects encountered with antithyroid drugs.,7504976_1,-1,-1,-1,14530,-1,0.0029803412,0.9970196
14531,antithyroid drugs,16,18,105,122,OBJECTIVE: This study was conducted to assess the occurrence of hepatic adverse effects encountered with antithyroid drugs.,7504976_1,-1,-1,-1,14531,-1,0.99764746,0.0023525278
14533,toxic hepatitis,11,13,51,66,RESULTS: Four patients (1.7%) were identified with toxic hepatitis which could reasonably be attributed to the use of antithyroid agent.,7504976_3,-1,-1,-1,14533,-1,0.0023173168,0.9976827
14534,cholestatic hepatitis,4,6,19,40,Two patients had a cholestatic hepatitis induced by carbimazole (N  omercazole).,7504976_4,-1,-1,-1,14534,-1,0.003262839,0.9967372
14536,cholestatic,6,7,24,35,Two others had a mixed (cholestatic and cytolytic) hepatitis following carbimazole.,7504976_5,-1,-1,-1,14536,-1,0.0059427116,0.9940573
14540,Benzylthiouracil,14,15,94,110,One of the latter two patients further experienced a cytolytic hepatitis which appeared after Benzylthiouracil (Basd  ne) had replaced carbimazole.,7504976_6,-1,-1,-1,14540,-1,0.999087,0.00091308175
14541,ne,18,19,118,120,One of the latter two patients further experienced a cytolytic hepatitis which appeared after Benzylthiouracil (Basd  ne) had replaced carbimazole.,7504976_6,-1,-1,-1,14541,-1,0.99648917,0.0035108929
14545,Toxic hepatitis,2,4,12,27,"CONCLUSION: Toxic hepatitis is a potential adverse effect of antithyroid drugs which warrants, as for haematological disturbances, a pre-therapeutic determination and a careful follow-up of relevant biological markers.",7504976_9,-1,-1,-1,14545,-1,0.0029303252,0.9970696
14546,antithyroid drugs,10,12,61,78,"CONCLUSION: Toxic hepatitis is a potential adverse effect of antithyroid drugs which warrants, as for haematological disturbances, a pre-therapeutic determination and a careful follow-up of relevant biological markers.",7504976_9,-1,-1,-1,14546,-1,0.99809164,0.0019083824
14548,antithyroid agents,11,13,63,81,"Moreover, hepatotoxicity may not be restricted to one class of antithyroid agents.",7504976_10,-1,-1,-1,14548,-1,0.98884404,0.011156001
14549,Na,8,9,59,61,"The effects of varying the extracellular concentrations of Na and Ca ([Na]o and [Ca]o) on both, the spontaneous beating and the negative chronotropic action of verapamil, were studied in the isolated rat atria.",7516729_1,-1,-1,-1,14549,-1,0.998145,0.001854984
14550,Ca,10,11,66,68,"The effects of varying the extracellular concentrations of Na and Ca ([Na]o and [Ca]o) on both, the spontaneous beating and the negative chronotropic action of verapamil, were studied in the isolated rat atria.",7516729_1,-1,-1,-1,14550,-1,0.9976519,0.0023480942
14552,mM Na,5,7,39,44,in control Krebs-Ringer containing 137 mM Na and 1.35 mM Ca (N).,7516729_3,-1,-1,-1,14552,-1,0.99280775,0.007192235
14553,mM Ca,9,11,54,59,in control Krebs-Ringer containing 137 mM Na and 1.35 mM Ca (N).,7516729_3,-1,-1,-1,14553,-1,0.98701024,0.012989696
14554,N,12,13,61,62,in control Krebs-Ringer containing 137 mM Na and 1.35 mM Ca (N).,7516729_3,-1,-1,-1,14554,-1,0.986416,0.013583957
14555,mM,13,14,50,52,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,-1,14555,-1,0.8092764,0.19072354
14556,mM,29,30,109,111,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,-1,14556,-1,0.80964154,0.1903584
14557,mM,34,35,131,133,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,-1,14557,-1,0.85114425,0.14885578
14558,mM,49,50,182,184,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,-1,14558,-1,0.740739,0.25926107
14559,mM,55,56,214,216,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,-1,-1,-1,14559,-1,0.76061,0.23939005
14560,mM,7,8,33,35,"At normal [Na]o, decrease (0.675 mM) or increase (3.6 mM) of [Ca]o did not modify BF; a reduction of ten times (0.135 mM of normal [Ca]o was effective to reduce BF by 40 +/- 13%.",7516729_5,-1,-1,-1,14560,-1,0.8939695,0.10603056
14561,mM,13,14,54,56,"At normal [Na]o, decrease (0.675 mM) or increase (3.6 mM) of [Ca]o did not modify BF; a reduction of ten times (0.135 mM of normal [Ca]o was effective to reduce BF by 40 +/- 13%.",7516729_5,-1,-1,-1,14561,-1,0.8118829,0.18811709
14562,mM,29,30,118,120,"At normal [Na]o, decrease (0.675 mM) or increase (3.6 mM) of [Ca]o did not modify BF; a reduction of ten times (0.135 mM of normal [Ca]o was effective to reduce BF by 40 +/- 13%.",7516729_5,-1,-1,-1,14562,-1,0.8250734,0.17492656
14565,Na,6,7,40,42,"Independent but not additive effects of Na and Ca are shown by decreases in the values of [verapamil]o needed to reduce BF by 30% (IC30) with the following order of inhibitory potency: LNa > LCa > HCa > N, resulting LNa+HCa similar to LNa.",7516729_8,-1,-1,-1,14565,-1,0.99841034,0.0015896684
14566,Ca,8,9,47,49,"Independent but not additive effects of Na and Ca are shown by decreases in the values of [verapamil]o needed to reduce BF by 30% (IC30) with the following order of inhibitory potency: LNa > LCa > HCa > N, resulting LNa+HCa similar to LNa.",7516729_8,-1,-1,-1,14566,-1,0.99830997,0.0016900082
14567,N,42,43,203,204,"Independent but not additive effects of Na and Ca are shown by decreases in the values of [verapamil]o needed to reduce BF by 30% (IC30) with the following order of inhibitory potency: LNa > LCa > HCa > N, resulting LNa+HCa similar to LNa.",7516729_8,-1,-1,-1,14567,-1,0.99372745,0.0062724873
14568,N.,25,26,125,127,The [verapamil]o that arrested atrial beating (AC) was also potentiated with the order LNa = LNa+LCa = LNa+HCa = LCa > HCa = N. The results indicate that rat atrial spontaneous beating is more dependent on [Na]o than on [Ca]o in a range of +/- 50% of their normal concentration.,7516729_9,-1,-1,-1,14568,-1,0.9666852,0.033314794
14571,cyclosporin A,2,4,18,31,Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase.,7542793_0,-1,-1,-1,14571,-1,0.99845374,0.0015462488
14572,FK506,5,6,36,41,Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase.,7542793_0,-1,-1,-1,14572,-1,0.9988927,0.0011072598
14573,Cyclosporin A,0,2,0,13,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,-1,-1,-1,14573,-1,0.9982822,0.0017178743
14574,CsA,3,4,15,18,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,-1,-1,-1,14574,-1,0.9980636,0.0019363499
14575,Fujimycine,9,10,34,44,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,-1,-1,-1,14575,-1,0.9987515,0.0012484138
14576,FK506,11,12,46,51,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,-1,-1,-1,14576,-1,0.99884427,0.0011557103
14577,macrolide,21,22,83,92,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,-1,-1,-1,14577,-1,0.99626935,0.0037306163
14580,CsA,4,5,28,31,The molecular mechanisms of CsA and FK506 toxicity were investigated.,7542793_2,-1,-1,-1,14580,-1,0.99875116,0.0012488444
14581,FK506 toxicity,6,8,36,50,The molecular mechanisms of CsA and FK506 toxicity were investigated.,7542793_2,-1,-1,-1,14581,-1,0.911083,0.08891705
14582,Cyclophilin A,0,2,0,13,"Cyclophilin A and FK506-binding protein, the main intracytoplasmic receptors for CsA and FK506, respectively, were each detected in renal tissue extract.",7542793_3,-1,-1,-1,14582,-1,0.9942861,0.005713915
14583,CsA,11,12,81,84,"Cyclophilin A and FK506-binding protein, the main intracytoplasmic receptors for CsA and FK506, respectively, were each detected in renal tissue extract.",7542793_3,-1,-1,-1,14583,-1,0.99851424,0.001485801
14584,FK506,13,14,89,94,"Cyclophilin A and FK506-binding protein, the main intracytoplasmic receptors for CsA and FK506, respectively, were each detected in renal tissue extract.",7542793_3,-1,-1,-1,14584,-1,0.99901485,0.0009851173
14585,immunosuppressants CsA,19,21,121,143,"In the kidney, high levels of immunoreactive and enzymatically active calcineurin were found which were inhibited by the immunosuppressants CsA and FK506, but not by rapamycin.",7542793_4,-1,-1,-1,14585,-1,0.9827671,0.017232923
14586,FK506,22,23,148,153,"In the kidney, high levels of immunoreactive and enzymatically active calcineurin were found which were inhibited by the immunosuppressants CsA and FK506, but not by rapamycin.",7542793_4,-1,-1,-1,14586,-1,0.9989141,0.0010859466
14588,CsA,11,12,89,92,"Finally, specific immunophilin-drug-calcineurin complexes formed only in the presence of CsA and FK506, but not rapamycin.",7542793_5,-1,-1,-1,14588,-1,0.9985921,0.001407892
14589,FK506,13,14,97,102,"Finally, specific immunophilin-drug-calcineurin complexes formed only in the presence of CsA and FK506, but not rapamycin.",7542793_5,-1,-1,-1,14589,-1,0.99887043,0.00112953
14592,CsA,8,9,54,57,These results suggest that the nephrotoxic effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase.,7542793_6,-1,-1,-1,14592,-1,0.99894387,0.0010561292
14593,FK506,10,11,62,67,These results suggest that the nephrotoxic effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase.,7542793_6,-1,-1,-1,14593,-1,0.9991979,0.0008021444
14594,Acute renal failure,0,3,0,19,Acute renal failure in high dose carboplatin chemotherapy.,7565311_0,-1,-1,-1,14594,-1,0.002481795,0.9975182
14596,acute renal failure,6,9,39,58,Carboplatin has been reported to cause acute renal failure when administered in high doses to adult patients.,7565311_1,-1,-1,-1,14596,-1,0.0022478353,0.99775213
14598,embryonal rhabdomyosarcoma,15,17,104,130,We report a 4 1/2-year-old girl who was treated with high-dose carboplatin for metastatic parameningeal embryonal rhabdomyosarcoma.,7565311_2,-1,-1,-1,14598,-1,0.005178136,0.9948219
14599,Acute renal failure,0,3,0,19,Acute renal failure developed followed by a slow partial recovery of renal function.,7565311_3,-1,-1,-1,14599,-1,0.0028214213,0.99717855
14602,Triniol,7,8,52,59,Two patients treated with parenteral paramethasone (Triniol) and dexamethasone (Sedionbel) are described.,7582165_1,-1,-1,-1,14602,-1,0.99838495,0.0016150898
14605,conjunctivitis,19,20,97,111,"A few minutes after administration of the drugs, they presented urticaria (patients 1 and 2) and conjunctivitis (patient 1).",7582165_2,-1,-1,-1,14605,-1,0.002618555,0.9973814
14614,prostacyclin,7,8,55,67,Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol.,7596955_0,-1,-1,-1,14614,-1,0.99926406,0.0007359722
14615,beraprost,9,10,77,86,Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol.,7596955_0,-1,-1,-1,14615,-1,0.9992725,0.0007274841
14616,cilostazol,13,14,119,129,Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol.,7596955_0,-1,-1,-1,14616,-1,0.9990657,0.00093431433
14617,prostacyclin analogue beraprost,10,13,59,90,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14617,-1,0.99886656,0.0011335193
14618,BPT,14,15,92,95,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14618,-1,0.99731195,0.002688102
14619,cilostazol,21,22,138,148,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14619,-1,0.99917006,0.00082990463
14620,CLZ,23,24,150,153,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14620,-1,0.99830174,0.0016982744
14621,cAMP,38,39,250,254,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14621,-1,0.99660313,0.0033968107
14622,"cyclic adenosine 3',5'-monophosphate",40,43,256,292,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,-1,-1,-1,14622,-1,0.9907137,0.009286298
14623,BPT,13,14,83,86,"Twelve healthy volunteers were assigned to take BPT/CLZ in the following schedule; BPT: 40 micrograms at day 1 and 120 micrograms t.i.d. from day 7 to 14, CLZ: 200 mg t.i.d. from day 3 to 14.",7596955_3,-1,-1,-1,14623,-1,0.99855417,0.001445795
14624,CLZ,31,32,155,158,"Twelve healthy volunteers were assigned to take BPT/CLZ in the following schedule; BPT: 40 micrograms at day 1 and 120 micrograms t.i.d. from day 7 to 14, CLZ: 200 mg t.i.d. from day 3 to 14.",7596955_3,-1,-1,-1,14624,-1,0.99832565,0.0016743995
14625,mg,34,35,164,166,"Twelve healthy volunteers were assigned to take BPT/CLZ in the following schedule; BPT: 40 micrograms at day 1 and 120 micrograms t.i.d. from day 7 to 14, CLZ: 200 mg t.i.d. from day 3 to 14.",7596955_3,-1,-1,-1,14625,-1,0.9801072,0.019892866
14627,cAMP,19,20,137,141,"At various time intervals, physical examination and blood collection for ex vivo platelet aggregation and determination of intraplatelet cAMP were performed.",7596955_4,-1,-1,-1,14627,-1,0.99832183,0.0016781641
14629,facial flush in,12,15,79,94,"Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of CLZ.",7596955_6,-1,-1,-1,14629,-1,0.012033382,0.9879666
14631,CLZ,25,26,148,151,"Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of CLZ.",7596955_6,-1,-1,-1,14631,-1,0.9988883,0.0011116813
14632,cAMP,1,2,14,18,Intraplatelet cAMP content was gradually but significantly increased to 9.84 +/- 4.59 pmol per 10(9) platelets at day 14 in comparison with the initial value (6.87 +/- 2.25 pmol).,7596955_8,-1,-1,-1,14632,-1,0.9979169,0.002083153
14634,inflammatory myopathy,4,6,16,37,"A case of acute inflammatory myopathy associated with the use of pravastatin, a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported.",7604176_2,-1,-1,-1,14634,-1,0.002153691,0.99784636
14636,coenzyme A reductase,18,21,123,143,"A case of acute inflammatory myopathy associated with the use of pravastatin, a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported.",7604176_2,-1,-1,-1,14636,-1,0.9938892,0.0061107883
14637,diabetes mellitus,10,12,69,86,"The patient, a 69-year-old man was affected by non-insulin-dependent diabetes mellitus and hypertension.",7604176_3,-1,-1,-1,14637,-1,0.003094365,0.9969056
14644,autoimmune thyroiditis,9,11,61,83,"A previously unknown hypothyroidism, probably due to chronic autoimmune thyroiditis, was evidenced.",7604176_6,-1,-1,-1,14644,-1,0.0041418397,0.99585813
14649,ammonia coma,2,4,12,24,Reversal of ammonia coma in rats by L-dopa: a peripheral effect.,761833_0,-1,-1,-1,14649,-1,0.14032857,0.85967135
14650,Ammonia coma,0,2,0,12,Ammonia coma was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1.7 mmol NH4CL.,761833_1,-1,-1,-1,14650,-1,0.1649235,0.8350765
14651,NH4CL,17,18,101,106,Ammonia coma was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1.7 mmol NH4CL.,761833_1,-1,-1,-1,14651,-1,0.99811316,0.001886823
14653,ammonium salt,16,18,96,109,This coma was prevented with 1.68 mmol L-dopa given by gastric intubation 15 minutes before the ammonium salt injection.,761833_2,-1,-1,-1,14653,-1,0.9987884,0.0012115649
14654,ammonia,13,14,71,78,"The effect of L-dopa was correlated with a decrease in blood and brain ammonia, an increase in brain dopamine, and an increase in renal excretion of ammonia and urea.",761833_3,-1,-1,-1,14654,-1,0.9986272,0.0013728119
14656,ammonia,28,29,149,156,"The effect of L-dopa was correlated with a decrease in blood and brain ammonia, an increase in brain dopamine, and an increase in renal excretion of ammonia and urea.",761833_3,-1,-1,-1,14656,-1,0.9981857,0.001814273
14660,ammonia coma,18,20,116,128,Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations.,761833_4,-1,-1,-1,14660,-1,0.21587639,0.78412366
14661,ammonia,26,27,160,167,Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations.,761833_4,-1,-1,-1,14661,-1,0.9968267,0.0031732756
14662,ammonia,12,13,84,91,Bilateral nephrectomy eliminated the beneficial effect of L-dopa on blood and brain ammonia and the ammonia coma was not prevented.,761833_5,-1,-1,-1,14662,-1,0.98911893,0.010881035
14663,ammonia coma,15,17,100,112,Bilateral nephrectomy eliminated the beneficial effect of L-dopa on blood and brain ammonia and the ammonia coma was not prevented.,761833_5,-1,-1,-1,14663,-1,0.11089134,0.8891087
14664,ammonia,8,9,39,46,"Thus, the reduction in blood and brain ammonia and the prevention of ammonia coma after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.",761833_6,-1,-1,-1,14664,-1,0.9959125,0.0040874896
14665,ammonia coma,13,15,69,81,"Thus, the reduction in blood and brain ammonia and the prevention of ammonia coma after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.",761833_6,-1,-1,-1,14665,-1,0.1651607,0.8348393
14667,encephalopathic,13,14,91,106,These results provide a reasonable explanation for the beneficial effects observed in some encephalopathic patients receiving L-dopa.,761833_7,-1,-1,-1,14667,-1,0.002064354,0.99793565
14668,myocardial infarction,1,3,18,39,Etoposide-related myocardial infarction.,7619765_0,-1,-1,-1,14668,-1,0.00262677,0.9973732
14669,myocardial infarction,4,6,20,41,"The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide, in a man with no risk factors for coronary heart disease.",7619765_1,-1,-1,-1,14669,-1,0.0023504472,0.9976496
14671,coronary heart disease,21,24,129,151,"The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide, in a man with no risk factors for coronary heart disease.",7619765_1,-1,-1,-1,14671,-1,0.002659014,0.997341
14672,vitamin B12,5,7,21,32,Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine.,7628595_0,-1,-1,-1,14672,-1,0.9977574,0.0022426676
14674,hematologic toxicity,13,15,80,100,Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine.,7628595_0,-1,-1,-1,14674,-1,0.002425205,0.99757475
14676,vitamin B12,12,14,70,81,"A prospective, randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine (ZDV)-induced bone marrow suppression.",7628595_1,-1,-1,-1,14676,-1,0.99770856,0.0022914296
14680,human immunodeficiency virus,1,4,13,41,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,14680,-1,0.109737076,0.8902629
14681,ZDV,18,19,132,135,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,14681,-1,0.99887675,0.0011232655
14682,mg,21,22,141,143,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,14682,-1,0.96908456,0.030915428
14683,n,29,30,167,168,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,14683,-1,0.2076444,0.79235554
14685,mg,41,42,215,217,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,14685,-1,0.94149244,0.058507618
14686,vitamin B12,46,48,243,254,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,14686,-1,0.996555,0.0034450362
14687,n,57,58,292,293,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,-1,-1,-1,14687,-1,0.22441092,0.7755891
14689,vitamin B12,4,6,18,29,"During the study, vitamin B12 and folate levels were significantly higher in group II patients; however, no differences in hemoglobin, hematocrit, mean corpuscular volume, and white-cell, neutrophil and platelet counts were observed between groups at 3, 6, 9 and 12 months.",7628595_5,-1,-1,-1,14689,-1,0.99762636,0.0023736977
14690,folate,7,8,34,40,"During the study, vitamin B12 and folate levels were significantly higher in group II patients; however, no differences in hemoglobin, hematocrit, mean corpuscular volume, and white-cell, neutrophil and platelet counts were observed between groups at 3, 6, 9 and 12 months.",7628595_5,-1,-1,-1,14690,-1,0.9980317,0.0019682625
14691,hematologic toxicity,1,3,7,27,Severe hematologic toxicity (neutrophil count < 1000/mm3 and/or hemoglobin < 8 g/dl) occurred in 4 patients assigned to group I and 7 assigned to group II.,7628595_6,-1,-1,-1,14691,-1,0.0028263573,0.99717367
14692,vitamin B12,5,7,33,44,There was no correlation between vitamin B12 or folate levels and development of myelosuppression.,7628595_7,-1,-1,-1,14692,-1,0.99806863,0.0019313893
14693,folate,8,9,48,54,There was no correlation between vitamin B12 or folate levels and development of myelosuppression.,7628595_7,-1,-1,-1,14693,-1,0.99809164,0.0019083587
14696,ZDV,7,8,48,51,"Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced myelotoxicity in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.",7628595_8,-1,-1,-1,14696,-1,0.9985166,0.0014833304
14697,myelotoxicity,18,19,119,132,"Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced myelotoxicity in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.",7628595_8,-1,-1,-1,14697,-1,0.0021399558,0.99786
14702,trifluoroacetyl,9,10,67,82,An antibody response to a protein-bound biotransformation product (trifluoroacetyl adduct) has been detected on halothane hepatitis patients.,7647582_3,-1,-1,-1,14702,-1,0.9990264,0.00097360316
14703,halothane hepatitis,16,18,112,131,An antibody response to a protein-bound biotransformation product (trifluoroacetyl adduct) has been detected on halothane hepatitis patients.,7647582_3,-1,-1,-1,14703,-1,0.91002554,0.08997442
14714,halothane hepatitis,23,25,159,178,This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration.,7647582_8,-1,-1,-1,14714,-1,0.990948,0.009051962
14717,echothiophate iodide,7,9,59,79,Cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops.,7650771_0,-1,-1,-1,14717,-1,0.99858,0.0014200521
14718,echothiophate iodide,11,13,66,86,"A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis.",7650771_1,-1,-1,-1,14718,-1,0.99869424,0.001305815
14719,muscle weakness,19,21,129,144,"A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis.",7650771_1,-1,-1,-1,14719,-1,0.003085336,0.9969146
14720,myasthenia gravis,28,30,186,203,"A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis.",7650771_1,-1,-1,-1,14720,-1,0.006941481,0.99305856
14723,flumazenil,2,3,14,24,Seizure after flumazenil administration in a pediatric patient.,7651879_0,-1,-1,-1,14723,-1,0.99909115,0.00090882566
14724,Flumazenil,0,1,0,10,Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines.,7651879_1,-1,-1,-1,14724,-1,0.9993235,0.00067652855
14726,respiratory depression,11,13,80,102,Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines.,7651879_1,-1,-1,-1,14726,-1,0.0026300126,0.99737
14732,flumazenil,7,8,56,66,Little information exists concerning adverse effects of flumazenil in children.,7651879_4,-1,-1,-1,14732,-1,0.99927026,0.00072975125
14734,flumazenil,17,18,118,128,We report the occurrence of a generalized tonic-clonic seizure in a pediatric patient following the administration of flumazenil.,7651879_5,-1,-1,-1,14734,-1,0.99920386,0.0007961391
14735,neuroblastoma,9,10,55,68,Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation.,7707116_0,-1,-1,-1,14735,-1,0.0032560301,0.9967439
14736,neuroblastoma,4,5,22,35,PURPOSE: Treatment of neuroblastoma cell lines with 13-cis-retinoic acid (cis-RA) can cause sustained inhibition of proliferation.,7707116_1,-1,-1,-1,14736,-1,0.009564223,0.9904358
14737,neuroblastoma,7,8,52,65,"Since cis-RA has demonstrated clinical responses in neuroblastoma patients, it may be effective in preventing relapse after cytotoxic therapy.",7707116_2,-1,-1,-1,14737,-1,0.0054830383,0.9945169
14739,neuroblastoma,29,30,182,195,"This phase I trial was designed to determine the maximal-tolerated dosage (MTD), toxicities, and pharmacokinetics of cis-RA administered on an intermittent schedule in children with neuroblastoma following bone marrow transplantation (BMT).",7707116_3,-1,-1,-1,14739,-1,0.0031990572,0.9968009
14743,n,13,14,88,89,"Dose-limiting toxicities in six of nine patients at 200 mg/m2/d included hypercalcemia (n = 3), rash (n = 2), and anemia/thrombocytopenia/emesis/rash (n = 1).",7707116_8,-1,-1,-1,14743,-1,0.06246715,0.93753284
14745,n,20,21,102,103,"Dose-limiting toxicities in six of nine patients at 200 mg/m2/d included hypercalcemia (n = 3), rash (n = 2), and anemia/thrombocytopenia/emesis/rash (n = 1).",7707116_8,-1,-1,-1,14745,-1,0.06683385,0.9331661
14746,n,28,29,151,152,"Dose-limiting toxicities in six of nine patients at 200 mg/m2/d included hypercalcemia (n = 3), rash (n = 2), and anemia/thrombocytopenia/emesis/rash (n = 1).",7707116_8,-1,-1,-1,14746,-1,0.094748266,0.9052518
14748,metastases,7,8,49,59,Three complete responses were observed in marrow metastases.,7707116_10,-1,-1,-1,14748,-1,0.0039880103,0.996012
14749,neuroblastoma,7,8,43,56,Serum levels known to be effective against neuroblastoma in vitro were achieved at this dose.,7707116_13,-1,-1,-1,14749,-1,0.0053677596,0.99463224
14753,oxypurines,6,7,43,53,"Time dependence of plasma malondialdehyde, oxypurines, and nucleosides during incomplete cerebral ischemia in the rat.",7710775_0,-1,-1,-1,14753,-1,0.9987004,0.00129954
14754,nucleosides,9,10,59,70,"Time dependence of plasma malondialdehyde, oxypurines, and nucleosides during incomplete cerebral ischemia in the rat.",7710775_0,-1,-1,-1,14754,-1,0.9972006,0.0027994146
14755,cerebral ischemia,12,14,89,106,"Time dependence of plasma malondialdehyde, oxypurines, and nucleosides during incomplete cerebral ischemia in the rat.",7710775_0,-1,-1,-1,14755,-1,0.003465429,0.9965346
14756,cerebral ischemia,1,3,11,28,Incomplete cerebral ischemia (30 min) was induced in the rat by bilaterally clamping the common carotid arteries.,7710775_1,-1,-1,-1,14756,-1,0.003153963,0.996846
14759,"malondialdehyde, oxypurines",17,20,131,158,"Plasma extracts were analyzed by a highly sensitive high-performance liquid chromatographic method for the direct determination of malondialdehyde, oxypurines, and nucleosides.",7710775_3,-1,-1,-1,14759,-1,0.99850595,0.0014940859
14760,nucleosides,22,23,164,175,"Plasma extracts were analyzed by a highly sensitive high-performance liquid chromatographic method for the direct determination of malondialdehyde, oxypurines, and nucleosides.",7710775_3,-1,-1,-1,14760,-1,0.9918189,0.008181105
14762,oxypurines,8,9,53,63,"During ischemia, a time-dependent increase of plasma oxypurines and nucleosides was observed.",7710775_4,-1,-1,-1,14762,-1,0.99889153,0.0011084541
14763,nucleosides,10,11,68,79,"During ischemia, a time-dependent increase of plasma oxypurines and nucleosides was observed.",7710775_4,-1,-1,-1,14763,-1,0.99752754,0.0024724738
14765,SD,17,18,100,102,"Plasma malondialdehyde, which was present in minimal amount at zero time (0.058 mumol/liter plasma; SD 0.015), increased after 5 min of ischemia, resulting in a fivefold increase after 30 min of carotid occlusion (0.298 mumol/liter plasma; SD 0.078).",7710775_5,-1,-1,-1,14765,-1,0.40315986,0.59684014
14767,SD,44,45,240,242,"Plasma malondialdehyde, which was present in minimal amount at zero time (0.058 mumol/liter plasma; SD 0.015), increased after 5 min of ischemia, resulting in a fivefold increase after 30 min of carotid occlusion (0.298 mumol/liter plasma; SD 0.078).",7710775_5,-1,-1,-1,14767,-1,0.22773908,0.77226084
14769,acetylsalicylate,29,30,184,200,"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.",7710775_6,-1,-1,-1,14769,-1,0.9990589,0.00094115105
14776,oxypurines,10,11,69,79,"The present data indicate that the determination of malondialdehyde, oxypurines, and nucleosides in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena.(ABSTRACT TRUNCATED AT 250 WORDS)",7710775_7,-1,-1,-1,14776,-1,0.998276,0.0017239591
14777,nucleosides,13,14,85,96,"The present data indicate that the determination of malondialdehyde, oxypurines, and nucleosides in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena.(ABSTRACT TRUNCATED AT 250 WORDS)",7710775_7,-1,-1,-1,14777,-1,0.9966433,0.0033567091
14778,ischemic,30,31,195,203,"The present data indicate that the determination of malondialdehyde, oxypurines, and nucleosides in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena.(ABSTRACT TRUNCATED AT 250 WORDS)",7710775_7,-1,-1,-1,14778,-1,0.0040457905,0.9959543
14779,Acute renal toxicity,0,3,0,20,Acute renal toxicity of doxorubicin (adriamycin)-loaded cyanoacrylate nanoparticles.,7724492_0,-1,-1,-1,14779,-1,0.0027217905,0.9972783
14781,cyanoacrylate,6,7,56,69,Acute renal toxicity of doxorubicin (adriamycin)-loaded cyanoacrylate nanoparticles.,7724492_0,-1,-1,-1,14781,-1,0.99822897,0.001770995
14785,DX,10,11,49,51,"In normal rats, 2/6 rats given free doxorubicin (DX) (5 mg/kg) died within one week, whereas all control animals and all rats having received free NP or DXNP survived.",7724492_2,-1,-1,-1,14785,-1,0.9985266,0.0014733837
14787,DX,16,17,94,96,A 3 times higher proteinuria appeared in animals treated with DXNP than in those treated with DX.,7724492_3,-1,-1,-1,14787,-1,0.99853456,0.0014654561
14789,DX,14,15,81,83,"Two hr post-injection, DXNP was 2.7 times more concentrated in kidneys than free DX (p < 0.025).",7724492_5,-1,-1,-1,14789,-1,0.99856335,0.0014366687
14790,p,16,17,85,86,"Two hr post-injection, DXNP was 2.7 times more concentrated in kidneys than free DX (p < 0.025).",7724492_5,-1,-1,-1,14790,-1,0.45811114,0.5418889
14792,DX,10,11,68,70,"In rats with immune experimental glomerulonephritis, 5/6 rats given DX died within 7 days, in contrast to animals treated by DXNP, NP, or untreated, which all survived.",7724492_6,-1,-1,-1,14792,-1,0.9986957,0.0013043552
14793,contrast,17,18,94,102,"In rats with immune experimental glomerulonephritis, 5/6 rats given DX died within 7 days, in contrast to animals treated by DXNP, NP, or untreated, which all survived.",7724492_6,-1,-1,-1,14793,-1,0.09922275,0.9007773
14795,p,15,16,68,69,"Proteinuria appeared in all series, but was 2-5 times more intense (p > 0.001) and prolonged after doxorubicin treatment (400-700 mg/day), without significant difference between DXNP and DX.",7724492_7,-1,-1,-1,14795,-1,0.27044806,0.729552
14797,DX,37,38,187,189,"Proteinuria appeared in all series, but was 2-5 times more intense (p > 0.001) and prolonged after doxorubicin treatment (400-700 mg/day), without significant difference between DXNP and DX.",7724492_7,-1,-1,-1,14797,-1,0.99129784,0.008702216
14798,DX,16,17,101,103,"These results demonstrate that, in these experimental conditions, DXNP killed less animals than free DX, despite of an enhanced renal toxicity of the former.",7724492_9,-1,-1,-1,14798,-1,0.9987406,0.0012593997
14801,bladder hyperactivity,2,4,25,46,"Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins?In normal conscious rats investigated by continuous cystometry, intravesically instilled prostaglandin (PG) E2 facilitated micturition and increased basal intravesical pressure.",7752389_0,-1,-1,-1,14801,-1,0.0028004956,0.99719954
14802,prostaglandin (PG) E2,23,28,190,211,"Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins?In normal conscious rats investigated by continuous cystometry, intravesically instilled prostaglandin (PG) E2 facilitated micturition and increased basal intravesical pressure.",7752389_0,-1,-1,-1,14802,-1,0.9970891,0.0029109712
14803,"RP 67,580",11,13,72,81,"The effect was attenuated by both the NK1 receptor selective antagonist RP 67,580 and the NK2 receptor selective antagonist SR 48,968, given intra-arterially, suggesting that it was mediated by stimulation of both NK1 and NK2 receptors.",7752389_1,-1,-1,-1,14803,-1,0.9977939,0.0022061542
14804,"SR 48,968",19,21,124,133,"The effect was attenuated by both the NK1 receptor selective antagonist RP 67,580 and the NK2 receptor selective antagonist SR 48,968, given intra-arterially, suggesting that it was mediated by stimulation of both NK1 and NK2 receptors.",7752389_1,-1,-1,-1,14804,-1,0.99758327,0.002416697
14805,PGE2,2,3,23,27,"Intra-arterially given PGE2 produced a distinct increase in bladder pressure before initiating a micturition reflex, indicating that the PG had a direct contractant effect on the detrusor smooth muscle.",7752389_2,-1,-1,-1,14805,-1,0.99836844,0.0016316127
14806,PG,19,20,137,139,"Intra-arterially given PGE2 produced a distinct increase in bladder pressure before initiating a micturition reflex, indicating that the PG had a direct contractant effect on the detrusor smooth muscle.",7752389_2,-1,-1,-1,14806,-1,0.9974195,0.0025805605
14807,PGE2,4,5,29,33,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,-1,-1,-1,14807,-1,0.99811816,0.0018818509
14808,"RP 67,580",11,13,73,82,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,-1,-1,-1,14808,-1,0.9975776,0.0024224517
14809,"SR 48,968",14,16,86,95,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,-1,-1,-1,14809,-1,0.99637884,0.003621114
14810,PGE2,28,29,180,184,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,-1,-1,-1,14810,-1,0.9982128,0.0017871914
14811,PG,40,41,251,253,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,-1,-1,-1,14811,-1,0.9972128,0.0027872066
14812,PGE2,7,8,53,57,"The present results thus suggest that intra-arterial PGE2, given near the bladder, may initiate micturition in the normal rat chiefly by directly contracting the smooth muscle of the detrusor.",7752389_4,-1,-1,-1,14812,-1,0.99820733,0.0017927055
14813,PGE2,6,7,36,40,"However, when given intravesically, PGE2 may stimulate micturition by releasing tachykinins from nerves in and/or immediately below the urothelium.",7752389_5,-1,-1,-1,14813,-1,0.99832684,0.001673114
14814,tachykinins,12,13,80,91,"However, when given intravesically, PGE2 may stimulate micturition by releasing tachykinins from nerves in and/or immediately below the urothelium.",7752389_5,-1,-1,-1,14814,-1,0.98663294,0.01336708
14815,tachykinins,1,2,6,17,"These tachykinins, in turn, initiate a micturition reflex by stimulating NK1 and NK2 receptors.",7752389_6,-1,-1,-1,14815,-1,0.98589087,0.014109202
14816,tachykinins,6,7,32,43,"Prostanoids may, via release of tachykinins, contribute to both urge and bladder hyperactivity seen in inflammatory conditions of the lower urinary tract.",7752389_7,-1,-1,-1,14816,-1,0.9905488,0.0094511835
14817,bladder hyperactivity,13,15,73,94,"Prostanoids may, via release of tachykinins, contribute to both urge and bladder hyperactivity seen in inflammatory conditions of the lower urinary tract.",7752389_7,-1,-1,-1,14817,-1,0.0032434557,0.9967565
14818,cardiogenic shock,1,3,11,28,Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment.,7785794_0,-1,-1,-1,14818,-1,0.0024824257,0.9975176
14819,heart block,5,7,42,53,Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment.,7785794_0,-1,-1,-1,14819,-1,0.0031770742,0.99682295
14822,heart block,6,8,55,66,A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of metoprolol.,7785794_2,-1,-1,-1,14822,-1,0.0028555535,0.9971444
14827,heart block,8,10,58,69,"The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.",7785794_3,-1,-1,-1,14827,-1,0.002775035,0.99722505
14831,calcium chloride,8,10,46,62,"However, shortly after the use of intravenous calcium chloride, the refractory hypotension and complete heart block resolved.",7785794_4,-1,-1,-1,14831,-1,0.99901235,0.0009876366
14833,heart block,16,18,104,115,"However, shortly after the use of intravenous calcium chloride, the refractory hypotension and complete heart block resolved.",7785794_4,-1,-1,-1,14833,-1,0.003070704,0.99692935
14834,misoprostol,3,4,21,32,Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients.,7791169_0,-1,-1,-1,14834,-1,0.99942505,0.0005750191
14837,misoprostol,9,10,58,69,OBJECTIVE: To evaluate the possible protective effects of misoprostol on renal function in hospitalized elderly patients treated with indomethacin.,7791169_1,-1,-1,-1,14837,-1,0.99947697,0.0005230697
14839,NSAID,20,21,130,135,"METHODS: Forty-five hospitalized elderly patients (> 65 years old) who required therapy with nonsteroidal antiinflammatory drugs (NSAID) were randomly assigned to receive either indomethacin, 150 mg/day (Group A), or indomethacin 150 mg/day plus misoprostol at 0.6 mg/day (Group B).",7791169_2,-1,-1,-1,14839,-1,0.99801123,0.001988762
14842,misoprostol,42,43,246,257,"METHODS: Forty-five hospitalized elderly patients (> 65 years old) who required therapy with nonsteroidal antiinflammatory drugs (NSAID) were randomly assigned to receive either indomethacin, 150 mg/day (Group A), or indomethacin 150 mg/day plus misoprostol at 0.6 mg/day (Group B).",7791169_2,-1,-1,-1,14842,-1,0.999318,0.000682011
14845,BUN,13,14,79,82,"Laboratory variables of renal function [serum creatinine, blood urea nitrogen (BUN) and electrolytes] were evaluated before initiation of therapy and every 2 days, until termination of the study (a period of at least 6 days).",7791169_3,-1,-1,-1,14845,-1,0.99714273,0.0028572814
14847,BUN,17,18,82,85,"RESULTS: Forty-two patients completed the study, 22 in Group A and 20 in Group B. BUN and creatinine increased by > 50% of baseline levels in 54 and 45% of Group A patients, respectively, compared to only 20 and 10% of Group B patients (p < 0.05).",7791169_5,-1,-1,-1,14847,-1,0.9977102,0.002289797
14849,p,52,53,237,238,"RESULTS: Forty-two patients completed the study, 22 in Group A and 20 in Group B. BUN and creatinine increased by > 50% of baseline levels in 54 and 45% of Group A patients, respectively, compared to only 20 and 10% of Group B patients (p < 0.05).",7791169_5,-1,-1,-1,14849,-1,0.18038008,0.8196199
14851,K,2,3,11,12,"Potassium (K) increment of 0.6 mEq/l or more was observed in 50% of Group A, but in only 15% of Group B patients (p < 0.05).",7791169_6,-1,-1,-1,14851,-1,0.99763894,0.0023610843
14852,p,29,30,114,115,"Potassium (K) increment of 0.6 mEq/l or more was observed in 50% of Group A, but in only 15% of Group B patients (p < 0.05).",7791169_6,-1,-1,-1,14852,-1,0.23105952,0.7689405
14853,BUN,4,5,23,26,"The mean increments in BUN, creatinine, and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A. Response to treatment did not differ significantly between the 2 groups.",7791169_7,-1,-1,-1,14853,-1,0.9977106,0.0022894004
14855,K,9,10,44,45,"The mean increments in BUN, creatinine, and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A. Response to treatment did not differ significantly between the 2 groups.",7791169_7,-1,-1,-1,14855,-1,0.99712473,0.0028752703
14858,misoprostol,2,3,12,23,Addition of misoprostol can minimize this renal impairment without affecting pain control.,7791169_9,-1,-1,-1,14858,-1,0.99939644,0.00060360157
14859,renal impairment,6,8,42,58,Addition of misoprostol can minimize this renal impairment without affecting pain control.,7791169_9,-1,-1,-1,14859,-1,0.00347058,0.9965294
14863,panic disorder,5,7,37,51,Controlled study in agoraphobia with panic disorder.,7802851_1,-1,-1,-1,14863,-1,0.004713656,0.9952864
14866,panic disorder,7,9,42,56,"The efficacy of alprazolam and placebo in panic disorder with agoraphobia, and the side-effect and adverse effect profiles of both drug groups were measured.",7802851_3,-1,-1,-1,14866,-1,0.00288843,0.99711156
14868,panic disorder,13,15,72,86,METHOD: In London and Toronto 154 patients who met DSM-III criteria for panic disorder with agoraphobia were randomised to alprazolam or placebo.,7802851_4,-1,-1,-1,14868,-1,0.003652662,0.99634737
14872,mg,7,8,36,38,RESULTS: Mean alprazolam dose was 5 mg daily.,7802851_7,-1,-1,-1,14872,-1,0.94942653,0.05057346
14875,enuresis,21,22,112,120,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,-1,-1,-1,14875,-1,0.060276594,0.9397234
14878,impaired memory,36,38,212,227,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,-1,-1,-1,14878,-1,0.005184521,0.9948154
14879,weight loss,39,41,229,240,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,-1,-1,-1,14879,-1,0.0044234386,0.9955766
14882,dextromethorphan,6,7,48,64,Cognitive deterioration from long-term abuse of dextromethorphan: a case report.,7803371_0,-1,-1,-1,14882,-1,0.99902546,0.00097457296
14883,Dextromethorphan,0,1,0,16,"Dextromethorphan (DM), the dextrorotatory isomer of 3-hydroxy-N-methylmorphinan, is the main ingredient in a number of widely available, over-the-counter antitussives.",7803371_1,-1,-1,-1,14883,-1,0.99916387,0.00083618914
14884,DM,2,3,18,20,"Dextromethorphan (DM), the dextrorotatory isomer of 3-hydroxy-N-methylmorphinan, is the main ingredient in a number of widely available, over-the-counter antitussives.",7803371_1,-1,-1,-1,14884,-1,0.9952821,0.004717895
14886,restlessness,17,18,82,94,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,14886,-1,0.0035236578,0.99647635
14887,insomnia,19,20,96,104,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,14887,-1,0.0027073347,0.9972927
14889,nystagmus,26,27,133,142,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,14889,-1,0.0035603296,0.99643964
14890,inattention,34,35,184,195,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,14890,-1,0.0054016868,0.99459827
14891,disorientation,36,37,197,211,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,14891,-1,0.0030283474,0.9969716
14893,al,43,44,247,249,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,14893,-1,0.7485393,0.25146067
14894,al,58,59,314,316,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,14894,-1,0.64662194,0.35337806
14895,al,74,75,389,391,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,-1,-1,14895,-1,0.6400677,0.3599323
14896,DM,8,9,50,52,There have also been two reported fatalities from DM overdoses (Fleming 1986).,7803371_5,-1,-1,-1,14896,-1,0.99168795,0.008312047
14897,cognitive deterioration,6,8,32,55,This report describes a case of cognitive deterioration resulting from prolonged use of DM.,7803371_7,-1,-1,-1,14897,-1,0.002310072,0.99768996
14898,DM,13,14,88,90,This report describes a case of cognitive deterioration resulting from prolonged use of DM.,7803371_7,-1,-1,-1,14898,-1,0.9836482,0.016351799
14901,coronary artery disease,13,16,83,106,Effects of ouabain on myocardial oxygen supply and demand in patients with chronic coronary artery disease.,783197_0,-1,-1,-1,14901,-1,0.0040808655,0.99591917
14902,heart failure,11,13,67,80,"A hemodynamic, volumetric, and metabolic study in patients without heart failure.",783197_1,-1,-1,-1,14902,-1,0.0042175404,0.9957825
14903,digitalis glycosides,3,5,15,35,"The effects of digitalis glycosides on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease, but have not been measured previously in man.",783197_2,-1,-1,-1,14903,-1,0.99884784,0.0011520869
14905,coronary artery disease,20,23,133,156,"The effects of digitalis glycosides on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease, but have not been measured previously in man.",783197_2,-1,-1,-1,14905,-1,0.0037966226,0.99620336
14907,body weight,9,11,48,59,"We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.",783197_3,-1,-1,-1,14907,-1,0.9156981,0.084301844
14908,coronary artery disease,26,29,149,172,"We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.",783197_3,-1,-1,-1,14908,-1,0.0054833866,0.99451655
14909,congestive heart failure,31,34,190,214,"We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.",783197_3,-1,-1,-1,14909,-1,0.0030008901,0.99699914
14912,mm Hg,12,14,86,91,Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed.,783197_6,-1,-1,-1,14912,-1,0.23037644,0.7696235
14913,P,15,16,93,94,Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed.,783197_6,-1,-1,-1,14913,-1,0.28543612,0.71456385
14914,P,32,33,191,192,Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed.,783197_6,-1,-1,-1,14914,-1,0.24810107,0.7518989
14915,h,38,39,211,212,Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed.,783197_6,-1,-1,-1,14915,-1,0.16821872,0.83178127
14917,P,15,16,120,121,The maximum velocity of contractile element shortening increased from 1.68+/-0.11 ml/s to 2.18+/-0.21 muscle-lengths/s (P less than 0.05) and is consistent with an increase in contractility.,783197_7,-1,-1,-1,14917,-1,0.35604,0.64396
14921,coronary artery disease,7,10,42,65,We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end-diastolic volume falls after ouabain administration even when it is initially normal.,783197_10,-1,-1,-1,14921,-1,0.0066339066,0.99336606
14922,congestive heart failure,15,18,90,114,We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end-diastolic volume falls after ouabain administration even when it is initially normal.,783197_10,-1,-1,-1,14922,-1,0.003756502,0.9962435
14928,pulmonary tuberculosis,9,11,91,113,Crescentic fibrillary glomerulonephritis associated with intermittent rifampin therapy for pulmonary tuberculosis.,7834920_0,-1,-1,-1,14928,-1,0.007594827,0.9924051
14933,pulmonary tuberculosis,11,13,72,94,This patient underwent a 10-month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy.,7834920_2,-1,-1,-1,14933,-1,0.0043305503,0.9956695
14934,renal failure,22,24,148,161,This patient underwent a 10-month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy.,7834920_2,-1,-1,-1,14934,-1,0.0025958193,0.99740416
14941,lead,5,6,43,47,PURPOSE: Glucocorticoid administration can lead to the development of ocular hypertension and corticosteroid glaucoma in a subset of the population through a decrease in the aqueous humor outflow facility.,7843916_1,-1,-1,-1,14941,-1,0.024879592,0.9751204
14942,ocular hypertension,10,12,70,89,PURPOSE: Glucocorticoid administration can lead to the development of ocular hypertension and corticosteroid glaucoma in a subset of the population through a decrease in the aqueous humor outflow facility.,7843916_1,-1,-1,-1,14942,-1,0.0028187179,0.9971813
14943,corticosteroid glaucoma,13,15,94,117,PURPOSE: Glucocorticoid administration can lead to the development of ocular hypertension and corticosteroid glaucoma in a subset of the population through a decrease in the aqueous humor outflow facility.,7843916_1,-1,-1,-1,14943,-1,0.2591686,0.74083143
14946,mm Hg,30,32,170,175,RESULTS: A significant increase in intraocular pressure developed in 13 of the 44 pairs of eyes perfused with dexamethasone with an average pressure rise of 17.5 +/- 3.8 mm Hg after 12 days of dexamethasone exposure.,7843916_7,-1,-1,-1,14946,-1,0.14531524,0.85468477
14949,contrast,1,2,3,11,"In contrast, the dexamethasone-treated hypertensive eyes had thickened trabecular beams, decreased intertrabecular spaces, thickened juxtacanalicular tissue, activated trabecular meshwork cells, and increased amounts of amorphogranular extracellular material, especially in the juxtacanalicular tissue and beneath the endothelial lining of the canal of Schlemm.",7843916_10,-1,-1,-1,14949,-1,0.07680036,0.9231996
14950,hypertensive eyes,5,7,39,56,"In contrast, the dexamethasone-treated hypertensive eyes had thickened trabecular beams, decreased intertrabecular spaces, thickened juxtacanalicular tissue, activated trabecular meshwork cells, and increased amounts of amorphogranular extracellular material, especially in the juxtacanalicular tissue and beneath the endothelial lining of the canal of Schlemm.",7843916_10,-1,-1,-1,14950,-1,0.00576415,0.9942358
14952,ocular hypertension,15,17,104,123,"CONCLUSION: Dexamethasone treatment of isolated, perfusion-cultured human eyes led to the generation of ocular hypertension in approximately 30% of the dexamethasone-treated eyes.",7843916_12,-1,-1,-1,14952,-1,0.0021865729,0.99781346
14954,corticosteroid glaucoma,15,17,107,130,Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma.,7843916_13,-1,-1,-1,14954,-1,0.4015608,0.59843916
14955,open angle glaucoma,18,21,135,154,Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma.,7843916_13,-1,-1,-1,14955,-1,0.0059175002,0.9940825
14956,steroid glaucoma,16,18,95,111,This system may provide an acute model in which to study the pathogenic mechanisms involved in steroid glaucoma and primary open angle glaucoma.,7843916_14,-1,-1,-1,14956,-1,0.27299455,0.7270054
14957,primary open angle glaucoma,19,23,116,143,This system may provide an acute model in which to study the pathogenic mechanisms involved in steroid glaucoma and primary open angle glaucoma.,7843916_14,-1,-1,-1,14957,-1,0.007472807,0.99252725
14961,cisplatinum,9,10,74,85,"A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.",7858459_1,-1,-1,-1,14961,-1,0.9985886,0.0014113884
14965,gastric adenocarcinoma,26,28,181,203,"A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.",7858459_1,-1,-1,-1,14965,-1,0.003370341,0.99662966
14967,disorientation,9,10,60,74,"He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.",7858459_2,-1,-1,-1,14967,-1,0.0028391613,0.9971609
14977,5-fluorouracil neurotoxicity,3,5,20,48,"The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.",7858459_5,-1,-1,-1,14977,-1,0.85475725,0.14524272
14978,fluoroacetate,14,15,89,102,"The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.",7858459_5,-1,-1,-1,14978,-1,0.9991008,0.0008992781
14979,fluorocitrate,16,17,107,120,"The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.",7858459_5,-1,-1,-1,14979,-1,0.99911124,0.0008887703
14980,thiamine deficiency,18,20,122,141,"The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.",7858459_5,-1,-1,-1,14980,-1,0.91516966,0.08483033
14981,dihydrouracil,22,23,146,159,"The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.",7858459_5,-1,-1,-1,14981,-1,0.9983328,0.0016672632
14984,oxcarbazepine,5,6,37,50,Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics.,7862923_0,-1,-1,-1,14984,-1,0.9992211,0.00077894365
14985,neuroleptics,11,12,75,87,Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics.,7862923_0,-1,-1,-1,14985,-1,0.9957377,0.00426229
14987,oxcarbazepine,7,8,51,64,"Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.",7862923_2,-1,-1,-1,14987,-1,0.999316,0.0006840478
14989,organic psychotic,13,15,111,128,"Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.",7862923_2,-1,-1,-1,14989,-1,0.003978935,0.9960211
14993,neuroleptics,21,22,92,104,This change resulted within 2-4 weeks in the 50-200% increase in the plasma levels of these neuroleptics and the appearance of extrapyramidal symptoms.,7862923_3,-1,-1,-1,14993,-1,0.99843496,0.0015650459
14995,contrast,11,12,57,65,The results of this case report support the idea that in contrast with carbamazepine oxcarbazepine does not induce the hepatic microsomal enzyme systems regulating the inactivation of antipsychotic drugs.,7862923_5,-1,-1,-1,14995,-1,0.6407455,0.35925454
14996,carbamazepine oxcarbazepine,13,15,71,98,The results of this case report support the idea that in contrast with carbamazepine oxcarbazepine does not induce the hepatic microsomal enzyme systems regulating the inactivation of antipsychotic drugs.,7862923_5,-1,-1,-1,14996,-1,0.9991959,0.0008040759
14997,antipsychotic drugs,27,29,184,203,The results of this case report support the idea that in contrast with carbamazepine oxcarbazepine does not induce the hepatic microsomal enzyme systems regulating the inactivation of antipsychotic drugs.,7862923_5,-1,-1,-1,14997,-1,0.9953129,0.004687047
15000,h,23,24,104,105,"Three audiometric threshold measurements (0.25-18 kHz) were made: the first before IBPB, the second 2-6 h after surgery and the third on the first day after operation.",7880714_3,-1,-1,-1,15000,-1,0.25832167,0.7416783
15001,hearing impairment,3,5,17,35,"In four patients hearing impairment on the side of the block was demonstrated after operation, in three measurements on the day of surgery and in one on the following day.",7880714_4,-1,-1,-1,15001,-1,0.0030737096,0.99692625
15003,auditory dysfunction,4,6,25,45,"IBPB may cause transient auditory dysfunction in the ipsilateral ear, possibly via an effect on sympathetic innervation.",7880714_8,-1,-1,-1,15003,-1,0.0034758975,0.99652404
15005,puromycin aminonucleoside,11,13,74,99,"Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced nephropathy, with antioxidants significantly reducing the proteinuria.",7881871_1,-1,-1,-1,15005,-1,0.99851173,0.00148822
15009,puromycin aminonucleoside,9,11,48,73,"Rats were treated with a single IV injection of puromycin aminonucleoside, (PAN, 7.5 mg/kg) and 24 hour urine samples were obtained prior to sacrifice on days 3,5,7,10,17,27,41 (N = 5-10 per group).",7881871_3,-1,-1,-1,15009,-1,0.99875283,0.001247192
15010,PAN,13,14,76,79,"Rats were treated with a single IV injection of puromycin aminonucleoside, (PAN, 7.5 mg/kg) and 24 hour urine samples were obtained prior to sacrifice on days 3,5,7,10,17,27,41 (N = 5-10 per group).",7881871_3,-1,-1,-1,15010,-1,0.99687827,0.0031217383
15011,N,32,33,178,179,"Rats were treated with a single IV injection of puromycin aminonucleoside, (PAN, 7.5 mg/kg) and 24 hour urine samples were obtained prior to sacrifice on days 3,5,7,10,17,27,41 (N = 5-10 per group).",7881871_3,-1,-1,-1,15011,-1,0.21277355,0.78722644
15012,thiobarbituric acid reactive substances,17,21,109,148,Tissue lipid peroxidation was measured in whole homogenates as well as in lipid extracts from homogenates as thiobarbituric acid reactive substances.,7881871_6,-1,-1,-1,15012,-1,0.9845428,0.015457173
15014,proteinuric injury,11,13,68,86,This study supports the role of lipid peroxidation in mediating the proteinuric injury in PAN nephropathy.,7881871_9,-1,-1,-1,15014,-1,0.02178243,0.9782176
15015,PAN nephropathy,14,16,90,105,This study supports the role of lipid peroxidation in mediating the proteinuric injury in PAN nephropathy.,7881871_9,-1,-1,-1,15015,-1,0.017418906,0.9825811
15016,gall bladder stones,2,5,15,34,Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid.,7890216_0,-1,-1,-1,15016,-1,0.0066049066,0.99339515
15018,ursodeoxycholic acid,12,14,80,100,Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid.,7890216_0,-1,-1,-1,15018,-1,0.99889624,0.0011037351
15020,acromegaly,6,7,39,49,"Octreotide, an effective treatment for acromegaly, induces gall bladder stones in 13-60% of patients.",7890216_1,-1,-1,-1,15020,-1,0.29481262,0.7051873
15021,gall bladder stones,9,12,59,78,"Octreotide, an effective treatment for acromegaly, induces gall bladder stones in 13-60% of patients.",7890216_1,-1,-1,-1,15021,-1,0.009692097,0.99030787
15023,acromegalic,30,31,192,203,"Because knowledge of stone composition is essential for studies of their pathogenesis, treatment, and prevention, this was investigated by direct and indirect methods in 14 octreotide treated acromegalic patients with gall stones.",7890216_2,-1,-1,-1,15023,-1,0.32462716,0.6753729
15024,gall stones,33,35,218,229,"Because knowledge of stone composition is essential for studies of their pathogenesis, treatment, and prevention, this was investigated by direct and indirect methods in 14 octreotide treated acromegalic patients with gall stones.",7890216_2,-1,-1,-1,15024,-1,0.032562546,0.9674375
15025,gall stones,3,5,21,32,"Chemical analysis of gall stones retrieved at cholecystectomy from two patients, showed that they contained 71% and 87% cholesterol by weight.",7890216_3,-1,-1,-1,15025,-1,0.17809136,0.8219086
15031,ursodeoxycholic acid,7,9,39,59,"Of the 12 patients considered for oral ursodeoxycholic acid (UDCA) treatment, two had a blocked cystic duct and were not started on UDCA while one was lost to follow up.",7890216_7,-1,-1,-1,15031,-1,0.99905676,0.00094330334
15032,UDCA,10,11,61,65,"Of the 12 patients considered for oral ursodeoxycholic acid (UDCA) treatment, two had a blocked cystic duct and were not started on UDCA while one was lost to follow up.",7890216_7,-1,-1,-1,15032,-1,0.9988048,0.0011951944
15033,UDCA,25,26,132,136,"Of the 12 patients considered for oral ursodeoxycholic acid (UDCA) treatment, two had a blocked cystic duct and were not started on UDCA while one was lost to follow up.",7890216_7,-1,-1,-1,15033,-1,0.9988971,0.001102941
15034,n,16,17,88,89,"After one year of treatment, five of the remaining nine patients showed either partial (n = 3) or complete (n = 2) gall stone dissolution, suggesting that their stones were cholesterol rich.",7890216_8,-1,-1,-1,15034,-1,0.113300964,0.886699
15035,n,23,24,108,109,"After one year of treatment, five of the remaining nine patients showed either partial (n = 3) or complete (n = 2) gall stone dissolution, suggesting that their stones were cholesterol rich.",7890216_8,-1,-1,-1,15035,-1,0.11201673,0.88798326
15036,gall stone,27,29,115,125,"After one year of treatment, five of the remaining nine patients showed either partial (n = 3) or complete (n = 2) gall stone dissolution, suggesting that their stones were cholesterol rich.",7890216_8,-1,-1,-1,15036,-1,0.2915738,0.70842624
15038,gall stone,14,16,68,78,"This corresponds, by actuarial (life table) analysis, to a combined gall stone dissolution rate of 58.3 (15.9%).",7890216_9,-1,-1,-1,15038,-1,0.8475306,0.15246941
15040,gall stones,5,7,34,45,"In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.",7890216_10,-1,-1,-1,15040,-1,0.017829522,0.98217046
15042,gall stone disease,22,25,135,153,"In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.",7890216_10,-1,-1,-1,15042,-1,0.007794637,0.9922053
15043,gall stones,38,40,226,237,"In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.",7890216_10,-1,-1,-1,15043,-1,0.008652349,0.9913476
15045,SC-48334,8,9,65,73,"The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.",7905523_0,-1,-1,-1,15045,-1,0.9964019,0.0035981268
15047,HIV-1 infection,15,17,107,122,"The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.",7905523_0,-1,-1,-1,15047,-1,0.042265024,0.95773494
15048,SC-48334,43,44,294,302,"The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.",7905523_0,-1,-1,-1,15048,-1,0.9960335,0.0039665443
15052,SC-48334,19,20,106,114,Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo.,7905523_1,-1,-1,-1,15052,-1,0.9983234,0.0016766565
15053,mg,22,23,121,123,Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo.,7905523_1,-1,-1,-1,15053,-1,0.90020335,0.0997966
15054,h,25,26,132,133,Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo.,7905523_1,-1,-1,-1,15054,-1,0.90803796,0.09196206
15056,mg,31,32,155,157,Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo.,7905523_1,-1,-1,-1,15056,-1,0.8694083,0.13059168
15057,h,34,35,166,167,Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo.,7905523_1,-1,-1,-1,15057,-1,0.8537628,0.14623722
15061,p,25,26,120,121,"Twenty-three patients (38%) and 15 (26%), in the combination and zidovudine groups, respectively, discontinued therapy (p = 0.15).",7905523_3,-1,-1,-1,15061,-1,0.3166421,0.6833579
15062,SC-48334,2,3,9,17,The mean SC-48334 steady-state trough level (4.04 +/- 0.99 micrograms/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV).,7905523_4,-1,-1,-1,15062,-1,0.9973347,0.002665263
15063,human immunodeficiency virus,21,24,126,154,The mean SC-48334 steady-state trough level (4.04 +/- 0.99 micrograms/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV).,7905523_4,-1,-1,-1,15063,-1,0.20878945,0.79121053
15065,p,24,25,136,137,"The mean increase in CD4 cells at week 4 was 73.8 cells/mm3 and 52.4 cells/mm3 for the combination and zidovudine groups, respectively (p > 0.36).",7905523_5,-1,-1,-1,15065,-1,0.36082202,0.63917804
15069,p,32,33,143,144,"The number of patients with suppression of HIV p24 antigenemia in the combination and zidovudine groups was six (40%) and two (11%) at week 4 (p = 0.10) and five (45%) and two (14%) at week 24 (p = 0.08), respectively.",7905523_7,-1,-1,-1,15069,-1,0.26688904,0.73311096
15070,p,52,53,194,195,"The number of patients with suppression of HIV p24 antigenemia in the combination and zidovudine groups was six (40%) and two (11%) at week 4 (p = 0.10) and five (45%) and two (14%) at week 24 (p = 0.08), respectively.",7905523_7,-1,-1,-1,15070,-1,0.20300326,0.7969967
15071,flatulence,2,3,10,20,"Diarrhea, flatulence, abdominal pain, and weight loss were common for combination recipients.(ABSTRACT TRUNCATED AT 250 WORDS)",7905523_8,-1,-1,-1,15071,-1,0.0038783646,0.9961216
15072,abdominal pain,4,6,22,36,"Diarrhea, flatulence, abdominal pain, and weight loss were common for combination recipients.(ABSTRACT TRUNCATED AT 250 WORDS)",7905523_8,-1,-1,-1,15072,-1,0.0029762718,0.99702376
15073,weight loss,8,10,42,53,"Diarrhea, flatulence, abdominal pain, and weight loss were common for combination recipients.(ABSTRACT TRUNCATED AT 250 WORDS)",7905523_8,-1,-1,-1,15073,-1,0.006111646,0.99388844
15075,nondepolarizing neuromuscular blocking agents,4,8,27,72,Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids.,7910951_0,-1,-1,-1,15075,-1,0.9914635,0.0085364655
15077,nondepolarizing neuromuscular blocking agents,4,8,21,66,"The long-term use of nondepolarizing neuromuscular blocking agents (ND-NMBA) has recently been implicated as a cause of prolonged muscle weakness, although the site of the lesion and the predisposing factors have been unclear.",7910951_1,-1,-1,-1,15077,-1,0.9885417,0.011458281
15078,muscle weakness,20,22,130,145,"The long-term use of nondepolarizing neuromuscular blocking agents (ND-NMBA) has recently been implicated as a cause of prolonged muscle weakness, although the site of the lesion and the predisposing factors have been unclear.",7910951_1,-1,-1,-1,15078,-1,0.0030961288,0.99690384
15079,respiratory insufficiency,13,15,50,75,We report 3 patients (age 37-52 years) with acute respiratory insufficiency who developed prolonged weakness following the discontinuation of ND-NMBAs.,7910951_2,-1,-1,-1,15079,-1,0.0024418996,0.9975581
15083,vecuronium,2,3,10,20,"The serum vecuronium level measured in 1 patient 14 days after the drug had been discontinued was 172 ng/mL. A muscle biopsy in this patient showed loss of thick, myosin filaments.",7910951_7,-1,-1,-1,15083,-1,0.9994168,0.0005831531
15085,pathology at both the neuromuscular junction,8,14,41,85,The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to corticosteroids).,7910951_8,-1,-1,-1,15085,-1,0.012480859,0.98751915
15088,Erythema multiforme,0,2,0,19,Erythema multiforme and hypersensitivity myocarditis caused by ampicillin.,7919560_0,-1,-1,-1,15088,-1,0.004377423,0.9956226
15089,hypersensitivity myocarditis,3,5,24,52,Erythema multiforme and hypersensitivity myocarditis caused by ampicillin.,7919560_0,-1,-1,-1,15089,-1,0.0025460422,0.997454
15091,erythema multiforme,7,9,31,50,OBJECTIVE: To report a case of erythema multiforme and hypersensitivity myocarditis caused by ampicillin.,7919560_1,-1,-1,-1,15091,-1,0.004856938,0.99514306
15092,hypersensitivity myocarditis,10,12,55,83,OBJECTIVE: To report a case of erythema multiforme and hypersensitivity myocarditis caused by ampicillin.,7919560_1,-1,-1,-1,15092,-1,0.0023138402,0.99768615
15096,septicemia,15,16,96,106,CASE SUMMARY: A 13-year-old boy was treated with ampicillin and gentamicin because of suspected septicemia.,7919560_2,-1,-1,-1,15096,-1,0.0022418993,0.9977581
15097,erythema multiforme,4,6,35,54,Medications were discontinued when erythema multiforme and congestive heart failure caused by myocarditis occurred.,7919560_3,-1,-1,-1,15097,-1,0.005747676,0.99425226
15098,congestive heart failure,7,10,59,83,Medications were discontinued when erythema multiforme and congestive heart failure caused by myocarditis occurred.,7919560_3,-1,-1,-1,15098,-1,0.0028132924,0.9971867
15103,erythema multiforme,6,8,42,61,"DISCUSSION: After most infections causing erythema multiforme and myocarditis were ruled out, a drug-induced allergic reaction was suspected.",7919560_6,-1,-1,-1,15103,-1,0.0046820357,0.99531794
15108,Hypersensitivity myocarditis,2,4,13,41,CONCLUSIONS: Hypersensitivity myocarditis is a rare and dangerous manifestation of allergy to penicillins.,7919560_8,-1,-1,-1,15108,-1,0.0029669474,0.997033
15109,allergy,11,12,83,90,CONCLUSIONS: Hypersensitivity myocarditis is a rare and dangerous manifestation of allergy to penicillins.,7919560_8,-1,-1,-1,15109,-1,0.004044653,0.99595535
15110,penicillins,13,14,94,105,CONCLUSIONS: Hypersensitivity myocarditis is a rare and dangerous manifestation of allergy to penicillins.,7919560_8,-1,-1,-1,15110,-1,0.998021,0.0019789508
15111,sleep disturbance,1,3,21,38,Clomipramine-induced sleep disturbance does not impair its prolactin-releasing action.,7930386_0,-1,-1,-1,15111,-1,0.0026085095,0.99739146
15112,sleep disturbance,10,12,56,73,"The present study was undertaken to examine the role of sleep disturbance, induced by clomipramine administration, on the secretory rate of prolactin (PRL) in addition to the direct drug effect.",7930386_1,-1,-1,-1,15112,-1,0.004127538,0.99587244
15114,PRL,25,26,151,154,"The present study was undertaken to examine the role of sleep disturbance, induced by clomipramine administration, on the secretory rate of prolactin (PRL) in addition to the direct drug effect.",7930386_1,-1,-1,-1,15114,-1,0.99263084,0.007369152
15115,n,19,20,117,118,"Two groups of supine subjects were studied under placebo-controlled conditions, one during the night, when sleeping (n = 7) and the other at daytime, when awake (n = 6).",7930386_2,-1,-1,-1,15115,-1,0.21521214,0.78478783
15116,n,32,33,162,163,"Two groups of supine subjects were studied under placebo-controlled conditions, one during the night, when sleeping (n = 7) and the other at daytime, when awake (n = 6).",7930386_2,-1,-1,-1,15116,-1,0.1953593,0.8046407
15117,mg,6,7,34,36,Each subject received a single 50 mg dose of clomipramine given orally 2 hours before blood collection.,7930386_3,-1,-1,-1,15117,-1,0.973637,0.026363028
15119,PRL,1,2,7,10,Plasma PRL concentrations were analysed at 10 min intervals and underlying secretory rates calculated by a deconvolution procedure.,7930386_4,-1,-1,-1,15119,-1,0.9977658,0.0022341923
15120,PRL,11,12,69,72,"For both experiments the drug intake led to significant increases in PRL secretion, acting preferentially on tonic secretion as pulse amplitude and frequency did not differ significantly from corresponding control values.",7930386_5,-1,-1,-1,15120,-1,0.9971576,0.002842388
15122,PRL,5,6,28,31,"As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies (46 +/- 19% vs 34 +/- 10%), it can be concluded that the observed sleep disturbance did not interfere with the drug action per se.",7930386_7,-1,-1,-1,15122,-1,0.9959622,0.004037832
15123,sleep disturbance,46,48,214,231,"As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies (46 +/- 19% vs 34 +/- 10%), it can be concluded that the observed sleep disturbance did not interfere with the drug action per se.",7930386_7,-1,-1,-1,15123,-1,0.005400652,0.99459934
15124,se,56,57,275,277,"As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies (46 +/- 19% vs 34 +/- 10%), it can be concluded that the observed sleep disturbance did not interfere with the drug action per se.",7930386_7,-1,-1,-1,15124,-1,0.1912585,0.8087415
15126,indocyanine green,4,6,27,44,Survey of complications of indocyanine green angiography in Japan.,7977601_0,-1,-1,-1,15126,-1,0.99873143,0.0012686031
15127,indocyanine green,7,9,36,53,PURPOSE: We evaluated the safety of indocyanine green for use in fundus angiography.,7977601_1,-1,-1,-1,15127,-1,0.99894446,0.0010555394
15128,indocyanine green,9,11,61,78,"METHODS: We sent a questionnaire concerning complications of indocyanine green to 32 institutions in Japan, which were selected on the basis of the client list from the Topcon Company, which manufactures the indocyanine green fundus camera.",7977601_2,-1,-1,-1,15128,-1,0.9990938,0.0009062445
15129,indocyanine green,35,37,208,225,"METHODS: We sent a questionnaire concerning complications of indocyanine green to 32 institutions in Japan, which were selected on the basis of the client list from the Topcon Company, which manufactures the indocyanine green fundus camera.",7977601_2,-1,-1,-1,15129,-1,0.99888486,0.0011151534
15130,indocyanine green,13,15,83,100,"RESULTS: Ophthalmologists at 15 institutions responded, reporting a total of 3,774 indocyanine green angiograms performed on 2,820 patients between June 1984 and September 1992.",7977601_3,-1,-1,-1,15130,-1,0.9987056,0.0012943891
15131,indocyanine green,6,8,47,64,"Before angiography, intradermal or intravenous indocyanine green testing, or both was performed at 13 of 15 institutions.",7977601_4,-1,-1,-1,15131,-1,0.9988715,0.0011284158
15132,indocyanine green,3,5,14,31,"The dosage of indocyanine green used for angiography varied from 25 to 75 mg, depending upon the institution.",7977601_6,-1,-1,-1,15132,-1,0.999,0.0009999712
15133,mg,13,14,74,76,"The dosage of indocyanine green used for angiography varied from 25 to 75 mg, depending upon the institution.",7977601_6,-1,-1,-1,15133,-1,0.97240776,0.027592255
15135,exanthema,22,23,99,108,"There were 13 cases of adverse reactions (0.34%), ten of which were mild reactions such as nausea, exanthema, urtication, itchiness, and urgency to defecate, and did not require treatment.",7977601_7,-1,-1,-1,15135,-1,0.007569074,0.992431
15136,urtication,24,25,110,120,"There were 13 cases of adverse reactions (0.34%), ten of which were mild reactions such as nausea, exanthema, urtication, itchiness, and urgency to defecate, and did not require treatment.",7977601_7,-1,-1,-1,15136,-1,0.00853679,0.99146324
15137,itchiness,26,27,122,131,"There were 13 cases of adverse reactions (0.34%), ten of which were mild reactions such as nausea, exanthema, urtication, itchiness, and urgency to defecate, and did not require treatment.",7977601_7,-1,-1,-1,15137,-1,0.12185495,0.87814504
15142,indocyanine green,10,12,63,80,CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is a safe as fluorescein for use in angiography.,7977601_10,-1,-1,-1,15142,-1,0.99909127,0.0009086905
15143,fluorescein sodium,21,23,141,159,CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is a safe as fluorescein for use in angiography.,7977601_10,-1,-1,-1,15143,-1,0.99872655,0.0012734607
15144,indocyanine green,25,27,175,192,CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is a safe as fluorescein for use in angiography.,7977601_10,-1,-1,-1,15144,-1,0.99909866,0.0009013648
15147,pulmonary edema,12,14,62,77,"A 72-year-old woman was admitted to the hospital with ""flash"" pulmonary edema, preceded by chest pain, requiring intubation.",7988234_1,-1,-1,-1,15147,-1,0.0025355236,0.9974644
15148,chest pain,17,19,91,101,"A 72-year-old woman was admitted to the hospital with ""flash"" pulmonary edema, preceded by chest pain, requiring intubation.",7988234_1,-1,-1,-1,15148,-1,0.002828105,0.99717194
15149,coronary artery disease,4,7,29,52,"Her medical history included coronary artery disease with previous myocardial infarctions, hypertension, and diabetes mellitus.",7988234_2,-1,-1,-1,15149,-1,0.008320067,0.99167997
15150,myocardial infarctions,9,11,67,89,"Her medical history included coronary artery disease with previous myocardial infarctions, hypertension, and diabetes mellitus.",7988234_2,-1,-1,-1,15150,-1,0.014048877,0.9859511
15152,diabetes mellitus,15,17,109,126,"Her medical history included coronary artery disease with previous myocardial infarctions, hypertension, and diabetes mellitus.",7988234_2,-1,-1,-1,15152,-1,0.004253751,0.9957463
15154,lisinopril,6,7,37,47,A history of angioedema secondary to lisinopril therapy was elicited.,7988234_3,-1,-1,-1,15154,-1,0.99894434,0.0010556203
15155,enzyme inhibitors,6,8,59,76,Current medications did not include angiotensin-converting enzyme inhibitors or beta-blockers.,7988234_4,-1,-1,-1,15155,-1,0.9879758,0.012024267
15160,diphenhydramine,9,10,68,83,The angioedema resolved after therapy with intravenous steroids and diphenhydramine hydrochloride.,7988234_7,-1,-1,-1,15160,-1,0.9990792,0.00092069904
15169,water intoxication,3,5,14,32,Four cases of water intoxication in connection with oxytocin administration during saline-induced abortions are described.,803783_1,-1,-1,-1,15169,-1,0.045766443,0.9542335
15171,abortions,12,13,98,107,Four cases of water intoxication in connection with oxytocin administration during saline-induced abortions are described.,803783_1,-1,-1,-1,15171,-1,0.0029451782,0.9970548
15172,water intoxication,3,5,17,35,The mechanism of water intoxication is discussed in regard to these cases.,803783_2,-1,-1,-1,15172,-1,0.047459994,0.95254
15173,abortions,4,5,52,61,"Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.",803783_3,-1,-1,-1,15173,-1,0.004132573,0.9958675
15174,water intoxication,28,30,184,202,"Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.",803783_3,-1,-1,-1,15174,-1,0.054502897,0.9454971
15175,asthenia,45,46,287,295,"Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.",803783_3,-1,-1,-1,15175,-1,0.0028882623,0.9971117
15177,headaches,51,52,323,332,"Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.",803783_3,-1,-1,-1,15177,-1,0.0028260993,0.9971739
15179,lactate,8,9,45,52,"The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions.",803783_4,-1,-1,-1,15179,-1,0.99660563,0.003394384
15180,lactate,15,16,81,88,"The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions.",803783_4,-1,-1,-1,15180,-1,0.9954364,0.004563628
15181,dextrose,21,22,106,114,"The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions.",803783_4,-1,-1,-1,15181,-1,0.9982645,0.0017354878
15192,tuberculous,8,9,35,46,as well as of those of seven other tuberculous patients.,804391_4,-1,-1,-1,15192,-1,0.010048174,0.9899518
15194,KF17837,0,1,0,7,KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.,8045270_0,-1,-1,-1,15194,-1,0.99438983,0.005610172
15196,KF17837,0,1,0,7,KF17837 is a novel selective adenosine A2A receptor antagonist.,8045270_1,-1,-1,-1,15196,-1,0.9983359,0.0016641087
15198,KF17837,3,4,23,30,"Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.",8045270_2,-1,-1,-1,15198,-1,0.9983694,0.0016306544
15199,cataleptic,15,16,88,98,"Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.",8045270_2,-1,-1,-1,15199,-1,0.019957231,0.9800427
15200,CGS 21680,28,30,197,206,"Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.",8045270_2,-1,-1,-1,15200,-1,0.99833363,0.0016663449
15204,KF17837,2,3,10,17,"Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.).",8045270_5,-1,-1,-1,15204,-1,0.99655616,0.0034438332
15205,"L-3,4-dihydroxyphenylalanine",18,19,102,130,"Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.).",8045270_5,-1,-1,-1,15205,-1,0.9967955,0.0032044793
15206,benserazide,28,29,160,171,"Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.).",8045270_5,-1,-1,-1,15206,-1,0.9987999,0.0012000941
15207,KF17837,4,5,29,36,These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists.,8045270_6,-1,-1,-1,15207,-1,0.9986374,0.0013626087
15210,KF17837,2,3,13,20,"Furthermore, KF17837 may be a useful drug in the treatment of parkinsonism.",8045270_7,-1,-1,-1,15210,-1,0.99806076,0.0019392152
15214,teratogenic,17,18,82,93,"Coniine, an alkaloid from Conium maculatum (poison hemlock), has been shown to be teratogenic in livestock.",8073369_1,-1,-1,-1,15214,-1,0.003600312,0.99639964
15215,teratogenic,2,3,10,21,"The major teratogenic outcome is arthrogryposis, presumably due to nicotinic receptor blockade.",8073369_2,-1,-1,-1,15215,-1,0.002796518,0.99720347
15216,arthrogryposis,5,6,33,47,"The major teratogenic outcome is arthrogryposis, presumably due to nicotinic receptor blockade.",8073369_2,-1,-1,-1,15216,-1,0.0031173772,0.9968827
15218,arthrogryposis,7,8,39,53,"However, coniine has failed to produce arthrogryposis in rats or mice and is only weakly teratogenic in rabbits.",8073369_3,-1,-1,-1,15218,-1,0.0027384004,0.99726164
15219,teratogenic,16,17,89,100,"However, coniine has failed to produce arthrogryposis in rats or mice and is only weakly teratogenic in rabbits.",8073369_3,-1,-1,-1,15219,-1,0.003401479,0.99659854
15224,deformations,3,4,22,34,Both compounds caused deformations and lethality in a dose-dependent manner.,8073369_6,-1,-1,-1,15224,-1,0.0029850465,0.997015
15225,nicotine sulfate,3,5,22,38,All concentrations of nicotine sulfate caused some lethality but a no effect level for coniine lethality was 0.75%.,8073369_7,-1,-1,-1,15225,-1,0.99856514,0.0014348768
15227,deformations,1,2,4,16,The deformations caused by both coniine and nicotine sulfate were excessive flexion or extension of one or more toes.,8073369_8,-1,-1,-1,15227,-1,0.003068378,0.99693155
15230,excessive flexion or extension of one or more toes,10,19,66,116,The deformations caused by both coniine and nicotine sulfate were excessive flexion or extension of one or more toes.,8073369_8,-1,-1,-1,15230,-1,0.014098156,0.98590183
15231,cranial hemorrhage,25,27,146,164,"No histopathological alterations or differences in bone formation were seen in the limbs or toes of any chicks from any group; however, extensive cranial hemorrhage occurred in all nicotine sulfate-treated chicks.",8073369_9,-1,-1,-1,15231,-1,0.0039164415,0.9960835
15233,P,6,7,39,40,There was a statistically significant (P < or = 0.01) decrease in movement in coniine and nicotine sulfate treated chicks as determined by ultrasound.,8073369_10,-1,-1,-1,15233,-1,0.28409603,0.715904
15237,arthrogryposis,16,17,105,119,"In summary, the chick embryo provides a reliable and simple experimental animal model of coniine-induced arthrogryposis.",8073369_12,-1,-1,-1,15237,-1,0.0024917496,0.99750817
15241,allergic,27,28,159,167,"A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.",8092427_2,-1,-1,-1,15241,-1,0.005843242,0.9941567
15242,allergic,34,35,219,227,"A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.",8092427_2,-1,-1,-1,15242,-1,0.003464197,0.9965358
15244,AX,39,40,254,256,"A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.",8092427_2,-1,-1,-1,15244,-1,0.9979838,0.002016147
15246,benzylpenicilloyl-poly-L-lysine,5,6,31,62,"Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ampicillin (AMP), and AX.",8092427_3,-1,-1,-1,15246,-1,0.99600875,0.0039912374
15247,benzylpenicilloate,10,11,74,92,"Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ampicillin (AMP), and AX.",8092427_3,-1,-1,-1,15247,-1,0.9982926,0.0017074188
15248,benzylpenicillin,12,13,94,110,"Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ampicillin (AMP), and AX.",8092427_3,-1,-1,-1,15248,-1,0.9979907,0.002009338
15249,PG,14,15,112,114,"Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ampicillin (AMP), and AX.",8092427_3,-1,-1,-1,15249,-1,0.99649245,0.0035074875
15251,AMP,19,20,129,132,"Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ampicillin (AMP), and AX.",8092427_3,-1,-1,-1,15251,-1,0.99457055,0.005429402
15252,AX,23,24,139,141,"Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ampicillin (AMP), and AX.",8092427_3,-1,-1,-1,15252,-1,0.99715364,0.002846314
15253,BPO,7,8,33,36,"When both skin test and RAST for BPO were negative, single-blind, placebo-controlled challenge tests were done to ensure tolerance of PG or sensitivity to AX.",8092427_5,-1,-1,-1,15253,-1,0.9979068,0.0020932509
15254,PG,22,23,134,136,"When both skin test and RAST for BPO were negative, single-blind, placebo-controlled challenge tests were done to ensure tolerance of PG or sensitivity to AX.",8092427_5,-1,-1,-1,15254,-1,0.9982665,0.0017335411
15255,AX,26,27,155,157,"When both skin test and RAST for BPO were negative, single-blind, placebo-controlled challenge tests were done to ensure tolerance of PG or sensitivity to AX.",8092427_5,-1,-1,-1,15255,-1,0.9984327,0.0015673217
15256,allergic,8,9,42,50,A total of 177 patients were diagnosed as allergic to beta-lactam antibiotics.,8092427_6,-1,-1,-1,15256,-1,0.004802227,0.99519783
15257,AX allergy,11,13,46,56,We selected the 54 (30.5%) cases of immediate AX allergy with good tolerance of PG.,8092427_7,-1,-1,-1,15257,-1,0.21151122,0.78848875
15258,PG,17,18,80,82,We selected the 54 (30.5%) cases of immediate AX allergy with good tolerance of PG.,8092427_7,-1,-1,-1,15258,-1,0.9863268,0.013673185
15262,BPO,8,9,44,47,"All the patients were skin test negative to BPO; 49 of 51 (96%) were also negative to MDM, and 44 of 46 (96%) to PG.",8092427_9,-1,-1,-1,15262,-1,0.99749064,0.0025093812
15263,MDM,21,22,86,89,"All the patients were skin test negative to BPO; 49 of 51 (96%) were also negative to MDM, and 44 of 46 (96%) to PG.",8092427_9,-1,-1,-1,15263,-1,0.9978079,0.0021920518
15264,PG,32,33,113,115,"All the patients were skin test negative to BPO; 49 of 51 (96%) were also negative to MDM, and 44 of 46 (96%) to PG.",8092427_9,-1,-1,-1,15264,-1,0.9972957,0.0027043421
15265,AX,3,4,16,18,Skin tests with AX were positive in 34 (63%) patients.,8092427_10,-1,-1,-1,15265,-1,0.9979527,0.002047282
15266,AX,4,5,22,24,RAST was positive for AX in 22 patients (41%) and to BPO in just 5 (9%).,8092427_11,-1,-1,-1,15266,-1,0.99734586,0.002654222
15267,BPO,14,15,53,56,RAST was positive for AX in 22 patients (41%) and to BPO in just 5 (9%).,8092427_11,-1,-1,-1,15267,-1,0.98213243,0.01786754
15268,AX,8,9,40,42,None of the sera with negative RAST for AX were positive to BPO.,8092427_12,-1,-1,-1,15268,-1,0.99773765,0.0022623579
15269,BPO,12,13,60,63,None of the sera with negative RAST for AX were positive to BPO.,8092427_12,-1,-1,-1,15269,-1,0.9968545,0.0031455606
15270,AX,3,4,21,23,"Challenge tests with AX were performed in 23 subjects (43%) to establish the diagnosis of immediate allergic reaction to AX, and in 15 cases (28%) both skin test and RAST for AX were negative.",8092427_13,-1,-1,-1,15270,-1,0.99750227,0.002497704
15272,AX,22,23,121,123,"Challenge tests with AX were performed in 23 subjects (43%) to establish the diagnosis of immediate allergic reaction to AX, and in 15 cases (28%) both skin test and RAST for AX were negative.",8092427_13,-1,-1,-1,15272,-1,0.9965934,0.003406607
15273,AX,38,39,175,177,"Challenge tests with AX were performed in 23 subjects (43%) to establish the diagnosis of immediate allergic reaction to AX, and in 15 cases (28%) both skin test and RAST for AX were negative.",8092427_13,-1,-1,-1,15273,-1,0.9971727,0.0028272092
15274,PG,0,1,0,2,PG was well tolerated by all 54 patients.,8092427_14,-1,-1,-1,15274,-1,0.9976452,0.0023547984
15275,PG,11,12,73,75,We describe the largest group of AX-allergic patients who have tolerated PG reported so far.,8092427_15,-1,-1,-1,15275,-1,0.99732673,0.0026732206
15284,myocardial infarctions,5,7,35,57,"Ten patients with acute transmural myocardial infarctions received intravenous nitroglycerin, sufficient to reduce mean arterial pressure from 107 +/- 6 to 85 +/- 6 mm Hg (P less than 0.001), for 60 minutes.",809711_3,-1,-1,-1,15284,-1,0.0039561135,0.9960439
15286,mm Hg,27,29,165,170,"Ten patients with acute transmural myocardial infarctions received intravenous nitroglycerin, sufficient to reduce mean arterial pressure from 107 +/- 6 to 85 +/- 6 mm Hg (P less than 0.001), for 60 minutes.",809711_3,-1,-1,-1,15286,-1,0.4866501,0.51334995
15287,P,30,31,172,173,"Ten patients with acute transmural myocardial infarctions received intravenous nitroglycerin, sufficient to reduce mean arterial pressure from 107 +/- 6 to 85 +/- 6 mm Hg (P less than 0.001), for 60 minutes.",809711_3,-1,-1,-1,15287,-1,0.5348075,0.46519247
15288,mm Hg,15,17,70,75,Left ventricular filling pressure decreased from 19 +/- 2 to 11 +/- 2 mm Hg (P less than 0.001).,809711_4,-1,-1,-1,15288,-1,0.24909507,0.7509049
15289,P,18,19,77,78,Left ventricular filling pressure decreased from 19 +/- 2 to 11 +/- 2 mm Hg (P less than 0.001).,809711_4,-1,-1,-1,15289,-1,0.41131034,0.5886896
15290,P,14,15,77,78,"SigmaST, the sum of ST-segment elevations in 16 precordial leads, decreased (P less than 0.02) with intravenous nitroglycerin.",809711_5,-1,-1,-1,15290,-1,0.4259919,0.5740081
15293,mm Hg,17,19,108,113,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,-1,-1,-1,15293,-1,0.28670236,0.71329767
15294,P,20,21,115,116,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,-1,-1,-1,15294,-1,0.4770985,0.5229015
15295,mm Hg,39,41,206,211,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,-1,-1,-1,15295,-1,0.14213154,0.85786843
15296,P,42,43,213,214,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,-1,-1,-1,15296,-1,0.3356936,0.6643064
15297,P,53,54,273,274,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,-1,-1,-1,15297,-1,0.27328777,0.7267122
15303,MPTP,11,12,65,69,A group of four monkeys was rendered parkinsonian with the toxin MPTP.,8106150_1,-1,-1,-1,15303,-1,0.9986272,0.0013728028
15306,dyskinetic movements,22,24,135,155,A series of agents acting primarily on neurotransmitters other than dopamine were then tested in combination with L-DOPA to see if the dyskinetic movements would be modified.,8106150_4,-1,-1,-1,15306,-1,0.0025044826,0.9974955
15308,physostigmine,6,7,36,49,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,-1,-1,-1,15308,-1,0.9990827,0.0009173498
15309,methysergide,8,9,51,63,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,-1,-1,-1,15309,-1,0.99914765,0.0008523612
15310,5-MDOT,10,11,65,71,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,-1,-1,-1,15310,-1,0.9979373,0.0020627545
15312,MK-801,15,16,90,96,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,-1,-1,-1,15312,-1,0.9975407,0.0024592807
15313,dyskinetic movements,20,22,119,139,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,-1,-1,-1,15313,-1,0.0023219383,0.9976781
15316,meperidine,4,5,23,33,"However, yohimbine and meperidine reduced predominantly the dyskinetic movements.",8106150_6,-1,-1,-1,15316,-1,0.99924445,0.000755528
15317,dyskinetic movements,8,10,60,80,"However, yohimbine and meperidine reduced predominantly the dyskinetic movements.",8106150_6,-1,-1,-1,15317,-1,0.0024036842,0.9975963
15318,Baclofen,0,1,0,8,Baclofen was also useful in one monkey against a more dystonic form of dyskinesia.,8106150_7,-1,-1,-1,15318,-1,0.99924433,0.0007556345
15319,dystonic,10,11,54,62,Baclofen was also useful in one monkey against a more dystonic form of dyskinesia.,8106150_7,-1,-1,-1,15319,-1,0.0022366385,0.9977634
15322,dystonic movements,3,5,23,41,Atropine converted the dystonic movements into chorea.,8106150_8,-1,-1,-1,15322,-1,0.002359087,0.99764097
15323,chorea,6,7,47,53,Atropine converted the dystonic movements into chorea.,8106150_8,-1,-1,-1,15323,-1,0.0023904324,0.9976096
15337,hallucinatory,22,23,148,161,"The clinician should be alerted for possible ifosfamide-induced hallucinations, which may occur without other signs of neurotoxicity. ""Eyes-closed"" hallucinatory experiences appear to be an unusual feature of this presentation.",8111719_9,-1,-1,-1,15337,-1,0.0037171463,0.9962829
15339,neuroleptics,6,7,42,54,"If agitation becomes marked, high-potency neuroleptics (i.e., haloperidol) may be effective.",8111719_12,-1,-1,-1,15339,-1,0.9983955,0.0016044712
15342,neuromuscular disorders,7,9,69,92,Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders.,8170551_0,-1,-1,-1,15342,-1,0.0030982443,0.99690175
15345,myotonia,14,15,109,117,We studied 20 patients receiving long-term carbonic anhydrase inhibitor treatment for periodic paralysis and myotonia.,8170551_2,-1,-1,-1,15345,-1,0.00218058,0.9978194
15346,acetazolamide,3,4,18,31,Three patients on acetazolamide (15%) developed renal calculi.,8170551_3,-1,-1,-1,15346,-1,0.99932766,0.0006723544
15347,renal calculi,9,11,48,61,Three patients on acetazolamide (15%) developed renal calculi.,8170551_3,-1,-1,-1,15347,-1,0.0028863568,0.9971136
15348,calculus,6,7,56,64,"Extracorporeal lithotripsy successfully removed a renal calculus in one patient and surgery removed a staghorn calculus in another, permitting continued treatment.",8170551_4,-1,-1,-1,15348,-1,0.005382523,0.9946175
15349,calculus,15,16,111,119,"Extracorporeal lithotripsy successfully removed a renal calculus in one patient and surgery removed a staghorn calculus in another, permitting continued treatment.",8170551_4,-1,-1,-1,15349,-1,0.0064654127,0.99353456
15351,acetazolamide,5,6,37,50,Nephrolithiasis is a complication of acetazolamide but does not preclude its use.,8170551_6,-1,-1,-1,15351,-1,0.9994246,0.0005754785
15352,calcium channel blockers,2,5,11,35,Effects of calcium channel blockers on bupivacaine-induced toxicity.,8231633_0,-1,-1,-1,15352,-1,0.9936864,0.006313677
15355,blockers,13,14,78,86,The purpose of this study was to investigate the influence of calcium channel blockers on bupivacaine-induced acute toxicity.,8231633_1,-1,-1,-1,15355,-1,0.9942339,0.00576606
15357,calcium channel blockers,6,9,29,53,"For each of the three tested calcium channel blockers (diltiazem, verapamil and bepridil) 6 groups of mice were treated by two different doses, i.e. 2 and 10 mg/kg/i.p., or an equal volume of saline for the control group (n = 20); 15 minutes later, all the animals were injected with a single 50 mg/kg/i.p.",8231633_2,-1,-1,-1,15357,-1,0.979783,0.020217026
15361,n,45,46,222,223,"For each of the three tested calcium channel blockers (diltiazem, verapamil and bepridil) 6 groups of mice were treated by two different doses, i.e. 2 and 10 mg/kg/i.p., or an equal volume of saline for the control group (n = 20); 15 minutes later, all the animals were injected with a single 50 mg/kg/i.p.",8231633_2,-1,-1,-1,15361,-1,0.19026463,0.8097354
15363,calcium channel blockers,11,14,90,114,The local anesthetic-induced mortality was significantly increased by the three different calcium channel blockers.,8231633_5,-1,-1,-1,15363,-1,0.9932296,0.0067703566
15366,blockers,12,13,90,98,The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced convulsions; this effect was less pronounced with bepridil.,8231633_6,-1,-1,-1,15366,-1,0.98879784,0.011202202
15369,telangiectasia,3,4,43,57,Photodistributed nifedipine-induced facial telangiectasia.,8251368_0,-1,-1,-1,15369,-1,0.0031505018,0.9968495
15371,Adalat,6,7,39,45,"Five months after starting nifedipine (Adalat), two patients developed photodistributed facial telangiectasia, which became more noticeable with time.",8251368_1,-1,-1,-1,15371,-1,0.9983322,0.0016678507
15372,telangiectasia,14,15,95,109,"Five months after starting nifedipine (Adalat), two patients developed photodistributed facial telangiectasia, which became more noticeable with time.",8251368_1,-1,-1,-1,15372,-1,0.0031633275,0.99683666
15373,flushing,6,7,50,58,Neither patient complained of photosensitivity or flushing.,8251368_2,-1,-1,-1,15373,-1,0.05005883,0.9499411
15374,amlodipine,6,7,39,49,"One commenced the closely related drug amlodipine 3 years later, with recurrence of telangiectasia.",8251368_4,-1,-1,-1,15374,-1,0.99935454,0.0006454314
15375,telangiectasia,14,15,84,98,"One commenced the closely related drug amlodipine 3 years later, with recurrence of telangiectasia.",8251368_4,-1,-1,-1,15375,-1,0.0034885756,0.9965114
15376,telangiectasia,4,5,29,43,The photodistribution of the telangiectasia suggests a significant drug/light interaction.,8251368_5,-1,-1,-1,15376,-1,0.0035428097,0.99645716
15381,RPGN,11,12,96,100,A 67-year-old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment.,8267029_1,-1,-1,-1,15381,-1,0.003843148,0.9961569
15385,antiplatelet agents,12,14,81,100,"The patient was treated with steroid pulse, plasmapheresis, cyclophosphamide and antiplatelet agents.",8267029_4,-1,-1,-1,15385,-1,0.9875453,0.012454726
15386,RPGN,4,5,17,21,This new case of RPGN in the course of D-penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and proteinuria in these patients.,8267029_6,-1,-1,-1,15386,-1,0.0039791316,0.99602085
15388,polymyositis,3,4,10,22,A case of polymyositis in a patient with primary biliary cirrhosis treated with D-penicillamine.,8268147_0,-1,-1,-1,15388,-1,0.002988758,0.9970112
15389,primary biliary cirrhosis,8,11,41,66,A case of polymyositis in a patient with primary biliary cirrhosis treated with D-penicillamine.,8268147_0,-1,-1,-1,15389,-1,0.0055235988,0.9944764
15390,rheumatologic diseases,7,9,48,70,"Although D-penicillamine has been used for many rheumatologic diseases, toxicity limits its usefulness in many patients.",8268147_1,-1,-1,-1,15390,-1,0.0028208268,0.99717915
15392,primary biliary cirrhosis,5,8,25,50,"We report a patient with primary biliary cirrhosis, who developed polymyositis while receiving D-penicillamine therapy.",8268147_3,-1,-1,-1,15392,-1,0.0048017325,0.9951983
15393,polymyositis,11,12,66,78,"We report a patient with primary biliary cirrhosis, who developed polymyositis while receiving D-penicillamine therapy.",8268147_3,-1,-1,-1,15393,-1,0.003299043,0.99670094
15401,hyperesthesia,6,7,51,64,Five patients developed universal hyperalgesia and hyperesthesia which in 2 cases were accompanied by myoclonus.,8278214_3,-1,-1,-1,15401,-1,0.0025008875,0.99749905
15406,prostaglandin E1,4,6,27,43,Epidural blood flow during prostaglandin E1 or trimethaphan induced hypotension.,8302922_0,-1,-1,-1,15406,-1,0.99777764,0.0022223464
15407,trimethaphan,7,8,47,59,Epidural blood flow during prostaglandin E1 or trimethaphan induced hypotension.,8302922_0,-1,-1,-1,15407,-1,0.9991128,0.0008871884
15409,prostaglandin E1,5,7,26,42,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,-1,-1,-1,15409,-1,0.9967064,0.0032936418
15410,PGE1),8,10,44,49,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,-1,-1,-1,15410,-1,0.9935307,0.0064693685
15411,trimethaphan,11,12,53,65,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,-1,-1,-1,15411,-1,0.9991042,0.0008957642
15412,TMP,13,14,67,70,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,-1,-1,-1,15412,-1,0.9971558,0.0028441574
15415,PGE1,7,8,47,51,"An initial dose of 0.1 microgram.kg-1.min-1 of PGE1 (15 patients), or 10 micrograms.kg-1.min-1 of TMP (15 patients) was administered intravenously after the dural opening and the dose was adjusted to maintain the mean arterial blood pressure (MAP) at about 60 mmHg.",8302922_2,-1,-1,-1,15415,-1,0.9982672,0.0017327738
15416,TMP,17,18,98,101,"An initial dose of 0.1 microgram.kg-1.min-1 of PGE1 (15 patients), or 10 micrograms.kg-1.min-1 of TMP (15 patients) was administered intravenously after the dural opening and the dose was adjusted to maintain the mean arterial blood pressure (MAP) at about 60 mmHg.",8302922_2,-1,-1,-1,15416,-1,0.9986123,0.0013877308
15417,MAP,42,43,243,246,"An initial dose of 0.1 microgram.kg-1.min-1 of PGE1 (15 patients), or 10 micrograms.kg-1.min-1 of TMP (15 patients) was administered intravenously after the dural opening and the dose was adjusted to maintain the mean arterial blood pressure (MAP) at about 60 mmHg.",8302922_2,-1,-1,-1,15417,-1,0.10231861,0.89768136
15419,PGE1,2,3,15,19,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,-1,-1,-1,15419,-1,0.99832207,0.0016778989
15420,TMP,4,5,23,26,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,-1,-1,-1,15420,-1,0.9983851,0.0016149625
15421,MAP,6,7,28,31,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,-1,-1,-1,15421,-1,0.9039813,0.09601861
15422,P,21,22,122,123,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,-1,-1,-1,15422,-1,0.38443825,0.6155617
15424,PGE1,33,34,170,174,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,-1,-1,-1,15424,-1,0.99821043,0.0017896303
15425,PGE1,5,6,27,31,"EBFF did not change during PGE1 infusion whereas in the TMP group, EBF decreased significantly at 30 and 60 min after the start of TMP (preinfusion: 45.9 +/- 13.9 ml/100g/min.",8302922_6,-1,-1,-1,15425,-1,0.9983943,0.0016057267
15426,TMP,10,11,56,59,"EBFF did not change during PGE1 infusion whereas in the TMP group, EBF decreased significantly at 30 and 60 min after the start of TMP (preinfusion: 45.9 +/- 13.9 ml/100g/min.",8302922_6,-1,-1,-1,15426,-1,0.99817336,0.0018266819
15427,TMP,25,26,131,134,"EBFF did not change during PGE1 infusion whereas in the TMP group, EBF decreased significantly at 30 and 60 min after the start of TMP (preinfusion: 45.9 +/- 13.9 ml/100g/min.",8302922_6,-1,-1,-1,15427,-1,0.99871516,0.0012848147
15428,P,10,11,35,36,30 min: 32.3 +/- 9.9 ml/100 g/min (P < 0.05).,8302922_7,-1,-1,-1,15428,-1,0.35872388,0.64127606
15429,P,10,11,33,34,60 min: 30 +/- 7.5 ml/100 g/min (P < 0.05)).,8302922_8,-1,-1,-1,15429,-1,0.29568782,0.70431215
15430,PGE1,4,5,27,31,These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF.,8302922_9,-1,-1,-1,15430,-1,0.9983291,0.0016709164
15431,TMP,9,10,53,56,These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF.,8302922_9,-1,-1,-1,15431,-1,0.99876153,0.0012385255
15433,TMP,17,18,111,114,These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF.,8302922_9,-1,-1,-1,15433,-1,0.9985092,0.0014907669
15435,Kaposi's sarcoma,4,7,35,51,Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study.,8305357_0,-1,-1,-1,15435,-1,0.011348787,0.9886513
15437,DaunoXome,18,19,112,121,We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin (DaunoXome) in the treatment of AIDS related Kaposi's sarcoma.,8305357_1,-1,-1,-1,15437,-1,0.99914277,0.0008572425
15438,AIDS,24,25,143,147,We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin (DaunoXome) in the treatment of AIDS related Kaposi's sarcoma.,8305357_1,-1,-1,-1,15438,-1,0.01749179,0.98250824
15439,Kaposi's sarcoma,26,29,156,172,We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin (DaunoXome) in the treatment of AIDS related Kaposi's sarcoma.,8305357_1,-1,-1,-1,15439,-1,0.009140982,0.990859
15440,Kaposi's sarcoma,5,8,36,52,Eleven homosexual men with advanced Kaposi's sarcoma were entered in the trial.,8305357_2,-1,-1,-1,15440,-1,0.07007181,0.9299282
15441,oedema,7,8,39,45,"Changes in size, colour and associated oedema of selected 'target' lesions were measured.",8305357_3,-1,-1,-1,15441,-1,0.0035091715,0.9964908
15443,Kaposi's sarcoma,2,5,17,33,"Stabilization of Kaposi's sarcoma occurred in the remaining six, maintained until the end of the trial period in four.",8305357_7,-1,-1,-1,15443,-1,0.038801778,0.9611983
15449,Kaposi's sarcoma,19,22,115,131,"In this small patient sample, liposomal daunorubicin was an effective and well tolerated agent in the treatment of Kaposi's sarcoma.",8305357_11,-1,-1,-1,15449,-1,0.016933644,0.9830663
15450,Dup 753,0,2,0,7,Dup 753 prevents the development of puromycin aminonucleoside-induced nephrosis.,8319760_0,-1,-1,-1,15450,-1,0.99740356,0.0025963748
15452,nephrotic syndromes,3,5,18,37,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,-1,-1,-1,15452,-1,0.0022206446,0.9977793
15454,hypoalbuminemia,9,10,59,74,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,-1,-1,-1,15454,-1,0.0044811843,0.9955188
15456,increase in blood nitrogen urea,13,18,101,132,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,-1,-1,-1,15456,-1,0.80504924,0.19495076
15457,puromycin aminonucleoside,25,27,166,191,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,-1,-1,-1,15457,-1,0.9988105,0.0011894498
15458,Dup 753,34,36,241,248,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,-1,-1,-1,15458,-1,0.99827313,0.0017268172
15461,hearing loss,9,11,72,84,Neuroplasticity of the adult primate auditory cortex following cochlear hearing loss.,8372922_0,-1,-1,-1,15461,-1,0.024681695,0.97531825
15462,hearing loss,17,19,110,122,The purpose of this study was to determine if changes occur in this tonotopic organization following cochlear hearing loss.,8372922_3,-1,-1,-1,15462,-1,0.007905877,0.9920941
15465,hearing loss,16,18,100,112,The region of cortex that represents the low frequencies was not obviously affected by the cochlear hearing loss.,8372922_10,-1,-1,-1,15465,-1,0.0058831125,0.9941169
15467,Lymphoma,5,6,34,42,Forty patients with Non-Hodgkin's Lymphoma treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system.,8384253_1,-1,-1,-1,15467,-1,0.0030478307,0.9969522
15469,mg,17,18,110,112,Forty patients with Non-Hodgkin's Lymphoma treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system.,8384253_1,-1,-1,-1,15469,-1,0.9867627,0.013237245
15471,neuropathic symptoms,7,9,47,67,The patients were interviewed with emphasis on neuropathic symptoms.,8384253_2,-1,-1,-1,15471,-1,0.003583965,0.996416
15473,neuropathic symptoms,3,5,31,51,Twenty-seven patients reported neuropathic symptoms.,8384253_4,-1,-1,-1,15473,-1,0.002891285,0.99710876
15474,signs and symptoms,4,7,26,44,In these patients sensory signs and symptoms predominated.,8384253_6,-1,-1,-1,15474,-1,0.0061148964,0.9938851
15475,Neuropathic,0,1,0,11,Neuropathic complaints were not very troublesome on the long term.,8384253_11,-1,-1,-1,15475,-1,0.0031081822,0.9968918
15477,vincristine neuropathy,15,17,94,116,It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of vincristine neuropathy are reversible for a great deal and prognosis is fairly good.,8384253_12,-1,-1,-1,15477,-1,0.9148417,0.08515832
15478,Sodium bicarbonate,0,2,0,18,Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction.,8386779_0,-1,-1,-1,15478,-1,0.99897337,0.001026685
15480,erectile dysfunction,10,12,83,103,Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction.,8386779_0,-1,-1,-1,15480,-1,0.0031633077,0.99683666
15483,sodium bicarbonate,42,44,275,293,"In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication, we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications.",8386779_1,-1,-1,-1,15483,-1,0.99879164,0.0012083702
15484,impotence,12,13,68,77,A total of 38 consecutive patients who presented to our clinic with impotence received 0.2 ml.,8386779_2,-1,-1,-1,15484,-1,0.998192,0.001807974
15485,mg,8,9,31,33,of a combination of 3 drugs: 6 mg.,8386779_3,-1,-1,-1,15485,-1,0.97609234,0.023907663
15487,phentolamine,0,1,0,12,phentolamine and 10 micrograms.,8386779_5,-1,-1,-1,15487,-1,0.99876666,0.001233388
15488,prostaglandin E1,0,2,0,16,prostaglandin E1 with (pH 7.05) or without (pH 4.17) the addition of sodium bicarbonate (0.03 mEq.).,8386779_6,-1,-1,-1,15488,-1,0.9981187,0.0018812752
15489,sodium bicarbonate,16,18,69,87,prostaglandin E1 with (pH 7.05) or without (pH 4.17) the addition of sodium bicarbonate (0.03 mEq.).,8386779_6,-1,-1,-1,15489,-1,0.99846625,0.0015337206
15490,sodium bicarbonate,5,7,27,45,"Of the 19 patients without sodium bicarbonate added to the medication 11 (58%) complained of penile pain due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of penile pain.",8386779_7,-1,-1,-1,15490,-1,0.9990945,0.0009055833
15492,sodium bicarbonate,38,40,173,191,"Of the 19 patients without sodium bicarbonate added to the medication 11 (58%) complained of penile pain due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of penile pain.",8386779_7,-1,-1,-1,15492,-1,0.9990637,0.0009363676
15497,ddI,7,8,36,39,The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.,8387218_0,-1,-1,-1,15497,-1,0.99816316,0.001836804
15499,(AZT)One,16,17,103,111,The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.,8387218_0,-1,-1,-1,15499,-1,0.87714833,0.122851625
15501,AZT,25,26,169,172,The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.,8387218_0,-1,-1,-1,15501,-1,0.9967168,0.0032831295
15503,ddI,30,31,195,198,The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.,8387218_0,-1,-1,-1,15503,-1,0.9975719,0.0024281011
15504,opportunistic infections,4,6,33,57,Seventy patients developed major opportunistic infections whilst on therapy; this was the first AIDS diagnosis in 17.,8387218_2,-1,-1,-1,15504,-1,0.0035747576,0.9964252
15505,AIDS,14,15,96,100,Seventy patients developed major opportunistic infections whilst on therapy; this was the first AIDS diagnosis in 17.,8387218_2,-1,-1,-1,15505,-1,0.010401496,0.9895985
15506,AIDS,12,13,68,72,"Only minor changes in CD4+ lymphocyte subset count were observed in AIDS patients, although a more significant rise occurred in those with earlier stages of disease.",8387218_3,-1,-1,-1,15506,-1,0.008519612,0.99148035
15508,diarrhoea,5,6,32,41,"The most common side-effect was diarrhoea, which resulted in cessation of therapy in 19 individuals.",8387218_8,-1,-1,-1,15508,-1,0.0027411412,0.9972588
15510,pancreatitis,7,8,50,62,Peripheral neuropathy occurred in 12 patients and pancreatitis in six.,8387218_9,-1,-1,-1,15510,-1,0.0024730419,0.99752694
15512,glucose tolerance curves,3,6,25,49,"Seven patients developed glucose tolerance curves characteristic of diabetes but these were mild, did not require treatment and returned to normal on ceasing didanosine.",8387218_11,-1,-1,-1,15512,-1,0.010973965,0.989026
15515,adenomas,1,2,8,16,Hepatic adenomas and focal nodular hyperplasia of the liver in young women on oral contraceptives: case reports.,839274_0,-1,-1,-1,15515,-1,0.0032489656,0.99675107
15516,focal nodular hyperplasia,3,6,21,46,Hepatic adenomas and focal nodular hyperplasia of the liver in young women on oral contraceptives: case reports.,839274_0,-1,-1,-1,15516,-1,0.0037876447,0.99621236
15518,adenoma,4,5,21,28,"Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives, are reported.",839274_1,-1,-1,-1,15518,-1,0.0029204115,0.9970796
15519,focal nodular hyperplasia,8,11,40,65,"Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives, are reported.",839274_1,-1,-1,-1,15519,-1,0.0032082333,0.9967918
15521,adenoma,7,8,65,72,Histologic differences and clinical similarities between hepatic adenoma and focal nodular hyperplasia of the liver are discussed.,839274_4,-1,-1,-1,15521,-1,0.0040521203,0.9959479
15522,focal nodular hyperplasia,9,12,77,102,Histologic differences and clinical similarities between hepatic adenoma and focal nodular hyperplasia of the liver are discussed.,839274_4,-1,-1,-1,15522,-1,0.0050442605,0.9949557
15523,neurofilament proteins,5,7,47,69,Immunohistochemical studies with antibodies to neurofilament proteins on axonal damage in experimental focal lesions in rat.,8410052_0,-1,-1,-1,15523,-1,0.97791904,0.022080934
15524,axonal damage,8,10,73,86,Immunohistochemical studies with antibodies to neurofilament proteins on axonal damage in experimental focal lesions in rat.,8410052_0,-1,-1,-1,15524,-1,0.0036421749,0.99635786
15525,axonal injury,26,28,160,173,"Immunohistochemistry with monoclonal antibodies against neurofilament (NF) proteins of middle and high molecular weight class, NF-M and NF-H, was used to study axonal injury in the borderzone of focal lesions in rats.",8410052_1,-1,-1,-1,15525,-1,0.003348943,0.9966511
15526,injury in the cortex,1,5,6,26,Focal injury in the cortex was produced by infusion of lactate at acid pH or by stab caused by needle insertion.,8410052_2,-1,-1,-1,15526,-1,0.014528683,0.98547137
15527,lactate,10,11,55,62,Focal injury in the cortex was produced by infusion of lactate at acid pH or by stab caused by needle insertion.,8410052_2,-1,-1,-1,15527,-1,0.99883157,0.0011684858
15528,Infarcts,0,1,0,8,Infarcts in substantia nigra pars reticulata were evoked by prolonged pilocarpine-induced status epilepticus.,8410052_3,-1,-1,-1,15528,-1,0.0031960858,0.9968039
15529,status epilepticus,11,13,90,108,Infarcts in substantia nigra pars reticulata were evoked by prolonged pilocarpine-induced status epilepticus.,8410052_3,-1,-1,-1,15529,-1,0.003242904,0.9967571
15530,axonal damage,11,13,67,80,These immunohistochemical changes of NFs can serve as a marker for axonal damage in various experimental traumatic or ischemic lesions.,8410052_6,-1,-1,-1,15530,-1,0.0034433245,0.99655676
15531,traumatic,16,17,105,114,These immunohistochemical changes of NFs can serve as a marker for axonal damage in various experimental traumatic or ischemic lesions.,8410052_6,-1,-1,-1,15531,-1,0.012202619,0.9877973
15532,ischemic lesions,18,20,118,134,These immunohistochemical changes of NFs can serve as a marker for axonal damage in various experimental traumatic or ischemic lesions.,8410052_6,-1,-1,-1,15532,-1,0.0035813372,0.9964187
15535,glutamic acid,9,11,56,69,In situ hybridization methods were used to determine if glutamic acid decarboxylase (GAD) mRNA-containing neurons within the hilus of the dentate gyrus are vulnerable to seizure-induced damage in a model of chronic seizures.,8410199_1,-1,-1,-1,15535,-1,0.99833715,0.0016627689
15540,neuronal degeneration,9,11,71,92,"Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.",8410199_4,-1,-1,-1,15540,-1,0.003039745,0.9969602
15541,glial fibrillary acidic protein,17,21,136,167,"Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.",8410199_4,-1,-1,-1,15541,-1,0.9374125,0.06258752
15542,neuronal loss,36,38,257,270,"Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.",8410199_4,-1,-1,-1,15542,-1,0.0034300245,0.99657
15543,confusion.15,9,10,83,95,Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion.15 cases of cimetidine-associated mental confusion have been reported.,84204_0,-1,-1,-1,15543,-1,0.06022924,0.93977076
15546,liver dysfunction,7,9,36,53,"These 6 patients had both renal and liver dysfunction (P less than 0.05), as well as cimetidine trough-concentrations of more than 1.25 microgram/ml (P less than 0.05).",84204_2,-1,-1,-1,15546,-1,0.003335385,0.9966646
15547,P,10,11,55,56,"These 6 patients had both renal and liver dysfunction (P less than 0.05), as well as cimetidine trough-concentrations of more than 1.25 microgram/ml (P less than 0.05).",84204_2,-1,-1,-1,15547,-1,0.18608887,0.81391114
15549,P,27,28,150,151,"These 6 patients had both renal and liver dysfunction (P less than 0.05), as well as cimetidine trough-concentrations of more than 1.25 microgram/ml (P less than 0.05).",84204_2,-1,-1,-1,15549,-1,0.17517379,0.82482624
15554,hepatic dysfunction,17,19,116,135,Patients likely to have both raised trough-concentrations and mental confusion are those with both severe renal and hepatic dysfunction.,84204_5,-1,-1,-1,15554,-1,0.0030501962,0.99694985
15557,gallstone,16,17,107,116,Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.,8421099_0,-1,-1,-1,15557,-1,0.012487071,0.9875129
15558,acromegalic,20,21,138,149,Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.,8421099_0,-1,-1,-1,15558,-1,0.007867321,0.9921327
15559,acromegaly,17,18,120,130,This article reports the changes in gallbladder function examined by ultrasonography in 20 Chinese patients with active acromegaly treated with sc injection of the somatostatin analog octreotide in dosages of 300-1500 micrograms/day for a mean of 24.2 +/- 13.9 months.,8421099_1,-1,-1,-1,15559,-1,0.00746937,0.99253064
15562,gallstones,12,13,71,81,"During treatment with octreotide, 17 patients developed sludge, 10 had gallstones, and 1 developed acute cholecystitis requiring surgery.",8421099_2,-1,-1,-1,15562,-1,0.008385686,0.99161434
15563,acute cholecystitis,17,19,99,118,"During treatment with octreotide, 17 patients developed sludge, 10 had gallstones, and 1 developed acute cholecystitis requiring surgery.",8421099_2,-1,-1,-1,15563,-1,0.0027016094,0.9972984
15566,gallstones,8,9,54,64,"After withdrawal of octreotide in 10 patients without gallstones, 8 patients assessed had return of normal gallbladder contractility within 1 month.",8421099_5,-1,-1,-1,15566,-1,0.9267561,0.073243886
15567,gallstones,9,10,48,58,"In 8 of the remaining 10 patients who developed gallstones during treatment, gallbladder contractility normalized in 5 patients (3 of whom has disappearance of their stones within 3 weeks), and remained depressed in 3 (2 of whom had stones present at 6 months).",8421099_6,-1,-1,-1,15567,-1,0.058557715,0.9414423
15569,gallstones,20,21,127,137,"Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge, gallstones, and cholecystitis during octreotide therapy in Chinese acromegalic patients.",8421099_7,-1,-1,-1,15569,-1,0.014325701,0.9856743
15570,cholecystitis,23,24,143,156,"Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge, gallstones, and cholecystitis during octreotide therapy in Chinese acromegalic patients.",8421099_7,-1,-1,-1,15570,-1,0.0029241988,0.9970758
15572,acromegalic,29,30,194,205,"Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge, gallstones, and cholecystitis during octreotide therapy in Chinese acromegalic patients.",8421099_7,-1,-1,-1,15572,-1,0.015929753,0.9840702
15574,acromegalic,17,18,116,127,It is therefore very important to follow the changes of gallbladder function during long-term octreotide therapy of acromegalic patients.,8421099_8,-1,-1,-1,15574,-1,0.017070279,0.9829297
15575,Parkinson disability,2,4,12,32,Increase of Parkinson disability after fluoxetine medication.,8423889_0,-1,-1,-1,15575,-1,0.00528198,0.994718
15577,Parkinson's disease,7,10,42,61,Depression is a major clinical feature of Parkinson's disease.,8423889_1,-1,-1,-1,15577,-1,0.00883047,0.9911696
15579,idiopathic Parkinson's disease,12,16,73,103,We report the increased amount of motor disability in four patients with idiopathic Parkinson's disease after exposure to the antidepressant fluoxetine.,8423889_2,-1,-1,-1,15579,-1,0.0037625565,0.9962374
15580,antidepressant fluoxetine,20,22,126,151,We report the increased amount of motor disability in four patients with idiopathic Parkinson's disease after exposure to the antidepressant fluoxetine.,8423889_2,-1,-1,-1,15580,-1,0.9988306,0.0011694011
15582,Parkinson's disease,11,14,89,108,The possibility of a clinically relevant dopamine-antagonistic capacity of fluoxetine in Parkinson's disease patients must be considered.,8423889_3,-1,-1,-1,15582,-1,0.0058004744,0.9941995
15586,function,11,12,93,101,Effects of deliberate hypotension induced by labetalol with isoflurane on neuropsychological function.,8424298_0,-1,-1,-1,15586,-1,0.004664297,0.99533576
15596,anxiety,37,38,214,221,"The following psychological tests were performed: four subtests of the Wechsler Adult Intelligence Scale (similarities, digit span, vocabulary and digit symbol), Trail-Making tests A and B, Zung tests (self-rating anxiety scale and self-rating depression scale) and two-part memory test battery with immediate and delayed recall.",8424298_5,-1,-1,-1,15596,-1,0.058876682,0.94112337
15603,bradyarrhythmias,15,16,122,138,The administration of intermittent intravenous infusions of cimetidine is infrequently associated with the development of bradyarrhythmias.,8437969_1,-1,-1,-1,15603,-1,0.0019696136,0.99803036
15604,leukemia,4,5,23,31,"A 40-year-old man with leukemia and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour.",8437969_2,-1,-1,-1,15604,-1,0.0029197284,0.99708027
15605,cardiac disease,9,11,50,65,"A 40-year-old man with leukemia and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour.",8437969_2,-1,-1,-1,15605,-1,0.002640624,0.99735934
15606,sinus arrest,18,20,114,126,"A 40-year-old man with leukemia and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour.",8437969_2,-1,-1,-1,15606,-1,0.0036597562,0.9963403
15611,sinus arrest,7,9,35,47,This is the first reported case of sinus arrest associated with continuous-infusion cimetidine.,8437969_4,-1,-1,-1,15611,-1,0.0023200305,0.99768
15615,RA,16,17,108,110,We describe the induction of sustained remissions and possible cure of severe erosive rheumatoid arthritis (RA) by bone marrow transplantation (BMT) in 2 patients.,8441146_1,-1,-1,-1,15615,-1,0.004459057,0.9955409
15617,gold,12,13,65,69,BMT was used to treat severe aplastic anemia which was caused by gold in one case and D-penicillamine in the other.,8441146_2,-1,-1,-1,15617,-1,0.99745303,0.0025469773
15618,RA,26,27,140,142,"In the 8 and 6 years since the transplants (representing 8 and 4 years since cessation of all immunosuppressive therapy, respectively), the RA in each case has been completely quiescent.",8441146_3,-1,-1,-1,15618,-1,0.019871501,0.98012847
15619,RA,6,7,40,42,"Although short term remission of severe RA following BMT has been reported, these are the first cases for which prolonged followup has been available.",8441146_4,-1,-1,-1,15619,-1,0.004796544,0.9952035
15620,synovitis,20,21,129,138,This experience raises the question of the role of BMT itself as a therapeutic option for patients with uncontrolled destructive synovitis.,8441146_5,-1,-1,-1,15620,-1,0.0026241215,0.99737585
15623,fluvoxamine,6,7,36,47,It seems that combined treatment of fluvoxamine with phenothiazines may possess proconvulsive activity.,8473723_2,-1,-1,-1,15623,-1,0.9993917,0.0006083412
15624,phenothiazines,8,9,53,67,It seems that combined treatment of fluvoxamine with phenothiazines may possess proconvulsive activity.,8473723_2,-1,-1,-1,15624,-1,0.9989434,0.0010565931
15625,pentamidine,3,4,13,24,Case report: pentamidine and polymorphic ventricular tachycardia revisited.,8475949_0,-1,-1,-1,15625,-1,0.9993667,0.0006332587
15627,ventricular tachyarrhythmias,6,8,49,77,"Pentamidine isethionate has been associated with ventricular tachyarrhythmias, including torsade de pointes.",8475949_1,-1,-1,-1,15627,-1,0.0028278911,0.9971722
15628,torsade de pointes,10,13,89,107,"Pentamidine isethionate has been associated with ventricular tachyarrhythmias, including torsade de pointes.",8475949_1,-1,-1,-1,15628,-1,0.0082990555,0.99170095
15629,torsade de pointes,1,4,20,38,Pentamidine-induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.,8475949_3,-1,-1,-1,15629,-1,0.00635322,0.99364686
15631,hypomagnesemia,12,13,84,98,Pentamidine-induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.,8475949_3,-1,-1,-1,15631,-1,0.026598135,0.9734019
15632,torsade,16,17,126,133,Pentamidine-induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.,8475949_3,-1,-1,-1,15632,-1,0.0027858142,0.99721426
15633,Torsade de pointes,0,3,0,18,Torsade de pointes occurred after an average of 10 days of treatment with pentamidine.,8475949_4,-1,-1,-1,15633,-1,0.004817316,0.9951827
15634,pentamidine,13,14,74,85,Torsade de pointes occurred after an average of 10 days of treatment with pentamidine.,8475949_4,-1,-1,-1,15634,-1,0.9993925,0.0006074402
15635,pentamidine,10,11,50,61,"In these patients, no other acute side effects of pentamidine were observed.",8475949_5,-1,-1,-1,15635,-1,0.9994773,0.0005227305
15636,Torsade de pointes,0,3,0,18,"Torsade de pointes can be treated when recognized early, possibly without discontinuation of pentamidine.",8475949_6,-1,-1,-1,15636,-1,0.00748882,0.99251115
15637,pentamidine,14,15,93,104,"Torsade de pointes can be treated when recognized early, possibly without discontinuation of pentamidine.",8475949_6,-1,-1,-1,15637,-1,0.9993687,0.00063125574
15638,QTc interval prolongation,1,4,5,30,"When QTc interval prolongation is observed, early magnesium supplementation is advocated.",8475949_7,-1,-1,-1,15638,-1,0.022254964,0.9777451
15646,mg,40,41,234,236,"DESIGN: The Expanded Clinical Evaluation of Lovastatin (EXCEL) Study, a multicenter, double-blind, diet- and placebo-controlled trial, in which participants were randomly assigned to receive placebo or lovastatin at doses of 20 or 40 mg once daily, or 20 or 40 mg twice daily for 48 weeks.",8480959_2,-1,-1,-1,15646,-1,0.9686368,0.03136314
15647,mg,48,49,261,263,"DESIGN: The Expanded Clinical Evaluation of Lovastatin (EXCEL) Study, a multicenter, double-blind, diet- and placebo-controlled trial, in which participants were randomly assigned to receive placebo or lovastatin at doses of 20 or 40 mg once daily, or 20 or 40 mg twice daily for 48 weeks.",8480959_2,-1,-1,-1,15647,-1,0.9707379,0.029262153
15648,n,4,5,17,18,PATIENTS: Women (n = 3390) from the total cohort of 8245 volunteers.,8480959_4,-1,-1,-1,15648,-1,0.22304669,0.77695334
15650,triglycerides,20,21,111,124,"MEASUREMENTS: Plasma total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol, and triglycerides; and laboratory and clinical evidence of adverse events monitored periodically throughout the study.",8480959_5,-1,-1,-1,15650,-1,0.99483323,0.0051667457
15652,P,23,24,108,109,"RESULTS: Among women, lovastatin (20 to 80 mg/d) produced sustained (12- to 48-week), dose-related changes (P < 0.001): decreases in LDL cholesterol (24% to 40%) and triglycerides (9% to 18%), and increases in HDL cholesterol (6.7% to 8.6%).",8480959_6,-1,-1,-1,15652,-1,0.24475214,0.75524783
15654,triglycerides,39,40,166,179,"RESULTS: Among women, lovastatin (20 to 80 mg/d) produced sustained (12- to 48-week), dose-related changes (P < 0.001): decreases in LDL cholesterol (24% to 40%) and triglycerides (9% to 18%), and increases in HDL cholesterol (6.7% to 8.6%).",8480959_6,-1,-1,-1,15654,-1,0.89512545,0.10487461
15659,creatine kinase,7,9,42,57,"Myopathy, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg).",8480959_9,-1,-1,-1,15659,-1,0.99564195,0.004358091
15661,mg,34,35,200,202,"Myopathy, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg).",8480959_9,-1,-1,-1,15661,-1,0.97819406,0.021805903
15669,hypokalemia,3,4,21,32,"Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.",8492347_1,-1,-1,-1,15669,-1,0.008993644,0.9910063
15671,hypomagnesemia,7,8,51,65,"Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.",8492347_1,-1,-1,-1,15671,-1,0.016691176,0.98330885
15672,hypokalemia,2,3,13,24,"While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).",8492347_2,-1,-1,-1,15672,-1,0.04462541,0.95537454
15673,muscle weakness,5,7,35,50,"While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).",8492347_2,-1,-1,-1,15673,-1,0.0026934405,0.9973066
15674,hypomagnesemia,9,10,59,73,"While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).",8492347_2,-1,-1,-1,15674,-1,0.036017563,0.96398246
15675,muscle spasms,13,15,93,106,"While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).",8492347_2,-1,-1,-1,15675,-1,0.0025995,0.9974005
15679,obese,16,17,101,106,"Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or edematous.",8492347_3,-1,-1,-1,15679,-1,0.00823222,0.99176776
15680,edematous,18,19,110,119,"Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or edematous.",8492347_3,-1,-1,-1,15680,-1,0.0049216747,0.9950783
15681,hypokalemia,1,2,12,23,"Symptomatic hypokalemia has been reported in such patients (3-7) and in one case hypocalcemia was observed (8), but the effects of magnesium depletion were not noted in these patients.",8492347_4,-1,-1,-1,15681,-1,0.0049558645,0.9950441
15689,acute renal failure,6,9,40,59,Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed.,8494478_2,-1,-1,-1,15689,-1,0.0022653695,0.99773467
15692,Allergic interstitial nephritis,0,3,0,31,Allergic interstitial nephritis is believed to be the underlying pathological-process.,8494478_4,-1,-1,-1,15692,-1,0.005449534,0.9945505
15693,acute renal failure,19,22,155,174,An improvement in renal function that followed the discontinuation of the offending antibiotic supports the presumptive diagnosis of ciprofloxacin-induced acute renal failure.,8494478_6,-1,-1,-1,15693,-1,0.0022330435,0.997767
15694,Venous complications,0,2,0,20,Venous complications of midazolam versus diazepam.,8514073_0,-1,-1,-1,15694,-1,0.0043691415,0.99563086
15697,venous complications,6,8,43,63,"Although some studies have suggested fewer venous complications are associated with midazolam than with diazepam for endoscopic procedures, this variable has not been well documented.",8514073_1,-1,-1,-1,15697,-1,0.0038036848,0.9961964
15700,venous complications,6,8,44,64,We prospectively evaluated the incidence of venous complications after intravenous injection of diazepam or midazolam in 122 consecutive patients undergoing colonoscopy and esophagogastroduodenoscopy.,8514073_2,-1,-1,-1,15700,-1,0.0041245874,0.9958754
15703,venous complications,2,4,9,29,"Overall, venous complications were more frequent with diazepam (22 of 62 patients) than with midazolam (4 of 60 patients) (p < 0.001).",8514073_3,-1,-1,-1,15703,-1,0.003358801,0.99664116
15706,p,25,26,123,124,"Overall, venous complications were more frequent with diazepam (22 of 62 patients) than with midazolam (4 of 60 patients) (p < 0.001).",8514073_3,-1,-1,-1,15706,-1,0.27396542,0.7260346
15709,p,36,37,148,149,"A palpable venous cord was present in 23% (14 of 62) of patients in the diazepam group, compared with 2% (1 of 60 patients) in the midazolam group (p < 0.002).",8514073_4,-1,-1,-1,15709,-1,0.26652226,0.7334777
15713,p,35,36,148,149,Pain at the injection site occurred in 35% (22 of 62) of patients in the diazepam group compared with 7% (4 of 60 patients) in the midazolam group (p < 0.001).,8514073_5,-1,-1,-1,15713,-1,0.20735084,0.7926492
15714,Swelling,0,1,0,8,Swelling and warmth at the injection site were not significantly different between the two groups.,8514073_6,-1,-1,-1,15714,-1,0.0028595696,0.9971404
15718,venous complications,32,34,180,200,"Smoking, nonsteroidal anti-inflammatory drug use, intravenous catheter site, dwell time of the needle, alcohol use, and pain during the injection had no effect on the incidence of venous complications.",8514073_7,-1,-1,-1,15718,-1,0.0050841356,0.99491584
15721,renal failure,8,10,50,63,Visual hallucinations are a rare event in chronic renal failure and not related to uremia per se.,8546130_1,-1,-1,-1,15721,-1,0.010813577,0.98918647
15722,uremia,14,15,83,89,Visual hallucinations are a rare event in chronic renal failure and not related to uremia per se.,8546130_1,-1,-1,-1,15722,-1,0.7947798,0.20522025
15723,se,16,17,94,96,Visual hallucinations are a rare event in chronic renal failure and not related to uremia per se.,8546130_1,-1,-1,-1,15723,-1,0.82852596,0.17147408
15725,macrolide,13,14,92,101,"Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic, clarithromycin.",8546130_2,-1,-1,-1,15725,-1,0.99842286,0.0015771857
15726,clarithromycin,16,17,114,128,"Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic, clarithromycin.",8546130_2,-1,-1,-1,15726,-1,0.9993574,0.0006425456
15727,renal disease,10,12,52,65,We describe such a case in a patient with end-stage renal disease (ESRD) maintained on continuous ambulatory peritoneal dialysis (CAPD).,8546130_3,-1,-1,-1,15727,-1,0.0028020914,0.99719787
15728,ESRD,13,14,67,71,We describe such a case in a patient with end-stage renal disease (ESRD) maintained on continuous ambulatory peritoneal dialysis (CAPD).,8546130_3,-1,-1,-1,15728,-1,0.004264877,0.99573505
15729,clarithromycin,8,9,45,59,"The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this neurotoxic side effect.",8546130_4,-1,-1,-1,15729,-1,0.99935204,0.0006479742
15731,aluminum,23,24,145,153,"The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this neurotoxic side effect.",8546130_4,-1,-1,-1,15731,-1,0.99636793,0.0036321178
15734,ESRD,33,34,204,208,"It is important to understand the pharmacokinetics of medications in face of chronic renal failure, the possibility of drug interactions, and how these factors should help guide medication therapy in the ESRD patient.",8546130_5,-1,-1,-1,15734,-1,0.0045865476,0.9954135
15735,hepatoma,7,8,50,58,Changes in peroxisomes in preneoplastic liver and hepatoma of mice induced by alpha-benzene hexachloride.,85485_0,-1,-1,-1,15735,-1,0.0029185293,0.99708146
15736,hepatomas,2,3,15,24,Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm alpha-benzene hexachloride were examined histochemically and electron microscopically.,85485_1,-1,-1,-1,15736,-1,0.0028895317,0.9971105
15737,liver lesions,6,8,56,69,Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm alpha-benzene hexachloride were examined histochemically and electron microscopically.,85485_1,-1,-1,-1,15737,-1,0.0029434785,0.9970565
15738,hepatomas,4,5,21,30,"Although most of the hepatomas were well-differentiated tumors and contained a considerable number of peroxisomes, the tumor cells did not respond to ethyl-alpha-p-chlorophenoxyisobutyrate with proliferation of peroxisomes.",85485_2,-1,-1,-1,15738,-1,0.0039952486,0.99600476
15741,hepatomas,17,18,96,105,"These cells proliferated further, replacing the most part of the nodules, and with this process hepatomas appeared to have been formed.",85485_6,-1,-1,-1,15741,-1,0.0037877099,0.99621236
15743,squamous cell esophageal carcinoma,7,11,44,78,Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma.,8558192_0,-1,-1,-1,15743,-1,0.006525197,0.9934748
15747,VNB,27,28,180,183,European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma. PATIENTS AND METHODS: Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy.,8558192_1,-1,-1,-1,15747,-1,0.9980013,0.0019987398
15748,squamous cell esophageal carcinoma,36,40,230,264,European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma. PATIENTS AND METHODS: Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy.,8558192_1,-1,-1,-1,15748,-1,0.0073626223,0.9926374
15750,VNB,0,1,0,3,VNB was administered weekly as a 25-mg/m2 short intravenous (i.v.) infusion.,8558192_3,-1,-1,-1,15750,-1,0.9986695,0.0013305196
15751,CR,16,17,73,75,"One of 16 patients (6%) with prior chemotherapy had a complete response (CR) of 31 weeks' duration (95% CI, 0% to 30%).",8558192_6,-1,-1,-1,15751,-1,0.0057447613,0.99425524
15752,CR,17,18,78,80,"The overall response rate (World Health Organization [WHO] criteria) was 15% (CR, 2%; PR 13%; 95% CI, 6% to 29%).",8558192_7,-1,-1,-1,15752,-1,0.008107741,0.9918922
15753,DI,4,5,27,29,The median dose-intensity (DI) was 20 mg/m2/wk.,8558192_8,-1,-1,-1,15753,-1,0.95271325,0.04728669
15754,VNB,0,1,0,3,VNB was well tolerated and zero instances of WHO grade 4 nonhematologic toxicity occurred.,8558192_9,-1,-1,-1,15754,-1,0.99855345,0.0014465627
15756,granulocytopenia,9,10,37,53,At least one episode of grade 3 or 4 granulocytopenia was seen in 59% of patients.,8558192_10,-1,-1,-1,15756,-1,0.0045920694,0.9954079
15759,peripheral neurotoxicity,7,9,34,58,"Other side effects were rare, and peripheral neurotoxicity has been minor (26% grade 1).",8558192_12,-1,-1,-1,15759,-1,0.0034239874,0.996576
15760,VNB,6,7,37,40,CONCLUSION: These data indicate that VNB is an active agent in metastatic esophageal squamous cell carcinoma.,8558192_13,-1,-1,-1,15760,-1,0.99847275,0.0015272581
15761,esophageal squamous cell carcinoma,13,17,74,108,CONCLUSION: These data indicate that VNB is an active agent in metastatic esophageal squamous cell carcinoma.,8558192_13,-1,-1,-1,15761,-1,0.0059150713,0.99408495
15763,VNB,12,13,78,81,"Given its excellent tolerance profile and low toxicity, further evaluation of VNB in combination therapy is warranted.",8558192_14,-1,-1,-1,15763,-1,0.99858284,0.0014171333
15767,sodium chloride,30,32,202,217,"OBJECTIVE: To test the hypothesis that, in lifetime captopril-treated spontaneously hypertensive rats (SHR), the sympathetic nervous system contributes importantly to the hypertensive effect of dietary sodium chloride supplementation.",8586822_1,-1,-1,-1,15767,-1,0.9989747,0.0010253888
15769,sodium chloride,25,27,131,146,METHODS: Male SHR (aged 6 weeks) that had been treated from conception onward with either captopril or vehicle remained on a basal sodium chloride diet or were fed a high sodium chloride diet.,8586822_2,-1,-1,-1,15769,-1,0.9988232,0.001176757
15770,sodium chloride,33,35,171,186,METHODS: Male SHR (aged 6 weeks) that had been treated from conception onward with either captopril or vehicle remained on a basal sodium chloride diet or were fed a high sodium chloride diet.,8586822_2,-1,-1,-1,15770,-1,0.9981194,0.0018805705
15774,MAP,13,14,92,95,Intravenous infusion of the ganglionic blocker hexamethonium resulted in a rapid decline in MAP that eliminated the dietary sodium chloride-induced increase in MAP in both groups.,8586822_5,-1,-1,-1,15774,-1,0.2478559,0.75214416
15776,MAP,22,23,160,163,Intravenous infusion of the ganglionic blocker hexamethonium resulted in a rapid decline in MAP that eliminated the dietary sodium chloride-induced increase in MAP in both groups.,8586822_5,-1,-1,-1,15776,-1,0.27328533,0.7267146
15777,alpha2-adrenergic receptor agonist clonidine,6,10,39,83,Infusion of the central nervous system alpha2-adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high (compared with the basal) sodium chloride diet.,8586822_6,-1,-1,-1,15777,-1,0.9966091,0.0033908787
15778,MAP,17,18,124,127,Infusion of the central nervous system alpha2-adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high (compared with the basal) sodium chloride diet.,8586822_6,-1,-1,-1,15778,-1,0.18392749,0.81607246
15779,sodium chloride,34,36,199,214,Infusion of the central nervous system alpha2-adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high (compared with the basal) sodium chloride diet.,8586822_6,-1,-1,-1,15779,-1,0.9986739,0.0013260943
15780,sodium chloride,22,24,141,156,"CONCLUSIONS: In both lifetime captopril-treated and control SHR, the sympathetic nervous system contributes to the pressor effects of a high sodium chloride diet.",8586822_7,-1,-1,-1,15780,-1,0.9985856,0.0014144239
15781,aponidine hydrochloride,5,7,35,58,Evaluation of adverse reactions of aponidine hydrochloride ophthalmic solution.,8590259_0,-1,-1,-1,15781,-1,0.9990491,0.00095090986
15782,apraclonidine,7,8,52,65,We prospectively evaluated the adverse reactions of apraclonidine in 20 normal volunteers by instilling a single drop of 1% apraclonidine in their right eyes.,8590259_1,-1,-1,-1,15782,-1,0.99919635,0.00080366386
15783,apraclonidine,20,21,124,137,We prospectively evaluated the adverse reactions of apraclonidine in 20 normal volunteers by instilling a single drop of 1% apraclonidine in their right eyes.,8590259_1,-1,-1,-1,15783,-1,0.9991534,0.0008466427
15784,IOP,16,17,98,101,"Examinations, including blood pressure, pulse rate, conjunctiva and cornea, intraocular pressure (IOP), pupil diameter, basal tear secretion and margin reflex distance of both upper and lower eyelids, were performed prior to entry and at 1, 3, 5 and 7 hours after instillation.",8590259_2,-1,-1,-1,15784,-1,0.9712431,0.028756885
15785,ocular hypotensive,1,3,4,22,The ocular hypotensive effects were statistically significant for apraclonidine-treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1% apraclonidine.,8590259_3,-1,-1,-1,15785,-1,0.0022557096,0.9977443
15786,apraclonidine-treated,8,9,66,87,The ocular hypotensive effects were statistically significant for apraclonidine-treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1% apraclonidine.,8590259_3,-1,-1,-1,15786,-1,0.95787853,0.0421215
15787,apraclonidine,29,30,224,237,The ocular hypotensive effects were statistically significant for apraclonidine-treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1% apraclonidine.,8590259_3,-1,-1,-1,15787,-1,0.99912626,0.0008737114
15788,Decreases in systolic blood pressure,0,5,0,36,"Decreases in systolic blood pressure were statistically, but not clinically, significant.",8590259_4,-1,-1,-1,15788,-1,0.06841561,0.93158436
15789,mydriasis,3,4,27,36,Conjunctival blanching and mydriasis were commonly found.,8590259_6,-1,-1,-1,15789,-1,0.020070812,0.97992915
15790,lid,1,2,6,9,Upper lid retraction was frequently noted.,8590259_7,-1,-1,-1,15790,-1,0.05042236,0.9495777
15791,lid,6,7,34,37,"While the elevations of the upper lid margin in most subjects were not more than 2 mm and did not cause noticeable change in appearance, one subject suffered from mechanical entropion and marked corneal abrasion 3 hours after instillation of the medication.",8590259_8,-1,-1,-1,15791,-1,0.11749471,0.8825053
15792,mm,16,17,83,85,"While the elevations of the upper lid margin in most subjects were not more than 2 mm and did not cause noticeable change in appearance, one subject suffered from mechanical entropion and marked corneal abrasion 3 hours after instillation of the medication.",8590259_8,-1,-1,-1,15792,-1,0.09490149,0.90509856
15793,entropion,31,32,174,183,"While the elevations of the upper lid margin in most subjects were not more than 2 mm and did not cause noticeable change in appearance, one subject suffered from mechanical entropion and marked corneal abrasion 3 hours after instillation of the medication.",8590259_8,-1,-1,-1,15793,-1,0.007513091,0.99248695
15794,corneal abrasion,34,36,195,211,"While the elevations of the upper lid margin in most subjects were not more than 2 mm and did not cause noticeable change in appearance, one subject suffered from mechanical entropion and marked corneal abrasion 3 hours after instillation of the medication.",8590259_8,-1,-1,-1,15794,-1,0.0038635198,0.9961365
15801,C,3,4,18,19,"Patients in Group C received 2 ml normal saline, Group L, 2 ml, lidocaine 2% (40 mg) and Group T, 2 ml thiopentone 2.5% (50 mg).",8595686_3,-1,-1,-1,15801,-1,0.6057887,0.39421132
15803,mg,21,22,81,83,"Patients in Group C received 2 ml normal saline, Group L, 2 ml, lidocaine 2% (40 mg) and Group T, 2 ml thiopentone 2.5% (50 mg).",8595686_3,-1,-1,-1,15803,-1,0.9360262,0.06397383
15805,mg,34,35,124,126,"Patients in Group C received 2 ml normal saline, Group L, 2 ml, lidocaine 2% (40 mg) and Group T, 2 ml thiopentone 2.5% (50 mg).",8595686_3,-1,-1,-1,15805,-1,0.8859947,0.1140053
15807,Loss of consciousness,0,3,0,21,Loss of consciousness occurred in 60-90 sec. Visual analogue scores (mean +/- SD) during induction were lower in Groups L (3.3 +/- 2.5) and T (4.1 +/- 2.7) than in Group C (5.6 +/- 2.3); P = 0.0031.,8595686_5,-1,-1,-1,15807,-1,0.005293372,0.9947067
15808,SD,16,17,78,80,Loss of consciousness occurred in 60-90 sec. Visual analogue scores (mean +/- SD) during induction were lower in Groups L (3.3 +/- 2.5) and T (4.1 +/- 2.7) than in Group C (5.6 +/- 2.3); P = 0.0031.,8595686_5,-1,-1,-1,15808,-1,0.16249605,0.83750397
15809,C,42,43,170,171,Loss of consciousness occurred in 60-90 sec. Visual analogue scores (mean +/- SD) during induction were lower in Groups L (3.3 +/- 2.5) and T (4.1 +/- 2.7) than in Group C (5.6 +/- 2.3); P = 0.0031.,8595686_5,-1,-1,-1,15809,-1,0.7212134,0.27878666
15810,P,50,51,187,188,Loss of consciousness occurred in 60-90 sec. Visual analogue scores (mean +/- SD) during induction were lower in Groups L (3.3 +/- 2.5) and T (4.1 +/- 2.7) than in Group C (5.6 +/- 2.3); P = 0.0031.,8595686_5,-1,-1,-1,15810,-1,0.26161936,0.7383806
15811,P,14,15,64,65,The incidence of venous discomfort was lower in Group L (76.6%; P < 0.05) than in Group C (100%) but not different from Group T (90%).,8595686_6,-1,-1,-1,15811,-1,0.2612936,0.7387064
15812,C,21,22,88,89,The incidence of venous discomfort was lower in Group L (76.6%; P < 0.05) than in Group C (100%) but not different from Group T (90%).,8595686_6,-1,-1,-1,15812,-1,0.9241785,0.07582151
15814,P,24,25,121,122,The VAS scores for recall of pain in the recovery room were correlated with the VAS scores during induction (r = 0.7045; P < 0.0001).,8595686_7,-1,-1,-1,15814,-1,0.44568762,0.55431235
15815,C,7,8,44,45,Recovery room discharge times were similar: C (75.9 +/- 19.4 min); L 73.6 +/- 21.6 min); T (77.1 +/- 18.9 min).,8595686_8,-1,-1,-1,15815,-1,0.8591532,0.14084676
15821,droperidol,3,4,27,37,Angioedema associated with droperidol administration.,8599504_0,-1,-1,-1,15821,-1,0.9987109,0.0012891775
15822,angioneurotic edema,5,7,26,45,"Angioedema, also known as angioneurotic edema or Quincke's disease, is a well-demarcated, localized edema involving the subcutaneous tissues that may cause upper-airway obstruction.",8599504_1,-1,-1,-1,15822,-1,0.0046374286,0.9953625
15823,Quincke's disease,8,11,49,66,"Angioedema, also known as angioneurotic edema or Quincke's disease, is a well-demarcated, localized edema involving the subcutaneous tissues that may cause upper-airway obstruction.",8599504_1,-1,-1,-1,15823,-1,0.16639759,0.8336024
15825,drug allergies,13,15,73,87,We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol.,8599504_2,-1,-1,-1,15825,-1,0.03260985,0.9673902
15827,swelling,21,22,131,139,We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol.,8599504_2,-1,-1,-1,15827,-1,0.0024296863,0.99757034
15828,droperidol,37,38,228,238,We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol.,8599504_2,-1,-1,-1,15828,-1,0.99890864,0.0010914131
15830,bone tumor,7,9,52,62,Late cardiotoxicity after treatment for a malignant bone tumor.,8600333_0,-1,-1,-1,15830,-1,0.0046947324,0.9953053
15831,bone tumors,9,11,66,77,"Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.",8600333_1,-1,-1,-1,15831,-1,0.003365827,0.9966342
15832,Rosen's T5,16,19,108,118,"Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.",8600333_1,-1,-1,-1,15832,-1,0.939258,0.060742058
15833,T10,20,21,122,125,"Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.",8600333_1,-1,-1,-1,15833,-1,0.9585959,0.041404113
15838,ventricular dilation,31,33,172,192,"Eighteen of 31 (58%) patients showed cardiac toxicity, defined as having one or more of the following abnormalities: late potentials, complex ventricular arrhythmias, left ventricular dilation, decreased shortening fraction, or decreased ejection fraction.",8600333_5,-1,-1,-1,15838,-1,0.008831038,0.991169
15839,cardiac abnormalities,3,5,17,38,The incidence of cardiac abnormalities increased with length of follow-up (P< or = .05).,8600333_6,-1,-1,-1,15839,-1,0.0029544116,0.9970456
15840,P,11,12,75,76,The incidence of cardiac abnormalities increased with length of follow-up (P< or = .05).,8600333_6,-1,-1,-1,15840,-1,0.36600927,0.63399076
15850,n,4,5,29,30,Borderline hypertensive men (n = 24) were selected with screening systolic blood pressure (BP) of 140 to 160 mm Hg and/or diastolic BP 90 to 99 mm Hg.,8607407_3,-1,-1,-1,15850,-1,0.25397098,0.74602896
15851,mm Hg,22,24,109,114,Borderline hypertensive men (n = 24) were selected with screening systolic blood pressure (BP) of 140 to 160 mm Hg and/or diastolic BP 90 to 99 mm Hg.,8607407_3,-1,-1,-1,15851,-1,0.38090143,0.61909854
15852,mm Hg,30,32,144,149,Borderline hypertensive men (n = 24) were selected with screening systolic blood pressure (BP) of 140 to 160 mm Hg and/or diastolic BP 90 to 99 mm Hg.,8607407_3,-1,-1,-1,15852,-1,0.32629147,0.6737085
15853,n,3,4,19,20,Low-risk controls (n = 24) reported no parental history of hypertension and had screening BP < 130/85 mm Hg.,8607407_4,-1,-1,-1,15853,-1,0.3074323,0.69256765
15855,mm Hg,19,21,102,107,Low-risk controls (n = 24) reported no parental history of hypertension and had screening BP < 130/85 mm Hg.,8607407_4,-1,-1,-1,15855,-1,0.2739744,0.7260256
15857,mm Hg,23,25,120,125,"Caffeine-induced changes in diastolic BP were 2 to 3 times larger in borderline subjects than in controls (+8.4 vs +3.8 mm Hg, p < 0.0001), and were attributable to larger changes in impedance-derived measures of systemic vascular resistance (+135 vs +45 dynes.s.cm-5, p < 0.004).",8607407_6,-1,-1,-1,15857,-1,0.12746422,0.8725358
15858,p,26,27,127,128,"Caffeine-induced changes in diastolic BP were 2 to 3 times larger in borderline subjects than in controls (+8.4 vs +3.8 mm Hg, p < 0.0001), and were attributable to larger changes in impedance-derived measures of systemic vascular resistance (+135 vs +45 dynes.s.cm-5, p < 0.004).",8607407_6,-1,-1,-1,15858,-1,0.3267844,0.6732156
15859,p,52,53,269,270,"Caffeine-induced changes in diastolic BP were 2 to 3 times larger in borderline subjects than in controls (+8.4 vs +3.8 mm Hg, p < 0.0001), and were attributable to larger changes in impedance-derived measures of systemic vascular resistance (+135 vs +45 dynes.s.cm-5, p < 0.004).",8607407_6,-1,-1,-1,15859,-1,0.32144636,0.67855364
15864,hypertensives,34,35,219,232,"Thus, in borderline hypertensive men, exaggerated responses to caffeine were: selective for diastolic BP, consistent with greater vasoconstriction, replicated in 2 protocols, and representative of nearly all borderline hypertensives.",8607407_10,-1,-1,-1,15864,-1,0.004388959,0.995611
15866,disease progression,22,24,145,164,"We suspect that the potential for caffeine to stabilize high resistance states in susceptible persons suggests that its use may facilitate their disease progression, as well as hinder accurate diagnosis and treatment.",8607407_11,-1,-1,-1,15866,-1,0.0032066524,0.9967933
15868,cognitive impairment,9,11,63,83,Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol.,8617710_0,-1,-1,-1,15868,-1,0.0023415699,0.9976584
15874,mg,12,13,65,67,METHOD: All subjects received placebo on Day 1 and haloperidol 2 mg on Days 2 and 25.,8617710_2,-1,-1,-1,15874,-1,0.9812646,0.018735483
15877,Impairment of cognitive function,2,6,9,41,RESULTS: Impairment of cognitive function was observed 6 to 8 hours after administration of haloperidol on Day 2 but was not evident 23 hours after dosing.,8617710_5,-1,-1,-1,15877,-1,0.0037404867,0.99625957
15885,cognitive impairment,8,10,52,72,CONCLUSION: Haloperidol produced a clear profile of cognitive impairment that was not worsened by concomitant sertraline administration.,8617710_11,-1,-1,-1,15885,-1,0.0022656182,0.9977343
15888,atracurium,6,7,44,54,Persistent paralysis after prolonged use of atracurium in the absence of corticosteroids.,8638206_0,-1,-1,-1,15888,-1,0.99915993,0.00084011815
15890,Neuromuscular blocking agents,0,3,0,29,Neuromuscular blocking agents (NMBAs) are often used for patients requiring prolonged mechanical ventilation.,8638206_1,-1,-1,-1,15890,-1,0.9829625,0.01703745
15892,vecuronium bromide,18,20,130,148,"Reports of persistent paralysis after the discontinuance of these drugs have most often involved aminosteroid-based NMBAs such as vecuronium bromide, especially when used in conjunction with corticosteroids.",8638206_2,-1,-1,-1,15892,-1,0.9990916,0.00090839015
15894,benzylisoquinolinium,5,6,36,56,"Atracurium besylate, a short-acting benzylisoquinolinium NMBA that is eliminated independently of renal or hepatic function, has also been associated with persistent paralysis, but only when used with corticosteroids.",8638206_3,-1,-1,-1,15894,-1,0.99882036,0.0011795784
15902,hemiparesis,13,14,87,98,"A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.",8638876_2,-1,-1,-1,15902,-1,0.0023720046,0.99762803
15906,Diabetes mellitus,0,2,0,17,Diabetes mellitus (DM) was found during admission.,8638876_3,-1,-1,-1,15906,-1,0.0057670698,0.99423295
15907,DM,3,4,19,21,Diabetes mellitus (DM) was found during admission.,8638876_3,-1,-1,-1,15907,-1,0.0101212645,0.9898788
15908,hemorrhagic infarct,4,6,29,48,Computed tomography showed a hemorrhagic infarct in the right frontal lobe and increased density in the superior sagittal sinus (SSS).,8638876_4,-1,-1,-1,15908,-1,0.0030098567,0.9969901
15912,DM,17,18,98,100,"In this case, the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity, which provided a common denominator for thrombosis of both the ICA and the venous sinus.",8638876_8,-1,-1,-1,15912,-1,0.05215792,0.94784206
15914,lung cancer,6,8,51,62,Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.,8643966_0,-1,-1,-1,15914,-1,0.0039385054,0.9960615
15917,Taxol,2,3,12,17,"Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.",8643966_1,-1,-1,-1,15917,-1,0.9985733,0.0014266641
15921,lung cancer,18,20,120,131,Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.,8643966_2,-1,-1,-1,15921,-1,0.0045974324,0.9954026
15922,NSCLC,21,22,133,138,Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.,8643966_2,-1,-1,-1,15922,-1,0.005595743,0.9944042
15927,NSCLC,24,25,139,144,We investigated the efficacy and toxicity of a 3-hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC.,8643966_4,-1,-1,-1,15927,-1,0.0047655874,0.99523443
15928,NSCLC,9,10,35,40,Most patients (72.4%) had stage IV NSCLC.,8643966_6,-1,-1,-1,15928,-1,0.0059512774,0.9940487
15930,disease progression,28,30,106,125,"Of 50 patients evaluable for response, 12 (24%) had partial remission, 26 (52%) had no change, and 12 had disease progression (24%).",8643966_8,-1,-1,-1,15930,-1,0.0035501434,0.9964498
15940,NSCLC,12,13,82,87,"Further phase II studies with paclitaxel combined with other drugs active against NSCLC are indicated, and phase III studies comparing paclitaxel with standard chemotherapy remain to be completed.",8643966_14,-1,-1,-1,15940,-1,0.008984623,0.9910154
15944,head and neck cancers,12,16,74,95,A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.,8643971_0,-1,-1,-1,15944,-1,0.006787566,0.99321246
15945,head and neck carcinomas,5,9,38,62,Improved outcomes among patients with head and neck carcinomas require investigations of new drugs for induction therapy.,8643971_1,-1,-1,-1,15945,-1,0.006527152,0.9934729
15947,Taxol,13,14,95,100,"Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.",8643971_2,-1,-1,-1,15947,-1,0.99875236,0.0012476067
15948,head and neck cancer,32,36,193,213,"Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.",8643971_2,-1,-1,-1,15948,-1,0.0064915842,0.99350846
15953,head and neck carcinoma,32,36,243,266,We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma.,8643971_3,-1,-1,-1,15953,-1,0.005876159,0.9941239
15961,Alopecia,0,1,0,8,"Alopecia, paresthesias, and arthralgias/myalgias have occurred frequently, but with one exception (a grade 3 myalgia) they have been grade 1 or 2.",8643971_16,-1,-1,-1,15961,-1,0.004308653,0.99569136
15962,paresthesias,2,3,10,22,"Alopecia, paresthesias, and arthralgias/myalgias have occurred frequently, but with one exception (a grade 3 myalgia) they have been grade 1 or 2.",8643971_16,-1,-1,-1,15962,-1,0.0038320704,0.99616796
15964,hematologic toxicity,2,4,17,37,No dose-limiting hematologic toxicity has been seen.,8643971_17,-1,-1,-1,15964,-1,0.0027806577,0.9972193
15965,head and neck cancer,9,13,84,104,Paclitaxel/cisplatin is an effective first-line regimen for locoregionally advanced head and neck cancer and continued study is warranted.,8643971_18,-1,-1,-1,15965,-1,0.0065425527,0.9934575
15971,Taxol,14,15,74,79,"In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.",8643973_1,-1,-1,-1,15971,-1,0.99884063,0.0011594109
15981,granulocytopenia,11,12,80,96,"The dose-limiting toxicity of the combination was myelosuppression (leukopenia, granulocytopenia, and thrombocytopenia).",8643973_5,-1,-1,-1,15981,-1,0.004121662,0.99587834
15984,disease progression,3,5,15,34,No patient had disease progression.,8643973_8,-1,-1,-1,15984,-1,0.0029977828,0.9970022
15991,Parkinson's disease,7,10,61,80,Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease.,8649546_0,-1,-1,-1,15991,-1,0.004700698,0.9952992
15992,Parkinson's disease,4,7,30,49,Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment.,8649546_1,-1,-1,-1,15992,-1,0.0044899364,0.9955101
15993,PD,8,9,51,53,Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment.,8649546_1,-1,-1,-1,15993,-1,0.0029721376,0.99702793
15997,parkinsonian motor disability,14,17,84,113,There was a significant 40% improvement in the dyskinesia score without increase of parkinsonian motor disability.,8649546_2,-1,-1,-1,15997,-1,0.0027319202,0.9972681
16001,PD,18,19,135,137,This study suggests that administration of low doses of beta-blockers may improve levodopa-induced ballistic and choreic dyskinesia in PD.,8649546_4,-1,-1,-1,16001,-1,0.003245769,0.9967542
16006,C,15,16,85,86,"Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or triamcinolone (T) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in M and T, respectively).",8665051_3,-1,-1,-1,16006,-1,0.995096,0.004903956
16008,triamcinolone,24,25,116,129,"Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or triamcinolone (T) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in M and T, respectively).",8665051_3,-1,-1,-1,16008,-1,0.99896526,0.0010347437
16009,reduction of food intake,45,49,225,249,"Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or triamcinolone (T) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in M and T, respectively).",8665051_3,-1,-1,-1,16009,-1,0.014962034,0.985038
16010,loss in body weight,6,10,35,54,This was associated with a similar loss in body weight.,8665051_4,-1,-1,-1,16010,-1,0.018798348,0.98120165
16012,twitches,1,2,8,16,"Maximal twitches of the diaphragm were lower in the C group (653 +/- 174 g/cm(2)) than in the M group (837 +/- 171 g/cm(2); p < 0.05) and the T group (765 +/- 145 g/cm(2), NS).",8665051_7,-1,-1,-1,16012,-1,0.005268971,0.99473107
16013,C,9,10,52,53,"Maximal twitches of the diaphragm were lower in the C group (653 +/- 174 g/cm(2)) than in the M group (837 +/- 171 g/cm(2); p < 0.05) and the T group (765 +/- 145 g/cm(2), NS).",8665051_7,-1,-1,-1,16013,-1,0.9341355,0.0658645
16014,p,32,33,124,125,"Maximal twitches of the diaphragm were lower in the C group (653 +/- 174 g/cm(2)) than in the M group (837 +/- 171 g/cm(2); p < 0.05) and the T group (765 +/- 145 g/cm(2), NS).",8665051_7,-1,-1,-1,16014,-1,0.23221397,0.767786
16015,NS,48,49,172,174,"Maximal twitches of the diaphragm were lower in the C group (653 +/- 174 g/cm(2)) than in the M group (837 +/- 171 g/cm(2); p < 0.05) and the T group (765 +/- 145 g/cm(2), NS).",8665051_7,-1,-1,-1,16015,-1,0.08486456,0.91513544
16017,tetanic,20,21,111,118,"Half-relaxation time was prolonged in both steroid groups, and time to peak tension was longer with M, whereas tetanic tensions were similar.",8665051_8,-1,-1,-1,16017,-1,0.3032657,0.6967343
16019,p,22,23,130,131,Steroid treatment also induced a leftward shift of the force-frequency curve at 25 and 50 Hz when compared with saline treatment (p < 0.05).,8665051_9,-1,-1,-1,16019,-1,0.3188435,0.68115646
16024,C,14,15,54,55,"Finally, a pair-fed (PF) study, performed in 18 rats (C, T, and PF), showed that muscle atrophy was considerably less pronounced in PF animals than in T-treated animals.",8665051_11,-1,-1,-1,16024,-1,0.979786,0.020214062
16025,muscle atrophy,24,26,81,95,"Finally, a pair-fed (PF) study, performed in 18 rats (C, T, and PF), showed that muscle atrophy was considerably less pronounced in PF animals than in T-treated animals.",8665051_11,-1,-1,-1,16025,-1,0.0037734357,0.99622655
16037,renal disease,26,28,173,186,"Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end-stage renal disease (ESRD), with a relative risk in the range of 4 to 19.",8669433_1,-1,-1,-1,16037,-1,0.0028526348,0.9971474
16038,ESRD,29,30,188,192,"Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end-stage renal disease (ESRD), with a relative risk in the range of 4 to 19.",8669433_1,-1,-1,-1,16038,-1,0.003076841,0.99692315
16042,ESRD,36,37,202,206,"However, three case control studies, one each in North Carolina, northern Maryland, and West Berlin, Germany, showed that habitual use of acetaminophen is also associated with chronic renal failure and ESRD, with a relative risk in the range of 2 to 4.",8669433_3,-1,-1,-1,16042,-1,0.002768258,0.9972318
16045,ESRD,14,15,93,97,"These studies suggest that both phenacetin and acetaminophen may contribute to the burden of ESRD, with the risk of the latter being somewhat less than that of the former.",8669433_4,-1,-1,-1,16045,-1,0.0028661105,0.99713385
16051,ESRD,12,13,79,83,"The possibility that habitual use of acetaminophen alone increases the risk of ESRD has not been clearly demonstrated, but cannot be dismissed.",8669433_8,-1,-1,-1,16051,-1,0.0026622126,0.99733776
16053,hemorrhagic cystitis,8,10,78,98,Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.,8677458_0,-1,-1,-1,16053,-1,0.0020460482,0.9979539
16061,emesis,34,35,223,229,"In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations, such as in a patient taking oral mesna who experiences severe ifosfamide-induced emesis and is unable to absorb the drug.",8677458_4,-1,-1,-1,16061,-1,0.0020825525,0.9979175
16071,critically ill,4,6,27,41,This article describes two critically ill patients in whom transient episodes of hypotension reproducibly developed after administration of acetaminophen.,8682684_4,-1,-1,-1,16071,-1,0.0042032297,0.9957968
16076,vasopressor,8,9,55,66,The hypotensive episodes were severe enough to require vasopressor administration.,8682684_6,-1,-1,-1,16076,-1,0.99876714,0.0012328723
16079,Leg and back pain,0,4,0,17,Leg and back pain after spinal anaesthesia involving hyperbaric 5% lignocaine.,8686832_0,-1,-1,-1,16079,-1,0.005020955,0.9949791
16084,p,6,7,36,37,The patients affected were younger (p < 0.05) and the site of the dural puncture was higher (p < 0.01) than those individuals without pain.,8686832_3,-1,-1,-1,16084,-1,0.2820141,0.7179859
16085,p,20,21,93,94,The patients affected were younger (p < 0.05) and the site of the dural puncture was higher (p < 0.01) than those individuals without pain.,8686832_3,-1,-1,-1,16085,-1,0.36620712,0.6337929
16090,Leg and/or back pain,0,4,0,20,Leg and/or back pain is associated with the intrathecal use of hyperbaric 5% lignocaine.,8686832_5,-1,-1,-1,16090,-1,0.004947357,0.99505264
16095,cuprolinic blue,33,35,223,238,"Heparan sulphate-associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by streptozotocin and in age- adn sex-matched control rats, employing the cationic dye cuprolinic blue.",8690168_1,-1,-1,-1,16095,-1,0.99846494,0.0015351388
16096,heparan sulphate,1,3,4,20,"The heparan sulphate specificity of the cuprolinic blue staining was demonstrated by glycosaminoglycan-degrading enzymes, showing that pretreatment of the sections with heparitinase abolished all staining, whereas chondroitinase ABC had no effect.",8690168_3,-1,-1,-1,16096,-1,0.99652785,0.0034721107
16097,cuprolinic blue,6,8,40,55,"The heparan sulphate specificity of the cuprolinic blue staining was demonstrated by glycosaminoglycan-degrading enzymes, showing that pretreatment of the sections with heparitinase abolished all staining, whereas chondroitinase ABC had no effect.",8690168_3,-1,-1,-1,16097,-1,0.9986203,0.0013797837
16099,p<0.001,33,34,202,209,"A minority of anionic sites were scattered throughout the lamina densa and lamina rara interna, and were significantly smaller than those in the lamina rara externa of the glomerular basement membrane (p<0.001 and p<0.01 for diabetic and control rats, respectively).",8690168_5,-1,-1,-1,16099,-1,0.5263813,0.47361875
16103,h,13,14,82,83,"Diabetic rats progressively developed albuminuria reaching 40.3 (32.2-62.0) mg/24 h after 8 months in contrast to the control animals (0.8 (0.2-0.9) mg/24 h, p<0.002).",8690168_6,-1,-1,-1,16103,-1,0.7621364,0.23786362
16104,contrast,18,19,102,110,"Diabetic rats progressively developed albuminuria reaching 40.3 (32.2-62.0) mg/24 h after 8 months in contrast to the control animals (0.8 (0.2-0.9) mg/24 h, p<0.002).",8690168_6,-1,-1,-1,16104,-1,0.10430289,0.89569706
16105,h,31,32,155,156,"Diabetic rats progressively developed albuminuria reaching 40.3 (32.2-62.0) mg/24 h after 8 months in contrast to the control animals (0.8 (0.2-0.9) mg/24 h, p<0.002).",8690168_6,-1,-1,-1,16105,-1,0.7051596,0.29484037
16106,p<0.002,33,34,158,165,"Diabetic rats progressively developed albuminuria reaching 40.3 (32.2-62.0) mg/24 h after 8 months in contrast to the control animals (0.8 (0.2-0.9) mg/24 h, p<0.002).",8690168_6,-1,-1,-1,16106,-1,0.3660206,0.63397944
16107,heparan sulphate,8,10,32,48,"At the same time, the number of heparan sulphate anionic sites and the total anionic site surface (number of anionic sites x mean anionic site surface) in the lamina rara externa of the glomerular basement membrane was reduced by 19% (p<0.021) and by 26% (p<0.02), respectively.",8690168_7,-1,-1,-1,16107,-1,0.99857247,0.0014275318
16108,p<0.021,45,46,235,242,"At the same time, the number of heparan sulphate anionic sites and the total anionic site surface (number of anionic sites x mean anionic site surface) in the lamina rara externa of the glomerular basement membrane was reduced by 19% (p<0.021) and by 26% (p<0.02), respectively.",8690168_7,-1,-1,-1,16108,-1,0.4338838,0.5661162
16109,p<0.02,52,53,256,262,"At the same time, the number of heparan sulphate anionic sites and the total anionic site surface (number of anionic sites x mean anionic site surface) in the lamina rara externa of the glomerular basement membrane was reduced by 19% (p<0.021) and by 26% (p<0.02), respectively.",8690168_7,-1,-1,-1,16109,-1,0.45528725,0.5447128
16110,heparan sulphate,15,17,104,120,"We conclude that in streptozotocin-diabetic rats with an increased urinary albumin excretion, a reduced heparan sulphate charge barrier/density is found at the lamina rara externa of the glomerular basement membrane.",8690168_9,-1,-1,-1,16110,-1,0.9980673,0.0019326728
16113,MK-486,18,19,112,118,L-Dopa (5 mg/kg i.v.) decreased blood pressure and heart rate after extracerebral decarboxylase inhibition with MK-486 (25 mg/kg i.v.) in anesthetize MAO-inhibited dogs.,869641_1,-1,-1,-1,16113,-1,0.9978237,0.002176287
16117,FLA-63,0,1,0,6,"FLA-63, a dopamine-beta-oxidase inhibitor, did not have any effect on the hypotension, bradycardia or reflex-enhancing effect of L-dopa.",869641_3,-1,-1,-1,16117,-1,0.99790704,0.0020929778
16120,Pimozide,0,1,0,8,Pimozide did not affect the actions of L-dopa on blood pressure and heart rate but completely blocked the enhancement of reflexes.,869641_4,-1,-1,-1,16120,-1,0.9993205,0.0006795284
16124,5-HTP,0,1,0,5,5-HTP (5 mg/kg i.v.) decreased blood pressure and heart rate and decreased the reflex bradycardia to norepinephrine.,869641_7,-1,-1,-1,16124,-1,0.99820924,0.0017908232
16130,FK506,4,5,47,52,Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy.,8701950_0,-1,-1,-1,16130,-1,0.99903333,0.0009667171
16132,microangiopathic hemolytic anemia,5,8,26,59,We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.,8701950_1,-1,-1,-1,16132,-1,0.002588671,0.9974113
16133,MAHA,9,10,61,65,We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.,8701950_1,-1,-1,-1,16133,-1,0.0041449233,0.99585503
16134,FK506,17,18,101,106,We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.,8701950_1,-1,-1,-1,16134,-1,0.9991505,0.0008494504
16136,FK506,6,7,34,39,"In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and dipyridamole led to resolution of MAHA.",8701950_2,-1,-1,-1,16136,-1,0.9992323,0.0007677514
16140,MAHA,28,29,173,177,"In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and dipyridamole led to resolution of MAHA.",8701950_2,-1,-1,-1,16140,-1,0.016902445,0.98309755
16141,FK506,6,7,34,39,"In one patient, reintroduction of FK506 led to rapid recurrence of MAHA.",8701950_3,-1,-1,-1,16141,-1,0.9991196,0.0008804003
16142,MAHA,12,13,67,71,"In one patient, reintroduction of FK506 led to rapid recurrence of MAHA.",8701950_3,-1,-1,-1,16142,-1,0.125331,0.87466896
16143,MAHA,1,2,17,21,FK506-associated MAHA is probably rare but physicians must be aware of this severe complication.,8701950_4,-1,-1,-1,16143,-1,0.0060319873,0.993968
16144,FK506,9,10,51,56,"In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.",8701950_5,-1,-1,-1,16144,-1,0.99921703,0.0007829343
16145,cyclosporin A,16,18,91,104,"In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.",8701950_5,-1,-1,-1,16145,-1,0.99825925,0.0017408098
16146,CyA,19,20,106,109,"In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.",8701950_5,-1,-1,-1,16146,-1,0.99666935,0.0033306899
16147,MAHA,29,30,163,167,"In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.",8701950_5,-1,-1,-1,16147,-1,0.0156064425,0.98439354
16148,succinylcholine apnoea,6,8,35,57,The use of serum cholinesterase in succinylcholine apnoea.,871943_0,-1,-1,-1,16148,-1,0.56202805,0.43797192
16152,succinylcholine apnoea,6,8,35,57,The use of serum cholinesterase in succinylcholine apnoea provided considerable relief to both patient and anaesthetist.,871943_6,-1,-1,-1,16152,-1,0.59992254,0.4000775
16153,deoxycholic acid,6,8,58,74,Increased sulfation and decreased 7alpha-hydroxylation of deoxycholic acid in ethinyl estradiol-induced cholestasis in rats.,873132_0,-1,-1,-1,16153,-1,0.9988944,0.001105588
16155,Deoxycholic acid,0,2,0,16,"Deoxycholic acid conjugation, transport capacity, and metabolism were compared in control and ethinyl estradiol-treated rats.",873132_1,-1,-1,-1,16155,-1,0.9986992,0.0013008156
16156,deoxycholic acid,11,13,62,78,"Control rats were found to have a lower capacity to transport deoxycholic acid than taurodeoxycholic acid, and both were decreased by ethinyl estradiol treatment.",873132_2,-1,-1,-1,16156,-1,0.9988223,0.0011776782
16157,taurodeoxycholic acid,14,16,84,105,"Control rats were found to have a lower capacity to transport deoxycholic acid than taurodeoxycholic acid, and both were decreased by ethinyl estradiol treatment.",873132_2,-1,-1,-1,16157,-1,0.9988669,0.0011331323
16158,ethinyl estradiol,22,24,134,151,"Control rats were found to have a lower capacity to transport deoxycholic acid than taurodeoxycholic acid, and both were decreased by ethinyl estradiol treatment.",873132_2,-1,-1,-1,16158,-1,0.9988023,0.0011977302
16159,14C]sodium deoxycholate,3,5,11,34,"During [24-14C]sodium deoxycholate infusion, [14C]biliary bile acid secretion increased, but bile flow did not change significantly in either control or ethinyl estradiol-treated rats.",873132_3,-1,-1,-1,16159,-1,0.9972779,0.0027220543
16160,bile acid,8,10,58,67,"During [24-14C]sodium deoxycholate infusion, [14C]biliary bile acid secretion increased, but bile flow did not change significantly in either control or ethinyl estradiol-treated rats.",873132_3,-1,-1,-1,16160,-1,0.9966133,0.003386687
16161,taurocholic acid,8,10,69,85,"Ethinyl estradiol-treated animals excreted significantly less 14C as taurocholic acid than did control animals, consistent with an impairment of 7alpha-hydroxylation of taurodeoxycholic acid.",873132_4,-1,-1,-1,16161,-1,0.9987679,0.0012320364
16162,taurodeoxycholic acid,22,24,169,190,"Ethinyl estradiol-treated animals excreted significantly less 14C as taurocholic acid than did control animals, consistent with an impairment of 7alpha-hydroxylation of taurodeoxycholic acid.",873132_4,-1,-1,-1,16162,-1,0.99864,0.0013600249
16163,deoxycholic acid,8,10,58,74,"Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid, but did result in an increase in sulfation of taurodeoxycholic acid from 1.5% in controls to nearly 4.0% (P less than 0.01).",873132_5,-1,-1,-1,16163,-1,0.99834216,0.0016578292
16164,taurodeoxycholic acid,20,22,122,143,"Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid, but did result in an increase in sulfation of taurodeoxycholic acid from 1.5% in controls to nearly 4.0% (P less than 0.01).",873132_5,-1,-1,-1,16164,-1,0.99880886,0.0011911518
16165,P,32,33,182,183,"Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid, but did result in an increase in sulfation of taurodeoxycholic acid from 1.5% in controls to nearly 4.0% (P less than 0.01).",873132_5,-1,-1,-1,16165,-1,0.3416045,0.6583955
16166,deoxycholic acid,15,17,89,105,These results are consistent with the hypothesis that the rat has a poorer tolerance for deoxycholic acid than do certain other species.,873132_6,-1,-1,-1,16166,-1,0.9989324,0.0010675723
16167,deoxycholic acid,5,7,30,46,"Furthermore, the rat converts deoxycholic acid, a poor choleretic, to taurocholic acid, a good choleretic.",873132_7,-1,-1,-1,16167,-1,0.9987565,0.0012434295
16168,taurocholic acid,13,15,70,86,"Furthermore, the rat converts deoxycholic acid, a poor choleretic, to taurocholic acid, a good choleretic.",873132_7,-1,-1,-1,16168,-1,0.9987446,0.0012553476
16169,ethinyl estradiol,6,8,38,55,"When this conversion is impaired with ethinyl estradiol treatment, sulfation may be an important alternate pathway for excretion of this potentially harmful bile acid.",873132_8,-1,-1,-1,16169,-1,0.9988065,0.0011935346
16170,bile acid,23,25,157,166,"When this conversion is impaired with ethinyl estradiol treatment, sulfation may be an important alternate pathway for excretion of this potentially harmful bile acid.",873132_8,-1,-1,-1,16170,-1,0.9858575,0.014142497
16173,nitrogranulogen,8,9,51,66,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16173,-1,0.99715424,0.002845728
16174,NG,10,11,68,70,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16174,-1,0.99640095,0.0035990325
16176,MTX,15,16,87,90,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16176,-1,0.9975575,0.0024424107
16178,5-FU,20,21,109,113,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16178,-1,0.99740463,0.002595303
16180,CY,25,26,137,139,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16180,-1,0.99774927,0.0022506774
16181,MTX,33,34,179,182,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16181,-1,0.9971904,0.0028096524
16182,5-FU,35,36,185,189,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16182,-1,0.9975338,0.0024661818
16183,CY,37,38,192,194,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,-1,-1,-1,16183,-1,0.9974011,0.0025989471
16186,MTX,1,2,6,9,After MTX administration a significant increase (p = 0.0228) in the plasma creatinine concentration and a significant (p = 0.0001) decrease in creatinine clearance was noted compared to controls.,8739323_4,-1,-1,-1,16186,-1,0.9988256,0.001174409
16187,p,7,8,49,50,After MTX administration a significant increase (p = 0.0228) in the plasma creatinine concentration and a significant (p = 0.0001) decrease in creatinine clearance was noted compared to controls.,8739323_4,-1,-1,-1,16187,-1,0.3345935,0.66540647
16189,p,20,21,119,120,After MTX administration a significant increase (p = 0.0228) in the plasma creatinine concentration and a significant (p = 0.0001) decrease in creatinine clearance was noted compared to controls.,8739323_4,-1,-1,-1,16189,-1,0.30274186,0.6972581
16191,NG,4,5,28,30,"After the administration of NG, 5-FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics.",8739323_5,-1,-1,-1,16191,-1,0.998382,0.0016180336
16192,5-FU,6,7,32,36,"After the administration of NG, 5-FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics.",8739323_5,-1,-1,-1,16192,-1,0.9985758,0.001424239
16193,CY,8,9,41,43,"After the administration of NG, 5-FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics.",8739323_5,-1,-1,-1,16193,-1,0.99900395,0.0009960277
16196,CMF regimen,5,7,39,50,"Following polytherapy according to the CMF regimen, a statistically significant decrease (p = 0.0343) in creatinine clearance was found, but creatinine concentration did not increase significantly compared to controls.",8739323_6,-1,-1,-1,16196,-1,0.9861438,0.0138561595
16197,p,13,14,90,91,"Following polytherapy according to the CMF regimen, a statistically significant decrease (p = 0.0343) in creatinine clearance was found, but creatinine concentration did not increase significantly compared to controls.",8739323_6,-1,-1,-1,16197,-1,0.3225001,0.6774999
16200,CY,0,1,0,2,"CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.",8739323_7,-1,-1,-1,16200,-1,0.9981573,0.0018427209
16201,hemorrhagic cystitis,2,4,10,30,"CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.",8739323_7,-1,-1,-1,16201,-1,0.0021057022,0.99789435
16202,5-FU,20,21,105,109,"CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.",8739323_7,-1,-1,-1,16202,-1,0.99854386,0.0014561067
16203,MTX,22,23,114,117,"CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.",8739323_7,-1,-1,-1,16203,-1,0.9987232,0.0012767792
16204,MTX,10,11,69,72,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16204,-1,0.9989624,0.0010375581
16205,CY,12,13,74,76,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16205,-1,0.9988217,0.0011782981
16206,NG,14,15,81,83,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16206,-1,0.9987054,0.0012945746
16207,5-FU,23,24,125,129,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16207,-1,0.9988275,0.0011725064
16208,MTX,28,29,158,161,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16208,-1,0.99881727,0.0011827558
16209,5-FU,30,31,164,168,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16209,-1,0.9984804,0.0015195915
16210,CY,32,33,171,173,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,-1,-1,-1,16210,-1,0.9986915,0.0013085696
16212,MTX,6,7,44,47,Our studies indicate that nephrotoxicity of MTX + 5-FU + CY administered jointly is lower than in monotherapy.,8739323_9,-1,-1,-1,16212,-1,0.9988439,0.0011561112
16213,5-FU,8,9,50,54,Our studies indicate that nephrotoxicity of MTX + 5-FU + CY administered jointly is lower than in monotherapy.,8739323_9,-1,-1,-1,16213,-1,0.99858534,0.0014147306
16214,CY,10,11,57,59,Our studies indicate that nephrotoxicity of MTX + 5-FU + CY administered jointly is lower than in monotherapy.,8739323_9,-1,-1,-1,16214,-1,0.9990007,0.0009992584
16216,kainic acid,5,7,31,42,Partial lesions were made with kainic acid in the interpeduncular nucleus of the ventral midbrain of the rat.,8741744_1,-1,-1,-1,16216,-1,0.9993012,0.0006987796
16217,p,8,9,61,62,"Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity.",8741744_2,-1,-1,-1,16217,-1,0.5447039,0.45529613
16218,locomotor hypoactivity,21,23,110,132,"Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity.",8741744_2,-1,-1,-1,16218,-1,0.0038561933,0.9961438
16220,mg,28,29,157,159,"Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity.",8741744_2,-1,-1,-1,16220,-1,0.95424366,0.04575634
16223,p,15,16,120,121,"Lesions reduced the extent of immunohistological staining for choline acetyltransferase in the interpeduncular nucleus (p <0.025), but not for tyrosine hydroxylase in the surrounding catecholaminergic A10 region.",8741744_3,-1,-1,-1,16223,-1,0.44470742,0.55529255
16226,acetaminophen hepatotoxicity,7,9,44,72,Influence of diet free of NAD-precursors on acetaminophen hepatotoxicity in mice.,8742498_0,-1,-1,-1,16226,-1,0.58437,0.41562995
16227,nicotinic acid amide,8,11,58,78,"Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.",8742498_1,-1,-1,-1,16227,-1,0.9982703,0.0017296637
16230,NAD,13,14,75,78,"The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.",8742498_2,-1,-1,-1,16230,-1,0.9985574,0.0014426151
16231,AAP hepatitis,27,29,139,152,"The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.",8742498_2,-1,-1,-1,16231,-1,0.77907515,0.22092485
16233,Liver injuries,0,2,0,14,Liver injuries were quantified as serum activities of glutamate-oxaloacetate transaminase (GOT) and glutamate-pyruvate transaminase (GPT).,8742498_3,-1,-1,-1,16233,-1,0.0030334683,0.99696654
16234,AAP,1,2,6,9,"While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.",8742498_4,-1,-1,-1,16234,-1,0.9983889,0.0016111779
16236,nicotinic acid amide,28,31,179,199,"While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.",8742498_4,-1,-1,-1,16236,-1,0.99822515,0.0017748525
16237,NAA,32,33,201,204,"While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.",8742498_4,-1,-1,-1,16237,-1,0.9972722,0.0027277712
16238,AAP,17,18,105,108,"In these animals, only minor increases of serum transaminase activities were measured in the presence of AAP, and unlike the exacerbation caused by ethanol in mice on a standard diet, the liver damage was inhibited by 50% by ethanol.",8742498_5,-1,-1,-1,16238,-1,0.9983265,0.0016734926
16243,NAA,11,12,56,59,"A further 64% reduction of hepatitis was observed, when NAA was given to ethanol/AAP-mice.",8742498_6,-1,-1,-1,16243,-1,0.99877816,0.0012218853
16246,NAA,23,24,151,154,Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.,8742498_7,-1,-1,-1,16246,-1,0.9983102,0.0016897458
16247,NAD,33,34,205,208,Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.,8742498_7,-1,-1,-1,16247,-1,0.9980894,0.0019106051
16248,NAA,6,7,31,34,We see the main application of NAA as for the combinational use in pharmaceutical preparations of acetaminophen in order to avoid hepatic damage in patients treated with this widely used analgesic.,8742498_8,-1,-1,-1,16248,-1,0.99864596,0.0013540386
16251,cognitive and functional deficits,1,5,19,52,Lithium-associated cognitive and functional deficits reduced by a switch to divalproex sodium: a case series.,8752018_0,-1,-1,-1,16251,-1,0.0038304378,0.9961695
16252,divalproex sodium,10,12,76,93,Lithium-associated cognitive and functional deficits reduced by a switch to divalproex sodium: a case series.,8752018_0,-1,-1,-1,16252,-1,0.9985966,0.0014033313
16254,bipolar disorder,14,16,94,110,BACKGROUND: Lithium remains a first-line treatment for the acute and maintenance treatment of bipolar disorder.,8752018_1,-1,-1,-1,16254,-1,0.0069492026,0.9930508
16260,loss of creativity,33,36,189,207,"Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.",8752018_2,-1,-1,-1,16260,-1,0.04522741,0.9547726
16261,functional,38,39,213,223,"Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.",8752018_2,-1,-1,-1,16261,-1,0.009562687,0.9904373
16264,divalproex sodium,12,14,84,101,This report summarizes our experience in switching bipolar patients from lithium to divalproex sodium to alleviate such cognitive and functional impairments.,8752018_3,-1,-1,-1,16264,-1,0.99872524,0.0012747598
16265,cognitive and functional impairments,17,21,120,156,This report summarizes our experience in switching bipolar patients from lithium to divalproex sodium to alleviate such cognitive and functional impairments.,8752018_3,-1,-1,-1,16265,-1,0.0043492443,0.9956508
16267,divalproex sodium,17,19,94,111,"RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients.",8752018_5,-1,-1,-1,16267,-1,0.9986688,0.0013312593
16268,"cognitive, motivational, or creative deficits",25,32,150,195,"RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients.",8752018_5,-1,-1,-1,16268,-1,0.011829174,0.98817086
16271,divalproex sodium,7,9,40,57,"CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.",8752018_6,-1,-1,-1,16271,-1,0.99884284,0.0011571435
16275,loss of creativity,22,25,149,167,"CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.",8752018_6,-1,-1,-1,16275,-1,0.037661277,0.9623388
16276,functional impairments,27,29,173,195,"CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.",8752018_6,-1,-1,-1,16276,-1,0.0049328757,0.9950671
16278,tramadol,7,8,56,64,Nightmares and hallucinations after long-term intake of tramadol combined with antidepressants.,8766220_0,-1,-1,-1,16278,-1,0.9994597,0.00054035214
16280,Tramadol,0,1,0,8,Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain.,8766220_1,-1,-1,-1,16280,-1,0.99956137,0.00043865357
16281,cancer pain,17,19,110,121,Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain.,8766220_1,-1,-1,-1,16281,-1,0.0081264265,0.99187356
16284,dosulepine hydrochloride,9,11,59,83,This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.,8766220_2,-1,-1,-1,16284,-1,0.9988949,0.0011051159
16285,tetraparetic,13,14,89,101,This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.,8766220_2,-1,-1,-1,16285,-1,0.004226295,0.99577373
16286,chronic pain,16,18,115,127,This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.,8766220_2,-1,-1,-1,16286,-1,0.002895536,0.99710447
16288,tramadol,21,22,152,160,Fifty-six days after initiation of the treatment the patient presented hallucinations that only stopped after the withdrawal of psycho-active drugs and tramadol.,8766220_3,-1,-1,-1,16288,-1,0.99947363,0.00052638777
16292,calcium chloride,2,4,10,26,Effect of calcium chloride and 4-aminopyridine therapy on desipramine toxicity in rats.,8800187_0,-1,-1,-1,16292,-1,0.9985884,0.0014115955
16293,4-aminopyridine,5,6,31,46,Effect of calcium chloride and 4-aminopyridine therapy on desipramine toxicity in rats.,8800187_0,-1,-1,-1,16293,-1,0.9985184,0.0014816561
16294,desipramine toxicity,8,10,58,78,Effect of calcium chloride and 4-aminopyridine therapy on desipramine toxicity in rats.,8800187_0,-1,-1,-1,16294,-1,0.9092449,0.090755075
16296,antidepressant overdose,11,13,73,96,BACKGROUND: Hypotension is a major contributor to mortality in tricyclic antidepressant overdose.,8800187_1,-1,-1,-1,16296,-1,0.09754783,0.9024522
16303,4-aminopyridine,2,3,10,25,CaCl2 and 4-aminopyridine.,8800187_5,-1,-1,-1,16303,-1,0.99738556,0.0026144674
16304,antidepressant desipramine,5,7,41,67,"Anesthetized rats received the tricyclic antidepressant desipramine IP to produce hypotension, QRS prolongation, and bradycardia.",8800187_6,-1,-1,-1,16304,-1,0.998979,0.0010210001
16307,CaCl2,6,7,36,41,"Fifteen min later, animals received CaCl2, NaHCO3, or saline.",8800187_7,-1,-1,-1,16307,-1,0.9980976,0.0019023826
16308,NaHCO3,8,9,43,49,"Fifteen min later, animals received CaCl2, NaHCO3, or saline.",8800187_7,-1,-1,-1,16308,-1,0.9966853,0.0033146648
16309,antidepressant desipramine,8,10,48,74,"In a second experiment, rats received tricyclic antidepressant desipramine IP followed in 15 min by 4-aminopyridine or saline.",8800187_8,-1,-1,-1,16309,-1,0.99917126,0.00082873355
16310,4-aminopyridine,16,17,100,115,"In a second experiment, rats received tricyclic antidepressant desipramine IP followed in 15 min by 4-aminopyridine or saline.",8800187_8,-1,-1,-1,16310,-1,0.9983883,0.001611738
16311,NaHCO3,2,3,9,15,RESULTS: NaHCO3 briefly (5 min) reversed hypotension and QRS prolongation.,8800187_9,-1,-1,-1,16311,-1,0.99849296,0.0015070589
16313,4-aminopyridine,2,3,10,25,CaCl2 and 4-aminopyridine failed to improve blood pressure.,8800187_10,-1,-1,-1,16313,-1,0.9983134,0.0016865797
16315,p,6,7,42,43,The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups.,8800187_11,-1,-1,-1,16315,-1,0.21277718,0.78722286
16317,p,13,14,67,68,The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups.,8800187_11,-1,-1,-1,16317,-1,0.18944982,0.81055015
16318,CaCl2,19,20,84,89,The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups.,8800187_11,-1,-1,-1,16318,-1,0.998445,0.0015550607
16319,4-aminopyridine,7,8,43,58,CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.,8800187_12,-1,-1,-1,16319,-1,0.9986639,0.0013361024
16321,CaCl2,0,1,0,5,CaCl2 therapy may possibly worsen both cardiovascular and central nervous system toxicity.,8800187_13,-1,-1,-1,16321,-1,0.9985317,0.0014683022
16341,comatose,5,6,32,40,"Four patients who were rendered comatose or stuporous by drug intoxication, but who were not hypoxic, are described.",88336_1,-1,-1,-1,16341,-1,0.0052764765,0.99472356
16342,stuporous,7,8,44,53,"Four patients who were rendered comatose or stuporous by drug intoxication, but who were not hypoxic, are described.",88336_1,-1,-1,-1,16342,-1,0.004721886,0.9952781
16343,drug intoxication,9,11,57,74,"Four patients who were rendered comatose or stuporous by drug intoxication, but who were not hypoxic, are described.",88336_1,-1,-1,-1,16343,-1,0.10761876,0.89238125
16344,hypoxic,16,17,93,100,"Four patients who were rendered comatose or stuporous by drug intoxication, but who were not hypoxic, are described.",88336_1,-1,-1,-1,16344,-1,0.006356709,0.9936433
16345,chlormethiazole,6,7,38,53,"Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of nitrazepam.",88336_2,-1,-1,-1,16345,-1,0.99926347,0.0007365876
16346,alcohol withdrawal symptoms,8,11,58,85,"Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of nitrazepam.",88336_2,-1,-1,-1,16346,-1,0.05689651,0.94310343
16348,nitrazepam,19,20,123,133,"Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of nitrazepam.",88336_2,-1,-1,-1,16348,-1,0.9991111,0.0008888841
16349,nitrazepam overdose,3,5,17,36,"The patient with nitrazepam overdose and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG.",88336_3,-1,-1,-1,16349,-1,0.5785658,0.42143416
16350,chlormethiazole,10,11,59,74,"The patient with nitrazepam overdose and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG.",88336_3,-1,-1,-1,16350,-1,0.99917173,0.00082832854
16352,chlormethiazole,7,8,45,60,The fourth patient who was unconscious after chlormethiazole administration exhibite generalized non-reactive activity in the slow beta range.,88336_4,-1,-1,-1,16352,-1,0.99924207,0.0007579995
16353,neurological sequelae,5,7,38,59,All four recovered completely without neurological sequelae following the withdrawal of the offending agents.,88336_5,-1,-1,-1,16353,-1,0.0024320902,0.99756783
16356,hypoxaemia,21,22,139,149,"It is concluded that when this electroencephalographic and behavioural picture is seen in drug intoxication, in the absence of significant hypoxaemia, a favourable outcome may be anticipated.",88336_8,-1,-1,-1,16356,-1,0.0043657236,0.99563426
16357,Valsartan,0,1,0,9,"Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.",8841157_0,-1,-1,-1,16357,-1,0.99930894,0.0006910952
16358,II,5,6,29,31,"Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.",8841157_0,-1,-1,-1,16358,-1,0.9950517,0.004948364
16359,essential hypertension,11,13,64,86,"Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.",8841157_0,-1,-1,-1,16359,-1,0.0050159167,0.99498403
16360,amlodipine,23,24,143,153,"Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.",8841157_0,-1,-1,-1,16360,-1,0.99916244,0.00083753833
16361,angiotensin II,10,12,61,75,"OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, valsartan, with a reference therapy, amlodipine.",8841157_1,-1,-1,-1,16361,-1,0.997163,0.0028369303
16362,valsartan,14,15,88,97,"OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, valsartan, with a reference therapy, amlodipine.",8841157_1,-1,-1,-1,16362,-1,0.9993832,0.000616729
16363,amlodipine,21,22,125,135,"OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, valsartan, with a reference therapy, amlodipine.",8841157_1,-1,-1,-1,16363,-1,0.9991786,0.00082133646
16365,mg valsartan,24,26,165,177,METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.,8841157_2,-1,-1,-1,16365,-1,0.99802136,0.0019786118
16366,mg amlodipine,28,30,183,196,METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.,8841157_2,-1,-1,-1,16366,-1,0.9977508,0.002249178
16367,mg amlodipine,15,17,84,97,"After 8 weeks of therapy, in patients whose blood pressure remained uncontrolled, 5 mg amlodipine was added to the initial therapy.",8841157_3,-1,-1,-1,16367,-1,0.99811244,0.0018875998
16368,valsartan,3,4,14,23,"RESULTS: Both valsartan and amlodipine were effective at lowering blood pressure at 4, 8, and 12 weeks.",8841157_7,-1,-1,-1,16368,-1,0.99936444,0.00063559785
16369,amlodipine,5,6,28,38,"RESULTS: Both valsartan and amlodipine were effective at lowering blood pressure at 4, 8, and 12 weeks.",8841157_7,-1,-1,-1,16369,-1,0.9992435,0.0007565627
16370,mm Hg,8,10,48,53,"For the primary variable the difference was 0.5 mm Hg in favor of valsartan (p = 0.68; 95% confidence interval, -2.7 to 1.7).",8841157_9,-1,-1,-1,16370,-1,0.6439819,0.3560182
16371,valsartan,13,14,66,75,"For the primary variable the difference was 0.5 mm Hg in favor of valsartan (p = 0.68; 95% confidence interval, -2.7 to 1.7).",8841157_9,-1,-1,-1,16371,-1,0.99922585,0.00077415473
16372,p,15,16,77,78,"For the primary variable the difference was 0.5 mm Hg in favor of valsartan (p = 0.68; 95% confidence interval, -2.7 to 1.7).",8841157_9,-1,-1,-1,16372,-1,0.41144657,0.58855337
16373,valsartan,9,10,42,51,Responder rates at 8 weeks were 66.7% for valsartan and 60.2% for amlodipine (p = 0.39).,8841157_10,-1,-1,-1,16373,-1,0.9993747,0.0006252796
16374,amlodipine,14,15,66,76,Responder rates at 8 weeks were 66.7% for valsartan and 60.2% for amlodipine (p = 0.39).,8841157_10,-1,-1,-1,16374,-1,0.9992453,0.0007547156
16375,p,16,17,78,79,Responder rates at 8 weeks were 66.7% for valsartan and 60.2% for amlodipine (p = 0.39).,8841157_10,-1,-1,-1,16375,-1,0.38094592,0.61905414
16377,amlodipine,11,12,73,83,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16377,-1,0.9992673,0.00073276693
16378,mg,20,21,120,122,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16378,-1,0.964128,0.03587197
16379,mg valsartan,28,30,144,156,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16379,-1,0.99772424,0.0022757298
16380,mg amlodipine,35,37,169,182,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16380,-1,0.9967037,0.0032962784
16381,valsartan,41,42,191,200,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16381,-1,0.9993679,0.0006320796
16382,mg amlodipine,44,46,208,221,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16382,-1,0.99553216,0.004467786
16383,mg amlodipine,51,53,236,249,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,-1,-1,-1,16383,-1,0.9960342,0.00396581
16384,valsartan,6,7,32,41,CONCLUSIONS: The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate hypertension.,8841157_13,-1,-1,-1,16384,-1,0.99944943,0.00055061217
16385,amlodipine,13,14,70,80,CONCLUSIONS: The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate hypertension.,8841157_13,-1,-1,-1,16385,-1,0.99931705,0.0006829528
16387,valsartan,4,5,22,31,"The results also show valsartan to be well tolerated and suggest that it is not associated with side effects characteristic of this comparator class, dihydropyridine calcium antagonists.",8841157_14,-1,-1,-1,16387,-1,0.9992149,0.00078513275
16388,dihydropyridine calcium antagonists,25,28,150,185,"The results also show valsartan to be well tolerated and suggest that it is not associated with side effects characteristic of this comparator class, dihydropyridine calcium antagonists.",8841157_14,-1,-1,-1,16388,-1,0.9976913,0.0023086942
16389,pupillary oscillation,3,5,13,34,A measure of pupillary oscillation as a marker of cocaine-induced paranoia.,8854309_0,-1,-1,-1,16389,-1,0.01830088,0.9816991
16390,paranoia,10,11,66,74,A measure of pupillary oscillation as a marker of cocaine-induced paranoia.,8854309_0,-1,-1,-1,16390,-1,0.0042740386,0.995726
16391,paranoia,1,2,16,24,Cocaine-induced paranoia (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.,8854309_1,-1,-1,-1,16391,-1,0.002969032,0.997031
16392,CIP,3,4,26,29,Cocaine-induced paranoia (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.,8854309_1,-1,-1,-1,16392,-1,0.014569701,0.98543024
16393,paranoia,12,13,85,93,Cocaine-induced paranoia (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.,8854309_1,-1,-1,-1,16393,-1,0.002909394,0.9970906
16394,pupillary oscillation,2,4,12,33,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16394,-1,0.05722674,0.9427733
16395,crack cocaine,13,15,94,107,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16395,-1,0.9984456,0.0015544514
16396,CIP,18,19,131,134,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16396,-1,0.064695805,0.9353042
16397,n,20,21,136,137,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16397,-1,0.27049473,0.7295053
16398,crack,28,29,166,171,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16398,-1,0.9978235,0.002176523
16399,CIP,33,34,196,199,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16399,-1,0.04650436,0.9534957
16400,n,35,36,201,202,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,-1,-1,-1,16400,-1,0.21300429,0.7869957
16402,phenytoin overdosages,10,12,75,96,Magnetic resonance volumetry of the cerebellum in epileptic patients after phenytoin overdosages.,8864707_0,-1,-1,-1,16402,-1,0.9552304,0.044769574
16404,cerebellar atrophy,14,16,88,106,The aim of this study was to evaluate the relationship between phenytoin medication and cerebellar atrophy in patients who had experienced clinical intoxication.,8864707_1,-1,-1,-1,16404,-1,0.0027193825,0.9972806
16408,phenytoin overdosage,3,5,17,37,We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.,8864707_10,-1,-1,-1,16408,-1,0.9593662,0.040633764
16409,cerebellar atrophy,10,12,69,87,We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.,8864707_10,-1,-1,-1,16409,-1,0.0023416614,0.9976584
16411,cerebellar atrophy,24,26,155,173,We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.,8864707_10,-1,-1,-1,16411,-1,0.0024212534,0.9975788
16412,cerebellar disorders,13,15,103,123,Quantitative morphometric studies of the cerebellum provide valuable insights into the pathogenesis of cerebellar disorders.,8864707_11,-1,-1,-1,16412,-1,0.0035662823,0.99643373
16413,Serotonin syndrome,0,2,0,18,Serotonin syndrome from venlafaxine-tranylcypromine interaction.,8888541_0,-1,-1,-1,16413,-1,0.08123935,0.91876066
16415,muscle rigidity,17,19,117,132,"Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.",8888541_1,-1,-1,-1,16415,-1,0.003401062,0.9965989
16416,salivation,20,21,134,144,"Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.",8888541_1,-1,-1,-1,16416,-1,0.005344184,0.99465585
16420,monoamine oxidase,12,14,67,84,The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.,8888541_2,-1,-1,-1,16420,-1,0.99756026,0.0024397355
16426,serotonin syndrome,9,11,62,80,We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.,8888541_4,-1,-1,-1,16426,-1,0.1744235,0.82557654
16427,tranylcypromine,18,19,115,130,We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.,8888541_4,-1,-1,-1,16427,-1,0.9990509,0.000949038
16430,h,2,3,9,10,"Within 2 h he became confused with jerking movements of his extremities, tremors and rigidity.",8888541_6,-1,-1,-1,16430,-1,0.07588366,0.9241164
16435,salivation,24,25,128,138,"He was brought directly to a hospital where he was found to be agitated and confused with shivering, myoclonic jerks, rigidity, salivation and diaphoresis.",8888541_7,-1,-1,-1,16435,-1,0.008906938,0.9910931
16436,diaphoresis,26,27,143,154,"He was brought directly to a hospital where he was found to be agitated and confused with shivering, myoclonic jerks, rigidity, salivation and diaphoresis.",8888541_7,-1,-1,-1,16436,-1,0.06241757,0.93758243
16437,mm,4,5,18,20,His pupils were 7 mm and sluggishly reactive to light.,8888541_8,-1,-1,-1,16437,-1,0.0624471,0.93755287
16438,mm Hg,7,9,40,45,"Vital signs were: blood pressure 120/67 mm Hg, heart rate 127/min, respiratory rate 28/min, and temperature 97 F. After 180 mg of diazepam i.v. he remained tremulous with muscle rigidity and clenched jaws.",8888541_9,-1,-1,-1,16438,-1,0.44559568,0.5544044
16439,mg,24,25,124,126,"Vital signs were: blood pressure 120/67 mm Hg, heart rate 127/min, respiratory rate 28/min, and temperature 97 F. After 180 mg of diazepam i.v. he remained tremulous with muscle rigidity and clenched jaws.",8888541_9,-1,-1,-1,16439,-1,0.98858416,0.011415821
16441,muscle rigidity,33,35,171,186,"Vital signs were: blood pressure 120/67 mm Hg, heart rate 127/min, respiratory rate 28/min, and temperature 97 F. After 180 mg of diazepam i.v. he remained tremulous with muscle rigidity and clenched jaws.",8888541_9,-1,-1,-1,16441,-1,0.004103987,0.995896
16442,hypoventilation,9,10,54,69,"He was intubated for airway protection and because of hypoventilation, and was paralyzed to control muscle rigidity.",8888541_10,-1,-1,-1,16442,-1,0.6776954,0.3223046
16443,paralyzed,13,14,79,88,"He was intubated for airway protection and because of hypoventilation, and was paralyzed to control muscle rigidity.",8888541_10,-1,-1,-1,16443,-1,0.96891296,0.031087078
16444,muscle rigidity,16,18,100,115,"He was intubated for airway protection and because of hypoventilation, and was paralyzed to control muscle rigidity.",8888541_10,-1,-1,-1,16444,-1,0.0048600133,0.99513996
16450,HUS,10,11,53,56,A case is reported of the hemolytic uremic syndrome (HUS) in a woman taking oral contraceptives.,891050_1,-1,-1,-1,16450,-1,0.0025564388,0.99744356
16455,HUS,6,7,42,45,"This case emphasizes the possibility that HUS in adults is not invariably irreversible and that, despite prolonged oliguria, recovery of renal function can be obtained.",891050_3,-1,-1,-1,16455,-1,0.003068432,0.99693155
16456,oliguria,18,19,115,123,"This case emphasizes the possibility that HUS in adults is not invariably irreversible and that, despite prolonged oliguria, recovery of renal function can be obtained.",891050_3,-1,-1,-1,16456,-1,0.0061384384,0.99386156
16457,HUS,7,8,41,44,"Therefore, in adult patients affected by HUS, dialysis should not be discontinued prematurely; moreover, bilateral nephrectomy, for treatment of severe hypertension and microangiopathic hemolytic anemia, should be performed with caution.",891050_4,-1,-1,-1,16457,-1,0.0038235083,0.9961765
16459,microangiopathic hemolytic anemia,27,30,169,202,"Therefore, in adult patients affected by HUS, dialysis should not be discontinued prematurely; moreover, bilateral nephrectomy, for treatment of severe hypertension and microangiopathic hemolytic anemia, should be performed with caution.",891050_4,-1,-1,-1,16459,-1,0.003829319,0.9961707
16463,urothelial cancer,15,17,102,119,"PURPOSE: We gained knowledge of the etiology, treatment and prevention of cyclophosphamide associated urothelial cancer.",8911359_1,-1,-1,-1,16463,-1,0.0061205854,0.99387944
16470,bladder tumor,4,6,41,54,CONCLUSIONS: Cyclophosphamide associated bladder tumor is an aggressive disease.,8911359_7,-1,-1,-1,16470,-1,0.0039663785,0.9960336
16471,bladder tumors,12,14,81,95,"However, long-term survival is possible when radical cystectomy is performed for bladder tumors with any sign of invasion and for recurrent high grade disease, even when noninvasive.",8911359_8,-1,-1,-1,16471,-1,0.008159425,0.9918406
16473,valproate,11,12,96,105,Morphological features of encephalopathy after chronic administration of the antiepileptic drug valproate to rats.,8919272_0,-1,-1,-1,16473,-1,0.99913955,0.00086040533
16474,sodium valproate,7,9,61,77,"Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral ""Polfa"") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (""valproate encephalopathy"").",8919272_2,-1,-1,-1,16474,-1,0.9992286,0.0007713678
16475,Vupral,10,11,79,85,"Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral ""Polfa"") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (""valproate encephalopathy"").",8919272_2,-1,-1,-1,16475,-1,0.99909484,0.0009051938
16476,Polfa,12,13,87,92,"Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral ""Polfa"") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (""valproate encephalopathy"").",8919272_2,-1,-1,-1,16476,-1,0.990112,0.009888041
16477,neurological disorders,40,42,193,215,"Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral ""Polfa"") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (""valproate encephalopathy"").",8919272_2,-1,-1,-1,16477,-1,0.002297877,0.9977022
16478,cerebellum damage,43,45,227,244,"Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral ""Polfa"") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (""valproate encephalopathy"").",8919272_2,-1,-1,-1,16478,-1,0.0035314553,0.99646854
16479,valproate encephalopathy,47,49,247,271,"Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral ""Polfa"") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (""valproate encephalopathy"").",8919272_2,-1,-1,-1,16479,-1,0.8474602,0.15253976
16484,valproate encephalopathy,15,17,93,117,"The possible influence of the hepatic damage, mainly hyperammonemia, upon the development of valproate encephalopathy is discussed.",8919272_15,-1,-1,-1,16484,-1,0.8908452,0.10915479
16485,intracranial bleeding,1,3,6,27,Fatal intracranial bleeding associated with prehospital use of epinephrine.,8953972_0,-1,-1,-1,16485,-1,0.0025869922,0.997413
16488,pulmonary edema,23,25,126,141,We present a case of paramedic misjudgment in the execution of a protocol for the treatment of allergic reaction in a case of pulmonary edema with wheezing.,8953972_1,-1,-1,-1,16488,-1,0.0023374166,0.99766254
16489,wheezing,26,27,147,155,We present a case of paramedic misjudgment in the execution of a protocol for the treatment of allergic reaction in a case of pulmonary edema with wheezing.,8953972_1,-1,-1,-1,16489,-1,0.0036348056,0.9963652
16490,respiratory distress,4,6,20,40,"The sudden onset of respiratory distress, rash, and a history of a new medicine led the two paramedics on the scene to administer subcutaneous epinephrine.",8953972_2,-1,-1,-1,16490,-1,0.002828527,0.99717146
16494,subarachnoid hemorrhage,7,9,45,68,"Subsequently, acute cardiac arrest and fatal subarachnoid hemorrhage occurred.",8953972_3,-1,-1,-1,16494,-1,0.007206591,0.99279344
16506,Hoe-140,24,25,192,199,Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled dextran before and during phenylephrine-induced acute hypertension in rats treated with vehicle and Hoe-140 (0.1 microM).,8955532_3,-1,-1,-1,16506,-1,0.9984332,0.0015668682
16511,antipurine,7,8,32,42,A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.,8958188_0,-1,-1,-1,16511,-1,0.99572146,0.0042785113
16512,lometrexol,9,10,54,64,A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.,8958188_0,-1,-1,-1,16512,-1,0.9992818,0.00071815366
16513,DDATHF,11,12,66,72,A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.,8958188_0,-1,-1,-1,16513,-1,0.9990976,0.00090245745
16514,folic acid,16,18,90,100,A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.,8958188_0,-1,-1,-1,16514,-1,0.99887663,0.0011233333
16516,purine,19,20,129,135,"Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.",8958188_1,-1,-1,-1,16516,-1,0.9965779,0.0034220663
16517,lometrexol,9,10,65,75,"Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably methotrexate.",8958188_2,-1,-1,-1,16517,-1,0.9993345,0.00066541496
16518,tumours,13,14,97,104,"Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably methotrexate.",8958188_2,-1,-1,-1,16518,-1,0.00355363,0.99644643
16520,lometrexol,7,8,45,55,"However, the initial clinical development of lometrexol was curtailed because of severe and cumulative antiproliferative toxicities.",8958188_3,-1,-1,-1,16520,-1,0.99929047,0.0007095626
16523,lometrexol,8,9,61,71,"Preclinical murine studies demonstrated that the toxicity of lometrexol can be prevented by low dose folic acid administration, i.e. for 7 days prior to and 7 days following a single bolus dose.",8958188_4,-1,-1,-1,16523,-1,0.999387,0.0006129179
16524,folic acid,15,17,101,111,"Preclinical murine studies demonstrated that the toxicity of lometrexol can be prevented by low dose folic acid administration, i.e. for 7 days prior to and 7 days following a single bolus dose.",8958188_4,-1,-1,-1,16524,-1,0.9991602,0.0008398808
16525,lometrexol,9,10,54,64,This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.,8958188_5,-1,-1,-1,16525,-1,0.9993143,0.0006856828
16526,folic acid,12,14,76,86,This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.,8958188_5,-1,-1,-1,16526,-1,0.998858,0.0011419733
16528,lometrexol,22,23,144,154,This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.,8958188_5,-1,-1,-1,16528,-1,0.99931204,0.00068796263
16529,folic acid,28,30,182,192,This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.,8958188_5,-1,-1,-1,16529,-1,0.9987992,0.0012008306
16534,folate,13,14,83,89,There was no clear relationship between clinical toxicity and the extent of plasma folate elevation.,8958188_7,-1,-1,-1,16534,-1,0.99848723,0.0015127772
16535,lometrexol,4,5,37,47,Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance.,8958188_8,-1,-1,-1,16535,-1,0.9992933,0.00070665503
16536,folic acid,11,13,92,102,Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance.,8958188_8,-1,-1,-1,16536,-1,0.9991854,0.0008145696
16538,lometrexol,24,25,194,204,Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance.,8958188_8,-1,-1,-1,16538,-1,0.9992866,0.0007134454
16542,cocaine toxicity,15,17,108,124,Fatal excited delirium following cocaine use: epidemiologic findings provide new evidence for mechanisms of cocaine toxicity.,8988571_0,-1,-1,-1,16542,-1,0.42534387,0.5746561
16545,EDDs,11,12,73,77,"We describe an outbreak of deaths from cocaine-induced excited delirium (EDDs) in Dade County, Florida between 1979 and 1990.",8988571_1,-1,-1,-1,16545,-1,0.02014307,0.9798569
16547,EDDs,19,20,90,94,"From a registry of all cocaine-related deaths in Dade County, Florida, from 1969-1990, 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited delirium.",8988571_2,-1,-1,-1,16547,-1,0.054270737,0.94572926
16548,cocaine overdose,27,29,140,156,"From a registry of all cocaine-related deaths in Dade County, Florida, from 1969-1990, 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited delirium.",8988571_2,-1,-1,-1,16548,-1,0.18474483,0.81525517
16550,EDDs,4,5,24,28,"Compared with controls, EDDs were more frequently black, male, and younger.",8988571_3,-1,-1,-1,16550,-1,0.028893203,0.9711068
16560,sudden death,37,39,250,262,"The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.",8988571_6,-1,-1,-1,16560,-1,0.0027418272,0.9972582
16562,preterm infants,7,9,46,61,Risk factors of sensorineural hearing loss in preterm infants.,8996652_0,-1,-1,-1,16562,-1,0.02428247,0.9757176
16564,hearing loss,6,8,39,51,Perinatal risk factors of infants with hearing loss were compared with those of two control groups matched for gestation and birth weight and for perinatal complications.,8996652_2,-1,-1,-1,16564,-1,0.0033510667,0.99664897
16565,birth weight,20,22,125,137,Perinatal risk factors of infants with hearing loss were compared with those of two control groups matched for gestation and birth weight and for perinatal complications.,8996652_2,-1,-1,-1,16565,-1,0.19225448,0.80774546
16566,hearing loss,6,8,48,60,Our observations demonstrated an association of hearing loss with a higher incidence of perinatal complications.,8996652_3,-1,-1,-1,16566,-1,0.004718297,0.99528164
16568,ototoxic drugs,13,15,92,106,"Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs, particularly aminoglycosides and furosemide.",8996652_4,-1,-1,-1,16568,-1,0.08556943,0.9144306
16571,hearing loss,17,19,120,132,"Finally, we strongly recommend to prospectively and regularly perform audiologic assessment in sick preterm children as hearing loss is of delayed onset and in most cases bilateral and severe.",8996652_5,-1,-1,-1,16571,-1,0.0040539764,0.995946
16572,Pemoline,0,1,0,8,Pemoline induced acute choreoathetosis: case report and review of the literature.,9022662_0,-1,-1,-1,16572,-1,0.9982986,0.0017014658
16573,choreoathetosis,3,4,23,38,Pemoline induced acute choreoathetosis: case report and review of the literature.,9022662_0,-1,-1,-1,16573,-1,0.008731428,0.9912685
16574,Pemoline,2,3,12,20,BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.,9022662_1,-1,-1,-1,16574,-1,0.9987613,0.0012387502
16575,oxazolidine,5,6,27,38,BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.,9022662_1,-1,-1,-1,16575,-1,0.9991079,0.00089213817
16576,amphetamines,12,13,86,98,BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.,9022662_1,-1,-1,-1,16576,-1,0.9986994,0.0013005232
16577,attention deficit disorder,19,22,128,154,BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.,9022662_1,-1,-1,-1,16577,-1,0.005917977,0.99408203
16578,Pemoline,0,1,0,8,Pemoline has not been commonly associated in the literature as a cause of acute movement disorders.,9022662_2,-1,-1,-1,16578,-1,0.9987307,0.0012692937
16579,movement disorders,14,16,80,98,Pemoline has not been commonly associated in the literature as a cause of acute movement disorders.,9022662_2,-1,-1,-1,16579,-1,0.0023076185,0.99769247
16580,pemoline,9,10,64,72,The following case describes two children acutely poisoned with pemoline who experienced profound choreoathetosis.,9022662_3,-1,-1,-1,16580,-1,0.9987004,0.0012996051
16581,choreoathetosis,13,14,98,113,The following case describes two children acutely poisoned with pemoline who experienced profound choreoathetosis.,9022662_3,-1,-1,-1,16581,-1,0.009885408,0.99011457
16582,emergency department,14,16,76,96,"CASE REPORT: Two, 3-year-old male, identical twin siblings presented to the emergency department after found playing with a an empty bottle of pemoline originally containing 59 tablets.",9022662_4,-1,-1,-1,16582,-1,0.00960175,0.9903983
16583,pemoline,25,26,143,151,"CASE REPORT: Two, 3-year-old male, identical twin siblings presented to the emergency department after found playing with a an empty bottle of pemoline originally containing 59 tablets.",9022662_4,-1,-1,-1,16583,-1,0.998321,0.0016789903
16584,attention deficit disorder,8,11,51,77,The children had a medical history significant for attention deficit disorder previously treated with methylphenidate without success.,9022662_5,-1,-1,-1,16584,-1,0.00920372,0.9907962
16586,pemoline,6,7,28,36,This was their first day of pemoline therapy.,9022662_6,-1,-1,-1,16586,-1,0.99845123,0.0015487957
16587,choreoathetoid movements,1,3,4,28,The choreoathetoid movements began 45 min to 1 h after ingestion.,9022662_7,-1,-1,-1,16587,-1,0.016716143,0.9832839
16588,h,8,9,47,48,The choreoathetoid movements began 45 min to 1 h after ingestion.,9022662_7,-1,-1,-1,16588,-1,0.16495492,0.83504504
16589,movement disorders,7,9,38,56,The children gave no history of prior movement disorders and there was no family history of movement disorders.,9022662_8,-1,-1,-1,16589,-1,0.0029850309,0.997015
16590,movement disorders,16,18,92,110,The children gave no history of prior movement disorders and there was no family history of movement disorders.,9022662_8,-1,-1,-1,16590,-1,0.002745389,0.99725467
16592,choreoathetoid movements,17,19,130,154,The children received gastrointestinal decontamination and high doses of intravenous benzodiazepines in an attempt to control the choreoathetoid movements.,9022662_9,-1,-1,-1,16592,-1,0.30447522,0.6955248
16593,choreoathetosis,8,9,50,65,"Despite treatment, the children continued to have choreoathetosis for approximately 24 hours.",9022662_10,-1,-1,-1,16593,-1,0.03406945,0.9659305
16594,Pemoline,2,3,12,20,CONCLUSION: Pemoline associated movement disorder has been rarely reported in the acute toxicology literature.,9022662_12,-1,-1,-1,16594,-1,0.99865437,0.0013456412
16595,movement disorder,4,6,32,49,CONCLUSION: Pemoline associated movement disorder has been rarely reported in the acute toxicology literature.,9022662_12,-1,-1,-1,16595,-1,0.0022262556,0.9977737
16596,choreoathetoid movements,3,5,19,43,The possibility of choreoathetoid movements should be considered in patients presenting after pemoline overdose.,9022662_13,-1,-1,-1,16596,-1,0.009821505,0.99017847
16597,pemoline overdose,12,14,94,111,The possibility of choreoathetoid movements should be considered in patients presenting after pemoline overdose.,9022662_13,-1,-1,-1,16597,-1,0.6514443,0.3485557
16598,venlafaxine overdose,4,6,25,45,Seizure resulting from a venlafaxine overdose.,9034419_0,-1,-1,-1,16598,-1,0.77913374,0.2208663
16599,venlafaxine overdose,7,9,31,51,OBJECTIVE: To report a case of venlafaxine overdose.,9034419_1,-1,-1,-1,16599,-1,0.75763214,0.24236791
16606,venlafaxine overdose,13,15,65,85,"DISCUSSION: To our knowledge, this is the first reported case of venlafaxine overdose that resulted in a generalized seizure.",9034419_5,-1,-1,-1,16606,-1,0.7854799,0.21452008
16609,venlafaxine overdose,3,5,17,37,CONCLUSIONS: The venlafaxine overdose in our patient resulted in a single episode of generalized seizure but elicited no further sequelae.,9034419_7,-1,-1,-1,16609,-1,0.85500246,0.14499757
16611,elevated intraocular pressure,12,15,65,94,"During the follow-up, 3 patients (12%) developed steroid-induced elevated intraocular pressure (IOP) that resolved after corticosteroid therapy was discontinued.",9041081_6,-1,-1,-1,16611,-1,0.018106513,0.98189354
16612,IOP,16,17,96,99,"During the follow-up, 3 patients (12%) developed steroid-induced elevated intraocular pressure (IOP) that resolved after corticosteroid therapy was discontinued.",9041081_6,-1,-1,-1,16612,-1,0.1488722,0.85112774
16613,corticosteroid,21,22,121,135,"During the follow-up, 3 patients (12%) developed steroid-induced elevated intraocular pressure (IOP) that resolved after corticosteroid therapy was discontinued.",9041081_6,-1,-1,-1,16613,-1,0.99867165,0.0013283963
16614,IOP rise,3,5,30,38,The transient steroid-induced IOP rise did not seem to cause functional impairment.,9041081_9,-1,-1,-1,16614,-1,0.4608573,0.53914267
16616,hydrogen peroxide,3,5,26,43,Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure.,9061311_0,-1,-1,-1,16616,-1,0.9982874,0.0017126505
16619,hydrogen peroxide,4,6,26,43,Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).,9061311_1,-1,-1,-1,16619,-1,0.99824524,0.0017547898
16620,bacterial infections,15,17,98,118,Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).,9061311_1,-1,-1,-1,16620,-1,0.008464601,0.9915354
16622,ALF,24,25,157,160,Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).,9061311_1,-1,-1,-1,16622,-1,0.003344766,0.9966552
16624,ALF,11,12,65,68,"In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.",9061311_2,-1,-1,-1,16624,-1,0.04955722,0.9504428
16625,paracetamol overdose,14,16,76,96,"In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.",9061311_2,-1,-1,-1,16625,-1,0.8654787,0.1345213
16626,ALF,3,4,20,23,Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum.,9061311_3,-1,-1,-1,16626,-1,0.12077634,0.87922364
16627,ALF,15,16,107,110,Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum.,9061311_3,-1,-1,-1,16627,-1,0.9913748,0.008625239
16629,hydrogen peroxide,2,4,15,32,Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).,9061311_4,-1,-1,-1,16629,-1,0.99751127,0.0024887365
16630,ALF,6,7,47,50,Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).,9061311_4,-1,-1,-1,16630,-1,0.97977394,0.020226086
16631,ALF,13,14,102,105,Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).,9061311_4,-1,-1,-1,16631,-1,0.9940077,0.0059922864
16632,P,24,25,174,175,Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).,9061311_4,-1,-1,-1,16632,-1,0.28299323,0.7170068
16633,P,12,13,72,73,This defect persisted when zymosan opsonized by control serum was used (P < 0.05).,9061311_5,-1,-1,-1,16633,-1,0.24618044,0.7538195
16635,hydrogen peroxide,2,4,15,32,Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.,9061311_6,-1,-1,-1,16635,-1,0.99783367,0.0021663476
16636,fMLP,11,12,114,118,Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.,9061311_6,-1,-1,-1,16636,-1,0.9982145,0.0017855145
16637,ALF,17,18,138,141,Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.,9061311_6,-1,-1,-1,16637,-1,0.038853906,0.96114606
16638,ALF,8,9,57,60,Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects (P < 0.0005).,9061311_7,-1,-1,-1,16638,-1,0.040035114,0.9599649
16639,P,15,16,102,103,Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects (P < 0.0005).,9061311_7,-1,-1,-1,16639,-1,0.329972,0.67002803
16640,ALF,7,8,49,52,"These results demonstrate a neutrophil defect in ALF due to paracetamol overdose, that is complement dependent but independent of serum complement, possibly connected to the complement receptor.",9061311_8,-1,-1,-1,16640,-1,0.009779055,0.9902209
16641,paracetamol overdose,10,12,60,80,"These results demonstrate a neutrophil defect in ALF due to paracetamol overdose, that is complement dependent but independent of serum complement, possibly connected to the complement receptor.",9061311_8,-1,-1,-1,16641,-1,0.85856503,0.14143501
16644,carbon tetrachloride,14,16,106,126,"Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.",9067481_0,-1,-1,-1,16644,-1,0.99857724,0.0014227438
16645,chloroform,17,18,128,138,"Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.",9067481_0,-1,-1,-1,16645,-1,0.9977659,0.0022341488
16646,galactosamine,19,20,143,156,"Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.",9067481_0,-1,-1,-1,16646,-1,0.99787056,0.0021294046
16647,cholesteryl hemisuccinate,11,13,64,89,"In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).",9067481_1,-1,-1,-1,16647,-1,0.9978777,0.0021223288
16648,tris salt,14,16,91,100,"In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).",9067481_1,-1,-1,-1,16648,-1,0.996842,0.0031579954
16649,CS,17,18,102,104,"In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).",9067481_1,-1,-1,-1,16649,-1,0.99763703,0.0023629824
16651,carbon tetrachloride,32,34,189,209,"In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).",9067481_1,-1,-1,-1,16651,-1,0.9984623,0.0015376874
16652,CCl4,35,36,211,215,"In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).",9067481_1,-1,-1,-1,16652,-1,0.99673414,0.0032659357
16653,CS,8,9,49,51,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,16653,-1,0.9976146,0.0023854305
16654,CS,21,22,125,127,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,16654,-1,0.9977906,0.0022094354
16655,ether,25,26,153,158,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,16655,-1,0.9891403,0.010859664
16656,CS,28,29,167,169,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,16656,-1,0.9977964,0.0022035858
16657,tris salt,33,35,205,214,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,16657,-1,0.99429905,0.0057009314
16658,CSE,36,37,216,219,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,16658,-1,0.9942796,0.005720407
16659,carbon,43,44,258,264,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,-1,-1,-1,16659,-1,0.99787676,0.002123257
16661,CS,13,14,64,66,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,-1,-1,-1,16661,-1,0.99843997,0.0015600126
16663,CCl4,30,31,155,159,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,-1,-1,-1,16663,-1,0.99804074,0.0019593076
16664,CHCl3,32,33,161,166,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,-1,-1,-1,16664,-1,0.99790645,0.0020935955
16666,galactosamine,36,37,186,199,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,-1,-1,-1,16666,-1,0.99804074,0.001959333
16669,h,10,11,82,83,Maximal CS-mediated protection was observed in experimental animals pretreated 24 h prior to the toxic insult.,9067481_5,-1,-1,-1,16669,-1,0.29434237,0.7056576
16670,CS,4,5,24,26,These data suggest that CS intervenes in a critical cellular event that is an important common pathway to toxic cell death.,9067481_6,-1,-1,-1,16670,-1,0.9969893,0.003010668
16672,CS,3,4,17,19,The mechanism of CS protection does not appear to be dependent on the inhibition of chemical bioactivation to a toxic reactive intermediate (in light of the protection observed against galactosamine hepatotoxicity).,9067481_7,-1,-1,-1,16672,-1,0.99682117,0.0031788293
16673,galactosamine hepatotoxicity,30,32,185,213,The mechanism of CS protection does not appear to be dependent on the inhibition of chemical bioactivation to a toxic reactive intermediate (in light of the protection observed against galactosamine hepatotoxicity).,9067481_7,-1,-1,-1,16673,-1,0.3327963,0.6672037
16674,CS,15,16,78,80,"However, based on the data presented, we can not exclude the possibility that CS administration inhibits chemical bioactivation.",9067481_8,-1,-1,-1,16674,-1,0.9982158,0.0017842505
16675,CS,16,17,101,103,"Our findings do suggest that CS-mediated protection is dependent on the action of the intact anionic CS molecule (non-hydrolyzable CSE was as protective as CS), whose mechanism has yet to be defined.",9067481_9,-1,-1,-1,16675,-1,0.99741995,0.0025800006
16676,CSE,20,21,131,134,"Our findings do suggest that CS-mediated protection is dependent on the action of the intact anionic CS molecule (non-hydrolyzable CSE was as protective as CS), whose mechanism has yet to be defined.",9067481_9,-1,-1,-1,16676,-1,0.99690634,0.0030936247
16677,CS,25,26,156,158,"Our findings do suggest that CS-mediated protection is dependent on the action of the intact anionic CS molecule (non-hydrolyzable CSE was as protective as CS), whose mechanism has yet to be defined.",9067481_9,-1,-1,-1,16677,-1,0.997391,0.002608936
16680,prostaglandin E1,4,6,30,46,Combined effects of prolonged prostaglandin E1 (PGE1)-induced hypotension and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery.,9088814_1,-1,-1,-1,16680,-1,0.997759,0.00224104
16683,n,16,17,79,80,"The patients were randomly allocated to one of three groups; those in group A (n = 10) were subjected to controlled hypotension alone, those in group B (n = 10) to haemodilution alone and those in group C (n = 10) to both controlled hypotension and haemodilution.",9088814_2,-1,-1,-1,16683,-1,0.25454193,0.74545807
16685,n,32,33,153,154,"The patients were randomly allocated to one of three groups; those in group A (n = 10) were subjected to controlled hypotension alone, those in group B (n = 10) to haemodilution alone and those in group C (n = 10) to both controlled hypotension and haemodilution.",9088814_2,-1,-1,-1,16685,-1,0.26771727,0.7322827
16687,C,43,44,203,204,"The patients were randomly allocated to one of three groups; those in group A (n = 10) were subjected to controlled hypotension alone, those in group B (n = 10) to haemodilution alone and those in group C (n = 10) to both controlled hypotension and haemodilution.",9088814_2,-1,-1,-1,16687,-1,0.3590816,0.64091843
16688,n,45,46,206,207,"The patients were randomly allocated to one of three groups; those in group A (n = 10) were subjected to controlled hypotension alone, those in group B (n = 10) to haemodilution alone and those in group C (n = 10) to both controlled hypotension and haemodilution.",9088814_2,-1,-1,-1,16688,-1,0.25151846,0.7484815
16692,C,5,6,30,31,"Haemodilution in groups B and C was produced by withdrawing approximately 1000 mL of blood and replacing it with the same amount of dextran solution, and final haematocrit values were 21 or 22%.",9088814_3,-1,-1,-1,16692,-1,0.37636834,0.62363166
16693,dextran solution,23,25,132,148,"Haemodilution in groups B and C was produced by withdrawing approximately 1000 mL of blood and replacing it with the same amount of dextran solution, and final haematocrit values were 21 or 22%.",9088814_3,-1,-1,-1,16693,-1,0.99603903,0.003960985
16695,C,6,7,39,40,Controlled hypotension in groups A and C was induced with PGE1 to maintain mean arterial blood pressure at 55 mmHg for 180 min.,9088814_4,-1,-1,-1,16695,-1,0.3736595,0.62634045
16696,PGE1,10,11,58,62,Controlled hypotension in groups A and C was induced with PGE1 to maintain mean arterial blood pressure at 55 mmHg for 180 min.,9088814_4,-1,-1,-1,16696,-1,0.99830425,0.0016956958
16697,ketone,3,4,31,37,"Measurements included arterial ketone body ratio (AKBR, aceto-acetate/3-hydroxybutyrate) and clinical hepatic function parameters.",9088814_5,-1,-1,-1,16697,-1,0.9967738,0.0032262423
16698,C,20,21,115,116,"AKBR and biological hepatic function tests showed no change throughout the time course in groups A and B. In group C, AKBR showed a significant decrease at 120 min (-40%) and at 180 min (-49%) after the start of hypotension and at 60 min (-32%) after recovery of normotension, and SGOT, SGPT, LDH and total bilirubin showed significant increases after operation.",9088814_6,-1,-1,-1,16698,-1,0.23015286,0.7698471
16703,impairment of hepatic function,20,24,137,167,The results suggest that a prolonged combination of more than 120 min of PGE1-induced hypotension and moderate haemodilution would cause impairment of hepatic function.,9088814_7,-1,-1,-1,16703,-1,0.0062142625,0.99378574
16704,adenomyosis,4,5,18,29,"A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.",9098464_0,-1,-1,-1,16704,-1,0.0032504732,0.9967495
16706,fluoxetine hydrochloride,12,14,76,100,"A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.",9098464_0,-1,-1,-1,16706,-1,0.99922025,0.0007797339
16707,selective serotonin reuptake inhibitor,16,20,104,142,"A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.",9098464_0,-1,-1,-1,16707,-1,0.98993146,0.010068563
16708,adenomyosis,22,23,147,158,"A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.",9098464_0,-1,-1,-1,16708,-1,0.0037365756,0.99626344
16711,adenomyosis,26,27,170,181,OBJECTIVE: The aim of this study was to investigate whether fluoxetine given to castrated and noncastrated rats caused hyperprolactinemia and its effects with respect to adenomyosis.,9098464_1,-1,-1,-1,16711,-1,0.003809898,0.9961901
16713,serotonin reuptake inhibitor,5,8,22,50,"DESIGN: Fluoxetine, a serotonin reuptake inhibitor, was given to Wistar Albino rats for 98 days to produce hyperprolactinemia.",9098464_2,-1,-1,-1,16713,-1,0.99396616,0.006033914
16716,adenomyosis,6,7,42,53,"Histological studies revealed 11 cases of adenomyosis, all within the noncastrated group receiving fluoxetine.",9098464_8,-1,-1,-1,16716,-1,0.0030690723,0.9969309
16719,adenomyosis,5,6,39,50,This invasion eventually progresses to adenomyosis.,9098464_10,-1,-1,-1,16719,-1,0.0073861303,0.9926139
16720,calcium channel blockers,7,10,53,77,Cardiovascular alterations in rat fetuses exposed to calcium channel blockers.,9100294_0,-1,-1,-1,16720,-1,0.9948602,0.005139816
16722,Ro 40-5967,11,15,84,94,"Preclinical toxicologic investigation suggested that a new calcium channel blocker, Ro 40-5967, induced cardiovascular alterations in rat fetuses exposed to this agent during organogenesis.",9100294_1,-1,-1,-1,16722,-1,0.99774796,0.0022519846
16723,cardiovascular alterations,17,19,104,130,"Preclinical toxicologic investigation suggested that a new calcium channel blocker, Ro 40-5967, induced cardiovascular alterations in rat fetuses exposed to this agent during organogenesis.",9100294_1,-1,-1,-1,16723,-1,0.0035438081,0.9964562
16724,calcium channel blockers,10,13,66,90,The present study was designed to investigate the hypothesis that calcium channel blockers in general induce cardiovascular malformations indicating a pharmacologic class effect.,9100294_2,-1,-1,-1,16724,-1,0.994638,0.005361984
16725,cardiovascular malformations,16,18,109,137,The present study was designed to investigate the hypothesis that calcium channel blockers in general induce cardiovascular malformations indicating a pharmacologic class effect.,9100294_2,-1,-1,-1,16725,-1,0.003127892,0.9968721
16730,calcium channel blockers,7,10,45,69,Pregnant rats were administered one of these calcium channel blockers during the period of cardiac morphogenesis and the offspring examined on day 20 of gestation for cardiovascular malformations.,9100294_4,-1,-1,-1,16730,-1,0.9954081,0.0045918124
16731,cardiovascular malformations,26,28,167,195,Pregnant rats were administered one of these calcium channel blockers during the period of cardiac morphogenesis and the offspring examined on day 20 of gestation for cardiovascular malformations.,9100294_4,-1,-1,-1,16731,-1,0.0034474682,0.99655247
16732,cardiovascular malformations,4,6,19,47,"A low incidence of cardiovascular malformations was observed after exposure to each of the four calcium channel blockers, but this incidence was statistically significant only for verapamil and nifedipine.",9100294_5,-1,-1,-1,16732,-1,0.0028968554,0.99710315
16733,calcium channel blockers,15,18,96,120,"A low incidence of cardiovascular malformations was observed after exposure to each of the four calcium channel blockers, but this incidence was statistically significant only for verapamil and nifedipine.",9100294_5,-1,-1,-1,16733,-1,0.9942766,0.0057234615
16736,Ro 40-5967,16,20,111,121,"All four agents were associated with aortic arch branching variants, although significantly increased only for Ro 40-5967 and verapamil.",9100294_6,-1,-1,-1,16736,-1,0.99768543,0.0023145557
16738,ventricular septal defect,1,4,15,40,Postinfarction ventricular septal defect associated with long-term steroid therapy.,9105126_0,-1,-1,-1,16738,-1,0.008583084,0.991417
16740,ventricular septal rupture,4,7,28,54,Two cases of postinfarction ventricular septal rupture in patients on long-term steroid therapy are presented and the favourable outcome in both cases described.,9105126_1,-1,-1,-1,16740,-1,0.009656933,0.9903431
16743,septal rupture,9,11,77,91,A possible association between steroid therapy and subsequent postinfarction septal rupture is discussed.,9105126_2,-1,-1,-1,16743,-1,0.0082100425,0.99178994
16746,status epilepticus,11,13,94,112,Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice.,9121607_0,-1,-1,-1,16746,-1,0.0022337746,0.99776626
16748,deoxycorticosterone,12,13,96,115,"Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.",9121607_1,-1,-1,-1,16748,-1,0.9985393,0.0014606745
16753,status epilepticus,31,33,209,227,"Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).",9121607_2,-1,-1,-1,16753,-1,0.0020879484,0.997912
16755,benzodiazepine clonazepam,10,12,73,98,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,-1,-1,-1,16755,-1,0.9986572,0.0013427825
16756,pilocarpine seizures,15,17,121,141,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,-1,-1,-1,16756,-1,0.9060296,0.093970425
16759,clonazepam,44,45,312,322,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,-1,-1,-1,16759,-1,0.99875295,0.001247049
16764,kainic acid,23,25,148,159,"Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.",9121607_5,-1,-1,-1,16764,-1,0.9991333,0.00086673844
16768,status epilepticus,27,29,156,174,"However, when a second dose of the steroid was administered 1 hr after the first dose, complete protection from the kainic acid-induced limbic seizures and status epilepticus was obtained.",9121607_6,-1,-1,-1,16768,-1,0.00246409,0.99753594
16770,NMDA,8,9,51,55,"The steroids also caused a dose-dependent delay in NMDA (257 mg/kg, s.c.)-induced lethality, but did not completely protect against NMDA seizures or lethality.",9121607_7,-1,-1,-1,16770,-1,0.9984085,0.0015914942
16771,NMDA seizures,22,24,132,145,"The steroids also caused a dose-dependent delay in NMDA (257 mg/kg, s.c.)-induced lethality, but did not completely protect against NMDA seizures or lethality.",9121607_7,-1,-1,-1,16771,-1,0.27576083,0.7242392
16774,status epilepticus,17,19,131,149,"We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.",9121607_8,-1,-1,-1,16774,-1,0.0021210557,0.9978789
16775,status epilepticus,34,36,215,233,"We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.",9121607_8,-1,-1,-1,16775,-1,0.002122046,0.99787796
16776,nephrotic syndrome,10,12,76,94,Hepatic and extrahepatic angiotensinogen gene expression in rats with acute nephrotic syndrome.,9154656_0,-1,-1,-1,16776,-1,0.0031413485,0.9968586
16777,nephrotic syndrome,15,17,107,125,Plasma concentration and urine excretion of the renin-angiotensin system proteins are altered in rats with nephrotic syndrome (NS).,9154656_1,-1,-1,-1,16777,-1,0.0028947047,0.9971053
16778,NS,18,19,127,129,Plasma concentration and urine excretion of the renin-angiotensin system proteins are altered in rats with nephrotic syndrome (NS).,9154656_1,-1,-1,-1,16778,-1,0.024672111,0.9753279
16779,ribonucleic acid,5,7,27,43,"In this work the messenger ribonucleic acid (mRNA) levels of angiotensinogen (Ao) were analyzed with the slot-blot hybridization technique in liver and other extrahepatic tissues: kidney, heart, brain, and adrenal gland from control, nephrotic, and pair-fed (PF) rats.",9154656_2,-1,-1,-1,16779,-1,0.94406885,0.055931095
16781,NS,0,1,0,2,NS was induced by a single injection of puromycin amino-nucleoside (PAN).,9154656_3,-1,-1,-1,16781,-1,0.46523532,0.53476465
16782,PAN,11,12,68,71,NS was induced by a single injection of puromycin amino-nucleoside (PAN).,9154656_3,-1,-1,-1,16782,-1,0.99643373,0.0035662616
16783,PAN,17,18,100,103,"Although a great urinary excretion and half-normal plasma levels of Ao were observed on day 6 after PAN injection, when NS was clearly established, hepatic Ao mRNA levels did not change.",9154656_4,-1,-1,-1,16783,-1,0.99836737,0.0016326989
16784,NS,21,22,120,122,"Although a great urinary excretion and half-normal plasma levels of Ao were observed on day 6 after PAN injection, when NS was clearly established, hepatic Ao mRNA levels did not change.",9154656_4,-1,-1,-1,16784,-1,0.99832255,0.0016774316
16785,PAN,36,37,155,158,"Furthermore, the Ao mRNA levels did not change in any of the extrahepatic tissues studied on day 6, nor did its hepatic levels at days 1, 3, 5, or 7 after PAN injection.",9154656_5,-1,-1,-1,16785,-1,0.9976768,0.0023232563
16786,NS,19,20,118,120,These data suggest that the hepatic and extrahepatic Ao mRNA levels are unaltered during the development of the acute NS induced by PAN.,9154656_6,-1,-1,-1,16786,-1,0.3554566,0.64454347
16787,PAN,22,23,132,135,These data suggest that the hepatic and extrahepatic Ao mRNA levels are unaltered during the development of the acute NS induced by PAN.,9154656_6,-1,-1,-1,16787,-1,0.9968081,0.003191884
16789,Neuroleptic malignant syndrome,0,3,0,30,Neuroleptic malignant syndrome is thought to be a result of dopamine D2 receptor blockade in the striatum of the basal ganglia.,9165568_1,-1,-1,-1,16789,-1,0.43357918,0.56642085
16792,benzisoxazole,3,4,15,28,"Risperidone, a benzisoxazole derivative antipsychotic, has high serotonin 5-HT2 receptor blockade and dose-related D2 receptor blockade.",9165568_2,-1,-1,-1,16792,-1,0.9989649,0.0010351535
16797,neuroleptic malignant syndrome,14,17,84,114,"With this low frequency of extrapyramidal symptoms, it was thought the frequency of neuroleptic malignant syndrome might also be lowered.",9165568_4,-1,-1,-1,16797,-1,0.42674488,0.57325506
16798,neuroleptic malignant syndrome,4,7,30,60,A 73-year-old woman developed neuroleptic malignant syndrome after monotherapy with risperidone.,9165568_5,-1,-1,-1,16798,-1,0.37823692,0.6217631
16801,dantrolene,10,11,82,92,The syndrome reversed after discontinuing risperidone and starting treatment with dantrolene and bromocriptine.,9165568_6,-1,-1,-1,16801,-1,0.998657,0.0013430077
16804,neuroleptic malignant syndrome,17,20,122,152,It appears that the protection from extrapyramidal side effects observed with risperidone does not ensure protection from neuroleptic malignant syndrome.,9165568_7,-1,-1,-1,16804,-1,0.3699488,0.63005126
16807,tingling or burning sensations,5,9,32,62,Two patients are presented with tingling or burning sensations limited to areas of heat exposure or sunburn.,9195768_3,-1,-1,-1,16807,-1,0.0052682036,0.9947318
16808,sunburn,16,17,100,107,Two patients are presented with tingling or burning sensations limited to areas of heat exposure or sunburn.,9195768_3,-1,-1,-1,16808,-1,0.100085385,0.8999146
16812,endophthalmitis,11,12,98,113,"BACKGROUND: Although intravitreal aminoglycosides have substantially improved visual prognosis in endophthalmitis, macular infarction may impair full visual recovery.",9199746_1,-1,-1,-1,16812,-1,0.019023055,0.980977
16814,amikacin retinal toxicity,8,11,39,64,METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.,9199746_2,-1,-1,-1,16814,-1,0.6549749,0.34502506
16817,streptococcal endophthalmitis,19,21,135,164,METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.,9199746_2,-1,-1,-1,16817,-1,0.011286765,0.98871326
16818,Endophthalmitis,2,3,9,24,RESULTS: Endophthalmitis resolved with improvement in visual acuity to 6/24 at three months.,9199746_3,-1,-1,-1,16818,-1,0.033821806,0.9661782
16820,telangiectasis,8,9,71,85,Fundus fluorescein angiography confirmed macular capillary closure and telangiectasis.,9199746_4,-1,-1,-1,16820,-1,0.005477173,0.9945228
16821,retinal toxicity,9,11,75,91,CONCLUSIONS: Currently accepted intravitreal antibiotic regimens may cause retinal toxicity and macular ischaemia.,9199746_5,-1,-1,-1,16821,-1,0.003484017,0.996516
16822,ischaemia,13,14,104,113,CONCLUSIONS: Currently accepted intravitreal antibiotic regimens may cause retinal toxicity and macular ischaemia.,9199746_5,-1,-1,-1,16822,-1,0.0023850936,0.997615
16824,carteolol hydrochloride,4,6,26,49,"The attenuating effect of carteolol hydrochloride, a beta-adrenoceptor antagonist, on neuroleptic-induced catalepsy in rats.",9201797_0,-1,-1,-1,16824,-1,0.99875844,0.0012415379
16826,akathisia,12,13,81,90,"It is known that beta-adrenoceptor antagonists are effective in the treatment of akathisia, one of the extrapyramidal side effects that occur during neuroleptic treatment.",9201797_1,-1,-1,-1,16826,-1,0.035570905,0.9644291
16827,neuroleptic,23,24,149,160,"It is known that beta-adrenoceptor antagonists are effective in the treatment of akathisia, one of the extrapyramidal side effects that occur during neuroleptic treatment.",9201797_1,-1,-1,-1,16827,-1,0.9989347,0.0010653433
16829,akathisia,20,21,161,170,"Neuroleptic-induced catalepsy, a model of neuroleptic-induced extrapyramidal side effects, was considered suitable as a model for predicting neuroleptic-induced akathisia in humans, although neuroleptic-induced catalepsy was not considered a specific test for neuroleptic-induced akathisia.",9201797_2,-1,-1,-1,16829,-1,0.0029603846,0.9970396
16831,akathisia,35,36,280,289,"Neuroleptic-induced catalepsy, a model of neuroleptic-induced extrapyramidal side effects, was considered suitable as a model for predicting neuroleptic-induced akathisia in humans, although neuroleptic-induced catalepsy was not considered a specific test for neuroleptic-induced akathisia.",9201797_2,-1,-1,-1,16831,-1,0.002957627,0.99704236
16832,carteolol,5,6,26,35,"Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.",9201797_3,-1,-1,-1,16832,-1,0.9991736,0.0008264277
16835,biperiden,26,27,179,188,"Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.",9201797_3,-1,-1,-1,16835,-1,0.99859935,0.0014006838
16837,biperiden,7,8,38,47,"Carteolol, as well as propranolol and biperiden, inhibited the haloperidol-induced catalepsy.",9201797_4,-1,-1,-1,16837,-1,0.9987612,0.0012388049
16839,carteolol,4,5,25,34,"The inhibitory effect of carteolol was almost comparable to that of propranolol, but was weaker than that of biperiden.",9201797_5,-1,-1,-1,16839,-1,0.9991315,0.00086856267
16841,biperiden,19,20,109,118,"The inhibitory effect of carteolol was almost comparable to that of propranolol, but was weaker than that of biperiden.",9201797_5,-1,-1,-1,16841,-1,0.9984681,0.0015319043
16842,Carteolol,0,1,0,9,Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.,9201797_6,-1,-1,-1,16842,-1,0.999116,0.00088399963
16843,hyperlocomotion,13,14,107,122,Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.,9201797_6,-1,-1,-1,16843,-1,0.004046747,0.9959532
16845,carteolol,3,4,13,22,"In addition, carteolol did not evoke 5-HT1A receptor-stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit 5-hydroxytryptophan-induced head twitch in rats.",9201797_8,-1,-1,-1,16845,-1,0.99891365,0.0010863686
16846,twitch,25,26,182,188,"In addition, carteolol did not evoke 5-HT1A receptor-stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit 5-hydroxytryptophan-induced head twitch in rats.",9201797_8,-1,-1,-1,16846,-1,0.0027060655,0.9972939
16847,carteolol,2,3,9,18,"Finally, carteolol did not inhibit physostigmine-induced lethality in rats.",9201797_9,-1,-1,-1,16847,-1,0.9989812,0.0010188271
16848,carteolol,5,6,36,45,These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.,9201797_10,-1,-1,-1,16848,-1,0.9991806,0.00081936194
16850,akathisia,24,25,185,194,These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.,9201797_10,-1,-1,-1,16850,-1,0.006645921,0.9933541
16851,antipsychotic effects,28,30,235,256,These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.,9201797_10,-1,-1,-1,16851,-1,0.21184386,0.7881561
16853,Granulosa cell tumor of the ovary,0,6,0,33,Granulosa cell tumor of the ovary associated with antecedent tamoxifen use.,9205462_0,-1,-1,-1,16853,-1,0.017466012,0.982534
16863,granulosa cell tumor of the ovary,19,25,104,137,"After an additional 17 months of elevated serum transaminases, the patient was found to have a stage Ic granulosa cell tumor of the ovary.",9205462_5,-1,-1,-1,16863,-1,0.025323514,0.9746765
16864,liver dysfunction,5,7,44,61,CONCLUSION: Patients with tamoxifen-induced liver dysfunction may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism.,9205462_6,-1,-1,-1,16864,-1,0.0029399977,0.99706
16865,granulosa cell tumors,13,16,91,112,CONCLUSION: Patients with tamoxifen-induced liver dysfunction may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism.,9205462_6,-1,-1,-1,16865,-1,0.018771462,0.98122853
16868,AZT,7,8,48,51,Lifetime treatment of mice with azidothymidine (AZT) produces myelodysplasia.,9209318_0,-1,-1,-1,16868,-1,0.9949934,0.005006673
16869,myelodysplasia,10,11,62,76,Lifetime treatment of mice with azidothymidine (AZT) produces myelodysplasia.,9209318_0,-1,-1,-1,16869,-1,0.0022813655,0.9977187
16870,AZT,0,1,0,3,AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy.,9209318_1,-1,-1,-1,16870,-1,0.9986725,0.0013275051
16871,macrocytic anemia,4,6,18,35,AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy.,9209318_1,-1,-1,-1,16871,-1,0.0027705452,0.9972294
16872,AIDS,7,8,39,43,AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy.,9209318_1,-1,-1,-1,16872,-1,0.0074500577,0.9925499
16873,AZT,12,13,66,69,AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy.,9209318_1,-1,-1,-1,16873,-1,0.9984244,0.001575596
16874,AZT,13,14,75,78,It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.,9209318_2,-1,-1,-1,16874,-1,0.99836415,0.001635892
16875,thymidine,20,21,106,115,It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.,9209318_2,-1,-1,-1,16875,-1,0.9981509,0.0018490419
16876,phosphate hydroxyl,24,26,136,154,It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.,9209318_2,-1,-1,-1,16876,-1,0.9725036,0.027496424
16877,AZT,5,6,28,31,"CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg.",9209318_3,-1,-1,-1,16877,-1,0.9986362,0.0013638149
16878,H2O,8,9,43,46,"CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg.",9209318_3,-1,-1,-1,16878,-1,0.9963851,0.003614933
16879,H2O,27,28,126,129,"CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg.",9209318_3,-1,-1,-1,16879,-1,0.9958865,0.004113489
16880,AZT,36,37,170,173,"CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg.",9209318_3,-1,-1,-1,16880,-1,0.9985286,0.0014713865
16881,mg,47,48,224,226,"CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg.",9209318_3,-1,-1,-1,16881,-1,0.99372065,0.006279321
16882,mg,9,10,39,41,At 687 days mice that had been on 0.75 mg had average platelet counts of 2.5 x 10(6).,9209318_4,-1,-1,-1,16882,-1,0.9942894,0.0057105403
16884,myelodysplastic syndrome,14,16,99,123,Histological examination on 9 of 10 mice with such thrombocytopenia showed changes compatible with myelodysplastic syndrome (MDS).,9209318_5,-1,-1,-1,16884,-1,0.0033761133,0.9966239
16885,MDS,17,18,125,128,Histological examination on 9 of 10 mice with such thrombocytopenia showed changes compatible with myelodysplastic syndrome (MDS).,9209318_5,-1,-1,-1,16885,-1,0.0027024096,0.9972976
16886,myelodysplasia,6,7,37,51,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,16886,-1,0.005675833,0.9943242
16887,hyperplastic marrow,35,37,251,270,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,16887,-1,0.010213064,0.989787
16888,dysmyelopoiesis,38,39,272,287,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,16888,-1,0.009143039,0.99085695
16889,dysmyelopoiesis,38,39,272,287,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,16889,-1,0.009143039,0.99085695
16890,hypocellular,41,42,294,306,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,16890,-1,0.0076845926,0.9923154
16891,myelodysplasia,47,48,331,345,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,16891,-1,0.0048486437,0.9951513
16892,dyserythropoiesis,49,50,351,368,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,16892,-1,0.008819,0.991181
16893,hemosiderosis,51,52,370,383,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,16893,-1,0.016503463,0.98349655
16894,hypocellular marrow,54,56,390,409,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,-1,-1,-1,16894,-1,0.011833004,0.988167
16895,AZT,2,3,16,19,"Above mentioned AZT incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells, which is known to be seen commonly in the myelodysplastic syndrome.",9209318_8,-1,-1,-1,16895,-1,0.99860483,0.0013952379
16896,myelodysplastic syndrome,26,28,167,191,"Above mentioned AZT incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells, which is known to be seen commonly in the myelodysplastic syndrome.",9209318_8,-1,-1,-1,16896,-1,0.0034129198,0.99658704
16900,mg,10,11,56,58,Injections of ketamine in doses from 100 microgram to 3 mg into the artery produced a depression of the SA nodal activity by a direct action.,921394_2,-1,-1,-1,16900,-1,0.98672056,0.013279404
16905,pituitary tumors,16,18,118,134,Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis.,9214597_0,-1,-1,-1,16905,-1,0.0053589703,0.99464095
16907,Estrogens,0,1,0,9,"Estrogens, which have been associated with several types of human and animal cancers, can induce tumor angiogenesis in the pituitary of Fischer 344 rats.",9214597_1,-1,-1,-1,16907,-1,0.99462837,0.0053716945
16911,estrogen carcinogenesis,9,11,64,87,"The mechanistic details of tumor angiogenesis induction, during estrogen carcinogenesis, are still unknown.",9214597_2,-1,-1,-1,16911,-1,0.4011463,0.5988537
16914,factor VIII,27,29,155,166,"To elucidate the role of estrogen in the regulation of tumor angiogenesis in the pituitary of female rats, the density of blood vessels was analysed using factor VIII related antigen (FVIIIRAg) immunohistochemistry and the expression of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) was examined by Western blot and immunohistochemical analysis.",9214597_3,-1,-1,-1,16914,-1,0.9947977,0.005202278
16915,E2,6,7,48,50,"The results demonstrated that 17beta-estradiol (E2) induces neovascularization, as well as the growth and enlargement of blood vessels after 7 days of exposure.",9214597_5,-1,-1,-1,16915,-1,0.9976888,0.0023111864
16916,E2,15,16,103,105,The high tumor angiogenic potential was associated with an elevated VEGF/VPF protein expression in the E2 exposed pituitary of ovariectomized (OVEX) rats.,9214597_6,-1,-1,-1,16916,-1,0.9959741,0.0040258802
16917,E2,4,5,17,19,"After 15 days of E2 exposure, VEGF/VPF protein expression, in the non-endothelial cell population, sharply declined and was restricted to the blood vessels.",9214597_8,-1,-1,-1,16917,-1,0.99659485,0.003405084
16918,E2,26,27,181,183,"Furthermore, immunohistochemical studies demonstrated that VEGFR-2 (flk-1/KDR), expression was elevated significantly in the endothelial cells of microblood vessels after 7 days of E2 exposure.",9214597_10,-1,-1,-1,16918,-1,0.9968939,0.003106153
16921,nephrogenic diabetes insipidus,1,4,11,41,Persistent nephrogenic diabetes insipidus following lithium therapy.,9226773_0,-1,-1,-1,16921,-1,0.004148178,0.9958519
16924,head injury,14,16,92,103,We report the case of a patient who developed severe hypernatraemic dehydration following a head injury.,9226773_1,-1,-1,-1,16924,-1,0.004183273,0.99581677
16925,nephrogenic diabetes insipidus,10,13,67,97,"Ten years previously he had been diagnosed to have lithium-induced nephrogenic diabetes insipidus, and lithium therapy had been discontinued.",9226773_2,-1,-1,-1,16925,-1,0.003500548,0.9964994
16927,polyuric,4,5,24,32,"He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion, with clear evidence of nephrogenic diabetes insipidus.",9226773_3,-1,-1,-1,16927,-1,0.0047722235,0.9952278
16930,nephrogenic diabetes insipidus,28,31,191,221,"He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion, with clear evidence of nephrogenic diabetes insipidus.",9226773_3,-1,-1,-1,16930,-1,0.0054463865,0.99455357
16932,nephrogenic diabetes insipidus,2,5,16,46,Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped.,9226773_4,-1,-1,-1,16932,-1,0.0034079333,0.99659204
16935,nephrogenic diabetes insipidus,15,18,110,140,We discuss the possible renal mechanisms and the implications for management of patients with lithium-induced nephrogenic diabetes insipidus.,9226773_5,-1,-1,-1,16935,-1,0.0040338915,0.9959661
16936,NIK-247,2,3,11,18,Effects of NIK-247 on cholinesterase and scopolamine-induced amnesia.,9228650_0,-1,-1,-1,16936,-1,0.99696165,0.0030383118
16938,NIK-247,3,4,15,22,"The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.",9228650_1,-1,-1,-1,16938,-1,0.998164,0.0018360121
16940,cholinesterase inhibitors tacrine,21,24,151,184,"The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.",9228650_1,-1,-1,-1,16940,-1,0.9963946,0.0036054442
16941,E-2020,25,26,189,195,"The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.",9228650_1,-1,-1,-1,16941,-1,0.9968266,0.003173328
16942,tacrine,2,3,9,16,"NIK-247, tacrine and E-2020 all strongly inhibited acetylcholinesterase (AChE) in human red blood cells (IC50s = 1.0 x 10(-6), 2.9 x 10(-7) and 3.7 x 10(-8) M, respectively).",9228650_2,-1,-1,-1,16942,-1,0.99860615,0.0013939145
16943,E-2020,4,5,21,27,"NIK-247, tacrine and E-2020 all strongly inhibited acetylcholinesterase (AChE) in human red blood cells (IC50s = 1.0 x 10(-6), 2.9 x 10(-7) and 3.7 x 10(-8) M, respectively).",9228650_2,-1,-1,-1,16943,-1,0.9965249,0.0034751182
16944,NIK-247,3,4,13,20,"In addition, NIK-247 and tacrine, but not E-2020, strongly inhibited butyrylcholinestrase (BuChE) in human serum.",9228650_3,-1,-1,-1,16944,-1,0.9976683,0.0023316927
16945,tacrine,5,6,25,32,"In addition, NIK-247 and tacrine, but not E-2020, strongly inhibited butyrylcholinestrase (BuChE) in human serum.",9228650_3,-1,-1,-1,16945,-1,0.9988312,0.0011687697
16946,E-2020,9,10,42,48,"In addition, NIK-247 and tacrine, but not E-2020, strongly inhibited butyrylcholinestrase (BuChE) in human serum.",9228650_3,-1,-1,-1,16946,-1,0.9976896,0.0023104502
16947,NIK-247,6,7,35,42,"Moreover, the inhibitory effect of NIK-247 on AChE was reversible.",9228650_5,-1,-1,-1,16947,-1,0.9973833,0.0026167054
16950,NIK-247,4,5,28,35,These findings suggest that NIK-247 at a low dose (0.1-1 mg/kg p.o.) improves scopolamine-induced amnesia but does not affect spontaneous movement.,9228650_8,-1,-1,-1,16950,-1,0.99820364,0.0017963458
16952,NIK-247,4,5,26,33,The findings suggest that NIK-247 may be a useful drug for the treatment of Alzheimer's disease.,9228650_9,-1,-1,-1,16952,-1,0.99772805,0.0022719197
16953,Alzheimer's disease,14,17,76,95,The findings suggest that NIK-247 may be a useful drug for the treatment of Alzheimer's disease.,9228650_9,-1,-1,-1,16953,-1,0.005981577,0.99401844
16955,cardiovascular disease,6,8,40,62,The role of nicotine in smoking-related cardiovascular disease.,9245658_0,-1,-1,-1,16955,-1,0.0035912506,0.99640876
16957,cardiovascular disease,13,15,86,108,Nicotine activates the sympathetic nervous system and in this way could contribute to cardiovascular disease.,9245658_1,-1,-1,-1,16957,-1,0.0034675435,0.99653244
16963,carbon monoxide,39,41,261,276,"Almost certainly, nicotine via its hemodynamic effects contributes to acute cardiovascular events, although current evidence suggests that the effects of nicotine are much less important than are the prothrombotic effects of cigarette smoking or the effects of carbon monoxide.",9245658_3,-1,-1,-1,16963,-1,0.998716,0.0012840232
16970,atrioventricular reentrant tachycardia,3,6,35,73,Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy.,9249847_0,-1,-1,-1,16970,-1,0.12098349,0.87901646
16972,idiopathic dilated cardiomyopathy,18,21,165,198,Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy.,9249847_0,-1,-1,-1,16972,-1,0.004012987,0.995987
16973,WPW syndrome,4,6,18,30,"In a patient with WPW syndrome and idiopathic dilated cardiomyopathy, intractable atrioventricular reentrant tachycardia (AVRT) was iatrogenically induced.",9249847_1,-1,-1,-1,16973,-1,0.0104667405,0.98953325
16974,idiopathic dilated cardiomyopathy,7,10,35,68,"In a patient with WPW syndrome and idiopathic dilated cardiomyopathy, intractable atrioventricular reentrant tachycardia (AVRT) was iatrogenically induced.",9249847_1,-1,-1,-1,16974,-1,0.0037933348,0.99620664
16975,atrioventricular reentrant tachycardia,12,15,82,120,"In a patient with WPW syndrome and idiopathic dilated cardiomyopathy, intractable atrioventricular reentrant tachycardia (AVRT) was iatrogenically induced.",9249847_1,-1,-1,-1,16975,-1,0.13352826,0.8664717
16976,AVRT,16,17,122,126,"In a patient with WPW syndrome and idiopathic dilated cardiomyopathy, intractable atrioventricular reentrant tachycardia (AVRT) was iatrogenically induced.",9249847_1,-1,-1,-1,16976,-1,0.9940054,0.005994656
16978,AVRT,24,25,178,182,"QRS without preexcitation, caused by junctional escape beats after verapamil or unidirectional antegrade block of accessory pathway after catheter ablation, established frequent AVRT attack.",9249847_2,-1,-1,-1,16978,-1,0.97972393,0.020276058
16980,A-86929,11,12,73,80,"Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.",9270571_0,-1,-1,-1,16980,-1,0.9949536,0.0050463933
16982,DA,6,7,34,36,The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease (PD) is still unclear.,9270571_1,-1,-1,-1,16982,-1,0.99723274,0.0027672471
16983,Parkinson's disease,15,18,79,98,The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease (PD) is still unclear.,9270571_1,-1,-1,-1,16983,-1,0.004901599,0.9950984
16984,PD,19,20,100,102,The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease (PD) is still unclear.,9270571_1,-1,-1,-1,16984,-1,0.003438373,0.9965616
16985,DA,5,6,33,35,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,16985,-1,0.9937808,0.006219229
16986,SKF-82958,11,12,65,74,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,16986,-1,0.9983175,0.0016825356
16987,"6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide",13,16,76,165,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,16987,-1,0.9934715,0.006528509
16988,A-77636,18,19,171,178,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,16988,-1,0.9921731,0.007826882
16989,"[1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride)",20,29,180,276,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,16989,-1,0.94987637,0.050123636
16990,too,40,41,337,340,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,16990,-1,0.04930571,0.9506943
16991,SKF-82958,43,44,351,360,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,16991,-1,0.99817383,0.0018261324
16992,A-77636,53,54,387,394,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,16992,-1,0.9941434,0.0058565754
16993,> 20,55,57,396,400,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,-1,-1,-1,16993,-1,0.32644734,0.67355263
16994,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",10,11,69,113,"We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.",9270571_3,-1,-1,-1,16994,-1,0.99659747,0.0034024813
16996,dyskinetic,24,25,225,235,"We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.",9270571_3,-1,-1,-1,16996,-1,0.0024757395,0.9975242
16997,A-86929,39,40,301,308,"We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.",9270571_3,-1,-1,-1,16997,-1,0.9924982,0.00750171
16999,DA,3,4,17,19,"Levodopa and the DA D2-like receptor agonist, LY-171555 ([4aR-trans]-4,4a,5,6,7,8,8a,9-o-dihydro-5n-propyl-2H-pyrazo lo-3-4-quinoline hydrochloride) were also used for comparison.",9270571_4,-1,-1,-1,16999,-1,0.99632555,0.0036744708
17000,LY-171555,8,9,46,55,"Levodopa and the DA D2-like receptor agonist, LY-171555 ([4aR-trans]-4,4a,5,6,7,8,8a,9-o-dihydro-5n-propyl-2H-pyrazo lo-3-4-quinoline hydrochloride) were also used for comparison.",9270571_4,-1,-1,-1,17000,-1,0.9974492,0.0025507668
17001,A-86929,3,4,24,31,"Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.",9270571_5,-1,-1,-1,17001,-1,0.9977204,0.0022795582
17004,LY-171555,14,15,108,117,"Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.",9270571_5,-1,-1,-1,17004,-1,0.9984219,0.0015780455
17006,LY-171555,31,32,219,228,"Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.",9270571_5,-1,-1,-1,17006,-1,0.99829406,0.0017059784
17008,DA,4,5,29,31,Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with levodopa and selective DA D2 receptor agonist.,9270571_6,-1,-1,-1,17008,-1,0.9976502,0.0023497539
17010,DA,37,38,230,232,Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with levodopa and selective DA D2 receptor agonist.,9270571_6,-1,-1,-1,17010,-1,0.9975683,0.002431674
17011,A-86929,13,14,79,86,Potent DA D1 receptor agents with an intermediate duration of efficacy such as A-86929 (approximately 4 hr at higher doses tested) are potential therapeutic tools in PD and merit further attention.,9270571_7,-1,-1,-1,17011,-1,0.99636334,0.0036366463
17012,PD,28,29,166,168,Potent DA D1 receptor agents with an intermediate duration of efficacy such as A-86929 (approximately 4 hr at higher doses tested) are potential therapeutic tools in PD and merit further attention.,9270571_7,-1,-1,-1,17012,-1,0.008107227,0.9918928
17014,hydrochlorofluorocarbons,6,7,36,60,Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons.,9284778_0,-1,-1,-1,17014,-1,0.9989969,0.0010031143
17015,chlorofluorocarbons,12,13,98,117,Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons.,9284778_0,-1,-1,-1,17015,-1,0.9989378,0.001062275
17016,Hydrochlorofluorocarbons,2,3,12,36,BACKGROUND: Hydrochlorofluorocarbons (HCFCs) are used increasingly in industry as substitutes for ozone-depleting chlorofluorocarbons (CFCs).,9284778_1,-1,-1,-1,17016,-1,0.998713,0.0012870211
17017,HCFCs,4,5,38,43,BACKGROUND: Hydrochlorofluorocarbons (HCFCs) are used increasingly in industry as substitutes for ozone-depleting chlorofluorocarbons (CFCs).,9284778_1,-1,-1,-1,17017,-1,0.9961081,0.0038918767
17018,chlorofluorocarbons,15,16,114,133,BACKGROUND: Hydrochlorofluorocarbons (HCFCs) are used increasingly in industry as substitutes for ozone-depleting chlorofluorocarbons (CFCs).,9284778_1,-1,-1,-1,17018,-1,0.99861753,0.0013824055
17019,CFCs,17,18,135,139,BACKGROUND: Hydrochlorofluorocarbons (HCFCs) are used increasingly in industry as substitutes for ozone-depleting chlorofluorocarbons (CFCs).,9284778_1,-1,-1,-1,17019,-1,0.99651957,0.0034803997
17023,HCFC 123,23,25,165,173,"We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).",9284778_3,-1,-1,-1,17023,-1,0.9956958,0.004304163
17024,"and 1-chloro-1,2,2,2-tetrafluoroethane",26,28,175,213,"We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).",9284778_3,-1,-1,-1,17024,-1,0.98730034,0.012699718
17025,HCFC 124,29,31,215,223,"We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).",9284778_3,-1,-1,-1,17025,-1,0.9951132,0.0048868107
17026,"1-bromo-1-chloro-2,2,2-trifluoroethane (halothane",9,12,50,99,"Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the hepatotoxicity of halothane.",9284778_5,-1,-1,-1,17026,-1,0.9949856,0.0050144414
17027,trifluoroacetyl,16,17,118,133,"Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the hepatotoxicity of halothane.",9284778_5,-1,-1,-1,17027,-1,0.99702007,0.0029798935
17030,HCFCs,5,6,25,30,We aimed to test whether HCFCs 123 and 124 can result in serious liver disease.,9284778_6,-1,-1,-1,17030,-1,0.99780875,0.0021912646
17032,trifluoroacetyl,16,17,109,124,METHODS: For one severely affected worker liver biopsy and immunohistochemical stainings for the presence of trifluoroacetyl protein adducts were done.,9284778_7,-1,-1,-1,17032,-1,0.999019,0.0009809233
17033,hepatocellular necrosis,7,9,41,64,FINDINGS: The liver biopsy sample showed hepatocellular necrosis which was prominent in perivenular zone three and extended focally from portal tracts to portal tracts and centrilobular areas (bridging necrosis).,9284778_9,-1,-1,-1,17033,-1,0.0040586265,0.99594134
17035,halothane hepatitis,10,12,67,86,"Autoantibodies against P450 2E1 or P58, previously associated with halothane hepatitis, were detected in the serum of five affected workers.",9284778_11,-1,-1,-1,17035,-1,0.9086518,0.0913482
17036,HCFCs 123,8,10,53,62,INTERPRETATION: Repeated exposure of human beings to HCFCs 123 and 124 can result in serious liver injury in a large proportion of the exposed population.,9284778_12,-1,-1,-1,17036,-1,0.99619627,0.0038037223
17039,hamartoma,2,3,10,19,Bile duct hamartoma occurring in association with long-term treatment with danazol.,9293063_0,-1,-1,-1,17039,-1,0.0056077708,0.9943922
17041,hamartoma,7,8,30,39,We report a case of bile duct hamartoma which developed in a patient who had been on long-term danazol treatment.,9293063_1,-1,-1,-1,17041,-1,0.007249361,0.99275064
17043,liver mass,5,7,26,36,"If the patient develops a liver mass, because of non-specific clinical features and imaging appearances, biopsy may be the only way to achieve a definitive diagnosis.",9293063_3,-1,-1,-1,17043,-1,0.0042508272,0.9957491
17047,TLE,23,24,145,148,Neuropeptide-Y (NPY) is expressed by granule cells and mossy fibres of the hippocampal dentate gyrus during experimental temporal lobe epilepsy (TLE).,9305828_1,-1,-1,-1,17047,-1,0.0071663707,0.9928336
17049,PILO,3,4,17,21,The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.,9305828_3,-1,-1,-1,17049,-1,0.9938099,0.00619018
17051,status epilepticus,15,17,80,98,The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.,9305828_3,-1,-1,-1,17051,-1,0.003257854,0.9967422
17054,PILO,3,4,13,17,"In addition, PILO injected animals exhibited a reduction in the number of NPY-immunoreactive interneurons compared with controls.",9305828_7,-1,-1,-1,17054,-1,0.99814415,0.0018558503
17055,PILO,30,31,174,178,"The results demonstrate that changes in NPY expression, including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons, are present in the PILO model of TLE.",9305828_8,-1,-1,-1,17055,-1,0.9872006,0.012799422
17056,TLE,33,34,188,191,"The results demonstrate that changes in NPY expression, including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons, are present in the PILO model of TLE.",9305828_8,-1,-1,-1,17056,-1,0.0080147,0.9919853
17057,Parkinson's disease,5,8,46,65,Posteroventral medial pallidotomy in advanced Parkinson's disease.,9321531_0,-1,-1,-1,17057,-1,0.008052494,0.9919475
17058,Parkinson's disease,13,16,112,131,"BACKGROUND: Posteroventral medial pallidotomy sometimes produces striking improvement in patients with advanced Parkinson's disease, but the studies to date have involved small numbers of patients and short-term follow-up.",9321531_1,-1,-1,-1,17058,-1,0.00555177,0.9944482
17059,Parkinson's disease,5,8,29,48,"METHODS: Forty patients with Parkinson's disease underwent serial, detailed assessments both after drug withdrawal (""off"" period) and while taking their optimal medical regimens (""on"" period).",9321531_2,-1,-1,-1,17059,-1,0.0062300013,0.99376994
17064,bradykinesia,13,14,96,108,"The improvements in dyskinesias and the total scores for off-period parkinsonism, contralateral bradykinesia, and rigidity were sustained in the 11 patients examined at two years.",9321531_5,-1,-1,-1,17064,-1,0.002264309,0.9977356
17067,Parkinson's disease,4,7,27,46,"CONCLUSIONS: In late-stage Parkinson's disease, pallidotomy significantly reduces levodopa-induced dyskinesias and off-period disability.",9321531_9,-1,-1,-1,17067,-1,0.0052121836,0.9947878
17070,Clarithromycin,0,1,0,14,Clarithromycin is a relatively new macrolide antibiotic that offers twice-daily dosing.,9326871_1,-1,-1,-1,17070,-1,0.99934894,0.00065111375
17071,macrolide,5,6,35,44,Clarithromycin is a relatively new macrolide antibiotic that offers twice-daily dosing.,9326871_1,-1,-1,-1,17071,-1,0.9983907,0.0016093872
17072,erythromycin,3,4,16,28,It differs from erythromycin only in the methylation of the hydroxyl group at position 6.,9326871_2,-1,-1,-1,17072,-1,0.9981439,0.0018560799
17073,hydroxyl,10,11,60,68,It differs from erythromycin only in the methylation of the hydroxyl group at position 6.,9326871_2,-1,-1,-1,17073,-1,0.9134351,0.08656485
17074,erythromycin,5,6,36,48,"Although the side-effect profile of erythromycin is established, including gastroenteritis and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer macrolides is still being recorded.",9326871_3,-1,-1,-1,17074,-1,0.9990771,0.00092287635
17075,gastroenteritis,10,11,75,90,"Although the side-effect profile of erythromycin is established, including gastroenteritis and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer macrolides is still being recorded.",9326871_3,-1,-1,-1,17075,-1,0.002351004,0.997649
17076,macrolides,27,28,205,215,"Although the side-effect profile of erythromycin is established, including gastroenteritis and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer macrolides is still being recorded.",9326871_3,-1,-1,-1,17076,-1,0.9985864,0.0014136301
17078,erythromycin,11,12,87,99,Cardiotoxicity has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides.,9326871_4,-1,-1,-1,17078,-1,0.9990551,0.0009448652
17079,macrolides,20,21,143,153,Cardiotoxicity has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides.,9326871_4,-1,-1,-1,17079,-1,0.99837613,0.0016238798
17080,ventricular dysrhythmias,5,7,20,44,We report a case of ventricular dysrhythmias that occurred after six therapeutic doses of clarithromycin.,9326871_5,-1,-1,-1,17080,-1,0.0028894574,0.9971105
17081,clarithromycin,14,15,90,104,We report a case of ventricular dysrhythmias that occurred after six therapeutic doses of clarithromycin.,9326871_5,-1,-1,-1,17081,-1,0.99935097,0.0006490301
17082,dysrhythmias,1,2,4,16,The dysrhythmias resolved after discontinuation of the drug.,9326871_6,-1,-1,-1,17082,-1,0.0027693545,0.9972306
17083,erectile dysfunction,6,8,38,58,"Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy.",9334596_0,-1,-1,-1,17083,-1,0.0049894424,0.9950106
17085,erectile dysfunction,18,20,121,141,"PURPOSE: We reviewed the results of serum testosterone and prolactin determination in 1,022 patients referred because of erectile dysfunction and compared the data with history, results of physical examination, other etiological investigations and effects of endocrine therapy to refine the rules of cost-effective endocrine screening and to pinpoint actual responsibility for hormonal abnormalities.",9334596_1,-1,-1,-1,17085,-1,0.003751962,0.99624807
17089,gynecomastia,20,21,115,127,"Every patient was screened for testosterone and 451 were screened for prolactin on the basis of low sexual desire, gynecomastia or testosterone less than 4 ng./ml.",9334596_3,-1,-1,-1,17089,-1,0.0035745506,0.99642545
17091,erectile dysfunction,15,17,96,116,"Prolactin results were compared with those of a previous personal cohort of 1,340 patients with erectile dysfunction and systematic prolactin determination.",9334596_5,-1,-1,-1,17091,-1,0.004024632,0.99597543
17092,gynecomastia,17,18,117,129,"Main clinical criteria tested regarding efficiency in hormone determination were low sexual desire, small testes and gynecomastia.",9334596_6,-1,-1,-1,17092,-1,0.0029249417,0.9970751
17093,testosterone heptylate,4,6,31,53,Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.,9334596_7,-1,-1,-1,17093,-1,0.9989532,0.0010468066
17094,human chorionic gonadotropin,7,10,57,85,Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.,9334596_7,-1,-1,-1,17094,-1,0.9931947,0.006805294
17095,hypogonadism,11,12,90,102,Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.,9334596_7,-1,-1,-1,17095,-1,0.0049958,0.99500424
17100,pituitary tumors,1,3,4,20,Two pituitary tumors were discovered after testosterone determination.,9334596_11,-1,-1,-1,17100,-1,0.002993876,0.9970061
17103,hypothalamic dysfunction,12,14,75,99,"Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%).",9334596_12,-1,-1,-1,17103,-1,0.0040666503,0.99593335
17104,luteinizing hormone,18,20,124,143,"Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%).",9334596_12,-1,-1,-1,17104,-1,0.997459,0.0025409732
17105,erectile dysfunction,30,32,191,211,"Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%).",9334596_12,-1,-1,-1,17105,-1,0.0032040258,0.99679595
17110,prolactinomas,7,8,28,41,"in 1.86% of 1,821 patients, prolactinomas in 7, 0.38%).",9334596_18,-1,-1,-1,17110,-1,0.04447599,0.95552397
17114,erectile dysfunction,13,15,83,103,CONCLUSIONS: Low prevalences and effects of low testosterone and high prolactin in erectile dysfunction cannot justify their routine determination.,9334596_22,-1,-1,-1,17114,-1,0.0032625846,0.9967374
17115,pituitary tumors,21,23,130,146,"However, cost-effective screening strategies recommended so far missed 40 to 50% of cases improved with endocrine therapy and the pituitary tumors.",9334596_23,-1,-1,-1,17115,-1,0.0047434215,0.9952566
17119,gynecomastia,12,13,67,79,"Prolactin should be determined only in cases of low sexual desire, gynecomastia and/or testosterone less than 4 ng./ml.",9334596_25,-1,-1,-1,17119,-1,0.0033293003,0.9966708
17123,antipsychotic,3,4,18,31,Risperidone is an antipsychotic drug with high affinity at dopamine D2 and serotonin 5-HT2 receptors.,9351491_1,-1,-1,-1,17123,-1,0.9760426,0.02395734
17128,neuroleptics,33,34,241,253,Previous clinical studies have proposed that risperidone's pharmacologic profile may produce improved efficacy for negative psychotic symptoms and decreased propensity for extrapyramidal side effects; features shared by so-called 'atypical' neuroleptics.,9351491_2,-1,-1,-1,17128,-1,0.87198097,0.12801898
17131,n,40,41,254,255,"To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects, we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7).",9351491_3,-1,-1,-1,17131,-1,0.27684256,0.72315747
17133,n,47,48,278,279,"To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects, we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7).",9351491_3,-1,-1,-1,17133,-1,0.234713,0.76528704
17144,5-FU,15,16,118,122,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,-1,-1,-1,17144,-1,0.99820256,0.0017974491
17145,leucovorin,17,18,127,137,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,-1,-1,-1,17145,-1,0.999116,0.00088398665
17146,MFL,19,20,139,142,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,-1,-1,-1,17146,-1,0.99758005,0.0024199523
17151,5-FU,8,9,70,74,"Combination chemotherapy with mitoxantrone, high-dose 5-fluorouracil (5-FU) and leucovorin (MFL regimen) had been reported as an effective and well tolerated regimen.",9390208_2,-1,-1,-1,17151,-1,0.9978521,0.0021478878
17152,leucovorin,11,12,80,90,"Combination chemotherapy with mitoxantrone, high-dose 5-fluorouracil (5-FU) and leucovorin (MFL regimen) had been reported as an effective and well tolerated regimen.",9390208_2,-1,-1,-1,17152,-1,0.9992717,0.0007283387
17153,MFL,13,14,92,95,"Combination chemotherapy with mitoxantrone, high-dose 5-fluorouracil (5-FU) and leucovorin (MFL regimen) had been reported as an effective and well tolerated regimen.",9390208_2,-1,-1,-1,17153,-1,0.9971956,0.002804384
17156,5-FU,30,31,184,188,"From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.",9390208_3,-1,-1,-1,17156,-1,0.9982693,0.0017306175
17157,leucovorin,37,38,216,226,"From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.",9390208_3,-1,-1,-1,17157,-1,0.99892575,0.0010742177
17158,h,44,45,246,247,"From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.",9390208_3,-1,-1,-1,17158,-1,0.13330545,0.8666945
17159,metastasis,13,14,69,79,"Most of these patients had more than two metastatic sites, with lung metastasis predominant.",9390208_5,-1,-1,-1,17159,-1,0.003505265,0.9964947
17161,MFL regimen,5,7,28,39,Median number of courses of MFL regimen given was six and the median cumulative dose of mitoxantrone was 68.35 mg/m2.,9390208_8,-1,-1,-1,17161,-1,0.99053323,0.009466722
17167,MFL regimen,1,3,4,15,The MFL regimen achieves little palliative benefit and induces severe toxicity at a fairly high rate.,9390208_17,-1,-1,-1,17167,-1,0.99000764,0.009992397
17170,impaired heart function,17,20,110,133,Administration of this regimen to breast cancer patients who have been treated by chemotherapy and those with impaired heart function requires careful attention.,9390208_18,-1,-1,-1,17170,-1,0.0052883523,0.99471164
17173,Agranulocytosis,0,1,0,15,"Agranulocytosis occurred 3-20 weeks after initiation of ticlopidine, so frequent examination of white cell count during treatment is recommended.",9401499_5,-1,-1,-1,17173,-1,0.0062615154,0.99373853
17177,calcium channel blockers,11,14,58,82,"The fact that 5 of the 6 patients who received concurrent calcium channel blockers died, should alert clinicians to be more cautious when using these two drugs simultaneously.",9401499_8,-1,-1,-1,17177,-1,0.99786574,0.002134256
17179,diabetes insipidus,16,18,119,137,Upregulation of the expression of vasopressin gene in the paraventricular and supraoptic nuclei of the lithium-induced diabetes insipidus rat.,9406968_0,-1,-1,-1,17179,-1,0.013196115,0.98680395
17180,arginine vasopressin,3,5,18,38,"The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced polyuria, using in situ hybridization histochemistry and radioimmunoassay.",9406968_1,-1,-1,-1,17180,-1,0.99684805,0.0031519367
17181,AVP,6,7,40,43,"The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced polyuria, using in situ hybridization histochemistry and radioimmunoassay.",9406968_1,-1,-1,-1,17181,-1,0.99426055,0.0057395156
17184,LiCl,9,10,53,57,The male Wistar rats consuming a diet that contained LiCl (60 mmol/kg) for 4 weeks developed marked polyuria.,9406968_2,-1,-1,-1,17184,-1,0.99878806,0.0012119354
17186,hypotonic,8,9,47,56,The Li-treated rats produced a large volume of hypotonic urine with low ionic concentrations.,9406968_3,-1,-1,-1,17186,-1,0.023031732,0.9769682
17188,AVP,3,4,24,27,Plasma concentration of AVP and transcripts of AVP gene in the PVN and SON were significantly increased in the Li-treated rats compared with controls.,9406968_5,-1,-1,-1,17188,-1,0.9978264,0.002173553
17189,AVP,7,8,47,50,Plasma concentration of AVP and transcripts of AVP gene in the PVN and SON were significantly increased in the Li-treated rats compared with controls.,9406968_5,-1,-1,-1,17189,-1,0.99552476,0.004475224
17191,AVP and,19,21,131,138,These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.,9406968_6,-1,-1,-1,17191,-1,0.96545213,0.0345479
17192,AVP gene,24,26,159,167,These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.,9406968_6,-1,-1,-1,17192,-1,0.984963,0.015036921
17193,diabetes insipidus,36,38,220,238,These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.,9406968_6,-1,-1,-1,17193,-1,0.007408846,0.99259114
17194,glyceryl trinitrate,2,4,10,29,Effect of glyceryl trinitrate on the sphincter of Oddi spasm evoked by prostigmine-morphine administration.,9431903_0,-1,-1,-1,17194,-1,0.99911314,0.0008868479
17196,glyceryl trinitrate,8,10,39,58,OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine-morphine-induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia.,9431903_1,-1,-1,-1,17196,-1,0.9990557,0.0009442739
17198,sphincter of Oddi dyskinesia,24,28,162,190,OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine-morphine-induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia.,9431903_1,-1,-1,-1,17198,-1,0.0053904695,0.9946095
17200,mg prostigmine,13,15,88,102,METHOD: Sphincter of Oddi spasm was induced by prostigmine-morphine administration (0.5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously) and visualized by quantitative hepatobiliary scintigraphy.,9431903_2,-1,-1,-1,17200,-1,0.99809533,0.0019047237
17201,mg morphine,18,20,126,137,METHOD: Sphincter of Oddi spasm was induced by prostigmine-morphine administration (0.5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously) and visualized by quantitative hepatobiliary scintigraphy.,9431903_2,-1,-1,-1,17201,-1,0.9962692,0.0037307667
17202,glyceryl trinitrate,6,8,41,60,The entire procedure was repeated during glyceryl trinitrate infusion (Nitrolingual 1 microg/kg/min for 120 min).,9431903_3,-1,-1,-1,17202,-1,0.99902654,0.00097349746
17203,Nitrolingual 1,10,12,71,85,The entire procedure was repeated during glyceryl trinitrate infusion (Nitrolingual 1 microg/kg/min for 120 min).,9431903_3,-1,-1,-1,17203,-1,0.99465984,0.005340203
17205,Glyceryl trinitrate,0,2,0,19,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,-1,-1,-1,17205,-1,0.9990557,0.00094430905
17206,glyceryl trinitrate,79,81,382,401,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,-1,-1,-1,17206,-1,0.99906284,0.0009371673
17207,glyceryl trinitrate,12,14,77,96,CONCLUSION: These results provide the first evidence of the effectiveness of glyceryl trinitrate on the morphine-induced sphincter of Oddi spasm in humans.,9431903_6,-1,-1,-1,17207,-1,0.99919885,0.0008011124
17209,glyceryl trinitrate,1,3,6,25,"Since glyceryl trinitrate is able to overcome even the drastic effect of morphine, it might be of relevance in the treatment of sphincter of Oddi dyskinesia.",9431903_7,-1,-1,-1,17209,-1,0.9991679,0.00083205523
17211,sphincter,23,24,128,137,"Since glyceryl trinitrate is able to overcome even the drastic effect of morphine, it might be of relevance in the treatment of sphincter of Oddi dyskinesia.",9431903_7,-1,-1,-1,17211,-1,0.04986697,0.9501331
17212,Oddi dyskinesia,25,27,141,156,"Since glyceryl trinitrate is able to overcome even the drastic effect of morphine, it might be of relevance in the treatment of sphincter of Oddi dyskinesia.",9431903_7,-1,-1,-1,17212,-1,0.008985841,0.9910142
17214,pirenzepine,17,18,137,148,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17214,-1,0.99911946,0.0008805958
17215,dicyclomine,19,20,153,164,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17215,-1,0.99904877,0.0009511929
17217,hemicholinium-3,24,25,196,211,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17217,-1,0.997675,0.0023250245
17219,gamma-aminobutyric,35,36,260,278,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17219,-1,0.9963972,0.003602781
17220,acidB,36,37,279,284,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17220,-1,0.9858326,0.014167458
17222,the H3,41,43,343,349,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17222,-1,0.97696555,0.02303449
17223,quinpirole,49,50,403,413,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17223,-1,0.99914515,0.00085477915
17225,"2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride,",54,60,451,532,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17225,-1,0.9584794,0.041520644
17226,5-hydroxytryptamin1A,61,62,537,557,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17226,-1,0.9772291,0.02277089
17227,1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide,63,65,569,638,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17227,-1,0.9933728,0.0066272165
17228,polyamines,67,68,647,657,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,-1,-1,-1,17228,-1,0.98882806,0.011171983
17230,mg,5,6,18,20,(+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.,9495837_4,-1,-1,-1,17230,-1,0.83682764,0.16317235
17233,mg,20,21,86,88,(+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.,9495837_4,-1,-1,-1,17233,-1,0.80940807,0.19059192
17234,dicyclomine,26,27,104,115,(+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.,9495837_4,-1,-1,-1,17234,-1,0.99911493,0.0008851174
17235,mg,29,30,119,121,(+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.,9495837_4,-1,-1,-1,17235,-1,0.7544829,0.24551712
17237,glomerular disease,3,5,41,59,Immunopathology of penicillamine-induced glomerular disease.,950631_0,-1,-1,-1,17237,-1,0.0026070806,0.9973929
17241,membranous glomerulonephritis,8,10,44,73,"The findings were similar to those in early membranous glomerulonephritis, differences being observed however in the results of staining for the early-acting complement components C1q and C4.",950631_5,-1,-1,-1,17241,-1,0.0037790758,0.996221
17244,migraine without aura,15,18,79,100,"Using a positron emission tomography (PET) study it was shown recently that in migraine without aura certain areas in the brain stem were activated during the headache state, but not in the headache free interval.",9514561_1,-1,-1,-1,17244,-1,0.0064032716,0.9935967
17252,burning painful sensation,15,18,93,118,A small amount of capsaicin was administered subcutaneously in the right forehead to evoke a burning painful sensation in the first division of the trigeminal nerve.,9514561_4,-1,-1,-1,17252,-1,0.0031363145,0.9968637
17254,acute pain,21,23,124,134,Using the same stereotactic space limits as in the above mentioned migraine study no brain stem activation was found in the acute pain state compared to the pain free state.,9514561_6,-1,-1,-1,17254,-1,0.0087616565,0.9912383
17258,cluster headache,42,44,236,252,"The increase of activation in the region of the cavernous sinus however, suggests that this structure is more likely to be involved in trigeminal transmitted pain as such, rather than in a specific type of headache as was suggested for cluster headache.",9514561_7,-1,-1,-1,17258,-1,0.0037777654,0.99622226
17259,hearing loss,7,9,46,58,The effect of different anaesthetic agents in hearing loss following spinal anaesthesia.,9522143_0,-1,-1,-1,17259,-1,0.0042872145,0.99571276
17260,hearing loss,3,5,13,25,The cause of hearing loss after spinal anaesthesia is unknown.,9522143_1,-1,-1,-1,17260,-1,0.0036122168,0.99638784
17262,hearing loss,9,11,43,55,The aim of this study was to describe this hearing loss and to investigate other factors influencing the degree of hearing loss.,9522143_3,-1,-1,-1,17262,-1,0.0044789477,0.99552107
17263,hearing loss,20,22,115,127,The aim of this study was to describe this hearing loss and to investigate other factors influencing the degree of hearing loss.,9522143_3,-1,-1,-1,17263,-1,0.0040249904,0.99597496
17265,mL bupivacaine,23,25,112,126,Two groups of 22 similar patients were studied: one group received 6 mL prilocaine 2%; and the other received 3 mL bupivacaine 0.5%.,9522143_4,-1,-1,-1,17265,-1,0.99692696,0.0030730462
17267,hearing loss,8,10,54,66,Patients given prilocaine were more likely to develop hearing loss (10 out of 22) than those given bupivacaine (4 out of 22) (P < 0.05).,9522143_5,-1,-1,-1,17267,-1,0.002648084,0.9973519
17269,P,27,28,126,127,Patients given prilocaine were more likely to develop hearing loss (10 out of 22) than those given bupivacaine (4 out of 22) (P < 0.05).,9522143_5,-1,-1,-1,17269,-1,0.2736197,0.7263803
17270,hearing loss,2,4,12,24,The average hearing loss for speech frequencies was about 10 dB after prilocaine and 15 dB after bupivacaine.,9522143_6,-1,-1,-1,17270,-1,0.0043405555,0.9956594
17273,hearing loss,7,9,46,58,None of the patients complained of subjective hearing loss.,9522143_7,-1,-1,-1,17273,-1,0.003192735,0.99680734
17274,transient neurological deficit,1,4,2,32,A transient neurological deficit following intrathecal injection of 1% hyperbaric bupivacaine for unilateral spinal anaesthesia.,9522152_0,-1,-1,-1,17274,-1,0.002121943,0.9978781
17276,neurological deficit,6,8,32,52,We describe a case of transient neurological deficit that occurred after unilateral spinal anaesthesia with 8 mg of 1% hyperbaric bupivacaine slowly injected through a 25-gauge pencil-point spinal needle.,9522152_1,-1,-1,-1,17276,-1,0.002048779,0.9979512
17277,mg,16,17,110,112,We describe a case of transient neurological deficit that occurred after unilateral spinal anaesthesia with 8 mg of 1% hyperbaric bupivacaine slowly injected through a 25-gauge pencil-point spinal needle.,9522152_1,-1,-1,-1,17277,-1,0.98774815,0.012251842
17279,hypoaesthesia,19,20,103,116,"The surgery and anaesthesia were uneventful, but 3 days after surgery, the patient reported an area of hypoaesthesia over L3-L4 dermatomes of the leg which had been operated on (loss of pinprick sensation) without reduction in muscular strength.",9522152_2,-1,-1,-1,17279,-1,0.004344291,0.99565566
17280,loss of pinprick sensation,32,36,178,204,"The surgery and anaesthesia were uneventful, but 3 days after surgery, the patient reported an area of hypoaesthesia over L3-L4 dermatomes of the leg which had been operated on (loss of pinprick sensation) without reduction in muscular strength.",9522152_2,-1,-1,-1,17280,-1,0.031045279,0.9689547
17281,lead,49,50,304,308,"However, we suggest that a low solution concentration should be preferred for unilateral spinal anaesthesia with a hyperbaric anaesthetic solution (if pencil-point needle and slow injection rate are employed), in order to minimize the risk of a localized high peak anaesthetic concentration, which might lead to a transient neurological deficit.",9522152_5,-1,-1,-1,17281,-1,0.011206481,0.98879355
17282,neurological deficit,53,55,324,344,"However, we suggest that a low solution concentration should be preferred for unilateral spinal anaesthesia with a hyperbaric anaesthetic solution (if pencil-point needle and slow injection rate are employed), in order to minimize the risk of a localized high peak anaesthetic concentration, which might lead to a transient neurological deficit.",9522152_5,-1,-1,-1,17282,-1,0.0021647802,0.9978352
17286,transient neurologic symptoms,6,9,42,71,BACKGROUND: Recent evidence suggests that transient neurologic symptoms (TNSs) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine.,9523805_1,-1,-1,-1,17286,-1,0.0021243212,0.9978757
17287,TNSs,10,11,73,77,BACKGROUND: Recent evidence suggests that transient neurologic symptoms (TNSs) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine.,9523805_1,-1,-1,-1,17287,-1,0.0059883455,0.9940116
17296,TNSs,24,25,164,168,"Accordingly, the present, prospective double-blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs.",9523805_4,-1,-1,-1,17296,-1,0.006567471,0.9934325
17303,TNSs,12,13,67,71,"In the evening of postoperative day 1, patients were evaluated for TNSs by a physician unaware of the drug administered and the details of the anesthetic procedure.",9523805_8,-1,-1,-1,17303,-1,0.15875936,0.84124064
17305,TNSs,9,10,61,65,"RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.",9523805_9,-1,-1,-1,17305,-1,0.008876036,0.99112403
17307,P,18,19,106,107,"RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.",9523805_9,-1,-1,-1,17307,-1,0.4176189,0.58238107
17309,TNSs,33,34,176,180,"RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.",9523805_9,-1,-1,-1,17309,-1,0.008101333,0.99189866
17313,P,37,38,190,191,"Times to ambulate and to void were similar after lidocaine and prilocaine (150 vs. 165 min and 238 vs. 253 min, respectively) but prolonged after bupivacaine (200 and 299 min, respectively; P < 0.05).",9523805_10,-1,-1,-1,17313,-1,0.2500399,0.74996006
17316,TNSs,25,26,154,158,CONCLUSIONS: Prilocaine may be preferable to lidocaine for short surgical procedures because it has a similar duration of action but a lower incidence of TNSs.,9523805_11,-1,-1,-1,17316,-1,0.008668902,0.9913311
17318,iron dextran,16,18,120,132,Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.,9523850_0,-1,-1,-1,17318,-1,0.99819165,0.0018083276
17319,blind,21,22,143,148,Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.,9523850_0,-1,-1,-1,17319,-1,0.23954853,0.7604515
17320,iron dextran,12,14,56,68,The safety and efficacy of total dose infusion (TDI) of iron dextran has been well documented.,9523850_1,-1,-1,-1,17320,-1,0.9982482,0.0017518614
17322,MP,23,24,148,150,"The purpose of this randomized, double-blind, prospective study was to investigate whether intravenous (i.v.) administration of methylprednisolone (MP) prevents this complication.",9523850_3,-1,-1,-1,17322,-1,0.99736136,0.0026385738
17323,mg,29,30,129,131,"Sixty-five patients, 34 women and 31 men, ages 36 to 80 years, received either normal saline before and after TDI (group 1), 125 mg i.v.",9523850_4,-1,-1,-1,17323,-1,0.9865877,0.01341232
17324,MP,0,1,0,2,"MP before and saline after TDI (group 2), or 125 mg i.v.",9523850_5,-1,-1,-1,17324,-1,0.99786395,0.0021360288
17325,mg,13,14,49,51,"MP before and saline after TDI (group 2), or 125 mg i.v.",9523850_5,-1,-1,-1,17325,-1,0.98143494,0.018565098
17326,MP,0,1,0,2,MP before and after TDI (group 3).,9523850_6,-1,-1,-1,17326,-1,0.99672097,0.0032789751
17327,MP,6,7,46,48,These data demonstrate that administration of MP before and after TDI reduces the frequency and severity of the arthralgia-myalgia syndrome.,9523850_11,-1,-1,-1,17327,-1,0.9988445,0.001155451
17328,mg,4,5,21,23,We conclude that 125 mg i.v.,9523850_12,-1,-1,-1,17328,-1,0.9892063,0.010793707
17329,MP,0,1,0,2,MP should be given routinely before and after TDI of iron dextran.,9523850_13,-1,-1,-1,17329,-1,0.9971392,0.002860787
17330,iron dextran,10,12,53,65,MP should be given routinely before and after TDI of iron dextran.,9523850_13,-1,-1,-1,17330,-1,0.9979741,0.0020259086
17331,Prolongation of the QT interval,0,5,0,31,Prolongation of the QT interval related to cisapride-diltiazem interaction.,9545159_0,-1,-1,-1,17331,-1,0.02937506,0.970625
17333,gastrointestinal motility disorders,18,21,95,130,"Cisapride, a cytochrome P450 3A4 (CYP3A4) substrate, is widely prescribed for the treatment of gastrointestinal motility disorders.",9545159_1,-1,-1,-1,17333,-1,0.0031618525,0.9968381
17334,torsades de pointes,5,8,29,48,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,-1,-1,-1,17334,-1,0.014616823,0.98538315
17335,sudden cardiac death have,10,14,54,79,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,-1,-1,-1,17335,-1,0.006085881,0.99391407
17336,erythromycin,20,21,132,144,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,-1,-1,-1,17336,-1,0.99906486,0.00093515683
17337,azole antifungal agents,22,25,148,171,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,-1,-1,-1,17337,-1,0.9974661,0.0025339322
17339,gastroesophageal reflux disorder,14,17,89,121,"A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.",9545159_3,-1,-1,-1,17339,-1,0.0030784283,0.9969216
17350,n,47,48,288,289,"We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.",9549528_1,-1,-1,-1,17350,-1,0.1278694,0.8721306
17352,n,59,60,346,347,"We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.",9549528_1,-1,-1,-1,17352,-1,0.1290088,0.87099123
17353,dyskinetic parkinsonian,1,3,4,27,"The dyskinetic parkinsonian patients exhibited a pattern of response which was markedly different from those of the normal subjects and non-dyskinetic parkinsonian patients, with a significant overactivation in the supplementary motor area and the ipsi- and contralateral primary motor areas.",9549528_4,-1,-1,-1,17353,-1,0.004213383,0.9957866
17354,hyperkinetic abnormal involuntary movement,9,13,57,99,"These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement, like L-dopa-induced peak dose dyskinesia, is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop.",9549528_5,-1,-1,-1,17354,-1,0.0034311167,0.9965689
17357,sinusitis,10,11,75,84,Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults.,9564988_0,-1,-1,-1,17357,-1,0.0022571406,0.9977429
17359,mg,12,13,66,68,PURPOSE: To evaluate the efficacy and safety of levofloxacin (500 mg orally once daily for 10 to 14 days) in treating adult outpatients with acute bacterial sinusitis.,9564988_1,-1,-1,-1,17359,-1,0.96828955,0.031710424
17360,sinusitis,29,30,157,166,PURPOSE: To evaluate the efficacy and safety of levofloxacin (500 mg orally once daily for 10 to 14 days) in treating adult outpatients with acute bacterial sinusitis.,9564988_1,-1,-1,-1,17360,-1,0.002355166,0.99764484
17361,signs and symptoms,8,11,47,65,Clinical response was assessed on the basis of signs and symptoms and sinus radiograph or computed tomography results.,9564988_4,-1,-1,-1,17361,-1,0.008186377,0.99181366
17364,flatulence,9,10,59,69,"The most common drug-related adverse events were diarrhea, flatulence, and nausea; most adverse events were mild to moderate in severity.",9564988_13,-1,-1,-1,17364,-1,0.0044017863,0.99559826
17367,mg,11,12,69,71,CONCLUSION: The results of this study indicate that levofloxacin 500 mg once daily is an effective and safe treatment for acute bacterial sinusitis.,9564988_14,-1,-1,-1,17367,-1,0.9840152,0.01598479
17368,sinusitis,23,24,138,147,CONCLUSION: The results of this study indicate that levofloxacin 500 mg once daily is an effective and safe treatment for acute bacterial sinusitis.,9564988_14,-1,-1,-1,17368,-1,0.0024023717,0.99759763
17369,endometrial carcinoma,3,5,20,41,Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study.,9579567_0,-1,-1,-1,17369,-1,0.0043710456,0.99562895
17371,des Centres de,6,9,23,37,"F  d  ration Nationale des Centres de Lutte Contre le Cancer (FNCLCC).Since tamoxifen is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer, its endometrial iatrogenic effects must be carefully examined.",9579567_1,-1,-1,-1,17371,-1,0.3610753,0.63892466
17381,n,9,10,59,60,"Cases of endometrial cancer diagnosed after breast cancer (n = 135) and 467 controls matched for age, year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included.",9579567_3,-1,-1,-1,17381,-1,0.2634114,0.7365886
17385,p,26,27,152,153,"Women who had received tamoxifen were significantly more likely to have endometrial cancer diagnosed than those who had not (crude relative risk = 4.9, p = 0.0001).",9579567_4,-1,-1,-1,17385,-1,0.3150353,0.68496466
17386,p,15,16,94,95,"Univariate and adjusted analyses showed that the risk increased with the length of treatment (p = 0.0001) or the cumulative dose of tamoxifen received (p = 0.0001), irrespective of the daily dose.",9579567_5,-1,-1,-1,17386,-1,0.31462902,0.685371
17388,p,27,28,152,153,"Univariate and adjusted analyses showed that the risk increased with the length of treatment (p = 0.0001) or the cumulative dose of tamoxifen received (p = 0.0001), irrespective of the daily dose.",9579567_5,-1,-1,-1,17388,-1,0.30769676,0.69230324
17389,p,18,19,95,96,"Women who had undergone pelvic radiotherapy also had a higher risk (crude relative risk = 7.8, p = 0.0001).",9579567_6,-1,-1,-1,17389,-1,0.33910838,0.6608916
17391,p,14,15,82,83,"After adjusting for confounding factors, the risk was higher for tamoxifen users (p = 0.0012), treatment for more than 3 years (all p < 0.03) and pelvic radiotherapy (p = 0.012).",9579567_7,-1,-1,-1,17391,-1,0.3277406,0.67225933
17392,p,27,28,132,133,"After adjusting for confounding factors, the risk was higher for tamoxifen users (p = 0.0012), treatment for more than 3 years (all p < 0.03) and pelvic radiotherapy (p = 0.012).",9579567_7,-1,-1,-1,17392,-1,0.39487034,0.6051297
17393,p,35,36,167,168,"After adjusting for confounding factors, the risk was higher for tamoxifen users (p = 0.0012), treatment for more than 3 years (all p < 0.03) and pelvic radiotherapy (p = 0.012).",9579567_7,-1,-1,-1,17393,-1,0.29839972,0.70160025
17396,advanced disease,11,13,69,85,Women who had endometrial cancer and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment.,9579567_8,-1,-1,-1,17396,-1,0.003809981,0.99618995
17412,hyperkalaemia,16,17,90,103,The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of suxamethonium in a 23-year-old Malawian woman.,9587734_1,-1,-1,-1,17412,-1,0.006079821,0.9939202
17419,hyperkalaemia,30,31,167,180,"Apart from the reduction in the patient's level of consciousness, there were no signs of motor neurone damage or of any of the other known predisposing conditions for hyperkalaemia following the administration of suxamethonium.",9587734_6,-1,-1,-1,17419,-1,0.007191922,0.9928081
17425,erythroblastocytopenia,8,9,50,72,"Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone.",9625142_0,-1,-1,-1,17425,-1,0.0077214376,0.9922786
17427,acute hepatitis,4,6,27,42,An 80-yr-old man developed acute hepatitis shortly after ingesting oral ceftriaxone.,9625142_1,-1,-1,-1,17427,-1,0.0023026469,0.9976973
17431,erythroblastocytopenia,35,36,240,262,"Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic, there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and erythroblastocytopenia.",9625142_2,-1,-1,-1,17431,-1,0.004299278,0.99570066
17433,beta lactam,20,22,122,133,Despite the widespread use of these agents this triad of side effects has not previously been reported in connection with beta lactam antibiotics.,9625142_4,-1,-1,-1,17433,-1,0.9985544,0.0014456062
17435,NMDA,6,7,36,40,Contribution of the glycine site of NMDA receptors in rostral and intermediate-caudal parts of the striatum to the regulation of muscle tone in rats.,9630698_0,-1,-1,-1,17435,-1,0.99822,0.001779921
17437,NMDA,16,17,83,87,The aim of the present study was to assess the contribution of the glycine site of NMDA receptors in the striatum to the regulation of muscle tone.,9630698_1,-1,-1,-1,17437,-1,0.99846673,0.0015333579
17438,Muscle rigidity,0,2,0,15,Muscle rigidity was induced by haloperidol (2.5 mg/kg i.p.).,9630698_3,-1,-1,-1,17438,-1,0.0025007757,0.99749917
17440,"5,7-DCKA",3,4,28,36,"5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG).",9630698_4,-1,-1,-1,17440,-1,0.9963433,0.0036566483
17442,muscle rigidity,35,37,220,235,"5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG).",9630698_4,-1,-1,-1,17442,-1,0.00253135,0.9974687
17445,NMDA,11,12,65,69,The present results suggest that blockade of the glycine site of NMDA receptors in the rostral part of the striatum may be mainly responsible for the antiparkinsonian action of this drug.,9630698_6,-1,-1,-1,17445,-1,0.99866843,0.0013316359
17448,CBDCA,10,11,59,64,BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects.,9636837_1,-1,-1,-1,17448,-1,0.9991559,0.00084407954
17450,CDDP,15,16,82,86,BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects.,9636837_1,-1,-1,-1,17450,-1,0.9978836,0.002116376
17452,CBDCA,5,6,20,25,"However, the use of CBDCA higher-intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to peripheral nervous system damage.",9636837_2,-1,-1,-1,17452,-1,0.999281,0.0007190196
17454,peripheral nervous system damage,27,31,177,209,"However, the use of CBDCA higher-intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to peripheral nervous system damage.",9636837_2,-1,-1,-1,17454,-1,0.004131413,0.99586856
17455,CBDCA,8,9,50,55,MATERIALS AND METHODS: Two different schedules of CBDCA administration (10 mg/kg and 15 mg/kg i.p. twice a week for nine times) were evaluated in Wistar rats.,9636837_3,-1,-1,-1,17455,-1,0.9991658,0.0008342456
17457,CBDCA,2,3,9,14,RESULTS: CBDCA administration induced dose-dependent peripheral neurotoxicity.,9636837_5,-1,-1,-1,17457,-1,0.99915457,0.00084545737
17460,CDDP,23,24,125,129,"The dorsal root ganglia sensory neurons and, to a lesser extent, satellite cells showed the same changes as those induced by CDDP, mainly affecting the nucleus and nucleolus of ganglionic sensory neurons.",9636837_7,-1,-1,-1,17460,-1,0.99796426,0.0020358013
17461,platinum,5,6,33,41,"Moreover, significant amounts of platinum were detected in the dorsal root ganglia and kidney after CBDCA treatment.",9636837_8,-1,-1,-1,17461,-1,0.9974354,0.0025645832
17462,CBDCA,16,17,100,105,"Moreover, significant amounts of platinum were detected in the dorsal root ganglia and kidney after CBDCA treatment.",9636837_8,-1,-1,-1,17462,-1,0.99896944,0.0010306053
17463,CBDCA,2,3,13,18,"CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism.",9636837_9,-1,-1,-1,17463,-1,0.9990736,0.0009263243
17465,CDDP,25,26,137,141,"CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism.",9636837_9,-1,-1,-1,17465,-1,0.998531,0.0014689574
17467,CBDCA,17,18,89,94,This model can be used alone or in combination with other drugs to explore the effect of CBDCA on the peripheral nervous system.,9636837_10,-1,-1,-1,17467,-1,0.9992167,0.00078333024
17468,thyrotoxicosis,7,8,36,50,Thyroxine abuse: an unusual case of thyrotoxicosis in pregnancy.,9653867_0,-1,-1,-1,17468,-1,0.12192594,0.878074
17469,Eating disorders,0,2,0,16,Eating disorders and the associated behavioural problems and drug abuse are uncommon in pregnancy.,9653867_1,-1,-1,-1,17469,-1,0.0054034856,0.99459654
17471,eating disorders,14,16,81,97,"This case illustrates a number of problems that may be encountered in women with eating disorders in pregnancy, including prolonged and recurrent metabolic disturbances and diuretic abuse.",9653867_3,-1,-1,-1,17471,-1,0.006278414,0.9937216
17472,metabolic disturbances,23,25,146,168,"This case illustrates a number of problems that may be encountered in women with eating disorders in pregnancy, including prolonged and recurrent metabolic disturbances and diuretic abuse.",9653867_3,-1,-1,-1,17472,-1,0.0040138904,0.99598604
17473,diuretic abuse,26,28,173,187,"This case illustrates a number of problems that may be encountered in women with eating disorders in pregnancy, including prolonged and recurrent metabolic disturbances and diuretic abuse.",9653867_3,-1,-1,-1,17473,-1,0.86925524,0.13074471
17474,eating disorders,14,16,94,110,"In particular it illustrates the derangements of thyroid function seen in pregnant women with eating disorders and reminds us that when a cause for thyrotoxicosis remains obscure, thyroxine abuse should be considered and explored.",9653867_4,-1,-1,-1,17474,-1,0.005940292,0.9940597
17475,thyrotoxicosis,24,25,148,162,"In particular it illustrates the derangements of thyroid function seen in pregnant women with eating disorders and reminds us that when a cause for thyrotoxicosis remains obscure, thyroxine abuse should be considered and explored.",9653867_4,-1,-1,-1,17475,-1,0.3185631,0.6814369
17477,trimipramine,1,2,9,21,Repeated trimipramine induces dopamine D2/D3 and alpha1-adrenergic up-regulation.,9660111_0,-1,-1,-1,17477,-1,0.99949837,0.0005016334
17479,Trimipramine,0,1,0,12,"Trimipramine (TRI), which shows a clinical antidepressant activity, is chemically related to imipramine but does not inhibit the reuptake of noradrenaline and 5-hydroxytryptamine, nor does it induce beta-adrenergic down-regulation.",9660111_1,-1,-1,-1,17479,-1,0.99948114,0.00051893183
17480,TRI,2,3,14,17,"Trimipramine (TRI), which shows a clinical antidepressant activity, is chemically related to imipramine but does not inhibit the reuptake of noradrenaline and 5-hydroxytryptamine, nor does it induce beta-adrenergic down-regulation.",9660111_1,-1,-1,-1,17480,-1,0.99799734,0.0020025955
17482,imipramine,16,17,93,103,"Trimipramine (TRI), which shows a clinical antidepressant activity, is chemically related to imipramine but does not inhibit the reuptake of noradrenaline and 5-hydroxytryptamine, nor does it induce beta-adrenergic down-regulation.",9660111_1,-1,-1,-1,17482,-1,0.9994506,0.0005494316
17486,TRI,11,12,53,56,"The aim of the present study was to find out whether TRI given repeatedly was able to induce adaptive changes in the dopaminergic and alpha1-adrenergic systems, demonstrated by us previously for various antidepressants.",9660111_3,-1,-1,-1,17486,-1,0.9985661,0.0014338885
17488,TRI,0,1,0,3,TRI was given to male Wistar rats and male Albino Swiss mice perorally twice daily for 14 days.,9660111_4,-1,-1,-1,17488,-1,0.998585,0.0014150079
17489,TRI,4,5,24,27,In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats.,9660111_5,-1,-1,-1,17489,-1,0.9983034,0.0016965437
17490,reserpine hypothermia,14,16,65,86,In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats.,9660111_5,-1,-1,-1,17490,-1,0.9223698,0.07763022
17491,5-hydroxytryptophan head twitches,23,26,123,156,In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats.,9660111_5,-1,-1,-1,17491,-1,0.5262154,0.4737846
17492,TRI,0,1,0,3,"TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).",9660111_6,-1,-1,-1,17492,-1,0.99767166,0.0023283272
17494,quinpirole,13,14,93,103,"TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).",9660111_6,-1,-1,-1,17494,-1,0.999323,0.0006770316
17496,stereotypies,1,2,4,16,The stereotypies induced by d-amphetamine or apomorphine are not potentiated by TRI.,9660111_7,-1,-1,-1,17496,-1,0.002451067,0.9975489
17498,TRI,11,12,80,83,The stereotypies induced by d-amphetamine or apomorphine are not potentiated by TRI.,9660111_7,-1,-1,-1,17498,-1,0.9973688,0.0026311283
17503,TRI,13,14,83,86,"It may be concluded that, like other tricyclic antidepressants studied previously, TRI given repeatedly increases the responsiveness of brain dopamine D2 and D3 (locomotor activity but not stereotypy) as well as alpha1-adrenergic receptors to their agonists.",9660111_9,-1,-1,-1,17503,-1,0.99867934,0.0013206745
17508,irritable bowel syndrome,13,16,91,115,Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.,9669632_0,-1,-1,-1,17508,-1,0.0032696598,0.9967303
17509,Irritable bowel syndrome,2,5,12,36,BACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility.,9669632_1,-1,-1,-1,17509,-1,0.0063063214,0.99369365
17510,abdominal pain,10,12,58,72,BACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility.,9669632_1,-1,-1,-1,17510,-1,0.0029953385,0.9970047
17511,disordered gastrointestinal motility,19,22,110,146,BACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility.,9669632_1,-1,-1,-1,17511,-1,0.005461771,0.99453825
17513,irritable bowel syndrome,25,28,146,170,"Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).",9669632_2,-1,-1,-1,17513,-1,0.0046727257,0.99532723
17514,IBS,29,30,172,175,"Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).",9669632_2,-1,-1,-1,17514,-1,0.0043641035,0.9956359
17515,IBS,5,6,36,39,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,-1,-1,-1,17515,-1,0.0036896826,0.9963103
17516,n,9,10,67,68,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,-1,-1,-1,17516,-1,0.12704733,0.87295264
17517,n,15,16,98,99,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,-1,-1,-1,17517,-1,0.10759598,0.8924041
17519,mg,35,36,201,203,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,-1,-1,-1,17519,-1,0.96315014,0.03684987
17520,n,40,41,223,224,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,-1,-1,-1,17520,-1,0.22777537,0.7722246
17521,n,47,48,243,244,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,-1,-1,-1,17521,-1,0.1965868,0.8034133
17523,mm Hg,20,22,128,133,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,-1,17523,-1,0.094926864,0.90507317
17525,P,27,28,161,162,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,-1,17525,-1,0.2520365,0.7479635
17526,mm Hg,38,40,200,205,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,-1,17526,-1,0.09534813,0.9046519
17528,P,63,64,308,309,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,-1,17528,-1,0.25897157,0.7410284
17530,P,99,100,462,463,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,-1,-1,-1,17530,-1,0.2527444,0.7472556
17531,IBS,11,12,90,93,No significant differences in jejunal motility were found in the constipation-predominant IBS group.,9669632_6,-1,-1,-1,17531,-1,0.0120555,0.9879445
17533,IBS,13,14,113,116,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,-1,-1,-1,17533,-1,0.0036856043,0.99631447
17534,mm,27,28,160,162,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,-1,-1,-1,17534,-1,0.08381883,0.9161812
17536,P,33,34,190,191,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,-1,-1,-1,17536,-1,0.22298172,0.7770183
17537,mm,44,45,225,227,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,-1,-1,-1,17537,-1,0.07649976,0.92350024
17538,IBS,1,2,22,25,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,-1,-1,-1,17538,-1,0.0034214195,0.99657863
17541,mm,23,24,118,120,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,-1,-1,-1,17541,-1,0.14072418,0.8592758
17543,P,29,30,148,149,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,-1,-1,-1,17543,-1,0.20173813,0.7982618
17544,mm,40,41,183,185,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,-1,-1,-1,17544,-1,0.12701653,0.87298346
17546,IBS,11,12,87,90,CONCLUSION: Cisapride affects jejunal contraction characteristics and some symptoms in IBS.,9669632_10,-1,-1,-1,17546,-1,0.004399689,0.99560034
17567,hypertriglyceridaemia,16,17,97,118,"Compared with the placebo group, there was a significantly increased risk of vascular events and hypertriglyceridaemia among women on tamoxifen.",9672273_15,-1,-1,-1,17567,-1,0.008330033,0.99167
17579,analgesia,13,14,102,111,A healthy 17-year-old male received standard intermittent doses of pethidine via a patient-controlled analgesia (PCA) pump for management of postoperative pain control.,9672936_1,-1,-1,-1,17579,-1,0.97483873,0.02516127
17581,h,1,2,13,14,Twenty-three h postoperatively he developed a brief self-limited seizure.,9672936_2,-1,-1,-1,17581,-1,0.2310278,0.76897216
17584,norpethidine,4,5,26,38,Both plasma pethidine and norpethidine were elevated in the range associated with clinical manifestations of central nervous system excitation.,9672936_3,-1,-1,-1,17584,-1,0.9991289,0.0008711478
17588,norpethidine,17,18,118,130,This method allowed frequent self-dosing of pethidine at short time intervals and rapid accumulation of pethidine and norpethidine.,9672936_5,-1,-1,-1,17588,-1,0.998987,0.0010129696
17590,analgesia,12,13,68,77,The routine use of pethidine via PCA even for a brief postoperative analgesia should be reconsidered.,9672936_6,-1,-1,-1,17590,-1,0.06865548,0.9313445
17591,mepivacaine,8,9,47,58,An unusual toxic reaction to axillary block by mepivacaine with adrenaline.,9698967_0,-1,-1,-1,17591,-1,0.9993339,0.00066604756
17593,atrial fibrillation,8,10,46,65,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17593,-1,0.017674176,0.98232585
17595,loss of consciousness,16,19,106,127,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17595,-1,0.01075362,0.9892463
17596,ASA,26,27,157,160,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17596,-1,0.8801552,0.11984483
17597,mepivacaine,43,44,267,278,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17597,-1,0.99930835,0.00069168716
17598,mg,45,46,283,285,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17598,-1,0.9874357,0.012564239
17600,mg,49,50,314,316,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17600,-1,0.98509973,0.014900209
17601,Dupuytren,54,55,336,345,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17601,-1,0.9804095,0.019590473
17602,'s contracture,55,57,345,359,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,-1,-1,-1,17602,-1,0.009669769,0.9903302
17606,atrial fibrillation,12,14,83,102,The block was successful and surgery was conducted as scheduled despite persisting atrial fibrillation.,9698967_3,-1,-1,-1,17606,-1,0.22216992,0.77783006
17607,mepivacaine,18,19,115,126,Both the temporal relationship of events and the response to treatment suggest that a rapid systemic absorption of mepivacaine with adrenaline and/or interaction of these drugs with the patient's cardiovascular medications were responsible for the perioperative complications.,9698967_5,-1,-1,-1,17607,-1,0.9994165,0.0005835832
17609,vanishing bile duct,2,5,28,47,Drug-associated acute-onset vanishing bile duct and Stevens-Johnson syndromes in a child.,9721172_0,-1,-1,-1,17609,-1,0.06641297,0.933587
17610,vanishing bile duct syndrome,1,5,6,34,"Acute vanishing bile duct syndrome is a rare but established cause of progressive cholestasis in adults, is most often drug or toxin related, and is of unknown pathogenesis.",9721172_1,-1,-1,-1,17610,-1,0.0074204733,0.9925795
17612,hypersensitivity reaction,7,9,70,95,"Stevens-Johnson syndrome is a well-recognized immune complex-mediated hypersensitivity reaction that affects all age groups, is drug or infection induced, and has classic systemic, mucosal, and dermatologic manifestations.",9721172_3,-1,-1,-1,17612,-1,0.0037678725,0.9962321
17614,vanishing bile duct syndrome,12,16,76,104,"A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after Stevens-Johnson syndrome is described; this was temporally associated with ibuprofen use.",9721172_4,-1,-1,-1,17614,-1,0.007987263,0.9920128
17616,ursodeoxycholic acid,3,5,21,41,"Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.",9721172_5,-1,-1,-1,17616,-1,0.99883145,0.0011685615
17619,cholestatic disease,13,15,80,99,"Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.",9721172_5,-1,-1,-1,17619,-1,0.0043674987,0.99563247
17621,vanishing bile duct syndrome,5,9,39,67,This case documents acute drug-related vanishing bile duct syndrome in the pediatric age group and suggests shared immune mechanisms in the pathogenesis of both Stevens-Johnson syndrome and vanishing bile duct syndrome.,9721172_6,-1,-1,-1,17621,-1,0.010725602,0.98927444
17622,vanishing bile duct syndrome,27,31,190,218,This case documents acute drug-related vanishing bile duct syndrome in the pediatric age group and suggests shared immune mechanisms in the pathogenesis of both Stevens-Johnson syndrome and vanishing bile duct syndrome.,9721172_6,-1,-1,-1,17622,-1,0.011491779,0.98850816
17626,appetite suppressant drugs,20,23,122,148,"Primary pulmonary hypertension is a rare, progressive and incurable disease, which has been associated with the intake of appetite suppressant drugs.",9727773_1,-1,-1,-1,17626,-1,0.994335,0.0056649665
17630,fenfluramines,11,12,80,93,"Twenty-three of the patients had previously taken appetite suppressants, mainly fenfluramines, as compared with only 5 of the controls (66 versus 6%, p<0.0001).",9727773_5,-1,-1,-1,17630,-1,0.9991961,0.0008039136
17631,p<0.0001,27,28,150,158,"Twenty-three of the patients had previously taken appetite suppressants, mainly fenfluramines, as compared with only 5 of the controls (66 versus 6%, p<0.0001).",9727773_5,-1,-1,-1,17631,-1,0.49478126,0.50521874
17637,lead,9,10,67,71,A policy of unrestricted prescription of appetite suppressants may lead to a high incidence of associated primary pulmonary hypertension.,9727773_9,-1,-1,-1,17637,-1,0.029817285,0.9701827
17642,absence seizures,8,10,61,77,Inappropriate use of carbamazepine and vigabatrin in typical absence seizures.,9746003_0,-1,-1,-1,17642,-1,0.0032045713,0.9967955
17644,absence seizures,7,9,60,76,Carbamazepine and vigabatrin are contraindicated in typical absence seizures.,9746003_1,-1,-1,-1,17644,-1,0.0032845528,0.9967154
17651,sodium valproate,8,10,50,66,"Optimal control of the absences was achieved with sodium valproate, lamotrigine, or ethosuximide alone or in combination.",9746003_6,-1,-1,-1,17651,-1,0.9991912,0.0008087835
17652,lamotrigine,11,12,68,79,"Optimal control of the absences was achieved with sodium valproate, lamotrigine, or ethosuximide alone or in combination.",9746003_6,-1,-1,-1,17652,-1,0.999143,0.0008570265
17653,ethosuximide,14,15,84,96,"Optimal control of the absences was achieved with sodium valproate, lamotrigine, or ethosuximide alone or in combination.",9746003_6,-1,-1,-1,17653,-1,0.99900585,0.0009941747
17655,movement abnormalities,7,9,54,76,Choreatiform hyperkinesias are known to be occasional movement abnormalities during intoxications with cocaine but not opiates.,9754849_1,-1,-1,-1,17655,-1,0.0027523823,0.99724764
17657,choreoathetoid movements,8,10,38,62,This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine.,9754849_2,-1,-1,-1,17657,-1,0.012901368,0.98709863
17659,heroine,28,29,197,204,This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine.,9754849_2,-1,-1,-1,17659,-1,0.99886274,0.0011372376
17661,folic acid,3,5,26,36,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,-1,-1,-1,17661,-1,0.99896014,0.0010398325
17662,folic acid,10,12,61,71,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,-1,-1,-1,17662,-1,0.9988298,0.0011702682
17663,epilepsy)OBJECTIVE,13,14,76,94,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,-1,-1,-1,17663,-1,0.035562843,0.9644372
17665,birth defects,39,41,262,275,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,-1,-1,-1,17665,-1,0.003995905,0.99600405
17667,folic acid,8,10,53,63,"RESULTS: Of 60 epileptic women with periconceptional folic acid (0.8 mg)-containing multivitamin supplementation, no one developed epilepsy-related side effects during the periconception period.",9758264_2,-1,-1,-1,17667,-1,0.9990683,0.00093174167
17669,cleft lip,7,9,45,54,One epileptic woman delivered a newborn with cleft lip and palate.,9758264_3,-1,-1,-1,17669,-1,0.004887133,0.99511284
17673,folic acid,11,13,81,91,This 22-year-old epileptic woman was treated continuously by carbamazepine and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation.,9758264_5,-1,-1,-1,17673,-1,0.99880254,0.0011974986
17674,status epilepticus,2,4,14,32,She developed status epilepticus and later symptoms of systemic lupus erythematodes.,9758264_6,-1,-1,-1,17674,-1,0.0035387082,0.99646133
17675,systemic lupus erythematodes,8,11,55,83,She developed status epilepticus and later symptoms of systemic lupus erythematodes.,9758264_6,-1,-1,-1,17675,-1,0.01600115,0.98399884
17676,stillbirth,4,5,25,35,Her pregnancy ended with stillbirth.,9758264_7,-1,-1,-1,17676,-1,0.004552566,0.99544746
17678,autoimmune disease,7,9,46,64,"CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.",9758264_8,-1,-1,-1,17678,-1,0.0028256716,0.99717426
17679,lupus,12,13,88,93,"CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.",9758264_8,-1,-1,-1,17679,-1,0.0026579367,0.99734205
17680,mg,29,30,173,175,"CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.",9758264_8,-1,-1,-1,17680,-1,0.98052865,0.019471383
17681,folic acid,32,34,180,190,"CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.",9758264_8,-1,-1,-1,17681,-1,0.9989298,0.0010701668
17683,mg,5,6,23,25,"Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for epileptic seizures.",9758264_9,-1,-1,-1,17683,-1,0.9697776,0.030222427
17684,folic acid,8,10,30,40,"Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for epileptic seizures.",9758264_9,-1,-1,-1,17684,-1,0.99894553,0.0010544885
17686,autoimmune disease,21,23,97,115,"Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for epileptic seizures.",9758264_9,-1,-1,-1,17686,-1,0.002839207,0.9971608
17687,epileptic seizures,30,32,147,165,"Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for epileptic seizures.",9758264_9,-1,-1,-1,17687,-1,0.0023496824,0.9976503
17688,antipsychotics,5,6,32,46,Adverse effects of the atypical antipsychotics.,9766615_0,-1,-1,-1,17688,-1,0.9890147,0.0109853055
17689,antipsychotics,3,4,19,33,Adverse effects of antipsychotics often lead to noncompliance.,9766615_2,-1,-1,-1,17689,-1,0.99373996,0.0062600253
17690,lead,5,6,40,44,Adverse effects of antipsychotics often lead to noncompliance.,9766615_2,-1,-1,-1,17690,-1,0.025579542,0.9744204
17691,antipsychotics,7,8,41,55,The side effect profiles of the atypical antipsychotics are more advantageous than those of the conventional neuroleptics.,9766615_4,-1,-1,-1,17691,-1,0.99593383,0.0040662237
17692,neuroleptics,16,17,109,121,The side effect profiles of the atypical antipsychotics are more advantageous than those of the conventional neuroleptics.,9766615_4,-1,-1,-1,17692,-1,0.99845505,0.0015449522
17694,EPS,15,16,116,119,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,-1,-1,-1,17694,-1,0.0054887016,0.99451125
17695,tardive dyskinesia,18,20,122,140,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,-1,-1,-1,17695,-1,0.0031678756,0.9968321
17698,weight gain,51,53,328,339,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,-1,-1,-1,17698,-1,0.0062053166,0.9937947
17699,EPS,9,10,47,50,"The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).",9766615_6,-1,-1,-1,17699,-1,0.004240413,0.99575955
17700,weight gain,26,28,154,165,"The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).",9766615_6,-1,-1,-1,17700,-1,0.016045056,0.983955
17703,agranulocytosis,44,45,257,272,"The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).",9766615_6,-1,-1,-1,17703,-1,0.0056693517,0.99433064
17705,lead,27,28,175,179,"Since the incidence and severity of specific adverse effects differ among the various atypicals, the clinician should carefully consider which side effects are most likely to lead to the individual's dissatisfaction and noncompliance before choosing an antipsychotic for a particular patient.",9766615_7,-1,-1,-1,17705,-1,0.033673093,0.96632695
17716,emergency department,25,27,143,163,"We attempted to identify all incident strokes in women ages 15-44 years during a 3-year period using hospital admission and discharge records, emergency department logs, and payment requests for out-of-plan hospitalizations.",9799166_4,-1,-1,-1,17716,-1,0.24224097,0.75775903
17727,psychosis,9,10,74,83,"A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.",9812111_0,-1,-1,-1,17727,-1,0.002758686,0.99724126
17728,disruptive behaviors,11,13,88,108,"A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.",9812111_0,-1,-1,-1,17728,-1,0.0037594906,0.9962405
17729,Alzheimer's disease,14,17,112,131,"A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.",9812111_0,-1,-1,-1,17729,-1,0.007782024,0.992218
17731,psychosis,26,27,139,148,OBJECTIVE: The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer's disease.,9812111_1,-1,-1,-1,17731,-1,0.00274147,0.99725854
17732,disruptive behaviors,28,30,153,173,OBJECTIVE: The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer's disease.,9812111_1,-1,-1,-1,17732,-1,0.0039733853,0.99602664
17733,Alzheimer's disease,33,36,191,210,OBJECTIVE: The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer's disease.,9812111_1,-1,-1,-1,17733,-1,0.0070831096,0.99291694
17736,Alzheimer's disease,45,48,213,232,"METHOD: In a 6-week random-assignment, double-blind, placebo-controlled trial (phase A), haloperidol, 2-3 mg/day (standard dose), and haloperidol, 0.50-0.75 mg/day (low dose), were compared in 71 outpatients with Alzheimer's disease.",9812111_2,-1,-1,-1,17736,-1,0.006459427,0.9935406
17742,psychosis,31,32,197,206,"RESULTS: For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation.",9812111_4,-1,-1,-1,17742,-1,0.0032319457,0.9967681
17743,psychomotor agitation,35,37,221,242,"RESULTS: For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation.",9812111_4,-1,-1,-1,17743,-1,0.0027174798,0.9972825
17744,extrapyramidal signs,17,19,84,104,"The advantage of standard dose over low dose was replicated in phase B. In phase A, extrapyramidal signs tended to be greater with the standard dose than in the other two conditions, primarily because of a subgroup (20%) who developed moderate to severe signs.",9812111_6,-1,-1,-1,17744,-1,0.0036917967,0.9963082
17747,extrapyramidal signs,26,28,156,176,"CONCLUSIONS: The results indicated a favorable therapeutic profile for haloperidol in doses of 2-3 mg/day, although a subgroup developed moderate to severe extrapyramidal signs.",9812111_8,-1,-1,-1,17747,-1,0.0034668844,0.99653304
17749,neuroleptics,12,13,80,92,The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer's disease patients with psychosis and disruptive behaviors.,9812111_10,-1,-1,-1,17749,-1,0.99867505,0.0013248735
17750,Alzheimer's disease,15,18,101,120,The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer's disease patients with psychosis and disruptive behaviors.,9812111_10,-1,-1,-1,17750,-1,0.009627685,0.9903723
17751,psychosis,20,21,135,144,The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer's disease patients with psychosis and disruptive behaviors.,9812111_10,-1,-1,-1,17751,-1,0.0025095756,0.9974904
17752,disruptive behaviors,22,24,149,169,The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer's disease patients with psychosis and disruptive behaviors.,9812111_10,-1,-1,-1,17752,-1,0.0038490728,0.996151
17753,Acute renal failure,0,3,0,19,Acute renal failure subsequent to the administration of rifampicin.,982002_0,-1,-1,-1,17753,-1,0.0027283498,0.9972716
17754,rifampicin,8,9,56,66,Acute renal failure subsequent to the administration of rifampicin.,982002_0,-1,-1,-1,17754,-1,0.99883956,0.0011604727
17755,acute renal failure,16,19,72,91,A clinical presentation is made of a 2-3 year follow-up of six cases of acute renal failure that have been reported earlier.,982002_2,-1,-1,-1,17755,-1,0.002346146,0.9976539
17756,renal failure,5,7,37,50,The patients had developed transient renal failure after the intermittent administration of rifampicin.,982002_3,-1,-1,-1,17756,-1,0.002153691,0.99784636
17757,rifampicin,12,13,92,102,The patients had developed transient renal failure after the intermittent administration of rifampicin.,982002_3,-1,-1,-1,17757,-1,0.9990663,0.0009336891
17758,renal lesions,6,8,32,45,"Although in the acute stage the renal lesions histologically appeared toxic, evidence suggestive of an immunological mechanism cannot be excluded.",982002_11,-1,-1,-1,17758,-1,0.0032808648,0.9967192
17767,radiocalcium,15,16,79,91,"Infusions of epinephrine (4 mug per kilogram per minute for 6 hours) increased radiocalcium uptakes into intact myocardium and each of its subcellular components with the mitochondrial fraction showing the most consistent changes when compared to saline-infused control animals (4,957 vs. 827 counts per minute per gram of dried tissue or fraction).",983936_2,-1,-1,-1,17767,-1,0.99799037,0.0020096246
17769,Gm,13,14,91,93,Myocardial concentrations of calcium also increased significantly (12.0 vs. 5.0 mg.per 100 Gm. of fat-free dry weight).,983936_3,-1,-1,-1,17769,-1,0.550326,0.44967404
17770,calcium chloride,2,4,13,29,Infusions of calcium chloride sufficient to raise serum calcium concentrations 2 mEq.,983936_4,-1,-1,-1,17770,-1,0.9984193,0.0015807045
17773,radiocalcium,1,2,14,26,"Mitochondrial radiocalcium uptakes were significantly decreased in animals pretreated with acetylsalicylic acid or dipyridamole or when hydrocortisone was added to the epinephrine infusion (2,682,2,803, and 3,424 counts per minute per gram of dried fraction, respectively).",983936_6,-1,-1,-1,17773,-1,0.99581546,0.004184568
17779,mg,13,14,74,76,"Myocardial calcium concentrations also were decreased (11.2, 8.3, and 8.9 mg. per 100 Gm. of fat-free dry weight, respectively) in the three treatment groups, being significantly decreased only in the last two.",983936_7,-1,-1,-1,17779,-1,0.8847533,0.11524673
17780,Gm,17,18,86,88,"Myocardial calcium concentrations also were decreased (11.2, 8.3, and 8.9 mg. per 100 Gm. of fat-free dry weight, respectively) in the three treatment groups, being significantly decreased only in the last two.",983936_7,-1,-1,-1,17780,-1,0.6616197,0.3383803
17784,SM-5887,9,10,63,70,Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs.,9848575_0,-1,-1,-1,17784,-1,0.9982255,0.0017745054
17787,SM-5887,11,12,76,83,This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.,9848575_1,-1,-1,-1,17787,-1,0.99901056,0.0009894407
17788,SM-5887,18,19,123,130,This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.,9848575_1,-1,-1,-1,17788,-1,0.9989498,0.0010502308
17792,SM-5887,29,30,149,156,"In the chronic treatment, beagle dogs of each sex were given intravenously once every 3 weeks, either a sublethal dose of doxorubicin (1.5 mg/kg) or SM-5887 (2.5 mg/kg).",9848575_2,-1,-1,-1,17792,-1,0.9978229,0.0021771414
17795,SM-5887,33,34,238,245,"Animals which received over six courses of doxorubicin demonstrated the electrocardiogram (ECG) changes, decrease of blood pressure and high-grade histopathological cardiomyopathy, while animals which were terminally sacrificed after the SM-5887 administration did not show any changes in ECG, blood pressure and histopathological examinations.",9848575_4,-1,-1,-1,17795,-1,0.99830735,0.0016925957
17797,SM-5887,8,9,58,65,"To examine a possibly deteriorating cardiotoxic effect of SM-5887, low-grade cardiomyopathy was induced in dogs by four courses of doxorubicin (1.5 mg/kg).",9848575_5,-1,-1,-1,17797,-1,0.99879396,0.0012060602
17801,SM-5887,18,19,98,105,"Nine weeks after pre-treatment, dogs were given four courses of either doxorubicin (1.5 mg/kg) or SM-5887 (2.5 mg/kg) once every 3 weeks.",9848575_6,-1,-1,-1,17801,-1,0.9982607,0.0017393817
17804,SM-5887,5,6,21,28,"On the contrary, the SM-5887 treatment did not progress the grade of cardiomyopathy.",9848575_8,-1,-1,-1,17804,-1,0.99738497,0.0026150355
17806,SM-5887,3,4,15,22,"In conclusion, SM-5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on doxorubicin-induced cardiotoxicity in dogs.",9848575_9,-1,-1,-1,17806,-1,0.9984303,0.0015696499
17810,FK506,11,12,86,91,Clinical and histopathologic examination of renal allografts treated with tacrolimus (FK506) for at least one year.,9855119_0,-1,-1,-1,17810,-1,0.9989768,0.0010232038
17812,FK506,19,20,131,136,BACKGROUND: We clinically and pathologically analyzed renal allografts from 1 9 renal transplant patients treated with tacrolimus (FK506) for more than 1 year.,9855119_1,-1,-1,-1,17812,-1,0.99912435,0.00087570556
17813,n,16,17,80,81,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,17813,-1,0.093512595,0.9064874
17814,CR,24,25,107,109,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,17814,-1,0.02570127,0.9742988
17815,n=5,26,27,111,114,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,17815,-1,0.12556924,0.8744307
17816,n,31,32,124,125,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,17816,-1,0.074455045,0.9255449
17817,IgA nephropathy,37,39,141,156,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,17817,-1,0.04848412,0.9515159
17818,n,40,41,158,159,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,17818,-1,0.07367865,0.9263214
17819,n,48,49,182,183,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,17819,-1,0.086286366,0.9137137
17820,FK506 nephropathy,55,57,210,227,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,17820,-1,0.82718277,0.17281723
17821,n,58,59,229,230,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,17821,-1,0.0793368,0.9206632
17822,FK506 nephropathy,65,67,251,268,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,17822,-1,0.82815063,0.17184938
17823,n,68,69,270,271,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,-1,-1,-1,17823,-1,0.08635744,0.9136425
17824,FK506 nephropathy,14,16,87,104,"Of the nonepisode biopsies, 7 and 4 biopsies showed minimal-type and mild-type chronic FK506 nephropathy, respectively.",9855119_5,-1,-1,-1,17824,-1,0.881548,0.118451975
17825,FK506 nephropathy,1,3,8,25,"Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).",9855119_6,-1,-1,-1,17825,-1,0.87900424,0.12099577
17826,focal segmental glomerulosclerosis,27,30,163,197,"Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).",9855119_6,-1,-1,-1,17826,-1,0.004363271,0.99563676
17827,interstitial fibrosis,39,41,235,256,"Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).",9855119_6,-1,-1,-1,17827,-1,0.0034324864,0.9965675
17829,FK506 nephropathy,10,12,65,82,"The serum creatinine levels of patients in the mild-type chronic FK506 nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0.001).",9855119_7,-1,-1,-1,17829,-1,0.9068441,0.09315586
17830,P,32,33,215,216,"The serum creatinine levels of patients in the mild-type chronic FK506 nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0.001).",9855119_7,-1,-1,-1,17830,-1,0.22520658,0.77479345
17831,FK506 nephropathy,7,9,50,67,"CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.",9855119_8,-1,-1,-1,17831,-1,0.901435,0.09856496
17832,FK506 nephropathy,27,29,202,219,"CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.",9855119_8,-1,-1,-1,17832,-1,0.88759583,0.11240419
17833,lead,34,35,245,249,"CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.",9855119_8,-1,-1,-1,17833,-1,0.019987538,0.9800125
17834,extrahepatic cholestasis,14,16,104,128,Different lobular distributions of altered hepatocyte tight junctions in rat models of intrahepatic and extrahepatic cholestasis.,9862868_0,-1,-1,-1,17834,-1,0.00583848,0.99416155
17836,intrahepatic,5,6,22,34,We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.,9862868_5,-1,-1,-1,17836,-1,0.014466531,0.98553354
17838,ethinyl estradiol,8,10,50,67,We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.,9862868_5,-1,-1,-1,17838,-1,0.99892515,0.0010747694
17839,EE,11,12,69,71,We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.,9862868_5,-1,-1,-1,17839,-1,0.9982468,0.0017532319
17840,extrahepatic,15,16,87,99,We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.,9862868_5,-1,-1,-1,17840,-1,0.011312314,0.98868775
17842,contrast,1,2,3,11,"In contrast, 7H6 and ZO-1 immunostaining was more discontinuous, outlining the bile canaliculi after BDL.",9862868_8,-1,-1,-1,17842,-1,0.18629478,0.81370527
17843,EE,1,2,6,8,"After EE treatment, changes in immunostaining for 7H6 and ZO-1 were similar to those seen in periportal hepatocytes after BDL, but distributed more diffusely throughout the lobule.",9862868_10,-1,-1,-1,17843,-1,0.9976699,0.0023301078
17844,EE,25,26,151,153,This study is the first to demonstrate that impairment of hepatocyte TJs occurs heterogenously in the liver lobule after BDL and suggests that BDL and EE treatments produce different lobular distributions of increased paracellular permeability.,9862868_11,-1,-1,-1,17844,-1,0.9982216,0.0017784263
17846,fenfluramine,8,9,47,59,Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication.,9867728_0,-1,-1,-1,17846,-1,0.9992211,0.00077895593
17847,dexfenfluramine,10,11,64,79,Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication.,9867728_0,-1,-1,-1,17847,-1,0.99916804,0.0008319645
17848,fenfluramine,18,19,103,115,"BACKGROUND: Because uncontrolled echocardiographic surveys suggested that up to 30% to 38% of users of fenfluramine and dexfenfluramine had valvular disease, these drugs were withdrawn from the market.",9867728_1,-1,-1,-1,17848,-1,0.9992712,0.0007287849
17849,dexfenfluramine,20,21,120,135,"BACKGROUND: Because uncontrolled echocardiographic surveys suggested that up to 30% to 38% of users of fenfluramine and dexfenfluramine had valvular disease, these drugs were withdrawn from the market.",9867728_1,-1,-1,-1,17849,-1,0.9992162,0.00078384095
17850,valvular disease,22,24,140,156,"BACKGROUND: Because uncontrolled echocardiographic surveys suggested that up to 30% to 38% of users of fenfluramine and dexfenfluramine had valvular disease, these drugs were withdrawn from the market.",9867728_1,-1,-1,-1,17850,-1,0.0057790102,0.994221
17851,valvular abnormalities,10,12,54,76,OBJECTIVE: To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications.,9867728_2,-1,-1,-1,17851,-1,0.005504205,0.9944958
17852,fenfluramine,15,16,92,104,OBJECTIVE: To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications.,9867728_2,-1,-1,-1,17852,-1,0.99923074,0.00076927914
17853,dexfenfluramine,17,18,108,123,OBJECTIVE: To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications.,9867728_2,-1,-1,-1,17853,-1,0.9991412,0.0008587045
17854,fenfluramine,6,7,31,43,PATIENTS: 46 patients who used fenfluramine or dexfenfluramine for 14 days or more and had echocardiograms obtained before therapy.,9867728_5,-1,-1,-1,17854,-1,0.9992274,0.0007725456
17855,dexfenfluramine,8,9,47,62,PATIENTS: 46 patients who used fenfluramine or dexfenfluramine for 14 days or more and had echocardiograms obtained before therapy.,9867728_5,-1,-1,-1,17855,-1,0.99913895,0.0008610495
17856,valvulopathy,7,8,41,53,"The primary outcome was new or worsening valvulopathy, defined as progression of either aortic or mitral regurgitation by at least one degree of severity and disease that met U.S. Food and Drug Administration criteria (at least mild aortic regurgitation or moderate mitral regurgitation).",9867728_7,-1,-1,-1,17856,-1,0.026274592,0.9737254
17858,aortic regurgitation,39,41,233,253,"The primary outcome was new or worsening valvulopathy, defined as progression of either aortic or mitral regurgitation by at least one degree of severity and disease that met U.S. Food and Drug Administration criteria (at least mild aortic regurgitation or moderate mitral regurgitation).",9867728_7,-1,-1,-1,17858,-1,0.016732868,0.9832671
17861,bicuspid aortic valve,3,6,17,38,One had baseline bicuspid aortic valve and mild aortic regurgitation that progressed to moderate regurgitation.,9867728_9,-1,-1,-1,17861,-1,0.047962014,0.95203805
17862,aortic regurgitation,8,10,48,68,One had baseline bicuspid aortic valve and mild aortic regurgitation that progressed to moderate regurgitation.,9867728_9,-1,-1,-1,17862,-1,0.0063401796,0.9936598
17863,aortic insufficiency,6,8,42,62,The second patient developed new moderate aortic insufficiency.,9867728_10,-1,-1,-1,17863,-1,0.0045089107,0.9954911
17866,PG-9,17,18,130,134,"Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG-9.The effects of PG-9 (3alpha-tropyl 2-(p-bromophenyl)propionate), the acetylcholine releaser, on memory processes and nerve growth factor (NGF) synthesis were evaluated.",9869257_0,-1,-1,-1,17866,-1,0.99741876,0.002581179
17868,NGF,35,36,253,256,"Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG-9.The effects of PG-9 (3alpha-tropyl 2-(p-bromophenyl)propionate), the acetylcholine releaser, on memory processes and nerve growth factor (NGF) synthesis were evaluated.",9869257_0,-1,-1,-1,17868,-1,0.98778105,0.012218983
17869,PG-9,6,7,37,41,"In the mouse passive-avoidance test, PG-9 (10-30 mg/kg, i.p.), administered 20 min before the training session, prevented amnesia induced by both the non selective antimuscarinic drug scopolamine and the M1-selective antagonist S-(-)-ET-126.",9869257_1,-1,-1,-1,17869,-1,0.99812704,0.0018729763
17870,10-,8,10,43,46,"In the mouse passive-avoidance test, PG-9 (10-30 mg/kg, i.p.), administered 20 min before the training session, prevented amnesia induced by both the non selective antimuscarinic drug scopolamine and the M1-selective antagonist S-(-)-ET-126.",9869257_1,-1,-1,-1,17870,-1,0.9460542,0.05394576
17873,S-(-)-ET-126,40,41,228,240,"In the mouse passive-avoidance test, PG-9 (10-30 mg/kg, i.p.), administered 20 min before the training session, prevented amnesia induced by both the non selective antimuscarinic drug scopolamine and the M1-selective antagonist S-(-)-ET-126.",9869257_1,-1,-1,-1,17873,-1,0.9949462,0.0050538927
17874,PG-9,6,7,37,41,"In the same experimental conditions, PG-9 (5-20 microg per mouse, i.c.v.) was also able to prevent antimuscarine-induced amnesia, demonstrating a central localization of the activity.",9869257_2,-1,-1,-1,17874,-1,0.9975313,0.002468658
17875,5-,8,10,43,45,"In the same experimental conditions, PG-9 (5-20 microg per mouse, i.c.v.) was also able to prevent antimuscarine-induced amnesia, demonstrating a central localization of the activity.",9869257_2,-1,-1,-1,17875,-1,0.8261791,0.1738209
17877,PG-9,6,7,32,36,"At the highest effective doses, PG-9 did not produce any collateral symptoms as revealed by the Irwin test, and it did not modify spontaneous motility and inspection activity, as revealed by the hole-board test.",9869257_3,-1,-1,-1,17877,-1,0.9974734,0.0025265743
17878,PG-9,0,1,0,4,PG-9 was also able to increase the amount of NGF secreted in vitro by astrocytes in a dose-dependent manner.,9869257_4,-1,-1,-1,17878,-1,0.9969494,0.0030506486
17879,NGF,9,10,45,48,PG-9 was also able to increase the amount of NGF secreted in vitro by astrocytes in a dose-dependent manner.,9869257_4,-1,-1,-1,17879,-1,0.9976513,0.002348718
17880,NGF,2,3,12,15,The maximal NGF contents obtained by PG-9 were 17.6-fold of the control value.,9869257_5,-1,-1,-1,17880,-1,0.9976973,0.0023026953
17881,PG-9,6,7,37,41,The maximal NGF contents obtained by PG-9 were 17.6-fold of the control value.,9869257_5,-1,-1,-1,17881,-1,0.9962049,0.0037951118
17882,PG-9,12,13,83,87,"During culture, no morphological changes were found at effective concentrations of PG-9.",9869257_6,-1,-1,-1,17882,-1,0.99720865,0.0027912955
17883,PG-9,7,8,42,46,The current work indicates the ability of PG-9 to induce beneficial effects on cognitive processes and stimulate activity of NGF synthesis in astroglial cells.,9869257_7,-1,-1,-1,17883,-1,0.99801767,0.0019822854
17884,NGF,19,20,125,128,The current work indicates the ability of PG-9 to induce beneficial effects on cognitive processes and stimulate activity of NGF synthesis in astroglial cells.,9869257_7,-1,-1,-1,17884,-1,0.99710697,0.002893048
17885,PG-9,2,3,11,15,"Therefore, PG-9 could represent a potential useful drug able to improve the function of impaired cognitive processes.",9869257_8,-1,-1,-1,17885,-1,0.9961857,0.0038142365
17887,tobramicyn,15,16,84,94,OBJECTIVE: To evaluate the effect of dosage regimen (once-daily vs. twice-daily) of tobramicyn on steady-state serum concentrations and toxicity.,9875685_1,-1,-1,-1,17887,-1,0.99923515,0.00076487823
17890,n,3,4,10,11,Group OD (n = 22) received a once-daily dose of tobramycin and group TD (n = 21) received the same dose divided into two doses daily.,9875685_3,-1,-1,-1,17890,-1,0.23638871,0.76361126
17892,TD,15,16,69,71,Group OD (n = 22) received a once-daily dose of tobramycin and group TD (n = 21) received the same dose divided into two doses daily.,9875685_3,-1,-1,-1,17892,-1,0.9066109,0.093389116
17893,n,17,18,73,74,Group OD (n = 22) received a once-daily dose of tobramycin and group TD (n = 21) received the same dose divided into two doses daily.,9875685_3,-1,-1,-1,17893,-1,0.23032823,0.7696718
17895,body weight,14,16,66,77,"RESULTS: The two groups were comparable with respect to sex, age, body weight and renal function.",9875685_6,-1,-1,-1,17895,-1,0.34964713,0.6503529
17896,TD,19,20,81,83,Peak concentrations were > 6 microg/ml in 100% of the OD group and in 67% of the TD group (P< 0.01).,9875685_9,-1,-1,-1,17896,-1,0.9979365,0.0020635193
17897,P,22,23,91,92,Peak concentrations were > 6 microg/ml in 100% of the OD group and in 67% of the TD group (P< 0.01).,9875685_9,-1,-1,-1,17897,-1,0.33760244,0.66239756
17898,TD,15,16,108,110,Mean peak concentrations were markedly different: 11.00+/-2.89 microg/ml in OD vs. 6.53+/-1.45 microg/ml in TD (P< 0.01).,9875685_10,-1,-1,-1,17898,-1,0.9977964,0.0022036512
17899,P,17,18,112,113,Mean peak concentrations were markedly different: 11.00+/-2.89 microg/ml in OD vs. 6.53+/-1.45 microg/ml in TD (P< 0.01).,9875685_10,-1,-1,-1,17899,-1,0.26253602,0.73746395
17900,TD,14,15,84,86,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,17900,-1,0.8364297,0.16357024
17901,h,21,22,108,109,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,17901,-1,0.053730264,0.9462697
17902,h,26,27,132,133,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,17902,-1,0.046725277,0.9532747
17903,TD,28,29,137,139,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,17903,-1,0.6908654,0.3091346
17904,TD,41,42,193,195,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,17904,-1,0.9209495,0.079050496
17905,TD,54,55,259,261,"The pharmacokinetics parameters were: Ke, (0.15+/-0.03/h in OD vs. 0.24+/-0.06/h in TD), t1/2, (4.95+/-1.41 h in OD vs. 3.07+/-0.71 h in TD), Vd (0.35+/-0.11 l/kg in OD vs. 0.33+/-0.09 l/kg in TD), Cl (0.86+/-0.29 ml/min/kg in OD vs. 1.28+/-0.33 ml/min/kg in TD).",9875685_11,-1,-1,-1,17905,-1,0.85823864,0.14176136
17907,TD,18,19,91,93,"Increased serum creatinine was observed in 73% of patients in OD versus 57% of patients in TD, without evidence of nephrotoxicity.",9875685_12,-1,-1,-1,17907,-1,0.99509454,0.0049054567
17909,TD,1,2,3,5,"In TD group, three patients developed decreased auditory function, of which one presented with an auditory loss of -30 dB, whereas in the OD group only one patient presented decreased auditory function.",9875685_13,-1,-1,-1,17909,-1,0.031410024,0.96858996
17910,decreased auditory function,7,10,38,65,"In TD group, three patients developed decreased auditory function, of which one presented with an auditory loss of -30 dB, whereas in the OD group only one patient presented decreased auditory function.",9875685_13,-1,-1,-1,17910,-1,0.014643666,0.9853563
17911,auditory loss,17,19,98,111,"In TD group, three patients developed decreased auditory function, of which one presented with an auditory loss of -30 dB, whereas in the OD group only one patient presented decreased auditory function.",9875685_13,-1,-1,-1,17911,-1,0.014927973,0.98507196
17912,decreased auditory function,32,35,174,201,"In TD group, three patients developed decreased auditory function, of which one presented with an auditory loss of -30 dB, whereas in the OD group only one patient presented decreased auditory function.",9875685_13,-1,-1,-1,17912,-1,0.013693239,0.9863067
17918,vasodilators,8,9,56,68,"High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).",9915601_1,-1,-1,-1,17918,-1,0.29455656,0.7054434
17925,pindolol,7,8,65,73,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,-1,-1,-1,17925,-1,0.9990056,0.0009944257
17927,atenolol,11,12,89,97,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,-1,-1,-1,17927,-1,0.99828184,0.0017181778
17931,methylatropine,8,9,53,67,Enhancement was not observed in rats pretreated with methylatropine or previously vagotomised.,9915601_4,-1,-1,-1,17931,-1,0.9992224,0.00077757647
17934,rat.-Tacrolimus,7,8,49,64,"Mechanisms of FK 506-induced hypertension in the rat.-Tacrolimus (FK 506) is a powerful, widely used immunosuppressant.",9931093_0,-1,-1,-1,17934,-1,0.8575346,0.14246546
17935,FK 506,9,11,66,72,"Mechanisms of FK 506-induced hypertension in the rat.-Tacrolimus (FK 506) is a powerful, widely used immunosuppressant.",9931093_0,-1,-1,-1,17935,-1,0.9985259,0.0014741044
17936,FK 506,4,6,24,30,The clinical utility of FK 506 is complicated by substantial hypertension and nephrotoxicity.,9931093_1,-1,-1,-1,17936,-1,0.9989071,0.0010928502
17940,FK 506,15,17,92,98,"To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.",9931093_2,-1,-1,-1,17940,-1,0.99884605,0.0011539167
17941,FR 139317,13,15,78,87,"In addition, the effect of the specific endothelin type A receptor antagonist FR 139317 on FK 506-induced hypertension in rats was studied.",9931093_3,-1,-1,-1,17941,-1,0.99861467,0.0013853083
17943,FK 506,0,2,0,6,"FK 506, 5 mg.",9931093_4,-1,-1,-1,17943,-1,0.9981517,0.001848236
17944,mg,4,5,10,12,"FK 506, 5 mg.",9931093_4,-1,-1,-1,17944,-1,0.91250515,0.08749481
17945,mm Hg,13,15,73,78,"d-1 given for 4 weeks, elevated blood pressure from 102+/-13 to 152+/-15 mm Hg and increased the synthesis of ET-1 and the levels of ET-1 mRNA in the mesenteric artery (240% and 230%, respectively).",9931093_6,-1,-1,-1,17945,-1,0.13707504,0.862925
17946,FK 506,0,2,0,6,"FK 506 decreased eNOS activity and the levels of eNOS mRNA in the aorta (48% and 55%, respectively).",9931093_8,-1,-1,-1,17946,-1,0.99850106,0.0014989102
17947,FR 139317,3,5,22,31,The administration of FR 139317 (10 mg. kg-1.,9931093_9,-1,-1,-1,17947,-1,0.9980242,0.0019757478
17948,mg,7,8,36,38,The administration of FR 139317 (10 mg. kg-1.,9931093_9,-1,-1,-1,17948,-1,0.87739724,0.12260276
17950,FK 506,4,6,28,34,These results indicate that FK 506 may increase blood pressure not only by increasing ET-1 production but also by decreasing NO synthesis in the vasculature.,9931093_11,-1,-1,-1,17950,-1,0.9985043,0.0014957216
17951,Structural,0,1,0,10,Structural and functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression.,9952311_0,-1,-1,-1,17951,-1,0.00965618,0.9903438
17952,functional impairment of mitochondria,2,6,15,52,Structural and functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression.,9952311_0,-1,-1,-1,17952,-1,0.053094916,0.94690514
17955,ADR,5,6,23,26,The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity.,9952311_1,-1,-1,-1,17955,-1,0.9976739,0.002326029
17957,cardiovascular toxicity,17,19,90,113,The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity.,9952311_1,-1,-1,-1,17957,-1,0.0046297377,0.9953702
17958,ADR,3,4,26,29,Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p. treated with ADR for several weeks.,9952311_2,-1,-1,-1,17958,-1,0.9982323,0.001767734
17959,c,8,9,70,71,Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p. treated with ADR for several weeks.,9952311_2,-1,-1,-1,17959,-1,0.98677933,0.0132206315
17960,ADR,22,23,143,146,Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p. treated with ADR for several weeks.,9952311_2,-1,-1,-1,17960,-1,0.9982161,0.0017838776
17961,ADR,40,41,256,259,Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p. treated with ADR for several weeks.,9952311_2,-1,-1,-1,17961,-1,0.99840015,0.0015999024
17962,damage,19,20,134,140,"At various times during treatment, the animals were assessed for cardiovascular functions by electrocardiography and for heart tissue damage by electron microscopy.",9952311_3,-1,-1,-1,17962,-1,0.0037211324,0.9962788
17963,ADR,10,11,53,56,"Our results indicated that 1) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.",9952311_6,-1,-1,-1,17963,-1,0.997632,0.0023679526
17964,cardiovascular arrhythmias,12,14,64,90,"Our results indicated that 1) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.",9952311_6,-1,-1,-1,17964,-1,0.0026610964,0.99733895
17966,body weight,39,41,229,240,"Our results indicated that 1) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.",9952311_6,-1,-1,-1,17966,-1,0.83758867,0.16241129
17967,swelling,51,52,295,303,"Our results indicated that 1) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.",9952311_6,-1,-1,-1,17967,-1,0.0072485306,0.9927515
17968,ADR,31,32,172,175,"Such abnormalities were not observed in the mitochondria of liver tissue; and 3) among the three genes of COX enzyme examined, only COXII gene expression was suppressed by ADR treatment, mainly after 8 weeks in both heart and liver.",9952311_7,-1,-1,-1,17968,-1,0.9986355,0.0013644756
17969,ADR,21,22,126,129,"Knowing that heart mitochondria represent almost 40% of heart muscle by weight, we conclude that the deteriorating effects of ADR on cardiovascular function involve mitochondrial structural and functional impairment.",9952311_8,-1,-1,-1,17969,-1,0.99826187,0.0017382007
17970,structural and functional,27,30,179,204,"Knowing that heart mitochondria represent almost 40% of heart muscle by weight, we conclude that the deteriorating effects of ADR on cardiovascular function involve mitochondrial structural and functional impairment.",9952311_8,-1,-1,-1,17970,-1,0.03544808,0.9645519
16195,creatinine,21,22,136,146,"After the administration of NG, 5-FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics.",8739323_5,0,-1,0,16195,-1,0.997081,0.002919015
14174,potassium,13,14,87,96,In conclusion we found that thiazide diuretics cause hypokalemia and depletion of body potassium.,6942642_11,0,-1,0,14174,-1,0.99793494,0.002065098
601,isoproterenol,10,11,72,85,This study was conducted to examine whether prolonged pretreatment with isoproterenol could abolish bromocriptine-induced tachycardia in conscious rats.,10721819_2,0,-1,0,601,-1,0.9992225,0.0007774242
12183,metronidazole,4,5,25,38,"While the involvement of metronidazole in the aetiology of the haemolytic-uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic-uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic-uraemic syndrome.",3173180_3,0,-1,0,12183,-1,0.99926645,0.00073359074
11491,cocaine,47,48,240,247,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,0,-1,0,11491,-1,0.9982492,0.001750805
11971,captopril,13,14,79,88,His renal function remained impaired but stable during 2 years' treatment with captopril but returned to pre-treatment levels soon after cessation of the drug.,3070035_2,0,-1,0,11971,-1,0.99946433,0.0005357366
1056,vigabatrin,8,9,45,55,Six of the patients were no longer receiving vigabatrin.,11077455_3,0,-1,0,1056,-1,0.9993253,0.0006747417
151,rapamycin,5,6,32,41,BACKGROUND: Sirolimus (formerly rapamycin) is an immunosuppressive agent that interferes with T-cell activation.,10328196_1,0,-1,0,151,-1,0.9983101,0.0016898714
17294,lidocaine,11,12,82,91,"Accordingly, the present, prospective double-blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs.",9523805_4,0,-1,0,17294,-1,0.9988772,0.0011227791
15163,heparin,14,15,101,108,"Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.",8012887_2,0,-1,0,15163,-1,0.9984219,0.001578096
17702,clozapine,40,41,241,250,"The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).",9766615_6,0,-1,0,17702,-1,0.99945456,0.0005454159
8464,Doxorubicin,0,1,0,11,Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.,18674790_6,0,-1,0,8464,-1,0.99835443,0.0016456455
12596,indomethacin,17,18,116,128,Hyperkalemia has recently been recognized as a complication of nonsteroidal antiinflammatory agents (NSAID) such as indomethacin.,3560096_1,0,-1,0,12596,-1,0.9991486,0.0008513555
11117,picrotoxin,7,8,43,53,"In vitro, gamma-HCH, pentylenetetrazol and picrotoxin were shown to inhibit 3H-TBOB binding in mouse whole brain, with IC50 values of 4.6, 404 and 9.4 microM, respectively.",2440413_5,0,-1,0,11117,-1,0.99925405,0.0007459217
6366,adrenaline,14,15,82,92,"Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.",1700207_3,0,-1,0,6366,-1,0.9988918,0.001108218
10779,morphine,6,7,45,53,Facilitation of memory retrieval by pre-test morphine and its state dependency in the step-through type passive avoidance learning test in mice.,2273650_0,0,-1,0,10779,-1,0.9987231,0.0012768758
10862,ifosfamide,11,12,62,72,"We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension.",2320800_6,0,-1,0,10862,-1,0.9992536,0.0007464479
16034,phenacetin,16,17,92,102,Habitual use of acetaminophen as a risk factor for chronic renal failure: a comparison with phenacetin.,8669433_0,0,-1,0,16034,-1,0.99937195,0.0006280839
4966,reserpine,14,15,91,100,"A decreased glutamate uptake was observed in the subcortical parts of animals treated with reserpine and haloperidol, compared to the control.",15649445_6,0,-1,0,4966,-1,0.9991658,0.00083419506
3364,dopamine,45,46,279,287,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,0,-1,0,3364,-1,0.9980761,0.0019238904
7835,morphine,7,8,50,58,Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain.,18221780_0,0,-1,0,7835,-1,0.9988342,0.0011657731
5708,ketoconazole,24,25,137,149,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,0,-1,0,5708,-1,0.9993569,0.00064308534
17301,bupivacaine,51,52,288,299,"METHODS: Ninety patients classified as American Society of Anesthesiologists physical status I or II who were scheduled for short gynecologic procedures under spinal anesthesia were randomly allocated to receive 2.5 ml 2% lidocaine in 7.5% glucose, 2% prilocaine in 7.5% glucose, or 0.5% bupivacaine in 7.5% glucose.",9523805_5,0,-1,0,17301,-1,0.99928087,0.0007191601
6039,alprazolam,7,8,34,44,"On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.",16720068_3,0,-1,0,6039,-1,0.99909115,0.000908846
13819,catecholamines,10,11,57,71,"The present studies were designed to clarify the role of catecholamines and pineal idolamines on ketamine-induced catatonia in the intact, pinealectomized or hypophysectomized chick and rat.",6540303_1,0,-1,0,13819,-1,0.9983626,0.0016373394
14092,noradrenaline,7,8,55,68,Blood pressure response to chronic low-dose intrarenal noradrenaline infusion in conscious rats.,6861444_0,0,-1,0,14092,-1,0.9992735,0.00072658656
10479,ribavirin,19,20,127,136,"In contrast with the literature, serum levels of angiogenesis factors did not change significantly by pegylated interferon and ribavirin therapy.",20698227_6,0,-1,0,10479,-1,0.9990902,0.00090975524
3881,quinine,17,18,105,112,The reaction may be mediated by the presence of antibodies reactive against platelets in the presence of quinine.,1415380_3,0,-1,0,3881,-1,0.9988913,0.001108689
5964,alcohol,1,2,4,11,Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers.,16634859_11,0,-1,0,5964,-1,0.9979073,0.0020928006
13659,propranolol,14,15,89,100,Both drugs impaired immediate free recall but the decrease was greater for diazepam than propranolol.,6387529_2,0,-1,0,13659,-1,0.99908423,0.0009157574
7518,ciprofloxacin,10,11,74,87,"INTRODUCTION: The possible anxiogenic effects of fluoroquinolones, namely ciprofloxacin and norfloxacin, were investigated in adult Charles Foster albino rats of either sex, weighing 150-200 g. METHODS: The drugs were given orally, in doses of 50 mg/kg for five consecutive days and the experiments were performed on the fifth day.",17975693_1,0,-1,0,7518,-1,0.9988092,0.0011907694
6613,Sirolimus,0,1,0,9,Sirolimus represents a major therapeutic advance in the prevention of acute renal allograft rejection and chronic allograft nephropathy.,17147461_2,0,-1,0,6613,-1,0.9993573,0.0006427477
775,nimodipine,30,31,156,166,"METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).",10835440_3,0,-1,0,775,-1,0.9994023,0.0005977563
13394,ranitidine,10,11,51,61,The rates of onset of the action of cimetidine and ranitidine were the same.,6150641_3,0,-1,0,13394,-1,0.9992889,0.0007110873
9209,ecstasy,6,7,36,43,It has been consistently shown that ecstasy users display impairments in learning and memory performance.,19631624_1,0,-1,0,9209,-1,0.99924254,0.000757494
13739,captopril,9,10,63,72,The possibility of reproducing the same renal abnormality with captopril was examined in SHR.,6454943_2,0,-1,0,13739,-1,0.99945825,0.0005417373
15711,diazepam,18,19,73,81,Pain at the injection site occurred in 35% (22 of 62) of patients in the diazepam group compared with 7% (4 of 60 patients) in the midazolam group (p < 0.001).,8514073_5,0,-1,0,15711,-1,0.99939024,0.000609711
16502,bradykinin,13,14,73,83,The goal of this study was to determine the role of synthesis/release of bradykinin to activate B2 receptors in disruption of the blood-brain barrier during acute hypertension.,8955532_2,0,-1,0,16502,-1,0.9985103,0.0014896733
4952,reserpine,1,2,6,15,Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.,15649445_0,0,-1,0,4952,-1,0.9991738,0.00082616706
3668,morphine,44,45,216,224,"Flumazenil (mean dose, 0.76 mg) or placebo (mean dose, 8.9 ml) was administered intravenously to 130 and 67 patients, respectively, who had been given diazepam in conjunction with an opioid (fentanyl, meperidine, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.",1286498_2,0,-1,0,3668,-1,0.9981364,0.0018636272
5590,Nicotine,2,3,12,20,BACKGROUND: Nicotine polacrilex lozenges deliver 25% to 27% more nicotine compared with equivalent doses of nicotine polacrilex gum.,16330293_1,0,-1,0,5590,-1,0.9983962,0.0016037188
6748,statins,9,10,48,55,"What is less well known is a phenomenon whereby statins may induce a myopathy, which persists or may progress after stopping the drug.",17241784_2,0,-1,0,6748,-1,0.9987539,0.0012461175
6092,carbachol,5,6,33,42,Case report: acute unintentional carbachol intoxication.,16740173_0,0,-1,0,6092,-1,0.99937844,0.00062149734
823,pyridoxine,1,2,9,19,Neonatal pyridoxine responsive convulsions due to isoniazid therapy.,1085609_0,0,-1,0,823,-1,0.9987663,0.0012337493
17566,tamoxifen,49,50,304,313,"There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone-replacement therapy during the trial: among 390 women on such therapy and allocated to placebo, we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen.",9672273_14,0,-1,0,17566,-1,0.99830866,0.0016912798
15951,paclitaxel,14,15,85,95,We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma.,8643971_3,0,-1,0,15951,-1,0.99877614,0.0012238843
1013,methylprednisolone,14,15,84,102,"To our knowledge, this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid myopathy.",11058428_6,0,-1,0,1013,-1,0.9992519,0.00074810284
12543,deferoxamine,1,2,5,17,"When deferoxamine therapy was discontinued and serial studies were performed, audiograms in seven cases reverted to normal or near normal within two to three weeks, and nine of 13 patients with symptoms became asymptomatic.",3503576_3,0,-1,0,12543,-1,0.9994413,0.0005586428
5336,azithromycin,11,12,64,76,OBJECTIVE: To report a case of persistent hiccups associated by azithromycin therapy.,15985056_1,0,-1,0,5336,-1,0.999297,0.00070297223
3724,methylphenidate,3,4,16,31,It appears that methylphenidate precipitated the patient's pathological behavior.,12907924_4,0,-1,0,3724,-1,0.99930346,0.0006965712
6631,sirolimus,29,30,168,177,"Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.",17147461_10,0,-1,0,6631,-1,0.9993241,0.00067593105
190,calcium,4,5,25,32,"After lithium treatment, calcium levels were higher than either baseline levels or control levels.",10354657_12,0,-1,0,190,-1,0.99834025,0.0016597218
3930,dopamine,25,26,143,151,"A single 18.4 mg/kg (i.p.) dose of (+/-)-amphetamine hemisulfate, given to rats pretreated with iprindole, resulted in persistent depletion of dopamine in the striatum 1 week later.",1436384_3,0,-1,0,3930,-1,0.9979437,0.0020562822
11730,glutamate,17,18,107,116,"25 mg/kg, i.v. thiopental produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem.",2893236_3,0,-1,0,11730,-1,0.99891496,0.001085022
5903,prostaglandins,4,5,24,38,Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder.,16600756_0,0,-1,0,5903,-1,0.99538773,0.0046122596
7643,propranolol,16,17,126,137,"In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.",18083142_7,0,-1,0,7643,-1,0.99919456,0.0008055028
8237,metoprolol,5,6,26,36,"There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs (72 +/- 7 ng.ml-1) than EMs (42 +/- 8 ng.ml-1, P less than .001).(ABSTRACT TRUNCATED AT 250 WORDS)",1848636_11,0,-1,0,8237,-1,0.9995192,0.000480822
4567,lidocaine,19,20,71,80,"The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.",15278670_2,0,-1,0,4567,-1,0.99898714,0.0010128495
11984,lovastatin,23,24,130,140,"Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.",3076126_12,0,-1,0,11984,-1,0.9992337,0.00076634326
178,magnesium,8,9,50,59,"OUTCOME MEASURES: Laboratory analyses of calcium, magnesium and thyroid-stimulating hormone levels performed before beginning lithium therapy and at biannual follow-up.",10354657_7,0,-1,0,178,-1,0.9984633,0.0015367131
668,capsaicin,7,8,43,52,Infusion started 15 min after injection of capsaicin.,10743446_5,0,-1,0,668,-1,0.99929535,0.00070463965
907,tacrolimus,7,8,47,57,Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA.,11007689_10,0,-1,0,907,-1,0.99914193,0.0008580539
8697,epinephrine,26,27,152,163,"The management options in the ED, as exemplified by four individual case reports, in particular the use of a minimally invasive method of intracorporal epinephrine instillation, are discussed.",18996674_3,0,-1,0,8697,-1,0.9984705,0.0015295111
1715,dopamine,15,16,104,112,"The three compounds vary in their affinities for sigma2 receptors and exhibit negligible affinities for dopamine, opioid, GABA(A) and NMDA receptors.",11426838_4,0,-1,0,1715,-1,0.9982901,0.0017099215
11742,glutamate,12,13,59,68,"Naloxone (2.5 mg/kg, i.v.) reversed respiratory paralysis, glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum.",2893236_6,0,-1,0,11742,-1,0.9987984,0.001201561
8302,Dexamethasone,0,1,0,13,Dexamethasone had no significant effect on the incidence or severity of postoperative nausea and vomiting.,18544179_7,0,-1,0,8302,-1,0.9988649,0.0011351835
508,Warfarin,17,18,103,111,"In the current study, we investigated the synergy between these 2 treatments and found that concurrent Warfarin administration dramatically increased the extent of calcification in the media of vitamin D-treated rats at 3 and 4 days.",10669626_11,0,-1,0,508,-1,0.99893326,0.001066757
7158,phenobarbital,6,7,52,65,Hepatonecrosis and cholangitis related to long-term phenobarbital therapy: an autopsy report of two patients.,17574447_0,0,-1,0,7158,-1,0.99899346,0.001006516
13830,Ketamine,0,1,0,8,"Ketamine was more potent in the hypophysectomized chick and the circadian rhythm noted in the intact chick was absent; furthermore, melatonin did not augment the ketamine DOC whereas dopamine continued to do so.",6540303_5,0,-1,0,13830,-1,0.9990694,0.000930606
15476,vincristine,8,9,46,57,It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of vincristine neuropathy are reversible for a great deal and prognosis is fairly good.,8384253_12,0,-1,0,15476,-1,0.99941456,0.00058546854
5273,benzoylecgonine,11,12,63,78,"We evaluated the potential of the major metabolite of cocaine, benzoylecgonine (BE), to cause seizures.",1592014_3,0,-1,0,5273,-1,0.9989159,0.001084152
7859,trihexyphenidyl,19,20,122,137,OBJECTIVES: The objectives of this study were to examine the relationship between APOE epsilon4 and subjective effects of trihexyphenidyl on measures reflecting sedation and confusion and to investigate the relationship between trihexyphenidyl-induced subjective effects and objective memory performance.,18239197_1,0,-1,0,7859,-1,0.999121,0.000878956
15239,amoxicillin,4,5,32,43,Immediate allergic reactions to amoxicillin.,8092427_0,0,-1,0,15239,-1,0.9991099,0.00089002994
7361,progesterone,32,33,163,175,"Briefly, cells were differentiated for 72 h with 100 nM PMA to obtain a macrophage-like phenotype in the presence or absence of 1 nM 17beta-estradiol (E2), 100 nM progesterone or vehicle (0.01% ethanol).",17879945_7,0,-1,0,7361,-1,0.998466,0.001534056
15655,cholesterol,52,53,214,225,"RESULTS: Among women, lovastatin (20 to 80 mg/d) produced sustained (12- to 48-week), dose-related changes (P < 0.001): decreases in LDL cholesterol (24% to 40%) and triglycerides (9% to 18%), and increases in HDL cholesterol (6.7% to 8.6%).",8480959_6,0,-1,0,15655,-1,0.85743463,0.14256532
1916,prochlorperazine,15,16,96,112,STUDY OBJECTIVE: We sought to compare the rate of akathisia after administration of intravenous prochlorperazine as a 2-minute bolus or 15-minute infusion.,11679859_1,0,-1,0,1916,-1,0.99924695,0.0007530478
16555,cocaine,11,12,80,87,"The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.",8988571_6,0,-1,0,16555,-1,0.9986364,0.0013635382
5627,gabapentin,29,30,209,219,"These findings indicate that gabapentin has a measurable antinociceptive effect and a stronger antihyperalgesic effect most evident in the brain areas undergoing deactivation, thus supporting the concept that gabapentin is more effective in modulating nociceptive transmission when central sensitization is present.",16330766_9,0,-1,0,5627,-1,0.9993305,0.00066950964
12090,alfentanil,20,21,109,119,"Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone.",3115150_5,0,-1,0,12090,-1,0.9991032,0.0008968385
10168,cisplatin,15,16,107,116,Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin.,20510337_4,0,-1,0,10168,-1,0.99883014,0.0011698089
17022,"1,1-dichloro-2,2,2-trifluoroethane",21,22,129,163,"We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).",9284778_3,0,-1,0,17022,-1,0.9941507,0.005849259
13984,gentamicin,5,6,27,37,"To quantify the effects of gentamicin, kanamycin and netilmicin on renal protein reabsorption and accumulation, these drugs were administered to rats intraperitoneally (30 mg/kg/day) for 7, 14 or 21 days.",6728084_1,0,-1,0,13984,-1,0.9988624,0.0011376076
14675,zidovudine,16,17,104,114,Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine.,7628595_0,0,-1,0,14675,-1,0.99890876,0.001091191
9929,methamphetamine,5,6,38,53,Oral rehabilitation of patients using methamphetamine can be challenging.,20098969_4,0,-1,0,9929,-1,0.998735,0.0012649513
7728,methylphenidate,9,10,64,79,There were no suggestions of interactions between clonidine and methylphenidate regarding cardiovascular outcomes.,18182964_7,0,-1,0,7728,-1,0.99920636,0.0007936297
8618,cisplatin,5,6,34,43,Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons.,18809400_4,0,-1,0,8618,-1,0.9989127,0.0010873138
4577,sevoflurane,12,13,76,87,"The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.",15278670_5,0,-1,0,4577,-1,0.99946254,0.0005374254
6313,steroid,13,14,102,109,"OBJECTIVE: Conventional treatment methods of lumbusacral radiculopathy are physical therapy, epidural steroid injections, oral medications, and spinal manipulative therapy.",16904497_1,0,-1,0,6313,-1,0.9983707,0.0016292739
2675,ribavirin,8,9,53,62,OBJECTIVE: We report our experience with intravenous ribavirin therapy for severe adenovirus disease in a series of immunocompromised children and review the literature.,12093990_10,0,-1,0,2675,-1,0.99932086,0.0006791513
12705,isoflurane,19,20,94,104,"Controlled hypotension to an average MAP of 50-55 mm Hg was induced by increasing the dose of isoflurane, and maintained at an inspired concentration of 2.2 +/- 0.2%.",3676049_4,0,-1,0,12705,-1,0.9985833,0.0014167373
7054,iron,57,58,381,385,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,0,-1,0,7054,-1,0.99561065,0.004389312
5610,nicotine,8,9,47,55,CONCLUSION: The 4-mg nicotine lozenge and 4-mg nicotine gum had comparable safety profiles in these patients with label-restricted medical conditions.,16330293_18,0,-1,0,5610,-1,0.9988889,0.0011111271
13691,carbamazepine,10,11,65,78,"Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children.",6415512_0,0,-1,0,13691,-1,0.99918395,0.0008159804
15362,bupivacaine,2,3,8,19,dose of bupivacaine.,8231633_3,0,-1,0,15362,-1,0.9992576,0.0007423752
15081,corticosteroids,5,6,39,54,Two patients also received intravenous corticosteroids.,7910951_3,0,-1,0,15081,-1,0.9984901,0.0015099131
14835,indomethacin,5,6,36,48,Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients.,7791169_0,0,-1,0,14835,-1,0.9991516,0.0008484409
14366,Indomethacin,0,1,0,12,Indomethacin was first given four weeks prior to the onset of symptoms.,7263204_3,0,-1,0,14366,-1,0.9990823,0.0009176374
991,ketamine,19,20,125,133,Significant increases in drowsiness were reported in patients treated with ketamine in both groups and were more marked with ketamine 0.50 mg/kg.,11027905_9,0,-1,0,991,-1,0.9990645,0.00093555346
4528,lidocaine,9,10,67,76,Treatment of tinnitus by intratympanic instillation of lignocaine (lidocaine) 2 per cent through ventilation tubes.,1527456_0,0,-1,0,4528,-1,0.998494,0.0015059916
15468,vincristine,8,9,56,67,Forty patients with Non-Hodgkin's Lymphoma treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system.,8384253_1,0,-1,0,15468,-1,0.99947697,0.0005230685
8137,cholesterol,21,22,125,136,Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis.,18442015_4,0,-1,0,8137,-1,0.99804807,0.0019519087
12717,bromocriptine,4,5,29,42,These cases demonstrate that bromocriptine may cause psychosis even when given in low doses.,3686155_3,0,-1,0,12717,-1,0.9993612,0.00063873956
288,ephedrine,12,13,54,63,"The haemodynamic effects of adding 15, 20 or 25 mg of ephedrine to 200 mg of propofol were compared to control in 40 ASA 3/4 patients over 60 years presenting for genito-urinary surgery.",10520387_2,0,-1,0,288,-1,0.9993716,0.00062838284
11547,morphine,7,8,50,58,"Catalepsy induced by combinations of ketamine and morphine: potentiation, antagonism, tolerance and cross-tolerance in the rat.",2716967_0,0,-1,0,11547,-1,0.99900925,0.0009907051
9398,olanzapine,10,11,56,66,"Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.",19759529_8,0,-1,0,9398,-1,0.9992717,0.00072830194
6118,dopamine,16,17,66,74,"High doses of atropine (up to 50 mg per 24 hours), adrenaline and dopamine were necessary.",16740173_12,0,-1,0,6118,-1,0.99838054,0.0016193998
9533,tacrolimus,5,6,23,33,"Thus, we conclude that tacrolimus induces reversible myocardial hypertrophy.",19917396_8,0,-1,0,9533,-1,0.99918026,0.00081973796
12889,morphine,16,17,78,86,"The results suggest that rigidity, which is assumed to be due to an action of morphine in the striatum, can be antagonized by another process leading to dopaminergic activation in the striatum.",3780846_9,0,-1,0,12889,-1,0.9987068,0.0012931321
10207,haloperidol,37,38,195,206,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).",20520283_2,0,-1,0,10207,-1,0.99903935,0.000960573
15893,corticosteroids,27,28,191,206,"Reports of persistent paralysis after the discontinuance of these drugs have most often involved aminosteroid-based NMBAs such as vecuronium bromide, especially when used in conjunction with corticosteroids.",8638206_2,0,-1,0,15893,-1,0.99814665,0.00185334
15678,calcium,25,26,161,168,"While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).",8492347_2,0,-1,0,15678,-1,0.99819994,0.0018000837
7376,telithromycin,6,7,41,54,Acute hepatitis attack after exposure to telithromycin.,17919553_0,0,-1,0,7376,-1,0.99907434,0.00092569535
7088,cocaine,13,14,94,101,Clinical and experimental data published to date suggest several possible mechanisms by which cocaine may result in acute myocardial infarction.,1749407_1,0,-1,0,7088,-1,0.998793,0.0012069702
15816,propofol,9,10,57,65,"Assessing their overall satisfaction, 89.7% would choose propofol anaesthesia again.",8595686_9,0,-1,0,15816,-1,0.99882764,0.0011723624
7696,Sulpiride,0,1,0,9,"Sulpiride induced only SOCS-1 in the medial preoptic area, where GnRH neurons are regulated, but in the arcuate nucleus and choroid plexus, PRL-R, SOCS-3, and CIS mRNA levels were also induced.",18162529_9,0,-1,0,7696,-1,0.99892116,0.001078919
13732,captopril,2,3,10,19,Effect of captopril on pre-existing and aminonucleoside-induced proteinuria in spontaneously hypertensive rats.,6454943_0,0,-1,0,13732,-1,0.9993907,0.0006092637
11072,prednisolone,14,15,85,97,This view supports the contention that the liver and muscle are independent sites of prednisolone action.,2425813_4,0,-1,0,11072,-1,0.9991553,0.0008446665
4002,amphetamine,13,14,89,100,A diet promoting sugar dependency causes behavioral cross-sensitization to a low dose of amphetamine.,14596845_0,0,-1,0,4002,-1,0.9993956,0.0006043683
9339,pilocarpine,9,10,51,62,"This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism, using both aconitine-induced rat and ouabain-induced guinea pig arrhythmia models.",19721134_1,0,-1,0,9339,-1,0.9995005,0.00049943646
1284,doxorubicin,14,15,141,152,"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.",11230490_0,0,-1,0,1284,-1,0.9981976,0.0018024336
3296,thalidomide,27,28,166,177,"INTERVENTION: Each patient received either intravenous docetaxel 30 mg/m2/week for 3 consecutive weeks, followed by 1 week off, or the combination of continuous oral thalidomide 200 mg every evening plus the same docetaxel regimen.",12627929_5,0,-1,0,3296,-1,0.9992506,0.0007493286
4660,yohimbine,13,14,87,96,RESULTS: Five of the six patients experienced improved sexual functioning after taking yohimbine.,1535072_7,0,-1,0,4660,-1,0.99921346,0.00078652217
11461,Captopril,13,14,71,80,"The contents of albumin in the lungs were not changed, indicating that Captopril did not influence the extravasation of protein.",2670794_4,0,-1,0,11461,-1,0.9993599,0.00064005976
1913,prochlorperazine,3,4,30,46,"Intravenous administration of prochlorperazine by 15-minute infusion versus 2-minute bolus does not affect the incidence of akathisia: a prospective, randomized, controlled trial.",11679859_0,0,-1,0,1913,-1,0.9992316,0.00076838775
5733,methylphenidate,12,13,64,79,We report the case of a 63-year-old female who was treated with methylphenidate due to hyperactivity and suffered from multiple ischaemic strokes.,16428221_3,0,-1,0,5733,-1,0.99927884,0.00072120153
3038,bupropion,32,33,198,207,"DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.",12549952_9,0,-1,0,3038,-1,0.9994703,0.00052968063
2601,morphine,2,3,22,30,Metamizol potentiates morphine antinociception but not constipation after chronic treatment.,12063090_0,0,-1,0,2601,-1,0.99861777,0.0013822773
1642,antidepressant,41,42,219,233,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,0,-1,0,1642,-1,0.99677986,0.003220148
1892,citalopram,8,9,36,46,This may have been a side effect of citalopram as it remitted with redistribution of doses.,11642480_3,0,-1,0,1892,-1,0.9992607,0.0007392873
11498,nitroprusside,6,7,41,54,A randomized comparison of labetalol and nitroprusside for induced hypotension.,2696505_0,0,-1,0,11498,-1,0.9988506,0.001149443
12265,potassium,10,11,62,71,Timolol also reduced the rise in plasma aldosterone and urine potassium excretion following bendrofluazide and increased the urine sodium/potassium ratio.,326460_2,0,-1,0,12265,-1,0.9985936,0.0014063644
14715,halothane,30,31,209,218,This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration.,7647582_8,0,-1,0,14715,-1,0.9992623,0.0007377347
13328,propranolol,20,21,143,154,"The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.",6115999_5,0,-1,0,13328,-1,0.9991598,0.0008401833
2448,nicotine,16,17,125,133,"Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus nicotine.",11900788_5,0,-1,0,2448,-1,0.9988337,0.0011662929
2694,ribavirin,2,3,21,30,"Although intravenous ribavirin was not effective for all children with severe adenovirus disease in this series or in the literature, therapy is unlikely to be of benefit if begun late in the course of the infection.",12093990_22,0,-1,0,2694,-1,0.99928206,0.0007179032
1476,verapamil,23,24,157,166,Underlying electrophysiological mechanisms were studied in detail in five additional dogs under control conditions and in the presence of the higher dose of verapamil.,11282081_7,0,-1,0,1476,-1,0.99932873,0.0006713326
6714,cisplatin,5,6,26,35,None of them had received cisplatin chemotherapy.,1720453_3,0,-1,0,6714,-1,0.99834216,0.0016578481
7854,morphine,10,11,89,97,These findings demonstrate a sexually-dimorphic interaction between NMDA antagonists and morphine in a persistent pain model that can be distinguished from those observed in acute pain models.,18221780_8,0,-1,0,7854,-1,0.9988765,0.0011234751
7536,alcohol,12,13,71,78,"CONCLUSION: In patients with risk factors, e.g. regular consumption of alcohol, liver failure is possible when therapeutic doses are ingested.",18004067_5,0,-1,0,7536,-1,0.9985959,0.0014040546
6720,phosphate,25,26,164,173,"Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.",1720453_6,0,-1,0,6720,-1,0.99660766,0.0033923197
14407,sodium nitroprusside,3,5,27,47,Rebound hypertensive after sodium nitroprusside prevented by saralasin in rats.,7352670_0,0,-1,0,14407,-1,0.9989215,0.001078531
916,levodopa,26,27,193,201,A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off-periods even in patients with complex on-off motor swings.,11009181_3,0,-1,0,916,-1,0.9991297,0.00087030313
14601,paramethasone,5,6,37,50,Two patients treated with parenteral paramethasone (Triniol) and dexamethasone (Sedionbel) are described.,7582165_1,0,-1,0,14601,-1,0.9989606,0.0010393566
2977,carboplatin,16,17,101,112,"However, we experienced a case of severe ocular and orbital toxicity after intracarotid injection of carboplatin, which is infrequently reported.",12483326_5,0,-1,0,2977,-1,0.99935085,0.00064911455
3403,Hydrocortisone acetate,0,2,0,22,Hydrocortisone acetate (50 mg) was given orally every 6 hours for 24 hours after a 5-day fixed-salt diet (150 mmol/d).,12707296_4,0,-1,0,3403,-1,0.9987871,0.0012129436
3614,Aspirin,0,1,0,7,"Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.",12852481_2,0,-1,0,3614,-1,0.9984156,0.0015843789
14129,carbachol,49,50,292,301,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,0,-1,0,14129,-1,0.9994318,0.0005681832
16977,verapamil,10,11,67,76,"QRS without preexcitation, caused by junctional escape beats after verapamil or unidirectional antegrade block of accessory pathway after catheter ablation, established frequent AVRT attack.",9249847_2,0,-1,0,16977,-1,0.9992362,0.0007638199
2115,Adenosine,2,3,9,18,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,0,-1,0,2115,-1,0.99885046,0.0011494763
4485,aspirin,28,29,119,126,The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).,15266215_4,0,-1,0,4485,-1,0.99881315,0.0011868537
15639,magnesium,8,9,50,59,"When QTc interval prolongation is observed, early magnesium supplementation is advocated.",8475949_7,0,-1,0,15639,-1,0.99883705,0.0011629132
5892,pilocarpine,20,21,100,111,"Male Sprague-Dawley rats were injected with saline on postnatal day (P) 20, or a convulsant dose of pilocarpine on P20 or P45.",16596970_4,0,-1,0,5892,-1,0.99937195,0.000628056
8990,bradykinin,11,12,62,72,RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia.,19300402_3,0,-1,0,8990,-1,0.9982774,0.0017225508
9222,ecstasy,2,3,8,15,"In both ecstasy and cannabis groups brain activation was decreased in the right medial frontal gyrus, left parahippocampal gyrus, left dorsal cingulate gyrus, and left caudate.",19631624_10,0,-1,0,9222,-1,0.9993486,0.0006514371
1349,cyclophosphamide,9,10,47,63,"When tumors were treated with a single dose of cyclophosphamide (60 mg/kg i.p.) 5 days after implantation, a growth delay with a subsequent regrowth of the tumors was observed.",11245434_7,0,-1,0,1349,-1,0.9993001,0.0006998966
1323,diazepam,35,36,142,150,"In the first experiment, four groups of mice received physiological saline (0.9%), L-arginine (300 mg/kg, i.p.), L-NAME (100 mg/kg, i.p.) and diazepam (2 mg/kg), respectively.",11243580_2,0,-1,0,1323,-1,0.9988456,0.0011543785
9603,omeprazole,4,5,27,37,"After she discontinued the omeprazole, her hemoglobin and hematocrit gradually returned to normal.",1992636_7,0,-1,0,9603,-1,0.9993741,0.00062595645
6506,Dex,10,11,78,81,"Endothelial-dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group (P < 0.05 and P < 0.0001, respectively).",17042910_12,0,-1,0,6506,-1,0.998577,0.0014230392
8784,methotrexate,5,6,38,50,A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).,19135948_1,0,-1,0,8784,-1,0.99849534,0.0015046715
16788,risperidone,4,5,36,47,Neuroleptic malignant syndrome with risperidone.,9165568_0,0,-1,0,16788,-1,0.99904567,0.0009543639
10433,curcumin,4,5,24,32,These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.,20667451_12,0,-1,0,10433,-1,0.99858356,0.0014165007
2103,adenosine,35,36,220,229,"BACKGROUND: Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of acute and chronic pain in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation.",11752998_1,0,-1,0,2103,-1,0.99896085,0.001039126
15873,haloperidol,10,11,51,62,METHOD: All subjects received placebo on Day 1 and haloperidol 2 mg on Days 2 and 25.,8617710_2,0,-1,0,15873,-1,0.99926525,0.00073471357
15990,propranolol,5,6,46,57,Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease.,8649546_0,0,-1,0,15990,-1,0.9992011,0.00079885096
8579,ciprofloxacin,12,13,94,107,Haematological adverse reactions associated with fatal outcome are rare during treatment with ciprofloxacin.,18791946_1,0,-1,0,8579,-1,0.99905866,0.0009413842
9249,alcohol,9,10,43,50,"In less than 1 hour after the ingestion of alcohol, he developed malaise with flushing of the face, tachycardia, and dyspnea.",19657887_5,0,-1,0,9249,-1,0.99854505,0.0014549445
1865,tacrolimus,7,8,49,59,"Calcineurin inhibitors, such as cyclosporine and tacrolimus, have been available for almost 20 years.",11583940_1,0,-1,0,1865,-1,0.9988673,0.0011326978
4085,calcitonin,8,9,54,64,NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release.,14659530_0,0,-1,0,4085,-1,0.9976991,0.002300872
5744,choline,2,3,19,26,Daidzein activates choline acetyltransferase from MC-IXC cells and improves drug-induced amnesia.,16428827_0,0,-1,0,5744,-1,0.99803466,0.0019653519
1791,trihexyphenidyl,6,7,42,57,The symptom was treated successfully with trihexyphenidyl anticholinergic therapy.,11532387_4,0,-1,0,1791,-1,0.9989833,0.001016692
5252,magnesium,3,4,29,38,"Thyroid-stimulating hormone, magnesium, and potassium levels were within normal limits, urine drug screen was negative, and alcohol use was denied.",15899738_6,0,-1,0,5252,-1,0.99872273,0.001277279
2984,corticosteroids,9,10,59,74,RESULTS: He was treated with intravenous administration of corticosteroids and glycerin for 6 days after the injection.,12483326_9,0,-1,0,2984,-1,0.9987023,0.00129767
10234,nelarabine,6,7,24,34,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,0,-1,0,10234,-1,0.9988657,0.0011343186
7881,cyclosporine,11,12,72,84,"In this study, long-term cardiac transplant patients were switched from cyclosporine to Srl-based IS.",18261172_4,0,-1,0,7881,-1,0.9992505,0.00074946356
531,dopamine,28,29,169,177,"Apomorphine, a nonselective dopamine agonist, was selected due to its biphasic behavioral effects, its ability to induce hypothermia, and to produce distinct changes to dopamine turnover in the rodent brain.",10683478_2,0,-1,0,531,-1,0.9981635,0.001836505
15405,morphine,25,26,189,197,"Although only few clinical descriptions of the relationship between hyperalgesia/myoclonus and high doses of morphine are available, experimental support from animal studies indicates that morphine, or its metabolites, plays a causative role for the observed behavioural syndrome.",8278214_5,0,-1,0,15405,-1,0.99897265,0.0010273394
3485,Estradiol,0,1,0,9,Estradiol reduces seizure-induced hippocampal injury in ovariectomized female but not in male rats.,12757899_0,0,-1,0,3485,-1,0.998601,0.0013990114
16224,tyrosine,23,24,143,151,"Lesions reduced the extent of immunohistological staining for choline acetyltransferase in the interpeduncular nucleus (p <0.025), but not for tyrosine hydroxylase in the surrounding catecholaminergic A10 region.",8741744_3,0,-1,0,16224,-1,0.9980124,0.0019875586
17150,5-fluorouracil,6,7,54,68,"Combination chemotherapy with mitoxantrone, high-dose 5-fluorouracil (5-FU) and leucovorin (MFL regimen) had been reported as an effective and well tolerated regimen.",9390208_2,0,-1,0,17150,-1,0.9985744,0.0014256572
2782,alcohol,31,32,221,228,"BACKGROUND: The septo-hippocampal cholinergic pathway has been implicated in epileptogenesis, and genetic factors influence the response to cholinergic agents, but limited data are available on cholinergic involvement in alcohol withdrawal severity.",12198388_1,0,-1,0,2782,-1,0.99842083,0.0015791632
1643,antidepressant,48,49,278,292,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,0,-1,0,1643,-1,0.99518234,0.0048176865
10854,ifosfamide,28,29,174,184,"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.",2320800_1,0,-1,0,10854,-1,0.9990452,0.0009547717
16329,tacrolimus,5,6,33,43,"Two groups of patients receiving tacrolimus were compared over a period of 1 year, one group comprising hypertensive patients who were receiving nifedipine, and the other comprising nonhypertensive patients not receiving nifedipine.",8829025_2,0,-1,0,16329,-1,0.9992111,0.0007889133
11174,Lindane,0,1,0,7,"Lindane is also widely used as an agricultural and industrial pesticide, and as a result the toxic profile of this insecticide is well understood.",2476560_1,0,-1,0,11174,-1,0.998804,0.0011960566
13132,steroid,26,27,172,179,"Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis, immediate withdrawal of amiodarone, and prompt but continued steroid therapy to ensure full recovery.",3997294_4,0,-1,0,13132,-1,0.9984421,0.0015578542
2424,isoproterenol,12,13,80,93,Histological studies demonstrated that the rats developed an infarct 18 h after isoproterenol administration.,11897407_5,0,-1,0,2424,-1,0.99910235,0.00089771993
13338,urea,7,8,37,41,"Mean serum potassium level fell, and urea and uric acid levels rose, in men and women taking bendrofluazide.",6115999_8,0,-1,0,13338,-1,0.9989091,0.0010908538
17647,carbamazepine,9,10,62,75,"Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks, which resolved on withdrawal of carbamazepine.",9746003_4,0,-1,0,17647,-1,0.9992237,0.0007762249
15795,Thiopentone,0,1,0,11,Thiopentone pretreatment for propofol injection pain in ambulatory patients.,8595686_0,0,-1,0,15795,-1,0.9994228,0.000577215
14590,rapamycin,17,18,112,121,"Finally, specific immunophilin-drug-calcineurin complexes formed only in the presence of CsA and FK506, but not rapamycin.",7542793_5,0,-1,0,14590,-1,0.9984073,0.001592716
15029,cholesterol,31,32,145,156,"All six patients had supersaturated bile (mean (SEM) cholesterol saturation index of 1.19 (0.08) (range 1.01-1.53)) and all had abnormally rapid cholesterol microcrystal nucleation times (< 4 days (range 1-4)), whilst in four, the bile contained cholesterol microcrystals immediately after sampling.",7890216_6,0,-1,0,15029,-1,0.9941704,0.005829574
5012,amiodarone,26,27,179,189,"We briefly describe two patients suffering from recent-onset atrial fibrillation, who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading.",15686794_2,0,-1,0,5012,-1,0.9991916,0.0008084561
15022,octreotide,28,29,173,183,"Because knowledge of stone composition is essential for studies of their pathogenesis, treatment, and prevention, this was investigated by direct and indirect methods in 14 octreotide treated acromegalic patients with gall stones.",7890216_2,0,-1,0,15022,-1,0.99929,0.0007099735
15245,penicillin,46,47,292,302,"A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.",8092427_2,0,-1,0,15245,-1,0.998387,0.0016130345
921,apomorphine,13,14,97,108,"In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa-induced dyskinesias.",11009181_6,0,-1,0,921,-1,0.9994005,0.000599517
6091,cocaine,17,18,142,149,Desipramine-induced sensitization of lidocaine seizures may have a mechanism distinct from kindling resulting from repeated administration of cocaine.,16725121_10,0,-1,0,6091,-1,0.9989813,0.0010187295
2444,hexamethonium,5,6,47,60,"Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus nicotine.",11900788_5,0,-1,0,2444,-1,0.99933654,0.00066346966
2849,cocaine,16,17,88,95,Cocaine related chest pain: are we seeing the tip of an iceberg?The recreational use of cocaine is on the increase.,12443032_0,0,-1,0,2849,-1,0.99826473,0.0017352981
8243,everolimus,8,9,72,82,Recovery of tacrolimus-associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient--case report and review of the literature.,18503483_0,0,-1,0,8243,-1,0.99904376,0.0009562042
12040,ketoconazole,9,10,52,64,In two of the three deaths probably associated with ketoconazole treatment the drug had been continued after the onset of jaundice and other symptoms of hepatitis.,3101906_13,0,-1,0,12040,-1,0.99940896,0.000591072
8863,salt,7,8,28,32,Blood pressure (BP) is more salt sensitive in men than in premenopausal women.,19211690_1,0,-1,0,8863,-1,0.99646676,0.00353328
4417,estrogen,5,6,28,36,We have recently shown that estrogen negatively modulates the hypotensive effect of clonidine (mixed alpha2-/I1-receptor agonist) in female rats and implicates the cardiovascular autonomic control in this interaction.,15145918_1,0,-1,0,4417,-1,0.99793327,0.0020666863
4020,amphetamine,33,34,201,212,"These results suggest that a diet comprised of alternating deprivation and access to a sugar solution and chow produces bingeing on sugar that leads to a long lasting state of increased sensitivity to amphetamine, possibly due to a lasting alteration in the dopamine system.",14596845_8,0,-1,0,4020,-1,0.9990657,0.00093433616
1812,terodiline,16,17,75,85,"These data indicate that the free ED50 in plasma for terfenadine (1.9 nM), terodiline (76 nM), cisapride (11 nM) and E4031 (1.9 nM) closely correlate with the free concentration in man causing QT effects.",11569530_9,0,-1,0,1812,-1,0.9992424,0.0007576153
7072,corticosterone,24,25,154,168,"Acute treatment with apomorphine caused disruption of prepulse inhibition (PPI) in controls and in rats that had undergone either maternal deprivation or corticosterone treatment, but was surprisingly absent in rats that had undergone the combined early and late stress.",17490864_3,0,-1,0,7072,-1,0.9982741,0.0017258509
17143,mitoxantrone,8,9,60,72,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,0,-1,0,17143,-1,0.9992237,0.00077623565
16836,propranolol,5,6,22,33,"Carteolol, as well as propranolol and biperiden, inhibited the haloperidol-induced catalepsy.",9201797_4,0,-1,0,16836,-1,0.99919635,0.0008036122
16297,antidepressants,5,6,35,50,Recent data suggest that tricyclic antidepressants inhibit calcium influx in some tissues.,8800187_2,0,-1,0,16297,-1,0.9987036,0.0012964397
4620,salbutamol,4,5,23,33,"Tremor side effects of salbutamol, quantified by a laser pointer technique.",15338796_0,0,-1,0,4620,-1,0.99939525,0.0006046866
608,isoproterenol,5,6,52,65,"Bromocriptine-induced hypotension was unaffected by isoproterenol pretreatment, while tachycardia was reversed to significant bradycardia, an effect that was partly reduced by i.v.",10721819_5,0,-1,0,608,-1,0.9990859,0.00091412495
9832,bupropion,11,12,74,83,These results provide empirical support for conducting a further study of bupropion.,20067456_13,0,-1,0,9832,-1,0.99935025,0.000649687
5678,nitrendipine,11,12,66,78,"The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.",1639466_1,0,-1,0,5678,-1,0.9990085,0.0009915577
16605,venlafaxine,10,11,53,64,"She was admitted to the medical intensive care unit, venlafaxine was discontinued, and no further sequelae were seen.",9034419_4,0,-1,0,16605,-1,0.99886847,0.0011316233
17803,doxorubicin,9,10,66,77,The low-grade cardiotoxic changes were enhanced by the additional doxorubicin treatment.,9848575_7,0,-1,0,17803,-1,0.99872965,0.001270352
10151,cocaine,43,44,256,263,"Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.",20477932_3,0,-1,0,10151,-1,0.99788207,0.0021179395
13943,caffeine,8,9,76,84,Cerebral hemorrhage associated with phenylpropanolamine in combination with caffeine.,6695415_0,0,-1,0,13943,-1,0.99858236,0.0014176536
8497,papaverine,1,2,8,18,Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients.,18726058_5,0,-1,0,8497,-1,0.9993338,0.00066612556
5262,creatine,4,5,26,34,"Vegetarians may also take creatine to replace what they are not consuming from meat, fish, and other animal products.",15899738_11,0,-1,0,5262,-1,0.998514,0.0014860117
15093,ampicillin,14,15,94,104,OBJECTIVE: To report a case of erythema multiforme and hypersensitivity myocarditis caused by ampicillin.,7919560_1,0,-1,0,15093,-1,0.99883336,0.0011665984
8232,terbutaline,9,10,52,63,"Blood samples for the analysis of plasma potassium, terbutaline, metoprolol (racemic, R- and S-isomer), and alpha-hydroxymetoprolol concentrations were taken at regular time intervals, during 8 hr after metoprolol.",1848636_8,0,-1,0,8232,-1,0.9995492,0.00045075515
14642,pravastatin,17,18,90,101,He was admitted with acute myopathy of the lower limbs which resolved in a few days after pravastatin discontinuation.,7604176_5,0,-1,0,14642,-1,0.9988543,0.0011457633
3330,sodium,1,2,11,17,Epithelial sodium channel (ENaC) subunit mRNA and protein expression in rats with puromycin aminonucleoside-induced nephrotic syndrome.,12653683_0,0,-1,0,3330,-1,0.9930841,0.0069158925
14829,dopamine,28,29,167,175,"The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.",7785794_3,0,-1,0,14829,-1,0.99844414,0.0015558671
2627,ifosfamide,25,26,146,156,"We report a case of a 51-year-old man who developed severe, disabling negative myoclonus of the upper and lower extremities after the infusion of ifosfamide for plasmacytoma.",12084448_2,0,-1,0,2627,-1,0.9991806,0.00081941864
2550,Reserpine,0,1,0,9,"Reserpine (1 mg/kg), administered 90 min before the test and followed by apomophine injection (0.1 mg/kg) 5 min before the test, did not produce oral dyskinesia in mice.",11999899_7,0,-1,0,2550,-1,0.9990701,0.0009298991
1466,verapamil,19,20,106,115,"METHODS: To evaluate the potential mechanisms of AF promotion by Ca(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs.",11282081_3,0,-1,0,1466,-1,0.99924916,0.00075078383
3918,timolol,13,14,74,81,"In a double blind cross-over study with control group, the patients under timolol treatment presented higher depression values measured through the Beck and the Zung-Conde scales (p < 0.001 vs control).",1428568_5,0,-1,0,3918,-1,0.9992254,0.000774613
16954,nicotine,3,4,12,20,The role of nicotine in smoking-related cardiovascular disease.,9245658_0,0,-1,0,16954,-1,0.9984268,0.0015731803
9383,amphetamine,28,29,181,192,"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).",19759529_5,0,-1,0,9383,-1,0.9992674,0.00073260075
8132,cholesterol,47,48,295,306,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,0,-1,0,8132,-1,0.99774796,0.0022520293
16177,5-fluorouracil,18,19,93,107,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,0,-1,0,16177,-1,0.9982364,0.0017635603
14608,corticosteroids,10,11,62,77,We also carried out oral and parenteral challenges with other corticosteroids and found intolerance to some of them.,7582165_7,0,-1,0,14608,-1,0.99812824,0.0018717411
3406,cortisol,1,2,7,15,"Plasma cortisol concentrations were significantly raised during the active phase (323+/-43 to 1082+/-245 mmol/L, P<0.05).",12707296_9,0,-1,0,3406,-1,0.9985744,0.0014256353
8038,sulfasalazine,6,7,51,64,CONCLUSION: Serious hepatotoxicity associated with sulfasalazine appears to be under-appreciated and intensive monitoring and vigilance in the first 6 weeks of treatment is especially important.,18405372_15,0,-1,0,8038,-1,0.9994066,0.0005934185
13829,ketamine,25,26,147,155,"Serotonin and N-acetyl serotonin which augmented ketamine DOC, did not do so in the absence of the pineal gland, whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick.",6540303_4,0,-1,0,13829,-1,0.9988128,0.0011871697
2908,Rizatriptan,0,1,0,11,Rizatriptan is a selective 5-HT(1B/1D) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine.,12464714_1,0,-1,0,2908,-1,0.999146,0.00085400825
4338,proteinuria,8,9,48,59,"After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.",15075188_5,-1,1,1,4338,-1,0.0031276587,0.99687237
14747,toxicities,1,2,4,14,All toxicities resolved after cis-RA was discontinued.,7707116_9,-1,1,1,14747,-1,0.0027395033,0.99726045
139,neurotoxicity,10,11,53,66,Three of the cases were most likely caused by direct neurotoxicity of hyperbaric 5% lignocaine.,10225068_4,-1,1,1,139,-1,0.0023707862,0.9976292
12739,acidosis,16,17,96,104,"Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.",3703509_3,-1,1,1,12739,-1,0.0033210986,0.99667895
3723,psychiatric,5,6,25,36,"The patient had no prior psychiatric history, but he had a sister with obsessive-compulsive disorder.",12907924_3,-1,1,1,3723,-1,0.0044304747,0.9955695
15666,rhabdomyolysis,2,3,11,25,Tetany and rhabdomyolysis due to surreptitious furosemide--importance of magnesium supplementation.,8492347_0,-1,1,1,15666,-1,0.0030379016,0.99696213
5776,myoclonus,3,4,34,43,Remifentanil pretreatment reduces myoclonus after etomidate.,16563323_0,-1,1,1,5776,-1,0.0042764596,0.9957235
4623,Tremor,2,3,9,15,METHODS: Tremor was measured using a laser pointer technique.,15338796_4,-1,1,1,4623,-1,0.0029288505,0.99707115
4563,convulsions,6,7,50,61,The influence of sevoflurane on lidocaine-induced convulsions was studied in cats.,15278670_1,-1,1,1,4563,-1,0.0022721265,0.99772793
6080,convulsions,17,18,145,156,Daily administration of desipramine increased the incidence of appearance of lidocaine-induced convulsions and decreased that of cocaine-induced convulsions.,16725121_5,-1,1,1,6080,-1,0.0024696728,0.9975304
4039,Cystitis,0,1,0,8,Cystitis was evaluated 24 h after its induction by the changes in bladder wet weight and by macroscopic and microscopic analysis.,14633084_5,-1,1,1,4039,-1,0.0027909293,0.997209
14297,death,3,4,28,33,"Convulsions always preceded death, except after precipitous cardiopulmonary arrest from extreme doses.",7189975_4,-1,1,1,14297,-1,0.0030250077,0.99697495
12864,carcinogenesis,8,9,40,54,"It is concluded that PB, which promotes carcinogenesis when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with DEN.",3780814_7,-1,1,1,12864,-1,0.0037938103,0.99620616
1974,glaucoma,8,9,64,72,"METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).",11704023_4,-1,1,1,1974,-1,0.0032047199,0.99679524
15739,tumors,7,8,56,62,"Although most of the hepatomas were well-differentiated tumors and contained a considerable number of peroxisomes, the tumor cells did not respond to ethyl-alpha-p-chlorophenoxyisobutyrate with proliferation of peroxisomes.",85485_2,-1,1,1,15739,-1,0.0039497786,0.9960502
3128,reduction in glomerular number,30,34,163,193,"Hypertension was observed in animals that had a reduction in glomeruli as well as in a group that did not have a reduction in glomerular number, suggesting that a reduction in glomerular number is not the sole cause for the development of hypertension.",12574103_9,-1,1,1,3128,-1,0.04363109,0.95636886
11442,hypertension,23,24,165,177,"In both cases normal plasma and urinary free cortisol levels had been achieved following ketoconazole therapy, yet continuous blood pressure monitoring demonstrated hypertension 31 (patient 1) and 52 weeks (patient 2) after treatment.",2632720_2,-1,1,1,11442,-1,0.0031764992,0.99682355
10904,apnoea,5,6,43,49,The incidence of postoperative respiratory apnoea was compared between five patients receiving a continuous i.v.,2334618_2,-1,1,1,10904,-1,0.0035961797,0.9964038
3793,hypertensive,24,25,189,201,Studies were performed to evaluate whether chronic prazosin treatment alters the alpha 2-adrenoceptor function for orthostatic control of arterial blood pressure in conscious spontaneously hypertensive rats (SHR).,1355091_1,-1,1,1,3793,-1,0.005513806,0.99448615
9119,breast cancer,40,42,240,253,"Long-term oestrogen-only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.",19370593_11,-1,1,1,9119,-1,0.0043594814,0.9956405
14982,cancers,13,14,105,112,High-dose 5-fluorouracil/folinic acid infusion therapy has recently become a popular regimen for various cancers.,7858459_6,-1,1,1,14982,-1,0.0041378965,0.9958621
5801,pruritus,24,25,156,164,"CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.",16563323_11,-1,1,1,5801,-1,0.0036060985,0.99639386
3714,toxicity,19,20,136,144,The results of this study suggest that the blockade of mGluR5 by MPEP may protect dopaminergic neurones against methamphetamine-induced toxicity.,12907309_7,-1,1,1,3714,-1,0.0026409142,0.9973591
14300,seizures,22,23,109,117,"A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the chloroprocaine group, and in 6% of the lidocaine group.",7189975_5,-1,1,1,14300,-1,0.0022017278,0.9977983
9381,hyperactivity,19,20,129,142,"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).",19759529_5,-1,1,1,9381,-1,0.0023914753,0.99760854
2639,anemia,10,11,88,94,Antagonism between interleukin 3 and erythropoietin in mice with azidothymidine-induced anemia and in bone marrow endothelial cells.,12090760_0,-1,1,1,2639,-1,0.0025959278,0.99740404
1637,manic,4,5,27,32,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,-1,1,1,1637,-1,0.0049678357,0.9950322
14630,nausea,17,18,103,109,"Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of CLZ.",7596955_6,-1,1,1,14630,-1,0.0021618446,0.9978382
10319,catalepsy,13,14,119,128,Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol-induced catalepsy.,20558148_0,-1,1,1,10319,-1,0.00565869,0.99434125
11815,catalepsy,13,14,97,106,"However, inhibition of postsynaptic 5-HT receptors neither inhibited nor potentiated reversal of catalepsy and leaves open the question as to the site or mechanism for this effect.",2907585_5,-1,1,1,11815,-1,0.25013742,0.7498626
7523,Acute liver failure,0,3,0,19,Acute liver failure in two patients with regular alcohol consumption ingesting paracetamol at therapeutic dosage.,18004067_0,-1,1,1,7523,-1,0.0024323217,0.99756765
16306,bradycardia,16,17,117,128,"Anesthetized rats received the tricyclic antidepressant desipramine IP to produce hypotension, QRS prolongation, and bradycardia.",8800187_6,-1,1,1,16306,-1,0.0020316108,0.9979684
1840,seizures,18,19,96,104,The patient had a history of alcohol abuse; alcohol intake as well as withdrawal can also cause seizures.,11573852_5,-1,1,1,1840,-1,0.0023524829,0.99764746
6309,catalepsy,12,13,73,82,"The data may indicate that although D-2 receptor blockade is involved in catalepsy, the D-1 receptor may plan a role.",1687392_9,-1,1,1,6309,-1,0.013631852,0.9863681
10278,leukopenia,7,8,38,48,"Acute normal tissue toxicities (i.e., leukopenia and thrombocytopenia) and late normal tissue toxicities (i.e., myocardial and kidney injury) were evaluated by functional/physiological assays and by morphological techniques.",2054792_3,-1,1,1,10278,-1,0.0038484915,0.9961515
17796,cardiotoxic,5,6,36,47,"To examine a possibly deteriorating cardiotoxic effect of SM-5887, low-grade cardiomyopathy was induced in dogs by four courses of doxorubicin (1.5 mg/kg).",9848575_5,-1,1,1,17796,-1,0.002067601,0.99793243
2058,ototoxicity,17,18,125,136,"Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.",11745184_5,-1,1,1,2058,-1,0.0025690764,0.997431
15211,parkinsonism,12,13,62,74,"Furthermore, KF17837 may be a useful drug in the treatment of parkinsonism.",8045270_7,-1,1,1,15211,-1,0.0025234867,0.9974765
8546,proteinuria,14,15,96,107,"This report demonstrates that not only intravenous, but also oral bisphosphonates can aggravate proteinuria and acute renal failure.",18754075_5,-1,1,1,8546,-1,0.0024292034,0.9975708
9447,dilated cardiomyopathy,9,11,52,74,"One of the twins developed complete heart block and dilated cardiomyopathy related to lopinavir/ritonavir therapy, a boosted protease-inhibitor agent, while the other twin developed mild bradycardia.",19820426_2,-1,1,1,9447,-1,0.0021909447,0.9978091
1920,nausea,12,13,76,82,"Patients aged 18 years or older treated with prochlorperazine for headache, nausea, or vomiting were eligible for inclusion.",11679859_3,-1,1,1,1920,-1,0.0024574085,0.9975426
8335,mitral regurgitation,22,24,83,103,"RESULTS: Compared to controls, aortic regurgitation (OR: 3.1; 95% IC: 1.1-8.8) and mitral regurgitation (OR: 10.7; 95% IC: 2.1-53) were more frequent in PD patients (tricuspid: NS).",18560792_9,-1,1,1,8335,-1,0.01209969,0.98790026
6481,hypertension,6,7,62,74,Anti-oxidant effects of atorvastatin in dexamethasone-induced hypertension in the rat.1.,17042910_0,-1,1,1,6481,-1,0.002596481,0.99740344
4542,seizures,12,13,98,106,The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice.,15275829_0,-1,1,1,4542,-1,0.0021090773,0.9978909
17620,cirrhosis,19,20,122,131,"Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.",9721172_5,-1,1,1,17620,-1,0.002683765,0.9973162
17097,hyperprolactinemia,15,16,125,143,Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.,9334596_7,-1,1,1,17097,-1,0.0077496166,0.9922504
10570,liver injury,16,18,107,119,We compared age-specific mortality rates from 1 year post-discharge through 2008 between those in whom the liver injury led to an acute liver failure and those in whom it did not.,20735774_4,-1,1,1,10570,-1,0.004428145,0.99557185
7129,nephropathy,17,18,115,126,Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease.,17562951_0,-1,1,1,7129,-1,0.003052346,0.9969477
1228,hypotension,22,23,157,168,"The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.",11198499_4,-1,1,1,1228,-1,0.0022060974,0.9977939
4146,epileptic,14,15,96,105,"This case suggests that the psychotic symptoms that occur following phenytoin treatment in some epileptic patients may be the direct result of medication, unrelated to seizures.",14698717_3,-1,1,1,4146,-1,0.0031124006,0.9968876
9139,pain,5,6,28,32,Here we show that perceived pain intensity in secondary hyperalgesia is decreased when attention is distracted away from the painful pinprick stimulus with a visual task.,19387625_3,-1,1,1,9139,-1,0.0032484918,0.99675155
7319,peripheral neuropathy,9,11,35,56,AIM: To report a case of optic and peripheral neuropathy after chronic use of disulfiram for alcohol dependence management.,17786501_1,-1,1,1,7319,-1,0.0027569614,0.99724305
16287,hallucinations,10,11,71,85,Fifty-six days after initiation of the treatment the patient presented hallucinations that only stopped after the withdrawal of psycho-active drugs and tramadol.,8766220_3,-1,1,1,16287,-1,0.0022312817,0.99776876
14892,aggressive behavior,38,40,216,235,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,-1,1,1,14892,-1,0.0037328356,0.99626714
14311,aggressiveness,6,7,53,67,"Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.",7197363_2,-1,1,1,14311,-1,0.0031799208,0.9968201
7565,Pain,0,1,0,4,Pain was less severe in Groups R4 and R6 than in the control and R2 groups (P<0.001).,18006530_8,-1,1,1,7565,-1,0.0027467676,0.99725324
10856,hypotension,13,14,84,95,"A prerenal component could have contributed to renal failure because of a transient hypotension, due to an increasing ascitis, occurring just before anuria.",2320800_3,-1,1,1,10856,-1,0.0023312822,0.9976687
605,hypotension,12,13,79,90,"In control rats, intravenous bromocriptine (150 microg/kg) induced significant hypotension and tachycardia.",10721819_4,-1,1,1,605,-1,0.0023099247,0.9976901
972,pain,26,27,167,171,"Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_2,-1,1,1,972,-1,0.0030276824,0.9969723
7814,Cancer,19,20,128,134,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,-1,1,1,7814,-1,0.023148818,0.97685117
7610,polyneuropathy,18,19,114,128,This was a case of acute palsy of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal polyneuropathy caused by high-dose disulfiram intoxication.,18023325_12,-1,1,1,7610,-1,0.002517124,0.99748296
7238,pain,24,25,174,178,"BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.",17615423_2,-1,1,1,7238,-1,0.0034306014,0.9965694
2278,seizures,6,7,34,42,Here we analyze the occurrence of seizures and neurotoxicity in D2R -/- mice treated with the cholinergic agonist pilocarpine.,11860278_4,-1,1,1,2278,-1,0.0022176513,0.9977824
17204,spasm,107,108,453,458,"RESULTS: Prostigmine-morphine provocation caused significant increases in the time to peak activity (Tmax) over the hepatic hilum (HH: 34.33 +/- 5.05 vs. 22.77 +/- 3.26) and the common bile duct (CBD: 60.44 +/- 5.99 vs. 40.0 +/- 2.88) and in the half-time of excretion (T1/2) over the liver parenchyma (LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19), HH (117.61 +/- 14.71 vs. 31.85 +/- 3.99) and CBD (158.11 +/- 9.18 vs. 40.1 +/- 6.24), indicating a complete spasm at the level of the sphincter of Oddi.",9431903_4,-1,1,1,17204,-1,0.003199664,0.9968003
3129,hypertension,43,44,239,251,"Hypertension was observed in animals that had a reduction in glomeruli as well as in a group that did not have a reduction in glomerular number, suggesting that a reduction in glomerular number is not the sole cause for the development of hypertension.",12574103_9,-1,1,1,3129,-1,0.0024857456,0.99751425
3014,seizure,17,18,129,136,The possibility of drug-induced aggravation should be considered whenever an unexpected increase in seizure frequency and/or new seizure types appear following a change in drug treatment.,12536034_6,-1,1,1,3014,-1,0.0026807128,0.9973193
2323,cardiotoxicity,14,15,84,98,"Thus, we hypothesized that the activation of PARP may contribute to the DOX-induced cardiotoxicity.",11861791_3,-1,1,1,2323,-1,0.0024316239,0.9975683
5118,thrombotic microangiopathy,3,5,16,42,Causes of acute thrombotic microangiopathy in patients receiving kidney transplantation.,15859940_0,-1,1,1,5118,-1,0.002675023,0.99732494
13216,overdose,10,11,57,65,"Among the common side effects of diphenylhydantoin (DPH) overdose, the most frequently encountered neurological signs are those of cerebellar dysfunction.",430165_2,-1,1,1,13216,-1,0.0043705683,0.99562943
9000,diabetic,21,22,130,138,CONCLUSIONS: Results of these studies suggest that B1 and B2 receptors are engaged in transmission of nociceptive stimuli in both diabetic and toxic neuropathy.,19300402_7,-1,1,1,9000,-1,0.0038173597,0.9961826
17493,locomotor hyperactivity,7,9,43,66,"TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).",9660111_6,-1,1,1,17493,-1,0.0031373356,0.99686265
11223,migraine,3,4,15,23,No early onset migraine was observed.,2515254_3,-1,1,1,11223,-1,0.0024595582,0.9975405
756,aneurysms,4,5,22,31,The majority of these aneurysms were smaller than those of the control group (8 +/- 6.08 mm versus 11 +/- 5.4 mm; P = 0.05).,10807237_8,-1,1,1,756,-1,0.0038278785,0.99617213
368,toxicity,33,34,168,176,"Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable toxicity and improvement in symptoms and quality of life.",10526274_3,-1,1,1,368,-1,0.002964796,0.99703526
16114,bradycardia,4,5,20,31,"In addition, reflex bradycardia caused by injected norepinephrine was significantly enhanced by L-dopa, DL-Threo-dihydroxyphenylserine had no effect on blood pressure, heart rate or reflex responses to norepinephrine.",869641_2,-1,1,1,16114,-1,0.0019458022,0.99805427
8563,ascites,30,31,170,177,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.",18768591_5,-1,1,1,8563,-1,0.0035715222,0.99642855
681,hyperalgesia,18,19,116,128,The differential effects of ketamine and lidocaine on static and dynamic hyperalgesia suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology.,10743446_10,-1,1,1,681,-1,0.0024099376,0.99759007
4825,proteinuria,9,10,61,72,"RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.",15572383_9,-1,1,1,4825,-1,0.0026126713,0.99738735
5723,vasculitis,5,6,51,61,"The diagnosis of propylthiouracil (PTU)-associated vasculitis was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of PTU.",16418614_4,-1,1,1,5723,-1,0.0022427721,0.99775726
7658,bradycardia,21,22,76,87,"Peri-operative hypotension (26%, OR 3.80, 95% CI 1.91-7.54, p = 0.0001) and bradycardia (17%, OR 5.45, 95% CI 2.98-9.95, p < 0.00001) were significantly increased.",18086064_7,-1,1,1,7658,-1,0.0020828191,0.99791723
17453,neurotoxic,13,14,84,94,"However, the use of CBDCA higher-intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to peripheral nervous system damage.",9636837_2,-1,1,1,17453,-1,0.0022902524,0.99770975
10826,neuropathy,6,7,42,52,"The full syndrome of subacute myelo-optic neuropathy was more frequent in women, but they tended to have taken greater quantities of the drug.",230316_11,-1,1,1,10826,-1,0.0020656951,0.99793434
8987,diabetic,90,91,472,480,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,-1,1,1,8987,-1,0.003165114,0.99683493
13167,hyperkalemia,11,12,61,73,"We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.",4071154_1,-1,1,1,13167,-1,0.009356884,0.9906431
2183,convulsive,14,15,98,108,FINDINGS: FS containing tAMCA caused paroxysmal brain activity which was associated with distinct convulsive behaviours.,11807648_8,-1,1,1,2183,-1,0.002131308,0.99786866
17379,endometrial cancer,2,4,9,27,"Cases of endometrial cancer diagnosed after breast cancer (n = 135) and 467 controls matched for age, year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included.",9579567_3,-1,1,1,17379,-1,0.0074189166,0.992581
13071,prostate cancer,14,16,112,127,Experimental designs should consider genetic susceptibility as a basic prerequisite for studies on experimental prostate cancer.,3969369_6,-1,1,1,13071,-1,0.0054053254,0.99459463
15979,myelosuppression,7,8,50,66,"The dose-limiting toxicity of the combination was myelosuppression (leukopenia, granulocytopenia, and thrombocytopenia).",8643973_5,-1,1,1,15979,-1,0.02348394,0.97651607
1600,death,16,17,74,79,"Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.",11334364_11,-1,1,1,1600,-1,0.0028484368,0.99715155
5745,amnesia,10,11,89,96,Daidzein activates choline acetyltransferase from MC-IXC cells and improves drug-induced amnesia.,16428827_0,-1,1,1,5745,-1,0.002095794,0.9979042
12989,nephrotoxicity,3,4,24,38,Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin.,3950060_0,-1,1,1,12989,-1,0.0024553032,0.9975447
7116,dyskinesia,11,12,75,85,Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia.,17532790_0,-1,1,1,7116,-1,0.0020203516,0.9979797
8452,cardiotoxicity,14,15,83,97,"Often, chemotherapy by doxorubicin (Adriamycin) is limited due to life threatening cardiotoxicity in patients during and posttherapy.",18674790_1,-1,1,1,8452,-1,0.002166957,0.9978331
10989,cerebral haemorrhage,15,17,80,100,Cause of death among patients with Parkinson's disease: a rare mortality due to cerebral haemorrhage.,2355241_0,-1,1,1,10989,-1,0.0028302812,0.9971697
10028,tuberculosis,16,17,86,98,"In 44 (62.8%) patients, ATT was prescribed empirically without definitive evidence of tuberculosis.",20196116_6,-1,1,1,10028,-1,0.005213113,0.99478686
10934,seizures,5,6,38,46,Neither patient had reported previous seizures or seizure-like activity nor was receiving anticonvulsant agents.,2343592_2,-1,1,1,10934,-1,0.0021475696,0.99785244
15854,hypertension,12,13,59,71,Low-risk controls (n = 24) reported no parental history of hypertension and had screening BP < 130/85 mm Hg.,8607407_4,-1,1,1,15854,-1,0.0040540146,0.995946
6341,diabetes,7,8,57,65,"The association remained after additional adjustment for diabetes, cholesterol level, systolic blood pressure, or alcohol use.",16938416_7,-1,1,1,6341,-1,0.008925187,0.9910748
10507,hyperactivity,24,25,166,179,"The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.",20705401_2,-1,1,1,10507,-1,0.0022823862,0.9977176
16458,hypertension,25,26,152,164,"Therefore, in adult patients affected by HUS, dialysis should not be discontinued prematurely; moreover, bilateral nephrectomy, for treatment of severe hypertension and microangiopathic hemolytic anemia, should be performed with caution.",891050_4,-1,1,1,16458,-1,0.0033340314,0.996666
3261,nephrotoxicity,25,26,130,144,In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.,12617329_1,-1,1,1,3261,-1,0.002397853,0.99760216
2549,tremor,9,10,61,67,"However, MK-801 injection produced a significant increase of tremor in reserpine-treated mice.",11999899_6,-1,1,1,2549,-1,0.0019389468,0.998061
17919,tachycardia,14,15,104,115,"High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).",9915601_1,-1,1,1,17919,-1,0.002141923,0.9978581
4492,thrombotic,4,5,20,30,The risk of serious thrombotic events was also similar for each valdecoxib dose.,15266215_6,-1,1,1,4492,-1,0.0027869828,0.99721307
464,catalepsy,5,6,44,53,"NRA0160 and clozapine significantly induced catalepsy in rats, although their effects did not exceed 50% induction even at the highest dose given.",10579464_6,-1,1,1,464,-1,0.0027310783,0.99726886
2804,convulsions,9,10,70,81,"When hippocampal ACh was measured during testing for handling-induced convulsions, extracellular ACh was significantly elevated (192%) in WSP mice, but was nonsignificantly elevated (59%) in WSR mice.",12198388_11,-1,1,1,2804,-1,0.0027291803,0.99727076
724,pain,21,22,116,120,"Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or photophobia, in order of decreasing frequency.",1079693_7,-1,1,1,724,-1,0.0030733487,0.9969266
10463,cognitive deficits,18,20,108,126,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",20683499_10,-1,1,1,10463,-1,0.0023455624,0.9976545
16074,allergic reactions,3,5,18,36,Other symptoms of allergic reactions were not clinically detectable.,8682684_5,-1,1,1,16074,-1,0.0031085694,0.99689144
13454,hypertrophy,19,20,103,114,"However, prolonged stimulation (8-12 days) appears to represent a complex integration of both cellular hypertrophy and hyperplasia within the heart.",6203632_11,-1,1,1,13454,-1,0.0037119708,0.99628806
1363,pericarditis,11,12,86,98,OBJECTIVE: To describe a case of propylthiouracil-induced vasculitis manifesting with pericarditis.,11250767_1,-1,1,1,1363,-1,0.003056795,0.9969432
16433,myoclonic jerks,19,21,101,116,"He was brought directly to a hospital where he was found to be agitated and confused with shivering, myoclonic jerks, rigidity, salivation and diaphoresis.",8888541_7,-1,1,1,16433,-1,0.0056227227,0.9943772
949,pain,21,22,127,131,"Providing pain management for known opioid abusers is a challenging clinical task, in part because little is known about their pain experience and analgesic requirements.",11027904_1,-1,1,1,949,-1,0.0054498743,0.99455017
11620,seizures,23,24,181,189,The differential effects of CBZ depending upon stage of seizure development suggest that distinct mechanisms underlie the development versus maintenance of local anesthetic-kindled seizures.,2790457_7,-1,1,1,11620,-1,0.0026233892,0.9973767
5785,nausea,14,15,54,60,"The grade of sedation (none, mild, moderate, severe), nausea, pruritus, and apnea were recorded after injection of both drugs.",16563323_7,-1,1,1,5785,-1,0.0024632178,0.9975368
6726,toxicity,1,2,7,15,"Severe toxicity was correlated with the higher cumulative dose of 60 g/m2 of ifosfamide, a younger age (less than 2 1/2 years old), and a predominance of vesicoprostatic tumor involvement.",1720453_10,-1,1,1,6726,-1,0.0023430912,0.99765694
15643,hypercholesterolemia,14,15,84,104,OBJECTIVE: To evaluate the efficacy and safety of lovastatin in women with moderate hypercholesterolemia.,8480959_1,-1,1,1,15643,-1,0.03592103,0.96407896
9893,hypotension,1,2,10,21,Transient hypotension (SAP<90mmHg) occurred in 1 patient (0.7%).,20084309_10,-1,1,1,9893,-1,0.0022568537,0.9977431
13114,pain,19,20,147,151,"Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.",3985451_3,-1,1,1,13114,-1,0.0028288655,0.9971711
1362,vasculitis,8,9,58,68,OBJECTIVE: To describe a case of propylthiouracil-induced vasculitis manifesting with pericarditis.,11250767_1,-1,1,1,1362,-1,0.002251044,0.9977489
17459,Pain,0,1,0,4,"Pain perception and nerve conduction velocity in the tail were significantly impaired, particularly after the high-dose treatment.",9636837_6,-1,1,1,17459,-1,0.004943279,0.99505675
61,dyskinesia,15,16,78,88,"Compared with the score at rest (1.3+/-0.3), a significant aggravation of the dyskinesia score was observed during speaking aloud (5.2+/-1.1, p<0.05), movements of right (4.5+/-1.0, p<0.05) and left (3.7+/-0.8, p<0.05) fingers, movements of the neck (5.1+/-1.0, p<0.05), and mental calculation (3.1+/-1.0, p<0.05).",10091616_2,-1,1,1,61,-1,0.002244375,0.9977556
8422,proteinuria,19,20,135,146,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.,18631865_3,-1,1,1,8422,-1,0.0027986295,0.99720144
5427,Hypersensitivity,0,1,0,16,"Hypersensitivity to various auditory, tactile, and visual stimulation was present and shifts in the brainstem ambient power spectral frequency occurred in response to tactile stimulation.",1610717_7,-1,1,1,5427,-1,0.0039111665,0.99608886
10836,incontinence,20,21,158,170,"Patients who present with stress incontinence while taking prazosin should change their antihypertensive medication before considering surgery, because their incontinence may resolve spontaneously with a change in drug therapy.",2304736_7,-1,1,1,10836,-1,0.002928298,0.99707174
17176,aplastic anemia,3,5,34,49,Treatment for ticlopidine-induced aplastic anemia with colony-stimulating factors seemed to have little effect.,9401499_7,-1,1,1,17176,-1,0.0023624056,0.9976376
4757,stroke,32,33,155,161,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,-1,1,1,4757,-1,0.0029247107,0.9970753
12421,hemolytic anemia,16,18,82,98,A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.,3425586_1,-1,1,1,12421,-1,0.0022721395,0.99772793
17464,neurotoxic,4,5,22,32,"CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism.",9636837_9,-1,1,1,17464,-1,0.0027321433,0.99726784
3053,nephropathy,11,12,63,74,BACKGROUND: The use of iodinated contrast medium can result in nephropathy.,12571256_1,-1,1,1,3053,-1,0.00278274,0.9972173
12524,hepatitis,10,11,63,72,We report the case of a patient in whom troleandomycin-induced hepatitis was followed by prolonged anicteric cholestasis.,3496378_1,-1,1,1,12524,-1,0.00211949,0.9978806
1750,hepatotoxicity,24,25,144,158,"Given the onset of his jaundice 2 wk after the initiation of metformin, we believe that this case represents an example of metformin-associated hepatotoxicity, the first such case reported.",11467664_6,-1,1,1,1750,-1,0.0024486822,0.9975514
13841,hemorrhage,6,7,50,60,"Heparin-induced thrombocytopenia, thrombosis, and hemorrhage.",6615052_0,-1,1,1,13841,-1,0.0025409888,0.997459
14730,Overdose,0,1,0,8,Overdose patients who have coingested tricyclic antidepressants have a higher risk of these complications.,7651879_3,-1,1,1,14730,-1,0.004877632,0.9951224
7616,idiopathic epilepsy,7,9,43,62,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,-1,1,1,7616,-1,0.0032640393,0.996736
2904,myalgia,22,23,137,144,"In conclusion, where succinylcholine is used, lidocaine is proven to be the useful pretreatment agent for the reduction of postoperative myalgia.",12452237_12,-1,1,1,2904,-1,0.0018384893,0.9981615
9035,hemorrhage,3,4,24,34,"Twenty-four hours after hemorrhage induction, hemorrhagic blood volume was quantified using a photometric hemoglobin assay.",19319147_8,-1,1,1,9035,-1,0.003947899,0.9960521
16022,atrophy,25,26,153,160,"ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T, whereas histologic examinations revealed a normal muscular pattern with absence of necrosis.",8665051_10,-1,1,1,16022,-1,0.003319719,0.99668026
12039,deaths,5,6,20,26,In two of the three deaths probably associated with ketoconazole treatment the drug had been continued after the onset of jaundice and other symptoms of hepatitis.,3101906_13,-1,1,1,12039,-1,0.0035871984,0.9964128
3548,anemia,32,33,154,160,"All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).",12820454_3,-1,1,1,3548,-1,0.0027811895,0.99721885
14758,ischemia,33,34,152,160,"Peripheral venous blood samples were withdrawn from the femoral vein four times (once every 5 min) before ischemia (0 time) and 5, 15, and 30 min after ischemia.",7710775_2,-1,1,1,14758,-1,0.02023717,0.97976285
5628,epilepsy,9,10,72,80,Investigation of mitochondrial involvement in the experimental model of epilepsy induced by pilocarpine.,16337777_0,-1,1,1,5628,-1,0.0025034382,0.99749655
4840,Hypoxia,0,1,0,7,Hypoxia in renal disease with proteinuria and/or glomerular hypertension.,15579441_0,-1,1,1,4840,-1,0.9347731,0.065226905
15423,hypotension,30,31,151,162,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,-1,1,1,15423,-1,0.0020950781,0.9979049
1745,edema,12,13,81,86,"A percutaneous liver biopsy was obtained showing marked cholestasis, with portal edema, ductular proliferation, and acute inflammation.",11467664_4,-1,1,1,1745,-1,0.002932288,0.99706775
982,confusion,16,17,78,87,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,-1,1,1,982,-1,0.003078484,0.9969215
17470,drug abuse,8,10,61,71,Eating disorders and the associated behavioural problems and drug abuse are uncommon in pregnancy.,9653867_1,-1,1,1,17470,-1,0.17817551,0.82182443
9888,hypoxia,1,2,5,12,Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.,20084309_9,-1,1,1,9888,-1,0.0033692678,0.9966307
8632,poisoning,10,11,64,73,"Although MHb formers are generally applied as treatments for CN poisoning, it has been proposed that a stable, long-acting MHb former could serve as a CN pretreatment.",18821488_1,-1,1,1,8632,-1,0.004129101,0.9958709
7443,Pain,0,1,0,4,Pain intensity and pain period were statistically significantly lower for the 30-second injection than for the 10-second injection.,17931375_12,-1,1,1,7443,-1,0.003460633,0.99653935
7740,myopathy,4,5,27,35,Renal Fanconi syndrome and myopathy after liver transplantation: drug-related mitochondrial cytopathy?Advances in the field of transplantation provide a better quality of life and allow more favorable conditions for growth and development in children.,18186898_0,-1,1,1,7740,-1,0.0023945759,0.99760544
2049,neurotoxicity,24,25,161,174,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,-1,1,1,2049,-1,0.0030770837,0.9969229
15544,confusion,14,15,134,143,Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion.15 cases of cimetidine-associated mental confusion have been reported.,84204_0,-1,1,1,15544,-1,0.0020985764,0.99790144
812,edema,21,22,126,131,"At the time of administration of morphine, histological modifications of the bladder wall, such as chorionic and muscle layer edema, were observed.",10840460_17,-1,1,1,812,-1,0.003138714,0.99686134
13590,bradycardia,14,15,132,143,"Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.",6308526_3,-1,1,1,13590,-1,0.0018550925,0.99814487
950,pain,6,7,36,40,This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).,11027904_2,-1,1,1,950,-1,0.0068985373,0.9931015
11244,nausea,13,14,75,81,"Symptomatic adverse effects were present in 96% of subjects, most commonly nausea (64%), fatigue (55%) and headache (49%).",2528969_5,-1,1,1,11244,-1,0.0030435913,0.99695647
6635,Proteinuria,0,1,0,11,Proteinuria after conversion to sirolimus in renal transplant recipients.,17175308_0,-1,1,1,6635,-1,0.0031150144,0.996885
2907,migraine,13,14,100,108,Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine.,12464714_0,-1,1,1,2907,-1,0.0030644191,0.9969356
983,dry mouth,19,21,93,102,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,-1,1,1,983,-1,0.0037180504,0.9962819
14316,neurotoxicity,16,17,84,97,The possible role of low pH as well as total volume as potential factors in causing neurotoxicity was evaluated.,7199841_2,-1,1,1,14316,-1,0.0023550708,0.99764496
8193,cystitis,17,18,145,153,Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout (VIP-/-) mice with cyclophosphamide (CYP)-induced cystitis.,18483878_0,-1,1,1,8193,-1,0.0025076484,0.9974923
6639,proteinuria,3,4,15,26,"More recently, proteinuria has been reported as a consequence of sirolimus therapy, although the mechanism has remained unclear.",17175308_2,-1,1,1,6639,-1,0.002485696,0.99751437
11419,hypertensive,19,20,108,120,"The results showed a high prevalence of depression in both groups of patients, with no preponderance in the hypertensive group.",26094_2,-1,1,1,11419,-1,0.0067870775,0.99321294
17424,autoimmune hemolytic anemia,3,6,17,44,"Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone.",9625142_0,-1,1,1,17424,-1,0.0025236285,0.9974764
14448,nephrotoxicity,10,11,82,96,Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.,7420681_3,-1,1,1,14448,-1,0.002076148,0.99792385
323,hypertension,28,29,173,185,"This is, in part, due to ROS-mediated NO inactivation, lead-associated inhibition of NOS activity, and perhaps stimulatory actions of increased shear stress associated with hypertension.",10523326_10,-1,1,1,323,-1,0.0028053895,0.9971945
10193,cholestasis,13,14,87,98,It is believed that this is the first reported case of reversible azathioprine-induced cholestasis associated with histological evidence of bile duct injury.,2051906_5,-1,1,1,10193,-1,0.004506489,0.99549353
1306,cardiotoxicity,21,22,102,116,RESULTS: Six percent of MC patients versus 21% (including five cases of CHF) of AC patients developed cardiotoxicity (P =.0002).,11230490_5,-1,1,1,1306,-1,0.002141353,0.9978586
183,hypothyroidism,13,14,96,110,All patients having first-degree relatives affected by thyroid illness had accelerated onset of hypothyroidism (3.7 years after onset of lithium therapy) compared with patients without a family history (8.6 years after onset of lithium therapy).,10354657_9,-1,1,1,183,-1,0.0027601859,0.9972398
11245,fatigue,19,20,89,96,"Symptomatic adverse effects were present in 96% of subjects, most commonly nausea (64%), fatigue (55%) and headache (49%).",2528969_5,-1,1,1,11245,-1,0.002901321,0.9970987
6662,proteinuria,6,7,50,61,Twenty-eight percent of patients showed increased proteinuria to the nephrotic range.,17175308_11,-1,1,1,6662,-1,0.0030464197,0.9969536
10624,apnea,7,8,64,69,Butyrylcholinesterase gene mutations in patients with prolonged apnea after succinylcholine for electroconvulsive therapy.,21029050_0,-1,1,1,10624,-1,0.002578757,0.99742126
11077,arrhythmia,27,28,211,221,"Using two-stage coronary ligation-, digitalis-, and adrenaline-induced canine ventricular arrhythmias, antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined.",2435991_1,-1,1,1,11077,-1,0.0023000578,0.9976999
14740,toxicity,11,12,67,75,The dose was escalated from 100 to 200 mg/m2/d until dose-limiting toxicity (DLT) was observed.,7707116_5,-1,1,1,14740,-1,0.0025533475,0.99744666
8262,hypotension,1,2,17,28,Oxytocin-induced hypotension at cesarean delivery may be incorrectly attributed to blood loss.,18513945_4,-1,1,1,8262,-1,0.0021919745,0.99780804
13321,Hypertension,11,12,69,81,Report of Medical Research Council Working Party on Mild to Moderate Hypertension.,6115999_1,-1,1,1,13321,-1,0.0055319974,0.994468
15887,paralysis,1,2,11,20,Persistent paralysis after prolonged use of atracurium in the absence of corticosteroids.,8638206_0,-1,1,1,15887,-1,0.0021688703,0.99783117
17405,breast cancer,5,7,32,45,Women who receive tamoxifen for breast cancer should be offered gynaecological surveillance during and after treatment.,9579567_12,-1,1,1,17405,-1,0.0059239324,0.994076
2998,visual hallucinations,22,24,141,162,"Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased.",12523465_2,-1,1,1,2998,-1,0.0023266897,0.99767333
16830,catalepsy,26,27,211,220,"Neuroleptic-induced catalepsy, a model of neuroleptic-induced extrapyramidal side effects, was considered suitable as a model for predicting neuroleptic-induced akathisia in humans, although neuroleptic-induced catalepsy was not considered a specific test for neuroleptic-induced akathisia.",9201797_2,-1,1,1,16830,-1,0.0031876643,0.9968123
1843,seizure,7,8,41,48,"However, these other potential causes of seizure were ruled out.",11573852_7,-1,1,1,1843,-1,0.0025401302,0.99745995
14867,agoraphobia,10,11,62,73,"The efficacy of alprazolam and placebo in panic disorder with agoraphobia, and the side-effect and adverse effect profiles of both drug groups were measured.",7802851_3,-1,1,1,14867,-1,0.008220615,0.9917794
12169,cardiotoxicity,17,18,98,112,"Based on the combined data from the present study and the literature, we suggest that MMC-related cardiotoxicity is dose dependent, occurring at cumulative dose levels of 30 mg m-2 or more, mainly in patients also (previously or simultaneously) treated with doxorubicin.",3137399_10,-1,1,1,12169,-1,0.0022162579,0.9977837
8264,Hypotension,0,1,0,11,"Hypotension in response to oxytocin was associated with a decrease in systemic vascular resistance and a compensatory increase in stroke volume, heart rate and cardiac output.",18513945_7,-1,1,1,8264,-1,0.002209465,0.9977906
10273,tumor,9,10,62,67,Effect of adriamycin combined with whole body hyperthermia on tumor and normal tissues.,2054792_0,-1,1,1,10273,-1,0.0037217438,0.9962782
7442,bruising,8,9,39,47,It was determined that the size of the bruising was smaller in the 30-second injection.,17931375_11,-1,1,1,7442,-1,0.004088019,0.99591196
607,hypotension,1,2,22,33,"Bromocriptine-induced hypotension was unaffected by isoproterenol pretreatment, while tachycardia was reversed to significant bradycardia, an effect that was partly reduced by i.v.",10721819_5,-1,1,1,607,-1,0.0021314675,0.99786854
8498,vasospasm,11,12,69,78,Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients.,18726058_5,-1,1,1,8498,-1,0.0019505029,0.9980495
13457,arrhythmia,11,12,81,91,International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings.,6209318_0,-1,1,1,13457,-1,0.0034011446,0.9965989
10041,encephalopathy,33,34,179,193,"In multivariate analysis, three factors independently predicted mortality: serum bilirubin (>or=10.8 mg/dL), prothrombin time (PT) prolongation (>or=26 seconds), and grade III/IV encephalopathy at presentation.",20196116_14,-1,1,1,10041,-1,0.002471316,0.99752873
13195,nausea,14,15,86,92,"Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients.",424937_3,-1,1,1,13195,-1,0.0031711753,0.99682885
12047,hepatotoxicity,1,2,13,27,"Drug-induced hepatotoxicity, although common, has been reported only infrequently with sulfonylureas.",3107448_1,-1,1,1,12047,-1,0.0022650245,0.9977349
4946,hyperemia,13,14,103,112,Thallium-201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole-induced hyperemia; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).,1564236_9,-1,1,1,4946,-1,0.002576919,0.99742305
1833,seizures,8,9,55,63,"Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.",11573852_3,-1,1,1,1833,-1,0.0021204858,0.9978795
3550,anemia,4,5,30,36,Severe and clinically evident anemia of Hb < 11 g/dl with clinical symptoms was detected in 6 patients (14.3%).,12820454_8,-1,1,1,3550,-1,0.0030491436,0.99695086
15710,Pain,0,1,0,4,Pain at the injection site occurred in 35% (22 of 62) of patients in the diazepam group compared with 7% (4 of 60 patients) in the midazolam group (p < 0.001).,8514073_5,-1,1,1,15710,-1,0.0025551526,0.99744487
